PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Zhao, ZQ; Hao, DP; Wang, L; Li, JJ; Meng, Y; Li, PP; Wang, Y; Zhang, C; Zhou, HS; Gardner, K; Di, LJ				Zhao, Zhiqiang; Hao, Dapeng; Wang, Li; Li, Jingjing; Meng, Yuan; Li, Peipei; Wang, Yuan; Zhang, Chao; Zhou, Haisheng; Gardner, Kevin; Di, Li-Jun			CtBP promotes metastasis of breast cancer through repressing cholesterol and activating TGF-beta signaling	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TERMINAL BINDING-PROTEIN; COREPRESSOR CTBP; TRANSCRIPTIONAL REGULATION; E-CADHERIN; CELLS; PROGRESSION; EXPRESSION; RECEPTOR; SURVIVAL	Metastasis is the process through which the primary cancer cells spread beyond the primary tumor and disseminate to other organs. Most cancer patients die of metastatic disease. EMT is proposed to be the initial event associated with cancer metastasis and how it occurred is still a mystery. CtBP is known as a co-repressor abundantly expressed in many types of cancer and regulates genes involved in cancer initiation, progression, and metastasis. We found that CtBP regulates intracellular cholesterol homeostasis in breast cancer cells by forming a complex with ZEB1 and transcriptionally repressing SREBF2 expression. Importantly, CtBP repression of intracellular cholesterol abundance leads to increased EMT and cell migration. The reason is that cholesterol negatively regulates the stability of TGF-beta receptors on the cell membrane. Interestingly, TGF-beta is also capable of reducing intracellular cholesterol relying on the increased recruitment of ZEB1 and CtBP complex to SREBF2 promoter. Thus, we propose a feedback loop formed by CtBP, cholesterol, and TGF-beta signaling pathway, through which TGF-beta triggers the cascade that mobilizes the cancer cells for metastasis. Consistently, the intravenous injection of breast cancer cells with ectopically CtBP expression show increased lung metastasis depending on the reduction of intracellular cholesterol. Finally, we analyzed the public breast cancer datasets and found that CtBP expression negatively correlates with SREBF2 and HMGCR expressions. High expression of CtBP and low expression of SREBF2 and HMGCR significantly correlates with high EMT of the primary tumors.	[Zhao, Zhiqiang; Hao, Dapeng; Wang, Li; Li, Jingjing; Meng, Yuan; Li, Peipei; Wang, Yuan; Zhang, Chao; Di, Li-Jun] Univ Macau, Fac Hlth Sci, Canc Ctr, Macau, Peoples R China; [Wang, Li] Univ Macau, Fac Hlth Sci, Metabol Core, Macau, Peoples R China; [Zhou, Haisheng] Anhui Med Univ, Dept Biochem & Mol Biol, Hefei, Anhui, Peoples R China; [Gardner, Kevin] Columbia Univ, Dept Pathol & Cell Biol, Irving Med Ctr, New York, NY USA; [Hao, Dapeng] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA	University of Macau; University of Macau; Anhui Medical University; Columbia University; NewYork-Presbyterian Hospital; Baylor College of Medicine	Di, LJ (corresponding author), Univ Macau, Fac Hlth Sci, Canc Ctr, Macau, Peoples R China.	lijundi@um.edu.mo	Li, Jing/GYU-5036-2022		Science and Technology Development Fund (FDCT) of Macao SAR [FDCT 014/2018/A1]; Multi-Year Research Grant from the University of Macau [MYRG2018-00158-FHS, MYRG2016-00251-FHS]; National Natural Science Foundation of China [31701153, 81772980, 81372911, 81772909]	Science and Technology Development Fund (FDCT) of Macao SAR; Multi-Year Research Grant from the University of Macau; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	DL is supported by the Science and Technology Development Fund (FDCT) of Macao SAR (FDCT 014/2018/A1), the Multi-Year Research Grant from the University of Macau (MYRG2018-00158-FHS), and National Natural Science Foundation of China (grant no. 81772980). LW is supported by the Multi-Year Research Grant from the University of Macau (MYRG2016-00251-FHS). HZ is supported by National Natural Science Foundation of China (grant no. 81372911, 81772909). DH is supported by National Natural Science Foundation of China (grant no. 31701153).	Ahmad A, 2011, CANCER RES, V71, P3400, DOI 10.1158/0008-5472.CAN-10-0965; Barcelo-Coblijn G, 2011, P NATL ACAD SCI USA, V108, P19569, DOI 10.1073/pnas.1115484108; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bizama C, 2014, INT J CANCER, V134, P755, DOI 10.1002/ijc.28405; Bjarnadottir O, 2015, CLIN CANCER RES, V21, P3402, DOI 10.1158/1078-0432.CCR-14-1403; Cardwell CR, 2014, J CLIN ONCOL, V32, P3177, DOI 10.1200/JCO.2013.54.4569; Chang TI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109628; Chen CL, 2008, J CELL PHYSIOL, V215, P223, DOI 10.1002/jcp.21303; Chen CL, 2007, J CELL SCI, V120, P3509, DOI 10.1242/jcs.006916; Chen YG, 2009, CELL RES, V19, P58, DOI 10.1038/cr.2008.315; Chiarugi P, 2008, BIOCHEM PHARMACOL, V76, P1352, DOI 10.1016/j.bcp.2008.07.023; Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349; Debiais- Delpech C, 2013, UROL ONCOL, V32, P426; Deng H, 2013, J INVEST DERMATOL, V133, P1294, DOI 10.1038/jid.2012.487; Deng Y, 2012, MOL CARCINOGEN, V51, P500, DOI 10.1002/mc.20813; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Di LJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2438; Di LJ, 2010, NAT STRUCT MOL BIOL, V17, P1406, DOI 10.1038/nsmb.1941; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Funasaka T, 2009, CANCER RES, V69, P5349, DOI 10.1158/0008-5472.CAN-09-0488; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Ginestier C, 2012, STEM CELLS, V30, P1327, DOI 10.1002/stem.1122; Goluszko P, 2005, INFECT IMMUN, V73, P7791, DOI 10.1128/IAI.73.12.7791-7796.2005; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Halldorsson S, 2017, CANCER LETT, V396, P117, DOI 10.1016/j.canlet.2017.03.019; Hamabe A, 2014, P NATL ACAD SCI USA, V111, P15526, DOI 10.1073/pnas.1407717111; Hamada F, 2004, DEV CELL, V7, P677, DOI 10.1016/j.devcel.2004.08.022; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Jacobs EJ, 2011, CANCER RES, V71, P1763, DOI 10.1158/0008-5472.CAN-10-2953; Jiang FJ, 2016, BIOCHEM BIOPH RES CO, V469, P985, DOI 10.1016/j.bbrc.2015.12.078; Jiang L, 2015, ONCOGENE, V34, P3908, DOI 10.1038/onc.2014.321; Kojima K, 1993, Nagoya J Med Sci, V56, P1; Kuzu OF, 2016, CANCER RES, V76, P2063, DOI 10.1158/0008-5472.CAN-15-2613; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee S, 2011, BBA-MOL CELL RES, V1813, P713, DOI 10.1016/j.bbamcr.2011.01.035; Lin X, 2003, MOL CELL BIOL, V23, P9081, DOI 10.1128/MCB.23.24.9081-9093.2003; Liu KY, 2017, INT J ONCOL, V50, P252, DOI 10.3892/ijo.2016.3774; Liu Y, 2012, CANCER SCI, V103, P1420, DOI 10.1111/j.1349-7006.2012.02347.x; Mahammad S, 2015, METHODS MOL BIOL, V1232, P91, DOI 10.1007/978-1-4939-1752-5_8; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Maxfield FR, 2002, J CLIN INVEST, V110, P891, DOI 10.1172/JCI200216500; Maxfield FR, 2012, METHOD CELL BIOL, V108, P367, DOI 10.1016/B978-0-12-386487-1.00017-1; Morrison CD, 2013, CANCER LETT, V341, P30, DOI 10.1016/j.canlet.2013.02.048; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Nath A, 2015, SCI REP-UK, V5, DOI 10.1038/srep14752; Nelson ER, 2013, SCIENCE, V342, P1094, DOI 10.1126/science.1241908; Paliwal Seema, 2012, Genes Cancer, V3, P481, DOI 10.1177/1947601912463695; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pena C, 2006, INT J CANCER, V119, P2098, DOI 10.1002/ijc.22083; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Postigo AA, 2003, EMBO J, V22, P2453, DOI 10.1093/emboj/cdg226; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Renkawitz J, 2009, NAT CELL BIOL, V11, P1438, DOI 10.1038/ncb1992; Rios Garcia M, 2017, CELL METAB, V26; Sanchez-Tillo E, 2012, CELL MOL LIFE SCI, V69, P3429, DOI 10.1007/s00018-012-1122-2; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tan TZ, 2014, EMBO MOL MED, V6, P1279, DOI 10.15252/emmm.201404208; Turajlic S, 2016, SCIENCE, V352, P169, DOI 10.1126/science.aaf2784; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; van Grunsven LA, 2003, J BIOL CHEM, V278, P26135, DOI 10.1074/jbc.M300597200; Wang L, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.587; Wang R, 2012, NEOPLASIA, V14, P905, DOI 10.1593/neo.121192; Warita K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07593; Yang T, 2013, CELL PHYSIOL BIOCHEM, V31, P863, DOI 10.1159/000350104; Yang WH, 2012, NAT CELL BIOL, V14, P366, DOI 10.1038/ncb2455; Zadran S, 2014, P NATL ACAD SCI USA, V111, P13235, DOI 10.1073/pnas.1414714111; Zhang QH, 2007, P NATL ACAD SCI USA, V104, P829, DOI 10.1073/pnas.0610590104; Zhang QH, 2006, P NATL ACAD SCI USA, V103, P9029, DOI 10.1073/pnas.0603269103; Zhang XL, 2013, ONCOL REP, V30, P809, DOI 10.3892/or.2013.2537; Zhao WN, 2016, CANCER RES, V76, P2037, DOI 10.1158/0008-5472.CAN-15-1970; Zhou HJ, 2014, BIOMATERIALS, V35, P1597, DOI 10.1016/j.biomaterials.2013.11.020; Zhuang LY, 2005, J CLIN INVEST, V115, P959	81	46	48	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2076	2091		10.1038/s41388-018-0570-z	http://dx.doi.org/10.1038/s41388-018-0570-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30442980				2022-12-17	WOS:000461822600006
J	Zeng, KX; Chen, XX; Hu, XX; Liu, XX; Xu, T; Sun, HL; Pan, YQ; He, BS; Wang, SK				Zeng, Kaixuan; Chen, Xiaoxiang; Hu, Xiuxiu; Liu, Xiangxiang; Xu, Tao; Sun, Huiling; Pan, Yuqin; He, Bangshun; Wang, Shukui			LACTB, a novel epigenetic silenced tumor suppressor, inhibits colorectal cancer progression by attenuating MDM2-mediated p53 ubiquitination and degradation	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; NUCLEAR EXPORT; MUTANT P53; IN-VIVO; MDM2; PROTEIN; PATHWAY; PROMOTES; ORIGINS; CELLS	Colorectal cancer (CRC) is one of the most common aggressive malignancies. Like other solid tumors, inactivation of tumor suppressor genes and activation of oncogenes occur during CRC development and progression. Recently, a novel tumor suppressor, LACTB, was proposed to inhibit tumor progression, but the functional and clinical significance of this tumor suppressor in CRC remains unexplored. Herein, we found LACTB was significantly downregulated in CRC due to promoter methylation and histone deacetylation, which was associated with metastasis and advanced clinical stage. CRC patients with low LACTB expression had poorer overall survival and LACTB also determined to be an independent prognostic factor for poorer outcome. Ectopic expression of LACTB suppressed CRC cells proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) in vitro and inhibited CRC growth and metastasis in vivo, while knockout of LACTB by CRISPR/Cas9 gene editing technique resulted in an opposite phenotype. Interestingly, LACTB could exert antitumorigenic effect only in HCT116 and HCT8 cells harboring wild-type TP53, but not in HT29 and SW480 cells harboring mutant TP53 or HCT116 p53(-/-) cells. Mechanistic studies demonstrated that LACTB could directly bind to the C terminus of p53 to inhibit p53 degradation by preventing MDM2 from interacting with p53. Moreover, ablation of p53 attenuated the antitumorigenic effects of LACTB overexpression in CRC. Collectively, our findings successfully demonstrate for the first time that LACTB is a novel epigenetic silenced tumor suppressor through modulating the stability of p53, supporting the pursuit of LACTB as a potential therapeutic target for CRC.	[Zeng, Kaixuan; Chen, Xiaoxiang; Wang, Shukui] Southeast Univ, Sch Med, Nanjing 210009, Jiangsu, Peoples R China; [Zeng, Kaixuan; Chen, Xiaoxiang; Hu, Xiuxiu; Liu, Xiangxiang; Xu, Tao; Sun, Huiling; Pan, Yuqin; He, Bangshun; Wang, Shukui] Nanjing Med Univ, Nanjing Hosp 1, Gen Clin Res Ctr, Nanjing 210006, Jiangsu, Peoples R China	Southeast University - China; Nanjing Medical University	Wang, SK (corresponding author), Southeast Univ, Sch Med, Nanjing 210009, Jiangsu, Peoples R China.; Wang, SK (corresponding author), Nanjing Med Univ, Nanjing Hosp 1, Gen Clin Res Ctr, Nanjing 210006, Jiangsu, Peoples R China.	sk_wang@njmu.edu.cn			National Nature Science Foundation of China [81472027, 81501820]; Innovation team of Jiangsu provincial health-strengthening engineering by science and education	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation team of Jiangsu provincial health-strengthening engineering by science and education	This project was supported by grants from the National Nature Science Foundation of China (No. 81472027, 81501820) to SKW and YQP; Innovation team of Jiangsu provincial health-strengthening engineering by science and education to SKW.	Bains RK, 2004, ENDOCRINOLOGY, V145, P2666, DOI 10.1210/en.2003-1608; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chen YC, 2007, J CELL BIOCHEM, V100, P981, DOI 10.1002/jcb.21079; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirano Y, 2006, CELL, V127, P675, DOI 10.1016/j.cell.2006.11.003; Inoue T, 2001, J BIOL CHEM, V276, P45255, DOI 10.1074/jbc.M107477200; Joerger AC, 2016, ANNU REV BIOCHEM, V85, P375, DOI 10.1146/annurev-biochem-060815-014710; Keckesova Z, 2017, NATURE, V543, P681, DOI 10.1038/nature21408; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lang V, 2014, MOL ONCOL, V8, P1026, DOI 10.1016/j.molonc.2014.04.002; Leslie PL, 2016, ONCOGENE, V35, P6157, DOI 10.1038/onc.2016.88; Lessel D, 2017, J CLIN INVEST, V127, P3598, DOI 10.1172/JCI92171; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li HT, 2019, ONCOL RES, V27, P423, DOI 10.3727/096504017X15030178624579; Liu Q, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0654-3; Lu JB, 2016, ARCH BIOCHEM BIOPHYS, V590, P64, DOI 10.1016/j.abb.2015.11.007; Ma YL, 2016, GUT, V65, P1494, DOI 10.1136/gutjnl-2014-308392; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Mukhopadhyay S, 2017, BLOOD, V129, P3245, DOI 10.1182/blood-2016-07-727180; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Nomura K, 2017, NAT STRUCT MOL BIOL, V24, P578, DOI 10.1038/nsmb.3414; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Peitsaro N, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-26; Polianskyte Z, 2009, P NATL ACAD SCI USA, V106, P18960, DOI 10.1073/pnas.0906734106; Powell E, 2014, CANCER DISCOV, V4, P405, DOI 10.1158/2159-8290.CD-13-0136; Russo A, 2013, CELL CYCLE, V12, P76, DOI 10.4161/cc.22963; Sarkar S, 2017, MOL CANCER RES, V15, P1678, DOI 10.1158/1541-7786.MCR-17-0287; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith TS, 2001, GENOMICS, V78, P12, DOI 10.1006/geno.2001.6643; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Walerych D, 2016, NAT CELL BIOL, V18, P897, DOI 10.1038/ncb3380; Willer Cristen J, 2013, Nat Genet, V45, P1274, DOI 10.1038/ng.2797; Xia LM, 2017, CANCER CELL, V31, P653, DOI 10.1016/j.ccell.2017.04.005; Ye J, 2017, ONCOGENE, V36, P6391, DOI 10.1038/onc.2017.241; Yuan XW, 2013, J BIOL CHEM, V288, P31206, DOI 10.1074/jbc.M113.480285; Zeng KX, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1185582	41	46	48	0	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2018	37	41					5534	5551		10.1038/s41388-018-0352-7	http://dx.doi.org/10.1038/s41388-018-0352-7			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GW5QO	29899406				2022-12-17	WOS:000446991200005
J	Liu, YS; Lin, HY; Lai, SW; Huang, CY; Huang, BR; Chen, PY; Wei, KC; Lu, DY				Liu, Y-S; Lin, H-Y; Lai, S-W; Huang, C-Y; Huang, B-R; Chen, P-Y; Wei, K-C; Lu, D-Y			MiR-181b modulates EGFR-dependent VCAM-1 expression and monocyte adhesion in glioblastoma	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; CANCER-RELATED INFLAMMATION; PROTEIN PHOSPHATASE 2A; TUMOR IMMUNE EVASION; FACTOR RECEPTOR; GLIOMA-CELLS; STIMULATING FACTOR; BREAST-CANCER; STEM-CELLS; MACROPHAGE	Tumor-associated macrophages (TAMs) originate as circulating monocytes, and are recruited to gliomas, where they facilitate tumor growth and migration. Understanding the interaction between TAM and cancer cells may identify therapeutic targets for glioblastoma multiforme (GBM). Vascular cell adhesion molecule-1 (VCAM-1) is a cytokine-induced adhesion molecule expressed on the surface of cancer cells, which is involved in interactions with immune cells. Analysis of the glioma patient database and tissue immunohistochemistry showed that VCAM-1 expression correlated with the clinico-pathological grade of gliomas. Here, we found that VCAM-1 expression correlated positively with monocyte adhesion to GBM, and knockdown of VCAM-1 abolished the enhancement of monocyte adhesion. Importantly, upregulation of VCAM-1 is dependent on epidermal-growth-factor-receptor (EGFR) expression, and inhibition of EGFR effectively reduced VCAM-1 expression and monocyte adhesion activity. Moreover, GBM possessing higher EGFR levels (U251 cells) had higher VCAM-1 levels compared to GBMs with lower levels of EGFR (GL261 cells). Using two-and three-dimensional cultures, we found that monocyte adhesion to GBM occurs via integrin alpha 4 beta 1, which promotes tumor growth and invasion activity. Increased proliferation and tumor necrosis factor-alpha and IFN-gamma levels were also observed in the adherent monocytes. Using a genetic modification approach, we demonstrated that VCAM-1 expression and monocyte adhesion were regulated by the miR-181 family, and lower levels of miR-181b correlated with high-grade glioma patients. Our results also demonstrated that miR-181b/protein phosphatase 2A-modulated SP-1 de-phosphorylation, which mediated the EGFR-dependent VCAM-1 expression and monocyte adhesion to GBM. We also found that the EGFR-dependent VCAM-1 expression is mediated by the p38/STAT3 signaling pathway. Our study suggested that VCAM-1 is a critical modulator of EGFR-dependent interaction of monocytes with GBM, which raises the possibility of developing effective and improved therapies for GBM.	[Liu, Y-S; Lai, S-W] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan; [Lin, H-Y; Lu, D-Y] China Med Univ, Sch Med, Dept Pharmacol, 91 Hsueh Shih Rd, Taichung 40402, Taiwan; [Huang, C-Y; Wei, K-C] Chang Gung Mem Hosp, Linkou Med Ctr, Dept Neurosurg, Taoyuan 33302, Taiwan; [Huang, C-Y; Wei, K-C] Chang Gung Univ, Coll Med, Taoyuan 33302, Taiwan; [Huang, B-R] Taichung Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Neurosurg, Taichung, Taiwan; [Chen, P-Y] Chang Gung Mem Hosp, Dept Neurosurg, Keelung, Taiwan; [Chen, P-Y] Chang Gung Univ, Sch Med, Taoyuan, Taiwan; [Lu, D-Y] Asia Univ, Dept Photon & Commun Engn, Taichung, Taiwan	China Medical University Taiwan; China Medical University Taiwan; Chang Gung Memorial Hospital; Chang Gung University; Buddhist Tzu Chi General Hospital; Taichung Tzu Chi Hospital; Chang Gung Memorial Hospital; Chang Gung University; Asia University Taiwan	Lu, DY (corresponding author), China Med Univ, Sch Med, Dept Pharmacol, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.; Wei, KC (corresponding author), Chang Gung Mem Hosp, Linkou Med Ctr, Dept Neurosurg, Taoyuan 33302, Taiwan.; Wei, KC (corresponding author), Chang Gung Univ, Coll Med, Taoyuan 33302, Taiwan.	kuochenwei@adm.cgmh.org.tw; dahyuu@mail.cmu.edu.tw		Wei, Kuochen/0000-0003-3505-2196	Ministry of Science Technology [102-2320-B-039-051-MY3, 105-2628-B-039-007-MY3]; China Medical University [CMU104-S-12, CMU105-AWARD-01]; Chang Gung Memorial Hospital [CIRPG3E0032, CMRPG3D1113]; National Health Research Institutes [NHRI-EX106-10502NI]; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [MOHW106-TDU-B-212-113004]	Ministry of Science Technology; China Medical University(China Medical University); Chang Gung Memorial Hospital(Chang Gung Memorial Hospital); National Health Research Institutes(National Health Research Institutes, JapanNational Health Research Institutes - Taiwan); Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence	This work was partly supported by grants from the Ministry of Science & Technology (102-2320-B-039-051-MY3 and 105-2628-B-039-007-MY3) and China Medical University (CMU104-S-12 and CMU105-AWARD-01), Chang Gung Memorial Hospital Research Grant (CIRPG3E0032 and CMRPG3D1113), National Health Research Institutes (NHRI-EX106-10502NI) and Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW106-TDU-B-212-113004).	Abou-Ghazal M, 2008, CLIN CANCER RES, V14, P8228, DOI 10.1158/1078-0432.CCR-08-1329; Alvarez James V, 2007, Transl Oncogenomics, V2, P99; Avdi NJ, 2002, J BIOL CHEM, V277, P40687, DOI 10.1074/jbc.M204455200; Benasciutti E, 2004, BLOOD, V104, P256, DOI 10.1182/blood-2003-08-2661; Bhat FA, 2014, J NUTR BIOCHEM, V25, P1132, DOI 10.1016/j.jnutbio.2014.06.008; Chen G, 2010, ONCOL REP, V23, P997, DOI 10.3892/or_00000725; Chen JH, 2016, MOL NEUROBIOL, V53, P6218, DOI 10.1007/s12035-015-9529-z; Chen Q, 2012, CLIN CANCER RES, V18, P5520, DOI 10.1158/1078-0432.CCR-11-2904; Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025; Clarke J, 2010, ARCH NEUROL-CHICAGO, V67, P279, DOI 10.1001/archneurol.2010.5; Coniglio SJ, 2012, MOL MED, V18, P519, DOI 10.2119/molmed.2011.00217; Conti A, 2009, J NEURO-ONCOL, V93, P325, DOI 10.1007/s11060-009-9797-4; Crusz SM, 2015, NAT REV CLIN ONCOL, V12, P584, DOI 10.1038/nrclinonc.2015.105; de Groot J, 2012, ONCOTARGET, V3, P1036; Ding YB, 2003, WORLD J GASTROENTERO, V9, P1409, DOI 10.3748/wjg.v9.i7.1409; Feng X, 2015, ONCOTARGET, V6, P15077, DOI 10.18632/oncotarget.3730; Germano G, 2008, CYTOKINE, V43, P374, DOI 10.1016/j.cyto.2008.07.014; Gopisetty G, 2013, ONCOGENE, V32, P3119, DOI 10.1038/onc.2012.331; Gordon IK, 2015, MOL CANCER THER, V14, P1540, DOI 10.1158/1535-7163.MCT-14-0614; Greenwood J, 2011, NEUROPATH APPL NEURO, V37, P24, DOI 10.1111/j.1365-2990.2010.01140.x; Guan HY, 2012, INT J CANCER, V130, P593, DOI 10.1002/ijc.26049; Halatsch ME, 2006, CANCER TREAT REV, V32, P74, DOI 10.1016/j.ctrv.2006.01.003; Hambardzumyan D, 2016, NAT NEUROSCI, V19, P20, DOI 10.1038/nn.4185; Hara-Chikuma M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8454; Hofstetter CP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030059; HURTT MR, 1992, J NEUROPATH EXP NEUR, V51, P84, DOI 10.1097/00005072-199201000-00010; Hussain SF, 2006, NEURO-ONCOLOGY, V8, P261, DOI 10.1215/15228517-2006-008; Chimal-Ramirez GK, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6031486; Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370; Kumar D, 2009, J IMMUNOL, V182, P1011, DOI 10.4049/jimmunol.182.2.1011; Lacroix I, 2002, J BIOL CHEM, V277, P9598, DOI 10.1074/jbc.M111444200; Lewis C, 2005, AM J PATHOL, V167, P627, DOI 10.1016/S0002-9440(10)62038-X; Lin KY, 2007, CANCER RES, V67, P1832, DOI 10.1158/0008-5472.CAN-06-3014; Lindemann C, 2011, ACTA NEUROPATHOL, V122, P241, DOI 10.1007/s00401-011-0832-0; Lo HW, 2008, CLIN CANCER RES, V14, P6042, DOI 10.1158/1078-0432.CCR-07-4923; Lu J, 2009, P NATL ACAD SCI USA, V106, P11697, DOI 10.1073/pnas.0905930106; Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002; Luo JY, 2015, MOL BIOL CELL, V26, P430, DOI 10.1091/mbc.E14-10-1443; Maenpaa A, 1997, ACTA NEUROPATHOL, V94, P216, DOI 10.1007/s004010050696; Mandal T, 2014, CELL SIGNAL, V26, P1725, DOI 10.1016/j.cellsig.2014.04.003; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mantovani A, 2007, NATURE, V448, P547, DOI 10.1038/448547a; Markovic DS, 2009, P NATL ACAD SCI USA, V106, P12530, DOI 10.1073/pnas.0804273106; Maruno M, 1997, J CLIN PATHOL, V50, P559, DOI 10.1136/jcp.50.7.559; MEERSCHAERT J, 1995, J IMMUNOL, V154, P4099; MUNN DH, 1990, J EXP MED, V172, P231, DOI 10.1084/jem.172.1.231; Nicholas MK, 2006, CLIN CANCER RES, V12, P7261, DOI 10.1158/1078-0432.CCR-06-0874; Parney IF, 2009, J NEUROSURG, V110, P572, DOI 10.3171/2008.7.JNS08475; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Ruano Y, 2009, AM J CLIN PATHOL, V131, P257, DOI 10.1309/AJCP64YBDVCTIRWV; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Seznec J, 2011, J NEURO-ONCOL, V101, P365, DOI 10.1007/s11060-010-0266-x; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Shi L, 2008, BRAIN RES, V1236, P185, DOI 10.1016/j.brainres.2008.07.085; Shinojima N, 2003, CANCER RES, V63, P6962; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Sun XH, 2012, J CLIN INVEST, V122, P1973, DOI 10.1172/JCI61495; Sun YC, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-611; Talasila KM, 2013, ACTA NEUROPATHOL, V125, P683, DOI 10.1007/s00401-013-1101-1; Tran CT, 1998, NEUROPATH APPL NEURO, V24, P293, DOI 10.1046/j.1365-2990.1998.00120.x; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vicart A, 2006, J MOL BIOL, V364, P897, DOI 10.1016/j.jmb.2006.09.036; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; Wu TC, 2007, CANCER RES, V67, P6003, DOI 10.1158/0008-5472.CAN-07-1543; Yeh WL, 2012, J CELL PHYSIOL, V227, P558, DOI 10.1002/jcp.22746; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zahonero C, 2014, CELL MOL LIFE SCI, V71, P3465, DOI 10.1007/s00018-014-1608-1; Zhan Q, 2011, BRAZ J MED BIOL RES, V44, P489, DOI 10.1590/S0100-879X2011007500052; Zhang LY, 2007, J NEUROIMMUNOL, V184, P188, DOI 10.1016/j.jneuroim.2006.12.006; Zheng QF, 2014, NEURO-ONCOLOGY, V16, P1229, DOI 10.1093/neuonc/nou046; Zheng YH, 2013, J BIOL CHEM, V288, P31488, DOI 10.1074/jbc.M113.499020; Zhi F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109124; Zhi F, 2010, EUR J CANCER, V46, P1640, DOI 10.1016/j.ejca.2010.02.003; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090	77	46	50	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5006	5022		10.1038/onc.2017.129	http://dx.doi.org/10.1038/onc.2017.129			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28459461				2022-12-17	WOS:000408768800006
J	Chakravarthi, BVSK; Goswami, MT; Pathi, SS; Robinson, AD; Cieslik, M; Chandrashekar, DS; Agarwal, S; Siddiqui, J; Daignault, S; Carskadon, SL; Jing, X; Chinnaiyan, AM; Kunju, LP; Palanisamy, N; Varambally, S				Chakravarthi, B. V. S. K.; Goswami, M. T.; Pathi, S. S.; Robinson, A. D.; Cieslik, M.; Chandrashekar, D. S.; Agarwal, S.; Siddiqui, J.; Daignault, S.; Carskadon, S. L.; Jing, X.; Chinnaiyan, A. M.; Kunju, L. P.; Palanisamy, N.; Varambally, S.			MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer	ONCOGENE			English	Article							POSITIVE COACTIVATOR 4; RNA-POLYMERASE-II; POLO-LIKE KINASES; GENE-EXPRESSION; FUNCTIONAL-CHARACTERIZATION; CELL-PROLIFERATION; GASTRIC-CANCER; PC4; ACTIVATION; DNA	MicroRNA-101, a tumor suppressor microRNA (miR), is often downregulated in cancer and is known to target multiple oncogenes. Some of the genes that are negatively regulated by miR-101 expression include histone methyltransferase EZH2 (enhancer of zeste homolog 2), COX2 (cyclooxygenase-2), POMP (proteasome maturation protein), CERS6, STMN1, MCL-1 and ROCK2, among others. In the present study, we show that miR-101 targets transcriptional coactivator SUB1 homolog (Saccharomyces cerevisiae)/PC4 (positive cofactor 4) and regulates its expression. SUB1 is known to have diverse role in vital cell processes such as DNA replication, repair and heterochromatinization. SUB1 is known to modulate transcription and acts as a mediator between the upstream activators and general transcription machinery. Expression profiling in several cancers revealed SUB1 overexpression, suggesting a potential role in tumorigenesis. However, detailed regulation and function of SUB1 has not been elucidated. In this study, we show elevated expression of SUB1 in aggressive prostate cancer. Knockdown of SUB1 in prostate cancer cells resulted in reduced cell proliferation, invasion and migration in vitro, and tumor growth and metastasis in vivo. Gene expression analyses coupled with chromatin immunoprecipitation revealed that SUB1 binds to the promoter regions of several oncogenes such as PLK1 (Polo-like kinase 1), C-MYC, serine-threonine kinase BUB1B and regulates their expression. Additionally, we observed SUB1 downregulated CDKN1B expression. PLK1 knockdown or use of PLK1 inhibitor can mitigate oncogenic function of SUB1 in benign prostate cancer cells. Thus, our study suggests that miR-101 loss results in increased SUB1 expression and subsequent activation of known oncogenes driving prostate cancer progression and metastasis. This study therefore demonstrates functional role of SUB1 in prostate cancer, and identifies its regulation and potential downstream therapeutic targets of SUB1 in prostate cancer.	[Chakravarthi, B. V. S. K.; Goswami, M. T.; Pathi, S. S.; Cieslik, M.; Siddiqui, J.; Carskadon, S. L.; Jing, X.; Chinnaiyan, A. M.; Kunju, L. P.; Palanisamy, N.; Varambally, S.] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA; [Chakravarthi, B. V. S. K.; Goswami, M. T.; Pathi, S. S.; Cieslik, M.; Carskadon, S. L.; Jing, X.; Chinnaiyan, A. M.; Kunju, L. P.; Palanisamy, N.; Varambally, S.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Chakravarthi, B. V. S. K.; Robinson, A. D.; Chandrashekar, D. S.; Agarwal, S.; Varambally, S.] Univ Alabama Birmingham, Dept Pathol, Mol & Cellular Pathol, Birmingham, AL 35294 USA; [Daignault, S.] Univ Michigan, Dept Biostat, Ctr Canc Biostat, Ann Arbor, MI 48109 USA; [Chinnaiyan, A. M.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; [Chinnaiyan, A. M.] Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; [Chinnaiyan, A. M.; Palanisamy, N.; Varambally, S.] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Varambally, S.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA; [Pathi, S. S.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Carskadon, S. L.; Palanisamy, N.] Henry Ford Hlth Syst, Vattikuti Urol Inst, Dept Urol, Detroit, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Alabama System; University of Alabama Birmingham; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Alabama System; University of Alabama Birmingham; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Henry Ford Health System; Henry Ford Hospital	Varambally, S (corresponding author), Univ Alabama Birmingham, Dept Pathol, Ctr Comprehens Canc, Mol & Cellular Pathol, Birmingham, AL 35233 USA.	soorya@uab.edu	AGARWAL, SUMIT/I-9349-2019; Palanisamy, Nallasivam/ABC-8844-2020; Daignault-Newton, Stephanie/GYD-6133-2022	AGARWAL, SUMIT/0000-0003-4051-7146; Palanisamy, Nallasivam/0000-0002-0633-9772; Varambally, Sooryanarayana/0000-0002-2277-1127; Robinson, Alyncia/0000-0002-9369-7665	National Institutes of Health [R01CA157845]; University of Michigan Prostate Cancer SPORE Career Development award;  [R01CA154980]; NATIONAL CANCER INSTITUTE [R01CA154980, R01CA157845] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Michigan Prostate Cancer SPORE Career Development award; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Twani Dhar, Sherin John, Sivakumar Nallasivam, Samuel Lee and Sai Akshaya Hodigere Balasubramanya for their assistance. We also thank the University of Michigan Vector Core for generating lentivirus. This work is supported, in part, by National Institutes of Health R01CA157845. SV is also supported by R01CA154980 and the University of Michigan Prostate Cancer SPORE Career Development award (to SV). Gene expression data has been deposited in the GEO database under accession number GSE74895.	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Bargiela-Iparraguirre J, 2014, CELL CYCLE, V13, P3590, DOI 10.4161/15384101.2014.962952; Batta K, 2007, MOL CELL BIOL, V27, P7603, DOI 10.1128/MCB.01064-07; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Chain B, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-344; Chakravarthi BVSK, 2014, ONCOTARGET, V5, P6654, DOI 10.18632/oncotarget.2208; Chen L, 2014, J NEUROL SCI, V346, P293, DOI 10.1016/j.jns.2014.09.014; Conesa C, 2010, RNA BIOL, V7, P287, DOI 10.4161/rna.7.3.11491; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Das C, 2010, J MOL BIOL, V397, P1, DOI 10.1016/j.jmb.2009.12.058; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Ferreira PG, 2014, GENOME RES, V24, P212, DOI 10.1101/gr.152132.112; Frith MC, 2004, NUCLEIC ACIDS RES, V32, P1372, DOI 10.1093/nar/gkh299; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Gjertsen BT, 2015, LEUKEMIA, V29, P11, DOI 10.1038/leu.2014.222; Goswami MT, 2015, ONCOTARGET, V6, P23445, DOI 10.18632/oncotarget.4352; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Hammitzsch A, 2015, P NATL ACAD SCI USA, V112, P10768, DOI 10.1073/pnas.1501956112; Henry NL, 1996, J BIOL CHEM, V271, P21842, DOI 10.1074/jbc.271.36.21842; Holloway AF, 2000, J BIOL CHEM, V275, P21668, DOI 10.1074/jbc.M909058199; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; Kannan F, 1999, MOL CELL BIOL, V19, P899; Kershnar E, 1998, J BIOL CHEM, V273, P34444, DOI 10.1074/jbc.273.51.34444; Kim JM, 2015, NUCLEIC ACIDS RES, V43, P8868, DOI 10.1093/nar/gkv874; Kleivi K, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-2; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; Kottakis F, 2011, MOL CELL, V43, P285, DOI 10.1016/j.molcel.2011.06.020; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; Lada AG, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005217; Lee JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122628; Lin CC, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-3725; Liu XQ, 2015, TRANSL ONCOL, V8, P185, DOI 10.1016/j.tranon.2015.03.010; Luo L, 2012, MED ONCOL, V29, P1681, DOI 10.1007/s12032-011-0085-8; Luo Y, 1998, MOL CELL BIOL, V18, P3803, DOI 10.1128/MCB.18.7.3803; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Maragkakis M, 2009, NUCLEIC ACIDS RES, V37, pW273, DOI 10.1093/nar/gkp292; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Pan ZQ, 1996, J BIOL CHEM, V271, P22111, DOI 10.1074/jbc.271.36.22111; Peng Y, 2012, CANCER GENE THER, V19, P690, DOI 10.1038/cgt.2012.52; Pezuk JA, 2013, CANCER GENE THER, V20, P499, DOI 10.1038/cgt.2013.46; Qian D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.416; Rudolph D, 2009, CLIN CANCER RES, V15, P3094, DOI 10.1158/1078-0432.CCR-08-2445; Sato N, 2004, AM J PATHOL, V164, P903, DOI 10.1016/S0002-9440(10)63178-1; Shi CM, 2008, EXP HEMATOL, V36, pS82; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sikorski TW, 2011, MOL CELL, V44, P397, DOI 10.1016/j.molcel.2011.09.013; Smith M, 2012, AACR 103 ANN M S, V72; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Suzuki M, 2016, J CLIN INVEST, V126, P254, DOI 10.1172/JCI79775; Tao SL, 2015, AM J CANCER RES, V5, P1878; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Wang L, 2015, CANCER CELL, V28, P240, DOI 10.1016/j.ccell.2015.07.005; Wang L, 2014, HEPATOLOGY, V59, P1850, DOI 10.1002/hep.26720; Wang R., 2012, MATH PROBL ENG, V2012, P1, DOI DOI 10.1109/IEVC2012.6183284.URL; Wang R, 2012, NEOPLASIA, V14, P905, DOI 10.1593/neo.121192; Werten S, 1998, EMBO J, V17, P5103, DOI 10.1093/emboj/17.17.5103; Wissing MD, 2013, FASEB J, V27, P4279, DOI 10.1096/fj.12-222893; Wolfer A, 2011, CANCER RES, V71, P2034, DOI 10.1158/0008-5472.CAN-10-3776; Yan F, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.380; Yang J, 2015, BIOCHEM BIOPH RES CO, V463, P900, DOI 10.1016/j.bbrc.2015.06.032; Yokoi S, 2002, AM J PATHOL, V161, P207, DOI 10.1016/S0002-9440(10)64172-7; Zhang X, 2015, MOL CELL, V59, P243, DOI 10.1016/j.molcel.2015.05.036; Zheng F, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004873; Zhong L, 2003, GENE, V320, P155, DOI 10.1016/S0378-1119(03)00823-0; Zhu YT, 2014, NAT METHODS, V11, P599, DOI 10.1038/nmeth.2956	75	46	48	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2016	35	49					6330	6340		10.1038/onc.2016.164	http://dx.doi.org/10.1038/onc.2016.164			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TJ	27270442	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000390247000006
J	Chien, CW; Hou, PC; Wu, HC; Chang, YL; Lin, SC; Lin, SC; Lin, BW; Lee, JC; Chang, YJ; Sun, HS; Tsai, SJ				Chien, C-W; Hou, P-C; Wu, H-C; Chang, Y-L; Lin, S-C; Lin, S-C; Lin, B-W; Lee, J-C; Chang, Y-J; Sun, H. S.; Tsai, S-J			Targeting TYRO3 inhibits epithelial-mesenchymal transition and increases drug sensitivity in colon cancer	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; ARREST-SPECIFIC GENE-6; MONOCLONAL-ANTIBODY; BREAST-CANCER; COLORECTAL-CANCER; STEM-CELLS; AXL; SURVIVAL; GROWTH; OVEREXPRESSION	Colon cancer is the third leading cause of death from cancer worldwide with less than 10% survival rate at the late stage. Although mutations of certain genes have been implicated in familial colon cancer development, the etiology of the majority of colon cancer remains unknown. Herein, we identified TYRO3 as a potential oncogene. Immunohistochemical staining results demonstrated that levels of TYRO3 were markedly elevated in polyps and colon cancer cells and were negatively correlated with prognosis. Overexpression of TYRO3 enhanced cell motility, invasion, anchorage-independent growth and metastatic ability, while knockdown of TYRO3 impaired all these processes. Results from meta-analysis showed that TYRO3 was associated with epithelial-mesenchymal transition (EMT) signatures. Gain-of-function and loss-of-function experiments demonstrated that expression of SNAI1, the master regulator of EMT, was regulated by TYRO3 and played a major role in mediating TYRO3-induced EMT processes. The murine model also demonstrated that Tyro3 and Snai1 were upregulated in the early stage of colon cancer development. To provide a proof-of-concept that TYRO3 is a druggable target in colon cancer therapy, we raised anti-TYRO3 human antibodies and showed that treatment with the human antibody abolished TYRO3-induced EMT process. More importantly, administration of this anti-TYRO3 antibody increased drug sensitivity in primary cultured colon cancer cells and xenografted mouse tumors. These findings demonstrate that TYRO3 is a novel oncogene and a druggable target in colon cancer.	[Chien, C-W; Hou, P-C; Sun, H. S.; Tsai, S-J] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan; [Wu, H-C; Chang, Y-L] Acad Sinica, Inst Cellular & Organism Biol, Taipei, Taiwan; [Lin, S-C; Tsai, S-J] Natl Cheng Kung Univ, Coll Med, Dept Physiol, 1 Univ Rd, Tainan 701, Taiwan; [Lin, S-C; Lin, B-W; Lee, J-C] Natl Cheng Kung Univ, Coll Med, Dept Surg, Tainan, Taiwan; [Chang, Y-J] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Sun, H. S.] Natl Cheng Kung Univ, Coll Med, Inst Mol Med, 1 Univ Rd, Tainan 701, Taiwan	National Cheng Kung University; Academia Sinica - Taiwan; National Cheng Kung University; National Cheng Kung University; Taipei Medical University; National Cheng Kung University	Tsai, SJ (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Physiol, 1 Univ Rd, Tainan 701, Taiwan.; Sun, HS (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Mol Med, 1 Univ Rd, Tainan 701, Taiwan.	hssun@mail.ncku.edu.tw; seantsai@mail.ncku.edu.tw	Tsai, Shaw-Jenq/AAG-6569-2019; Wu, Han-Chung/B-1209-2011	Wu, Han-Chung/0000-0002-5185-1169; Sun, Sunny/0000-0002-3661-4448; TSAI, SHAW-JENQ/0000-0002-3569-5813; Hou, Pei-Chi/0000-0002-3709-5934	National Science Council of Taiwan [NSC 101-2321-B-006-020, NSC 102-2321-B-006-011]; Top University Grant of National Cheng Kung University [D103-35A17]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Top University Grant of National Cheng Kung University	We thank Miss Yi-Hsuan Yeh and Miss Yi-Chen Tang for technical assistance with IHC and animal study. This work was supported by grants from National Science Council of Taiwan (NSC 101-2321-B-006-020 and NSC 102-2321-B-006-011) and by Top University Grant of National Cheng Kung University (grant # D103-35A17).	Asiedu MK, 2014, ONCOGENE, V33, P1316, DOI 10.1038/onc.2013.57; Avilla E, 2011, CANCER RES, V71, P1792, DOI 10.1158/0008-5472.CAN-10-2186; BIESECKER LG, 1993, P NATL ACAD SCI USA, V90, P7044, DOI 10.1073/pnas.90.15.7044; Budinska E, 2013, J PATHOL, V231, P63, DOI 10.1002/path.4212; CARON PC, 1994, CANCER, V73, P1049, DOI 10.1002/1097-0142(19940201)73:3+<1049::AID-CNCR2820731344>3.0.CO;2-1; Chan HH, 2007, NUCL ACIDS RES; Chien CW, 2008, CLIN CANCER RES, V14, P8043, DOI 10.1158/1078-0432.CCR-08-1651; Crosier KE, 1997, PATHOLOGY, V29, P131, DOI 10.1080/00313029700169744; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; Duijkers FAM, 2013, GENE, V521, P62, DOI 10.1016/j.gene.2013.03.029; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Gerloff J, 2012, AM J PATHOL, V180, P2134, DOI 10.1016/j.ajpath.2012.01.036; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Golan T, 2013, CANCER-AM CANCER SOC, V119, P3084, DOI 10.1002/cncr.28143; Goldenberg MM, 1999, CLIN THER, V21, P309, DOI 10.1016/S0149-2918(00)88288-0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Lemke G, 2008, NAT REV IMMUNOL, V8, P327, DOI 10.1038/nri2303; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Lu RM, 2011, BIOMATERIALS, V32, P3265, DOI 10.1016/j.biomaterials.2010.12.061; Neubauer A, 1997, LEUKEMIA LYMPHOMA, V25, P91, DOI 10.3109/10428199709042499; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Prewett M, 1996, J IMMUNOTHER, V19, P419, DOI 10.1097/00002371-199611000-00006; Sawabu T, 2007, MOL CARCINOGEN, V46, P155, DOI 10.1002/mc.20211; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Song XZ, 2011, CANCER-AM CANCER SOC, V117, P734, DOI 10.1002/cncr.25483; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Sun WS, 2004, ONCOLOGY-BASEL, V66, P450, DOI 10.1159/000079499; Sun WS, 2003, MOL HUM REPROD, V9, P701, DOI 10.1093/molehr/gag082; Takayama T, 1998, NEW ENGL J MED, V339, P1277, DOI 10.1056/NEJM199810293391803; Taylor ICA, 1995, ONCOGENE, V11, P2619; Zhu ST, 2009, P NATL ACAD SCI USA, V106, P17025, DOI 10.1073/pnas.0909292106	32	46	46	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5872	5881		10.1038/onc.2016.120	http://dx.doi.org/10.1038/onc.2016.120			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27132510				2022-12-17	WOS:000387560800006
J	Carmona, G; Perera, U; Gillett, C; Naba, A; Law, AL; Sharma, VP; Wang, J; Wyckoff, J; Balsamo, M; Mosis, F; De Piano, M; Monypenny, J; Woodman, N; McConnell, RE; Mouneimne, G; Van Hemelrijck, M; Cao, Y; Condeelis, J; Hynes, RO; Gertler, FB; Krause, M				Carmona, G.; Perera, U.; Gillett, C.; Naba, A.; Law, A-L; Sharma, V. P.; Wang, J.; Wyckoff, J.; Balsamo, M.; Mosis, F.; De Piano, M.; Monypenny, J.; Woodman, N.; McConnell, R. E.; Mouneimne, G.; Van Hemelrijck, M.; Cao, Y.; Condeelis, J.; Hynes, R. O.; Gertler, F. B.; Krause, M.			Lamellipodin promotes invasive 3D cancer cell migration via regulated interactions with Ena/VASP and SCAR/WAVE	ONCOGENE			English	Article							ACTIN-FILAMENT ELONGATION; BREAST-CARCINOMA CELLS; ABL-FAMILY KINASES; LEADING-EDGE; INVADOPODIUM FORMATION; EXPRESSION SIGNATURE; FIBROBLAST MOTILITY; MAMMARY-TUMORS; BARBED ENDS; METASTASIS	Cancer invasion is a hallmark of metastasis. The mesenchymal mode of cancer cell invasion is mediated by elongated membrane protrusions driven by the assembly of branched F-actin networks. How deregulation of actin regulators promotes cancer cell invasion is still enigmatic. We report that increased expression and membrane localization of the actin regulator Lamellipodin correlate with reduced metastasis-free survival and poor prognosis in breast cancer patients. In agreement, we find that Lamellipodin depletion reduced lung metastasis in an orthotopic mouse breast cancer model. Invasive 3D cancer cell migration as well as invadopodia formation and matrix degradation was impaired upon Lamellipodin depletion. Mechanistically, we show that Lamellipodin promotes invasive 3D cancer cell migration via both actin-elongating Ena/VASP proteins and the Scar/WAVE complex, which stimulates actin branching. In contrast, Lamellipodin interaction with Scar/WAVE but not with Ena/VASP is required for random 2D cell migration. We identified a phosphorylation-dependent mechanism that regulates selective recruitment of these effectors to Lamellipodin: Abl-mediated Lamellipodin phosphorylation promotes its association with both Scar/WAVE and Ena/VASP, whereas Src-dependent phosphorylation enhances binding to Scar/WAVE but not to Ena/VASP. Through these selective, regulated interactions Lamellipodin mediates directional sensing of epidermal growth factor (EGF) gradients and invasive 3D migration of breast cancer cells. Our findings imply that increased Lamellipodin levels enhance Ena/VASP and Scar/WAVE activities at the plasma membrane to promote 3D invasion and metastasis.	[Carmona, G.; Naba, A.; Wyckoff, J.; Balsamo, M.; McConnell, R. E.; Hynes, R. O.; Gertler, F. B.] MIT, Koch Inst Integrat Canc Res, BLDG 76-361,77 Massachusetts Ave, Cambridge, MA 02139 USA; [Perera, U.; Law, A-L; Mosis, F.; Monypenny, J.; Krause, M.] Kings Coll London, Randall Div Cell & Mol Biophys, New Hunts House,Guys Campus, London SE1 1UL, England; [Gillett, C.; Monypenny, J.; Woodman, N.] Kings Coll London, Res Oncol, Div Canc Studies, Fac Life Sci & Med, London, England; [Sharma, V. P.; Condeelis, J.] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10467 USA; [Sharma, V. P.; Condeelis, J.] Albert Einstein Coll Med, Gruss Lipper Biophoton Ctr, Bronx, NY 10467 USA; [Wang, J.; Cao, Y.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [De Piano, M.; Van Hemelrijck, M.] Kings Coll London, Div Canc Studies, Canc Epidemiol Grp, London, England; [Monypenny, J.] Kings Coll London, Div Canc Studies, Richard Dimbleby Dept Canc Res, London, England; [Mouneimne, G.] Univ Arizona, Ctr Canc, Tucson, AZ USA; [Hynes, R. O.] MIT, Howard Hughes Med Inst, Cambridge, MA USA	Massachusetts Institute of Technology (MIT); University of London; King's College London; University of London; King's College London; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Karolinska Institutet; University of London; King's College London; University of London; King's College London; University of Arizona; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Gertler, FB (corresponding author), MIT, Koch Inst Integrat Canc Res, BLDG 76-361,77 Massachusetts Ave, Cambridge, MA 02139 USA.; Krause, M (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, New Hunts House,Guys Campus, London SE1 1UL, England.	fgertler@mit.edu; Matthias.Krause@kcl.ac.uk	Krause, Matthias/D-9814-2013; Balsamo, Michele/AAJ-3247-2020; Naba, Alexandra/E-6867-2010	Krause, Matthias/0000-0002-3200-3199; Balsamo, Michele/0000-0002-2315-4761; Naba, Alexandra/0000-0002-4796-5614; Van Hemelrijck, Mieke/0000-0002-7317-0858	Experimental Cancer Medicine Centre at King's College London; Department of Health via the National Institute for Health Research comprehensive Biomedical Research Centre award; Ludwig Fund for Cancer Research; King's College Overseas Research PhD Studentship (KORS); National Cancer Institute [U54-CA112967, U54-CA163109]; Ludwig Center for Metastasis Research at MIT; Koch Institute Support Grant from the National Cancer Institute [P30-CA14051]; Biotechnology and Biological Science Research Council, UK [BB/F011431/1, BB/J000590/1, BB/N000226/1]; Wellcome Trust [082907/Z/07/Z]; Biotechnology and Biological Sciences Research Council [BB/J000590/1, BB/N000226/1, BB/F011431/1] Funding Source: researchfish; Medical Research Council [1522273] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [R01CA150344, U54CA163109, P30CA014051, U54CA112967, P01CA100324] Funding Source: NIH RePORTER; BBSRC [BB/N000226/1, BB/F011431/1, BB/J000590/1] Funding Source: UKRI	Experimental Cancer Medicine Centre at King's College London; Department of Health via the National Institute for Health Research comprehensive Biomedical Research Centre award; Ludwig Fund for Cancer Research; King's College Overseas Research PhD Studentship (KORS); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ludwig Center for Metastasis Research at MIT; Koch Institute Support Grant from the National Cancer Institute; Biotechnology and Biological Science Research Council, UK(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome Trust); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We thank members of the Gertler and Krause laboratories for helpful discussions and technical assistance; R Weinberg for his helpful discussions; J Lamar, S Hansen, D Mullins, M Way, C Cepko, D Sabatini, T Koleske and M Hemann for reagents; the Koch Institute Swanson Biotechnology Center - specifically M Griffin (Flow Cytometry Core Facility), E Vasile (Microscopy Core Facility) and K Cormier (Hope Babette Tang Histology Facility) for technical support. D Barry and M Way (LRI, CRICK, UK) for adapting the Image J plugin ADAPT for us to V1.33. Patient samples and data were provided by King's Health Partners Cancer Biobank, London, UK, which is supported by the Experimental Cancer Medicine Centre at King's College London and the Department of Health via the National Institute for Health Research comprehensive Biomedical Research Centre award. GC received a postdoctoral fellowship from the Ludwig Fund for Cancer Research and UP received a King's College Overseas Research PhD Studentship (KORS). This work was supported by grants from the National Cancer Institute (U54-CA112967 and U54-CA163109), funds from the Ludwig Center for Metastasis Research at MIT (FBG, GC, AN and ROH), the Koch Institute Support Grant P30-CA14051 from the National Cancer Institute, the Biotechnology and Biological Science Research Council, UK (BB/F011431/1; BB/J000590/1; BB/N000226/1) and the Wellcome Trust (082907/Z/07/Z) (MK).	Arjonen A, 2014, J CLIN INVEST, V124, P1069, DOI 10.1172/JCI67280; Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; Barry DJ, 2015, J CELL BIOL, V209, P163, DOI 10.1083/jcb.201501081; Barzik M, 2005, J BIOL CHEM, V280, P28653, DOI 10.1074/jbc.M503957200; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Beaty BT, 2014, EUR J CELL BIOL, V93, P438, DOI 10.1016/j.ejcb.2014.07.003; Bisi S, 2013, CURR OPIN CELL BIOL, V25, P565, DOI 10.1016/j.ceb.2013.04.001; Bradley WD, 2009, J CELL SCI, V122, P3441, DOI 10.1242/jcs.039859; Breitsprecher D, 2008, EMBO J, V27, P2943, DOI 10.1038/emboj.2008.211; Breitsprecher D, 2011, EMBO J, V30, P456, DOI 10.1038/emboj.2010.348; Chereau D, 2006, J STRUCT BIOL, V155, P195, DOI 10.1016/j.jsb.2006.01.012; Derivery E, 2009, CELL MOTIL CYTOSKEL, V66, P777, DOI 10.1002/cm.20342; Di Modugno F, 2006, CLIN CANCER RES, V12, P1470, DOI 10.1158/1078-0432.CCR-05-2027; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Eccles SA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3493; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Gligorijevic B, 2012, J CELL SCI, V125, P724, DOI 10.1242/jcs.092726; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Greuber EK, 2013, NAT REV CANCER, V13, P559, DOI 10.1038/nrc3563; Hansen SD, 2010, J CELL BIOL, V191, P571, DOI 10.1083/jcb.201003014; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Iglesias PA, 2008, CURR OPIN CELL BIOL, V20, P35, DOI 10.1016/j.ceb.2007.11.011; Ignatoski KMW, 1999, BREAST CANCER RES TR, V54, P173, DOI 10.1023/A:1006135331912; Insall RH, 2009, DEV CELL, V17, P310, DOI 10.1016/j.devcel.2009.08.012; Janetopoulos C, 2008, FEBS LETT, V582, P2075, DOI 10.1016/j.febslet.2008.04.035; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Krause M, 2004, DEV CELL, V7, P571, DOI 10.1016/j.devcel.2004.07.024; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Krause M, 2014, NAT REV MOL CELL BIO, V15, P577, DOI 10.1038/nrm3861; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Law AL, 2013, J CELL BIOL, V203, P673, DOI 10.1083/jcb.201304051; Lebrand C, 2004, NEURON, V42, P37, DOI 10.1016/S0896-6273(04)00108-4; Lee SLC, 2009, P NATL ACAD SCI USA, V106, P19485, DOI 10.1073/pnas.0909228106; Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Lyulcheva E, 2008, DEV CELL, V15, P680, DOI 10.1016/j.devcel.2008.09.020; Michael M, 2010, CURR BIOL, V20, P783, DOI 10.1016/j.cub.2010.03.048; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156; Mouneimne G, 2006, CURR BIOL, V16, P2193, DOI 10.1016/j.cub.2006.09.016; Newsome TP, 2006, CELL MICROBIOL, V8, P233, DOI 10.1111/j.1462-5822.2005.00613.x; Pasic L, 2008, J BIOL CHEM, V283, P9814, DOI 10.1074/jbc.M710475200; Philippar U, 2008, DEV CELL, V15, P813, DOI 10.1016/j.devcel.2008.09.003; Poincloux R, 2009, J CELL SCI, V122, P3015, DOI 10.1242/jcs.034561; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Roussos ET, 2011, NAT REV CANCER, V11, P573, DOI 10.1038/nrc3078; Roussos ET, 2011, J CELL SCI, V124, P2120, DOI 10.1242/jcs.086231; Roussos ET, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2784; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Sharma VP, 2013, CURR BIOL, V23, P2079, DOI 10.1016/j.cub.2013.08.044; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vehlow A, 2013, EMBO J, V32, P2722, DOI 10.1038/emboj.2013.212; Youssef G, 2014, MODERN PATHOL, V27, P361, DOI 10.1038/modpathol.2013.129	58	46	46	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5155	5169		10.1038/onc.2016.47	http://dx.doi.org/10.1038/onc.2016.47			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	26996666	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000384433000007
J	Bharti, R; Dey, G; Ojha, PK; Rajput, S; Jaganathan, SK; Sen, R; Mandal, M				Bharti, R.; Dey, G.; Ojha, P. K.; Rajput, S.; Jaganathan, S. K.; Sen, R.; Mandal, M.			Diacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancer	ONCOGENE			English	Article							MULTIPLE-MYELOMA; PROSTATE-CANCER; CELL-SURVIVAL; INTERLEUKIN-6; PATHWAY; STAT3; IL-6; GP130; PHOSPHORYLATION; GROWTH	Interleukin-6 (IL-6) signaling network has been implicated in oncogenic transformations making it attractive target for the discovery of novel cancer therapeutics. In this study, potent antiproliferative and apoptotic effect of diacerein were observed against breast cancer. In vitro apoptosis was induced by this drug in breast cancer cells as verified by increased sub-G(1) population, LIVE/DEAD assay, cell cytotoxicity and presence of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells, as well as downregulation of antiapoptotic proteins Bcl-2 and Bcl-xL and upregulation of apoptotic protein Bax. In addition, apoptosis induction was found to be caspase dependent. Further molecular investigations indicated that diacerein instigated apoptosis was associated with inhibition of IL-6/IL-6R autocrine signaling axis. Suppression of STAT3, MAPK and Akt pathways were also observed as a consequence of diacerein-mediated upstream inhibition of IL-6/IL-6R. Fluorescence study and western blot analysis revealed cytosolic accumulation of STAT3 in diacerein-treated cells. The docking study showed diacerein/IL-6R interaction that was further validated by competitive binding assay and isothermal titration calorimetry. Most interestingly, it was found that diacerein considerably suppressed tumor growth in MDA-MB-231 xenograft model. The in vivo antitumor effect was correlated with decreased proliferation (Ki-67), increased apoptosis (TUNEL) and inhibition of IL-6/IL-6R-mediated STAT3, MAPK and Akt pathway in tumor remnants. Taken together, diacerein offered a novel blueprint for cancer therapy by hampering IL-6/IL-6R/STAT3/MAPK/Akt network.	[Bharti, R.; Dey, G.; Rajput, S.; Mandal, M.] Indian Inst Technol Kharagpur, Sch Med Sci & Technol, Kharagpur 721302, W Bengal, India; [Ojha, P. K.] Jadavpur Univ, Dept Pharmaceut Technol, Div Med & Pharmaceut Chem, Drug Theoret & Cheminformat Lab, Kolkata, India; [Jaganathan, S. K.] Univ Teknol, Fac Biosci & Med Engn, IJN UTM Cardiovasc Engn Ctr, Skudai, Johor, Malaysia; [Sen, R.] Indian Inst Technol Kharagpur, Dept Biotechnol, Kharagpur, W Bengal, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kharagpur; Jadavpur University; Universiti Teknologi Malaysia; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kharagpur	Mandal, M (corresponding author), Indian Inst Technol Kharagpur, Sch Med Sci & Technol, Kharagpur 721302, W Bengal, India.	mahitosh@smst.iitkgp.ernet.in	JAIN, SHASHI/N-8877-2017; jain, shashi/AAF-4706-2020; Mandal, Mahitosh/Q-7421-2016; Sen, Ramkrishna/C-8772-2014; Mandal, Mahitosh/GMW-6195-2022; Jaganathan, Saravana Kumar/N-2385-2017	JAIN, SHASHI/0000-0001-9428-0135; jain, shashi/0000-0001-9428-0135; Mandal, Mahitosh/0000-0003-3861-3323; Sen, Ramkrishna/0000-0002-6207-3307; Mandal, Mahitosh/0000-0003-3861-3323; Jaganathan, Saravana Kumar/0000-0002-2785-137X; Dey, Goutam/0000-0002-8210-3219; OJHA, PROBIR KUMAR/0000-0003-4796-3915; Bharti, Rashmi/0000-0002-7612-7695	MHRD; CSIR; MoES, India [MoES/16/48/09/RDEAS]	MHRD; CSIR(Council of Scientific & Industrial Research (CSIR) - India); MoES, India	We thank MHRD, CSIR and MoES, India (Grant No: MoES/16/48/09/RDEAS; Date: 15-07-2010).	Andersen JL, 2014, ACTA CRYSTALLOGR D, V70, P451, DOI 10.1107/S1399004713030149; Ara T, 2010, EUR J CANCER, V46, P1223, DOI 10.1016/j.ejca.2010.02.026; Ataie-Kachoie P, 2013, CYTOKINE GROWTH F R, V24, P163, DOI 10.1016/j.cytogfr.2012.09.001; Berishaj M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1680; Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Brinkmann K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.61; Calisto KL, 2012, CRIT CARE, V16, DOI 10.1186/cc11478; Cavarretta IT, 2007, ONCOGENE, V26, P2822, DOI 10.1038/sj.onc.1210097; Chakravarti N, 2006, INT J CANCER, V119, P1268, DOI 10.1002/ijc.21967; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Conze D, 2001, CANCER RES, V61, P8851; Culig Z, 2011, BBA-MOL CELL RES, V1813, P308, DOI 10.1016/j.bbamcr.2010.12.010; Das Subhasis, 2012, J Exp Ther Oncol, V10, P139; Dey G, 2015, SCI REP-UK, V5, DOI 10.1038/srep10316; Dolled-Filhart M, 2003, CLIN CANCER RES, V9, P594; Gadotti VM, 2012, PHARMACOL BIOCHEM BE, V102, P549, DOI 10.1016/j.pbb.2012.06.018; Ghofrani HA, 2006, NAT REV DRUG DISCOV, V5, P689, DOI 10.1038/nrd2030; Gibson RM, 2000, J BIOL CHEM, V275, P22574, DOI 10.1074/jbc.M907658199; Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007; Hideshima T, 2001, BLOOD, V98, p639a; Johnson Christopher, 2012, Transl Gastrointest Cancer, V1, P58; Jones SA, 2011, J CLIN INVEST, V121, P3375, DOI 10.1172/JCI57158; Kamran MZ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/421821; Liu Y, 2011, CANCER PREV RES, V4, P1296, DOI 10.1158/1940-6207.CAPR-10-0317; Liu Y, 2010, J BIOL CHEM, V285, P27429, DOI 10.1074/jbc.M110.142752; Liu YX, 2009, MOL PHARMACOL, V76, P91, DOI 10.1124/mol.109.056085; Lu ZM, 2006, IUBMB LIFE, V58, P621, DOI 10.1080/15216540600957438; Mahata D, 2014, INT J BIOL MACROMOL, V69, P5, DOI 10.1016/j.ijbiomac.2014.05.017; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Michaud-Levesque J, 2012, EXP CELL RES, V318, P925, DOI 10.1016/j.yexcr.2012.02.017; Palumbo A, 2008, BLOOD, V111, P3968, DOI 10.1182/blood-2007-10-117457; Plotnikov A, 2011, BBA-MOL CELL RES, V1813, P1619, DOI 10.1016/j.bbamcr.2010.12.012; Pooja S, 2012, CYTOKINE, V60, P122, DOI 10.1016/j.cyto.2012.06.241; Puthier D, 1999, BRIT J HAEMATOL, V107, P392, DOI 10.1046/j.1365-2141.1999.01705.x; Rajput S, 2013, LIFE SCI, V93, P783, DOI 10.1016/j.lfs.2013.09.009; Rajput S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061342; Rawlings JS, 2004, J CELL SCI, V117, P1281, DOI 10.1242/jcs.00963; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; Rose-John S, 2002, TRENDS BIOTECHNOL, V20, P417, DOI 10.1016/S0167-7799(02)02056-5; Sachdev JC, 2012, CLIN BREAST CANCER, V12, P19, DOI 10.1016/j.clbc.2011.07.001; Sarkar S, 2011, J CELL PHYSIOL, V226, P375, DOI 10.1002/jcp.22343; Sethi G, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-66; Shariat SF, 2011, J UROLOGY, V186, P2107, DOI 10.1016/j.juro.2011.06.048; Silver JS, 2010, J LEUKOCYTE BIOL, V88, P1145, DOI 10.1189/jlb.0410217; Su JL, 2005, CANCER RES, V65, P4827, DOI 10.1158/0008-5472.CAN-05-0188; Varghese JN, 2002, P NATL ACAD SCI USA, V99, P15959, DOI 10.1073/pnas.232432399; Venkatesan P, 2011, BIOMATERIALS, V32, P3794, DOI 10.1016/j.biomaterials.2011.01.027; Venkatesan SK, 2010, J COMPUT CHEM, V31, P2463, DOI 10.1002/jcc.21538; Voorhees PM, 2007, CLIN CANCER RES, V13, P6469, DOI 10.1158/1078-0432.CCR-07-1293; Witsch E, 2010, PHYSIOLOGY, V25, P85, DOI 10.1152/physiol.00045.2009; Yosifov DY, 2012, LEUKEMIA RES, V36, P764, DOI 10.1016/j.leukres.2012.02.016	52	46	47	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3965	3975		10.1038/onc.2015.466	http://dx.doi.org/10.1038/onc.2015.466			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26616855				2022-12-17	WOS:000381013100008
J	Sartorius, CA; Hanna, CT; Gril, B; Cruz, H; Serkova, NJ; Huber, KM; Kabos, P; Schedin, TB; Borges, VF; Steeg, PS; Cittelly, DM				Sartorius, C. A.; Hanna, C. T.; Gril, B.; Cruz, H.; Serkova, N. J.; Huber, K. M.; Kabos, P.; Schedin, T. B.; Borges, V. F.; Steeg, P. S.; Cittelly, D. M.			Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism	ONCOGENE			English	Article							RECEPTOR-ALPHA; AROMATASE EXPRESSION; PROGNOSTIC-FACTORS; TUMOR-GROWTH; SURVIVAL; S100A4; BETA; INVASION; ANGIOGENESIS; CARCINOMA	Brain metastases (BM) are a devastating consequence of breast cancer. BM occur more frequently in patients with estrogen receptor-negative (ER-) breast cancer subtypes; HER2 overexpressing (HER2+) tumors and triple-negative (TN) (ER-, progesterone receptor-negative (PR-) and normal HER2) tumors. Young age is an independent risk factor for the development of BM, thus we speculated that higher circulating estrogens in young, pre-menopausal women could exert paracrine effects through the highly estrogen-responsive brain microenvironment. Using a TN experimental metastases model, we demonstrate that ovariectomy decreased the frequency of magnetic resonance imaging-detectable lesions by 56% as compared with estrogen supplementation, and that the combination of ovariectomy and letrozole further reduced the frequency of large lesions to 14.4% of the estrogen control. Human BM expressed 4.2-48.4% ER+ stromal area, particularly ER+ astrocytes. In vitro, E2-treated astrocytes increased proliferation, migration and invasion of 231BR-EGFP cells in an ER-dependent manner. E2 upregulated epidermal growth factor receptor (EGFR) ligands Egf, Ereg and Tgfa mRNA and protein levels in astrocytes, and activated EGFR in brain metastatic cells. Co-culture of 231BR-EGFP cells with E2-treated astrocytes led to the upregulation of the metastatic mediator S100 Calcium-binding protein A4 (S100A4) (1.78-fold, P < 0.05). Exogenous EGF increased S100A4 mRNA levels in 231BR-EGFP cells (1.40 +/- 0.02-fold, P < 0.01 compared with vehicle control) and an EGFR/HER2 inhibitor blocked this effect, suggesting that S100A4 is a downstream effector of EGFR activation. Short hairpin RNA-mediated S100A4 silencing in 231BR-EGFP cells decreased their migration and invasion in response to E2-CM, abolished their increased proliferation in co-cultures with E2-treated astrocytes and decreased brain metastatic colonization. Thus, S100A4 is one effector of the paracrine action of E2 in brain metastatic cells. These studies provide a novel mechanism by which estrogens, acting through ER+ astrocytes in the brain microenvironment, can promote BM of TN breast cancers, and suggests existing endocrine agents may provide some clinical benefit towards reducing and managing BM.	[Sartorius, C. A.; Hanna, C. T.; Cruz, H.; Cittelly, D. M.] Univ Colorado Denver, Dept Pathol, Anschutz Med Campus, Aurora, CO 80045 USA; [Gril, B.; Steeg, P. S.] NCI, Womens Malignancies Branch, Bethesda, MD 20892 USA; [Serkova, N. J.; Huber, K. M.] Univ Colorado Denver, Dept Anesthesiol, Anschutz Med, Aurora, CO 80045 USA; [Kabos, P.; Schedin, T. B.; Borges, V. F.] Univ Colorado Denver, Div Med Oncol, Dept Med, Anschutz Med Campus, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Cittelly, DM (corresponding author), Univ Colorado Denver, Dept Pathol, Anschutz Med Campus,12801 E 17th Ave MS8104, Aurora, CO 80045 USA.	Diana.Cittelly@ucdenver.edu		Cittelly, Diana/0000-0002-8392-0800	NCI [P30CA046934, K22CA181250]; CTSA Center grant [UL1TR001082]; DOD BCRP [W81XWH-11-1-0101]; ACS IRG [57-001-53]; NIH [R01 CA140985]; NATIONAL CANCER INSTITUTE [K08CA164048, K22CA181250, ZIABC010538, R01CA140985, P30CA046934] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048520] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CTSA Center grant; DOD BCRP(United States Department of Defense); ACS IRG(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank the University of Colorado Cancer Center Animal Imaging Shared Resources, Tissue Culture Core, Cytometry and Cell Sorting Shared Resource and Functional Genomics Facility supported by NCI P30CA046934 and CTSA UL1TR001082 Center grants. Susan Edgerton provided de-identified tissue. This work was supported by DOD BCRP W81XWH-11-1-0101 (DMC), ACS IRG # 57-001-53 (DMC) and NCI K22CA181250 (DMC). CAS was supported by NIH R01 CA140985.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Arnold S, 2005, NEUROBIOL DIS, V20, P82, DOI 10.1016/j.nbd.2005.02.002; Arnold S, 2012, J STEROID BIOCHEM, V131, P2, DOI 10.1016/j.jsbmb.2012.01.012; Azcoitia I, 2010, EUR J NEUROSCI, V32, P1995, DOI 10.1111/j.1460-9568.2010.07516.x; Barouk S, 2011, ENDOCRINOLOGY, V152, P1745, DOI 10.1210/en.2010-1290; BOOGERD W, 1993, J NEURO-ONCOL, V15, P165, DOI 10.1007/BF01053937; Braccini AL, 2013, BREAST, V22, P993, DOI 10.1016/j.breast.2013.05.011; Brufsky AM, 2011, CLIN CANCER RES, V17, P4834, DOI 10.1158/1078-0432.CCR-10-2962; Cheng X, 2007, CANCER METAST REV, V26, P635, DOI 10.1007/s10555-007-9083-x; Dahlmann M, 2012, ONCOTARGET, V3, P783, DOI 10.18632/oncotarget.572; Dhandapani KM, 2005, ENDOCRINOLOGY, V146, P2749, DOI 10.1210/en.2005-0014; Evans AJ, 2004, CLIN ONCOL-UK, V16, P345, DOI 10.1016/j.clon.2004.03.012; Fidler IJ, 2011, SEMIN CANCER BIOL, V21, P107, DOI 10.1016/j.semcancer.2010.12.009; Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094; Frey L, 2014, NEUROL RES, V36, P26, DOI 10.1179/1743132813Y.0000000269; Garcia-Ovejero D, 2002, J COMP NEUROL, V450, P256, DOI 10.1002/cne.10325; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Garcia-Segura LM, 1999, NEUROSCIENCE, V89, P567, DOI 10.1016/S0306-4522(98)00340-6; GARCIASEGURA LM, 1989, DEV BRAIN RES, V47, P298, DOI 10.1016/0165-3806(89)90186-7; Gril B, 2008, JNCI-J NATL CANCER I, V100, P1092, DOI 10.1093/jnci/djn216; Gril B, 2013, AM J PATHOL, V182, P2368, DOI 10.1016/j.ajpath.2013.02.043; Hicks DG, 2006, AM J SURG PATHOL, V30, P1097; Hung MH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089389; Iyer V, 2012, CANCER RES, V72, P2705, DOI 10.1158/0008-5472.CAN-11-3287; Jenkinson SR, 2004, BRIT J CANCER, V90, P253, DOI 10.1038/sj.bjc.6601483; Kaal EC, 2005, LANCET NEUROL, V4, P289, DOI 10.1016/S1474-4422(05)70072-7; Kim SJ, 2011, NEOPLASIA, V13, P286, DOI 10.1593/neo.11112; Kodack DP, 2015, CANCER CELL, V27, P163, DOI 10.1016/j.ccell.2015.01.001; Lee E, 2012, GLIA, V60, P1024, DOI 10.1002/glia.22329; Lee SS, 2008, BREAST CANCER RES TR, V111, P523, DOI 10.1007/s10549-007-9806-2; LEE YTNM, 1983, J SURG ONCOL, V23, P175, DOI 10.1002/jso.2930230311; Lin NU, 2012, CANCER-AM CANCER SOC, V118, P5463, DOI 10.1002/cncr.27581; Lin NU, 2004, J CLIN ONCOL, V22, P3608, DOI 10.1200/JCO.2004.01.175; MA YJ, 1994, J NEUROSCI, V14, P5644; Montelli S, 2012, BRAIN RES, V1475, P11, DOI 10.1016/j.brainres.2012.08.010; Morissette M, 2008, J STEROID BIOCHEM, V108, P327, DOI 10.1016/j.jsbmb.2007.09.011; Neman J, 2013, CLIN EXP METASTAS, V30, P753, DOI 10.1007/s10585-013-9576-7; OSBORNE CK, 1985, CANCER RES, V45, P584; Palmieri D, 2007, CANCER RES, V67, P4190, DOI 10.1158/0008-5472.CAN-06-3316; Pequeux C, 2012, CANCER RES, V72, P3010, DOI 10.1158/0008-5472.CAN-11-3768; Pettersson K, 2001, ANNU REV PHYSIOL, V63, P165, DOI 10.1146/annurev.physiol.63.1.165; Razmara A, 2008, J PHARMACOL EXP THER, V325, P782, DOI 10.1124/jpet.107.134072; Saleem M, 2006, P NATL ACAD SCI USA, V103, P14825, DOI 10.1073/pnas.0606747103; Stanczyk FZ, 2015, STEROIDS, V99, P91, DOI 10.1016/j.steroids.2014.12.011; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Tham YL, 2006, CANCER, V107, P696, DOI 10.1002/cncr.22041; TSUKADA Y, 1983, CANCER-AM CANCER SOC, V52, P2349, DOI 10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; Wang L, 2012, ACTA BIOCHIM POL, V59, P593; Wang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080933; Wu P, 2002, NAT NEUROSCI, V5, P1271, DOI 10.1038/nn974; Yague JG, 2006, NEUROSCIENCE, V138, P389, DOI 10.1016/j.neuroscience.2005.11.054; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486	54	46	47	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2881	2892		10.1038/onc.2015.353	http://dx.doi.org/10.1038/onc.2015.353			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26411365	Green Accepted			2022-12-17	WOS:000377473700008
J	O'Leary, L; van der Sloot, AM; Reis, CR; Deegan, S; Ryan, AE; Dhami, SPS; Murillo, LS; Cool, RH; de Sampaio, PC; Thompson, K; Murphy, G; Quax, WJ; Serrano, L; Samali, A; Szegezdi, E				O'Leary, L.; van der Sloot, A. M.; Reis, C. R.; Deegan, S.; Ryan, A. E.; Dhami, S. P. S.; Murillo, L. S.; Cool, R. H.; de Sampaio, P. Correa; Thompson, K.; Murphy, G.; Quax, W. J.; Serrano, L.; Samali, A.; Szegezdi, E.			Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity	ONCOGENE			English	Article							INDUCED APOPTOSIS; DEATH; EXPRESSION; SIGNALS; FADD	Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a death ligand cytokine known for its cytotoxic activity against malignantly transformed cells. TRAIL induces cell death through binding to death receptors DR4 and DR5. The inhibitory decoy receptors (DcR1 and DcR2) co-expressed with death receptor 4 (DR4)/DR5 on the same cell can block the transmission of the apoptotic signal. Here, we show that DcRs also regulate TRAIL sensitivity at a supracellular level and thus represent a mechanism by which the microenvironment can diminish tumour TRAIL sensitivity. Mathematical modelling and layered or spheroid stroma-extracellular matrix-tumour cultures were used to model the tumour microenvironment. By engineering TRAIL to escape binding by DcRs, we found that DcRs do not only act in a cell-autonomous or cis-regulatory manner, but also exert trans-cellular regulation originating from stromal cells and affect tumour cells, highlighting the potent inhibitory effect of DcRs in the tumour tissue and the necessity of selective targeting of the two death-inducing TRAIL receptors to maximise efficacy.	[O'Leary, L.; Deegan, S.; Dhami, S. P. S.; Samali, A.; Szegezdi, E.] Natl Univ Ireland, Apoptosis Res Ctr, Galway, Ireland; [van der Sloot, A. M.; Serrano, L.] CRG, EMBL CRG Syst Biol Res Unit, Barcelona, Spain; [van der Sloot, A. M.] Univ Montreal, Inst Res Immunol & Canc, 2950 Chemin Polytech Pavillon Marcelle Coutu, Montreal, PQ, Canada; [Reis, C. R.; Cool, R. H.; Quax, W. J.] Univ Groningen, Dept Pharmaceut Biol, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands; [Ryan, A. E.] Natl Univ Ireland, Sch Med, Discipline Pharmacol & Therapeut, Galway, Ireland; [Murillo, L. S.] Natl Univ Ireland, Natl Ctr Biomed Engn Sci, Galway, Ireland; [de Sampaio, P. Correa; Murphy, G.] Univ Cambridge, Canc Res UK Cambridge Res Inst, Dept Oncol, Li Ka Shing Ctr, Cambridge, England; [Thompson, K.] Natl Univ Ireland, Ctr Microscopy & Imaging, Galway, Ireland; [O'Leary, L.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England; [Reis, C. R.] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA; [de Sampaio, P. Correa] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Metastasis Res Ctr, Houston, TX 77030 USA	Ollscoil na Gaillimhe-University of Galway; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Universite de Montreal; University of Groningen; Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Ollscoil na Gaillimhe-University of Galway; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center	Samali, A; Szegezdi, E (corresponding author), Natl Univ Ireland, Apoptosis Res Ctr, Discipline Biochem, Univ Rd, Galway, Ireland.	afshin.samali@nuigalway.ie; eva.szegezdi@nuigalway.ie	Szegezdi, Eva/B-7142-2008; Samali, Afshin/A-9571-2008; Ryan, Aideen/H-3909-2019; Quax, Wim/K-2802-2012; Deegan, Shane/P-4793-2017; Quax, Wim/O-2875-2019; Serrano, Luis/B-3355-2013; Dhami, Sukhraj Pal Singh/AFP-2634-2022; van der Sloot, Almer/M-7083-2015	Szegezdi, Eva/0000-0002-5708-3535; Samali, Afshin/0000-0002-8610-8375; Ryan, Aideen/0000-0002-5831-6783; Quax, Wim/0000-0002-5162-9947; Deegan, Shane/0000-0001-8824-9617; Quax, Wim/0000-0002-5162-9947; Serrano, Luis/0000-0002-5276-1392; Dhami, Sukhraj Pal Singh/0000-0003-1326-9845; Thompson, Kerry/0000-0003-2721-8977; Cool, Robbert/0000-0002-9845-2202; van der Sloot, Almer/0000-0003-0049-2044; Correa de Sampaio, Pedro/0000-0001-5597-2825	Enterprise Ireland; National Development Plan of Ireland; Commercialisation Fund [CFTD/06/112]; SFI SIRG award [09/SIRG/B1575]; NUIG	Enterprise Ireland; National Development Plan of Ireland; Commercialisation Fund; SFI SIRG award; NUIG	Financial Support: The project was funded by Enterprise Ireland, National Development Plan of Ireland, Commercialisation Fund to AS and ES (CFTD/06/112), SFI SIRG award to ES (09/SIRG/B1575) and Millennium Grant to ES from the NUIG.	Allen JE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004828; Ander M., 2004, Systems Biology, V1, P129, DOI 10.1049/sb:20045017; Anees M, 2011, CANCER-AM CANCER SOC, V117, P1172, DOI 10.1002/cncr.25504; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boland K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.250; Chamuleau MED, 2011, LEUKEMIA RES, V35, P741, DOI 10.1016/j.leukres.2010.12.032; Clancy L, 2005, P NATL ACAD SCI USA, V102, P18099, DOI 10.1073/pnas.0507329102; Cullen SP, 2013, MOL CELL, V49, P1034, DOI 10.1016/j.molcel.2013.01.025; de Sampaio PC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030753; Dublanche Y, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100081; Dyer MJS, 2007, J CLIN ONCOL, V25, P4505, DOI 10.1200/JCO.2007.13.1011; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Finnberg N, 2008, J CLIN INVEST, V118, P111, DOI 10.1172/JCI29900; Furth PA, 1997, APOPTOSIS, V2, P19, DOI 10.1023/A:1026454207398; Ganten TM, 2009, J MOL MED, V87, P995, DOI 10.1007/s00109-009-0510-z; Ivanov VN, 2014, APOPTOSIS, V19, P399, DOI 10.1007/s10495-013-0925-4; Kim KL, 2005, AM J RESP CELL MOL, V33, P541, DOI 10.1165/rcmb.2004-0355OC; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Koksal IT, 2008, UROL ONCOL-SEMIN ORI, V26, P158, DOI 10.1016/j.urolonc.2007.01.022; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lemke J, 2014, CELL DEATH DIFFER, V21, P1350, DOI 10.1038/cdd.2014.81; Luce A, 2009, CARCINOGENESIS, V30, P432, DOI 10.1093/carcin/bgp008; Mahalingam D, 2010, BRIT J CANCER, V102, P754, DOI 10.1038/sj.bjc.6605545; Mahalingam D, 2009, CANCER TREAT REV, V35, P280, DOI 10.1016/j.ctrv.2008.11.006; Merino D, 2006, MOL CELL BIOL, V26, P7046, DOI 10.1128/MCB.00520-06; Milo R, 2010, NUCLEIC ACIDS RES, V38, pD750, DOI 10.1093/nar/gkp889; Perez-Garijo A, 2013, ELIFE, V2, DOI 10.7554/eLife.01004; Reis CR, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.61; Riccioni R, 2005, HAEMATOLOGICA, V90, P612; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Sanlioglu AD, 2007, INT J RADIAT ONCOL, V69, P716, DOI 10.1016/j.ijrobp.2007.03.057; Schneider P, 2003, J BIOL CHEM, V278, P5444, DOI 10.1074/jbc.M210783200; Schymkowitz J, 2005, NUCLEIC ACIDS RES, V33, pW382, DOI 10.1093/nar/gki387; Shareef MM, 2007, CANCER RES, V67, P11811, DOI 10.1158/0008-5472.CAN-07-0722; Shirley S, 2011, RECENT PAT ANTI-CANC, V6, P311, DOI 10.2174/157489211796957757; Szegezdi E, 2012, MOL CELL PROTEOMICS, P11; Szegezdi E, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.013730; Szegezdi E, 2011, J CELL MOL MED, V15, P2216, DOI 10.1111/j.1582-4934.2010.01211.x; Tur V, 2008, J BIOL CHEM, V283, P20560, DOI 10.1074/jbc.M800457200; Van der Sloot AM, 2006, P NATL ACAD SCI USA, V103, P8634, DOI 10.1073/pnas.0510187103; van Dijk M, 2013, CELL DEATH DIS, P4; Wang QD, 2002, J BIOL CHEM, V277, P36602, DOI 10.1074/jbc.M206306200; Wilson NS, 2012, CANCER CELL, V22, P80, DOI 10.1016/j.ccr.2012.05.014; Wu GS, 1999, CANCER RES, V59, P2770; Zhang XD, 1999, CANCER RES, V59, P2747	46	46	48	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1261	1270		10.1038/onc.2015.180	http://dx.doi.org/10.1038/onc.2015.180			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26050621	Green Published			2022-12-17	WOS:000371763100006
J	Potze, L; Di Franco, S; Grandela, C; Pras-Raves, ML; Picavet, DI; van Veen, HA; van Lenthe, H; Mullauer, FB; van der Wel, NN; Luyf, A; van Kampen, AHC; Kemp, S; Everts, V; Kessler, JH; Vaz, FM; Medema, JP				Potze, L.; Di Franco, S.; Grandela, C.; Pras-Raves, M. L.; Picavet, D. I.; van Veen, H. A.; van Lenthe, H.; Mullauer, F. B.; van der Wel, N. N.; Luyf, A.; van Kampen, A. H. C.; Kemp, S.; Everts, V.; Kessler, J. H.; Vaz, F. M.; Medema, J. P.			Betulinic acid induces a novel cell death pathway that depends on cardiolipin modification	ONCOGENE			English	Article							STEAROYL-COA DESATURASE; CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; GENE-EXPRESSION CHANGES; ATP CITRATE LYASE; CANCER-CELLS; FATTY-ACIDS; MASS-SPECTROMETRY; PROSTATE-CANCER; BARTH SYNDROME	Cancer is associated with strong changes in lipid metabolism. For instance, normal cells take up fatty acids (FAs) from the circulation, while tumour cells generate their own and become dependent on de novo FA synthesis, which could provide a vulnerability to target tumour cells. Betulinic acid (BetA) is a natural compound that selectively kills tumour cells through an ill-defined mechanism that is independent of BAX and BAK, but depends on mitochondrial permeability transition-pore opening. Here we unravel this pathway and show that BetA inhibits the activity of steroyl-CoA-desaturase (SCD-1). This enzyme is overexpressed in tumour cells and critically important for cells that utilize de novo FA synthesis as it converts newly synthesized saturated FAs to unsaturated FAs. Intriguingly, we find that inhibition of SCD-1 by BetA or, alternatively, with a specific SCD-1 inhibitor directly and rapidly impacts on the saturation level of cardiolipin (CL), a mitochondrial lipid that has important structural and metabolic functions and at the same time regulates mitochondria-dependent cell death. As a result of the enhanced CL saturation mitochondria of cancer cells, but not normal cells that do not depend on de novo FA synthesis, undergo ultrastructural changes, release cytochrome c and quickly induce cell death. Importantly, addition of unsaturated FAs circumvented the need for SCD-1 activity and thereby prevented BetA-induced CL saturation and subsequent cytotoxicity, supporting the importance of this novel pathway in the cytotoxicity induced by BetA.	[Potze, L.; Di Franco, S.; Grandela, C.; Mullauer, F. B.; Kessler, J. H.; Medema, J. P.] Univ Amsterdam, Acad Med Ctr, Ctr Expt & Mol Med, Lab Expt Oncol & radiobiol LEXOR, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [Di Franco, S.] Univ Palermo, Cellular & Mol Pathophysiol Lab, Dept Surg & Oncol Sci, Palermo, Italy; [Pras-Raves, M. L.; Luyf, A.; van Kampen, A. H. C.] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, Bioinformat Lab, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [Picavet, D. I.; van Veen, H. A.; van der Wel, N. N.; Everts, V.] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, Core Facil Cellular Imaging, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [van Lenthe, H.; Kemp, S.; Vaz, F. M.] Univ Amsterdam, Acad Med Ctr, Dept Clin Chem, Lab Genet Metab Dis, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; University of Palermo; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Medema, JP (corresponding author), Univ Amsterdam, Acad Med Ctr, Ctr Expt & Mol Med, Lab Expt Oncol & radiobiol LEXOR, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.p.medema@amc.uva.nl	di franco, simone/M-3714-2019; Di Franco, Simone/J-4874-2016; Van Der Wel, Nicole/AAE-7569-2020; Di Franco, Simone/AAD-4391-2019; Kemp, Stephan/A-3935-2008	di franco, simone/0000-0002-6217-2161; Di Franco, Simone/0000-0002-6217-2161; Kemp, Stephan/0000-0003-2023-064X; Vaz, Frederic/0000-0002-9048-1041; Medema, Jan Paul/0000-0003-3045-2924	Stichting Nationaal Fonds tegen Kanker (SNFK), Amsterdam, The Netherlands	Stichting Nationaal Fonds tegen Kanker (SNFK), Amsterdam, The Netherlands(Netherlands Government)	We thank Inge Dijkstra, Rob Ofman, Femke Beers-Stet for technical assistance and Louis Vermeulen for his valuable scientific input and helpful discussions. This work was supported by a grant of the Stichting Nationaal Fonds tegen Kanker (SNFK), Amsterdam, The Netherlands (LP).	Acehan D, 2011, BIOPHYS J, V100, P2184, DOI 10.1016/j.bpj.2011.03.031; Alavian KN, 2014, P NATL ACAD SCI USA, V111, P10580, DOI 10.1073/pnas.1401591111; BARTH PG, 1983, J NEUROL SCI, V62, P327, DOI 10.1016/0022-510X(83)90209-5; Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; BOUGNOUX P, 1992, BREAST CANCER RES TR, V20, P185; Clarke SLN, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-23; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DeBerardinis RJ, 2012, CELL, V148, P1132, DOI 10.1016/j.cell.2012.02.032; Engelen M, 2008, BBA-MOL CELL BIOL L, V1781, P105, DOI 10.1016/j.bbalip.2007.12.003; Fritz V, 2010, MOL CANCER THER, V9, P1740, DOI 10.1158/1535-7163.MCT-09-1064; FRY M, 1981, J BIOL CHEM, V256, P1874; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 1998, CANCER RES, V58, P4453; Gonzalvez F, 2007, APOPTOSIS, V12, P877, DOI 10.1007/s10495-007-0718-8; Gonzalvez F, 2008, J CELL BIOL, V183, P681, DOI 10.1083/jcb.200803129; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Houtkooper RH, 2008, CELL MOL LIFE SCI, V65, P2493, DOI 10.1007/s00018-008-8030-5; Houtkooper RH, 2009, ANAL BIOCHEM, V387, P230, DOI 10.1016/j.ab.2009.01.032; Huttemann M, 2011, MITOCHONDRION, V11, P369, DOI 10.1016/j.mito.2011.01.010; Igal RA, 2010, CARCINOGENESIS, V31, P1509, DOI 10.1093/carcin/bgq131; Jourdain A, 2009, INT J BIOCHEM CELL B, V41, P1884, DOI 10.1016/j.biocel.2009.05.001; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kessler JH, 2007, CANCER LETT, V251, P132, DOI 10.1016/j.canlet.2006.11.003; Kiebish MA, 2008, J LIPID RES, V49, P2545, DOI 10.1194/jlr.M800319-JLR200; Kumar-Sinha C, 2003, CANCER RES, V63, P132; Landes T, 2011, BBA-MOL CELL RES, V1813, P540, DOI 10.1016/j.bbamcr.2011.01.021; LI J, 1994, INT J CANCER, V57, P348, DOI 10.1002/ijc.2910570310; Li JN, 2000, EXP CELL RES, V261, P159, DOI 10.1006/excr.2000.5054; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Lu JX, 1997, MOL CARCINOGEN, V20, P204, DOI 10.1002/(SICI)1098-2744(199710)20:2<204::AID-MC7>3.0.CO;2-M; Martinou JC, 2006, CELL DEATH DIFFER, V13, P1291, DOI 10.1038/sj.cdd.4401985; MEDES G, 1953, CANCER RES, V13, P27; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Morgan-Lappe SE, 2007, CANCER RES, V67, P4390, DOI 10.1158/0008-5472.CAN-06-4132; Mullauer FB, 2011, ANTI-CANCER DRUG, V22, P223, DOI 10.1097/CAD.0b013e3283421035; Mullauer FB, 2010, ANTI-CANCER DRUG, V21, P215, DOI 10.1097/CAD.0b013e3283357c62; Mullauer FB, 2009, APOPTOSIS, V14, P191, DOI 10.1007/s10495-008-0290-x; Nogueira V, 2013, CLIN CANCER RES, V19, P4309, DOI 10.1158/1078-0432.CCR-12-1424; OOKHTENS M, 1984, AM J PHYSIOL, V247, pR146, DOI 10.1152/ajpregu.1984.247.1.R146; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Paradies G, 2014, BBA-BIOENERGETICS, V1837, P408, DOI 10.1016/j.bbabio.2013.10.006; Patil VA, 2013, ADV EXP MED BIOL, V991, P195, DOI 10.1007/978-94-007-6331-9_11; Paton CM, 2009, AM J PHYSIOL-ENDOC M, V297, pE28, DOI 10.1152/ajpendo.90897.2008; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Pellegrini L, 2007, CELL DEATH DIFFER, V14, P1275, DOI 10.1038/sj.cdd.4402145; Potze L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.139; Ren MD, 2014, PROG LIPID RES, V55, P1, DOI 10.1016/j.plipres.2014.04.001; Roongta UV, 2011, MOL CANCER RES, V9, P1551, DOI 10.1158/1541-7786.MCR-11-0126; RUGGIERI S, 1979, J LIPID RES, V20, P772; Rzeski W, 2006, N-S ARCH PHARMACOL, V374, P11, DOI 10.1007/s00210-006-0090-1; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Scaglia N, 2005, J BIOL CHEM, V280, P25339, DOI 10.1074/jbc.M501159200; Scaglia N, 2005, BBA-MOL CELL BIOL L, V1687, P141, DOI 10.1016/j.bbalip.2004.11.015; Scaglia N, 2008, INT J ONCOL, V33, P839, DOI 10.3892/ijo_00000072; Scaglia N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006812; Schug ZT, 2009, BBA-BIOMEMBRANES, V1788, P2022, DOI 10.1016/j.bbamem.2009.05.004; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Swinnen JV, 2000, INT J CANCER, V88, P176, DOI 10.1002/1097-0215(20001015)88:2<176::AID-IJC5>3.0.CO;2-3; Thai SF, 2001, CARCINOGENESIS, V22, P1317, DOI 10.1093/carcin/22.8.1317; Tuominen EKJ, 2002, J BIOL CHEM, V277, P8822, DOI 10.1074/jbc.M200056200; Valianpour F, 2003, MOL GENET METAB, V79, P189, DOI 10.1016/S1096-7192(03)00098-2; WARBURG O, 1956, SCIENCE, V124, P269; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Waterhouse NJ, 2003, CELL DEATH DIFFER, V10, P853, DOI 10.1038/sj.cdd.4401263; Yahagi N, 2005, EUR J CANCER, V41, P1316, DOI 10.1016/j.ejca.2004.12.037; Zhang TJ, 2013, BBA-MOL CELL BIOL L, V1831, P1542, DOI 10.1016/j.bbalip.2013.03.001; Zuco V, 2002, CANCER LETT, V175, P17, DOI 10.1016/S0304-3835(01)00718-2	70	46	46	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					427	437		10.1038/onc.2015.102	http://dx.doi.org/10.1038/onc.2015.102			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25893306				2022-12-17	WOS:000369056700003
J	Cao, LL; Wei, F; Du, Y; Song, B; Wang, D; Shen, C; Lu, X; Cao, Z; Yang, Q; Gao, Y; Wang, L; Zhao, Y; Wang, H; Yang, Y; Zhu, WG				Cao, L-L; Wei, F.; Du, Y.; Song, B.; Wang, D.; Shen, C.; Lu, X.; Cao, Z.; Yang, Q.; Gao, Y.; Wang, L.; Zhao, Y.; Wang, H.; Yang, Y.; Zhu, W-G			ATM-mediated KDM2A phosphorylation is required for the DNA damage repair	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; MRE11-RAD50-NBS1 COMPLEX; HOMOLOGOUS RECOMBINATION; HISTONE DEMETHYLASE; CELLULAR-RESPONSE; MRE11 COMPLEX; METHYLATION; PROTEIN; CHECKPOINT; PROMOTES	The ataxia-telangiectasia mutated (ATM) protein is a key signaling molecule that modulates the DNA damage response. However, the exact mechanism by which ATM regulates DNA damage repair has not yet been elucidated. Here, we report that ATM regulates the DNA damage response by phosphorylating lysine-specific demethylase 2A (KDM2A), a histone demethylase that acts at sites of H3K36 dimethylation. ATM interacts with KDM2A, and their interaction significantly increases in response to DNA double-stranded, but not single-stranded, breaks. ATM specifically phosphorylates KDM2A at threonine 632 (T632) following DNA damage, as demonstrated by a mutagenesis assay and mass spectrometric analysis. Although KDM2A phosphorylation does not alter its own demethylase activity, T632 phosphorylation of KDM2A largely abrogates its chromatin-binding capacity, and H3K36 dimethylation near DNA damage sites is significantly increased. Consequently, enriched H3K36 dimethylation serves as a platform to recruit the MRE11 complex to DNA damage sites by directly interacting with the BRCT2 domain of NBS1, which results in efficient DNA damage repair and enhanced cell survival. Collectively, our study reveals a novel mechanism for ATM in connecting histone modifications with the DNA damage response.	[Cao, L-L; Wei, F.; Du, Y.; Song, B.; Wang, D.; Shen, C.; Lu, X.; Cao, Z.; Yang, Q.; Wang, L.; Zhao, Y.; Wang, H.; Yang, Y.; Zhu, W-G] Peking Univ, Hlth Sci Ctr,Dept Biochem & Mol Biol,Sch Basic Me, Key Lab Carcinogenesis & Translat Res Minist Educ, State Key Lab Nat & Biomimet Drugs,Beijing Key La, Beijing 100871, Peoples R China; [Gao, Y.] Tsinghua Univ, Sch Biol Sci, Prot Chem Facil, Beijing 100084, Peoples R China; [Zhu, W-G] Peking Univ Tsinghua Univ Joint Ctr Life Sci, Beijing, Peoples R China	Peking University; Tsinghua University; Tsinghua University	Zhu, WG (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Xueyuan Rd 38, Beijing 100191, Peoples R China.	zhuweiguo@bjmu.edu.cn	Du, Yipeng/O-1223-2013	Lu, Xiaopeng/0000-0001-7746-5322; Wang, Haiying/0000-0001-7729-0649; Zhu, Wei-Guo/0000-0001-8385-6581	National Key Basic Research Program of China [2011CB504200, 2013CB911000]; National Natural Science Foundation of China [31070691, 81321003, 91319302]; Minister of Education of China '111 Project'	National Key Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Minister of Education of China '111 Project'	We thank Dr David J Chen at University of Texas Southwestern Medical Center for kindly providing YFP-ATM plasmid. We also thank Drs Jun Huang at Zhejiang University and Jiadong Wang at Peking University Health Science Center for kindly providing NBS1 deleted mutants. This work was supported by National Key Basic Research Program of China grant 2011CB504200, 2013CB911000; National Natural Science Foundation of China grants 31070691, 81321003, 91319302; Minister of Education of China '111 Project'.	Aymard F, 2014, NAT STRUCT MOL BIOL, V21, P366, DOI 10.1038/nsmb.2796; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Blackledge NP, 2010, MOL CELL, V38, P179, DOI 10.1016/j.molcel.2010.04.009; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Butler LR, 2012, EMBO J, V31, P3918, DOI 10.1038/emboj.2012.232; Cadet J, 2005, MUTAT RES-FUND MOL M, V571, P3, DOI 10.1016/j.mrfmmm.2004.09.012; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Cheng ZJ, 2014, GENE DEV, V28, P1758, DOI 10.1101/gad.246561.114; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Fnu S, 2011, P NATL ACAD SCI USA, V108, P540, DOI 10.1073/pnas.1013571108; Frescas D, 2008, CELL CYCLE, V7, P3539, DOI 10.4161/cc.7.22.7062; Guo CY, 1999, J BIOL CHEM, V274, P18715, DOI 10.1074/jbc.274.26.18715; Haince JF, 2008, J BIOL CHEM, V283, P1197, DOI 10.1074/jbc.M706734200; Hari FJ, 2010, EMBO REP, V11, P387, DOI 10.1038/embor.2010.30; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Huang YF, 2015, TUMOR BIOL, V36, P271, DOI 10.1007/s13277-014-2630-5; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Iwase S, 2007, CELL, V128, P1077, DOI 10.1016/j.cell.2007.02.017; Jha DK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4965; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khoury-Haddad H, 2014, P NATL ACAD SCI USA, V111, pE728, DOI 10.1073/pnas.1317585111; Kim GD, 1999, J BIOL CHEM, V274, P31127, DOI 10.1074/jbc.274.44.31127; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; Kozlov SV, 2006, EMBO J, V25, P3504, DOI 10.1038/sj.emboj.7601231; Lan F, 2007, NATURE, V448, P718, DOI 10.1038/nature06034; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Li F, 2013, CELL, V153, P590, DOI 10.1016/j.cell.2013.03.025; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Liang CY, 2013, MOL BIOL CELL, V24, P3251, DOI 10.1091/mbc.E12-11-0820; Liang CY, 2011, NUCLEIC ACIDS RES, V39, P4151, DOI 10.1093/nar/gkr040; Lisby M, 2004, CURR OPIN CELL BIOL, V16, P328, DOI 10.1016/j.ceb.2004.03.011; Lloyd J, 2009, CELL, V139, P100, DOI 10.1016/j.cell.2009.07.043; Lu T, 2010, P NATL ACAD SCI USA, V107, P46, DOI 10.1073/pnas.0912493107; Lu T, 2009, P NATL ACAD SCI USA, V106, P16339, DOI 10.1073/pnas.0908560106; Mallette FA, 2012, EMBO J, V31, P1865, DOI 10.1038/emboj.2012.47; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Musselman CA, 2011, NUCLEIC ACIDS RES, V39, P9061, DOI 10.1093/nar/gkr613; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Pei HD, 2011, NATURE, V470, P124, DOI 10.1038/nature09658; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Pfister SX, 2014, CELL REP, V7, P2006, DOI 10.1016/j.celrep.2014.05.026; Rass E, 2009, NAT STRUCT MOL BIOL, V16, P819, DOI 10.1038/nsmb.1641; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2013, NAT REV MOL CELL BIO, V14, P197, DOI 10.1038/nrm3546; So SR, 2009, J CELL BIOL, V187, P977, DOI 10.1083/jcb.200906064; Stracker TH, 2011, NAT REV MOL CELL BIO, V12, P90, DOI 10.1038/nrm3047; Tanaka Y, 2010, EMBO J, V29, P1510, DOI 10.1038/emboj.2010.56; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Wagner EJ, 2012, NAT REV MOL CELL BIO, V13, P115, DOI 10.1038/nrm3274; Wagner KW, 2013, J CLIN INVEST, V123, P5231, DOI 10.1172/JCI68642; Wang DL, 2013, P NATL ACAD SCI USA, V110, P5516, DOI 10.1073/pnas.1216596110; Wang HY, 2012, DNA REPAIR, V11, P146, DOI 10.1016/j.dnarep.2011.10.014; Wang QH, 2014, EMBO J, V33, P862, DOI 10.1002/embj.201386064; WOZNIAK AJ, 1983, CANCER RES, V43, P120; Wu LM, 2008, P NATL ACAD SCI USA, V105, P11200, DOI 10.1073/pnas.0802885105; Xie AY, 2009, NAT STRUCT MOL BIOL, V16, P814, DOI 10.1038/nsmb.1640; Xu C, 2008, J MOL BIOL, V381, P361, DOI 10.1016/j.jmb.2008.05.087; Young LC, 2013, J BIOL CHEM, V288, P21376, DOI 10.1074/jbc.M113.491514; Zhou JC, 2012, MOL CELL BIOL, V32, P479, DOI 10.1128/MCB.06332-11; Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200	65	46	49	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					301	313		10.1038/onc.2015.81	http://dx.doi.org/10.1038/onc.2015.81			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25823024	Bronze			2022-12-17	WOS:000369055300004
J	Chung, H; Lee, YS; Mayoral, R; Oh, DY; Siu, JT; Webster, NJ; Sears, DD; Olefsky, JM; Ellies, LG				Chung, H.; Lee, Y. S.; Mayoral, R.; Oh, D. Y.; Siu, J. T.; Webster, N. J.; Sears, D. D.; Olefsky, J. M.; Ellies, L. G.			Omega-3 fatty acids reduce obesity-induced tumor progression independent of GPR120 in a mouse model of postmenopausal breast cancer	ONCOGENE			English	Article							POLYUNSATURATED FATTY-ACIDS; INSULIN-RESISTANCE; INFLAMMATION; RISK; RECEPTOR; METABOLISM; PREVENTION; OMEGA-6; FISH	Obesity and inflammation are both risk factors for a variety of cancers, including breast cancer in postmenopausal women. Intake of omega-3 polyunsaturated fatty acids (omega-3 PUFAs) decreases the risk of breast cancer, and also reduces obesity-associated inflammation and insulin resistance, but whether the two effects are related is currently unknown. We tested this hypothesis in a postmenopausal breast cancer model using ovariectomized, immune-competent female mice orthotopically injected with Py230 mammary tumor cells. Obesity, whether triggered genetically or by high-fat diet (HFD) feeding, increased inflammation in the mammary fat pad and promoted mammary tumorigenesis. The presence of tumor cells in the mammary fat pad further enhanced the local inflammatory milieu. Tumor necrosis factor-alpha (TNF-alpha) was the most highly upregulated cytokine in the obese mammary fat pad, and we observed that TNF-alpha dose-dependently stimulated Py230 cell growth in vitro. An omega-3 PUFA-enriched HFD (referred to as fish oil diet, FOD) reduced inflammation in the obese mammary fat pad in the absence of tumor cells and inhibited Py230 tumor growth in vivo. Although some anti-inflammatory effects of omega-3 PUFAs were previously shown to be mediated by the G-protein-coupled receptor 120 (GPR120), the FOD reduced Py230 tumor burden in GPR120-deficient mice to a similar degree as observed in wild-type mice, indicating that the effect of FOD to reduce tumor growth does not require GPR120 in the host mouse. Instead, in vitro studies demonstrated that omega-3 PUFAs act directly on tumor cells to activate c-Jun N-terminal kinase, inhibit proliferation and induce apoptosis. Our results show that obesity promotes mammary tumor progression in this model of postmenopausal breast cancer and that omega-3 PUFAs, independent of GPR120, inhibit mammary tumor progression in obese mice.	[Chung, H.; Lee, Y. S.; Mayoral, R.; Oh, D. Y.; Webster, N. J.; Sears, D. D.; Olefsky, J. M.] Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; [Mayoral, R.] Biomed Network Ctr Study Hepat & Digest Dis CIBER, Madrid, Spain; [Siu, J. T.; Ellies, L. G.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Webster, N. J.; Sears, D. D.; Olefsky, J. M.; Ellies, L. G.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Webster, N. J.] San Diego VA Healthcare Syst, San Diego, CA USA	University of California System; University of California San Diego; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Ellies, LG (corresponding author), Univ Calif San Diego, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	lellies@ucsd.edu	Sears, Dorothy D/AHE-5524-2022; Mayoral Monibas, Rafael/B-3563-2013; Lee, Yun Sok/ABC-9195-2021; Lee, Yun Sok/B-3265-2015; Webster, Nick/AAI-8410-2021	Sears, Dorothy D/0000-0002-9260-3540; Mayoral Monibas, Rafael/0000-0002-6645-7172; Lee, Yun Sok/0000-0001-7967-4734; Lee, Yun Sok/0000-0001-7967-4734; 	National Institutes of Health [U54 CA155435, P30 CA23100, P30 DK063491, K22 CA118182]; Department of Defense [BC102147]; Doris Howell Foundation Scholarship; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P50HD012303] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA023100, U54CA155435, K22CA118182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK063491, R01DK101395, P01DK074868] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000130] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Doris Howell Foundation Scholarship; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	We thank Dr Robert Cardiff for reviewing histologic sections of tumors and Hang Ha and Jonathan Hasselmann for assistance with animal maintenance. We thank the UCSD Histology Core lab for technical assistance with processing the tumor samples. The study was funded in part by the National Institutes of Health grants U54 CA155435, P30 CA23100, P30 DK063491 (JMO), K22 CA118182 (LGE), the Department of Defense grant BC102147 (JMO) and a Doris Howell Foundation Scholarship (JTS).	Biswas T, 2014, CANCER LETT, V346, P129, DOI 10.1016/j.canlet.2013.12.018; Calviello G, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/743171; Cui LF, 2008, HISTOPATHOLOGY, V53, P381, DOI 10.1111/j.1365-2559.2008.03128.x; de Lorgeril M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-50; Fares H, 2014, CURR ATHEROSCLER REP, V16, DOI 10.1007/s11883-013-0389-6; Golabek T, 2014, UROL INT, V92, P7, DOI 10.1159/000351325; Handgraaf S, 2013, DIABETES, V62, P4098, DOI 10.2337/db13-0282; Healy LA, 2010, CLIN ONCOL-UK, V22, P281, DOI 10.1016/j.clon.2010.02.001; Iyengar NM, 2013, CURR BREAST CANCER R, V5, P247, DOI 10.1007/s12609-013-0112-1; Jing KP, 2013, ANTI-CANCER AGENT ME, V13, P1162, DOI 10.2174/18715206113139990319; Kang KS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010296; Khaw KT, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4518; Kolodecik T, 2014, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00415; Li PP, 2010, J BIOL CHEM, V285, P15333, DOI 10.1074/jbc.M110.100263; Ligibel Jennifer A, 2013, Am Soc Clin Oncol Educ Book, P52, DOI 10.1200/EdBook_AM.2013.33.52; Maccio A, 2011, THESCIENTIFICWORLDJO, V11, P2020, DOI 10.1100/2011/806787; MacLennan MB, 2013, J NUTR BIOCHEM, V24, P388, DOI 10.1016/j.jnutbio.2012.08.002; Manni A, 2014, INT J CANCER, V134, P1549, DOI 10.1002/ijc.28490; Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041; Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846; Parada B, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/368178; Patterson RE, 2013, J ACAD NUTR DIET, V113, P288, DOI 10.1016/j.jand.2012.08.015; Ramos-Nino Maria E, 2013, ISRN Oncol, V2013, P697521, DOI 10.1155/2013/697521; Rose DP, 2009, EXPERT REV ANTICANC, V9, P1091, DOI 10.1586/ERA.09.71; Sczaniecka AK, 2012, NUTR CANCER, V64, P1131, DOI 10.1080/01635581.2012.718033; Seki E, 2012, GASTROENTEROLOGY, V143, P307, DOI 10.1053/j.gastro.2012.06.004; SheenChen SM, 1997, BREAST CANCER RES TR, V43, P211, DOI 10.1023/A:1005736712307; Signori C, 2011, CANCER RES, V71, P6091, DOI 10.1158/0008-5472.CAN-11-0977; Simopoulos AP, 2010, EXP BIOL MED, V235, P785, DOI 10.1258/ebm.2010.009298; Simpson ER, 2013, MOL ENDOCRINOL, V27, P715, DOI 10.1210/me.2013-1011; Subbaramaiah K, 2011, CANCER PREV RES, V4, P329, DOI 10.1158/1940-6207.CAPR-10-0381; Sundaram Sneha, 2013, J Carcinog, V12, P19, DOI 10.4103/1477-3163.119606; van Kruijsdijk RCM, 2009, CANCER EPIDEM BIOMAR, V18, P2569, DOI 10.1158/1055-9965.EPI-09-0372; Wong SW, 2009, J BIOL CHEM, V284, P27384, DOI 10.1074/jbc.M109.044065; Wu Q, 2013, ONCOGENE, V32, P5541, DOI 10.1038/onc.2013.264; Xue ML, 2014, J NUTR BIOCHEM, V25, P104, DOI 10.1016/j.jnutbio.2013.09.008; Zheng JS, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3706	37	46	48	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3504	3513		10.1038/onc.2014.283	http://dx.doi.org/10.1038/onc.2014.283			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25220417	Green Submitted, Green Accepted			2022-12-17	WOS:000357434900003
J	Mathsyaraja, H; Thies, K; Taffany, DA; Deighan, C; Liu, T; Yu, L; Fernandez, SA; Shapiro, C; Otero, J; Timmers, C; Lustberg, MB; Chalmers, J; Leone, G; Ostrowski, MC				Mathsyaraja, H.; Thies, K.; Taffany, D. A.; Deighan, C.; Liu, T.; Yu, L.; Fernandez, S. A.; Shapiro, C.; Otero, J.; Timmers, C.; Lustberg, M. B.; Chalmers, J.; Leone, G.; Ostrowski, M. C.			CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth	ONCOGENE			English	Article							BREAST-CANCER; IN-VIVO; IMMUNE-RESPONSE; MACROPHAGES; INHIBITION; DIFFERENTIATION; POLARIZATION; ANGIOGENESIS; ACTIVATION; EXPRESSION	Metastasis of solid tumors is associated with poor prognosis and bleak survival rates. Tumor-infiltrating myeloid cells (TIMs) are known to promote metastasis, but the mechanisms underlying their collaboration with tumor cells remain unknown. Here, we report an oncogenic role for microRNA (miR) in driving M2 reprogramming in TIMs, characterized by the acquisition of pro-tumor and pro-angiogenic properties. The expression of miR-21, miR-29a, miR-142-3p and miR-223 increased in myeloid cells during tumor progression in mouse models of breast cancer and melanoma metastasis. Further, we show that these miRs are regulated by the CSF1-ETS2 pathway in macrophages. A loss-of-function approach utilizing selective depletion of the miR-processing enzyme Dicer in mature myeloid cells blocks angiogenesis and metastatic tumor growth. Ectopic expression of miR-21 and miR-29a promotes angiogenesis and tumor cell proliferation through the downregulation of anti-angiogenic genes such as Col4a2, Spry1 and Timp3, whereas knockdown of the miRs impedes these processes. miR-21 and miR-29a are expressed in Csf1r+ myeloid cells associated with human metastatic breast cancer, and levels of these miRs in CD115+ non-classical monocytes correlates with metastatic tumor burden in patients. Taken together, our results suggest that miR-21 and miR-29a are essential for the pro-tumor functions of myeloid cells and the CSF1-ETS2 pathway upstream of the miRs serves as an attractive therapeutic target for the inhibition of M2 remodeling of macrophages during malignancy. In addition, miR-21 and miR-29a in circulating myeloid cells may potentially serve as biomarkers to measure therapeutic efficacy of targeted therapies for CSF1 signaling.	[Mathsyaraja, H.; Thies, K.; Taffany, D. A.; Ostrowski, M. C.] Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; [Mathsyaraja, H.; Thies, K.; Taffany, D. A.; Liu, T.; Shapiro, C.; Otero, J.; Timmers, C.; Lustberg, M. B.; Chalmers, J.; Leone, G.; Ostrowski, M. C.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Deighan, C.; Chalmers, J.] Ohio State Univ, Dept Chem Engn, Columbus, OH 43210 USA; [Yu, L.; Fernandez, S. A.] Ohio State Univ, Dept Biomed Informat, Ctr Biostat, Columbus, OH 43210 USA; [Shapiro, C.; Lustberg, M. B.] Ohio State Univ, Coll Med, Dept Internal Med, Columbus, OH 43210 USA; [Otero, J.] Ohio State Univ, Coll Med, Dept Pathol, Columbus, OH 43210 USA; [Leone, G.] Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Leone, G.] Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Ostrowski, MC (corresponding author), Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Tumor Microenvironm Program, 598 Biomed Res Tower,460W 12th Ave, Columbus, OH 43210 USA.	michael.ostrowski@osumc.edu	Otero, Jose Javier/B-8955-2013; yu, lianbo/B-3472-2010; Otero, Jose/AAI-4891-2020; Ostrowski, Michael/H-3108-2011	Otero, Jose/0000-0003-0680-4520; Ostrowski, Michael/0000-0003-2948-6297	National Institutes of Health [NIHPO1CA097189, RO1CA053271]; Evelyn Simmers Foundation; NATIONAL CANCER INSTITUTE [P30CA016058, P01CA097189, R01CA053271] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Evelyn Simmers Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Yongqi Wu for help with flow cytometry. We also wish to acknowledge the histology core, OSU Comprehensive Cancer Center Microarray, Nucleic Acids, Analytical Cytometry, Microscopy and Biostatistics Core Shared Resources for technical assistance. This work was funded through National Institutes of Health grants (NIHPO1CA097189 and RO1CA053271) and the Evelyn Simmers Foundation to MCO.	Brain O, 2013, IMMUNITY, V39, P521, DOI 10.1016/j.immuni.2013.08.035; BROCKER EB, 1987, CANCER IMMUNOL IMMUN, V25, P81; Chen PW, 2011, CLIN CANCER RES, V17, P7230, DOI 10.1158/1078-0432.CCR-11-1354; Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025; Cho HJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3195; Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Conway JG, 2005, P NATL ACAD SCI USA, V102, P16078, DOI 10.1073/pnas.0502000102; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; DUNHAM LJ, 1953, JNCI-J NATL CANCER I, V13, P1299; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; FIDLER IJ, 1975, CANCER RES, V35, P218; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gao D, 2009, TRENDS MOL MED, V15, P333, DOI 10.1016/j.molmed.2009.06.006; Gebeshuber CA, 2009, EMBO REP, V10, P400, DOI 10.1038/embor.2009.9; Hu R, 2007, MOL CELL BIOL, V27, P4018, DOI 10.1128/MCB.01839-06; Jensen TO, 2009, J CLIN ONCOL, V27, P3330, DOI 10.1200/JCO.2008.19.9919; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Lamagna C, 2006, J LEUKOCYTE BIOL, V80, P705, DOI 10.1189/jlb.1105656; Leek RD, 2002, J MAMMARY GLAND BIOL, V7, P177, DOI 10.1023/A:1020304003704; Liu G, 2013, ARTERIOSCL THROM VAS, V33, P170, DOI 10.1161/ATVBAHA.112.300068; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu TX, 2011, J IMMUNOL, V187, P3362, DOI 10.4049/jimmunol.1101235; Ma F, 2011, NAT IMMUNOL, V12, P861, DOI 10.1038/ni.2073; Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945-053X(01)00151-2; Mok S, 2014, CANCER RES, V74, P153, DOI 10.1158/0008-5472.CAN-13-1816; Mossadegh-Keller N, 2013, NATURE, V497, P239, DOI 10.1038/nature12026; O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708; Pei XF, 2004, IN VITRO CELL DEV-AN, V40, P14; Priceman SJ, 2010, BLOOD, V115, P1461, DOI 10.1182/blood-2009-08-237412; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Qian BZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006562; Rae F, 2007, DEV BIOL, V308, P232, DOI 10.1016/j.ydbio.2007.05.027; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Squadrito ML, 2012, CELL REPORTS, V1, P141, DOI 10.1016/j.celrep.2011.12.005; Strauss-Ayali D, 2007, J LEUKOCYTE BIOL, V82, P244, DOI 10.1189/jlb.0307191; Tagliani E, 2011, J EXP MED, V208, P1901, DOI 10.1084/jem.20110866; Wang T, 2012, PIGM CELL MELANOMA R, V25, P493, DOI 10.1111/j.1755-148X.2012.01005.x; Wei G, 2004, J IMMUNOL, V173, P1374, DOI 10.4049/jimmunol.173.2.1374; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315; Yan HH, 2010, CANCER RES, V70, P6139, DOI 10.1158/0008-5472.CAN-10-0706; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808; Yang M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-117; Zabuawala T, 2010, CANCER RES, V70, P1323, DOI 10.1158/0008-5472.CAN-09-1474; Zaidi MR, 2011, NATURE, V469, P548, DOI 10.1038/nature09666; Zonari E, 2013, BLOOD, V122, P243, DOI 10.1182/blood-2012-08-449306	58	46	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3651	3661		10.1038/onc.2014.294	http://dx.doi.org/10.1038/onc.2014.294			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25241894	Green Accepted			2022-12-17	WOS:000357679100004
J	Sausgruber, N; Coissieux, MM; Britschgi, A; Wyckoff, J; Aceto, N; Leroy, C; Stadler, MB; Voshol, H; Bonenfant, D; Bentires-Alj, M				Sausgruber, N.; Coissieux, M-M; Britschgi, A.; Wyckoff, J.; Aceto, N.; Leroy, C.; Stadler, M. B.; Voshol, H.; Bonenfant, D.; Bentires-Alj, M.			Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases	ONCOGENE			English	Article							FOCAL ADHESION KINASE; GROWTH-FACTOR; IN-VIVO; C-SRC; MIGRATION; PAXILLIN; PHOSPHORYLATION; METASTASIS; TUMORS; DEPHOSPHORYLATION	Tumor cell migration has a fundamental role in early steps of metastasis, the fatal hallmark of cancer. In the present study, we investigated the effects of the tyrosine phosphatase, SRC-homology 2 domain-containing phosphatase 2 (SHP2), on cell migration in metastatic triple-negative breast cancer (TNBC), an aggressive disease associated with a poor prognosis for which a targeted therapy is not yet available. Using mouse models and multiphoton intravital imaging, we have identified a crucial effect of SHP2 on TNBC cell motility in vivo. Further, analysis of TNBC cells revealed that SHP2 also influences cell migration, chemotaxis and invasion in vitro. Unbiased phosphoproteomics and biochemical analysis showed that SHP2 activates several SRC-family kinases and downstream targets, most of which are inducers of migration and invasion. In particular, direct interaction between SHP2 and c-SRC was revealed by a fluorescence resonance energy transfer assay. These results suggest that SHP2 is a crucial factor during early steps of TNBC migration to distant organs.	[Sausgruber, N.; Coissieux, M-M; Britschgi, A.; Wyckoff, J.; Aceto, N.; Leroy, C.; Stadler, M. B.; Bentires-Alj, M.] Friedrich Miescher Inst FMI Biomed Res, Mechanisms Canc, CH-4058 Basel, Switzerland; [Wyckoff, J.] MIT, Koch Inst Integrated Canc Res, Cambridge, MA 02139 USA; [Aceto, N.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA; [Leroy, C.; Voshol, H.; Bonenfant, D.] Novartis Inst Biomed Res, Analyt Sci & Imaging, Basel, Switzerland; [Stadler, M. B.] Swiss Inst Bioinformat, Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Massachusetts General Hospital; Novartis; Swiss Institute of Bioinformatics	Bentires-Alj, M (corresponding author), Friedrich Miescher Inst FMI Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	bentires@fmi.ch	Mohamed, Bentires-Alj/F-4484-2015; Aceto, Nicola/O-2484-2014	Mohamed, Bentires-Alj/0000-0001-6344-1127; Coissieux, Marie-May/0000-0001-5017-5253; Aceto, Nicola/0000-0001-9579-6918	FP7 Marie-Curie Fellowship; Novartis Research Foundation; European Research Council (ERC starting grant) [243211-PTPsBDC]; Swiss Cancer League; Krebsliga Beider Basel	FP7 Marie-Curie Fellowship; Novartis Research Foundation; European Research Council (ERC starting grant)(European Research Council (ERC)); Swiss Cancer League; Krebsliga Beider Basel	We thank C Kuperwasser for the SUM159 cells and S Gambhir for the pFU-Luc2-eGFP construct, L Bonapace for technical assistance with the intravital microscope, L Gelman for help with the FRET experiments, S Bourke and M Kirschmann for help with image acquisition and analysis, and I Klebba and H Brinkhaus for technical assistance. M-MC is supported by a FP7 Marie-Curie Fellowship and NA is a fellow of the Swiss National Science Foundation and the Human Frontiers Science Program. Research in the laboratory of MB-A is supported by the Novartis Research Foundation, the European Research Council (ERC starting grant 243211-PTPsBDC), the Swiss Cancer League and the Krebsliga Beider Basel.	Aceto N, 2012, NAT MED, V18, P529, DOI 10.1038/nm.2645; Bonapace L, 2012, J MAMMARY GLAND BIOL, V17, P125, DOI 10.1007/s10911-012-9250-8; Britschgi A, 2012, CANCER CELL, V22, P796, DOI 10.1016/j.ccr.2012.10.023; Dey JH, 2010, CANCER RES, V70, P4151, DOI 10.1158/0008-5472.CAN-09-4479; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Hartman ZR, 2013, MOL CANCER RES, V11, P651, DOI 10.1158/1541-7786.MCR-12-0578; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Iwasaki T, 2002, INT J CANCER, V97, P330, DOI 10.1002/ijc.1609; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107; Manes S, 1999, MOL CELL BIOL, V19, P3125; Meijering E, 2012, METHOD ENZYMOL, V504, P183, DOI 10.1016/B978-0-12-391857-4.00009-4; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Nakamura K, 2000, J BIOL CHEM, V275, P27155; Patsialou A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3344; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; PENG ZY, 1995, ONCOGENE, V11, P1955; Perou CM, 2010, ONCOLOGIST, V15, P39, DOI 10.1634/theoncologist.2010-S5-39; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Sachdev S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-12; Sanders MA, 2005, J BIOL CHEM, V280, P23516, DOI 10.1074/jbc.M413165200; Schober M, 2007, J CELL BIOL, V176, P667, DOI 10.1083/jcb.200608010; Wang FM, 2005, BREAST CANCER RES TR, V89, P5, DOI 10.1007/s10549-004-1002-z; Wang WG, 2002, CANCER RES, V62, P6278; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zomer A, 2011, CLIN TRANSL ONCOL, V13, P848, DOI 10.1007/s12094-011-0745-3	29	46	46	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2272	2278		10.1038/onc.2014.170	http://dx.doi.org/10.1038/onc.2014.170			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24931162				2022-12-17	WOS:000353473000012
J	Wang, J; Mikse, O; Liao, RG; Li, Y; Tan, L; Janne, PA; Gray, NS; Wong, KK; Hammerman, PS				Wang, J.; Mikse, O.; Liao, R. G.; Li, Y.; Tan, L.; Janne, P. A.; Gray, N. S.; Wong, K-k; Hammerman, P. S.			Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR RECEPTOR-3; SENSITIVE FGFR2; BREAST-CANCER; GENE FUSIONS; LUNG-CANCER; MUTATIONS; IDENTIFICATION; PROGRESSION; NVP-BGJ398	Somatic alterations of fibroblast growth factor receptors (FGFRs) have been described in a wide range of malignancies. A number of anti-FGFR therapies are currently under investigation in clinical trials for subjects with FGFR gene amplifications, mutations and translocations. Here, we develop cell line models of acquired resistance to FGFR inhibition by exposure of cell lines harboring FGFR3 gene amplification and translocation to the selective FGFR inhibitor BGJ398 and multitargeted FGFR inhibitor ponatinib. We show that the acquisition of resistance is rapid, reversible and characterized by an epithelial to mesenchymal transition and a switch from dependency on FGFR3 to ERBB family members. Acquired resistance was associated with demonstrable changes in gene expression including increased production of ERBB2/3 ligands, which were sufficient to drive resistance in the setting of FGFR3 dependency but not dependency on other FGFR family members. These data support the concept that activation of ERBB family members is sufficient to bypass dependency on FGFR3 and suggest that concurrent inhibition of these two pathways may be desirable when targeting FGFR3-dependent cancers.	[Wang, J.; Mikse, O.; Liao, R. G.; Li, Y.; Janne, P. A.; Wong, K-k; Hammerman, P. S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Wang, J.] Fudan Univ, Shanghai Med Coll, Dept Integrat Med & Neurobiol, Shanghai 200433, Peoples R China; [Liao, R. G.; Li, Y.; Hammerman, P. S.] Broad Inst Harvard & MIT, Cambridge, MA USA; [Tan, L.; Gray, N. S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Janne, P. A.; Wong, K-k] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Fudan University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Hammerman, PS (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Dana 810A, Boston, MA 02215 USA.	phammerman@partners.org		Tan, Li/0000-0002-1199-9046; Liao, Rachel/0000-0002-7830-1976	NCI [K08 CA163677]; V Foundation the Stephen D; Alice Cutler Fund; NSFC [81202746]; CSC; NATIONAL CANCER INSTITUTE [R01CA140594, R01CA166480, K08CA163677, P01CA154303] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); V Foundation the Stephen D; Alice Cutler Fund; NSFC(National Natural Science Foundation of China (NSFC)); CSC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	PSH is supported by NCI K08 CA163677, the V Foundation the Stephen D and Alice Cutler Fund. We thank M Meyerson for assisting with the planning of this study. JW is supported by NSFC 81202746 and CSC.	Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780; Andre F, 2013, CLIN CANCER RES, V19, P3693, DOI 10.1158/1078-0432.CCR-13-0190; Barr S, 2008, CLIN EXP METASTAS, V25, P685, DOI 10.1007/s10585-007-9121-7; Bublil EM, 2007, CURR OPIN CELL BIOL, V19, P124, DOI 10.1016/j.ceb.2007.02.008; Chell V, 2013, ONCOGENE, V32, P3059, DOI 10.1038/onc.2012.319; Cheng T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057284; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Courjal F, 1997, CANCER RES, V57, P4360; Dieci MV, 2013, CANCER DISCOV, V3, P264, DOI 10.1158/2159-8290.CD-12-0362; Dutt A, 2008, P NATL ACAD SCI USA, V105, P8713, DOI 10.1073/pnas.0803379105; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012; Guagnano V, 2012, CANCER DISCOV, V2, P1118, DOI 10.1158/2159-8290.CD-12-0210; Guagnano V, 2011, J MED CHEM, V54, P7066, DOI 10.1021/jm2006222; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harbinski F, 2012, CANCER DISCOV, V2, P948, DOI 10.1158/2159-8290.CD-12-0237; Herrera-Abreu MT, 2013, CANCER DISCOV, V3, P1058, DOI 10.1158/2159-8290.CD-12-0569; Jenndahl LE, 2005, INT J ONCOL, V27, P439; Katoh M, 2014, MED RES REV, V34, P280, DOI 10.1002/med.21288; Kim J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-383; Kunii K, 2008, CANCER RES, V68, P2340, DOI 10.1158/0008-5472.CAN-07-5229; Lamont FR, 2011, BRIT J CANCER, V104, P75, DOI 10.1038/sj.bjc.6606016; Lemieux S, 2013, ANTI-CANCER AGENT ME, V13, P748, DOI 10.2174/18715206113139990080; Liao RG, 2013, CANCER RES, V73, P5195, DOI 10.1158/0008-5472.CAN-12-3950; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Majewski IJ, 2013, J PATHOL, V230, P270, DOI 10.1002/path.4209; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Montero-Conde C, 2013, CANCER DISCOV, V3, P520, DOI 10.1158/2159-8290.CD-12-0531; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shien K, 2013, CANCER RES, V73, P3051, DOI 10.1158/0008-5472.CAN-12-4136; Singh D, 2012, SCIENCE, V337, P1231, DOI 10.1126/science.1220834; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; van Rhijn BWG, 2002, EUR J HUM GENET, V10, P819, DOI 10.1038/sj.ejhg.5200883; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Williams SV, 2013, HUM MOL GENET, V22, P795, DOI 10.1093/hmg/dds486; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Winter SF, 2007, ONCOGENE, V26, P4897, DOI 10.1038/sj.onc.1210288; Wolf J, 2012, CANC RES, V72; Wu YM, 2013, CANCER DISCOV, V3, P636, DOI 10.1158/2159-8290.CD-13-0050; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	46	46	60	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2167	2177		10.1038/onc.2014.161	http://dx.doi.org/10.1038/onc.2014.161			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24909170	Green Accepted			2022-12-17	WOS:000353473000003
J	Gong, C; Qu, S; Liu, B; Pan, S; Jiao, Y; Nie, Y; Su, F; Liu, Q; Song, E				Gong, C.; Qu, S.; Liu, B.; Pan, S.; Jiao, Y.; Nie, Y.; Su, F.; Liu, Q.; Song, E.			MiR-106b expression determines the proliferation paradox of TGF-beta in breast cancer cells	ONCOGENE			English	Article						TGF-beta; microRNA; breast cancer; cell proliferation	GROWTH-FACTOR-BETA; MICRORNA CLUSTER; GENE-PRODUCT; PHOSPHORYLATION; INHIBITION; AP-1; PRB	TGF-beta has paradoxical effects on cancer cell proliferation, as it suppresses proliferation of normal epithelial and low-invasive cancer cells, but enhances that of high-invasive cancer cells. However, how cancer cells acquire the ability to evade the tumor-suppressing effects of TGF-beta, yet still take advantage of its tumor-promoting effects, remains elusive. Here, we identified miR-106b as a molecular switch to determine TGF-beta effects on cell proliferation. TGF-beta 1 enhances the transcription of miR-106b via a promoter independent of its host gene MCM7 by activating c-jun. In high-invasive breast cancer cells, miR-106b is upregulated by TGF-beta 1 at a much higher level than that in normal or low-invasive cancer cells. Accumulation of miR-106b counterbalances TGF-beta growth-inhibiting effects by eliminating activated retinoblastoma (RB) and results in enhanced proliferation. Furthermore, miR-106b mediates TGF-beta effects on tumor growth and metastasis in breast cancer xenografts. In addition, miR-106b expression is elevated in higher stage tumors and correlated with tumor progression in breast cancer patients. These findings suggest that high level of miR-106b induced by TGF-beta determines the tumor-promoting effects of TGF-beta in breast cancer.	[Gong, C.; Qu, S.; Pan, S.; Jiao, Y.; Nie, Y.; Su, F.; Liu, Q.; Song, E.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Guangdong, Peoples R China; [Gong, C.; Qu, S.; Liu, B.; Pan, S.; Jiao, Y.; Nie, Y.; Su, F.; Liu, Q.; Song, E.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou 510120, Guangdong, Peoples R China; [Liu, B.; Song, E.] Sun Yat Sen Univ, Sch Life Sci, State Key Lab Biocontrol, Key Lab Gene Engn Minist, Guangzhou 510120, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Liu, Q (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, 107 Yanjiang West Rd, Guangzhou 510120, Guangdong, Peoples R China.	victorlq@hotmail.com; songew@mail.sysu.edu.cn	Liu, Bodu/AAR-9402-2021; Liu, Bodu/G-5222-2016	Liu, Bodu/0000-0003-2097-725X; Liu, Bodu/0000-0003-2097-725X; Liu, Qiang/0000-0002-5451-4862	973 Projects from Ministry of Science and Technology of China [2010CB912800, 2011CB504203]; Natural Science Foundation of China [81230060, 81261140373, 81272893, 81172524, 81372817, 81272894, 81072178]; National S&T Major Special Project on New Drug Innovation of China [2011ZX09102-010-02]; Program for New Century Excellent Talents in University [NCET-12-0565]; Science Foundation of Guangdong Province [S2012030006287, 2012J2200092]; Sun Yat-sen University Training Project [11ykpy28, 11ykzd12]; Translational medicine public platform of Guangdong Province [4202037]; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun-Yat-Sen University [KLB09001]; Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology [[2013]163]	973 Projects from Ministry of Science and Technology of China; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National S&T Major Special Project on New Drug Innovation of China; Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Sun Yat-sen University Training Project; Translational medicine public platform of Guangdong Province; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun-Yat-Sen University; Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology	This work was supported by grants from 973 (2010CB912800, 2011CB504203) Projects from Ministry of Science and Technology of China, the Natural Science Foundation of China (81230060, 81261140373, 81272893, 81172524, 81372817, 81272894, 81072178), National S&T Major Special Project on New Drug Innovation of China (No. 2011ZX09102-010-02), Program for New Century Excellent Talents in University(NCET-12-0565), Science Foundation of Guangdong Province (S2012030006287, 2012J2200092), Sun Yat-sen University Training Project (11ykpy28, 11ykzd12) and Translational medicine public platform of Guangdong Province(4202037), Grant KLB09001 from the Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun-Yat-Sen University,Grant [2013]163 from Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology.	Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Cai KM, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-73; Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458; Fang YJ, 2012, AM J PATHOL, V180, P650, DOI 10.1016/j.ajpath.2011.10.009; Francis SM, 2009, MOL CELL BIOL, V29, P4455, DOI 10.1128/MCB.00473-09; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Herrera RE, 1996, MOL BIOL CELL, V7, P1335, DOI 10.1091/mbc.7.9.1335; Kan T, 2009, GASTROENTEROLOGY, V136, P1689, DOI 10.1053/j.gastro.2009.02.002; Kappelmann M, 2013, ONCOGENE, V32, P2984, DOI 10.1038/onc.2012.307; KIM TA, 1994, J CELL PHYSIOL, V160, P1, DOI 10.1002/jcp.1041600102; Lee MK, 2007, EMBO J, V26, P3957, DOI 10.1038/sj.emboj.7601818; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Singha PK, 2010, CANCER RES, V70, P6377, DOI 10.1158/0008-5472.CAN-10-1180; Smith AL, 2012, ONCOGENE, V31, P5162, DOI 10.1038/onc.2012.11; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; van den Heuvel S, 2008, NAT REV MOL CELL BIO, V9, P713, DOI 10.1038/nrm2469; Wang HL, 2010, BRAIN RES, V1357, P166, DOI 10.1016/j.brainres.2010.08.023; Zhang BX, 2010, GASTROENTEROLOGY, V138, P969, DOI 10.1053/j.gastro.2009.11.004; Zhu F, 2006, CANCER RES, V66, P5729, DOI 10.1158/0008-5472.CAN-05-4466	26	46	49	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					84	93		10.1038/onc.2013.525	http://dx.doi.org/10.1038/onc.2013.525			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24292682				2022-12-17	WOS:000349740100008
J	Rahme, GJ; Israel, MA				Rahme, G. J.; Israel, M. A.			Id4 suppresses MMP2-mediated invasion of glioblastoma-derived cells by direct inactivation of Twist1 function	ONCOGENE			English	Article						Id4; glioma; invasion; MMP2; Twist1; helix-loop-helix	EPITHELIAL-MESENCHYMAL TRANSITION; MATRIX METALLOPROTEINASES; HEPATOCELLULAR-CARCINOMA; PROMOTER METHYLATION; GENE-EXPRESSION; DOWN-REGULATION; IN-VITRO; CANCER; GROWTH; DIFFERENTIATION	Tumor cell invasion is a major contributor to cancer morbidity, and is of particular importance in patients with glioblastoma multiforme (GBM), the highest grade and most aggressive primary brain tumor. Tumor cell invasion and the expression of matrix metalloproteinases (MMPs), which are required for GBM invasion, are enhanced by inhibitor of DNA binding (Id) gene family members, Id1, Id2 and Id3, which can be highly expressed in glioma. Id4 is expressed in GBM at more variable levels than these other family members and we sought to determine its role in invasion. We found, unexpectedly, that invasion was dramatically inhibited in cells expressing Id4 as a result of decreased MMP2, a secreted proteinase key for brain tumor invasion. We demonstrate that Id4 decreased MMP2 expression by a direct inhibitory interaction with Twist1, a basic helix-loop-helix transcription factor known to increase MMP2 expression. Importantly, using data from The Cancer Genome Atlas, we show that Id4 expression correlates with survival of glioblastoma patients and inversely correlates with MMP2 expression. These data suggest that the upregulation of MMP2 resulting from decreased Id4 expression in GBM may contribute to the morbidity and mortality of GBM patients.	[Rahme, G. J.; Israel, M. A.] Geisel Sch Med Dartmouth, Dept Genet, Hanover, NH USA; [Israel, M. A.] Geisel Sch Med Dartmouth, Dept Pediat, Hanover, NH USA; [Rahme, G. J.; Israel, M. A.] Norris Cotton Canc Ctr, Geisel Sch Med Dartmouth, Hanover, NH USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Israel, MA (corresponding author), Norris Cotton Canc Ctr, Geisel Sch Med Dartmouth, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	Mark.A.Israel@dartmouth.edu		Rahme, Gilbert/0000-0001-6060-1279	Hitchcock Foundation; Jordan and Kyra Memorial Foundation; Theodora B. Betz Foundation; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER	Hitchcock Foundation; Jordan and Kyra Memorial Foundation; Theodora B. Betz Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Constance Brinckerhoff for assisting in the development of the project and for providing antibodies to MMP1, 3 and 13. We are grateful for all the Israel Laboratory members for stimulating discussion, especially Dr Zhonghua Zhang for his expert opinions. We thank Dr Constance Brinckerhoff, Dr Zhonghua Zhang, Pranam Chatterjee and Henna Jones for their help on preparing the manuscript. We would like to thank Kenneth A Orndorff from the shared fluorescence imaging core at the Norris Cotton Cancer Center for his expert advice on confocal images. We thank Dr Christopher Dant and Ms Tabatha Richardson at Dartmouth for their editorial advice. This work is supported by the Hitchcock Foundation (GJR), the Jordan and Kyra Memorial Foundation (MAI) and the Theodora B. Betz Foundation (MAI).	Andres-Barquin PJ, 2000, HISTOL HISTOPATHOL, V15, P603, DOI 10.14670/HH-15.603; Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Asirvatharn AJ, 2007, PROSTATE, V67, P1411, DOI 10.1002/pros.20633; Bhat KPL, 2011, GENE DEV, V25, P2594, DOI 10.1101/gad.176800.111; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330; Chan ASW, 2003, ONCOGENE, V22, P6946, DOI 10.1038/sj.onc.1206799; Chen BB, 1997, NUCLEIC ACIDS RES, V25, P423, DOI 10.1093/nar/25.2.423; Chen SS, 2011, BLOOD, V117, P862, DOI 10.1182/blood-2010-05-284638; Choe GY, 2002, CLIN CANCER RES, V8, P2894; Clark I. M., 2001, MATRIX METALLOPROTEI; COMA A, 2010, CIRC FARM, V68, P5; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elias MC, 2005, NEOPLASIA, V7, P824, DOI 10.1593/neo.04352; Fong S, 2003, P NATL ACAD SCI USA, V100, P13543, DOI 10.1073/pnas.2230238100; Forsyth PA, 1999, BRIT J CANCER, V79, P1828, DOI 10.1038/sj.bjc.6690291; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Garcia-Baquero R, 2013, J UROLOGY, V190, P723, DOI 10.1016/j.juro.2013.01.105; Itahana Y, 2003, CANCER RES, V63, P7098; Kappert K, 2009, INT J BIOCHEM CELL B, V41, P1511, DOI 10.1016/j.biocel.2009.01.004; Kargiotis O, 2008, ONCOGENE, V27, P4830, DOI 10.1038/onc.2008.122; Kophengnavong T, 2000, MOL CELL BIOL, V20, P261, DOI 10.1128/MCB.20.1.261-272.2000; Kuzontkoski PM, 2010, ONCOGENE, V29, P3793, DOI 10.1038/onc.2010.147; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Ling YX, 2011, EUR J CANCER PREV, V20, P9, DOI 10.1097/CEJ.0b013e32833ebaa0; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Meng YG, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-75; Mikheeva SA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-194; Murad JM, 2010, J BIOL CHEM, V285, P24164, DOI 10.1074/jbc.M110.128744; Nakamura H, 2000, J BIOL CHEM, V275, P38885, DOI 10.1074/jbc.M003875200; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Niola F, 2013, J CLIN INVEST, V123, P405, DOI 10.1172/JCI63811; Noetzel E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-154; Paolella BR, 2011, STEM CELLS, V29, P1090, DOI 10.1002/stem.660; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Ruzinova MB, 2003, CANCER CELL, V4, P277, DOI 10.1016/S1535-6108(03)00240-X; Sakurai D, 2004, J IMMUNOL, V173, P5801, DOI 10.4049/jimmunol.173.9.5801; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; Sharma P, 2012, CANCER MED-US, V1, P176, DOI 10.1002/cam4.16; Shelton EL, 2008, DEV BIOL, V317, P282, DOI 10.1016/j.ydbio.2008.02.037; Smit MA, 2009, MOL CELL BIOL, V29, P3722, DOI 10.1128/MCB.01164-08; Soroceanu L, 2013, CANCER RES, V73, P1559, DOI 10.1158/0008-5472.CAN-12-1943; Sun T, 2010, HEPATOLOGY, V51, P545, DOI 10.1002/hep.23311; Tatenhorst L, 2005, BRAIN PATHOL, V15, P46; Tsunedomi R, 2008, CLIN CANCER RES, V14, P1025, DOI 10.1158/1078-0432.CCR-07-1116; Umetani N, 2004, CLIN CANCER RES, V10, P7475, DOI 10.1158/1078-0432.CCR-04-0689; Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang Maode, 2003, Brain Tumor Pathol, V20, P65, DOI 10.1007/BF02483449; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521; Zeng WF, 2010, J CANCER, V1, P1; Zhang Y, 2007, J NEUROSCI, V27, P4499, DOI 10.1523/JNEUROSCI.0200-07.2007; Zhao XL, 2011, J CELL MOL MED, V15, P691, DOI 10.1111/j.1582-4934.2010.01052.x	58	46	50	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					53	62		10.1038/onc.2013.531	http://dx.doi.org/10.1038/onc.2013.531			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24413082				2022-12-17	WOS:000349740100005
J	Kim, YR; Kim, IJ; Kang, TW; Choi, C; Kim, KK; Kim, MS; Nam, KI; Jung, C				Kim, Y-R; Kim, I-J; Kang, T. W.; Choi, C.; Kim, K. K.; Kim, M. S.; Nam, K. I.; Jung, C.			HOXB13 downregulates intracellular zinc and increases NF-kappa B signaling to promote prostate cancer metastasis	ONCOGENE			English	Article						HOXB13; metastasis; prostate cancer; zinc; ZnT4	ANDROGEN RECEPTOR GENE; UPTAKE TRANSPORTER; IN-VITRO; EXPRESSION; CELLS; ACTIVATION; SUPPRESSION; ADENOCARCINOMA; PROGRESSION; GROWTH	Characteristically, prostate cancer (PCa) cells exhibit marked decrease in intracellular zinc; however, the mechanism responsible is not clearly understood. HOXB13 is involved in PCa progression and is overexpressed in castration-resistant PCa. DNA microarray analysis of LNCaP Pca cells showed that ZnT zinc output transporters were strikingly upregulated among androgen-independent HOXB13 target genes. Furthermore, exogenous HOXB13 caused intracellular zinc concentrations to fall in PCa cells, stimulated NF-kappa B-mediated signaling by reducing inhibitor of NF-kappa B alpha (I kappa B alpha) and enhanced the nuclear translocation of RelA/p65. Human prostate tumors also exhibited strong inverse correlation between the protein expressions of HOXB13 and I kappa B alpha. Consequently, HOXB13 stimulated PCa cell invasion, and this was inhibited by the suppression of ZnT4. In addition, studies in a PC3 orthotopic mouse model of PCa metastasis showed that HOXB13 is a strong metastatic stimulator. Taken together, these results show that HOXB13 promotes PCa invasion and metastasis by decreasing intracellular zinc levels, thus stimulating NF-kappa B signals, and suggest that HOXB13 acts as a modulator of intracellular zinc levels that promotes the malignant characteristics of PCa.	[Kim, Y-R; Kim, I-J; Nam, K. I.; Jung, C.] Chonnam Natl Univ, Sch Med, Dept Anat, Kwangju 501190, South Korea; [Kang, T. W.] Chonnam Natl Univ, Sch Med, Dept Urol, Kwangju 501190, South Korea; [Choi, C.] Chonnam Natl Univ, Sch Med, Dept Pathol, Kwangju 501190, South Korea; [Kim, K. K.] Chonnam Natl Univ, Sch Med, Dept Pharmacol, Kwangju 501190, South Korea; [Kim, M. S.] Chonnam Natl Univ, Coll Nat Sci, Dept Stat, Kwangju 501190, South Korea	Chonnam National University; Chonnam National University; Chonnam National University; Chonnam National University; Chonnam National University	Jung, C (corresponding author), Chonnam Natl Univ, Sch Med, Dept Anat, 5 Hak Dong, Kwangju 501190, South Korea.	chjung@chonnam.ac.kr	Jung, Chaeyong/AAD-8357-2021; Nam, Kwang Il/C-4580-2019	Jung, Chaeyong/0000-0002-5557-4576; Nam, Kwang Il/0000-0001-5380-6815	Korea Science and Engineering Foundation through the Medical Research Center for Gene Regulation [2012-0009445]; Basic Science Research Program of the National Research Foundation of Korea (NRF) grant - Korea Government [2010-0003838]; Chonnam National University Research Institute of Medical Sciences [2010-CURIMS-DR011]	Korea Science and Engineering Foundation through the Medical Research Center for Gene Regulation(Korea Science and Engineering Foundation); Basic Science Research Program of the National Research Foundation of Korea (NRF) grant - Korea Government; Chonnam National University Research Institute of Medical Sciences	This work was supported by the Korea Science and Engineering Foundation through the Medical Research Center for Gene Regulation (2012-0009445), by the Basic Science Research Program of the National Research Foundation of Korea (NRF) grant funded by the Korea Government (2010-0003838), and by a grant from the Chonnam National University Research Institute of Medical Sciences ((2010-CURIMS-DR011).	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Beck FWJ, 2004, PROSTATE, V58, P374, DOI 10.1002/pros.10344; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen CD, 2002, MOL CELL BIOL, V22, P2862, DOI 10.1128/MCB.22.8.2862-2870.2002; Costello LC, 1999, J BIOL CHEM, V274, P17499, DOI 10.1074/jbc.274.25.17499; Costello LC, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-17; Economides KD, 2003, DEVELOPMENT, V130, P2061, DOI 10.1242/dev.00432; Edwards J, 2003, BRIT J CANCER, V89, P552, DOI 10.1038/sj.bjc.6601127; Franklin RB, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-32; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Golovine K, 2008, CLIN CANCER RES, V14, P5376, DOI 10.1158/1078-0432.CCR-08-0455; Golovine K, 2008, PROSTATE, V68, P1443, DOI 10.1002/pros.20810; Henshall SM, 2003, ONCOGENE, V22, P6005, DOI 10.1038/sj.onc.1206797; Ho LH, 2004, J IMMUNOL, V172, P7750, DOI 10.4049/jimmunol.172.12.7750; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Jeon KI, 2000, J IMMUNOL, V164, P5981, DOI 10.4049/jimmunol.164.11.5981; Jung C, 2005, BRIT J CANCER, V92, P2233, DOI 10.1038/sj.bjc.6602631; Jung C, 2004, CANCER RES, V64, P9185, DOI 10.1158/0008-5472.CAN-04-1330; Jung CY, 2001, GENE, V271, P143, DOI 10.1016/S0378-1119(01)00513-3; Kim SD, 2010, ANAT CELL BIOL, V43, P284, DOI 10.5115/acb.2010.43.4.284; Kim YR, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-124; Linja MJ, 2001, CANCER RES, V61, P3550; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; McMahon RJ, 1998, J NUTR, V128, P667, DOI 10.1093/jn/128.4.667; Michalczyk AA, 2002, BIOCHEM J, V364, P105, DOI 10.1042/bj3640105; Muenchen HJ, 2000, CLIN CANCER RES, V6, P1969; Murgia C, 1999, AM J PHYSIOL-GASTR L, V277, pG1231, DOI 10.1152/ajpgi.1999.277.6.G1231; Palmiter RD, 2004, PFLUG ARCH EUR J PHY, V447, P744, DOI 10.1007/s00424-003-1070-7; Rosoff B, 1981, Prog Clin Biol Res, V75A, P447; Salsi V, 2006, J BIOL CHEM, V281, P1992, DOI 10.1074/jbc.M510900200; Shaut CA, 2007, DEV DYNAM, V236, P951, DOI 10.1002/dvdy.21077; Shukla S, 2004, NEOPLASIA, V6, P390, DOI 10.1593/neo.04112; Shukla S, 2004, CLIN CANCER RES, V10, P3169, DOI 10.1158/1078-0432.CCR-03-0586; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sreenath T, 1999, PROSTATE, V41, P203, DOI 10.1002/(SICI)1097-0045(19991101)41:3<203::AID-PROS8>3.0.CO;2-J; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Sweeney C, 2004, CLIN CANCER RES, V10, P5501, DOI 10.1158/1078-0432.CCR-0571-03; Tricoli JV, 1996, GENE CHROMOSOME CANC, V15, P108, DOI 10.1002/(SICI)1098-2264(199602)15:2<108::AID-GCC5>3.0.CO;2-7; Uzzo RG, 2002, CLIN CANCER RES, V8, P3579; Uzzo RG, 2006, CARCINOGENESIS, V27, P1980, DOI 10.1093/carcin/bgl034; Yamashita A, 1996, PROSTATE, V29, P1; Zaichick V. Ye., 1997, International Urology and Nephrology, V29, P565, DOI 10.1007/BF02552202; Zhang LY, 2009, AM J PATHOL, V175, P489, DOI 10.2353/ajpath.2009.080727; Zou J, 2011, PROSTATE, V71, P1518, DOI 10.1002/pros.21368	46	46	50	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2014	33	37					4558	4567		10.1038/onc.2013.404	http://dx.doi.org/10.1038/onc.2013.404			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3UZ	24096478				2022-12-17	WOS:000342004800003
J	Bersani, C; Xu, LD; Vilborg, A; Lui, WO; Wiman, KG				Bersani, C.; Xu, L-D; Vilborg, A.; Lui, W-O; Wiman, K. G.			Wig-1 regulates cell cycle arrest and cell death through the p53 targets FAS and 14-3-3 sigma	ONCOGENE			English	Article						Wig-1; p53; FAS; 14-3-3 sigma; AU-rich element; AU-rich element-binding proteins	MESSENGER-RNA DECAY; AU-RICH ELEMENTS; ZINC-FINGER PROTEIN; DNA-DAMAGE; P53-ACTIVATED GENE; CCR4-NOT COMPLEX; EXPRESSION; HUR; STABILITY; STRESS	Wig-1, also known as ZMAT3, is a p53 target gene that encodes an RNA-binding zinc-finger protein involved in the regulation of mRNA stability through binding to AU-rich elements (AREs). We have used microarray analysis to identify novel Wig-1 target mRNAs. We identified 2447 transcripts with >fourfold differential expression between Wig-1 and control small interfering (si) RNA-treated HCT116 cells. Several p53 target genes were among the deregulated transcripts. We found that Wig-1 regulates FAS and 14-3-3 sigma mRNA independently of p53. We show that Wig-1 binds to FAS mRNA 3'-UTR and decreases its stability through an ARE in the 3'-UTR. Depletion of Wig-1 was associated with increased cell death and reduced cell cycle arrest upon DNA damage. Our results suggest a role of Wig-1 as a survival factor that directs the p53 stress response toward cell cycle arrest rather than apoptosis through the regulation of FAS and 14-3-3 sigma mRNA levels.	[Bersani, C.; Xu, L-D; Vilborg, A.; Lui, W-O; Wiman, K. G.] Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, SE-17176 Stockholm, Sweden	Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, SE-17176 Stockholm, Sweden.	Klas.Wiman@ki.se	Wiman, Klas/AAB-8399-2021; Lui, Weng-Onn/X-5957-2019; Lui, Weng-Onn/G-6703-2013; Bersani, Cinzia/M-7871-2014	Wiman, Klas/0000-0002-7113-524X; Lui, Weng-Onn/0000-0003-4717-4473; Lui, Weng-Onn/0000-0003-4717-4473; Bersani, Cinzia/0000-0001-7604-5211; Vilborg, Anna/0000-0003-0917-9062	Swedish Cancer Society; Swedish Research Council (VR); Gustaf V Jubilee Fund; Karolinska Institutet Distinguished Professor award	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council (VR)(Swedish Research Council); Gustaf V Jubilee Fund; Karolinska Institutet Distinguished Professor award	We thank Stefano Caramuta for assistance with the microarray analysis and Dr Bert Vogelstein for HCT116 cells. This work was supported by grants from the Swedish Cancer Society, the Swedish Research Council (VR), the Gustaf V Jubilee Fund and a Karolinska Institutet Distinguished Professor award to KGW.	Al-Haj L, 2012, NUCLEIC ACIDS RES, V40, P7739, DOI 10.1093/nar/gks545; Anderson P, 2008, TRENDS BIOCHEM SCI, V33, P141, DOI 10.1016/j.tibs.2007.12.003; Atasoy U, 1998, J CELL SCI, V111, P3145; Ball CA, 2005, NUCLEIC ACIDS RES, V33, pD580; Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012; Beisang D, 2012, WIRES RNA, V3, P719, DOI 10.1002/wrna.1125; Chang N, 2010, MOL CELL BIOL, V30, P3875, DOI 10.1128/MCB.00169-10; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Cho SJ, 2010, NUCLEIC ACIDS RES, V38, P2256, DOI 10.1093/nar/gkp1229; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dolken L, 2008, RNA, V14, P1959, DOI 10.1261/rna.1136108; Doidge R, 2012, BIOCHEM SOC T, V40, P896, DOI 10.1042/BST20120074; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gareau C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020254; Gillardon F, 1999, MOL BRAIN RES, V73, P138, DOI 10.1016/S0169-328X(99)00251-X; Gouble A, 2002, CANCER RES, V62, P1489; Hellborg F, 2004, INT J ONCOL, V24, P1559; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Higashi Y, 2002, J BIOL CHEM, V277, P42224, DOI 10.1074/jbc.M203594200; Ishimaru D, 2010, J BIOL CHEM, V285, P27182, DOI 10.1074/jbc.M109.098830; Khabar KSA, 2010, CELL MOL LIFE SCI, V67, P2937, DOI 10.1007/s00018-010-0383-x; Kim BC, 2012, EMBO J, V31, P4289, DOI 10.1038/emboj.2012.286; Kim HH, 2009, GENE DEV, V23, P1743, DOI 10.1101/gad.1812509; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lu JY, 2006, RNA, V12, P883, DOI 10.1261/rna.2308106; Mcgray AJR, 2011, CELL MOL BIOL LETT, V16, P55, DOI 10.2478/s11658-010-0037-x; Mendez-Vidal C, 2002, NUCLEIC ACIDS RES, V30, P1991, DOI 10.1093/nar/30.9.1991; Miller JE, 2012, CRIT REV BIOCHEM MOL, V47, P315, DOI 10.3109/10409238.2012.667214; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Sanduja S, 2011, WIRES RNA, V2, P42, DOI 10.1002/wrna.28; Schoenberg DR, 2012, NAT REV GENET, V13, P246, DOI 10.1038/nrg3160; Sedaghat Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029429; Thomas PD, 2006, NUCLEIC ACIDS RES, V34, pW645, DOI 10.1093/nar/gkl229; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; VarmehZiaie S, 1997, ONCOGENE, V15, P2699, DOI 10.1038/sj.onc.1201454; Vidal CM, 2006, FEBS LETT, V580, P4401, DOI 10.1016/j.febslet.2006.07.005; Vilborg A, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.33; Vilborg A, 2011, CELL DEATH DIFFER, V18, P1434, DOI 10.1038/cdd.2011.20; Vilborg A, 2009, P NATL ACAD SCI USA, V106, P15756, DOI 10.1073/pnas.0900862106; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; von Roretz C, 2011, WIRES RNA, V2, P336, DOI 10.1002/wrna.55; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340	45	46	48	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2014	33	35					4407	4417		10.1038/onc.2013.594	http://dx.doi.org/10.1038/onc.2013.594			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MR	24469038	Green Published, hybrid			2022-12-17	WOS:000341157800005
J	Mori, T; Sato, Y; Miyamoto, K; Kobayashi, T; Shimizu, T; Kanagawa, H; Katsuyama, E; Fujie, A; Hao, W; Tando, T; Iwasaki, R; Kawana, H; Morioka, H; Matsumoto, M; Saya, H; Toyama, Y; Miyamoto, T				Mori, T.; Sato, Y.; Miyamoto, K.; Kobayashi, T.; Shimizu, T.; Kanagawa, H.; Katsuyama, E.; Fujie, A.; Hao, W.; Tando, T.; Iwasaki, R.; Kawana, H.; Morioka, H.; Matsumoto, M.; Saya, H.; Toyama, Y.; Miyamoto, T.			TNF alpha promotes osteosarcoma progression by maintaining tumor cells in an undifferentiated state	ONCOGENE			English	Article						osteosarcoma; tumorigenesis; osteoblast differentiation; gene-mutation; TNF alpha	INFLAMMATION; PATHWAY; CANCER; EPIDEMIOLOGY	Chronic inflammation is frequently associated with tumorigenesis in elderly people. By contrast, young people without chronic inflammation often develop tumors considered independent of chronic inflammation but driven instead by mutations. Thus, whether inflammation has a significant role in tumor progression in tumors driven by mutations remains largely unknown. Here we show that TNF alpha is required for the tumorigenesis of osteosarcoma, the most common tumor in children and adolescents. We show that transplantation of AX osteosarcoma cells, which harbor mutations driving c-Myc overexpression and Ink4a-deficiency, in wild-type mice promotes lethal tumorigenesis accompanied by ectopic bone formation and multiple metastases, phenotypes seen in osteosarcoma patients. Such tumorigenesis was completely abrogated in TNF alpha-deficient mice. AX cells have the capacity to undergo osteoblastic differentiation; however, that activity was significantly inhibited by TNF alpha treatment, suggesting that TNF alpha maintains AX cells in an undifferentiated state. TNF alpha inhibition of AX cell osteoblastic differentiation occurred through ERK activation, and a pharmacological TNF alpha inhibitor effectively inhibited both AX cell tumorigenesis and increased osteoblastic gene expression and increased survival of tumor-bearing mice. Lethal tumorigenesis of AX cells was also abrogated in IL-1 alpha/IL-1 beta doubly deficient mice. We found that both TNF alpha and IL-1 maintained AX cells in an undifferentiated state via ERK activation. Thus, inflammatory cytokines are required to promote tumorigenesis even in mutation-induced tumors, and TNF alpha/IL-1 and ERK may represent therapeutic targets for osteosarcoma.	[Mori, T.; Sato, Y.; Miyamoto, K.; Kobayashi, T.; Kanagawa, H.; Katsuyama, E.; Fujie, A.; Hao, W.; Tando, T.; Morioka, H.; Matsumoto, M.; Toyama, Y.; Miyamoto, T.] Keio Univ, Sch Med, Dept Orthoped Surg, Tokyo 1608582, Japan; [Sato, Y.] Keio Univ, Sch Med, Dept Musculoskeletal Reconstruct & Regenerat Surg, Tokyo 1608582, Japan; [Kobayashi, T.; Miyamoto, T.] Keio Univ, Sch Med, Dept Integrated Bone Metab & Immunol, Tokyo 1608582, Japan; [Shimizu, T.; Saya, H.] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat, Tokyo 1608582, Japan; [Shimizu, T.] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Pathophysiol, Tokyo 142, Japan; [Iwasaki, R.; Kawana, H.] Keio Univ, Sch Med, Dept Dent & Oral Surg, Tokyo 1608582, Japan	Keio University; Keio University; Keio University; Keio University; Hoshi University; Keio University	Miyamoto, T (corresponding author), Keio Univ, Sch Med, Dept Orthoped Surg, 35 Shinano Machi, Tokyo 1608582, Japan.	miyamoto@z5.keio.jp	Saya, Hideyuki/J-4325-2013	Saya, Hideyuki/0000-0001-6610-1902	Takeda Science Foundation, Japan	Takeda Science Foundation, Japan(Takeda Science Foundation (TSF))	T Miyamoto was supported by a Grant-in-aid for Scientific Research, Takeda Science Foundation, Japan.	BENSTED JPM, 1961, BRIT J RADIOL, V34, P160, DOI 10.1259/0007-1285-34-399-160; DAHLIN DC, 1975, CLIN ORTHOP RELAT R, P23; Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hoejberg L, 2012, MELANOMA RES, V22, P327, DOI 10.1097/CMR.0b013e3283543d72; Ishikawa T, 2013, CANCER SCI, V104, P880, DOI 10.1111/cas.12163; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kim SJ, 2004, CLIN IMAG, V28, P291, DOI 10.1016/S0899-7071(03)00206-7; Kubota Y, 2009, J EXP MED, V206, P1089, DOI 10.1084/jem.20081605; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mavaddat N, 2013, JNCI-J NATL CANCER I, V105, P812, DOI 10.1093/jnci/djt095; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Morrison WB, 2012, J VET INTERN MED, V26, P18, DOI 10.1111/j.1939-1676.2011.00836.x; Nakamura T, 2011, ONCOL LETT, V2, P315, DOI 10.3892/ol.2011.238; Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978-1-4419-0284-9_1; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Picci P, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-6; Rutkowski P, 2003, J SURG ONCOL, V84, P151, DOI 10.1002/jso.10305; Sansone P, 2012, J CLIN ONCOL, V30, P1005, DOI 10.1200/JCO.2010.31.8907; Sheppard DG, 2001, CLIN RADIOL, V56, P22, DOI 10.1053/crad.2000.0599; Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312; Shimizu T, 2012, MOL CANCER RES, V10, P454, DOI 10.1158/1541-7786.MCR-11-0347; Ueki A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050621; Vasto S, 2009, MECH AGEING DEV, V130, P40, DOI 10.1016/j.mad.2008.06.003; Vendramini-Costa DB, 2012, CURR PHARM DESIGN, V18, P3831; Waldner MJ, 2012, INT J BIOL SCI, V8, P1248, DOI 10.7150/ijbs.4614; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; World Health Organization, 2007, 10 STAT HIGHL GLOB P; YOSHIKAWA H, 1985, CANCER, V56, P1682, DOI 10.1002/1097-0142(19851001)56:7<1682::AID-CNCR2820560735>3.0.CO;2-8	31	46	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2014	33	33					4236	4241		10.1038/onc.2013.545	http://dx.doi.org/10.1038/onc.2013.545			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MB	24336323	hybrid			2022-12-17	WOS:000341155800005
J	Cichon, MA; Szentpetery, Z; Caley, MP; Papadakis, ES; Mackenzie, IC; Brennan, CH; O'Toole, EA				Cichon, M. A.; Szentpetery, Z.; Caley, M. P.; Papadakis, E. S.; Mackenzie, I. C.; Brennan, C. H.; O'Toole, E. A.			The receptor tyrosine kinase Axl regulates cell-cell adhesion and stemness in cutaneous squamous cell carcinoma	ONCOGENE			English	Article						adhesion; Axl; cancer stem cell; chemotherapy resistance; epithelial-mesenchymal transition	EPITHELIAL-MESENCHYMAL TRANSITION; SIGNALING PATHWAY; GROWTH ARREST; UP-REGULATION; TUMOR-GROWTH; CANCER; CATENIN; RESISTANCE; IDENTIFICATION; INVOLVEMENT	Axl is a receptor tyrosine kinase (RTK) upregulated in various tumors including cutaneous squamous cell carcinoma (SCC). Axl expression correlates with poor prognosis and induction of epithelial-mesenchymal transition (EMT), hence we hypothesized that Axl is involved in the disruption of cell-cell adhesion to allow invasion and chemotherapy resistance of the cancer stem cell population. Cutaneous SCC cell lines with stable knockdown of Axl were generated using retroviral vectors. Axl depletion altered expression of intercellular junction molecules increasing cell-cell adhesion with downregulation of Wnt and TGF beta R signaling. Furthermore, Axl expression correlated with the expression of putative cancer stem cell markers, CD44 and ALDH1, increased resistance to chemotherapy drugs, enhanced sphere formation ability and expression of EMT features by cancer stem cells. Axl depletion resulted in loss of tumor formation in an in vivo zebrafish xenograft model. In conclusion, these data suggest that abrogation of Axl results in loss of cancer stem cell properties indicating a role for Axl as a therapeutic target in chemotherapy-resistant cancer.	[Cichon, M. A.; Szentpetery, Z.; Caley, M. P.; Mackenzie, I. C.; O'Toole, E. A.] Queen Mary Univ London, Barts & London SMD, Ctr Cutaneous Res, Blizard Inst, London E1 2AT, England; [Papadakis, E. S.] Univ Southampton, Canc Res UK Ctr, Canc Sci Div, Southampton, Hants, England; [Brennan, C. H.] Queen Mary Univ London, Sch Biol & Chem Sci, London, England	University of London; Queen Mary University London; Cancer Research UK; University of Southampton; University of London; Queen Mary University London	O'Toole, EA (corresponding author), Queen Mary Univ London, Barts & London SMD, Ctr Cutaneous Res, Blizard Inst, 4 Newark St, London E1 2AT, England.	e.a.otoole@qmul.ac.uk		O'Toole, Edel/0000-0002-4084-4836	DAT PhD studentship from the Medical Research Council; MRC Centenary award (MAC); DEBRA Ireland; British Skin Foundation; National Centre for the Replacement [G1000053/1, NC/L00061X/1] Funding Source: researchfish	DAT PhD studentship from the Medical Research Council; MRC Centenary award (MAC); DEBRA Ireland; British Skin Foundation; National Centre for the Replacement	We are grateful to Carolyn Byrne for the luciferase reporter plasmids, Irene Leigh and Charlotte Proby for the MET1 and SCC IC1 cell lines and Vera Martins-Cabecos for scientific advice. We would like to acknowledge Alan Storey who was integral to the initiation of this project. This work was supported by a DAT PhD studentship from the Medical Research Council, a MRC Centenary award (MAC) and project grants from DEBRA Ireland and the British Skin Foundation awarded to EAOT.	Asiedu MK, 2014, ONCOGENE, V33, P1316, DOI 10.1038/onc.2013.57; Bauer T, 2012, J EXP MED, V209, P2033, DOI 10.1084/jem.20120493; Biddle A, 2012, CANCER METAST REV, V31, P285, DOI 10.1007/s10555-012-9345-0; Biddle A, 2011, CANCER RES, V71, P5317, DOI 10.1158/0008-5472.CAN-11-1059; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chen YC, 2009, BIOCHEM BIOPH RES CO, V385, P307, DOI 10.1016/j.bbrc.2009.05.048; Chidgey M, 2007, BRIT J CANCER, V96, P1783, DOI 10.1038/sj.bjc.6603808; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; de Oliveira SS, 2005, FEBS LETT, V579, P6179, DOI 10.1016/j.febslet.2005.09.091; del Valle-Perez B, 2011, J CELL SCI, V124, P2298, DOI 10.1242/jcs.082693; Dontu G, 2005, J MAMMARY GLAND BIOL, V10, P75, DOI 10.1007/s10911-005-2542-5; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Garcia-Gras E, 2006, J CLIN INVEST, V116, P2012, DOI 10.1172/JCI27751; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Green J, 2006, BRIT J CANCER, V94, P1446, DOI 10.1038/sj.bjc.6603135; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Harper LJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-166; Harris TJ, 2012, NAT REV MOL CELL BIO, V11, P502; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Honoki K, 2010, ONCOL REP, V24, P501, DOI 10.3892/or_00000885; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; Jacob ANK, 1999, CANCER DETECT PREV, V23, P325; Kobielak A, 2004, NAT REV MOL CELL BIO, V5, P614, DOI 10.1038/nrm1433; Lee CH, 2012, ANN SURG ONCOL, V19, pS500, DOI 10.1245/s10434-011-1985-8; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Linger RM, 2010, EXPERT OPIN THER TAR, V14, P1073, DOI 10.1517/14728222.2010.515980; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martins VL, 2009, J CELL SCI, V122, P1788, DOI 10.1242/jcs.042895; McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633; Miwa N, 2001, ONCOL RES, V12, P469, DOI 10.3727/096504001108747477; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Palka HL, 1997, J CELL SCI, V110, P2359; Papadakis ES, 2011, J INVEST DERMATOL, V131, P509, DOI 10.1038/jid.2010.326; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Polette M, 2005, CANCER RES, V65, P7691, DOI 10.1158/0008-5472.CAN-04-4230; Proby CM, 2000, EXP DERMATOL, V9, P104, DOI 10.1034/j.1600-0625.2000.009002104.x; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rochlitz C, 1999, LEUKEMIA, V13, P1352, DOI 10.1038/sj.leu.2401484; Song X, 2010, CANCER, V117, P734; Stemmler MP, 2008, MOL BIOSYST, V4, P835, DOI 10.1039/b719215k; Takahashi-Yanaga F, 2007, J PHARMACOL SCI, V104, P293, DOI 10.1254/jphs.CR0070024; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wang JB, 2004, CURR OPIN GENET DEV, V14, P533, DOI 10.1016/j.gde.2004.07.013; Westerfield M, 2001, ZEBRAFISH BOOK GUIDE, P1; Ye X, 2010, ONCOGENE, V29, P5254, DOI 10.1038/onc.2010.268; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	53	46	47	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2014	33	32					4185	4192		10.1038/onc.2013.388	http://dx.doi.org/10.1038/onc.2013.388			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YK	24056961				2022-12-17	WOS:000340595700009
J	Marxer, M; Ma, HT; Man, WY; Poon, RYC				Marxer, M.; Ma, H. T.; Man, W. Y.; Poon, R. Y. C.			p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases	ONCOGENE			English	Article						mitosis; mitotic catastrophe; mitotic slippage	P53-DEFICIENT CANCER-CELLS; SMALL-MOLECULE INHIBITOR; IN-VIVO; POSTMITOTIC CHECKPOINT; CYTOKINESIS FAILURE; MAMMALIAN-CELLS; APOPTOSIS; TETRAPLOIDY; MITOSIS; CYCLE	A number of small-molecule inhibitors of Aurora kinases have been developed and are undergoing clinical trials for anti-cancer therapies. Different Aurora kinases, however, behave as very different targets: while inhibition of Aurora A (AURKA) induces a delay in mitotic exit, inhibition of Aurora B (AURKB) triggers mitotic slippage. Furthermore, while it is evident that p53 is regulated by Aurora kinase-dependent phosphorylation, how p53 may in turn regulate Aurora kinases remains mysterious. To address these issues, isogenic p53-containing and -negative cells were exposed to classic inhibitors that target both AURKA and AURKB (Alisertib and ZM447439), as well as to new generation of inhibitors that target AURKA (MK-5108), AURKB (Barasertib) individually. The fate of individual cells was then tracked with time-lapse microscopy. Remarkably, loss of p53, either by gene disruption or small interfering RNA-mediated depletion, sensitized cells to inhibition of both AURKA and AURKB, promoting mitotic arrest and slippage respectively. As the p53-dependent post-mitotic checkpoint is also important for preventing genome reduplication after mitotic slippage, these studies indicate that the loss of p53 in cancer cells represents a major opportunity for anti-cancer drugs targeting the Aurora kinases.	[Poon, R. Y. C.] Hong Kong Univ Sci & Technol, Ctr Canc Res, Div Life Sci, Hong Kong, Hong Kong, Peoples R China; [Poon, R. Y. C.] Hong Kong Univ Sci & Technol, State Key Lab Mol Neurosci, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, Ctr Canc Res, Div Life Sci, Hong Kong, Hong Kong, Peoples R China.	rycpoon@ust.hk		Poon, Randy/0000-0001-5571-6231; MA, Hoi Tang/0000-0001-5876-0107	Research Grants Council [HKU7/CRG/09]	Research Grants Council(Hong Kong Research Grants Council)	Many thanks are due to Michelle Chen, Nelson Lee and Kenji Nishiura for technical assistance. This work was supported in part by the Research Grants Council grant HKU7/CRG/09 to RYCP.	Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Chan YW, 2008, J BIOL CHEM, V283, P15716, DOI 10.1074/jbc.M800629200; Chan YW, 2008, CELL CYCLE, V7, P1449, DOI 10.4161/cc.7.10.5880; Curry J, 2009, CELL CYCLE, V8, P1921, DOI 10.4161/cc.8.12.8741; Dar AA, 2008, CANCER RES, V68, P8998, DOI 10.1158/0008-5472.CAN-08-2658; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Gautschi O, 2008, CLIN CANCER RES, V14, P1639, DOI 10.1158/1078-0432.CCR-07-2179; Girdler F, 2006, J CELL SCI, V119, P3664, DOI 10.1242/jcs.03145; Gizatullin F, 2006, CANCER RES, V66, P7668, DOI 10.1158/0008-5472.CAN-05-3353; Green MR, 2011, EXPERT OPIN DRUG DIS, V6, P291, DOI 10.1517/17460441.2011.555395; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hegarat N, 2011, J CELL BIOL, V195, P1103, DOI 10.1083/jcb.201105058; Karthigeyan D, 2011, MED RES REV, V31, P757, DOI 10.1002/med.20203; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Kimura M, 1999, J BIOL CHEM, V274, P7334, DOI 10.1074/jbc.274.11.7334; Li QY, 2004, J BIOL CHEM, V279, P52175, DOI 10.1074/jbc.M406802200; Ma HT, 2011, METHODS MOL BIOL, V761, P151, DOI 10.1007/978-1-61779-182-6_10; Ma HT, 2011, BIOCHEM J, V435, P17, DOI 10.1042/BJ20100284; Manfredi MG, 2011, CLIN CANCER RES, V17, P7614, DOI 10.1158/1078-0432.CCR-11-1536; On KF, 2011, MOL CANCER THER, V10, P784, DOI 10.1158/1535-7163.MCT-10-0809; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Ruchaud S, 2007, NAT REV MOL CELL BIO, V8, P798, DOI 10.1038/nrm2257; Scutt PJ, 2009, J BIOL CHEM, V284, P15880, DOI 10.1074/jbc.M109.005694; Shao SJ, 2006, J BIOL CHEM, V281, P28943, DOI 10.1074/jbc.M600235200; Shimomura T, 2010, MOL CANCER THER, V9, P157, DOI 10.1158/1535-7163.MCT-09-0609; Siu WY, 2004, MOL CANCER THER, V3, P621; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; Storchova Z, 2008, J CELL SCI, V121, P3859, DOI 10.1242/jcs.039537; Tao Y, 2008, ONCOGENE, V27, P3244, DOI 10.1038/sj.onc.1210990; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6; Yam CH, 2000, J BIOL CHEM, V275, P3158, DOI 10.1074/jbc.275.5.3158; Yang J, 2007, BLOOD, V110, P2034, DOI 10.1182/blood-2007-02-073700; Yasui Y, 2004, J BIOL CHEM, V279, P12997, DOI 10.1074/jbc.M311128200	36	46	46	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3550	3560		10.1038/onc.2013.325	http://dx.doi.org/10.1038/onc.2013.325			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23955083				2022-12-17	WOS:000338941100007
J	Tanaka, M; Suzuki, HI; Shibahara, J; Kunita, A; Isagawa, T; Yoshimi, A; Kurokawa, M; Miyazono, K; Aburatani, H; Ishikawa, S; Fukayama, M				Tanaka, M.; Suzuki, H. I.; Shibahara, J.; Kunita, A.; Isagawa, T.; Yoshimi, A.; Kurokawa, M.; Miyazono, K.; Aburatani, H.; Ishikawa, S.; Fukayama, M.			EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis	ONCOGENE			English	Article						pancreatic cancer; PanIN; EVI1; KRAS; microRNA	DUCTAL ADENOCARCINOMA; EXPRESSION PROFILES; DOWN-REGULATION; RAS ACTIVITY; BETA; MODULATION; CLAUDIN-18; MUTATIONS; PROGNOSIS; NEOPLASMS	Despite frequent KRAS mutation, the early molecular mechanisms of pancreatic ductal adenocarcinoma (PDAC) development have not been fully elucidated. By tracking a potential regulator of another feature of PDAC precursors, acquisition of foregut or gastric epithelial gene signature, we herein report that aberrant overexpression of ecotropic viral integration site 1 (EVI1) oncoprotein, which is usually absent in normal pancreatic duct, is a widespread marker across the full spectrum of human PDAC precursors and PDAC. In pancreatic cancer cells, EVI1 depletion caused remarkable inhibition of cell growth and migration, indicating its oncogenic roles. Importantly, we found that EVI1 upregulated KRAS expression through suppression of a potent KRAS suppressor, miR-96, in pancreatic cancer cells. Collectively, the present findings suggest that EVI1 overexpression and KRAS mutation converge on activation of the KRAS pathway in early phases of pancreatic carcinogenesis and propose EVI1 and/or miR-96 as early markers and therapeutic targets in this dismal disease.	[Tanaka, M.; Shibahara, J.; Kunita, A.; Ishikawa, S.; Fukayama, M.] Univ Tokyo, Dept Pathol, Tokyo 1130033, Japan; [Suzuki, H. I.; Miyazono, K.] Univ Tokyo, Dept Mol Pathol, Tokyo 1130033, Japan; [Isagawa, T.] Univ Tokyo, Dept Cardiovasc Med, Tokyo 1130033, Japan; [Yoshimi, A.; Kurokawa, M.] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1130033, Japan; [Aburatani, H.] Univ Tokyo, RCAST, Genome Sci Div, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo	Fukayama, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	mfukayama-tky@umin.ac.jp	Yoshimi, Akihide/I-3792-2019	Yoshimi, Akihide/0000-0002-0664-7281; Suzuki, Hiroshi/0000-0003-4682-5086	Industrial Technology Research Grant Program from the New Energy and Industrial Technology Development Organization (NEDO) of Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan; Cell Science Research Foundation; Grants-in-Aid for Scientific Research [26860474] Funding Source: KAKEN	Industrial Technology Research Grant Program from the New Energy and Industrial Technology Development Organization (NEDO) of Japan(New Energy and Industrial Technology Development Organization (NEDO)); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Cell Science Research Foundation(Cell Science Research Foundation, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank all members of the Department of Pathology, University of Tokyo. This work was supported by the Industrial Technology Research Grant Program (2008) from the New Energy and Industrial Technology Development Organization (NEDO) of Japan (SI), the Grant-in-Aid for Scientific Research on Innovative Areas (SI),<SUP>46</SUP> the Grant-in-Aid for Young Scientists (A),<SUP>46</SUP> the GCOE Program for 'Integrative Life Science Based on the Study of Biosignaling Mechanisms' (HIS, KM), and for 'Chemical Biology of the Diseases' (MF and MK) from the Ministry of Education, Culture, Sports, Science and Technology of Japan and the Cell Science Research Foundation (HIS, KM).	Bosman FT, 2010, WHO CLASSIFICATION T, P279; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chen X, 2009, ONCOGENE, V28, P1385, DOI 10.1038/onc.2008.474; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; De Weer A, 2011, BRIT J HAEMATOL, V154, P337, DOI 10.1111/j.1365-2141.2011.08737.x; Dickstein J, 2010, P NATL ACAD SCI USA, V107, P9783, DOI 10.1073/pnas.1004297107; Gao JS, 2011, FEBS LETT, V585, P693, DOI 10.1016/j.febslet.2011.01.033; Ge XJ, 2005, GENOMICS, V86, P127, DOI 10.1016/j.ygeno.2005.04.008; Gomez-Benito M, 2010, BRIT J CANCER, V103, P1292, DOI 10.1038/sj.bjc.6605874; Goyama S, 2009, CANCER SCI, V100, P990, DOI 10.1111/j.1349-7006.2009.01152.x; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Gysin S, 2005, CANCER RES, V65, P4870, DOI 10.1158/0008-5472.CAN-04-2848; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; HRUBAN RH, 2007, AFIP ATLAS TUMOR PAT, P51; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Jean-Paul D, 2008, P NATL ACAD SCI USA, V105, P18907, DOI 10.1073/pnas.0810111105; Ji BA, 2009, GASTROENTEROLOGY, V137, P1072, DOI 10.1053/j.gastro.2009.05.052; Jimenez RE, 1999, ANN SURG, V230, P501, DOI 10.1097/00000658-199910000-00006; Kanda M, 2012, GASTROENTEROLOGY, V142, P730, DOI 10.1053/j.gastro.2011.12.042; Kim GE, 2002, GASTROENTEROLOGY, V123, P1052, DOI 10.1053/gast.2002.36018; Kitago M, 2004, INT J CANCER, V110, P177, DOI 10.1002/ijc.20084; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 2000, EMBO J, V19, P2958, DOI 10.1093/emboj/19.12.2958; Kwei KA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000081; Liu Y, 2006, ONCOGENE, V25, P3565, DOI 10.1038/sj.onc.1209403; Logsdon CD, 2009, CLIN GASTROENTEROL H, V7, pS40, DOI 10.1016/j.cgh.2009.07.040; Matsuyama H, 2011, BLOOD, V118, P6881, DOI 10.1182/blood-2011-05-354654; Morris JP, 2010, NAT REV CANCER, V10, P683, DOI 10.1038/nrc2899; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; Nanjundan M, 2007, CANCER RES, V67, P3074, DOI 10.1158/0008-5472.CAN-06-2366; Prasad NB, 2005, CANCER RES, V65, P1619, DOI 10.1158/0008-5472.CAN-04-1413; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Sentani K, 2008, AM J SURG PATHOL, V32, P1182, DOI 10.1097/PAS.0b013e318163a8f8; Senyuk V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020793; Shin KH, 2011, BIOCHEM BIOPH RES CO, V404, P896, DOI 10.1016/j.bbrc.2010.12.055; Song Y, 2010, CANCER RES, V70, P2115, DOI 10.1158/0008-5472.CAN-09-2979; Suzuki HI, 2011, J BIOCHEM, V149, P15, DOI 10.1093/jb/mvq113; Suzuki HI, 2010, J MOL MED, V88, P1085, DOI 10.1007/s00109-010-0650-1; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Szafranska AE, 2007, ONCOGENE, V26, P4442, DOI 10.1038/sj.onc.1210228; Tanaka M, 2011, J HISTOCHEM CYTOCHEM, V59, P942, DOI 10.1369/0022155411420569; Vazquez I, 2011, HAEMATOL-HEMATOL J, V96, P1448, DOI 10.3324/haematol.2011.040535; Yonezawa S, 2010, J HEPATO-BIL-PAN SCI, V17, P108, DOI 10.1007/s00534-009-0174-7; Yoshimi A, 2011, ONCOTARGET, V2, P575, DOI 10.18632/oncotarget.304; Yoshimi A, 2011, BLOOD, V117, P3617, DOI 10.1182/blood-2009-12-261602; Yu SN, 2010, CANCER RES, V70, P6015, DOI 10.1158/0008-5472.CAN-09-4531	46	46	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2454	2463		10.1038/onc.2013.204	http://dx.doi.org/10.1038/onc.2013.204			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23752186				2022-12-17	WOS:000336033600005
J	Inagaki-Ohara, K; Mayuzumi, H; Kato, S; Minokoshi, Y; Otsubo, T; Kawamura, YI; Dohi, T; Matsuzaki, G; Yoshimura, A				Inagaki-Ohara, K.; Mayuzumi, H.; Kato, S.; Minokoshi, Y.; Otsubo, T.; Kawamura, Y. I.; Dohi, T.; Matsuzaki, G.; Yoshimura, A.			Enhancement of leptin receptor signaling by SOCS3 deficiency induces development of gastric tumors in mice	ONCOGENE			English	Article						leptin; SOCS3; gastric tumor	MOUSE OBESE GENE; HUMAN STOMACH; OB-R; INTESTINAL INFLAMMATION; GASTROINTESTINAL-TRACT; COLORECTAL-CANCER; BINDING PROTEIN; PROTECTIVE ROLE; STEM-CELLS; EXPRESSION	Leptin acts on its receptor (ObR) in the hypothalamus to inhibit food intake and energy expenditure. Leptin and ObR are also expressed in the gastrointestinal tract; however, the physiological significance of leptin signaling in the gut remains uncertain. Suppressor of cytokine signaling 3 (SOCS3) is a key negative feedback regulator of ObR-mediated signaling in the hypothalamus. We now show that gastrointestinal epithelial cell-specific SOCS3 conditional knockout (T3b-SOCS3 cKO) mice developed gastric tumors by enhancing leptin production and the ObRb/signal transducer and activator of transcription 3 (STAT3) signaling pathway. All T3b-SOCS3 cKO mice developed tumors in the stomach but not in the bowels by 2 months of age, even though the SOCS3 deletion occurred in both the epithelium of stomach and bowels. The tumors developed in the absence of the inflammatory response and all cKO mice died within 6 months. These tumors displayed pathology and molecular alterations, such as an increase in MUC2 (Mucin 2, oligomeric mucus/gel-forming) and TFF3 (trefoil factor 3), resembling human intestinal-type gastric tumors. Administration of antileptin antibody to T3b-SOCS3 cKO mice reduced hyperplasia of gastric mucosa, which is the step of the initiation of gastric tumor. These data suggest that SOCS3 is an antigastric tumor gene that suppresses leptin overexpression and ObRb/STAT3 hyperactivation, supporting the hypothesis that the leptin/ObRb/STAT3 axis accelerates tumorigenesis and that it may represent a new therapeutic target for the treatment of gastric cancer.	[Inagaki-Ohara, K.; Mayuzumi, H.; Matsuzaki, G.] Univ Ryukyus, Trop Biosphere Res Ctr, Ctr Mol Biosci COMB, Mol Microbiol Grp, Nishihara, Okinawa 90301, Japan; [Inagaki-Ohara, K.; Minokoshi, Y.] Natl Inst Physiol Sci, Dept Dev Physiol, Div Endocrinol & Metab, Okazaki, Aichi 444, Japan; [Inagaki-Ohara, K.; Otsubo, T.; Kawamura, Y. I.; Dohi, T.] Natl Ctr Global Hlth & Med NCGM, Res Inst, Res Ctr Hepatitis & Immunol, Dept Gastroenterol, Ichikawa, Chiba 2728516, Japan; [Kato, S.] Univ Ryukyus, Grad Sch, Dept Pathol & Cell Biol, Nishihara, Okinawa 90301, Japan; [Kato, S.] Univ Ryukyus, Fac Med, Nishihara, Okinawa 90301, Japan; [Yoshimura, A.] Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjyuku Ku, Tokyo, Japan	University of the Ryukyus; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); University of the Ryukyus; University of the Ryukyus; Keio University	Inagaki-Ohara, K (corresponding author), Natl Ctr Global Hlth & Med NCGM, Res Inst, Res Ctr Hepatitis & Immunol, Dept Gastroenterol, Konodai 1-7-1, Ichikawa, Chiba 2728516, Japan.	kyoinagaki@ri.ncgm.go.jp	Otsubo, Takeshi/G-6123-2014; Yoshimura, Akihiko/K-5515-2013; Matsuzaki, Goro/AAX-3110-2020	Minokoshi, Yasuhiko/0000-0002-7119-4805	Ministry of Education, Culture, Sports, Science and Technology of Japan [17590373, 19590432, 20599015, 23590272]; Takeda Science Foundation; Public Trust Haraguchi Memorial Cancer Research Fund; Ministry of Education, Science, Technology, Sports, and Culture of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Public Trust Haraguchi Memorial Cancer Research Fund; Ministry of Education, Science, Technology, Sports, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by grants from Grants-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (17590373, 19590432, 20599015 and 23590272), the Takeda Science Foundation and the Public Trust Haraguchi Memorial Cancer Research Fund (to KI-O) and Grants-in-aid for Scientific Research (S) from the Ministry of Education, Science, Technology, Sports, and Culture of Japan (to AY). We greatly thank Dr Jun-ichi Miyazaki (Osaka University) for the gift of the T3b-IL-12 vector, Ms Kozue Takahashi and Mr Takashi Kanna (University of the Ryukyus) for animal care, Dr Atsuo T Sasaki (Harvard University) for help in creating the T3b-cre construction, Dr Richard Blumberg (Harvard Medical School) and Dr Mayu Inaba (University of Michigan) for their constructive discussion and Dr Adrian L Smith (Oxford University) for reading carefully. We also thank Dr Takeshi Arakawa (University of the Ryukyus), Dr Shiki Okamoto, Ms Kumiko Saito (NIPS), Dr Miwa Tamura-Nakano and Dr Takeshi Nitta (NCGM) for steadfast supporting and encouraging us.	Aihara T, 1999, FEBS LETT, V463, P185, DOI 10.1016/S0014-5793(99)01608-7; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; Bennett BD, 1996, CURR BIOL, V6, P1170, DOI 10.1016/S0960-9822(02)70684-2; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Buyse M, 2001, J CLIN INVEST, V108, P1483, DOI 10.1172/JCI13219; Cascio S, 2009, J CELL PHYSIOL, V221, P189, DOI 10.1002/jcp.21843; Cinti S, 2000, INT J OBESITY, V24, P789, DOI 10.1038/sj.ijo.0801228; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Ernst M, 2008, J CLIN INVEST, V118, P1727, DOI 10.1172/JCI34944; Eyckerman S, 2000, FEBS LETT, V486, P33, DOI 10.1016/S0014-5793(00)02205-5; Feldman DE, 2012, P NATL ACAD SCI USA, V109, P829, DOI 10.1073/pnas.1114438109; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Guilmeau S, 2004, CURR OPIN PHARMACOL, V4, P561, DOI 10.1016/j.coph.2004.06.008; HE YF, 1995, J BIOL CHEM, V270, P28887, DOI 10.1074/jbc.270.48.28887; Howard JM, 2010, OBES REV, V11, P863, DOI 10.1111/j.1467-789X.2010.00718.x; Inagaki-Ohara K, 2006, GUT, V55, P212, DOI 10.1136/gut.2004.062653; Inagaki-Ohara K, 2004, J IMMUNOL, V173, P1390, DOI 10.4049/jimmunol.173.2.1390; Inagaki-Ohara K, 2011, IMMUNOLOGY, V134, P448, DOI 10.1111/j.1365-2567.2011.03503.x; Ishikawa M, 2006, WORLD J GASTROENTERO, V12, P5517, DOI 10.3748/wjg.v12.i34.5517; Judd LM, 2006, GASTROENTEROLOGY, V131, P1073, DOI 10.1053/j.gastro.2006.07.018; Kidder BL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003932; Kim BM, 2005, DEV CELL, V8, P611, DOI 10.1016/j.devcel.2005.01.015; Koda M, 2007, J CLIN PATHOL, V60, P902, DOI 10.1136/jcp.2006.041004; La Cava A, 2004, NAT REV IMMUNOL, V4, P371, DOI 10.1038/nri1350; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Li Y, 2010, GUT, V59, P227, DOI 10.1136/gut.2009.184176; Mix H, 2000, GUT, V47, P481, DOI 10.1136/gut.47.4.481; MONTERO C, 1980, HISTOPATHOLOGY, V4, P281, DOI 10.1111/j.1365-2559.1980.tb02922.x; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; Morton NM, 1998, J BIOL CHEM, V273, P26194, DOI 10.1074/jbc.273.40.26194; Nduati V, 2007, J BIOL CHEM, V282, P1359, DOI 10.1074/jbc.M604267200; Park HY, 2001, EXP MOL MED, V33, P95, DOI 10.1038/emm.2001.17; Rigby RJ, 2007, ONCOGENE, V26, P4833, DOI 10.1038/sj.onc.1210286; Rosivatz E, 2006, VIRCHOWS ARCH, V448, P277, DOI 10.1007/s00428-005-0118-9; Sitaraman S, 2004, FASEB J, V18, P696, DOI 10.1096/fj.03-0422fje; Sobhani I, 2000, GUT, V47, P178, DOI 10.1136/gut.47.2.178; Stringer EJ, 2008, FEBS LETT, V582, P2555, DOI 10.1016/j.febslet.2008.06.024; Suh E, 1996, MOL CELL BIOL, V16, P619; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wu LY, 2011, AM J PATHOL, V179, P2131, DOI 10.1016/j.ajpath.2011.06.028; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Zhang YJ, 2007, J CELL BIOCHEM, V102, P1256, DOI 10.1002/jcb.21356; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao L, 2005, WORLD J GASTROENTERO, V11, P7666, DOI 10.3748/wjg.v11.i48.7666; Zhao XL, 2007, J GASTROEN HEPATOL, V22, P1317, DOI 10.1111/j.1440-1746.2007.04941.x	53	46	47	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					74	84		10.1038/onc.2012.540	http://dx.doi.org/10.1038/onc.2012.540			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23178499				2022-12-17	WOS:000329212000009
J	Kitamoto, S; Yokoyama, S; Higashi, M; Yamada, N; Takao, S; Yonezawa, S				Kitamoto, S.; Yokoyama, S.; Higashi, M.; Yamada, N.; Takao, S.; Yonezawa, S.			MUC1 enhances hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors	ONCOGENE			English	Article						MUC1; hypoxia; pancreatic cancer; angiogenesis; mucin	TISSUE GROWTH-FACTOR; ANTIGEN-EXPRESSION; TUMOR HYPOXIA; CANCER; MUCINS; GENE; OVEREXPRESSION; ACTIVATION; CELLS; CTGF	Pancreatic cancer is one of the most lethal malignancies due to its aggressive growth and rapid development of distant metastases. In this context, mucin 1 (MUC1) overexpression and hypoxia are frequently observed events. However, their functional relationship remains largely unknown. This study provides evidence that MUC1 is overexpressed by hypoxia and contributes to hypoxia-driven angiogenesis. Using the conditioned medium obtained from hypoxia-stressed AsPC1 cells treated with MUC1 siRNAs, we demonstrated that MUC1 enhanced the endothelial tube formation, proliferation and migration ability, which induced by hypoxia-conditioned medium (HCM). In addition, MUC1 was significantly induced by hypoxia, especially in the pancreatic cancer cells derived from metastatic tumors (AsPC1, HPAF2 or Capan1), and MUC1-cytoplasmic tail (MUC1-CT) accumulated in the nucleus under hypoxia. As noted in a previous report, MUC1-CT was recruited to genomic regions upstream of the connective tissue growth factor (CTGF) accompanied with beta-catenin and p53, resulting in the hypoxic induction of CTGF. Moreover, hypoxia-induced MUC1 partially regulated two other hypoxia-inducible proangiogenic factors including vascular endothelial growth factor-A and platelet-derived growth factor-B. The neutralization assay revealed that endothelial tube formation induced by HCM was clearly suppressed by antibodies against these three factors, suggesting the importance of these factors in hypoxia-driven angiogenesis. In summary, this is the first report demonstrating a pivotal role of MUC1 in controlling the hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors in pancreatic cancer. Our findings provide the novel insights into the understanding of complex interactions between pancreatic cancer cells and tumor microenvironments.	[Kitamoto, S.; Yokoyama, S.; Higashi, M.; Yamada, N.; Yonezawa, S.] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Human Pathol, Field Oncol, Kagoshima 8908544, Japan; [Takao, S.] Kagoshima Univ, Frontier Sci Res Ctr, Kagoshima 8908544, Japan	Kagoshima University; Kagoshima University	Kitamoto, S (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Human Pathol, Field Oncol, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan.	s-kita@m3.kufm.kagoshima-u.ac.jp	Kitamoto, Sho/AAE-4549-2021	Kitamoto, Sho/0000-0003-3597-6647	Princess Takamastu Cancer Research Fund [11-24319]; Ministry of Education, Science, Sports, Culture and Technology, Japan [20014022, 23390085, 20590399]; International Educational Research Support Project for Islands, Environment and Medicine; JSPS [239349]; Pancreas Reserch Foundation of Japan; Kodama Memorial Foundation, Japan; Grants-in-Aid for Scientific Research [24701008] Funding Source: KAKEN	Princess Takamastu Cancer Research Fund; Ministry of Education, Science, Sports, Culture and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); International Educational Research Support Project for Islands, Environment and Medicine; JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Pancreas Reserch Foundation of Japan; Kodama Memorial Foundation, Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the Princess Takamastu Cancer Research Fund (11-24319; S Yonezawa); by the Scientific Research on Priority Areas 20014022 and Scientific Research (B) 23390085 (S Yonezawa) and Scientific Research (C) 20590399 (M Higashi) grants from the Ministry of Education, Science, Sports, Culture and Technology, Japan; by an International Educational Research Support Project for Islands, Environment and Medicine (S Yokoyama); by a JSPS Fellowship Grant-in-Aid (no. 239349; S Kitamoto); by a Pancreas Reserch Foundation of Japan (S Yokoyama) and Kodama Memorial Foundation, Japan (S Kitamoto, S Yokoyama and M Higashi). We would like to express our gratitude to Dr Ming-Sound Tsao for providing us with the immortalized human pancreatic duct epithelial cells. We also thank Mses Izumi Houjou and Yukari Nishimura for their excellent technical assistance.	Aubert S, 2009, CANCER RES, V69, P5707, DOI 10.1158/0008-5472.CAN-08-4905; Behrens ME, 2010, ONCOGENE, V29, P5667, DOI 10.1038/onc.2010.327; Bennewith KL, 2009, CANCER RES, V69, P775, DOI 10.1158/0008-5472.CAN-08-0987; BHASKAR KR, 1992, NATURE, V360, P458, DOI 10.1038/360458a0; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Carson DD, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127pe35; Chang Q, 2011, CANCER RES, V71, P3110, DOI 10.1158/0008-5472.CAN-10-4049; Chu CY, 2008, J BIOMED SCI, V15, P675, DOI 10.1007/s11373-008-9264-9; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Dornhofer N, 2006, CANCER RES, V66, P5816, DOI 10.1158/0008-5472.CAN-06-0081; Furukawa T, 1996, AM J PATHOL, V148, P1763; Giatromanolaki A, 2000, CLIN CANCER RES, V6, P1917; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Higgins DF, 2004, AM J PHYSIOL-RENAL, V287, pF1223, DOI 10.1152/ajprenal.00245.2004; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hong OY, 2000, AM J PATHOL, V157, P1623, DOI 10.1016/S0002-9440(10)64800-6; Kaira K, 2012, INT J SURG PATHOL, V20, P223, DOI 10.1177/1066896911429296; Kaira K, 2012, PATHOL ONCOL RES, V18, P439, DOI 10.1007/s12253-011-9465-9; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kitamoto S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044108; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Levitin F, 2005, J BIOL CHEM, V280, P33374, DOI 10.1074/jbc.M506047200; Linden SK, 2008, MUCOSAL IMMUNOL, V1, P183, DOI 10.1038/mi.2008.5; Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360; Macao B, 2006, NAT STRUCT MOL BIOL, V13, P71, DOI 10.1038/nsmb1035; Mikami Y, 2009, BIOCHEM BIOPH RES CO, V379, P1060, DOI 10.1016/j.bbrc.2009.01.002; Papadopoulos I, 2001, CLIN CANCER RES, V7, P1533; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Sahraei M, 2012, ONCOGENE, V31, P4935, DOI 10.1038/onc.2011.651; Sakamoto H, 1997, HUM PATHOL, V28, P1056, DOI 10.1016/S0046-8177(97)90059-9; Semenza GL, 2003, ANNU REV MED, V54, P17, DOI 10.1146/annurev.med.54.101601.152418; Shimo T, 2001, CANCER LETT, V174, P57, DOI 10.1016/S0304-3835(01)00683-8; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Woo JK, 2012, ONCOGENE, V31, P2187, DOI 10.1038/onc.2011.410; Yao MY, 2011, LUNG, V189, P453, DOI 10.1007/s00408-011-9327-y; Yin L, 2007, J BIOL CHEM, V282, P257, DOI 10.1074/jbc.M610156200; Yonezawa S, 2012, GASTRIC CANCER, DOI [10.1007/S10120-011-0125-2, DOI 10.1007/S10120-011-0125-2)]; Yonezawa S, 2011, PATHOL INT, V61, P697, DOI 10.1111/j.1440-1827.2011.02734.x; Zanetti JS, 2011, VIRCHOWS ARCH, V459, P367, DOI 10.1007/s00428-011-1142-6	40	46	49	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4614	4621		10.1038/onc.2012.478	http://dx.doi.org/10.1038/onc.2012.478			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23108411				2022-12-17	WOS:000325072200003
J	Amato, R; Scumaci, D; D'Antona, L; Iuliano, R; Menniti, M; Di Sanzo, M; Faniello, MC; Colao, E; Malatesta, P; Zingone, A; Agosti, V; Costanzo, FS; Mileo, AM; Paggi, MG; Lang, F; Cuda, G; Lavia, P; Perrotti, N				Amato, R.; Scumaci, D.; D'Antona, L.; Iuliano, R.; Menniti, M.; Di Sanzo, M.; Faniello, M. C.; Colao, E.; Malatesta, P.; Zingone, A.; Agosti, V.; Costanzo, F. S.; Mileo, A. M.; Paggi, M. G.; Lang, F.; Cuda, G.; Lavia, P.; Perrotti, N.			Sgk1 enhances RANBP1 transcript levels and decreases taxol sensitivity in RKO colon carcinoma cells	ONCOGENE			English	Article						Sgk1; RANBP1; taxol sensitivity; mitotic microtubule stabilization	INDUCIBLE PROTEIN-KINASE; BINDING PROTEIN-1; DOWN-REGULATION; CANCER-CELLS; SERUM; ACTIVATION; PHOSPHORYLATION; IDENTIFICATION; COORDINATION; EXPRESSION	The serum- and glucocorticoid-regulated kinase (Sgk1) is essential for hormonal regulation of epithelial sodium channel-mediated sodium transport and is involved in the transduction of growth factor-dependent cell survival and proliferation signals. Growing evidence now points to Sgk1 as a key element in the development and/or progression of human cancer. To gain insight into the mechanisms through which Sgk1 regulates cell proliferation, we adopted a proteomic approach to identify up- or downregulated proteins after Sgk1-specific RNA silencing. Among several proteins, the abundance of which was found to be up- or downregulated upon Sgk1 silencing, we focused our attention of RAN-binding protein 1 (RANBP1), a major effector of the GTPase RAN. We report that Sgk1-dependent regulation of RANBP1 has functional consequences on both mitotic microtubule activity and taxol sensitivity of cancer cells.	[Amato, R.; D'Antona, L.; Menniti, M.; Perrotti, N.] Magna Graecia Univ Catanzaro, Dept Human Hlth, Catanzaro, Italy; [Scumaci, D.; Iuliano, R.; Di Sanzo, M.; Faniello, M. C.; Agosti, V.; Costanzo, F. S.; Cuda, G.] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy; [Iuliano, R.; Colao, E.; Malatesta, P.; Perrotti, N.] Univ Hosp, Unit Med Genet & Pathol, Policlin Mater Domini, Catanzaro, Italy; [Zingone, A.] NCI, Multiple Myeloma Sect, Metab Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; [Mileo, A. M.; Paggi, M. G.] Natl Canc Inst Regina Elena, Dept Dev Therapeut Programs, Rome, Italy; [Lang, F.] Univ Tubingen, Dept Physiol, Tubingen, Germany; [Lavia, P.] Univ Roma La Sapienza, CNR, IBPM Inst Mol Biol & Pathol, I-00185 Rome, Italy	Magna Graecia University of Catanzaro; Magna Graecia University of Catanzaro; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Eberhard Karls University of Tubingen; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Lavia, P (corresponding author), Univ Roma La Sapienza, CNR, IBPM Inst Mol Biol & Pathol, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	patrizia.lavia@uniroma1.it; perrotti@unicz.it	Scumaci, Domenica/AAH-1493-2019; Lavia, Patrizia/J-5793-2019; Paggi, Marco G./K-3494-2018; Mileo, Anna Maria/J-3667-2016; Costanzo, Francesco Saverio/K-3168-2018; Cuda, Giovanni/AAC-2821-2019; Lavia, Patrizia/AAL-3982-2021; Cuda, Giovanni/F-5359-2012	Lavia, Patrizia/0000-0003-3310-6701; Mileo, Anna Maria/0000-0002-1970-3297; Costanzo, Francesco Saverio/0000-0002-3096-9416; Cuda, Giovanni/0000-0001-6313-1866; Cuda, Giovanni/0000-0001-6313-1866; Amato, Rosario/0000-0001-7162-1099; Scumaci, Domenica/0000-0002-8117-834X; AGOSTI, Valter/0000-0001-6785-093X; FANIELLO, Concetta Maria/0000-0001-6938-2754	Italian Association for Cancer Research (AIRC) [IG10164]; INAIL, CZ	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); INAIL, CZ	This work was supported in part by the Italian Association for Cancer Research (AIRC grant IG10164 to PL). RA was supported in part by INAIL, CZ.	Amato R, 2007, J MOL MED, V85, P707, DOI 10.1007/s00109-007-0205-2; Amato R, 2009, J MOL MED, V87, P1221, DOI 10.1007/s00109-009-0525-5; Archer MC, 2011, CELL METABOL GENES C, V2, P712; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Ciciarello M, 2007, CELL MOL LIFE SCI, V64, P1891, DOI 10.1007/s00018-007-6568-2; Clarke PR, 2008, NAT REV MOL CELL BIO, V9, P464, DOI 10.1038/nrm2410; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; Di Fiore B, 1999, J BIOL CHEM, V274, P10339, DOI 10.1074/jbc.274.15.10339; Di Fiore B, 2003, J CELL SCI, V116, P3399, DOI 10.1242/jcs.00624; Faletti CJ, 2001, AM J PHYSIOL, V283, pC494; Faniello MC, 2008, INT J BIOCHEM CELL B, V40, P2110, DOI 10.1016/j.biocel.2008.02.010; Feng Z, P NATL ACAD SCI US, V109, P7013; Firestone GL, 2003, CELL PHYSIOL BIOCHEM, V13, P1, DOI 10.1159/000070244; Gaspari M, 2007, J SEP SCI, V30, P2210, DOI 10.1002/jssc.200700192; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Guarguaglini G, 2000, CELL GROWTH DIFFER, V11, P455; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hong F, 2008, MOL CELL, V30, P701, DOI 10.1016/j.molcel.2008.04.027; Hu R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019490; Kalab P, 2008, J CELL SCI, V121, P1577, DOI 10.1242/jcs.005959; Kim HS, 2009, J BIOL CHEM, V284, P15475, DOI 10.1074/jbc.M808734200; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Lang F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005; Lang F, 2010, INT J BIOCHEM CELL B, V42, P1571, DOI 10.1016/j.biocel.2010.05.016; Leong MLL, 2003, J BIOL CHEM, V278, P5871, DOI 10.1074/jbc.M211649200; Li HY, 2007, CELL CYCLE, V6, P1886, DOI 10.4161/cc.6.15.4487; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; McCaig C, 2011, BIOCHEM BIOPH RES CO, V411, P227, DOI 10.1016/j.bbrc.2011.06.092; Menniti M, 2005, AM J PHYSIOL-CELL PH, V288, pC148, DOI 10.1152/ajpcell.00284.2004; Menniti M, 2010, CELL PHYSIOL BIOCHEM, V26, P587, DOI 10.1159/000322326; Nasir O, 2009, IUBMB LIFE, V61, P768, DOI 10.1002/iub.209; Peloponese JM, 2005, P NATL ACAD SCI USA, V102, P18974, DOI 10.1073/pnas.0506659103; Perrotti N, 2001, J BIOL CHEM, V276, P9406, DOI 10.1074/jbc.M007052200; Plafker K, 2002, J BIOL CHEM, V277, P30121, DOI 10.1074/jbc.M203006200; Rensen WM, 2009, ONCOGENE, V28, P1748, DOI 10.1038/onc.2009.24; Tan NY, 2009, MOL CELL BIOL, V29, P2483, DOI 10.1128/MCB.01828-08; Tedeschi A, 2007, J CELL SCI, V120, P3748, DOI 10.1242/jcs.009308; Wang K, 2010, CELL PHYSIOL BIOCHEM, V25, P271, DOI 10.1159/000276561; Yamada HY, 2010, CURR CANCER DRUG TAR, V10, P623, DOI 10.2174/156800910791859434; Yuen HF, 2012, CLIN CANCER RES, V18, P380, DOI 10.1158/1078-0432.CCR-11-2035; Zhang Y, 2010, INT J BIOCHEM CELL B, V42, P1964, DOI 10.1016/j.biocel.2010.08.007	42	46	47	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4572	4578		10.1038/onc.2012.470	http://dx.doi.org/10.1038/onc.2012.470			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23108393				2022-12-17	WOS:000324831300013
J	Jackson, JG; Lozano, G				Jackson, J. G.; Lozano, G.			The mutant p53 mouse as a pre-clinical model	ONCOGENE			English	Review						p53; mouse models; treatment response	ADVANCED BREAST-CANCER; LI-FRAUMENI-SYNDROME; IN-VIVO; CELL-CYCLE; TUMOR SUPPRESSION; LUNG-CANCER; GASTROINTESTINAL-SYNDROME; INDUCED APOPTOSIS; TRANSGENIC MICE; CHEMOTHERAPY	The p53 tumor-suppressor pathway is dismantled in the development of most cancers. Mice with various p53 mutant alleles either singly or in combination with other genetic alterations are predisposed to tumor development. Here, we review studies utilizing p53 mutant mice that have recapitulated and informed clinical observations. These studies have demonstrated the p53 contribution, sometimes beneficial and sometimes detrimental, to treatment response in lymphomas, and lung and breast cancers. Further, we examine how p53 mutant mouse models have been used to test the efficacy of p53 reactivation as a therapeutic strategy.	[Jackson, J. G.; Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Lozano, G (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genet, 1515 Holcombe Blvd,Unit 1010, Houston, TX 77030 USA.	gglozano@mdanderson.org		Jackson, James Griffith/0000-0002-2640-6442	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Abbas HA, 2011, CELL CYCLE, V10, P3257, DOI 10.4161/cc.10.19.17721; Abbas HA, 2010, CELL STEM CELL, V7, P606, DOI 10.1016/j.stem.2010.09.013; Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Bearss DJ, 2000, ONCOGENE, V19, P1114, DOI 10.1038/sj.onc.1203275; Berns EMJJ, 2000, CANCER RES, V60, P2155; Bertheau P, 2002, LANCET, V360, P852, DOI 10.1016/S0140-6736(02)09969-5; Bertheau P, 2008, PATHOBIOLOGY, V75, P132, DOI 10.1159/000123851; Bonetti A, 1998, CLIN CANCER RES, V4, P2331; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529; Chen Z, 2012, NATURE, V483, P613, DOI 10.1038/nature10937; Christophorou MA, 2005, NAT GENET, V37, P718, DOI 10.1038/ng1572; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Daniels M, 2012, J THORAC DIS, V4, P155, DOI 10.3978/j.issn.2072-1439.2012.02.01; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749; Jackson JG, 2012, CANCER CELL, V21, P793, DOI 10.1016/j.ccr.2012.04.027; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Karnoub Antoine E, 2006, Breast Dis, V26, P75; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kirsch DG, 2010, SCIENCE, V327, P593, DOI 10.1126/science.1166202; Komarova EA, 2004, ONCOGENE, V23, P3265, DOI 10.1038/sj.onc.1207494; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; LUNA RMD, 1995, NATURE, V378, P203; MacCallum DE, 1996, ONCOGENE, V13, P2575; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Ringshausen I, 2006, CANCER CELL, V10, P501, DOI 10.1016/j.ccr.2006.10.010; Rottenberg S, 2007, P NATL ACAD SCI USA, V104, P12117, DOI 10.1073/pnas.0702955104; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Soussi T, 2005, BIOCHEM BIOPH RES CO, V331, P834, DOI 10.1016/j.bbrc.2005.03.190; Soussi T, 2011, ADV CANCER RES, V110, P107, DOI 10.1016/B978-0-12-386469-7.00005-0; Suh YA, 2011, CANCER RES, V71, P7168, DOI 10.1158/0008-5472.CAN-11-0459; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Vaahtomeri K, 2011, FEBS LETT, V585, P944, DOI 10.1016/j.febslet.2010.12.034; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang YX, 2011, J CLIN INVEST, V121, P893, DOI 10.1172/JCI44504; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Xue W, 2011, CANCER DISCOV, V1, P236, DOI 10.1158/2159-8290.CD-11-0073; Zenz T, 2008, CELL CYCLE, V7, P3810, DOI 10.4161/cc.7.24.7245	69	46	47	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2013	32	37					4325	4330		10.1038/onc.2012.610	http://dx.doi.org/10.1038/onc.2012.610			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23318424				2022-12-17	WOS:000324404200001
J	Xin, L				Xin, L.			Cells of origin for cancer: an updated view from prostate cancer	ONCOGENE			English	Review						cells of origin; prostate cancer; prostate stem cells; lineage hierarchy; lineage tracing; tumor initiation	UROGENITAL SINUS MESENCHYME; EPITHELIAL STEM-CELLS; MURINE PROSTATE; MAMMARY-GLAND; INTERMEDIATE CELLS; TUMOR INITIATION; MIR-200 FAMILY; BASAL-CELLS; EXPRESSION; DIFFERENTIATION	The cells of origin for cancer are the cells within tissues that serve as the target for transformation. Understanding the nature of these cells will benefit disease prevention, diagnosis and prognosis. During the past decade, much progress has been made in understanding the cellular origin for prostate cancer. This review aims to summarize the previous findings, describe the most recent results and discuss some controversies and unresolved issues in this field.	[Xin, L.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Xin, L.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Xin, L.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Xin, L (corresponding author), Baylor Coll Med, M533 DeBakey Bldg BCM MS130,1 Baylor Plaza, Houston, TX 77030 USA.	xin@bcm.edu			NIH [R00CA125937, R01DK092202, U01CA141497]; NATIONAL CANCER INSTITUTE [R00CA125937, U01CA141497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK092202] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	I apologize to those authors whose work could not be cited because of space limitation, and thank Drs Michael Ittmann and Jeffrey Rosen for critical reading of the manuscript. This work is supported by NIH R00CA125937 (LX), R01DK092202 (LX) and U01CA141497 (MMI).	Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Baker CM, 2010, DEV BIOL, V343, P40, DOI 10.1016/j.ydbio.2010.04.005; Barabe F, 2007, SCIENCE, V316, P600, DOI 10.1126/science.1139851; Bethel CR, 2006, CANCER RES, V66, P10683, DOI 10.1158/0008-5472.CAN-06-0963; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; BONKHOFF H, 1994, PROSTATE, V24, P114, DOI 10.1002/pros.2990240303; Burger PE, 2005, P NATL ACAD SCI USA, V102, P7180, DOI 10.1073/pnas.0502761102; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Choi N, 2012, CANCER CELL, V21, P253, DOI 10.1016/j.ccr.2012.01.005; CHUNG LWK, 1983, PROSTATE, V4, P503, DOI 10.1002/pros.2990040509; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; De Marzo AM, 1998, AM J PATHOL, V153, P911, DOI 10.1016/S0002-9440(10)65632-5; de Visser KE, 2012, J PATHOL, V228, P300, DOI 10.1002/path.4096; Doupe DP, 2012, SCIENCE, V337, P1091, DOI 10.1126/science.1218835; Du ZJ, 2007, CELL CYCLE, V6, P823, DOI 10.4161/cc.6.7.4074; El-Alfy M, 2000, MICROSC RES TECHNIQ, V51, P436, DOI 10.1002/1097-0029(20001201)51:5<436::AID-JEMT6>3.0.CO;2-T; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Goldstein AS, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002169; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hudson DL, 2001, J HISTOCHEM CYTOCHEM, V49, P271, DOI 10.1177/002215540104900214; Humphrey PA, 2007, J CLIN PATHOL, V60, P35, DOI 10.1136/jcp.2005.036442; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Isaacs J.T., 1987, NIH PUBLICATION, P85; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Kuhbandner S, 2000, GENESIS, V28, P15, DOI 10.1002/1526-968X(200009)28:1<15::AID-GENE20>3.0.CO;2-C; Lapouge G, 2011, P NATL ACAD SCI USA, V108, P7431, DOI 10.1073/pnas.1012720108; Lawson DA, 2007, P NATL ACAD SCI USA, V104, P181, DOI 10.1073/pnas.0609684104; Lawson DA, 2010, P NATL ACAD SCI USA, V107, P2610, DOI 10.1073/pnas.0913873107; Leong KG, 2008, NATURE, V456, P804, DOI 10.1038/nature07427; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Litvinov IV, 2006, CANCER RES, V66, P8598, DOI 10.1158/0008-5472.CAN-06-1228; Liu AY, 2002, AM J PATHOL, V160, P37, DOI 10.1016/S0002-9440(10)64346-5; Liu J, 2011, MOL ENDOCRINOL, V25, P1849, DOI 10.1210/me.2011-1081; Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; MOELLER H, 1988, RES EXP MED, V188, P451, DOI 10.1007/BF01852003; NEUBAUER BL, 1983, J CELL BIOL, V96, P1671, DOI 10.1083/jcb.96.6.1671; Ousset M, 2012, NAT CELL BIOL, V14, P1130, DOI 10.1038/ncb2600; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pascal Laura E, 2007, BMC Urol, V7, P6, DOI 10.1186/1471-2490-7-6; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Peehl DM, 2005, ENDOCR-RELAT CANCER, V12, P19, DOI 10.1677/erc.1.00795; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621; Sharma MK, 2007, CANCER RES, V67, P890, DOI 10.1158/0008-5472.CAN-06-0973; Shizuru JA, 2005, ANNU REV MED, V56, P509, DOI 10.1146/annurev.med.54.101601.152334; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; SUTHERLAND K, 2011, TLS TIMES LIT S 0422, P19; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Taylor RA, 2006, NAT METHODS, V3, P179, DOI 10.1038/nmeth855; Taylor RA, 2009, STEM CELLS, V27, P3032, DOI 10.1002/stem.244; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tran CP, 2002, MOL CANCER RES, V1, P113; Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0; Valdez JM, 2012, CELL STEM CELL, V11, P676, DOI 10.1016/j.stem.2012.07.003; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; van Leenders G, 2000, LAB INVEST, V80, P1251, DOI 10.1038/labinvest.3780133; van Leenders GJLH, 2003, AM J PATHOL, V162, P1529, DOI 10.1016/S0002-9440(10)64286-1; Vashchenko N, 2005, EUR UROL, V47, P147, DOI 10.1016/j.eururo.2004.09.007; VERHAGEN APM, 1992, CANCER RES, V52, P6182; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; von Werder A, 2012, NAT PROTOC, V7, P1167, DOI 10.1038/nprot.2012.060; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Wang YZ, 2001, DIFFERENTIATION, V68, P270, DOI 10.1046/j.1432-0436.2001.680414.x; Welm AL, 2005, P NATL ACAD SCI USA, V102, P4324, DOI 10.1073/pnas.0500470102; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; Xin L, 2003, P NATL ACAD SCI USA, V100, P11896, DOI 10.1073/pnas.1734139100; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Zhang L, 2010, PROSTATE, V70, P297, DOI 10.1002/pros.21064; Zong Y, 2009, P NATL ACAD SCI USA, V106, P12465, DOI 10.1073/pnas.0905931106	80	46	51	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2013	32	32					3655	3663		10.1038/onc.2012.541	http://dx.doi.org/10.1038/onc.2012.541			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	23178496	Green Accepted			2022-12-17	WOS:000322904400001
J	Calao, M; Sekyere, EO; Cui, HJ; Cheung, BB; Thomas, WD; Keating, J; Chen, JB; Raif, A; Jankowski, K; Davies, NP; Bekkum, MV; Chen, B; Tan, O; Ellis, T; Norris, MD; Haber, M; Kim, ES; Shohet, JM; Trahair, TN; Liu, T; Wainwright, BJ; Ding, HF; Marshall, GM				Calao, M.; Sekyere, E. O.; Cui, H. J.; Cheung, B. B.; Thomas, W. D.; Keating, J.; Chen, J. B.; Raif, A.; Jankowski, K.; Davies, N. P.; Bekkum, M. V.; Chen, B.; Tan, O.; Ellis, T.; Norris, M. D.; Haber, M.; Kim, E. S.; Shohet, J. M.; Trahair, T. N.; Liu, T.; Wainwright, B. J.; Ding, H. F.; Marshall, G. M.			Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation	ONCOGENE			English	Article						Bmi1; p53; MYCN; neuroblastoma; medulloblastoma; apoptosis	MYC TRANSGENIC MICE; STEM-CELLS; IN-VIVO; NEUROBLASTOMA; MEDULLOBLASTOMA; LINES; AMPLIFICATION; EXPRESSION; MECHANISM; APOPTOSIS	Embryonal cancer can arise from postnatally persistent embryonal remnant or rest cells, which are uniquely characterized by the absence of p53 mutations. Perinatal overexpression of the MycN oncoprotein in embryonal cancer precursor cells causes postnatal rests, and later tumor formation through unknown mechanisms. However, overexpression of Myc in adult tissues normally activates apoptosis and/or senescence signals as an organismal defense mechanism against cancer. Here, we show that perinatal neuroblastoma precursor cells exhibited a transiently diminished p53 response to MycN oncoprotein stress and resistance to trophic factor withdrawal, compared with their adult counterpart cells from the TH-MYCN-/- transgenic mouse model of neuroblastoma. The adult stem cell maintenance factor and Polycomb group protein, Bmi1 (B-cell-specific Moloney murine leukemia virus integration site), had a critical role at neuroblastoma initiation in the model, by repressing p53 responses in precursor cells. We further show in neuroblastoma tumor cells that Bmi1 could directly bind p53 in a complex with other Polycomb complex proteins, Ring1A or Ring1B, leading to increased p53 ubiquitination and degradation. Repressed p53 signal responses were also seen in precursor cells for other embryonal cancer types, medulloblastoma and acute lymphoblastic leukemia. Collectively, these date indicate a general mechanism for p53 inactivation in some embryonal cell types and consequent susceptibility to MycN oncogenesis at the point of embryonal tumor initiation.	[Calao, M.; Sekyere, E. O.; Cheung, B. B.; Thomas, W. D.; Keating, J.; Chen, J. B.; Raif, A.; Jankowski, K.; Davies, N. P.; Bekkum, M. V.; Chen, B.; Tan, O.; Norris, M. D.; Haber, M.; Trahair, T. N.; Liu, T.; Marshall, G. M.] Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia Med Res, Sydney, NSW 2031, Australia; [Cui, H. J.] Southwest Univ, Inst Sericulture & Syst Biol, State Key Lab Silkworm Funct Genome Biol, Chongqing, Peoples R China; [Ellis, T.; Wainwright, B. J.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia; [Kim, E. S.; Shohet, J. M.] Texas Childrens Hosp, Houston, TX 77030 USA; [Trahair, T. N.; Marshall, G. M.] Sydney Childrens Hosp, Sydney, NSW, Australia; [Ding, H. F.] Med Coll Georgia, Augusta, GA 30912 USA	Children's Cancer Institute; Children's Medical Research Institute - Australia; University of New South Wales Sydney; Southwest University - China; University of Queensland; Baylor College of Medicine; University of Sydney; University System of Georgia; Augusta University	Marshall, GM (corresponding author), Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia Med Res, Sydney, NSW 2031, Australia.	g.marshall@ccia.unsw.edu.au	Chen, Jinbiao/J-5868-2013; Liu, Tao/A-3922-2015; Chen, Jinbiao/N-9905-2019	Chen, Jinbiao/0000-0003-0339-5880; Chen, Jinbiao/0000-0003-0339-5880; Haber, Michelle/0000-0003-2036-8817; Ding, Han-Fei/0000-0001-5702-3439; Liu, Tao/0000-0001-6244-7316; Tan, Owen/0000-0002-0303-7138; Kim, Eugene/0000-0001-7959-5614; Trahair, Toby/0000-0002-3295-228X; Wainwright, Brandon/0000-0003-0406-2092; Cheung, Belamy/0000-0001-8784-860X	National Health & Medical Research Council of Australia; Cancer Institute New South Wales; Cure for Life Foundation; Cancer Council New South Wales	National Health & Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute New South Wales; Cure for Life Foundation; Cancer Council New South Wales(Cancer Council New South Wales)	We thank W Weiss for the TH-MYCN mice, and D Kaplan for the adenoviral vector MYCN constructs. This work was supported by the National Health & Medical Research Council of Australia, Cancer Institute New South Wales, Cure for Life Foundation and the Cancer Council New South Wales.	Alajez NM, 2009, CELL DEATH DIFFER, V16, P1469, DOI 10.1038/cdd.2009.85; Alchanati I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008104; BECKWITH JB, 1963, AM J PATHOL, V43, P1089; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Buchwald G, 2006, EMBO J, V25, P2465, DOI 10.1038/sj.emboj.7601144; Carr J, 2006, CANCER RES, V66, P2138, DOI 10.1158/0008-5472.CAN-05-2623; Chen LD, 2010, CANCER RES, V70, P1377, DOI 10.1158/0008-5472.CAN-09-2598; Chen ZW, 2009, NEOPLASIA, V11, P753, DOI 10.1593/neo.09466; Cheng AJ, 2007, EUR J CANCER, V43, P1467, DOI 10.1016/j.ejca.2007.03.008; Chesler L, 2008, NEOPLASIA, V10, P1268, DOI 10.1593/neo.08778; CICCARONE V, 1989, CANCER RES, V49, P219; Cohnheim J., 1889, LECT GEN PATHOLOGY; Cui HJ, 2007, AM J PATHOL, V170, P1370, DOI 10.2353/ajpath.2007.060754; Durante F., 1874, ARCH MEMOR OBSERV CH, V11, P217; Ellis T, 2003, GENESIS, V36, P158, DOI 10.1002/gene.10208; Fasano CA, 2007, CELL STEM CELL, V1, P87, DOI 10.1016/j.stem.2007.04.001; Gilbertson RJ, 2004, LANCET ONCOL, V5, P209, DOI 10.1016/S1470-2045(04)01424-X; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gurova KV, 2005, P NATL ACAD SCI USA, V102, P17448, DOI 10.1073/pnas.0508888102; Hansford LM, 2004, P NATL ACAD SCI USA, V101, P12664, DOI 10.1073/pnas.0401083101; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Hogarty MD, 2003, CANCER LETT, V197, P173, DOI 10.1016/S0304-3835(03)00103-4; Jasty R, 2001, NEOPLASIA, V3, P304, DOI 10.1038/sj.neo.7900171; Jiang LL, 2009, ACTA BIOCH BIOPH SIN, V41, P527, DOI 10.1093/abbs/gmp040; Johnsen J, 2009, APOPTOSIS, V14, P424, DOI 10.1007/s10495-009-0325-y; Kang MK, 2010, CELL CYCLE, V9, P2704, DOI 10.4161/cc.9.14.12322; Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Lossi L, 2003, PROG NEUROBIOL, V69, P287, DOI 10.1016/S0301-0082(03)00051-0; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Ochiai H, 2010, ONCOGENE, V29, P2681, DOI 10.1038/onc.2010.22; Peirce SK, 2010, CELL HEALTH CYTOSKEL, V2, P49; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; Scotting PJ, 2005, NAT REV CANCER, V5, P481, DOI 10.1038/nrc1633; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Taub JW, 2002, BLOOD, V99, P2992, DOI 10.1182/blood.V99.8.2992; Thomas WD, 2009, ONCOGENE, V28, P1605, DOI 10.1038/onc.2009.3; Thomas WD, 2004, INT J BIOCHEM CELL B, V36, P771, DOI 10.1016/S1357-2725(03)00254-1; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Wartiovaara K, 2002, J NEUROSCI, V22, P815, DOI 10.1523/JNEUROSCI.22-03-00815.2002; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Wetmore C, 2001, CANCER RES, V61, P513; WHITLOCK CA, 1987, METHOD ENZYMOL, V150, P275; Woods WG, 1996, LANCET, V348, P1682, DOI 10.1016/S0140-6736(96)06020-5; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003	47	46	46	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2013	32	31					3616	3626		10.1038/onc.2012.368	http://dx.doi.org/10.1038/onc.2012.368			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194MW	22907436	hybrid			2022-12-17	WOS:000322638400006
J	Ansari, KI; Kasiri, S; Mandal, SS				Ansari, K. I.; Kasiri, S.; Mandal, S. S.			Histone methylase MLL1 has critical roles in tumor growth and angiogenesis and its knockdown suppresses tumor growth in vivo	ONCOGENE			English	Article						MLL1; histone methylase; xenograft; antisense; hypoxia; tumor supression	CPG-BINDING-PROTEIN; METHYLTRANSFERASE ACTIVITY; CANCER XENOGRAFTS; GENE-EXPRESSION; CHROMATIN; LEUKEMIA; INHIBITION; ANTISENSE; TRITHORAX; HYPOXIA	Mixed lineage leukemias (MLLs) are human histone H3 lysine-4-specific methyl transferases that have critical roles in gene expression, epigenetics and cancer. Herein, we demonstrated that antisense-mediated knockdown of MLL1 induced cell-cycle arrest and apoptosis in cultured cells. Intriguingly, application of MLL1 antisense specifically knocked down MLL1 in vivo and suppressed the growth of xenografted cervical tumor implanted in nude mouse. MLL1 knockdown downregulated various growth and angiogenic factors, such as HIF1 alpha, VEGF and CD31, in tumor tissue affecting tumor growth. MLL1 is overexpressed along the line of vascular network and localized adjacent to endothelial cell layer expressing CD31, indicating potential roles of MLL1 in vasculogenesis. MLL1 is also overexpressed in the hypoxic regions along with HIF1 alpha. Overall, our studies demonstrated that MLL1 is a key factor in hypoxia signaling, vasculogenesis and tumor growth, and its depletion suppresses tumor growth in vivo, indicating its potential in novel cancer therapy.	[Ansari, K. I.; Kasiri, S.; Mandal, S. S.] Univ Texas Arlington, Dept Chem & Biochem, Arlington, TX 76019 USA	University of Texas System; University of Texas Arlington	Mandal, SS (corresponding author), Univ Texas Arlington, Dept Chem & Biochem, 700 Planetarium Pl, Arlington, TX 76019 USA.	smandal@uta.edu		Mandal, Subhrangsu/0000-0001-8495-9881	NIH [1R15 ES019129-01, 2R15 CA113747-02]; NSF [0821969]; NATIONAL CANCER INSTITUTE [R15CA113747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R15ES019129] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Linda Perrotti and Samara Morris-Bobzean for their technical assistance with tissue sectioning and Mandal lab members for discussion. Mandal research is supported by grants from NIH (1R15 ES019129-01, 2R15 CA113747-02) and NSF (0821969).	Ansari KI, 2008, BBA-GENE REGUL MECH, V1779, P66, DOI 10.1016/j.bbagrm.2007.11.006; Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050; Ansari KI, 2011, BIOCHEMISTRY-US, V50, P3517, DOI 10.1021/bi102037t; Ansari KI, 2010, FEBS J, V277, P1790, DOI 10.1111/j.1742-4658.2010.07606.x; Ansari KI, 2009, FEBS J, V276, P3299, DOI 10.1111/j.1742-4658.2009.07055.x; Ansari KI, 2009, J INORG BIOCHEM, V103, P818, DOI 10.1016/j.jinorgbio.2009.02.004; Bhaumik SR, 2007, NAT STRUCT MOL BIOL, V14, P1008, DOI 10.1038/nsmb1337; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Canaani E, 2004, BRIT J CANCER, V90, P756, DOI 10.1038/sj.bjc.6601639; Corey DR, 2002, ONCOGENE, V21, P631, DOI 10.1038/sj.onc.1205063; Crawford BD, 2006, ACS CHEM BIOL, V1, P495, DOI 10.1021/cb600367v; Cuthbert G, 2000, LEUKEMIA, V14, P1885, DOI 10.1038/sj.leu.2401919; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Deng LW, 2004, P NATL ACAD SCI USA, V101, P757, DOI 10.1073/pnas.2036345100; Diehl F, 2007, BLOOD, V109, P1472, DOI 10.1182/blood-2006-08-039651; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Glaser S, 2006, DEVELOPMENT, V133, P1423, DOI 10.1242/dev.02302; Gleave ME, 2005, NAT REV CANCER, V5, P468, DOI 10.1038/nrc1631; Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006; Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102; Halatsch ME, 2006, CANCER TREAT REV, V32, P74, DOI 10.1016/j.ctrv.2006.01.003; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hendriksen EM, 2009, MICROVASC RES, V77, P96, DOI 10.1016/j.mvr.2008.11.002; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Joaquin M, 2012, EMBO J, V31, P2952, DOI 10.1038/emboj.2012.122; Kang CS, 2006, CANCER GENE THER, V13, P530, DOI 10.1038/sj.cgt.7700932; Kurdistani SK, 2011, PROG DRUG RES, V67, P91, DOI 10.1007/978-3-7643-8989-5_5; Lee JS, 2008, CANCER LETT, V267, P189, DOI 10.1016/j.canlet.2008.03.013; Lee J, 2008, P NATL ACAD SCI USA, V105, P19229, DOI 10.1073/pnas.0810100105; Lee JH, 2002, J BIOL CHEM, V277, P42259, DOI 10.1074/jbc.M205054200; Lee K, 2007, PHARMACOL THERAPEUT, V113, P229, DOI 10.1016/j.pharmthera.2006.08.001; Lendahl U, 2009, NAT REV GENET, V10, P821, DOI 10.1038/nrg2665; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Liu H, 2010, NATURE, V467, P343, DOI 10.1038/nature09350; Lu B, 2004, CANCER RES, V64, P2840, DOI 10.1158/0008-5472.CAN-03-3547; Mishra BP, 2009, FEBS J, V276, P1629, DOI 10.1111/j.1742-4658.2009.06895.x; Monti Elena, 2011, Curr Mol Pharmacol, V4, P62; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892; Paulussen ADC, 2011, HUM MUTAT, V32, pE2018, DOI 10.1002/humu.21416; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Ruthenburg AJ, 2006, NAT STRUCT MOL BIOL, V13, P704, DOI 10.1038/nsmb1119; Ryan BM, 2009, CANCER TREAT REV, V35, P553, DOI 10.1016/j.ctrv.2009.05.003; Saigo K, 2008, HUM MUTAT, V29, P703, DOI 10.1002/humu.20701; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Sims RJ, 2004, NAT CELL BIOL, V6, P685, DOI 10.1038/ncb0804-685; Singhal SS, 2007, CANCER RES, V67, P4382, DOI 10.1158/0008-5472.CAN-06-4124; Travers J, 2011, NAT CHEM BIOL, V7, P663, DOI 10.1038/nchembio.661; Wang D, 2008, BIOTECH HISTOCHEM, V83, P179, DOI 10.1080/10520290802451085; Wang H, 2002, INT J ONCOL, V21, P73; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wang XX, 2011, PATHOL ONCOL RES, V17, P429, DOI 10.1007/s12253-010-9316-0; Watanabe Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023320; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004	59	46	47	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2013	32	28					3359	3370		10.1038/onc.2012.352	http://dx.doi.org/10.1038/onc.2012.352			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	180TM	22926525	Green Accepted, Bronze			2022-12-17	WOS:000321620200006
J	Agarwal, NK; Chen, CH; Cho, H; Boulbes, DR; Spooner, E; Sarbassov, DD				Agarwal, N. K.; Chen, C-H; Cho, H.; Boulbes, D. R.; Spooner, E.; Sarbassov, D. D.			Rictor regulates cell migration by suppressing RhoGDI2	ONCOGENE			English	Article						rictor (rapamycin-insensitive companion of mTOR); cell migration; Rho proteins; RhoGDI2	GDP-DISSOCIATION INHIBITOR; ENDOPLASMIC-RETICULUM; AKT PHOSPHORYLATION; MTOR COMPLEX; CANCER; METASTASIS; ACTIVATION; GROWTH; SITE; DICTYOSTELIUM	Rictor and its binding partner Sin1 are indispensable components of mTORC2 (mammalian target of rapamycin complex 2). The mTORC2 signaling complex functions as the regulatory kinase of the distinct members of AGC kinase family known to regulate cell proliferation and survival. In the early chemotaxis studies in Dictyostelium, the rictor's ortholog has been identified as a regulator of cell migration. How rictor regulates cell migration is poorly characterized. Here we show that rictor regulates cell migration by controlling a potent inhibitor of Rho proteins known as the Rho-GDP dissociation inhibitor 2 (RhoGDI2). On the basis of on our proteomics study we identified that the rictor-dependent deficiency in cell migration is caused by upregulation of RhoGDI2 leading to a low activity of Rac and Cdc42. We found that a suppression of RhoGDI2 by rictor is not related to the Sin1 or raptor function that excludes a role of mTORC2 or mTORC1 in regulation of RhoGDI2. Our study reveals that rictor by suppressing RhoGDI2 promotes activity of the Rho proteins and cell migration.	[Agarwal, N. K.; Chen, C-H; Cho, H.; Boulbes, D. R.; Sarbassov, D. D.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Chen, C-H; Cho, H.; Sarbassov, D. D.] Univ Texas Houston, Grad Sch Biomed Sci Houston, Houston, TX USA; [Spooner, E.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Massachusetts Institute of Technology (MIT); Whitehead Institute	Sarbassov, DD (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dsarbass@mdanderson.org	Sarbassov, Dos/AAS-4950-2020	Sarbassov, Dos/0000-0002-6848-1133	MD Anderson Metastasis Research Program; NIH [CA133522]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA133522] Funding Source: NIH RePORTER	MD Anderson Metastasis Research Program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank MA Magnuson for providing the immortalized rictor null MEFs, David A Guertin and David M Sabatini for providing the rictor null primary MEFs, and Bin Su for providing Sin1 null MEFs. This study was supported by the MD Anderson Metastasis Research Program and the NIH grant CA133522 (DDS).	Aimbetov R, 2012, ONCOGENE, V31, P2115, DOI 10.1038/onc.2011.404; Boulbes D, 2010, MOL CANCER RES, V8, P896, DOI 10.1158/1541-7786.MCR-09-0409; Boulbes DR, 2011, BIOCHEM BIOPH RES CO, V413, P46, DOI 10.1016/j.bbrc.2011.08.034; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Chen CH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001731; Chen MY, 1997, GENE DEV, V11, P3218, DOI 10.1101/gad.11.23.3218; Dihazi H, 2005, MOL CELL PROTEOMICS, V4, P1445, DOI 10.1074/mcp.M400184-MCP200; Dovas A, 2005, BIOCHEM J, V390, P1, DOI 10.1042/BJ20050104; Gao DM, 2010, MOL CELL, V39, P797, DOI 10.1016/j.molcel.2010.08.016; Gildea JJ, 2002, CANCER RES, V62, P6418; Hagan GN, 2008, MOL CELL BIOL, V28, P4215, DOI 10.1128/MCB.00867-07; Imai K, 2002, BIOCHEM BIOPH RES CO, V296, P305, DOI 10.1016/S0006-291X(02)00861-6; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Khyrul WAKM, 2004, J BIOL CHEM, V279, P54131, DOI 10.1074/jbc.M410051200; Kim SV, 2008, CELL MOL LIFE SCI, V65, P2128, DOI 10.1007/s00018-008-7435-5; Klemm EJ, 2011, J BIOL CHEM, V286, P37602, DOI 10.1074/jbc.M111.284794; Liu LH, 2010, DEV CELL, V19, P845, DOI 10.1016/j.devcel.2010.11.004; Masri J, 2007, CANCER RES, V67, P11712, DOI 10.1158/0008-5472.CAN-07-2223; McDonald PC, 2008, CANCER RES, V68, P1618, DOI 10.1158/0008-5472.CAN-07-5869; Moissoglu K, 2009, CANCER RES, V69, P2838, DOI 10.1158/0008-5472.CAN-08-1397; Oh WJ, 2010, EMBO J, V29, P3939, DOI 10.1038/emboj.2010.271; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Said N, 2009, CANCER METAST REV, V28, P327, DOI 10.1007/s10555-009-9197-4; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; Theodorescu D, 2004, CLIN CANCER RES, V10, P3800, DOI 10.1158/1078-0432.CCR-03-0653; Zhang YQ, 2009, J BIOL CHEM, V284, P12956, DOI 10.1074/jbc.M807845200; Zinzalla V, 2011, CELL, V144, P757, DOI 10.1016/j.cell.2011.02.014; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	33	46	48	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 16	2013	32	20					2521	2526		10.1038/onc.2012.287	http://dx.doi.org/10.1038/onc.2012.287			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22777355	Green Accepted			2022-12-17	WOS:000319274300003
J	Germann, S; Gratadou, L; Zonta, E; Dardenne, E; Gaudineau, B; Fougere, M; Samaan, S; Dutertre, M; Jauliac, S; Auboeuf, D				Germann, S.; Gratadou, L.; Zonta, E.; Dardenne, E.; Gaudineau, B.; Fougere, M.; Samaan, S.; Dutertre, M.; Jauliac, S.; Auboeuf, D.			Dual role of the ddx5/ddx17 RNA helicases in the control of the pro-migratory NFAT5 transcription factor	ONCOGENE			English	Article						ddx5; ddx17; NFAT5; cancer; transcriptional coregulator; splicing	CANCER CELL MOTILITY; DEAD-BOX PROTEINS; BINDING-PROTEIN; SPLICING REGULATION; LIPOCALIN 2; P68; EXPRESSION; S100A4; GENE; COACTIVATOR	Ddx5 and ddx17 are two highly related RNA helicases involved in both transcription and splicing. These proteins coactivate transcription factors involved in cancer such as the estrogen receptor alpha, p53 and beta-catenin. Ddx5 and ddx17 are part of the splicing machinery and can modulate alternative splicing, the main mechanism increasing the proteome diversity. Alternative splicing also has a role in gene expression level regulation when it is coupled to the nonsense-mediated mRNA decay (NMD) pathway. In this work, we report that ddx5 and ddx17 have a dual role in the control of the pro-migratory NFAT5 transcription factor. First, ddx5 and ddx17 act as transcriptional coactivators of NFAT5 and are required for activating NFAT5 target genes involved in tumor cell migration. Second, at the splicing level, ddx5 and ddx17 increase the inclusion of NFAT5 exon 5. As exon 5 contains a pre-mature translation termination codon, its inclusion leads to the regulation of NFAT5 mRNAs by the NMD pathway and to a decrease in NFAT5 protein level. Therefore, we demonstrated for the first time that a transcriptional coregulator can simultaneously regulate the transcriptional activity and alternative splicing of a transcription factor. This dual regulation, where ddx5 and ddx17 enhance the transcriptional activity of NFAT5 although reducing its protein expression level, suggests a critical role for ddx5 and ddx17 in tumor cell migration through the fine regulation of NFAT5 pathway. Oncogene (2012) 31, 4536-4549; doi:10.1038/onc.2011.618; published online 23 January 2012	[Auboeuf, D.] Ctr Leon Berard, Ctr Rech Cancerol Lyon, F-69008 Lyon, France; [Germann, S.; Gratadou, L.; Zonta, E.; Dardenne, E.; Samaan, S.; Dutertre, M.; Auboeuf, D.] Univ Lyon, Lyon, France; [Germann, S.; Gratadou, L.; Zonta, E.; Dardenne, E.; Samaan, S.; Dutertre, M.; Auboeuf, D.] INSERM, U1052, F-69008 Lyon, France; [Germann, S.; Gratadou, L.; Zonta, E.; Dardenne, E.; Samaan, S.; Dutertre, M.; Auboeuf, D.] CNRS, UMR5286, Lyon, France; [Germann, S.; Gratadou, L.; Zonta, E.; Dardenne, E.; Samaan, S.; Dutertre, M.; Auboeuf, D.] Univ Lyon 1, F-69365 Lyon, France; [Gaudineau, B.; Fougere, M.; Jauliac, S.] Univ Paris Diderot, Hop St Louis, Inst Hematol, CNRS,UMR7212,INSERM,U944, Paris, France	UNICANCER; Centre Leon Berard; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Auboeuf, D (corresponding author), Ctr Leon Berard, Ctr Rech Cancerol Lyon, 28 Rue Laennec, F-69008 Lyon, France.	didier.auboeuf@inserm.fr	Jauliac, Sebastien/B-7847-2010; Auboeuf, Didier/M-4610-2014; Dutertre, Martin/N-7060-2017; DUTERTRE, Martin/Q-1815-2019; Zonta, E/B-8928-2013	Jauliac, Sebastien/0000-0002-1712-3416; Dutertre, Martin/0000-0003-0278-4120; DUTERTRE, Martin/0000-0003-0278-4120; Zonta, E/0000-0001-8106-0504; Auboeuf, Didier/0000-0002-3757-0002	EC (NoE EURASNET); Institut National du Cancer; Association pour la Recherche sur le Cancer; Ligue Nationale Contre le Cancer; Agence Nationale de la Recherche; French Ministry of Education	EC (NoE EURASNET); Institut National du Cancer(Institut National du Cancer (INCA) France); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Agence Nationale de la Recherche(French National Research Agency (ANR)); French Ministry of Education	We thank S Kato and J Marie for providing wild-type and mutant ddx5 and ddx17 expression vectors. We thank Emanuele Buratti for providing pTB minigene construct. We thank Coralie Poulard and Muriel Le Romancer-Cherifi for their help with PLA. This work was supported by EC (NoE EURASNET), Institut National du Cancer, Association pour la Recherche sur le Cancer, Ligue Nationale Contre le Cancer and Agence Nationale de la Recherche. S Germann, B Gaudineau and M Fougere were supported by Association pour la Recherche sur le Cancer; L Gratadou by Agence Nationale de la Recherche; E Zonta by the French Ministry of Education; E Dardenne by Ligue Nationale Contre le Cancer.	Allemand E, 2008, CURR OPIN GENET DEV, V18, P145, DOI 10.1016/j.gde.2008.01.006; Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Auboeuf D, 2007, TRENDS ENDOCRIN MET, V18, P122, DOI 10.1016/j.tem.2007.02.003; Ayers M, 2004, J CLIN ONCOL, V22, P2284, DOI 10.1200/JCO.2004.05.166; Baksh S, 2002, MOL CELL, V10, P1071, DOI 10.1016/S1097-2765(02)00701-3; Barbier J, 2007, MOL CELL BIOL, V27, P7315, DOI 10.1128/MCB.00272-07; Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Bittencourt D, 2008, MOL CELL BIOL, V28, P5811, DOI 10.1128/MCB.02231-07; Blencowe BJ, 2003, CURR BIOL, V13, pR149, DOI 10.1016/S0960-9822(03)00079-4; Burg MB, 2007, PHYSIOL REV, V87, P1441, DOI 10.1152/physrev.00056.2006; Camats M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002926; Caretti G, 2006, DEV CELL, V11, P547, DOI 10.1016/j.devcel.2006.08.003; Carter CL, 2010, ONCOGENE, V29, P5427, DOI 10.1038/onc.2010.276; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Chang YF, 2007, J BIOL CHEM, V282, P29738, DOI 10.1074/jbc.M704372200; Chen M, 2011, AM J PHYSIOL-CELL PH, V300, pC1155, DOI 10.1152/ajpcell.00407.2010; Chen M, 2009, J BIOL CHEM, V284, P1484, DOI 10.1074/jbc.M803997200; Chen Y, 2007, AM J PHYSIOL-RENAL, V292, pP981, DOI 10.1152/ajprenal.00493.2005; Chuvpilo S, 2002, IMMUNITY, V16, P881, DOI 10.1016/S1074-7613(02)00329-1; Clark EL, 2008, CANCER RES, V68, P7938, DOI 10.1158/0008-5472.CAN-08-0932; Dahl SC, 2001, AM J PHYSIOL-CELL PH, V280, pC248, DOI 10.1152/ajpcell.2001.280.2.C248; Dalski A, 2002, CYTOGENET GENOME RES, V97, P179, DOI 10.1159/000066604; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; Davies MPA, 1996, ONCOGENE, V13, P1631; Dutertre M, 2010, RNA BIOL, V7, P403, DOI 10.4161/rna.7.4.12152; Dutertre M, 2010, CANCER RES, V70, P3760, DOI 10.1158/0008-5472.CAN-09-3988; Ferraris JD, 2002, P NATL ACAD SCI USA, V99, P739, DOI 10.1073/pnas.241637298; FLOWER DR, 1994, FEBS LETT, V354, P7, DOI 10.1016/0014-5793(94)01078-1; Fougere M, 2010, ONCOGENE, V29, P2292, DOI 10.1038/onc.2009.499; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Fuller-Pace FV, 2008, BIOCHEM SOC T, V36, P609, DOI 10.1042/BST0360609; Fuller-Pace FV, 2011, FUTURE ONCOL, V7, P239, DOI 10.2217/FON.11.1; Gardner LB, 2010, MOL CANCER RES, V8, P295, DOI 10.1158/1541-7786.MCR-09-0502; Garrett SC, 2006, J BIOL CHEM, V281, P677, DOI 10.1074/jbc.R500017200; Guil S, 2003, MOL CELL BIOL, V23, P2927, DOI 10.1128/MCB.23.8.2927-2941.2003; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Helfman DM, 2005, BRIT J CANCER, V92, P1955, DOI 10.1038/sj.bjc.6602613; Honig A, 2002, MOL CELL BIOL, V22, P5698, DOI 10.1128/MCB.22.16.5698-5707.2002; Irarrazabal CE, 2010, P NATL ACAD SCI USA, V107, P906, DOI 10.1073/pnas.0913415107; Jacobs AMF, 2007, ONCOGENE, V26, P5866, DOI 10.1038/sj.onc.1210387; Janknecht R, 2010, AM J TRANSL RES, V2, P223; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Kar A, 2011, MOL CELL BIOL, V31, P1812, DOI 10.1128/MCB.01149-10; Leng XH, 2011, J CELL PHYSIOL, V226, P309, DOI 10.1002/jcp.22403; Leng XH, 2009, CANCER RES, V69, P8579, DOI 10.1158/0008-5472.CAN-09-1934; Levy C, 2010, MOL CELL, V40, P841, DOI 10.1016/j.molcel.2010.11.020; Lewis BP, 2003, P NATL ACAD SCI USA, V100, P189, DOI 10.1073/pnas.0136770100; Li ZH, 2006, CANCER RES, V66, P5173, DOI 10.1158/0008-5472.CAN-05-3087; Lopez-Rodriguez C, 2001, IMMUNITY, V15, P47, DOI 10.1016/S1074-7613(01)00165-0; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Mancini M, 2009, NAT REV CANCER, V9, P810, DOI 10.1038/nrc2735; Maouyo D, 2002, AM J PHYSIOL-RENAL, V282, pF802, DOI 10.1152/ajprenal.00123.2001; McGlincy NJ, 2008, TRENDS BIOCHEM SCI, V33, P385, DOI 10.1016/j.tibs.2008.06.001; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mooney SM, 2010, J BIOL CHEM, V285, P30443, DOI 10.1074/jbc.M110.143792; Mooney SM, 2010, BIOCHEMISTRY-US, V49, P1, DOI 10.1021/bi901263m; Moore HC, 2010, ONCOGENE, V29, P6475, DOI 10.1038/onc.2010.381; Muller MR, 2010, NAT REV IMMUNOL, V10, P645, DOI 10.1038/nri2818; Neu-Yilik G, 2008, ADV GENET, V62, P185, DOI 10.1016/S0065-2660(08)00604-4; O'Connor RS, 2007, J CELL SCI, V120, P149, DOI 10.1242/jcs.03307; Rossow KL, 2003, ONCOGENE, V22, P151, DOI 10.1038/sj.onc.1206067; Shin S, 2007, CANCER RES, V67, P7572, DOI 10.1158/0008-5472.CAN-06-4652; Stamm S, 2005, GENE, V344, P1, DOI 10.1016/j.gene.2004.10.022; Warner DR, 2004, BIOCHEM BIOPH RES CO, V324, P70, DOI 10.1016/j.bbrc.2004.09.017; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Wilson BJ, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-11; Woo SK, 2000, AM J PHYSIOL-RENAL, V278, pF1006; Wortham NC, 2009, ONCOGENE, V28, P4053, DOI 10.1038/onc.2009.261; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Yang LQ, 2007, J BIOL CHEM, V282, P16811, DOI 10.1074/jbc.M610488200; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033	75	46	47	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	42					4536	4549		10.1038/onc.2011.618	http://dx.doi.org/10.1038/onc.2011.618			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	022SH	22266867				2022-12-17	WOS:000309982100005
J	Anensen, N; Hjelle, SM; Van Belle, W; Haaland, I; Silden, E; Bourdon, JC; Hovland, R; Tasken, K; Knappskog, S; Lonning, PE; Bruserud, O; Gjertsen, BT				Anensen, N.; Hjelle, S. M.; Van Belle, W.; Haaland, I.; Silden, E.; Bourdon, J-C; Hovland, R.; Tasken, K.; Knappskog, S.; Lonning, P. E.; Bruserud, O.; Gjertsen, B. T.			Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia	ONCOGENE			English	Article						p53 protein isoform; p53 beta; p53 gamma; acute myeloid leukemia/NPM1/FLT3-ITD	ACUTE MYELOGENOUS LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; BREAST-CANCER PATIENTS; WILD-TYPE P53; AML 10 TRIAL; FUNCTIONAL-CHARACTERIZATION; FAVORABLE PROGNOSIS; NUCLEOPHOSMIN NPM1; NORMAL KARYOTYPE; KINASE-ACTIVITY	The wild-type tumor-suppressor gene TP53 encodes several isoforms of the p53 protein. However, while the role of p53 in controlling normal cell cycle progression and tumor suppression is well established, the clinical significance of p53 isoform expression is unknown. A novel bioinformatic analysis of p53 isoform expression in 68 patients with acute myeloid leukemia revealed distinct p53 protein biosignatures correlating with clinical outcome. Furthermore, we show that mutated FLT3, a prognostic marker for short survival in AML, is associated with expression of full-length p53. In contrast, mutated NPM1, a prognostic marker for long-term survival, correlated with p53 isoforms beta and gamma expression. In conclusion, p53 biosignatures contain useful information for cancer evaluation and prognostication. Oncogene (2012) 31, 1533-1545; doi:10.1038/onc.2011.348; published online 22 August 2011	[Gjertsen, B. T.] Univ Bergen, Haukeland Univ Hosp, Hematol Sect, Dept Internal Med,Inst Med, N-5021 Bergen, Norway; [Van Belle, W.] Norut IT, Tromso, Norway; [Bourdon, J-C] Univ Dundee, Sch Med, Dept Surg & Mol Oncol, Inserm European Associated Lab Inserm, Dundee, Scotland; [Hovland, R.] Haukeland Hosp, Ctr Med Genet & Mol Med, N-5021 Bergen, Norway; [Tasken, K.] Univ Oslo, Biotechnol Ctr, Oslo, Norway; [Tasken, K.] Univ Oslo, Ctr Mol Med Norway, Nord EMBL Partnership, Oslo, Norway; [Knappskog, S.; Lonning, P. E.] Univ Bergen, Sect Oncol, Inst Med, N-5021 Bergen, Norway; [Knappskog, S.; Lonning, P. E.] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway; [Anensen, N.; Hjelle, S. M.; Haaland, I.; Silden, E.; Bruserud, O.; Gjertsen, B. T.] Univ Bergen, Inst Med, Hematol Sect, N-5021 Bergen, Norway	University of Bergen; Haukeland University Hospital; University of Dundee; University of Bergen; Haukeland University Hospital; University of Oslo; University of Oslo; University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen	Gjertsen, BT (corresponding author), Univ Bergen, Haukeland Univ Hosp, Hematol Sect, Dept Internal Med,Inst Med, N-5021 Bergen, Norway.	bjorn.gjertsen@med.uib.no	Gjertsen, Bjørn T/AAP-3281-2020; JC, Bourdon/A-4439-2008; Hjelle, Sigrun M./AAZ-5585-2020; Gjertsen, Bjorn T/O-1542-2015	Gjertsen, Bjørn T/0000-0001-9358-9704; JC, Bourdon/0000-0003-4623-9386; Gjertsen, Bjorn T/0000-0001-9358-9704; Knappskog, Stian/0000-0002-4153-1655; Lonning, Per Eystein/0000-0002-8890-6303; Tasken, Kjetil/0000-0003-2841-4697; Haaland, Ingvild/0000-0002-9974-2308	Research Council of Norway; Western Norway Regional Health Authority; Norwegian Cancer Society	Research Council of Norway(Research Council of Norway); Western Norway Regional Health Authority; Norwegian Cancer Society(Norwegian Cancer Society)	This study was supported by grants from the Research Council of Norway's National Program for Research in Functional Genomics, the Western Norway Regional Health Authority and the Norwegian Cancer Society.	Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Anensen N, 2006, CLIN CANCER RES, V12, P3985, DOI 10.1158/1078-0432.CCR-05-1970; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bourdon JC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2811; Bruserud O, 2003, HAEMATOLOGICA, V88, P416; Chen J, 2009, GENE DEV, V23, P278, DOI 10.1101/gad.1761609; Chrisanthar R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003062; Dohner K, 2005, BLOOD, V106, P3740, DOI 10.1182/blood-2005-05-2164; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; FENAUX P, 1992, BRIT J HAEMATOL, V80, P178, DOI 10.1111/j.1365-2141.1992.tb08897.x; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Gale RE, 2005, BLOOD, V106, P3768, DOI 10.1182/blood-2005-04-1746; Gale RE, 2005, BLOOD, V106, P3658, DOI 10.1182/blood-2005-03-1323; GJERTSEN BT, 1994, J CELL SCI, V107, P3363; Gjertsen BT, 2002, J HEMATOTH STEM CELL, V11, P469, DOI 10.1089/15258160260090933; Graupner V, 2009, CELL CYCLE, V8, P1238, DOI 10.4161/cc.8.8.8251; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Haferlach C, 2008, LEUKEMIA, V22, P1539, DOI 10.1038/leu.2008.143; Hainaut Pierre, 1995, Current Opinion in Oncology, V7, P76; Hall PA, 2006, J PATHOL, V208, P1, DOI 10.1002/path.1913; Irish JM, 2004, CELL, V118, P217, DOI 10.1016/j.cell.2004.06.028; Irish JM, 2007, BLOOD, V109, P2589, DOI 10.1182/blood-2006-02-004234; Kojima K, 2007, CANCER RES, V67, P8121, DOI 10.1158/0008-5472.CAN-06-4167; Komeno Y, 2005, LEUKEMIA, V19, P930, DOI 10.1038/sj.leu.2403736; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Lonning PE, 2003, LANCET ONCOL, V4, P177; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Lowenberg B, 2003, NEW ENGL J MED, V349, P743, DOI 10.1056/NEJMoa025406; Lowenberg Bob, 2008, Hematology Am Soc Hematol Educ Program, P1, DOI 10.1182/asheducation-2008.1.1; MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402; Pardee TS, 2011, EXP HEMATOL, V39, P473, DOI 10.1016/j.exphem.2011.01.009; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Preudhomme C, 1997, BRIT J HAEMATOL, V98, P502, DOI 10.1046/j.1365-2141.1997.2403057.x; Rohaly G, 2005, CELL, V122, P21, DOI 10.1016/j.cell.2005.04.032; Schnittger S, 2005, BLOOD, V106, P3733, DOI 10.1182/blood-2005-06-2248; SCHOTTELIUS A, 1994, LEUKEMIA, V8, P1673; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; Srinivasa SP, 2002, LEUKEMIA, V16, P244, DOI 10.1038/sj.leu.2402367; Tallman MS, 2005, BLOOD, V106, P1154, DOI 10.1182/blood-2005-01-0178; Van Belle Werner, 2006, BMC Bioinformatics, V7, P198, DOI 10.1186/1471-2105-7-198; Verhaak RGW, 2005, BLOOD, V106, P3747, DOI 10.1182/blood-2005-05-2168; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wahlin A, 1997, EUR J HAEMATOL, V58, P233; Wheatley K, 1999, BRIT J HAEMATOL, V107, P69, DOI 10.1046/j.1365-2141.1999.01684.x; Yeh PY, 2004, ONCOGENE, V23, P3580, DOI 10.1038/sj.onc.1207426	51	46	47	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	12					1533	1545		10.1038/onc.2011.348	http://dx.doi.org/10.1038/onc.2011.348			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21860418				2022-12-17	WOS:000302132000006
J	de Lange, J; Ly, LV; Lodder, K; Verlaan-de Vries, M; Teunisse, AFAS; Jager, MJ; Jochemsen, AG				de Lange, J.; Ly, L. V.; Lodder, K.; Verlaan-de Vries, M.; Teunisse, A. F. A. S.; Jager, M. J.; Jochemsen, A. G.			Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma	ONCOGENE			English	Article						uveal melanoma; p53; Nutlin-3; RITA; topotecan; hypoxia	INDUCIBLE FACTOR 1-ALPHA; CHRONIC LYMPHOCYTIC-LEUKEMIA; DOWN-REGULATION; CANCER-CELLS; IN-VIVO; APOPTOSIS; MDM2; HYPOXIA; ATM; RITA	The prognosis of patients with uveal melanoma is poor. Because of the limited efficacy of current treatments, new therapeutic strategies need to be developed. Because p53 mutations are uncommon in uveal melanoma, reactivation of p53 may be used to achieve tumor regression. We investigated the use of combination therapies for intraocular melanoma, based on the p53 activators Nutlin-3 and reactivation of p53 and induction of tumor cell apoptosis (RITA) and the topoisomerase I inhibitor Topotecan. Nutlin-3 treatment induced p53-dependent growth inhibition in human uveal melanoma cell lines. The sensitivity to Nutlin-3 of the investigated cell lines did not correlate with basal Hdm2 or Hdmx levels. Nutlin-3 synergized with RITA and Topotecan to induce apoptosis in uveal melanoma cell lines and short-term cultures. Drug synergy correlated with enhanced induction of p53-Ser46 phosphorylation, which was attenuated by ATM inhibition. Nutlin-3 and Topotecan also significantly delayed tumor growth in vivo in a murine B16F10 model for ocular melanoma. Combination treatment appeared to inhibit tumor growth slightly more efficient than either drug alone. Nutlin-3, RITA and Topotecan lead to comparable p53 activation and growth inhibition under normoxia and hypoxia. Treatment with Nutlin-3 or RITA had no effect on HIF-1 alpha induction by hypoxia, whereas the combination of these two drugs did inhibit hypoxia-induced HIF-1 alpha. Also Topotecan, alone or in combination with Nutlin-3, reduced HIF-1 alpha protein levels, suggesting that a certain level of DNA damage response is required for p53-mediated downregulation of HIF-1 alpha. In conclusion, combination treatments based on small-molecule-induced p53 activation may have clinical potential for uveal melanoma. Oncogene (2012) 31, 1105-1116; doi:10.1038/onc.2011.309; published online 18 July 2011	[de Lange, J.; Lodder, K.; Verlaan-de Vries, M.; Teunisse, A. F. A. S.; Jochemsen, A. G.] Leiden Univ, Dept Mol Cell Biol, Med Ctr, NL-2300 RC Leiden, Netherlands; [Ly, L. V.; Jager, M. J.] Leiden Univ, Dept Ophthalmol, Med Ctr, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Jochemsen, AG (corresponding author), Leiden Univ, Dept Mol Cell Biol, Med Ctr, POB 9600, NL-2300 RC Leiden, Netherlands.	A.G.Jochemsen@lumc.nl	Jager, Martine/AAR-3525-2020	Jager, Martine/0000-0003-2261-3820; de Lange, Job/0000-0002-9002-8829	Netherlands Organization for Scientific Research NWO [017.003.059]; EC [503576]	Netherlands Organization for Scientific Research NWO(Netherlands Organization for Scientific Research (NWO)); EC(European CommissionEuropean Commission Joint Research Centre)	We thank Dr PA van der Velden and M Versluis for the primer sets to detect the expression of the HIF target genes and the early cultures of primary uveal melanoma cells, Dr A Vertegaal for the antibodies detecting HIF-1 alpha and HIF-2 alpha proteins, Prof BR Ksander for providing the Mel cell lines, Dr G Selivanova for providing RITA and Dr A Levine for providing anti-Mdm2 antibody. This study was supported by grants from the Netherlands Organization for Scientific Research NWO (Mozaiek Grant 017.003.059) and by EC FP6 funding (contract 503576).	An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Augsburger JJ, 2009, AM J OPHTHALMOL, V148, P119, DOI 10.1016/j.ajo.2009.01.023; Barbieri E, 2006, MOL CANCER THER, V5, P2358, DOI 10.1158/1535-7163.MCT-06-0305; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chang AE, 1998, CANCER, V83, P1664, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G; Chou T.-C., 2007, COMPUSYN SOFTWARE DR; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Coll-Mulet L, 2006, BLOOD, V107, P4109, DOI 10.1182/blood-2005-08-3273; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DEWAARDSIEBINGA I, 1995, INT J CANCER, V62, P155, DOI 10.1002/ijc.2910620208; Enge M, 2009, CANCER CELL, V15, P171, DOI 10.1016/j.ccr.2009.01.019; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Kaluzova M, 2004, MOL CELL BIOL, V24, P5757, DOI 10.1128/MCB.24.13.5757-5766.2004; Kivela Tero, 2006, International Ophthalmology Clinics, V46, P133, DOI 10.1097/01.iio.0000195861.71558.13; Kodama M, 2010, MOL CELL BIOL, V30, P1620, DOI 10.1128/MCB.00810-09; Kojima K, 2006, BLOOD, V108, P993, DOI 10.1182/blood-2005-12-5148; Krajewski M, 2005, NAT MED, V11, P1135, DOI 10.1038/nm1105-1135; Lam S, 2010, ONCOGENE, V29, P2415, DOI 10.1038/onc.2009.522; LaRusch GA, 2007, CANCER RES, V67, P450, DOI 10.1158/0008-5472.CAN-06-2710; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lee YM, 2009, CARCINOGENESIS, V30, P1768, DOI 10.1093/carcin/bgp196; Li Y, 2010, MOL CANCER THER, V9, P113, DOI 10.1158/1535-7163.MCT-08-1189; Ly LV, 2010, J IMMUNOL, V185, P3481, DOI 10.4049/jimmunol.0903479; Moeller BJ, 2005, CANCER CELL, V8, P99, DOI 10.1016/j.ccr.2005.06.016; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Ravi R, 2000, GENE DEV, V14, P34; Rinaldo C, 2009, CANCER RES, V69, P6241, DOI 10.1158/0008-5472.CAN-09-0337; Saha MN, 2010, MOL CANCER THER, V9, P3041, DOI 10.1158/1535-7163.MCT-10-0471; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Tomicic MT, 2010, J PHARMACOL EXP THER, V332, P316, DOI 10.1124/jpet.109.159962; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; White JS, 2008, CELL CYCLE, V7, P1277, DOI 10.4161/cc.7.9.5961; Wynford-Thomas D, 1998, CARCINOGENESIS, V19, P29, DOI 10.1093/carcin/19.1.29; Yang J, 2009, MOL CELL BIOL, V29, P2243, DOI 10.1128/MCB.00959-08	37	46	48	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	9					1105	1116		10.1038/onc.2011.309	http://dx.doi.org/10.1038/onc.2011.309			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21765463				2022-12-17	WOS:000300945900004
J	Jennewein, C; Karl, S; Baumann, B; Micheau, O; Debatin, KM; Fulda, S				Jennewein, C.; Karl, S.; Baumann, B.; Micheau, O.; Debatin, K-M; Fulda, S.			Identification of a novel pro-apoptotic role of NF-kappa B in the regulation of TRAIL- and CD95-mediated apoptosis of glioblastoma cells	ONCOGENE			English	Article						TRAIL; apoptosis; NF-kappa B; glioblastoma; CD95	CANCER-THERAPY; INDUCTION; SENSITIZATION; CONTRIBUTES; EXPRESSION	We recently reported that nuclear factor-kappa B (NF-kappa B) promotes DNA damage-triggered apoptosis in glioblastoma, the most common brain tumor. In the present study, we investigated the role of NF-kappa B in death receptor-mediated apoptosis. Here, we identify a novel pro-apopotic function of NF-kappa B in TRAIL- and CD95-induced apoptosis. Inhibition of NF-kappa B by overexpression of the dominant-negative I kappa B alpha-superrepressor (I kappa B alpha-SR) significantly decreases tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)- or CD95-induced apoptosis. Vice versa, activation of NF-kappa B via overexpression of constitutively active I kappa B kinase complex (IKK)beta (IKK-EE) significantly increases TRAIL-mediated apoptosis. Intriguingly, NF-kappa B inhibition reduces the recruitment of Fas-associated death domain and caspase-8 and formation of the death-inducing signaling complex (DISC) upon stimulation of TRAIL receptors or CD95. This results in reduced TRAIL-mediated activation of caspases, loss of mitochondrial potential and cytochrome c release in I kappa B alpha-SR-expressing cells. In comparison, NF-kappa B inhibition strongly enhances TNF-alpha-mediated apoptosis. Comparative studies revealed that TNF-alpha rapidly stimulates transcriptional activation and upregulation of anti-apoptotic proteins, whereas TRAIL causes apoptosis before transcriptional activation. Thus, this study demonstrates for the first time that NF-kappa B exerts a pro-apoptotic role in TRAIL- and CD95-induced apoptosis in glioblastoma cells by facilitating DISC formation. Oncogene (2012) 31, 1468-1474; doi:10.1038/onc.2011.333; published online 8 August 2011	[Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Hesse, Germany; [Jennewein, C.; Karl, S.; Debatin, K-M; Fulda, S.] Univ Childrens Hosp, Ulm, Germany; [Baumann, B.] Univ Ulm, Inst Physiol Chem, Ulm, Germany; [Micheau, O.] INSERM, U866, Dijon, France	Goethe University Frankfurt; Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ulm University; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3A, D-60528 Frankfurt, Hesse, Germany.	simone.fulda@kgu.de	Debatin, Klaus-Michael/J-9704-2014; micheau, olivier/C-3574-2011	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417; micheau, olivier/0000-0001-8499-7984	Deutsche Forschungsgemeinschaft; European Community (ApopTrain, APO-SYS); International Graduate School of Molecular Medicine Ulm University;  [IAP6/18]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Community (ApopTrain, APO-SYS)(European CommissionEuropean Commission Joint Research Centre); International Graduate School of Molecular Medicine Ulm University; 	We thank R Marienfeld (Ulm, Germany) for providing NEMO knockout mouse embryonic fibroblasts. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, European Community (ApopTrain, APO-SYS) and IAP6/18 (to SF), and by a scholarship of the International Graduate School of Molecular Medicine Ulm University (to CJ).	Ammann JU, 2009, INT J CANCER, V124, P1301, DOI 10.1002/ijc.24068; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Farhana L, 2005, CANCER RES, V65, P4909, DOI 10.1158/0008-5472.CAN-04-4124; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Humphreys RC, 2008, ADV EXP MED BIOL, V615, P127, DOI 10.1007/978-1-4020-6554-5_7; Kang S, 2010, BIOCHEM BIOPH RES CO, V396, P731, DOI 10.1016/j.bbrc.2010.05.004; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karl S, 2009, J CELL MOL MED, V13, P4239, DOI 10.1111/j.1582-4934.2009.00888.x; Kohlhaas SL, 2007, J BIOL CHEM, V282, P12831, DOI 10.1074/jbc.M700438200; Mader I, 2010, FASEB J, V24, P1997, DOI 10.1096/fj.09-142943; Mattson MP, 2005, NEUROCHEM RES, V30, P883, DOI 10.1007/s11064-005-6961-x; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Pennarun B, 2010, BBA-REV CANCER, V1805, P123, DOI 10.1016/j.bbcan.2009.11.004; Plantivaux A, 2009, ANN NY ACAD SCI, V1171, P38, DOI 10.1111/j.1749-6632.2009.04725.x; Poppelmann B, 2005, J BIOL CHEM, V280, P15635, DOI 10.1074/jbc.M413006200; Radhakrishnan SK, 2006, BBA-REV CANCER, V1766, P53, DOI 10.1016/j.bbcan.2006.02.001; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Shou Y, 2002, J NEUROCHEM, V81, P842, DOI 10.1046/j.1471-4159.2002.00880.x; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Zhao XY, 2011, J NEURO-ONCOL, V102, P367, DOI 10.1007/s11060-010-0346-y	23	46	48	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	11					1468	1474		10.1038/onc.2011.333	http://dx.doi.org/10.1038/onc.2011.333			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21822306				2022-12-17	WOS:000301780000013
J	Lee, MH; Lahusen, T; Wang, RH; Xiao, C; Xu, X; Hwang, YS; He, WW; Shi, Y; Deng, CX				Lee, M-H; Lahusen, T.; Wang, R-H; Xiao, C.; Xu, X.; Hwang, Y-S; He, W-W; Shi, Y.; Deng, C-X			Yin Yang 1 positively regulates BRCA1 and inhibits mammary cancer formation	ONCOGENE			English	Article						BRCA1; breast cancer; promoter; nude mice; YY1	SPORADIC BREAST-CANCER; TUMOR-SUPPRESSOR; ADENOVIRUS E1A; TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; FACTOR YY1; C-MYC; PROMOTER; BINDING; YIN-YANG-1	Expression of the breast cancer-associated gene 1 (BRCA1) in sporadic breast cancers is usually reduced, yet the underlying mechanisms remains elusive. To identify factors that are responsible for reduced BRCA1 expression, we screened 92 known transcription factors for their ability to regulate expression of BRCA1. Among several potential regulators, the Gli-Krueppel-related transcription factor Yin Yang 1 (YY1) showed the most dramatic transactivation of the BRCA1 promoter. YY1 binds to the promoter of BRCA1, and its overexpression resulted in increased expression of BRCA1 and a number of BRCA1 downstream genes. We further showed that overexpression of YY1 in cancer cells inhibited cell proliferation, foci formation and tumor growth in nude mice. To assess the clinical relevance between YY1 and BRCA1, we studied expression of YY1 and BRCA1 from human breast cancer samples and tissue arrays, and detected a significant positive correlation between the level of YY1 and BRCA1 expression in these cancers. Taken together, these findings suggest that YY1 is a key regulator of BRCA1 expression and may be causally linked to the molecular etiology of human breast cancer. Oncogene (2012) 31, 116-127; doi: 10.1038/onc.2011.217; published online 13 June 2011	[Lee, M-H; Lahusen, T.; Wang, R-H; Xiao, C.; Xu, X.; Deng, C-X] NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; [Hwang, Y-S] NCI, Lab Cell & Dev Signaling, NIH, Frederick, MD 21701 USA; [He, W-W] Origene Technol Inc, Rockville, MD USA; [Shi, Y.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School	Deng, CX (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, 9000 Rockville Pike,Bldg 10,Rm 9N105, Bethesda, MD 20892 USA.	chuxiad@bdg10.niddk.nih.gov	deng, chuxia/N-6713-2016	Lee, Mi-Hye/0000-0002-5484-3383	National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056011, ZIADK056001, ZIADK056004, ZIADK056010, ZIADK056009] Funding Source: NIH RePORTER	National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank members of Dr Deng laboratory for their critical discussion of this work and technical assistance. This research was supported by the Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA.	Affar E, 2006, MOL CELL BIOL, V26, P3565, DOI 10.1128/MCB.26.9.3565-3581.2006; Alberg Anthony J., 1999, Current Opinion in Oncology, V11, P435, DOI 10.1097/00001622-199911000-00003; Atlas E, 2000, ONCOGENE, V19, P1933, DOI 10.1038/sj.onc.1203516; Atlas E, 2001, ONCOGENE, V20, P7110, DOI 10.1038/sj.onc.1204890; Austen M, 1998, ONCOGENE, V17, P511, DOI 10.1038/sj.onc.1201968; Baldassarre G, 2003, MOL CELL BIOL, V23, P2225, DOI 10.1128/MCB.23.7.2225-2238.2003; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522; Brody LC, 1998, MEDICINE, V77, P208, DOI 10.1097/00005792-199805000-00006; Castellano G, 2009, CELL CYCLE, V8, P1367, DOI 10.4161/cc.8.9.8314; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Drost RM, 2009, BRIT J CANCER, V101, P1651, DOI 10.1038/sj.bjc.6605350; Eccles DM, 2005, LANCET ONCOL, V6, P705, DOI 10.1016/S1470-2045(05)70318-1; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Ghosh Sagar, 2008, Int J Biomed Sci, V4, P260; Giacinti L, 2008, CLIN TER, V159, P347; Gilbert PM, 2010, J CLIN INVEST, V120, P1535, DOI 10.1172/JCI39534; Glait C, 2006, FEBS LETT, V580, P5268, DOI 10.1016/j.febslet.2006.08.071; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kluk BJ, 2010, INT J BIOL SCI, V6, P513; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Lee MH, 2005, J BIOL CHEM, V280, P35579, DOI 10.1074/jbc.M502267200; MacDonald G, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1753; Man YG, 2005, BREAST CANCER RES TR, V90, P241, DOI 10.1007/s10549-004-4492-9; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; Oliveira Andre M, 2005, Am J Clin Pathol, V124 Suppl, pS16; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; Rauch T, 2005, CELL CYCLE, V4, P1078; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Rivenbark AG, 2009, FRONT BIOSCI-LANDMRK, V14, P453, DOI 10.2741/3254; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Suen TC, 2001, ONCOGENE, V20, P440, DOI 10.1038/sj.onc.1204078; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Tan SH, 2003, VIROLOGY, V305, P486, DOI 10.1006/viro.2002.1779; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; Turner JMA, 2004, CURR BIOL, V14, P2135, DOI 10.1016/j.cub.2004.11.032; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wang CC, 2005, ONCOGENE, V24, P4081, DOI 10.1038/sj.onc.1208573; Wang CC, 2007, CANCER RES, V67, P4816, DOI 10.1158/0008-5472.CAN-07-0504; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Wu S, 2007, NUCL ACIDS S SER OXF, V51, P347; Wu S, 2007, NAT STRUCT MOL BIOL, V14, P1165, DOI 10.1038/nsmb1332; Wu S, 2009, MOL CELL BIOL, V29, P6245, DOI 10.1128/MCB.00679-09; Wu WW, 2010, CANCER RES, V70, P6384, DOI 10.1158/0008-5472.CAN-10-1304; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Xu XL, 2003, DEVELOPMENT, V130, P2001, DOI 10.1242/dev.00410; Zhang JR, 2005, MOL CANCER RES, V3, P531, DOI 10.1158/1541-7786.MCR-05-0192	54	46	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	1					116	127		10.1038/onc.2011.217	http://dx.doi.org/10.1038/onc.2011.217			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21666725	Green Accepted			2022-12-17	WOS:000299176200011
J	Choi, HH; Gully, C; Su, CH; Velazquez-Torres, G; Chou, PC; Tseng, C; Zhao, R; Phan, L; Shaiken, T; Chen, J; Yeung, SC; Lee, MH				Choi, H. H.; Gully, C.; Su, C-H; Velazquez-Torres, G.; Chou, P-C; Tseng, C.; Zhao, R.; Phan, L.; Shaiken, T.; Chen, J.; Yeung, S. C.; Lee, M-H			COP9 signalosome subunit 6 stabilizes COP1, which functions as an E3 ubiquitin ligase for 14-3-3 sigma	ONCOGENE			English	Article						14-3-3 sigma; CSN6; COP1; ubiquitination	REGULATES C-JUN; DNA-DAMAGE; NEGATIVE REGULATOR; LIGHT CONTROL; TUMOR-GROWTH; ARABIDOPSIS; PROTEINS; BREAST; CANCER; P53	14-3-3 sigma, a gene upregulated by p53 in response to DNA damage, exists as part of a positive-feedback loop, which activates p53 and is a human cancer epithelial marker downregulated in various cancer types. 14-3-3 sigma levels are critical for maintaining p53 activity in response to DNA damage and regulating signal mediators such as Akt. In this study, we identify mammalian constitutive photomorphogenic 1 (COP1) as a novel E3 ubiquitin ligase for targeting 14-3-3 sigma through proteasomal degradation. We show for the first time that COP9 signalosome subunit 6 (CSN6) associates with COP1 and is involved in 14-3-3 sigma ubiquitin-mediated degradation. Mechanistic studies show that CSN6 expression leads to stabilization of COP1 through reducing COP1 self-ubiquitination and decelerating COP1's turnover rate. We also show that CSN6-mediated 14-3-3 sigma ubiquitination is compromised when COP1 is knocked down. Thus, CSN6-mediates 14-3-3 sigma ubiquitination through enhancing COP1 stability. Subsequently, we show that CSN6 causes 14-3-3 sigma downregulation, thereby activating Akt and promoting cell survival. Also, CSN6 overexpression leads to increased cell growth, transformation and promotes tumorigenicity. Significantly, 14-3-3 sigma expression can correct the abnormalities mediated by CSN6 expression. These data suggest that the CSN6-COP1 axis is involved in 14-3-3 sigma degradation, and that deregulation of this axis will promote cell growth and tumorigenicity. Oncogene (2011) 30, 4791-4801; doi:10.1038/onc.2011.192; published online 30 May 2011	[Yeung, S. C.] Univ Texas MD Anderson Canc Ctr, Dept Gen Internal Med Ambulatory Treatment & Emer, Houston, TX 77030 USA; [Yeung, S. C.] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA; [Choi, H. H.; Gully, C.; Su, C-H; Velazquez-Torres, G.; Chou, P-C; Tseng, C.; Zhao, R.; Phan, L.; Shaiken, T.; Chen, J.; Lee, M-H] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Choi, H. H.; Velazquez-Torres, G.; Chou, P-C; Tseng, C.; Lee, M-H] Univ Texas Grad Sch Biomed Sci Houston, Program Canc Biol, Houston, TX USA; [Gully, C.; Su, C-H; Lee, M-H] Univ Texas Grad Sch Biomed Sci Houston, Program Genes & Dev, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Yeung, SC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gen Internal Med Ambulatory Treatment & Emer, 1515 Holcombe Blvd, Houston, TX 77030 USA.	syeung@mdanderson.org; mhlee@mdanderson.org	Yeung, Sai-Ching/AAI-6178-2021; Yeung, Sai-Ching/AAP-8079-2020	Yeung, Sai-Ching/0000-0001-5170-0822; Lee, Mong-Hong/0000-0001-8675-8215; Shaiken (Shaikenov), Tattym/0000-0002-8808-6229	National Institutes of Health (NIH) [R01CA089266]; Directed Medical Research Programs [DOD SIDA BC062166]; Susan G Komen Breast Cancer Foundation [KG081048]; cancer prevention fellowship [R25T CA57730]; NIH [CA16672]; NATIONAL CANCER INSTITUTE [R56CA089266, R01CA089266, R25CA057730, P30CA016672] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Directed Medical Research Programs; Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); cancer prevention fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Institutes of Health (NIH) (R01CA089266), Directed Medical Research Programs (DOD SIDA BC062166 to SJY and MHL) and Susan G Komen Breast Cancer Foundation (KG081048). This research was supported in part, by a cancer prevention fellowship for GVT (R25T CA57730). The University of Texas MD Anderson Cancer Center is supported by NIH core Grant CA16672.	Bianchi E, 2003, J BIOL CHEM, V278, P19682, DOI 10.1074/jbc.M212681200; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Dentin R, 2007, NATURE, V449, P366, DOI 10.1038/nature06128; Dornan D, 2004, CANCER RES, V64, P7226, DOI 10.1158/0008-5472.CAN-04-2601; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Dornan D, 2006, SCIENCE, V313, P1122, DOI 10.1126/science.1127335; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gusmaroli G, 2007, PLANT CELL, V19, P564, DOI 10.1105/tpc.106.047571; Hardtke CS, 2000, EMBO J, V19, P4997, DOI 10.1093/emboj/19.18.4997; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hoeller D, 2006, NAT REV CANCER, V6, P776, DOI 10.1038/nrc1994; Horie-Inoue K, 2006, SEMIN CANCER BIOL, V16, P235, DOI 10.1016/j.semcancer.2006.03.006; Karniol B, 2000, CURR OPIN PLANT BIOL, V3, P387, DOI 10.1016/S1369-5266(00)00101-1; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Lee MH, 2006, SEMIN CANCER BIOL, V16, P225, DOI 10.1016/j.semcancer.2006.03.009; Li DQ, 2009, P NATL ACAD SCI USA, V106, P17493, DOI 10.1073/pnas.0908027106; Li L, 2003, TRENDS CELL BIOL, V13, P507, DOI 10.1016/j.tcb.2003.08.002; Li ZM, 2009, AM J TRANSL RES, V1, P326; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Peng ZH, 2001, PLANT CELL, V13, P2393, DOI 10.1105/tpc.13.11.2393; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Qi L, 2006, SCIENCE, V312, P1763, DOI 10.1126/science.1123374; Richardson KS, 2005, MOL CANCER RES, V3, P645, DOI 10.1158/1541-7786.MCR-05-0233; Savio MG, 2008, ONCOGENE, V27, P2401, DOI 10.1038/sj.onc.1210892; Su CH, 2011, CANCER RES, V71, P884, DOI 10.1158/0008-5472.CAN-10-2518; Su CH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-243; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; Wang HY, 2001, SCIENCE, V294, P154, DOI 10.1126/science.1063630; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449; WEI N, 1992, PLANT CELL, V4, P1507, DOI 10.1105/tpc.4.12.1507; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang HY, 2007, ONCOGENE, V26, P7355, DOI 10.1038/sj.onc.1210540; Yang HL, 2006, CANCER RES, V66, P3096, DOI 10.1158/0008-5472.CAN-05-3620; Yang HL, 2005, ONCOGENE, V24, P1924, DOI 10.1038/sj.onc.1208352; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003; Yi CL, 2005, TRENDS CELL BIOL, V15, P618, DOI 10.1016/j.tcb.2005.09.007; Yi CL, 2005, CANCER RES, V65, P5835, DOI 10.1158/0008-5472.CAN-05-0423; Zhao RY, 2011, J CLIN INVEST, V121, P851, DOI 10.1172/JCI44111; Zou WG, 2006, J BIOL CHEM, V281, P3989, DOI 10.1074/jbc.M510787200	45	46	50	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2011	30	48					4791	4801		10.1038/onc.2011.192	http://dx.doi.org/10.1038/onc.2011.192			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863AH	21625211	Green Accepted			2022-12-17	WOS:000298134700003
J	Takahashi, F; Chiba, N; Tajima, K; Hayashida, T; Shimada, T; Takahashi, M; Moriyama, H; Brachtel, E; Edelman, EJ; Ramaswamy, S; Maheswaran, S				Takahashi, F.; Chiba, N.; Tajima, K.; Hayashida, T.; Shimada, T.; Takahashi, M.; Moriyama, H.; Brachtel, E.; Edelman, E. J.; Ramaswamy, S.; Maheswaran, S.			Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib	ONCOGENE			English	Article						breast cancer; BTG2; invasion; metastasis; ErbB/HER pathway	TRANSLOCATION GENE-2 PROTEIN; ESTROGEN-RECEPTOR; CANCER PATIENTS; MOLECULAR SIGNATURE; PHASE-II; GROWTH; CELLS; CARCINOMA; PROGNOSIS; GRADE	The B-cell translocation gene-2 (BTG2), a p53-inducible gene, is suppressed in mammary epithelial cells during gestation and lactation. In human breast cancer, decreased BTG2 expression correlates with high tumor grade and size, p53 status, blood and lymph vessel invasion, local and metastatic recurrence and decrease in overall survival, suggesting that suppression of BTG2 has a critical role in disease progression. To analyze the role of BTG2 in breast cancer progression, BTG2 expression was knocked down in mammary epithelial cells. Suppression of BTG2 enhances the motility of cells in vitro and tumor growth and metastasis in vivo. The effects of BTG2 knockdown are mediated through stabilization of the human epidermal growth factor receptor (HER) ligands neuregulin and epiregulin and activation of the HER2 and HER3 receptors, leading to elevated AKT phosphorylation. Suppression of HER activation using the tyrosine kinase inhibitor lapatinib abrogates the effects of BTG2 knockdown, including the increased cell migration observed in vitro and the enhancement of tumorigenesis and metastasis in vivo. These results link BTG2-dependent effects on tumor progression to ErbB receptor signaling, and raise the possibility that targeted inhibition of this pathway may be relevant in the treatment of breast cancers that have reduced BTG2 expression. Oncogene (2011) 30, 3084-3095; doi: 10.1038/onc.2011.24; published online 21 February 2011	[Maheswaran, S.] Massachusetts Gen Hosp, Ctr Canc, Dept Surg, Charlestown, MA 02129 USA; [Takahashi, F.; Chiba, N.; Tajima, K.; Hayashida, T.; Shimada, T.; Takahashi, M.; Moriyama, H.; Brachtel, E.; Edelman, E. J.; Ramaswamy, S.; Maheswaran, S.] Harvard Univ, Sch Med, Charlestown, MA USA; [Takahashi, F.; Chiba, N.; Tajima, K.; Hayashida, T.; Shimada, T.; Takahashi, M.; Edelman, E. J.; Ramaswamy, S.; Maheswaran, S.] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA; [Moriyama, H.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; [Brachtel, E.] Massachusetts Gen Hosp, Dept Pathol, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Maheswaran, S (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Dept Surg, Bldg 149,13th St, Charlestown, MA 02129 USA.	maheswaran@helix.mgh.harvard.edu			NIH/NCI [CA89138]; Susan G Komen for the Cure Grants [PDF0600282, KG090412]; ESSCO breast cancer research grant; NATIONAL CANCER INSTITUTE [R01CA089138] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen for the Cure Grants(Susan G. Komen Breast Cancer Foundation); ESSCO breast cancer research grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Isselbacher, Haber, Engelman and Zou for critically reading the paper. This work was supported by the NIH/NCI Grant CA89138 (to SM), the Susan G Komen for the Cure Grants PDF0600282 and KG090412 (to SM) and ESSCO breast cancer research grant (to SM).	Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Boersma BJ, 2008, INT J CANCER, V122, P1324, DOI 10.1002/ijc.23237; Boiko AD, 2006, GENE DEV, V20, P236, DOI 10.1101/gad.1372606; Calzolari F, 2008, NEOPLASIA, V10, P1373, DOI 10.1593/neo.08814; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Esteva FJ, 2010, NAT REV CLIN ONCOL, V7, P98, DOI 10.1038/nrclinonc.2009.216; Farioli-Vecchioli S, 2007, FASEB J, V21, P2215, DOI 10.1096/fj.06-7548com; Ficazzola MA, 2001, CARCINOGENESIS, V22, P1271, DOI 10.1093/carcin/22.8.1271; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gomez HL, 2008, J CLIN ONCOL, V26, P2999, DOI 10.1200/JCO.2007.14.0590; Gril B, 2008, JNCI-J NATL CANCER I, V100, P1092, DOI 10.1093/jnci/djn216; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Ha TU, 2000, J BIOL CHEM, V275, P37101, DOI 10.1074/jbc.M005701200; Hayashida T, 2010, P NATL ACAD SCI USA, V107, P1100, DOI 10.1073/pnas.0912710107; Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355; Hong JW, 2005, J BIOL CHEM, V280, P21256, DOI 10.1074/jbc.M500318200; Hsieh AC, 2007, BRIT J CANCER, V97, P453, DOI 10.1038/sj.bjc.6603910; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Hynes NE, 2001, ENDOCR-RELAT CANCER, V8, P151, DOI 10.1677/erc.0.0080151; Johnston S, 2008, J CLIN ONCOL, V26, P1066, DOI 10.1200/JCO.2007.13.9949; Johnston S, 2009, J CLIN ONCOL, V27, P5538, DOI 10.1200/JCO.2009.23.3734; Julka PK, 2008, BRIT J CANCER, V98, P1327, DOI 10.1038/sj.bjc.6604322; Kawakubo H, 2004, ONCOGENE, V23, P8310, DOI 10.1038/sj.onc.1208008; Kawakubo H, 2006, CANCER RES, V66, P7075, DOI 10.1158/0008-5472.CAN-06-0379; Kedrin D, 2009, CLIN CANCER RES, V15, P3733, DOI 10.1158/1078-0432.CCR-08-2163; Konecny GE, 2008, BRIT J CANCER, V98, P1076, DOI 10.1038/sj.bjc.6604278; Leary AF, 2010, CLIN CANCER RES, V16, P1486, DOI 10.1158/1078-0432.CCR-09-1764; LIM IK, 1995, J CANCER RES CLIN, V121, P279, DOI 10.1007/BF01209594; Lim IK, 1998, MOL CARCINOGEN, V23, P25, DOI 10.1002/(SICI)1098-2744(199809)23:1<25::AID-MC4>3.0.CO;2-G; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Mauxion F, 2008, EMBO J, V27, P1039, DOI 10.1038/emboj.2008.43; Mauxion F, 2009, TRENDS BIOCHEM SCI, V34, P640, DOI 10.1016/j.tibs.2009.07.008; Melamed J, 2002, TISSUE CELL, V34, P28, DOI 10.1054/tice.2001.0220; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Park S, 2004, MOL CELL BIOL, V24, P10256, DOI 10.1128/MCB.24.23.10256-10262.2004; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Sabbah M, 2008, DRUG RESIST UPDATE, V11, P123, DOI 10.1016/j.drup.2008.07.001; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Sithanandam G, 2005, ONCOGENE, V24, P1847, DOI 10.1038/sj.onc.1208381; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Struckmann K, 2004, CANCER RES, V64, P1632, DOI 10.1158/0008-5472.CAN-03-1687; Tripathy D, 1992, Cancer Treat Res, V63, P15; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Winkler GS, 2010, J CELL PHYSIOL, V222, P66, DOI 10.1002/jcp.21919; Xue CS, 2006, CANCER RES, V66, P1418, DOI 10.1158/0008-5472.CAN-05-0550; Yu K, 2006, CLIN CANCER RES, V12, P3288, DOI 10.1158/1078-0432.CCR-05-1530; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562; Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786	62	46	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	27					3084	3095		10.1038/onc.2011.24	http://dx.doi.org/10.1038/onc.2011.24			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	789IW	21339742				2022-12-17	WOS:000292510100008
J	Cash, TP; Gruber, JJ; Hartman, TR; Henske, EP; Simon, MC				Cash, T. P.; Gruber, J. J.; Hartman, T. R.; Henske, E. P.; Simon, M. C.			Loss of the Birt-Hogg-Dube tumor suppressor results in apoptotic resistance due to aberrant TGF beta-mediated transcription	ONCOGENE			English	Article						BHD; apoptosis; Bim; TGF beta; mTOR	RENAL-CELL CARCINOMA; BH3-ONLY PROTEIN BIM; BHD GENE; YOLK-SAC; SIGNALING PATHWAYS; MTOR ACTIVATION; EXPRESSION; GROWTH; MUTATIONS; CANCER	Birt-Hogg-Dube (BHD) syndrome is an inherited cancer susceptibility disease characterized by skin and kidney tumors, as well as cystic lung disease, which results from loss-of-function mutations in the BHD gene. BHD is also inactivated in a significant fraction of patients with sporadic renal cancers and idiopathic cystic lung disease, and little is known about its mode of action. To investigate the molecular and cellular basis of BHD tumor suppressor activity, we generated mutant Bhd mice and embryonic stem cell lines. BHD-deficient cells exhibited defects in cell-intrinsic apoptosis that correlated with reduced expression of the BH3-only protein Bim, which was similarly observed in all human and murine BHD-related tumors examined. We further demonstrate that Bim deficiency in Bhd(-/-) cells is not a consequence of elevated mTOR or ERK activity, but results instead from reduced Bim transcription associated with a general loss of TGF beta-mediated transcription and chromatin modifications. In aggregate, this work identifies a specific tumor suppressive mechanism for BHD in regulating TGF beta-dependent transcription and apoptosis, which has implications for the development of targeted therapies. Oncogene (2011) 30, 2534-2546; doi:10.1038/onc.2010.628; published online 24 January 2011	[Cash, T. P.; Gruber, J. J.; Simon, M. C.] Abramson Family Canc Res Inst, Philadelphia, PA USA; [Cash, T. P.; Simon, M. C.] Univ Penn, Sch Med, Dept Cell & Mol Biol, Philadelphia, PA 19104 USA; [Hartman, T. R.] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA; [Henske, E. P.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA; [Simon, M. C.] Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Fox Chase Cancer Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Howard Hughes Medical Institute; University of Pennsylvania	Simon, MC (corresponding author), 451 BRB 2-2,421 Curie Blvd, Philadelphia, PA 19104 USA.	celeste2@mail.med.upenn.edu	Simon, Celeste/AAG-3941-2021		Myrovlytis Trust (London, UK); NIH [CA104838]; NATIONAL CANCER INSTITUTE [P01CA104838] Funding Source: NIH RePORTER	Myrovlytis Trust (London, UK); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Myrovlytis Trust (London, UK) and NIH grant no. CA104838 for funding this work, Marc Yudkoff, Ilana Nissim, Evgueni Daikhin, Hongwei Yu, Anja Runge, and Terri Richardson for technical assistance and Brian Keith, Guoliang Qing, and Xianxin Hua for critically reviewing the manuscript. MCS is an investigator of the Howard Hughes Medical Institute.	Adelman DM, 1999, GENE DEV, V13, P2478, DOI 10.1101/gad.13.19.2478; Baba M, 2008, JNCI-J NATL CANCER I, V100, P140, DOI 10.1093/jnci/djm288; Baba M, 2006, P NATL ACAD SCI USA, V103, P15552, DOI 10.1073/pnas.0603781103; COOPER MC, 1974, P NATL ACAD SCI USA, V71, P1677, DOI 10.1073/pnas.71.5.1677; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Dehan E, 2009, MOL CELL, V33, P109, DOI 10.1016/j.molcel.2008.12.020; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Faast R, 2004, ONCOGENE, V23, P491, DOI 10.1038/sj.onc.1207133; Goumans MJ, 1999, DEVELOPMENT, V126, P3473; Gruber JJ, 2009, CELL, V138, P328, DOI 10.1016/j.cell.2009.04.046; Gunji Y, 2007, J MED GENET, V44, DOI 10.1136/jmg.2007.049874; Guo Y, 2009, ONCOGENE, V28, P1864, DOI 10.1038/onc.2009.35; Hartman TR, 2009, ONCOGENE, V28, P1594, DOI 10.1038/onc.2009.14; Hasumi Y, 2009, P NATL ACAD SCI USA, V106, P18722, DOI 10.1073/pnas.0908853106; Hong SB, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-160; Houde N, 2009, J BIOL CHEM, V284, P23397, DOI 10.1074/jbc.M109.019372; Hudon V, 2010, J MED GENET, V47, P182, DOI 10.1136/jmg.2009.072009; Khoo SK, 2003, CANCER RES, V63, P4583; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Lademann UA, 2008, THROMB HAEMOSTASIS, V100, P1041, DOI 10.1160/TH08-04-0266; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; McRonald FE, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-31; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; Okimoto K, 2004, P NATL ACAD SCI USA, V101, P2023, DOI 10.1073/pnas.0308071100; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Ramesh S, 2008, EMBO REP, V9, P990, DOI 10.1038/embor.2008.158; Ramjaun AR, 2007, ONCOGENE, V26, P970, DOI 10.1038/sj.onc.1209852; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Ross S, 2006, EMBO J, V25, P4490, DOI 10.1038/sj.emboj.7601332; Savatier P, 1996, ONCOGENE, V12, P309; Schmidt LS, 2005, AM J HUM GENET, V76, P1023, DOI 10.1086/430842; Singh SR, 2006, ONCOGENE, V25, P5933, DOI 10.1038/sj.onc.1209593; Su H, 2009, GENE DEV, V23, P304, DOI 10.1101/gad.1749809; Toro JR, 2008, J MED GENET, V45, P321, DOI 10.1136/jmg.2007.054304; van Slegtenhorst M, 2007, J BIOL CHEM, V282, P24583, DOI 10.1074/jbc.M700857200; Vocke CD, 2005, J NATL CANCER I, V97, P931, DOI 10.1093/jnci/dji154; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Woodward ER, 2008, CLIN CANCER RES, V14, P5925, DOI 10.1158/1078-0432.CCR-08-0608; Yu J, 2008, J CELL PHYSIOL, V215, P422, DOI 10.1002/jcp.21325; Zantl N, 2007, ONCOGENE, V26, P7038, DOI 10.1038/sj.onc.1210510; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	48	46	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	22					2534	2546		10.1038/onc.2010.628	http://dx.doi.org/10.1038/onc.2010.628			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21258407	Green Published, hybrid			2022-12-17	WOS:000291198400005
J	Alvarez-Moya, B; Lopez-Alcala, C; Drosten, M; Bachs, O; Agell, N				Alvarez-Moya, B.; Lopez-Alcala, C.; Drosten, M.; Bachs, O.; Agell, N.			K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function	ONCOGENE			English	Article						calmodulin; K-Ras; PKC; phosphorylation	C-MEDIATED PHOSPHORYLATION; ACTIVATED PROTEIN-KINASE; CELL-CYCLE; N-RAS; H-RAS; SIGNAL; GROWTH; RAF-1; GENE; PKC	Fine tuning of Ras activity is widely known as a mechanism to induce different cellular responses. Recently, we have shown that calmodulin (CaM) binds to K-Ras and that K-Ras phosphorylation inhibits its interaction with CaM. In this study we report that CaM inhibits K-Ras phosphorylation at Ser181 by protein kinase C (PKC) in vivo, and this is a mechanism to modulate K-Ras activity and signaling. Although CaM inhibition increased the activation of endogenous K-Ras, PKC inhibition decreased its activation status. We demonstrate that K-Ras phosphorylation decreased susceptibility to p120GAP activity. Accordingly, we also observed that non-phosphorylable K-Ras mutant exhibits a less sustained activation profile and do not efficiently activate AKT at low growth factor doses compared with wild-type K-Ras. It is interesting that the physiological responses induced by K-Ras are affected by this phosphorylation; when K-Ras cannot be phosphorylated it exhibits a remarkably decreased ability to stimulate proliferation in non-saturated serum conditions. Finally, we demonstrate that phosphorylation also regulates oncogenic K-Ras functions, as focus formation capacity, mobility and apoptosis resistance upon adriamycin treatment of cells expressing oncogenic K-Ras that cannot be phosphorylated are highly compromised. Moreover, at low serum concentration proliferation and survival is practically inhibited when cells cannot phosphorylate oncogenic K-Ras. In this condition, K-Ras phosphorylation is essential to ensure a proper activation of mitogen-activated protein kinase and PI3K/AKT pathways. In summary, our findings suggest that the interplay between CaM interaction and PKC phosphorylation is essential to regulate non-oncogenic and oncogenic K-Ras activity and functionality. Oncogene (2010) 29, 5911-5922; doi:10.1038/onc.2010.298; published online 30 August 2010	[Alvarez-Moya, B.; Lopez-Alcala, C.; Bachs, O.; Agell, N.] Univ Barcelona, Dept Biol Cellular Immunol & Neurociencies, Inst Invest Biomed August Pi & Sunyer, Fac Med, E-08036 Barcelona, Spain; [Drosten, M.] CNIO, Mol Oncol Programme, Madrid, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Centro Nacional de Investigaciones Oncologicas (CNIO)	Agell, N (corresponding author), Univ Barcelona, Dept Biol Cellular Immunol & Neurociencies, Inst Invest Biomed August Pi & Sunyer, Fac Med, C Casanova 143, E-08036 Barcelona, Spain.	neusagell@ub.edu	Agell, Neus/E-9640-2016	Agell, Neus/0000-0002-1205-6074; Drosten, Matthias/0000-0002-3205-456X; Alvarez Moya, Blanca/0000-0003-2573-7909	Ministerio de Educacion y Ciencia (Spain) [SAF2007-60491]; Generalitat de Catalunya (Spain)	Ministerio de Educacion y Ciencia (Spain)(Spanish Government); Generalitat de Catalunya (Spain)(Generalitat de Catalunya)	We thank Dr M Barbacid (CNIO, Spain) for the generous gift of Rasless and K-Ras<SUP>-/-</SUP> MEFs. We are also indebt with Anna Bosch and Maria Calvo (Confocal microscopy facility, SCT-University of Barcelona) for their help of performing the cell mobility assays. This study was supported by grant SAF2007-60491 from the Ministerio de Educacion y Ciencia (Spain). Blanca Alvarez-Moya was recipient of a pre-doctoral fellowship from the Generalitat de Catalunya (Spain).	Agell N, 2006, CELL CYCLE, V5, P3, DOI 10.4161/cc.5.1.2270; Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Ashery U, 2006, CELL MOL NEUROBIOL, V26, P471, DOI 10.1007/s10571-006-9059-3; BALLESTER R, 1987, J BIOL CHEM, V262, P2688; Bivona TG, 2006, MOL CELL, V21, P481, DOI 10.1016/j.molcel.2006.01.012; BOS JL, 1989, CANCER RES, V49, P4682; Bosch M, 1998, J BIOL CHEM, V273, P22145, DOI 10.1074/jbc.273.34.22145; Chakravarthy B, 1999, TRENDS NEUROSCI, V22, P12, DOI 10.1016/S0166-2236(98)01288-0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Downward J, 1996, CANCER SURV, V27, P87; Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7; Elad-Sfadia G, 2004, J BIOL CHEM, V279, P34922, DOI 10.1074/jbc.M312697200; Elad-Sfadia G, 2002, J BIOL CHEM, V277, P37169, DOI 10.1074/jbc.M205698200; Hamilton M, 2001, J BIOL CHEM, V276, P29079, DOI 10.1074/jbc.M102001200; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; Liao JH, 2006, J BIOL CHEM, V281, P29730, DOI 10.1074/jbc.M600668200; Liou JS, 2004, J CELL PHYSIOL, V198, P277, DOI 10.1002/jcp.10409; Lopez-Alcala C, 2008, J BIOL CHEM, V283, P10621, DOI 10.1074/jbc.M706238200; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matallanas D, 2006, MOL CELL BIOL, V26, P100, DOI 10.1128/MCB.26.1.100-116.2006; Moreto J, 2008, CELL SIGNAL, V20, P1092, DOI 10.1016/j.cellsig.2008.01.022; Omerovic J, 2007, CELL MOL LIFE SCI, V64, P2575, DOI 10.1007/s00018-007-7133-8; Plowman SJ, 2008, MOL CELL BIOL, V28, P4377, DOI 10.1128/MCB.00050-08; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Rodriguez-Vilarrupla A, 2005, MOL CELL BIOL, V25, P7364, DOI 10.1128/MCB.25.16.7364-7374.2005; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SHALOMFEUERSTEI.R, 2008, RES, V68, P6608; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; VEIGL ML, 1982, FED PROC, V41, P2283; Villalonga P, 2002, J BIOL CHEM, V277, P37929, DOI 10.1074/jbc.M202245200; Villalonga P, 2001, MOL CELL BIOL, V21, P7345, DOI 10.1128/MCB.21.21.7345-7354.2001; Xia SH, 2007, J BIOL CHEM, V282, P13199, DOI 10.1074/jbc.M610225200; Xia SH, 2009, CELL SIGNAL, V21, P502, DOI 10.1016/j.cellsig.2008.12.002; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	43	46	46	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	44					5911	5922		10.1038/onc.2010.298	http://dx.doi.org/10.1038/onc.2010.298			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20802526				2022-12-17	WOS:000283843400005
J	Goncharenko-Khaider, N; Lane, D; Matte, I; Rancourt, C; Piche, A				Goncharenko-Khaider, N.; Lane, D.; Matte, I.; Rancourt, C.; Piche, A.			The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells	ONCOGENE			English	Article						death receptors; ovarian carcinoma; resistance; PI3K/Akt pathway; TRAIL; Bid	CISPLATIN-INDUCED APOPTOSIS; SIGNALING COMPLEX DISC; X-LINKED INHIBITOR; MEDIATED APOPTOSIS; KINASE; DEATH; PROTEIN; PHOSPHORYLATION; CHEMOTHERAPY; CLEAVAGE	Epithelial ovarian cancer (EOC) cells often show increased activity of the PI3K/Akt pathway. In addition, we have previously shown that EOC ascites induce Akt activation in the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-sensitive EOC cell line, CaOV3, leading to TRAIL-mediated apoptosis inhibition. In this study, we investigated the role of Akt in intrinsic resistance to TRAIL, which is common in EOC cells. We report that Akt activation reduces the sensitivity of EOC cells to TRAIL. TRAIL-resistant SKOV3ip1 and COV2 cells were sensitized to TRAIL-induced apoptosis by PI3K or Akt inhibitors although inhibition of PI3K/Akt signaling pathway did not interfere with the recruitment and processing of caspase-8 to the death-inducing signaling complex. Conversely, overexpression of Akt1 in TRAIL-sensitive cells promoted resistance to TRAIL. Although the fact that TRAIL-induced caspase-8 activation was observed in both sensitive and resistant cell lines, Bid cleavage occurred only in sensitive cells or in SKOV3ip1 cells treated with LY294002. Bid expression was low in resistant cells and Akt activation down-regulated its expression. Depletion of Bid by siRNA in OVCAR3 cells was associated with a decrease in TRAIL-mediated apoptosis. Overexpression of Bid only in SKOV3ip1 cells enhanced TRAIL-induced apoptosis. Simultaneous blockade of Akt pathway further increased TRAIL-induced apoptosis. Thus, Akt acts upstream of mitochondria and inhibits TRAIL-induced apoptosis by decreasing Bid protein levels and possibly inhibiting its cleavage. Oncogene (2010) 29, 5523-5536; doi:10.1038/onc.2010.288; published online 26 July 2010	[Goncharenko-Khaider, N.; Lane, D.; Matte, I.; Rancourt, C.; Piche, A.] Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Piche, A (corresponding author), Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, 3001 12Ieme Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	Alain.Piche@USherbrooke.ca			Cancer Research Society	Cancer Research Society	This study was supported by a Grant from the Cancer Research Society (A.P.). We wish to thank the Tumor Bank from the Reseau de Recherche en Cancer du Fond de Recherche en Sante du Quebec, Canada for providing the primary tumor cell samples. We also thank Dr Louis Valiquette for his assistance with the statistical analyses.	Asselin E, 2001, CANCER RES, V61, P1862; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Cuello M, 2001, GYNECOL ONCOL, V81, P380, DOI 10.1006/gyno.2001.6194; Cuello M, 2004, CELL DEATH DIFFER, V11, P527, DOI 10.1038/sj.cdd.4401387; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Fraser M, 2003, CANCER RES, V63, P7081; Griffith TS, 1998, J IMMUNOL, V161, P2833; Hu LM, 2002, CANCER RES, V62, P1087; Izeradjene K, 2005, ONCOGENE, V24, P2050, DOI 10.1038/sj.onc.1208397; Jost PJ, 2009, NATURE, V460, P1035, DOI 10.1038/nature08229; Kandasamy K, 2002, CANCER RES, V62, P4929; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kang YC, 2004, CELL DEATH DIFFER, V11, P1287, DOI 10.1038/sj.cdd.4401489; Kim KM, 2005, J CELL BIOCHEM, V96, P376, DOI 10.1002/jcb.20512; Kim SH, 2008, CANCER RES, V68, P2062, DOI 10.1158/0008-5472.CAN-07-6278; Kim YH, 2007, J CELL BIOCHEM, V100, P998, DOI 10.1002/jcb.21098; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Klinck R, 2008, CANCER RES, V68, P657, DOI 10.1158/0008-5472.CAN-07-2580; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Lane D, 2008, INT J GYNECOL CANCER, V18, P670, DOI 10.1111/j.1525-1438.2007.01062.x; Lane D, 2004, GYNECOL ONCOL, V93, P594, DOI 10.1016/j.ygyno.2004.03.029; Lane D, 2006, MOL CANCER THER, V5, P509, DOI 10.1158/1535-7163.MCT-05-0362; Lane D, 2010, ONCOGENE, V29, P3519, DOI 10.1038/onc.2010.107; Lane D, 2007, INT J CANCER, V121, P1227, DOI 10.1002/ijc.22840; Larribere L, 2004, CELL DEATH DIFFER, V11, P1084, DOI 10.1038/sj.cdd.4401475; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mabuchi S, 2007, CLIN CANCER RES, V13, P4261, DOI 10.1158/1078-0432.CCR-06-2770; Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004; Ndozangue-Touriguine O, 2008, ONCOGENE, V27, P6012, DOI 10.1038/onc.2008.197; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Newsom-Davis T, 2009, APOPTOSIS, V14, P607, DOI 10.1007/s10495-009-0321-2; Page C, 2000, ANTICANCER RES, V20, P407; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Panner A, 2005, MOL CELL BIOL, V25, P8809, DOI 10.1128/MCB.25.20.8809-8823.2005; Siervo-Sassi RR, 2003, CANCER LETT, V190, P61, DOI 10.1016/S0304-3835(02)00579-7; Westfall SD, 2005, MOL CANCER THER, V4, P1764, DOI 10.1158/1535-7163.MCT-05-0192; Yang XK, 2006, CANCER RES, V66, P3126, DOI 10.1158/0008-5472.CAN-05-0425; Yap TA, 2009, NAT REV CANCER, V9, P167, DOI 10.1038/nrc2583; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792	48	46	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	40					5523	5536		10.1038/onc.2010.288	http://dx.doi.org/10.1038/onc.2010.288			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20661217	hybrid, Green Published			2022-12-17	WOS:000282945800009
J	Pines, G; Huang, PH; Zwang, Y; White, FM; Yarden, Y				Pines, G.; Huang, P. H.; Zwang, Y.; White, F. M.; Yarden, Y.			EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism	ONCOGENE			English	Article						EGFR mutations; glioblastoma; growth factor; signal transduction; tyrosine kinase	EPIDERMAL-GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; C-TERMINAL TAIL; HUMAN GLIOBLASTOMAS; EGF RECEPTOR; V-ERBB; DOMAIN; ACTIVATION; CELLS; MUTATIONS	Tumor cells often subvert normal regulatory mechanisms of signal transduction. This study shows this principle by studying yet uncharacterized mutants of the epidermal growth factor receptor (EGFR) previously identified in glioblastoma multiforme, which is the most aggressive brain tumor in adults. Unlike the well-characterized EGFRvIII mutant form, which lacks a portion of the ligand-binding cleft within the extracellular domain, EGFRvIVa and EGFRvIVb lack internal segments distal to the intracellular tyrosine kinase domain. By constructing the mutants and by ectopic expression in naive cells, we show that both mutants confer an oncogenic potential in vitro, as well as tumorigenic growth in animals. The underlying mechanisms entail constitutive receptor dimerization and basal activation of the kinase domain, likely through a mechanism that relieves a restraining molecular fold, along with stabilization due to association with HSP90. Phospho-proteomic analyses delineated the signaling pathways preferentially engaged by EGFRvIVb-identified unique substrates. This information, along with remarkable sensitivities to tyrosine kinase blockers and to a chaperone inhibitor, proposes strategies for pharmacological interception in brain tumors harboring EGFRvIV mutations. Oncogene (2010) 29, 5850-5860; doi: 10.1038/onc.2010.313; published online 2 August 2010	[Pines, G.; Zwang, Y.; Yarden, Y.] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; [Huang, P. H.; White, F. M.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA	Weizmann Institute of Science; Massachusetts Institute of Technology (MIT)	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Candiotty Bldg,Room 302,1 Hertzl St, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	Pines, Gur/X-7501-2019; YARDEN, YOSEF/K-1467-2012; Huang, Paul H./H-8591-2015	Pines, Gur/0000-0002-1757-6722; Huang, Paul H./0000-0003-3972-5087; White, Forest/0000-0002-1545-1651	Goldhirsh Foundation; US National Cancer Institute (NCI) [CA072981, CA118705, CA141556, U54-CA112967]; Israel Science Foundation; Dr Miriam and Sheldon G Adelson Medical Research Foundation; NATIONAL CANCER INSTITUTE [U54CA112967, R01CA118705, R37CA072981, U01CA141556, R01CA072981] Funding Source: NIH RePORTER	Goldhirsh Foundation; US National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Israel Science Foundation(Israel Science Foundation); Dr Miriam and Sheldon G Adelson Medical Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair. Our work is supported by research grants from the Goldhirsh Foundation, the US National Cancer Institute (NCI; CA072981 to YY, CA118705, CA141556 and U54-CA112967 to FMW), the Israel Science Foundation and Dr Miriam and Sheldon G Adelson Medical Research Foundation.	An WG, 2000, CELL GROWTH DIFFER, V11, P355; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Chiara F, 2004, J BIOL CHEM, V279, P19732, DOI 10.1074/jbc.M314070200; Chiosis G, 2003, MOL CANCER THER, V2, P123; Clarkson RWE, 2006, MOL ENDOCRINOL, V20, P675, DOI 10.1210/me.2005-0392; Dawson JP, 2005, MOL CELL BIOL, V25, P7734, DOI 10.1128/MCB.25.17.7734-7742.2005; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Frederick L, 2000, CANCER RES, V60, P1383; Gan HK, 2009, J CLIN NEUROSCI, V16, P748, DOI 10.1016/j.jocn.2008.12.005; Getz G, 2000, P NATL ACAD SCI USA, V97, P12079, DOI 10.1073/pnas.210134797; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Huang PH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.287re6; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Jeuken J, 2009, BRAIN PATHOL, V19, P661, DOI 10.1111/j.1750-3639.2009.00320.x; Jura N, 2009, CELL, V137, P1293, DOI 10.1016/j.cell.2009.04.025; Katz M, 2007, BBA-MOL CELL RES, V1773, P1161, DOI 10.1016/j.bbamcr.2007.01.002; Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083; Ladanyi M, 2008, MODERN PATHOL, V21, pS16, DOI 10.1038/modpathol.3801018; Landau M, 2004, STRUCTURE, V12, P2265, DOI 10.1016/j.str.2004.10.006; Lavictoire SJ, 2003, J BIOL CHEM, V278, P5292, DOI 10.1074/jbc.M209494200; Li JJ, 2009, ONCOGENE, V28, P1759, DOI 10.1038/onc.2009.15; McManus MJ, 1997, P NATL ACAD SCI USA, V94, P11351, DOI 10.1073/pnas.94.21.11351; Nagane M, 1996, CANCER RES, V56, P5079; PULCIANI S, 1982, J CELL BIOCHEM, V20, P51, DOI 10.1002/jcb.240200106; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5; Shimamura T, 2005, CANCER RES, V65, P6401, DOI 10.1158/0008-5472.CAN-05-0933; Shtiegman K, 2007, ONCOGENE, V26, P6968, DOI 10.1038/sj.onc.1210503; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Wykosky J, 2005, MOL CANCER RES, V3, P541, DOI 10.1158/1541-7786.MCR-05-0056; Zenz R, 2006, INT J BIOCHEM CELL B, V38, P1043, DOI 10.1016/j.biocel.2005.11.011; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; Zhang Y, 2005, MOL CELL PROTEOMICS, V4, P1240, DOI 10.1074/mcp.M500089-MCP200	39	46	48	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	43					5850	5860		10.1038/onc.2010.313	http://dx.doi.org/10.1038/onc.2010.313			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20676128	Green Accepted, Green Published			2022-12-17	WOS:000283586200010
J	Reeves, CV; Dufraine, J; Young, JAT; Kitajewski, J				Reeves, C. V.; Dufraine, J.; Young, J. A. T.; Kitajewski, J.			Anthrax toxin receptor 2 is expressed in murine and tumor vasculature and functions in endothelial proliferation and morphogenesis	ONCOGENE			English	Article						ANTXR2; CMG2; angiogenesis; endothelial cells	CAPILLARY MORPHOGENESIS; ANGIOGENESIS; PROTEIN-2; CELLS; IDENTIFICATION; COLLAGEN; MARKERS; CANCER; DOMAIN	The Capillary Morphogenesis Gene 2 (CMG2) gene encodes an Anthrax toxin receptor (ANTXR2), but the normal physiological function is not known. ANTXR2/CMG2 was originally identified as a result of up-regulation during capillary morphogenesis of endothelial cells (ECs) cultured in vitro. We explored the hypothesis that key steps of the angiogenic process are either dependent or are influenced by ANTXR2/CMG2 activity. We describe the expression pattern of ANTXR2/CMG2 in several murine tissues and in normal breast and breast tumors. Endothelial expression was found in all of the tissues analyzed, in cultured ECs and in breast tumor vessels; however, ANTXR2/CMG2 expression was not restricted to this cell type. To assess potential angiogenic function, we used RNA interference to achieve significant reduction of ANTXR2/CMG2 expression in cultured human umbilical venous endothelial cells (HUVECs). Reduced ANTXR2/CMG2 expression resulted in significant inhibition of proliferation and reduced capacity of ECs to form capillary-like networks in vitro, whereas overexpression of ANTXR2/CMG2 in HUVEC increased proliferation and capillary-like network formation. Little change in migration of ECs was observed on knockdown or overexpression. We conclude that ANTXR2/CMG2 functions to promote endothelial proliferation and morphogenesis during sprouting angiogenesis, consistent with the endothelial expression of ANTXR2/CMG2 in several vascular beds. Oncogene (2010) 29, 789-801; doi:10.1038/onc.2009.383; published online 9 November 2009	[Kitajewski, J.] Columbia Univ, Med Ctr, Dept Pathol, Off 926,Irving Canc Res Ctr, New York, NY 10035 USA; [Reeves, C. V.; Dufraine, J.; Kitajewski, J.] Columbia Univ, Med Ctr, OB GYN, New York, NY 10035 USA; [Young, J. A. T.] Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA; [Kitajewski, J.] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10035 USA	Columbia University; Columbia University; Salk Institute; Columbia University	Kitajewski, J (corresponding author), Columbia Univ, Med Ctr, Dept Pathol, Off 926,Irving Canc Res Ctr, 1130 St Nicholas Ave, New York, NY 10035 USA.	jkk9@columbia.edu		Young, John/0000-0003-1824-2561	NIH [RO1 HL62454, RO1 AI064654, DK07328, AI48489]; DOD Breast Cancer Program [X81WH-06-1-0355]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064654, R01AI048489, R01AI076852] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007328] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD Breast Cancer Program(United States Department of Defense); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH RO1 HL62454 (JKK) and NIH RO1 AI064654 (JKK). CVR was supported by endocrinology training grant DK07328 and by a fellowship from the DOD Breast Cancer Program X81WH-06-1-0355. JY was supported by NIH grant AI48489. We thank Dr Yasuhiro Funahashi, Ayelet Spitzer, and Eunice Kim for technical support, Dr David Owens for the gift of the antibodies and critical reading of the paper, and Dr Darrell Yamashiro for help with preparation of the figures.	Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7; Bell SE, 2001, J CELL SCI, V114, P2755; Bonuccelli G, 2005, AM J PHYSIOL-CELL PH, V288, pC1402, DOI 10.1152/ajpcell.00582.2004; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carson-Walter EB, 2001, CANCER RES, V61, P6649; Hanks S, 2003, AM J HUM GENET, V73, P791, DOI 10.1086/378418; Hotchkiss KA, 2005, EXP CELL RES, V305, P133, DOI 10.1016/j.yexcr.2004.12.025; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Li ER, 2000, EXP DERMATOL, V9, P431, DOI 10.1034/j.1600-0625.2000.009006431.x; Liu SL, 2009, P NATL ACAD SCI USA, V106, P12424, DOI 10.1073/pnas.0905409106; Mock M, 2003, CELL MICROBIOL, V5, P15, DOI 10.1046/j.1462-5822.2003.00253.x; Nanda A, 2004, CURR OPIN ONCOL, V16, P44, DOI 10.1097/00001622-200401000-00009; Nanda A, 2004, CANCER RES, V64, P817, DOI 10.1158/0008-5472.CAN-03-2408; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rmali KA, 2005, BIOCHEM BIOPH RES CO, V334, P231, DOI 10.1016/j.bbrc.2005.06.085; Rogers MS, 2007, CANCER RES, V67, P9980, DOI 10.1158/0008-5472.CAN-07-0829; Scobie HM, 2006, PLOS PATHOG, V2, P949, DOI 10.1371/journal.ppat.0020111; Scobie HM, 2005, J INFECT DIS, V192, P1047, DOI 10.1086/432731; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Shimaoka M, 2002, P NATL ACAD SCI USA, V99, P16737, DOI 10.1073/pnas.252633099; St Croix B, 2000, SCIENCE, V289, P1197; Tung JJ, 2009, ANGIOGENESIS, V12, P209, DOI 10.1007/s10456-009-9139-3; Xu QF, 2007, MICROB PATHOGENESIS, V43, P37, DOI 10.1016/j.micpath.2007.03.002	25	46	47	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					789	801		10.1038/onc.2009.383	http://dx.doi.org/10.1038/onc.2009.383			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19901963	Green Accepted			2022-12-17	WOS:000274397800002
J	Thobe, MN; Gurusamy, D; Pathrose, P; Waltz, SE				Thobe, M. N.; Gurusamy, D.; Pathrose, P.; Waltz, S. E.			The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells	ONCOGENE			English	Article						Ron receptor; prostate cancer; chemokines; receptor tyrosine kinase; Met receptor; angiogenesis	HEPATOCYTE GROWTH-FACTOR; FACTOR-LIKE PROTEIN; CXC-CHEMOKINES; TUMOR-GROWTH; C-MET; ALTERED EXPRESSION; ENHANCES GROWTH; BREAST-CANCER; KAPPA-B; PROGRESSION	Overexpression of the Ron receptor tyrosine kinase has recently been shown in a wide variety of human cancers. However, no studies have examined Ron receptor expression or function during prostate tumorigenesis. In this study we report that Ron is highly expressed in human prostate adenocarcinoma and metastatic lymph nodes when compared with normal prostate or benign prostate hyperplasia. Furthermore, we show that Ron is over-expressed in PC-3 and DU145 prostate cancer cell lines, and that the levels of angiogenic chemokines produced by prostate cancer cells positively correlate with Ron expression. The knockdown of Ron in PC-3 or DU145 cells results in a significant decrease in angiogenic chemokine production and is associated with a decreased activation of the transcription factor nuclear factor-kappa B (NF-kappa B). Moreover, exogenous overexpression of Ron in LNCaP cells is sufficient to induce a significant increase in angiogenic chemokines that can be abrogated by inhibition of NF-kappa B signaling. Given that the function of angiogenic chemokines is important in the development of new blood vessels, we also examined the ability of Ron to modulate endothelial cell migration. Our data show that knockdown of Ron in prostate cancer cells results in significantly less endothelial cell chemotaxis when compared with Ron-expressing cells in vitro as well as in reduced tumor growth and decreased microvessel density after orthotopic transplantation into the prostate in vivo. In total, our data suggest that the Ron receptor is important in modulating prostate tumor growth by modulating angiogenic chemokine production and subsequent endothelial cell recruitment. Oncogene (2010) 29, 214-226; doi:10.1038/onc.2009.331; published online 19 October 2009	[Thobe, M. N.; Gurusamy, D.; Pathrose, P.; Waltz, S. E.] Univ Cincinnati, Dept Canc & Cell Biol, Coll Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Waltz, SE (corresponding author), Univ Cincinnati, Dept Canc & Cell Biol, Coll Med, Vontz Bldg Mol Studies,3125 Eden Ave, Cincinnati, OH 45267 USA.	susan.waltz@uc.edu	Gurusamy, Devikala/T-3410-2019	Gurusamy, Devikala/0000-0002-1727-8653; Waltz, Susan/0000-0003-3572-4642	National Institutes of Health [CA-125370]; Department of Defense Congressionally Directed Medical Research Programs [PC060821]; NATIONAL CANCER INSTITUTE [R01CA125379, R21CA125370] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Congressionally Directed Medical Research Programs(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Sandy Schwemberger for her assistance with the flow cytometry experiments as well as Sarah Kader for her technical contributions. This work was supported by Public Health Services Grants CA-125370 (SEW) from the National Institutes of Health, and by grant project no. PC060821 (MNT) from the Department of Defense Congressionally Directed Medical Research Programs.	Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; Balbay MD, 1999, CLIN CANCER RES, V5, P783; Best CJM, 2005, CLIN CANCER RES, V11, P6823, DOI 10.1158/1078-0432.CCR-05-0585; Bezerra JA, 1998, J CLIN INVEST, V101, P1175, DOI 10.1172/JCI1744; BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Collado B, 2007, PEPTIDES, V28, P1896, DOI 10.1016/j.peptides.2007.04.015; CRAFT PS, 1994, ANN ONCOL, V5, P305, DOI 10.1093/oxfordjournals.annonc.a058829; Dhanasekaran SM, 2004, FASEB J, V18, P243, DOI 10.1096/fj.04-2415fje; Greene GF, 1997, AM J PATHOL, V150, P1571; Hepburn PJ, 1997, PROSTATE, V33, P123; Jimenez JA, 2006, UROL ONCOL-SEMIN ORI, V24, P260, DOI 10.1016/j.urolonc.2005.11.022; Keeley EC, 2008, ARTERIOSCL THROM VAS, V28, P1928, DOI 10.1161/ATVBAHA.108.162925; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Leonis Mike A, 2007, Future Oncol, V3, P441, DOI 10.2217/14796694.3.4.441; Li YH, 2003, CANCER BIOTHER RADIO, V18, P829, DOI 10.1089/108497803770418373; Lissbrant IF, 1997, PROSTATE, V33, P38; Loh SA, 2009, PLAST RECONSTR SURG, V123, p65S, DOI 10.1097/PRS.0b013e318191bdf4; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Moore BB, 1999, AM J PATHOL, V154, P1503, DOI 10.1016/S0002-9440(10)65404-1; NIKOLAIDIS NM, 2009, SHOCK IN PRESS; O'Toole JM, 2006, CANCER RES, V66, P9162, DOI 10.1158/0008-5472.CAN-06-0283; Peace BE, 2005, CANCER RES, V65, P1285, DOI 10.1158/0008-5472.CAN-03-3580; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; Puri N, 2007, CANCER RES, V67, P3529, DOI 10.1158/0008-5472.CAN-06-4416; Ren Y, 2005, CLIN CANCER RES, V11, P6190, DOI 10.1158/1078-0432.CCR-04-2553; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Salcedo R, 2000, FASEB J, V14, P2055, DOI 10.1096/fj.99-0963com; Sawa Y, 2008, CELL TISSUE RES, V333, P237, DOI 10.1007/s00441-008-0625-5; Shen H, 2006, FASEB J, V20, P59, DOI 10.1096/fj.05-4764com; Shen H, 2004, AM J PHYSIOL-CELL PH, V286, pC840, DOI 10.1152/ajpcell.00335.2003; Strieter RM, 2006, EUR J CANCER, V42, P768, DOI 10.1016/j.ejca.2006.01.006; Thomas RM, 2007, CANCER RES, V67, P6075, DOI 10.1158/0008-5472.CAN-06-4128; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008-5472.CAN-06-3552; Wagh PK, 2008, ADV CANCER RES, V100, P1, DOI 10.1016/S0065-230X(08)00001-8; Wang MH, 2007, J PATHOL, V213, P402, DOI 10.1002/path.2245; Waugh DJJ, 2008, FRONT BIOSCI, V13, P4595, DOI 10.2741/3025; Welm AL, 2007, P NATL ACAD SCI USA, V104, P7570, DOI 10.1073/pnas.0702095104; Wilson C, 2008, J PHARMACOL EXP THER, V327, P746, DOI 10.1124/jpet.108.143826; Yoshida S, 2002, J CLIN ENDOCR METAB, V87, P2376, DOI 10.1210/jc.87.5.2376; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075; Zinser GM, 2006, CANCER RES, V66, P11967, DOI 10.1158/0008-5472.CAN-06-2473	46	46	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					214	226		10.1038/onc.2009.331	http://dx.doi.org/10.1038/onc.2009.331			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19838218	Green Accepted			2022-12-17	WOS:000273650000005
J	Bauer, K; Kretzschmar, AK; Cvijic, H; Blumert, C; Loffler, D; Brocke-Heidrich, K; Schiene-Fischer, C; Fischer, G; Sinz, A; Clevenger, CV; Horn, F				Bauer, K.; Kretzschmar, A. K.; Cvijic, H.; Blumert, C.; Loeffler, D.; Brocke-Heidrich, K.; Schiene-Fischer, C.; Fischer, G.; Sinz, A.; Clevenger, C. V.; Horn, F.			Cyclophilins contribute to Stat3 signaling and survival of multiple myeloma cells	ONCOGENE			English	Article						Stat3; cyclophilin B; cyclophilin A; cyclosporine A; interleukin-6; multiple myeloma	PROTEIN EXPRESSION PROFILES; RHEUMATOID-ARTHRITIS; CONSTITUTIVE ACTIVATION; MASS-SPECTROMETRY; TRANSDUCER GP130; UP-REGULATION; IN-VIVO; INTERLEUKIN-6; BINDING; TRANSCRIPTION	Signal transducer and activator of transcription 3 (Stat3) is the major mediator of interleukin-6 (IL-6) family cytokines. In addition, Stat3 is known to be involved in the pathophysiology of many malignancies. Here, we show that the cis-trans peptidyl-prolyl isomerase cyclophilin (Cyp) B specifically interacts with Stat3, whereas the highly related CypA does not. CypB knockdown inhibited the IL-6-induced transactivation potential but not the tyrosine phosphorylation of Stat3. Binding of CypB to Stat3 target promoters and alteration of the intranuclear localization of Stat3 on CypB depletion suggested a nuclear function of Stat3/ CypB interaction. By contrast, CypA knockdown inhibited Stat3 IL-6-induced tyrosine phosphorylation and nuclear translocation. The Cyp inhibitor cyclosporine A (CsA) caused similar effects. However, Stat1 activation in response to IL-6 or interferon-gamma was not affected by Cyp silencing or CsA treatment. As a result, Cyp knockdown shifted IL-6 signaling to a Stat1-dominated pathway. Furthermore, Cyp depletion or treatment with CsA induced apoptosis in IL-6-dependent multiple myeloma cells, whereas an IL-6-independent line was not affected. Thus, Cyps support the anti-apoptotic action of Stat3. Taken together, CypA and CypB both play pivotal roles, yet at different signaling levels, for Stat3 activation and function. These data also suggest a novel mechanism of CsA action. Oncogene ( 2009) 28, 2784-2795; doi:10.1038/onc.2009.142; published online 8 June 2009	[Bauer, K.; Kretzschmar, A. K.; Cvijic, H.; Blumert, C.; Loeffler, D.; Brocke-Heidrich, K.; Horn, F.] Univ Leipzig, Inst Clin Immunol & Transfus Med, Fac Med, D-04103 Leipzig, Germany; [Bauer, K.; Loeffler, D.; Brocke-Heidrich, K.; Horn, F.] Univ Leipzig, Interdisciplinary Ctr Clin Res, D-04103 Leipzig, Germany; [Schiene-Fischer, C.; Fischer, G.] Max Planck Res Unit Enzymol Prot Folding, Halle, Saale, Germany; [Sinz, A.] Univ Halle Wittenberg, Inst Pharm, Dept Pharmaceut Chem & Bioanalyt, Halle, Saale, Germany; [Clevenger, C. V.] Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA; [Kretzschmar, A. K.; Horn, F.] Fraunhofer Inst Cell Therapy & Immunol, Leipzig, Germany	Leipzig University; Leipzig University; Max Planck Society; Martin Luther University Halle Wittenberg; Northwestern University; Fraunhofer Gesellschaft	Horn, F (corresponding author), Univ Leipzig, Inst Clin Immunol & Transfus Med, Fac Med, Johannisallee 30, D-04103 Leipzig, Germany.	friedemann.horn@medizin.uni-leipzig.de			Deutsche Forschungsgemeinschaft	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Hans- Georg Krausslich, University Heidelberg, Germany, and Stefan Rose- John, University Kiel, Germany, for CypA vector and recombinant IL- 6, respectively. INA- 6 cells were kindly provided by Renate Burger and Martin Gramatzki, University Kiel, Germany. This work was supported by SFB610 ( project C2) from the Deutsche Forschungsgemeinschaft.	Allain F, 1996, BIOCHEM J, V317, P565, DOI 10.1042/bj3170565; Arevalo-Rodriguez M, 2000, EMBO J, V19, P3739, DOI 10.1093/emboj/19.14.3739; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Billich A, 1997, J EXP MED, V185, P975, DOI 10.1084/jem.185.5.975; Brazin KN, 2002, P NATL ACAD SCI USA, V99, P1899, DOI 10.1073/pnas.042529199; Brocke-Heidrich K, 2006, ONCOGENE, V25, P7297, DOI 10.1038/sj.onc.1209711; Brocke-Heidrich K, 2004, BLOOD, V103, P242, DOI 10.1182/blood-2003-04-1048; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bukrinsky MI, 2002, TRENDS IMMUNOL, V23, P323, DOI 10.1016/S1471-4906(02)02237-8; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Choi KJ, 2007, CANCER RES, V67, P3654, DOI 10.1158/0008-5472.CAN-06-1759; Cui Y, 2002, J CELL BIOCHEM, V86, P630, DOI 10.1002/jcb.10253; De Ceuninck F, 2003, ARTHRITIS RHEUM, V48, P2197, DOI 10.1002/art.11099; Fang F, 2009, AM J PATHOL, V174, P297, DOI 10.2353/ajpath.2009.080753; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; HODGE DR, 2005, EUR J CANC; Howard BA, 2005, CANCER RES, V65, P8853, DOI 10.1158/0008-5472.CAN-05-1219; Howard BA, 2004, LUNG CANCER, V46, P313, DOI 10.1016/j.lungcan.2004.05.013; Ihling C, 2003, RAPID COMMUN MASS SP, V17, P1240, DOI 10.1002/rcm.1049; JENSEN ON, 1997, PROTEIN STRUCTURE PR, P48; Kitahara K, 2007, CURR OPIN RHEUMATOL, V19, P238, DOI 10.1097/BOR.0b013e328099af80; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; Kretzschmar AK, 2004, BIOCHEM J, V377, P289, DOI 10.1042/BJ20030708; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; LOFFLER D, 2007, BLOOD; Lufei C, 2007, ONCOGENE, V26, P7656, DOI 10.1038/sj.onc.1210567; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Mamane Y, 2000, IMMUNITY, V12, P129, DOI 10.1016/S1074-7613(00)80166-1; Mariller C, 1996, BBA-PROTEIN STRUCT M, V1293, P31, DOI 10.1016/0167-4838(95)00230-8; Obata Y, 2005, J BIOL CHEM, V280, P18355, DOI 10.1074/jbc.M501684200; Peters M, 1998, J IMMUNOL, V161, P3575; Podar K, 2003, J BIOL CHEM, V278, P5794, DOI 10.1074/jbc.M208636200; Puthier D, 2001, BRIT J HAEMATOL, V112, P358, DOI 10.1046/j.1365-2141.2001.02575.x; Rawat R, 2000, BLOOD, V96, P3514; Rycyzyn MA, 2002, P NATL ACAD SCI USA, V99, P6790, DOI 10.1073/pnas.092160699; Rycyzyn MA, 2000, MOL ENDOCRINOL, V14, P1175, DOI 10.1210/me.14.8.1175; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; SCHWARZE MMK, 1995, CANCER RES, V55, P2262; Shen JJ, 2004, CANCER RES, V64, P9018, DOI 10.1158/0008-5472.CAN-04-3262; SHERRY B, 1992, P NATL ACAD SCI USA, V89, P3511, DOI 10.1073/pnas.89.8.3511; Song J, 2004, J BIOL CHEM, V279, P24414, DOI 10.1074/jbc.M311406200; Syed F, 2003, ENDOCRINE, V20, P83, DOI 10.1385/ENDO:20:1-2:83; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; Wang P, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-226; Watashi K, 2005, MOL CELL, V19, P111, DOI 10.1016/j.molcel.2005.05.014; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Yang Y, 2008, RHEUMATOLOGY, V47, P1299, DOI 10.1093/rheumatology/ken225; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng JM, 2008, CANCER RES, V68, P7769, DOI 10.1158/0008-5472.CAN-08-0639	51	46	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28	31					2784	2795		10.1038/onc.2009.142	http://dx.doi.org/10.1038/onc.2009.142			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479TS	19503092				2022-12-17	WOS:000268684400002
J	Wu, D; Asiedu, M; Wei, Q				Wu, D.; Asiedu, M.; Wei, Q.			Myosin-interacting guanine exchange factor (MyoGEF) regulates the invasion activity of MDA-MB-231 breast cancer cells through activation of RhoA and RhoC	ONCOGENE			English	Article						MyoGEF; RhoA; RhoC; MDA-MB-231; cell motility; nonmuscle myosin II	BINDING PROTEIN RHO; MIGRATING CELLS; LIVING CELLS; MEMBRANE PROTRUSIONS; ADHESION DYNAMICS; CENTRAL SPINDLE; DISTINCT ROLES; HELA-CELLS; ANTI-RHOA; IN-VIVO	The small guanine triphosphatase (GTPase) proteins RhoA and RhoC are essential for tumor invasion and/or metastasis in breast carcinomas. However, it is poorly understood how RhoA and RhoC are activated in breast cancer cells. Here we describe the role of myosin-interacting guanine nucleotide exchange factor (MyoGEF) in regulating RhoA and RhoC activation as well as cell polarity and invasion in an invasive breast cancer cell line MDA-MB-231. RNA-interference (RNAi)-mediated depletion of MyoGEF in MDA-MB-231 cells not only suppresses the activation of RhoA and RhoC, but also decreases cell polarity and invasion activity. The dominant-negative mutants of RhoA and RhoC, but not Rac1 and Cdc42, dramatically decrease actin polymerization induced by MyoGEF. In addition, MyoGEF colocalizes with nonmuscle myosin IIA (NMIIA) to the front of migrating cells, and depletion of NMIIA by RNAi disrupts the polarized localization of MyoGEF at the cell leading edge, suggesting a role for NMIIA in regulating MyoGEF localization and function. Moreover, MyoGEF protein levels significantly increase in infiltrating ductal carcinomas as well as in invasive breast cancer cell lines. Taken together, our results suggest that MyoGEF cooperates with NMIIA to regulate the polarity and invasion activity of breast cancer cells through activation of RhoA and RhoC. Oncogene (2009) 28, 2219-2230; doi: 10.1038/onc.2009.96; published online 4 May 2009	[Wu, D.; Asiedu, M.; Wei, Q.] Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Wei, Q (corresponding author), Kansas State Univ, Dept Biochem, 141 Chalmers Hall, Manhattan, KS 66506 USA.	weiq@ksu.edu			National Institutes of Health (NIH) [P20 RR015563, k22 HL071542]; National Center for Research Resources; Kansas Agricultural Experiment Station, Manhattan, KS, USA [09-136-J]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015563] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K22HL071542] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Kansas Agricultural Experiment Station, Manhattan, KS, USA; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr Robert S Adelstein and Dr Mary Anne Conti for their criticalreading and comments on the manuscript. We thank Dr Keith Burridge (University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) and Dr Rick Cerione (Cornell University, Ithaca, NY, USA) for providing GSTRBD and GST- PBD plasmids. This publication was made possible by National Institutes of Health (NIH) Grant no. P20 RR015563 from the NationalCenter for Research Resources. This work was also supported by NIH Grant k22 HL071542 (to QW), as well as a fund from Terry C. Johnson Center for Basic Cancer Research (to QW). This is contribution 09-136-J from the Kansas Agricultural Experiment Station, Manhattan, KS, USA.	Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Ahram M, 2000, EXP CELL RES, V260, P292, DOI 10.1006/excr.2000.5031; Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Asiedu M, 2008, J BIOL CHEM, V283, P28392, DOI 10.1074/jbc.M801801200; Asiedu M, 2009, MOL BIOL CELL, V20, P1428, DOI 10.1091/mbc.E08-01-0001; Betapudi V, 2006, CANCER RES, V66, P4725, DOI 10.1158/0008-5472.CAN-05-4236; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chang F, 2002, SCIENCE, V297, P531, DOI 10.1126/science.1074649; Cheng L, 2004, J BIOL CHEM, V279, P12786, DOI 10.1074/jbc.M313099200; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Conti MA, 2008, J CELL SCI, V121, P11, DOI 10.1242/jcs.007112; Demou ZN, 2005, CANCER RES, V65, P5674, DOI 10.1158/0008-5472.CAN-04-1682; Wu D, 2006, CELL CYCLE, V5, P1234, DOI 10.4161/cc.5.11.2815; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Higashida C, 2004, SCIENCE, V303, P2007, DOI 10.1126/science.1093923; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kleer CG, 2002, AM J PATHOL, V160, P579, DOI 10.1016/S0002-9440(10)64877-8; Kleer CG, 2005, BREAST CANCER RES TR, V93, P101, DOI 10.1007/s10549-005-4170-6; Kleer CG, 2004, BREAST CANCER RES, V6, pR110, DOI 10.1186/bcr755; Kolega J, 2006, MOL BIOL CELL, V17, P4435, DOI 10.1091/mbc.E06-05-0431; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Krendel M, 2005, PHYSIOLOGY, V20, P239, DOI 10.1152/physiol.00014.2005; Kurokawa K, 2005, BIOCHEM SOC T, V33, P631, DOI 10.1042/BST0330631; Kurokawa K, 2005, MOL BIOL CELL, V16, P4294, DOI 10.1091/mbc.E04-12-1076; Kusama T, 2006, INT J ONCOL, V29, P217; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Lo CM, 2004, MOL BIOL CELL, V15, P982, DOI 10.1091/mbc.E03-06-0359; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Meshel AS, 2005, NAT CELL BIOL, V7, P157, DOI 10.1038/ncb1216; Nalbant P, 2004, SCIENCE, V305, P1615, DOI 10.1126/science.1100367; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Pertz O, 2006, NATURE, V440, P1069, DOI 10.1038/nature04665; Pille JY, 2006, HUM GENE THER, V17, P1019, DOI 10.1089/hum.2006.17.1019; Pille JY, 2005, MOL THER, V11, P267, DOI 10.1016/j.ymthe.2004.08.029; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2001, J CELL SCI, V114, P2713; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sahai E, 2007, J CELL BIOL, V176, P35, DOI 10.1083/jcb.200605135; Sandquist JC, 2006, J BIOL CHEM, V281, P35873, DOI 10.1074/jbc.M605343200; Sastry SK, 2006, J BIOL CHEM, V281, P11627, DOI 10.1074/jbc.M600897200; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Totsukawa G, 2004, J CELL BIOL, V164, P427, DOI 10.1083/jcb.200306172; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; Vicente-Manzanares M, 2007, J CELL BIOL, V176, P573, DOI 10.1083/jcb.200612043; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; Wei QZ, 2005, J BIOL CHEM, V280, P37790, DOI 10.1074/jbc.M502974200; Wells CM, 2004, J CELL SCI, V117, P1259, DOI 10.1242/jcs.00997; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; Yamana N, 2006, MOL CELL BIOL, V26, P6844, DOI 10.1128/MCB.00283-06; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	67	46	47	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	22					2219	2230		10.1038/onc.2009.96	http://dx.doi.org/10.1038/onc.2009.96			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453VF	19421144	Green Accepted			2022-12-17	WOS:000266640300004
J	Chen, LC; Liu, HP; Li, HP; Hsueh, C; Yu, JS; Liang, CL; Chang, YS				Chen, L-C; Liu, H-P; Li, H-P; Hsueh, C.; Yu, J-S; Liang, C-L; Chang, Y-S			Thymidine phosphorylase mRNA stability and protein levels are increased through ERK-mediated cytoplasmic accumulation of hnRNP K in nasopharyngeal carcinoma cells	ONCOGENE			English	Article						hnRNP K; thymidine phosphorylase; ERK signaling; nasopharyngeal carcinoma	NUCLEAR RIBONUCLEOPROTEIN-K; HYPOXIA-INDUCED APOPTOSIS; ENDOTHELIAL GROWTH-FACTOR; BINDING-PROTEIN; IN-VITRO; TRANSLATION; EXPRESSION; CANCER; METASTASIS; ACTIVATION	The cytoplasmic level of heterogeneous nuclear ribonucleoprotein K (hnRNP K) is significantly correlated with the elevated expression of thymidine phosphorylase (TP), and high levels of both proteins are predictive of a poor prognosis in nasopharyngeal carcinoma (NPC). We herein show that TP is highly induced by serum deprivation in NPC cells, and that this is due to an increase in the half-life of the TP mRNA, as shown by nuclear run-on and actinomycin D assays. We further show that the CU-rich element of the TP mRNA directly interacts with hnRNP K, as demonstrated by immunoprecipitation RT-PCR assays, and the nucleus-to-cytoplasm translocation of hnRNP K. Blockade of hnRNP K expression reduces TP expression, suggesting that hnRNP K acts in the upregulation of TP. Mechanistically, both MEK inhibitor and the hnRNP K ERK-phosphoacceptor-site mutant decrease cytoplasmic accumulation of hnRNP K, suggesting that ERK-dependent phosphorylation is critical for TP induction. Furthermore, we found that hnRNP K-mediated TP induction allows NPC cells to resist hypoxia-induced apoptosis. Our results collectively establish the regulation and role of ERK-mediated cytoplasmic accumulation of hnRNP K as an upstream modulator of TP, suggesting that hnRNP K may be an attractive candidate as a future therapeutic target for cancer.	[Chen, L-C; Liu, H-P; Hsueh, C.; Yu, J-S; Chang, Y-S] Chang Gung Univ, Chang Gung Mol Med Res Ctr, Tao Yuan 333, Taiwan; [Li, H-P; Yu, J-S; Chang, Y-S] Chang Gung Univ, Grad Inst Basic Med Sci, Tao Yuan 333, Taiwan; [Hsueh, C.] Chang Gung Mem Hosp Lin Kou, Dept Pathol, Tao Yuan, Taiwan; [Liang, C-L] Chung Shan Med Univ, Dept Microbiol & Immunol, Taichung, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Chung Shan Medical University	Chang, YS (corresponding author), Chang Gung Univ, Chang Gung Mol Med Res Ctr, 259 Wen Hwa 1st Rd, Tao Yuan 333, Taiwan.	ysc@mail.cgu.edu.tw	Liu, Hao-Ping/AAJ-3038-2020; Li, Hsin-Pai/C-7305-2014	Liu, Hao-Ping/0000-0001-5915-5128; Chang, Yu-Sun/0000-0002-6457-3890; Hsueh, Chuen/0000-0001-7860-5964; Yu, Jau-Song/0000-0002-4295-983X	Ministry of Education, Taiwan (to Chang Gung University); National Science Council, Taiwan [NSC 94-2314-B-182A-188, 94-3112-B-182-005, 95-2320-B-182-001]; Chang Gung Memorial Hospital, Taiwan [CMRPD150961, CMRPG360221]	Ministry of Education, Taiwan (to Chang Gung University)(Ministry of Education, Taiwan); National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Chang Gung Memorial Hospital, Taiwan(Chang Gung Memorial Hospital)	Grant support was provided by the Ministry of Education, Taiwan (to Chang Gung University), the National Science Council, Taiwan (grants NSC 94-2314-B-182A-188, 94-3112-B-182-005 and 95-2320-B-182-001 to Y-S Chang) and Chang Gung Memorial Hospital, Taiwan (grants CMRPD150961 and CMRPG360221 to Y-S Chang). Special thanks to Chung Shan Medical University for supporting CL Liang to attend the 12th International EBV Symposium.	Bomsztyk K, 2004, BIOESSAYS, V26, P629, DOI 10.1002/bies.20048; Carpenter B, 2006, BRIT J CANCER, V95, P921, DOI 10.1038/sj.bjc.6603349; Chen LC, 2008, CLIN CANCER RES, V14, P3807, DOI 10.1158/1078-0432.CCR-08-0155; Czyzyk-Krzeska MF, 1999, BLOOD, V93, P2111, DOI 10.1182/blood.V93.6.2111.406k24_2111_2120; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Emerald BS, 2007, J BIOL CHEM, V282, P680, DOI 10.1074/jbc.M600224200; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Goto H, 2001, CANCER RES, V61, P469; Griffiths L, 1997, CANCER RES, V57, P570; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Hatakeyama H, 2006, PROTEOMICS, V6, P6300, DOI 10.1002/pmic.200600488; Ikeda R, 2006, BIOCHEM BIOPH RES CO, V342, P280, DOI 10.1016/j.bbrc.2006.01.142; Inoue A, 2007, P NATL ACAD SCI USA, V104, P8983, DOI 10.1073/pnas.0607595104; Katz M, 2007, BBA-MOL CELL RES, V1773, P1161, DOI 10.1016/j.bbamcr.2007.01.002; Kim E, 2006, FEBS J, V273, P793, DOI 10.1111/j.1742-4658.2006.05112.x; Kitazono M, 1998, BIOCHEM BIOPH RES CO, V253, P797, DOI 10.1006/bbrc.1998.9852; LEE AWM, 1992, INT J RADIAT ONCOL, V23, P261, DOI 10.1016/0360-3016(92)90740-9; Lee PT, 2007, MOL BIOL CELL, V18, P5004, DOI 10.1091/mbc.E07-04-0384; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Liekens S, 2007, BIOCHEM PHARMACOL, V74, P1555, DOI 10.1016/j.bcp.2007.05.008; Lin JC, 2007, P NATL ACAD SCI USA, V104, P2235, DOI 10.1073/pnas.0611015104; Lynch M, 2005, MOL CELL BIOL, V25, P6436, DOI 10.1128/MCB.25.15.6436-6453.2005; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Notari M, 2006, BLOOD, V107, P2507, DOI 10.1182/blood-2005-09-3732; Ostareck-Lederer A, 2004, BIOL CELL, V96, P407, DOI 10.1016/j.biolcel.2004.03.010; Pino I, 2003, LUNG CANCER-J IASLC, V41, P131, DOI 10.1016/S0169-5002(03)00193-4; Roychoudhury P, 2007, BRIT J CANCER, V97, P574, DOI 10.1038/sj.bjc.6603911; Schwartz EL, 1998, CANCER RES, V58, P1551; Seibel NM, 2007, ANAL BIOCHEM, V368, P95, DOI 10.1016/j.ab.2007.05.025; Tsai CL, 2006, CANCER RES, V66, P11668, DOI 10.1158/0008-5472.CAN-06-2194; Tse KP, 2007, CLIN CANCER RES, V13, P6320, DOI 10.1158/1078-0432.CCR-07-1029; Waggoner SA, 2003, EXP BIOL MED, V228, P387, DOI 10.1177/153537020322800409; Wang SB, 2006, NUCLEIC ACIDS RES, V34, P3044, DOI 10.1093/nar/gkl386; Yao YX, 2005, J NEURO-ONCOL, V72, P217, DOI 10.1007/s11060-004-3012-4; Zhu GH, 2002, ONCOGENE, V21, P8477, DOI 10.1038/sj.onc.1206030	35	46	47	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2009	28	17					1904	1915		10.1038/onc.2009.55	http://dx.doi.org/10.1038/onc.2009.55			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PX	19330019				2022-12-17	WOS:000265640600003
J	Kitagaki, J; Yang, Y; Saavedra, JE; Colburn, NH; Keefer, LK; Perantoni, AO				Kitagaki, J.; Yang, Y.; Saavedra, J. E.; Colburn, N. H.; Keefer, L. K.; Perantoni, A. O.			Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53	ONCOGENE			English	Article						JS-K; nitric oxide (NO); ubiquitin; tumor; apoptosis; p53	IN-VITRO; BETA-CATENIN; APOPTOSIS; CANCER; DESTRUCTION; TRANSLATION; GLUTATHIONE; PATHWAYS; SYSTEM; GROWTH	Nitric oxide (NO) is a major effector molecule in cancer prevention. A number of studies have shown that NO prodrug JS-K (O-2-(2,4-dinitrophenyl) 1-[(4-ethoxy-carbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate) induces apoptotic cell death in vitro and in vivo, indicating that it is a promising new therapeutic for cancer. However, the mechanism of its tumor-killing activity remains unclear. Ubiquitin plays an important role in the regulation of tumorigenesis and cell apoptosis. Our earlier report has shown that inactivation of the ubiquitin system through blocking E1(ubiquitin-activating enzyme) activity preferentially induces apoptosis in p53-expressing transformed cells. As E1 has an active cysteine residue that could potentially interact with NO, we hypothesized that JS-K could inactivate E1 activity. E1 activity was evaluated by detecting ubiquitin-E1 conjugates through immunoblotting. JS-K strikingly inhibits the ubiquitin-E1 thioester formation in cells in a dose-dependent manner with an IC50 of approximately 2 mu M, whereas a JS-K analog that cannot release NO did not affect these levels in cells. Moreover, JS-K decreases total ubiquitylated proteins and increases p53 levels, which is mainly regulated by ubiquitin and proteasomal degradation. Furthermore, JS-K preferentially induces cell apoptosis in p53-expressing transformed cells. These findings indicate that JS-K inhibits E1 activity and kills transformed cells harboring wild-type p53.	[Kitagaki, J.; Yang, Y.; Perantoni, A. O.] Natl Canc Inst Frederick, Canc & Dev Biol Lab, Ctr Canc Res, Natl Inst Hlth, Frederick, MD 21702 USA; [Saavedra, J. E.] Natl Canc Inst Frederick, Basic Res Program, SAIC Frederick, Ctr Canc Res,Natl Inst Hlth, Frederick, MD 21702 USA; [Colburn, N. H.] Natl Canc Inst Frederick, Lab Canc Prevent, Ctr Canc Res, NIH, Frederick, MD 21702 USA; [Keefer, L. K.] Natl Canc Inst Frederick, Comparat Carcinogenesis Lab, Ctr Canc Res, Natl Inst Hlth, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Perantoni, AO (corresponding author), Natl Canc Inst Frederick, Canc & Dev Biol Lab, Ctr Canc Res, Natl Inst Hlth, Bldg 538,Rm 221,1050 Boyles St, Frederick, MD 21702 USA.	yangyili@ncifcrf.gov; peranton@ncifcrf.gov	Keefer, Larry K/N-3247-2014	Keefer, Larry K/0000-0001-7489-9555	NIH; National Cancer Institute; Center for Cancer Research; National Cancer Institute [NOI-CO-12400]; NATIONAL CANCER INSTITUTE [ZIABC011188, ZIABC010025] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to the NIH Fellows Editorial Board for revisions of this paper. This work was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research and by National Cancer Institute Contract No. NOI-CO-12400 to SAIC Inc. JK was a fellow of the Japanese Society for the Promotion of Science.	Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Giarre M, 1998, ANN NY ACAD SCI, V857, P43, DOI 10.1111/j.1749-6632.1998.tb10106.x; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Kiziltepe T, 2007, BLOOD, V110, P709, DOI 10.1182/blood-2006-10-052845; Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580; Liu J, 2004, MOL CANCER THER, V3, P709; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Ren ZG, 2003, J CELL PHYSIOL, V197, P426, DOI 10.1002/jcp.10380; Saavedra JE, 2006, J MED CHEM, V49, P1157, DOI 10.1021/jm050700k; Shami PJ, 2006, J MED CHEM, V49, P4356, DOI 10.1021/jm060022h; Shami PJ, 2003, MOL CANCER THER, V2, P409; Simeone AM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2095; Turchi JJ, 2006, P NATL ACAD SCI USA, V103, P4337, DOI 10.1073/pnas.0601001103; Yang YL, 2007, CANCER RES, V67, P9472, DOI 10.1158/0008-5472.CAN-07-0568; Yang YL, 2005, CANCER CELL, V7, P547, DOI 10.1016/j.ccr.2005.04.029; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Ying L, 2007, CANCER RES, V67, P1407, DOI 10.1158/0008-5472.CAN-06-2149	26	46	47	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					619	624		10.1038/onc.2008.401	http://dx.doi.org/10.1038/onc.2008.401			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18978812	Green Accepted			2022-12-17	WOS:000262866500015
J	Raafat, A; Lawson, S; Bargo, S; Klauzinska, M; Strizzi, L; Goldhar, AS; Buono, K; Salomon, D; Vonderhaar, BK; Callahan, R				Raafat, A.; Lawson, S.; Bargo, S.; Klauzinska, M.; Strizzi, L.; Goldhar, A. S.; Buono, K.; Salomon, D.; Vonderhaar, B. K.; Callahan, R.			Rbpj conditional knockout reveals distinct functions of Notch4/Int3 in mammary gland development and tumorigenesis	ONCOGENE			English	Article						RBP-J; Int3; tumorigenesis	TRUNCATED INT3 GENE; NEOPLASTIC TRANSFORMATION; CELL-DIFFERENTIATION; NOTCH; ACTIVATION; TUMOR; EXPRESSION; SUPPRESSOR; EPITHELIUM; MICE	Transgenic mice expressing the Notch 4 intracellular domain (ICD) (Int3) in the mammary gland have two phenotypes: arrest of mammary alveolar/lobular development and mammary tumorigenesis. Notch4 signaling is mediated primarily through the interaction of Int3 with the transcription repressor/activator Rbpj. We have conditionally ablated the Rbpj gene in the mammary glands of mice expressing whey acidic protein (Wap)-Int3. Interestingly, Rbpj knockout mice (Wap-Cre(+)/Rbpj(-/-)/Wap-Int3) have normal mammary gland development, suggesting that the effect of endogenous Notch signaling on mammary gland development is complete by day 15 of pregnancy. RBP-J heterozygous (Wap-Cre(+)/Rbpj(-/-)/Wap-Int3) and Rbpj control (Rbpj(flox/flox)/Wap-Int3) mice are phenotypically the same as Wap-Int3 mice with respect to mammary gland development and tumorigenesis. In addition, the Wap-Cre(+)/Rbpj(-/-)/Wap-Int3- knockout mice also developed mammary tumors at a frequency similar to Rbpj heterozygous and Wap-Int3 control mice but with a slightly longer latency. Thus, the effect on mammary gland development is dependent on the interaction of the Notch ICD with the transcription repressor/activator Rbpj, and Notch-induced mammary tumor development is independent of this interaction.	[Raafat, A.; Lawson, S.; Bargo, S.; Klauzinska, M.; Strizzi, L.; Goldhar, A. S.; Salomon, D.; Vonderhaar, B. K.; Callahan, R.] NCI, Mammary Biol & Tumorigenesis Lab, NIH, Bethesda, MD 20892 USA; [Buono, K.] NIDDKD, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Callahan, R (corresponding author), NCI, Mammary Biol & Tumorigenesis Lab, NIH, 37 Convent Dr,Bldg 37,Room 1118A, Bethesda, MD 20892 USA.	rc54d@nih.gov			NIH; National Cancer Institute; Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC008226, ZIABC005148] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The Rbpj<SUP>flox/flox</SUP> mice were kindly provided by Dr Tasuku Honjo, Department of Medical Chemistry, Graduate School of Medicine, Kyoto University, Kyoto, Japan, and the WAP-Cre mice were kindly provided by Dr Lothar Hennighausen, Laboratory of Genetics and Physiology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.	Bashyam MD, 2002, CANCER, V94, P1821, DOI 10.1002/cncr.10362; Bray S, 2001, CURR BIOL, V11, pR217, DOI 10.1016/S0960-9822(01)00109-9; Buono KD, 2006, DEV BIOL, V293, P565, DOI 10.1016/j.ydbio.2006.02.043; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Dumont E, 2000, ONCOGENE, V19, P556, DOI 10.1038/sj.onc.1203352; Furriols M, 2001, CURR BIOL, V11, P60, DOI 10.1016/S0960-9822(00)00044-0; Furriols M, 2000, DEV BIOL, V227, P520, DOI 10.1006/dbio.2000.9923; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Gallahan D, 1996, CANCER RES, V56, P1775; Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030; Hu CY, 2006, AM J PATHOL, V168, P973, DOI 10.2353/ajpath.2006.050416; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kato H, 1996, FEBS LETT, V395, P221, DOI 10.1016/0014-5793(96)01046-0; KORDON EC, 1995, J VIROL, V69, P8066, DOI 10.1128/JVI.69.12.8066-8069.1995; Leong KG, 2007, J EXP MED, V204, P2935, DOI 10.1084/jem.20071082; Levy OA, 2002, DEV NEUROSCI-BASEL, V24, P79, DOI 10.1159/000064948; Luo D, 2005, SEMIN CELL DEV BIOL, V16, P612, DOI 10.1016/j.semcdb.2005.07.002; MacKenzie F, 2004, J BIOL CHEM, V279, P11657, DOI 10.1074/jbc.M312102200; Oakes SR, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1411; Raafat A, 2007, ONCOGENE, V26, P662, DOI 10.1038/sj.onc.1209823; Raafat A, 2004, ONCOGENE, V23, P9401, DOI 10.1038/sj.onc.1208187; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Shawber C, 1996, DEVELOPMENT, V122, P3765; Shin HM, 2006, EMBO J, V25, P129, DOI 10.1038/sj.emboj.7600902; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Yoder BJ, 2007, BREAST J, V13, P172, DOI 10.1111/j.1524-4741.2007.00393.x; Zheng X, 2008, P NATL ACAD SCI USA, V105, P3368, DOI 10.1073/pnas.0711591105	32	46	46	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					219	230		10.1038/onc.2008.379	http://dx.doi.org/10.1038/onc.2008.379			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18836481	Green Accepted			2022-12-17	WOS:000262501100006
J	Lei, K; Townsend, DM; Tew, KD				Lei, K.; Townsend, D. M.; Tew, K. D.			Protein cysteine sulfinic acid reductase (sulfiredoxin) as a regulator of cell proliferation and drug response	ONCOGENE			English	Article						sulfiredoxin; redox; glutathione; thiols; phosphatases; regulatory kinases	TYROSINE PHOSPHATASES; S-GLUTATHIONYLATION; SIGNAL-TRANSDUCTION; REDOX REGULATION; TRANSCRIPTIONAL RESPONSE; LUNG-CANCER; ACTIVE-SITE; PEROXIREDOXIN; THIOREDOXIN; PHOSPHORYLATION	Sulfiredoxin (Srx) is one of a family of low molecular weight sulfur containing proteins linked with maintenance of cellular redox balance. One function of Srx is the reduction of cysteine sulfinic acid to sulfenic acid in proteins subject to oxidative stress. Other redox active protein families have multiple functions in regulating redox and controlling proliferation/death pathways; increased Srx has been linked with oncogenic transformation. To explore the biological functions of Srx in tumors, we established cell lines that overexpress Srx. Enhanced levels of Srx promoted cell proliferation and enhanced cell death following cisplatin. Srx overexpression triggered an alteration in expression and phosphorylation of cell cycle regulators p21, p27 and p53; stabilized the phosphatase PTEN and, importantly, interacted directly with, and enhanced the activity of, phosphatase PTP1B. In turn, this promoted Src kinase activity by dephosphorylating its inhibitory tyrosine residue (Y530). Srx expression was stimulated by cell exposure to certain growth factors. These data support a role for Srx in controlling the phosphorylation status of key regulatory kinases through effects upon phosphatase activity with an ultimate effect on pathways that influence cell proliferation.	[Lei, K.; Tew, K. D.] Med Univ S Carolina, Dept Cell & Mol Pharmacol, Charleston, SC 29425 USA; [Townsend, D. M.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Tew, KD (corresponding author), Med Univ S Carolina, Dept Cell & Mol Pharmacol, 173 Ashley Ave,POB 250505, Charleston, SC 29425 USA.	tewk@musc.edu			KL [T32 CA119945-02]; KDT [CA08660]; NATIONAL CANCER INSTITUTE [R01CA085660, T32CA119945] Funding Source: NIH RePORTER	KL; KDT; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Carola A Neumann for providing retroviral vectors and packaging cells. This work was supported by a postdoctoral fellowship grant (T32 CA119945-02) to KL and by CA08660 to KDT. We thank the Drug Metabolism and Pharmacokinetics facility for GSH measurements.	Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; Basu MK, 2005, CELL CYCLE, V4, P947, DOI 10.4161/cc.4.7.1786; Biteau B, 2003, NATURE, V425, P980, DOI 10.1038/nature02075; Bondareva AA, 2007, FREE RADICAL BIO MED, V43, P911, DOI 10.1016/j.freeradbiomed.2007.05.026; Bozonet SM, 2005, J BIOL CHEM, V280, P23319, DOI 10.1074/jbc.M502757200; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Chang TS, 2004, J BIOL CHEM, V279, P50994, DOI 10.1074/jbc.M409482200; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; CZECH MP, 1974, P NATL ACAD SCI USA, V71, P4173, DOI 10.1073/pnas.71.10.4173; Demasi APD, 2006, FEBS J, V273, P805, DOI 10.1111/j.1742-4658.2006.05116.x; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Diet A, 2007, J BIOL CHEM, V282, P36199, DOI 10.1074/jbc.M706420200; Dube N, 2005, BBA-PROTEINS PROTEOM, V1754, P108, DOI 10.1016/j.bbapap.2005.07.030; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Findlay VJ, 2006, CANCER RES, V66, P6800, DOI 10.1158/0008-5472.CAN-06-0484; Findlay VJ, 2005, BIOMED PHARMACOTHER, V59, P374, DOI 10.1016/j.biopha.2005.07.003; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082; Gallogly MM, 2007, CURR OPIN PHARMACOL, V7, P381, DOI 10.1016/j.coph.2007.06.003; Gius D, 2006, ANTIOXID REDOX SIGN, V8, P1249, DOI 10.1089/ars.2006.8.1249; Glauser DA, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-54; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Hatahet F, 2007, FEBS J, V274, P5223, DOI 10.1111/j.1742-4658.2007.06058.x; Hirabayashi Hirohisa, 2002, Nihon Rinsho, V60 Suppl 5, P263; Holmgren A, 2005, BIOCHEM SOC T, V33, P1375, DOI 10.1042/BST0331375; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jacob C, 2004, ORG BIOMOL CHEM, V2, P1953, DOI 10.1039/b406180b; Jeong W, 2006, J BIOL CHEM, V281, P14400, DOI 10.1074/jbc.M511082200; Jonsson A, 2008, J BACTERIOL, V190, P434, DOI 10.1128/JB.01058-07; Jonsson TJ, 2007, BIOCHEMISTRY-US, V46, P5709, DOI 10.1021/bi7001218; Jonsson TJ, 2005, BIOCHEMISTRY-US, V44, P8634, DOI 10.1021/bi050131i; Kaldis P, 2007, CELL, V128, P241, DOI 10.1016/j.cell.2007.01.006; Lee DY, 2006, BIOCHEMISTRY-US, V45, P15301, DOI 10.1021/bi061824h; Lee HJ, 2005, BEHAV BRAIN FUNCT, V1, DOI 10.1186/1744-9081-1-15; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; Liu XP, 2006, CELL RES, V16, P287, DOI 10.1038/sj.cr.7310036; Martinez-Ruiz A, 2007, CARDIOVASC RES, V75, P220, DOI 10.1016/j.cardiores.2007.03.016; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Rey P, 2007, PLANT J, V49, P505, DOI 10.1111/j.1365-313X.2006.02969.x; Rhee SG, 2007, KIDNEY INT, V72, pS3, DOI 10.1038/sj.ki.5002380; Rhee SG, 2005, CURR OPIN CELL BIOL, V17, P183, DOI 10.1016/j.ceb.2005.02.004; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Singhal S, 2005, CLIN CANCER RES, V11, P3974, DOI 10.1158/1078-0432.CCR-04-2661; SUN Y, 1995, J BIOL CHEM, V270, P19312, DOI 10.1074/jbc.270.33.19312; Tew KD, 2007, BIOCHEM PHARMACOL, V73, P1257, DOI 10.1016/j.bcp.2006.09.027; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; Townsend DM, 2007, MOL INTERV, V7, P313, DOI 10.1124/mi.7.6.7; Townsend DM, 2006, MOL PHARMACOL, V69, P501, DOI 10.1124/mol.105.018523; TOWNSEND DM, 2008, CANC RES IN PRESS; Velu CS, 2007, BIOCHEMISTRY-US, V46, P7765, DOI 10.1021/bi700425y; Vivancos AP, 2005, P NATL ACAD SCI USA, V102, P8875, DOI 10.1073/pnas.0503251102; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Woo HA, 2005, J BIOL CHEM, V280, P3125, DOI 10.1074/jbc.C400496200; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zhu CQ, 2006, J CLIN PATHOL, V59, P790, DOI 10.1136/jcp.2005.031351	63	46	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2008	27	36					4877	4887		10.1038/onc.2008.132	http://dx.doi.org/10.1038/onc.2008.132			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18454177	Green Accepted			2022-12-17	WOS:000258596900002
J	Hirabayashi, S; Nakagawa, K; Sumita, K; Hidaka, S; Kawai, T; Ikeda, M; Kawata, A; Ohno, K; Hata, Y				Hirabayashi, S.; Nakagawa, K.; Sumita, K.; Hidaka, S.; Kawai, T.; Ikeda, M.; Kawata, A.; Ohno, K.; Hata, Y.			Threonine 74 of MOB1 is a putative key phosphorylation site by MST2 to form the scaffold to activate nuclear Dbf2-related kinase 1	ONCOGENE			English	Article						NDR kinase; Hippo pathway; mammalian sterile 20-like kinase 2; Mps one binder 1	CELL-CYCLE EXIT; TUMOR-SUPPRESSOR; PROMOTES APOPTOSIS; PROTEIN-KINASE; NDR KINASES; HIPPO; DROSOPHILA; PROLIFERATION; SALVADOR; GROWTH	Mammalian nuclear Dbf2-related (NDR) kinases (LATS1 and 2, NDR1 and 2) play a role in cell proliferation, apoptosis and morphological changes. These kinases are regulated by mammalian sterile 20-like kinases (MSTs) and Mps one binder (MOB) 1. Okadaic acid (OA), which activates MST2, facilitates the complex formation of MOB1, MST2 and NDR1 in HEK293FT cells. The in vitro biochemical study demonstrates the phosphorylation of MOB1 by MST2. The phosphorylated MOB1 alone is capable to partially activate NDR1 in vitro, but MST2 is also required for the full activation. The knockdown of MOB1 or MST2 abolishes the OA-induced NDR1 activation in HEK293FT cells. Among MOB1 mutants, in which each serine or threonine residue is replaced with alanine, MOB1 T74A and T181A mutants fail to activate NDR1. Thr74, but not Thr181, is phosphorylated by MST2 in vitro, although MOB1 is also phosphorylated by MST2 at other site(s). The interaction of MOB1 T74A with NDR1 is barely enhanced by OA treatment. These findings indicate that the phosphorylation of MOB1 at Thr74 by MST2 is essential to make a complex of MOB1, MST2 and NDR1, and to fully activate NDR1.	[Hirabayashi, S.; Nakagawa, K.; Sumita, K.; Hidaka, S.; Kawai, T.; Ikeda, M.; Kawata, A.; Hata, Y.] Tokyo Med & Dent Univ, Grad Sch Med, Dept Med Biochem, Bunkyo Ku, Tokyo 1138519, Japan; [Sumita, K.; Ohno, K.] Tokyo Med & Dent Univ, Grad Sch Med, Dept Neurosurg, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Hata, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Med Biochem, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	yuhammch@tmd.ac.jp	Sumita, Kazutaka/AAI-1553-2019					Bichsel SJ, 2004, J BIOL CHEM, V279, P35228, DOI 10.1074/jbc.M404542200; Bothos J, 2005, CANCER RES, V65, P6568, DOI 10.1158/0008-5472.CAN-05-0862; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; Hariharan IK, 2006, CURR BIOL, V16, pR1037, DOI 10.1016/j.cub.2006.11.012; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; He Y, 2005, MOL BIOL CELL, V16, P4139, DOI 10.1091/mbc.E05-01-0018; Hergovich A, 2005, MOL CELL BIOL, V25, P8259, DOI 10.1128/MCB.25.18.8259-8272.2005; Hergovich A, 2006, NAT REV MOL CELL BIO, V7, P253, DOI 10.1038/nrm1891; Hergovich A, 2006, BIOCHEM BIOPH RES CO, V345, P50, DOI 10.1016/j.bbrc.2006.03.244; Ikeda M, 2007, EXP CELL RES, V313, P1484, DOI 10.1016/j.yexcr.2007.02.013; Jia JH, 2003, GENE DEV, V17, P2514, DOI 10.1101/gad.1134003; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Luca FC, 1998, MOL BIOL CELL, V9, P29, DOI 10.1091/mbc.9.1.29; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Stavridi ES, 2003, STRUCTURE, V11, P1163, DOI 10.1016/S0969-2126(03)00182-5; Stegert MR, 2005, MOL CELL BIOL, V25, P11019, DOI 10.1128/MCB.25.24.11019-11029.2005; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Valverde P, 2000, BIOCHEM BIOPH RES CO, V276, P990, DOI 10.1006/bbrc.2000.3582; Wei X, 2007, EMBO J, V26, P1772, DOI 10.1038/sj.emboj.7601630; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X	24	46	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4281	4292		10.1038/onc.2008.66	http://dx.doi.org/10.1038/onc.2008.66			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18362890				2022-12-17	WOS:000257691100003
J	Bottley, G; Watherston, OG; Hiew, YL; Norrild, B; Cook, GP; Blair, GE				Bottley, G.; Watherston, O. G.; Hiew, Y-L; Norrild, B.; Cook, G. P.; Blair, G. E.			High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells	ONCOGENE			English	Article						HPV; E7; MHC class I; cervical cancer; NK cells	CERVICAL KERATINOCYTES; CHROMATIN REPRESSION; DOWN-REGULATION; HLA-E; COMPLEX; GENES; E6	High-risk human papillomavirus (HPV) is a major causative agent of cervical cancer and the E6 and E7 genes encode the major HPV oncoproteins. The E7 protein from high-risk HPV types alters cell cycle progression and represses genes encoding components of the antigen-presentation pathway, suggesting a role for E7 in tumour immune evasion. We show that knockdown of E7 expression in HPV16- and HPV18-transformed cervical carcinoma cells by RNA interference increased expression of major histocompatibility complex (MHC) class I at the cell surface and reduced susceptibility of these cells to natural killer (NK) cells. Tetracycline-regulated induction of HPV16 E7 resulted in reduced expression of cell surface MHC class I molecules and increased NK cell killing. Our results suggest that, for HPV-associated malignancies, reduced MHC class I expression is the result of an active immune evasion strategy that has evolved to assist viral replication.	[Bottley, G.; Watherston, O. G.; Hiew, Y-L; Blair, G. E.] Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England; [Norrild, B.] Univ Copenhagen, Panum Inst, Inst Cellular & Mol Med, DK-2200 Copenhagen, Denmark; [Cook, G. P.] St James Univ Hosp, Leeds Inst Mol Med, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Copenhagen; Saint James's University Hospital; University of Leeds	Blair, GE (corresponding author), Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Garstang Bldg Room, Leeds LS2 9JT, W Yorkshire, England.	g.e.blair@leeds.ac.uk	Blair, George Eric/A-5906-2008; Norrild, Bodil/C-1115-2009	Blair, George Eric/0000-0003-0440-1795; Cook, Graham/0000-0003-0223-3652	Medical Research Council Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abele R, 2006, FEBS LETT, V580, P1156, DOI 10.1016/j.febslet.2005.11.048; Berger AJ, 2002, AM J PATHOL, V161, P603, DOI 10.1016/S0002-9440(10)64215-0; Bottley G, 2005, VIROLOGY, V338, P297, DOI 10.1016/j.virol.2005.05.017; Bottley Graham, 2007, Methods Mol Med, V131, P221; Brady CS, 2000, TISSUE ANTIGENS, V55, P401, DOI 10.1034/j.1399-0039.2000.550502.x; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; CROMME FV, 1993, ONCOGENE, V8, P2969; CROMME FV, 1994, J EXP MED, V179, P335, DOI 10.1084/jem.179.1.335; Garcia-Lora A, 2003, EUR J IMMUNOGENET, V30, P177, DOI 10.1046/j.1365-2370.2003.00384.x; Georgopoulos NT, 2000, ONCOGENE, V19, P4930, DOI 10.1038/sj.onc.1203860; Hall AHS, 2003, J VIROL, V77, P6066, DOI 10.1128/JVI.77.10.6066-6069.2003; Hewitt EW, 2003, IMMUNOLOGY, V110, P163, DOI 10.1046/j.1365-2567.2003.01738.x; HOWLEY PM, 2007, FIELDS VIROLOGY, P2299; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Kaznelson DW, 2004, VIROLOGY, V320, P301, DOI 10.1016/j.virol.2003.12.018; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Li H, 2006, BIOCHEM BIOPH RES CO, V349, P1315, DOI 10.1016/j.bbrc.2006.08.182; Marin R, 2003, IMMUNOGENETICS, V54, P767, DOI 10.1007/s00251-002-0526-9; Moretta L, 2004, EMBO J, V23, P255, DOI 10.1038/sj.emboj.7600019; O'Brien PM, 2003, TRENDS MICROBIOL, V11, P300, DOI 10.1016/S0966-842X(03)00145-8; Pett MR, 2006, P NATL ACAD SCI USA, V103, P3822, DOI 10.1073/pnas.0600078103; PROFFITT JL, 1994, NUCLEIC ACIDS RES, V22, P4779, DOI 10.1093/nar/22.22.4779; Tang S, 2006, J VIROL, V80, P4249, DOI 10.1128/JVI.80.9.4249-4263.2006; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Zhao BW, 2006, VIROLOGY, V352, P338, DOI 10.1016/j.virol.2006.04.036	27	46	49	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2008	27	12					1794	1799		10.1038/sj.onc.1210798	http://dx.doi.org/10.1038/sj.onc.1210798			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17828295				2022-12-17	WOS:000253962100015
J	Roelle, S; Grosse, R; Buech, T; Chubanov, V; Gudermann, T				Roelle, S.; Grosse, R.; Buech, T.; Chubanov, V.; Gudermann, T.			Essential role of Pyk2 and Src kinase activation in neuropeptide-induced proliferation of small cell lung cancer cells	ONCOGENE			English	Article						Pyk2; Src; Ca2+; small cell lung cancer cells; neuropeptides	FOCAL ADHESION KINASE; RAS-BINDING DOMAIN; PROTEIN-KINASE; CA2+ MOBILIZATION; CLONAL GROWTH; RECEPTORS; GALANIN; PHOSPHORYLATION; RAFTK/PYK2; INVASION	Neuropeptide hormones like bombesin/gastrin-releasing peptide, galanin or bradykinin, acting via auto and paracrine growth loops, represent the principal mitogens of small cell lung cancer (SCLC). These mitogenic neuropeptides activate G(q/11)-coupled receptors which stimulate phospholipase C beta activity, followed by rises of the intracellular calcium concent ration ([Ca2+](i)) and activation of protein kinase C (PKC). We report here that proline-rich tyrosine kinase Pyk2 is highly expressed in SCLC cells and provides a functional link between neuropeptide-induced increases in [Ca2+](i) and tumor cell proliferation. Activation of Pyk2 and its association with Src kinases critically depends on the elevation of [Ca2+](i), but is independent of PKC. Src kinase activities are crucial for neuropeptide-mediated GTP-loading of Ras and activation of extracellular signal-regulated kinases in SCLC cells. Pyk2 and Src kinases essentially contribute to anchorage-independent proliferation of SCLC cells. Inhibition of either Pyk2 or Src kinases by lentiviral RNAi or pharmacological inhibition with PP2, respectively, attenuated basal and neuropeptide-elicited survival and proliferation of SCLC cells in liquid culture and in soft agar. Thus, neuropeptides stimulate anchorage-independent survival and proliferation of SCLC cells via pathways involving Pyk2 and Src kinases. Therefore, Ca2+-induced Pyk2/Src complex formation may be a rewarding molecular target for novel therapeutic strategies in SCLC cells.	[Roelle, S.; Buech, T.; Chubanov, V.; Gudermann, T.] Univ Marburg, Inst Pharmakol & Toxikol, D-35043 Marburg, Germany; [Grosse, R.] Univ Heidelberg, Inst Pharmakol, D-6900 Heidelberg, Germany	Philipps University Marburg; Ruprecht Karls University Heidelberg	Gudermann, T (corresponding author), Univ Marburg, Inst Pharmakol & Toxikol, Karl Von Frischstr 1, D-35043 Marburg, Germany.	guderman@staff.uni-marburg.de		Grosse, Robert/0000-0002-3380-5273				Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Beekman A, 1998, CANCER RES, V58, P910; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Cook SJ, 2006, CELL CALCIUM, V39, P101, DOI 10.1016/j.ceca.2005.10.014; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Fernandis AZ, 2004, ONCOGENE, V23, P157, DOI 10.1038/sj.onc.1206910; Grosse R, 2000, J BIOL CHEM, V275, P12251, DOI 10.1074/jbc.275.16.12251; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Jones K, 1999, TRENDS BIOTECHNOL, V17, P477, DOI 10.1016/S0167-7799(99)01379-7; Laskin J, 2003, JNCI-J NATL CANCER I, V95, P1099, DOI 10.1093/jnci/djg013; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lipinski CA, 2005, NEOPLASIA, V7, P435, DOI 10.1593/neo.04712; MABRY M, 1989, J CLIN INVEST, V84, P194, DOI 10.1172/JCI114140; MacKinnon AC, 1999, BRIT J CANCER, V80, P1026, DOI 10.1038/sj.bjc.6690458; McMullen M, 2004, ONCOGENE, V23, P1275, DOI 10.1038/sj.onc.1207243; Moore SM, 1998, CANCER RES, V58, P5239; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Rintoul RC, 2001, LANCET ONCOL, V2, P437, DOI 10.1016/S1470-2045(00)00421-6; Rocic P, 2001, AM J PHYSIOL-CELL PH, V280, pC90, DOI 10.1152/ajpcell.2001.280.1.C90; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Rozengurt E, 2002, TRENDS ENDOCRIN MET, V13, P128, DOI 10.1016/S1043-2760(01)00544-6; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; SETHI T, 1991, CANCER RES, V51, P1674; SETHI T, 1992, CANCER RES, V52, pS2737; SETHI T, 1993, CANCER RES, V53, P5208; Seufferlein T, 1996, CANCER RES, V56, P3895; Seufferlein T, 1996, CANCER RES, V56, P5758; Sorokin A, 2001, J BIOL CHEM, V276, P21521, DOI 10.1074/jbc.M008869200; Teti A, 2002, CALCIFIED TISSUE INT, V71, P293, DOI 10.1007/s00223-001-2071-1; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Wei L, 2004, ONCOGENE, V23, P9052, DOI 10.1038/sj.onc.1208091; Wittau N, 2000, ONCOGENE, V19, P4199, DOI 10.1038/sj.onc.1203777; Zrihan-Licht S, 2000, ONCOGENE, V19, P1318, DOI 10.1038/sj.onc.1203422; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695	39	46	51	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1737	1748		10.1038/sj.onc.1210819	http://dx.doi.org/10.1038/sj.onc.1210819			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17906699				2022-12-17	WOS:000253962100009
J	Scotlandi, K; Zuntini, M; Manara, MC; Sciandra, M; Rocchi, A; Benini, S; Nicoletti, G; Bernard, G; Nanni, P; Lollini, PL; Bernard, A; Picci, P				Scotlandi, K.; Zuntini, M.; Manara, M. C.; Sciandra, M.; Rocchi, A.; Benini, S.; Nicoletti, G.; Bernard, G.; Nanni, P.; Lollini, P-L; Bernard, A.; Picci, P.			CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity	ONCOGENE			English	Article						CD99; splice variants; osteosarcoma; migration; metastases	PROSTATE-CANCER CELLS; EWINGS-SARCOMA CELLS; HUMAN OSTEOSARCOMA CELLS; EXPRESSION; ADHESION; PATHWAY; ENGAGEMENT; APOPTOSIS; MOTILITY; MIC2	CD99 gene encodes two distinct proteins, produced by alternative splicing of CD99 gene transcript. Full- length CD99 isoform ( CD99wt) is formed by an extracellular domain, followed by a transmembrane domain and a 36 amino- acid intracytoplasmic domain, which is partially deleted in the truncated, short form ( CD99sh). A differential expression of these two CD99 molecules can lead to distinct functional outcomes in lymphocytes. To investigate the functional effects of CD99 molecules on malignancy, forced overexpression of the two CD99 isoforms was induced in osteosarcoma and prostate cancer cells. The two isoforms exhibited opposite functions: the major form dramatically inhibits anchorage- independent growth, anoikis resistance, migration and metastasis, whereas the CD99sh remarkably favours the phenomena. A mechanistic analysis of CD99-transfected osteosarcoma cells points to involvement of c-Src family kinase activity in regulating CD99 functions in malignancy. Ser168 residue of CD99 plays a pivotal role in the reversion of the malignant phenotype. Our findings highlight the involvement of CD99 in crucial processes of cancer malignancy, serving as a curtain raiser for this, so far neglected molecule. In addition, a dualistic role for the two CD99 isoforms was shown in agreement with what was observed for other cell adhesion molecules.	Inst Orthoped Rizzoli, Lab Ric Oncol, I-40136 Bologna, Italy; Hosp Archet, INSERM, UMR 576, Nice, France; Univ Bologna, Dipt Patol Sperimentale, Sez Cancerol, Bologna, Italy	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Bologna	Scotlandi, K (corresponding author), Inst Orthoped Rizzoli, Lab Ric Oncol, Via Barbiano 1-10, I-40136 Bologna, Italy.	katia.scotlandi@ior.it	Rocchi, Anna/AAA-7748-2019; Scotlandi, Katia/J-9009-2016; Sciandra, Marika/C-8724-2018; Lollini, Pier Luigi/A-7644-2008; Manara, Maria Cristina/K-3366-2018; Picci, Piero/J-5979-2016; BENINI, STEFANIA/D-1804-2019	Rocchi, Anna/0000-0002-1334-9063; Scotlandi, Katia/0000-0001-6114-9499; Sciandra, Marika/0000-0001-7147-6960; Lollini, Pier Luigi/0000-0003-1702-4108; Manara, Maria Cristina/0000-0001-5686-720X; Picci, Piero/0000-0002-8519-4101; BENINI, STEFANIA/0000-0003-0958-9088; Nanni, Patrizia/0000-0001-5319-0803				Alberti I, 2002, FASEB J, V16, P1946, DOI 10.1096/fj.02-0049fje; AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; Ayrapetov MK, 2006, J BIOL CHEM, V281, P23776, DOI 10.1074/jbc.M604219200; Benini S, 1999, INT J CANCER, V80, P581, DOI 10.1002/(SICI)1097-0215(19990209)80:4<581::AID-IJC16>3.3.CO;2-F; Bernard G, 2000, EUR J IMMUNOL, V30, P3061, DOI 10.1002/1521-4141(200010)30:10<3061::AID-IMMU3061>3.0.CO;2-M; Bernard G, 1997, J IMMUNOL, V158, P2543; Boyer B, 2002, ONCOGENE, V21, P2347, DOI 10.1038/sj.onc.1205298; Byun HJ, 2006, J BIOL CHEM, V281, P34833, DOI 10.1074/jbc.M605483200; Cerisano V, 2004, ONCOGENE, V23, P5664, DOI 10.1038/sj.onc.1207741; Dworzak MN, 2004, LEUKEMIA, V18, P703, DOI 10.1038/sj.leu.2403303; Fouchet C, 2000, BLOOD, V95, P1819, DOI 10.1182/blood.V95.5.1819.005k05_1819_1826; Goto A, 2004, HISTOPATHOLOGY, V45, P384, DOI 10.1111/j.1365-2559.2004.01967.x; Hahn JH, 1997, J IMMUNOL, V159, P2250; Huang WC, 2005, CANCER RES, V65, P2303, DOI 10.1158/0008-5472.CAN-04-3448; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Jee B, 2003, EXP MOL MED, V35, P30, DOI 10.1038/emm.2003.5; Jung KC, 2002, J KOREAN MED SCI, V17, P483, DOI 10.3346/jkms.2002.17.4.483; Kim SH, 2000, BLOOD, V95, P294; Kreppel M, 2006, ONCOGENE, V25, P2795, DOI 10.1038/sj.onc.1209300; Maitra A, 2003, CLIN CANCER RES, V9, P5988; Manara MC, 2006, MOL BIOL CELL, V17, P1910, DOI 10.1091/mbc.E05-10-0971; Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Recchi I, 2003, EUR J CANCER, V39, P1927, DOI 10.1016/S0959-8049(03)00394-0; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Scotlandi K, 2000, CANCER RES, V60, P5134; Scotlandi K, 1996, HUM PATHOL, V27, P408, DOI 10.1016/S0046-8177(96)90115-X; SCOTLANDI K, 1993, INT J ONCOL, V3, P963; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; Wijetunge S, 1996, FEBS LETT, V399, P63, DOI 10.1016/S0014-5793(96)01177-5	30	46	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6604	6618		10.1038/sj.onc.1210481	http://dx.doi.org/10.1038/sj.onc.1210481			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17471235				2022-12-17	WOS:000250081500003
J	Oh, KB; Stanton, MJ; West, WW; Todd, GL; Wagner, KU				Oh, K. B.; Stanton, M. J.; West, W. W.; Todd, G. L.; Wagner, K-U			Tsg101 is upregulated in a subset of invasive human breast cancers and its targeted overexpression in transgenic mice reveals weak oncogenic properties for mammary cancer initiation	ONCOGENE			English	Article						Tsg101; breast cancer; mammary gland; transgenic; epidermal growth factor receptor	TUMOR SUSCEPTIBILITY GENE; CELL-CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION; EXPRESSION; RECEPTOR; PATHWAY; GROWTH; DIFFERENTIATION; PROLIFERATION; ABNORMALITIES	Previous studies reported that the Tumor Susceptibility Gene 101 ( TSG101) is upregulated in selected human malignancies, and the expression of exogenous Tsg101 was suggested to transform immortalized fibroblasts in culture. To date, the potential oncogenic properties of Tsg101 have not been examined in vivo owing to the lack of appropriate model systems. In this study, we show that Tsg101 is highly expressed in a subset of invasive human breast cancers. Based on this observation, we generated the first transgenic mouse model with a targeted overexpression of Tsg101 in the developing mammary gland to test whether exogenous Tsg101 is capable of initiating tumorigenesis. Normal functionality of exogenous Tsg101 was tested by rescuing the survival of Tsg101-deficient mammary epithelial cells in conditional knockout mice. The overexpression of Tsg101 resulted in increased phosphorylation of the epidermal growth factor receptor and downstream activation of MAP kinases. Despite an increase in the activation of these signal transducers, the mammary gland of females expressing exogenous Tsg101 developed normally throughout the reproductive cycle. In aging females, the overexpression of Tsg101 seemed to increase the susceptibility of mammary epithelia toward malignant transformation. However, owing to the long latency of tumor formation and the sporadic occurrence of bona. de mammary cancers, we conclude that the Tsg101 protein has only weak oncogenic properties. Instead of cancer initiation, it is therefore likely that Tsg101 plays a more predominant role in the progression of a subset of spontaneously arising breast cancers.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Wagner, KU (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Room 8009,986805, Omaha, NE 68198 USA.	kuwagner@unmc.edu	Wagner, Kay-Uwe/B-6044-2009	Wagner, Kay-Uwe/0000-0002-5081-0226	NATIONAL CANCER INSTITUTE [R01CA093797] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016469] Funding Source: NIH RePORTER; NCI NIH HHS [CA 93797] Funding Source: Medline; NCRR NIH HHS [P20 RR 16469] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; BURDON T, 1991, J BIOL CHEM, V266, P6909; Carstens MJ, 2004, J BIOL CHEM, V279, P35984, DOI 10.1074/jbc.M400408200; Cerrito MG, 2004, J CELL PHYSIOL, V201, P244, DOI 10.1002/jcp.20077; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Krempler A, 2002, J BIOL CHEM, V277, P43216, DOI 10.1074/jbc.M207662200; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Liu RT, 2002, ONCOGENE, V21, P4830, DOI 10.1038/sj.onc.1205612; Lo YF, 2000, BREAST CANCER RES TR, V60, P259, DOI 10.1023/A:1006426400524; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; Merlo GR, 1996, EUR J CELL BIOL, V70, P97; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Ruland J, 2001, P NATL ACAD SCI USA, V98, P1859, DOI 10.1073/pnas.98.4.1859; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Sun ZJ, 1997, ONCOGENE, V15, P3121, DOI 10.1038/sj.onc.1201521; Wagner KU, 2003, MOL CELL BIOL, V23, P150, DOI 10.1128/MCB.23.1.150-162.2003; Wagner KU, 1998, ONCOGENE, V17, P2761, DOI 10.1038/sj.onc.1202529; Wakefield LM, 2003, COMPARATIVE MED, V53, P424; Watanabe M, 1998, BIOCHEM BIOPH RES CO, V245, P900, DOI 10.1006/bbrc.1998.8547; Zhong Q, 1998, CANCER RES, V58, P2699; Zhu G, 2003, ONCOGENE, V22, P3742, DOI 10.1038/sj.onc.1206428	29	46	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2007	26	40					5950	5959		10.1038/sj.onc.1210401	http://dx.doi.org/10.1038/sj.onc.1210401			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369844				2022-12-17	WOS:000249123100012
J	Sakakura, C; Miyagawa, K; Fukuda, KI; Nakashima, S; Yoshikawa, T; Kin, S; Nakase, Y; Ida, H; Yazumi, S; Yamagishi, H; Okanoue, T; Chiba, T; Ito, K; Hagiwara, A; Ito, Y				Sakakura, C.; Miyagawa, K.; Fukuda, K. I.; Nakashima, S.; Yoshikawa, T.; Kin, S.; Nakase, Y.; Ida, H.; Yazumi, S.; Yamagishi, H.; Okanoue, T.; Chiba, T.; Ito, K.; Hagiwara, A.; Ito, Y.			Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis	ONCOGENE			English	Article						radioresistance; esophageal cancer; RUNX3; methylation	GROWTH-FACTOR-BETA; GENE-EXPRESSION PROFILES; GASTRIC-CANCER; RADIATION SENSITIVITY; EPITHELIAL-CELLS; TUMOR-SUPPRESSOR; APOPTOSIS; RADIOSENSITIVITY; CLASSIFICATION; COOPERATION	Radiotherapy is an effective treatment for some esophageal cancers, but the molecular mechanisms of radiosensitivity remain unknown. RUNX3, a novel tumor suppressor of gastric cancer, functions in transforming growth factor ( TGF)-beta-dependent apoptosis. We obtained paired samples from 62 patients with advanced esophageal cancers diagnosed initially as T3 or T4 with image diagnosis; one sample was obtained from a biopsy before presurgical radiotherapy, and the other was resected in surgical specimens after radiotherapy. RUNX3 was repressed in 67.7% cases of the pretreatment biopsy samples and 96.7% cases of the irradiated, resected samples. The nuclear expression of RUNX3 was associated with radiosensitivity and a better prognosis than cytoplasmic or no RUNX3 expression ( P < 0.003); cytoplasmic RUNX3 expression was strictly associated with radioresistance. RUNX3 was downregulated and its promoter was hypermethylated in all radioresistant esophageal cancer cell lines examined. Stable transfection of esophageal cancer cells with RUNX3 slightly inhibited cell proliferation in vitro, enhanced the antiproliferative and apoptotic effects of TGF-beta and increased radiosensitivity in conjunction with Bim induction. In contrast, transfection of RUNX3-expressing cells with a RUNX3 antisense construct or a Bim-specific small interfering RNA induced radioresistance. Treatment with 5-aza-2'-deoxycytidine restored RUNX3 expression, increased radiosensitivity and induced Bim in both control and radioresistant cells. These results suggest that RUNX3 silencing promotes radioresistance in esophageal cancers. Examination of RUNX3 expression in pretreatment specimens may predict radiosensitivity, and induction of RUNX3 expression may increase tumor radiosensitivity.	Kyoto Prefectural Univ Med, Grad Sch Med Sci, Div Surg & Physiol Digest Syst, Dept Surg & Regenerat Med,Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Univ, Grad Sch Internal Med, Div Gastroenterol & Hepatol, Sakyo Ku, Kyoto, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Div Surg & Oncol Digest Syst, Dept Surg & Regenerat Med,Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Prefectural Univ Med, Grad Sch Internal Med, Div Gastroenterol, Kamigyo Ku, Kyoto 6028566, Japan; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore	Kyoto Prefectural University of Medicine; Kyoto University; Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Sakakura, C (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Div Surg & Oncol Digest Syst, Dept Surg & Regenerat Med,Kamigyo Ku, Kawaramachi Dori, Kyoto 6028566, Japan.	sakakura@koto.kpu-m.ac.jp		Nakase, Yuen/0000-0002-2351-2709				Alcock RA, 2002, ONCOGENE, V21, P7883, DOI 10.1038/sj.onc.1205948; BIARD DSF, 1994, CANCER RES, V54, P3361; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Coleman C N, 1996, Oncology (Williston Park), V10, P399; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; EIFEL PJ, 1994, INT J RADIAT ONCOL, V29, P9, DOI 10.1016/0360-3016(94)90220-8; Ewan KB, 2002, CANCER RES, V62, P5627; Fukuchi M, 2002, CANCER, V95, P737, DOI 10.1002/cncr.10727; Fukuda K, 2004, BRIT J CANCER, V91, P1543, DOI 10.1038/sj.bjc.6602187; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hanna E, 2001, CANCER RES, V61, P2376; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hsiao M, 1997, BIOCHEM BIOPH RES CO, V233, P329, DOI 10.1006/bbrc.1997.6450; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; *JAP SOC ES DIS, 1999, GEN RUL CLIN PATH ST; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; Kim AH, 2003, INT J ONCOL, V23, P1593; Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647; Kitada S, 1996, ONCOGENE, V12, P187; Kitahara O, 2002, NEOPLASIA, V4, P295, DOI 10.1038/sj.neo.7900251; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Maity A, 1997, INT J RADIAT ONCOL, V37, P639, DOI 10.1016/S0360-3016(96)00598-6; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsumura Y, 1997, CANCER LETT, V115, P91, DOI 10.1016/S0304-3835(97)04714-9; Meyn RE, 1996, CANCER METAST REV, V15, P119, DOI 10.1007/BF00049491; Nakase Y, 2005, BRIT J CANCER, V92, P562, DOI 10.1038/sj.bjc.6602372; Natsugoe S, 2002, CLIN CANCER RES, V8, P1838; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; Sakai K, 1996, PROTEIN EXPRES PURIF, V7, P67, DOI 10.1006/prep.1996.0010; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; Sakakura C, 2005, CLIN CANCER RES, V11, P6479, DOI 10.1158/1078-0432.CCR-05-0729; Sakakura C, 2002, BRIT J CANCER, V87, P1153, DOI 10.1038/sj.bjc.6600580; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; SINCLAIR WK, 1966, RADIAT RES, V29, P450, DOI 10.2307/3572025; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; Sobin LH, 1997, CANCER, V80, P1803, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9; Vodovotz Y, 2000, INT J CANCER, V90, P13, DOI 10.1002/(SICI)1097-0215(20000220)90:1<13::AID-IJC2>3.3.CO;2-L; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05	41	46	47	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5927	5938		10.1038/sj.onc.1210403	http://dx.doi.org/10.1038/sj.onc.1210403			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17384682				2022-12-17	WOS:000249123100010
J	Lafon, A; Chang, CS; Scott, EM; Jacobson, SJ; Pillus, L				Lafon, A.; Chang, C. S.; Scott, E. M.; Jacobson, S. J.; Pillus, L.			MYST opportunities for growth control: yeast genes illuminate human cancer gene functions	ONCOGENE			English	Review						chromatin; transcription; Saccharomyces cerevisiae; silencing	HISTONE ACETYLTRANSFERASE COMPLEX; CHROMATIN-REMODELING COMPLEXES; H2A VARIANT HTZ1; SACCHAROMYCES-CEREVISIAE; SILENCING PROTEIN; H4 ACETYLATION; NUA4; INTERACTS; FAMILY; RECRUITMENT	The MYST family of histone acetyltransferases ( HATs) was initially dfined by human genes with disease connections and by yeast genes identified for their role in epigenetic transcriptional silencing. Since then, many new MYST genes have been discovered through genetic and genomic approaches. Characterization of the complexes through which MYST proteins act, regions of the genome to which they are targeted and biological consequences when they are disrupted, all deepen the connections of MYST proteins to development, growth control and human cancers. Many of the insights into MYST family function have come from studies in model organisms. Herein, we review functions of two of the founding MYST genes, yeast SAS2 and SAS3, and the essential yeast MYST ESA1. Analysis of these genes in yeast has de. fined roles for MYST proteins in transcriptional activation and silencing, and chromatin-mediated boundary formation. They have further roles in DNA damage repair and nuclear integrity. The observation that MYST protein complexes share subunits with other HATs, histone deacetylases and other key nuclear proteins, many with connections to human cancers, strengthens the idea that coordinating distinct chromatin modi. cations is critical for regulation.	Univ Calif San Diego, Mol Biol Sect, Div Biol Sci, Moores Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Pillus, L (corresponding author), Univ Calif San Diego, Mol Biol Sect, Div Biol Sci, Moores Canc Ctr, La Jolla, CA 92093 USA.	lpillus@ucsd.edu						Akhtar A, 2000, NATURE, V407, P405, DOI 10.1038/35030169; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Altaf M, 2007, MUTAT RES-FUND MOL M, V618, P81, DOI 10.1016/j.mrfmmm.2006.09.009; Anafi M, 2000, MOL ENDOCRINOL, V14, P718, DOI 10.1210/me.14.5.718; Avvakumov N, 2007, ONCOGENE, V26, P5395, DOI 10.1038/sj.onc.1210608; Babiarz JE, 2006, GENE DEV, V20, P700, DOI 10.1101/gad.1386306; Baker SP, 2007, ONCOGENE, V26, P5329, DOI 10.1038/sj.onc.1210603; Bedalov A, 2001, P NATL ACAD SCI USA, V98, P15113, DOI 10.1073/pnas.261574398; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Bittner CB, 2004, EUKARYOT CELL, V3, P976, DOI 10.1128/EC.3.4.976-983.2004; BORRESEN B, 1996, P 10 INT S MOLT SALT, V7, P11; Boudreault AA, 2003, GENE DEV, V17, P1415, DOI 10.1101/gad.1056603; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Brown K, 2003, J BIOL CHEM, V278, P39402, DOI 10.1074/jbc.M307832200; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Carrozza MJ, 2005, CELL, V123, P581, DOI 10.1016/j.cell.2005.10.023; Choy JS, 2002, MOL CELL BIOL, V22, P8215, DOI 10.1128/MCB.22.23.8215-8225.2002; Choy JS, 2001, J BIOL CHEM, V276, P43653, DOI 10.1074/jbc.M102531200; Clarke AS, 2006, MOL BIOL CELL, V17, P1744, DOI 10.1091/mbc.E05-07-0613; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Daniel JA, 2005, CELL CYCLE, V4, P919, DOI 10.4161/cc.4.7.1824; Debernardi S, 2002, BLOOD, V99, P275, DOI 10.1182/blood.V99.1.275; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Dziak R, 2003, J BIOL CHEM, V278, P27372, DOI 10.1074/jbc.M301110200; EhrenhoferMurray AE, 1997, GENETICS, V145, P923; Eisen A, 2001, J BIOL CHEM, V276, P3484, DOI 10.1074/jbc.M008159200; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Georgiakaki M, 2006, MOL ENDOCRINOL, V20, P2122, DOI 10.1210/me.2005-0149; Gomez EB, 2005, MOL CELL BIOL, V25, P8887, DOI 10.1128/MCB.25.20.8887-8903.2005; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; Gupta A, 2005, MOL CELL BIOL, V25, P5292, DOI 10.1128/MCB.25.12.5292-5305.2005; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Howe L, 2002, MOL CELL BIOL, V22, P5047, DOI 10.1128/MCB.22.14.5047-5053.2002; Howe L, 2001, GENE DEV, V15, P3144, DOI 10.1101/gad.931401; Iizuka M, 2006, MOL CELL BIOL, V26, P1098, DOI 10.1128/MCB.26.3.1098-1108.2006; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Jacobson S, 2004, MOL CELL BIOL, V24, P6029, DOI 10.1128/MCB.24.13.6029-6039.2004; John S, 2000, GENE DEV, V14, P1196; Kabani M, 2005, BIOCHEM BIOPH RES CO, V332, P398, DOI 10.1016/j.bbrc.2005.04.158; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Keogh MC, 2006, GENE DEV, V20, P660, DOI 10.1101/gad.1388106; Keogh MC, 2005, CELL, V123, P593, DOI 10.1016/j.cell.2005.10.025; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Kirchmaier AL, 2001, SCIENCE, V291, P646, DOI 10.1126/science.291.5504.646; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Krogan NJ, 2004, P NATL ACAD SCI USA, V101, P13513, DOI 10.1073/pnas.0405753101; Krogan NJ, 2003, MOL CELL, V12, P1565, DOI 10.1016/S1097-2765(03)00497-0; Le Masson I, 2003, MOL CELL BIOL, V23, P6086, DOI 10.1128/MCB.23.17.6086-6102.2003; Legube G, 2004, J BIOL CHEM, V279, P44825, DOI 10.1074/jbc.M407478200; Li YC, 2001, SCIENCE, V291, P650, DOI 10.1126/science.291.5504.650; Liu Y, 2000, MOL GEN GENET, V262, P1132, DOI 10.1007/PL00008656; Lonard DM, 2006, CELL, V125, P411, DOI 10.1016/j.cell.2006.04.021; Martin DGE, 2006, MOL CELL BIOL, V26, P3018, DOI 10.1128/MCB.26.8.3018-3028.2006; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Meijsing SH, 2001, GENE DEV, V15, P3169, DOI 10.1101/gad.929001; Millar CB, 2006, GENE DEV, V20, P711, DOI 10.1101/gad.1395506; Murr R, 2007, ONCOGENE, V26, P5358, DOI 10.1038/sj.onc.1210605; Nishikawa J, 1999, TOXICOL APPL PHARM, V154, P76, DOI 10.1006/taap.1998.8557; Nourani A, 2004, EMBO J, V23, P2597, DOI 10.1038/sj.emboj.7600230; Nourani A, 2003, J BIOL CHEM, V278, P19171, DOI 10.1074/jbc.C300036200; Nourani A, 2001, MOL CELL BIOL, V21, P7629, DOI 10.1128/MCB.21.22.7629-7640.2001; Ogryzko VV, 2001, CELL MOL LIFE SCI, V58, P683, DOI 10.1007/PL00000892; Olaharski AJ, 2005, PLOS GENET, V1, P689, DOI 10.1371/journal.pgen.0010077; Ooi SL, 2006, TRENDS GENET, V22, P56, DOI 10.1016/j.tig.2005.11.003; Osada S, 2001, GENE DEV, V15, P3155, DOI 10.1101/gad.907201; Panchenko MV, 2004, J BIOL CHEM, V279, P56032, DOI 10.1074/jbc.M410487200; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Pray-Grant MG, 2002, MOL CELL BIOL, V22, P8774, DOI 10.1128/MCB.22.24.8774-8786.2002; Rea S, 2007, ONCOGENE, V26, P5385, DOI 10.1038/sj.onc.1210607; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Robert F, 2004, MOL CELL, V16, P199, DOI 10.1016/j.molcel.2004.09.021; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Schreiner SA, 1999, LEUKEMIA, V13, P1525, DOI 10.1038/sj.leu.2401534; Selleck W, 2005, MOL CELL BIOL, V25, P5535, DOI 10.1128/MCB.25.13.5535-5542.2005; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; Shia WJ, 2006, GENE DEV, V20, P2507, DOI 10.1101/gad.1439206; Shia WJ, 2005, J BIOL CHEM, V280, P11987, DOI 10.1074/jbc.M500276200; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Smith JS, 1998, GENETICS, V149, P1205; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Sterner DE, 2002, P NATL ACAD SCI USA, V99, P11622, DOI 10.1073/pnas.182021199; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; SUTTON WS, 1903, BIOL BULL, V4, P5; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; Tamburini BA, 2005, MOL CELL BIOL, V25, P4903, DOI 10.1128/MCB.25.12.4903-4913.2005; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Taverna SD, 2006, MOL CELL, V24, P785, DOI 10.1016/j.molcel.2006.10.026; Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Troke PJF, 2006, BIOCHEM SOC SYMP, V73, P23; Utley RT, 2003, CURR TOP MICROBIOL, V274, P203; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Xu EY, 1999, GENETICS, V153, P25; Xu EY, 1999, GENETICS, V153, P13; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; Zhang HY, 2004, MOL CELL BIOL, V24, P9424, DOI 10.1128/MCB.24.21.9424-9436.2004; Zhang WZ, 2006, J BIOL CHEM, V281, P18059, DOI 10.1074/jbc.M601903200; Zhang YM, 2006, DNA REPAIR, V5, P1282, DOI 10.1016/j.dnarep.2006.05.020; Zhou MI, 2002, J BIOL CHEM, V277, P39887, DOI 10.1074/jbc.M205040200; Zong HL, 2005, FEBS LETT, V579, P3579, DOI 10.1016/j.febslet.2005.05.039	119	46	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5373	5384		10.1038/sj.onc.1210606	http://dx.doi.org/10.1038/sj.onc.1210606			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694079				2022-12-17	WOS:000248674300006
J	Castilho, RM; Squarize, CH; Patel, V; Millar, SE; Zheng, Y; Molinolo, A; Gutkind, JS				Castilho, R. M.; Squarize, C. H.; Patel, V.; Millar, S. E.; Zheng, Y.; Molinolo, A.; Gutkind, J. S.			Requirement of Rac1 distinguishes follicular from interfollicular epithelial stem cells	ONCOGENE			English	Article						epithelial stem cells; hair follicle; Rho GTPases; Rac1; epidermal regeneration	LABEL-RETAINING CELLS; EPIDERMAL PROLIFERATIVE UNIT; POPULATIONS; SKIN; BIOLOGY	Epithelial stem cells in the bulge region within the hair follicle maintain the cyclic hair growth, but whether these stem cells also contribute to the epidermal renewal remains unclear. Here, we observed that the conditional deletion of the Rac1 gene in the mouse skin, including the potential follicular and epidermal stem cell compartments, results in alopecia owing to defective hair development. Surprisingly, mice lacking the expression of this Rho GTPase do not display major alterations in the interfollicular skin. Furthermore, Rac1 excision from primary epithelial keratinocytes results in the inability to reconstitute hair follicles and sebaceous glands when grafted onto mice, but epithelial cells lacking Rac1 can nonetheless form a healthy epidermi s. Together, these findings support the emerging view that the epidermis and the hair follicles are maintained by different epithelial stem cells, and provide evidence that the requirement for Rac1 function can distinguish these distinct stem cells populations.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Cincinnati, Childrens Hosp, Med Ctr, Div Expt Hematol, Cincinnati, OH USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Pennsylvania; University of Pennsylvania; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Bldg 30,Room 211, Bethesda, MD 20892 USA.	sg39v@nih.gov	Gutkind, J. Silvio/A-1053-2009; Zheng, Yi/J-7235-2015; Castilho, Rogerio M/E-4987-2010; Gutkind, J. Silvio/J-1201-2016	Zheng, Yi/0000-0001-7089-6074; Castilho, Rogerio M/0000-0001-5358-612X; Gutkind, J. Silvio/0000-0002-5150-4482; Millar, Sarah/0000-0001-8792-6890; Squarize, Cristiane/0000-0002-6782-3429	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Andl T, 2004, DEVELOPMENT, V131, P2257, DOI 10.1242/dev.01125; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; BICKENBACH JR, 1981, J DENT RES, V60, P1611, DOI 10.1177/002203458106000311011; BICKENBACH JR, 1986, CELL TISSUE KINET, V19, P325, DOI 10.1111/j.1365-2184.1986.tb00684.x; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Braun KM, 2003, DEVELOPMENT, V130, P5241, DOI 10.1242/dev.00703; Chrostek A, 2006, MOL CELL BIOL, V26, P6957, DOI 10.1128/MCB.00075-06; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Cotsarelis G, 2001, TRENDS MOL MED, V7, P293, DOI 10.1016/S1471-4914(01)02027-5; Cotsarelis G, 2006, J INVEST DERMATOL, V126, P1459, DOI 10.1038/sj.jid.5700376; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Levy V, 2005, DEV CELL, V9, P855, DOI 10.1016/j.devcel.2005.11.003; LICHTI U, 1993, J INVEST DERMATOL, V101, pS124, DOI 10.1111/1523-1747.ep12363165; Millar SE, 2002, J INVEST DERMATOL, V118, P216, DOI 10.1046/j.0022-202x.2001.01670.x; MORRIS RJ, 1985, J INVEST DERMATOL, V84, P277, DOI 10.1111/1523-1747.ep12265358; POTTEN CS, 1974, CELL TISSUE KINET, V7, P77, DOI 10.1111/j.1365-2184.1974.tb00401.x; Squarize CH, 2002, J ORAL PATHOL MED, V31, P379, DOI 10.1034/j.1600-0714.2002.00142.x; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Verdier-Sevrain S, 2006, EXP DERMATOL, V15, P83, DOI 10.1111/j.1600-0625.2005.00377.x	25	46	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5078	5085		10.1038/sj.onc.1210322	http://dx.doi.org/10.1038/sj.onc.1210322			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17334398				2022-12-17	WOS:000248487400006
J	Waters, LC; Veverka, V; Bohm, M; Schmedt, T; Choong, PT; Muskett, FW; Klempnauer, KH; Carr, MD				Waters, L. C.; Veverka, V.; Boehm, M.; Schmedt, T.; Choong, P. T.; Muskett, F. W.; Klempnauer, K-H; Carr, M. D.			Structure of the C-terminal MA-3 domain of the tumour suppressor protein Pdcd4 and characterization of its interaction with eIF4A	ONCOGENE			English	Article						Pdcd4; MA-3; eIF4A; HEAT; NMR; translation	BOX RNA HELICASE; TRANSLATION INITIATION FACTOR-4A; TORSION ANGLE DYNAMICS; TRANSFORMATION SUPPRESSOR; EUKARYOTIC TRANSLATION; MUTATIONAL ANALYSIS; TISSUE INHIBITOR; CHEMICAL-SHIFT; BINDING; METALLOPROTEINASES-2	Programmed cell death protein 4(Pdcd4) is a novel tumour suppressor protein, which is involved in the control of eukaryotic transcription and translation. The regulation of translation involves specific interactions with eukaryotic initiation factor (eIF) 4A and eIF4G, which are mediated via the two tandem MA-3 domains. We have determined the structure of the C-terminal MA-3 domain of Pdcd4(Pdc d4MA-3 C), characterized its interaction with eIF4A and compared the features of nuclear magnetic resonance (NMR) spectra obtained from the single domain and tandem MA-3 region. Pdcd4M A-3(C) is composed of three layers of helix-turn-helix hairpins capped by a single helix and shows close structural homology to the atypical HEAT repeats found in many eIFs. The sequence conservation and NMR data strongly suggest that the tandem MA-3 region is composed of two equivalent domains connected by a somewhat. exible linker. Pdcd4 MA-3 C was found to interact with the Nterminal domain of eIF4A through a conserved surface region encompassing the loop connecting alpha 5 and alpha 6 and the turn linking alpha 3 and alpha 4. This site is strongly conserved in other MA-3 domains known to interact with eIF4A, including the preceding domain of Pdcd4, suggesting a common mode of binding.	Univ Leicester, Dept Biochem, Henry Wellcome Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England; Univ Munster, Inst Biochem, D-4400 Munster, Germany	University of Leicester; University of Munster	Carr, MD (corresponding author), Univ Leicester, Dept Biochem, Henry Wellcome Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	mdc12@le.ac.uk	Veverka, Vaclav/P-5251-2019; Veverka, Vaclav/G-9174-2014	Veverka, Vaclav/0000-0003-3782-5279; Veverka, Vaclav/0000-0003-3782-5279; Choong, Peter/0000-0001-7333-7665; Carr, Mark/0000-0002-3939-0996	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Bellsolell L, 2006, STRUCTURE, V14, P913, DOI 10.1016/j.str.2006.03.012; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; CHEN S, 2003, P ICASSP HONG KONG C, V4, P640; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Jansen AP, 2004, MOL CANCER THER, V3, P103; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LaRonde-LeBlanc N, 2007, MOL CELL BIOL, V27, P147, DOI 10.1128/MCB.00867-06; Marcotrigiano J, 2001, MOL CELL, V7, P193, DOI 10.1016/S1097-2765(01)00167-8; Marintchev A, 2004, Q REV BIOPHYS, V37, P197, DOI 10.1017/S0033583505004026; Mazza C, 2001, MOL CELL, V8, P383, DOI 10.1016/S1097-2765(01)00299-4; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Oberer M, 2005, GENE DEV, V19, P2212, DOI 10.1101/gad.1335305; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Ponting CP, 2000, TRENDS BIOCHEM SCI, V25, P423, DOI 10.1016/S0968-0004(00)01628-5; Renshaw PS, 2002, J BIOL CHEM, V277, P21598, DOI 10.1074/jbc.M201625200; Renshaw PS, 2005, EMBO J, V24, P2491, DOI 10.1038/sj.emboj.7600732; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Svitkin YV, 2001, RNA, V7, P1743; Tanner NK, 2003, MOL CELL, V11, P127, DOI 10.1016/S1097-2765(03)00006-6; Waters L, 2006, J BIOL CHEM, V281, P14787, DOI 10.1074/jbc.M600237200; Waters LC, 2006, J BIOMOL NMR, V36, P18, DOI 10.1007/s10858-005-5887-6; Williamson RA, 1997, BIOCHEMISTRY-US, V36, P13882, DOI 10.1021/bi9712091; Yamamoto Y, 2005, P NATL ACAD SCI USA, V102, P16164, DOI 10.1073/pnas.0507960102; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Zakowicz H, 2005, RNA, V11, P261, DOI 10.1261/rna.7191905	43	46	51	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4941	4950		10.1038/sj.onc.1210305	http://dx.doi.org/10.1038/sj.onc.1210305			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310995				2022-12-17	WOS:000248322500006
J	Wu, Y; McRoberts, K; Berr, SS; Frierson, HF; Conaway, M; Theodorescu, D				Wu, Y.; McRoberts, K.; Berr, S. S.; Frierson, H. F., Jr.; Conaway, M.; Theodorescu, D.			Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia	ONCOGENE			English	Article						neoplasm metastasis; endothelial growth factors; bladder neoplasms; gene expression profiling; xenograft model antitumor assays	HUMAN BLADDER-CANCER; ENDOTHELIN AXIS; PROSTATE-CANCER; CELLS; PROGRESSION; EXPRESSION; INVASION; GENE; IDENTIFICATION; RECEPTORS	Most deaths from urinary bladder cancer are owing to metastatic disease. A reduction in Rho GDP Dissociation Inhibitor 2 (RhoGDI2) protein has been associated with increased risk of metastasis in patients with locally advanced bladder cancer, whereas in animal models, RhoGDI2 reconstitution in cells without expression results in lung metastasis suppression. Recently, we noted an inverse correlation between tumor RhoGDI2 and Neuromedin U (NMU) expression, suggesting that NMU might be a target of the lung metastasis suppressor effect of RhoGDI2. Here we evaluated whether NMU is regulated by RhoGDI2 and is functionally important in tumor progression. We used small interfering RNA knockdown of endogenous RhoGDI2 in poorly tumorigenic and non-metastatic human bladder cancer T24 cells and observed increased NMU RNA expression. Although NMU overexpression did not increase the monolayer growth of T24 or related T24T poorly metastatic human bladder cancer cells, it did augment anchorage-independent growth for the latter. Overexpression of NMU in T24 and T24T cells significantly promoted tumor formation of both cell lines in nude mice, but did not alter the growth rate of established tumors. Furthermore, NMU-overexpressing xenografts were associated with lower animal body weight than control tumors, indicating a possible role of NMU in cancer cachexia. NMU overexpression in T24T cells significantly enhanced their lung metastatic ability. Bioluminescent in vivo imaging revealed that lung metastases in T24T grew faster than the same tumors in the subcutaneous microenvironment. In conclusion, NMU is a RhoGDI2-regulated gene that appears important for tumorigenicity, lung metastasis and cancer cachexia, and thus a promising therapeutic target in cancer.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Dept Radiol, Charlottesville, VA USA; Univ Virginia, Dept Pathol, Charlottesville, VA USA; Univ Virginia, Dept Hlth Evaluat Sci, Charlottesville, VA USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia	Theodorescu, D (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, Box 800422, Charlottesville, VA 22908 USA.	dt9d@virginia.edu			NATIONAL CANCER INSTITUTE [R01CA075115, R29CA075115] Funding Source: NIH RePORTER; NCI NIH HHS [CA075115] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHAI E, 2002, NAT REV CANCER, V2, P133; Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685; Brighton PJ, 2004, PHARMACOL REV, V56, P231, DOI 10.1124/pr.56.2.3; Cameron MD, 2000, CANCER RES, V60, P2541; Cao CQ, 2003, PAIN, V104, P609, DOI 10.1016/S0304-3959(03)00118-0; Chan ISF, 1999, BIOMETRICS, V55, P1202, DOI 10.1111/j.0006-341X.1999.01202.x; Chung LWK, 2005, J UROLOGY, V173, P10, DOI 10.1097/01.ju.0000141582.15218.10; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Euer NI, 2005, ONCOL REP, V13, P375; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Gildea JJ, 2002, CANCER RES, V62, P6418; Gildea JJ, 2000, GENE CHROMOSOME CANC, V27, P252, DOI 10.1002/(SICI)1098-2264(200003)27:3<252::AID-GCC5>3.0.CO;2-9; Hanada R, 2004, NAT MED, V10, P1067, DOI 10.1038/nm1106; Harding MA, 2002, CANCER RES, V62, P6981; Howard AD, 2000, NATURE, V406, P70, DOI 10.1038/35017610; Ida T, 2005, ENDOCRINOLOGY, V146, P4217, DOI 10.1210/en.2005-0107; Im JH, 2004, CANCER RES, V64, P8613, DOI 10.1158/0008-5472.CAN-04-2078; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jenkins DE, 2003, CLIN EXP METASTAS, V20, P745, DOI 10.1023/B:CLIN.0000006817.25962.87; Johnson EN, 2004, J IMMUNOL, V173, P7230, DOI 10.4049/jimmunol.173.12.7230; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kamai T, 2003, BJU INT, V91, P234, DOI 10.1046/j.1464-410X.2003.03063.x; Kowalski TJ, 2005, J ENDOCRINOL, V185, P151, DOI 10.1677/joe.1.05948; Martignoni Marcus E, 2003, Mol Cancer, V2, P36, DOI 10.1186/1476-4598-2-36; Moriyama M, 2006, BIOCHEM BIOPH RES CO, V341, P1149, DOI 10.1016/j.bbrc.2006.01.075; Moriyama M, 2005, J EXP MED, V202, P217, DOI 10.1084/jem.20050248; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Oxford G, 2003, J UROLOGY, V170, P1987, DOI 10.1097/01.ju.0000088670.02905.78; Robinson Victoria L, 2004, Cancer Treat Res, V118, P1; Seraj MJ, 2001, CLIN EXP METASTAS, V18, P519, DOI 10.1023/A:1011819621859; Shetzline SE, 2004, BLOOD, V104, P1833, DOI 10.1182/blood-2003-10-3577; Shousha S, 2006, NEUROSCI LETT, V391, P87, DOI 10.1016/j.neulet.2005.08.033; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; STRASSMANN G, 1995, CYTOKINES MOL THER, V1, P107; Theodorescu D, 2004, CLIN CANCER RES, V10, P3800, DOI 10.1158/1078-0432.CCR-03-0653; Tisdale MJ, 2005, PHYSIOLOGY, V20, P340, DOI 10.1152/physiol.00019.2005; Titus B, 2005, CANCER RES, V65, P7320, DOI 10.1158/0008-5472.CAN-05-1403; Welch DR, 2004, BREAST CANCER RES, V6, P61, DOI 10.1186/bcr736; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Yu XH, 2003, NEUROSCIENCE, V120, P467, DOI 10.1016/S0306-4522(03)00300-2; Zheng XX, 2005, BIOORG MED CHEM LETT, V15, P4531, DOI 10.1016/j.bmcl.2005.07.003; Zhou XW, 2004, RADIAT RES, V162, P287, DOI 10.1667/RR3220	42	46	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					765	773		10.1038/sj.onc.1209835	http://dx.doi.org/10.1038/sj.onc.1209835			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16878152				2022-12-17	WOS:000243902200013
J	Strozyk, E; Poppelmann, B; Schwarz, T; Kulms, D				Strozyk, E.; Poeppelmann, B.; Schwarz, T.; Kulms, D.			Differential effects of NF-kappa B on apoptosis induced by DNA-damaging agents: the type of DNA damage determines the final outcome	ONCOGENE			English	Article						apoptosis; DNA damage; NF-kappa B; TNF-alpha	PROTECTS TRANSFORMED KERATINOCYTES; RADIATION-INDUCED APOPTOSIS; GENE-EXPRESSION; HUMAN-CELLS; ACTIVATION; ALPHA; RECEPTOR; NUCLEAR; PHOSPHORYLATION; RECOGNITION	The transcription factor nuclear factor kappa-B ( NF-kB) is generally regarded as an antiapoptotic factor. Accordingly, NF-kB activation inhibits death ligand-induced apoptosis. In contrast, ultraviolet light B (UVB)-induced apoptosis is not inhibited but even enhanced upon NF-kappa B activation by interleukin-1 (IL-1). This study was performed to identify the molecular mechanisms underlying this switch of NF-kappa B. Enhancement of UVB-induced apoptosis was always associated with increased release of tumour necrosis factor-alpha (TNF-alpha), which was dependent on NF-kappa B activation. The same was observed when UVA and cisplatin were used, which like UVB induce base modi. cations. In contrast, apoptosis caused by DNA strand breaks was not enhanced by IL-1, indicating that the type of DNA damage is critical for switching the effect of NF-kappa B on apoptosis. Surprisingly, activated NF-kappa B induced TNF-alpha mRNA expression in the presence of all DNA damage-inducing agents. However, in the presence of DNA strand breaks, there was no release of the TNF-alpha protein, which is so crucial for enhancing apoptosis. Together, this indicates that induction of DNA damage may have a significant impact on biological effects but it is the type of DNA damage that determines the final outcome. This may have implications for the role of NF-kappa B in carcinogenesis and for the application of NF-kappa B inhibitors in anticancer therapy.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Univ Kiel, Dept Dermatol, D-2300 Kiel, Germany; Univ Munster, Dept Dermatol, D-4400 Munster, Germany	University of Stuttgart; University of Kiel; University of Munster	Kulms, D (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	Dagmar.Kulms@izi.uni-stuttgart.de	Schwarz, Thomas/A-9148-2010; Kulms, Dagmar/H-1653-2014					Abdel-Raheem IT, 2005, BRIT J PHARMACOL, V145, P415, DOI 10.1038/sj.bjp.0706207; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Beissert S, 1999, J INVEST DERM SYMP P, V4, P61, DOI 10.1038/sj.jidsp.5640183; Besaratinia A, 2005, P NATL ACAD SCI USA, V102, P10058, DOI 10.1073/pnas.0502311102; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cornelis S, 2005, ONCOGENE, V24, P1552, DOI 10.1038/sj.onc.1208401; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Hailer MK, 2005, DNA REPAIR, V4, P41, DOI 10.1016/j.dnarep.2004.07.006; Ho WC, 2005, CANCER RES, V65, P4273, DOI 10.1158/0008-5472.CAN-04-3494; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hur GM, 2003, GENE DEV, V17, P873, DOI 10.1101/gad.1062403; Konemann S, 2005, APOPTOSIS, V10, P177, DOI 10.1007/s10495-005-6072-9; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Kulms D, 2002, ONCOGENE, V21, P5844, DOI 10.1038/sj.onc.1205743; Kulms D, 2002, BIOCHEM PHARMACOL, V64, P837, DOI 10.1016/S0006-2952(02)01146-2; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Kulms D, 2000, J BIOL CHEM, V275, P15060, DOI 10.1074/jbc.M910113199; Lee JY, 2000, J BIOL CHEM, V275, P29290, DOI 10.1074/jbc.M000170200; Mezyk R, 2003, ACTA BIOCHIM POL, V50, P625; Nakajima S, 2004, J BIOL CHEM, V279, P46674, DOI 10.1074/jbc.M406070200; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Poppelmann B, 2005, J BIOL CHEM, V280, P15635, DOI 10.1074/jbc.M413006200; Rosell Rafael, 2003, Cancer Control, V10, P297; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sclabas GM, 2005, CANCER-AM CANCER SOC, V103, P2485, DOI 10.1002/cncr.21075; Sordet Olivier, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P271, DOI 10.2174/1568011033482378; Sun NK, 1996, BIOCHEM J, V313, P441, DOI 10.1042/bj3130441; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; Thyss R, 2005, EMBO J, V24, P128, DOI 10.1038/sj.emboj.7600501; Wajant H, 2005, CYTOKINE GROWTH F R, V16, P55, DOI 10.1016/j.cytogfr.2004.12.001; Xu CJ, 2005, ONCOGENE, V24, P4486, DOI 10.1038/sj.onc.1208656; Zavrski I, 2005, ANTI-CANCER DRUG, V16, P475, DOI 10.1097/00001813-200506000-00002	38	46	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2006	25	47					6239	6251		10.1038/sj.onc.1209655	http://dx.doi.org/10.1038/sj.onc.1209655			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16702954				2022-12-17	WOS:000241218200002
J	Yeh, AH; Bohula, EA; Macaulay, VM				Yeh, A. H.; Bohula, E. A.; Macaulay, V. M.			Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs	ONCOGENE			English	Article						IGF1R; melanoma; B-RAF; siRNA; apoptosis; chemosensitization	GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; BREAST-CANCER CELLS; METASTATIC MELANOMA; ONCOGENIC MUTATIONS; SIGNALING PATHWAY; BRAF; IGF-1; B-V599E-RAF; SENSITIVITY	The type 1 insulin-like growth factor receptor (IGF1R) is overexpressed by malignant melanomas compared with benign naevi, and mediates proliferation, motility and protection from apoptosis. However, the utility of IGF1R targeting as anti-cancer therapy may be limited by activating mutations in downstream signaling intermediates. We previously showed that IGF1R knockdown blocked survival of prostate cancer cells in which Akt activation was deregulated by PTEN loss. The current study investigated effects of IGF1R targeting in cells harboring activating RAS-RAF mutations, found in 70-80% of human melanomas. We assembled a panel of eight human melanoma cell lines: two expressing wild-type (WT) B-RAF and N-RAS, two with activating N-RAS mutations and four harboring V600E B-RAF. We also generated isogenic cell populations overexpressing WT or V600E BRAF. Cells expressing V600E B-RAF were relatively resistant to apoptosis. However, IGF1R gene silencing was capable of inducing significant inhibition of survival, enhancement of apoptosis, and similar to two-fold sensitization to cisplatin and temozolomide. These effects were independent of mutation status and were associated with reduced activation of Akt and also, unexpectedly, of ERKs. These results support development of IGF1R targeting as therapy for melanoma, regardless of the presence of activating mutations in the RAS-RAF pathway.	Univ Oxford, Weatherall Inst Mol Med, ICF Grp, Canc Res UK Labs, Oxford OX1 2JD, England	Cancer Research UK; University of Oxford	Macaulay, VM (corresponding author), Weatherall Inst Mol Med, ICF Grp, Mol Oncol Labs, Oxford OX3 9DS, England.	macaulay@cancer.org.uk	Bohula, Erin/AAW-7276-2020					Benini S, 2004, INT J CANCER, V108, P358, DOI 10.1002/ijc.11576; Bohula EA, 2003, ANTI-CANCER DRUG, V14, P669, DOI 10.1097/01.cad.0000092782.37568.04; Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; BOS JL, 1989, CANCER RES, V49, P4682; Brose MS, 2002, CANCER RES, V62, P6997; Camp ER, 2005, CLIN CANCER RES, V11, P397; Danson S, 2003, J CLIN ONCOL, V21, P2551, DOI 10.1200/JCO.2003.10.039; Danson S J, 2001, Expert Rev Anticancer Ther, V1, P13, DOI 10.1586/14737140.1.1.13; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Dunn SE, 1997, CANCER RES, V57, P2687; Garber K, 2005, J NATL CANCER I, V97, P790, DOI 10.1093/jnci/97.11.790; GEIER A, 1995, J CELL PHYSIOL, V163, P570, DOI 10.1002/jcp.1041630318; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gorden A, 2003, CANCER RES, V63, P3955; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hellawell GO, 2003, BJU INT, V91, P271, DOI 10.1046/j.1464-410X.2003.04061.x; Hingorani SR, 2003, CANCER RES, V63, P5198; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kanter-Lewensohn L, 2000, GROWTH FACTORS, V17, P193, DOI 10.3109/08977190009001068; Kumar R, 2003, CLIN CANCER RES, V9, P3362; LeRoith D, 2000, ENDOCRINOLOGY, V141, P1287, DOI 10.1210/en.141.4.1287; Macaluso M, 2002, J CELL PHYSIOL, V192, P125, DOI 10.1002/jcp.10109; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; McMenamin ME, 1999, CANCER RES, V59, P4291; Min YF, 2003, CANCER RES, V63, P6432; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; O'Connor R, 2003, HORM METAB RES, V35, P771; Park S, 2005, ONCOGENE, V24, P3535, DOI 10.1038/sj.onc.1208435; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; RESNICOFF M, 1994, CANCER RES, V54, P4848; Rochester MA, 2005, CANCER GENE THER, V12, P90, DOI 10.1038/sj.cgt.7700775; Sato S, 2004, J BIOL CHEM, V279, P33759, DOI 10.1074/jbc.M402055200; SELL C, 1995, CANCER RES, V55, P303; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao D, 2005, MOL CARCINOGEN, V43, P130, DOI 10.1002/mc.20099	45	46	48	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6574	6581		10.1038/sj.onc.1209674	http://dx.doi.org/10.1038/sj.onc.1209674			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16715137				2022-12-17	WOS:000241569700002
J	Gloire, G; Charlier, E; Rahmouni, S; Volanti, C; Chariot, A; Erneux, C; Piette, J				Gloire, G.; Charlier, E.; Rahmouni, S.; Volanti, C.; Chariot, A.; Erneux, C.; Piette, J.			Restoration of SHIP-1 activity in human leukemic cells modifies NF-kappa B activation pathway and cellular survival upon oxidative stress	ONCOGENE			English	Article						NF-kappa B; oxidative stress; SHIP-1; IKK; leukemic cells; apoptosis	TYROSINE PHOSPHORYLATION; PHOSPHOINOSITIDE 3-KINASE; HEMATOPOIETIC-CELLS; 5-PHOSPHATASE SHIP; INVOLVEMENT; ALPHA; PHOSPHATASE; APOPTOSIS; TRANSDUCTION; COMPLEX	Nuclear factor-kappa B (NF-kappa B) is an important prosurvival transcription factor activated in response to a large array of external stimuli, including reactive oxygen species (ROS). Previous works have shown that NF-kappa B activation by ROS involved tyrosine phosphorylation of the inhibitor I kappa B alpha through an I kappa B kinase (IKK)-independent mechanism. In the present work, we investigated with more details NF-kappa B redox regulation in human leukemic cells. By using different cell lines (CEM, Jurkat and the subclone Jurkat JR), we clearly showed that NF-kappa B activation by hydrogen peroxide (H2O2) is cell-type dependent: it activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha in Jurkat cells, whereas it induces an IKK-mediated I kappa B alpha phosphorylation on S32 and 36 in CEM and Jurkat JR cells. We showed that this H2O2-induced IKK activation in CEM and Jurkat JR cells is mediated by SH2-containing inositol 5'-phosphatase 1 (SHIP-1), a lipid phosphatase that is absent in Jurkat cells. Indeed, the complementation of SHIP-1 in Jurkat cells made them shift to an IKK-dependent mechanism upon oxidative stress stimulation. We also showed that Jurkat cells expressing SHIP-1 are more resistant to H2O2-induced apoptosis than the parental cells, suggesting that SHIP-1 has an important role in leukemic cell responses to ROS in terms of signal transduction pathways and apoptosis resistance, which can be of interest in improving ROS-mediated chemotherapies.	CBIG, GIGA, Virol & Immunol Unit, Inst Pathol, B-4000 Liege, Belgium; Univ Liege, Virol Immunol Unit, B-4000 Liege, Belgium; Univ Liege, Pathol Unit, B-4000 Liege, Belgium; Univ Liege, CBIG, GIGA, Med Chem Unit, B-4000 Liege, Belgium; Univ Brussels, IRIBHM, Brussels, Belgium	University of Liege; University of Liege; University of Liege; Universite Libre de Bruxelles	Piette, J (corresponding author), CBIG, GIGA, Virol & Immunol Unit, Inst Pathol, B23, B-4000 Liege, Belgium.	jpiette@ulg.ac.be		Chariot, Alain/0000-0002-1691-4347				Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Ambruso DR, 2004, MOL GENET METAB, V81, P313, DOI 10.1016/j.ymgme.2004.01.009; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Backers K, 2003, ADV ENZYME REGUL, V43, P15, DOI 10.1016/S0065-2571(02)00043-2; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Boer AK, 2001, LEUKEMIA, V15, P1750, DOI 10.1038/sj.leu.2402261; Bruyns C, 1999, BIOL CHEM, V380, P969, DOI 10.1515/BC.1999.120; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chandra J, 2003, BLOOD, V102, P4512, DOI 10.1182/blood-2003-02-0562; Chou WC, 2005, CURR OPIN HEMATOL, V12, P1, DOI 10.1097/01.moh.0000148552.93303.45; Drayer AL, 1996, BIOCHEM BIOPH RES CO, V225, P243, DOI 10.1006/bbrc.1996.1161; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Fang HQ, 2004, J IMMUNOL, V173, P360, DOI 10.4049/jimmunol.173.1.360; Freeburn RW, 2002, J IMMUNOL, V169, P5441, DOI 10.4049/jimmunol.169.10.5441; Genova ML, 2004, ANN NY ACAD SCI, V1011, P86, DOI 10.1196/annals.1293.010; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hildeman DA, 2004, FREE RADICAL BIO MED, V36, P1496, DOI 10.1016/j.freeradbiomed.2004.03.023; Horn S, 2004, LEUKEMIA, V18, P1839, DOI 10.1038/sj.leu.2403529; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Karin M, 2005, IUBMB LIFE, V57, P283, DOI 10.1080/15216540500097111; Kim H, 2005, ONCOGENE, V24, P1252, DOI 10.1038/sj.onc.1208282; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Livolsi A, 2001, EUR J BIOCHEM, V268, P1508, DOI 10.1046/j.1432-1327.2001.02028.x; Muraille E, 1999, BIOCHEM J, V342, P697, DOI 10.1042/0264-6021:3420697; Ogawa Y, 2003, INT J MOL MED, V11, P27; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Ravet E, 2002, J HEMATOTH STEM CELL, V11, P327, DOI 10.1089/152581602753658510; Robson JD, 2004, MOL CELL BIOL, V24, P2332, DOI 10.1128/MCB.24.6.2332-2343.2004; Rohrschneider LR, 2000, GENE DEV, V14, P505; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Tomlinson MG, 2004, J BIOL CHEM, V279, P55089, DOI 10.1074/jbc.M408141200; van Dijk TB, 2000, BLOOD, V96, P3406; Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2	38	46	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5485	5494		10.1038/sj.onc.1209542	http://dx.doi.org/10.1038/sj.onc.1209542			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16619039				2022-12-17	WOS:000240370400002
J	Yamada, A; Fujita, N; Sato, T; Okamoto, R; Ooshio, T; Hirota, T; Morimoto, K; Irie, K; Takai, Y				Yamada, A.; Fujita, N.; Sato, T.; Okamoto, R.; Ooshio, T.; Hirota, T.; Morimoto, K.; Irie, K.; Takai, Y.			Requirement of nectin, but not cadherin, for formation of claudin-based tight junctions in annexin II-knockdown MDCK cells	ONCOGENE			English	Article						adherens junctions; tight junctions; nectin; afadin; annexin II	CANINE KIDNEY-CELLS; ADHESION MOLECULE NECTIN; SMALL G-PROTEINS; ADHERENS JUNCTIONS; EPITHELIAL-CELLS; ALPHA-CATENIN; ACTIN-FILAMENTS; INTERCELLULAR-JUNCTIONS; FUNCTIONAL-ANALYSIS; TRANS-INTERACTIONS	Adherens junctions (AJs) and tight junctions (TJs) comprise a junctional complex which plays key roles not only in cell adhesion and polarization but also in regulation of cell movement and proliferation in epithelial cells. E-Cadherin and nectin are major cell-cell adhesion molecules (CAMs) at AJs, whereas claudin is a major CAM at TJs. We have shown that the cadherin-based cell-cell adhesion is not formed in MDCK cells in which annexin II, a Ca2+- and phospholipid-binding protein, is knocked down. Here, we found that TJs and the nectin-based cell-cell adhesions were formed in annexin II-knockdown cells. The formation of TJs in annexin II-knockdown MDCK cells required the nectin-based cell-cell adhesion and afadin, a nectin- and actin-filament-binding protein. In addition, it required the activation of Cdc42 and Rac small G proteins and subsequent reorganization of the IQGAP1-dependent actin cytoskeleton which were induced by the nectin- based cell-cell adhesion. These results indicate that the nectin-based cell-cell adhesion and afadin, but not the cadherin-based cell-cell adhesion, are necessary for the formation of TJs and that the signaling by nectin and the subsequent reorganization of the actin cytoskeleton are also necessary for the formation of TJs under certain conditions.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; KAN Res Inst Inc, Shimogyo Ku, Kyoto, Japan	Osaka University; KAN Research Institute	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp						ABERCROMBIE M, 1953, EXP CELL RES, V5, P111, DOI 10.1016/0014-4827(53)90098-6; Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Andreeva AY, 2001, J BIOL CHEM, V276, P38480, DOI 10.1074/jbc.M104923200; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FISHER HW, 1967, SCIENCE, V155, P581, DOI 10.1126/science.155.3762.581; Fukuhara A, 2002, ONCOGENE, V21, P7642, DOI 10.1038/sj.onc.1205875; Fukuhara A, 2002, GENES CELLS, V7, P1059, DOI 10.1046/j.1365-2443.2002.00578.x; Fukuhara T, 2004, J CELL BIOL, V166, P393, DOI 10.1083/jcb.200401093; Fukuyama T, 2005, J BIOL CHEM, V280, P815, DOI 10.1074/jbc.M411099200; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Getsios S, 2004, NAT REV MOL CELL BIO, V5, P271, DOI 10.1038/nrm1356; GONZALEZMARISCAL L, 1985, J MEMBRANE BIOL, V86, P113, DOI 10.1007/BF01870778; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Harris TJC, 2004, J CELL BIOL, V167, P135, DOI 10.1083/jcb.200406024; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Honda T, 2003, BIOCHEM BIOPH RES CO, V306, P104, DOI 10.1016/S0006-291X(03)00919-7; Honda T, 2003, GENES CELLS, V8, P51, DOI 10.1046/j.1365-2443.2003.00616.x; Hoshino T, 2005, J BIOL CHEM, V280, P24095, DOI 10.1074/jbc.M414447200; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Izumi G, 2004, J CELL BIOL, V166, P237, DOI 10.1083/jcb.200401078; Katata T, 2003, ONCOGENE, V22, P2097, DOI 10.1038/sj.onc.1206255; Kawakatsu T, 2005, J BIOL CHEM, V280, P4940, DOI 10.1074/jbc.M408710200; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Ma TY, 2000, AM J PHYSIOL-GASTR L, V279, pG875, DOI 10.1152/ajpgi.2000.279.5.G875; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Okamoto R, 2005, GENES CELLS, V10, P435, DOI 10.1111/j.1365-2443.2005.00846.x; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Quinlan MP, 1999, CELL GROWTH DIFFER, V10, P839; Roh MH, 2003, AM J PHYSIOL-RENAL, V285, pF377, DOI 10.1152/ajprenal.00086.2003; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Sakisaka T, 2004, CURR OPIN CELL BIOL, V16, P513, DOI 10.1016/j.ceb.2004.07.007; Sato T, 2006, J BIOL CHEM, V281, P5288, DOI 10.1074/jbc.M510070200; Shimizu K, 2003, J BIOCHEM, V134, P631, DOI 10.1093/jb/mvg198; Sonoda N, 1999, J CELL BIOL, V147, P195, DOI 10.1083/jcb.147.1.195; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; STEVENSON BR, 1994, J CELL SCI, V107, P367; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takekuni K, 2003, J BIOL CHEM, V278, P5497, DOI 10.1074/jbc.C200707200; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Umeda K, 2004, J BIOL CHEM, V279, P44785, DOI 10.1074/jbc.M406563200; vanHengel J, 1997, J CELL BIOL, V137, P1103, DOI 10.1083/jcb.137.5.1103; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Wittchen ES, 2000, J CELL BIOL, V151, P825, DOI 10.1083/jcb.151.4.825; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Yagi T, 2000, GENE DEV, V14, P1169; Yamada A, 2005, J BIOL CHEM, V280, P6016, DOI 10.1074/jbc.M408215200; Yamada A, 2004, GENES CELLS, V9, P843, DOI 10.1111/j.1365-2443.2004.00768.x; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595	65	46	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2006	25	37					5085	5102		10.1038/sj.onc.1209525	http://dx.doi.org/10.1038/sj.onc.1209525			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16607281				2022-12-17	WOS:000240063700002
J	Chini, C; Wood, J; Chen, J				Chini, C. C. S.; Wood, J.; Chen, J.			Chk1 is required to maintain Claspin stability	ONCOGENE			English	Article						claspin; Chk1; protein stability; cell cycle	DNA-REPLICATION; CHECKPOINT; BRCA1; PROTEIN; ATR; PHOSPHORYLATION; UBIQUITINATION; LOCALIZATION; ACTIVATION; EXPRESSION	Claspin is a Chk1-interacting protein that participates in the DNA replication checkpoint. Expression of Claspin fluctuates in a cell cycle-dependent manner, but the mechanisms involved in the regulation of Claspin protein levels have not been explored. In this study, we show that Claspin expression is downregulated by the proteasome-mediated degradation pathway and that Chk1 is required to maintain Claspin stability. Downregulation of Chk1 expression by siRNA or inhibition of Chk1 activity by UCN01 decreases Claspin levels in cells. Conversely, overexpression of Chk1 increases Claspin levels. These data indicate a role of Chk1 in regulating Claspin stability in the cell. Since Claspin has also been shown to participate in Chk1 activation following DNA damage, we further explored the exact role of Claspin during Chk1 activation following replication stress. We observed that while Rad17 is required for early Chk1 activation after hydroxyurea treatment, Claspin is only required to sustain Chk1 activation. Based on these findings, we propose that Claspin functions at late stages of Chk1 activation following DNA damage. Once Chk1 is activated, it stabilizes Claspin, which in turn helps to maintain Chk1 activation during replication stress. In summary, these data indicate that the interaction between Claspin and Chk1 is complex. These proteins regulate each other and thus ensure the proper cell cycle progression and replication checkpoint control.	Mayo Clin & Mayo Fdn, Coll Med, Dept Oncol Res, Rochester, MN 55905 USA	Mayo Clinic	Chen, J (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Oncol Res, 200 1st St SW, Rochester, MN 55905 USA.	Chen.Junjie@mayo.edu			NCI NIH HHS [CA92312, CA89239, CA100109] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100109, R01CA092312, R01CA089239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal R, 2003, J BIOL CHEM, V278, P45027, DOI 10.1074/jbc.M306783200; Busby EC, 2000, CANCER RES, V60, P2108; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Chini CCS, 2004, DNA REPAIR, V3, P1033, DOI 10.1016/j.dnarep.2004.03.001; Choudhury AD, 2004, J BIOL CHEM, V279, P33909, DOI 10.1074/jbc.M403646200; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Clarke CAL, 2005, BIOCHEM J, V388, P705, DOI 10.1042/BJ20041966; Hackbarth JS, 2004, BIOTECHNIQUES, V37, P835; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Kim JE, 2005, MOL CELL BIOL, V25, P10907, DOI 10.1128/MCB.25.24.10907-10915.2005; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(05)00092-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Sorensen CS, 2004, CELL CYCLE, V3, P941; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wang X, 2003, GENE DEV, V17, P965, DOI 10.1101/gad.1065103; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	26	46	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4165	4171		10.1038/sj.onc.1209447	http://dx.doi.org/10.1038/sj.onc.1209447			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501606				2022-12-17	WOS:000239004800004
J	Moretti, S; Macchiarulo, A; De Falco, V; Avenia, N; Barbi, F; Carta, C; Cavaliere, A; Melillo, RM; Passeri, L; Santeusanio, F; Tartaglia, M; Santoro, M; Puxeddu, E				Moretti, S.; Macchiarulo, A.; De Falco, V.; Avenia, N.; Barbi, F.; Carta, C.; Cavaliere, A.; Melillo, R. M.; Passeri, L.; Santeusanio, F.; Tartaglia, M.; Santoro, M.; Puxeddu, E.			Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma	ONCOGENE			English	Article						papillary thyroid carcinoma; BRAF mutation; kinase assay; molecular dynamic simulation	BRAF MUTATIONS; ACTIVATION; CANCER; GENE; PREVALENCE; MECHANISM; PATHWAY	Activating mutations of the BRAF gene are the most common genetic alterations in papillary thyroid carcinomas (PTCs) and the T1799A transversion, resulting in BRAF(V600E), appeared virtually unique in this cancer type. Here, we report on the identification in a classic PTC of a novel BRAF mutation, namely a 1795GTT insertion, resulting in BRAF(V599Ins), and describe its biochemical and molecular characterization. Kinase assays carried out on BRAF(V599Ins) and BRAF(V600E) revealed a three- to five-fold increase in the enzymatic activity of both mutants with respect to BRAF(WT). Similarly, evaluation of BRAF-induced phosphorylation of MEK, MAPK and RSK revealed a significant MAPK cascade activation in cells expressing BRAF(V599Ins) or BRAF(V600E), but not in cells expressing BRAF(WT). Molecular dynamic simulations showed a destabilization of the inactive conformation of the enzyme in both BRAF(V599Ins) and BRAF(V600E) mutants, but not in BRAF(WT). The analysis of the interaction energies inside the catalytic site allowed to demonstrate the presence of repulsive electrostatic forces acting on the activation loop and moving from inward to outward of the mutant enzymes. Finally, focus assays in NIH-3T3 cells confirmed a high transformation rate in the cells transfected either with BRAF(V599Ins) or BRAF(V600E). In conclusion, this study demonstrated that BRAF(V599Ins), as BRAF(V600E), is a 'gain of function' mutation, characterized by a constitutive catalytic activation, which accounts for its causative role in the studied PTC.	Univ Perugia, Dipartimento Med Interna, Sez MISEM, I-06126 Perugia, Italy; Univ Perugia, Dipartimento Chim & Tecnol Farm, I-06126 Perugia, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Naples, Italy; Univ Perugia, Ctr Riferimento Reg Endocrinochirurg, I-06126 Perugia, Italy; Ist Super Sanita, Dipartimento Biol Cellulare & Neurosci, I-00161 Rome, Italy; Univ Perugia, Ist Anat Patol, I-06126 Perugia, Italy	University of Perugia; University of Perugia; University of Naples Federico II; University of Perugia; Istituto Superiore di Sanita (ISS); University of Perugia	Puxeddu, E (corresponding author), Univ Perugia, Dipartimento Med Interna, Sez MISEM, Via Enrico dal Pozzo, I-06126 Perugia, Italy.	efisio@dimisem.med.unipg.it	Carta, Claudio/A-7305-2013; Tartaglia, Marco/K-2955-2018; Macchiarulo, Antonio/L-2846-2017; Puxeddu, Efisio/I-8188-2012; DE FALCO, VALENTINA/C-2061-2015; melillo, rosa marina/O-5255-2015; Avenia, Nicola/AAL-4546-2021	Carta, Claudio/0000-0003-3545-198X; Tartaglia, Marco/0000-0001-7736-9672; Macchiarulo, Antonio/0000-0001-9535-4183; DE FALCO, VALENTINA/0000-0002-8972-7921; MELILLO, Rosa Marina/0000-0002-9233-5275				Bennasroune A, 2004, CRIT REV ONCOL HEMAT, V50, P23, DOI 10.1016/j.critrevonc.2003.08.004; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Carta C, 2006, CLIN ENDOCRINOL, V64, P105, DOI 10.1111/j.1365-2265.2005.02401.x; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dibb NJ, 2004, NAT REV CANCER, V4, P718, DOI 10.1038/nrc1434; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Greene F, 2002, AJCC CANC STAGING MA, P77; GRUBMULLER H, 1996, SOLVATE V10 THEORETI; Jerome L, 2003, ENDOCR-RELAT CANCER, V10, P561, DOI 10.1677/erc.0.0100561; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Oler G, 2005, CLIN ENDOCRINOL, V62, P509, DOI 10.1111/j.1365-2265.2005.02235.x; Puxeddu E, 2004, J CLIN ENDOCR METAB, V89, P2414, DOI 10.1210/jc.2003-031425; Santoro M, 2004, ENDOCRINOLOGY, V145, P5448, DOI 10.1210/en.2004-0922; Tartaglia M, 2004, CURR OPIN HEMATOL, V11, P44, DOI 10.1097/00062752-200401000-00007; Trovisco V, 2005, VIRCHOWS ARCH, V446, P589, DOI 10.1007/s00428-005-1236-0; Trovisco V, 2005, HUM PATHOL, V36, P694, DOI 10.1016/j.humpath.2005.04.011; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978	23	46	47	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4235	4240		10.1038/sj.onc.1209448	http://dx.doi.org/10.1038/sj.onc.1209448			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501605				2022-12-17	WOS:000239004800011
J	Lynch, CJ; Milner, J				Lynch, C. J.; Milner, J.			Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency	ONCOGENE			English	Article						p53; haplo-insufficiency; Li-Fraumeni; survivin; SIRT1; mRNA	WILD-TYPE P53; P53-MEDIATED G(1) ARREST; TUMOR-SUPPRESSOR GENES; LI-FRAUMENI-SYNDROME; DNA-DAMAGE; HUMAN CANCERS; IN-VIVO; MODEL; TRANSCRIPTION; ACTIVATION	A haploid genotype may be insufficient to support normal wild-type function. Such haplo-insufficiency has recently been documented for numerous tumour suppressor genes. p53 is a crucial tumour suppressor governing DNA repair, cell cycle arrest and apoptosis via its role as a stress-responsive transcription factor. p53 haplo-insufficiency has been observed in vivo with human familial cancer in Li-Fraumeni Syndrome (LFS) and in mouse p53-knockout models of LFS. The increased tumorigenesis associated with loss of one p53 allele has been attributed to reduced p53-dependent stress responses. However, the underlying biochemical basis for such attenuated responses in p53(+/-) cells remains unclear. Here we have determined basal p53 messenger RNA ( mRNA) and protein levels, and compared the p53 stress response in p53+/+, p53+/- and p53-/- isogenic clones derived from HCT116 cells. Basal expression of p53 in p53+/- cells was 25% relative to p53+/+ cells, and this differential was maintained following oncogenic stress. This deficiency was manifested at both p53 mRNA and protein levels and resulted in attenuated p53 stress responses, in particular for p21(waf1) upregulation and survivin downregulation, and reduced G1 arrest and apoptosis. These observations identify a molecular basis for wild-type p53 haplo-insufficiency, which may explain the attenuated tumour-suppressive phenotype observed in cells with a single wild-type p53 allele and in humans with LFS.	Univ York, Res Grp YCR p53, Res Lab YCR p53, Dept Biol, York YO10 5DD, N Yorkshire, England	University of York - UK	Lynch, CJ (corresponding author), Univ York, Res Grp YCR p53, Res Lab YCR p53, Dept Biol, Zone 14, York YO10 5DD, N Yorkshire, England.	ajm24@york.ac.uk	Lynch, Christopher J./E-6875-2010; Lynch, Cian/AIC-5510-2022; Stoklosa, Tomasz A/I-8825-2017; Lynch, Cian J/K-2191-2017	Lynch, Christopher J./0000-0003-2453-5838; Lynch, Cian/0000-0003-0187-3527; Lynch, Cian J/0000-0003-0187-3527				Allison SJ, 2003, CANCER RES, V63, P6674; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CAMPLEJOHN RS, 1995, BRIT J CANCER, V72, P654, DOI 10.1038/bjc.1995.390; Cook WD, 2000, ONCOGENE, V19, P3434, DOI 10.1038/sj.onc.1203653; de Moor CH, 2005, SEMIN CELL DEV BIOL, V16, P49, DOI 10.1016/j.semcdb.2004.11.007; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FOFO T, 2002, DRUG RESIST UPDAT, V50, P209; Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Fu LN, 1999, ONCOGENE, V18, P6419, DOI 10.1038/sj.onc.1203064; GENG L, 2004, NAT GENET, V36, P63; Giannakou ME, 2004, TRENDS CELL BIOL, V14, P408, DOI 10.1016/j.tcb.2004.07.006; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu VW, 2001, FASEB J, V15, P1562, DOI 10.1096/fj.01-0102com; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Komarova EA, 1998, SEMIN CANCER BIOL, V8, P389, DOI 10.1006/scbi.1998.0101; Latonen L, 2005, BBA-REV CANCER, V1755, P71, DOI 10.1016/j.bbcan.2005.04.003; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Mirzayans R, 2003, ONCOGENE, V22, P5562, DOI 10.1038/sj.onc.1206514; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Parant JM, 2003, HUM MUTAT, V21, P321, DOI 10.1002/humu.10186; Payne SR, 2005, CARCINOGENESIS, V26, P2031, DOI 10.1093/carcin/bgi223; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Soussi T, 2005, BIOCHEM BIOPH RES CO, V331, P834, DOI 10.1016/j.bbrc.2005.03.190; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Venkatachalam S, 2001, TOXICOL PATHOL, V29, P147, DOI 10.1080/019262301753178555; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; WALDMAN T, 1995, CANCER RES, V55, P5187; Williams KJ, 1997, ONCOGENE, V14, P277, DOI 10.1038/sj.onc.1200838; Yanokura M, 2000, INT J RADIAT BIOL, V76, P295, DOI 10.1080/095530000138637	49	46	49	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3463	3470		10.1038/sj.onc.1209387	http://dx.doi.org/10.1038/sj.onc.1209387			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16449974				2022-12-17	WOS:000238448100011
J	Taube, ME; Liu, XW; Fridman, R; Kim, HRC				Taube, M. E.; Liu, X-W; Fridman, R.; Kim, H-RC			TIMP-1 regulation of cell cycle in human breast epithelial cells via stabilization of p27(KIP1) protein	ONCOGENE			English	Article						TIMP-1; cell cycle; p27(KIP1); apoptosis	ERYTHROID-POTENTIATING ACTIVITY; TISSUE INHIBITOR; RETINOBLASTOMA PROTEIN; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; METALLOPROTEINASES-1 TIMP-1; BRANCHING MORPHOGENESIS; SIGNAL-TRANSDUCTION; LIVER FIBROSIS; MAMMARY-GLAND	Increasing evidence suggests that tissue inhibitor of metalloproteinases-1 (TIMP-1) can directly regulate cell growth and apoptosis independent of its matrix metalloproteinases (MMPs)-inhibitory activity. While TIMP-1's antiapoptotic activity has been well demonstrated, con. flicting data has been reported regarding TIMP-1's role in growth regulation. Here we show that TIMP-1 reduces the growth rate of human breast epithelial (MCF10A)cells by inducing cell cycle arrest at G(1). TIMP-1-mediated cell cycle arrest is associated with its downregulation of cyclin D-1 and upregulation of p27(KIP1), resulting in inhibition of cyclin-dependent kinase activity necessary for phosphorylation of the tumor suppressor retinoblastoma protein. We further show that TIMP-1 modulation of cyclin D1 and p27KIP1 is achieved through TIMP-1-mediated differential regulation of protein stability independent of growth factor signaling. We also show that TIMP-1-mediated differential regulation of cyclin D1 and p27KIP1 is independent of cell adhesion signaling. Whereas approximately 50% of MCF10A cells with reduced TIMP-1 expression underwent cell death following loss of cell adhesion (anoikis), TIMP-1 overexpressing cells remained viable with prominent cell cycle arrest without detectable cell death. Taken together, we propose that TIMP-1-mediated cell survival independent of cell adhesion is accompanied with cell cycle arrest in human breast epithelial cells, although cell cycle regulation may not be a prerequisite for TIMP-1 regulation of apoptosis in general.	Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Kim, HRC (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, 540 E Canfield Ave, Detroit, MI 48201 USA.	hrckim@med.wayne.edu			NCI NIH HHS [CA89113] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089113] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; AVALOS BR, 1988, BLOOD, V71, P1720; BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; BERTAUX B, 1991, J INVEST DERMATOL, V97, P679, DOI 10.1111/1523-1747.ep12483956; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DECLERCK YA, 1992, CANCER RES, V52, P701; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; DULBECCO R, 1986, CANCER RES, V46, P2449; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Fata JE, 1999, DEV BIOL, V211, P238, DOI 10.1006/dbio.1999.9313; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GOLDE DW, 1980, P NATL ACAD SCI-BIOL, V77, P593, DOI 10.1073/pnas.77.1.593; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 1998, BLOOD, V92, P1342, DOI 10.1182/blood.V92.4.1342.416k22_1342_1349; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; Henriet P, 1999, APMIS, V107, P111, DOI 10.1111/j.1699-0463.1999.tb01533.x; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lee SJ, 2003, BIOCHEM BIOPH RES CO, V312, P1196, DOI 10.1016/j.bbrc.2003.11.050; Lelievre S, 1996, RECENT PROG HORM RES, V51, P417; Li GY, 1999, CANCER RES, V59, P6267; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Liu XW, 2005, CANCER RES, V65, P898; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; McCarthy K, 1999, INT J CANCER, V84, P44, DOI 10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.0.CO;2-P; Mohammed FF, 2005, HEPATOLOGY, V41, P857, DOI 10.1002/hep.20618; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; Murphy FR, 2002, J BIOL CHEM, V277, P11069, DOI 10.1074/jbc.M111490200; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Porter JF, 2004, BRIT J CANCER, V90, P463, DOI 10.1038/sj.bjc.6601533; Ree AH, 1997, CLIN CANCER RES, V3, P1623; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; Schmidt J W, 1993, Semin Cell Biol, V4, P161, DOI 10.1006/scel.1993.1020; Schrohl AS, 2004, CLIN CANCER RES, V10, P2289, DOI 10.1158/1078-0432.CCR-03-0360; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Wiseman BS, 2003, J CELL BIOL, V162, P1123, DOI 10.1083/jcb.200302090; Yoshiji H, 2002, HEPATOLOGY, V36, P850, DOI 10.1053/jhep.2002.35625; Yoshiji H, 1996, INT J CANCER, V69, P131, DOI 10.1002/(SICI)1097-0215(19960422)69:2<131::AID-IJC11>3.0.CO;2-C	53	46	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3041	3048		10.1038/sj.onc.1209336	http://dx.doi.org/10.1038/sj.onc.1209336			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407831				2022-12-17	WOS:000237950800008
J	Lin, M; Smith, LT; Smiraglia, DJ; Kazhiyur-Mannar, R; Lang, JC; Schuller, DE; Kornacker, K; Wenger, R; Plass, C				Lin, M; Smith, LT; Smiraglia, DJ; Kazhiyur-Mannar, R; Lang, JC; Schuller, DE; Kornacker, K; Wenger, R; Plass, C			DNA copy number gains in head and neck squamous cell carcinoma	ONCOGENE			English	Article						amplification; HNSCC; RLGS	COMPARATIVE-GENOMIC-HYBRIDIZATION; GENE AMPLIFICATION; CANDIDATE ONCOGENE; 3Q GAIN; C-MYC; CANCER; IDENTIFICATION; SEQUENCES; REGIONS; OVARIAN	Gene amplification, a common mechanism for oncogene activation in cancer, has been used as a tag for the identification of novel oncogenes. DNA amplification is frequently observed in head and neck squamous cell carcinoma (HNSCC) and potential oncogenes have already been reported. We applied restriction landmark genome scanning (RLGS) to study gene amplifications and low-level copy number changes in HNSCC in order to locate previously uncharacterized regions with copy number gains in primary tumor samples. A total of 63 enhanced RLGS fragments, indicative of DNA copy number changes, including gains of single alleles, were scored. Enhanced sequences were identified from 33 different chromosomal regions including those previously reported (e.g. 3q26.3 and 11q13.3) as well as novel regions (e.g. 3q29, 8q13.1, 8q22.3, 9q32, 10q24.32, 14q32.32, 17q25.1 and 20q13.33). Furthermore, our data suggest that amplicons 11q13.3 and 3q26.3-q29 may be divided into possibly two and three independent amplicons, respectively, an observation supported by published microarray expression data.	Ohio State Univ, Div Human Canc Genet, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Otolaryngol, Columbus, OH 43210 USA; Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA; Ohio State Univ, Mol Cellular & Dev Biol Grad Program, Columbus, OH 43210 USA; Roswell Pk Canc Inst, Dept Canc Genet & Comprehens Canc Ctr, Buffalo, NY USA; Ohio State Univ, Comp Informat Sci Dept, Columbus, OH USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Roswell Park Cancer Institute; University System of Ohio; Ohio State University	Plass, C (corresponding author), Ohio State Univ, Div Human Canc Genet, Dept Mol Virol Immunol & Med Genet, 420 W 12th Ave,Room 464A, Columbus, OH 43210 USA.	plass-1@medctr.osu.edu	Reever, Larson/H-9685-2019; Smiraglia, Dominic/R-2069-2019; Plass, Christoph/H-7192-2014	Reever, Larson/0000-0002-5692-4793; Smiraglia, Dominic/0000-0001-8852-1510; 	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013123] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE13123-02] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Arai H, 2003, CANCER GENET CYTOGEN, V146, P16, DOI 10.1016/S0165-4608(03)00106-7; Bitzer M, 2003, ANTICANCER RES, V23, P1489; Bruch J, 1998, GENE CHROMOSOME CANC, V23, P167, DOI 10.1002/(SICI)1098-2264(199810)23:2<167::AID-GCC10>3.0.CO;2-L; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Clancy JL, 2003, ONCOGENE, V22, P5070, DOI 10.1038/sj.onc.1206775; Costello JF, 1997, CANCER RES, V57, P1250; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; Curtis LJ, 1998, GENOMICS, V53, P42, DOI 10.1006/geno.1998.5405; Dai ZY, 2003, HUM MOL GENET, V12, P791, DOI 10.1093/hmg/ddg083; Du Plessis L, 1999, CANCER RES, V59, P1877; Estilo CL, 2003, CLIN CANCER RES, V9, P2300; Fan CS, 2000, HUM PATHOL, V31, P169, DOI 10.1016/S0046-8177(00)80216-6; Garnis C, 2004, GENE CHROMOSOME CANC, V39, P93, DOI 10.1002/gcc.10294; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hermsen M, 2001, J PATHOL, V194, P177; HIROTSUNE S, 1992, CANCER RES, V52, P3642; Huang Q, 2002, GENE CHROMOSOME CANC, V34, P224, DOI 10.1002/gcc.10062; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Knuutila S, 1998, AM J PATHOL, V152, P1107; Komiyama T, 1997, JPN J CANCER RES, V88, P476, DOI 10.1111/j.1349-7006.1997.tb00406.x; Larramendy ML, 2000, CANCER GENET CYTOGEN, V119, P132, DOI 10.1016/S0165-4608(99)00226-5; Lukasova E, 2004, CHROMOSOMA, V112, P221, DOI 10.1007/s00412-003-0263-3; Lyons SK, 1997, BRIT MED BULL, V53, P554; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; Matsumura K, 2000, GENE CHROMOSOME CANC, V29, P207, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1032>3.0.CO;2-U; Neve RM, 2001, ANN ONCOL, V12, P9, DOI 10.1023/A:1011199404516; Oga A, 2001, CANCER GENET CYTOGEN, V127, P24, DOI 10.1016/S0165-4608(00)00430-1; Pimkhaokham A, 2000, JPN J CANCER RES, V91, P1126, DOI 10.1111/j.1349-7006.2000.tb00895.x; Racz A, 1999, EUR J CANCER, V35, P641, DOI 10.1016/S0959-8049(98)00419-5; Rao PH, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-5; Redon R, 2002, CANCER RES, V62, P6211; Riazimand SH, 2002, ONCOLOGY-BASEL, V63, P385, DOI 10.1159/000066220; Rodrigo JP, 2000, CLIN CANCER RES, V6, P3177; SCHIMKE RT, 1990, CANCER CELL-MON REV, V2, P149; Schwab M, 1999, SEMIN CANCER BIOL, V9, P319, DOI 10.1006/scbi.1999.0126; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Singh B, 2001, CANCER RES, V61, P4506; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; SPEICHER MR, 1995, CANCER RES, V55, P1010; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Tang TCM, 2002, CANCER RES, V62, P7157; Thoraval D, 1996, GENE CHROMOSOME CANC, V17, P234, DOI 10.1002/(SICI)1098-2264(199612)17:4<234::AID-GCC5>3.0.CO;2-4; Wu R, 2003, AM J PATHOL, V162, P1603, DOI 10.1016/S0002-9440(10)64294-0	45	46	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1424	1433		10.1038/sj.onc.1209166	http://dx.doi.org/10.1038/sj.onc.1209166			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247453				2022-12-17	WOS:000235708200017
J	Essayem, S; Kovacic-Milivojevic, B; Baumbusch, C; McDonagh, S; Dolganov, G; Howerton, K; Larocque, N; Mauro, T; Ramirez, A; Ramos, DM; Fisher, SJ; Jorcano, JL; Beggs, HE; Reichardt, LF; Ilic, D				Essayem, S; Kovacic-Milivojevic, B; Baumbusch, C; McDonagh, S; Dolganov, G; Howerton, K; Larocque, N; Mauro, T; Ramirez, A; Ramos, DM; Fisher, SJ; Jorcano, JL; Beggs, HE; Reichardt, LF; Ilic, D			Hair cycle and wound healing in mice with a keratinocyte-restricted deletion of FAK	ONCOGENE			English	Article						FAK; wound healing; hair; migration; proliferation; keratinocytes; stem cells	FOCAL ADHESION KINASE; STEM-CELLS; GROWTH-FACTOR; IN-VITRO; EXPRESSION; DIFFERENTIATION; ACTIVATION; MIGRATION; SKIN; BETA-1-INTEGRINS	Focal adhesion kinase (FAK) is a critical component in transducing signals downstream of both integrins and growth factor receptors. To determine how the loss of FAK affects the epidermis in vivo, we have generated a mouse model with a keratinocyte-restricted deletion of fak (FAK(K5 KO) mice). FAKK5 KO mice displayed three major phenotypes-irregularities of hair cycle, sebaceous glands hypoplasia, and a thinner epidermis-pointing to defects in the proliferative capacity of multipotent stem cells found in the bulge. FAK-null keratinocytes in conventional primary culture undergo massive apoptosis hindering further analyses, whereas the defects observed in vivo do not shorten the mouse lifespan. These results suggest that the structure and the signaling environment of the native tissue may overcome the lack of signaling through FAK. Our findings point to the importance of in vivo and three-dimensional in vitro models in analyses of cell migration, proliferation, and survival. Surprisingly, the difference between FAK(loxP/+) and FAK(K5) (KO) mice in wound closure was not statistically significant, suggesting that in vivo loss of FAK does not affect migration/proliferation of basal keratinocytes in the same way as it affects multipotent stem cells of the skin.	Univ Calif San Francisco, Dept Cell & Tissue Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pulm, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; CIEMAT, Dept Epithelial Damage, Repair & Tissue Engn Program, E-28040 Madrid, Spain; Univ Calif San Francisco, Dept Orofacial Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Ilic, D (corresponding author), StemLifeLine Inc, 1300 Ind Rd,13, San Carlos, CA 94070 USA.	dilic@stemlifeline.com	Ramirez, Angel/A-4800-2018	Ramirez, Angel/0000-0001-7745-5108; ILIC, DUSKO/0000-0003-1647-0026	NCI NIH HHS [CA87652, K01 CA087652] Funding Source: Medline; NCRR NIH HHS [C06 RR016490, C06RR16490] Funding Source: Medline; NINDS NIH HHS [R01 NS019090-25, R01 NS019090] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA087652] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR016490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019090] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbi S, 2002, HISTOL HISTOPATHOL, V17, P1163, DOI 10.14670/HH-17.1163; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; Alonso L, 2003, P NATL ACAD SCI USA, V100, P11830, DOI 10.1073/pnas.1734203100; ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; Beggs HE, 2003, NEURON, V40, P501, DOI 10.1016/S0896-6273(03)00666-4; Brakebusch C, 2000, EMBO J, V19, P3990, DOI 10.1093/emboj/19.15.3990; Cary LA, 1996, J CELL SCI, V109, P1787; Coulombe PA, 1997, BIOCHEM BIOPH RES CO, V236, P231, DOI 10.1006/bbrc.1997.6945; Cui CY, 2003, HUM MOL GENET, V12, P2931, DOI 10.1093/hmg/ddg325; Damsky CH, 2002, CURR OPIN CELL BIOL, V14, P594, DOI 10.1016/S0955-0674(02)00368-X; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FURUTA Y, 1995, ONCOGENE, V11, P1989; Grose R, 2002, DEVELOPMENT, V129, P2303; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Hauck CR, 2001, CANCER RES, V61, P7079; Ilic D, 2004, J CELL SCI, V117, P177, DOI 10.1242/jcs.00845; Ilic D, 2001, AM J PATHOL, V159, P93, DOI 10.1016/S0002-9440(10)61677-X; ILIC D, 1995, BIOCHEM BIOPH RES CO, V209, P300, DOI 10.1006/bbrc.1995.1503; Ilic D, 1998, J CELL BIOL, V143, P547; ILLC D, 1995, NATURE, V377, P539; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kovacic-Milivojevic B, 2001, MOL BIOL CELL, V12, P2290, DOI 10.1091/mbc.12.8.2290; Liu YP, 2003, J INVEST DERMATOL, V121, P963, DOI 10.1046/j.1523-1747.2003.12600.x; Ma DR, 2004, ANN ACAD MED SINGAP, V33, P784; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; McLean GW, 2003, EXPERT OPIN PHARMACO, V4, P227, DOI 10.1517/eoph.4.2.227.21093; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Morasso MI, 2005, BIOL CELL, V97, P173; Nolan K, 1999, MOL CELL BIOL, V19, P6120; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; Raghavan S, 2000, J CELL BIOL, V150, P1149, DOI 10.1083/jcb.150.5.1149; Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	43	46	47	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1081	1089		10.1038/sj.onc.1209130	http://dx.doi.org/10.1038/sj.onc.1209130			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247468	Green Accepted			2022-12-17	WOS:000235361000012
J	Chow, LSN; Lam, CW; Chan, SYY; Tsao, SW; To, KF; Tong, SF; Hung, WK; Dammann, R; Huang, DP; Lo, KW				Chow, LSN; Lam, CW; Chan, SYY; Tsao, SW; To, KF; Tong, SF; Hung, WK; Dammann, R; Huang, DP; Lo, KW			Identification of RASSF1A modulated genes in nasopharyngeal carcinoma	ONCOGENE			English	Article						RASSF1A; Id2; microarray; tumor suppressor; nasopharyngeal carcinoma	TUMOR-SUPPRESSOR RASSF1A; PROMOTER HYPERMETHYLATION; EPIGENETIC INACTIVATION; EPITHELIAL-CELLS; PROTEIN; 3P21.3; LUNG; EXPRESSION; APOPTOSIS; INTERACTS	RASSF1A is a tumor suppressor gene on 3p21.3 frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma (NPC). To identify RASSF1A target genes in NPC, we have investigated the expression pro. le of the stable RASSF1A transfectants and controls by high-density oligonucleotide array. A total of 57 genes showed differential expression in the RASSF1A-expressing cells. These RASSF1A target genes were involved in multiple cellular regulatory processes such as transcription, signal transduction, cell adhesion and RNA processing. The RASSF1A-modulated expression of eight selected genes with the highest fold changes (ATF5, TCRB, RGS1, activin beta E, HNRPH1, HNRPD, Id2 and CKS2) by RASSF1A was confirmed in both stable and transient transfectants. Compared with the RASSF1A transfectants, an inverse expression pattern of activin bE, Id2 and ATF5 was shown in the immortalized nasopharyngeal epithelial cells treated with siRNA against RASSF1A. The findings imply that the expression of activin bE, Id2 and ATF5 was tightly regulated by RASSF1A and may associate with its tumor suppressor function. Strikingly, overexpression of Id2 is common in NPC and RASSF1A-induced repression of Id2 was mediated by the overexpression of activin bE. The results suggest a novel RASSF1A pathway in which both activin bE and Id2 are involved.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Univ Halle Wittenberg, Inst Humangenet & Med Biol, D-06097 Halle An Der Saale, Germany	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; University of Hong Kong; Martin Luther University Halle Wittenberg	Lo, KW (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China.	kwlo@cuhk.edu.hk						Agathanggelou A, 2003, CANCER RES, V63, P5344; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Chabicovsky M, 2003, ENDOCRINOLOGY, V144, P3497, DOI 10.1210/en.2003-0388; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Chow LSN, 2004, INT J CANCER, V109, P839, DOI 10.1002/ijc.20079; Coppe JP, 2003, EXP CELL RES, V285, P131, DOI 10.1016/S0014-4827(03)00014-4; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kwong J, 2002, CLIN CANCER RES, V8, P131; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Liu WJ, 2004, BIOCHEM BIOPH RES CO, V321, P954, DOI 10.1016/j.bbrc.2004.07.053; Lo KW, 2000, CANCER RES, V60, P3348; Lo KW, 2004, CANCER CELL, V5, P423, DOI 10.1016/S1535-6108(04)00119-9; Lo KW, 2001, CANCER RES, V61, P3877; Lo KW, 2002, SEMIN CANCER BIOL, V12, P451, DOI 10.1016/S1044579X02000883; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Persengiev SP, 2002, GENE DEV, V16, P1806, DOI 10.1101/gad.992202; Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Tommasi S, 2005, CANCER RES, V65, P92; TSAO SW, 2002, BIOCHIM BIOPHYS ACTA, V12, P158; TSAO SW, 2002, BIOCHIM BIOPHYS ACTA, V12, P1590; Vejda S, 2003, CARCINOGENESIS, V24, P1801, DOI 10.1093/carcin/bgg154; Zhang Y, 1999, J BIOL CHEM, V274, P2851, DOI 10.1074/jbc.274.5.2851	27	46	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					310	316		10.1038/sj.onc.1209001	http://dx.doi.org/10.1038/sj.onc.1209001			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16116475				2022-12-17	WOS:000234583600016
J	Baxendale, AJ; Dawson, CW; Stewart, SE; Mudaliar, V; Reynolds, G; Gordon, J; Murray, PG; Young, LS; Eliopoulos, AG				Baxendale, AJ; Dawson, CW; Stewart, SE; Mudaliar, V; Reynolds, G; Gordon, J; Murray, PG; Young, LS; Eliopoulos, AG			Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth	ONCOGENE			English	Article						CD40; NF-kappa B; transformation; oncogenesis	EPSTEIN-BARR-VIRUS; TUMOR-NECROSIS-FACTOR; LATENT MEMBRANE-PROTEIN; NF-KAPPA-B; BURKITT-LYMPHOMA CELLS; FACTOR-ALPHA; T-CELLS; RHEUMATOID-ARTHRITIS; EPITHELIAL-CELLS; CARCINOMA-CELLS	CD40, a tumour necrosis factor (TNF) receptor family member, is expressed in a variety of cell types, including B lymphocytes, macrophages, fibroblasts, endothelial and epithelial cells, and this widespread expression is likely to account for its central role in normal physiology and disease pathogenesis. In this study, we provide evidence to support a role for constitutive CD40 signalling in cell transformation. We show that the ligand for CD40 (CD40L/CD154) is expressed in CD40-positive human breast tumour biopsies, suggesting that the constitutive activation of the CD40 receptor in vivo may contribute to the oncogenic process. Coexpression of CD40 and CD40L confers oncogenic effects on immortalized human epithelial cells in vitro, increasing their proliferation, motility and invasion. Expression of LMP:CD40, a hybrid molecule comprising the N-terminus and transmembrane domains of the Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) fused to the cytoplasmic tail of CD40, mimics a constitutively active CD40 receptor and promotes the transformation of immortalized rodent fibroblasts in vitro and their oncogenicity in vivo. The observed effects of aberrant CD40 activation on cell transformation are largely diminished upon suppression of the oncogenic NF-kappa B signalling pathway. Taken together, our results suggest a role for the constitutive engagement of the CD40L/CD40/NF-kappa B activation pathway in cell transformation and neoplastic growth. Strategies that neutralize this pathway may therefore be useful in cancer treatment and prevention.	Univ Birmingham, Sch Med, Canc Res UK, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England; Royal Shrewsbury Hosp, Dept Histopathol, Shrewsbury SY3 8LR, Salop, England; Univ Birmingham, Sch Med, MRC Ctr Immune Regulat, Birmingham B15 2TT, W Midlands, England	Cancer Research UK; University of Birmingham; University of Birmingham	Eliopoulos, AG (corresponding author), Univ Birmingham, Sch Med, Canc Res UK, Inst Canc Studies, Vincent Dr, Birmingham B15 2TA, W Midlands, England.	A.G.Eliopoulos@bham.ac.uk	Reynolds, Gary/F-8641-2014; Young, Lawrence S/B-7213-2009; ELIOPOULOS, ARISTIDES/ABI-6632-2020; ELIOPOULOS, ARISTIDES/R-9449-2018	Reynolds, Gary/0000-0002-3250-0582; Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761				Adawi A, 1998, CLIN IMMUNOL IMMUNOP, V89, P222, DOI 10.1006/clin.1998.4606; Anderson GM, 2004, CURR OPIN PHARMACOL, V4, P314, DOI 10.1016/j.coph.2004.04.004; Baker MP, 1998, BLOOD, V92, P2830, DOI 10.1182/blood.V92.8.2830.420k10_2830_2843; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Brown KD, 2001, J EXP MED, V193, P943, DOI 10.1084/jem.193.8.943; Challa A, 2002, BLOOD, V99, P3411, DOI 10.1182/blood.V99.9.3411; Cooke PW, 1999, J PATHOL, V188, P38; Costello RT, 1999, IMMUNOL TODAY, V20, P488, DOI 10.1016/S0167-5699(99)01507-8; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; Eggermont AMM, 2003, LANCET ONCOL, V4, P429, DOI 10.1016/S1470-2045(03)01141-0; Eliopoulos AG, 2000, MOL CELL BIOL, V20, P5503, DOI 10.1128/MCB.20.15.5503-5515.2000; Eliopoulos AG, 2004, CURR OPIN PHARMACOL, V4, P360, DOI 10.1016/j.coph.2004.02.008; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 2003, J VIROL, V77, P1316, DOI 10.1128/JVI.77.2.1316-1328.2003; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; FloresRomo L, 1997, J EXP MED, V185, P341, DOI 10.1084/jem.185.2.341; Fulda S, 2004, CURR OPIN PHARMACOL, V4, P327, DOI 10.1016/j.coph.2004.02.005; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; Ghamande S, 2001, CANCER RES, V61, P7556; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; GORDON J, 1995, BLOOD REV, V9, P53, DOI 10.1016/0268-960X(95)90040-3; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He ZM, 2000, CANCER RES, V60, P1845; Henriquez NV, 1999, J IMMUNOL, V162, P3298; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; Hill SC, 2005, J IMMUNOL, V174, P41, DOI 10.4049/jimmunol.174.1.41; Hirano A, 1999, BLOOD, V93, P2999; Houston A, 2004, CURR OPIN PHARMACOL, V4, P321, DOI 10.1016/j.coph.2004.03.008; Kiener PA, 1997, J IMMUNOL, V159, P1594; Kyburz D, 2000, ARTHRITIS RHEUM, V43, P2571, DOI 10.1002/1529-0131(200011)43:11<2571::AID-ANR26>3.0.CO;2-4; Liao Zhongxing, 2004, Expert Rev Anticancer Ther, V4, P543, DOI 10.1586/14737140.4.4.543; MacDonald KPA, 1997, J CLIN INVEST, V100, P2404, DOI 10.1172/JCI119781; Martinez-Lorenzo MJ, 1998, EUR J IMMUNOL, V28, P2714, DOI 10.1002/(SICI)1521-4141(199809)28:09<2714::AID-IMMU2714>3.0.CO;2-9; Mehling A, 2001, J EXP MED, V194, P615, DOI 10.1084/jem.194.5.615; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; MOHAN C, 1995, J IMMUNOL, V154, P1470; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; O'Byrne KJ, 2001, BRIT J CANCER, V85, P473, DOI 10.1054/bjoc.2001.1943; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; Ohta Y, 2004, DERMATOLOGY, V209, P21, DOI 10.1159/000078582; Ottaiano A, 2004, CLIN CANCER RES, V10, P2824, DOI 10.1158/1078-0432.CCR-0139-03; Pham LV, 2002, IMMUNITY, V16, P37, DOI 10.1016/S1074-7613(01)00258-8; Phipps RP, 2000, P NATL ACAD SCI USA, V97, P6930, DOI 10.1073/pnas.97.13.6930; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Tong AW, 2001, CLIN CANCER RES, V7, P691; Tutt AL, 1998, J IMMUNOL, V161, P3176; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; Vonderheide RH, 2001, J CLIN ONCOL, V19, P3280, DOI 10.1200/JCO.2001.19.13.3280; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wykes M, 1998, EUR J IMMUNOL, V28, P548, DOI 10.1002/(SICI)1521-4141(199802)28:02<548::AID-IMMU548>3.0.CO;2-2; Young LS, 1998, IMMUNOL TODAY, V19, P502, DOI 10.1016/S0167-5699(98)01340-1; Zhang Y, 1998, J IMMUNOL, V160, P1053; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	62	46	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7913	7923		10.1038/sj.onc.1208929	http://dx.doi.org/10.1038/sj.onc.1208929			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16091748				2022-12-17	WOS:000233463000010
J	Ghosh, MK; Sharma, P; Harbor, PC; O Rahaman, S; Haque, SJ				Ghosh, MK; Sharma, P; Harbor, PC; O Rahaman, S; Haque, SJ			PI3K-AKT pathway negatively controls EGFR-dependent DNA-binding activity of Stat3 in glioblastoma multiforme cells	ONCOGENE			English	Article						glioblastoma multiforme; apoptosis; Stat3; AKT; EGFR	EPIDERMAL-GROWTH-FACTOR; PROTEIN-KINASE-B; FACTOR RECEPTOR GENE; CONSTITUTIVE ACTIVATION; MOLECULAR-MECHANISMS; MALIGNANT GLIOMA; PHOSPHATASE 2A; EXPRESSION; APOPTOSIS; TYROSINE	Glioblastoma multiforme (GBM) cells frequently harbor amplification and/or gain-of-function mutation of the EGFR gene leading to the activation of mul tiple signaling pathways. Blockade of EGFR activation inhibited the activation of both AKT and Stat3 in U87 and D54 GBM cells and induced spontaneous apoptosis, which were associated with reduction in the steady-state level of Mcl-1. Surprisingly, inhibition of PI3 kinase (PI3K) activity, which in turn inhibited AKT activation, significantly increased the DNA-binding activity of Stat3 in U87 and D54 cells. This was not due to an increase in the level of tyrosine-phosphorylated Stat3. Conversely, ectopic expression of constitutively activated AKT significantly decreased the DNA-binding activity of Stat3 in 293T cells. Interestingly, blockade of protein phosphatase 2A activity in GBM or 293T cells by calyculin A, which activated AKT, stabilized the phosphorylation of mul tiple Ser/Thr residues that were located in the transactivation domain (TAD) of Stat3 and this in turn completely ablated the DNA-binding activity of Stat3. Collectively, these results suggest that both Stat3 and AKT provide survival signals in U87 and D54 cells, and Ser/Thr phosphorylation of Stat3-TAD by the PI3K-AKT pathway negatively controls the DNA-binding function of Stat3.	Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Brain Tumor Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Haque, SJ (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, NB4-85,9500 Euclid Ave, Cleveland, OH 44195 USA.	haquej@ccf.org	Sharma, Pankaj/AAH-7468-2019; sharma, pankaj/HGE-4423-2022	Sharma, Pankaj/0000-0001-7405-1706; 	NATIONAL CANCER INSTITUTE [R01CA095006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060533] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA095006] Funding Source: Medline; NIGMS NIH HHS [R01-GM60533] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aldape KD, 2004, J NEUROPATH EXP NEUR, V63, P700, DOI 10.1093/jnen/63.7.700; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; DiDonato JA, 2000, METHOD ENZYMOL, V322, P393; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Fukuchi K, 2000, BBA-MOL CELL RES, V1496, P207, DOI 10.1016/S0167-4889(00)00018-5; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Goswami S, 1998, J NEUROCHEM, V71, P1837; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Kortylewski M, 2003, J BIOL CHEM, V278, P5242, DOI 10.1074/jbc.M205403200; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; MAITI NR, 2005, IN PRESS J INTERFERO; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Rahaman SO, 2005, CANCER RES, V65, P2956, DOI 10.1158/0008-5472.CAN-04-3592; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; Rolhion C, 2001, J NEUROSURG, V94, P97, DOI 10.3171/jns.2001.94.1.0097; Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Tchirkov A, 2001, BRIT J CANCER, V85, P518, DOI 10.1054/bjoc.2001.1942; VAN MEIR E, 1990, CANCER RES, V50, P6683; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Weissenberger J, 2004, ONCOGENE, V23, P3308, DOI 10.1038/sj.onc.1207455; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Woetmann A, 1999, P NATL ACAD SCI USA, V96, P10620, DOI 10.1073/pnas.96.19.10620; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wu YJ, 2004, J CELL SCI, V117, P2227, DOI 10.1242/jcs.01057; Yonezawa K, 2003, CURR TOP MICROBIOL, V279, P271; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	52	46	52	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7290	7300		10.1038/sj.onc.1208894	http://dx.doi.org/10.1038/sj.onc.1208894			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16007122				2022-12-17	WOS:000233142100005
J	Park, SW; Sung, MW; Heo, DS; Inoue, H; Shim, SH; Kim, KH				Park, SW; Sung, MW; Heo, DS; Inoue, H; Shim, SH; Kim, KH			Nitric oxide upregulates the cyclooxygenase-2 expression through the cAMP-response element in its promoter in several cancer cell lines	ONCOGENE			English	Article						nitric oxide; NO; cyclooxygenase-2; COX-2; cAMP-response element; CRE	TRANSCRIPTION FACTOR; PROSTAGLANDIN E-2; KAPPA-B; EPITHELIAL-CELLS; CARCINOMA CELLS; NECK-CANCER; HEAD; SYNTHASE; GROWTH; COX-2	We previously showed that nitric oxide (NO) induces overexpression of cyclooxygenase-2 (COX-2) and production of prostaglandin E-2 in cancer cells. Here, we investigated the mechanisms by which NO induces COX-2 expression in cancer cells. We found that the cAMP-response element (CRE) is a critical factor in NO-induced COX-2 expression in all cells tested. We found that in cancer cells, three transcription factors (TFs) cAMP response element-binding protein (CREB), activating transcription factor-2 (ATF-2) and c-jun, bound the CRE in the COX-2 promoter, and their activities were increased by addition of the NO donor, S-nitroso-N-acetyl-D, L-penicillamine (SNAP). NO-induced activation of soluble guanylate cyclase (sGC), p38 and c-Jun NH2 terminal kinase (JNK) upregulated the three TFs, leading to COX-2 overexpression. Addition of dibutyryl-cGMP (db-cGMP) induced COX-2 expression in a manner similar to SNAP; this induction was blocked by a p38 inhibitor (SB202190), but not by a JNK inhibitor (SP600125). NO-induced cGMP was found to activate CREB and ATF-2 in a p38, but not c-jun- dependent manner,while NO induced JNK in a cGMP-independent manner, leading to subsequent activation of c-jun and ATF-2. These results suggest that the low concentrations of endogenous NO present in cancer cell may induce the expression of many genes, including COX-2, which promotes the growth and survival of tumor cells.	Seoul Natl Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Dept Tumor Biol, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Clin Res Inst, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Nara Womens Univ, Dept Food Sci & Nutr, Nara 630, Japan	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Nara Womens University	Sung, MW (corresponding author), Seoul Natl Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, 28 Yongon Dong, Seoul 110744, South Korea.	mwsung@snu.ac.kr	Kim, Kwang Hyun/J-5385-2012; Heo, Dae/J-2184-2012	Heo, Dae/0000-0001-5221-173X				Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; Browning DD, 2000, J BIOL CHEM, V275, P2811, DOI 10.1074/jbc.275.4.2811; Chabot-Fletcher M., 1996, PHARM REV COMMUN, V8, P317; Chan G, 1999, CANCER RES, V59, P991; Chung PS, 2000, LARYNGOSCOPE, V110, P1312, DOI 10.1097/00005537-200008000-00016; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; Gallo O, 1998, J NATL CANCER I, V90, P587, DOI 10.1093/jnci/90.8.587; Guo YS, 2001, J BIOL CHEM, V276, P22941, DOI 10.1074/jbc.M101801200; Habib A, 1997, J IMMUNOL, V158, P3845; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; HEO DS, 1989, CANCER RES, V49, P5167; Howe LR, 2001, J BIOL CHEM, V276, P20108, DOI 10.1074/jbc.M010692200; Inoue H, 2000, J BIOL CHEM, V275, P28028; Lee DW, 2002, ANTICANCER RES, V22, P2089; Liaudet L, 2000, CRIT CARE MED, V28, pN37, DOI 10.1097/00003246-200004001-00005; Liu YM, 2004, J BIOL CHEM, V279, P18694, DOI 10.1074/jbc.M308136200; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Nose F, 2002, AM J CLIN PATHOL, V117, P546; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Park SW, 2003, INT J CANCER, V107, P729, DOI 10.1002/ijc.11498; Park YG, 1999, J BIOL CHEM, V274, P1573, DOI 10.1074/jbc.274.3.1573; Posadas I, 2000, N-S ARCH PHARMACOL, V361, P98, DOI 10.1007/s002109900150; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Slice LW, 2000, BIOCHEM BIOPH RES CO, V276, P406, DOI 10.1006/bbrc.2000.3487; Son HJ, 2001, J CLIN GASTROENTEROL, V33, P383, DOI 10.1097/00004836-200111000-00008; Song SH, 2001, CANCER RES, V61, P4628; STADLER J, 1993, J LEUKOCYTE BIOL, V53, P165, DOI 10.1002/jlb.53.2.165; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Sun YJ, 2002, CANCER RES, V62, P6323; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Tamura M, 2002, J BIOL CHEM, V277, P26208, DOI 10.1074/jbc.M201347200; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; Tang QB, 2001, ONCOGENE, V20, P5164, DOI 10.1038/sj.onc.1204667; TSAI AL, 1994, ARCH BIOCHEM BIOPHYS, V313, P367, DOI 10.1006/abbi.1994.1400; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; Xu XM, 1997, J BIOL CHEM, V272, P6943, DOI 10.1074/jbc.272.11.6943	38	46	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6689	6698		10.1038/sj.onc.1208816	http://dx.doi.org/10.1038/sj.onc.1208816			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007171				2022-12-17	WOS:000232367800010
J	Wegiel, B; Bjartell, A; Ekberg, J; Gadaleanu, V; Brunhoff, C; Persson, JL				Wegiel, B; Bjartell, A; Ekberg, J; Gadaleanu, V; Brunhoff, C; Persson, JL			A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer	ONCOGENE			English	Article						cyclin A1; VEGF; androgen; androgen receptor; Rb; prostate cancer	TUMOR-GROWTH; FACTOR VEGF; ANDROGEN; ANGIOGENESIS; PROGRESSION; RECEPTORS; PROTEIN; CELLS	Elevated levels of cyclin A1 expression have been implicated in acute myeloid leukemia and in male germ cell tumors. However, a role of cyclin A1 in tumorigenesis of prostate cancer has not been reported. In the present study, expression of cyclin A1 in patients with prostate cancer and a role of cyclin A1 in mediating expression of vascular endothelial growth factor ( VEGF) were investigated. Cyclin A1 was highly expressed in aggressive tumors and was significantly correlated with VEGF expression in 96 patients with prostate cancer. Treatment of LNCaP cells with R1881, a synthetic androgen resulted in increased cyclin A1 expression. Induction of cyclin A1 expression in LNCaP cells led to an increase in VEGF expression and this effect was manifested upon the R1881 treatment. Cyclin A1 failed to mediate VEGF activation in DU-145 cells lacking a functional Rb and an androgen receptor (AR). Although AR expression was induced into DU-145 cells, cyclin A1 was unable to mediate VEGF expression. However, induced coexpression of cyclin A1, Rb and AR in DU-145 cells in the presence of R1881 greatly promoted VEGF promoter activity. This suggests that cyclin A1 mediates VEGF expression in cooperation with Rb- and androgen-dependent pathways in prostate cancer.	Lund Univ, Univ Hosp, Div Pathol, Dept Lab Med, S-20502 Malmo, Sweden; Lund Univ, Univ Hosp, Dept Urol, Malmo, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital	Persson, JL (corresponding author), Lund Univ, Univ Hosp, Div Pathol, Dept Lab Med, S-20502 Malmo, Sweden.	jenny.persson@pat.mas.lu.se		Persson, Jenny/0000-0001-7682-7678				Ali IU, 2001, UROLOGY, V57, P143, DOI 10.1016/S0090-4295(00)00961-4; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Borre M, 2000, CLIN CANCER RES, V6, P1882; Chevalier S, 2002, MOL CELL ENDOCRINOL, V189, P169, DOI 10.1016/S0303-7207(01)00728-6; Coffey RNT, 2002, PROSTATE, V53, P300, DOI 10.1002/pros.10159; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Culig Z, 2002, MOL CELL ENDOCRINOL, V197, P231, DOI 10.1016/S0303-7207(02)00263-0; Dasgupta P, 2004, MOL CELL BIOL, V24, P9527, DOI 10.1128/MCB.24.21.9527-9541.2004; Ekberg J, 2004, ONCOGENE, V23, P9082, DOI 10.1038/sj.onc.1208090; Ferrer FA, 1997, J UROLOGY, V157, P2329, DOI 10.1016/S0022-5347(01)64775-X; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Haggstrom S, 1999, J UROLOGY, V161, P1620, DOI 10.1016/S0022-5347(05)68994-X; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Hrouda D, 2003, UROL RES, V30, P347, DOI 10.1007/s00240-002-0287-9; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jackson MW, 2002, CANCER RES, V62, P854; Jozkowicz A, 2004, BIOCHEM BIOPH RES CO, V314, P31, DOI 10.1016/j.bbrc.2003.12.059; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kimura K, 2001, CANCER RES, V61, P5611; Klocker H, 1999, EUR UROL, V35, P413, DOI 10.1159/000019918; Liao C, 2004, INT J CANCER, V108, P654, DOI 10.1002/ijc.11573; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; LILJA H, 1991, CLIN CHEM, V37, P1618; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Lu JM, 1998, J BIOL CHEM, V273, P31528, DOI 10.1074/jbc.273.47.31528; Marker PC, 2003, DEV BIOL, V253, P165, DOI 10.1016/S0012-1606(02)00031-3; Muller-Tidow C, 2003, CANCER LETT, V190, P89, DOI 10.1016/S0304-3835(02)00582-7; Nicholson B, 2004, J CELL BIOCHEM, V91, P125, DOI 10.1002/jcb.10772; Porkka KP, 2004, EUR UROL, V45, P683, DOI 10.1016/j.eururo.2004.01.012; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Strohmeyer D, 2000, PROSTATE, V45, P216, DOI 10.1002/1097-0045(20001101)45:3<216::AID-PROS3>3.0.CO;2-C; Suzuki H, 2003, ENDOCR-RELAT CANCER, V10, P209, DOI 10.1677/erc.0.0100209; Sweeney C, 1996, DEVELOPMENT, V122, P53; Taneja SS, 2002, J CELL BIOCHEM, V84, P188, DOI 10.1002/jcb.1278; Tokumaru Y, 2004, CANCER RES, V64, P5982, DOI 10.1158/0008-5472.CAN-04-0993; van Moorselaar RJA, 2002, MOL CELL ENDOCRINOL, V197, P239, DOI 10.1016/S0303-7207(02)00262-9; Yang R, 1999, MOL CELL BIOL, V19, P2400; Yang R, 1997, CANCER RES, V57, P913	39	46	47	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6385	6393		10.1038/sj.onc.1208795	http://dx.doi.org/10.1038/sj.onc.1208795			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007189				2022-12-17	WOS:000232038200006
J	Qiu, HQ; Zappacosta, F; Su, WJ; Annan, RS; Miller, WT				Qiu, HQ; Zappacosta, F; Su, WJ; Annan, RS; Miller, WT			Interaction between Brk kinase and insulin receptor substrate-4	ONCOGENE			English	Article						Brk; tyrosine kinase; IRS-4	NONRECEPTOR TYROSINE KINASE; MAMMARY EPITHELIAL-CELLS; GROWTH-FACTOR; GASTROINTESTINAL-TRACT; THERAPEUTIC TARGET; PROTEIN; EXPRESSION; PROLIFERATION; DIFFERENTIATION; IDENTIFICATION	Breast tumor kinase (Brk) is a member of the Frk family of nonreceptor tyrosine kinases that is overexpressed in a high percentage of human breast tumors. The downstream substrates and effectors of Brk remain largely unidentified. In this study, we carried out immunoprecipitation and mass spectrometry experiments to identify new Brk binding partners. One interacting protein was insulin receptor substrate 4 (IRS-4), a member of the IRS family. We confirmed that Brk associates with IRS-4 in resting and insulin-like growth factor 1 (IGF-1)-stimulated HEK 293 cells. The SH3 and SH2 domains of Brk are both involved in the association. The tyrosine phosphorylation of Brk increases after stimulation with IGF-1, and in MCF-7 breast cancer cells we show that the presence of IRS-4 enhances this effect. Finally, we demonstrate that endogenous Brk and IRS-4 interact in A431 human epidermoid carcinoma cells.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; GlaxoSmithKline Pharmaceut, Dept Computat Analyt & Struct Sci, Proteom & Biol Mass Spect Lab, King Of Prussia, PA 19406 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; GlaxoSmithKline	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Basic Sci Tower,T-6, Stony Brook, NY 11794 USA.	todd.miller@stonybrook.edu			NCI NIH HHS [CA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Derry JJ, 2003, ONCOGENE, V22, P4212, DOI 10.1038/sj.onc.1206465; Escribano O, 2003, HEPATOLOGY, V37, P1461, DOI 10.1053/jhep.2003.50245; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; Fantin VR, 1999, BIOCHEM BIOPH RES CO, V260, P718, DOI 10.1006/bbrc.1999.0967; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; Harvey AJ, 2004, ANTI-CANCER DRUG, V15, P107, DOI 10.1097/01.cad.0000113339.62364.b5; Harvey AJ, 2003, ONCOGENE, V22, P5006, DOI 10.1038/sj.onc.1206577; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Karas M, 2001, ENDOCRINOLOGY, V142, P1835, DOI 10.1210/en.142.5.1835; Koval AP, 1998, J BIOL CHEM, V273, P14780, DOI 10.1074/jbc.273.24.14780; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Lingohr MK, 2003, MOL CELL ENDOCRINOL, V209, P17, DOI 10.1016/j.mce.2003.08.003; Llor X, 1999, CLIN CANCER RES, V5, P1767; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Qiu HQ, 2004, ONCOGENE, V23, P2216, DOI 10.1038/sj.onc.1207339; Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200; Qu BH, 1999, J BIOL CHEM, V274, P31179, DOI 10.1074/jbc.274.44.31179; Sesti G, 2001, FASEB J, V15, P2099, DOI 10.1096/fj.01-0009rev; Sesti G, 2000, Pharmacogenomics, V1, P343, DOI 10.1517/14622416.1.3.343; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; Tseng YH, 2004, MOL CELL BIOL, V24, P1918, DOI 10.1128/MCB.24.5.1918-1929.2004; Uchida T, 2000, MOL CELL BIOL, V20, P126, DOI 10.1128/MCB.20.1.126-138.2000; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; Zhang P, 2005, J BIOL CHEM, V280, P1982, DOI 10.1074/jbc.M412038200	34	46	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5656	5664		10.1038/sj.onc.1208721	http://dx.doi.org/10.1038/sj.onc.1208721			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	15870689				2022-12-17	WOS:000231296100012
J	Lesca, C; Germanier, M; Raynaud-Messina, B; Pichereaux, C; Etievant, C; Emond, S; Burlet-Schiltz, O; Monsarrat, B; Wright, M; Defais, M				Lesca, C; Germanier, M; Raynaud-Messina, B; Pichereaux, C; Etievant, C; Emond, S; Burlet-Schiltz, O; Monsarrat, B; Wright, M; Defais, M			DNA damage induce gamma-tubulin-RAD51 nuclear complexes in mammalian cells	ONCOGENE			English	Article						DNA lesions; Rad51 recombinase complex; gamma-tubulin; nuclear foci	GAMMA-TUBULIN COMPLEXES; STRAND BREAK REPAIR; HUMAN RAD51 PROTEIN; HOMOLOGOUS RECOMBINATION; MICROTUBULE NUCLEATION; MITOTIC SPINDLE; CANCER SUSCEPTIBILITY; IONIZING-RADIATION; CHROMOSOMAL BREAKS; CENTROSOME	Rad51 protein plays an essential role in recombination repair of DNA double-strand breaks and DNA cross-linking adducts. It is part of complexes which can vary with the stage of the cell cycle and the nature of the DNA lesions. During a search for Rad51-associated proteins in CHO nuclear extracts of S-phase cells by mass spectrometry of proteins immunoprecipitated with Rad51 antibodies, we identified a centrosomal protein, c-tubulin. This association was confirmed by the reverse immunoprecipitation with gamma-tubulin antibodies. Both proteins copurified from HeLa cells nuclear extracts following a tandem affinity purification of double-tagged Rad51. Immuno. fluorescence analysis showed colocalization of both Rad51 and gamma-tubulin in discrete foci in mammalian cell nuclei. The number of colocalized foci and their overlapping area increased in the presence of DNA damage produced by genotoxic treatments either during S phase or in exponentially growing cells. These variations did not result from an overall stress because microtubule cytoskeleton poisons devoid of direct interactions with DNA, such as taxol or colcemid, did not lead to an increase of this association. The recruitment of Rad51 and gamma-tubulin in the same nuclear complex suggests a link between DNA recombination repair and the centrosome function during the cell cycle.	Univ Toulouse 3, CNRS, UMR 5089, IPBS, F-31077 Toulouse, France; CNRS, ISTMT, CRPS, UMR2587, F-31400 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Defais, M (corresponding author), Univ Toulouse 3, CNRS, UMR 5089, IPBS, 205 Route Narbonne, F-31077 Toulouse, France.	martine.defais@ipbs.fr		Pichereaux, Carole/0000-0002-7559-5358; Emond, Stephane/0000-0002-5160-0917; Schiltz, Odile/0000-0002-3606-2356				Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Arnaudeau C, 1999, J MOL BIOL, V289, P1231, DOI 10.1006/jmbi.1999.2856; Bertrand P, 2003, ONCOGENE, V22, P7587, DOI 10.1038/sj.onc.1206998; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Feng Y, 1999, BIOCHEM J, V339, P435, DOI 10.1042/0264-6021:3390435; Fukushima T, 2001, J BIOL CHEM, V276, P44413, DOI 10.1074/jbc.M106295200; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Haaf T, 1999, J CELL BIOL, V144, P11, DOI 10.1083/jcb.144.1.11; Herreros L, 2000, J BIOL CHEM, V275, P26436, DOI 10.1074/jbc.M003970200; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hung LY, 2000, MOL CELL BIOL, V20, P7813, DOI 10.1128/MCB.20.20.7813-7825.2000; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; Job D, 2003, CURR OPIN CELL BIOL, V15, P111, DOI 10.1016/S0955-0674(02)00003-0; JULIAN M, 1993, J CELL SCI, V105, P145; Korver W, 2003, INT J CANCER, V104, P283, DOI 10.1002/ijc.10945; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Kukharskyy V, 2004, EXP CELL RES, V298, P218, DOI 10.1016/j.yexcr.2004.04.016; LAJOIEMAZENC I, 1994, J CELL SCI, V107, P2825; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Linke SP, 2003, CANCER RES, V63, P2596; Lisby M, 2003, CELL CYCLE, V2, P479, DOI 10.4161/cc.2.5.483; Maacke H, 2000, INT J CANCER, V88, P907, DOI 10.1002/1097-0215(20001215)88:6<907::AID-IJC11>3.0.CO;2-4; MARGULIS TN, 1974, J AM CHEM SOC, V96, P899, DOI 10.1021/ja00810a041; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 2001, CANCER RES, V61, P4842; Pellegrini L, 2004, TRENDS BIOCHEM SCI, V29, P310, DOI 10.1016/j.tibs.2004.04.009; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rios RM, 2004, CELL, V118, P323; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Takada S, 2003, CELL, V113, P87, DOI 10.1016/S0092-8674(03)00202-2; Takahashi M, 2002, MOL BIOL CELL, V13, P3235, DOI 10.1091/mbc.E02-02-0112; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tarsounas M, 2003, ONCOGENE, V22, P1115, DOI 10.1038/sj.onc.1206263; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Tashiro S, 1996, ONCOGENE, V12, P2165; Thompson HM, 2004, NAT CELL BIOL, V6, P335, DOI 10.1038/ncb1112; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Tutt A, 2002, TRENDS MOL MED, V8, P571, DOI 10.1016/S1471-4914(02)02434-6; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; Wiese C, 1999, CURR OPIN STRUC BIOL, V9, P250, DOI 10.1016/S0959-440X(99)80035-9; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yoshikawa K, 2000, INT J CANCER, V88, P28, DOI 10.1002/1097-0215(20001001)88:1<28::AID-IJC5>3.0.CO;2-4; Yuan SSF, 1999, CANCER RES, V59, P3547; Zhao JH, 2003, J CELL SCI, V116, P4011, DOI 10.1242/jcs.00700	60	46	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5165	5172		10.1038/sj.onc.1208723	http://dx.doi.org/10.1038/sj.onc.1208723			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897881				2022-12-17	WOS:000230964600003
J	Majeed, N; Blouin, MJ; Kaplan-Lefko, PJ; Barry-Shaw, J; Greenberg, NM; Gaudreau, P; Bismar, TA; Pollak, M				Majeed, N; Blouin, MJ; Kaplan-Lefko, PJ; Barry-Shaw, J; Greenberg, NM; Gaudreau, P; Bismar, TA; Pollak, M			A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model	ONCOGENE			English	Article						lit; TRAMP; prostate carcinogenesis; survival	GROWTH-FACTOR-I; HORMONE RECEPTOR; MUTANT MICE; RISK; GHRH; EXPRESSION; PHENOTYPE; SYSTEM; DWARF	Circulating insulin-like growth factor-I (IGF-I) levels have been shown to be related to risk of prostate cancer in epidemiologic studies. While specific genetic loci responsible for interindividual variation in circulating IGF-I levels in normal men have not been identified, candidate genes include those involved in the growth hormone (GH) IGF-I axis such as the hypothalamic factors GH releasing hormone (GHRH) and somatostatin and their receptors. To investigate the role of the GH-IGF-I axis on in vivo prostate carcinogenesis and neoplastic progression, we generated mice genetically predisposed to prostate cancer (the TRAMP model) to be homozygous for lit, a mutation that inactivates the GHRH receptor (GHRH-R) and reduces circulating levels of GH and IGF-I. The lit mutation significantly reduced the percentage of the prostate gland showing neoplastic changes at 35 weeks of age (P = 0.0005) and was also associated with improved survival (P < 0.01). These data provide an example of a germ line mutation that reduces risk in an experimental prostate carcinogenesis model. The results suggest that prostate carcinogenesis and progression may be influenced by germ line variation of genes encoding signalling molecules in the GH-IGF-I axis.	McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; Univ Montreal, Dept Med, Lab Neuroendocrinol Aging, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Pathol, Montreal, PQ, Canada	Lady Davis Institute; McGill University; McGill University; Baylor College of Medicine; Fred Hutchinson Cancer Center; Universite de Montreal; McGill University	Pollak, M (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	michael.pollak@mcgill.ca	Pollak, Michael/G-9094-2011	Pollak, Michael/0000-0003-3047-0604				Aleppo G, 1997, ENDOCRINOLOGY, V138, P1058, DOI 10.1210/en.138.3.1058; Arantes-Oliveira N, 2003, SCIENCE, V302, P611, DOI 10.1126/science.1089169; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chandrashekar V, 2004, BIOL REPROD, V71, P17, DOI 10.1095/biolreprod.103.027060; Chopin LK, 2001, PROSTATE, V49, P116, DOI 10.1002/pros.1125; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; CULIG Z, 1994, CANCER RES, V54, P5474; Dillin A, 2002, SCIENCE, V298, P830, DOI 10.1126/science.1074240; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; Gingrich JR, 1999, PROSTATE CANCER P D, V2, P70, DOI 10.1038/sj/pcan/4500296; GODFREY P, 1993, NAT GENET, V4, P227, DOI 10.1038/ng0793-227; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Harrela M, 1996, J CLIN INVEST, V98, P2612, DOI 10.1172/JCI119081; Hellawell GO, 2002, CANCER RES, V62, P2942; HOLZENBERGER M, 2002, NATURE, V421, P125; JANSSON JO, 1986, SCIENCE, V232, P511, DOI 10.1126/science.3008329; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; Letsch M, 2003, P NATL ACAD SCI USA, V100, P1250, DOI 10.1073/pnas.0337496100; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; Longo VD, 2003, SCIENCE, V299, P1342, DOI 10.1126/science.1077991; Maheshwari HG, 1998, J CLIN ENDOCR METAB, V83, P4065, DOI 10.1210/jc.83.11.4065; O'Connor R, 2000, BIOCHEM SOC T, V28, P47, DOI 10.1042/bst0280047; Peng XD, 2001, ENDOCRINOLOGY, V142, P1117, DOI 10.1210/en.142.3.1117; Pollak M, 1998, CANCER METAST REV, V17, P383, DOI 10.1023/A:1006154108619; Pollak M, 2001, EPIDEMIOL REV, V23, P59, DOI 10.1093/oxfordjournals.epirev.a000796; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Shaneyfelt T, 2000, J CLIN ONCOL, V18, P847, DOI 10.1200/JCO.2000.18.4.847; Stattin P, 2004, J CLIN ONCOL, V22, P3104, DOI 10.1200/JCO.2004.10.105; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Tissenbaum HA, 2002, DEV CELL, V2, P9, DOI 10.1016/S1534-5807(01)00098-3; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Wajnrajch MP, 1996, NAT GENET, V12, P88, DOI 10.1038/ng0196-88; Wang J, 2004, MOL CELL ENDOCRINOL, V219, P171, DOI 10.1016/j.mce.2003.12.018; Wolk A, 1998, J NATL CANCER I, V90, P911, DOI 10.1093/jnci/90.12.911	37	46	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4736	4740		10.1038/sj.onc.1208572	http://dx.doi.org/10.1038/sj.onc.1208572			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15870705				2022-12-17	WOS:000230304500012
J	Xie, Q; Gao, CF; Shinomiya, N; Sausville, E; Hay, R; Gustafson, M; Shen, YH; Wenkert, D; Vande Woude, GF				Xie, Q; Gao, CF; Shinomiya, N; Sausville, E; Hay, R; Gustafson, M; Shen, YH; Wenkert, D; Vande Woude, GF			Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion	ONCOGENE			English	Article						geldanamycin; HGF/SF; Met; HSP90; uPA; molecular target; urokinase-type plasminogen activator	UROKINASE PLASMINOGEN-ACTIVATOR; SHOCK-PROTEIN 90; MOLECULAR CHAPERONES; BREAST-CANCER; IN-VIVO; GROWTH; RECEPTOR; MET; DEGRADATION; EXPRESSION	Induction of the urokinase-type plasminogen activator (uPA) by hepatocyte growth factor/scatter factor (HGF/ SF) plays an important role in tumor cell invasion and metastasis that is mediated through the Met receptor tyrosine kinase. Geldanamycins (GA) are antitumor drugs that bind and inhibit HSP90 chaperone activity at nanomolarconcent rations (nM-GAi) by preventing proper folding and functioning of certain oncoproteins. Previously, we have shown that a subset of GA derivatives exhibit exquisite potency, inhibiting HGF/ SF-induced uPA-plasmin activation at femtomolarconcent rations (fM-GAi) in canine MDCK cells. Here, we report that ( 1) inhibition of HGF/ SF-induced uPA activity by fM-GAi is not uncommon, in that several human tumor glioblastoma cell lines (DBTRG, U373 and SNB19), as well as SK-LMS-1 human leiomyosarcoma cells are also sensitive to fM-GAi; ( 2) fM-GAi drugs only display inhibitory activity against HGF/SF-induced uPA activity ( rather than basal activity), and only when the observed magnitude of uPA activity induction by HGF/ SF is at least 1.5 times basal uPA activity; and ( 3) not only do fM-GAi derivatives strongly inhibit uPA activity but they also block MDCK cell scattering and in vitro invasion of human glioblastoma cells at similarly low drug concentrations. These effects of fM-GAi drugs on the Met-activated signaling pathway occur at concentrations well below those required to measurably affect Met expression or cell proliferation. We also examined the effect of Radicicol ( RA), a drug with higher affinity than GA for HSP90. RA displays uPA activity inhibition at nanomolar levels, but not at lower concentrations, indicating that HSP90 is not likely the fM-GAi molecular tar get. Thus, we show that certain GA drugs ( fM-GAi) in an HGF/ SF-dependent mannerblock uPA-plasmin activation in tumor cells at femtomolar levels. This inhibition can also be observed in scattering and in vitro invasion assays. Our findings also provide strong circumstantial evidence for a novel non-HSP90 molecular target that is involved in HGF/SF-mediated tumor cell invasion.	Van Andel Res Inst, Mol Oncol Lab, Grand Rapids, MI 49503 USA; NCI, Dev Therapeut Program, Bethesda, MD 20892 USA; Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA	Van Andel Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Michigan State University	Vande Woude, GF (corresponding author), Van Andel Res Inst, Mol Oncol Lab, 333 Bostwick NE, Grand Rapids, MI 49503 USA.	michelle.reed@vai.org	Shen, Yuehai/J-7829-2012; Shinomiya, Nariyoshi/I-9666-2014					Bhattacharya A, 2001, CLIN CANCER RES, V7, P267; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; Bonvini P, 2001, CANCER RES, V61, P1671; Chavany C, 1996, J BIOL CHEM, V271, P4974; Duffy MJ, 1996, ENZYME PROTEIN, V49, P85, DOI 10.1159/000468618; Duffy MJ, 1996, CLIN CANCER RES, V2, P613; ELLIS V, 1993, METHOD ENZYMOL, V223, P223; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; GLADSON CL, 1995, AM J PATHOL, V146, P1150; Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316; Gondi CS, 2003, ONCOGENE, V22, P5967, DOI 10.1038/sj.onc.1206535; Harbeck N, 2002, CANCER RES, V62, P4617; Hattori N, 2004, AM J PATHOL, V164, P1091, DOI 10.1016/S0002-9440(10)63196-3; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Koochekpour S, 1997, CANCER RES, V57, P5391; Lakka SS, 2003, CANCER RES, V63, P2454; LEE YB, 1995, J MED CHEM, V38, P3053, DOI 10.1021/jm00016a008; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Maulik G, 2002, CLIN CANCER RES, V8, P620; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Nimmanapalli R, 2001, CANCER RES, V61, P1799; Ochel HJ, 2001, CELL STRESS CHAPERON, V6, P105, DOI 10.1379/1466-1268(2001)006<0105:GTPOAC>2.0.CO;2; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; Schweinitz A, 2004, J BIOL CHEM, V279, P33613, DOI 10.1074/jbc.M314151200; Solit DB, 2002, CLIN CANCER RES, V8, P986; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Tacchini L, 2003, EXP CELL RES, V290, P391, DOI 10.1016/S0014-4827(03)00348-3; Tikhomirov O, 2000, J BIOL CHEM, V275, P26625, DOI 10.1074/jbc.M003114200; Webb CP, 2000, CANCER RES, V60, P342; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; YAMAMOTO M, 1994, CANCER RES, V54, P3656; Yang J, 2001, CANCER RES, V61, P4010; Zhang X, 2000, J CLIN NEUROSCI, V7, P116, DOI 10.1054/jocn.1999.0161	41	46	53	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3697	3707		10.1038/sj.onc.1208499	http://dx.doi.org/10.1038/sj.onc.1208499			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782129				2022-12-17	WOS:000229346300001
J	Matthess, Y; Kappel, S; Spankuch, B; Zimmer, B; Kaufmann, M; Strebhardt, K				Matthess, Y; Kappel, S; Spankuch, B; Zimmer, B; Kaufmann, M; Strebhardt, K			Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1	ONCOGENE			English	Article						RNA interference; H1 promoter; doxycycline; polo-like kinase 1	RNA-POLYMERASE-III; POLO-LIKE KINASE; MAMMARY-TUMOR VIRUS; CIS-ACTING ELEMENTS; SHORT HAIRPIN RNAS; GENE-EXPRESSION; DOWN-REGULATION; TRANSCRIPTION; CENTROSOME; ACTIVATION	RNA interference (RNAi) is a powerful tool for studying gene function. We developed an inducible genetic element for short interfering RNA-mediated gene silencing. This system uses a tetracycline (Tet)-responsive derivative of the H1 promoter and the Tet repressor (TetR) for conditional expression of short hairpin RNA (shRNA) in HeLa cells. Promoter constructs were generated, which contain the Tet operator (TetO) derived from a prokaryotic Tet resistance transposon upstream and/or downstream of the TATA box. To quantify the response of controllable transcription units for shRNA expression, we examined the functional activity of polo-like kinase 1 (PLK1), a key component of mitotic progression, that is overexpressed in many human tumors. Cotransfection of plasmids for the expression of TetR and shRNA/PLK1 under the control of an H1 promoter-variant carrying TetO upstream of the TATA box did not alter PLK1 expression and proliferation properties of HeLa cells in the absence of doxycycline. Addition of the antibiotic led to marked downregulation of endogenous PLK1 accompanied by strong inhibition of cellular proliferation. Our data indicate that an inducible transcription system for shRNAs based on the human H1 promoter could be a versatile tool for controlled gene silencing in vitro.	Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Strebhardt, K (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Theodor Stern Kai 7,Haus 15, D-60590 Frankfurt, Germany.	strebhardt@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; BRINSTER RL, 1982, NATURE, V296, P39, DOI 10.1038/296039a0; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Chong SS, 2001, J BIOL CHEM, V276, P20727, DOI 10.1074/jbc.M100088200; DANZEISER DA, 1993, MOL CELL BIOL, V13, P4670, DOI 10.1128/MCB.13.8.4670; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; DINGERMANN T, 1992, EMBO J, V11, P1487, DOI 10.1002/j.1460-2075.1992.tb05193.x; DINGERMANN T, 1992, MOL CELL BIOL, V12, P4038, DOI 10.1128/MCB.12.9.4038; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HANNON GJ, 1991, J BIOL CHEM, V266, P22796; HILLEN W, 1984, J MOL BIOL, V172, P185, DOI 10.1016/S0022-2836(84)80037-6; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; HYNES NE, 1981, P NATL ACAD SCI-BIOL, V78, P2038, DOI 10.1073/pnas.78.4.2038; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; LOBO SM, 1990, NUCLEIC ACIDS RES, V18, P2891, DOI 10.1093/nar/18.10.2891; Luukkonen BGM, 1998, RNA, V4, P231; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; Mittal V, 1996, MOL CELL BIOL, V16, P1955; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; Myslinski E, 2001, NUCLEIC ACIDS RES, V29, P2502, DOI 10.1093/nar/29.12.2502; Noonberg SB, 1996, J BIOL CHEM, V271, P10477, DOI 10.1074/jbc.271.18.10477; NOUER L, 1991, HEAT SHOCK RESPONSE, P167; Ohkawa J, 2000, HUM GENE THER, V11, P577, DOI 10.1089/10430340050015761; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Spankuch B, 2004, JNCI-J NATL CANCER I, V96, P862, DOI 10.1093/jnci/djh146; SPANKUCH B, 2004, IN PRESS CURR PHARM; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; STREBHARDT K, 2001, ENCY MOL MED, P2530; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Watanabe Y, 2003, NAT CELL BIOL, V5, P379, DOI 10.1038/ncb0503-379; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Yuan JP, 1997, AM J PATHOL, V150, P1165	44	46	55	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2973	2980		10.1038/sj.onc.1208472	http://dx.doi.org/10.1038/sj.onc.1208472			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735719				2022-12-17	WOS:000228649500006
J	Muranen, T; Gronholm, MG; Renkema, GH; Carpen, O				Muranen, T; Gronholm, MG; Renkema, GH; Carpen, O			Cell cycle-dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor merlin	ONCOGENE			English	Article						merlin; NF2; ERM; nucleus; cell cycle	TYPE-2 GENE-PRODUCT; ERM PROTEINS; P21-ACTIVATED KINASE; NUCLEAR EXPORT; GROWTH; LOCALIZATION; PHOSPHORYLATION; INHIBITION; ADHESION; SIGNAL	The neurofibromatosis 2 tumour suppressor merlin/schwannomin is structurally related to the ezrin-radixin-moesin family of proteins, which anchor actin cytoskeleton to specific membrane proteins and participate in cell signalling. Merlin inhibits cell growth with a yet unknown mechanism. As most tumour suppressors are linked to cell cycle control, we investigated merlin's behaviour during cell cycle. In glioma and osteosarcoma cells, endogenous merlin was targeted to the nucleus in a cell cycle-specific manner. Merlin accumulated perinuclearly at the G2/M phase, and shifted to the nucleus at early G1. During mitosis, merlin localized to mitotic spindles and at the contractile ring. Nuclear merlin was strongly reduced in confluent cells. Blocking of the CRM1/exportin nuclear export pathway led to accumulation of merlin in the nucleus. Activation of the p21-activated kinase or protein kinase A, which result in phosphorylation of merlin, did not affect its nuclear localization. Merlin regulates the activity of extracellular signal-regulated kinase 2 (ERK2) and nuclear localization of both proteins was induced by cell adhesion. Unlike ERK2, nuclear localization of merlin was not, however, dependent on intact actin cytoskeleton. These results link merlin to events related to cell cycle control and may help to resolve its tumour suppressor function.	Univ Helsinki, Neurosci Program, Biomedicum Helsinki, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Helsinki Hosp, Helsinki 00014, Finland; Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Tampere University; Tampere University; Tampere University Hospital	Muranen, T (corresponding author), Univ Helsinki, Neurosci Program, Biomedicum Helsinki, Dept Pathol, PB 63, FIN-00014 Helsinki, Finland.	taru.muranen@helsinki.fi	Renkema, Herma/L-1489-2015; Muranen, Taru/AAM-9349-2021	Renkema, Herma/0000-0002-8174-6538; Muranen, Taru/0000-0003-4158-9002; Gronholm, Mikaela/0000-0002-2378-8924				Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Aplin AE, 2003, FEBS LETT, V534, P11, DOI 10.1016/S0014-5793(02)03840-1; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Baser ME, 2003, CURR OPIN NEUROL, V16, P27, DOI 10.1097/00019052-200302000-00004; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Burke B, 2002, NAT REV MOL CELL BIO, V3, P487, DOI 10.1038/nrm860; CORREAS I, 1991, BIOCHEM J, V279, P581, DOI 10.1042/bj2790581; DeCarcer G, 1995, BIOCHEM J, V312, P871, DOI 10.1042/bj3120871; DENBAKKER MA, 1995, ONCOGENE, V10, P757; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Gascard P, 1999, MOL BIOL CELL, V10, P1783, DOI 10.1091/mbc.10.6.1783; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Giovannini M, 2000, GENE DEV, V14, P1617; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; Gronholm M, 1999, J CELL SCI, V112, P895; GUSELLA JF, 1999, BIOCHIM BIOPHYS ACTA, V1423, P29; Huynh DP, 1996, ONCOGENE, V13, P73; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; Kressel M, 2002, HUM MOL GENET, V11, P2269, DOI 10.1093/hmg/11.19.2269; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lallena MJ, 1997, J CELL SCI, V110, P239; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lim JY, 2003, BIOCHEM BIOPH RES CO, V302, P238, DOI 10.1016/S0006-291X(03)00124-4; Lohez OD, 2003, J CELL BIOL, V161, P67, DOI 10.1083/jcb.200208140; LUTCHMAN M, 1995, CANCER RES, V55, P2270; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; McClatchey AI, 2003, NAT REV CANCER, V3, P877, DOI 10.1038/nrc1213; Sainio M, 1997, J CELL SCI, V110, P2249; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; Shaw RJ, 1998, CELL GROWTH DIFFER, V9, P287; Shollar D, 2004, ONCOGENE, V23, P5459, DOI 10.1038/sj.onc.1207728; Vanhoutte P, 2001, J BIOL CHEM, V276, P5189, DOI 10.1074/jbc.M006678200; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	41	46	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2005	24	7					1150	1158		10.1038/sj.onc.1208283	http://dx.doi.org/10.1038/sj.onc.1208283			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15580288				2022-12-17	WOS:000226898700003
J	Myer, DL; Bahassi, EM; Stambrook, PJ				Myer, DL; Bahassi, EM; Stambrook, PJ			The Plk3-Cdc25 circuit	ONCOGENE			English	Article						Polo-like kinases; Cdc25 phosphatases; phosphorylation; cell-cycle regulation	POLO-LIKE KINASE; CELL-CYCLE PROGRESSION; ANAPHASE-PROMOTING COMPLEX; XENOPUS CDC25 PHOSPHATASE; INTEGRIN-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; SERINE/THREONINE KINASE; CRYSTAL-STRUCTURE; DNA-DAMAGE; PHOSPHORYLATES CDC2	Polo-like kinases (Plks) are key regulators of the cell cycle, especially in the G2 phase and mitosis. They are incorporated into signaling networks that regulate many aspects of the cell cycle, including but not limited to centrosome maturation and separation, mitotic entry, chromosome segregation, mitotic exit, and cytokinesis. The Plks have well conserved 30-amino-acid elements, designated polo boxes (PBs), located in their carboxyl-termini, which with their flanking regions constitute a functional Polo-box domain (PBD). Members of the Plk family exist in a variety of organisms including Polo in Drosophila melanogaster; Cdc5 in Saccharomyces cerevisiae; Plo1 in Schizosaccharomyces pombe; Plx1 in Xenopus laevis; and Plk1, Snk/Plk2, Fnk/Prk/Plk3, and Sak in mammals. Polo, Cdc5, and Plo1 are essential for viability. The Plks can be separated into two groups according to their functions. The first group ( Polo, Cdc5, plo1, Plx1, and Plk1) primarily performs mitotic functions, whereas the second group (Plk2 and Plk3) appears to have additional functions during the G1, S, and G2 phases of the cell cycle. Several contributions to this issue will discuss different aspects of Plk involvement in cell-cycle regulation. This review, therefore, will focus on the role of Plk3 in regulating Cdc25 phosphatase function and its effect on the cell cycle.	Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Stambrook, PJ (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, 3125 Eden Ave, Cincinnati, OH 45267 USA.	peter.stambrook@uc.edu			NATIONAL CANCER INSTITUTE [R01CA090934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250, U01ES011038, P30ES006096] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA90934] Funding Source: Medline; NIEHS NIH HHS [P30 ES05652, U01 ES011038, T32 ES07250, P30-ES06096] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abrieu A, 1998, J CELL SCI, V111, P1751; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; Bahassi ELM, 2004, ONCOGENE, V23, P2658, DOI 10.1038/sj.onc.1207425; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Bartholomew CR, 2001, MOL CELL BIOL, V21, P4949, DOI 10.1128/MCB.21.15.4949-4959.2001; Bernardi R, 2000, ONCOGENE, V19, P2447, DOI 10.1038/sj.onc.1203564; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Brassac T, 2000, ONCOGENE, V19, P3782, DOI 10.1038/sj.onc.1203724; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Chase D, 1998, BIOCHEM J, V333, P655, DOI 10.1042/bj3330655; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Conn CW, 2000, CANCER RES, V60, P6826; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Eckstein J., 1997, BIOCHIM BIOPHYS ACTA, V1332, P53; ELIA AE, 2003, SCIENCE, V299, P1190; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; Giles N, 2003, J BIOL CHEM, V278, P28580, DOI 10.1074/jbc.M304027200; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Holtrich U, 2000, ONCOGENE, V19, P4832, DOI 10.1038/sj.onc.1203845; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; Karaiskou A, 2004, DEVELOPMENT, V131, P1543, DOI 10.1242/dev.01050; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lammer C, 1998, J CELL SCI, V111, P2445; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; Ma S, 2003, MOL CANCER RES, V1, P376; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Margolis SS, 2003, EMBO J, V22, P5734, DOI 10.1093/emboj/cdg545; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; Nurse P, 1998, NAT MED, V4, P1103, DOI 10.1038/2594; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Okano-Uchida T, 2003, EMBO J, V22, P5633, DOI 10.1093/emboj/cdg535; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Reynolds RA, 1999, J MOL BIOL, V293, P559, DOI 10.1006/jmbi.1999.3168; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Ruan Q, 2004, EXP CELL RES, V294, P51, DOI 10.1016/j.yexcr.2003.10.022; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Wilborn M, 2001, BIOCHEMISTRY-US, V40, P14200, DOI 10.1021/bi015638h; Xie SQ, 2004, ONCOGENE, V23, P3822, DOI 10.1038/sj.onc.1207479; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	94	46	48	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					299	305		10.1038/sj.onc.1208278	http://dx.doi.org/10.1038/sj.onc.1208278			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640846				2022-12-17	WOS:000226183100011
J	Michod, D; Yang, JY; Chen, JH; Bonny, C; Widmann, C				Michod, D; Yang, JY; Chen, JH; Bonny, C; Widmann, C			A RasGAP-derived cell permeable peptide potently enhances genotoxin-induced cytotoxicity in tumor cells	ONCOGENE			English	Article						cancer; RasGAP; cell permeable peptides; TAT; genotoxins	NF-KAPPA-B; APOPTOSIS; TRANSDUCTION; INHIBITOR; DELIVERY; PROTECTS; CLEAVAGE	Treatment of many cancers relies on the combined action of several genotoxins, but the detrimental effect of these drugs on normal cells can cause severe side effects. One major challenge in anticancer therapy is therefore to increase the selectivity of current treatments toward cancer cells in order to spare normal cells. We have recently demonstrated that a RasGAP caspase cleavage fragment is able to sensitize HeLa cells towards cisplatin-induced apoptosis. Here, we extend this observation by showing that this fragment also enhances cell death induced by adriamycin and mitoxantrone, two other widely used genotoxins. Furthermore, we have delineated a short sequence within this fragment that still bears the genotoxin-sensitization property. The peptide encoded by this sequence, when fused to the TAT cell permeation sequence, potently sensitized a number of tumors cells, but not normal cells, towards apoptosis induced by cisplatin, adriamycin and mitoxantrone. This sensitization effect was not mediated through modulation of NFkappaB activity or activation of the JNK and p38 MAPK pathways. Our results demonstrate the feasibility in enhancing the efficacy of currently used drugs to selectively kill cancer cells using peptides derived from pro-apoptotic caspase substrate fragments.	Univ Lausanne, DBCM, CH-1005 Lausanne, Switzerland; CHU Vaudois, Med Genet Unit, CH-1011 Lausanne, Switzerland	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Widmann, C (corresponding author), Univ Lausanne, DBCM, Bugnon 9, CH-1005 Lausanne, Switzerland.	Christian.Widmann@ibcm.unil.ch	Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363; Michod, David/0000-0002-4187-405X				Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Yang JY, 2002, EUR CYTOKINE NETW, V13, P404; Yang JY, 2002, J BIOL CHEM, V277, P14641, DOI 10.1074/jbc.M111540200; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001	18	46	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8971	8978		10.1038/sj.onc.1207999	http://dx.doi.org/10.1038/sj.onc.1207999			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467750				2022-12-17	WOS:000225354600012
J	Perry, E; Tsruya, R; Levitsky, P; Pomp, O; Taller, M; Weisberg, S; Parris, W; Kulkarni, S; Malovani, H; Pawson, T; Shpungin, S; Nir, U				Perry, E; Tsruya, R; Levitsky, P; Pomp, O; Taller, M; Weisberg, S; Parris, W; Kulkarni, S; Malovani, H; Pawson, T; Shpungin, S; Nir, U			TMF/ARA160 is a BC-box-containing protein that mediates the degradation of Stat3	ONCOGENE			English	Article						TMF/AR160; Stat3; ubiquitination; degradation	TYROSINE KINASE FER; ELEMENT MODULATORY FACTOR; IN-VIVO; CARCINOMA CELLS; UBIQUITIN; PHOSPHORYLATION; INDUCTION; NUCLEAR; COMPLEX; GROWTH	TMF/ARA160 is a Golgi resident protein whose cellular functions have not been conclusively revealed. Herein we show that TMF/ARA160 can direct the proteasomal degradation of the key cell growth regulator-Stat3. TMF/ARA160 was dispersed in the cytoplasm of myogenic C2C12 cells that were grown under low-serum conditions. The cytoplasmic distribution of TMF/ARA160 was accompanied by its transient association with the tyrosine kinase Fer and with Stat3, which underwent proteasomal degradation under those conditions. Moreover, serum deprivation induced the association of ubiquitinated proteins, with the TMF/ARA160 complex. However, TMF/ARA160 did not bind Stat1, whose cellular levels were increased in serum-starved C2C12 cells. Amino-acid sequence analysis identified a BC-box element in TMF/ARA160 that mediated the binding of this protein to elongin C. Ectopic expression of TMF/ARA160 in serum-starved C2C12 cells drove the ubiquitination and proteasomal degradation of Stat3, an effect that was not caused by TMF/ARA160 devoid of the BC-box motif. Thus, the Golgi apparatus harbors a novel BC-box-containing protein that can direct Stat3 to proteasomal degradation. Interestingly, the level of TMF/ARA160 was significantly decreased in malignant brain tumors, implying a suppressive role of that protein in tumor progression.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; Rabin Med Ctr, Dept Oncol, Petah Tiqwa, Israel; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Bar Ilan University; Rabin Medical Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Nir, U (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.	nir@mail.biu.ac.il						Allard P, 2000, MOL CELL ENDOCRINOL, V159, P63, DOI 10.1016/S0303-7207(99)00205-1; Ben-Dor I, 1999, CELL GROWTH DIFFER, V10, P113; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2001, METHOD ENZYMOL, V333, P138; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chapman JR, 1999, MOL UROL, V3, P11; Colanzi A, 2003, CURR OPIN CELL BIOL, V15, P462, DOI 10.1016/S0955-0674(03)00067-X; Conaway JW, 1998, BBA-REV CANCER, V1377, pM49, DOI 10.1016/S0304-419X(97)00035-8; Craig AWB, 2001, MOL CELL BIOL, V21, P603, DOI 10.1128/MCB.21.2.603-613.2001; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Daino H, 2000, BLOOD, V95, P2577; DEAN BL, 1990, RADIOLOGY, V174, P411, DOI 10.1148/radiology.174.2.2153310; DEPREZ RHL, 1995, J NEUROPATH EXP NEUR, V54, P224, DOI 10.1097/00005072-199503000-00009; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; Fridmann-Sirkis Y, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-18; GARCIA JA, 1992, P NATL ACAD SCI USA, V89, P9372, DOI 10.1073/pnas.89.20.9372; Halachmy S, 1997, ONCOGENE, V14, P2871, DOI 10.1038/sj.onc.1201145; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HAO QL, 1991, MOL CELL BIOL, V11, P1180, DOI 10.1128/MCB.11.2.1180; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Jackson PK, 2002, MOL CELL, V9, P923, DOI 10.1016/S1097-2765(02)00538-5; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; Kamura Takumi, 2002, Prog Mol Subcell Biol, V29, P1; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; KIM L, 1995, MOL CELL BIOL, V15, P4553; Kronfeld-Kinar Y, 1999, CELL GROWTH DIFFER, V10, P201; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; LETWIN K, 1988, ONCOGENE, V3, P621; Lu ZM, 2001, MOL BIOL CELL, V12, P795, DOI 10.1091/mbc.12.4.795; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Magrassi L, 1999, J NEUROSURG, V91, P440, DOI 10.3171/jns.1999.91.3.0440; Mori K, 2002, FEBS LETT, V520, P127, DOI 10.1016/S0014-5793(02)02803-X; Orlovsky K, 2000, BIOCHEMISTRY-US, V39, P11084, DOI 10.1021/bi0005153; Orlovsky K, 2002, ONCOGENE, V21, P4997, DOI 10.1038/sj.onc.1205624; Paulson R, 1997, ONCOGENE, V14, P641, DOI 10.1038/sj.onc.1200875; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Priel-Halachmi S, 2000, J BIOL CHEM, V275, P28902, DOI 10.1074/jbc.M003402200; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Scheffler IE, 2001, ADV DRUG DELIVER REV, V49, P3, DOI 10.1016/S0169-409X(01)00123-5; Schwartz Y, 1998, FEBS LETT, V434, P339, DOI 10.1016/S0014-5793(98)01003-5; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Taler M, 2003, MOL ENDOCRINOL, V17, P1580, DOI 10.1210/me.2002-0328; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Weisberg S, 2001, AM J PATHOL, V159, P1193, DOI 10.1016/S0002-9440(10)62504-7; WILLIAMS RW, 1988, ANNU REV NEUROSCI, V11, P423, DOI 10.1146/annurev.ne.11.030188.002231; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhou YH, 2001, ONCOLOGY-BASEL, V60, P330, DOI 10.1159/000058529	55	46	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8908	8919		10.1038/sj.onc.1208149	http://dx.doi.org/10.1038/sj.onc.1208149			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467733				2022-12-17	WOS:000225354600006
J	Kawamura-Tsuzuku, J; Suzuki, T; Yoshida, Y; Yamamoto, T				Kawamura-Tsuzuku, J; Suzuki, T; Yoshida, Y; Yamamoto, T			Nuclear localization of Tob is important for regulation of its antiproliferative activity	ONCOGENE			English	Article						Tob; NLS; NES; antiproliferative activity; subcellular localization	EXPORT SIGNALS; NUCLEOCYTOPLASMIC TRANSPORT; PC3/BTG/TOB FAMILY; TOB/BTG1 FAMILY; PROTEIN BTG1; MICE LACKING; REV PROTEIN; IDENTIFICATION; MEMBER; GENE	tob is a member of an antiproliferative gene family that includes btg1, pc3/tis21/btg2, pc3b, ana/btg3, and tob2. Exogenous overexpression of the family proteins suppresses cell proliferation. These proteins participate in transcriptional regulation of several genes. Here, we show that Tob is a nuclear protein that is imported into the nucleus through a nuclear localization signal (NLS)mediated mechanism. Mutation in the NLS sequence of Tob affects its nuclear localization and impairs antiproliferative activity. Additionally, Tob contains a nuclear export signal (NES). In oncogenic ErbB2-transformed cells, nuclear export of Tob is facilitated by NES-mediated mechanism, resulting in decrease of its antiproliferative activity. These results indicate that regulation of nuclear localization of Tob is important for its antiproliferative activity.	Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp						ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; Bear J, 1999, MOL CELL BIOL, V19, P6306; Bogdan JA, 1998, BIOCHEM J, V336, P471, DOI 10.1042/bj3360471; Buanne P, 2000, GENOMICS, V68, P253, DOI 10.1006/geno.2000.6288; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; Luo JC, 2001, ONCOGENE, V20, P1435, DOI 10.1038/sj.onc.1204228; MARCHAL S, 1993, BIOL CELL, V78, P191, DOI 10.1016/0248-4900(93)90129-3; MARCHAL S, 1995, EXP CELL RES, V220, P1, DOI 10.1006/excr.1995.1285; MARSHALL CJ, 1995, METHOD ENZYMOL, V255, P273; Matsuda S, 1996, ONCOGENE, V12, P705; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakamura T, 2004, NAT GENET, V36, P528, DOI 10.1038/ng1344; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; Rodier A, 2001, ONCOGENE, V20, P2691, DOI 10.1038/sj.onc.1204398; Rodier A, 1999, EXP CELL RES, V249, P337, DOI 10.1006/excr.1999.4486; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Sasajima H, 2002, EUR J BIOCHEM, V269, P3596, DOI 10.1046/j.1432-1033.2002.03052.x; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Yoshida Y, 1998, ONCOGENE, V16, P2687, DOI 10.1038/sj.onc.1201805; Yoshida Y, 2003, GENE DEV, V17, P1201, DOI 10.1101/gad.1088003	45	46	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6630	6638		10.1038/sj.onc.1207890	http://dx.doi.org/10.1038/sj.onc.1207890			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15235587				2022-12-17	WOS:000223530800010
J	Honda, K; Yamada, T; Seike, M; Hayashida, Y; Idogawa, M; Kondo, T; Ino, Y; Hirohashi, S				Honda, K; Yamada, T; Seike, M; Hayashida, Y; Idogawa, M; Kondo, T; Ino, Y; Hirohashi, S			Alternative splice variant of actinin-4 in small cell lung cancer	ONCOGENE			English	Article						actin; actinin-4; alternative splicing; cancer-testis antigen; small-cell lung cancer	ALPHA-ACTININ-4; ACTN4	Tumor-associated alternative RNA splicing has gained considerable attention. We identified a novel alternative splice variant RNA of actinin-4 in human small cell lung caner (SCLC). Expression of the splice variant was highly specific to SCLC cell lines (10/10), biopsies (3/3), and testis. The variant encoded a peptide with a three amino-acid change in exon 8, where the germline missense mutation takes place in familial focal segmental glomerulosclerosis (FSGS). The variant protein showed high affinity to filamentous actin polymers and was not localized with cortical actin. Alternatively spliced actinin-4 may be a new diagnostic marker of SCLC and a candidate target for selective therapy.	Natl Canc Ctr, Res Inst, Canc Proteom Project, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Yamada, T (corresponding author), Natl Canc Ctr, Res Inst, Canc Proteom Project, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tyamada@gan2.res.ncc.go.jp	Kondo, Tadashi/I-4819-2019; Idogawa, Masashi/B-5208-2008	Kondo, Tadashi/0000-0001-6405-7792; Idogawa, Masashi/0000-0002-8507-1726				Araki N, 2000, J CELL SCI, V113, P3329; Arora VK, 2003, ACTA CYTOL, V47, P216, DOI 10.1159/000326507; Behrens J, 1992, Semin Cell Biol, V3, P169; CARNEY DN, 1985, SEMIN ONCOL, V12, P289; Djinovic-Carugo K, 2002, FEBS LETT, V513, P119, DOI 10.1016/S0014-5793(01)03304-X; dos Santos NR, 2000, CANCER RES, V60, P1654; Echchakir H, 2001, CANCER RES, V61, P4078; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Jager E, 1999, CANCER METAST REV, V18, P143, DOI 10.1023/A:1006220707618; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Levi F, 1996, EUR J CANCER, V32A, P652, DOI 10.1016/0959-8049(95)00582-X; Michaud JL, 2003, J AM SOC NEPHROL, V14, P1200, DOI 10.1097/01.ASN.0000059864.88610.5E; Nikolopoulos SN, 2000, ONCOGENE, V19, P380, DOI 10.1038/sj.onc.1203310; SHIMOSATO Y, 1986, CANCER LETT, V33, P241, DOI 10.1016/0304-3835(86)90064-9; Small JV, 1999, CURR OPIN CELL BIOL, V11, P54, DOI 10.1016/S0955-0674(99)80007-6	16	46	51	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5257	5262		10.1038/sj.onc.1207652	http://dx.doi.org/10.1038/sj.onc.1207652			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122314				2022-12-17	WOS:000222382500015
J	Park, HU; Jeong, JH; Chung, JH; Brady, JN				Park, HU; Jeong, JH; Chung, JH; Brady, JN			Human T-cell leukemia virus type 1 Tax interacts with Chk1 and attenuates DNA-damage induced G(2) arrest mediated by Chk1	ONCOGENE			English	Article						HTLV-1 Tax; Chk1; interaction; attenuation; G(2) checkpoint	TELANGIECTASIA-MUTATED ATM; PRIMARY HUMAN-LYMPHOCYTES; S-PHASE CHECKPOINT; HTLV-I; IONIZING-RADIATION; TRANSACTIVATION FUNCTION; TUMOR-SUPPRESSOR; GENE-EXPRESSION; PROTEIN-KINASE; CANCER-CELLS	Checkpoint kinase 1 (Chk1) mediates diverse cellular responses to genotoxic stress, regulating the network of genome-surveillance pathways that coordinate cell cycle progression with DNA repair. Chk1 is essential for mammalian development and viability, and has been shown to be important for both S and G(2) checkpoints. We now present evidence that the HTLV-1 Tax protein interacts directly with Chk1 and impairs its kinase activities in vitro and in vivo. The direct and physical interaction of Chk1 and Tax was observed in HTLV-1-infected T cells (C81, HuT 102 and MT-2) and transfected fibroblasts (293 T) by coimmunoprecipitation and by in vitro GST pull-down assays. Interestingly, Tax inhibited the kinase activity of Chk1 protein in in vitro and in vivo kinase assays. Consistent with these results, Tax inhibited the phosphorylation-dependent degradation of Cdc25A and G(2) arrest in response to gamma-irradiation (IR) in a dose-dependent manner in vivo. The G(2) arrest did not require Chk2 or p53. These studies provide the first example of a viral transforming protein targeting Chk1 and provide important insights into checkpoint pathway regulation.	NCI, Virus Tumor Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Brady, JN (corresponding author), NCI, Virus Tumor Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA.	bradyj@exchange.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC005691, Z01BC005691] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002243, Z01HL002243] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Anderson CW, 1998, J PROTEIN CHEM, V17, P527; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Ariumi Y, 2003, ONCOGENE, V22, P1611, DOI 10.1038/sj.onc.1206244; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Chen ZH, 2003, MOL CANCER THER, V2, P543; Clifford B, 2003, CANCER RES, V63, P4074; Coscoy L, 1998, VIROLOGY, V248, P332, DOI 10.1006/viro.1998.9298; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Guerra B, 2003, ONCOGENE, V22, P4933, DOI 10.1038/sj.onc.1206721; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Haoudi A, 2003, VIROLOGY, V305, P229, DOI 10.1006/viro.2002.1642; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jeang KT, 1997, J VIROL, V71, P6277, DOI 10.1128/JVI.71.9.6277-6278.1997; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Lemoine FJ, 2000, AIDS RES HUM RETROV, V16, P1623, DOI 10.1089/08892220050193056; Liu QH, 2000, GENE DEV, V14, P1448; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; MIWA M, 1984, GANN, V75, P752; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Pise-Masison CA, 2001, J BIOL CHEM, V276, P200, DOI 10.1074/jbc.M005601200; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Sugiyama K, 2000, INT J CANCER, V85, P703, DOI 10.1002/(SICI)1097-0215(20000301)85:5<703::AID-IJC17>3.0.CO;2-7; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yu Q, 2002, CANCER RES, V62, P5743; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M201233200; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	73	46	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					4966	4974		10.1038/sj.onc.1207644	http://dx.doi.org/10.1038/sj.onc.1207644			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107832				2022-12-17	WOS:000222237300002
J	Nimer, SD; Moore, MAS				Nimer, SD; Moore, MAS			Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells	ONCOGENE			English	Article						AML; AML1-ETO; stem cell biology; transcription factors	ACUTE MYELOID-LEUKEMIA; T(8/21) FUSION PROTEIN; ACUTE MYELOGENOUS LEUKEMIA; EMBRYONIC LETHALITY; MURINE MODEL; C/EBP-ALPHA; EXPRESSION; MOUSE; AML1/ETO; RECEPTOR	Insights into the pathogenesis of human leukemia have relied heavily on studies of the identified chromosomal translocations found in this group of malignant diseases. Acquired, balanced translocations in acute myclogenous leukemia (AML) generally involve transcriptional regulatory genes, whereas in the myeloproliferative disorders tyrosine kinases are frequently involved. These rearrangements alter the function of at least one and often both of the involved genes. In this review, we focus on the AML1-ETO (a. k. a. RUNX1-ETO) fusion protein, which is found in t(8; 21) + AML. Expression of AML1-ETO in human hematopoietic stem cells (HSCs) preferentially enhances their maintenance, as opposed to their differentiation. The direct effects of AML1-ETO on human and murine HSCs, and the potentially cooperating events that may contribute to its leukemogenic properties, are discussed.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Lab Dev Hematopoiesis, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Nimer, SD (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Lab Mol Aspects Hematopoiesis, 1275 York Ave, New York, NY 10021 USA.	s-nimer@mskcc.org						Abu-Duhier FM, 2003, BRIT J HAEMATOL, V123, P749, DOI 10.1046/j.1365-2141.2003.04681.x; Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Bernardi R, 2002, ONCOGENE, V21, P3445, DOI 10.1038/sj.onc.1205313; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bristow CAP, 2003, NUCLEIC ACIDS RES, V31, P2735, DOI 10.1093/nar/gkg401; Burel S, 2003, BLOOD, V102, p585A; CAMMENGA J, 2001, BLOOD, pA1183; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Care RS, 2003, BRIT J HAEMATOL, V121, P775, DOI 10.1046/j.1365-2141.2003.04362.x; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; DEGREEF GE, 1995, LEUKEMIA, V9, P282; Elsasser A, 2003, ONCOGENE, V22, P5646, DOI 10.1038/sj.onc.1206673; FIALKOW PJ, 1967, P NATL ACAD SCI USA, V58, P1468, DOI 10.1073/pnas.58.4.1468; Forbes LV, 2002, ONCOGENE, V21, P5981, DOI 10.1038/sj.onc.1205767; Frank R, 1995, ONCOGENE, V11, P2667; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; Fukushima T, 2003, LEUKEMIA RES, V27, P387, DOI 10.1016/S0145-2126(02)00214-X; Grisolano JL, 2003, P NATL ACAD SCI USA, V100, P9506, DOI 10.1073/pnas.1531730100; GUERRASIO A, 1995, BRIT J HAEMATOL, V90, P364, DOI 10.1111/j.1365-2141.1995.tb05160.x; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; Kalev-Zylinska ML, 2002, DEVELOPMENT, V129, P2015; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Kung AL, 2000, GENE DEV, V14, P272; Lacorazza HD, 2002, BLOOD, V100, p59A; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Ley TJ, 2003, P NATL ACAD SCI USA, V100, P14275, DOI 10.1073/pnas.2335924100; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu BL, 2003, EXP HEMATOL, V31, P824, DOI 10.1016/S0301-472X(03)00161-9; Liu JY, 2003, BLOOD, V102, P1815, DOI 10.1182/blood-2002-12-3772; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Mulloy JC, 2003, BLOOD, V102, P4369, DOI 10.1182/blood-2003-05-1762; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Phan VT, 2003, MOL CELL BIOL, V23, P4573, DOI 10.1128/MCB.23.13.4573-4585.2003; Rangarajan A, 2003, NAT REV CANCER, V3, P952, DOI 10.1038/nrc1235; Reuther GW, 2000, MOL CELL BIOL, V20, P8655, DOI 10.1128/MCB.20.23.8655-8666.2000; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rhoades KL, 2000, BLOOD, V96, P2108; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Shimada H, 2000, BLOOD, V96, P655; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; UCHIDA N, 1992, J EXP MED, V175, P175, DOI 10.1084/jem.175.1.175; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; Wiemels JL, 2002, BLOOD, V99, P3801, DOI 10.1182/blood.V99.10.3801; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zheng R, 2003, BLOOD, V102, p363A	59	46	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4249	4254		10.1038/sj.onc.1207673	http://dx.doi.org/10.1038/sj.onc.1207673			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156180				2022-12-17	WOS:000221586000009
J	Li, JX; Tang, MS; Liu, BC; Shi, XL; Huang, C				Li, JX; Tang, MS; Liu, BC; Shi, XL; Huang, C			A critical role of PI-3K/Akt/JNKs pathway in benzo[a]pyrene diol-epoxide (B[a]PDE)-induced AP-1 transactivation in mouse epidermal Cl41 cells	ONCOGENE			English	Article						PI-3K; Akt; MAP kinase; PAH; AP-1	POLYCYCLIC AROMATIC-HYDROCARBONS; P70 S6 KINASE; PHOSPHOINOSITIDE 3-KINASE; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIVATED PROTEIN-1; OPTICAL ENANTIOMERS; CATALYTIC SUBUNIT; TRANSFORMATION; GENE	Mouse skin tumorigenicity studies indicate that benzo[a]-pyrene-7,8-diol-9,10-epoxide (B[a]PDE) contributes to carcinogenesis as both a tumor initiator and promoter. However, the mechanisms that mediate B[a] PDE tumor promotion effects remain unclear. Our results demonstrated that in mouse epidermal Cl41 cells, B[a] PDE treatment resulted in marked activation of AP-1 and its upstream MAPKs, including ERKs, JNKs and p38K. B[a] PDE exposure also led to activation of phosphotidy-linositol 3-kinase (PI-3K), Akt and p70 S6 kinase (p70(S6k)). B[a]PDE-induced AP-1 transactivation was inhibited by pretreatment of cells with PI-3K inhibitors, wortmannin or Ly294002. In contrast, inhibition of p70(S6k) with rapamycin did not show any inhibitory effects. An overexpression of dominant-negative mutant of PI-3K, Deltap85, impaired B[a]PDE-induced activation of PI-3K, Akt and AP-1 transactivation. Furthermore, an overexpression of dominant-negative Akt mutant, Akt-T308A/S473A, blocked B[a]PDE-induced activation of Akt, AP-1 and JNKs, while it did not affect the activation of p70S6k, ERKs and p38 kinase. These results demonstrated that B[a] PDE was able to induce AP-1 transactivation and this AP-1 induction was specific through PI-3K/Akt/JNKs-dependent and p70(S6k)-independent pathways. This study also indicated that Akt-T308A/S473A blocks B[a]PDE-induced AP-1 activation specific through impairing JNK pathway. These findings will help us to understand the signal transduction pathways involved in the carcinogenic effects of B[a] PDE.	NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; Chinese Ctr Dis Control & Prevent, Natl Inst Occupat Hlth & Poisons Control, Beijing 100050, Peoples R China; Chinese Acad Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China	New York University; Chinese Center for Disease Control & Prevention; Chinese Academy of Sciences	Huang, C (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	chuanshu@env.med.nyu.edu	Shi, Xianglin/B-8588-2012	Huang, Chuanshu/0000-0003-4133-5096	NATIONAL CANCER INSTITUTE [R01CA103180, R01CA112557, R01CA094964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012451] Funding Source: NIH RePORTER; NCI NIH HHS [CA112557, CA094964, CA103180] Funding Source: Medline; NIEHS NIH HHS [ES012451] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBERT RE, 1991, CARCINOGENESIS, V12, P1273, DOI 10.1093/carcin/12.7.1273; Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; BERNELOTMOENS C, 1990, CARCINOGENESIS, V11, P781, DOI 10.1093/carcin/11.5.781; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Bostrom CE, 2002, ENVIRON HEALTH PERSP, V110, P451, DOI 10.1289/ehp.02110s3451; Bral CM, 1997, MOL PHARMACOL, V52, P974, DOI 10.1124/mol.52.6.974; BRESNICK E, 1977, CANCER RES, V37, P984; BUENING MK, 1978, P NATL ACAD SCI USA, V75, P5358, DOI 10.1073/pnas.75.11.5358; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CONNEY AH, 1994, DRUG METAB REV, V26, P125, DOI 10.3109/03602539409029788; CONNEY AH, 1982, CANCER RES, V42, P4875; Cooper SJ, 2003, MOL CANCER RES, V1, P848; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DONG ZG, 1995, INT J ONCOL, V7, P359; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; EISENSTADT E, 1982, P NATL ACAD SCI-BIOL, V79, P1945, DOI 10.1073/pnas.79.6.1945; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FUKUI Y, 1991, ONCOGENE, V6, P407; Funakoshi-Tago M, 2003, EUR J BIOCHEM, V270, P1257, DOI 10.1046/j.1432-1033.2003.03487.x; Gonzales M, 2002, ONCOGENE, V21, P2721, DOI 10.1038/sj.onc.1205366; HALL M, 1989, CARCINOGENESIS, V10, P1815, DOI 10.1093/carcin/10.10.1815; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HECHT SS, 1974, JNCI-J NATL CANCER I, V53, P1121, DOI 10.1093/jnci/53.4.1121; Heidelberger C, 1973, Adv Cancer Res, V18, P317, DOI 10.1016/S0065-230X(08)60756-3; Hoffmann D, 1997, PREV MED, V26, P427, DOI 10.1006/pmed.1997.0183; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 2002, CANCER RES, V62, P6857; Huang CS, 2002, CANCER RES, V62, P5689; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Huang CS, 2001, J BIOL CHEM, V276, P40234, DOI 10.1074/jbc.M103684200; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Lei W, 1998, CANCER RES, V58, P2102; LEVIN W, 1977, CANCER RES, V37, P3356; Li JJ, 1997, CANCER RES, V57, P3569; Merimsky O, 1998, CLIN DERMATOL, V16, P585, DOI 10.1016/S0738-081X(98)00043-1; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x; Parrish AR, 1998, TOXICOL APPL PHARM, V152, P302, DOI 10.1006/taap.1998.8525; Parrish AR, 2002, BIOCHEM PHARMACOL, V64, P31, DOI 10.1016/S0006-2952(02)01054-7; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PHILLIPS DH, 1983, NATURE, V303, P468, DOI 10.1038/303468a0; Pitot HC, 1996, CASARETT DOULLS TOXI, P201; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; RODRIGUEZ H, 1993, CARCINOGENESIS, V14, P373, DOI 10.1093/carcin/14.3.373; SEILKIRK JK, 1982, MECH CHEM CARCINOGEN, P331; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shimada T, 1999, CHEM RES TOXICOL, V12, P623, DOI 10.1021/tx990028s; Sims P, 1974, Adv Cancer Res, V20, P165, DOI 10.1016/S0065-230X(08)60111-6; SLAGA TJ, 1979, CANCER RES, V39, P67; Smith LE, 2000, JNCI-J NATL CANCER I, V92, P803, DOI 10.1093/jnci/92.10.803; SMITH MJ, 1992, BLOOD, V79, P2107; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; Tannheimer SL, 1998, CARCINOGENESIS, V19, P1291, DOI 10.1093/carcin/19.7.1291; Thompson EJ, 2002, CANCER RES, V62, P3044; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANG JL, 1991, CARCINOGENESIS, V12, P71, DOI 10.1093/carcin/12.1.71; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	79	46	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3932	3944		10.1038/sj.onc.1207501	http://dx.doi.org/10.1038/sj.onc.1207501			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15021902				2022-12-17	WOS:000221382000005
J	Jefford, CE; Feki, A; Harb, J; Krause, KH; Irminger-Finger, I				Jefford, CE; Feki, A; Harb, J; Krause, KH; Irminger-Finger, I			Nuclear-cytoplasmic translocation of BARD1 is linked to its apoptotic activity	ONCOGENE			English	Article						BARD1; BRCA1; apoptosis; nuclear export; protein stability; RING	CANCER-PREDISPOSING MUTATIONS; MAMMARY EPITHELIAL-CELLS; BRCA1 TUMOR-SUPPRESSOR; RING DOMAIN; UBIQUITIN LIGASE; GENE-PRODUCT; DNA-DAMAGE; PROTEIN; IDENTIFICATION; BRCA1-BARD1	The tumor suppressor protein BARD1 plays a dual role in response to genotoxic stress: DNA repair as a BARD1 BRCA1 heterodimer and induction of apoptosis in a BRCA1-independent manner. We have constructed a series of BARD1 deletion mutants and analysed their cellular distribution and capacity to induce apoptosis. As opposed to previous studies suggesting an exclusively nuclear localization of BARD1, we found, both in tissues and cell cultures, nuclear and cytoplasmic localization of BARD1. Enhanced cytoplasmic localization of BARD1, as well as appearance of a 67 kDa C-terminal proteolytic cleavage product, coincided with apoptosis. BARD1 translocates to the nucleus independently of BRCA1. For recruitment to nuclear dots, however, the BRCA1-interacting RING finger domain is required but not sufficient. Protein levels of N-terminal RING finger deletion mutants were much higher than those of full-length BARD1, despite comparable mRNA levels, suggesting that the N-terminal region comprising the RING finger is important for BARD1 degradation. Sequences required for apoptosis induction were mapped between the ankyrin repeats and the BRCT domains coinciding with two known cancer-associated missense mutations. We suggest that nuclear and cytoplasmic localization of BARD1 reflect its dual function and that the increased cytoplasmic localization of BARD1 is associated with apoptosis.	Univ Geneva, Dept Geriatr, Biol Aging Lab, CH-1225 Geneva, Switzerland; INSERM, U419, Inst Biol, F-44035 Nantes 03, France	University of Geneva; Institut National de la Sante et de la Recherche Medicale (Inserm)	Irminger-Finger, I (corresponding author), Univ Geneva, Dept Geriatr, Biol Aging Lab, CH-1225 Geneva, Switzerland.	irmgard.irminger@medecine.unige.ch	Krause, Karl-Heinz/E-8030-2011; Harb, Jean/S-9610-2017	Krause, Karl-Heinz/0000-0002-9033-6768; Harb, Jean/0000-0002-1727-8610; Feki, Anis/0000-0002-9817-9445				Ayi TC, 1998, ONCOGENE, V17, P2143, DOI 10.1038/sj.onc.1202123; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Baer R, 2001, NAT STRUCT BIOL, V8, P822, DOI 10.1038/nsb1001-822; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chiba N, 2002, CANCER RES, V62, P4222; Conus S, 2000, CELL DEATH DIFFER, V7, P947, DOI 10.1038/sj.cdd.4400729; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Gautier F, 2000, CANCER RES, V60, P6895; Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Irminger-Finger I, 2001, MOL CELL, V8, P1255, DOI 10.1016/S1097-2765(01)00406-3; Irminger-Finger I, 2002, INT J BIOCHEM CELL B, V34, P582, DOI 10.1016/S1357-2725(01)00161-3; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(01)00270-7; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Lotti LV, 2002, GENE CHROMOSOME CANC, V35, P193, DOI 10.1002/gcc.10105; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; Morris JR, 2002, J BIOL CHEM, V277, P9382, DOI 10.1074/jbc.M109249200; Parvin JD, 2001, P NATL ACAD SCI USA, V98, P5952, DOI 10.1073/pnas.121184998; RODRIGUEZ JA, 2003, ONCOGENE; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Soriano JV, 2000, ADV EXP MED BIOL, V480, P175; Spahn L, 2002, CANCER RES, V62, P4583; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199	40	46	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3509	3520		10.1038/sj.onc.1207427	http://dx.doi.org/10.1038/sj.onc.1207427			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077185	Bronze			2022-12-17	WOS:000221101700002
J	Neben, K; Tews, B; Wrobel, G; Hahn, M; Kokocinski, F; Giesecke, C; Krause, U; Ho, AD; Kramer, A; Lichter, P				Neben, K; Tews, B; Wrobel, G; Hahn, M; Kokocinski, F; Giesecke, C; Krause, U; Ho, AD; Kramer, A; Lichter, P			Gene expression patterns in acute myeloid leukemia correlate with centrosome aberrations and numerical chromosome changes	ONCOGENE			English	Article						centrosome aberrations; aneuploidy; numerical chromosome changes; acute myeloid leukemia	CHRONIC LYMPHOCYTIC-LEUKEMIA; CELL-CYCLE; INSTABILITY; CANCER; PATHWAYS; DISTINCT; REVEALS	Centrosomes, which mediate accurate chromosome segregation during mitosis, undergo duplication precisely once per cell division at the G(1)/S boundary. Recently, we described centrosome aberrations as a possible cause of aneuploidy in acute myeloid leukemia (AML) and found a correlation of the percentage of cells carrying abnormal centrosomes to their cytogenetic risk pro. le. To elucidate the molecular events responsible for the development of centrosome aberrations in AML, tumor RNA of 29 AML samples was hybridized to cDNA microarrays. The microarrays comprised some 2800 different genes with relevance to hematopoiesis, tumorigenesis and mitosis and included a set of 359 centrosome-associated genes. We identified two gene expression signatures, which allowed an accurate classification according to the extent of centrosome aberrations and the ploidy status in 28 of 29 patients each. Specifically, 18 genes were present in both signatures, including genes that code for cell cycle regulatory proteins (cyclin A2, cyclin D3, cyclin H, CDK6, p18(INK4c), p21(Cip1), PAK1) and centrosome-associated proteins ( pericentrin, alpha2-tubulin, NUMA1, TUBGCP2, PRKAR2A). In conclusion, the high expression of centrosome-associated genes matches the description of centrosome aberrations in several tumor types. Moreover, in AML the identification of G(1)/S-phase stimulatory genes suggests that one mechanism of aneuploidy induction might be the deregulation of centrosome replication at the G(1)/S boundary.	Deutsch Krebsforschungszentrum, Div Mol Genet B060, D-69120 Heidelberg, Germany; Heidelberg Univ, Med Klin & Poliklin 5, D-69115 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Lichter, P (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Genet B060, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	m.macleod@dkfz.de		Kokocinski, Felix/0000-0002-8472-9207				Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chen QH, 2003, ONCOGENE, V22, P992, DOI 10.1038/sj.onc.1206193; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Debernardi S, 2003, GENE CHROMOSOME CANC, V37, P149, DOI 10.1002/gcc.10198; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Korshunov A, 2003, AM J PATHOL, V163, P1721, DOI 10.1016/S0002-9440(10)63530-4; Korz C, 2002, BLOOD, V99, P4554, DOI 10.1182/blood.V99.12.4554; Kramer A, 2002, LEUKEMIA, V16, P767, DOI 10.1038/sj.leu.2402454; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Marx J, 2001, SCIENCE, V292, P426, DOI 10.1126/science.292.5516.426; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Merdes A, 1997, J CELL BIOL, V138, P953, DOI 10.1083/jcb.138.5.953; Neben K, 2003, BLOOD, V101, P289, DOI 10.1182/blood-2002-04-1188; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pihan GA, 2001, CANCER RES, V61, P2212; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Stratowa C, 2001, INT J CANCER, V91, P474, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1078>3.0.CO;2-C; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Virtaneva K, 2001, P NATL ACAD SCI USA, V98, P1124, DOI 10.1073/pnas.98.3.1124; Waters JC, 1997, CURR OPIN CELL BIOL, V9, P37, DOI 10.1016/S0955-0674(97)80149-4; Wrobel G, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng067; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	28	46	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2379	2384		10.1038/sj.onc.1207401	http://dx.doi.org/10.1038/sj.onc.1207401			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14767474				2022-12-17	WOS:000220427700012
J	Li, XR; Cowell, JK; Sossey-Alaoui, K				Li, XR; Cowell, JK; Sossey-Alaoui, K			CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer	ONCOGENE			English	Article						CLCA2; tumour suppressor gene; 1p31; breast cancer; epigenetics	ACTIVATED CHLORIDE CHANNEL; SPORADIC BREAST; 5-METHYLCYTOSINE RESIDUES; DNA HYPERMETHYLATION; ALLELIC IMBALANCE; OVARIAN-CANCER; CHROMOSOME 1P; HUMAN HOMOLOG; REGION; METHYLATION	The calcium-activated chloride channel gene family is clustered in the 1p31 region, which is frequently deleted in sporadic breast cancer. Recent studies have indicated the association of the second member of this gene family (CLCA2) with the development of breast cancer and metastasis. We have now shown the absence of expression of CLCA2 in several breast cancer tumours and cell lines, which confirms the results from other reports. When overexpressed in CLCA2-negative cell lines, their tumorigenicity and metastasis capability were significantly reduced, suggesting a tumour suppressor role for CLCA2 in breast cancer. The mechanisms behind the silencing of CLCA2 in breast cancer, however, have not been elucidated to date. Although we were able to identify CLCA2 mutations in breast cancers, somatic mutations are not the major cause of CLCA2 gene silencing. On the other hand, treatment of breast cancer CLCA2-negative cell lines with demethylating agents was able to restore CLCA2 expression, suggesting an epigenetic inactivation of this gene. Bisulphite-sequencing of the promoter-associated CpG island of the CLCA2 gene in breast tumours demonstrated that the absence of expression in these tumours was caused by hypermethylation of the promoter CpG island. In contrast, in breast cancer cell lines, tumours, and control cell lines that express CLCA2, a much lower level, and often absence, of methylation of the promoter were demonstrated. These findings demonstrate that CLCA2 is frequently inactivated in breast cancer by promoter region hypermethylation, which makes it an excellent candidate for the 1p31 breast cancer tumour suppressor gene.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Sossey-Alaoui, K (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, 110 C&V Bldg,Elm & Carlton St, Buffalo, NY 14263 USA.	khalid.sossey-alaoui@roswellpark.org		Cowell, John/0000-0002-2079-5950	NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollahi A, 2003, J BIOL CHEM, V278, P6041, DOI 10.1074/jbc.M210361200; Agnel M, 1999, FEBS LETT, V455, P295, DOI 10.1016/S0014-5793(99)00891-1; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BUBIEN JK, 1990, SCIENCE, V248, P1416, DOI 10.1126/science.2162561; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; Dallol A, 2002, CANCER RES, V62, P5874; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; DEANE KHO, 1992, EUR J IMMUNOL, V22, P1165, DOI 10.1002/eji.1830220509; Elble RC, 2001, J BIOL CHEM, V276, P40510, DOI 10.1074/jbc.M104821200; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6; GRIGG G, 1994, BIOESSAYS, V16, P431, DOI 10.1002/bies.950160612; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 1999, CANCER RES, V59, P5488; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; Hoff C, 2001, CANCER GENET CYTOGEN, V129, P145, DOI 10.1016/S0165-4608(01)00450-2; HOGGARD N, 1995, GENOMICS, V30, P233, DOI 10.1006/geno.1995.9882; HOLLIDAY R, 1993, MUTAT RES, V285, P61, DOI 10.1016/0027-5107(93)90052-H; Lichy JH, 1998, AM J PATHOL, V153, P271, DOI 10.1016/S0002-9440(10)65568-X; NAGAI H, 1995, CANCER RES, V55, P1752; Pauli BU, 2000, CLIN EXP PHARMACOL P, V27, P901, DOI 10.1046/j.1440-1681.2000.03358.x; Roy D, 2003, INT J CANCER, V103, P730, DOI 10.1002/ijc.10895; Sossey-Alaoui K, 2002, ONCOGENE, V21, P5967, DOI 10.1038/sj.onc.1205734; Sossey-Alaoui K, 2002, GENOMICS, V80, P5, DOI 10.1006/geno.2002.6792; Sossey-Alaoui K, 2001, INT J MOL MED, V7, P543; SOULE HD, 1990, CANCER RES, V50, P6075; Su GF, 1999, GENOMICS, V55, P157, DOI 10.1006/geno.1998.5633; Tsukamoto K, 1998, CANCER-AM CANCER SOC, V82, P317, DOI 10.1002/(SICI)1097-0142(19980115)82:2<323::AID-CNCR11>3.3.CO;2-P; Ullrich N, 1997, AM J PHYSIOL-CELL PH, V273, pC1290, DOI 10.1152/ajpcell.1997.273.4.C1290; White GRM, 1998, ONCOGENE, V17, P3513, DOI 10.1038/sj.onc.1202487; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	38	46	48	5	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1474	1480		10.1038/sj.onc.1207249	http://dx.doi.org/10.1038/sj.onc.1207249			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14973555				2022-12-17	WOS:000189035800015
J	Gao, J; Huang, HY; Pak, J; Cheng, J; Zhang, ZT; Shapiro, E; Pellicer, A; Sun, TT; Wu, XR				Gao, J; Huang, HY; Pak, J; Cheng, J; Zhang, ZT; Shapiro, E; Pellicer, A; Sun, TT; Wu, XR			p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis	ONCOGENE			English	Article						bladder cancer; p53; ras; oncogene; tumor suppressor gene	SUPERFICIAL BLADDER-CANCER; TRANSITIONAL-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; C-TERMINAL DOMAIN; IN-SITU; NUCLEAR OVEREXPRESSION; MOLECULAR-GENETICS; TUMOR SUPPRESSION; ONCOGENIC RAS; EXPRESSION	Mutation and deletion of the p53 tumor suppressor gene are arguably the most prevalent among the multiple genetic alterations found in human bladder cancer, but these p53 defects are primarily associated with the advanced diseases, and their roles in bladder tumor initiation and in synergizing with oncogenes in tumor progression have yet to be defined. Using the mouse uroplakin II gene promoter, we have targeted into urothelium of transgenic mice a dominant-negative mutant of p53 that lacks the DNA-binding domain but retains the tetramerization domain. Urothelium-expressed p53 mutant binds to and stabilizes the endogenous wild-type p53, induces nuclear abnormality, hyperplasia and occasionally dysplasia, without eliciting frank carcinomas. Concurrent expression of the p53 mutant with an activated Ha-ras, the latter of which alone induces urothelial hyperplasia, fails to accelerate tumor formation. In contrast, the expression of the activated Ha-ras in the absence of p53, as accomplished by crossing the activated Ha-ras transgenic mice with the p53 knockout mice, results in early-onset bladder tumors that are either low-grade superficial papillary or high grade in nature. These results provide the first in vivo experimental evidence that p53 deficiency predisposes the urothelium to hyperproliferation, but is insufficient for bladder tumorigenesis; that the mere reduction of p53 dosage, as produced in transgenic mice expressing the dominant-negative p53 or in heterozygous p53 knockouts, is incapable of synergizing with Ha-ras to induce bladder tumors; and that the complete loss of p53 is a prerequisite for collaborating with activated Ha-ras to promote bladder tumorigenesis.	Vet Affairs Med Ctr Manhattan, Urol Res Labs, New York, NY 10010 USA; NYU, Sch Med, Dept Urol, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Pathol, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Dermatol, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University; New York University; New York University; New York University	Wu, XR (corresponding author), Vet Affairs Med Ctr Manhattan, Urol Res Labs, 423 E 23 St,18th Floor,Room 18064 S, New York, NY 10010 USA.	xue-ru.wu@med.nyu.edu	Sun, Tung-Tien/J-4425-2015; MARTINEZ, ANTONIO PELLICER/C-4832-2015	Sun, Tung-Tien/0000-0002-6841-1063; Wu, Xue-Ru/0000-0001-6058-6291; Pellicer, Angel/0000-0002-5062-0692	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK052206, R01DK056903] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52206, DK56903] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; Cheng J, 2003, CANCER RES, V63, P179; Cheng J, 2002, CANCER RES, V62, P4157; Cordon-Cardo C, 1994, Important Adv Oncol, P71; Cordon-Cardo C, 2000, SCAND J UROL NEPHROL, V34, P82, DOI 10.1080/003655900750169338; CordonCardo C, 1997, SEMIN SURG ONCOL, V13, P319, DOI 10.1002/(SICI)1098-2388(199709/10)13:5<319::AID-SSU5>3.0.CO;2-G; CordonCardo C, 1997, WORLD J UROL, V15, P112, DOI 10.1007/BF02201982; Cote RJ, 1998, CANCER RES, V58, P1090; CZERNIAK B, 1992, HUM PATHOL, V23, P1199, DOI 10.1016/0046-8177(92)90285-B; Dahse R, 2000, ONCOL REP, V7, P931; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; FITZGERALD JM, 1995, J NATL CANCER I, V87, P129, DOI 10.1093/jnci/87.2.129; Fradet Y, 2000, Curr Opin Urol, V10, P441, DOI 10.1097/00042307-200009000-00013; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gottifredi V, 2000, COLD SPRING HARB SYM, V65, P483, DOI 10.1101/sqb.2000.65.483; Grossman HB, 1998, CLIN CANCER RES, V4, P829; KIKUCHIYANOSHITA R, 1995, ONCOGENE, V11, P1339; Knowles MA, 2001, J CLIN PATHOL-MOL PA, V54, P215, DOI 10.1136/mp.54.4.215; KNOWLES MA, 1995, BRIT J UROL, V75, P57; KOSS LGS, 1992, J CELL BIOCHEM, V16, P23; Lacombe L, 1996, J CLIN ONCOL, V14, P2646, DOI 10.1200/JCO.1996.14.10.2646; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liebert M, 1996, Semin Urol Oncol, V14, P62; LIN JH, 1995, P NATL ACAD SCI USA, V92, P679, DOI 10.1073/pnas.92.3.679; Llopis J, 2000, EUR UROL, V37, P644, DOI 10.1159/000020232; MESSING EM, 1992, SEMIN SURG ONCOL, V8, P285, DOI 10.1002/ssu.2980080507; Orntoft TF, 1998, UROL RES, V26, P223, DOI 10.1007/s002400050050; Pohar KS, 2002, CANCER PRECURSORS: EPIDEMIOLOGY, DETECTION, AND PREVENTION, P344, DOI 10.1007/0-387-21605-7_22; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Raghavan D, 2003, CANCER, V97, P2083, DOI 10.1002/cncr.11281; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Reiher F, 2002, J UROLOGY, V167, P1469, DOI 10.1016/S0022-5347(05)65347-5; Reznikoff CA, 1996, SEMIN ONCOL, V23, P571; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; SARKIS AS, 1994, J UROLOGY, V152, P388, DOI 10.1016/S0022-5347(17)32745-3; SARKIS AS, 1993, J NATL CANCER I, V85, P53, DOI 10.1093/jnci/85.1.53; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, CANCER RES, V51, P5232; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; SPRUCK CH, 1994, CANCER RES, V54, P784; Theodorescu D, 2003, HISTOL HISTOPATHOL, V18, P259, DOI 10.14670/HH-18.259; Vageli D, 1996, CANCER LETT, V107, P241, DOI 10.1016/0304-3835(96)04372-8; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952; Zhang ZT, 1999, CANCER RES, V59, P3512; Zhang ZT, 2001, ONCOGENE, V20, P1973, DOI 10.1038/sj.onc.1204315	52	46	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					687	696		10.1038/sj.onc.1207169	http://dx.doi.org/10.1038/sj.onc.1207169			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737103				2022-12-17	WOS:000188304900007
J	Paronetto, MP; Venables, JP; Elliott, DJ; Geremia, R; Rossi, P; Sette, C				Paronetto, MP; Venables, JP; Elliott, DJ; Geremia, R; Rossi, P; Sette, C			tr-kit promotes the formation of a multimolecular complex composed by Fyn, PLC gamma 1 and Sam68	ONCOGENE			English	Article						tyrosine kinase; SH3; RNA; adaptor proteins; signal transduction	RNA-BINDING PROTEIN; FAMILY TYROSINE KINASES; C-KIT; SIGNAL-TRANSDUCTION; EGG ACTIVATION; TRUNCATED FORM; SH3 DOMAINS; MOUSE EGGS; SRC; PHOSPHORYLATION	tr-kit is a truncated form of the tyrosine kinase receptor c-kit expressed in the haploid phase of spermatogenesis. Upon microinjection, tr-kit triggers metaphase-to-anaphase transition in mouse eggs by the sequential activation of Fyn and PLCgamma1. Here, we show that tr-kit promotes the interaction of several tyrosine-phosphorylated proteins with the SH3 domain of PLCgamma1. Western blot analysis indicates that one of these proteins is Sam68, an RNA-binding protein that is known to interact with and be phosphorylated by Src-like kinases in mitosis. tr-kit promotes the association of Sam68 with PLCgamma1 and Fyn in a multimolecular complex, as demonstrated by co-immunoprecipitation of the phosphorylated forms of these proteins using antibodies directed to anyone of the partners of the complex. Expression of tr-kit potentiates the interaction of endogenous Sam68 also with the SH3 domain of Fyn. Further more, the subcellular localization of Sam68 is affected by tr-kit through activation of Fyn in live cells. Lastly, we show that interaction with the SH3 domain of Fyn triggers the release of Sam68 from bound RNA. Thus, our data suggest that tr-kit promotes the formation of a multimolecular complex composed of Fyn, PLCgamma1 and Sam68, which allows phosphorylation of PLCgamma1 by Fyn, and may modulate RNA metabolism.	Univ Roma Tor Vergata, Sect Anat, Dipartimento Sanita Pubbl & Biol Cellulare, I-00133 Rome, Italy; Univ Newcastle Upon Tyne, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Rome Tor Vergata; Newcastle University - UK	Sette, C (corresponding author), Univ Roma Tor Vergata, Sect Anat, Dipartimento Sanita Pubbl & Biol Cellulare, Via Montpellier 1, I-00133 Rome, Italy.		Rossi, Pellegrino/AAA-7072-2019; Sette, Claudio/S-4307-2019; Paronetto, Maria Paola/A-9578-2012	Sette, Claudio/0000-0003-2864-8266; Paronetto, Maria Paola/0000-0001-5324-0903; ROSSI, PELLEGRINO/0000-0003-4796-327X; GEREMIA, Raffaele/0000-0001-9056-6603; Elliott, David/0000-0002-6930-0699				Albanesi C, 1996, DEVELOPMENT, V122, P1291; BESMER P, 1993, DEVELOPMENT, P125; Blume-Jensen P, 2000, NAT GENET, V24, P157, DOI 10.1038/72814; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; Lang V, 1999, J IMMUNOL, V162, P7224; Lee MH, 2001, GENE DEV, V15, P2408, DOI 10.1101/gad.915901; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; Li JL, 2002, J VIROL, V76, P8374, DOI 10.1128/JVI.76.16.8374-8382.2002; Liu K, 2000, J BIOL CHEM, V275, P40195, DOI 10.1074/jbc.M006194200; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Oh B, 2000, DEVELOPMENT, V127, P3795; Oneyama C, 2002, ONCOGENE, V21, P2037, DOI 10.1038/sj.onc.1205271; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROSSI P, 1992, DEV BIOL, V152, P203, DOI 10.1016/0012-1606(92)90172-D; Runft LL, 2002, DEV BIOL, V245, P237, DOI 10.1006/dbio.2002.0600; Sette C, 2002, EMBO J, V21, P5386, DOI 10.1093/emboj/cdf553; Sette C, 1998, J CELL BIOL, V142, P1063, DOI 10.1083/jcb.142.4.1063; Sette C, 1997, DEVELOPMENT, V124, P2267; Shen ZW, 1999, ONCOGENE, V18, P4647, DOI 10.1038/sj.onc.1203079; SORRENTINO V, 1991, ONCOGENE, V6, P149; Takaoka A, 1997, CANCER LETT, V115, P257, DOI 10.1016/S0304-3835(97)04746-0; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TOYOTA M, 1994, CANCER RES, V54, P272; Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; Zhang YY, 2003, EMBO J, V22, P1801, DOI 10.1093/emboj/cdg171	33	46	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8707	8715		10.1038/sj.onc.1207016	http://dx.doi.org/10.1038/sj.onc.1207016			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647465	Bronze			2022-12-17	WOS:000186844900008
J	Sigurdson, AJ; Jones, IM				Sigurdson, AJ; Jones, IM			Second cancers after radiotherapy: any evidence for radiation-induced genomic instability?	ONCOGENE			English	Article						second primary cancer; radiation therapy; genomic instability; chromosomal instability; review	DNA-REPAIR GENES; THERAPY-RELATED LEUKEMIA; HODGKINS-DISEASE; IONIZING-RADIATION; LUNG-CANCER; P53 MUTATIONS; SOLID TUMORS; MICROSATELLITE INSTABILITY; CHROMOSOMAL-ABERRATIONS; MARROW TRANSPLANTATION	Do second primary cancers in humans arise from radiation-induced somatic genomic instability after radiotherapy for the first malignancy? The amount of truly pertinent human information on this issue is sparse, leading to the conclusion that we cannot confirm or refute that instability induction by radiation is involved. However, the in vitro findings of radiation-induced genomic instability through bystander effects or increased mutation rates in cell progeny of apparently normal but irradiated cells are provocative and their transferability to human in vivo biology deserves further investigation. We describe possible animal and human studies to stimulate ideas, but the collaborative commitment of multiple large institutions to tumor tissue procurement and retrieval will be essential. In addition, detecting the temporal progression of genomic instability and identifying the salient genetic events as being radiation-induced will be pivotal. Execution of some of the studies suggested is not possible now, but applying next-generation methods could bring the concepts to fruition. As nearly one in 10 cancer diagnoses are second (or higher) malignancies, it is important to understand the contribution of radiotherapy to second cancer induction and pursue well-coordinated efforts to determine the role of induced genomic instability.	NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, Bethesda, MD 20892 USA; Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94551 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Sigurdson, AJ (corresponding author), NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, 6120 Execut Blvd,EPS 7092,MSC 7238, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [Z01CP010131, ZIACP010131] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTER BP, 1998, HEMATOLOGY INFANCY C, V1, P259; Backlund MG, 2001, CANCER RES, V61, P6577; Barcellos-Hoff MH, 2001, RADIAT RES, V156, P618, DOI 10.1667/0033-7587(2001)156[0618:ESTTMA]2.0.CO;2; Bauchinger M, 1998, MUTAT RES-FUND MOL M, V404, P89, DOI 10.1016/S0027-5107(98)00098-0; Behrens C, 2000, CANCER EPIDEM BIOMAR, V9, P1027; BenYehuda D, 1996, BLOOD, V88, P4296; Berwick M, 2000, JNCI-J NATL CANCER I, V92, P874, DOI 10.1093/jnci/92.11.874; BERWICK M, 2002, BIOMARKERS ENV ASS D, P84; Bhatia S, 1996, NEW ENGL J MED, V334, P745, DOI 10.1056/NEJM199603213341201; BOICE JD, 1988, RADIAT RES, V116, P3, DOI 10.2307/3577477; BOICE JD, 1987, J NATL CANCER I, V79, P1295; Boice Jr JD, 1996, CANC EPIDEMIOLOGY PR, P319; BOIVIN JF, 1995, JNCI-J NATL CANCER I, V87, P732, DOI 10.1093/jnci/87.10.732; Brat DJ, 1999, AM J PATHOL, V154, P1431, DOI 10.1016/S0002-9440(10)65397-7; Chauveinc L, 1999, CANCER GENET CYTOGEN, V114, P1, DOI 10.1016/S0165-4608(99)00038-2; Chen Z, 2002, AM J MED GENET, V115, P130, DOI 10.1002/ajmg.10689; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; de Vathaire F, 1999, ARCH INTERN MED, V159, P2713, DOI 10.1001/archinte.159.22.2713; DeBenedetti VMG, 1996, CANCER EPIDEM BIOMAR, V5, P93; Deeg HJ, 1996, BLOOD, V87, P386, DOI 10.1182/blood.V87.1.386.bloodjournal871386; Dores GM, 2002, J CLIN ONCOL, V20, P3484, DOI 10.1200/JCO.2002.09.038; Fang NY, 2003, P NATL ACAD SCI USA, V100, P5372, DOI 10.1073/pnas.0831102100; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Finnon P, 1999, INT J RADIAT BIOL, V75, P1215, DOI 10.1080/095530099139368; Friedberg EC, 2003, DNA REPAIR, V2, P501, DOI 10.1016/S1568-7864(03)00005-3; Gafanovich A, 1999, CANCER-AM CANCER SOC, V85, P504; Gilbert ES, 2003, RADIAT RES, V159, P161, DOI 10.1667/0033-7587(2003)159[0161:LCATFH]2.0.CO;2; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Gray JW, 2000, CARCINOGENESIS, V21, P443, DOI 10.1093/carcin/21.3.443; Horiike S, 1999, LEUKEMIA, V13, P1235, DOI 10.1038/sj.leu.2401466; Inskip PD, 1999, MULTIPLE PRIMARY CANCERS, P91; KALDOR JM, 1992, INT J CANCER, V52, P677, DOI 10.1002/ijc.2910520502; KLEINERMAN RA, 1990, RADIAT RES, V123, P93, DOI 10.2307/3577663; Kodama Y, 2001, RADIAT RES, V156, P337, DOI 10.1667/0033-7587(2001)156[0337:SCAIAB]2.0.CO;2; Lefevre SH, 2001, ONCOGENE, V20, P8092, DOI 10.1038/sj.onc.1205009; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Lorimore SA, 2003, INT J RADIAT BIOL, V79, P15, DOI 10.1080/0955300021000045664; MENDELSOHN ML, 1995, MODELING BIOL EFFECT, P185; Mertens F, 2000, CANCER GENET CYTOGEN, V116, P89, DOI 10.1016/S0165-4608(99)00105-3; Mohrenweiser HW, 2003, MUTAT RES-FUND MOL M, V526, P93, DOI 10.1016/S0027-5107(03)00049-6; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Platz EA, 2000, INT J RADIAT BIOL, V76, P955, DOI 10.1080/09553000050050963; Robison LL, 2002, MED PEDIATR ONCOL, V38, P229, DOI 10.1002/mpo.1316; Ronen A, 2001, ENVIRON MOL MUTAGEN, V37, P241, DOI 10.1002/em.1033; Shoshan Y, 2000, J NEUROPATH EXP NEUR, V59, P614, DOI 10.1093/jnen/59.7.614; SWERDLOW AJ, 1992, BRIT MED J, V304, P1137, DOI 10.1136/bmj.304.6835.1137; Tarkkanen M, 2001, CANCER, V92, P1992, DOI 10.1002/1097-0142(20011001)92:7<1992::AID-CNCR1719>3.0.CO;2-2; Travis LB, 2000, JNCI-J NATL CANCER I, V92, P1165, DOI 10.1093/jnci/92.14.1165; Travis LB, 2002, JNCI-J NATL CANCER I, V94, P182, DOI 10.1093/jnci/94.3.182; TUCKER JD, 1993, INT J RADIAT BIOL, V64, P27, DOI 10.1080/09553009314551081; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; TUCKER MA, 1991, CANCER RES, V51, P2885; Ullrich RL, 1998, INT J RADIAT BIOL, V74, P747, DOI 10.1080/095530098141023; VANLEEUWEN FE, 1994, J CLIN ONCOL, V12, P312, DOI 10.1200/JCO.1994.12.2.312; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Wright EG, 1999, J PATHOL, V187, P19, DOI 10.1002/(SICI)1096-9896(199901)187:1<19::AID-PATH233>3.0.CO;2-1; Yu YJ, 2001, CANCER RES, V61, P1820; Zablotska LB, 2003, CANCER, V97, P1404, DOI 10.1002/cncr.11214	61	46	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2003	22	45					7018	7027		10.1038/sj.onc.1206989	http://dx.doi.org/10.1038/sj.onc.1206989			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557806				2022-12-17	WOS:000185903900006
J	Maliekal, TT; Antony, ML; Nair, A; Paulmurugan, R; Karunagaran, D				Maliekal, TT; Antony, ML; Nair, A; Paulmurugan, R; Karunagaran, D			Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer	ONCOGENE			English	Article						Smads; TGF-beta; cervical cancer; SQRT-PCR	GROWTH-FACTOR-BETA; SQUAMOUS-CELL CARCINOMA; TGF-BETA; TUMOR-SUPPRESSOR; JUVENILE POLYPOSIS; COLORECTAL-CANCER; PANCREATIC-CANCER; DPC4 EXPRESSION; II GENE; RECEPTOR	Mutations in Smads, intermediates of transforming growth factor-beta signaling, are known to contribute to the loss of sensitivity to transforming growth factor-beta, a common feature of many neoplastic cells. However, not much information is available on Smad alterations in cervical cancer and so we probed, for the first time, for alterations in Smad 2 and Smad 4 genes using human cervical cancer cell lines and human cervical tissue samples. Using PCR/reverse transcription-PCR, single-stranded conformation polymorphism analysis and DNA sequencing, we observed a deletion of 'G' in the L3 loop (crucial in Smad-receptor interaction) in C-33A cells, and an insertion of 'A' in codon 122 (loss of MH2 domain) from a cervical tumor sample, both of which caused frame shift and pretermination in Smad 2. In addition, a G/A transition at 31 bp upstream-nontranslated regions of exon 8 of Smad 4 was found in Bu 25TK cells. Smad 2 expression was less in some of the cervical tumor samples than that of nonmalignant samples and six cancer samples showed C-terminal deletions that abolish Smad 2 phosphorylation sites. The loss of expression of Smad 4 found in some cervical tumor samples was due to transcription loss rather than deletion of the gene. Our results highlight an important role for Smad 2 and Smad 4 in human cervical tumors.	Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Karunagaran, D (corresponding author), Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India.	dkarunagaran@hotmail.com	Antony, Marie Lue/AAB-3952-2019; Karunagaran, Devarajan/A-8148-2010	Karunagaran, Devarajan/0000-0001-9331-8947; Paulmurugan, Ramasamy/0000-0001-7155-4738; Maliekal, Tessy/0000-0002-7311-7950				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Barabas E, 2001, BRAZ J MED BIOL RES, V34, P1271, DOI 10.1590/S0100-879X2001001000006; Barbera VM, 2000, BBA-MOL BASIS DIS, V1502, P283, DOI 10.1016/S0925-4439(00)00054-5; Bevan S, 1999, GUT, V45, P406, DOI 10.1136/gut.45.3.406; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; Cain JM, 2000, SCIENCE, V288, P1753, DOI 10.1126/science.288.5472.1753; Chu TY, 1999, INT J CANCER, V80, P506, DOI 10.1002/(SICI)1097-0215(19990209)80:4<506::AID-IJC4>3.3.CO;2-5; Costentin L, 2002, PANCREATOLOGY, V2, P17, DOI 10.1159/000049443; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Dellas A, 1999, CANCER RES, V59, P3475; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Hahn SA, 1996, CANCER RES, V56, P490; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hilgers W, 2000, GENE CHROMOSOME CANC, V27, P353, DOI 10.1002/(SICI)1098-2264(200004)27:4<353::AID-GCC3>3.3.CO;2-X; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Kaneko H, 1998, ACTA HAEMATOL-BASEL, V99, P187, DOI 10.1159/000040837; Kang SH, 1998, INT J CANCER, V77, P620, DOI 10.1002/(SICI)1097-0215(19980812)77:4<620::AID-IJC23>3.0.CO;2-8; Kim SK, 1996, CANCER RES, V56, P2519; Kong XT, 1997, CANCER RES, V57, P3772; Lee SH, 2001, INT J CANCER, V94, P500, DOI 10.1002/ijc.1494; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Lohmann DR, 1996, AM J HUM GENET, V58, P940; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Maitra A, 2000, AM J PATHOL, V157, P1105, DOI 10.1016/S0002-9440(10)64625-1; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Muliokandov MR, 1996, CANCER RES, V56, P197; Muro-Cacho CA, 2001, CLIN CANCER RES, V7, P1618; Nguyen HN, 1999, SEMIN SURG ONCOL, V16, P217, DOI 10.1002/(SICI)1098-2388(199904/05)16:3<217::AID-SSU4>3.0.CO;2-U; Osawa H, 2000, INT J ONCOL, V17, P723; Patel SA, 2002, AM J SURG PATHOL, V26, P1071, DOI 10.1097/00000478-200208000-00014; Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56; Schoell WMJ, 1999, SEMIN SURG ONCOL, V16, P203, DOI 10.1002/(SICI)1098-2388(199904/05)16:3<203::AID-SSU2>3.0.CO;2-C; Schutte M, 1996, CANCER RES, V56, P2527; Tanaka S, 2000, BRIT J CANCER, V82, P1557; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Uchida K, 1996, CANCER RES, V56, P5583; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Xie W, 2002, CANCER RES, V62, P497	42	46	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4889	4897		10.1038/sj.onc.1206806	http://dx.doi.org/10.1038/sj.onc.1206806			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894231				2022-12-17	WOS:000184344600013
J	Mulholland, NM; Soeth, E; Smith, CL				Mulholland, NM; Soeth, E; Smith, CL			Inhibition of MMTV transcription by HDAC inhibitors occurs independent of changes in chromatin remodeling and increased histone acetylation	ONCOGENE			English	Article						histone deacetylase; transcription; chromatin; mouse mammary tumor virus	TUMOR VIRUS PROMOTER; LONG TERMINAL REPEAT; GLUCOCORTICOID-RECEPTOR; DEACETYLASE INHIBITORS; GENE-EXPRESSION; IN-VIVO; SACCHAROMYCES-CEREVISIAE; SODIUM-BUTYRATE; N-COR; ACTIVATION	Increased histone acetylation has been associated with activated gene transcription and decreased acetylation with repression. However, there is a growing number of genes known, which are downregulated by histone deacetylase (HDAC) inhibitors through unknown mechanisms. This study examines the mechanism by which the mouse mammary tumor virus (MMTV) promoter is repressed by the HDAC inhibitor, trichostatin A (TSA). We find that this repression is transcriptional in nature and that it occurs in the presence and absence of glucocorticoids. TSA decreases MMTV transcription at a rapid rate, reaching maximum in 30-60 min. In contrast with previous reports, the repression does not correlate with an inhibition of glucocorticoid-induced nuclease hypersensitivity or NF1-binding at the MMTV promoter. Surprisingly, TSA does not induce sizable increases in histone acetylation at the MMTV promoter nor does it inhibit histone deacetylation, which accompanies deactivation of the glucocorticoid-activated MMTV promoter. Repression of MMTV transcription by TSA does not depend on the chromatin organization of the promoter because a transiently transfected MMTV promoter construct with a disorganized nucleoprotein structure was also repressed by TSA treatment. Mutational analysis of the MMTV promoter indicates that repression by TSA is mediated through the TATA box region. These results suggest a novel mechanism that involves acetylation of nonhistone proteins necessary for basal transcription.	NCI, Signal Transduct Grp, Lab Receptor Biol & Gene Express, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; George Washington Univ, Dept Genet, Washington, DC 20052 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); George Washington University	Smith, CL (corresponding author), NCI, Signal Transduct Grp, Lab Receptor Biol & Gene Express, Ctr Canc Res,NIH, Bldg 41,Room B608,41 Library Dr,MSC 5055, Bethesda, MD 20892 USA.	smithcat@exchange.nih.gov			NATIONAL CANCER INSTITUTE [Z01BC010599] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; DeRubertis F, 1996, NATURE, V384, P589; Fletcher TM, 2002, MOL CELL BIOL, V22, P3255, DOI 10.1128/MCB.22.10.3255-3263.2002; Fragoso G, 1998, MOL CELL BIOL, V18, P3633, DOI 10.1128/MCB.18.6.3633; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Galasinski SK, 2000, MOL CELL BIOL, V20, P1923, DOI 10.1128/MCB.20.6.1923-1930.2000; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HONG L, 1993, J BIOL CHEM, V268, P305; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Katan-Khaykovich Y, 2002, GENE DEV, V16, P743, DOI 10.1101/gad.967302; Kim SY, 2003, J VIROL, V77, P3394, DOI 10.1128/JVI.77.6.3394-3401.2003; Koyama Y, 2000, BLOOD, V96, P1490, DOI 10.1182/blood.V96.4.1490.h8001490_1490_1495; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Kristjuhan A, 2002, MOL CELL, V10, P925, DOI 10.1016/S1097-2765(02)00647-0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774; Lambert JR, 1998, J BIOL CHEM, V273, P32708, DOI 10.1074/jbc.273.49.32708; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; MCKNIGHT SL, 1982, COLD SPRING HARB SYM, V47, P945; MELLENTINMICHELOTTI J, 1994, J BIOL CHEM, V269, P31983; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MOYER ML, 1993, J BIOL CHEM, V268, P22933; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Myers CA, 1998, MOL CELL BIOL, V18, P2184, DOI 10.1128/MCB.18.4.2184; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PENNIE WD, 1995, MOL CELL BIOL, V15, P2125; PIERCE J, 1993, J VIROL, V67, P415, DOI 10.1128/JVI.67.1.415-424.1993; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sekinger EA, 2001, CELL, V105, P403, DOI 10.1016/S0092-8674(01)00329-4; Sewack GF, 2001, MOL CELL BIOL, V21, P1404, DOI 10.1128/MCB.21.4.1404-1415.2001; Sheldon LA, 2001, J BIOL CHEM, V276, P32423, DOI 10.1074/jbc.C100315200; Siavoshian S, 2000, GUT, V46, P507, DOI 10.1136/gut.46.4.507; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; VanLint C, 1996, GENE EXPRESSION, V5, P245; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Weidle UH, 2000, ANTICANCER RES, V20, P1471; Wilson MA, 2002, J BIOL CHEM, V277, P15171, DOI 10.1074/jbc.M200349200	61	46	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4807	4818		10.1038/sj.onc.1206722	http://dx.doi.org/10.1038/sj.onc.1206722			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894222				2022-12-17	WOS:000184344600004
J	Yu, Y; Feig, LA				Yu, Y; Feig, LA			Involvement of R-Ras and Ral GTPases in estrogen-independent proliferation of breast cancer cells	ONCOGENE			English	Article						breast cancer; Ral; R-Ras	GTP-BINDING PROTEINS; TAMOXIFEN RESISTANCE; C-SRC; RECEPTOR; ACTIVATION; GROWTH; SPECIFICITY; ALPHA; RAP1; EGF	A key step in the progression of breast cancer is the conversion of cells front an estrogen-dependent to an estrogen-independent state. Yet the molecular mechanisms underlying this transition in the control of cell proliferation of breast cancer cells remain poorly understood. A potential role for Ras-related GTPases in this process was suggested by the finding that BCAR3/AND-34, a protein isolated on the basis of its ability to convert MCF-7 and ZR-75 breast cancer cell lines to estrogen independence and tamoxifen resistance, is a guanine nucleotide exchange factor with the potential to activate the Ras-related Ral, R-Ras and Rap GTPases. In this study we investigated the potential contribution of these GTPases to the generation of estrogen-independence in MCF-7 cells. We found that elevated R-Ras but not Ral or Rap activity was sufficient to induce estrogen-independent proliferation of MCF-7 cells. The effect of R-Ras was dependent upon its ability to constitutively activate the AKT kinase. Interestingly, although AKT was also constitutively activated when estrogen-independent proliferation was induced by overexpression of EGF receptors, this mechanism of hormone independence did not require AKT activation. In contrast, EGF receptors did require Ral activation to induce estrogen-independent proliferation, while Ral activation was not required for estrogen-induced proliferation of MCF-7 cells. These findings suggest that Ral activity takes on a significant role in controlling cell proliferation of breast cancer cells when progression to estrogen-independence is associated with over-expression of EGF receptor family members. Moreover, because R-Ras promotes hormone-independent growth in a manner distinct from EGF receptors, it may participate in the conversion of breast cancer cells to estrogen independence when over-expression of EGF receptor family members is not involved.	Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts University	Feig, LA (corresponding author), Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA.				NATIONAL CANCER INSTITUTE [R01CA047391] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA47391] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Oh AS, 2001, MOL ENDOCRINOL, V15, P1344, DOI 10.1210/me.15.8.1344; OHTSUKA T, 1996, J BIOL CHEM, V271, P1253; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Polzin A, 2002, MOL CELL BIOL, V22, P1714, DOI 10.1128/MCB.22.6.1714-1722.2002; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rusanescu G, 2001, MOL CELL BIOL, V21, P2650, DOI 10.1128/MCB.21.8.2650-2658.2001; Salh B, 2002, INT J CANCER, V98, P148, DOI 10.1002/ijc.10147; Scott JA, 1991, ENDOCRINE DEPENDENT, P179; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tian XJ, 2002, EMBO J, V21, P1327, DOI 10.1093/emboj/21.6.1327; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; VANAGTHOVEN T, 1992, CANCER RES, V52, P5082; Wang SC, 2001, SEMIN ONCOL, V28, P21, DOI 10.1053/sonc.2001.29724; WIEBE VJ, 1993, CRIT REV ONCOL HEMAT, V14, P173, DOI 10.1016/1040-8428(93)90008-R; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	39	46	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7557	7568		10.1038/sj.onc.1205961	http://dx.doi.org/10.1038/sj.onc.1205961			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386818				2022-12-17	WOS:000178618200011
J	Ader, I; Muller, C; Bonnet, J; Favre, G; Cohen-Jonathan, E; Salles, B; Toulas, C				Ader, I; Muller, C; Bonnet, J; Favre, G; Cohen-Jonathan, E; Salles, B; Toulas, C			The radioprotective effect of the 24 kDa FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit	ONCOGENE			English	Article						high molecular form of FGF-2; DNA repair; NHEJ; DNA-PK; radioresistance	FIBROBLAST-GROWTH-FACTOR; DOUBLE-STRAND BREAKS; PHOSPHATIDYLINOSITOL 3-KINASE; V(D)J RECOMBINATION; GENE-EXPRESSION; MESSENGER-RNA; KU-PROTEIN; IN-VITRO; REPAIR; WORTMANNIN	We previously reported that overexpression of the 24 kDa basic fibroblast factor (or FGF-2) isoform provides protection from the cytotoxic effect of ionizing radiation (IR). DNA double-strand breaks (DSB), the IR-induced lethal lesions, are mainly repaired in human cells by non-homologous end joining system (NHEJ). NHEJ reaction is dependent on the DNA-PK holoenzyme (composed of a regulatory sub-unit, Ku, and a catalytic sub-unit, DNA-PKcs) that assembles at sites of DNA damage. We demonstrated here that the activity of DNA-PK was increased by twofold in two independent radioresistant cell lines, HeLa 3A and CAPAN A3, overexpressing the 24 kDa FGF-2. This increase was associated with an overexpression of the DNA-PKcs without modification of Ku expression or activity. This overexpression was due to an up-regulation of the DNA-PKcs gene transcription by the 24 kDa FGF-2 isoform. Finally, HeLa 3A cells exhibited the hallmarks of phenotypic changes associated with the overexpression of an active DNA-PKcs. Indeed, a faster repair rate of DSB and sensitization to IR by wortmannin was observed in these cells. Our results represent the characterization of a new mechanism of control of DNA repair and radioresistance in human tumor cells dependent on the overproduction of the 24 kDa FGF-2 isoform.	Ctr Lutte Contre Canc Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563, F-31052 Toulouse, France; Ctr Lutte Contre Canc Claudius Regaud, Dept Radiotherapie, F-31052 Toulouse, France; CNRS, UMR 5089, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Toulas, C (corresponding author), Ctr Lutte Contre Canc Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563, 20-24 Rue Pont St Pierre, F-31052 Toulouse, France.		Toulas, Christine/P-3838-2014; salles, bernard/B-8531-2008; Ader-Perarnau, Isabelle/F-7160-2017; MULLER, Catherine/M-2185-2018; Moyal, Elizabeth/A-9802-2015; FAVRE, Gilles/K-9189-2014; MULLER, Catherine/E-2060-2011	Toulas, Christine/0000-0003-1261-1725; Moyal, Elizabeth/0000-0002-6593-9276; FAVRE, Gilles/0000-0002-2344-1883; ADER, isabelle/0000-0001-5103-8509				Anderson CW, 1996, CURR TOP MICROBIOL, V217, P91; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; Boulton S, 1996, CARCINOGENESIS, V17, P2285, DOI 10.1093/carcin/17.11.2285; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CohenJonathan E, 1997, CANCER RES, V57, P1364; Connelly MA, 1998, GENOMICS, V47, P71, DOI 10.1006/geno.1997.5076; Estival A., 2001, International Journal of Molecular Medicine, V8, pS88; FERTIL B, 1984, RADIAT RES, V99, P73, DOI 10.2307/3576448; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Fujimoto M, 1997, DNA Res, V4, P151, DOI 10.1093/dnares/4.2.151; FUKS Z, 1994, CANCER RES, V54, P2582; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GODWIN AR, 1994, P NATL ACAD SCI USA, V91, P12554, DOI 10.1073/pnas.91.26.12554; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grein S, 1999, MOL CELL BIOCHEM, V191, P121, DOI 10.1023/A:1006806226764; Guo CH, 1999, MOL CELL BIOCHEM, V191, P135, DOI 10.1023/A:1006881405383; Han ZY, 1996, J BIOL CHEM, V271, P14098, DOI 10.1074/jbc.271.24.14098; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; MIMORI T, 1986, J BIOL CHEM, V261, P375; Muller C, 1998, ONCOGENE, V16, P1553, DOI 10.1038/sj.onc.1201676; Muller C, 1998, NUCLEIC ACIDS RES, V26, P1382, DOI 10.1093/nar/26.6.1382; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; OKADA T, 1994, J BIOL CHEM, V269, P3563; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Price BD, 1996, CANCER RES, V56, P246; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; Santiago FS, 2001, J BIOL CHEM, V276, P41143, DOI 10.1074/jbc.M104913200; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shen B, 1998, BIOCHEM BIOPH RES CO, V252, P524, DOI 10.1006/bbrc.1998.9677; Shen HX, 1998, BBA-GEN SUBJECTS, V1381, P131, DOI 10.1016/S0304-4165(98)00020-8; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Spencer JA, 1999, MOL CELL BIOL, V19, P3977; Stachowiak EK, 1997, ONCOGENE, V14, P2201, DOI 10.1038/sj.onc.1201057; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; Van den Berghe L, 2000, MOL ENDOCRINOL, V14, P1709, DOI 10.1210/me.14.11.1709; Xu WM, 2000, NAT CELL BIOL, V2, P339, DOI 10.1038/35014028; ZAGZAG D, 1990, CANCER RES, V50, P7393; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2; Zhou YY, 2001, MOL CELL BIOCHEM, V220, P1, DOI 10.1023/A:1011087910699; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	49	46	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6471	6479		10.1038/sj.onc.1205838	http://dx.doi.org/10.1038/sj.onc.1205838			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226750				2022-12-17	WOS:000177925300007
J	Chen, YQ; Zhou, YQ; Fisher, JH; Wang, MH				Chen, YQ; Zhou, YQ; Fisher, JH; Wang, MH			Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo	ONCOGENE			English	Article						receptor tyrosine kinase; transgenic mice; lung tumors; type II cells	MACROPHAGE-STIMULATING PROTEIN; HEPATOCYTE GROWTH-FACTOR; TRANSGENIC MICE; PULMONARY ADENOCARCINOMAS; C GENE; MOUSE; ACTIVATION; OVEREXPRESSION; IDENTIFICATION; CARCINOMA	RON, a member of the MET proto-oncogene family, has been implicated in the progression of certain epithelial cancers. The purpose of this study was to determine the oncogenic potential of RON in vivo in lung epithelial cells. Transgenic mice were established using surfactant protein C promoter to express human RON in the distal lung epithelial cells. These mice were born normal but developed multiple lung tumors with distinct morphology and growth patterns. Tumors appeared as a single mass in the lung around 2 months of age and gradually developed into multiple nodules located mostly in the peripheral portions of the lung. A transition from early adenomas to later adenocarcinomas was observed. Morphologically, tumors were characterized as cuboidal epithelial cells with a type 11 cell phenotype, grew along the alveolar walls, and projected into the alveolar septa. RON was highly expressed and constitutively activated in tumors. These results indicate that overexpression of human wild-type RON causes the formation of lung tumors with unique biological characteristics in vivo. This model provides opportunities to study the role of RON in the pathogenesis of lung tumors and to elucidate the mechanisms underlying this distinct lung tumor.	UCHSC, Dept Med, Denver Hlth Med Ctr, Denver, CO 80204 USA; Univ Colorado, Sch Med, Dept Med, Div Pulm Sci & Crit Care,CU Canc Ctr, Denver, CO 80204 USA; Zhejiang Univ, Sch Med, Div Neurosurg, Affiliated Hosp 1, Hangzhou 310003, Peoples R China	Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Zhejiang University	Wang, MH (corresponding author), UCHSC, Dept Med, Denver Hlth Med Ctr, 777 Bannock St,Mail Box 4000, Denver, CO 80204 USA.				NATIONAL CANCER INSTITUTE [R01CA091980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043516] Funding Source: NIH RePORTER; NCI NIH HHS [CA91980] Funding Source: Medline; NIAID NIH HHS [R01 AI43516] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angeloni D, 2000, GENE CHROMOSOME CANC, V29, P147, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.3.CO;2-E; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Clark JC, 2001, AM J PHYSIOL-LUNG C, V280, pL705, DOI 10.1152/ajplung.2001.280.4.L705; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; Ho YS, 1998, AM J RESP CELL MOL, V18, P538, DOI 10.1165/ajrcmb.18.4.2959; HOGAN B, 1996, MANIPULATING MOUSE E; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; Kerkhoff E, 2000, CELL GROWTH DIFFER, V11, P185; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEBEL M, 1995, CELL GROWTH DIFFER, V6, P1591; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Malkinson AM, 1998, EXP LUNG RES, V24, P541, DOI 10.3109/01902149809087385; Mason RJ, 2000, AM J PATHOL, V156, P175, DOI 10.1016/S0002-9440(10)64717-7; Muraoka RS, 1999, J CLIN INVEST, V103, P1277, DOI 10.1172/JCI6091; RONSIN C, 1993, ONCOGENE, V8, P1195; Sakamoto O, 1997, J CLIN INVEST, V99, P701, DOI 10.1172/JCI119214; SANDMOLLER A, 1995, CELL GROWTH DIFFER, V6, P97; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Singh G, 1997, AM J RESP CELL MOL, V17, P141, DOI 10.1165/ajrcmb.17.2.f138; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; Wang MH, 1996, ONCOGENE, V13, P2167; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WIKENHEISER KA, 1992, CANCER RES, V52, P5342; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; Willett CG, 1997, J CLIN INVEST, V99, P2979, DOI 10.1172/JCI119493	30	46	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6382	6386		10.1038/sj.onc.1205783	http://dx.doi.org/10.1038/sj.onc.1205783			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214279				2022-12-17	WOS:000177829000015
J	He, Q; Luo, XQ; Huang, Y; Sheikh, MS				He, Q; Luo, XQ; Huang, Y; Sheikh, MS			Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells	ONCOGENE			English	Article						NSAIDs; TRAIL/Apo2L; death receptor 5; Bax; caspases; colon cancer	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYTOCHROME-C; COLORECTAL-CANCER; DEATH RECEPTORS; GENE-EXPRESSION; IN-VIVO; LIGAND; COLON; MECHANISMS; RELEASE	The nonsteroidal anti-inflammatory drugs (NSAIDs) are believed to mediate their anticancer effects by inducing apoptosis but the molecular mechanisms of their apoptotic effects remain largely unknown. Here we report that two different NSAIDs, sulindac sulfide and SC-'236 engage the death receptor 5 (DR5) and mitochondrial pathways to mediate apoptosis in human colon cancer cells. We show that sulindac sulfide and SC-'236-induced apoptosis is coupled with upregulation of DR5, caspase 8 activation and Bid cleavage. Thus, a cross talk appears to exist between the DR5 and mitochondrial pathways during apoptosis induced by these NSAIDs. We further show that sulindac sulfide and SC-'236-induced DR5 upregulation occurs independent of the COX inhibitory effects of these NSAIDs. Using Bax-proficient (Bax+/-) and Bax-deficient (Bax-/-) HCT116 human colon cancer cells, we further demonstrate that Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac sulfide and SC-'236. For example, sulindac sulfide upregulates DR5 in both Bax-deficient and proficient cells, but Apo2L/TRAIL efficiently potentiates sulindac sulfide-induced apoptosis as well as activation of caspase-8, -9 and -3 only in Bax-proficient cells. SC-'236 also upregulates DR5 in both Bax-proficient and Bax-deficient cells but Apo2L/TRAIL potentiates SC-'236- mediated apoptosis and caspases-8 and -3 activation in both Bax-proficient and Bax-deficient cells. Further, in Bax-deficient cells, neither sulindac sulfide nor SC-'236 in combination with Apo2L/TRAIL effectively promotes the release of cytochrome c from mitochondria into cytosol and caspase-9 activation. Collectively, our results suggest that unlike sulindac sulfide, SC-'236 in combination with Apo2L/TRAIL can overcome Bax deficiency to induce apoptosis. These results have important clinical implications in that the tumors harboring Bax mutations are likely to develop resistance to sulindac but not to SC-'236-like NSAIDs. In conclusion, the data presented herein form the basis of future in-depth studies to further explore the utility of Apo2L/TRAIL and NSAIDs, in combination, as a novel cancer preventive/therapeutic strategy.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	sheikhm@mail.upstate.edu			NCI NIH HHS [CA89043] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA089043] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahnen DJ, 1998, EUR J SURG, V164, P111, DOI 10.1080/11024159850191544; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Burns TF, 2001, J BIOL CHEM, V276, P37879; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han ZY, 2001, J BIOL CHEM, V276, P38748, DOI 10.1074/jbc.M106214200; Huang Y, 2001, CANCER RES, V61, P6918; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; LANCASTER T, 1994, DIGEST DIS, V12, P170, DOI 10.1159/000171450; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lynch HT, 1999, J MED GENET, V36, P801; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ravi R, 2002, CANCER RES, V62, P1583; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Sheikh MS, 1998, CANCER RES, V58, P1593; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Song XQ, 2002, J NATL CANCER I, V94, P585; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wei MC, 2000, GENE DEV, V14, P2060; Williams CS, 2000, CANCER RES, V60, P6045; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	34	46	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6032	6040		10.1038/sj.onc.1205897	http://dx.doi.org/10.1038/sj.onc.1205897			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203115				2022-12-17	WOS:000177671300006
J	Sossey-Alaoui, K; Su, GF; Malaj, E; Roe, B; Cowell, JK				Sossey-Alaoui, K; Su, GF; Malaj, E; Roe, B; Cowell, JK			WAVE3, an actin-polymerization gene, is truncated and inactivated as a result of a constitutional t(1;13)(q21;q12) chromosome translocation in a patient with ganglioneuroblastoma	ONCOGENE			English	Article						WAVE3; neuroblastoma; actin polymerization	NEURO-BLASTOMA; MOLECULAR CHARACTERIZATION; NEUROBLASTOMA; FAMILY; REGION; RETINOBLASTOMA; BREAKPOINT; MUTATION; DELETION; CANCER	Neuroblastoma (Nb) is a malignancy of the sympathetic nervous system which affects children in their first decade. It is the most common extra-cranial solid tumor in children with an incidence of approximately 1 in 8 - 10 000 live births annually and accounts for approximately 10% of all children's cancers. Ganglioneuroblastoma is a relatively benign form of Nb and consists of a mixture of fibrils, mature and maturing ganglion cells, as well as undifferentiated neuroblasts. During routine cytogenetic analysis of patients with different manifestations of neuroblastoma we have identified one patient with ganglioneuroblastoma that carries an apparently balanced t(1:13)(q21:q12) reciprocal translocation. Positional cloning of the translocation breakpoint on chromosome 13 resulted in the mapping of the breakpoint between coding exon 2 and exon 3 of WAVE3, a member of WASP gene family. Although the breakpoint region on chromosome I was localized to within 2 kb of genomic sequence, no gene was found to be interrupted on this chromosome. The WAVE3 transcript is mainly expressed in the nervous system and, like all the members of the WASP gene family, WAVE3 is a key element in actin polymerization and cytoskeleton organization. WAVE3, therefore, is important for cell differentiation and motility and its expression is lost in a number of low grade and stage 4S tumors. From analysis of its expression pattern and function, WAVE3 is a candidate tumor suppressor gene, at least in some forms of neuroblastoma.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Univ Oklahoma, Dept Chem, Norman, OK 73019 USA	Roswell Park Cancer Institute; University of Oklahoma System; University of Oklahoma - Norman	Cowell, JK (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.			Cowell, John/0000-0002-2079-5950; Koculi, Eda/0000-0001-9477-555X	NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035791] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 16056-26] Funding Source: Medline; NINDS NIH HHS [NS35791] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anderson J, 2001, BRIT J CANCER, V85, P493, DOI 10.1054/bjoc.2001.1979; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Castleberry RP, 1999, J PEDIAT HEMATOL ONC, V21, P178, DOI 10.1097/00043426-199905000-00004; Chernova OB, 1998, ONCOGENE, V17, P2873, DOI 10.1038/sj.onc.1202481; Chernova OB, 2001, ONCOGENE, V20, P5378, DOI 10.1038/sj.onc.1204694; DANGIO GJ, 1971, LANCET, V1, P1046; FOUNTAIN JW, 1989, SCIENCE, V244, P1085, DOI 10.1126/science.2543076; Fryns JP, 1996, GENET COUNSEL, V7, P73; Hirai M, 1999, GENE CHROMOSOME CANC, V25, P261, DOI 10.1002/(SICI)1098-2264(199907)25:3<261::AID-GCC8>3.0.CO;2-#; Kitamura E, 2000, ONCOGENE, V19, P5772, DOI 10.1038/sj.onc.1203978; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KUSHNER BH, 1986, CANCER-AM CANCER SOC, V57, P1887, DOI 10.1002/1097-0142(19860501)57:9<1887::AID-CNCR2820570931>3.0.CO;2-7; LANCIOTTI M, 1992, CELL MOL NEUROBIOL, V12, P225, DOI 10.1007/BF00712928; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; MEAD RS, 1995, CANCER GENET CYTOGEN, V81, P151; MICHALSKI AJ, 1993, GENOMICS, V18, P141, DOI 10.1006/geno.1993.1439; MICHALSKI AJ, 1992, ONCOGENE, V7, P1595; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; MITCHELL CD, 1991, BRIT MED BULL, V47, P136, DOI 10.1093/oxfordjournals.bmb.a072452; MITCHELL CD, 1989, ONCOGENE, V4, P253; Mora J, 2000, J MOL DIAGN, V2, P37, DOI 10.1016/S1525-1578(10)60613-7; NAGANO H, 1980, JPN J HUM GENET, V25, P39, DOI 10.1007/BF01876544; OCONNELL P, 1989, SCIENCE, V244, P1087, DOI 10.1126/science.2543077; PONZONI M, 1991, CELL MOL NEUROBIOL, V11, P397, DOI 10.1007/BF00711421; RICCARDI VM, 1978, PEDIATRICS, V61, P604; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; Roberts T, 1998, CANCER GENET CYTOGEN, V100, P10, DOI 10.1016/S0165-4608(97)00013-7; Sambrook J, 1989, MOL CLONING LAB MANU; SANGER WG, 1984, CANCER GENET CYTOGEN, V11, P153, DOI 10.1016/0165-4608(84)90109-2; Sossey-Alaoui K, 1999, GENOMICS, V60, P330, DOI 10.1006/geno.1999.5924; Sossey-Alaoui K, 2001, INT J MOL MED, V7, P543; Still IH, 1998, BLOOD, V92, P1456, DOI 10.1182/blood.V92.4.1456.splL3_1456_1458; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Takenawa T, 2001, J CELL SCI, V114, P1801; Van Roy N, 1997, EUR J CANCER, V33, P1974, DOI 10.1016/S0959-8049(97)00319-5; VARESCO L, 1989, P NATL ACAD SCI USA, V86, P10118, DOI 10.1073/pnas.86.24.10118; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; XU Y, 1994, ISMB, V2, P376; YUNIS JJ, 1978, AM J DIS CHILD, V132, P161, DOI 10.1001/archpedi.1978.02120270059012	42	46	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5967	5974		10.1038/sj.onc.1205734	http://dx.doi.org/10.1038/sj.onc.1205734			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185600				2022-12-17	WOS:000177520900020
J	Kim, NG; Rhee, H; Li, LS; Kim, H; Lee, JS; Kim, JH; Kim, H				Kim, NG; Rhee, H; Li, LS; Kim, H; Lee, JS; Kim, JH; Kim, H			Identification of MARCKS, FLJ11383 and TAF1B as putative novel target genes in colorectal carcinomas with microsatellite instability	ONCOGENE			English	Article						DNA mismatch repair; microsatellite instability; coding mononucleotide repeats; frameshift mutation; colorectal carcinoma	SOMATIC FRAMESHIFT MUTATIONS; DNA MISMATCH REPAIR; C-KINASE SUBSTRATE; II RECEPTOR GENE; MUTATOR PHENOTYPE; GROWTH-FACTOR; CANCER-CELLS; GASTROINTESTINAL CANCER; MONONUCLEOTIDE REPEATS; COLON CANCERS	Somatic frameshift mutations in some genes containing coding mononucleotide repeats (cMNRs) are well known characteristics of tumors with high microsatellite instability (MSI-H). We identified 22 novel and 11 known target genes containing cMNRs with a length of 10 or more nucleotides by using a systematic database search. Frameshift mutation analysis was performed with these 33 genes in 39 MSI-H and 24 microsatellite stable (MSS) colorectal carcinomas by assessing the mobility shifts of PCR products in gel electrophoresis and by sequencing. All the 39 MSI-H colorectal carcinomas, except one, showed mutations in more than one gene, while no mutations were found in 24 MSS colorectal carcinomas. Of these MSI-H tumors, 11 genes were mutated in more than 40%. The most frequently mutated novel genes were MARCKS (72%), FLJ11383 (74%) and TAF1B (82%). Bialletic inactivation in MARCKS and FLJ11383 was also frequent in MSI-H tumors. The observed mutation frequency of the 11 known target genes was compatible with that found by previous studies. The very high frequency of mutations, biallelic mutations and the predicted truncation of protein products suggests that mutations of MARCKS, FLJ11383 and TAF1B are selected, and play a role in the tumorigenesis of MSI-H colorectal carcinomas.	Yonsei Univ, Coll Med, Dept Pathol, Seoul 120749, South Korea; Yonsei Univ, Dept Canc Metastasis Res Ctr, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Dept Brain Korea 21 Projects Med Sci, Seoul 120749, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University; Yonsei University Health System	Kim, H (corresponding author), Yonsei Univ, Coll Med, Dept Pathol, CPO Box 8044, Seoul 120749, South Korea.	hkyonsei@yumc.yonsei.ac.kr		LEE, JIN-SUNG/0000-0002-1262-8597; Kim, Nam-Kyu/0000-0003-0639-5632				Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Boland CR, 1998, CANCER RES, V58, P5248; Brooks G, 1996, CARCINOGENESIS, V17, P683, DOI 10.1093/carcin/17.4.683; BROOKS SF, 1992, J BIOL CHEM, V267, P14212; CHEN JS, 1995, CANCER RES, V55, P174; CHOI SJ, 1998, J KOREAN CANC ASS, V30, P527; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; Duval A, 1999, ONCOGENE, V18, P6806, DOI 10.1038/sj.onc.1203287; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; HERGET T, 1993, P NATL ACAD SCI USA, V90, P2945, DOI 10.1073/pnas.90.7.2945; Kim JJ, 1999, LAB INVEST, V79, P1113; Kim NG, 2001, CANCER RES, V61, P36; Ku JL, 1999, EUR J CANCER, V35, P1724, DOI 10.1016/S0959-8049(99)00206-3; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; Manenti S, 1998, CANCER RES, V58, P1429; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mori Y, 2001, CANCER RES, V61, P6046; Ohmiya N, 2001, GENE, V272, P301, DOI 10.1016/S0378-1119(01)00517-0; Park J, 2002, CANCER RES, V62, P1284; PARK JG, 1987, CANCER RES, V47, P6710; PARSONS R, 1995, CANCER RES, V55, P5548; Perucho M, 1996, BIOL CHEM, V377, P675; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Schwartz S, 1999, CANCER RES, V59, P2995; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Tran HT, 1997, MOL CELL BIOL, V17, P2859, DOI 10.1128/MCB.17.5.2859; Woerner SM, 2001, INT J CANCER, V93, P12, DOI 10.1002/ijc.1299; Yamamoto H, 1997, CANCER RES, V57, P4420; Zhang L, 2001, CANCER RES, V61, P3801	33	46	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5081	5087		10.1038/sj.onc.1205703	http://dx.doi.org/10.1038/sj.onc.1205703			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140758				2022-12-17	WOS:000176975900006
J	Xiang, H; Fox, JA; Totpal, K; Aikawa, M; Dupree, K; Sinicropi, D; Lowe, J; Escandon, E				Xiang, H; Fox, JA; Totpal, K; Aikawa, M; Dupree, K; Sinicropi, D; Lowe, J; Escandon, E			Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors	ONCOGENE			English	Article						Apo2L/TRAIL; CPT-11; SN-38; p21; DR4; DR5	APOPTOSIS-INDUCING LIGAND; FAS-MEDIATED APOPTOSIS; IONIZING-RADIATION; ANTITUMOR-ACTIVITY; COMPLEX-FORMATION; CANCER-CELLS; CASPASE 3; DEATH; INDUCTION; P53	Apo2L/TRAIL exhibits enhanced apoptotic activity in tumor xenograft models when used in combination with the topoisomerase 1 inhibitor CPT-11. To investigate the cellular mechanisms involved in this increased tumor-killing activity, a series of in vitro experiments were conducted using the human colon carcinoma cell line (HCT116). Apo2L/TRAIL induced a transient upregulation of DR5 mRNA, while CPT-11 increased both death and decoy receptor expression. Upregulation of decoy receptors by CPT-11 was partially inhibited by co-administration of Apo2L/TRAIL. CPT-11 treatment resulted in accumulation of cells at G(2)M-phase and correlated with a substantial increase in the protein levels of the cyclin-dependent kinase inhibitor p21. However, cells co-treated with CPT-11 and Apo2L/TRAIL, or pretreated with CPT-11 for up to 24 h followed by 2 h Apo2L/TRAIL, resulted in a caspase-dependent degradation of p21, reversal of G(2)-M phase arrest with a concomitant increase in apoptosis. The sequential treatment produced the greatest induction of DR5 and DR4, caspase-3-like cleavage/activation and p21 degradation, as well as increased apoptosis. These data indicate that the up-regulation of Apo2L/TRAIL ligand and its death receptors as well as cleavage of p21 protein in the Apo2L/TRAIL plus CPT-11 treatment contributes to the positive cooperation between these agents in enhancing tumor cell apoptosis.	Genentech Inc, Dept Clin & Expt Pharmacol, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept BioAnalyt R&D, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Escandon, E (corresponding author), Genentech Inc, Dept Clin & Expt Pharmacol, 1 DNA Way, San Francisco, CA 94080 USA.							Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Chai F, 2000, CARCINOGENESIS, V21, P7, DOI 10.1093/carcin/21.1.7; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Choi SH, 1998, CANCER LETT, V124, P15, DOI 10.1016/S0304-3835(97)00428-X; Deptala A, 1999, INT J ONCOL, V15, P861; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farczadi E, 1999, NEOPLASMA, V46, P219; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gliniak B, 1999, CANCER RES, V59, P6153; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; HARPER JW, 1993, CELL, V75, P805; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; McDonald AC, 1998, BRIT J CANCER, V78, P745, DOI 10.1038/bjc.1998.571; Nagane M, 2000, CANCER RES, V60, P847; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; ROTHENBERG ML, 1993, J CLIN ONCOL, V11, P2194, DOI 10.1200/JCO.1993.11.11.2194; Scott N, 1998, EUR J SURG ONCOL, V24, P169, DOI 10.1016/S0748-7983(98)92861-X; Sellers WR, 1999, J CLIN INVEST, V104, P1655, DOI 10.1172/JCI9053; Sheikh MS, 1998, CANCER RES, V58, P1593; Sparreboom A, 1998, CLIN CANCER RES, V4, P2747; Strasser A, 1999, INT J CANCER, V81, P505, DOI 10.1002/(SICI)1097-0215(19990517)81:4<505::AID-IJC1>3.0.CO;2-J; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; TISHLER RB, 1993, CANCER RES, V53, P2212; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; Zhang YK, 1999, INT J CANCER, V83, P790, DOI 10.1002/(SICI)1097-0215(19991210)83:6<790::AID-IJC15>3.0.CO;2-6; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	42	46	53	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3611	3619		10.1038/sj.onc.1205449	http://dx.doi.org/10.1038/sj.onc.1205449			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032863				2022-12-17	WOS:000175793700012
J	Ueki, T; Walter, KM; Skinner, H; Jaffee, E; Hruban, RH; Goggins, M				Ueki, T; Walter, KM; Skinner, H; Jaffee, E; Hruban, RH; Goggins, M			Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived	ONCOGENE			English	Article						CpG island methylation; pancreatic adenocarcinoma; cell line	DNA METHYLATION; DENOVO METHYLATION; EPITHELIAL-CELLS; SUPPRESSOR ROLE; INACTIVATION; GENE; HYPERMETHYLATION; CARCINOMA; EXPRESSION; PANCREAS	A higher prevalence of epigenetic inactivation of tumor suppressor genes has been reported in cancer cell tine populations compared to primary cancer populations. Cancer-related genes are commonly methylated in cancer cell lines but it is not known the extent to which tumor suppressor genes may be artificially methylated in vitro. We therefore examined 10 pancreatic cancer cell lines and corresponding primary tumors for aberrant DNA methylation of promoter CpG islands of eight genes and seven CpG islands. Using methylation-specific PCR (MSP), methylation was not detected at any of the 15 CpG islands in 15 normal pancreata or in an immortalized normal pancreatic duct epithelial (HPDE) cell line. Of 150 loci examined, 49 loci were methylated in both primary carcinomas and their corresponding cell lines, 95 loci were not methylated in either cell lines or their corresponding primary carcinomas. There were four loci methylated only in cell lines while another two loci were methylated only in primary carcinomas. Overall, the methylation status of primary carcinomas and their cell lines were concordant in 96% of cases (144 of 150) (J statistic; J=0.92, P<0.0001). We conclude that most of the DNA methylation of tumor suppressor genes observed in cancer cell lines is present in the primary carcinomas from which they were derived.	Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Goggins, M (corresponding author), Johns Hopkins Med Inst, Dept Pathol, 632 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mgoggins@jhmi.edu	Skinner, Halcyon/A-1049-2009	Skinner, Halcyon G./0000-0002-0220-9110; Jaffee, Elizabeth/0000-0003-3841-6549	NCI NIH HHS [CA62924] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA062924] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Bachman KE, 1999, CANCER RES, V59, P798; Baylin SB, 1998, ADV CANCER RES, V72, P141; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Esteller M, 2001, CANCER RES, V61, P3225; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jarrard DF, 1999, CANCER RES, V59, P2957; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; Liu N, 1998, AM J PATHOL, V153, P263, DOI 10.1016/S0002-9440(10)65567-8; Markl IDC, 2001, CANCER RES, V61, P5875; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Schutte M, 1997, CANCER RES, V57, P3126; Toyota M, 1999, CANCER RES, V59, P2307; Ueki T, 2000, CANCER RES, V60, P1835; Ueki T, 2001, CANCER RES, V61, P8540; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Wilentz RE, 2000, AM J PATHOL, V156, P1641, DOI 10.1016/S0002-9440(10)65035-3; Wilentz RE, 1998, CANCER RES, V58, P4740	24	46	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2114	2117		10.1038/sj.onc.1205275	http://dx.doi.org/10.1038/sj.onc.1205275			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960385				2022-12-17	WOS:000174827000019
J	Morcinek, JC; Weisser, C; Geissinger, E; Schartl, M; Wellbrock, C				Morcinek, JC; Weisser, C; Geissinger, E; Schartl, M; Wellbrock, C			Activation of STAT5 triggers proliferation and contributes to anti-apoptotic signalling mediated by the oncogenic Xmrk kinase	ONCOGENE			English	Article						STAT5; Xmrk; melanoma; bcl-x; apoptosis; proliferation	RECEPTOR TYROSINE KINASE; EPIDERMAL-GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CELLULAR-RESPONSE; FAMILY-MEMBER; CELLS; EGF; TRANSFORMATION; PHOSPHORYLATION; SUPPRESSION	Extensive studies of primary tumors and tumor derived cell lines revealed that inappropriate activation of specific STATs (particularly of STAT3 and STAT5) occurs with high frequency in a wide variety of human cancers. We reported recently that the melanoma inducing EGFR-related receptor Xmrk specifically induces constitutive activation of STAT5 in fish melanoma cells. However. little is known about the role of STAT5 in solid tumours in general and its function in melanoma in particular. Recent examinations suggest that activated STAT signalling participates in oncogenesis by stimulating cell proliferation and preventing apoptosis. As an initial approach to understanding the consequences of Xmrk-induced STAT5 signalling we used the well characterized pro B-cell line Ba/F3 as a sensitive system to analyse mitogenic as well as anti-apoptotic signalling. We identified STAT5 activation as being involved in both growth and survival signalling triggered by the Xmrk kinase possibly due to STAT5 induced expression of phnI and bcl-x. We also found a new mechanism of activation of STAT5 by receptor tyrosine kinases, whereby direct interaction of the receptor kinase domain with the STAT protein in a phosphotyrosine independent way led to activation of STAT5 in terms of DNA binding and target gene expression.	Univ Wurzburg, Theodor Boveri Inst, Bioctr, Dept Physiol Chem 1, D-97074 Wurzburg, Germany	University of Wurzburg	Wellbrock, C (corresponding author), Univ Wurzburg, Theodor Boveri Inst, Bioctr, Dept Physiol Chem 1, Hubland, D-97074 Wurzburg, Germany.	wellbrock@biozentrum.uni-wuerzburg.de		Wellbrock, Claudia/0000-0002-3825-6381; Schartl, Manfred/0000-0001-9882-5948				Baudler M, 1999, EXP CELL RES, V249, P212, DOI 10.1006/excr.1999.4470; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DiGiovanna MP, 1998, ONCOGENE, V17, P1877, DOI 10.1038/sj.onc.1202091; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; FENDLY BM, 1990, CANCER RES, V50, P1550; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; Jaster R, 1999, CELL SIGNAL, V11, P769, DOI 10.1016/S0898-6568(99)00050-9; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Lischke A, 1996, ANAL BIOCHEM, V236, P322, DOI 10.1006/abio.1996.0173; Mayr S, 1998, EUR J BIOCHEM, V258, P784, DOI 10.1046/j.1432-1327.1998.2580784.x; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; Paukku K, 2000, BIOCHEM J, V345, P759, DOI 10.1042/0264-6021:3450759; PERIS K, 1991, ARCH DERMATOL RES, V283, P500, DOI 10.1007/BF00371922; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wellbrock C, 1999, EUR J BIOCHEM, V260, P275, DOI 10.1046/j.1432-1327.1999.00180.x; Wellbrock C, 1998, ONCOGENE, V16, P3047, DOI 10.1038/sj.onc.1201844; Wellbrock C, 2000, EUR J BIOCHEM, V267, P3513, DOI 10.1046/j.1432-1327.2000.01378.x; WINKLER C, 1994, ONCOGENE, V9, P1517; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; Zhang K, 1996, J BIOL CHEM, V271, P3884; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	42	46	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1668	1678		10.1038/sj.onc.1205148	http://dx.doi.org/10.1038/sj.onc.1205148			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896598				2022-12-17	WOS:000174214200005
J	Tobin, SW; Douville, K; Benbow, U; Brinckerhoff, CE; Memoli, VA; Arrick, BA				Tobin, SW; Douville, K; Benbow, U; Brinckerhoff, CE; Memoli, VA; Arrick, BA			Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects	ONCOGENE			English	Article						TGF-beta; autocrine; paracrine; breast cancer	GROWTH-FACTOR-BETA; COLON-CARCINOMA CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; PROSTATE-CANCER; II RECEPTOR; DISEASE PROGRESSION; GASTRIC-CARCINOMA; MAMMARY-TUMOR; IN-VIVO; TUMORIGENICITY	To characterize the impact of increased production of TGF-beta in a xenograft model of human breast cancer, TGF-beta -responsive MDA-231 cells were genetically modified by stable transfection so as to increase their production of active TGF-beta1. Compared with control cells, cells that produced increased amounts of TGF-beta proliferated in vitro more slowly. In vivo, however, tumors derived from these cells exhibited increased proliferation and grew at an accelerated pace. To evaluate the role of autocrine TGF-beta signaling, cells were also transfected with a dominant-negative truncated type II TGF-beta receptor (T beta RII). Disruption of autocrine TGF-beta signaling in the TGF-beta -overexpressing cells reduced their in vivo growth rate. Co-inoculation of Matrigel with the TGF-beta -overexpressing cells expressing the truncated T beta RII compensated for their diminished in vivo growth capacity, compared with the TGF-beta -overexpressing cells with an intact autocrine loop. Tissue invasion by the tumor was a distinctive feature of the TGF-beta -overexpressing cells, whether or not the autocrine loop was intact. Furthermore, tumors derived from TGF-beta -overexpressing cells, irrespective of the status of the autocrine TGF-beta -signaling pathway, had a higher incidence of lung metastasis. Consistent with the suggestion that TGF-beta 's enhancement of invasion and metastasis is paracrine-based, we observed no significant differences among the cell clones in an in vitro invasion assay. Thus, in this experimental model system in vitro assays of cell proliferation and invasion do not accurately reflect in vivo observations, perhaps due to autocrine and paracrine effects of TGF-beta that influence the important in vivo-based phenomena of tumor growth, invasion, and metastasis.	Dartmouth Coll Sch Med, Dept Med, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Pathol, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Dartmouth College	Arrick, BA (corresponding author), Dartmouth Coll Sch Med, Dept Med, Kellogg Box 0128, Hanover, NH 03755 USA.	Bradley.Arrick@dartmouth.edu			NATIONAL CANCER INSTITUTE [T32CA009658, R01CA060928] Funding Source: NIH RePORTER; NCI NIH HHS [CA09658, CA60928] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Anbazhagan R, 1999, CANCER RES, V59, P3363; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; ARRICK BA, 1996, MOL ENDOCRINOLOGY CA, P51; Arteaga CL, 1999, JNCI-J NATL CANCER I, V91, P46, DOI 10.1093/jnci/91.1.46; ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871; Ausubel F.M., 1987, CURRENT PROTOCOLS MO; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; BAO L, 1994, BRIT J CANCER, V70, P228, DOI 10.1038/bjc.1994.284; Benbow U, 1999, CLIN EXP METASTAS, V17, P231, DOI 10.1023/A:1006639214618; BRAND T, 1995, J BIOL CHEM, V270, P8274, DOI 10.1074/jbc.270.14.8274; BRUNNER AM, 1989, J BIOL CHEM, V264, P13660; CHANG HL, 1993, CANCER RES, V53, P4391; Chen TP, 1998, CANCER RES, V58, P4805; DALAL BI, 1993, AM J PATHOL, V143, P381; FRIEDMAN E, 1995, CANCER EPIDEM BIOMAR, V4, P549; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; Gobbi H, 2000, HISTOPATHOLOGY, V36, P168; GORSCH SM, 1992, CANCER RES, V52, P6949; HSU S, 1994, CELL GROWTH DIFFER, V5, P267; INGE TH, 1992, CANCER RES, V52, P1386; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kinugasa S, 1998, ONCOLOGY-BASEL, V55, P582, DOI 10.1159/000011916; Koli KM, 1996, J MAMMARY GLAND BIOL, V1, P373, DOI 10.1007/BF02017393; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Lu ML, 2000, ONCOGENE, V19, P6351, DOI 10.1038/sj.onc.1204025; Maehara Y, 1999, J CLIN ONCOL, V17, P607, DOI 10.1200/JCO.1999.17.2.607; Matsuzaki K, 2000, CANCER RES, V60, P1394; Matthews E, 2000, BRIT J CANCER, V83, P519, DOI 10.1054/bjoc.2000.1257; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; Mullen P, 1996, INT J CANCER, V67, P816, DOI 10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#; Nguyen AV, 2000, DEVELOPMENT, V127, P3107; NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Ohmori T, 1998, EXP CELL RES, V245, P350, DOI 10.1006/excr.1998.4261; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Reiss M, 1997, BREAST CANCER RES TR, V45, P81, DOI 10.1023/A:1005865812918; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Saito H, 1999, CANCER, V86, P1455, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1455::AID-CNCR11>3.0.CO;2-L; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; STEINER MS, 1992, MOL ENDOCRINOL, V6, P15, DOI 10.1210/me.6.1.15; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TAKANAMI I, 1994, J CLIN PATHOL, V47, P1098, DOI 10.1136/jcp.47.12.1098; Tobin SW, 2001, CELL GROWTH DIFFER, V12, P109; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; UEKI N, 1993, JPN J CANCER RES, V84, P589, DOI 10.1111/j.1349-7006.1993.tb02017.x; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; VANSLOOTEN HJ, 1995, BRIT J CANCER, V72, P22, DOI 10.1038/bjc.1995.271; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q; WANG DH, 1995, J BIOL CHEM, V270, P14154, DOI 10.1074/jbc.270.23.14154; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; Wikstrom P, 1998, PROSTATE, V37, P19, DOI 10.1002/(SICI)1097-0045(19980915)37:1<19::AID-PROS4>3.0.CO;2-3; Ye SC, 1999, CANCER RES, V59, P4725; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	55	46	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2002	21	1					108	118		10.1038/sj.onc.1205026	http://dx.doi.org/10.1038/sj.onc.1205026			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791181				2022-12-17	WOS:000172887800011
J	Um, JH; Kang, CD; Lee, BG; Kim, DW; Chung, BS; Kim, SH				Um, JH; Kang, CD; Lee, BG; Kim, DW; Chung, BS; Kim, SH			Increased and correlated nuclear factor-kappa B and Ku autoantigen activities are associated with development of multidrug resistance	ONCOGENE			English	Article						multidrug resistance; NF-kappa B; Ku autoantigen; PKA inhibitor; anticancer drug	DEPENDENT PROTEIN-KINASE; CHRONIC LYMPHOCYTIC-LEUKEMIA; INDUCED APOPTOSIS; CYCLIC-AMP; CROSS-RESISTANCE; GENE-EXPRESSION; CANCER-THERAPY; DNA-DAMAGE; CELL-DEATH; INDUCIBLE CHEMORESISTANCE	In this study, we investigated possible engagement of NF-kappaB and Ku autoantigen (Ku) activation in development of multidrug resistance (MDR) and circumvention of MDR by modulation of NF-kappaB and Ku. The NF-kappaB activity and NF-kappaB p65 subunit level were constitutively higher in MDR cells than in drug-sensitive parental cells. Interestingly, a faster running NF-kappaB DNA binding complex was identified as Ku, a DNA damage sensor and a key double strand break repair protein, and was positively correlated with the NF-kappaB activity in MDR cells and Ku- or both subunits of NF-kappaB-transfected cells. Also both NF-kappaB and Ku activities were activated or inhibited by treatment with etoposide (VP-16) or MG-132 (a proteasome inhibitor), respectively. Furthermore, PKA inhibitor suppressed markedly the constitutive and drug-induced activities of NF-kappaB and Ku in MDR cells and subsequently potentiated the cytotoxic activity of anticancer drugs. Our results proposed that the NF-kappaB and Ku activation could be one of multi-factorial MDR mechanism, and PKA inhibitor, likely via inhibition of NF-kappaB and Ku activities, could enhance the effectiveness of anticancer drugs against MDR cells with high activities of NF-kappaB and Ku.	Pusan Natl Univ, Coll Med, Dept Biochem, Pusan 602739, South Korea; Pusan Natl Univ, Coll Med, Res Ctr Mol Med, Pusan 602739, South Korea; Chang Won Natl Univ, Coll Nat Sci, Dept Microbiol, Chang Won 641773, South Korea	Pusan National University; Pusan National University; Changwon National University	Kim, SH (corresponding author), Pusan Natl Univ, Coll Med, Dept Biochem, Pusan 602739, South Korea.							ALBERT DA, 1995, J CLIN INVEST, V95, P1490, DOI 10.1172/JCI117820; Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bjork-Eriksson T, 1999, INT J RADIAT ONCOL, V45, P1005, DOI 10.1016/S0360-3016(99)00268-0; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Chao CCK, 1996, EUR J PHARMACOL, V305, P213, DOI 10.1016/0014-2999(96)00168-9; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; Christodoulopoulos G, 1998, CANCER RES, V58, P1789; Cusack JC, 2000, CANCER RES, V60, P2323; Cvijic ME, 1997, CELL GROWTH DIFFER, V8, P1243; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jhappan C, 2000, MOL CELL BIOL, V20, P4075, DOI 10.1128/MCB.20.11.4075-4083.2000; Jin SF, 1997, CANCER SURV, V29, P221; Jin SF, 1998, CARCINOGENESIS, V19, P965, DOI 10.1093/carcin/19.6.965; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Kang CD, 2000, EXP CELL RES, V256, P300, DOI 10.1006/excr.2000.4807; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KIM SH, 1993, CANCER LETT, V74, P37, DOI 10.1016/0304-3835(93)90041-7; Kim SH, 1999, CANCER RES, V59, P4012; Kim SH, 2000, LEUKEMIA RES, V24, P917, DOI 10.1016/S0145-2126(00)00061-8; Lee HJ, 2001, J NEUROCHEM, V76, P602, DOI 10.1046/j.1471-4159.2001.00076.x; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; McKenna SL, 1997, BRIT J HAEMATOL, V96, P659, DOI 10.1046/j.1365-2141.1997.d01-2095.x; MICKISCH G, 1991, UROL RES, V19, P99, DOI 10.1007/BF00368184; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; NEUMANN M, 1992, ANTICANCER RES, V12, P2297; Nueda A, 1999, J BIOL CHEM, V274, P14988, DOI 10.1074/jbc.274.21.14988; Pae HO, 1999, IMMUNOPHARM IMMUNOT, V21, P233, DOI 10.3109/08923979909052760; Pajonk F, 2000, INT J RADIAT ONCOL, V47, P1025, DOI 10.1016/S0360-3016(00)00516-2; Palissot V, 1998, BIOCHEM BIOPH RES CO, V245, P918, DOI 10.1006/bbrc.1998.8550; Pernin D, 2000, B CANCER, V87, P635; Ruchaud S, 1997, ONCOGENE, V15, P827, DOI 10.1038/sj.onc.1201248; SATTA T, 1992, CANCER, V69, P941, DOI 10.1002/1097-0142(19920215)69:4<941::AID-CNCR2820690418>3.0.CO;2-H; Shackelford DA, 1999, J NEUROSCI, V19, P4727; Shen HX, 1998, BBA-GEN SUBJECTS, V1381, P131, DOI 10.1016/S0304-4165(98)00020-8; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Stavrovskaya AA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P95; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JS, 1998, J BIOL CHEM, V273, P31068, DOI 10.1074/jbc.273.47.31068; Watanabe K, 2000, BIOCHEM PHARMACOL, V60, P823, DOI 10.1016/S0006-2952(00)00387-7; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; Zhao HJ, 2000, CLIN CANCER RES, V6, P1073; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhou DC, 1996, INT J CANCER, V65, P365, DOI 10.1002/(SICI)1097-0215(19960126)65:3<365::AID-IJC15>3.0.CO;2-9; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	61	46	52	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6048	6056		10.1038/sj.onc.1204732	http://dx.doi.org/10.1038/sj.onc.1204732			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593412				2022-12-17	WOS:000171056300012
J	Yang, HY; Shao, RP; Hung, MC; Lee, MH				Yang, HY; Shao, RP; Hung, MC; Lee, MH			p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis	ONCOGENE			English	Article						HER2/neu; tetracycline-regulated gene expression; tumor suppression; CDK; p27	DEPENDENT KINASE INHIBITOR; HUMAN-BREAST-CANCER; TUMOR SUPPRESSION; INDUCED APOPTOSIS; GENE-EXPRESSION; NEU ONCOGENE; HER-2/NEU; P27(KIP1); ANTIBODY; TRANSFORMATION	HER2/neu, a receptor tyrosine kinase oncogene, promotes mitogenic growth and transformation of cancer cells. We previously identified that its oncogenic signals down-regulate the cyclin-dependent kinase inhibitor p27 Kip1, which is defined as a haplo-insufficient tumor suppressor. Here, we applied the human p27 gene as a novel anticancer agent for HER2/neu-overexpressing cells under the control of a tetracycline (tet)-regulated gene expression system, Overexpression of p27 inhibits HER2/neu-activated CDK2 activity, cell proliferation, and transformation. Most significantly for clinical application, p27 expression in HER2/neu-overexpressing cells can be regulated in vivo and reduce the tumor volume in a tumor model, The findings demonstrate the applicability of employing p27 in HER2/neu-associated cancer gene therapy.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Breast Canc Res Program, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lee, MH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Box 108, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Lee, Mong-Hong/0000-0001-8675-8215	NCI NIH HHS [R01 CA089266, P30 CA016672, R56 CA089266] Funding Source: Medline; NCRR NIH HHS [UL1 RR024148] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089266, R56CA089266, P30CA016672] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Baselga J, 1998, CANCER RES, V58, P2825; Clurman BE, 1998, P NATL ACAD SCI USA, V95, P15158, DOI 10.1073/pnas.95.26.15158; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Le XF, 2000, CANCER RES, V60, P3522; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Newman L, 2001, MOL CARCINOGEN, V30, P169, DOI 10.1002/mc.1025; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REARDON DB, 1993, J BIOL CHEM, V268, P18136; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Wen Y, 2000, CANCER RES, V60, P42; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	20	46	54	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3695	3702		10.1038/sj.onc.1204472	http://dx.doi.org/10.1038/sj.onc.1204472			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439332				2022-12-17	WOS:000169400200010
J	Maurici, D; Monti, P; Campomenosi, P; North, S; Frebourg, T; Fronza, G; Hainaut, P				Maurici, D; Monti, P; Campomenosi, P; North, S; Frebourg, T; Fronza, G; Hainaut, P			Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	ONCOGENE			English	Article						amifostine; p53; yeast functional assay	TUMOR-SUPPRESSOR P53; DNA-BINDING; CELL-CYCLE; GENE-EXPRESSION; IN-VITRO; IDENTIFICATION; MUTATIONS; APOPTOSIS; SPECTRUM; LINES	Many p53 mutants found in human cancer have an altered ability to bind DNA and transactivate gene expression. Re-expression of functional p53 in cells in which the endogenous TP53 gene is inactivated has been demonstrated to restore a non-tumorigenic phenotype, Pharmacological modulation of p53 mutant conformation may therefore represent a mechanism to reactivate p53 function and consequently improve response to radio- and chemotherapy, We have recently reported that the radio- and chemoprotector Amifostine (WR2721, Ethyol(H)) activates wild-type p53 in cultured mammalian cells. In the present study, we have used a yeast functional assay to investigate the effect of WR2721 on the transcriptional activity of p53. WR2721 restored this activity in a temperature-sensitive mutant V272M (valine to methionine at codon 272) expressed at the nonpermissive temperature and it also partially restored the transcriptional activity of several other conformationally flexible p53 mutants. The results indicate that the yeast functional assay may be used to identify compounds that modulate p53 activity, with potential therapeutic implications.	Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon, France; Natl Canc Inst, Mutagenesis Lab, IST, I-16132 Genoa, Italy; Fac Med & Pharm, INSERM EPI, F-76183 Rouen, France	World Health Organization; International Agency for Research on Cancer (IARC); Institut National de la Sante et de la Recherche Medicale (Inserm)	Hainaut, P (corresponding author), Int Agcy Res Canc, Grp Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon, France.		Monti, Paola/Y-1118-2019; Fronza, Gilberto/AAG-8735-2019; Campomenosi, Paola/C-9729-2011; Hainaut, Pierre/B-6018-2012; Frebourg, Thierry/AAK-8390-2020	Monti, Paola/0000-0002-1978-4998; Fronza, Gilberto/0000-0003-3722-553X; Campomenosi, Paola/0000-0002-8853-1134; Hainaut, Pierre/0000-0002-1303-1610; 				Barnas C, 1997, INT J CANCER, V71, P79, DOI 10.1002/(SICI)1097-0215(19970328)71:1<79::AID-IJC14>3.0.CO;2-4; CALABROJONES PM, 1985, INT J RADIAT BIOL, V47, P23, DOI 10.1080/09553008514550041; Capizzi RL, 1999, SEMIN ONCOL, V26, P72; Capizzi RL, 1999, SEMIN ONCOL, V26, P1; Capizzi RL, 1999, SEMIN ONCOL, V26, P3; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Di Como CJ, 1998, ONCOGENE, V16, P2527; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GRDINA DJ, 1995, CARCINOGENESIS, V16, P767, DOI 10.1093/carcin/16.4.767; Hainaut P, 2000, ADV CANCER RES, V77, P81; HAINAUT P, 1993, CANCER RES, V53, P4469; Inga A, 1997, CARCINOGENESIS, V18, P2019, DOI 10.1093/carcin/18.10.2019; Inga A, 1999, CANCER RES, V59, P689; Inga A, 1998, CARCINOGENESIS, V19, P741, DOI 10.1093/carcin/19.5.741; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; Kelly JD, 1999, J BIOL CHEM, V274, P18327, DOI 10.1074/jbc.274.26.18327; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kramer DL, 1998, BIOCHEM SOC T, V26, P609, DOI 10.1042/bst0260609; Kramer DL, 1999, CANCER RES, V59, P1278; Lang D, 1998, ONCOGENE, V16, P1593, DOI 10.1038/sj.onc.1201665; Li L, 1999, AM J PHYSIOL-CELL PH, V276, pC946, DOI 10.1152/ajpcell.1999.276.4.C946; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Marzatico F, 2000, CANCER CHEMOTH PHARM, V45, P172, DOI 10.1007/s002800050026; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; North S, 2000, ONCOGENE, V19, P1206, DOI 10.1038/sj.onc.1203413; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Oren M, 1999, CELL MOL LIFE SCI, V55, P9, DOI 10.1007/s000180050265; PEGG AE, 1988, CANCER RES, V48, P759; Pollard KJ, 1999, EMBO J, V18, P5622, DOI 10.1093/emboj/18.20.5622; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563; ROLLEY N, 1995, ONCOGENE, V11, P763; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SHIGEMATSU N, 1994, MUTAGENESIS, V9, P355, DOI 10.1093/mutage/9.4.355; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699	44	46	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2001	20	27					3533	3540		10.1038/sj.onc.1204428	http://dx.doi.org/10.1038/sj.onc.1204428			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429700				2022-12-17	WOS:000169478300009
J	Fattman, CL; Delach, SM; Dou, QP; Johnson, DE				Fattman, CL; Delach, SM; Dou, QP; Johnson, DE			Sequential two-step cleavage of the retinoblastoma protein by caspase-3/-7 during etoposide-induced apoptosis	ONCOGENE			English	Article						retinoblastoma; caspase; apoptosis; etoposide; cleavage	S-PHASE ENTRY; TRANSCRIPTION FACTOR; GENE-PRODUCT; CELL-CYCLE; P53-MEDIATED APOPTOSIS; SUSCEPTIBILITY GENE; CANCER-CELLS; RB; DEPHOSPHORYLATION; E2F-1	During cellular apoptosis, retinoblastoma protein (RB) is subjected to cleavage near the carboxyl terminus by a caspase-3-like protease, In addition, an heretofore unidentified protease cleaves RB internally, generating fragments of 68 and 48 kDa, Internal cleavage abrogates the ability of RB to associate with E2F, To investigate the mechanism of RB internal cleavage, we developed and employed an in vitro cleavage assay. Incubation of in vitro translated S-35-RB with apoptotic cell extracts led to RB cleavage at the C-terminus, followed by internal cleavage. The caspase peptide inhibitors z-VAD-FMK or z-DEVD-FMK blocked both cleavage events. Rapid C-terminal and internal cleavage were also observed when recombinant caspase-3 was added to S-35-RB. Moreover, when caspase-3 was added to nonapoptotic cell extract, efficient internal cleavage of cellular RB was observed. Caspase-mediated internal cleavage occurred following RB residue aspartate(349) in the sequence DSID349. This sequence is consistent with a DXXD recognition motif for caspase-3-like enzymes. Interestingly, ne also observed RB internal cleavage in caspase-3-deficient MCF-7 cells, indicating that other caspases are capable of cleaving RB internally. Indeed, caspase-7, a member of the caspase-3 subfamily, was found to cleave S-35-RB at both the carboxyl terminus, and following aspartate(349). By contrast, caspases that are not members of the caspase-3 subfamily failed to cleave RB. Taken together, our findings demonstrate that during apoptosis, a caspase-3-like protease is responsible for degradation and functional inactivation of RB by cleaving the protein internally following aspartate(349). Oncogene (2001) 20, 2918-2926.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Div Hematol Oncol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Dept Biochem & Mol Biol, Drug DIscovery Program, Tampa, FL 33612 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Johnson, DE (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, Div Hematol Oncol, BST E1055,211 Lothrop St, Pittsburgh, PA 15213 USA.			Dou, Qingping/0000-0002-6465-1473	NATIONAL CANCER INSTITUTE [R29CA066044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R55AG013300, R29AG013300] Funding Source: NIH RePORTER; NCI NIH HHS [CA66044] Funding Source: Medline; NIA NIH HHS [AG13300] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; An B, 1996, CANCER RES, V56, P438; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; Berry DE, 1996, ONCOGENE, V12, P1809; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; Dou QP, 1997, APOPTOSIS, V2, P5; Dou QP, 1997, J CELL BIOCHEM, V64, P586; Fattman CL, 1998, CANCER LETT, V130, P103, DOI 10.1016/S0304-3835(98)00121-9; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; HASSKOGAN DA, 1995, EMBO J, V14, P461; HAUPT Y, 1995, ONCOGENE, V10, P1563; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Kurokawa H, 1999, ONCOL REP, V6, P33; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; McConkey DJ, 1996, ONCOGENE, V13, P1693; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	38	46	49	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2918	2926		10.1038/sj.onc.1204414	http://dx.doi.org/10.1038/sj.onc.1204414			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420704				2022-12-17	WOS:000168901800007
J	Dell'Era, P; Belleri, M; Stabile, H; Massardi, ML; Ribatti, D; Presta, M				Dell'Era, P; Belleri, M; Stabile, H; Massardi, ML; Ribatti, D; Presta, M			Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells	ONCOGENE			English	Article						angiogenesis; cell transfection; endothelium; FGF; FGF receptor; hemangioma	NIH 3T3 CELLS; FACTOR RECEPTOR; FGF RECEPTOR; KAPOSIS-SARCOMA; BIOLOGICAL PROPERTIES; ANGIOGENIC ACTIVITY; FACTOR FAMILY; HEPARIN; EXPRESSION; PROTEIN	Recombinant Fibroblast Growth Factor-4 (FGF4) and FGF2 induce extracellular signal-regulated kinase-1/2 activation and DNA synthesis in murine aortic endothelial (MAE) cells. These cells co-express the IIIc/Ig-3 loops and the novel glyccpsaminoglycan-modified Illc/Ig-2 loops isoforms of FGF receptor-2 (FGFR2). The affinity of FGP4/FGFR2 interaction is 20-30 times lower than that of FGF2 and is enhanced by heparin, Overexpression of FGF2 or FGF4 cDNA in MAE cells results in a transformed phenotype and increased proliferative capacity, more evident for FGF2 than FGF4 transfectants, Both transfectants induce angiogenesis when applied on the top of the chick embryo chorioallantoic membrane. However, in contrast with FG2-transfected cells, FGF4 transfectants show a limited capacity to growth under anchorage-independent conditions and lack the ability to invade 3D fibrin gel and to undergo morphogenesis in vitro. Also, they fail to induce hemangiomas when injected into the allantoic sac of the chick embryo. In conclusion, although exogenous FGF2 and FGF4 exert a similar response in MAE cells, significant differences are observed in the biological behavior of FGF4 ver sus FGF2 transfectants, indicating that the expression of the various members of the FGF family can differently affect the behavior of endothelial cells and, possibly, of other cell types, including tumor cells.	Univ Brescia, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy; Univ Bari, Dept Human Anat & Histol, I-70124 Bari, Italy	University of Brescia; Universita degli Studi di Bari Aldo Moro	Presta, M (corresponding author), Univ Brescia, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy.		Presta, Marco/B-4345-2010; Dell'Era, Patrizia/ABD-5848-2020; Dell'Era, Patrizia/N-6964-2019; Dell'Era, Patrizia/G-5294-2010	Dell'Era, Patrizia/0000-0001-6682-6321; PRESTA, Marco/0000-0002-4398-8376				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLTRINI D, 1994, BIOCHEM J, V303, P583, DOI 10.1042/bj3030583; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1994, J CLIN INVEST, V94, P1736, DOI 10.1172/JCI117521; Escaffit F, 2000, INT J CANCER, V85, P555, DOI 10.1002/(SICI)1097-0215(20000215)85:4<555::AID-IJC18>3.0.CO;2-H; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Gaubert F, 2001, J BIOL CHEM, V276, P1545, DOI 10.1074/jbc.M001184200; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; GRINSPAN JB, 1983, J CELL PHYSIOL, V114, P328, DOI 10.1002/jcp.1041140312; GUALANDRIS A, 1994, J CELL PHYSIOL, V161, P149, DOI 10.1002/jcp.1041610118; Gualandris A, 1996, CELL GROWTH DIFFER, V7, P147; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Kiuru-Kuhlefelt S, 2000, MODERN PATHOL, V13, P433, DOI 10.1038/modpathol.3880074; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; Oliver R T, 1999, Curr Opin Oncol, V11, P236; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; Ribatti D, 1999, J PATHOL, V189, P590; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Ribatti D, 1999, J CELL SCI, V112, P4213; Sakaguchi K, 1999, MOL CELL BIOL, V19, P6754; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Shimon I, 1998, CLIN ENDOCRINOL, V48, P23, DOI 10.1046/j.1365-2265.1998.00332.x; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; TAKAHASHI K, 1994, J CLIN INVEST, V93, P2357, DOI 10.1172/JCI117241; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; THEILLET C, 1989, ONCOGENE, V4, P915; Twigg SRF, 1998, HUM MOL GENET, V7, P685, DOI 10.1093/hmg/7.4.685; Uematsu F, 2000, BIOCHEM BIOPH RES CO, V272, P830, DOI 10.1006/bbrc.2000.2872; YOSHIDA T, 1994, CANCER LETT, V83, P261, DOI 10.1016/0304-3835(94)90328-X	51	46	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2001	20	21					2655	2663		10.1038/sj.onc.1204368	http://dx.doi.org/10.1038/sj.onc.1204368			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420677				2022-12-17	WOS:000168652600006
J	Hohenstein, P; Kielman, MF; Breukel, C; Bennett, LM; Wiseman, R; Krimpenfort, P; Cornelisse, G; van Ommen, GJ; Devilee, P; Fodde, R				Hohenstein, P; Kielman, MF; Breukel, C; Bennett, LM; Wiseman, R; Krimpenfort, P; Cornelisse, G; van Ommen, GJ; Devilee, P; Fodde, R			A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage	ONCOGENE			English	Article						Brca1(1700T); mouse model; hereditary breast cancer; p53; genotype-phenotype correlation; DNA damage	DNA-DAMAGE; BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; GENETIC INSTABILITY; TUMOR SPECTRUM; MEIOTIC CELLS; MODEL; EXPRESSION; REPAIR; MICE	A mouse model with a targeted mutation in the 3' end of the endogenous Brca1 gene, Brca1(1700T), was generated to compare the phenotypic consequences of truncated SI cal proteins with other mutant Brca1 models reported in the literature to date. Mice heterozygous for the Brca1(1700T) mutation do not show any predisposition to tumorigenesis, Treatment of these mice with ionizing radiation or breeding with Ape, Msh-2 or Tp53 mutant mouse models did not show any change in the tumor phenotype, Like other Brca1 mouse models, the Brca1(1700T) mutation is embryonic lethal in homozygous state, However, homozygous Brca1(1700T) embryos reach the headfold stage but are delayed in their development and fail to turn. Thus, in contrast to Brca1(null) models, the mutant embryos do not undergo growth arrest leading to a developmental block at 6.5 dpc, but continue to proliferate and differentiate until 9.5 dpc. Homozygous embryos die between 9.5-10.5 dpc due to massive apoptosis throughout the embryo. These results indicate that a C-terminal truncating Brca1 mutation removing the last BRCT repeat has a different effect on normal cell function than does the complete absence of Brca1.	Leiden Univ, Med Ctr, Dept Human & Clin Genet, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RA Leiden, Netherlands; NIEHS, Res Triangle Pk, NC 27709 USA; Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Netherlands Cancer Institute	Fodde, R (corresponding author), Leiden Univ, Med Ctr, Dept Human & Clin Genet, POB 9503, NL-2300 RA Leiden, Netherlands.		DEVILEE, PETER/ABR-2140-2022; Fodde, Riccardo/AAW-9394-2021; Hohenstein, Peter/Y-2428-2018	Fodde, Riccardo/0000-0001-9839-4324; Hohenstein, Peter/0000-0001-8548-4734	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES023000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Blaszyk H, 2000, INT J CANCER, V89, P32, DOI 10.1002/(SICI)1097-0215(20000120)89:1<32::AID-IJC6>3.0.CO;2-G; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Chandler J, 2001, GENESIS, V29, P72, DOI 10.1002/1526-968X(200102)29:2<72::AID-GENE1007>3.0.CO;2-B; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Grade K, 1997, J CANCER RES CLIN, V123, P69, DOI 10.1007/BF01212618; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Smits R, 2000, GENE CHROMOSOME CANC, V29, P229, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1033>3.0.CO;2-R; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Sobol A, 1996, CANCER RES, V56, P3216; Sobol H, 1997, INT J ONCOL, V10, P349; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; van Oordt CWVH, 1999, GENE CHROMOSOME CANC, V24, P191; vanOordt CWV, 1997, CARCINOGENESIS, V18, P2197, DOI 10.1093/carcin/18.11.2197; Wang Y, 2000, GENE DEV, V14, P927; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yu VPCC, 2000, GENE DEV, V14, P1400; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	43	46	47	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2544	2550		10.1038/sj.onc.1204363	http://dx.doi.org/10.1038/sj.onc.1204363			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420664				2022-12-17	WOS:000168652500005
J	NicAmhlaoibh, R; Shtivelman, E				NicAmhlaoibh, R; Shtivelman, E			Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro	ONCOGENE			English	Article						angiogenesis; metastasis; CC3	TAT-ACTIVATED TRANSCRIPTION; LUNG-CARCINOMA; THROMBOSPONDIN; ANGIOPOIETIN-1; PROLIFERATION; CHEMOKINE; APOPTOSIS; COFACTOR; GROWTH; FAMILY	Resistance to apoptosis and ability to promote angiogenesis are integral features of the metastatic phenotype. Human gene CC3 is a metastasis suppressor for variant small cell lung carcinoma and a mouse melanoma in vivo. We have shown previously that metastasis-suppressing function of CC3 might be due at least in part to the ability of CC3 protein to predispose tumor cells to apoptosis, Here we demonstrate that CC3 has a previously unidentified effect on the ability of tumor cells to induce angiogenesis in vitro. Expression of CC3 in three different tumor cell lines significantly diminished their angiogenic character as manifested in the in vitro proliferation and migration assays with endothelial cells of both macro- and microvascular origin. Expression of CC3 induced changes in RNA levels of several angiogenic modulators consistent with the overall reduction in angiogenic properties. These results indicate that expression of CC3 has a dual effect on phenotype of tumor cells ultimately inhibiting their metastatic potential.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Shtivelman, E (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St, San Francisco, CA 94143 USA.				NATIONAL CANCER INSTITUTE [R01CA071422] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA71422] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Addison CL, 2000, HUM GENE THER, V11, P247, DOI 10.1089/10430340050015996; Baker ME, 1999, CURR BIOL, V9, pR471, DOI 10.1016/S0960-9822(99)80297-8; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; DEARING MP, 1990, J CLIN ONCOL, V8, P1042, DOI 10.1200/JCO.1990.8.6.1042; Gentilini G, 1999, BLOOD, V93, P25, DOI 10.1182/blood.V93.1.25.401a47_25_33; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Liu Y, 1999, J BIOL CHEM, V274, P13338, DOI 10.1074/jbc.274.19.13338; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; SHTIVELMAN E, 1995, P NATL ACAD SCI USA, V92, P4661, DOI 10.1073/pnas.92.10.4661; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Whitman S, 2000, MOL CELL BIOL, V20, P583, DOI 10.1128/MCB.20.2.583-593.2000; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Xiao H, 2000, EMBO J, V19, P956, DOI 10.1093/emboj/19.5.956; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146; Zhai YF, 1999, FASEB J, V13, P181, DOI 10.1096/fasebj.13.1.181	24	46	58	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					270	275		10.1038/sj.onc.1204075	http://dx.doi.org/10.1038/sj.onc.1204075			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313954				2022-12-17	WOS:000166410900014
J	Jabbur, JR; Huang, P; Zhang, W				Jabbur, JR; Huang, P; Zhang, W			DNA damage-induced phosphorylation of p53 at serine 20 correlates with p21 and Mdm-2 induction in vivo	ONCOGENE			English	Article						phosphorylation; ionizing radiation; p53; p21	TUMOR-SUPPRESSOR PROTEIN; ONCOPROTEIN MDM2; KINASE; ACTIVATION; STABILITY; APOPTOSIS; RADIATION; DEGRADATION; TERMINUS; DOMAIN	We investigated the induction and physiological role of Ser20 phosphorylation of p53 in response to DNA damage caused by ionizing radiation (IR) or ultraviolet radiation (UV), A polyclonal antibody that specifically recognizes a p53 peptide containing phosphorylated Ser20 was generated and used to detect p53 phosphorylation at Ser20, Western blot analyses of p53 in four cell lines with this antibody revealed that the p53 protein was phosphorylated at Ser20 to a different extent after treatment with IR or UV, The phosphorylation of Ser20 of wild-type p53 correlated with enhanced induction of the p53 downstream target genes p21(WAF1/Cip1) (p21) and mdm-2. These results suggest that DNA damage-induced phosphorylation of p53 at Ser20 enhances the transactivation function of p53 for p21 and mdm-2 in vivo.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Zhang, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA55164, CA16672, CA77339, CA67987] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R29CA077339, P01CA055164, R29CA067987] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Keller D, 1999, BIOCHEM BIOPH RES CO, V261, P464, DOI 10.1006/bbrc.1999.1023; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kobayashi T, 1998, CELL DEATH DIFFER, V5, P584, DOI 10.1038/sj.cdd.4400382; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Mayo LD, 1997, CANCER RES, V57, P5013; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; WATTHEW JF, 1998, NAT GENET, V19, P175; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	48	46	46	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6203	6208		10.1038/sj.onc.1204017	http://dx.doi.org/10.1038/sj.onc.1204017			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175334				2022-12-17	WOS:000166210500003
J	Suzuki, A; Kadota, N; Hara, T; Nakagami, Y; Izumi, T; Takenawa, T; Sabe, H; Endo, T				Suzuki, A; Kadota, N; Hara, T; Nakagami, Y; Izumi, T; Takenawa, T; Sabe, H; Endo, T			Meltrin alpha cytoplasmic domain interacts with SH3 domains of Src and Grb2 and is phosphorylated by v-Src	ONCOGENE			English	Article						ADAM/MDC family; meltrin alpha/ADAM12; SH3 domain; Src family; Grb2/Ash; tyrosine phosphorylation	NECROSIS-FACTOR-ALPHA; ROUS-SARCOMA VIRUS; METALLOPROTEASE-DISINTEGRIN; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; INTRACELLULAR MATURATION; HOMOLOGY-3 DOMAINS; CELL-ADHESION; MOUSE EMBRYO; PROTEIN	Meltrin alpha /ADAM12 is a member of the ADAM/MDC family proteins characterized by the presence of metalloprotease and disintegrin domains. This protein also contains a single transmembrane domain and a relatively long cytoplasmic domain containing several proline-rich sequences. These sequences are compatible with the consensus sequences for binding the Src homology 3 (SH3) domains. To determine whether the proline-rich sequences interact with SH3 domains in several proteins, binding of recombinant SH3 domains to the meltrin alpha cytoplasmic domain was analysed by pull-down assays. The SH3 domains of Src and Yes bound strongly, but that of Abl or phosphatidylinositol 3-kinase p85 subunit did not. Full-length Grb2/Ash bound strongly, whereas its N-terminal SH3 domain alone did less strongly. Src and Grb2 in bovine brain extracts also bound to meltrin alpha cytoplasmic domain on affinity resin, Furthermore, immunoprecipitation with alpha monoclonal antibody to meltrin alpha resulted in coprecipitation of Src and Grb2 with meltrin alpha in cell extracts, suggesting that Src and Grb2 are associated in vivo with meltrin alpha cytoplasmic domain. This notion was also supported by the findings that exogenously expressed meltrin cytoplasmic domain coexisted with Src and Grb2 on the membrane ruffles. The C-terminal Tyr901 of meltrin alpha was phosphorylated both initio and in cultured cells by v-Src. These results may imply that meltrin alpha cytoplasmic domain is involved in a signal transduction for some biological function through the interaction with SH3-containing proteins.	Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan; Univ Tokyo, Inst Med Sci, Dept Biochem, Tokyo 1088639, Japan; Osaka Biosci Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan	Chiba University; University of Tokyo	Endo, T (corresponding author), Chiba Univ, Fac Sci, Dept Biol, Inage Ku, 1-33 Yayoicho, Chiba 2638522, Japan.		Sabe, Hisataka/A-4066-2012; Sabe, Hisataka/GPF-4385-2022					ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Alfandari D, 1997, DEV BIOL, V182, P314, DOI 10.1006/dbio.1996.8458; ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTER N, 1997, CURRENT PROTOCOLS PR; Chen MS, 1999, J CELL BIOL, V144, P549, DOI 10.1083/jcb.144.3.549; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P321, DOI 10.1093/oxfordjournals.jbchem.a123899; Endo T, 1996, J BIOL CHEM, V271, P27855, DOI 10.1074/jbc.271.44.27855; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; Endo T, 1998, J CELL SCI, V111, P1081; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Huovila APJ, 1996, CURR OPIN CELL BIOL, V8, P692, DOI 10.1016/S0955-0674(96)80111-6; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; Kurisaki T, 1998, MECH DEVELOP, V73, P211, DOI 10.1016/S0925-4773(98)00043-4; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MIKI H, 1994, J BIOL CHEM, V269, P5489; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nath D, 1999, J CELL SCI, V112, P579; NIGG EA, 1982, P NATL ACAD SCI-BIOL, V79, P5322, DOI 10.1073/pnas.79.17.5322; Okkenhaug K, 1998, J BIOL CHEM, V273, P21194, DOI 10.1074/jbc.273.33.21194; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHIBASAKI F, 1994, BIOCHEM J, V302, P551, DOI 10.1042/bj3020551; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	61	46	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5842	5850		10.1038/sj.onc.1203986	http://dx.doi.org/10.1038/sj.onc.1203986			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127814				2022-12-17	WOS:000165563100002
J	Van Rompaey, L; Potter, M; Adams, C; Grosveld, G				Van Rompaey, L; Potter, M; Adams, C; Grosveld, G			Tel induces a G1 arrest and suppresses Ras-induced transformation	ONCOGENE			English	Article						Tel; transformation; tumor suppressor	ACUTE LYMPHOBLASTIC-LEUKEMIA; MEDIATED CELLULAR-TRANSFORMATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; ABL TYROSINE KINASE; HEMATOLOGIC MALIGNANCIES; MYELOPROLIFERATIVE DISORDERS; TRANSCRIPTIONAL REPRESSOR; CONGENITAL FIBROSARCOMA; TUMOR-SUPPRESSOR	The Tel gene is a major target of translocations in leukemia and loss of heterozygosity is regularly observed for the non-translocated allele, thus supporting the notion that Tel is a tumor suppressor. Most tumor suppressors influence cellular proliferation, differentiation and cell death and thereby prevent oncogenic transformation and genetic instability. We found that overexpression of Tel retards proliferation of many cell types, primary cells and immortalized cells, by inducing a G1 arrest. Tel's block of cellular proliferation is rescued by high seeding densities. Furthermore, Tel suppressed Ras-mediated colony growth in soft agar and tumor formation in nude mice. The Pointed and DNA binding (DB) domains of Tel were required for all Tel-induced phenotype.	St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Grosveld, G (corresponding author), St Jude Childrens Res Hosp, Dept Genet, 332 N Lauderdale St, Memphis, TN 38105 USA.				NCI NIH HHS [CA21765, CA72999-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baens M, 1999, GENOMICS, V56, P40, DOI 10.1006/geno.1998.5685; BUIJS A, 1995, ONCOGENE, V10, P1511; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chakrabarti SR, 1999, P NATL ACAD SCI USA, V96, P7467, DOI 10.1073/pnas.96.13.7467; Chase A, 1999, BLOOD, V93, P1025, DOI 10.1182/blood.V93.3.1025.403a20_1025_1031; Cools J, 1999, BLOOD, V94, P1820, DOI 10.1182/blood.V94.5.1820.417k09_1820_1824; Du W, 1999, CANCER RES, V59, P2059; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GOLUB T, 1996, BIOCHIM BIOPHYS ACTA, V1288, P7; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Hoglund M, 1996, BLOOD, V87, P324, DOI 10.1182/blood.V87.1.324.bloodjournal871324; Iijima Y, 2000, BLOOD, V95, P2126; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Knezevich SR, 1998, CANCER RES, V58, P5046; KWIATKOWSKI B, 1999, AM SOC HEMATOLOGY, V94, pA1155; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; La Starza R, 1999, BRIT J HAEMATOL, V107, P340, DOI 10.1046/j.1365-2141.1999.01724.x; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Liu Q, 2000, EMBO J, V19, P1827, DOI 10.1093/emboj/19.8.1827; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, CANCER RES, V57, P564; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; Ritchie KA, 1999, LEUKEMIA, V13, P1790, DOI 10.1038/sj.leu.2401494; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; Sato Y, 1997, BLOOD, V90, P4886; SATO Y, 1995, BLOOD, V86, P1525, DOI 10.1182/blood.V86.4.1525.bloodjournal8641525; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHUMAKER DK, 1994, EXP CELL RES, V214, P440, DOI 10.1006/excr.1994.1280; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; STEGMAIER K, 1995, BLOOD, V86, P38, DOI 10.1182/blood.V86.1.38.bloodjournal86138; Stegmaier K, 1996, CANCER RES, V56, P1413; Suto Y, 1997, GENE CHROMOSOME CANC, V18, P254, DOI 10.1002/(SICI)1098-2264(199704)18:4<254::AID-GCC3>3.0.CO;2-#; Takeuchi S, 1997, LEUKEMIA, V11, P1220, DOI 10.1038/sj.leu.2400743; Tomasson MH, 1999, BLOOD, V93, P1707, DOI 10.1182/blood.V93.5.1707.405k24_1707_1714; Tomasson MH, 2000, J CLIN INVEST, V105, P423, DOI 10.1172/JCI8902; Van Rompaey L., 1999, Neoplasia (New York), V1, P526; Wai DH, 2000, ONCOGENE, V19, P906, DOI 10.1038/sj.onc.1203396; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK C, 1994, ONCOGENE, V9, P3665; Wlodarska I, 1996, CYTOGENET CELL GENET, V72, P229, DOI 10.1159/000134197; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Yagasaki F, 1999, GENE CHROMOSOME CANC, V26, P192, DOI 10.1002/(SICI)1098-2264(199911)26:3<192::AID-GCC2>3.0.CO;2-E; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	62	46	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2000	19	46					5244	5250		10.1038/sj.onc.1203899	http://dx.doi.org/10.1038/sj.onc.1203899			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077441				2022-12-17	WOS:000165059700005
J	Gordon, J; Del Valle, L; Otte, J; Khalili, K				Gordon, J; Del Valle, L; Otte, J; Khalili, K			Pituitary neoplasia induced by expression of human neurotropic polyomavirus, JCV, early genome in transgenic mice	ONCOGENE			English	Article						JC virus; T-antigen pituitary neoplasia; transgenic animal model	EARLY PROTEIN; HUMAN BRAIN; TUMORS; VIRUS; GENE; P53; ADENOMAS; GROWTH; PATHOGENESIS; PAPOVAVIRUS	In recent years, there has been mounting evidence pointing to the association of polyomaviruses with a wide range of human cancers. The human neurotropic polyomavirus, JCV, infecting greater than 75% of the human population produces a regulators protein named T-antigen which is expressed at the early phase of viral lytic infection and plays a critical role in completion of the viral life cycle, Furthermore, this protein has the ability to transform neural cells in vivo and its expression has been detected in several human neural-origin tumors. To further investigate the oncogenic potential of the JCV early protein in vivo, transgenic mice expressing JCV T-antigen under the control of its own promoter were generated, Nearly 50% of the animals developed large, solid masses within the base of the skull by 1 year of age. Evaluation of the location as well as histological and immunohistochemical data suggest that the tumors arise from the pituitary gland. As T-antigen is known to interact with several cell cycle regulators, the neoplasms were analysed for the presence of the tumor suppressor protein, p53. Immunoprecipitation/Western blot analysis demonstrated overexpression of wild-type, but not mutant p53 within tumor tissue. In addition, co-immunoprecipitation established an interaction between p53 and T-antigen and overexpression of p53 downstream target protein, p21/WAF1, This report describes the analysis of inheritable pituitary adenomas induced by expression of the human polyomavirus. JCV T-antigen in transgenic mice where T-antigen disrupts the p53 pathway by binding to and sequestering mild-type p53, This animal model may serve as a useful tool to further evaluate mechanisms of tumorigenesis by JCV T-antigen.	Temple Univ, Coll Sci & Technol, Ctr Neurobiol & Canc Biol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurobiol & Canc Biol, 1900 N 12th St,Room 203, Philadelphia, PA 19122 USA.		Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206				ARBEIT JM, 1993, AM J PATHOL, V142, P1187; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; BUCKLEY N, 1994, J CLIN ENDOCR METAB, V79, P1513, DOI 10.1210/jc.79.5.1513; Franks RR, 1996, ONCOGENE, V12, P2573; Frisque RJ, 1992, MOL NEUROVIROLOGY PA, P25; Gallia GL, 1998, J NEUROVIROL, V4, P175, DOI 10.3109/13550289809114517; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gordon J, 1998, DEV BIOL STAND, V94, P93; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; HAAS S, 1994, VIROLOGY, V202, P89, DOI 10.1006/viro.1994.1325; HELSETH A, 1992, AM J PATHOL, V140, P1071; KOVACS K, 1983, ATLAS TUMOR PATHOLOG, V10; Krynska B, 1997, J CELL BIOCHEM, V67, P223, DOI 10.1002/(SICI)1097-4644(19971101)67:2<223::AID-JCB7>3.0.CO;2-Z; LEON SP, 1994, NEUROSURGERY, V34, P708, DOI 10.1227/00006123-199404000-00021; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVY A, 1994, CLIN ENDOCRINOL, V41, P809, DOI 10.1111/j.1365-2265.1994.tb02797.x; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; Marx S, 1998, ANN INTERN MED, V129, P484, DOI 10.7326/0003-4819-129-6-199809150-00011; Shimon I, 1997, J CLIN ENDOCR METAB, V82, P1675, DOI 10.1210/jc.82.6.1675; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; SPADA A, 1994, EUR J ENDOCRINOL, V130, P43, DOI 10.1530/eje.0.1300043; Thapar K, 1996, NEUROSURGERY, V38, P765, DOI 10.1227/00006123-199604000-00027; Woloschak M, 1996, CANCER RES, V56, P2493; Zeng YX, 1996, ONCOGENE, V12, P1557; ZURHEIN GM, 1983, POLYOMAVIRUSES HUMAN, P205	27	46	46	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4840	4846		10.1038/sj.onc.1203849	http://dx.doi.org/10.1038/sj.onc.1203849			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039901				2022-12-17	WOS:000089757800006
J	Welman, A; Burger, MM; Hagmann, J				Welman, A; Burger, MM; Hagmann, J			Structure and function of the C-terminal hypervariable region of K-Ras4B in plasma membrane targetting and transformation	ONCOGENE			English	Article						K-Ras4B; hypervariable domain; positive charge	PROTEIN-KINASE; K-RAS; INDEPENDENT PATHWAYS; ACTIVATE RAF-1; P21 PROTEIN; CAAX MOTIF; BINDING; PRENYLATION; SIGNAL; DOMAIN	The C-terminal hypervariable domain of K-Ras4B targets the protein to the plasma membrane by a combination of positive charge and a hydrophobic signal (farnesyl group), We analysed the contribution of several structural features of the domain: net charge, charge distribution, amino acid sequence and lipid specificity to membrane targetting and function by using artificial 'hypervariable' domains fused to either EGFP or V12K-Ras4B, We found that charge and a lipid residue are sufficient for plasma membrane localization and function of the constitutively active V12K-Ras4B. However, the amount of net charge, charge distribution and the length of the anchoring domain are important, Increasing the net charge and concentrating it close to the C-terminus increases not only the percentage of membrane bound protein, but also shifts the distribution from internal membranes, including the nuclear envelope, to the plasma membrane, While plasma membrane binding is necessary for V12K-Ras4B activity (MAPK activation and focus formation), we found that there are additional restrictions. In particular, mutants with very highly charged domains that bind almost exclusively to the plasma membrane show less transforming potential than expected. In addition, a construct with a short 'hypervariable' domain (7 amino acids) also has decreased transformation activity. These results suggest that specific interactions between K-Ras4B and the plasma membrane are required.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hagmann, J (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.							AHUJA HG, 1990, BLOOD, V75, P1684; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Booden MA, 1999, J BIOL CHEM, V274, P1423, DOI 10.1074/jbc.274.3.1423; BOS JL, 1989, CANCER RES, V49, P4682; BRANDTRAUF PW, 1990, J PROTEIN CHEM, V9, P137, DOI 10.1007/BF01025304; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Coats SG, 1999, BIOCHEMISTRY-US, V38, P12926, DOI 10.1021/bi9909290; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; Hagmann J, 1999, J CELL BIOCHEM, V73, P488, DOI 10.1002/(SICI)1097-4644(19990615)73:4<488::AID-JCB7>3.0.CO;2-P; Hagmann J, 1998, J CELL SCI, V111, P2181; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Hart KC, 1997, ONCOGENE, V14, P945, DOI 10.1038/sj.onc.1200908; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leventis R, 1998, BIOCHEMISTRY-US, V37, P7640, DOI 10.1021/bi973077h; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Ludin B, 1996, GENE, V173, P107, DOI 10.1016/0378-1119(95)00899-3; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; MONACO R, 1995, J PROTEIN CHEM, V14, P457, DOI 10.1007/BF01888140; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Niv H, 1999, J BIOL CHEM, V274, P1606, DOI 10.1074/jbc.274.3.1606; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Siddiqui AA, 1998, J BIOL CHEM, V273, P3712, DOI 10.1074/jbc.273.6.3712; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Willumsen BM, 1996, ONCOGENE, V13, P1901; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	46	46	46	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2000	19	40					4582	4591		10.1038/sj.onc.1203818	http://dx.doi.org/10.1038/sj.onc.1203818			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030147				2022-12-17	WOS:000089438200004
J	Gopalkrishnan, RV; Roberts, T; Tuli, S; Kang, D; Christiansen, KA; Fisher, PB				Gopalkrishnan, RV; Roberts, T; Tuli, S; Kang, D; Christiansen, KA; Fisher, PB			Molecular characterization of prostate carcinoma tumor antigen-1, PCTA-1, a human Galectin-8 related gene	ONCOGENE			English	Article						prostate; genomic structure; chromosomal localization; 1q42-43; SEM	BINDING PROTEIN GALECTIN-3; SURFACE-EPITOPE MASKING; ANIMAL LECTINS; CELL-ADHESION; SUPPRESSOR GENE; T-CELLS; EXPRESSION; GROWTH; CANCER; DIFFERENTIATION	The galectin family of proteins has been associated with several diverse cellular processes. More than 30 years since the discovery of the first member, precise biological functions for the family as a whole, or for individual members has pro, cn elusive. The isolation of Prostate Carcinoma Tumor Antigen-1 (PCTA-1), a cDNA closely related to rat and human Galectin-8, as a surface marker associated with prostate cancer was achieved using a previously described immunological subtraction approach, Surface Epitope Masking (SEM) approach, in combination,with expression screening. It appears that PCTA-1 expression is almost ubiquitous in normal human tissues and could alter in specific contests such as transformation or metastasis. Multiple expression isoforms of PCTA-1 at the mRNA level are observed. PCTA-1 maps to 1q42-43, a locus associated with predisposition to prostate cancer. We have determined the genomic structure of PCTA-1 to account for the several observed isoforms, performed expression analysis to determine distribution in normal and transformed contests at the RNA and protein level and conducted over-expression studies to determine effects on cellular phenotype.	Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, BB-1501,603 W 168th St, New York, NY 10032 USA.		Roberts, Terry/A-8211-2014					Akahani S, 1997, CANCER RES, V57, P5272; Arata Y, 1997, J BIOCHEM-TOKYO, V121, P1002, DOI 10.1093/oxfordjournals.jbchem.a021686; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Bassen R, 1999, ANTICANCER RES, V19, P5429; Berthon P, 1998, AM J HUM GENET, V62, P1416, DOI 10.1086/301879; Blaser C, 1998, EUR J IMMUNOL, V28, P2311, DOI 10.1002/(SICI)1521-4141(199808)28:08<2311::AID-IMMU2311>3.0.CO;2-G; Bresalier RS, 1996, CANCER RES, V56, P4354; Bresalier RS, 1997, CANCER, V80, P776; Chadli A, 1997, J NEUROCHEM, V68, P1640; Chammas R, 1996, BRAZ J MED BIOL RES, V29, P1141; CHO MJ, 1995, J BIOL CHEM, V270, P5198, DOI 10.1074/jbc.270.10.5198; CHO MJ, 1995, J BIOL CHEM, V270, P5207, DOI 10.1074/jbc.270.10.5207; Colnot C, 1996, BIOCHEM SOC T, V24, P141, DOI 10.1042/bst0240141; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; Cooper DNW, 1997, J BIOL CHEM, V272, P1514, DOI 10.1074/jbc.272.3.1514; Cortegano I, 1998, J IMMUNOL, V161, P385; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Ellerhorst J, 1999, INT J ONCOL, V14, P217; FEICHTINGER W, 1989, HUM GENET, V83, P145, DOI 10.1007/BF00286707; FEINSTEIN E, 1995, GENOMICS, V29, P305, DOI 10.1006/geno.1995.1255; Gillenwater A, 1996, HEAD NECK-J SCI SPEC, V18, P422, DOI 10.1002/(SICI)1097-0347(199609/10)18:5<422::AID-HED5>3.3.CO;2-S; Gitt MA, 1998, J BIOL CHEM, V273, P2961, DOI 10.1074/jbc.273.5.2961; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; Gitt MA, 1998, J BIOL CHEM, V273, P2954, DOI 10.1074/jbc.273.5.2954; Gopalkrishnan RV, 1996, ONCOGENE, V13, P2671; Gopalkrishnan RV, 1999, NUCLEIC ACIDS RES, V27, P4775, DOI 10.1093/nar/27.24.4775; Greenhalgh CJ, 1999, MOL BIOCHEM PARASIT, V98, P285, DOI 10.1016/S0166-6851(98)00167-4; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; Hebert E, 1996, CR ACAD SCI III-VIE, V319, P871; Hsu DK, 1999, INT J CANCER, V81, P519, DOI 10.1002/(SICI)1097-0215(19990517)81:4<519::AID-IJC3>3.3.CO;2-S; Hughes D, 1997, DRUG DISCOV TODAY, V2, P2, DOI 10.1016/S1359-6446(97)81331-1; Iglesias MM, 1998, GLYCOBIOLOGY, V8, P59, DOI 10.1093/glycob/8.1.59; INOHARA H, 1995, CANCER RES, V55, P3267; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Kaltner H, 1998, ACTA ANAT, V161, P162; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; Li YS, 1995, CANCER GENET CYTOGEN, V84, P46, DOI 10.1016/0165-4608(95)00065-8; LOTAN R, 1994, GLYCOCONJUGATE J, V11, P462, DOI 10.1007/BF00731282; Lu Y, 1999, BBA-GENE STRUCT EXPR, V1444, P85, DOI 10.1016/S0167-4781(98)00257-7; Lu Y, 1998, BIOL CHEM, V379, P1323, DOI 10.1515/bchm.1998.379.11.1323; Lutomski D, 1997, GLYCOBIOLOGY, V7, P1193, DOI 10.1093/glycob/7.8.1193; Maldonado CA, 1999, INVEST OPHTH VIS SCI, V40, P2971; Maquoi E, 1997, PLACENTA, V18, P433, DOI 10.1016/S0143-4004(97)80044-6; Mehul B, 1997, J CELL SCI, V110, P1169; MURTY VVVS, 1994, CANCER RES, V54, P3983; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Puch S, 1999, UROLOGY, V53, P848, DOI 10.1016/S0090-4295(98)00619-0; Remmelink M, 1999, J CANCER RES CLIN, V125, P275, DOI 10.1007/s004320050274; RINI JM, 1995, CURR OPIN STRUC BIOL, V5, P617, DOI 10.1016/0959-440X(95)80053-0; Sahraoui YH, 1996, J CELL BIOCHEM, V62, P529, DOI 10.1002/(SICI)1097-4644(19960915)62:4<529::AID-JCB10>3.0.CO;2-A; Sarafian V, 1998, INT J CANCER, V75, P105, DOI 10.1002/(SICI)1097-0215(19980105)75:1<105::AID-IJC16>3.3.CO;2-L; SCHOEPPNER HL, 1995, CANCER, V75, P2818, DOI 10.1002/1097-0142(19950615)75:12<2818::AID-CNCR2820751206>3.0.CO;2-#; SHEN RQ, 1994, J NATL CANCER I, V86, P91, DOI 10.1093/jnci/86.2.91; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Vyakarnam A, 1998, EXP CELL RES, V242, P419, DOI 10.1006/excr.1998.4111; Vyakarnam A, 1997, MOL CELL BIOL, V17, P4730, DOI 10.1128/MCB.17.8.4730; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; WagnerHulsmann C, 1996, GLYCOBIOLOGY, V6, P785, DOI 10.1093/glycob/6.8.785-d; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WELCH DR, 1994, ONCOGENE, V9, P255; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737	64	46	49	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4405	4416		10.1038/sj.onc.1203767	http://dx.doi.org/10.1038/sj.onc.1203767			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980616				2022-12-17	WOS:000089271900011
J	Girnita, L; Girnita, A; Wang, M; Meis-Kindblom, JM; Kindblom, LG; Larsson, O				Girnita, L; Girnita, A; Wang, M; Meis-Kindblom, JM; Kindblom, LG; Larsson, O			A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells	ONCOGENE			English	Article						EWS/FLI-1; bFGF; cell growth; Ewing's sarcoma	FACTOR-I RECEPTOR; NEUROECTODERMAL TUMOR; FUSION PROTEIN; INSULIN; TRANSLOCATION; GLYCOSYLATION; TRANSFORMATION; PROLIFERATION; EXPRESSION; TARGET	The EWS/FLI-1 fusion gene is characteristic of most cases of Ewing's sarcoma and has been shown to be crucial for tumor transformation and cell growth. In this study we demonstrate a drastic down-regulation of the EWS/FLI-1 protein, and a growth arrest, following serum depletion of Ewing's sarcoma cells. This indicates that growth factor circuits may be involved in regulation of the fusion gene product. Of four different growth factors tested, basic fibroblast growth factor (bFGF) was found to be of particular significance. In fact, upon treatment of serum-depleted cells with bFGF, expression of the EWS/FLI-1 protein and growth of the Ewing's sarcoma cells were restored. In addition, a bFGF-neutralizing antibody, which was confirmed to inhibit FGF receptor (FGFR) phosphorylation, caused downregulation of EWS/FLI-1. Experiments using specific cell cycle blockers (thymidine and colcemide) suggest that EWS/FLI-1 is directly linked to bFGF stimulation, and not indirectly to cell proliferation. We also demonstrated expression of FGFRs in several tumor samples of Ewing's sarcoma, Taken together, our data suggest that expression of FGFR is a common feature of Ewing's sarcoma and, in particular, that the bFGF pathway may be important for the maintenance of a malignant phenotype of Ewing's sarcoma cells through up-regulating the EWS/FLI-1 protein.	Karolinska Hosp, Dept Oncol & Pathol Cellular & Mol Tumor Pathol, CCK, SE-17176 Stockholm, Sweden; Sahlgrens Univ Hosp, Musculoskeletal Tumor Ctr, Dept Pathol, S-41345 Gothenburg, Sweden	Karolinska Institutet; Karolinska University Hospital; Sahlgrenska University Hospital	Larsson, O (corresponding author), Karolinska Hosp, Dept Oncol & Pathol Cellular & Mol Tumor Pathol, CCK, R8-04, SE-17176 Stockholm, Sweden.		Girnita, Leonard/A-4168-2008; Girnita, Ada/AAC-4518-2020	Girnita, Leonard/0000-0003-0280-9500; 				BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Carlberg M, 1996, J BIOL CHEM, V271, P17453, DOI 10.1074/jbc.271.29.17453; COLLIER E, 1993, BIOCHEMISTRY-US, V32, P7818, DOI 10.1021/bi00081a029; DOYLE JW, 1993, J CELL PHYSIOL, V155, P171, DOI 10.1002/jcp.1041550122; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; GAMMELTOFT S, 1991, PEPTIDE HORMONE ACTI, P1; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; HOFBAUER S, 1993, EUR J CANCER, V29A, P241, DOI 10.1016/0959-8049(93)90183-G; HORI A, 1991, CANCER RES, V51, P6180; Jayson GC, 1999, INT J CANCER, V82, P298, DOI 10.1002/(SICI)1097-0215(19990719)82:2<298::AID-IJC23>3.3.CO;2-0; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klint Peter, 1999, Frontiers in Bioscience, V4, pD165, DOI 10.2741/Klint; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; KULL FC, 1983, J BIOL CHEM, V258, P6561; Scotlandi K, 1996, CANCER RES, V56, P4570; TAKAHASHI H, 1998, JAPAN J UROL, V89, P836; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; VANVALEN F, 1992, J CANCER RES CLIN, V118, P269, DOI 10.1007/BF01208615; Wang M, 1999, EXP CELL RES, V246, P38, DOI 10.1006/excr.1998.4280; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910	22	46	51	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4298	4301		10.1038/sj.onc.1203755	http://dx.doi.org/10.1038/sj.onc.1203755			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980604				2022-12-17	WOS:000089032900013
J	Bartkova, J; Thullberg, M; Rajpert-De Meyts, E; Skakkebaek, NE; Bartek, J				Bartkova, J; Thullberg, M; Rajpert-De Meyts, E; Skakkebaek, NE; Bartek, J			Lack of p19(INK4d) in human testicular germ-cell tumours contrasts with high expression during normal spermatogenesis	ONCOGENE			English	Article						p19(INK4d); RB pathway; spermatogenesis; carcinoma in situ; testicular germ cell tumours	RETINOBLASTOMA PROTEIN PATHWAY; CARCINOMA IN-SITU; CDK INHIBITORS; DEPENDENT KINASES; TUMORS; CANCER; TESTIS; DIFFERENTIATION; PROLIFERATION; TUMORIGENESIS	p19(INK4d) a member of the INK4 family of cyclin-dependent kinase inhibitors, negatively regulates the proto-oncogenic cyclin D/CDK4(6) complexes whose ability to phosphorylate the retinoblastoma tumour suppressor (RB) promotes G1/S transition. In contrast to the related p16(INK4a) tumour suppressor, expression patterns of 19(INK4d) in human tissues and tumours remain unknown. As the RE pathway is commonly targeted in cancer, and mouse models suggest a role for p19(INK4d) in spermatogenesis, ne examined the abundance and localization of p19(INK4d) in the human testis, both during normal development and at various stages of germ-cell tumour pathogenesis. Our data show that the p19(INK4d) protein is abundant in spermatocytes of normal human adult testes, whereas virtually no p19(INK4d) is detectable in testicular cancer, including the preinvasive carcinoma ill situ stage. Together with the lack of p19(INK4d) in human foetal germ cells, these results support the concept of foetal origin of the testicular germ-cell tumours, and help better understand the emerging role of the RE pathway in spermatogenesis and tumorigenesis in the human testis.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen O, Denmark; Univ Copenhagen, Dept Growth & Reprod, Rigshosp, Copenhagen, Denmark	Danish Cancer Society; Rigshospitalet; University of Copenhagen	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Bartek, Jiri/G-5870-2014; Rajpert-De Meyts, Ewa/H-6526-2019	Rajpert-De Meyts, Ewa/0000-0002-5946-7559				Andrews PW, 1998, APMIS, V106, P158, DOI 10.1111/j.1699-0463.1998.tb01331.x; BARKOVA J, 2000, INT J CANCER, V85, P370; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bartkova J, 1999, J PATHOL, V187, P573, DOI 10.1002/(SICI)1096-9896(199904)187:5<573::AID-PATH289>3.0.CO;2-H; BERNARDS R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P33; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chaubert P, 1997, AM J PATHOL, V151, P859; Dieckmann KP, 1999, INT J CANCER, V83, P815, DOI 10.1002/(SICI)1097-0215(19991210)83:6<815::AID-IJC21>3.3.CO;2-Q; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; GRIGOR KM, 1993, EUR UROL, V23, P93; Grigor KM, 1998, APMIS, V106, P221, DOI 10.1111/j.1699-0463.1998.tb01339.x; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Heidenreich A, 1998, J UROLOGY, V159, P1725, DOI 10.1097/00005392-199805000-00101; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; HUSTIN J, 1987, INT J ANDROL, V10, P29, DOI 10.1111/j.1365-2605.1987.tb00162.x; JORGENSEN N, 1995, LAB INVEST, V72, P223; MOSTOFI FK, 1986, GERM CELL TUMOURS, V2, P1; OOSTERHUIS JW, 1993, EUR UROL, V23, P245; Rajpert-De Meyts E, 1998, APMIS, V106, P198; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; STROHMEYER T, 1991, P NATL ACAD SCI USA, V88, P6662, DOI 10.1073/pnas.88.15.6662; Thullberg M, 2000, HYBRIDOMA, V19, P63, DOI 10.1089/027245700315806; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	36	46	48	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4146	4150		10.1038/sj.onc.1203769	http://dx.doi.org/10.1038/sj.onc.1203769			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962575				2022-12-17	WOS:000088955100008
J	Ahmad, M; Shi, YF				Ahmad, M; Shi, YF			TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention	ONCOGENE			English	Article						apoptosis; thyroid cancer; Fas; TNF-alpha; TRAIL	DEATH RECEPTORS; CYTOCHROME-C; LIGAND TRAIL; PROTEIN; EXPRESSION; MODULATION; INHIBITOR; CASPASES; MELANOMA; PATHWAY	To determine whether the apoptotic machinery of thyroid cancer cells is functional and could be activated for tumoricidal purposes, we examined the apoptosis induced by the cytokines TNF-alpha, Fas and TRAIL in thyroid cancer cell lines, NPA. and SW579. Interestingly, out of these cytokines, only TRAIL was able to trigger significant apoptosis, The tumoricidal effect of TRAIL was further enhanced by CHX, suggesting the presence of CHX-sensitive inhibitor(s) of apoptosis in these thyroid cancer cell lines, The anti-apoptotic proteins like FLAME-1, Bcl-2 and Bcl-xL are believed to be such CHX-sensitive inhibitors in various types of cancer cells. We, however provide the evidence using NPA and SW579 cell lines that these proteins were not affected by the CHX treatment in thyroid cancer cells. The apoptosis of thyroid cancer cells,vas mediated by the classical activation of caspases that in turn activated the DNA Fragmentation Factor (DFF-45). To elucidate the role of individual caspases in TRAIL-mediated apoptosis, the inhibitory effects of several general and specific tetrapeptide caspase inhibitors were studied. The inhibitors of caspase-1, -6, -8, and -9 as well as general upstream inhibitors of apoptosis could dramatically inhibit TRAIL-induced apoptosis in thyroid cancer cells. Caspase-2 and -3 inhibitors, on the other hand, had no significant effect. When the cells were treated with either agonistic Fas antibody (CH11) or TNF-alpha, no apoptotic changes mere observed, The apoptosis induced by agonistic Fas Ab could be seen only after a prolonged exposure (24 h) to CHX, whereas TNF-alpha had no effect even in the presence of CHX. The efficacy of TRAIL nas also tested on other types of thyroid cancer cells like ARO, FRO (anaplastic carcinoma) and TPC-1 (papillary carcinoma) and compared to that triggered by other death inducing cytokines Fast and TNF-alpha. Again TRAIL tvas more potent in triggering apoptosis than Fas and TNF-alpha. Since TRAIL is effective in selectively killing thyroid tumor cells without affecting normal thyrocytes and also does not cause organ toxicity and inflammation in vivo, its potential for the treatment of thyroid cancer seems very promising.	King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, Lab Mol Apoptosis & Canc Therapy, Riyadh 11211, Saudi Arabia	King Faisal Specialist Hospital & Research Center	Ahmad, M (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, Lab Mol Apoptosis & Canc Therapy, 226,MBC-03,POB 3354, Riyadh 11211, Saudi Arabia.		Shi, Yufei/ABG-5228-2020	Shi, Yufei/0000-0002-6999-0191				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; Burow ME, 1998, CANCER RES, V58, P4940; Cerutti J, 1996, CLIN CANCER RES, V2, P119; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FARID NR, 1994, ENDOCR REV, V15, P202, DOI 10.1210/er.15.2.202; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Griffith TS, 1998, J IMMUNOL, V161, P2833; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Knauf JA, 1999, J BIOL CHEM, V274, P23414, DOI 10.1074/jbc.274.33.23414; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Rudin CM, 1997, ANNU REV MED, V48, P267; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shi Y, 1996, BRIT J CANCER, V74, P1336, DOI 10.1038/bjc.1996.546; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tung WS, 1996, MOL CARCINOGEN, V15, P5; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Zhang XD, 1999, CANCER RES, V59, P2747	31	46	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3363	3371		10.1038/sj.onc.1203679	http://dx.doi.org/10.1038/sj.onc.1203679			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918593				2022-12-17	WOS:000088198100004
J	Spence, HJ; Johnston, I; Ewart, K; Buchanan, SJ; Fitzgerald, U; Ozanne, BW				Spence, HJ; Johnston, I; Ewart, K; Buchanan, SJ; Fitzgerald, U; Ozanne, BW			Krp1, a novel kelch related protein that is involved in pseudopod elongation in transformed cells	ONCOGENE			English	Article						Kelch; Krp1; v-fos; pseudopodia; cytoskeleton	CROSS-LINKING PROTEIN; OSTEO-SARCOMA VIRUS; C-JUN; CELLULAR-TRANSFORMATION; HYALURONAN RECEPTOR; NEGATIVE REGULATION; GENE-EXPRESSION; LIMULUS SPERM; AP-1 FUNCTION; FOS	We have previously shown that the transcription factor AP-1 regulates the expression of genes which allow neoplastically transformed rat fibroblasts to become invasive. Searches for further AP-1 target genes led to the identification of a gene encoding a novel rat kelch family member, named kelch related protein 1 (Krp1), Reich family members are characterized by a series of repeats at their carboxyl terminus and a BTB/POZ domain near their amino terminus. Rat Krp1 has a primarily cytoplasmic localization, and a small fraction appears to accumulate and co-localize with F-actin at membrane ruffle-like structures in the tips of pseudopodia. Overexpression of Krp1 in transformed rat fibroblasts led to the formation of dramatically elongated pseudopodia, while expression of truncated Krp1 polypeptides resulted in a reduction in the length of pseudopodia. We propose that the transformation-specific expression of Krp1 is required for pseudopod elongation, which are structures that are required for cell motility and invasion.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Ozanne, BW (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.			Fitzgerald, Una/0000-0002-8019-6546				Adams JC, 1998, EMBO J, V17, P4964, DOI 10.1093/emboj/17.17.4964; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; BUSHEL P, 1995, ONCOGENE, V10, P1361; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DECESARE D, 1995, ONCOGENE, V11, P365; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; FINKEL MP, 1975, FRONTIERS RADIATION, V10, P28; GUIRGUIS R, 1987, NATURE, V329, P261, DOI 10.1038/329261a0; HAY ED, 1989, CELL MOTIL CYTOSKEL, V14, P455, DOI 10.1002/cm.970140403; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Hernandez MC, 1998, EXP CELL RES, V242, P470, DOI 10.1006/excr.1998.4109; Hernandez MC, 1997, J NEUROSCI, V17, P3038; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOOSS KU, 1995, ONCOGENE, V10, P603; KAPLAN PL, 1983, CELL, V33, P931, DOI 10.1016/0092-8674(83)90036-3; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; Kim TA, 1998, J CELL BIOL, V141, P553, DOI 10.1083/jcb.141.3.553; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Liotta L A, 1991, Semin Cancer Biol, V2, P111; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Mata J, 1997, CELL, V89, P939, DOI 10.1016/S0092-8674(00)80279-2; Nabi IR, 1999, J CELL SCI, V112, P1803; Philips J, 1998, J CELL BIOL, V143, P375, DOI 10.1083/jcb.143.2.375; RAPP UR, 1994, ONCOGENE, V9, P3493; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Taylor A, 1998, MOL CELL BIOCHEM, V183, P105, DOI 10.1023/A:1006824331819; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VARKEY JP, 1995, GENE DEV, V9, P1074, DOI 10.1101/gad.9.9.1074; Vega LR, 1997, CELL, V89, P825, DOI 10.1016/S0092-8674(00)80266-4; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; WAY M, 1995, J CELL SCI, V108, P3155; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yonemura S, 1999, J CELL BIOL, V145, P1497, DOI 10.1083/jcb.145.7.1497	49	46	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2000	19	10					1266	1276		10.1038/sj.onc.1203433	http://dx.doi.org/10.1038/sj.onc.1203433			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713668				2022-12-17	WOS:000085743800003
J	Yamaguchi, M; Hirose, F; Inoue, YH; Shiraki, M; Hayashi, Y; Nishi, Y; Matsukage, A				Yamaguchi, M; Hirose, F; Inoue, YH; Shiraki, M; Hayashi, Y; Nishi, Y; Matsukage, A			Ectopic expression of human p53 inhibits entry into S phase and induces apoptosis in the Drosophila eye imaginal disc	ONCOGENE			English	Article						p53; Drosophila; cell cycle; apoptosis; P35	PROGRAMMED CELL-DEATH; WILD-TYPE P53; BACULOVIRUS P35; DNA-DAMAGE; CAENORHABDITIS-ELEGANS; PROTEIN P35; LUNG-CANCER; GENE; CYCLE; GROWTH	Transgenic flies in which ectopic expression of human p53 was targeted to the Drosophila eye imaginal disc were established. On sectioning of adult fly eyes which displayed a severe rough eye phenotype, most ommatidia were found to be fused and irregular shapes of rabdomeres were observed. In addition, many pigment cells were lost. In the developing eye imaginal disc, photoreceptor cell differentiation was initiated normally despite the ectopic expression of p53, However, expression of p53 inhibited cell cycle progression in eye imaginal disc cells and the S phase zone (the second mitotic wave) behind the morphogenetic furrow was almost completely abolished. Furthermore, expression of p53 induced extensive apoptosis of eye imaginal disc cells, and co-expression of baculovirus P35 in the eye imaginal disc suppressed the p53-induced rough eye phenotype, These results are consistent,vith the known functions of human p53 and indicate the existence of signaling systems with elements corresponding to human p53 in Drosophila eye imaginal disc cells. Genetic crosses of transgenic flies expressing p53 to a collection of Drosophila deficiency stocks allowed us to identify several genomic regions, deletions of which caused enhancement or suppression of the p53-induced rough eye phenotype, The transgenic flies established in this study should be useful to identify novel targets of p53 and its positive or negative regulators in Drosophila.	Aichi Canc Ctr, Res Inst, Cell Biol Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Biophys Unit, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center; Aichi Cancer Center	Yamaguchi, M (corresponding author), Aichi Canc Ctr, Res Inst, Cell Biol Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan.			Hirose, Fumiko/0000-0003-4586-4892; Yamaguchi, Masamitsu/0000-0002-6321-9750				Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Butler SJ, 1997, DEVELOPMENT, V124, P781; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; Foley K, 1998, DEVELOPMENT, V125, P1075; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAY BA, 1994, DEVELOPMENT, V120, P2121; HENGARTNER MO, 1995, SCIENCE, V270, P931, DOI 10.1126/science.270.5238.931; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McCall K, 1997, TRENDS GENET, V13, P222, DOI 10.1016/S0168-9525(97)01126-8; MOSES K, 1991, GENE DEV, V5, P583, DOI 10.1101/gad.5.4.583; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; ROBERTSON HM, 1988, GENETICS, V118, P461; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; SOUSSI T, 1990, ONCOGENE, V5, P945; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WILDER EL, 1995, DEVELOPMENT, V121, P477; WOLFF T, 1991, DEVELOPMENT, V113, P825; Wolff Tanya, 1993, P1277; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YAMAGUCHI M, 1994, EUR J BIOCHEM, V221, P227, DOI 10.1111/j.1432-1033.1994.tb18733.x; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w; Zhou XL, 1999, CANCER RES, V59, P843; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	46	46	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6767	6775		10.1038/sj.onc.1203113	http://dx.doi.org/10.1038/sj.onc.1203113			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597285				2022-12-17	WOS:000083792000019
J	Chen, XM; Lowe, M; Keyomarsi, K				Chen, XM; Lowe, M; Keyomarsi, K			UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent	ONCOGENE			English	Article						UCN-01; cell cycle; p53; pRb; E6; E7	PROTEIN-KINASE-C; MAMMARY EPITHELIAL-CELLS; HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA PROTEIN; CDK INHIBITOR; CYCLE ARREST; REDUNDANT CYCLIN; CANCER CELLS; PHASE ARREST; P53 PROTEIN	In this study we investigated the growth inhibitory effects of UCN-01 in several normal and tumor-derived human breast epithelial cells. We found that while normal mammary epithelial cells were very sensitive to UCN-01 with an IC50 of 10 nM, tumor cells displayed little to no inhibition of growth with any measurable IC,, at low UCN-01 concentrations (i.e. 0-80 nM). The UCN-01 treated normal cells arrested in G1 phase and displayed decreased expression of most key cell cycle regulators examined, resulting in inhibition of CDK2 activity due to increased binding of p27 to CDK2, Tumor cells on the other hand displayed no change in any cell cycle distribution or expression of cell cycle regulators. Examination of E6- and E7-derived strains of normal cells revealed that pRb and not p53 function is essential for UCN-01-mediated G1 arrest. Lastly, treatment of normal and tumor cells with high doses of UCN-01 (i.e. 300 nM) revealed a necessary role for a functional G1 checkpoint in mediating growth arrest. Normal cells, which have a functional G1 checkpoint, always arrest in G1 even at very high concentrations of UCN-01, Tumor cells on the other hand have a defective G1 checkpoint and only arrest in S phase with high concentrations of UCN-01, The effect of UCN-01 on the cell cycle is thus quite different from staurosporine, a structural analogue of UCN-01, which arrests normal cells in both G1 and G2, while tumor cells arrest only in the G2 phase of the cell cycle. Our results show the different sensitivity to UCN-01 of normal compared to tumor cells is dependent on a functional pRb and a regulated G1 checkpoint.	Wadsworth Ctr, Div Mol Med, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12222 USA	Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Keyomarsi, K (corresponding author), Wadsworth Ctr, Div Mol Med, Empire State Plaza,POB 509, Albany, NY 12201 USA.		Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849				Akiyama T, 1997, CANCER RES, V57, P1495; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BERNS A, 1994, CURR BIOL, V4, P137, DOI 10.1016/S0960-9822(94)00031-X; Boorne AJ, 1998, BREAST CANCER RES TR, V48, P117, DOI 10.1023/A:1005985832647; Bunch RT, 1997, CELL GROWTH DIFFER, V8, P779; CARMICHAEL J, 1988, BRIT J CANCER, V57, P540, DOI 10.1038/bjc.1988.125; COURAGE C, 1995, BRIT J CANCER, V71, P697, DOI 10.1038/bjc.1995.137; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; GrayBablin J, 1997, CANCER RES, V57, P604; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HESSLING JJ, 1980, J IMMUNOL METHODS, V38, P315, DOI 10.1016/0022-1759(80)90280-X; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; Iavarone A, 1997, NATURE, V387, P417; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kawakami K, 1996, BIOCHEM BIOPH RES CO, V219, P778, DOI 10.1006/bbrc.1996.0310; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; MICHIELI P, 1994, CANCER RES, V54, P3391; Orr MS, 1998, J BIOL CHEM, V273, P3803, DOI 10.1074/jbc.273.7.3803; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Pollack IF, 1996, J NEUROSURG, V84, P1024, DOI 10.3171/jns.1996.84.6.1024; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; Reznikoff CA, 1996, CANCER RES, V56, P2886; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; SEYNAEVE CM, 1993, CANCER RES, V53, P2081; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SOULE HD, 1990, CANCER RES, V50, P6075; TAKAHASHI I, 1989, J ANTIBIOT, V42, P564, DOI 10.7164/antibiotics.42.564; TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WANG QZ, 1995, CELL GROWTH DIFFER, V6, P927; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	47	46	46	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5691	5702		10.1038/sj.onc.1202948	http://dx.doi.org/10.1038/sj.onc.1202948			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW					2022-12-17	WOS:000083016500010
J	Sharma, P; Schreiber-Agus, N				Sharma, P; Schreiber-Agus, N			Mouse models of prostate cancer	ONCOGENE			English	Article						mouse model; prostate cancer; transgenic	MESSENGER-RNA LEVELS; ANTIGEN TRANSGENIC MICE; GENE-EXPRESSION; INTRAEPITHELIAL NEOPLASIA; MAMMARY ADENOCARCINOMA; RECONSTITUTION MODEL; REGULATED EXPRESSION; MOLECULAR-BIOLOGY; RAST24 DRIVEN; ANIMAL-MODELS	The pathogenetic basis of prostate cancer remains highly elusive; its clarification could be facilitated greatly by laboratory and clinical models of the disease. Although the genetically manipulated mouse has been invaluable for the modeling of other human cancer types, it has fared less well with respect to prostate cancer. Nevertheless, several highly valuable transgenic models exist and are highlighted in this review. Emerging reagents and strategies may allow us to use the mouse more effectively to define the molecular, cellular and physiological events that lead to prostate cancer initiation and progression.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Schreiber-Agus, N (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, 1300 Morris Pk Ave, Bronx, NY 10461 USA.							BARRIOS R, 1996, TRANSGENICS, V2, P23; BARRIOS R, 1994, TRANSGENICS, V1, P411; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Brothman AR, 1999, PROSTATE, V38, P303; Buttyan R, 1997, PROSTATE, V33, P164, DOI 10.1002/(SICI)1097-0045(19971101)33:3<164::AID-PROS3>3.0.CO;2-J; CARTER BS, 1990, CANCER RES, V50, P6830; CHOI YW, 1987, J VIROL, V61, P3013, DOI 10.1128/JVI.61.10.3013-3019.1987; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; De Marzo AM, 1999, UROLOGY, V53, P29, DOI 10.1016/S0090-4295(98)00536-6; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; di Sant'Agnese PA, 1998, PROSTATE, P74; Donjacour AA, 1998, DIFFERENTIATION, V62, P227, DOI 10.1046/j.1432-0436.1998.6250227.x; EGAWA S, 1992, MOL CARCINOGEN, V5, P52, DOI 10.1002/mc.2940050110; Foster BA, 1997, CANCER RES, V57, P3325; Furth PA, 1998, DEV BIOL STAND, V94, P281; Garabedian EM, 1998, P NATL ACAD SCI USA, V95, P15382, DOI 10.1073/pnas.95.26.15382; GHONIEM GM, 1994, NEUROUROL URODYNAM, V13, P91, DOI 10.1002/nau.1930130203; Gingrich JR, 1996, CANCER RES, V56, P4096; Gingrich JR, 1997, CANCER RES, V57, P4687; Green JE, 1998, PROSTATE, V36, P59, DOI 10.1002/(SICI)1097-0045(19980615)36:1<59::AID-PROS11>3.0.CO;2-H; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; Haggman MJ, 1997, J UROLOGY, V158, P12, DOI 10.1097/00005392-199707000-00004; Hall SJ, 1999, CANCER GENE THER, V6, P54, DOI 10.1038/sj.cgt.7700004; Hall SJ, 1997, INT J CANCER, V70, P183, DOI 10.1002/(SICI)1097-0215(19970117)70:2<183::AID-IJC8>3.0.CO;2-T; HENNIGHAUSEN L, 1994, CELL GROWTH DIFFER, V5, P607; Isaacs WB, 1998, GENETIC BASIS HUMAN, P653; Kaplan PJ, 1999, CANCER RES, V59, P2203; Kasper S, 1998, LAB INVEST, V78, pI; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitsberg DI, 1996, ONCOGENE, V13, P2507; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Kwon ED, 1997, P NATL ACAD SCI USA, V94, P8099, DOI 10.1073/pnas.94.15.8099; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Lee WH, 1997, CANCER EPIDEM BIOMAR, V6, P443; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lucia MS, 1998, PROSTATE, V36, P49, DOI 10.1002/(SICI)1097-0045(19980615)36:1<49::AID-PROS9>3.0.CO;2-6; Maini A, 1997, IN VIVO, V11, P293; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MERZ VW, 1991, MOL ENDOCRINOL, V5, P503, DOI 10.1210/mend-5-4-503; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; PerezStable C, 1996, LAB INVEST, V74, P363; PerezStable C, 1997, CANCER RES, V57, P900; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; PRICE DOROTHY, 1963, NATL CANCER INST MONOGR, V12, P1; Pylkkanen L, 1996, EUR UROL, V30, P243; Qian JQ, 1999, EUR UROL, V35, P479, DOI 10.1159/000019883; Ren CZ, 1998, CANCER RES, V58, P1285; Royai R, 1996, SEMIN ONCOL, V23, P35; SCHAFFNER DL, 1995, LAB INVEST, V72, P283; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; Sciavolino PJ, 1998, ANN MED, V30, P357, DOI 10.3109/07853899809029935; Shi XB, 1996, WORLD J UROL, V14, P318, DOI 10.1007/BF00184605; Shibata MA, 1998, TOXICOL PATHOL, V26, P177, DOI 10.1177/019262339802600121; Shibata MA, 1996, CANCER RES, V56, P4894; SKALNIK DG, 1991, MOL CELL BIOL, V11, P4518, DOI 10.1128/MCB.11.9.4518; SLAWIN K, 1993, CANCER RES, V53, P4461; Small Eric J., 1998, Current Opinion in Oncology, V10, P244, DOI 10.1097/00001622-199805000-00012; Stearns ME, 1998, PROSTATE, V36, P56; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tehranian A, 1996, AM J PATHOL, V149, P1177; THOMPSON TC, 1993, MOL CARCINOGEN, V7, P165, DOI 10.1002/mc.2940070307; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; THOMPSON TC, 1995, ONCOGENE, V10, P869; THOMPSON TC, 1991, CANCER SURV, V11, P55; TUTRONE RF, 1993, J UROLOGY, V149, P633, DOI 10.1016/S0022-5347(17)36169-4; Waters DJ, 1998, PROSTATE, V36, P64; Waters DJ, 1998, PROSTATE, V36, P47; Wei CW, 1997, P NATL ACAD SCI USA, V94, P6369, DOI 10.1073/pnas.94.12.6369; Wei CW, 1998, INT J MOL MED, V2, P487; Willis RA, 1998, INT J MOL MED, V1, P379; Yan Y, 1997, PROSTATE, V32, P129; Yang G, 1998, CLIN CANCER RES, V4, P1873; Zhang XJ, 1997, PROSTATE, V32, P16, DOI 10.1002/(SICI)1097-0045(19970615)32:1<16::AID-PROS3>3.0.CO;2-A; Zlotta AR, 1999, EUR UROL, V35, P498, DOI 10.1159/000019887	78	46	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	1999	18	38					5349	5355		10.1038/sj.onc.1203037	http://dx.doi.org/10.1038/sj.onc.1203037			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498888				2022-12-17	WOS:000082808400014
J	Van Orden, K; Yan, JP; Ulloa, A; Nyborg, JK				Van Orden, K; Yan, JP; Ulloa, A; Nyborg, JK			Binding of the human T-cell leukemia virus Tax protein to the coactivator CBP interferes with CBP-mediated transcriptional control	ONCOGENE			English	Article						transformation; c-jun; CBP/p300; leukemogenesis	ACUTE MYELOID-LEUKEMIA; I TAX; TRANSACTIVATOR TAX; DNA-BINDING; HISTONE ACETYLTRANSFERASE; 21-BASE-PAIR REPEATS; MOLECULAR MECHANISM; INDUCED STIMULATION; CREB PROTEIN; TYPE-1 TAX	The HTLV-I oncoprotein Tax is required for high level viral transcription and is strongly linked to HTLV-I associated malignant transformation. Tax stimulates HTLV-I transcription through high affinity binding to the KIX domain of CBP, a pleiotropic coactivator. Several cellular proteins, including c-jun, also bind to KIX and utilize CBP as a coactivator. To test whether Tax binding to KIX may disable cellular CBP function, we examined the potential interplay between Tax and c-jun for binding to KIX. We show that Tax represses the transcription function of c-jun in vivo and demonstrate that both transcription factors bind to an overlapping minimal region of KIX in vitro. c-jun binding to KIX is displaced by Tax, indicating that their binding is mutually exclusive and providing a molecular basis for the observed repression. The competition between Tax and cellular transcription factors for CBP represents a novel pathway for HTLV-I dependent deregulation of gene expression, and may have significant implications for cellular homeostasis and transformation in the HTLV-I infected T-cell.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Nyborg, JK (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.							ADAMS ME, 1990, BIOCHEMISTRY-US, V29, P7414, DOI 10.1021/bi00484a009; ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BEIMLING P, 1992, ONCOGENE, V7, P257; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; BRAUWEILER A, 1995, J BIOL CHEM, V270, P12814, DOI 10.1074/jbc.270.21.12814; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Giles RH, 1997, LEUKEMIA, V11, P2087, DOI 10.1038/sj.leu.2400882; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3551; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kimzey AL, 1998, J BIOL CHEM, V273, P13768, DOI 10.1074/jbc.273.22.13768; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; RADHAKRISHNAN I, 1997, CELL, V91, P7441; Rowley JD, 1997, BLOOD, V90, P535; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SLAMON DJ, 1985, SCIENCE, V228, P1427, DOI 10.1126/science.2990027; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; Smits PHM, 1996, ONCOGENE, V12, P1529; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; TAKE T, 1997, BLOOD, V89, P3945; Yan JP, 1998, J MOL BIOL, V281, P395, DOI 10.1006/jmbi.1998.1951; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; Yin MJ, 1996, MOL CELL BIOL, V16, P3156; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	50	46	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3766	3772		10.1038/sj.onc.1202703	http://dx.doi.org/10.1038/sj.onc.1202703			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391685				2022-12-17	WOS:000081140200011
J	Loubat, A; Rochet, N; Turchi, L; Rezzonico, R; Far, DF; Auberger, P; Rossi, B; Ponzio, G				Loubat, A; Rochet, N; Turchi, L; Rezzonico, R; Far, DF; Auberger, P; Rossi, B; Ponzio, G			Evidence for a p23 caspase-cleaved form of p27([KIP1]) involved in G(1) growth arrest	ONCOGENE			English	Article						p27([KIP1]); caspase; cell cycle; CDK2; CDK4; growth arrest	DEPENDENT KINASE INHIBITOR; CELL-CYCLE; POLY(ADP-RIBOSE) POLYMERASE; CPP32-LIKE PROTEASES; PHASE PROGRESSION; P27(KIP1); APOPTOSIS; ACTIVATION; PROTEIN; CDK	p27([KIP1]) (p27) is a cyclin dependent kinase inhibitor, involved in the negative regulation of G(1) progression in response to a number of anti-proliferative signals, In this study we show, in growing mouse hybridoma (7TD1) and human myeloma (U266) cell lines, that p27 is highly expressed but slightly upregulated when cells are arrested, regardless to the phases of the cell cycle, In contrast, the specific blockade of these cells in early G(1) phase reveals the induction of a protein of 23 kDa (p23) specifically recognized by polyclonal anti-p27 antibodies raised against the NH2 terminal part of p27 but not by anti-p21([CIP1]) antibodies. Experiments using caspase inhibitors strongly suggest that p23 results from the proteolysis of p27 by a 'caspase-3-like' protease. This cleavage leads to the cytosolic sequestration of p23 but does not alter its binding properties to CDK2 and CDK4 kinases. Indeed, p23 associated in vivo with high molecular weight complexes and coprecipitated with CDK2 and CDK4. We demonstrate by transfection experiments in SaOS-2 cells that p23 induces a G(1) phase growth arrest by inhibition of cyclin/CDK2 activity. In summary we describe here a caspase-cleaved form of p27, induced in absence of detectable apoptosis and likely involved in cell cycle regulation.	Fac Med Nice, INSERM, U364, Unite Immunol Cellulaire & Mol, F-06107 Nice 02, France; Fac Med Nice, CJF INSERM 96 05, F-06107 Nice, France; Hop Cantonal Geneva, Clin Immunol Lab, Geneva 14, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Geneva	Ponzio, G (corresponding author), Fac Med Nice, INSERM, U364, Unite Immunol Cellulaire & Mol, Ave Valombrose, F-06107 Nice 02, France.		ROCHET, Nathalie/S-3027-2019; Ponzio, Gilles/Q-1256-2016; REZZONICO, Roger/N-9626-2016; AUBERGER, Patrick/G-1491-2013; ROCHET, Nathalie/N-1819-2018	ROCHET, Nathalie/0000-0002-9995-6699; Ponzio, Gilles/0000-0003-2741-0248; REZZONICO, Roger/0000-0002-8460-1641; AUBERGER, Patrick/0000-0002-2481-8275; ROCHET, Nathalie/0000-0002-9995-6699; Turchi, Laurent/0000-0003-2020-5831				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; CASTEDO M, 1996, J IMMUNOL, V157, P515; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; HALL M, 1995, ONCOGENE, V11, P1581; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HULTNER L, 1989, IMMUNOLOGY, V67, P408; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LIU J, 1994, CELL IMMUNOL, V155, P428, DOI 10.1006/cimm.1994.1135; LUCAS JJ, 1992, J IMMUNOL, V148, P1804; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mazars GR, 1997, P NATL ACAD SCI USA, V94, P151, DOI 10.1073/pnas.94.1.151; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Ponzio G, 1998, ONCOGENE, V17, P1159, DOI 10.1038/sj.onc.1202040; PROUDFOOT AEI, 1993, J PROTEIN CHEM, V12, P489, DOI 10.1007/BF01025050; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REZZONICO R, 1995, ONCOGENE, V11, P1069; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINGER II, 1995, J EXP MED, V182, P1447, DOI 10.1084/jem.182.5.1447; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TAKASE K, 1992, CELL GROWTH DIFFER, V3, P515; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tchou WW, 1996, J BIOL CHEM, V271, P29556, DOI 10.1074/jbc.271.47.29556; TEROAKA H, 1996, EX CELL RES, V222, P218; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Uren A, 1997, J BIOL CHEM, V272, P21669, DOI 10.1074/jbc.272.35.21669; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107	49	46	46	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3324	3333		10.1038/sj.onc.1202668	http://dx.doi.org/10.1038/sj.onc.1202668			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362353				2022-12-17	WOS:000080589300003
J	Mantovani, F; Banks, L				Mantovani, F; Banks, L			Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines	ONCOGENE			English	Article						HPV; E6; p53; proteasome	HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; HPV-18 E6; GROWTH SUPPRESSION; DNA-BINDING; IDENTIFICATION; E7; TRANSACTIVATION; TRANSCRIPTION; KERATINOCYTES	The E6 proteins derived from tumour associated papillomavirus types target the cellular tumour suppressor protein p53 for ubiquitin mediated degradation, In cell lines derived from cervical tumours the p53 protein is present in very low amounts, but it can be activated ba appropriate DNA damaging agents, indicating that functional p53 is present within these lines. Recent studies have also shown that different polymorphic forms of the p53 protein are differentially susceptible to E6 mediated degradation. Therefore we have been interested in analysing the effects of different HPV E6 proteins upon p53 levels in a variety of cervical tumour derived cell lines, We show that inhibition of E6 mediated degradation of p53 frequently results in increased levels of p53 expression. However, there are notable exceptions to this where increased p53 levels are only obtained following DNA damage and proteasome inhibition. We also show in E6 expressing cells, that as well as p53 being targeted for degradation, the localization of p53 to the nucleus is also inhibited, consistent with previous observations which indicate that degradation of p53 is not essential for E6 mediated inhibition of p53 function. These results have important implications for any potential therapies which might aim to block mediated degradation of p53.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.							ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; Bouvard V, 1996, INT J ONCOL, V8, P159; BUTZ K, 1995, ONCOGENE, V10, P927; Crook T, 1998, ONCOGENE, V16, P1429, DOI 10.1038/sj.onc.1201699; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Knippschild U, 1996, ONCOGENE, V12, P1755; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; MIYASHITA T, 1995, CELL, V80, P293; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIM D, 1994, ONCOGENE, V9, P1869; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STOREY A, 1992, ONCOGENE, V7, P459; STOREY A, 1995, ONCOGENE, V11, P653; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; THOMAS M, 1995, ONCOGENE, V10, P261; Thomas M, 1996, ONCOGENE, V13, P265; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	39	46	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	1999	18	22					3309	3315		10.1038/sj.onc.1202688	http://dx.doi.org/10.1038/sj.onc.1202688			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362351				2022-12-17	WOS:000080589300001
J	Umbricht, CB; Sherman, ME; Dome, J; Carey, LA; Marks, J; Kim, N; Sukumar, S				Umbricht, CB; Sherman, ME; Dome, J; Carey, LA; Marks, J; Kim, N; Sukumar, S			Telomerase activity in ductal carcinoma in situ and invasive breast cancer	ONCOGENE			English	Article						telomerase; breast cancer; ductal carcinoma in situ; microdissection; cancer progression	REPLICATIVE SENESCENCE; CELLULAR SENESCENCE; ALLELIC LOSS; IN-SITU; LESIONS; IMMORTALITY; EXPRESSION; TUMORS; MARKER; CELLS	The increasing number of breast carcinoma in situ detected by screening procedures makes it imperative to develop improved markers to stratify the risk of invasive cancer, Telomerase is detectable in invasive cancer, but not in normal tissues. We have microdissected frozen tissue blocks containing both DCIS and invasive cancer to assay the telomerase activity of these two lesions. The 46 available cases of concurrent DCIS and invasive breast cancer resulted in 43 DCIS samples and 38 invasive cancer samples adequate for analysis. Seventy per cent of the DCIS and all invasive cancer samples tested had detectable telomerase activity. In addition, we analysed telomerase activity in ten cases of DCIS that were not associated with invasive cancer, and detected telomerase activity in seven (70%). Mixing experiments showed no evidence of telomerase inhibitors in telomerase negative samples. Furthermore, periductal inflammatory infiltrates were shown to be a potential confounding source of telomerase activity. Since DCIS lesions appear to be heterogeneous with respect to telomerase activity, and telomerase activation appears to precede the development of invasive cancer, telomerase activity may be a useful adjunct in stratifying the risk of developing invasive breast cancer in patients with DCIS.	Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Duke Univ, Dept Surg, Durham, NC USA; Geron Corp, Menlo Park, CA USA	Johns Hopkins University; Johns Hopkins University; Duke University; Geron Corporation	Sukumar, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Ross Bldg 370,720 Rutland Ave, Baltimore, MD 21205 USA.		Dome, Jeffrey/AAH-7825-2019					BACCHETTI S, 1995, INT J ONCOL, V7, P423; Bednarek AK, 1997, CLIN CANCER RES, V3, P11; Bednenko J, 1997, EMBO J, V16, P2507, DOI 10.1093/emboj/16.9.2507; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carey LA, 1998, CLIN CANCER RES, V4, P435; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; Clark GM, 1997, J NATL CANCER I, V89, P1874, DOI 10.1093/jnci/89.24.1874; FLINT J, 1994, AM J HUM GENET, V55, P505; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; Greider CW, 1996, SCI AM, V274, P92, DOI 10.1038/scientificamerican0296-92; GREIDER CW, 1994, CURR OPIN GENET DEV, V4, P203, DOI 10.1016/S0959-437X(05)80046-2; HAY R, 1994, ATCC CELL LINES HYBR; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; Hoos A, 1998, INT J CANCER, V79, P8, DOI 10.1002/(SICI)1097-0215(19980220)79:1<8::AID-IJC2>3.0.CO;2-5; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Klingelhutz AJ, 1997, J MOL MED-JMM, V75, P45, DOI 10.1007/s001090050085; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Landberg G, 1997, CANCER RES, V57, P549; Meeker AK, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1323; Melek M, 1996, BIOESSAYS, V18, P301, DOI 10.1002/bies.950180408; Nawaz S, 1997, AM J CLIN PATHOL, V107, P542; Nelson NJ, 1996, J NATL CANCER I, V88, P1021, DOI 10.1093/jnci/88.15.1021; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; Page DL, 1998, MODERN PATHOL, V11, P120; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Poremba C, 1998, INT J ONCOL, V12, P641; Sambrook J, 1989, MOL CLONING LAB MANU; SHAY JW, 1995, MOL MED TODAY, V1, P378, DOI 10.1016/S1357-4310(95)93872-9; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Sugino T, 1996, INT J CANCER, V69, P301, DOI 10.1002/(SICI)1097-0215(19960822)69:4<301::AID-IJC11>3.0.CO;2-8; Tsao JI, 1997, CLIN CANCER RES, V3, P627; Umbricht CB, 1997, CANCER RES, V57, P2144; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3; Yashima K, 1998, CLIN CANCER RES, V4, P229; ZHUANG A, 1995, AM J PATHOL, V146, P620; ZHUANG ZP, 1995, CANCER RES, V55, P467	38	46	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3407	3414		10.1038/sj.onc.1202714	http://dx.doi.org/10.1038/sj.onc.1202714			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362362	Bronze			2022-12-17	WOS:000080589300012
J	Schmandt, R; Liu, SK; McGlade, CJ				Schmandt, R; Liu, SK; McGlade, CJ			Cloning and characterization of mPAL, a novel Shc SH2 domain-binding protein expressed in proliferating cells	ONCOGENE			English	Article						SHC; SH2 domain; phosphotyrosine-independent; cell proliferation	NUCLEOTIDE EXCHANGE FACTOR; PHOSPHOTYROSINE-INDEPENDENT LIGAND; TYROSINE-PHOSPHORYLATED PROTEIN; GROWTH-FACTOR RECEPTORS; ADAPTER PROTEIN; SIGNAL-TRANSDUCTION; CONSTITUTIVE PHOSPHORYLATION; NEURONAL DIFFERENTIATION; KINASE ACTIVATION; DEPENDENT MANNER	Shc adaptor proteins play a role in linking activated cell surface receptors to the Ras signaling pathway in response to receptor mediated tyrosine kinase activation. While the function of Shc in the activation of the Ras pathway, ia binding to Grb2 has been well characterized, it is becoming increasingly apparent that Shc participates in additional signaling pathways through interactions with other cytoplasmic proteins. Using the yeast two-hybrid system, we have identified a unique She binding protein designated PAL (Protein expressed in Activated Lymphocytes) with no similarity to other known proteins. mPAL binds specifically to the Shc SH2 domain and unlike previously described Shc SH2 domain-protein interactions, the association of mPAL and She is phosphotyrosine-independent. RNA and protein expression are restricted to tissues containing actively dividing cells and proliferating cells in culture, mPAL expression is induced upon growth factor stimulation and is down-regulated upon growth inhibition. This pattern, and timing of mPAL expression and its association with the She adaptor molecule suggests a role for this protein in signaling pathways governing cell cycle progression.	Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	McGlade, CJ (corresponding author), Univ Toronto, Dept Med Biophys, Ontario Canc Inst, 620 Univ Ave,Suite 706, Toronto, ON M5G 2C1, Canada.			Liu, Stanley/0000-0001-6851-0857				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bai C, 1996, METHOD ENZYMOL, V273, P331; BALDARI CT, 1995, ONCOGENE, V10, P1141; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/0968-0004(96)10033-5; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; CROWE AJ, 1994, ONCOGENE, V9, P537; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V82, P2296; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Gotoh N, 1995, ONCOGENE, V11, P2525; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU SK, 1998, IN PRESS ONCOGENE; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; MALEK SN, 1994, J BIOL CHEM, V269, P33009; Marengere LEM, 1997, J IMMUNOL, V159, P70; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; O'Bryan JP, 1998, J BIOL CHEM, V273, P20431, DOI 10.1074/jbc.273.32.20431; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Raffel GD, 1996, J BIOL CHEM, V271, P4640; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUDNICKI MA, 1990, J CELL PHYSIOL, V142, P89, DOI 10.1002/jcp.1041420112; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SAXTON TM, 1994, J IMMUNOL, V153, P623; SEGATTO O, 1993, ONCOGENE, V8, P2105; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	79	46	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	1999	18	10					1867	1879		10.1038/sj.onc.1202507	http://dx.doi.org/10.1038/sj.onc.1202507			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086341				2022-12-17	WOS:000079090000010
J	Russo, I; Silver, ARJ; Cuthbert, AP; Griffin, DK; Trott, DA; Newbold, RF				Russo, I; Silver, ARJ; Cuthbert, AP; Griffin, DK; Trott, DA; Newbold, RF			A telomere-independent senescence mechanism is the sole barrier to Syrian hamster cell immortalization	ONCOGENE			English	Article						telomere; telomerase; senescence; immortalization; hamster; carcinogenesis	MALIGNANT TRANSFORMATION; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; HUMAN CANCER; MOUSE CELLS; IN-VITRO; LENGTH; DNA; CARCINOMA; EXPRESSION	Reactivation of telomerase and stabilization of telomeres occur simultaneously during human cell immortalization in, vitro and the vast majority of human cancers possess high le, els of telomerase activity, Telomerase repression in human somatic cells may therefore have evolved as a powerful resistance mechanism against immortalization, clonal evolution and malignant progression. The comparative ease with, which rodent cells immortalize in vitro suggests that they have less stringent controls over replicative senescence than human cells. Here, we report that Syrian hamster dermal fibroblasts possess substantial levels of telomerase activity throughout their culture life-span, even after growth arrest in senescence. In our studies, telomerase,vas also detected in uncultured new-horn hamster skin, in several adult tissues, and in cultured fibroblasts induced to enter the post-mitotic state irreversibly by serum withdrawal. Transfection of near-senescent dermal fibroblasts with a selectable plasmid vector expressing the SV40 T-antigen gene resulted in high-frequency single-step immortalization without the crisis typically observed during the immortalization of human cells, Collectively, these data provide an explanation for the increased susceptibility of rodent cells to immortalization (and malignant transformation) compared with their human equivalents, and provide evidence for a novel, growth factor-sensitive, mammalian senescence mechanism unrelated to telomere maintenance.	Brunel Univ, Dept Biol & Biochem, Human Canc Genet Unit, Uxbridge UB8 3PH, Middx, England; Natl Radiol Protect Board, Biomed Effects Dept, Chilton OX11 0RQ, Oxon, England	Brunel University	Newbold, RF (corresponding author), Brunel Univ, Dept Biol & Biochem, Human Canc Genet Unit, Uxbridge UB8 3PH, Middx, England.							ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ANNAND R, 1986, TRENDS GENET, V2, P278; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; CHADENEAU C, 1995, ONCOGENE, V11, P893; COSTA M, 1995, AM J CLIN NUTR, V61, p666S, DOI 10.1093/ajcn/61.3.666S; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; GONOS ES, 1992, INT J ONCOL, V1, P209; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hara E, 1996, MOL CELL BIOL, V16, P859; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Holliday R, 1996, BIOESSAYS, V18, P3, DOI 10.1002/bies.950180103; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; Kipling D., 1995, TELOMERE; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; Mazars GR, 1997, P NATL ACAD SCI USA, V94, P151, DOI 10.1073/pnas.94.1.151; Meijne EIM, 1996, GENE CHROMOSOME CANC, V16, P230, DOI 10.1002/(SICI)1098-2264(199608)16:4<230::AID-GCC2>3.0.CO;2-Z; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Newbold R F, 1985, Carcinog Compr Surv, V9, P17; NEWBOLD RF, 1982, NATURE, V299, P633, DOI 10.1038/299633a0; NEWBOLD RF, 1993, TOXICOL LETT, V67, P211, DOI 10.1016/0378-4274(93)90057-5; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Ramirez RD, 1997, J INVEST DERMATOL, V108, P113, DOI 10.1111/1523-1747.ep12285654; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SILVER A, 1991, GENE CHROMOSOME CANC, V3, P376, DOI 10.1002/gcc.2870030508; SLIJEPCEVIC P, 1995, CYTOGENET CELL GENET, V69, P87, DOI 10.1159/000133944; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STARLING JA, 1990, NUCLEIC ACIDS RES, V18, P6881, DOI 10.1093/nar/18.23.6881; TROTT DA, 1995, CARCINOGENESIS, V16, P193, DOI 10.1093/carcin/16.2.193; VAZIRI H, 1993, AM J HUM GENET, V52, P661; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WynfordThomas D, 1997, EUR J CANCER, V33, P716, DOI 10.1016/S0959-8049(97)00064-6; Yamasaki H, 1996, MUTAT RES-FUND MOL M, V356, P1, DOI 10.1016/0027-5107(96)90031-7; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	62	46	47	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3417	3426		10.1038/sj.onc.1202261	http://dx.doi.org/10.1038/sj.onc.1202261			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030665				2022-12-17	WOS:000078086200002
J	Tran, Y; Benbatoul, K; Gorse, K; Rempel, S; Futreal, A; Green, M; Newsham, I				Tran, Y; Benbatoul, K; Gorse, K; Rempel, S; Futreal, A; Green, M; Newsham, I			Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain and breast	ONCOGENE			English	Article						loss of heterozygosity; chromosome 18p; Non-small cell lung cancer; breast cancer; glioblastoma	MICROSATELLITE INSTABILITY; COMMON REGION; HETEROZYGOSITY; CANCER; CARCINOMAS; ABNORMALITIES; PROGRESSION; SEQUENCES; LOCUS; PANEL	Lung cancer is now the number one cause of cancer death for both men and women. An age-adjusted analysis over the past 25 gears shows that in women specifically, lung cancer incidence is on the rise. It is estimated that 10-20 genetic events including the alteration of oncogenes and tumor suppressor genes will have occurred by the time a lung tumor becomes clinically evident. In an effort to identify regions containing novel cancer genes, chromosome 18p11, a band not previously implicated in disease, was examined for loss of heterozygosity (LOH). In this study, 50 matched normal and NSCLC tumor samples were examined using sis 18p11 and one 18q12.3 PCR-based polymorphic markers. In addition, LOH was examined in 29 glioblastoma pairs and 14 paired breast carcinomas. This analysis has revealed potentially two regions of LOH in 18p11 in up to 38% of the tumor samples examined, The regions of LOH identified included a 2 cm area between markers D18S59 and D18S476, and a more proximal, 25 cm region of intermediate frequency between D18S452 and D18S453, These results provide evidence for the presence of one or more potential tumor suppressor genes on the short arm of chromosome 18 which may be involved in NSCLC, brain tumors and possibly breast carcinomas as well.	Univ Calif San Diego, Dept Med, Theodore Gildred Canc Ctr, La Jolla, CA 92093 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; Duke Univ, Dept Surg, Durham, NC 27710 USA; Med Univ S Carolina, Med Ctr, Hollings Canc Ctr, Charleston, SC 29425 USA	University of California System; University of California San Diego; Virginia Commonwealth University; Henry Ford Health System; Henry Ford Hospital; Duke University; Medical University of South Carolina	Newsham, I (corresponding author), Univ Calif San Diego, Dept Med, Theodore Gildred Canc Ctr, La Jolla, CA 92093 USA.				NATIONAL CANCER INSTITUTE [P20CA066215, R29CA077730, P30CA023100] Funding Source: NIH RePORTER; NCI NIH HHS [R29-CA77730-02, 5-P30-CA23100-13, 1 P20-CA66215-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI J, 1995, GENE CHROMOSOME CANC, V14, P301, DOI 10.1002/gcc.2870140409; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; CENTER R, 1993, GENE CHROMOSOME CANC, V7, P47, DOI 10.1002/gcc.2870070108; FONG KM, 1995, CANCER RES, V55, P4268; FONG KM, 1995, CANCER RES, V55, P220; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAMPTON GM, 1994, CANCER RES, V54, P4586; HUANG THM, 1995, DIAGN MOL PATHOL, V4, P6672; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; KISHIMOTO Y, 1995, JNCI-J NATL CANCER I, V87, P1224, DOI 10.1093/jnci/87.16.1224; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; LUKEIS R, 1993, GENE CHROMOSOME CANC, V8, P262, DOI 10.1002/gcc.2870080409; MERLENS F, 1997, CANCER RES, V57, P2765; Nagatake M, 1996, CANCER RES, V56, P1886; Nagatake M, 1996, CANCER RES, V56, P2718; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RASIO D, 1995, CANCER RES, V55, P3988; REMPEL SA, 1993, CANCER RES, V53, P2386; ROJAS K, 1995, GENOMICS, V25, P329, DOI 10.1016/0888-7543(95)80153-D; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; SHRIDHAR V, 1994, CANCER RES, V54, P2084; TESTA JR, 1992, CANCER RES, V52, pS2702; TESTA JR, 1994, GENE CHROMOSOME CANC, V11, P178, DOI 10.1002/gcc.2870110307; Tran YK, 1996, CANCER RES, V56, P2916; WINQVIST R, 1995, CANCER RES, V55, P2660; Zhu JG, 1996, ONCOGENE, V12, P1417	29	46	50	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3499	3505		10.1038/sj.onc.1202258	http://dx.doi.org/10.1038/sj.onc.1202258			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030674				2022-12-17	WOS:000078086200011
J	Dirks, PB; Rutka, JT; Hubbard, SL; Mondal, S; Hamel, PA				Dirks, PB; Rutka, JT; Hubbard, SL; Mondal, S; Hamel, PA			The E2P-family proteins induce distinct cell cycle regulatory factors in pl6-arrested, U343 astrocytoma cells	ONCOGENE			English	Article						E2F-family; p16; astrocytomas; cell cycle; apoptosis	DIHYDROFOLATE-REDUCTASE GENE; E2F TRANSCRIPTION FACTOR; HUMAN MYC PROMOTER; RETINOBLASTOMA-PROTEIN; GROWTH SUPPRESSION; IN-VIVO; EXPRESSION PATTERNS; TRANS-ACTIVATION; BINDING PROTEIN; FAMILY PROTEINS	We previously demonstrated that P16(Ink4a) (p16) expression in p16-deficient U343 astrocytoma cells causes a G(1) cell cycle arrest, profound changes in cytoskeletal proteins and alterations in expression and activity of the pRB and E2F family proteins, We examine here the effects of expressing wild type or mutant versions of the downstream targets of p16 in U343 astrocytomas, We first attempted to block proliferation of U343 cells using the dominant mutant of pRB, Delta p34. Expression of this mutant in the human osteosarcoma, SAOS-2, potently blocked proliferation but did not affect the cell cycle of U343 cells. We next showed that expression of E2F-1, E2F-2, E2F-3 and E2F-4 are each able to overcome this p16-dependent cell cycle arrest but exhibit distinct biological activities, Adenoviral-mediated expression of E2F-1, E2F-2, E2F-3, or E2F-4 overcame the p16-dependent cell cycle block and induced alterations in cell morphology, E2F-5, only in conjunction with DP1, promoted cell cycle progression. For both E2F-1 and E2F-2, bat not E2F-3 or E2F-5/DP1, cell cycle re-entry was associated with almost quantitative cell death, Only small numbers of dying cells were observed in E2F-4-expressing cultures. Expression of the different E2F's altered the expression of distinct sets of cell cycle regulatory proteins. E2F-1 induced endogenous E2F-4 expression and also caused an increase in pRB, p107 and cyclin E levels. Expression of E2F-4 caused a weak increase in E2F-1 levels but also strongly induced pRB, p107, p130 and cyclin E, However, E2F-1 and E2F-4 clearly regulate expression of distinct genes, demonstrated when E2F-4 caused a threefold increase in the levels of cdk2 whereas E2F-1 failed to increase in this cyclin dependent kinase, Similarly, expression of E2F-1 or E2F-2 were shown to have distinct effects on the expression of cdk2, cyclin E and pRB despite both of these closely related E2F-family members potently inducing cell death, Thus, E2F-1, E2F-2, E2F-3 and E2F-4 are able to overcome the p16-dependent proliferative block in U343 astrocytoma cells, While overcoming this cell cycle block, each of the E2F's uniquely affect the expression of a number of cell cycle regulatory proteins and have distinct abilities to promote cell death.	Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Hosp Sick Children, Div Neurosurg, Toronto, ON M5S 1A8, Canada; Univ Toronto, Hosp Sick Children, Div Surg Res, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Hamel, PA (corresponding author), Univ Toronto, Dept Lab Med & Pathol, 100 Coll St, Toronto, ON M5S 1A8, Canada.							BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Botz J, 1996, MOL CELL BIOL, V16, P3401; BUCK V, 1995, ONCOGENE, V11, P31; Dagnino L, 1997, MECH DEVELOP, V66, P13, DOI 10.1016/S0925-4773(97)00083-X; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dirks PB, 1997, ONCOGENE, V15, P2037, DOI 10.1038/sj.onc.1201392; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P2392, DOI 10.1128/MCB.6.7.2392; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1992, ONCOGENE, V7, P693; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hirai H, 1996, MOL CELL BIOL, V16, P6457; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; Jiang Z, 1997, ONCOGENE, V14, P1789, DOI 10.1038/sj.onc.1201014; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KIESS M, 1995, ONCOGENE, V10, P159; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LEE WH, 1988, J CELL BIOCHEM, V38, P213, DOI 10.1002/jcb.240380309; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUKAS J, 1995, CANCER RES, V55, P4818; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MUNCASTER MM, 1992, CANCER RES, V52, P654; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIMIZU M, 1995, MOL CELL BIOL, V15, P2882; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V12, P5620; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; Ueki K, 1996, CANCER RES, V56, P150; WADE M, 1995, J BIOL CHEM, V270, P9783, DOI 10.1074/jbc.270.17.9783; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU CL, 1995, MOL CELL BIOL, V15, P2536; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; YEAGER T, 1995, CANCER RES, V55, P493; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	69	46	50	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					867	876		10.1038/sj.onc.1202008	http://dx.doi.org/10.1038/sj.onc.1202008			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780003				2022-12-17	WOS:000075448800008
J	Butz, K; Geisen, C; Ullmann, A; Zentgraf, H; Hoppe-Seyler, F				Butz, K; Geisen, C; Ullmann, A; Zentgraf, H; Hoppe-Seyler, F			Uncoupling of p21(WAF1/CIP1/SDI1) mRNA and protein expression upon genotoxic stress	ONCOGENE			English	Article						p21(WAF1/CIP1/SDI1); DNA damage; p53; HPV; mdm-2	P53-MEDIATED G(1) ARREST; CYCLIN-DEPENDENT KINASES; POSITIVE CANCER-CELLS; P53-INDEPENDENT PATHWAY; DNA-DAMAGE; P21; INHIBITOR; P53; DIFFERENTIATION; INDUCTION	The p21(WAF1/CIP1SDI1) gene is an important regulator of crucial cellular processes, including cell cycle control, cellular differentiation, and the response to genotoxic stress, Induction of p21 gene expression upon DNA damage :is,widely believed to be p53-dependent. In the present study we analysed the expression of p21 following genotoxic stress, using different DNA-damaging agents and cellular systems. We found that the p21 response markedly varied between different cell lines and also for different genotoxic agents within the same cell line. Genotoxic induction of p21 mRNA expression can occur in the presence of p53-antagonists, such as overexpressed mdm-2 or human papillomavirus (HPV) E6, and in cells harbouring mutated p53 genes. Moreover, upon genotoxic stress, p21 mRNA and protein expression were found to be uncoupled in several cell lines. Thus, transcriptional and postranscriptional changes:in p21 expression following DNA damage are not necessarily linked to the intracellular p53 status but strongly depend on the individual cellular background and the type of DNA-damaging agent. Our findings indicate that p21 expression following genotoxic stress underlies a complex control and can be substantially modulated on the posttranscriptional level in a cell-specific manner.	Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Hoppe-Seyler, F (corresponding author), Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.			Hoppe-Seyler, Felix/0000-0002-1864-300X				Boyer SN, 1996, CANCER RES, V56, P4620; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUTZ K, 1995, ONCOGENE, V10, P927; Butz K, 1996, INT J CANCER, V68, P506, DOI 10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Englert C, 1997, CANCER RES, V57, P1429; FUNK O, 1997, GENE DEV, V11, P2090; GUDAS J, 1995, ONCOGENE, V11, P253; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEBAER J, 1997, GENE DEV, V11, P847; Loignon M, 1997, CANCER RES, V57, P3390; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; McDonald E, 1996, CANCER RES, V56, P2250; MICHIELI P, 1994, CANCER RES, V54, P3391; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MITSUDOMI T, 1992, ONCOGENE, V7, P171; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; WHITAKER SJ, 1992, EUR J CANCER, V28A, P273, DOI 10.1016/0959-8049(92)90432-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	43	46	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					781	787		10.1038/sj.onc.1201995	http://dx.doi.org/10.1038/sj.onc.1201995			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715280				2022-12-17	WOS:000075337200013
J	Burchert, A; Attar, EC; McCloskey, P; Fridell, YWC; Liu, ET				Burchert, A; Attar, EC; McCloskey, P; Fridell, YWC; Liu, ET			Determinants for transformation induced by the Axl receptor tyrosine kinase	ONCOGENE			English	Article						receptor tyrosine kinase; retroviruses, mutations; transformations; Axl	GROWTH-FACTOR RECEPTOR; LONG TERMINAL REPEAT; ALTERED AUTOPHOSPHORYLATION SITES; MURINE LEUKEMIA-VIRUS; POINT MUTATION; PROTO-ONCOGENE; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; CELLS; GENE	The Axl receptor tyrosine kinase is a transforming oncogene in NIH3T3 cells, In order to define structural requirements of the Axl receptor necessary for transformation me passaged recombinant retroviruses carrying the axl cDNA in NIH3T3 cells, generating randomly mutated axl variants. Using this strategy, we have isolated three axl viral strains (1B1, SV8, and FFa4) that show augmented 3T3 cell transforming capacity associated with elevated p140(Axl). Upon sequencing, the 1B1 and SV8 proviruses possessed only silent mutations, making p140(Axl) overexpression the most likely explanation for their increased transformation activity. However, the characterization of FFa4 revealed a deletion of sequences encoding the carboxy-terminal 45 amino acids leading to the generation of a chimeric transcript comprised of a truncated Axl receptor with a segment of the 3' UTR region. Mutational analysis revealed that the transforming activity of FFa4 was specific to the formation of the chimeric receptor rather than to the carboxyl-terminal truncation, Intriguingly, none of the viral strains were able to transform the murine cell lines. NR-6 and 32D despite equivalent expression of surface p140(Axl) protein. Further analysis showed that Axl's transforming potential is dependent on the host cell type, the presence of a putative pp190 as a facilitator for transformation, and the level of p140(Axl) expression, Taken together, these results underscore the complexity of Axl biology which is dependent on receptor stoichiometry and the cellular background.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Liu, ET (corresponding author), NCI, Div Clin Sci, NIH, 31-3A11,31 Ctr Dr,MSC 2440, Bethesda, MD 20892 USA.		Liu, Edison/C-4141-2008; Burchert, Andreas/S-9563-2017	Burchert, Andreas/0000-0002-8411-8844	NATIONAL CANCER INSTITUTE [R01CA049240, P50CA058223] Funding Source: NIH RePORTER; NCI NIH HHS [CA58223-04, R01-CA49240] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ALVAREZ CV, 1995, J BIOL CHEM, V270, P16271, DOI 10.1074/jbc.270.27.16271; ANDO A, 1992, J BIOL CHEM, V267, P12788; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER TH, 1995, VIROLOGY, V212, P277, DOI 10.1006/viro.1995.1484; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FAN H, 1988, VIROLOGY, V166, P58, DOI 10.1016/0042-6822(88)90146-8; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; Goruppi S, 1996, ONCOGENE, V12, P471; GREZ M, 1991, J VIROL, V65, P4691, DOI 10.1128/JVI.65.9.4691-4698.1991; HANECAK R, 1991, J VIROL, V65, P5357, DOI 10.1128/JVI.65.10.5357-5363.1991; HERBST R, 1995, ONCOGENE, V10, P369; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; JIA R, 1992, J VIROL, V66, P5975, DOI 10.1128/JVI.66.10.5975-5987.1992; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; LAI C, 1994, ONCOGENE, V9, P2567; Li RH, 1996, J NEUROSCI, V16, P2012; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; MCCLOSKEY P, 1994, CELL GROWTH DIFFER, V5, P1105; MCMANUS MJ, 1995, J VIROL, V69, P3631, DOI 10.1128/JVI.69.6.3631-3638.1995; MEDORI R, 1992, BIOTECHNIQUES, V12, P346; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MONK RJ, 1992, J VIROL, V66, P3683, DOI 10.1128/JVI.66.6.3683-3689.1992; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; QUONG RYY, 1994, MELANOMA RES, V4, P313, DOI 10.1097/00008390-199410000-00008; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Taylor ICA, 1995, ONCOGENE, V11, P2619; THIES RS, 1989, J BIOL CHEM, V264, P12820; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; Zhang QK, 1996, J VIROL, V70, P8089, DOI 10.1128/JVI.70.11.8089-8097.1996	53	46	46	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3177	3187		10.1038/sj.onc.1201865	http://dx.doi.org/10.1038/sj.onc.1201865			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671397				2022-12-17	WOS:000074261300011
J	Mills, JJ; Falls, JG; De Souza, AT; Jirtle, RL				Mills, JJ; Falls, JG; De Souza, AT; Jirtle, RL			Imprinted M6p/Igf2 receptor is mutated in rat liver tumors	ONCOGENE			English	Article						M6p/Igf2r; genomic imprinting; liver cancer; tumor suppressor	FACTOR-II RECEPTOR; FACTOR TYPE-2 RECEPTOR; GROWTH-FACTOR-BETA; MOUSE; GENE; LOCUS; IGF2R; HETEROZYGOSITY; BINDING	We have previously shown that inactivation of mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/ IGF2R) is a common early event in both human liver and breast carcinogenesis. The M6p/Igf2r is imprinted in mice while expression is biallelic in most humans. In this investigation the M6p/Igf2r gene is shown to also be imprinted in the liver of Fischer 344, Lewis and Brown Norway rats. In addition, we have identified mutations in the expressed allele of the M6p/Igf2r in 40% of diethylnitrosamine-initiated rat liver tumors. These results provide further evidence that the M6P/IGF2R functions as a liver tumor suppressor gene. They also suggest that mice and rats would be more sensitive than humans to those hepatocarcinogens in which the M6p/ Igf2r is mechanistically involved in transformation since one rather than two alleles would need to be inactivated.	Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA; Zeneca Pharmaceut, Dept Safety Med, Macclesfield SK10 4TG, Cheshire, England	Duke University	Jirtle, RL (corresponding author), Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA.			Mills, Jeremy James/0000-0003-1719-9047	NCI NIH HHS [CA25951] Funding Source: Medline; NIEHS NIH HHS [ES08823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA025951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; Dahms NM, 1996, BIOCHEM SOC T, V24, P136, DOI 10.1042/bst0240136; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; deSouza AT, 1997, FASEB J, V11, P60, DOI 10.1096/fasebj.11.1.9034167; Franklin GC, 1996, PLACENTA, V17, P3, DOI 10.1016/S0143-4004(05)80638-1; Hankins GR, 1996, ONCOGENE, V12, P2003; HASEMAN JK, 1987, ENVIRON HEALTH PERSP, V74, P229, DOI 10.2307/3430453; JIRTLE RL, 1994, CARCINOGENESIS, V15, P1473, DOI 10.1093/carcin/15.8.1473; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; Kang JX, 1997, P NATL ACAD SCI USA, V94, P13671, DOI 10.1073/pnas.94.25.13671; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; MILLS JJ, 1995, LIVER REGENERATION C, P199; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; Moser GJ, 1996, CARCINOGENESIS, V17, P1835, DOI 10.1093/carcin/17.9.1835; Ouyang H, 1997, CANCER RES, V57, P1851; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SZEBENYI G, 1994, GENOMICS, V19, P120, DOI 10.1006/geno.1994.1021; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631; XU YQ, 1993, BIOCHEM BIOPH RES CO, V197, P747, DOI 10.1006/bbrc.1993.2542; Yamada T, 1997, P NATL ACAD SCI USA, V94, P10351, DOI 10.1073/pnas.94.19.10351	25	46	46	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2797	2802		10.1038/sj.onc.1201801	http://dx.doi.org/10.1038/sj.onc.1201801			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652747	Green Submitted			2022-12-17	WOS:000073812200012
J	Bonvini, P; Nguyen, P; Trepel, J; Neckers, LM				Bonvini, P; Nguyen, P; Trepel, J; Neckers, LM			In vivo degradation of N-myc in neuroblastoma cells is mediated by the 26S proteasome	ONCOGENE			English	Article						N-myc; ubiquitin; proteasome	MULTICATALYTIC PROTEINASE COMPLEX; NUCLEAR PROTEINS; NEURO-BLASTOMA; M-CALPAIN; ORNITHINE DECARBOXYLASE; SELECTIVE INHIBITORS; PROTEOLYTIC SYSTEM; KAPPA-B; UBIQUITIN; AMPLIFICATION	N-myc is a short-lived transcription factor, frequently amplified in human neuroblastomas. The ubiquitin-proteasome system is involved in the degradation of many short-lived cellular proteins and previous studies have shown that ubiquitin-dependent proteolysis is implicated in the turn-over of N-myc in vitro. However, calpain has also been implicated in N-myc degradation in vitro. Here we report that, in vivo, N-myc is a sensitive substrate for the 26S proteasome in N-myc amplified neuroblastoma cells. We observed that inhibition of the 26S proteasome with two inhibitors, ALLnL and lactacystin, led to an elevation of the N-myc protein steady-state and increased N-myc protein polyubiquitination, as revealed by ubiquitin Western blotting. Pulse-chase experiments have shown that the increased N-myc levels resulted from stabilization of the protein. In contrast treatment with several calpain and cathepsin inhibitors failed to block N-myc degradation in vivo. Furthermore, fluorescence microscopy of ALLnL-treated cells localized N-myc exclusively to the nuclear compartment, suggesting the absence of a requirement for transport to the cytoplasm prior to degradation.	NCI, Dept Cell & Canc Biol, Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bonvini, P (corresponding author), NCI, Dept Cell & Canc Biol, Med Branch, NIH, Bethesda, MD 20892 USA.		Bonvini, Paolo/J-9877-2018	Bonvini, Paolo/0000-0003-2889-108X				AKESON R, 1990, MOL CELL BIOL, V10, P2012, DOI 10.1128/MCB.10.5.2012; ATSMA DE, 1995, CIRC RES, V76, P1071, DOI 10.1161/01.RES.76.6.1071; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARILLO S, 1994, ONCOGENE, V9, P1679; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; COHN SL, 1990, ONCOGENE, V5, P1821; DIAS P, 1990, INT J CANCER, V45, P593, DOI 10.1002/ijc.2910450403; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Fenteany G, 1996, CHEM BIOL, V3, P905, DOI 10.1016/S1074-5521(96)90179-9; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V62, P1989; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; HAYASHI Y, 1990, INT J CANCER, V45, P705, DOI 10.1002/ijc.2910450423; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KATAGIRI M, 1995, J ANTIBIOT, V48, P344, DOI 10.7164/antibiotics.48.344; Knuehl C, 1996, EXP CELL RES, V225, P67, DOI 10.1006/excr.1996.0157; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; MELLGREN RL, 1993, J BIOL CHEM, V268, P653; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; Oda K, 1996, BIOCHEM BIOPH RES CO, V219, P800, DOI 10.1006/bbrc.1996.0314; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; Rivett AJ, 1990, CURR OPIN CELL BIOL, V2, P1143, DOI 10.1016/0955-0674(90)90168-E; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SATO M, 1992, INT J ONCOL, V1, P539; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; TSUBUKI S, 1993, BIOCHEM BIOPH RES CO, V196, P1195, DOI 10.1006/bbrc.1993.2378; Umezawa H, 1976, Methods Enzymol, V45, P678; WADA RK, 1993, CANCER, V72, P3346, DOI 10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E; WANG KKW, 1990, TRENDS PHARMACOL SCI, V11, P139, DOI 10.1016/0165-6147(90)90060-L; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120	62	46	46	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1131	1139		10.1038/sj.onc.1201625	http://dx.doi.org/10.1038/sj.onc.1201625			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528855				2022-12-17	WOS:000072336000004
J	Frederick, A; Rolfe, M; Chiu, MI				Frederick, A; Rolfe, M; Chiu, MI			The human UNP locus at 3p21.31 encodes two tissue-selective, cytoplasmic isoforms with deubiquitinating activity that have reduced expression in small cell lung carcinoma cell lines	ONCOGENE			English	Article						ubiquitin protease; small cell lung cancer; 3p21	FAT-FACETS GENE; PROTEIN-DEGRADATION; TRE ONCOGENE; ENZYME; CANCER; UBIQUITIN; PROTOONCOGENE; RECEPTORS; SUBUNIT; KINASE	The human Unp gene at 3p21.3 has sequence similarity to ubiquitin proteases and has been suggested to play a role in carcinogenesis of the lung (Gray et al., 1995). To investigate this possibility, we isolated cDNAs from several human tissue libraries and found evidence for two major isoforms, encoding proteins predicted to either contain an internal 47 amino acid segment or not. Both are functional in deubiquitination assays, and mutation of a critical conserved cysteine residue to alanine abolished activity. Unp specifies two closely-migrating transcripts whose relative abundance varies among human adult tissues. Antibodies specific to UNP confirm the presence of at least two endogenous protein isoforms of approximately 105-110 kDa in cell lysates, as predicted from the cDNA sequences. Cellular fractionation and immunocytochemistry revealed UNP expression localized primarily in the cytoplasm. When we examined a panel of lung-derived cell lines for both UNP mRNA and protein expression, we found reduced levels of UNP protein in all four small cell lung carcinoma cell lines tested. These findings directly contradict and offer alternative interpretations to a number of previously published observations on Unp.	Mitotix Inc, Cambridge, MA 02139 USA		Chiu, MI (corresponding author), Mitotix Inc, 1 Kendall Sq,Bldg 600, Cambridge, MA 02139 USA.							BeerRomero P, 1997, ONCOGENE, V14, P595, DOI 10.1038/sj.onc.1200872; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; GRAY DA, 1995, ONCOGENE, V10, P2179; GUPTA K, 1993, ONCOGENE, V8, P2307; GUPTA K, 1994, ONCOGENE, V9, P1729; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; HIBI K, 1992, ONCOGENE, V7, P445; HIBI K, 1994, ONCOGENE, V9, P611; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Jackers P, 1996, ONCOGENE, V13, P495; Kalderon D, 1996, CURR BIOL, V6, P662, DOI 10.1016/S0960-9822(09)00443-6; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NAKAMURA T, 1992, ONCOGENE, V7, P733; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Roche J, 1996, ONCOGENE, V12, P1289; Rolfe M, 1997, J MOL MED-JMM, V75, P5, DOI 10.1007/s001090050081; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; TAM SW, 1994, CANCER RES, V54, P5816; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275; Zhu YA, 1997, J BIOL CHEM, V272, P51	37	46	49	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					153	165		10.1038/sj.onc.1201537	http://dx.doi.org/10.1038/sj.onc.1201537			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464533				2022-12-17	WOS:000071427100002
J	Simonian, PL; Grillot, DAM; Nunez, G				Simonian, PL; Grillot, DAM; Nunez, G			Bak can accelerate chemotherapy-induced cell death independently of its heterodimerization with Bcl-X-L and Bcl-2	ONCOGENE			English	Article						Bak; Bcl-X-L; Ecl-2; apoptosis; chemotherapy; cell death	HOMOLOG BAK; APOPTOSIS; EXPRESSION; CISPLATIN; SURVIVAL; BCL-X(L); DOMAIN; BH1	Bak has been shown to both promote apoptosis and to inhibit cell death while two other members of the Bcl-2 family of proteins, Bcl-X-L and Bcl-2 delay apoptosis induced by various stimuli including chemotherapeutic agents. We generated clones with stable expression of Bak wild-type (wt) and Bak with its BH3 (Delta 78-86) domain deleted (Delta BH3) in FL5.12 cells or FL5.12 cells expressing either Bcl-X-L or Bcl-2 to determine if Bak could accelerate apoptosis and antagonize the death repressor activity of Bcl-X-L and Bcl-2 during chemotherapy-induced apoptosis. We found that Bah accelerated cell death in FL5.12 cells treated with etoposide, fluorouracil or taxol. In FL5.12 cells expressing Bcl-X-L and Bak wt or Bak Delta BH3, both Bak wt or Bak Delta BH3 were able to antagonize the protective effect of Bcl-X-L when treated with etoposide or fluorouracil. Bak wt or Bak Delta BH3 were also able to abrogate the protective effect of Bcl-2 in cells expressing Bcl-2 and Bak wt or Bak Delta BH3 when challenged by etoposide or fluorouracil. Immunoprecipitation studies revealed that deletion of BH3 disrupted heterodimerization between Bak and Bcl-X-L and that both Bak wt and Bak Delta BH3 failed to interact with Bcl-2. These results demonstrate that Bak does not require its BH3 domain to promote apoptosis in stably transfected cells. Furthermore, Bak can accelerate chemotherapy-induced cell death independently of its heterodimerization with Bcl-X-L and Bcl-2.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR COMPREHENS CANC,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Nuñez, Gabriel/A-7160-2014		NCI NIH HHS [CA-64556, CA-64421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064556, K04CA064421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Krajewska M, 1996, CANCER RES, V56, P2422; Middleton G, 1996, DEVELOPMENT, V122, P695; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MIYASHITA T, 1993, BLOOD, V81, P151; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	18	46	46	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1871	1875		10.1038/sj.onc.1201350	http://dx.doi.org/10.1038/sj.onc.1201350			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362454				2022-12-17	WOS:A1997XZ72500014
J	Friedman, SL; Shaulian, E; Littlewood, T; Resnitzky, D; Oren, M				Friedman, SL; Shaulian, E; Littlewood, T; Resnitzky, D; Oren, M			Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells	ONCOGENE			English	Article						p53 tumor suppressor; pRb; hepatocellular carcinoma; apoptosis; differentiation	WILD-TYPE P53; HUMAN HEPATOCELLULAR-CARCINOMA; RETINOBLASTOMA GENE-PRODUCT; HEPATITIS-B VIRUS; MONOCLONAL-ANTIBODIES; IMMUNOCHEMICAL ANALYSIS; ERYTHROLEUKEMIA-CELLS; SUPPRESSOR GENES; PROTEIN; EXPRESSION	Mutations in the tumor suppressor p53 are a common event in hepatocellular carcinoma (HCC), Because HCCs typically occur in livers with chronic injury and impaired function, we have explored the role of mild-type p53 in regulating the growth and differentiation of Hep 3B hepatoma cells, a p53-negative line derived from a liver cancer, Stable Hep 3B cell lines were generated in which inducible p53 was introduced using either a temperature-sensitive mutant (p53val135) or a tamoxifen-regulated p53-estrogen receptor chimera (p53mER(tm)-pBabepuro), In both cell lines, induction of transcriptionally active p53 was confirmed by assessing several p53 targets: Mdm2 protein, p21(waf1) mRNA and protein, and the cyclin G promoter, Despite marked induction of p21(waf1), cells with active p53 failed to undergo growth arrest, which is probably due to the presence of a non-functional retinoblastoma protein (pRb) in these cells, Apoptosis also was not observed, even after prolonged (48 h) serum starvation or exposure to cisplatinum. Lack of apoptosis was correlated with unchanged bax mRNA levels following p53 induction, Additionally, albumin mRNA levels remained unchanged, and there was no change in basal transactivation of a reporter containing the promoter of the haptoglobin gene, encoding an acute phase protein, This suggests that growth arrest may be required to promote liver-specific gene expression, Overall, our data demonstrate that introduction of transcriptionally active p53 does not alter the malignant, dedifferentiated phenotype of Hep 3B hepatoma cells, Hence, not all cancer cells are equally responsive to the re-activation of wild-type 53, The ability of a cancer cell to undergo p53-mediated phenotypic alterations may depend on the retention of functional downstream effector pathways.	IMPERIAL CANC RES FUND,BIOCHEM CELL NUCLEUS LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	Friedman, SL (corresponding author), WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL.				NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA40099] Funding Source: Medline; NIDDK NIH HHS [R01 DK37340] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUMANN H, 1987, J BIOL CHEM, V262, P9756; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chojkier M, 1995, Prog Liver Dis, V13, P37; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Constance CM, 1996, MOL CELL BIOL, V16, P3878; DOERR R, 1989, CANCER RES, V49, P384; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FRIEDMAN JM, 1986, MOL CELL BIOL, V6, P3791, DOI 10.1128/MCB.6.11.3791; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HOSONO S, 1993, ONCOGENE, V8, P491; HSIA CC, 1994, J MED VIROL, V44, P67, DOI 10.1002/jmv.1890440113; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MIYASHITA T, 1995, CELL, V80, P293; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NEVINS JR, 1992, SCIENCE, V258, P424; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PUISIEUX A, 1993, ONCOGENE, V8, P487; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; RAMSEY WH, 1995, DIGEST DIS, V13, P81, DOI 10.1159/000171490; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SEKI S, 1995, HUM PATHOL, V26, P366, DOI 10.1016/0046-8177(95)90135-3; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; TABOR E, 1994, J MED VIROL, V42, P357, DOI 10.1002/jmv.1890420406; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; Vater CA, 1996, ONCOGENE, V13, P739; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHANG X, 1994, CANCER RES, V54, P4177	61	46	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					63	70		10.1038/sj.onc.1201149	http://dx.doi.org/10.1038/sj.onc.1201149			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233778	Bronze			2022-12-17	WOS:A1997XH58600007
J	Bigoni, R; Negrini, M; Veronese, ML; Cuneo, A; Castoldi, GL; Croce, CM				Bigoni, R; Negrini, M; Veronese, ML; Cuneo, A; Castoldi, GL; Croce, CM			Characterization of t(11;14) translocation in mantle cell lymphoma by fluorescent in situ hybridization	ONCOGENE			English	Article						bcl-1; chromosome translocation; mantle cell lymphoma	CHRONIC LYMPHOCYTIC-LEUKEMIA; CENTROCYTIC LYMPHOMA; T(11-14)(Q13-Q32) TRANSLOCATION; INTERMEDIATE DIFFERENTIATION; CHROMOSOME-TRANSLOCATION; BREAKPOINT REGION; TUMOR-CELLS; BCL-1 GENE; EXPRESSION; KARYOTYPE	Characterization of chromosome abnormalities in leukemia and lymphoma have contributed to the understanding of the molecular basis of these neoplastic diseases, In addition, specific chromosomal aberrations have acquired diagnostic or prognostic value. The t(11;14)(q13;q32) chromosome translocation has been detected in mantle cell lymphomas, However, possibly due to the limits of conventional cytogenetic analysis and the presence of different breakpoints at the molecular level, it is possible that the true percentage of association is underestimated, In our study, we used a yeast artificial chromosome, spanning the entire area where the rearrangements occur on chromosome 11q13, to detect the presence of translocations by fluorescent in situ hybridization experiments. We detected BCL-1 translocations in eight of eight patients with clinical and immunological features of mantle cell lymphoma, suggesting that the t(11;14) translocation is a critical event in the pathogenesis of MCL and may be a primary element for the diagnosis. Since this translocation is associated with poor prognosis, its detection may help to make a correct diagnosis as well as to evaluate residual disease, which is critical to plan a rational chemotherapy regimen.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, KIMMEL CANC CTR, BLSB, PHILADELPHIA, PA 19107 USA; UNIV FERRARA, DIPARTIMENTO SCI BIOMED & TERAPIE AVANZATE, SEZ EMATOL, FERRARA, ITALY	Jefferson University; University of Ferrara			Negrini, Massimo/J-2377-2016; Cuneo, Antonio/K-7617-2016; Young, Richard A/F-6495-2012	Negrini, Massimo/0000-0002-0007-1920; Young, Richard A/0000-0001-8855-8647	NATIONAL CANCER INSTITUTE [R35CA039860] Funding Source: NIH RePORTER; NCI NIH HHS [CA39860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; BANKS PM, 1992, AM J SURG PATHOL, V16, P637, DOI 10.1097/00000478-199207000-00001; BERGER R, 1979, HUM GENET, V53, P111, DOI 10.1007/BF00289460; BOSCH F, 1994, BLOOD, V84, P2726; BRITO-BABAPULLE V, 1987, Hematologic Pathology, V1, P27; CASTOLDI GL, 1987, CANCER GENET CYTOGEN, V26, P75, DOI 10.1016/0165-4608(87)90135-X; CHAGANTI RSK, 1987, CYTOGENET CELL GENET, V45, P93, DOI 10.1159/000132436; Coignet LJA, 1996, BLOOD, V87, P1512, DOI 10.1182/blood.V87.4.1512.bloodjournal8741512; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; CUNEO A, 1995, BRIT J HAEMATOL, V90, P409; CUNEO A, 1994, LEUKEMIA LYMPHOMA, V15, P167, DOI 10.3109/10428199409051693; CUNEO A, 1992, BRIT J HAEMATOL, V81, P192, DOI 10.1111/j.1365-2141.1992.tb08206.x; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; GOULD J, 1988, BLOOD, V71, P453; JULIUSSON G, 1991, LEUKEMIA LYMPHOMA, V5, P21, DOI 10.3109/10428199109103374; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; LARDELLI P, 1990, AM J SURG PATHOL, V14, P752, DOI 10.1097/00000478-199008000-00007; LEBEAU MM, 1993, BLOOD, V81, P1979; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MEEKER TC, 1989, BLOOD, V74, P1801; MEEKER TC, 1991, LEUKEMIA, V5, P733; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NEWMAN RA, 1993, BLOOD, V82, P1239; RAYNAUD SD, 1993, GENE CHROMOSOME CANC, V8, P80, DOI 10.1002/gcc.2870080204; RIMOKH R, 1993, BLOOD, V81, P3063; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SETO M, 1992, ONCOGENE, V7, P1401; SZEPETOWSKI P, 1995, CYTOGENET CELL GENET, V69, P101, DOI 10.1159/000133948; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; VANDENBERGHE E, 1991, J PATHOL, V163, P13, DOI 10.1002/path.1711630104; VANDENBERGHE E, 1994, BLOOD REV, V8, P79, DOI 10.1016/S0268-960X(05)80011-6; VANDENBERGHE H, 1979, CANCER, V44, P188, DOI 10.1002/1097-0142(197907)44:1<188::AID-CNCR2820440131>3.0.CO;2-F; WILLIAMS ME, 1992, CANCER RES, V52, pS5541; WILLIAMS ME, 1990, BLOOD, V76, P1387; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; YUNIS JJ, 1984, CANCER GENET CYTOGEN, V13, P17, DOI 10.1016/0165-4608(84)90084-0; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; YUNIS JJ, 1987, NEW ENGL J MED, V79, P316	43	46	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					797	802						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761301				2022-12-17	WOS:A1996VD43300015
J	Oridate, N; Esumi, N; Lotan, D; Hong, WK; RochetteEgly, C; Chambon, P; Lotan, R				Oridate, N; Esumi, N; Lotan, D; Hong, WK; RochetteEgly, C; Chambon, P; Lotan, R			Implication of retinoic acid receptor gamma in squamous differentiation and response to retinoic acid in head and neck SqCC/Y1 squamous carcinoma cells	ONCOGENE			English	Article						retinoic acid; squamous differentiation; nuclear receptor; retinoic acid receptor gamma	EPIDERMAL GROWTH-FACTOR; ANCHORAGE-INDEPENDENT GROWTH; GENE-EXPRESSION; TERMINAL DIFFERENTIATION; NEGATIVE REGULATION; MOUSE; PROMOTER; IMMUNODETECTION; PHOSPHORYLATION; TRANSFORMATION	Nuclear retinoic acid receptors are considered to be the mediators of most of the effects of retinoic acid (RA) on gene expression. To explore the role of RA receptor gamma (RAR gamma) in the growth and differentiation of SqCC/Y1 head and neck squamous carcinoma cells, they were transfected with RAR gamma sense and antisense expression vectors and stable clones in which RAR gamma expression was either increased or blocked were isolated. The growth inhibitory effect of RA in monolayer culture was enhanced in the sense transfectants and decreased in the antisense ones. The ability to form colonies in semisolid medium was abolished by RA in the sense transfectants, while the antisense transfected clones exhibited heterogeneous responses. The expression of the squamous differentiation markers cytokeratin K1, transglutaminase type I, and involucrin was increased in the absence of exogenous retinoid in a sense transfected clone and decreased in an antisense transfected clone. RA suppressed squamous differentiation in both types of transfectant. The expression of epidermal growth factor receptor (EGFR) was higher in the antisense and lower in the sense transfectant than in the parental cells and RA decreased EGFR mRNA level in the parental and the sense transfectant but not in the antisense transfectant. In addition activator protein-1 (AP-1) binding activity was decreased by the RA treatment in the sense clones, but not in the antisense ones. These results suggest that RAR gamma mediates the effects of RA on the cell growth both in monolayer culture and in semisolid medium possibly through AP-1 suppression.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT THORAC HEAD & NECK MED ONCOL, HOUSTON, TX 77030 USA; IGBMC, GENET MOLEC EUCARYOTES LAB, F-67085 STRASBOURG, FRANCE	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Institut National de la Sante et de la Recherche Medicale (Inserm)			Oridate, Nobuhiko/G-5365-2012; Oridate, Nobuhiko/ABC-4116-2020	Oridate, Nobuhiko/0000-0002-6968-3028	NCI NIH HHS [P01 CA 52051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANESKIEVICH BJ, 1992, MOL CELL BIOL, V12, P4862, DOI 10.1128/MCB.12.11.4862; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BLUMENBERG M, 1992, J INVEST DERMATOL, V98, pS42, DOI 10.1111/1523-1747.ep12462194; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; ELDER JT, 1991, J INVEST DERMATOL, V96, P425, DOI 10.1111/1523-1747.ep12469889; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FISHER GJ, 1994, J BIOL CHEM, V269, P20629; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Gudas Lorraine J., 1994, P443; HIROSE T, 1995, BIOCHEM BIOPH RES CO, V211, P83, DOI 10.1006/bbrc.1995.1781; HU L, 1991, CANCER RES, V51, P3972; HUDSON LG, 1989, MOL ENDOCRINOL, V3, P400, DOI 10.1210/mend-3-2-400; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; KING I, 1989, CANCER RES, V49, P5677; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOTAN R, 1982, EXP CELL RES, V141, P79, DOI 10.1016/0014-4827(82)90070-2; LOTAN R, 1993, J CELL BIOCHEM, P167; Mangelsdorf David J., 1994, P319; Maniatis T, 1989, MOL CLONING; MIQUEL C, 1992, MOL BIOL REP, V17, P35; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; ORIDATE N, 1995, IN PRESS IN VITRO CE; Oridate Nobuhiko, 1994, Molecular and Cellular Differentiation, V2, P413; Pfahl Magnus, 1994, Seminars in Cell Biology, V5, P95, DOI 10.1006/scel.1994.1013; PITMAN SW, 1983, P AM ASSOC CANC RES, V24, P5; REISS M, 1991, CANCER RES, V51, P6254; REISS M, 1985, J NATL CANCER I, V74, P1015; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUDD CJ, 1993, CANCER LETT, V73, P41, DOI 10.1016/0304-3835(93)90186-D; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; STEINERT PM, 1985, J BIOL CHEM, V260, P7142; SUNDQVIST K, 1991, CANCER COMMUN-US, V3, P331, DOI 10.3727/095535491820873731; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VOLLBERG TM, 1992, MOL ENDOCRINOL, V6, P667, DOI 10.1210/mend.6.5.1318502; Wan H., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P510; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; XU XC, 1994, CANCER RES, V54, P3580; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022; ZHENG ZS, 1992, CELL GROWTH DIFFER, V3, P225; ZHENG ZS, 1990, CANCER RES, V50, P1201; ZOU CP, 1994, CANCER RES, V54, P5479	60	46	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					2019	2028						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649863				2022-12-17	WOS:A1996UK49800021
J	HUANG, Y; SAEZ, R; CHAO, L; SANTOS, E; AARONSON, SA; CHAN, AML				HUANG, Y; SAEZ, R; CHAO, L; SANTOS, E; AARONSON, SA; CHAN, AML			A NOVEL INSERTIONAL MUTATION IN THE TC21 GENE ACTIVATES ITS TRANSFORMING ACTIVITY IN A HUMAN LEIOMYOSARCOMA CELL-LINE	ONCOGENE			English	Article						RAS; TC21; ONCOGENE; SSCP; MUTATION; LEIOMYOSARCOMA	RAS-RELATED GENE; MOLECULAR SWITCH; DIRECT REPEATS; DELETIONS; ONCOGENES; PROTEIN	TC21 is the fourth member of the pas gene family to exhibit oncogenic activation in human tumor cells. To assess the prevalence of activated TC21 oncogenes in human tumors, we have developed sensitive single-strand conformational polymorphism (SSCP) conditions and immunological reagents for the detection of both single base alterations and/or overt overexpression in a wide spectrum of human tumor cell lines and surgical samples. In an initial examination of 33 human tumor specimens, we observed a novel nine basepair three amino acids insertion at TC21 codon 24 in one human uterine leiomyosarcoma cell line, SK-UT-1. This mutant allele when transfected into NIH3T3 cells, displayed high transforming activity comparable to that of the Leu72 oncogenic mutant identified by expression cDNA cloning from a human ovarian carcinoma cell line. Comparing the level of GTP-binding by the mutant and normal TC21 products revealed that this novel lesion increases the GTP-bound form of the TC21 molecule. These findings imply that the mechanism by which mutations activate the oncogenic properties of this ras-related molecule is analogous to that of previously known ras family members.	MT SINAI MED CTR,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464				ALBERTINI AM, 1982, CELL, V29, P319, DOI 10.1016/0092-8674(82)90148-9; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; COX AD, 1994, ONCOGENE, V9, P3281; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; GERNER RE, 1975, ANN SURG, V181, P803, DOI 10.1097/00000658-197506000-00007; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HIGINBOTHAM KG, 1994, ONCOGENE, V9, P2455; JEGO N, 1993, ONCOGENE, V8, P209; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PATTERSON H, 1994, BRIT J CANCER, V69, P1052, DOI 10.1038/bjc.1994.207; PORRAS A, 1992, J BIOL CHEM, V267, P21124; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; SAEZ R, 1994, ONCOGENE, V9, P2977; SATOH T, 1992, J BIOL CHEM, V267, P24149; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4648; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P	26	46	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1255	1260						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478545				2022-12-17	WOS:A1995RY96700005
J	RODABAUGH, KJ; BIGGS, RB; QURESHI, JA; BARRETT, AJ; WELCH, WR; BELL, DA; BERKOWITZ, RS; MOK, SC				RODABAUGH, KJ; BIGGS, RB; QURESHI, JA; BARRETT, AJ; WELCH, WR; BELL, DA; BERKOWITZ, RS; MOK, SC			DETAILED DELETION MAPPING OF CHROMOSOME 9P AND P16 GENE ALTERATIONS IN HUMAN BORDERLINE AND INVASIVE EPITHELIAL OVARIAN-TUMORS	ONCOGENE			English	Article						BORDERLINE OVARIAN TUMOR; OVARIAN CANCER; CHROMOSOME 9P; LOSS OF HETEROZYGOSITY; P16 GENE	UNIFOCAL ORIGIN; CARCINOMAS; HETEROZYGOSITY; CANCER	We used PCR amplification of tandem repeats to study the pattern of allelic loss in borderline and invasive ovarian epithelial tumors using 12 primer pairs to generate a detailed deletion map of chromosome 9p. In the invasive ovarian carcinomas, there were three regions displaying high frequency of loss of heterozygosity (LOH) ranging from 31-38%. In contrast, LOH was a rare event among the borderline ovarian tumors, with one region revealing a rate of 20% and the remaining regions only 0-8% LOH. Therefore, allelic loss does not seem to be important for the development of borderline ovarian tumors. We also examined p16 gene expression and mutations in ovarian cancer cell lines and invasive and borderline ovarian tumor tissues. Southern blot analysis revealed no losses of the p16 gene in either the invasive or borderline ovarian tumors. However, the ovarian carcinoma cell lines showed a 50% homozygous deletion rate, SSCP analysis detected a mobility shift in only one (borderline) tumor. Since the primary invasive ovarian tumors did not show any deletions or mutations, it appears that p16 does not play a role in the pathogenesis of these tumors.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED, DEPT OBSTET GYNECOL & REPROD BIOL, GYNECOL ONCOL LAB, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital					NATIONAL CANCER INSTITUTE [R01CA063381] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA63381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI T, 1994, GENE CHROMOSOME CANC, V10, P177, DOI 10.1002/gcc.2870100305; CAIRNS P, 1995, CANCER RES, V55, P224; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; CHENG JQ, 1994, CANCER RES, V54, P5547; EHLEN T, 1990, ONCOGENE, V5, P219; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; HUANG DP, 1994, CANCER RES, V54, P4003; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KRUK PA, 1990, LAB INVEST, V63, P132; LEE JH, 1990, CANCER RES, V50, P2724; MOK CH, 1992, CANCER RES, V52, P5119; MOK SC, 1995, GYNECOL ONCOL, V57, P299, DOI 10.1006/gyno.1995.1146; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; RUPPERT JM, 1993, CANCER RES, V53, P5093; SATO T, 1991, CANCER RES, V51, P5118; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; TSAO SW, 1993, GYNECOL ONCOL, V48, P5, DOI 10.1006/gyno.1993.1002; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; WERTHEIM I, 1995, P AM ASSOC CANC RES, V36, P545; XU L, 1994, CANCER RES, V54, P5262; ZHANG SY, 1994, CANCER RES, V54, P5050; ZHOU XL, 1994, ONCOGENE, V9, P3737; 1987, OBSTET GYNECOL, V156, P263	27	46	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1249	1254						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478544				2022-12-17	WOS:A1995RY96700004
J	SALVATI, PD; RANFORD, PR; FORD, J; KEES, UR				SALVATI, PD; RANFORD, PR; FORD, J; KEES, UR			HOX11 EXPRESSION IN PEDIATRIC ACUTE LYMPHOBLASTIC-LEUKEMIA IS ASSOCIATED WITH T-CELL PHENOTYPE	ONCOGENE			English	Article						HOX11; 10Q24; T-ALL; PEDIATRIC ALL	DNA-BINDING MOTIF; HOMEOBOX GENE; CHROMOSOMAL TRANSLOCATION; MYELOID-LEUKEMIA; PRE-B; PROTEIN; CHILDHOOD; ONCOGENE; ENCODES; DIFFERENTIATION	Based on cytogenetic analysis, chromosomal translocations involving band 10q24 occur in 4-7% of T-cell acute lymphoblastic leukemia (T-ALL). The HOX11 gene is located in this chromosomal band and is activated by translocations t(10;14) (q24;q11) and t(7;10) (q35;q24). Ectopic expression of the HOX11 gene appears to be involved in the development of T-cell tumors. The aim of this study was to determine the frequency of HOX11 activation in pediatric ALL patients and to correlate gene expression with ALL immunophenotype. None of 53 B-lineage ALLs was positive for HOX11 expression, however, Northern blot and RT-PCR analysis revealed that four out of 12 T-ALLs (33%) showed expression of the gene. In order to assess whether HOX11 expression is present in other pediatric malignancies we examined a panel of 20 tumor cell lines established from solid tumors and leukemias, but none of them showed expression of HOX11. Using our RT-PCR method we confirmed that HOX11 expression is not detectable in normal T-cells. These findings indicate that HOX11 expression in pediatric ALL is exclusive to T-ALL and does not occur in B-lineage ALL. The frequency detected by molecular techniques was significantly higher than the frequency reported in the literature based on cytogenetic analysis. These results support the notion that ectopic expression of the HOX11 homeobox gene is a crucial step in T-cell tumorigenesis.	TVW TELETHON INST CHILD HLTH RES, DIV CHILDRENS LEUKAEMIA & CANC RES, PERTH, WA 6872, AUSTRALIA	Telethon Kids Institute; University of Western Australia								ADAMS JM, 1992, CANCER SURV, V15, P119; BASH RO, 1993, BLOOD, V81, P2110; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1991, ONCOGENE, V6, P695; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DUBE ID, 1991, BLOOD, V78, P2996; EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAWLEY RG, 1994, ONCOGENE, V9, P1; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAGAN J, 1994, CANCER RES, V54, P226; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KEES UR, 1989, BLOOD, V74, P369; KEES UR, 1987, LEUKEMIA RES, V11, P489, DOI 10.1016/0145-2126(87)90082-8; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; LARSON RC, 1994, ONCOGENE, V9, P3675; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MING L, 1992, ONCOGENE, V7, P1325; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; RAIMONDI SC, 1993, BLOOD, V81, P2237; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SCHNEIDER EL, 1975, IN VITRO CELL DEV B, V11, P20; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	38	46	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1333	1338						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478554				2022-12-17	WOS:A1995RY96700014
J	LORENZI, MV; LONG, JE; MIKI, T; AARONSON, SA				LORENZI, MV; LONG, JE; MIKI, T; AARONSON, SA			EXPRESSION CLONING, DEVELOPMENTAL EXPRESSION AND CHROMOSOMAL LOCALIZATION OF FIBROBLAST GROWTH FACTOR-VIII	ONCOGENE			English	Note						GROWTH FACTORS; FGF-8; AIGF; EXPRESSION CLONING	CDNA CLONING; FACTOR-I; FAMILY; GENE; PROTEIN; TRANSFORMATION; RECEPTORS; SEQUENCE; MEMBER; CELLS	A mouse testis cDNA library in lambda pCEV27 eukaryotic expression vector was transfected in NIH3T3 fibroblasts and several transformed foci were identified. A plasmid with high-titered focus forming activity was rescued from one of these transformants. Structural analysis of this cDNA predicted a protein identical to androgen induced growth factor (AIGF), recently identified as the eighth member of the fibroblast growth factor (FGF) family, A 1.6 kiIobasepair transcript of the FGF-8 gene was detected in testis but not in other adult tissues analysed. During development, expression of FGF-8 was restricted to embryonic days 9 through 13 suggesting that the growth factor plays a role during a discrete stage of mouse embryogenesis, An exon-containing genomic clone of human FGF-8 was isolated and structural comparisons indicated that the gene structure of this region is highly conserved among the FGF genes. Using a panel of human-rodent somatic cell hybrids, the FGF-8 gene was localized to human chromosome 10.	MT SINAI SCH MED,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BROOKES S, 1989, ONCOGENE, V24, P429; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; HAN IS, 1993, MOL ENDOCRINOL, V7, P889, DOI 10.1210/me.7.7.889; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; KELLEY MJ, 1992, P NATL ACAD SCI USA, V89, P9287, DOI 10.1073/pnas.89.19.9287; KOUHARA H, 1994, ONCOGENE, V9, P455; MARICS I, 1989, ONCOGENE, V4, P335; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERGIA A, 1989, BIOCHEM BIOPH RES CO, V164, P1121, DOI 10.1016/0006-291X(89)91785-3; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MULLANEY BP, 1992, ENDOCRINOLOGY, V131, P2928, DOI 10.1210/en.131.6.2928; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YU YL, 1992, J EXP MED, V175, P1073, DOI 10.1084/jem.175.4.1073; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	29	46	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					2051	2055						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761105				2022-12-17	WOS:A1995QZ92600019
J	MORISHITA, K; SUZUKAWA, K; TAKI, T; IHLE, JN; YOKOTA, J				MORISHITA, K; SUZUKAWA, K; TAKI, T; IHLE, JN; YOKOTA, J			EVI-1 ZINC-FINGER PROTEIN WORKS AS A TRANSCRIPTIONAL ACTIVATOR VIA BINDING TO A CONSENSUS SEQUENCE OF GACAAGATAAGATAAN(1-28) CTCATCTTC	ONCOGENE			English	Article						ZINC FINGER PROTEIN; EVI-1; DNA-BINDING; CONSENSUS SEQUENCE; TRANSCRIPTIONAL REGULATION	MYELOID-TRANSFORMING GENE; CYCLIC AMPLIFICATION; CELL-LINES; EXPRESSION; IDENTIFICATION; TRANSLOCATIONS; KILOBASES; SELECTION; COMPLEXES; LEUKEMIAS	Previously, the DNA-binding consensus sequences for domains 1 (GACAAGATAAGATAA) and 2 (GAAGATGAG) of the EVI-1 protein were identified using GST fusion proteins of each domain in binding and amplification reactions, We have utilized full-length EVI-1 protein to confirm these consensus sequences and determine the spacial and orientation requirements for binding, Our data demonstrate that full-length EVI-1 can independently bind the consensus sequences in gel mobility shift assays. In binding and amplification reactions only the domain I consensus sequence (D1-CONS) was obtained with full-length EVI-1 protein. However, by using constructs in which D1-CONS was anchored, products were obtained in which the domain 2 consensus sequence (D2-CONS) was observed with the spacing and orientation of GACAAGATAATATAAN(1-28) CTCATCTTC. Using this consensus sequence we show that EVI-1 can activate transcription from reporter constructs. No transcriptional activation was seen with the reporter construct containing DT-CONS atone while activation was seen with the construct-containing D2-CONS alone. These results indicate that the EVI-1 protein works as a transcriptional activator and the binding of the domain 2 with D2-CONS is essential for its activation.	NATL CANC CTR, RES INST, DIV BIOL, CHUO KU, TOKYO 104, JAPAN; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	National Cancer Center - Japan; St Jude Children's Research Hospital				Suzukawa, Kazumi/0000-0001-9904-3905				Ausubel F.M., 1987, CURRENT PROTOCOLS MO; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FICHELSON S, 1992, LEUKEMIA, V6, P93; FUNABIKI T, 1994, ONCOGENE, V9, P1575; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T, 1989, MOL CLONING; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MORISHITA K, 1990, ONCOGENE, V5, P1419; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PERKINS AS, 1991, DEVELOPMENT, V111, P479; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; SUZUKAWA K, 1994, BLOOD, V84, P2681; WRIGHT WE, 1993, TRENDS BIOCHEM SCI, V18, P77, DOI 10.1016/0968-0004(93)90156-H; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0	26	46	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					1961	1967						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761097				2022-12-17	WOS:A1995QZ92600010
J	LEDENT, C; MARCOTTE, A; DUMONT, JE; VASSART, G; PARMENTIER, M				LEDENT, C; MARCOTTE, A; DUMONT, JE; VASSART, G; PARMENTIER, M			DIFFERENTIATED CARCINOMAS DEVELOP AS A CONSEQUENCE OF THE THYROID-SPECIFIC EXPRESSION OF A THYROGLOBULIN-HUMAN PAPILLOMAVIRUS TYPE-16 E7 TRANSGENE	ONCOGENE			English	Article						RETINOBLASTOMA SUSCEPTIBILITY; GENE PRODUCT; THYROID TUMORS; TRANSGENIC MODEL	TISSUE-SPECIFIC EXPRESSION; MICE; GENE; PROTEIN; TUMORIGENESIS; ONCOGENES; CLONING; COEXPRESSION; THYROTROPIN; FRAGMENTS	The oncogenic properties of the high risk human papillomaviruses (HPV) E7 protein are attributed to its interaction with the retinoblastoma susceptibility gene product RB1 and other related proteins, We report here the generation of a transgenic model expressing the E7 oncogene of HPV16 in thyroid follicular cells, under control of the bovine thyroglobulin gene promoter. Transgenics develop differentiated and functionally regulated thyroid goitres, due to thyroid cell proliferation and accumulation of colloid, On the background of this colloid goitre, the mice develop foci of more actively proliferating cells that become invasive and ultimately tend to loose their differentiation, Old mice display secondary tumour nodules that mimic the various histological aspects of the human differentiated thyroid cancers: the follicular and papillary carcinomas, The development of totally undifferentiated carcinoma is in contrast exceptional, We conclude that RB1, and/or related proteins, are responsible for the strict negative control of proliferation that characterizes the thyroid cell of the adult, Inactivation of these proteins results in a continuous growth of the thyroid, without affecting its differentiation, function and regulation, Given the high frequency of progression to highly malignant phenotypes, the retinoblastoma susceptibility and related genes are good candidates as targets for mutations or deletions in early steps of human thyroid carcinogenesis. The search for such mutations in human thyroid cancers will test if this hypothesis holds true.	FREE UNIV BRUSSELS,SERV GENET MED,B-1070 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel	LEDENT, C (corresponding author), FREE UNIV BRUSSELS,IRIBHN,CAMPUS ERASME,808 ROUTE LENNIK,B-1070 BRUSSELS,BELGIUM.			Parmentier, Marc/0000-0001-8081-4685				AASLAND R, 1988, BRIT J CANCER, V57, P358, DOI 10.1038/bjc.1988.82; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; CHRISTOPHE D, 1990, TRENDS ENDOCRIN MET, V1, P351, DOI 10.1016/1043-2760(90)90083-F; COCLET J, 1989, CLIN ENDOCRINOL, V31, P655, DOI 10.1111/j.1365-2265.1989.tb01290.x; CORDONCARDO C, 1994, AM J PATHOL, V144, P500; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIGGE J, 1991, AM J PATHOL, V139, P1213; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; HEDINGER C, 1988, INT HISTOLOGICAL CLA; Hogan B., 1986, MANIPULATING MOUSE E; HOLM R, 1994, J PATHOL, V172, P267, DOI 10.1002/path.1711720307; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KONDOH G, 1991, J VIROL, V65, P3335, DOI 10.1128/JVI.65.6.3335-3339.1991; LAMBERT PF, 1993, P NATL ACAD SCI USA, V90, P5583, DOI 10.1073/pnas.90.12.5583; LEDENT C, 1994, EUR J ENDOCRINOL, V130, P8, DOI 10.1530/eje.0.1300008; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; LEDENT C, 1990, P NATL ACAD SCI USA, V87, P6176, DOI 10.1073/pnas.87.16.6176; LEMOINE NR, 1989, ONCOGENE, V4, P159; LOWY DR, 1994, P NATL ACAD SCI USA, V91, P2436, DOI 10.1073/pnas.91.7.2436; MACMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MAYOL X, 1993, ONCOGENE, V8, P2561; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NEVINS JR, 1992, SCIENCE, V258, P424; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PONTA H, 1994, BBA-REV CANCER, V1198, P1, DOI 10.1016/0304-419X(94)90002-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMITH P, 1989, THYROID TUMORS MOL B; STUDER H, 1986, SIMPLE NODULAR SPORA; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WILLIAMS DW, 1989, THYROID TUMORS MOL B; WYLLIE FS, 1989, BRIT J CANCER, V60, P561, DOI 10.1038/bjc.1989.313; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	47	46	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1789	1797						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753555				2022-12-17	WOS:A1995QX46900012
J	JOOSS, KU; MULLER, R				JOOSS, KU; MULLER, R			DEREGULATION OF GENES ENCODING MICROFILAMENT-ASSOCIATED PROTEINS DURING FOS-INDUCED MORPHOLOGICAL TRANSFORMATION	ONCOGENE			English	Note						FOS; MORPHOLOGICAL TRANSFORMATION; CYTOSKELETON; TROPOMYOSINS; EZRIN; GENE EXPRESSION	GROWTH-FACTORS; JUN; CELLS; SUPPRESSION; EXPRESSION; INDUCTION; ONCOGENE; VIRUS; AP-1; CDNA	The mechanism of Fos-induced transformation is still poorly understood. In the present study, we have asked whether genes whose products play a role in determining cell morphology might become deregulated in the course of Fos-induced transformation. A clear up-regulation in Fos-transformed rat fibroblasts was seen with ezrin, as well as tropomyosin (TM) -3 and -5B, while TM-1 was down-regulated. Significantly, the same genes were deregulated in a very similar, but hormone-inducible may in cells expressing a Fos-estrogen receptor fusion protein. In agreement with these results, Fos-expressing cells showed decreased levels of two TM isoforms of 36 and 38 kDa, and showed an impaired TM network. The significance of these observations is strengthened by the fact that the deregulation of TM expression has been shown to contribute to morphological transformation in other experimental systems. Deregulation of the TM and ezrin genes precedes the induction of morphological transformation suggesting that this deregulation is not merely a consequence of transformation. On the other hand, deregulation follows the induction of direct Fos target genes. We therefore propose that a cascade of regulatory events is triggered by Fos oncoproteins which eventually leads to the deregulation of genes encoding cytoskeleton-associated proteins.	UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ALGRAIN M, 1993, CURR BIOL, V3, P451, DOI 10.1016/0960-9822(93)90354-Q; ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BRASELMANN S, 1992, J CELL SCI, P97; BURGER C, 1994, J CELL SCI, V107, P241; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; JOOSS KU, 1994, EMBO J, V13, P1467, DOI 10.1002/j.1460-2075.1994.tb06401.x; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NEUBERG M, 1991, ONCOGENE, V6, P1325; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; SCHUERMANN M, 1993, ONCOGENE, V8, P2781; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SEWING A, 1993, J CELL SCI, V104, P545; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x	29	46	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					603	608						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845686				2022-12-17	WOS:A1995QF64800022
J	MURTY, VVVS; LI, RG; HOULDSWORTH, J; BRONSON, DL; REUTER, VE; BOSL, GJ; CHAGANTI, RSK				MURTY, VVVS; LI, RG; HOULDSWORTH, J; BRONSON, DL; REUTER, VE; BOSL, GJ; CHAGANTI, RSK			FREQUENT ALLELIC DELETIONS AND LOSS OF EXPRESSION CHARACTERIZE THE DCC GENE IN MALE GERM-CELL TUMORS	ONCOGENE			English	Article							SUPPRESSOR GENE; CYTOGENETIC ANALYSIS; HETEROZYGOSITY; CHROMOSOME-18; CARCINOMAS; CANCER; 18Q21	The DCC tumor suppressor gene has been shown to be frequently deleted or its expression reduced or absent in colorectal, gastro-intestinal, pancreatic, prostatic, and breast carcinomas, and glioblastomas. By allelotype analysis using the DCC-flanking polymorphic marker D18S5 we have previously shown that allelic deletions at 18q21 occur in 40% of male germ cell tumors (Murty et al., 1994). In order to further understand the role of DCC gene in germ cell tumorigenesis, we evaluated deletions by loss of heterozygosity (LOH) and mRNA expression by RT-PCR in tumor tissues and cell lines. Analysis of 61 paired normal-tumor DNAs using the probes D18S5, JOSH 4.4 (a polymorphism within the DCC locus) and a (CA)(n) polymorphism in an intron of DCC revealed that 45% of GCTs had allelic deletions. In addition, two homozygous deletions were found in the DCC gene among 91 (61 used in the LOH analysis and an additional 30) tumor DNAs when screened with the cDNA probes (pDCC 1,65, pDCC 1.9 and pDCC 1.0). By RT-PCR analysis of four normal testes, nine GCT cell lines and 14 tumor tissues, DCC gene expression was detected in all four normal testes, while four (45%) GCT cell lines and one (7%) tumor specimen showed lack of expression. In addition, DCC expression was highly reduced in three (21%) tumor tissues. The high frequency of LOH at 18q21 was characteristic of seminomas as well as all subsets of non-seminomas in primary as well as metastatic states. Frequent allelic loss in all histologic subsets, homozygous deletions, and loss of expression of DCC suggest that suppression of this gene's function is an early event in GCT development.	MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,CYTOGENET SERV,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR,NEW YORK,NY 10021; UNIV MINNESOTA,DEPT UROL SURG,MINNEAPOLIS,MN 55455	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Minnesota System; University of Minnesota Twin Cities	MURTY, VVVS (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.				NCI NIH HHS [CA-08748, CA-05826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA005826, P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHAGANTI RSK, 1994, LANCET, V343, P1130, DOI 10.1016/S0140-6736(94)90235-6; CHAGANTI RSK, 1993, UROL CLIN N AM, V20, P55; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; DAVIES PO, 1993, DEV BIOL, V3, P179; DEVILEE P, 1991, ONCOGENE, V6, P311; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GAO X, 1993, CANCER RES, V53, P2723; HOHNE MW, 1992, CANCER RES, V52, P2616; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; MURTY VVVS, 1994, ONCOGENE, V9, P2245; PORFIRI E, 1993, BLOOD, V81, P2696; RISINGER JI, 1992, HUM MOL GENET, V1, P657, DOI 10.1093/hmg/1.8.657-a; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; SCHECK AC, 1993, CANCER RES, V53, P5605; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287; UCHINO S, 1992, CANCER RES, V52, P3099	20	46	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3227	3231						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936646				2022-12-17	WOS:A1994PM65800015
J	BRADBURY, JM; NIEMEYER, CC; DALE, TC; EDWARDS, PAW				BRADBURY, JM; NIEMEYER, CC; DALE, TC; EDWARDS, PAW			ALTERATIONS OF THE GROWTH-CHARACTERISTICS OF THE FIBROBLAST CELL-LINE C3H 10T1/2 BY MEMBERS OF THE WNT GENE FAMILY	ONCOGENE			English	Article							MAMMARY ONCOGENE INT-1; NUCLEOTIDE-SEQUENCE; EXPRESSION INVITRO; PROTEIN; TRANSFORMATION; PROTOONCOGENE; GLAND; CONSTRUCTION; HYPERPLASIA; RETROVIRUS	Retroviral vectors were used to introduce members of the Wnt gene family into the embryonic fibroblast cell line C3H 10T1/2. In contrast to previous reports where no effect of Wnt genes on fibroblasts was seen, we found that the expression of Wnt-1, Wnt-6 and Wnt-7b altered the appearance of the cells when maintained at confluence. The cells were smaller and grew to a higher density than cells containing a control. retrovirus or cells expressing Wnt-4 or Wnt-5b. Detailed analysis of growth characteristics of polyclonally infected cultures demonstrated that the Wnt-1, Wnt-6 and Wnt-7b expressing cells grew to a higher density in 5% fetal calf serum than control or Wnt-5b expressing cells. Wnt-4 expressing cells grew to a marginally higher density than control cells. In 0.5% serum, growth of the Wnt-1, Wnt-6 and Wnt-7b containing cells appeared to be inhibited. No growth in soft agar was observed for either control cells or Wnt expressing cells. We conclude that at least some mesenchymal cells can respond to Wnt gene products. Our results are also the first report of biological effects of Wnt-6 and Wnt-7b.	INST CANC RES,HADDOW LABS,SUTTON SM2 5NG,SURREY,ENGLAND	University of London; Institute of Cancer Research - UK	BRADBURY, JM (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.		Edwards, Paul A/M-8291-2014; Dale, Trevor C/D-3749-2009	Edwards, Paul A/0000-0002-4789-3374; Dale, Trevor C/0000-0002-4880-9963				AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; BLASBAND A, 1992, ONCOGENE, V7, P153; BRADBURY JM, 1988, INT J CANCER, V42, P923, DOI 10.1002/ijc.2910420623; BRADBURY JM, 1991, INT J CANCER, V48, P908, DOI 10.1002/ijc.2910480619; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RIJSEWIJK FAM, 1986, NUCLEIC ACIDS RES, V14, P693, DOI 10.1093/nar/14.2.693; Sambrook J., 1989, MOL CLONING LAB MANU; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; WEBERHALL SJ, IN PRESS DIFFERENTIA	36	46	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2597	2603						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058323				2022-12-17	WOS:A1994PC05400019
J	OKAMURA, H; RESH, MD				OKAMURA, H; RESH, MD			DIFFERENTIAL BINDING OF PP60(C-SRC) AND PP60(V-SRC) TO CYTOSKELETON IS MEDIATED BY SH2 AND CATALYTIC DOMAINS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; PHOSPHOTYROSINE-CONTAINING PROTEINS; GTPASE-ACTIVATING PROTEIN; INSOLUBLE CELLULAR MATRIX; GROWTH-FACTOR RECEPTORS; TYROSINE KINASE; SIGNAL TRANSDUCTION; SRC GENE; MORPHOLOGICAL TRANSFORMATION; PP60C-SRC	The transforming protein of Rous sarcoma virus, pp60(v-src), and its normal cellular homolog, pp60(c-src), differ not only in oncogenic potential but also in their subcellular localization and cytoskeletal binding ability. pp60(v-src) has been shown to stably associate with a detergent-insoluble cytoskeletal matrix, whereas pp60(c-src) does not. We have generated a series of precise deletion and truncations of the Src homology domains within pp60(v-src) and pp60(c-src), based on the crystal and solution structures of these regions, to determine not only the region responsible for cytoskeletal association but also the mechanism accounting for the differential binding observed. Here we show that the SH2 domain, but not the SH3 domain, mediates cytoskeletal association of pp60(v-src) through a phosphotyrosine-dependent interaction. The ability to interact with the cytoskeletal matrix is regulated by the catalytic (SH1) domain. Truncation of the pp60(v-src) catalytic domain results in lower binding while removal of the catalytic domain of pp60(c-src) results in the acquisition of cytoskeletal binding similar to that of the analogous v-src construct. These results indicate that the SH2 and catalytic domains function coordinately to regulate the cytoskeletal association of pp60(v-src) and pp60(c-src).	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Memorial Sloan Kettering Cancer Center; Princeton University				Resh, Marilyn/0000-0001-6118-9466	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [NCI-P30-CA-08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HAMAGUCHI M, 1989, ONCOGENE RES, V4, P29; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KLAPPER A, 1992, BIOTECHNIQUES, V12, P651; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU XQ, 1993, ONCOGENE, V8, P1119; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SILVERMAN L, 1992, J CELL BIOL, V119, P415, DOI 10.1083/jcb.119.2.415; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	50	46	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2293	2303						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7518578				2022-12-17	WOS:A1994NX62900022
J	ZHANG, J; TRENT, JM; MELTZER, PS				ZHANG, J; TRENT, JM; MELTZER, PS			RAPID ISOLATION AND CHARACTERIZATION OF AMPLIFIED DNA BY CHROMOSOME MICRODISSECTION - IDENTIFICATION OF IGF1R AMPLIFICATION IN MALIGNANT-MELANOMA	ONCOGENE			English	Article							HOMOGENEOUSLY STAINING REGIONS; GENE AMPLIFICATION; CELL-LINES; N-MYC; INSULIN; RECEPTOR; ONCOGENE; CLONES	We describe a novel strategy characterizing gene amplification in human neoplasia based on targeting double minutes (dmin) and homogeneously staining regions (hsr) for chromosome microdissection. This strategy allows the rapid generation of an amplification unit microclone library and permits the rapid identification of the chromosomal origin of the amplified sequences following fluorescence in situ hybridization (FISH). This strategy has been applied to an hsr-bearing malignant melanoma cell line, HA-A, which was then demonstrated to encode multiple overexpressed copies of the IGF1R gene. This strategy combines all steps for detection, cloning, mapping and isolation of amplified gene(s) into a single process that is readily applicable to any specimen carrying cytologic evidence of gene amplification.	UNIV MICHIGAN,DEPT RADIAT ONCOL,MED SCI RES BLDG 2,ROOM C560,1150 W MED CTR DR,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PEDIAT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA029476, R37CA029476] Funding Source: NIH RePORTER; NCI NIH HHS [CA-29476] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNS EMJJ, 1992, CANCER RES, V52, P1036; COWELL JK, 1982, ANNU REV GENET, V16, P21, DOI 10.1146/annurev.ge.16.120182.000321; DJABALI M, 1991, GENOMICS, V10, P1053, DOI 10.1016/0888-7543(91)90198-N; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUMOTO M, 1988, P NATL ACAD SCI USA, V85, P6846, DOI 10.1073/pnas.85.18.6846; GUAN XY, 1992, GENOMICS, V14, P680, DOI 10.1016/S0888-7543(05)80168-5; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KINZLER KW, 1986, P NATL ACAD SCI USA, V83, P1031, DOI 10.1073/pnas.83.4.1031; KULL FC, 1983, J BIOL CHEM, V258, P6561; LEBON TR, 1986, J BIOL CHEM, V261, P7685; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MELTZER PS, 1992, NAT GENET, V1, P24, DOI 10.1038/ng0492-24; RODECK U, 1987, INT J CANCER, V40, P687, DOI 10.1002/ijc.2910400520; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STARK GR, 1984, ANN REV BIOCH, V53, P448; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; Trent J M, 1987, Methods Enzymol, V151, P267, DOI 10.1016/S0076-6879(87)51023-0; TRENT JM, 1984, CANCER RES, V44, P233; ZHANG J, 1993, BLOOD, V81, P3365	22	46	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2827	2831						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378091				2022-12-17	WOS:A1993LX34300025
J	DEBUIRE, B; PATERLINI, P; PONTISSO, P; BASSO, G; MAY, E				DEBUIRE, B; PATERLINI, P; PONTISSO, P; BASSO, G; MAY, E			ANALYSIS OF THE P53 GENE IN EUROPEAN HEPATOCELLULAR CARCINOMAS AND HEPATOBLASTOMAS	ONCOGENE			English	Note							TUMOR-SUPPRESSOR GENE; BREAST-CANCER; CELL-LINES; MUTATIONS; POLYMORPHISM; LYMPHOMA; SARCOMAS; TP53	Human hepatocellular carcinomas (HCC) and hepatoblastomas (HB) from patients in France and Italy, respectively, which are both areas with a low incidence of HCC and a low dietary exposure to aflatoxin B1 (AFB1), were analysed for alterations of the p53 tumour suppressor gene. An abnormality in the p53 gene was detected in only one of the seven HCCs examined. Sequencing of the cDNA of this HCC revealed a G to T transversion at the first nucleotide of codon 245 that was not found in normal tissue, excluding the possibility of germinal transmission of this alteration. All tumours had the wild-type sequence at codon 249, which has been reported to be a mutational hot spot in the p53 gene in HCCs from high incidence areas, such as China and Southern Africa. Seven samples of HB, the most common hepatic tumour of children, were also tested for loss of heterozygosity (LOH) and mutations in the p53 gene. In contrast to what is observed in HCC of adulthood, for which environmental conditions are important etiological risk factors, HB probably stems uniquely from genetic disorders. PCR-direct sequencing of exons 4 to 8 and PCR-single strand conformation polymorphism (PCR-SSCP) of exons 2, 3 and 9 revealed no mutations in the coding sequences examined. LOH was observed in one of the five informative cases when codon 72 and intron 6 were subjected to polymorphism analysis.	UNIV PADUA,PEDIAT CLIN,I-35123 PADUA,ITALY; CHU NECKER,INSERM,U75,F-75073 PARIS 15,FRANCE; UNIV PADUA,MED CLIN,I-35123 PADUA,ITALY	University of Padua; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Padua	DEBUIRE, B (corresponding author), CNRS,UPR 275,F-94801 VILLEJUIF,FRANCE.		PONTISSO, PATRIZIA/K-3574-2018	PONTISSO, PATRIZIA/0000-0003-2077-9202; BASSO, GIUSEPPE/0000-0002-2634-9302				BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; CHALLEN C, 1992, HEPATOLOGY, V16, P1362, DOI 10.1002/hep.1840160610; CHUMAKOV PM, 1991, NUCLEIC ACIDS RES, V19, P6969, DOI 10.1093/nar/19.24.6969-a; DEAN M, 1991, BIOTECHNIQUES, V10, P332; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DUTHU A, 1992, ONCOGENE, V7, P2161; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARRIS AL, 1991, NATURE, V350, P377, DOI 10.1038/350377a0; HAYWARD NK, 1991, NATURE, V352, P764, DOI 10.1038/352764a0; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KRESS S, 1992, CANCER RES, V52, P3220; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MURAKAMI Y, 1991, CANCER RES, V51, P5520; ODA T, 1992, CANCER RES, V52, P6358; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; ROMANO JW, 1989, ONCOGENE, V4, P1483; SCORSONE KA, 1992, CANCER RES, V52, P1635; SHEU JC, 1992, CANCER RES, V52, P6098; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494	27	46	46	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2303	2306						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393166				2022-12-17	WOS:A1993LP17100034
J	PROUTY, SM; HANSON, KD; BOYLE, AL; BROWN, JR; SHICHIRI, M; FOLLANSBEE, MR; KANG, W; SEDIVY, JM				PROUTY, SM; HANSON, KD; BOYLE, AL; BROWN, JR; SHICHIRI, M; FOLLANSBEE, MR; KANG, W; SEDIVY, JM			A CELL-CULTURE MODEL SYSTEM FOR GENETIC ANALYSES OF THE CELL-CYCLE BY TARGETED HOMOLOGOUS RECOMBINATION	ONCOGENE			English	Article							EMBRYONIC STEM-CELLS; MAMMALIAN-CELLS; POLYOMA-VIRUS; 3T3 CELLS; C-MYC; GROWTH; PROTEIN; TRANSFORMATION; ONCOGENE; EXPRESSION	Analysis of how external proliferation signals impinge on the regulation of the cell cycle is ideally performed in cells that are capable of normal physiological withdrawal into the quiescent (G0) phase of the cell cycle as well as resumption of growth following appropriate stimuli. Targeted homologous recombination (gene targeting) provides an important new approach to determine the function of specific genes in these cellular processes. Current gene targeting methodology necessitates the use of immortal and stably diploid cell lines. This report investigates several rodent cell lines, by both genetic and physiological criteria, for use in gene targeting studies of the G0 to G1 transition. All murine cell lines examined were aneuploid. Some rat cell lines were euploid by chromosome number, but three specific genes, c-myc, c-raf-1 and Rb, were not always diploid. Only one cell line, an early-passage subclone of the Rat-I cell line, was diploid for c-myc, c-raf-I and Rb. An hprt- derivative of this cell line was isolated (designated TGR-1) and its karyotype was established by G-banding. TGR-1 cells were shown to withdraw into G0 upon serum starvation and to uniformly enter S phase after refeeding. Expression patterns of the c-myc, c-raf-1 and Rb genes and several properties of the gene products were found to be normal. The frequency of targeted homologous recombination of the c-myc and c-raf-1 loci was found to be within values observed with other cell lines. Thus, by both genetic and physiological criteria the TGR-1 cell line is a good model system for the analysis of the roles of c-myc, c-raf-1 and Rb in signal transduction, and will probably prove useful in studies involving other genes.	YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, 333 CEDAR ST, NEW HAVEN, CT 06510 USA	Yale University				Shichiri, Masayoshi/0000-0002-5704-1378	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041690] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM41690] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BERINSTEIN N, 1992, MOL CELL BIOL, V12, P360, DOI 10.1128/MCB.12.1.360; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; CAMERINI-OTERO R D, 1990, New Biologist, V2, P337; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; DAVIS AC, 1992, MOL CELL BIOL, V12, P2769, DOI 10.1128/MCB.12.6.2769; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; FLUCK MM, 1979, VIROLOGY, V96, P205, DOI 10.1016/0042-6822(79)90185-5; FREEMAN AE, 1973, P NATL ACAD SCI USA, V70, P2415, DOI 10.1073/pnas.70.8.2415; HARLOW E, 1988, ANTOBODIES; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; HASTY P, 1991, MOL CELL BIOL, V11, P5586, DOI 10.1128/MCB.11.11.5586; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; JASIN M, 1988, GENE DEV, V2, P1353, DOI 10.1101/gad.2.11.1353; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KOLCH W, 1990, ONCOGENE, V5, P713; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LITTLEFIELD JW, 1963, P NATL ACAD SCI USA, V50, P568, DOI 10.1073/pnas.50.3.568; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MORTENSEN RM, 1991, P NATL ACAD SCI USA, V88, P7036, DOI 10.1073/pnas.88.16.7036; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; PARKER BA, 1979, J VIROL, V52, P456; PRASAD I, 1976, J VIROL, V18, P436, DOI 10.1128/JVI.18.2.436-444.1976; REID LH, 1991, MOL CELL BIOL, V11, P2769, DOI 10.1128/MCB.11.5.2769; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sambrook J., 1989, MOL CLONING; SEDIVY JM, 1989, P NATL ACAD SCI USA, V86, P227, DOI 10.1073/pnas.86.1.227; SEDIVY JM, 1987, CELL, V50, P379, DOI 10.1016/0092-8674(87)90492-2; SEDIVY JM, 1992, GENE TARGETING; SEIF R, 1977, J VIROL, V24, P721, DOI 10.1128/JVI.24.3.721-728.1977; SIMINOVITCH L, 1976, CELL, V7, P1, DOI 10.1016/0092-8674(76)90249-X; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINBERG RA, 1989, BLOOD, V74, P529	50	46	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					899	907						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455944				2022-12-17	WOS:A1993KT22000011
J	MARRIOTT, SJ; TRINH, D; BRADY, JN				MARRIOTT, SJ; TRINH, D; BRADY, JN			ACTIVATION OF INTERLEUKIN-2 RECEPTOR-ALPHA EXPRESSION BY EXTRACELLULAR HTLV-I TAX1 PROTEIN - A POTENTIAL ROLE IN HTLV-I PATHOGENESIS	ONCOGENE			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; PERIPHERAL-BLOOD LYMPHOCYTES; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; GENE-EXPRESSION; IL-2 RECEPTOR; TAT GENE; TRANSFORMATION	The Tax1 protein of human T cell leukemia/lymphoma virus type I (HTLV-1) has been shown to stimulate the proliferation of human lymphocytes. Here we report that lymphocyte proliferation can be induced at extracellular Tax1 concentrations as low as 25 pM. The proliferative response induced by extracellular Tax1 is accompanied by an activation of endogenous interleukin-2 receptor alpha-chain (IL-2R-alpha) expression in human lymphocytes. Functional activation of IL-2R-alpha expression in peripheral blood lymphocytes treated with Tax1 was demonstrated using an [I-125]IL-2-binding assay. In addition, an enzyme-linked immunosorbent assay demonstrated that soluble IL-2R-alpha in the medium of IL-2- and Tax1-treated cells was over 13-fold greater than in the medium of control treated cells. Overexpression of IL-2R-alpha is a common clinical feature of some patients with adult T-cell leukemia (ATL) and tropical spastic paraparesis/HTLV-I-associated myopathy (TSP/HAM). The ability of extracellular Tax1 protein to activate expression of IL-2R-alpha in both infected and uninfected lymphocytes may contribute to the abnormal lymphocyte proliferation observed in both ATL and TSP/HAM.	NIH,MOLEC VIROL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	MARRIOTT, SJ (corresponding author), BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030, USA.							ARYA SK, 1984, SCIENCE, V225, P1086; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; CANN AJ, 1988, ONCOGENE, V3, P123; COATES SR, 1990, J CLIN MICROBIOL, V28, P1139, DOI 10.1128/JCM.28.6.1139-1142.1990; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEPPER JM, 1984, J IMMUNOL, V133, P1691; DOI T, 1989, EMBO J, V8, P1953, DOI 10.1002/j.1460-2075.1989.tb03600.x; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; GESSAIN A, 1985, LANCET, V2, P407; GIAM CZ, 1988, P NATL ACAD SCI USA, V83, P7192; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HATTORI T, 1981, BLOOD, V58, P645; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ITOYAMA Y, 1988, NEUROLOGY, V38, P816, DOI 10.1212/WNL.38.5.816; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; JACOBSON S, 1988, NATURE, V331, P540, DOI 10.1038/331540a0; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KASHIWAGI S, 1990, J INFECT DIS, V161, P426, DOI 10.1093/infdis/161.3.426; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LINDHOLM P F, 1990, New Biologist, V2, P1034; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; MARRIOTT SJ, 1991, NEW BIOL, V3, P678; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RUBIN LA, 1985, J IMMUNOL, V135, P3172; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TENDLER CL, 1990, P NATL ACAD SCI USA, V87, P5218, DOI 10.1073/pnas.87.13.5218; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WALDMANN TA, 1986, SCIENCE, V232, P727, DOI 10.1126/science.3008337; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874; YODOI J, 1983, BLOOD, V62, P509; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534	45	46	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1749	1755						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501887				2022-12-17	WOS:A1992JJ37600011
J	YAMAOKA, S; TOBE, T; HATANAKA, M				YAMAOKA, S; TOBE, T; HATANAKA, M			TAX PROTEIN OF HUMAN T-CELL LEUKEMIA-VIRUS TYPE-I IS REQUIRED FOR MAINTENANCE OF THE TRANSFORMED PHENOTYPE	ONCOGENE			English	Article							HTLV-I; TRANSCRIPTIONAL ACTIVATOR; NEOPLASTIC TRANSFORMATION; GENE; INTERLEUKIN-2; EXPRESSION; ONCOGENES; RECEPTOR; LINES; RETROVIRUS	We have isolated and characterized revertants of a clonal cell line (40MRatcl-1) of human T-cell leukemia virus type I Tax-transformed Rat1 cells. The 40MRatcl-1 cells contain a single copy of tax gene, form large colonies in soft agar, elicit tumors rapidly in nude mice and revert to the normal phenotype at low frequency. From one of its subclones (B7) bearing pSV2gpt DNA as a marker gene, four morphologically reverse-transformed cell lines were isolated. They display contact inhibition at confluency, lose the ability to form colonies in soft agar, fail to form tumors in nude mice and restore the transformed phenotype similar to that of 40MRatcl-1 cells by retransfection with the tax-expression plasmid. Southern blot analysis revealed that they have lost the tax gene. Our results indicate that transformation of Rat1 cells by Tax is not the consequence of secondary mutations of cellular genes and that tax functions are directly required for establishment and maintenance of the transformed phenotype.	KYOTO UNIV,INST VIRUS RES,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT SURG 1,SAKYO KU,KYOTO 606,JAPAN	Kyoto University; Kyoto University								CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DOI T, 1989, EMBO J, V8, P1953, DOI 10.1002/j.1460-2075.1989.tb03600.x; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; GOH WC, 1985, SCIENCE, V227, P1227, DOI 10.1126/science.2983419; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KOBAYASHI N, 1984, EMBO J, V3, P1339, DOI 10.1002/j.1460-2075.1984.tb01974.x; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE TH, 1984, SCIENCE, V226, P57, DOI 10.1126/science.6089350; Maniatis T., 1982, MOL CLONING; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MORI K, 1987, J GEN VIROL, V68, P499, DOI 10.1099/0022-1317-68-2-499; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SLAMON DJ, 1985, SCIENCE, V228, P1427, DOI 10.1126/science.2990027; SLAMON DJ, 1984, SCIENCE, V226, P61, DOI 10.1126/science.6089351; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISS RA, 1990, CANCER CELL-MON REV, V2, P281; WONGSTAAL F, 1983, NATURE, V302, P626, DOI 10.1038/302626a0; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	38	46	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					433	437						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549359				2022-12-17	WOS:A1992HK00500005
J	SAXENA, A; ALI, IU				SAXENA, A; ALI, IU			INCREASED EXPRESSION OF GENES FROM GROWTH-FACTOR SIGNALING PATHWAYS IN GLIOBLASTOMA CELL-LINES	ONCOGENE			English	Article							MESSENGER RIBONUCLEIC-ACID; FACTOR-ALPHA; TRANSFORMED-CELLS; FACTOR RECEPTOR; BREAST-CANCER; DNA-SEQUENCE; FACTOR-BETA; FACTOR CDNA; AMPLIFICATION; RNAS	The concept of autocrine stimulation of cell proliferation postulates growth autonomy by acquisition of the ability to produce and respond to growth factors. Overproduction of several growth factors in a variety of human tumors and cell lines derived from these tumors has been reported. We have screened several cell lines derived from glioblastomas for anomalies in the expression of genes encoding transforming growth factor alpha (TGF-alpha), TGF-beta, basic fibroblast growth factor (bFGF) and its high-affinity receptor, flg. Compared with normal human brain tissue, we observed a generalized elevation in the levels of expression of these genes in glioblastoma cell lines and an SV40-transformed human astroglial cell line. Overexpression of these genes does not appear to be merely a reflection of the proliferative state of transformed cells since some other human tumor cell lines, when analysed for the expression of TGF-beta and bFGF, did not show a significant increase in these transcripts. The specificity of the elevated transcription of TGF-alpha, TGF-beta, bFGF and flg in glioblastoma cell lines is further suggested by the fact that the transcription of the proto-oncogene c-erbB2, which is overproduced in breast tumor cell lines, was not elevated in glioblastoma cell lines. Increased expression of growth factors, which are potent mitogens and angiogens, and/or their receptors may have critical roles in autonomous proliferation as well as neovascularization of glioblastomas.	NINCDS,SURG NEUROL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ALI IU, 1989, ONCOGENE, V4, P89; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BIARD A, 1987, BIOCHEM BIOPH RES CO, V142, P428; BLAM SB, 1988, ONCOGENE, V3, P129; BREM S, 1972, J NATL CANCER I, V48, P347; CLARK GM, 1991, CANCER RES, V51, P944; DERYNCK R, 1987, CANCER RES, V47, P707; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1988, AM J PATHOL, V130, P393; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KERBEL RS, 1991, BIOESSAYS, V13, P31, DOI 10.1002/bies.950130106; KERNOHAN JW, 1952, ATLAS TUMOR PATHOLOG; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KINZLER KW, 1986, P NATL ACAD SCI USA, V83, P1031, DOI 10.1073/pnas.83.4.1031; KRAUS MH, 1989, CANCER CEL, V7, P303; KUROKAWA T, 1987, FEBS LETT, V213, P189, DOI 10.1016/0014-5793(87)81489-8; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; MAXWELL M, 1991, CANCER RES, V51, P1345; MURPHY PR, 1988, MOL ENDOCRINOL, V2, P591, DOI 10.1210/mend-2-7-591; MYELLO JH, 1988, PROSTATE, V13, P241; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; NISTER M, 1988, CANCER RES, V48, P3910; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; RUSHDI A, 1983, SCIENCE, V222, P390; Russell D., 1989, PATHOLOGY TUMORS NER; SANETO RP, 1985, DEV NEUROSCI-BASEL, V7, P340, DOI 10.1159/000112301; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHLEGEL U, 1990, ONCOGENE, V5, P1839; Sporn M B, 1987, Important Adv Oncol, P75; STERNFELD MD, 1988, J CELL PHYSIOL, V136, P297, DOI 10.1002/jcp.1041360212; TAKAHASHI JA, 1991, BIOCHEM BIOPH RES CO, V177, P1, DOI 10.1016/0006-291X(91)91939-A; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WEIBEL M, 1985, INT J DEV NEUROSCI, V3, P617, DOI 10.1016/0736-5748(85)90052-8; WESTERMARK B, 1973, INT J CANCER, V12, P438, DOI 10.1002/ijc.2910120215; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; ZAGZAG D, 1990, CANCER RES, V50, P7393	47	46	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					243	247						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1347915				2022-12-17	WOS:A1992HG98200006
J	KUO, SS; MELLENTIN, JD; COPELAND, NG; GILBERT, DJ; JENKINS, NA; CLEARY, ML				KUO, SS; MELLENTIN, JD; COPELAND, NG; GILBERT, DJ; JENKINS, NA; CLEARY, ML			STRUCTURE, CHROMOSOME MAPPING, AND EXPRESSION OF THE MOUSE LYL-1 GENE	ONCOGENE			English	Article							T-CELL LEUKEMIA; DNA-BINDING DOMAIN; HEMATOPOIETIC-CELLS; PROTO-ONCOGENE; C-JUN; PRE-B; TRANSLOCATION; DIFFERENTIATION; PROTEINS; CLONING	The mouse Lyl-1 gene was cloned and shown to consist of four exons with extensive nucleotide and structural homology to the human LYL1 gene. The Lyl-1 gene was localized to the central region of mouse chromosome 8 which defines a new region of synteny with human chromosome 19p. The predicted mouse Lyl-1 protein is 78% identical to human LYL1. The region of highest similarity occurs in the basic DNA binding and helix-loop-helix dimerization motifs which are nearly identical in mouse and man differing by only one conservative amino acid substitution. Expression of the Lyl-1 gene was found to be low in murine spleen and undetectable in other tissues by Northern blot analysis. In lymphoid cell lines, Lyl-1 was expressed in most B lineage cells but downregulated during terminal differentiation and was not expressed in most T lineage cells. In a human T ALL cell line carrying a translocation that juxtaposed LYL1 with the beta TCR gene, the translocated LYL1 gene was transcriptionally active whereas the nontranslocated gene was transcriptionally silent. We conclude that LYL1 has the properties of a lineage- and differentiation-specific HLH protein that contributes to T-cell neoplasia through its deregulated expression following chromosomal translocation.	NCI,FREDERICK CANC RES FACIL & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	KUO, SS (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305, USA.				NATIONAL CANCER INSTITUTE [R37CA042971, R01CA042971, T32CA009302] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09302, CA42971, N01-CO-74101] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENBROOK DM, 1990, ONCOGENE, V5, P295; BUCHBERG AM, 1988, ONCOGENE RES, V2, P149; BUDARF M, 1990, GENOMICS, V8, P575, DOI 10.1016/0888-7543(90)90047-X; CECI JD, 1990, GENOMICS, V6, P72, DOI 10.1016/0888-7543(90)90449-5; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1988, J EXP MED, V167, P682, DOI 10.1084/jem.167.2.682; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DAVIDSON WF, 1984, J IMMUNOL, V133, P744; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EPSTEIN AL, 1978, CANCER, V42, P2379, DOI 10.1002/1097-0142(197811)42:5<2379::AID-CNCR2820420539>3.0.CO;2-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; Green EL, 1981, GENETICS PROBABILITY, P77; HOLMES KL, 1986, J EXP MED, V164, P443, DOI 10.1084/jem.164.2.443; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LASKOV R, 1970, Journal of Experimental Medicine, V131, P515, DOI 10.1084/jem.131.3.515; Lee W M, 1989, Cancer Treat Res, V47, P37; LEWIS S, 1985, SCIENCE, V228, P677, DOI 10.1126/science.3158075; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; LOENEN WAM, 1980, GENE, V10, P249, DOI 10.1016/0378-1119(80)90054-2; Lyon M., 1989, GENETIC VARIANTS STR; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MATTEI MG, 1990, ONCOGENE, V5, P151; MCKEARN JP, 1985, EUR J IMMUNOL, V15, P295, DOI 10.1002/eji.1830150316; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; RUTA M, 1988, ONCOGENE, V3, P9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SMITH SD, 1989, BLOOD, V73, P2182; SPOLSKI R, 1988, EUR J IMMUNOL, V18, P295; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; WARNER NL, 1979, IMMUNOL REV, V48, P197, DOI 10.1111/j.1600-065X.1979.tb00304.x; ZIJLSTRA M, 1986, BIOCHIM BIOPHYS ACTA, V865, P197, DOI 10.1016/0304-419X(86)90028-4	42	46	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					961	968						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	2067848				2022-12-17	WOS:A1991GU62200010
J	GARCIA, A; LAMONTAGNE, K; REAVIS, D; STOBERGRASSER, U; LIPSICK, JS				GARCIA, A; LAMONTAGNE, K; REAVIS, D; STOBERGRASSER, U; LIPSICK, JS			DETERMINANTS OF SEQUENCE-SPECIFIC DNA-BINDING BY P48V-MYB	ONCOGENE			English	Article							V-MYB ONCOGENE; AVIAN-MYELOBLASTOSIS VIRUS; AMINO-TERMINAL REGION; ENCODED PROTEIN DETECT; C-MYB; NUCLEOTIDE-SEQUENCE; TRANS-ACTIVATION; GENE-EXPRESSION; LEUKEMIA-VIRUS; ZEA-MAYS	The v-myb oncogene of the avian myeloblastosis virus encodes a nuclear protein, p48v-myb, which binds to DNA in a sequence-specific manner. We have used wild type and mutant forms of this protein expressed in E. coli to study the protein and DNA determinants for sequence-specific DNA-binding. We have shown that only the highly conserved domain at the amino terminus of p48v-myb is required for sequence-specific DNA-binding. However, neither of the tandem 50 amino acid repeats present in this domain is alone sufficient for such binding. We have also demonstrated that p48v-myb can recognize a single consensus myb binding site and appears to interact with DNA as a protein monomer. In addition, we have shown that sequence-specific binding by p48v-myb requires nucleotides which flank the previously reported PyAAC(T)/(G)G consensus.	SUNY STONY BROOK,SCH MED,DEPT MICROBIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [P01CA028146, R01CA043592, K04CA001457] Funding Source: NIH RePORTER; NCI NIH HHS [K04 CA-01457, R01 CA-43592, P01 CA-28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADING H, 1987, ONCOGENE, V1, P395; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; DURBAN EM, 1981, J VIROL, V37, P488, DOI 10.1128/JVI.37.1.488-492.1981; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1988, J VIROL, V62, P4398, DOI 10.1128/JVI.62.11.4398-4402.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Lipsick J S, 1986, Gene Amplif Anal, V4, P73; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MAROCCO A, 1989, MOL GEN GENET, V216, P183, DOI 10.1007/BF00334354; MCMAHON J, 1988, ONCOGENE, V3, P717; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	43	46	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					265	273						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	2000220				2022-12-17	WOS:A1991FZ13400012
J	ADACHI, M; TSUJIMOTO, Y				ADACHI, M; TSUJIMOTO, Y			POTENTIAL Z-DNA ELEMENTS SURROUND THE BREAKPOINTS OF CHROMOSOME-TRANSLOCATION WITHIN THE 5' FLANKING REGION OF BCL-2 GENE	ONCOGENE			English	Note									WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute					NCI NIH HHS [R01-CA50551] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050551] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; ADACHI M, 1989, P NATL ACAD SCI USA, V86, P2771, DOI 10.1073/pnas.86.8.2771; ADACHI M, 1989, ONCOGENE, V4, P1073; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BULLOCK P, 1986, MOL CELL BIOL, V6, P3948, DOI 10.1128/MCB.6.11.3948; CHEN SJ, 1989, NUCLEIC ACIDS RES, V17, P7631, DOI 10.1093/nar/17.19.7631; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COHEN JB, 1982, NUCLEIC ACIDS RES, V10, P3353, DOI 10.1093/nar/10.11.3353; FLANAGAN JG, 1984, CELL, V36, P681, DOI 10.1016/0092-8674(84)90348-9; FREUND AM, 1989, P NATL ACAD SCI USA, V86, P7465, DOI 10.1073/pnas.86.19.7465; HAMADA H, 1982, NATURE, V298, P396, DOI 10.1038/298396a0; KILPATRICK MW, 1984, J BIOL CHEM, V259, P7268; KLYSIK J, 1982, J BIOL CHEM, V257, P152; LAFER EM, 1981, P NATL ACAD SCI-BIOL, V78, P3546, DOI 10.1073/pnas.78.6.3546; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NORDHEIM A, 1982, CELL, V31, P309, DOI 10.1016/0092-8674(82)90124-6; NORDHEIM A, 1983, P NATL ACAD SCI-BIOL, V80, P1821, DOI 10.1073/pnas.80.7.1821; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; PECK LJ, 1982, P NATL ACAD SCI-BIOL, V79, P4560, DOI 10.1073/pnas.79.15.4560; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHEN SH, 1981, CELL, V26, P191, DOI 10.1016/0092-8674(81)90302-0; SLIGHTOM JL, 1980, CELL, V21, P627, DOI 10.1016/0092-8674(80)90426-2; STRINGER JR, 1982, NATURE, V296, P363, DOI 10.1038/296363a0; TRECO D, 1986, MOL CELL BIOL, V6, P3934, DOI 10.1128/MCB.6.11.3934; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TYCKO B, 1989, SCIENCE, V245, P1242, DOI 10.1126/science.2551037; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WEINREB A, 1988, P NATL ACAD SCI USA, V85, P529, DOI 10.1073/pnas.85.2.529	38	46	49	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1990	5	11					1653	1657						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EL401	2176281				2022-12-17	WOS:A1990EL40100006
J	MANGUES, R; SEIDMAN, I; PELLICER, A; GORDON, JW				MANGUES, R; SEIDMAN, I; PELLICER, A; GORDON, JW			TUMORIGENESIS AND MALE-STERILITY IN TRANSGENIC MICE EXPRESSING A MMTV-N-RAS ONCOGENE	ONCOGENE			English	Article									NYU MED CTR, DEPT PATHOL, NEW YORK, NY 10016 USA; NYU MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA; CUNY MT SINAI SCH MED, CTR MOLEC BIOL, DEPT GERIATR & ADULT DEV, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT OBSTET & GYNECOL & REPROD SCI, NEW YORK, NY 10029 USA	New York University; New York University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai				Mangues, Ramon/0000-0003-2661-9525; Pellicer, Angel/0000-0002-5062-0692	NATIONAL CANCER INSTITUTE [R01CA042103, P01CA016239, R37CA036327, R01CA036327] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36327, CA 16239, CA 42103] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM., 1988, CURRENT PROTOCOLS MO; BARDIN CW, 1981, ANNU REV PHYSIOL, V43, P189; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI YW, 1987, J VIROL, V61, P3013, DOI 10.1128/JVI.61.10.3013-3019.1987; DARBRE P, 1986, MOL CELL BIOL, V6, P2847, DOI 10.1128/MCB.6.8.2847; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GORDON JW, 1986, MOL CELL BIOL, V6, P2158, DOI 10.1128/MCB.6.6.2158; GORDON JW, 1986, J EXP ZOOL, V239, P347, DOI 10.1002/jez.1402390306; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GORDON JW, 1981, SCIENCE, V214, P1244, DOI 10.1126/science.6272397; GUERRERO I, 1984, SCIENCE, V225, P1041, DOI 10.1126/science.6089339; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; QUINN P, 1982, J REPROD FERTIL, V66, P161; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P383, DOI 10.1073/pnas.80.2.383; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; THADANI VM, 1982, J EXP ZOOL, V219, P277, DOI 10.1002/jez.1402190303; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; Yanagimachi R, 1981, FERTILIZATION EMBRYO, P81	29	46	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1990	5	10					1491	1497						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2174525				2022-12-17	WOS:A1990EK50200007
J	HALL, DJ				HALL, DJ			REGULATION OF C-MYC TRANSCRIPTION INVITRO - DEPENDENCE ON THE GUANINE-RICH PROMOTER ELEMENT ME1A1	ONCOGENE			English	Article									HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NCI NIH HHS [CA22042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASSELIN C, 1989, ONCOGENE, V4, P549; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY D, 1986, NATURE, V231, P702; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROSVELD GC, 1981, CELL, V25, P215, DOI 10.1016/0092-8674(81)90246-4; HALL DJ, 1987, J BIOL CHEM, V262, P15302; HALL DJ, 1989, MOL CELL BIOL, V9, P1705, DOI 10.1128/MCB.9.4.1705; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HU SL, 1981, P NATL ACAD SCI-BIOL, V78, P820, DOI 10.1073/pnas.78.2.820; HUANG DH, 1988, MOL CELL BIOL, V8, P1906, DOI 10.1128/MCB.8.5.1906; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; SASSONECORSI P, 1981, NUCLEIC ACIDS RES, V9, P3941, DOI 10.1093/nar/9.16.3941; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WEISINGER G, 1988, ONCOGENE, V3, P635; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x	39	46	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1990	5	1					47	54						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2181377				2022-12-17	WOS:A1990CM62000007
J	MIYAGAWA, K; SAKAMOTO, H; YOSHIDA, T; YAMASHITA, Y; MITSUI, Y; FURUSAWA, M; MAEDA, S; TAKAKU, F; SUGIMURA, T; TERADA, M				MIYAGAWA, K; SAKAMOTO, H; YOSHIDA, T; YAMASHITA, Y; MITSUI, Y; FURUSAWA, M; MAEDA, S; TAKAKU, F; SUGIMURA, T; TERADA, M			HST-1 TRANSFORMING PROTEIN - EXPRESSION IN SILKWORM CELLS AND CHARACTERIZATION AS A NOVEL HEPARIN-BINDING GROWTH-FACTOR	ONCOGENE			English	Article									NATL CANC CTR,RES INST,DIV GENET,CHUO KU,TSUKIJI 5 CHOME,TOKYO 104,JAPAN; DAIICHI SEIYAKO RES INST,MOLEC BIOL RES LAB,EDOGAWA KU,TOKYO 134,JAPAN; TOTTORI UNIV,FAC AGR,TOTTORI 680,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; AGCY IND SCI & TECHNOL,FERMENTAT RES INST,DIV CELL SCI & TECHNOL,IBARAKI 305,JAPAN	National Cancer Center - Japan; Tottori University; University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST)								ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; ESCH F, 1985, BIOCHEM BIOPH RES CO, V133, P554, DOI 10.1016/0006-291X(85)90942-8; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GARDINER GR, 1975, J INVERTEBRATE PATHO, V16, P284; GIMENEZGALLEGO G, 1985, SCIENCE, V230, P1385, DOI 10.1126/science.4071057; GOSPODAROWICZ D, 1987, METHOD ENZYMOL, V147, P106; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; IMAMURA T, 1987, EXP CELL RES, V172, P92, DOI 10.1016/0014-4827(87)90096-6; INAGAKI Y, 1988, J VIROL, V62, P1640, DOI 10.1128/JVI.62.5.1640-1646.1988; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; KODA T, 1987, JPN J CANCER RES, V78, P325; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINEMEYER DL, 1987, BIO-TECHNOL, V5, P960, DOI 10.1038/nbt0987-960; LOBB R, 1986, J BIOL CHEM, V261, P1924; LOBB RR, 1985, BIOCHEMISTRY-US, V24, P4969, DOI 10.1021/bi00340a001; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MAEDA S, 1985, NATURE, V315, P592, DOI 10.1038/315592a0; MARUMOTO Y, 1987, J GEN VIROL, V68, P2599, DOI 10.1099/0022-1317-68-10-2599; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; MIYAZONO K, 1985, BIOCHEM BIOPH RES CO, V126, P83, DOI 10.1016/0006-291X(85)90574-1; MOSCATELLI D, 1987, P NATL ACAD SCI USA, V84, P5778, DOI 10.1073/pnas.84.16.5778; NAKAGAMA H, 1987, JPN J CANCER RES, V78, P651; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SAKAMOTO H, 1988, BIOCHEM BIOPH RES CO, V151, P965, DOI 10.1016/S0006-291X(88)80460-1; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SOMMER A, 1987, BIOCHEM BIOPH RES CO, V144, P543, DOI 10.1016/S0006-291X(87)80001-3; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YOSHIDA MC, 1988, P NATL ACAD SCI USA, V85, P4861, DOI 10.1073/pnas.85.13.4861; YOSHIDA T, 1987, BIOCHEM BIOPH RES CO, V142, P1019, DOI 10.1016/0006-291X(87)91516-6; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YUASA Y, 1987, JPN J CANCER RES, V78, P1036	41	46	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					383	389						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	2978866				2022-12-17	WOS:A1988Q773900005
J	Zhou, Q; Wu, XY; Wang, XF; Yu, ZJ; Pan, T; Li, Z; Chang, XY; Jin, ZJ; Li, JF; Zhu, ZG; Liu, BY; Su, LP				Zhou, Quan; Wu, Xiongyan; Wang, Xiaofeng; Yu, Zhenjia; Pan, Tao; Li, Zhen; Chang, Xinyu; Jin, Zhijian; Li, Jianfang; Zhu, Zhenggang; Liu, Bingya; Su, Liping			The reciprocal interaction between tumor cells and activated fibroblasts mediated by TNF-alpha/IL-33/ST2L signaling promotes gastric cancer metastasis	ONCOGENE			English	Article							STROMAL FIBROBLASTS; INTERLEUKIN-33; RECEPTOR; IL-33; CYTOKINE; EXPRESSION; GROWTH; PROGRESSION; INITIATION; INVASION	Gastric cancer (GC) is characterized by extensive local invasion, distant metastasis and poor prognosis. In most cases, GC progression is associated with aberrant expression of cytokines or activation of signaling cascades mediated by tumor-stroma interactions. However, the mechanisms by which these interactions contribute to GC progression are poorly understood. In this study, we find that IL-33 and its receptor ST2L are upregulated in the human GC and served as prognostic markers for poor survival of GC patients. In a co-culture model with GC cells and cancer-associated fibroblasts (CAFs), we further demonstrate that CAFs-derived IL-33 enhances the migration and invasion of GC cells by inducing the epithelial-mesenchymal transition (EMT) through activation of the ERK1/2-SP1-ZEB2 pathway in a ST2L-dependent manner. Furthermore, the secretion of IL-33 by CAFs can be induced by the proinflammatory cytokines TNF-alpha that is released by GC cells via TNFR2-NF-kappa B-IRF-1 pathway. Additionally, silencing of IL-33 expression in CAFs or ST2L expression in GC cells inhibits the peritoneal dissemination and metastatic potential of GC cells in nude mice. Taken together, these results characterize a critical role of the interaction between epithelial-stroma mediated by the TNF-alpha/IL-33/ST2L signaling in GC progression, and provide a rationale for targeting this pathway to treat GC metastasis.	[Zhou, Quan; Wu, Xiongyan; Yu, Zhenjia; Pan, Tao; Li, Zhen; Chang, Xinyu; Jin, Zhijian; Li, Jianfang; Zhu, Zhenggang; Liu, Bingya; Su, Liping] Shanghai Jiao Tong Univ, Shanghai Key Lab Gastr Neoplasms, Shanghai Inst Digest Surg, Dept Surg,Ruijin Hosp,Sch Med, Shanghai 200025, Peoples R China; [Zhou, Quan] Shanghai Jiao Tong Univ, Ruijin Hosp, Ctr Organ Transplantat, Dept Urol,Sch Med, Shanghai 200025, Peoples R China; [Wang, Xiaofeng] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Gen Surg, Sch Med, Shanghai 200025, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Liu, BY; Su, LP (corresponding author), Shanghai Jiao Tong Univ, Shanghai Key Lab Gastr Neoplasms, Shanghai Inst Digest Surg, Dept Surg,Ruijin Hosp,Sch Med, Shanghai 200025, Peoples R China.	liubingya@sjtu.edu.cn; suliping@shsmu.edu.cn	Liu, Bingya/GMW-5655-2022	Liu, Bingya/0000-0002-4406-3762; su, liping/0000-0003-2401-0265	National Natural Science Foundation of China [81572798, 81871902, 81702385, 81672822, 81772509, 91529302]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20152505]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support	We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript. This work was supported by the National Natural Science Foundation of China (No. 81572798 and No. 81871902 to L.S., No. 81702385 to Q.Z., No. 81672822 to Z.Z., No. 81772509 and No. 91529302 to B.L.), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (No. 20152505 to L.S.).	Ajani JA, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.36; Akimoto M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.418; Andersson P, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122375; Avgustinova A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10305; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Bi S, 2016, SENSORS-BASEL, V16, DOI 10.3390/s16030318; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Cayrol C, 2018, IMMUNOL REV, V281, P154, DOI 10.1111/imr.12619; Chang KW, 2013, BIOCHEM BIOPH RES CO, V434, P854, DOI 10.1016/j.bbrc.2013.04.031; Chen SF, 2013, J PATHOL, V231, P180, DOI 10.1002/path.4226; Chia NY, 2016, ANN ONCOL, V27, P763, DOI 10.1093/annonc/mdw040; Cirri P, 2013, CELL CYCLE, V12, P204, DOI 10.4161/cc.23421; Cirri P, 2012, CANCER METAST REV, V31, P195, DOI 10.1007/s10555-011-9340-x; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Glentis A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00985-8; Gramatzki D, 2016, ONCOL LETT, V12, P445, DOI 10.3892/ol.2016.4626; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kakkar R, 2012, J BIOL CHEM, V287, P6941, DOI 10.1074/jbc.M111.298703; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Kasagi Y, 2016, CANCER RES, V76, P347, DOI 10.1158/0008-5472.CAN-15-1563; Labernadie A, 2017, NAT CELL BIOL, V19, P224, DOI 10.1038/ncb3478; Larsen KM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092676; Levescot A, 2014, CANCER RES, V74, P2669, DOI 10.1158/0008-5472.CAN-13-2797; Li J, 2014, J CLIN INVEST, V124, P3241, DOI 10.1172/JCI73742; Liew FY, 2016, NAT REV IMMUNOL, V16, P676, DOI 10.1038/nri.2016.95; Lin TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063966; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lordick F, 2017, ANN ONCOL, V28, P1767, DOI 10.1093/annonc/mdx051; Lu M, 2013, P NATL ACAD SCI USA, V110, P18144, DOI 10.1073/pnas.1318192110; Maywald RL, 2015, P NATL ACAD SCI USA, V112, pE2487, DOI 10.1073/pnas.1422445112; Nam EH, 2014, CARCINOGENESIS, V35, P302, DOI 10.1093/carcin/bgt340; Oboki Keisuke, 2010, Allergology International, V59, P143, DOI 10.2332/allergolint.10-RAI-0186; Ridge SM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0597-8; Schauer IG, 2011, NEOPLASIA, V13, P393, DOI 10.1593/neo.101720; Schmieder A, 2012, CYTOKINE, V60, P514, DOI 10.1016/j.cyto.2012.06.286; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Sun PH, 2011, DIGEST DIS SCI, V56, P3596, DOI 10.1007/s10620-011-1760-5; Tong XG, 2016, MOL ONCOL, V10, P113, DOI 10.1016/j.molonc.2015.06.004; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Tsujimoto H, 2010, GASTRIC CANCER, V13, P212, DOI 10.1007/s10120-010-0568-x; Wang XF, 2017, INT J CANCER, V141, P998, DOI 10.1002/ijc.30801; Wu XY, 2017, ONCOTARGET, V8, P20741, DOI 10.18632/oncotarget.15119; Wu XY, 2013, CANCER LETT, V335, P128, DOI 10.1016/j.canlet.2013.02.002; Xing F, 2010, FRONT BIOSCI-LANDMRK, V15, P166, DOI 10.2741/3613; Yang SG, 2015, J BIOL CHEM, V290, P861, DOI 10.1074/jbc.M114.586560; Yang YL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11385; Yang ZP, 2015, DIS MARKERS, V2015, P1, DOI 10.1155/2015/516895; Ye XL, 2015, ONCOL REP, V33, P2746, DOI 10.3892/or.2015.3898; Zhang BG, 2014, ONCOTARGET, V5, P10584, DOI 10.18632/oncotarget.2513	54	45	50	3	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1414	1428		10.1038/s41388-019-1078-x	http://dx.doi.org/10.1038/s41388-019-1078-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31659258	hybrid, Green Published			2022-12-17	WOS:000513289600003
J	Caslini, C; Hong, S; Ban, YJ; Chen, XS; Ince, TA				Caslini, Corrado; Hong, Sunhwa; Ban, Yuguang J.; Chen, Xi S.; Ince, Tan A.			HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells	ONCOGENE			English	Article							DEACETYLASE INHIBITORS; EXPRESSION; MATURATION; REPRESSION; PROMOTER; IDENTITY; ROLES; TIP60	Chromatin regulation through histone modifications plays an essential role in coordinated expression of multiple genes. Alterations in chromatin induced by histone modifiers and readers regulate critical transcriptional programs involved in both normal development and tumor differentiation. Recently, we identified that histone deacetylases HDAC1 and HDAC7 are necessary to maintain cancer stem cells (CSCs) in both breast and ovarian tumors. Here, we sought to investigate the CSC-specific function of HDAC1 and HDAC7 mechanistically by using a stem-like breast cancer (BrCa) cell model BPLER and matched nonstem tumor cell (nsTC)-like HMLER, along with conventional BrCa cell lines with different CSC enrichment levels. We found that HDAC1 and HDAC3 inhibition or knockdown results in HDAC7 downregulation, which is associated with a decrease in histone 3 lysine 27 acetylation (H3K27ac) at transcription start sites (TSS) and super-enhancers (SEs) prominently in stem-like BrCa cells. Importantly, these changes in chromatin landscape also correlate with the repression of many SE-associated oncogenes, including c-MYC, CD44, CDKN1B, SLUG, VDR, SMAD3, VEGFA, and XBP1. In stem-like BrCa cells, HDAC7 binds near TSS and to SEs of these oncogenes where it appears to contribute to both H3K27ac and transcriptional regulation. These results suggest that HDAC7 inactivation, directly or through inhibition of HDAC1 and HDAC3, can result in the inhibition of the CSC phenotype by downregulating multiple SE-associated oncogenes. The CSC selective nature of this mechanism and the prospect of inhibiting multiple oncogenes simultaneously makes development of HDAC7 specific inhibitors a compelling objective.	[Caslini, Corrado; Hong, Sunhwa; Ban, Yuguang J.; Chen, Xi S.; Ince, Tan A.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Biomed Res Bldg, Miami, FL 33136 USA; [Ban, Yuguang J.; Chen, Xi S.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA; [Ince, Tan A.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA; [Ince, Tan A.] Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami; University of Miami	Caslini, C; Ince, TA (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Biomed Res Bldg, Miami, FL 33136 USA.; Ince, TA (corresponding author), Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.; Ince, TA (corresponding author), Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst, Miami, FL 33136 USA.	ccaslini@med.miami.edu; TInce@med.miami.edu	Caslini, Corrado/W-6123-2019	Caslini, Corrado/0000-0001-8326-8368; Ince, Tan/0000-0003-0315-6425; Ban, Yuguang/0000-0002-2874-0647	Breast Cancer Research Foundation (NY); Florida Breast Cancer Foundation (FL); Sylvester Comprehensive Cancer Center	Breast Cancer Research Foundation (NY); Florida Breast Cancer Foundation (FL); Sylvester Comprehensive Cancer Center	We gratefully acknowledge the Sylvester Comprehensive Cancer Center, Onco-Genomics Shared Resource for ChIP, and RNA sequencing services. This work was funded by grants to TAI from Breast Cancer Research Foundation (NY), Florida Breast Cancer Foundation (FL), and Sylvester Comprehensive Cancer Center.	Afgan E, 2018, NUCLEIC ACIDS RES, V46, pW537, DOI 10.1093/nar/gky379; Ahn MY, 2017, J ORAL PATHOL MED, V46, P276, DOI 10.1111/jop.12560; Ai W, 2007, NUCLEIC ACIDS RES, V35, P6137, DOI 10.1093/nar/gkm656; Aude-Garcia C, 2010, BIOCHEM J, V430, P237, DOI 10.1042/BJ20100131; Barneda-Zahonero B, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.594; Caslini C, 2006, ONCOGENE, V25, P5446, DOI 10.1038/sj.onc.1209533; Dokmanovic M, 2007, MOL CANCER THER, V6, P2525, DOI 10.1158/1535-7163.MCT-07-0251; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Gao S, 2018, CLIN TRANSL ONCOL, V20, P703, DOI 10.1007/s12094-017-1770-7; Glaser KB, 2003, MOL CANCER THER, V2, P151; Greer CB, 2015, CELL REP, V13, P1444, DOI 10.1016/j.celrep.2015.10.013; Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Hull EE, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8797206; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Jensen ED, 2008, J BONE MINER RES, V23, P361, DOI 10.1359/JBMR.071104; Kaletsch A, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0531-y; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kato H, 2004, J BIOL CHEM, V279, P41966, DOI 10.1074/jbc.M406320200; Kim YJ, 2013, ONCOGENE, V32, P2828, DOI 10.1038/onc.2013.32; Laugesen A, 2014, CELL STEM CELL, V14, P735, DOI 10.1016/j.stem.2014.05.006; Lei YB, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0736-2; Li B, 2007, P NATL ACAD SCI USA, V104, P4571, DOI 10.1073/pnas.0700298104; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Ma C, 2011, J BIOL CHEM, V286, P4819, DOI 10.1074/jbc.M110.146860; Malik S, 2010, MOL CELL BIOL, V30, P399, DOI 10.1128/MCB.00907-09; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Morrison BE, 2006, MOL CELL BIOL, V26, P3550, DOI 10.1128/MCB.26.9.3550-3564.2006; Pasini D, 2010, NUCLEIC ACIDS RES, V38, P4958, DOI 10.1093/nar/gkq244; Rickels R, 2018, TRENDS CELL BIOL, V28, P608, DOI 10.1016/j.tcb.2018.04.003; Sanchez GJ, 2018, NUCLEIC ACIDS RES, V46, P1756, DOI 10.1093/nar/gkx1225; Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713; Singh J, 2002, ONCOGENE, V21, P1812, DOI 10.1038/sj.onc.1205252; Toh Y, 2003, ONCOL REP, V10, P333; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Whyte WA, 2012, NATURE, V482, P221, DOI 10.1038/nature10805; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; Witt AE, 2017, ONCOGENE, V36, P1707, DOI 10.1038/onc.2016.337; Xiao H, 2003, J BIOL CHEM, V278, P11197, DOI 10.1074/jbc.M210816200; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Yano M, 2018, ONCOL LETT, V15, P3524, DOI 10.3892/ol.2018.7726; Yu Y, 2017, CLIN TRANSL ONCOL, V19, P1045, DOI 10.1007/s12094-017-1639-9; Zhu CH, 2011, J MOL MED, V89, P279, DOI 10.1007/s00109-010-0701-7	45	45	45	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2019	38	39					6599	6614		10.1038/s41388-019-0897-0	http://dx.doi.org/10.1038/s41388-019-0897-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JA5AQ	31375747	hybrid			2022-12-17	WOS:000487856000003
J	Li, LC; Ameri, AH; Wang, SM; Jansson, KH; Casey, OM; Yang, Q; Beshiri, ML; Fang, L; Lake, RG; Agarwal, S; Alilin, AN; Xu, WH; Yin, JJ; Kelly, K				Li, Lechen; Ameri, Amir H.; Wang, Simeng; Jansson, Keith H.; Casey, Orla M.; Yang, Qi; Beshiri, Michael L.; Fang, Lei; Lake, Ross G.; Agarwal, Supreet; Alilin, Aian N.; Xu, Wanhai; Yin, JuanJuan; Kelly, Kathleen			EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis	ONCOGENE			English	Article							TRANSCRIPTION FACTOR EGR1; MESENCHYMAL TRANSITION; TGF-BETA; IN-VITRO; CELLS; GROWTH; BONE; EXPRESSION; RECEPTOR; PTEN	Early growth response-1 (EGR1) is a transcription factor correlated with prostate cancer (PC) progression in a variety of contexts. For example, EGR1 levels increase in response to suppressed androgen receptor signaling or loss of the tumor suppressor, PTEN. EGR1 has been shown to regulate genes influencing proliferation, apoptosis, immune cell activation, and matrix degradation, among others. Despite this, the impact of EGR1 on PC metastatic colonization is unclear. We demonstrate using a PC model (DU145/RasB1) of bone and brain metastasis that EGR1 expression regulates angiogenic and osteoclastogenic properties of metastases. We have shown previously that FN14 (TNFRSF12A) and downstream NF-kappa B signaling is required for metastasis in this model. Here we demonstrate that FN14 ligation also leads to NF-kappa B-independent, MEK-dependent EGR1 expression. EGR/ -depletion in DU145/RasB1 cells reduced both the number and size of metastases but did not affect primary tumor growth. Decreased EGR1 expression led to reduced blood vessel density in brain and bone metastases as well as decreased osteolytic bone lesion area and reduced numbers of osteoclasts at the bone-tumor interface. TWEAK (TNFSF12) induced several EGR/ -dependent angiogenic and osteoclastogenic factors (e.g., PDGFA, TGFB1, SPP1, IL6, IL8, and TGFA, among others). Consistent with this, in clinical samples of PC, the level of several genes encoding angiogenic/osteoclastogenic pathway effectors correlated with EGR1 levels. Thus, we show here that EGR1 has a direct effect on prostate cancer metastases. EGR1 regulates angiogenic and osteoclastogenic factors, informing the underlying signaling networks that impact autonomous and microenvironmental mechanisms of cancer metastases.	[Li, Lechen; Xu, Wanhai] Harbin Med Univ, Dept Urol, Hosp 4, Harbin, Heilongjiang, Peoples R China; [Ameri, Amir H.; Wang, Simeng; Jansson, Keith H.; Casey, Orla M.; Yang, Qi; Beshiri, Michael L.; Fang, Lei; Lake, Ross G.; Agarwal, Supreet; Alilin, Aian N.; Yin, JuanJuan; Kelly, Kathleen] NCI, Lab Genitourinary Canc Pathogenesis, CCR, Bethesda, MD 20892 USA	Harbin Medical University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Xu, WH (corresponding author), Harbin Med Univ, Dept Urol, Hosp 4, Harbin, Heilongjiang, Peoples R China.; Kelly, K (corresponding author), NCI, Lab Genitourinary Canc Pathogenesis, CCR, Bethesda, MD 20892 USA.	xuwanhai@163.com; kellyka@mail.nih.gov	agarwal, supreet/AAI-7296-2021	Beshiri, Michael/0000-0003-3128-3851; Ameri, Amir H./0000-0003-0284-8286; Li, Lechen/0000-0003-3978-9582	Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research; National Natural Science Foundation of China [81270022, 81611130070, 81771898]; NATIONAL CANCER INSTITUTE [ZICBC010947] Funding Source: NIH RePORTER	Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research and National Natural Science Foundation of China (81270022, 81611130070, and 81771898; to WX).	Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Adamson E, 2003, CANCER BIOL THER, V2, P617; Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Aytes A, 2013, P NATL ACAD SCI USA, V110, pE3506, DOI 10.1073/pnas.1303558110; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Caffo O, 2012, J NEURO-ONCOL, V107, P191, DOI 10.1007/s11060-011-0734-y; Cancro MP, 2009, NAT REV IMMUNOL, V9, P657, DOI 10.1038/nri2621; CHANG J, 1989, CANCER CELL-MON REV, V1, P17; Eid MA, 1998, CANCER RES, V58, P2461; Faltermeier CM, 2016, P NATL ACAD SCI USA, V113, pE172, DOI 10.1073/pnas.1521674112; Gitenay D, 2009, FUTURE ONCOL, V5, P993, DOI [10.2217/fon.09.67, 10.2217/FON.09.67]; Hardaway AL, 2015, CLIN EXP METASTAS, V32, P353, DOI 10.1007/s10585-015-9714-5; Hatzoglou V, 2014, J NEUROIMAGING, V24, P161, DOI 10.1111/j.1552-6569.2012.00767.x; Jansson KH, 2012, PROSTATE, V72, P1080, DOI 10.1002/pros.21512; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Juarez P, 2011, BONE, V48, P23, DOI 10.1016/j.bone.2010.08.004; Kinkade CW, 2008, J CLIN INVEST, V118, P3051, DOI 10.1172/JCI34764; Krones-Herzig A, 2005, CANCER RES, V65, P5133, DOI 10.1158/0008-5472.CAN-04-3742; Kundumani-Sridharan V, 2010, BLOOD, V115, P2105, DOI 10.1182/blood-2009-09-241802; Kuo PL, 2011, J CELL PHYSIOL, V226, P1224, DOI 10.1002/jcp.22445; Liao YJ, 2004, J BIOL CHEM, V279, P43107, DOI 10.1074/jbc.M407969200; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Mayer SI, 2009, J CELL SCI, V122, P3340, DOI 10.1242/jcs.048272; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Muller I, 2012, ENDOCRINOLOGY, V153, P3040, DOI 10.1210/en.2012-1064; Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Rostovskaya M, 2018, STEM CELL REP, V11, P212, DOI 10.1016/j.stemcr.2018.05.014; Ruscetti M, 2015, CANCER RES, V75, P2749, DOI 10.1158/0008-5472.CAN-14-3476; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; Singha B, 2014, J BIOL CHEM, V289, P2687, DOI 10.1074/jbc.M113.502641; Sperandio S, 2009, MOL CARCINOGEN, V48, P38, DOI 10.1002/mc.20454; Starmans MHW, 2012, RADIOTHER ONCOL, V102, P436, DOI 10.1016/j.radonc.2012.02.002; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tsai MH, 2007, CANCER RES, V67, P3845, DOI 10.1158/0008-5472.CAN-06-4250; Wang T, 2005, BLOOD, V105, P2836, DOI 10.1182/blood-2004-07-2878; Winkles JA, 2008, NAT REV DRUG DISCOV, V7, P411, DOI 10.1038/nrd2488; Wu JN, 2014, CANCER-AM CANCER SOC, V120, P818, DOI 10.1002/cncr.28485; Wu SY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11169; Yamamoto C, 2010, CANCER RES, V70, P8715, DOI 10.1158/0008-5472.CAN-10-0043; Yang SZ, 2006, J CELL BIOCHEM, V97, P1292, DOI 10.1002/jcb.20736; Yang SZ, 2003, J BIOL CHEM, V278, P39906, DOI 10.1074/jbc.M307250200; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yin JJ, 2010, CANCER RES, V70, P8662, DOI 10.1158/0008-5472.CAN-10-1435; Yin JJ, 2007, MOL CELL BIOL, V27, P7538, DOI 10.1128/MCB.00955-07; Yin JJ, 2014, CANCER RES, V74, P4306, DOI 10.1158/0008-5472.CAN-13-3233; Zagurovskaya M, 2009, ONCOGENE, V28, P1121, DOI 10.1038/onc.2008.461; Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685	55	45	46	2	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2019	38	35					6241	6255		10.1038/s41388-019-0873-8	http://dx.doi.org/10.1038/s41388-019-0873-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IU9RZ	31312026	Green Accepted			2022-12-17	WOS:000483919400001
J	Wang, Z; Kang, L; Zhang, HF; Huang, YY; Fang, L; Li, MH; Brown, PJ; Arrowsmith, CH; Li, JW; Wong, JM				Wang, Zhen; Kang, Li; Zhang, Huifang; Huang, Yuanyong; Fang, Lan; Li, Menghan; Brown, Peter J.; Arrowsmith, Cheryl H.; Li, Jiwen; Wong, Jiemin			AKT drives SOX2 overexpression and cancer cell stemness in esophageal cancer by protecting SOX2 from UBR5-mediated degradation	ONCOGENE			English	Article							TUMOR-INITIATING CELLS; UBIQUITIN LIGASE UBR5; SELF-RENEWAL; IN-VITRO; PROMOTES; TARGET; GROWTH; GENE; LUNG; PHOSPHORYLATION	As a transcription factor critical for embryonic and adult stem cell self-renewal and function, SOX2 gene amplification has been recognized as a driving factor for various cancers including esophageal cancer. SOX2 overexpression occurs more broadly in cancer than gene amplification, but the mechanism is poorly understood. Here we showed that in esophageal cancer cell lines the levels of SOX2 proteins are not directly correlated to the copy numbers of SOX2 genes and are strongly influenced by proteostasis. We showed that AKT is a major determinant for SOX2 overexpression and does so by protecting SOX2 from ubiquitin-dependent protein degradation. We identified UBR5 as a major ubiquitin E3 ligase that induces SOX2 degradation through ubiquitinating SOX2 at lysine 115. Phosphorylation of SOX2 at threonine 116 by AKT inhibits the interaction of UBR5 with SOX2 and thus stabilizes SOX2. We provided evidence that AKT inhibitor can effectively downregulate SOX2 and suppress esopheageal cancer cell proliferation and stemness. Taken together, our study provides new insight into the mechanism of SOX2 overexpression in cancer and evidence for targeting AKT as a potential therapeutic strategy for SOX2-positive cancers.	[Wang, Zhen; Kang, Li; Zhang, Huifang; Huang, Yuanyong; Fang, Lan; Li, Menghan; Li, Jiwen; Wong, Jiemin] East China Normal Univ, Fengxian Dist Cent Hosp ECNU Joint Ctr Translat M, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China; [Wang, Zhen; Kang, Li; Zhang, Huifang; Huang, Yuanyong; Fang, Lan; Li, Menghan; Li, Jiwen; Wong, Jiemin] East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China; [Brown, Peter J.; Arrowsmith, Cheryl H.] Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L7, Canada; [Wong, Jiemin] State Key Lab Oncogene & Related Genes, Shanghai, Peoples R China; [Fang, Lan] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Shanghai 200072, Peoples R China; [Fang, Lan] Tongji Univ, Sch Life Sci & Technol, Shanghai 200072, Peoples R China	East China Normal University; East China Normal University; University of Toronto; Structural Genomics Consortium; Tongji University; Tongji University	Li, JW; Wong, JM (corresponding author), East China Normal Univ, Fengxian Dist Cent Hosp ECNU Joint Ctr Translat M, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China.; Li, JW; Wong, JM (corresponding author), East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China.; Wong, JM (corresponding author), State Key Lab Oncogene & Related Genes, Shanghai, Peoples R China.	jwli@bio.ecnu.edu.cn; jmweng@bio.ecnu.edu.cn	Wang, Zhen/GYI-9962-2022	Wang, Zhen/0000-0002-1215-1661; Wong, Jiemin/0000-0002-5311-842X; Arrowsmith, Cheryl/0000-0002-4971-3250; Brown, Peter/0000-0002-8454-0367	National Natural Science Foundation of China [81530078]; Ministry of Science and Technology of China [2017YFA0504201, 2015CB910402]; State Key Laboratory of Oncogenes and Related Genes [90-17-05]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); State Key Laboratory of Oncogenes and Related Genes	We thank Dr. Shimin Zhao from Fudan University for providing expression plasmids for UBR5C, Dr. Tianbang Kang from SUN YAT-SEN University (Guangzhou, China) for providing K30, K140, K410 and K520 cells and Dr. Zhihua Liu at Cancer Hospital Chinese Academy of Medical Sciences (Beijing, China) for providing K70, K150, K450 and K510 cells. We also thank members of Wong's lab for valuable discussion. This study is supported by grants from the National Natural Science Foundation of China (81530078), the Ministry of Science and Technology of China (2017YFA0504201 and 2015CB910402 to J.W.) and the Grants from the State Key Laboratory of Oncogenes and Related Genes (No. 90-17-05).	Alonso MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026740; Arnold K, 2011, CELL STEM CELL, V9, P317, DOI 10.1016/j.stem.2011.09.001; Barsyte-Lovejoy D, 2014, P NATL ACAD SCI USA, V111, P12853, DOI 10.1073/pnas.1407358111; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Basu-Roy U, 2012, ONCOGENE, V31, P2270, DOI 10.1038/onc.2011.405; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Callaghan MJ, 1998, ONCOGENE, V17, P3479, DOI 10.1038/sj.onc.1202249; Cox JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062857; Fang L, 2014, MOL CELL, V55, P537, DOI 10.1016/j.molcel.2014.06.018; Fang XF, 2011, PROTEOMICS, V11, P921, DOI 10.1002/pmic.201000419; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Gen Y, 2013, CANCER SCI, V104, P810, DOI 10.1111/cas.12155; Gen Y, 2010, CANCER GENET CYTOGEN, V202, P82, DOI 10.1016/j.cancergencyto.2010.01.023; Gupta N, 2018, CANCERS, V10, DOI 10.3390/cancers10020041; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Hussenet T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008960; Ikushima H, 2011, J BIOL CHEM, V286, P41434, DOI 10.1074/jbc.M111.300863; Jeong CH, 2010, STEM CELLS, V28, P2141, DOI 10.1002/stem.540; Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805; Lefebvre V, 2007, INT J BIOCHEM CELL B, V39, P2195, DOI 10.1016/j.biocel.2007.05.019; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Liu KC, 2013, CELL STEM CELL, V12, P304, DOI 10.1016/j.stem.2013.01.007; Lu YX, 2014, CLIN CANCER RES, V20, P2631, DOI 10.1158/1078-0432.CCR-13-2348; Maier S, 2011, HUM PATHOL, V42, P1078, DOI 10.1016/j.humpath.2010.11.010; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Mayer IA, 2016, ANNU REV MED, V67, P11, DOI 10.1146/annurev-med-062913-051343; Meissner B, 2013, BLOOD, V121, P3161, DOI 10.1182/blood-2013-01-478834; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Ozen M, 2015, CANCER INVEST, V33, P251, DOI 10.3109/07357907.2015.1025407; Peltier J, 2011, STEM CELLS DEV, V20, P1153, DOI 10.1089/scd.2010.0130; Riggi N, 2010, GENE DEV, V24, P916, DOI 10.1101/gad.1899710; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Saunders DN, 2004, MOL CELL BIOL, V24, P7225, DOI 10.1128/MCB.24.16.7225-7234.2004; Shearer RF, 2015, MOL CANCER RES, V13, P1523, DOI 10.1158/1541-7786.MCR-15-0383; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Singh S, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-73; Tam WL, 2014, CANCER CELL, V26, P3, DOI 10.1016/j.ccr.2014.06.024; Vanner RJ, 2014, CANCER CELL, V26, P33, DOI 10.1016/j.ccr.2014.05.005; Wang H, 2018, METHODS MOL BIOL, V1692, P77, DOI 10.1007/978-1-4939-7401-6_7; Weina K, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001-1326-3-19; Wuebben EL, 2017, ONCOTARGET, V8, P44917, DOI 10.18632/oncotarget.16570; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Zhang HF, 2016, STEM CELLS, V34, P2040, DOI 10.1002/stem.2395; Zhang JQ, 2011, CELL RES, V21, P1723, DOI 10.1038/cr.2011.176	44	45	50	3	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5250	5264		10.1038/s41388-019-0790-x	http://dx.doi.org/10.1038/s41388-019-0790-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30894683				2022-12-17	WOS:000473025300010
J	Permata, TBM; Hagiwara, Y; Sato, H; Yasuhara, T; Oike, T; Gondhowiardjo, S; Held, KD; Nakano, T; Shibata, A				Permata, Tiara Bunga Mayang; Hagiwara, Yoshihiko; Sato, Hiro; Yasuhara, Takaaki; Oike, Takahiro; Gondhowiardjo, Soehartati; Held, Kathryn D.; Nakano, Takashi; Shibata, Atsushi			Base excision repair regulates PD-L1 expression in cancer cells	ONCOGENE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; STRAND BREAK REPAIR; MISMATCH-REPAIR; OXIDATIVE STRESS; NEOANTIGEN LOAD; PATHWAY CHOICE; DNA-DAMAGE; ASSOCIATION; DOCETAXEL; NIVOLUMAB	Programmed death-ligand 1 (PD-L1) is a key factor influencing cancer immunotherapy; however, the regulation of PD-L1 expression in cancer cells remains unclear, particularly regarding DNA damage, repair and its signalling. Herein, we demonstrate that oxidative DNA damage induced by exogenously applied hydrogen peroxide (H2O2) upregulates PD-L1 expression in cancer cells. Further, depletion of the base excision repair (BER) enzyme DNA glycosylase augments PD-L1 upregulation in response to H2O2. PD-L1 upregulation in BER-depleted cells requires ATR/Chkl kinase activities, demonstrating that PD-L1 upregulation is mediated by DNA damage signalling. Further analysis of The Cancer Genome Atlas revealed that the expression of PD-L1 is negatively correlated with that of the BER/single-strand break repair (SSBR) and tumours with low BER/SSBR gene expression show high microsatellite instability and neoantigen production. Hence, these results suggest that PD-L1 expression is regulated in cancer cells via the DNA damage signalling and neoantigen- interferon-gamma pathway under oxidative stress.	[Permata, Tiara Bunga Mayang; Hagiwara, Yoshihiko; Sato, Hiro; Oike, Takahiro; Nakano, Takashi] Gunma Univ, Grad Sch Med, Dept Radiat Oncol, Maebashi, Gunma 3718511, Japan; [Permata, Tiara Bunga Mayang; Gondhowiardjo, Soehartati] Dr Cipto Mangunkusumo Natl Gen Hosp, Dept Radiotherapy, Jakarta, Indonesia; [Yasuhara, Takaaki] Univ Tokyo, Grad Sch Med, Ctr Dis Biol & Integrat Med, Lab Mol Radiol,Bunkyo Ku, Tokyo 1138655, Japan; [Held, Kathryn D.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; [Held, Kathryn D.] Gunma Univ, Int Open Lab, Initiat Adv Res GIAR, Maebashi, Gunma 3718511, Japan; [Shibata, Atsushi] Gunma Univ, Grad Sch Med, Educ & Res Support Ctr, Maebashi, Gunma 3718511, Japan	Gunma University; University of Tokyo; Harvard University; Harvard Medical School; Massachusetts General Hospital; Gunma University; Gunma University	Shibata, A (corresponding author), Gunma Univ, Grad Sch Med, Educ & Res Support Ctr, Maebashi, Gunma 3718511, Japan.	shibata.at@gunma-u.ac.jp	Sato, Hiro/GWU-7659-2022; Shibata, Atsushi/AAX-1283-2021; Takaaki, Yasuhara/U-3345-2019	Shibata, Atsushi/0000-0001-8912-6977; Yasuhara, Takaaki/0000-0002-6719-5709; Permata, Tiara Bunga Mayang/0000-0002-5890-5545	Program of the network-type Joint Usage/Research Center for Radiation Disaster Medical Science of Hiroshima University; Nagasaki University; Fukushima Medical University; Ministry of Education, Culture, Sports, Science and Technology of Japan	Program of the network-type Joint Usage/Research Center for Radiation Disaster Medical Science of Hiroshima University; Nagasaki University; Fukushima Medical University; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by the Program of the network-type Joint Usage/Research Center for Radiation Disaster Medical Science of Hiroshima University, Nagasaki University and Fukushima Medical University. This work was also supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan for programs for Leading Graduate Schools, Cultivating Global Leaders in Heavy Ion Therapeutics and Engineering.	Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937; AQUILINA G, 1994, P NATL ACAD SCI USA, V91, P8905, DOI 10.1073/pnas.91.19.8905; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Caldecott KW, 2008, NAT REV GENET, V9, P619, DOI 10.1038/nrg2380; Chen BPC, 2012, CANCER LETT, V327, P103, DOI 10.1016/j.canlet.2011.12.004; Chen MF, 2016, ONCOTARGET, V7, P7913, DOI 10.18632/oncotarget.6861; Cortes-Ciriano I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15180; Eggermont AMM, 2018, NEW ENGL J MED, V378, P1789, DOI 10.1056/NEJMoa1802357; Ensminger M, 2014, J CELL BIOL, V206, P29, DOI 10.1083/jcb.201312078; Feng WR, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00634-0; Fiaschi Tania, 2012, Int J Cell Biol, V2012, P762825, DOI 10.1155/2012/762825; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hargadon KM, 2018, INT IMMUNOPHARMACOL, V62, P29, DOI 10.1016/j.intimp.2018.06.001; Howitt BE, 2015, JAMA ONCOL, V1, P1319, DOI 10.1001/jamaoncol.2015.2151; Hutter C, 2018, CELL, V173, P283, DOI 10.1016/j.cell.2018.03.042; Iwai Y, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0329-9; Karahalil B, 2012, HUM EXP TOXICOL, V31, P981, DOI 10.1177/0960327112444476; Kim ST, 2018, NAT MED, V24, P1449, DOI 10.1038/s41591-018-0101-z; Klein HL, 2002, MOL CELL, V9, P471, DOI 10.1016/S1097-2765(02)00493-8; Kumar B, 2008, CANCER RES, V68, P1777, DOI 10.1158/0008-5472.CAN-07-5259; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554; Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863; Maynard S, 2009, CARCINOGENESIS, V30, P2, DOI 10.1093/carcin/bgn250; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Mouw KW, 2018, BRIT J CANCER, V118, P933, DOI 10.1038/s41416-018-0017-x; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Qin Q, 2018, RADIAT RES, V190, P322, DOI 10.1667/RR15048.1; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Roger A, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1442166; Sato H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01883-9; Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015; Shen JF, 2018, NAT MED, V24, P556, DOI 10.1038/s41591-018-0012-z; Shibata A, 2017, MUTAT RES-FUND MOL M, V803, P51, DOI 10.1016/j.mrfmmm.2017.07.011; Shibata A, 2014, MOL CELL, V53, P7, DOI 10.1016/j.molcel.2013.11.003; Shin DS, 2017, CANCER DISCOV, V7, P188, DOI 10.1158/2159-8290.CD-16-1223; Strickland KC, 2016, ONCOTARGET, V7, P13587, DOI 10.18632/oncotarget.7277; Sunshine J, 2015, CURR OPIN PHARMACOL, V23, P32, DOI 10.1016/j.coph.2015.05.011; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tubbs A, 2017, CELL, V168, DOI 10.1016/j.cell.2017.01.002; UMAR A, 1994, J BIOL CHEM, V269, P14367; Vendetti FP, 2018, J CLIN INVEST, V128, P3926, DOI 10.1172/JCI96519; Wallace SS, 2012, CANCER LETT, V327, P73, DOI 10.1016/j.canlet.2011.12.038; Weren RDA, 2015, NAT GENET, V47, P668, DOI 10.1038/ng.3287	53	45	46	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4452	4466		10.1038/s41388-019-0733-6	http://dx.doi.org/10.1038/s41388-019-0733-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30755733				2022-12-17	WOS:000470240300002
J	Wang, WC; Yang, X; Dai, JL; Lu, Y; Zhang, J; Keller, ET				Wang, Wenchu; Yang, Xin; Dai, Jinlu; Lu, Yi; Zhang, Jian; Keller, Evan T.			Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; CELL-PROLIFERATION; FACTOR EGR-1; IN-VITRO; TUMOR; MICROENVIRONMENT; EXPRESSION; RECEPTOR; PROTEIN; DIFFERENTIATION	Bone is the most frequent site of prostate cancer (PCa) metastasis; however, little is known about the role of the most common cell in bone, the osteocyte (OCy), in cancer biology. In this study we explored the crosstalk between PCa cells and OCys to determine if it contributes to PCa progression. PCa cells induced OCys to promote PCa proliferation, migration and invasion. A chemokine screen revealed that PCa cell induced OCys to produce growth-derived factor 15 (GDF15). Knockdown of GDF15 in OCys demonstrated that PCa cells conferred the ability on OCys to promote PCa proliferation, migration and invasion through GDF15. Consistent with this finding was the observation that the GDF15 receptor, GFRAL, was expressed on multiple PCa cell lines. Transcription factor array screening of PCa cells exposed to OCys with or without knockdown of GDF15 revealed that GDF15 in OCys promoted early growth response 1 (EGR1) expression in the PCa cells. Knockdown of EGR1 expression in PCa cells revealed it was required for the OCy-derived GDF15-mediated induction of in vitro PCa cell proliferation, migration and invasion. Subcutaneous co-injection of PCa cells and OCys into mice revealed that OCys promoted tumor growth in vivo, which was diminished by knockdown of GDF15 in the OCys. Knockdown of GDF15 in the tibiae diminished growth of PCa cancer cells injected into the tibiae, which was accompanied by decreased tumor cell proliferation and EGR1 expression. These results shed light on a novel mechanism through which PCa cells educate OCys to promote progression of PCa bone metastasis. They also suggest that targeting of GDF15-based and EGR1-based signaling pathways should be further explored for their potential to diminish progression of PCa bone metastasis.	[Wang, Wenchu; Yang, Xin; Zhang, Jian] Guangxi Med Univ, Ctr Translat Med, Guangxi 530021, Peoples R China; [Wang, Wenchu; Yang, Xin; Dai, Jinlu; Keller, Evan T.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; [Wang, Wenchu; Yang, Xin; Zhang, Jian] Guangxi Med Univ, Sch Preclin Med, Guangxi, Peoples R China; [Wang, Wenchu; Yang, Xin; Zhang, Jian] Minist Educ, Key Lab Longev & Ageing Related Dis, Nanning, Peoples R China; [Lu, Yi; Zhang, Jian] Southern Univ Sci & Technol, Sch Med, Shenzhen, Guangdong, Peoples R China; [Keller, Evan T.] Univ Michigan, Biointerfaces Inst, Ann Arbor, MI 48109 USA	Guangxi Medical University; University of Michigan System; University of Michigan; Guangxi Medical University; Southern University of Science & Technology; University of Michigan System; University of Michigan	Keller, ET (corresponding author), Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA.; Keller, ET (corresponding author), Univ Michigan, Biointerfaces Inst, Ann Arbor, MI 48109 USA.	etkeller@umich.edu	ZHANG, JIAN/Q-6334-2018; Keller, Evan T/M-1446-2016; Lu, Yi/J-6746-2018; Dai, Jin/GVT-2414-2022	Keller, Evan T/0000-0002-7592-7535; Lu, Yi/0000-0002-1060-6925; Dai, Jin/0000-0003-3063-746X	NIH [R01-CA190554, P01-CA093900]; NSFC [81130046, 81773146, JCYJ20170412154619484]; NATIONAL CANCER INSTITUTE [R01CA190554, P01CA093900] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSFC(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH R01-CA190554, NIH P01-CA093900, NSFC Key Project 81130046, NSFC 81773146 and JCYJ20170412154619484.	Adamson E, 2003, CANCER BIOL THER, V2, P617; Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Arora S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-11-r166; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Baron V, 2003, ONCOGENE, V22, P4194, DOI 10.1038/sj.onc.1206560; Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224; Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320; Brown DA, 2006, CLIN CANCER RES, V12, P89, DOI 10.1158/1078-0432.CCR-05-1331; Bruzzese F, 2014, CANCER RES, V74, P3408, DOI 10.1158/0008-5472.CAN-13-2259; Bultynck G, 2016, BBA-REV CANCER, V1866, P121, DOI 10.1016/j.bbcan.2016.07.003; Compton JT, 2014, J BONE JOINT SURG AM, V96A, P1659, DOI 10.2106/JBJS.M.01096; Cui YX, 2016, ANTICANCER RES, V36, P1193; Dai JL, 2014, CLIN CANCER RES, V20, P617, DOI 10.1158/1078-0432.CCR-13-0839; Dai JL, 2010, CANCER RES, V70, P5014, DOI 10.1158/0008-5472.CAN-10-0100; Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012-1026; Delgado-Calle J, 2016, CANCER RES, V76, P1089, DOI 10.1158/0008-5472.CAN-15-1703; Deng XY, 2014, CANCER TREAT REV, V40, P730, DOI 10.1016/j.ctrv.2014.04.003; Emmerson PJ, 2017, NAT MED, V23, P1215, DOI 10.1038/nm.4393; Florkowska M, 2012, BMC MOL BIOL, V13, DOI 10.1186/1471-2199-13-8; Gartrell BA, 2015, EUR UROL, V68, P850, DOI 10.1016/j.eururo.2015.06.039; Gitenay D, 2009, FUTURE ONCOL, V5, P993, DOI [10.2217/fon.09.67, 10.2217/FON.09.67]; Hall CL, 2006, CANCER METAST REV, V25, P551, DOI 10.1007/s10555-006-9022-2; Han MH, 2013, TOXICOL LETT, V220, P157, DOI 10.1016/j.toxlet.2013.04.020; Hayes VM, 2006, CANCER EPIDEM BIOMAR, V15, P1223, DOI 10.1158/1055-9965.EPI-06-0063; Hensel J, 2016, UROLOGY, V92, P6, DOI 10.1016/j.urology.2015.12.039; Hinoi E, 2012, J BONE MINER RES, V27, P938, DOI 10.1002/jbmr.1538; Hsu JY, 2017, NATURE, V550, P255, DOI 10.1038/nature24042; Husaini Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043833; Kalajzic I, 2013, BONE, V54, P296, DOI 10.1016/j.bone.2012.09.040; Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014; Keller ET, 2001, CANCER METAST REV, V20, P333, DOI 10.1023/A:1015599831232; Korenchuk S, 2001, IN VIVO, V15, P163; KOUTSILIERIS M, 1993, ANTICANCER RES, V13, P443; Krishn SR, 2019, MATRIX BIOL, V77, P41, DOI 10.1016/j.matbio.2018.08.004; Languino LR, 2016, AM J TRANSL RES, V8, P2432; Li J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122249; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Ma JJ, 2009, J BIOL CHEM, V284, P34600, DOI 10.1074/jbc.M109.016246; Ma Y, 2016, ONCOL REP, V35, P3068, DOI 10.3892/or.2016.4641; Miftakhova R, 2016, CANCER RES, V76, P2453, DOI 10.1158/0008-5472.CAN-15-2340; Mullican SE, 2017, NAT MED, V23, P1150, DOI 10.1038/nm.4392; Ortiz A, 2012, RECENT RESULTS CANC, V192, P225, DOI 10.1007/978-3-642-21892-7_11; Ozen E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042717; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Parra E, 2013, ONCOL REP, V30, P911, DOI 10.3892/or.2013.2503; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Salah Z, 2007, CANCER RES, V67, P9835, DOI 10.1158/0008-5472.CAN-07-1886; Selander KS, 2007, CANCER EPIDEM BIOMAR, V16, P532, DOI 10.1158/1055-9965.EPI-06-0841; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Shin SY, 2010, MOL CANCER RES, V8, P507, DOI 10.1158/1541-7786.MCR-09-0454; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sottnik JL, 2015, CANCER RES, V75, P2151, DOI 10.1158/0008-5472.CAN-14-2493; Stern AR, 2012, BIOTECHNIQUES, V52, P361, DOI 10.2144/0000113876; Sun T, 2013, DIGEST DIS SCI, V58, P423, DOI 10.1007/s10620-012-2356-4; Tsai VWW, 2018, CELL METAB, V28, P353, DOI 10.1016/j.cmet.2018.07.018; Turner CJ, 2016, CURR OSTEOPOROS REP, V14, P170, DOI 10.1007/s11914-016-0323-2; Vanhara P, 2012, PROSTATE CANCER P D, V15, P320, DOI 10.1038/pcan.2012.6; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z; Yang LD, 2017, NAT MED, V23, P1158, DOI 10.1038/nm.4394; Yi JH, 2007, NEUROCHEM INT, V50, P1014, DOI 10.1016/j.neuint.2007.04.019; Zhang M, 2017, MOL CANCER RES, V15, P457, DOI 10.1158/1541-7786.MCR-16-0392; Zhang W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167222; Zhou JZ, 2016, ONCOGENE, V35, P5597, DOI 10.1038/onc.2016.101	66	45	49	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4540	4559		10.1038/s41388-019-0736-3	http://dx.doi.org/10.1038/s41388-019-0736-3			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30755731	Green Accepted			2022-12-17	WOS:000470240300008
J	Kumari, S; Srivastav, RK; Wilkesi, DW; Ross, T; Kim, S; Kowalski, J; Chatlal, S; Zhang, Q; Nayak, A; Guha, M; Fuchs, SY; Thomas, C; Chakrabarti, R				Kumari, Sushi; Srivastav, Ratnesh Kumar; Wilkesi, David W.; Ross, Taylor; Kim, Sabrina; Kowalski, Jules; Chatlal, Srinivas; Zhang, Qing; Nayak, Anupma; Guha, Manti; Fuchs, Serge Y.; Thomas, Christoforos; Chakrabarti, Rumela			Estrogen-dependent DLL1-mediated Notch signaling promotes luminal breast cancer	ONCOGENE			English	Article							STEM-CELLS; TARGETING NOTCH; RECEPTOR; HETEROGENEITY; ANGIOGENESIS; METASTASIS; SUBTYPES; MEDIATOR; PATHWAY; FATE	Aberrant Notch signaling is implicated in several cancers, including breast cancer. However, the mechanistic details of the specific receptors and function of ligand-mediated Notch signaling that promote breast cancer remains elusive. In our studies we show that DLL1, a Notch signaling ligand, is significantly overexpressed in ER alpha(+) luminal breast cancer. Intriguingly, DLL1 overexpression correlates with poor prognosis in ER alpha(+) luminal breast cancer, but not in other subtypes of breast cancer. In addition, this effect is specific to DLL1, as other Notch ligands (DLL3, JAGGED1, and JAGGED2) do not influence the clinical outcome of ER alpha(+) patients. Genetic studies show that DLL1-mediated Notch signaling in breast cancer is important for tumor cell proliferation, angiogenesis, and cancer stem cell function. Consistent with prognostic clinical data, we found the tumor-promoting function of DLL1 is exclusive to ER alpha(+) luminal breast cancer, as loss of DLL1 inhibits both tumor growth and lung metastasis of luminal breast cancer. Importantly, we find that estrogen signaling stabilizes DLL1 protein by preventing its proteasomal and lysososmal degradations. Moreover, estrogen inhibits ubiquitination of DLL1. Together, our results highlight an unexpected and novel subtype-specific function of DLL1 in promoting luminal breast cancer that is regulated by estrogen signaling. Our studies also emphasize the critical role of assessing subtype-specific mechanisms driving tumor growth and metastasis to generate effective subtype-specific therapeutics.	[Kumari, Sushi; Srivastav, Ratnesh Kumar; Wilkesi, David W.; Ross, Taylor; Kim, Sabrina; Kowalski, Jules; Chatlal, Srinivas; Guha, Manti; Fuchs, Serge Y.; Chakrabarti, Rumela] Univ Penn, Dept Biomed Sci, Sch Vet Med, Philadelphia, PA 19104 USA; [Zhang, Qing] Univ N Carolina, Dept Pathol & Lab Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Nayak, Anupma] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Hosp Univ Penn, Philadelphia, PA 19104 USA; [Thomas, Christoforos] Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Chakrabarti, R (corresponding author), Univ Penn, Dept Biomed Sci, Sch Vet Med, Philadelphia, PA 19104 USA.	rumela@vet.upenn.edu	ZHANG, QING/AGY-7972-2022; Chatla, Srinivas/AAA-9299-2020; Kumar, Sushil/AAF-1312-2019; Srivastav, Ratnesh/CAI-4994-2022	ZHANG, QING/0000-0002-6595-8995; Chatla, Srinivas/0000-0002-8509-8494; Kumar, Sushil/0000-0003-0547-745X; 	NCI NIH HHS [R01 CA092900] Funding Source: Medline; NIH HHS [T35 OD010919] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Andersson ER, 2014, NAT REV DRUG DISCOV, V13, P359, DOI 10.1038/nrd4252; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Bertucci Francois, 2008, J Biol, V7, P6, DOI 10.1186/jbiol67; Bray SJ, 2016, NAT REV MOL CELL BIO, V17, P722, DOI 10.1038/nrm.2016.94; Capaccione KM, 2013, CARCINOGENESIS, V34, P1420, DOI 10.1093/carcin/bgt127; Carroll JS, 2016, EUR J ENDOCRINOL, V175, pR41, DOI 10.1530/EJE-16-0124; Chakrabarti R, 2014, NAT CELL BIOL, V16; Chakrabarti R, 2018, SCIENCE, V360, P1421, DOI 10.1126/science.aan4153; Chakrabarti Rumela, 2015, Methods Mol Biol, V1267, P367, DOI 10.1007/978-1-4939-2297-0_18; Chakrabarti R, 2012, NAT CELL BIOL, V14, P1212, DOI 10.1038/ncb2607; Chakrabarti R, 2012, STEM CELLS, V30, P1496, DOI 10.1002/stem.1112; Chen L, 2012, BIOMATERIALS, V33, P1437, DOI 10.1016/j.biomaterials.2011.10.056; Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440; Choi YS, 2009, DEV BIOL, V329, P227, DOI 10.1016/j.ydbio.2009.02.032; Clarke R, 2015, MOL CELL ENDOCRINOL, V418, P220, DOI 10.1016/j.mce.2015.09.035; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785; Dikic I, 2017, ANNU REV BIOCHEM, V86, P193, DOI 10.1146/annurev-biochem-061516-044908; Doody RS, 2013, NEW ENGL J MED, V369, P341, DOI 10.1056/NEJMoa1210951; Dufraine J, 2008, ONCOGENE, V27, P5132, DOI 10.1038/onc.2008.227; Fessler E, 2013, CANCER LETT, V341, P97, DOI 10.1016/j.canlet.2012.10.015; Fisher R, 2013, BRIT J CANCER, V108, P479, DOI 10.1038/bjc.2012.581; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Huang YH, 2011, CANCER RES, V71, P6122, DOI 10.1158/0008-5472.CAN-10-4366; Kofler Natalie M, 2011, Genes Cancer, V2, P1106, DOI 10.1177/1947601911423030; Kwon YT, 2017, TRENDS BIOCHEM SCI, V42, P873, DOI 10.1016/j.tibs.2017.09.002; Li PP, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0479-5; Liu J, 2016, CRIT REV ONCOL HEMAT, V104, P21, DOI 10.1016/j.critrevonc.2016.05.010; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Miele L, 2006, CURR MOL MED, V6, P905, DOI 10.2174/156652406779010830; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; Moretti J, 2013, INT J MOL SCI, V14, P6359, DOI 10.3390/ijms14036359; Nandagopal N, 2018, CELL, V172, P869, DOI 10.1016/j.cell.2018.01.002; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Onitilo AA, 2009, CLIN MED RES, V7, P4, DOI 10.3121/cmr.2009.825; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Reedijk M, 2012, ADV EXP MED BIOL, V727, P241, DOI 10.1007/978-1-4614-0899-4_18; Rizzo P, 2008, CANCER RES, V68, P5226, DOI 10.1158/0008-5472.CAN-07-5744; Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022; Slemmons KK, 2017, MOL CANCER RES, V15, P1777, DOI 10.1158/1541-7786.MCR-17-0004; So JY, 2015, J STEROID BIOCHEM, V148, P111, DOI 10.1016/j.jsbmb.2014.12.013; Soares R, 2004, MOL ENDOCRINOL, V18, P2333, DOI 10.1210/me.2003-0362; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Thomas C, 2015, TRENDS ENDOCRIN MET, V26, P467, DOI 10.1016/j.tem.2015.06.007; Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093; van Es JH, 2012, NAT CELL BIOL, V14, P1099, DOI 10.1038/ncb2581; Volk-Draper LD, 2012, NEOPLASIA, V14, P926, DOI 10.1593/neo.12956; Wan LL, 2014, CANCER CELL, V26, P92, DOI 10.1016/j.ccr.2014.04.027; Wei YA, 2012, ONCOL REP, V27, P504, DOI 10.3892/or.2011.1536; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Xiao W, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0507-3; Yang F, 2016, INT J BIOL SCI, V12, P1568, DOI 10.7150/ijbs.16874; Yuan X, 2015, CANCER LETT, V369, P20, DOI 10.1016/j.canlet.2015.07.048; Zhang C, 2017, ONCOTARGET, V8, P33353, DOI 10.18632/oncotarget.16495	61	45	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2092	2107		10.1038/s41388-018-0562-z	http://dx.doi.org/10.1038/s41388-018-0562-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30442981	Green Published, hybrid			2022-12-17	WOS:000461822600007
J	Wang, C; Gu, YY; Zhang, EB; Zhang, K; Qin, N; Dai, JC; Zhu, M; Liu, J; Xie, KP; Jiang, Y; Guo, XJ; Liu, MX; Jin, GF; Ma, HX; Jiang, T; Yin, R; Xia, YK; Liu, L; Wang, SY; Shen, B; Huo, R; Xu, L; Sha, JH; Qu, B; Shen, HB; Hu, ZB				Wang, Cheng; Gu, Yayun; Zhang, Erbao; Zhang, Kai; Qin, Na; Dai, Juncheng; Zhu, Meng; Liu, Jia; Xie, Kaipeng; Jiang, Yue; Guo, Xuejiang; Liu, Mingxi; Jin, Guangfu; Ma, Hongxia; Jiang, Tao; Yin, Rong; Xia, Yankai; Liu, Li; Wang, Shouyu; Shen, Bin; Huo, Ran; Xu, Lin; Sha, Jiahao; Qu, Bin; Shen, Hongbing; Hu, Zhibin			A cancer-testis non-coding RNA LIN28B-AS1 activates driver gene LIN28B by interacting with IGF2BP1 in lung adenocarcinoma	ONCOGENE			English	Article							DIFFERENTIAL EXPRESSION ANALYSIS; COPY NUMBER ANALYSIS; INHIBITOR; REGULATOR; HALLMARKS; PACKAGE; PROTEIN; GROWTH	Our previous work found cancer-testis (CT) genes as a new source of epi-driver candidates of cancer. LIN28B was a CT gene, but the "driver" ability and the activation mechanism in lung adenocarcinoma (LUAD) remain unclear. We observed that LIN28B expression was restricted in testis. It was re-activated in LUAD patients without known genomic alterations in oncogenes and was related to poorer survival. In vitro and In vivo experiments confirmed that the activation of LIN28B could promote the proliferation and metastasis of LUAD cells and can influence cell cycle, DNA damage repair, and genome instability. In addition to the known let-7-LIN28B regulation loop, our results further revealed a let-7-independent Cis-regulator of LIN28B: LIN28B-ASI. LIN28B-ASI is a CT long non-coding RNA (CT-lncRNA). It altered the messenger RNA stability of LIN28B by directly interacting with another CT protein IGF2BP1 but not with LIN28B and constituted a novel regulation network. In sum, we identify that LIN28B is an "epi-driver" of LUAD and clarify a new lncRNA-activated mechanism of LIN28B, which provide new candidate targets for precise anticancer therapy in the future.	[Wang, Cheng; Gu, Yayun; Zhang, Erbao; Zhang, Kai; Qin, Na; Dai, Juncheng; Zhu, Meng; Liu, Jia; Xie, Kaipeng; Jiang, Yue; Guo, Xuejiang; Liu, Mingxi; Jin, Guangfu; Ma, Hongxia; Jiang, Tao; Shen, Bin; Huo, Ran; Sha, Jiahao; Shen, Hongbing; Hu, Zhibin] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 211166, Jiangsu, Peoples R China; [Wang, Cheng; Gu, Yayun; Zhang, Erbao; Zhang, Kai; Qin, Na; Dai, Juncheng; Zhu, Meng; Liu, Jia; Xie, Kaipeng; Jiang, Yue; Jin, Guangfu; Ma, Hongxia; Jiang, Tao; Shen, Hongbing; Hu, Zhibin] Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Ctr Global Hlth, Nanjing 211166, Jiangsu, Peoples R China; [Wang, Cheng; Gu, Yayun; Zhang, Erbao; Zhang, Kai; Qin, Na; Dai, Juncheng; Zhu, Meng; Liu, Jia; Xie, Kaipeng; Jiang, Yue; Jin, Guangfu; Ma, Hongxia; Jiang, Tao; Shen, Hongbing; Hu, Zhibin] Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China; [Wang, Cheng] Nanjing Med Univ, Sch Biomed Engn & Informat, Dept Bioinformat, Nanjing 211166, Jiangsu, Peoples R China; [Yin, Rong; Xu, Lin] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Collaborat Innovat Ctr Canc Personalized, Jiangsu Key Lab Mol & Translat Canc Res, Nanjing 210009, Jiangsu, Peoples R China; [Xia, Yankai; Wang, Shouyu] Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Dept Mol Cell Biol & Toxicol,Sch Publ Hlth, Nanjing 211166, Jiangsu, Peoples R China; [Liu, Li] Nanjing Med Univ, Digest Endoscopy Ctr, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China; [Qu, Bin] Saarland Univ, Sch Med, CIPMM, Dept Biophys, Saarbrucken, Germany	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Saarland University	Shen, HB; Hu, ZB (corresponding author), Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 211166, Jiangsu, Peoples R China.; Shen, HB; Hu, ZB (corresponding author), Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Ctr Global Hlth, Nanjing 211166, Jiangsu, Peoples R China.; Shen, HB; Hu, ZB (corresponding author), Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China.	hbshen@njmu.edu.cn; zhibin_hu@njmu.edu.cn	Shen, Bin/ABD-5084-2021; Guo, Xuejiang/J-9600-2014	Shen, Bin/0000-0002-8946-8448; Shen, Hongbing/0000-0002-2581-5906; Qin, Na/0000-0001-6878-9464; Liu, Mingxi/0000-0001-6499-7899; Ma, Hongxia/0000-0002-9821-6955; Xu, Lin/0000-0002-2153-4840; Guo, Xuejiang/0000-0002-0475-5705; zhang, erbao/0000-0002-5752-7976	Science Fund for Creative Research Groups of the National Natural Science Foundation of China [81521004]; State Key Program of National Natural Science of China [31530047]; National Key Research and Development Program of China [2017YFC0907905]; Young Scientists Fund of the National Natural Science Foundation of China [81703295, 81702266]; National Key Basic Research Program Grant [2015CB943003]; Ten Thousand Talent Program; Natural Science Foundation of Jiangsu Province [BK20160046]; Priority Academic Program for the Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine); Top-notch Academic Programs Project of Jiangsu Higher Education Institutions [PPZY2015A067]; Jiangsu Specially-Appointed Professor project	Science Fund for Creative Research Groups of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Program of National Natural Science of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Young Scientists Fund of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Basic Research Program Grant(National Basic Research Program of China); Ten Thousand Talent Program; Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Priority Academic Program for the Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine); Top-notch Academic Programs Project of Jiangsu Higher Education Institutions; Jiangsu Specially-Appointed Professor project	We thank the TCGA project for use of the multiomics data of LUAD samples, and the Genotype-Tissue Expression (GTEx) project for use of the expression abundance of multiple normal tissues. This work was supported by Science Fund for Creative Research Groups of the National Natural Science Foundation of China (81521004), the State Key Program of National Natural Science of China (31530047), National Key Research and Development Program of China (2017YFC0907905), the Young Scientists Fund of the National Natural Science Foundation of China (81703295, 81702266), the National Key Basic Research Program Grant (2015CB943003), the Ten Thousand Talent Program, Jiangsu Specially-Appointed Professor project, Natural Science Foundation of Jiangsu Province (BK20160046), the Priority Academic Program for the Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine), and Top-notch Academic Programs Project of Jiangsu Higher Education Institutions (PPZY2015A067).	Alajez NM, 2012, ONCOTARGET, V3, P1641; Ali PSS, 2012, FEBS LETT, V586, P3986, DOI 10.1016/j.febslet.2012.09.034; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anders S, 2013, NAT PROTOC, V8, P1765, DOI 10.1038/nprot.2013.099; Araujo AN, 2014, J CLIN ENDOCR METAB, V99, pE1104, DOI 10.1210/jc.2013-2993; Battistelli C, 2017, ONCOGENE, V36, P942, DOI 10.1038/onc.2016.260; Beachy SH, 2012, BLOOD, V120, P1048, DOI 10.1182/blood-2012-01-401760; Bergethon K, 2012, J CLIN ONCOL, V30, P863, DOI 10.1200/JCO.2011.35.6345; Busch B, 2016, NUCLEIC ACIDS RES, V44, P3845, DOI 10.1093/nar/gkw099; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Cuddihy AR, 2003, INT REV CYTOL, V222, P99; Darbre PD, 2014, J APPL TOXICOL, V34, P925, DOI 10.1002/jat.3027; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Drilon A, 2013, CANCER DISCOV, V3, P630, DOI 10.1158/2159-8290.CD-13-0035; Enright AJ, 2004, GENOME BIOL, V5; Fuentes-Mattei E, 2014, JNCI-J NATL CANCER I, P106; Gong XQ, 2017, CANCER CELL, V32, P761, DOI 10.1016/j.ccell.2017.11.006; Hu XW, 2014, CANCER CELL, V26, P344, DOI 10.1016/j.ccr.2014.07.009; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Kalb R, 2006, GENOME DYN, V1, P218, DOI 10.1159/000092510; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Khanam Tasneem, 2006, RNA Biol, V3, P170; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Leung ELH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014062; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Molenaar JJ, 2012, NAT GENET, V44, P1199, DOI 10.1038/ng.2436; Morris KV, 2014, NAT REV GENET, V15, P423, DOI 10.1038/nrg3722; Nguyen LH, 2014, CANCER CELL, V26, P248, DOI 10.1016/j.ccr.2014.06.018; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pineda CT, 2015, CELL, V160, P715, DOI 10.1016/j.cell.2015.01.034; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Roos M, 2016, ACS CHEM BIOL, V11, P2773, DOI 10.1021/acschembio.6b00232; Shyh-Chang N, 2013, CELL STEM CELL, V12, P395, DOI 10.1016/j.stem.2013.03.005; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Thornton JE, 2012, TRENDS CELL BIOL, V22, P474, DOI 10.1016/j.tcb.2012.06.001; Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10499; Watkins J, 2015, CANCER DISCOV, V5, P488, DOI 10.1158/2159-8290.CD-14-1092; Yamada K, 2013, MOL CELL, V49, P922, DOI 10.1016/j.molcel.2012.12.023; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang M, 2013, J PROTEOME RES, V12, P5260, DOI 10.1021/pr400476a	45	45	45	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1611	1624		10.1038/s41388-018-0548-x	http://dx.doi.org/10.1038/s41388-018-0548-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30353165				2022-12-17	WOS:000460423800003
J	Stamm, H; Klingler, F; Grossjohann, EM; Muschhammer, J; Vettorazzi, E; Heuser, M; Mock, U; Thol, F; Vohwinkel, G; Latuske, E; Bokemeyer, C; Kischel, R; Dos Santos, C; Stienen, S; Friedrich, M; Lutteropp, M; Nagorsen, D; Wellbrock, J; Fiedler, W				Stamm, Hauke; Klingler, Felix; Grossjohann, Eva-Maria; Muschhammer, Jana; Vettorazzi, Eik; Heuser, Michael; Mock, Ulrike; Thol, Felicitas; Vohwinkel, Gabi; Latuske, Emily; Bokemeyer, Carsten; Kischel, Roman; Dos Santos, Cedric; Stienen, Sabine; Friedrich, Matthias; Lutteropp, Michael; Nagorsen, Dirk; Wellbrock, Jasmin; Fiedler, Walter			Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option	ONCOGENE			English	Article							CELL-ENGAGING ANTIBODY; CD8 T-CELLS; POLIOVIRUS RECEPTOR; NECTIN-2 CD112; TIGIT; CD155; DNAM-1; EXPRESSION; CANCER; IDENTIFICATION	Immune checkpoints are promising targets in cancer therapy. Recently, poliovirus receptor (PVR) and poliovirus receptor-related 2 (PVRL2) have been identified as novel immune checkpoints. In this investigation we show that acute myeloid leukemia (AML) cell lines and AML patient samples highly express the T-cell immunoreceptor with Ig and ITIM domains (TIGIT) ligands PVR and PVRL2. Using two independent patient cohorts, we could demonstrate that high PVR and PVRL2 expression correlates with poor outcome in AML. We show for the first time that antibody blockade of PVR or PVRL2 on AML cell lines or primary AML cells or TIGIT blockade on immune cells increases the anti-leukemic effects mediated by PBMCs or purified CD3(+) cells in vitro. The cytolytic activity of the BiTE (R) antibody construct AMG 330 against leukemic cells could be further enhanced by blockade of the TIGIT-PVR/PVRL2 axis. This increased immune reactivity is paralleled by augmented secretion of Granzyme B by immune cells. Employing CRISPR/Cas9-mediated knockout of PVR and PVRL2 in MV4-11 cells, the cytotoxic effects of antibody blockade could be recapitulated in vitro. In NSG mice reconstituted with human T cells and transplanted with either MV4-11 PVR/PVRL2 knockout or wildtype cells, prolonged survival was observed for the knockout cells. This survival benefit could be further extended by treating the mice with AMG 330. Therefore, targeting the TIGIT-PVR/PVRL2 axis with blocking antibodies might represent a promising future therapeutic option in AML.	[Stamm, Hauke; Klingler, Felix; Grossjohann, Eva-Maria; Muschhammer, Jana; Vohwinkel, Gabi; Latuske, Emily; Bokemeyer, Carsten; Wellbrock, Jasmin; Fiedler, Walter] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hubertus Wald Univ Canc Ctr, Hamburg, Germany; [Vettorazzi, Eik] Univ Med Ctr Hamburg Eppendorf, Dept Med Biometry & Epidemiol, Hamburg, Germany; [Heuser, Michael; Thol, Felicitas] Hannover Med Sch, Hematol Hemostasis Oncol & Stem Cell Transplantat, Hannover, Germany; [Mock, Ulrike] Univ Med Ctr Hamburg Eppendorf, Res Dept Cell & Gene Therapy, Clin Stem Cell Transplantat, Hamburg, Germany; [Kischel, Roman; Stienen, Sabine; Friedrich, Matthias; Lutteropp, Michael] Amgen Res Munich GmbH, Munich, Germany; [Dos Santos, Cedric] Amgen Inc, Oncol Biomarkers & Early Clin Dev, San Francisco, CA USA; [Nagorsen, Dirk] Amgen Inc, Global Clin Dev, Thousand Oaks, CA USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf; Amgen; Amgen Research Munich GmbH; Amgen; Amgen	Fiedler, W (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hubertus Wald Univ Canc Ctr, Hamburg, Germany.	fiedler@uke.de	Heuser, Michael/S-2363-2017; Vettorazzi, Eik/B-8130-2019	Heuser, Michael/0000-0001-5318-9044; Vettorazzi, Eik/0000-0002-3737-6402; Fiedler, Walter/0000-0003-0275-8803	Lieselotte Beutel Stiftung; AMGEN Inc.	Lieselotte Beutel Stiftung; AMGEN Inc.(Amgen)	We gratefully thank Dr. Daniela Pende (IRCCS AOU San Martino-IST, Genoa, Italy) for scientific discussion and provision of the anti-PVRL2 L14 antibody. We gratefully acknowledge Prof. E. Tolosa of the Institute of Immunology, University Medical Center Hamburg-Eppendorf, Germany, for fruitful scientific discussions and technical support. We are grateful to Prof. C. Hagel, Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Germany, for scientific discussions. We would like to thank Dr. Malte Mohme for the scientific discussions and technical support. We would like to thank the members of the Center for Transfusion Medicine for providing buffy coats from healthy donors, the members of the Flow Cytometry UCCH Core Facility for sorting of the CRISPR/Cas9-generated double-knockout cells and the members of the Animal Facility for technical assistance and managing the mouse colonies, all located at the University Medical Center Hamburg-Eppendorf, Germany. The authors thank Prof. R. Schlenk (University Hospital Ulm, Germany) and all participating study centers for providing clinical data on study patients. This work was funded in part by the Lieselotte Beutel Stiftung and by AMGEN Inc.	Ahmadzadeh M, 2009, BLOOD, V114, P1537, DOI 10.1182/blood-2008-12-195792; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Callahan MK, 2013, J LEUKOCYTE BIOL, V94, P41, DOI 10.1189/jlb.1212631; Carlsten M, 2009, J IMMUNOL, V183, P4921, DOI 10.4049/jimmunol.0901226; Cella M, 2010, EUR J IMMUNOL, V40, P949, DOI 10.1002/eji.200940234; Chan CJ, 2014, NAT IMMUNOL, V15, P431, DOI 10.1038/ni.2850; Dao T, 2015, NAT BIOTECHNOL, V33, P1079, DOI 10.1038/nbt.3349; DAVER N, 2017, BLOOD S1, V0130; FREISTADT MS, 1993, VIROLOGY, V195, P798, DOI 10.1006/viro.1993.1433; Friedrich M, 2014, MOL CANCER THER, V13, P1549, DOI 10.1158/1535-7163.MCT-13-0956; Gerhardt T, 2015, CARDIOVASC RES, V107, P321, DOI 10.1093/cvr/cvv147; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Inozume T, 2016, J INVEST DERMATOL, V136, P255, DOI 10.1038/JID.2015.404; Johnston RJ, 2014, CANCER CELL, V26, P923, DOI 10.1016/j.ccell.2014.10.018; Kohnke T, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0213-6; Kong YX, 2016, CLIN CANCER RES, V22, P3057, DOI 10.1158/1078-0432.CCR-15-2626; Krupka C, 2016, LEUKEMIA, V30, P484, DOI 10.1038/leu.2015.214; Krupka C, 2014, BLOOD, V123, P356, DOI 10.1182/blood-2013-08-523548; Kurtulus S., 2014, J IMMUNOTHERAPY C S3, V2, pO13, DOI DOI 10.1186/2051-1426-2-S3-O13; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Laszlo GS, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.68; Le Mercier I, 2014, CANCER RES, V74, P1933, DOI 10.1158/0008-5472.CAN-13-1506; Levin SD, 2011, EUR J IMMUNOL, V41, P902, DOI 10.1002/eji.201041136; Li M, 2014, J BIOL CHEM, V289, P17647, DOI 10.1074/jbc.M114.572420; Liu S, 2013, CELL DEATH DIFFER, V20, P456, DOI 10.1038/cdd.2012.141; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236; Morse MA, 2015, VACCINE, V33, P7377, DOI 10.1016/j.vaccine.2015.10.057; Nishiwada S, 2015, ANTICANCER RES, V35, P2287; NOBIS P, 1985, J GEN VIROL, V66, P2563, DOI 10.1099/0022-1317-66-12-2563; Offner S, 2006, MOL IMMUNOL, V43, P763, DOI 10.1016/j.molimm.2005.03.007; Pende D, 2005, MOL IMMUNOL, V42, P463, DOI 10.1016/j.molimm.2004.07.028; RAVANDI F, 2017, BLOOD S1, V130; Schlenk RF, 2011, BLOOD, V118, P38, DOI 10.1182/blood.V118.21.80.80; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Sloan KE, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-73; Stanietsky N, 2009, P NATL ACAD SCI USA, V106, P17858, DOI 10.1073/pnas.0903474106; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Verhaak RGW, 2009, HAEMATOL-HEMATOL J, V94, P131, DOI 10.3324/haematol.13299; Yang H, 2014, LEUKEMIA, V28, P1280, DOI 10.1038/leu.2013.355; Yu X, 2009, NAT IMMUNOL, V10, P48, DOI 10.1038/ni.1674; Zhou Q, 2011, BLOOD, V117, P4501, DOI 10.1182/blood-2010-10-310425; Zhu YW, 2016, J EXP MED, V213, P167, DOI 10.1084/jem.20150785; Zugmaier G, 2015, MOL IMMUNOL, V67, P58, DOI 10.1016/j.molimm.2015.02.033	47	45	50	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2018	37	39					5269	5280		10.1038/s41388-018-0288-y	http://dx.doi.org/10.1038/s41388-018-0288-y			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV0NW	29855615	Green Published, hybrid			2022-12-17	WOS:000445759700002
J	Reebye, V; Huang, KW; Lin, V; Jarvis, S; Cutilas, P; Dorman, S; Ciriello, S; Andrikakou, P; Voutila, J; Saetrom, P; Mintz, PJ; Reccia, I; Rossi, JJ; Huber, H; Habib, R; Kostomitsopoulos, N; Blakey, DC; Habib, NA				Reebye, Vikash; Huang, Kai-Wen; Lin, Vivian; Jarvis, Sheba; Cutilas, Pedro; Dorman, Stephanie; Ciriello, Simona; Andrikakou, Pinelopi; Voutila, Jon; Saetrom, Pal; Mintz, Paul J.; Reccia, Isabella; Rossi, John J.; Huber, Hans; Habib, Robert; Kostomitsopoulos, Nikos; Blakey, David C.; Habib, Nagy A.			Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer	ONCOGENE			English	Article							CCAAT/ENHANCER-BINDING-PROTEIN; HUMAN HEPATOCELLULAR-CARCINOMA; C/EBP-ALPHA; TRANSCRIPTION FACTORS; IN-VIVO; PROLIFERATION; EXPRESSION; FIBROSIS; MORTALITY; DISEASE	Liver diseases are a growing epidemic worldwide. If unresolved, liver fibrosis develops and can lead to cirrhosis and clinical decompensation. Around 5% of cirrhotic liver diseased patients develop hepatocellular carcinoma (HCC), which in its advanced stages has limited therapeutic options and negative survival outcomes. CEPBA is a master regulator of hepatic function where its expression is known to be suppressed in many forms of liver disease including HCC. Injection of MTL-CEBPA, a small activating RNA oligonucleotide therapy (CEBPA-51) formulated in liposomal nanoparticles (NOV340- SMARTICLES) upregulates hepatic CEBPA expression. Here we show how MTL-CEBPA therapy promotes disease reversal in rodent models of cirrhosis, fibrosis, hepatosteatosis, and significantly reduces tumor burden in cirrhotic HCC. Restoration of liver function markers were observed in a carbon-tetrachloride-induced rat model of fibrosis following 2 weeks of MTL-CEBPA therapy. At 14 weeks, animals showed reduction in ascites and enhanced survival rates. MTLCEBPA reversed changes associated with hepatosteatosis in non-alcoholic methionine and cholic-deficient diet-induced steaotic liver disease. In diethylnitrosamine induced cirrhotic HCC rats, MTL-CEBPA treatment led to a significant reduction in tumor burden. The data included here and the rapid adoption of MTL-CEBPA into a Phase 1 study may lead to new therapeutic oligonucleotides for undruggable diseases.	[Reebye, Vikash; Dorman, Stephanie; Andrikakou, Pinelopi; Mintz, Paul J.; Reccia, Isabella; Habib, Nagy A.] Imperial Coll London, Dept Surg, London, England; [Huang, Kai-Wen; Lin, Vivian] Natl Taiwan Univ, Dept Surg & Hepatitis Res, Taipei, Taiwan; [Huang, Kai-Wen; Lin, Vivian] Natl Taiwan Univ, Grad Inst Clin Med, Taipei, Taiwan; [Jarvis, Sheba] Imperial Coll London, Dept Surg & Canc, London, England; [Cutilas, Pedro] Queen Mary Univ London, Barts Canc Inst, Cell Signalling & Prote Grp, Ctr Haematooncol, London, England; [Ciriello, Simona; Voutila, Jon; Habib, Robert; Blakey, David C.] MiNA Therapeut Ltd, London, England; [Saetrom, Pal] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, Trondheim, Norway; [Saetrom, Pal] Norwegian Univ Sci & Technol, Dept Comp & Informat Sci, Trondheim, Norway; [Rossi, John J.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol & Cellular Biol, Duarte, CA USA; [Huber, Hans] BioTD Strategies LLC, Lansdale, PA USA; [Kostomitsopoulos, Nikos] Biomed Res Fdn Acad Athens, Ctr Clin Expt Surg & Translat Res, Athens, Greece	Imperial College London; National Taiwan University; National Taiwan University; Imperial College London; University of London; Queen Mary University London; Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); City of Hope; Beckman Research Institute of City of Hope; Academy of Athens	Reebye, V (corresponding author), Imperial Coll London, Dept Surg, London, England.	v.reebye@ic.ac.uk; nagy.habib@ic.ac.uk	Reccia, Isabella/GXZ-6729-2022; Sætrom, Pål/AAH-1216-2019	Sætrom, Pål/0000-0001-8142-7441; Rodriguez Cutillas, Pedro/0000-0002-3426-2274; Reccia, Isabella/0000-0003-1194-8828; Voutila, Jon/0000-0001-7193-2110; HUANG, KAI-WEN/0000-0001-6375-8714; Andrikakou, Dr Pinelopi/0000-0002-3955-7995; Ciriello, Simona/0000-0002-5547-4778	MiNA Therapeutics; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042552] Funding Source: NIH RePORTER	MiNA Therapeutics; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded by MiNA Therapeutics.	Allen AM, 2016, HEPATOLOGY, V64, P2165, DOI 10.1002/hep.28812; Bader Andreas G., 2012, Frontiers in Genetics, V3, P120, DOI 10.3389/fgene.2012.00120; Ee HT, 2005, CANCER RES, V65, P10330; Ekstedt M, 2015, HEPATOLOGY, V61, P1547, DOI 10.1002/hep.27368; Ge PS, 2016, NEW ENGL J MED, V375, P767, DOI 10.1056/NEJMra1504367; Hong IH, 2014, J BIOL CHEM, V289, P1106, DOI 10.1074/jbc.M113.526780; Inoue Y, 2004, J BIOL CHEM, V279, P44740, DOI 10.1074/jbc.M405177200; Lu GD, 2010, GASTROENTEROLOGY, V139, P632, DOI 10.1053/j.gastro.2010.03.051; Mei S, 2007, HEPATOL RES, V37, P531, DOI 10.1111/j.1872-034X.2007.00074.x; Nerlov C, 2007, TRENDS CELL BIOL, V17, P318, DOI 10.1016/j.tcb.2007.07.004; Portnoy V, 2016, CELL RES, V26, P320, DOI 10.1038/cr.2016.22; Portnoy V, 2011, WIRES RNA, V2, P748, DOI 10.1002/wrna.90; Reebye V, 2014, HEPATOLOGY, V59, P216, DOI 10.1002/hep.26669; Rodrigueza WV, 2014, CANCER CHEMOTH PHARM, V74, P151, DOI 10.1007/s00280-014-2476-y; Shi YC, 2013, DIGEST LIVER DIS, V45, P844, DOI 10.1016/j.dld.2013.03.013; Starley BQ, 2010, HEPATOLOGY, V51, P1820, DOI 10.1002/hep.23594; Tao LL, 2012, APOPTOSIS, V17, P492, DOI 10.1007/s10495-012-0700-y; Tomizawa M, 2003, ANTICANCER RES, V23, P351; Voutila J, 2017, MOL THER, V25, P2705, DOI 10.1016/j.ymthe.2017.07.018; Watkins PJ, 1996, CANCER RES, V56, P1063; Xu L, 2001, CANCER RES, V61, P3176	21	45	48	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3216	3228		10.1038/s41388-018-0126-2	http://dx.doi.org/10.1038/s41388-018-0126-2			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29511346	Green Submitted, hybrid, Green Accepted			2022-12-17	WOS:000435526600003
J	Chen, ZZ; Gao, YF; Yao, LT; Liu, YT; Huang, L; Yan, ZY; Zhao, WS; Zhu, PP; Weng, HB				Chen, Zhenzhen; Gao, Yanfeng; Yao, Lintong; Liu, Yating; Huang, Lan; Yan, Zhongyi; Zhao, Wenshan; Zhu, Pingping; Weng, Haibo			LncFZD6 initiates Wnt/beta-catenin and liver TIC self-renewal through BRG1-mediated FZD6 transcriptional activation	ONCOGENE			English	Article							CANCER STEM-CELLS; SIDE POPULATION; WNT; GENE; MECHANISMS	Liver tumor-initiating cells (TICs), the drivers for liver tumorigenesis, accounts for liver tumor initiation, metastasis, drug resistance and relapse. Wnt/beta-catenin signaling pathway emerges as a critical modulator in liver TIC self-renewal. However, the molecular mechanism of Wnt/beta-catenin initiation in liver tumorigenesis and liver TICs is still elusive. Here, we examined the expression pattern of 10 Wnt receptors (FZD1-FZD10), and found only FZD6 is overexpressed along with liver tumorigenesis. What's more, a divergent lncRNA of FZD6, termed lncFZD6, is also highly expressed in liver cancer and liver TICs. LncFZD6 drives liver TIC self-renewal and tumor initiation capacity through FZD6-dependent manner. LncFZD6 interacts with BRG1-embedded SWI/SNF complex and recruits it to FZD6 promoter, and thus drives the transcriptional initiation of FZD6 by chromatin remodeling. WNT5A, a ligand of FZD6, is highly expressed in liver nonTICs and drives the self-renewal of liver TICs through lncFZD6-BRG1-FZD6-dependent manner. Through FZD6 transcriptional regulation in cis, lncFZD6 activates Wnt/beta-catenin signaling in liver TICs. LncFZD6-BRG1-Wnt5A/beta-catenin pathway can serve as a target for liver TIC elimination. Altogether, lncFZD6 promotes Wnt/beta-catenin activation and liver TIC self-renewal through BRG1-dependent FZD6 expression.	[Chen, Zhenzhen; Gao, Yanfeng; Yao, Lintong; Liu, Yating; Yan, Zhongyi; Zhao, Wenshan; Zhu, Pingping; Weng, Haibo] Zhengzhou Univ, Sch Life Sci, Zhengzhou 450001, Henan, Peoples R China; [Gao, Yanfeng] Collaborat Innovat Ctr New Drug Res & Safety Eval, Zhengzhou 450001, Henan, Peoples R China; [Huang, Lan] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China	Zhengzhou University; Zhengzhou University	Chen, ZZ; Zhu, PP; Weng, HB (corresponding author), Zhengzhou Univ, Sch Life Sci, Zhengzhou 450001, Henan, Peoples R China.	chenzz2015@zzu.edu.cn; pingpingchustc@hotmail.com; whb@zzu.edu.cn		Zhao, Wenshan/0000-0002-8018-5978; Huang, Lan/0000-0001-9594-4722; Zhu, Pingping/0000-0002-8009-2923; , Chen/0000-0003-2093-4639	National Natural Science Foundation of China [U1704174, U1604286, 81472557, 81601450]; development fund for outstanding young teachers of Zhengzhou University [1521311059]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); development fund for outstanding young teachers of Zhengzhou University	This work was supported by the National Natural Science Foundation of China (U1704174, U1604286, 81472557 and 81601450) and development fund for outstanding young teachers of Zhengzhou University (1521311059).	Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bruix J, 2014, GUT, V63, P844, DOI 10.1136/gutjnl-2013-306627; Chen ZZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12598; Chiba T, 2006, HEPATOLOGY, V44, P240, DOI 10.1002/hep.21227; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; De Marco P, 2012, HUM MUTAT, V33, P384, DOI 10.1002/humu.21643; Golan T, 2004, J BIOL CHEM, V279, P14879, DOI 10.1074/jbc.M306421200; Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550; Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hidaka S, 2016, J INTEGR NEUROSCI, V15, P571, DOI 10.1142/S021963521650031X; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Leucci E, 2016, NATURE, V531, P518, DOI 10.1038/nature17161; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Lien WH, 2014, GENE DEV, V28, P1517, DOI 10.1101/gad.244772.114; Luo S, 2016, CELL STEM CELL, V18, P637, DOI 10.1016/j.stem.2016.01.024; Lyons JP, 2004, EXP CELL RES, V298, P369, DOI 10.1016/j.yexcr.2004.04.036; Ma S, 2008, MOL CANCER RES, V6, P1146, DOI 10.1158/1541-7786.MCR-08-0035; MacDonald BT, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007880; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Naz G, 2012, BRIT J DERMATOL, V166, P1088, DOI 10.1111/j.1365-2133.2011.10800.x; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Roessler S, 2012, GASTROENTEROLOGY, V142, P957, DOI 10.1053/j.gastro.2011.12.039; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Yang W, 2008, CANCER RES, V68, P4287, DOI 10.1158/0008-5472.CAN-07-6691; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhu PP, 2017, PROG BIOCHEM BIOPHYS, V44, P697, DOI 10.16476/j.pibb.2017.0242; Zhu PP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13608; Zhu PP, 2016, NAT STRUCT MOL BIOL, V23, P631, DOI 10.1038/nsmb.3235; Zhu PP, 2015, J CLIN INVEST, V125, P3795, DOI 10.1172/JCI81979; Zhu PP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8122	42	45	48	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3098	3112		10.1038/s41388-018-0203-6	http://dx.doi.org/10.1038/s41388-018-0203-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29535420	Green Published, hybrid			2022-12-17	WOS:000434641400005
J	Zhao, SJ; Jiang, YQ; Xu, NW; Li, Q; Zhang, Q; Wang, SY; Li, J; Wang, YH; Zhang, YL; Jiang, SH; Wang, YJ; Huang, YJ; Zhang, XX; Tian, GA; Zhang, CC; Lv, YY; Dai, M; Liu, F; Zhang, R; Zhou, D; Zhang, ZG				Zhao, S-J; Jiang, Y-Q; Xu, N-W; Li, Q.; Zhang, Q.; Wang, S-Y; Li, J.; Wang, Y-H; Zhang, Y-L; Jiang, S-H; Wang, Y-J; Huang, Y-J; Zhang, X-X; Tian, G-A; Zhang, C-C; Lv, Y-Y; Dai, M.; Liu, F.; Zhang, R.; Zhou, D.; Zhang, Z-G			SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/beta-catenin signaling through stabilization of the WNT-receptor complex	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; NEGATIVE REGULATOR; SELF-RENEWAL; STEM-CELLS; GROWTH; SURVIVAL; CANCER; MECHANISMS; SARCOMAS; PATHWAY	Metastasis significantly reduces the survival rate of osteosarcoma (OS) patients. Therefore, identification of novel targets remains extremely important to prevent metastasis and treat OS. In this report, we show that SPARCL1 is downregulated in OS by epigenetic methylation of promoter DNA. In vitro and in vivo experiments revealed that SPARCL1 inhibits OS metastasis. We further demonstrated that SPARCL1-activated WNT/beta-catenin signaling by physical interaction with various frizzled receptors and lipoprotein receptor-related protein 5/6, leading to WNT-receptor complex stabilization. Activation of WNT/beta-catenin signaling contributes to the SPARCL1-mediated inhibitory effects on OS metastasis. Furthermore, we uncovered a paracrine effect of SPARCL1 on macrophage recruitment through activated WNT/beta-catenin signaling-mediated secretion of chemokine ligand5 from OS cells. These findings suggest that the targeting of SPARCL1 as a new anti-metastatic strategy for OS patients.	[Zhao, S-J; Jiang, Y-Q; Xu, N-W; Zhang, Q.; Wang, S-Y; Wang, Y-J; Huang, Y-J; Zhou, D.] Nanjing Med Univ, Changzhou Peoples Hosp 2, Affiliated Hosp, Dept Orthoped, Changzhou 213003, Jiangsu, Peoples R China; [Li, Q.; Li, J.; Wang, Y-H; Zhang, Y-L; Jiang, S-H; Zhang, X-X; Tian, G-A; Zhang, Z-G] Shanghai Jiao Tong Univ, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Sch Med,Ren Ji Hosp, Shanghai, Peoples R China; [Zhang, C-C; Lv, Y-Y; Zhang, R.] Southern Med Univ, Fengxian Hosp, Dept Obstet & Gynecol, Shanghai, Peoples R China; [Dai, M.; Liu, F.] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Obstet & Gynecol, Shanghai, Peoples R China	Nanjing Medical University; Shanghai Jiao Tong University; Southern Medical University - China; Shanghai Jiao Tong University	Zhou, D; Zhang, ZG (corresponding author), Nanjing Med Univ, Changzhou Peoples Hosp 2, Affiliated Hosp, Dept Orthoped, Changzhou 213003, Jiangsu, Peoples R China.	zhoudong1012@hotmail.com; zzhang@shsci.org	Jiang, Shuheng/M-6584-2019	Jiang, Shuheng/0000-0001-8516-6234; Zhao, Shujie/0000-0002-2820-2232	Major Program of Changzhou Health Bureau [CJ20160047]; Nineteenth Batch of Science Technology Program of Changzhou [2014YLC011]; H-level Medical Talents Training Project [2016CZBJ023]	Major Program of Changzhou Health Bureau; Nineteenth Batch of Science Technology Program of Changzhou; H-level Medical Talents Training Project	We are grateful to Dr Xiao-Li Zhou, Dr Xiao-Mei Yang, Dr Qin Yang, Dr Lei Zhu, Dr Li-Peng Hu and and Dr Xiao-Yan Cao for assistance with our experiments. This study was supported by grants from the Major Program of Changzhou Health Bureau (Grant number CJ20160047), the Nineteenth Batch of Science Technology Program of Changzhou (Grant number 2014YLC011) and the H-level Medical Talents Training Project (Grant number 2016CZBJ023).	Adamopoulos C, 2016, EXP BIOL MED, V241, P1296, DOI 10.1177/1535370216648806; Basu-Roy U, 2012, ONCOGENE, V31, P2270, DOI 10.1038/onc.2011.405; Basu-Roy U, 2013, CANCER LETT, V338, P158, DOI 10.1016/j.canlet.2012.05.028; Berraondo P, 2016, IMMUNOL REV, V274, P290, DOI 10.1111/imr.12464; Bhardwaj D, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00052; Bradshaw AD, 2012, INT J BIOCHEM CELL B, V44, P480, DOI 10.1016/j.biocel.2011.12.021; Buddingh EP, 2011, CLIN CANCER RES, V17, P2110, DOI 10.1158/1078-0432.CCR-10-2047; Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628; Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154; Chanmee T, 2014, CANCERS, V6, P1670, DOI 10.3390/cancers6031670; Chen EY, 2014, P NATL ACAD SCI USA, V111, P5349, DOI 10.1073/pnas.1317731111; Chiodoni C, 2010, CANCER METAST REV, V29, P295, DOI 10.1007/s10555-010-9221-8; Claeskens A, 2000, BRIT J CANCER, V82, P1123, DOI 10.1054/bjoc.1999.1051; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Dancsok AR, 2017, ONCOTARGET, V8, P7068, DOI 10.18632/oncotarget.12548; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; Du XL, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-450; Fu Y, 2014, ONCOTARGET, V5, P6701, DOI 10.18632/oncotarget.2239; Gibault L, 2011, J PATHOL, V223, P64, DOI 10.1002/path.2787; Goldstein SD, 2016, ONCOTARGET, V7, P21114, DOI 10.18632/oncotarget.8522; Halleskog C, 2011, GLIA, V59, P119, DOI 10.1002/glia.21081; Hao NB, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/948098; Hingorani P, 2016, CANCER GENET-NY, V209, P182, DOI 10.1016/j.cancergen.2016.03.004; Hu HG, 2012, CLIN CANCER RES, V18, P5438, DOI 10.1158/1078-0432.CCR-12-0124; Hurley PJ, 2015, CANCER RES, V75, P4322, DOI 10.1158/0008-5472.CAN-15-0024; Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838; Kim J, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6058147; Kovac M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9940; Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377; Meyers PA, 2008, J CLIN ONCOL, V26, P633, DOI 10.1200/JCO.2008.14.0095; Mintz MB, 2005, CANCER RES, V65, P1748, DOI 10.1158/0008-5472.CAN-04-2463; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Naschberger E, 2016, J CLIN INVEST, V126, P4187, DOI 10.1172/JCI78260; Nie J, 2009, J BIOL CHEM, V284, P1279, DOI 10.1074/jbc.M808285200; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111; Ren DN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7906; Ribeiro N, 2014, J CELL BIOCHEM, V115, P17, DOI 10.1002/jcb.24649; Sullivan MM, 2008, WOUND REPAIR REGEN, V16, P310, DOI 10.1111/j.1524-475X.2008.00370.x; Sullivan MM, 2004, INT J BIOCHEM CELL B, V36, P991, DOI 10.1016/j.biocel.2004.01.017; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999-008-0335-z; Wan Y, 2014, HUM PATHOL, V45, P1459, DOI 10.1016/j.humpath.2014.02.022; Zanganeh S, 2016, NAT NANOTECHNOL, V11, P986, DOI [10.1038/nnano.2016.168, 10.1038/NNANO.2016.168]; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang ZG, 2006, CELL MOL LIFE SCI, V63, P82, DOI 10.1007/s00018-005-5416-5; Zhao S, 2015, ONCOGENE, V34, P5069, DOI 10.1038/onc.2014.429	49	45	46	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1049	1061		10.1038/onc.2017.403	http://dx.doi.org/10.1038/onc.2017.403			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29084211	hybrid, Green Published			2022-12-17	WOS:000425905700008
J	Nagaraj, AB; Wang, QQ; Joseph, P; Zheng, C; Chen, Y; Kovalenko, O; Singh, S; Armstrong, A; Resnick, K; Zanotti, K; Waggoner, S; Xu, R; DiFeo, A				Nagaraj, A. B.; Wang, Q. Q.; Joseph, P.; Zheng, C.; Chen, Y.; Kovalenko, O.; Singh, S.; Armstrong, A.; Resnick, K.; Zanotti, K.; Waggoner, S.; Xu, R.; DiFeo, A.			Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment	ONCOGENE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; DISEASE GENETICS PREDICTION; STEM-CELLS; RISK; PREVENTION; HEALTH	Computation-based drug-repurposing/repositioning approaches can greatly speed up the traditional drug discovery process. To date, systematic and comprehensive computation-based approaches to identify and validate drug-repositioning candidates for epithelial ovarian cancer (EOC) have not been undertaken. Here, we present a novel drug discovery strategy that combines a computational drug-repositioning system (DrugPredict) with biological testing in cell lines in order to rapidly identify novel drug candidates for EOC. DrugPredict exploited unique repositioning opportunities rendered by a vast amount of disease genomics, phenomics, drug treatment, and genetic pathway and uniquely revealed that non-steroidal anti-inflammatories (NSAIDs) rank just as high as currently used ovarian cancer drugs. As epidemiological studies have reported decreased incidence of ovarian cancer associated with regular intake of NSAIDs, we assessed whether NSAIDs could have chemoadjuvant applications in EOC and found that (i) NSAID Indomethacin induces robust cell death in primary patient-derived platinum-sensitive and platinum-resistant ovarian cancer cells and ovarian cancer stem cells and (ii) downregulation of beta-catenin is partially driving effects of Indomethacin in cisplatin-resistant cells. In summary, we demonstrate that DrugPredict represents an innovative computational drug-discovery strategy to uncover drugs that are routinely used for other indications that could be effective in treating various cancers, thus introducing a potentially rapid and cost-effective translational opportunity. As NSAIDs are already in routine use in gynecological treatment regimens and have acceptable safety profile, our results will provide with a rationale for testing NSAIDs as potential chemoadjuvants in EOC patient trials.	[Nagaraj, A. B.; Joseph, P.; Kovalenko, O.; DiFeo, A.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Wang, Q. Q.] ThinTek LLC, Palo Alto, CA USA; [Zheng, C.; Chen, Y.; Xu, R.] Case Western Reserve Univ, Inst Computat Biol, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA; [Singh, S.] Metrohlth Med Ctr, Dept Gynecol, Div Gynecol Oncol, Cleveland, OH USA; [Armstrong, A.; Zanotti, K.; Waggoner, S.] Univ Hosp Cleveland, Div Gynecol Oncol, Dept Gynecol, Med Ctr, Cleveland, OH USA	Case Western Reserve University; Case Western Reserve University; MetroHealth System; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland	Xu, R (corresponding author), Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Inst Computat Biol, 2103 Cornell Rd, Cleveland, OH 44106 USA.; DiFeo, A (corresponding author), Case Comprehens Canc Ctr, Gen Med Sci Oncol, 2103 Cornell Rd, Cleveland, OH 44106 USA.	rxx@case.edu; avd11@case.edu	Nagaraj, Anil Belur/V-7779-2019; /S-1190-2019	/0000-0001-7488-250X; Xu, Rong/0000-0003-3127-4795; DiFeo, Analisa/0000-0001-8319-6763; Zheng, Chunlei/0000-0002-9737-461X	Mary Kay Foundation; Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under the NIH Director's New Innovator Award [DP2HD084068, R011CA197780-01A1]; Athymic Animal and Xenograft Core Facility of the Case Comprehensive Cancer Center [P30CA043703]; Cytometry & Imaging Microscopy Core Facility of the Case Comprehensive Cancer Center [P30CA043703]; Young Scientist Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [DP2HD084068] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA197780, P30CA043703] Funding Source: NIH RePORTER	Mary Kay Foundation; Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under the NIH Director's New Innovator Award; Athymic Animal and Xenograft Core Facility of the Case Comprehensive Cancer Center; Cytometry & Imaging Microscopy Core Facility of the Case Comprehensive Cancer Center; Young Scientist Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Norma C and Albert I Geller for their constant support of the Gynecological Cancer Translation Research Program at the Case Comprehensive Cancer Center. This work was supported by grants from The Mary Kay Foundation (AD & RX), the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under the NIH Director's New Innovator Award number DP2HD084068 (RX, The National Cancer Institute Award number R011CA197780-01A1 (AD)) and The Young Scientist Foundation (AD). This research was supported by the Athymic Animal and Xenograft Core Facility and the Cytometry & Imaging Microscopy Core Facility of the Case Comprehensive Cancer Center (P30CA043703).	Abu Saadeh F, 2013, EUR J OBSTET GYN R B, V170, P214, DOI 10.1016/j.ejogrb.2013.06.004; Ahnen DJ, 1998, EUR J SURG, V164, P111, DOI 10.1080/11024159850191544; Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468; Baandrup L, 2013, ACTA OBSTET GYN SCAN, V92, P245, DOI 10.1111/aogs.12069; Brasky TM, 2014, INT J CANCER, V135, P1869, DOI 10.1002/ijc.28823; Bult CJ, 2008, NUCLEIC ACIDS RES, V36, pD724, DOI 10.1093/nar/gkm961; Cai Xiaoshu, 2016, AMIA Jt Summits Transl Sci Proc, V2016, P22; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chen Y, 2017, BIOINFORMATICS, V33, P1031, DOI 10.1093/bioinformatics/btw737; Chen Y, 2016, J BIOMED INFORM, V64, P131, DOI 10.1016/j.jbi.2016.09.019; Chen Y, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2820-1; Chen Y, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2908-7; Chen Yang, 2015, AMIA Annu Symp Proc, V2015, P1851; Chen Y, 2015, BIOINFORMATICS, V31, P276, DOI 10.1093/bioinformatics/btv245; Chen Y, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S7-S9; Condello S, 2015, ONCOGENE, V34, P2297, DOI 10.1038/onc.2014.178; Cooke SL, 2011, LANCET ONCOL, V12, P1169, DOI 10.1016/S1470-2045(11)70123-1; Davis AP, 2011, NUCLEIC ACIDS RES, V39, pD1067, DOI 10.1093/nar/gkq813; Dudley JT, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002648; Dudley JT, 2011, BRIEF BIOINFORM, V12, P303, DOI 10.1093/bib/bbr013; Flesken-Nikitin A, 2013, NATURE, V495, P241, DOI 10.1038/nature11979; Goessling W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015; Gurpinar E, 2014, CLIN CANCER RES, V20, P1104, DOI 10.1158/1078-0432.CCR-13-1573; Heidel FH, 2012, CELL STEM CELL, V10, P412, DOI 10.1016/j.stem.2012.02.017; Hoehndorf R, 2014, BIOINFORMATICS, V30, P719, DOI 10.1093/bioinformatics/btt613; Hurle MR, 2013, CLIN PHARMACOL THER, V93, P335, DOI 10.1038/clpt.2013.1; Kino Y, 2005, PROSTAG LEUKOTR ESS, V73, P103, DOI 10.1016/j.plefa.2005.04.014; Landen CN, 2010, MOL CANCER THER, V9, P3186, DOI 10.1158/1535-7163.MCT-10-0563; Li J, 2016, BRIEF BIOINFORM, V17, P2, DOI 10.1093/bib/bbv020; Liu RH, 2015, ARCH GYNECOL OBSTET, V291, P1361, DOI 10.1007/s00404-014-3555-3; McGettigan P, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001826; Moore RA, 2011, J CLIN ONCOL, V29, P3466, DOI 10.1200/JCO.2011.35.5669; Murphy MA, 2012, CANCER CAUSE CONTROL, V23, P1839, DOI 10.1007/s10552-012-0063-2; Nagaraj AB, 2015, ONCOTARGET, V6, P23720, DOI 10.18632/oncotarget.4690; Nakanishi M, 2013, SEMIN IMMUNOPATHOL, V35, P123, DOI 10.1007/s00281-012-0342-8; Scannell JW, 2012, NAT REV DRUG DISCOV, V11, P191, DOI 10.1038/nrd3681; Schmidt M, 2011, J THROMB HAEMOST, V9, P1326, DOI 10.1111/j.1538-7836.2011.04354.x; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sirota M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001318; Swinney DC, 2011, NAT REV DRUG DISCOV, V10, P507, DOI 10.1038/nrd3480; Trabert B, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt431; Ulrich CM, 2006, NAT REV CANCER, V6, P130, DOI 10.1038/nrc1801; Ungprasert P, 2015, RHEUMATOLOGY, V54, P736, DOI 10.1093/rheumatology/keu408; Valle BL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061836; Wang CJ, 2004, J BONE JOINT SURG AM, V86A, P136, DOI 10.2106/00004623-200401000-00020; Wang QuanQiu, 2015, AMIA Annu Symp Proc, V2015, P1279; Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067; Xu R, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2910-0; Xu R, 2015, J BIOMED INFORM, V56, P348, DOI 10.1016/j.jbi.2015.06.027; Yue F, 2014, NATURE, V515, P355, DOI 10.1038/nature13992	50	45	46	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					403	414		10.1038/onc.2017.328	http://dx.doi.org/10.1038/onc.2017.328			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28967908	Green Published, hybrid			2022-12-17	WOS:000422753900012
J	Tarade, D; Ohh, M				Tarade, D.; Ohh, M.			The HIF and other quandaries in VHL disease	ONCOGENE			English	Review							TUMOR-SUPPRESSOR PROTEIN; RENAL-CELL CARCINOMA; HYPOXIA-INDUCIBLE FACTOR; HIPPEL-LINDAU GENE; BIOLOGICALLY-ACTIVE PRODUCT; ENDOTHELIAL GROWTH-FACTOR; HORMONE-RELATED PROTEIN; GERMLINE MUTATIONS; CONGENITAL POLYCYTHEMIA; PROLINE-HYDROXYLATION	Mutations in VHL underlie von Hippel-Lindau (VHL) disease, a hereditary cancer syndrome with several subtypes depending on the risk of developing certain combination of classic features, such as clear cell renal cell carcinoma (ccRCC), hemangioblastoma and pheochromocytoma. Although numerous potential substrates and functions of pVHL have been described over the past decade, the best-defined role of pVHL has remained as the negative regulator of the heterodimeric hypoxia-inducible factor (HIF) transcription factor via the oxygen-dependent ubiquitin-mediated degradation of HIF-alpha subunit. Despite the seminal discoveries that led to the molecular elucidation of the mammalian oxygen-sensing VHL-HIF axis, which have provided several rational therapies, the mechanisms underlying the complex genotype-phenotype correlation in VHL disease are unclear. This review will discuss and highlight the studies that have provided interesting insights as well as uncertainties to the underlying mechanisms governing VHL disease.	[Tarade, D.; Ohh, M.] Univ Toronto, Dept Lab Med & Pathobiol, MaRS Ctr West Tower,661 Univ Ave,Suite 1512, Toronto, ON M5G 1M1, Canada; [Ohh, M.] Univ Toronto, Dept Biochem, MaRS Ctr West Tower, Toronto, ON, Canada	University of Toronto; University of Toronto	Ohh, M (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, MaRS Ctr West Tower,661 Univ Ave,Suite 1512, Toronto, ON M5G 1M1, Canada.	michael.ohh@utoronto.ca		Tarade, Daniel/0000-0001-7029-9640	Canadian Institutes of Health Research (CIHR) [MOP 77718, 136978]; CIHR Scholarship	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR Scholarship(Canadian Institutes of Health Research (CIHR))	We thank Dr Claire Robinson, Shelley He and Aline Zara for helpful discussions and comments. This work was supported by funds from the Canadian Institutes of Health Research (CIHR, MOP 77718 and 136978). DT is a recipient of the CIHR Scholarship.	Albers J, 2013, EMBO MOL MED, V5, P949, DOI 10.1002/emmm.201202231; An JB, 2005, ONCOGENE, V24, P1563, DOI 10.1038/sj.onc.1208348; Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Arias-Gonzalez L, 2013, NEOPLASIA, V15, P649, DOI 10.1593/neo.121896; Beroukhim R, 2009, CANCER RES, V69, P4674, DOI 10.1158/0008-5472.CAN-09-0146; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bisgrove BW, 2006, DEVELOPMENT, V133, P4131, DOI 10.1242/dev.02595; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; BRAUCH H, 1995, HUM GENET, V95, P551, DOI 10.1007/BF00223868; Buffet A, 2014, J CLIN ENDOCR METAB, V99, pE369, DOI 10.1210/jc.2013-2600; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796; Cho H, 2016, NATURE, V539, P107, DOI 10.1038/nature19795; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Comino-Mendez I, 2013, HUM MOL GENET, V22, P2169, DOI 10.1093/hmg/ddt069; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Cummins EP, 2006, P NATL ACAD SCI USA, V103, P18154, DOI 10.1073/pnas.0602235103; Danilin S, 2009, CARCINOGENESIS, V30, P387, DOI 10.1093/carcin/bgn275; Darr R, 2016, ENDOCR-RELAT CANCER, V23, P899, DOI 10.1530/ERC-16-0231; Dart A, 2016, NAT REV CANCER, V16, P675, DOI 10.1038/nrc.2016.107; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Esteban MA, 2006, J AM SOC NEPHROL, V17, P1801, DOI 10.1681/ASN.2006020181; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Favier J, 2015, NAT REV ENDOCRINOL, V11, P101, DOI 10.1038/nrendo.2014.188; Fliedner SMJ, 2016, NEOPLASIA, V18, P567, DOI 10.1016/j.neo.2016.07.008; Fu LP, 2015, MOL CANCER RES, V13, P870, DOI 10.1158/1541-7786.MCR-14-0423; Fu LP, 2013, CANCER RES, V73, P2916, DOI 10.1158/0008-5472.CAN-12-3983; Fu LP, 2011, CANCER RES, V71, P6848, DOI 10.1158/0008-5472.CAN-11-1745; Gallou C, 1999, HUM MUTAT, V13, P464, DOI 10.1002/(SICI)1098-1004(1999)13:6<464::AID-HUMU6>3.0.CO;2-A; Garcia-Donas J, 2013, ANN ONCOL, V24, P2409, DOI 10.1093/annonc/mdt219; Gossage L, 2015, NAT REV CANCER, V15, P55, DOI 10.1038/nrc3844; Grosfeld A, 2007, J BIOL CHEM, V282, P13264, DOI 10.1074/jbc.M611648200; Gu YF, 2017, CANCER DISCOV, V7, P900, DOI 10.1158/2159-8290.CD-17-0292; Gudas LJ, 2014, J MOL MED, V92, P825, DOI 10.1007/s00109-014-1180-z; Guo JP, 2016, SCIENCE, V353, P929, DOI 10.1126/science.aad5755; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hildebrandt F, 2005, NAT REV GENET, V6, P928, DOI 10.1038/nrg1727; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Hu CJ, 2006, MOL CELL BIOL, V26, P3514, DOI 10.1128/MCB.26.9.3514-3526.2006; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; KANNO H, 1994, CANCER RES, V54, P4845; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Knauth K, 2006, ONCOGENE, V25, P370, DOI 10.1038/sj.onc.1209062; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kurban G, 2008, ONCOGENE, V27, P1004, DOI 10.1038/sj.onc.1210709; Kurban G, 2006, CANCER RES, V66, P1313, DOI 10.1158/0008-5472.CAN-05-2560; Ladroue C, 2008, NEW ENGL J MED, V359, P2685, DOI 10.1056/NEJMoa0806277; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee JY, 1998, CANCER RES, V58, P504; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Li LJ, 2007, MOL CELL BIOL, V27, P5381, DOI 10.1128/MCB.00282-07; LINDAU ARVID, 1927, ACTA OPHTHALMOL, V4, P193; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Lolkema MP, 2007, FEBS LETT, V581, P4571, DOI 10.1016/j.febslet.2007.08.050; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Lorenzo FR, 2013, J MOL MED, V91, P507, DOI 10.1007/s00109-012-0967-z; Los M, 1996, LAB INVEST, V75, P231; Lubensky IA, 1996, AM J PATHOL, V149, P2089; Lutz MS, 2006, CANCER RES, V66, P6903, DOI 10.1158/0008-5472.CAN-06-0501; MAHER ER, 1990, J MED GENET, V27, P311, DOI 10.1136/jmg.27.5.311; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Maher ER, 1996, J MED GENET, V33, P328, DOI 10.1136/jmg.33.4.328; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Massfelder T, 2004, CANCER RES, V64, P180, DOI 10.1158/0008-5472.CAN-03-1968; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mikhaylova O, 2008, MOL CELL BIOL, V28, P2701, DOI 10.1128/MCB.01231-07; Monzon FA, 2011, MODERN PATHOL, V24, P1470, DOI 10.1038/modpathol.2011.107; Morris MR, 2009, ANTICANCER RES, V29, P4337; Nargund AM, 2017, CELL REP, V18, P2893, DOI 10.1016/j.celrep.2017.02.074; NEUMANN HPH, 1995, JAMA-J AM MED ASSOC, V274, P1149; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Pacak K, 2013, J CLIN ONCOL, V31, P1690, DOI 10.1200/JCO.2012.47.1912; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pastore Y, 2003, AM J HUM GENET, V73, P412, DOI 10.1086/377108; Pietras A, 2009, P NATL ACAD SCI USA, V106, P16805, DOI 10.1073/pnas.0904606106; Qi H, 2003, CANCER RES, V63, P7076; Rankin EB, 2006, CANCER RES, V66, P2576, DOI 10.1158/0008-5472.CAN-05-3241; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Robinson CM, 2014, FEBS LETT, V588, P2704, DOI 10.1016/j.febslet.2014.02.026; Russell RC, 2011, NAT MED, V17, P845, DOI 10.1038/nm.2370; Schermer B, 2006, J CELL BIOL, V175, P547, DOI 10.1083/jcb.200605092; SCHLINGENSIEPEN KH, 1994, CELL MOL NEUROBIOL, V14, P487, DOI 10.1007/BF02088833; Schodel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427; Schonenberger D, 2016, CANCER RES, V76, P2025, DOI 10.1158/0008-5472.CAN-15-1859; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Sergeyeva A, 1997, BLOOD, V89, P2148, DOI 10.1182/blood.V89.6.2148; Shen C, 2013, SEMIN CANCER BIOL, V23, P18, DOI 10.1016/j.semcancer.2012.06.001; Shen C, 2011, CANCER DISCOV, V1, P222, DOI 10.1158/2159-8290.CD-11-0098; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K; Sun XF, 2007, HISTOL HISTOPATHOL, V22, P1387, DOI 10.14670/HH-22.1387; Taieb D, 2013, J CLIN ENDOCR METAB, V98, pE908, DOI 10.1210/jc.2013-1217; Thoma CR, 2007, NAT CELL BIOL, V9, P588, DOI 10.1038/ncb1579; Toledo RA, 2013, ENDOCR-RELAT CANCER, V20, P349, DOI 10.1530/ERC-13-0101; Toyoda H, 2014, PEDIATRICS, V133, pE1787, DOI 10.1542/peds.2013-2419; Von-Hippel E, 1904, ARCH OPHTHALMOL-CHIC, V59, P23, DOI [10.1007/BF01994821, DOI 10.1007/BF01994821]; Wallace EM, 2016, CANCER RES, V76, P5491, DOI 10.1158/0008-5472.CAN-16-0473; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Welander J, 2014, ENDOCR-RELAT CANCER, V21, P495, DOI 10.1530/ERC-13-0384; WHALEY JM, 1994, AM J HUM GENET, V55, P1092; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; Yang CZ, 2013, BLOOD, V121, P2563, DOI 10.1182/blood-2012-10-460972; Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010; Yuen JSP, 2007, ONCOGENE, V26, P6499, DOI 10.1038/sj.onc.1210474; Zhuang ZP, 2012, NEW ENGL J MED, V367, P922, DOI 10.1056/NEJMoa1205119; Zimmer M, 2004, MOL CANCER RES, V2, P89	125	45	46	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					139	147		10.1038/onc.2017.338	http://dx.doi.org/10.1038/onc.2017.338			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28925400				2022-12-17	WOS:000422631700001
J	Hardbower, DM; Coburn, LA; Asim, M; Singh, K; Sierra, JC; Barry, DP; Gobert, AP; Piazuelo, MB; Washington, MK; Wilson, KT				Hardbower, D. M.; Coburn, L. A.; Asim, M.; Singh, K.; Sierra, J. C.; Barry, D. P.; Gobert, A. P.; Piazuelo, M. B.; Washington, M. K.; Wilson, K. T.			EGFR-mediated macrophage activation promotes colitis-associated tumorigenesis	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; CANCER CELL-LINES; EPITHELIAL-CELLS; PROLIFERATION; INFLAMMATION; POLARIZATION; EXPRESSION; ANGIOGENESIS; PHENOTYPE; MODEL	Epidermal growth factor receptor (EGFR) signaling is a known mediator of colorectal carcinogenesis. Studies have focused on the role of EGFR signaling in epithelial cells, although the exact nature of the role of EGFR in colorectal carcinogenesis remains a topic of debate. Here, we present evidence that EGFR signaling in myeloid cells, specifically macrophages, is critical for colon tumorigenesis in the azoxymethane-dextran sodium sulfate (AOM-DSS) model of colitis-associated carcinogenesis (CAC). In a human tissue microarray, colonic macrophages demonstrated robust EGFR activation in the pre-cancerous stages of colitis and dysplasia. Utilizing the AOM-DSS model, mice with a myeloid-specific deletion of Egfr had significantly decreased tumor multiplicity and burden, protection from high-grade dysplasia and significantly reduced colitis. Intriguingly, mice with gastrointestinal epithelial cell-specific Egfr deletion demonstrated no differences in tumorigenesis in the AOM-DSS model. The alterations in tumorigenesis in myeloid-specific Egfr knockout mice were accompanied by decreased macrophage, neutrophil and T-cell infiltration. Pro-tumorigenic M2 macrophage activation was diminished in myeloid-specific Egfr-deficient mice, as marked by decreased Arg1 and Il10 mRNA expression and decreased interleukin (IL)-4, IL10 and IL-13 protein levels. Surprisingly, diminished M1 macrophage activation was also detectable, as marked by significantly reduced Nos2 and Il1b mRNA levels and decreased interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha and IL-1 beta protein levels. The alterations in M1 and M2 macrophage activation were confirmed in bone marrow-derived macrophages from mice with the myeloid-specific Egfr knockout. The combined effect of restrained M1 and M2 macrophage activation resulted in decreased production of pro-angiogenic factors, CXCL1 and vascular endothelial growth factor (VEGF), and reduced CD31(+) blood vessels, which likely contributed to protection from tumorigenesis. These data reveal that EGFR signaling in macrophages, but not in colonic epithelial cells, has a significant role in CAC. EGFR signaling in macrophages may prove to be an effective biomarker of CAC or target for chemoprevention in patients with inflammatory bowel disease.	[Hardbower, D. M.; Washington, M. K.; Wilson, K. T.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Hardbower, D. M.; Coburn, L. A.; Asim, M.; Singh, K.; Sierra, J. C.; Barry, D. P.; Gobert, A. P.; Piazuelo, M. B.; Wilson, K. T.] Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37232 USA; [Coburn, L. A.; Gobert, A. P.; Piazuelo, M. B.; Wilson, K. T.] Vanderbilt Univ, Med Ctr, Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA; [Coburn, L. A.; Wilson, K. T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA; [Wilson, K. T.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; [Wilson, K. T.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University	Wilson, KT (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Med Gastroenterol Hepatol & Nutr, 1030C Med Res Bldg 4,2215 Garland Ave, Nashville, TN 37232 USA.	keith.wilson@vanderbilt.edu	Barry, Daniel P/B-5647-2008	Barry, Daniel P/0000-0002-3972-3914; Coburn, Lori/0000-0003-3249-9806	NIH [P30CA068485, U24DK059637, R01DK053620, R01AT004821, R01CA190612, P01CA116087, P01CA028842, P50CA095103, P30DK058404]; DMH [T32GM008554, F31DK10715]; Veterans Affairs Career Development [1IK2BX002126]; Veterans Affairs Merit Review [I01BX001453]; Vanderbilt Center for Mucosal Inflammation and Cancer; Vanderbilt Mouse Metabolic Phenotyping Center; Thomas F Frist Sr Endowment; NATIONAL CANCER INSTITUTE [P01CA116087, P01CA028842, R01CA190612, P30CA068485] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053620, F31DK107159, P30DK058404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008554] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001453, IK2BX002126] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DMH; Veterans Affairs Career Development(US Department of Veterans Affairs); Veterans Affairs Merit Review(US Department of Veterans Affairs); Vanderbilt Center for Mucosal Inflammation and Cancer; Vanderbilt Mouse Metabolic Phenotyping Center; Thomas F Frist Sr Endowment; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	CD3, CD45R and CD31 staining was performed by the Vanderbilt University Medical Center Translational Pathology Shared Resource supported by NIH grant P30CA068485 and the Vanderbilt Mouse Metabolic Phenotyping Center, supported by NIH grant U24DK059637. Slide imaging and quantification was performed in the Digital Histology Shared Resource (www.mc.vanderbilt.edu/dhsr). This work was funded by NIH grants R01DK053620, R01AT004821, R01CA190612, P01CA116087 and P01CA028842 (KTW), Veterans Affairs Merit Review grant I01BX001453 (KTW), the Thomas F Frist Sr Endowment (KTW) and the Vanderbilt Center for Mucosal Inflammation and Cancer (KTW). The human TMA was supported by NIH grant P50CA095103 and the DDRC Tissue Morphology Subcore (NIH grant P30DK058404). DMH was supported by T32GM008554 and F31DK10715. LAC was supported by Veterans Affairs Career Development Award 1IK2BX002126.	Anderson CF, 2002, J LEUKOCYTE BIOL, V72, P101; Angelo LS, 2007, CLIN CANCER RES, V13, P2825, DOI 10.1158/1078-0432.CCR-06-2416; Barrett CW, 2011, CANCER RES, V71, P1302, DOI 10.1158/0008-5472.CAN-10-3317; Brower V, 2005, J NATL CANCER I, V97, P251, DOI 10.1093/jnci/97.4.251; Chandrasekar B, 2013, J INFECT DIS, V207, P1556, DOI 10.1093/infdis/jit067; Chaturvedi R, 2014, GASTROENTEROLOGY, V146, P1739, DOI 10.1053/j.gastro.2014.02.005; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; De Simone V, 2015, ONCOGENE, V34, P3493, DOI 10.1038/onc.2014.286; Dube PE, 2012, J CLIN INVEST, V122, P2780, DOI 10.1172/JCI62888; Engstrom A, 2014, INT J ONCOL, V44, P385, DOI 10.3892/ijo.2013.2203; Erreni M, 2011, CANCER MICROENVIRON, V4, P141, DOI 10.1007/s12307-010-0052-5; Feagins LA, 2009, NAT REV GASTRO HEPAT, V6, P297, DOI 10.1038/nrgastro.2009.44; Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735; Georgoudaki AM, 2016, CELL REP, V15, P2000, DOI 10.1016/j.celrep.2016.04.084; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hardbower DM, 2016, AMINO ACIDS, V48, P2375, DOI 10.1007/s00726-016-2231-2; Hardbower DM, 2016, J CLIN INVEST, V126, P3296, DOI 10.1172/JCI83585; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Hiemisch H, 1997, EMBO J, V16, P3995, DOI 10.1093/emboj/16.13.3995; Hol J, 2010, J LEUKOCYTE BIOL, V87, P501, DOI 10.1189/jlb.0809532; Holmfeldt P, 2016, J EXP MED, V213, P433, DOI 10.1084/jem.20150806; Huaux F, 2015, J PATHOL, V235, P698, DOI 10.1002/path.4487; Isidro RA, 2016, AM J PHYSIOL-GASTR L, V311, pG59, DOI 10.1152/ajpgi.00123.2016; Kanneganti M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/342637; Katz JP, 2005, GASTROENTEROLOGY, V128, P935, DOI 10.1053/j.gastro.2005.02.022; Krasinskas A. M., 2011, PATHOLOG RES INT, V2011, P6, DOI DOI 10.4061/2011/932932; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Markman B, 2010, ADV CLIN CHEM, V51, P71, DOI 10.1016/S0065-2423(10)51004-7; Martinez FO, 2014, F1000PRIME REP, V6, P13, DOI DOI 10.12703/P6-13; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Mousa Luay, 2015, Biomark Cancer, V7, P13, DOI 10.4137/BIC.S25250; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Ning Y, 2011, INT J CANCER, V128, P2038, DOI 10.1002/ijc.25562; Norton SE, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.21; Parang B, 2016, GUT, P1; Parang B, 2016, METHODS MOL BIOL, V1422, P297, DOI 10.1007/978-1-4939-3603-8_26; Payne CM, 1999, ANTIOXID REDOX SIGN, V1, P449, DOI 10.1089/ars.1999.1.4-449; Porta C, 2009, P NATL ACAD SCI USA, V106, P14978, DOI 10.1073/pnas.0809784106; Pusztaszeri MP, 2006, J HISTOCHEM CYTOCHEM, V54, P385, DOI 10.1369/jhc.4A6514.2005; Rmali KA, 2007, COLORECTAL DIS, V9, P3, DOI 10.1111/j.1463-1318.2006.01089.x; Sakamoto K, 2009, CLIN CANCER RES, V15, P2248, DOI 10.1158/1078-0432.CCR-08-1383; Sasaki T, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/546318; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Shibata W, 2010, GASTROENTEROLOGY, V138, P1022, DOI 10.1053/j.gastro.2009.11.054; Singh K, 2008, J BIOL CHEM, V283, P16752, DOI 10.1074/jbc.M710530200; Spano JP, 2005, ANN ONCOL, V16, P102, DOI 10.1093/annonc/mdi006; Sweet MJ, 2003, ARCH IMMUNOL THER EX, V51, P169; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Uronis JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006026; Valbuena G, 2003, AM J PATHOL, V163, P1357, DOI 10.1016/S0002-9440(10)63494-3; Van Overmeire E, 2016, CANCER RES, V76, P35, DOI 10.1158/0008-5472.CAN-15-0869; Wang N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00614; West NR, 2015, NAT REV IMMUNOL, V15, P615, DOI 10.1038/nri3896; Wu WK, 2010, IMMUNOBIOLOGY, V215, P796, DOI 10.1016/j.imbio.2010.05.025; Xie WD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058639; Yang JL, 2004, GUT, V53, P123, DOI 10.1136/gut.53.1.123; Yu HY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6218; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yue Xuetian, 2015, Cancer Cell Microenviron, V2	61	45	48	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3807	3819		10.1038/onc.2017.23	http://dx.doi.org/10.1038/onc.2017.23			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263971	Green Accepted			2022-12-17	WOS:000404848200002
J	Zhang, L; Wang, P; Qin, Y; Cong, Q; Shao, C; Du, Z; Ni, X; Li, P; Ding, K				Zhang, L.; Wang, P.; Qin, Y.; Cong, Q.; Shao, C.; Du, Z.; Ni, X.; Li, P.; Ding, K.			RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEIN-2; CLINICOPATHOLOGICAL SIGNIFICANCE; ACTIVATOR PROTEIN-1; FACTOR RECEPTOR; EXPRESSION; TRANSDUCTION; ANGIOGENESIS; METASTASIS; APOPTOSIS; GCS-100	Galectin-3 (Gal-3) has been implicated in pancreatic ductal adenocarcinoma (PDAC), and its candidacy as a therapeutic target has been evaluated. Gal-3 is widely upregulated in tumors, and its expression is associated with the development and malignancy of PDAC. In the present study, we demonstrate that a polysaccharide, RN1, purified from the flower of Panax notoginseng binds to Gal-3 and suppresses its expression. In addition, RN1 markedly inhibits PDAC cells growth in vitro, in vivo and in patient-derived xenografts. Mechanistically, RN1 binds to epidermal growth factor receptor (EGFR) and Gal-3, thereby disrupting the interaction between Gal-3 and EGFR and downregulating extracellular-related kinase (ERK) phosphorylation and the transcription factor of Gal-3, Runx1 expression. Inhibiting the expression of Runx1 by RN1, suppresses Gal-3 expression and inactivates Gal-3-associated signaling pathways, including the EGFR/ERK/Runx1, BMP/smad/Id-3 and integrin/FAK/JNK signaling pathways. In addition, RN1 can also bind to bone morphogenetic protein receptors (BMPR1A and BMPR2) and block the interaction between Gal-3 and the BMPRs. Thus, our results suggest that a novel Gal-3 inhibitor RN1 may be a potential candidate for human PDAC treatment via multiple targets and multiple signaling pathways.	[Zhang, L.; Wang, P.; Qin, Y.; Cong, Q.; Du, Z.; Ni, X.; Ding, K.] Chinese Acad Sci, Shanghai Inst Mat Med, Glycochem & Glycobiol Lab, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China; [Zhang, L.; Li, P.] China Pharmaceut Univ, State Key Lab Nat Med, 24 Tongjia Lane, Nanjing 210009, Jiangsu, Peoples R China; [Shao, C.] Second Mil Med Univ, Changzheng Hosp, Dept Gen Surg, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; China Pharmaceutical University; Naval Medical University	Ding, K (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Glycochem & Glycobiol Lab, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China.; Li, P (corresponding author), China Pharmaceut Univ, State Key Lab Nat Med, 24 Tongjia Lane, Nanjing 210009, Jiangsu, Peoples R China.	liping2004@126.com; dingkan@simm.ac.cn	Li, Ping/GYV-4914-2022	Cong, Qifei/0000-0002-4446-7222; Ding, Kan/0000-0002-8140-9259	National Natural Science Foundation of China [31230022]; New Drug Creation and Manufacturing Program [2012ZX09301001-003]; National Science Foundation of China [81421005]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Strategic Priority Research Program of the Chinese Academy of Sciences [XDA12010302]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); New Drug Creation and Manufacturing Program; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences)	This work was supported by grants from National Natural Science Foundation of China (31230022), New Drug Creation and Manufacturing Program (2012ZX09301001-003), Innovative Research Groups of the National Science Foundation of China (81421005), Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Strategic Priority Research Program of the Chinese Academy of Sciences (XDA12010302).	Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Asim M, 2010, J BIOL CHEM, V285, P20343, DOI 10.1074/jbc.M110.116988; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; Berberat PO, 2001, J HISTOCHEM CYTOCHEM, V49, P539, DOI 10.1177/002215540104900414; Blanchard H, 2014, EXPERT OPIN THER PAT, V24, DOI 10.1517/13543776.2014.947961; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Chauhan D, 2005, CANCER RES, V65, P8350, DOI 10.1158/0008-5472.CAN-05-0163; Deng HY, 2007, EXP CELL RES, V313, P1033, DOI 10.1016/j.yexcr.2006.12.020; DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235; Di Lella S, 2011, BIOCHEMISTRY-US, V50, P7842, DOI 10.1021/bi201121m; Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020; Friedman AD, 2009, J CELL PHYSIOL, V219, P520, DOI 10.1002/jcp.21738; Fukushi J, 2004, MOL BIOL CELL, V15, P3580, DOI 10.1091/mbc.E04-03-0236; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Iurisci I, 2000, CLIN CANCER RES, V6, P1389; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7; Kobayashi T, 2011, INT J CANCER, V129, P2775, DOI 10.1002/ijc.25946; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Liu W, 2012, J INVEST DERMATOL, V132, P2828, DOI 10.1038/jid.2012.211; Lopez-Bergami P, 2010, NAT REV CANCER, V10, P65, DOI 10.1038/nrc2681; Mendelsohn J, 2000, CLIN CANCER RES, V6, P747; Merlin J, 2011, ONCOGENE, V30, P2514, DOI 10.1038/onc.2010.631; Miyazono Kohei, 2002, Sci STKE, V2002, ppe40, DOI 10.1126/stke.2002.151.pe40; Nakahara S, 2005, APOPTOSIS, V10, P267, DOI 10.1007/s10495-005-0801-y; Nangia-Makker P, 2002, JNCI-J NATL CANCER I, V94, P1854, DOI 10.1093/jnci/94.24.1854; Ochieng J, 2002, GLYCOCONJUGATE J, V19, P527, DOI 10.1023/B:GLYC.0000014082.99675.2f; Partridge EA, 2004, SCIENCE, V306, P120, DOI 10.1126/science.1102109; Shimamura T, 2002, CLIN CANCER RES, V8, P2570; Shin S, 2009, MOL CANCER RES, V7, P745, DOI 10.1158/1541-7786.MCR-08-0462; Sorme P, 2005, J AM CHEM SOC, V127, P1737, DOI 10.1021/ja043475p; Stegmayr J, 2016, J BIOL CHEM, V291, P13318, DOI 10.1074/jbc.M116.721464; Streetly MJ, 2010, BLOOD, V115, P3939, DOI 10.1182/blood-2009-10-251660; Tellez-Sanz R, 2013, CURR MED CHEM, V20, P2979, DOI 10.2174/09298673113209990163; Tobita K, 2003, INT J MOL MED, V11, P305; Uegaki K, 1997, ANTICANCER RES, V17, P3841; Wang PP, 2015, CARBOHYD POLYM, V121, P328, DOI 10.1016/j.carbpol.2014.11.073; Xiao F, 2013, GLYCOBIOLOGY, V23, P524, DOI 10.1093/glycob/cwt004; YAMANAKA Y, 1993, ANTICANCER RES, V13, P565; Zhang HY, 2009, ENDOCRINE, V35, P101, DOI 10.1007/s12020-008-9129-z	44	45	46	5	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1297	1308		10.1038/onc.2016.306	http://dx.doi.org/10.1038/onc.2016.306			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27617577				2022-12-17	WOS:000395861300013
J	Cabrera, E; Hernandez-Perez, S; Koundrioukoff, S; Debatisse, M; Kim, D; Smolka, MB; Freire, R; Gillespie, DA				Cabrera, E.; Hernandez-Perez, S.; Koundrioukoff, S.; Debatisse, M.; Kim, D.; Smolka, M. B.; Freire, R.; Gillespie, D. A.			PERK inhibits DNA replication during the Unfolded Protein Response via Claspin and Chk1	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM; TRANSLATION; ACTIVATION; DYNAMICS; IMPACT; LUMEN; CELLS; RATES	Stresses such as hypoxia, nutrient deprivation and acidification disturb protein folding in the endoplasmic reticulum (ER) and activate the Unfolded Protein Response (UPR) to trigger adaptive responses through the effectors, PERK, IRE1 and ATF6. Most of these responses relate to ER homoeostasis; however, here we show that the PERK branch of the UPR also controls DNA replication. Treatment of cells with the non-genotoxic UPR agonist thapsigargin led to a rapid inhibition of DNA synthesis that was attributable to a combination of DNA replication fork slowing and reduced replication origin firing. DNA synthesis inhibition was dependent on the UPR effector PERK and was associated with phosphorylation of the checkpoint adaptor protein Claspin and activation of the Chk1 effector kinase, both of which occurred in the absence of detectable DNA damage. Remarkably, thapsigargin did not inhibit bulk DNA synthesis or activate Chk1 in cells depleted of Claspin, or when Chk1 was depleted or subject to chemical inhibition. In each case thapsigargin-resistant DNA synthesis was due to an increase in replication origin firing that compensated for reduced fork progression. Taken together, our results unveil a new aspect of PERK function and previously unknown roles for Claspin and Chk1 as negative regulators of DNA replication in the absence of genotoxic stress. Because tumour cells proliferate in suboptimal environments, and frequently show evidence of UPR activation, this pathway could modulate the response to DNA replication-targeted chemotherapies.	[Cabrera, E.; Hernandez-Perez, S.; Freire, R.] Hosp Univ Canarias, Inst Tecnol Biomed, Unidad Invest, Ofra S-N, San Cristobal la Laguna, Tenerife, Spain; [Koundrioukoff, S.; Debatisse, M.] Inst Curie, Ctr Rech, CNRS, UMR 3244, Paris 05, France; [Koundrioukoff, S.; Debatisse, M.] UPMC Univ Paris 06, Sorbonne Univ, Paris, France; [Koundrioukoff, S.; Debatisse, M.] CNRS, UMR 3244, Paris, France; [Kim, D.; Smolka, M. B.] Cornell Univ, Dept Mol Biol & Genet, Weill Inst Cell & Mol Biol, Ithaca, NY USA; [Gillespie, D. A.] Univ La Laguna, Fac Med, Ctr Invest Biomed Canarias, Inst Tecnol Biomed, Campus Ciencias Salud, San Cristobal la Laguna, Tenerife, Spain	Universidad de la Laguna; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; Universite Paris Cite; Cornell University; Universidad de la Laguna	Freire, R (corresponding author), Hosp Univ Canarias, Inst Tecnol Biomed, Unidad Invest, Ofra S-N, San Cristobal la Laguna, Tenerife, Spain.; Gillespie, DA (corresponding author), Univ La Laguna, Hosp Univ Canarias, Unidad Invest, Inst Tecnol Biomed, San Cristobal la Laguna 38320, Tenerife, Spain.	rfreire@ull.es; dgillesp@ull.es	Freire, Raimundo/Q-7660-2019; Cabrera, Elisa/GPX-3455-2022; Gillespie, David/R-4771-2019	Freire, Raimundo/0000-0003-4473-8894; Gillespie, David/0000-0002-6338-0544	Spanish Ministry of Economy and Competitiveness [SAF2013-49149-R, BFU2014-51672-REDC]; Fundacion CajaCanarias [AP2015/008]; IMBRAIN Project - EU FP7 [FP7-REGPOT-2012-CT2012-31637-IMBRAIN]; Gobierno de Canarias; World Wide Cancer Research (WWCR) [12-0149]	Spanish Ministry of Economy and Competitiveness(Spanish Government); Fundacion CajaCanarias; IMBRAIN Project - EU FP7; Gobierno de Canarias; World Wide Cancer Research (WWCR)	This work was supported by grants from the Spanish Ministry of Economy and Competitiveness (SAF2013-49149-R, BFU2014-51672-REDC to RF) and Fundacion CajaCanarias (AP2015/008 to RF), the IMBRAIN Project (FP7-REGPOT-2012-CT2012-31637-IMBRAIN to DAG) funded by EU FP7 and Gobierno de Canarias, and World Wide Cancer Research (WWCR; Project grant no. 12-0149 to DAG).	Anglana M, 2003, CELL, V114, P385, DOI 10.1016/S0092-8674(03)00569-5; Bianco JN, 2012, METHODS, V57, P149, DOI 10.1016/j.ymeth.2012.04.007; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Garrett MD, 2011, TRENDS PHARMACOL SCI, V32, P308, DOI 10.1016/j.tips.2011.02.014; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(05)00092-4; Labit H, 2008, BIOTECHNIQUES, V45, P649, DOI 10.2144/000113002; Malhotra JD, 2007, SEMIN CELL DEV BIOL, V18, P716, DOI 10.1016/j.semcdb.2007.09.003; Maly DJ, 2014, NAT CHEM BIOL, V10, P892, DOI 10.1038/nchembio.1664; Malzer E, 2010, J CELL SCI, V123, P2892, DOI 10.1242/jcs.070078; Mann MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047931; Martin Y, 2015, ONCOGENE, V34, P1058, DOI 10.1038/onc.2014.38; Maya-Mendoza A, 2007, EMBO J, V26, P2719, DOI 10.1038/sj.emboj.7601714; Mejlvang J, 2014, J CELL BIOL, V204, P29, DOI 10.1083/jcb.201305017; Palam LR, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.264; Petermann E, 2006, MOL CELL BIOL, V26, P3319, DOI 10.1128/MCB.26.8.3319-3326.2006; Petermann E, 2008, MOL BIOL CELL, V19, P2373, DOI 10.1091/mbc.E07-10-1035; Pytel D, 2016, ONCOGENE, V35, P1207, DOI 10.1038/onc.2015.178; Scorah J, 2009, CELL CYCLE, V8, P1036, DOI 10.4161/cc.8.7.8040; Semple JI, 2007, CELL DEATH DIFFER, V14, P1433, DOI 10.1038/sj.cdd.4402134; Sidrauski C, 2015, ELIFE, V4, DOI 10.7554/eLife.07314; Smith J, 2010, ADV CANCER RES, V108, P73, DOI 10.1016/S0065.230X(10)08002.4; Smits VAJ, 2015, FEBS J, V282, P3681, DOI 10.1111/febs.13387; Techer H, 2013, J MOL BIOL, V425, P4845, DOI 10.1016/j.jmb.2013.03.040; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Wang SY, 2012, J CELL BIOL, V197, P857, DOI 10.1083/jcb.201110131; Wu SY, 2002, J BIOL CHEM, V277, P18077, DOI 10.1074/jbc.M110164200	31	45	46	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					678	686		10.1038/onc.2016.239	http://dx.doi.org/10.1038/onc.2016.239			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27375025				2022-12-17	WOS:000394167700009
J	An, HT; Yoo, S; Ko, J				An, H-T; Yoo, S.; Ko, J.			alpha-Actinin-4 induces the epithelial-to-mesenchymal transition and tumorigenesis via regulation of Snail expression and beta-catenin stabilization in cervical cancer	ONCOGENE			English	Article							E-CADHERIN EXPRESSION; WNT SIGNALING PATHWAY; TRANSCRIPTION FACTOR; N-CADHERIN; DOWN-REGULATION; CELL-MIGRATION; OVARIAN-CANCER; KAPPA-B; INVASION; ACTININ-4	alpha-Actinin-4 (ACTN4) is frequently amplified and overexpressed in various cancers. Although ACTN4 functions in cancer cell migration and invasion, the roles of ACTN4 during the epithelial-to-mesenchymal transition (EMT) and cervical cancer tumorigenesis are unknown. In this study, we investigated the function of ACTN4 in the progression of cervical cancer and the mechanisms of EMT and tumorigenesis induced by ACTN4. We found that ACTN4 induced EMT by upregulating Snail, which was dependent on the Akt signaling pathway in cervical cancer. ACTN4 induced cell migration and invasion through Snail-mediated matrix metalloproteinase-9 expression. ACTN4 expression level was correlated with stabilization of beta-catenin. Accumulatioin of beta-catenin owing to ACTN4 induced tumorigenesis via upregulation of genes involved in cell proliferation, including cyclin D1 and c-myc. ACTN4 knockdown reduced cervical cancer cell proliferation and tumor formation in vivo. The expression level of ACTN4 is highly elevated in human cervical tumors, compared with that in normal cervical tissues. ACTN4-overexpressing MDCK cells induced tumor formation and metastatic nodules in nude mice. Our findings indicate that ACTN4 promotes EMT and tumorigenesis by regulating Snail expression and the Akt pathway in cervical cancer. We propose a novel mechanism for EMT and tumorigenesis in cervical cancer.	[An, H-T; Yoo, S.; Ko, J.] Korea Univ, Div Life Sci, 5-1 Anam Dong, Seoul 136701, South Korea	Korea University	Ko, J (corresponding author), Korea Univ, Div Life Sci, 5-1 Anam Dong, Seoul 136701, South Korea.	jesangko@korea.ac.kr		An, Hyoung-Tae/0000-0002-0732-2083	Basic Science Research Program [NRF-2014R1A2A2 A01002826]; Tunneling Nanotube Research Center through the National Research Foundation of Korea (NRF) - Korea government (MSIP) [NRF-2015R1A5A1009024]; Korea University Grant	Basic Science Research Program; Tunneling Nanotube Research Center through the National Research Foundation of Korea (NRF) - Korea government (MSIP); Korea University Grant	This work was supported by Basic Science Research Program (NRF-2014R1A2A2 A01002826) and Tunneling Nanotube Research Center (NRF-2015R1A5A1009024) through the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) and the Korea University Grant.	Aksenova V, 2013, ONCOTARGET, V4, P362, DOI 10.18632/oncotarget.901; Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; An HT, 2014, J BIOL CHEM, V289, P4969, DOI 10.1074/jbc.M113.515395; Babakov VN, 2008, EXP CELL RES, V314, P1030, DOI 10.1016/j.yexcr.2007.12.001; Barker N, 2000, BIOESSAYS, V22, P961; Bertelsen BI, 2006, INT J CANCER, V118, P1877, DOI 10.1002/ijc.21461; Bjorklund M, 2005, BBA-REV CANCER, V1755, P37, DOI 10.1016/j.bbcan.2005.03.001; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Bolshakova A, 2007, CELL BIOL INT, V31, P360, DOI 10.1016/j.cellbi.2007.01.021; Brognard J, 2001, CANCER RES, V61, P3986; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chakraborty S, 2006, J BIOL CHEM, V281, P35070, DOI 10.1074/jbc.M602474200; Chausovsky A, 2000, NAT CELL BIOL, V2, P797, DOI 10.1038/35041037; Di Croce L, 2003, EUR J CANCER, V39, P413, DOI 10.1016/S0959-8049(02)00815-8; Ding ZY, 2006, P NATL ACAD SCI USA, V103, P15014, DOI 10.1073/pnas.0606917103; Eastham AM, 2007, CANCER RES, V67, P11254, DOI 10.1158/0008-5472.CAN-07-2253; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hayashida Y, 2005, CANCER RES, V65, P8836, DOI 10.1158/0008-5472.CAN-05-0718; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Honda K, 2005, GASTROENTEROLOGY, V128, P51, DOI 10.1053/j.gastro.2004.10.004; Ilyas M, 1997, J PATHOL, V182, P128; Jawhari A, 1997, GASTROENTEROLOGY, V112, P46, DOI 10.1016/S0016-5085(97)70218-X; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; Kang H, 2011, J BIOL CHEM, V286, P42072, DOI 10.1074/jbc.M111.272302; Kumeta M, 2010, J CELL SCI, V123, P1020, DOI 10.1242/jcs.059568; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Medici D, 2008, MOL BIOL CELL, V19, P4875, DOI 10.1091/mbc.E08-05-0506; Nabeshima K, 2002, PATHOL INT, V52, P255, DOI 10.1046/j.1440-1827.2002.01343.x; Nakayama H, 2001, CANCER, V92, P3037, DOI 10.1002/1097-0142(20011215)92:12<3037::AID-CNCR10171>3.0.CO;2-#; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Polakis P, 2000, GENE DEV, V14, P1837; Prasad SB, 2014, J CANCER, V5, P655, DOI 10.7150/jca.6554; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Schmidt-Ott KM, 2007, DEVELOPMENT, V134, P3177, DOI 10.1242/dev.006544; Seidel B, 2004, ONCOGENE, V23, P5532, DOI 10.1038/sj.onc.1207718; Shao H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013921; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Xu DM, 2010, CANCER RES, V70, P6988, DOI 10.1158/0008-5472.CAN-10-0242; Yamamoto S, 2009, MODERN PATHOL, V22, P499, DOI 10.1038/modpathol.2008.234; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	47	45	47	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5893	5904		10.1038/onc.2016.117	http://dx.doi.org/10.1038/onc.2016.117			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27065319				2022-12-17	WOS:000387560800008
J	Perez, JG; Tran, NL; Rosenblum, MG; Schneider, CS; Connolly, NP; Kim, AJ; Woodworth, GF; Winkles, JA				Perez, J. G.; Tran, N. L.; Rosenblum, M. G.; Schneider, C. S.; Connolly, N. P.; Kim, A. J.; Woodworth, G. F.; Winkles, J. A.			The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics	ONCOGENE			English	Review							CONVECTION-ENHANCED DELIVERY; NF-KAPPA-B; BLOOD-BRAIN-BARRIER; FACTOR-INDUCIBLE 14; RANDOMIZED PHASE-III; MALIGNANT GLIOMAS; WEAK INDUCER; DRUG-DELIVERY; IN-VIVO; TUMOR-GROWTH	Fibroblast growth factor-inducible 14 (Fn14; TNFRSF12A) is the cell surface receptor for the tumor necrosis factor (TNF) family member TNF-like weak inducer of apoptosis (TWEAK). The Fn14 gene is normally expressed at low levels in healthy tissues but expression is significantly increased after tissue injury and in many solid tumor types, including glioblastoma (GB; formerly referred to as 'GB multiforme'). GB is the most common and aggressive primary malignant brain tumor and the current standard-of-care therapeutic regimen has a relatively small impact on patient survival, primarily because glioma cells have an inherent propensity to invade into normal brain parenchyma, which invariably leads to tumor recurrence and patient death. Despite major, concerted efforts to find new treatments, a new GB therapeutic that improves survival has not been introduced since 2005. In this review article, we summarize studies indicating that (i) Fn14 gene expression is low in normal brain tissue but is upregulated in advanced brain cancers and, in particular, in GB tumors exhibiting the mesenchymal molecular subtype; (ii) Fn14 expression can be detected in glioma cells residing in both the tumor core and invasive rim regions, with the maximal levels found in the invading glioma cells located within normal brain tissue; and (iii) TWEAK: Fn14 engagement as well as Fn14 overexpression can stimulate glioma cell migration, invasion and resistance to chemotherapeutic agents in vitro. We also discuss two new therapeutic platforms that are currently in development that leverage Fn14 overexpression in GB tumors as a way to deliver cytotoxic agents to the glioma cells remaining after surgical resection while sparing normal healthy brain cells.	[Perez, J. G.; Schneider, C. S.; Connolly, N. P.; Kim, A. J.; Woodworth, G. F.] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Tran, N. L.] Translat Genom Res Inst, Canc & Cell Biol Div, Phoenix, AZ USA; [Rosenblum, M. G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Kim, A. J.] Univ Maryland, Sch Med, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; [Kim, A. J.; Woodworth, G. F.; Winkles, J. A.] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Winkles, J. A.] Univ Maryland, Sch Med, Dept Surg, UMB BioPk Bldg 1,Room 320,800 West Baltimore St, Baltimore, MD 21201 USA; [Winkles, J. A.] Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; Translational Genomics Research Institute; University of Texas System; UTMD Anderson Cancer Center; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Winkles, JA (corresponding author), Univ Maryland, Sch Med, Dept Surg, UMB BioPk Bldg 1,Room 320,800 West Baltimore St, Baltimore, MD 21201 USA.	jwinkles@som.umaryland.edu	Kim, Anthony/A-1681-2012		NIH [R01 CA177796, T32 CA154274, K25 EB018370, K08 NS090430]; Ben & Catherine Ivy Foundation; Clayton Foundation for Research; DOD CDMRP Lung Cancer Research Program IDEA Award [W81XWH-14-1-0324]; NATIONAL CANCER INSTITUTE [T32CA154274, R01CA177796] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [K25EB018370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM055036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS090430] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ben & Catherine Ivy Foundation; Clayton Foundation for Research; DOD CDMRP Lung Cancer Research Program IDEA Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Drs David Hersh and Rudi Castellani (University of Maryland School of Medicine) for the GB patient MRI images and Fn14 IHC data, respectively. Research in the authors' laboratories is supported, in part, by NIH R01 CA177796 and The Ben & Catherine Ivy Foundation (NLT), The Clayton Foundation for Research (MGR), NIH T32 CA154274 (NPC), NIH K25 EB018370 (AJK), NIH K08 NS090430 (GFW) and DOD CDMRP Lung Cancer Research Program IDEA Award W81XWH-14-1-0324 (JAW).	Agarwal S, 2013, DRUG METAB DISPOS, V41, P33, DOI 10.1124/dmd.112.048322; Agemy L, 2011, P NATL ACAD SCI USA, V108, P17450, DOI 10.1073/pnas.1114518108; Akhtar MJ, 2014, CLIN CHIM ACTA, V436, P78, DOI 10.1016/j.cca.2014.05.004; Alewine C, 2015, ONCOLOGIST, V20, P176, DOI 10.1634/theoncologist.2014-0358; Allard E, 2009, BIOMATERIALS, V30, P2302, DOI 10.1016/j.biomaterials.2009.01.003; Allhenn D, 2012, INT J PHARMACEUT, V436, P299, DOI 10.1016/j.ijpharm.2012.06.025; Aryal M, 2014, ADV DRUG DELIVER REV, V72, P94, DOI 10.1016/j.addr.2014.01.008; Beers R, 2000, CLIN CANCER RES, V6, P2835; Sanz AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047440; Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Bernal GM, 2014, NANOMED-NANOTECHNOL, V10, P149, DOI 10.1016/j.nano.2013.07.003; Bertrand N, 2014, ADV DRUG DELIVER REV, V66, P2, DOI 10.1016/j.addr.2013.11.009; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Blanco-Colio LM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00003; BOBO RH, 1994, P NATL ACAD SCI USA, V91, P2076, DOI 10.1073/pnas.91.6.2076; BREM H, 1995, LANCET, V345, P1008, DOI 10.1016/S0140-6736(95)90755-6; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Brown SAN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065248; Brown SAN, 2010, J BIOL CHEM, V285, P17432, DOI 10.1074/jbc.M110.131979; Burkly LC, 2014, SEMIN IMMUNOL, V26, P229, DOI 10.1016/j.smim.2014.02.006; Burkly LC, 2011, IMMUNOL REV, V244, P99, DOI 10.1111/j.1600-065X.2011.01054.x; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chandramohan V, 2013, CLIN CANCER RES, V19, P4717, DOI 10.1158/1078-0432.CCR-12-3891; Chandramohan V, 2013, INT J CANCER, V132, P2339, DOI 10.1002/ijc.27919; Chandramohan V, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/480429; Chao DT, 2013, J CANCER RES CLIN, V139, P315, DOI 10.1007/s00432-012-1332-x; Chauhan VP, 2013, NAT MATER, V12, P958, DOI 10.1038/nmat3792; Chauhan VP, 2011, ANNU REV CHEM BIOMOL, V2, P281, DOI 10.1146/annurev-chembioeng-061010-114300; Chen Z, 2010, TRENDS MOL MED, V16, P594, DOI 10.1016/j.molmed.2010.08.001; Cheng E, 2015, MOL CANCER RES, V13, P575, DOI 10.1158/1541-7786.MCR-14-0411; Cheng E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00473; Cherry EM, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0273-1; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cloughesy TF, 2014, ANNU REV PATHOL-MECH, V9, P1, DOI 10.1146/annurev-pathol-011110-130324; COOMBER BL, 1987, J NEURO-ONCOL, V5, P299, DOI 10.1007/BF00148386; Culp PA, 2010, CLIN CANCER RES, V16, P497, DOI 10.1158/1078-0432.CCR-09-1929; Danhier F, 2010, J CONTROL RELEASE, V148, P135, DOI 10.1016/j.jconrel.2010.08.027; de Plater L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104227; Desplat-Jego S, 2005, CLIN IMMUNOL, V117, P15, DOI 10.1016/j.clim.2005.06.005; Dhruv H, 2013, J BIOL CHEM, V288, P32261, DOI 10.1074/jbc.M113.493536; Dhruv HD, 2014, CARCINOGENESIS, V35, P218, DOI 10.1093/carcin/bgt289; Dhruv HD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072134; Diaz RJ, 2014, NANOMED-NANOTECHNOL, V10, P1075, DOI 10.1016/j.nano.2013.12.006; Dohi T, 2012, J LEUKOCYTE BIOL, V92, P265, DOI 10.1189/jlb.0112042; Ensign SPF, 2013, J BIOL CHEM, V288, DOI 10.1074/jbc.M113.468686; Feng SLY, 2000, AM J PATHOL, V156, P1253, DOI 10.1016/S0002-9440(10)64996-6; Fortin SP, 2012, MOL CANCER RES, V10, P958, DOI 10.1158/1541-7786.MCR-11-0616; Fortin SP, 2009, MOL CANCER RES, V7, P1871, DOI 10.1158/1541-7786.MCR-09-0194; Fung LK, 1996, PHARM RES-DORDR, V13, P671, DOI 10.1023/A:1016083113123; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Gilbert MR, 2013, J CLIN ONCOL, V31, P4085, DOI 10.1200/JCO.2013.49.6968; Gill BJ, 2014, P NATL ACAD SCI USA, V111, P12550, DOI 10.1073/pnas.1405839111; Girgenrath M, 2006, EMBO J, V25, P5826, DOI 10.1038/sj.emboj.7601441; Gladson CL, 2010, ANNU REV PATHOL-MECH, V5, P33, DOI 10.1146/annurev-pathol-121808-102109; Gu LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057436; Gurunathan S, 2014, J BIOL CHEM, V289, P12976, DOI 10.1074/jbc.M114.563478; Hadjipanayis CG, 2010, CANCER RES, V70, P6303, DOI 10.1158/0008-5472.CAN-10-1022; Halliday J, 2014, P NATL ACAD SCI USA, V111, P5248, DOI 10.1073/pnas.1321014111; Hambardzumyan D, 2009, TRANSL ONCOL, V2, P89, DOI 10.1593/tlo.09100; Hatzikirou H, 2012, MATH MED BIOL, V29, P49, DOI 10.1093/imammb/dqq011; Healy Andrew T, 2015, Surg Neurol Int, V6, pS59, DOI 10.4103/2152-7806.151337; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Ho DH, 2004, CANCER RES, V64, P8968, DOI 10.1158/0008-5472.CAN-04-1879; Hu CMJ, 2012, BIOCHEM PHARMACOL, V83, P1104, DOI 10.1016/j.bcp.2012.01.008; Huang MG, 2011, CARCINOGENESIS, V32, P1589, DOI 10.1093/carcin/bgr182; Huse JT, 2013, ANNU REV MED, V64, P59, DOI 10.1146/annurev-med-100711-143028; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Jain RK, 2010, NAT REV CLIN ONCOL, V7, P653, DOI 10.1038/nrclinonc.2010.139; Jarboe JS, 2007, CANCER RES, V67, P7983, DOI 10.1158/0008-5472.CAN-07-1493; Ji Y, 1996, J NEURO-ONCOL, V30, P189; Joo KM, 2013, CELL REP, V3, P260, DOI 10.1016/j.celrep.2012.12.013; Juratli TA, 2013, PHARMACOL THERAPEUT, V139, P341, DOI 10.1016/j.pharmthera.2013.05.003; Kawakita T, 2004, BIOCHEM BIOPH RES CO, V318, P726, DOI 10.1016/j.bbrc.2004.04.084; Kim SS, 2015, NANOMED-NANOTECHNOL, V11, P301, DOI 10.1016/j.nano.2014.09.005; Kioi M, 2008, MOL CANCER THER, V7, P1579, DOI 10.1158/1535-7163.MCT-07-2131; Kuan CT, 2011, INT J CANCER, V129, P111, DOI 10.1002/ijc.25645; Kunwar S, 2007, J CLIN ONCOL, V25, P837, DOI 10.1200/JCO.2006.08.1117; Kunwar S, 2010, NEURO-ONCOLOGY, V12, P871, DOI 10.1093/neuonc/nop054; Lassen UN, 2015, CLIN CANCER RES, V21, P258, DOI 10.1158/1078-0432.CCR-14-1334; Lewis GK, 2012, J NEUROSURG, V117, P1128, DOI 10.3171/2012.7.JNS11144; Li A, 2009, CANCER RES, V69, P2091, DOI 10.1158/0008-5472.CAN-08-2100; Li XP, 2014, ANTI-CANCER DRUG, V25, P1152, DOI 10.1097/CAD.0000000000000153; Li YM, 2013, J NEURO-ONCOL, V114, P155, DOI 10.1007/s11060-013-1157-8; Lin BR, 2012, ANN SURG ONCOL, V19, pS385, DOI 10.1245/s10434-011-1825-x; Lipsman N, 2014, NEUROTHERAPEUTICS, V11, P593, DOI 10.1007/s13311-014-0281-2; Liu TF, 2005, CLIN CANCER RES, V11, P329; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; Madhankumar AB, 2009, MOL CANCER THER, V8, P648, DOI 10.1158/1535-7163.MCT-08-0853; Maeda H, 2013, ADV DRUG DELIVER REV, V65, P71, DOI 10.1016/j.addr.2012.10.002; Mangraviti Antonella, 2015, Surg Neurol Int, V6, pS78, DOI 10.4103/2152-7806.151345; Mariani L, 2001, J NEURO-ONCOL, V53, P161, DOI 10.1023/A:1012253317934; Meighan-Mantha RL, 1999, J BIOL CHEM, V274, P33166, DOI 10.1074/jbc.274.46.33166; Meyer M, 2015, P NATL ACAD SCI USA, V112, P851, DOI 10.1073/pnas.1320611111; Michaelson JS, 2011, MABS-AUSTIN, V3, P362, DOI 10.4161/mabs.3.4.16090; Mueller S, 2011, J NEURO-ONCOL, V101, P267, DOI 10.1007/s11060-010-0255-0; Murad GJA, 2006, CLIN CANCER RES, V12, P3145, DOI 10.1158/1078-0432.CCR-05-2583; Nakada M, 2007, CELL MOL LIFE SCI, V64, P458, DOI 10.1007/s00018-007-6342-5; Nance E, 2014, ACS NANO, V8, P10655, DOI 10.1021/nn504210g; Nance EA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003594; NICHOLSON C, 1993, BIOPHYS J, V65, P2277, DOI 10.1016/S0006-3495(93)81324-9; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Ostrom Q.T., 2014, NEUROONCOL S4, V16, piv1, DOI DOI 10.1093/NEU0NC/N0U223; Pang ZQ, 2011, BIOCONJUGATE CHEM, V22, P1171, DOI 10.1021/bc200062q; Pardridge William M, 2005, NeuroRx, V2, P3; Parker NR, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00055; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Pelekanou V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083250; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Prabhakar U, 2013, CANCER RES, V73, P2412, DOI 10.1158/0008-5472.CAN-12-4561; Rand RW, 2000, CLIN CANCER RES, V6, P2157; Roos C, 2010, J IMMUNOL, V185, P1593, DOI 10.4049/jimmunol.0903555; Rustamzadeh E, 2006, INT J CANCER, V118, P2594, DOI 10.1002/ijc.21647; Rustamzadeh E, 2007, INT J CANCER, V120, P411, DOI 10.1002/ijc.22278; del Burgo LS, 2014, NANOMED-NANOTECHNOL, V10, P905, DOI 10.1016/j.nano.2013.10.001; Salzmann S, 2013, J BIOL CHEM, V288, P13455, DOI 10.1074/jbc.M112.435917; Sampson JH, 2008, NEURO-ONCOLOGY, V10, P320, DOI 10.1215/15228517-2008-012; Sampson JH, 2007, NEUROSURGERY, V60, P89, DOI 10.1227/01.NEU.0000249256.09289.5F; Sampson JH, 2011, NEUROSURGERY, V69, P668, DOI 10.1227/NEU.0b013e3182181ba8; Sampson JH, 2010, J NEUROSURG, V113, P301, DOI 10.3171/2009.11.JNS091052; Schneider CS, 2015, BIOMATERIALS, V42, P42, DOI 10.1016/j.biomaterials.2014.11.054; Shimada K, 2012, CLIN CANCER RES, V18, P5247, DOI 10.1158/1078-0432.CCR-12-0955; Shirahata M, 2007, CLIN CANCER RES, V13, P7341, DOI 10.1158/1078-0432.CCR-06-2789; Shirahata M, 2009, CANCER SCI, V100, P165, DOI 10.1111/j.1349-7006.2008.01002.x; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Sugahara KN, 2009, CANCER CELL, V16, P510, DOI 10.1016/j.ccr.2009.10.013; Sullivan JP, 2014, CANCER DISCOV, V4, P1299, DOI 10.1158/2159-8290.CD-14-0471; Suzuki A, 2014, J NUCL MED, V55, P1323, DOI 10.2967/jnumed.114.138404; Sykova E, 2008, PHYSIOL REV, V88, P1277, DOI 10.1152/physrev.00027.2007; Tailor TD, 2010, MOL CANCER THER, V9, P1798, DOI 10.1158/1535-7163.MCT-09-0856; Tanner PG, 2007, NEUROSURGERY, V61, P880, DOI 10.1227/01.NEU.0000298922.77921.F2; Teesalu T, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00216; Thorne RG, 2006, P NATL ACAD SCI USA, V103, P5567, DOI 10.1073/pnas.0509425103; Torchilin VP, 2014, NAT REV DRUG DISCOV, V13, P813, DOI 10.1038/nrd4333; Tran NL, 2006, CANCER RES, V66, P9535, DOI 10.1158/0008-5472.CAN-06-0418; Tran NL, 2005, J BIOL CHEM, V280, P3483, DOI 10.1074/jbc.M409906200; Tran NL, 2003, AM J PATHOL, V162, P1313, DOI 10.1016/S0002-9440(10)63927-2; Tzeng SY, 2013, THER DELIV, V4, P687, DOI [10.4155/tde.13.38, 10.4155/TDE.13.38]; Vallera DA, 2002, J NATL CANCER I, V94, P597; van der Meel R, 2013, ADV DRUG DELIVER REV, V65, P1284, DOI 10.1016/j.addr.2013.08.012; van Tellingen O, 2015, DRUG RESIST UPDATE, V19, P1, DOI 10.1016/j.drup.2015.02.002; Varfolomeev E, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2001878; Vargova L, 2003, GLIA, V42, P77, DOI 10.1002/glia.10204; Vehlow A, 2013, BBA-REV CANCER, V1836, P236, DOI 10.1016/j.bbcan.2013.07.001; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wait SD, 2015, NEURO-ONCOLOGY, V17, pII9, DOI 10.1093/neuonc/nou360; Wajant H, 2013, BRIT J PHARMACOL, V170, P748, DOI 10.1111/bph.12337; Wang AZ, 2012, ANNU REV MED, V63, P185, DOI 10.1146/annurev-med-040210-162544; Watts GS, 2007, INT J CANCER, V121, P2132, DOI 10.1002/ijc.22898; Weaver M, 2003, J NEURO-ONCOL, V65, P3, DOI 10.1023/A:1026246500788; Weber F, 2003, J NEURO-ONCOL, V64, P125, DOI 10.1007/BF02700027; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Whitsett TG, 2014, CLIN EXP METASTAS, V31, P613, DOI 10.1007/s10585-014-9653-6; Whitsett TG, 2012, AM J PATHOL, V181, P111, DOI 10.1016/j.ajpath.2012.03.026; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; Willis AL, 2008, MOL CANCER RES, V6, P725, DOI 10.1158/1541-7786.MCR-08-0005; Winkles JA, 2006, CANCER LETT, V235, P11, DOI 10.1016/j.canlet.2005.03.048; Winkles JA, 2008, NAT REV DRUG DISCOV, V7, P411, DOI 10.1038/nrd2488; Winkles JA, 2007, FRONT BIOSCI-LANDMRK, V12, P2761, DOI 10.2741/2270; Wisniacki N, 2013, CLIN THER, V35, P1137, DOI 10.1016/j.clinthera.2013.06.008; Wolburg H, 2012, MOL ASPECTS MED, V33, P579, DOI 10.1016/j.mam.2012.02.003; Woodworth GE, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00126; Wykosky J, 2007, MOL CANCER THER, V6, P3208, DOI 10.1158/1535-7163.MCT-07-0200; Xi GF, 2014, NANOMED-NANOTECHNOL, V10, P381, DOI 10.1016/j.nano.2013.07.013; Xie Q, 2014, NEURO-ONCOLOGY, V16, P1575, DOI 10.1093/neuonc/nou147; Xu XY, 2015, TRENDS MOL MED, V21, P223, DOI 10.1016/j.molmed.2015.01.001; Yin JJ, 2014, CANCER RES, V74, P4306, DOI 10.1158/0008-5472.CAN-13-3233; Yin XF, 2013, CLIN CANCER RES, V19, P5686, DOI 10.1158/1078-0432.CCR-13-0405; Yoriki R, 2011, EXP THER MED, V2, P103, DOI 10.3892/etm.2010.181; Zhou H, 2014, MOL CANCER THER, V13, P2688, DOI 10.1158/1535-7163.MCT-14-0346; Zhou H, 2013, CANCER RES, V73, P4439, DOI 10.1158/0008-5472.CAN-13-0187; Zhou H, 2013, J INVEST DERMATOL, V133, P1052, DOI 10.1038/jid.2012.402; Zhou H, 2011, MOL CANCER THER, V10, P1276, DOI 10.1158/1535-7163.MCT-11-0161; Zhou JB, 2013, P NATL ACAD SCI USA, V110, P11751, DOI 10.1073/pnas.1304504110	180	45	46	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2145	2155		10.1038/onc.2015.310	http://dx.doi.org/10.1038/onc.2015.310			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26300004	Green Accepted			2022-12-17	WOS:000374986000001
J	Venturutti, L; Romero, LV; Urtreger, AJ; Chervo, MF; Russo, RIC; Mercogliano, MF; Inurrigarro, G; Pereyra, MG; Proietti, CJ; Izzo, F; Flaque, MCD; Sundblad, V; Roa, JC; Guzman, P; Joffe, EDBD; Charreau, EH; Schillaci, R; Elizalde, PV				Venturutti, L.; Romero, L. V.; Urtreger, A. J.; Chervo, M. F.; Cordo Russo, R. I.; Mercogliano, M. F.; Inurrigarro, G.; Pereyra, M. G.; Proietti, C. J.; Izzo, F.; Diaz Flaque, M. C.; Sundblad, V.; Roa, J. C.; Guzman, P.; Bal de Kier Joffe, E. D.; Charreau, E. H.; Schillaci, R.; Elizalde, P. V.			Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis	ONCOGENE			English	Article							PROGESTERONE-RECEPTOR; MICRORNA EXPRESSION; SIGNAL TRANSDUCER; TRANSGENIC MICE; MAMMARY-TUMORS; UP-REGULATION; TRANSCRIPTIONAL COMPLEX; TISSUE INHIBITOR; ACTIVATION; GROWTH	Membrane overexpression of the receptor tyrosine kinase ErbB-2 (MErbB-2) accounts for a clinically aggressive breast cancer (BC) subtype (ErbB-2-positive) with increased incidence of metastases. We and others demonstrated that nuclear ErbB-2 (NErbB-2) also plays a key role in BC and is a poor prognostic factor in ErbB-2-positive tumors. The signal transducer and activator of transcription 3 (Stat3), another player in BC, has been recognized as a downstream mediator of MErbB-2 action in BC metastasis. Here, we revealed an unanticipated novel direction of the ErbB-2 and Stat3 interaction underlying BC metastasis. We found that Stat3 binds to its response elements (GAS) at the ErbB-2 promoter to upregulate ErbB-2 transcription in metastatic, ErbB-2-positive BC. We validated these results in several BC subtypes displaying metastatic and non-metastatic ability, highlighting Stat3 general role as upstream regulator of ErbB-2 expression in BC. Moreover, we showed that Stat3 co-opts NErbB-2 function by recruiting ErbB-2 as its coactivator at the GAS sites in the promoter of microRNA-21 (miR-21), a metastasis-promoting microRNA (miRNA). Using an ErbB-2 nuclear localization domain mutant and a constitutively activated ErbB-2 variant, we found that NErbB-2 role as a Stat3 coactivator and also its direct role as transcription factor upregulate miR-21 in BC. This reveals a novel function of NErbB-2 as a regulator of miRNAs expression. Increased levels of miR-21, in turn, downregulate the expression of the metastasis-suppressor protein programmed cell death 4 (PDCD4), a validated miR-21 target. Using an in vivo model of metastatic ErbB-2-postive BC, in which we silenced Stat3 and reconstituted ErbB-2 or miR-21 expression, we showed that both are downstream mediators of Stat3-driven metastasis. Supporting the clinical relevance of our results, we found an inverse correlation between ErbB-2/Stat3 nuclear co-expression and PDCD4 expression in ErbB-2-positive primary invasive BCs. Our findings identify Stat3 and NErbB-2 as novel therapeutic targets to inhibit ErbB-2-positive BC metastasis.	[Venturutti, L.; Romero, L. V.; Chervo, M. F.; Cordo Russo, R. I.; Mercogliano, M. F.; Pereyra, M. G.; Proietti, C. J.; Izzo, F.; Diaz Flaque, M. C.; Sundblad, V.; Charreau, E. H.; Schillaci, R.; Elizalde, P. V.] Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, Lab Mol Mech Carcinogenesis, RA-1033 Buenos Aires, DF, Argentina; [Urtreger, A. J.; Bal de Kier Joffe, E. D.] Univ Buenos Aires, Inst Oncol Angel H Roffo, Res Area, Buenos Aires, DF, Argentina; [Inurrigarro, G.] Sanatorio Mater Dei, Serv Patol, Buenos Aires, DF, Argentina; [Roa, J. C.; Guzman, P.] Univ La Frontera, Dept Anat Patol BIOREN, Temuco, Chile; [Roa, J. C.] Pontificia Univ Catolica Chile, Escuela Med, Dept Anat Patol, Santiago, Chile; [Roa, J. C.] Pontificia Univ Catolica Chile, Adv Ctr Chron Dis ACCDIS, Santiago, Chile	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; University of Buenos Aires; Universidad de La Frontera; Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile	Schillaci, R; Elizalde, PV (corresponding author), Inst Biol & Med Expt IBYME, Lab Mol Mech Carcinogenesis, Vuelta de Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	rschillaci@ibyme.conicet.gov.ar; patriciaelizalde@ibyme.conicet.gov.ar	Roa, Juan C./K-4749-2014; Russo, Rosalia Cordo/O-9149-2017	Roa, Juan C./0000-0001-8313-8774; Russo, Rosalia Cordo/0000-0002-5984-9717; Mercogliano, Maria Florencia/0000-0003-1094-9247; Chervo, Maria Florencia/0000-0001-8878-5591; BAL de KIER JOFFE, ELISA DORA/0000-0001-6952-0029; Elizalde, Patricia V./0000-0002-5923-9898; Diaz Flaque, Maria Celeste/0000-0003-4167-6149	Susan G Komen for the Cure [KG090250]; National Agency of Scientific Promotion of Argentina [IDB/PICT 2012-668, PID 2012-066, IDB/PICT 2012-0382]; Oncomed-Reno CONICET from Henry Moore Institute of Argentina [1819/03]	Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); National Agency of Scientific Promotion of Argentina(ANPCyT); Oncomed-Reno CONICET from Henry Moore Institute of Argentina	We thank MC Hung (MD Anderson Cancer Center, Houston, TX, USA) for his generous gift of the hErbB-2.NLS, which indeed made this work possible, AA Molinolo (NIH, Bethesda, MD, USA) for his constant help and support and V Chiauzzi for her technical assistance. This work was supported by the Susan G Komen for the Cure KG090250 investigator-initiated research Grant, and IDB/PICT 2012-668 and PID 2012-066 from the National Agency of Scientific Promotion of Argentina, all of them awarded to PVE, IDB/PICT 2012-0382 (awarded to RS) and Oncomed-Reno CONICET 1819/03, from the Henry Moore Institute of Argentina (awarded to PVE and RS).	AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Alonso DF, 1999, BREAST CANCER RES TR, V57, P271, DOI 10.1023/A:1006291607871; Balana ME, 2001, ONCOGENE, V20, P34, DOI 10.1038/sj.onc.1204050; Barbieri I, 2010, CANCER RES, V70, P2558, DOI 10.1158/0008-5472.CAN-09-2840; Barbieri I, 2010, MOL CARCINOGEN, V49, P114, DOI 10.1002/mc.20605; Bates NP, 1997, ONCOGENE, V15, P473, DOI 10.1038/sj.onc.1201368; Beguelin W, 2010, MOL CELL BIOL, V30, P5456, DOI 10.1128/MCB.00012-10; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; Bourguignon LYW, 2012, ONCOGENE, V31, P149, DOI 10.1038/onc.2011.222; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Carnevale RP, 2007, MOL ENDOCRINOL, V21, P1335, DOI 10.1210/me.2006-0304; Chen J, 2014, CLIN TRANSL ONCOL, V16, P225, DOI 10.1007/s12094-013-1132-z; Russo RIC, 2015, ONCOGENE, V34, P3413, DOI 10.1038/onc.2014.272; Delacroix L, 2005, DNA CELL BIOL, V24, P582, DOI 10.1089/dna.2005.24.582; Flaque MCD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3587; Flaque MCD, 2013, STEROIDS, V78, P559, DOI 10.1016/j.steroids.2012.11.003; Finkle D, 2004, CLIN CANCER RES, V10, P2499, DOI 10.1158/1078-0432.CCR-03-0448; Freudenberg JA, 2009, EXP MOL PATHOL, V87, P1, DOI 10.1016/j.yexmp.2009.05.001; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Gomez-Martin C, 2014, CANCER LETT, V351, P30, DOI 10.1016/j.canlet.2014.05.019; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Han ML, 2012, MOL CELL BIOCHEM, V363, P427, DOI 10.1007/s11010-011-1195-5; Henderson IC, 1998, BREAST CANCER RES TR, V52, P261, DOI 10.1023/A:1006141703224; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Huang TH, 2009, J BIOL CHEM, V284, P18515, DOI 10.1074/jbc.M109.006676; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Izzo F, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0491-x; Kamran MZ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/421821; Kang HJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep07201; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Landgraf R, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1633; Li CH, 2014, EUR J CANCER, V50, P2560, DOI 10.1016/j.ejca.2014.07.008; Li LY, 2011, CANCER RES, V71, P4269, DOI 10.1158/0008-5472.CAN-10-3504; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lui WO, 2007, CANCER RES, V67, P6031, DOI 10.1158/0008-5472.CAN-06-0561; Marino ALF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-739; Meric-Bernstam F, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3343; Mitsui K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-863; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Nieves-Alicea R, 2009, BREAST CANCER RES TR, V114, P203, DOI 10.1007/s10549-008-9993-5; Niu JX, 2012, J BIOL CHEM, V287, P21783, DOI 10.1074/jbc.M112.355495; O'Brien NA, 2010, MOL CANCER THER, V9, P1489, DOI 10.1158/1535-7163.MCT-09-1171; Ou HS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109929; Peters MG, 2003, BREAST CANCER RES TR, V80, P221, DOI 10.1023/A:1024549729256; Petrovic N, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0867-x; Proietti C, 2005, MOL CELL BIOL, V25, P4826, DOI 10.1128/MCB.25.12.4826-4840.2005; Proietti CJ, 2009, MOL CELL BIOL, V29, P1249, DOI 10.1128/MCB.00853-08; Puricelli L, 2002, INT J CANCER, V100, P642, DOI 10.1002/ijc.10533; Qian L, 2006, BIOCHEM BIOPH RES CO, V345, P660, DOI 10.1016/j.bbrc.2006.04.153; Ranger JJ, 2009, CANCER RES, V69, P6823, DOI 10.1158/0008-5472.CAN-09-1684; Rivas MA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3187; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Schillaci R, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-74; Shishodia G, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-996; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Song B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-29; Tao RH, 2008, J CELL SCI, V121, P3207, DOI 10.1242/jcs.033399; Tetzlaff MT, 2007, ENDOCR PATHOL, V18, P163, DOI 10.1007/s12022-007-0023-7; Tran N, 2007, BIOCHEM BIOPH RES CO, V358, P12, DOI 10.1016/j.bbrc.2007.03.201; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Urtreger AJ, 1997, INT J ONCOL, V11, P489; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Welch DR, 1997, CLIN EXP METASTAS, V15, P272, DOI 10.1023/A:1018477516367; Wen YH, 2007, ONCOL REP, V18, P1387; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808; Yan M, 2014, CANCER TREAT REV, V40, P770, DOI 10.1016/j.ctrv.2014.02.008; Yang CH, 2011, J BIOL CHEM, V286, P39172, DOI 10.1074/jbc.M111.285098; Yang CH, 2010, CANCER RES, V70, P8108, DOI 10.1158/0008-5472.CAN-10-2579; Zhang J, 2012, BRIT J CANCER, V107, P352, DOI 10.1038/bjc.2012.251; Zhang ZY, 2008, LAB INVEST, V88, P1358, DOI 10.1038/labinvest.2008.94; Zhou X, 2014, ONCOL REP, V31, P2173, DOI 10.3892/or.2014.3114; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24; Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034	79	45	47	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2208	2222		10.1038/onc.2015.281	http://dx.doi.org/10.1038/onc.2015.281			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26212010	Green Published			2022-12-17	WOS:000374986000007
J	Wang, J; Ding, S; Duan, Z; Xie, Q; Zhang, T; Zhang, X; Wang, Y; Chen, X; Zhuang, H; Lu, F				Wang, J.; Ding, S.; Duan, Z.; Xie, Q.; Zhang, T.; Zhang, X.; Wang, Y.; Chen, X.; Zhuang, H.; Lu, F.			Role of p14ARF-HDM2-p53 axis in SOX6-mediated tumor suppression	ONCOGENE			English	Article							NUCLEOLAR-LOCALIZATION; NUCLEOPHOSMIN B23; DOWN-REGULATION; NUCLEAR EXPORT; P53 PROTEIN; ARF; SOX6; MDM2; HDM2; UBIQUITINATION	Sex-determining region Y box 6 (SOX6) has been described as a tumor-suppressor gene in several cancers. Our previous work has suggested that SOX6 upregulated p21(Waf1/Cip1)(p21) expression in a p53-dependent manner; however, the underlying mechanism has remained elusive. In this study, we confirmed that SOX6 can suppress cell proliferation in vitro and in vivo by stabilizing p53 protein and subsequently upregulating p21. Co-immunoprecipitation and immunocytofluorescence assays demonstrated that SOX6 can promote formation of the p14ARF-HDM2-p53 ternary complex by promoting translocation of p14ARF (p14 alternate reading frame tumor suppressor) to the nucleoplasm, thereby inhibiting HDM2-mediated p53 nuclear export and degradation. Chromatin immunoprecipitation combined with PCR assay proved that SOX6 can bind to a potential binding site in the regulatory region of the c-Myc gene. Furthermore, we confirmed that SOX6 can downregulate the expression of c-Myc, as well as its direct target gene nucleophosmin 1 (NPM1), and that the SOX6-induced downregulation of NPM1 is linked to translocation of p14ARF to the nucleoplasm. Finally, we showed that the highly conserved high-mobility group (HMG) domain of SOX6 is required for SOX6-mediated p53 stabilization and tumor inhibitory activity. Collectively, these results reveal a new mechanism of SOX6-mediated tumor suppression involving p21 upregulation via the p14ARF-HDM2-p53 axis in an HMG domain-dependent manner.	Peking Univ, Dept Microbiol, Sch Basic Med, Hlth Sci Ctr, Beijing 100871, Peoples R China; Peking Univ, Ctr Infect Dis, Sch Basic Med, Hlth Sci Ctr, Beijing 100871, Peoples R China	Peking University; Peking University	Chen, X; Lu, F (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Microbiol, 38 Xueyuan Rd, Beijing 100191, Peoples R China.; Chen, X; Lu, F (corresponding author), Peking Univ, Hlth Sci Ctr, Ctr Infect Dis, 38 Xueyuan Rd, Beijing 100191, Peoples R China.	xm_chen6176@bjmu.edu.cn; lu.fengmin@hsc.pku.edu.cn		Wang, Jie/0000-0001-6518-948X	973 Program [2015CB554000]; National S & T Major Project for Infectious Diseases [2012ZX10004-904]; Ministry of Education of China [20110001120017]; National Natural Science Foundation of China [81372603]; 111 Project [B07001]	973 Program(National Basic Research Program of China); National S & T Major Project for Infectious Diseases; Ministry of Education of China(Ministry of Education, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 111 Project(Ministry of Education, China - 111 Project)	This work was supported by grants from the 973 Program (2015CB554000), the National S & T Major Project for Infectious Diseases (2012ZX10004-904), the Doctoral Fund and of the Ministry of Education of China (20110001120017), the National Natural Science Foundation of China (81372603) and the 111 Project (B07001).	Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883; Cantu C, 2011, BLOOD, V117, P3669, DOI 10.1182/blood-2010-04-282350; Cantu' C, 2011, NUCLEIC ACIDS RES, V39, P486, DOI 10.1093/nar/gkq819; Chen DL, 2013, MOL CELL, V51, P46, DOI 10.1016/j.molcel.2013.05.006; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Gu JJ, 2001, CANCER RES, V61, P6703; Guo XD, 2013, CANCER EPIDEMIOL, V37, P732, DOI 10.1016/j.canep.2013.05.002; Hagiwara N, 2011, DEV DYNAM, V240, P1311, DOI 10.1002/dvdy.22639; Hamilton G, 2014, ONCOTARGET, V5, P6142, DOI 10.18632/oncotarget.2178; Huang YH, 2003, CANCER RES, V63, P3646; Iguchi H, 2007, J BIOL CHEM, V282, P19052, DOI 10.1074/jbc.M700460200; Kamachi Y, 2013, DEVELOPMENT, V140, P4129, DOI 10.1242/dev.091793; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lee C, 2005, CANCER RES, V65, P9834, DOI 10.1158/0008-5472.CAN-05-1759; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qin YR, 2011, CLIN CANCER RES, V17, P46, DOI 10.1158/1078-0432.CCR-10-1155; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795; Wang SS, 2012, J HEPATOL, V57, P322, DOI 10.1016/j.jhep.2012.03.029; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Wierstra I, 2008, ADV CANCER RES, V99, P113, DOI 10.1016/S0065-230X(07)99004-1; Xie Q, 2012, CANCER-AM CANCER SOC, V118, P2431, DOI 10.1002/cncr.26566; Zeller KI, 2001, J BIOL CHEM, V276, P48285, DOI 10.1074/jbc.M108506200; Zhang X, 2014, J VIRAL HEPATITIS, V21, P264, DOI 10.1111/jvh.12137; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	36	45	46	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1692	1702		10.1038/onc.2015.234	http://dx.doi.org/10.1038/onc.2015.234			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26119940	Green Published, hybrid			2022-12-17	WOS:000373064200008
J	Chang, YW; Tseng, CF; Wang, MY; Chang, WC; Lee, CC; Chen, LT; Hung, MC; Su, JL				Chang, Y-W; Tseng, C-F; Wang, M-Y; Chang, W-C; Lee, C-C; Chen, L-T; Hung, M-C; Su, J-L			Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer	ONCOGENE			English	Article							GLUCOSE-REGULATED PROTEIN; MOTILITY-FACTOR-RECEPTOR; HMG-COA REDUCTASE; ENDOPLASMIC-RETICULUM; PROTEASOME-SYSTEM; PROSTATE-CANCER; CELL-PROLIFERATION; CYP3A4 EXPRESSION; ADP-RIBOSYLATION; DOWN-REGULATION	Heat-shock protein 5 (HSPA5) is a marker for poor prognosis in breast cancer patients and has an important role in cancer progression, including promoting drug resistance and metastasis. In this study, we identify that the specific lysine residue 447 (K447) of HSPA5 could be modified with polyubiquitin for subsequent degradation through the ubiquitin proteasomal system, leading to the suppression of cell migration and invasion of breast cancer. We further found that GP78, an E3 ubiquitin ligase, interacted with the C-terminal region of HSPA5 and mediated HSPA5 ubiquitination and degradation. Knock down of GP78 significantly increased the expression of HSPA5 and enhanced migration/invasive ability of breast cancer cells. Knock down of histone deacetylase-6 (HDAC6) increased the acetylation of HSPA5 at lysine residues 353 (K353) and reduced GP78-mediated ubiquitination of HSPA5 at K447 and then increased cell migration/invasion. In addition, we demonstrate that E3 ubiquitin ligase GP78 preferentially binds to deacetylated HSPA5. Notably, the expression levels of GP78 inversely correlated with HSPA5 levels in breast cancer patients. Patients with low GP78 expression significantly correlated with invasiveness of breast cancer, advanced tumor stages and poor clinical outcome. Taken together, our results provide new mechanistic insights into the understanding that deacetylation of HSPA5 by HDAC6 facilitates GP78-mediated HSPA5 ubiquitination and suggest that post-translational regulation of HSPA5 protein is critical for HSPA5-mediated metastatic properties of breast cancer.	[Chang, Y-W; Tseng, C-F; Chen, L-T; Su, J-L] Natl Hlth Res Inst, Natl Inst Canc Res, 35 Keyan Rd, Zhunan 35053, Miaoli County, Taiwan; [Tseng, C-F] Natl Tsing Hua Univ, Coll Life Sci, Grad Program Biotechnol Med, Hsinchu, Taiwan; [Wang, M-Y] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Chang, W-C; Su, J-L] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Lee, C-C] Acad Sinica, Core Facil Prot Struct Anal, Taipei 115, Taiwan; [Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Su, J-L] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan; [Su, J-L] Asia Univ, Dept Biotechnol, Taichung, Taiwan	National Health Research Institutes - Taiwan; National Tsing Hua University; National Taiwan University; National Taiwan University Hospital; China Medical University Taiwan; Academia Sinica - Taiwan; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan	Su, JL (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, 35 Keyan Rd, Zhunan 35053, Miaoli County, Taiwan.	jlsu@nhri.org.tw	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	National Science Council grant from Taiwan [NSC 99-2314-B-400-006-MY3, NSC 101-2320-B-400-016-MY3, NSC 102-2314-B-038-028-MY3, NSC 103-2314-B-038-059, MOST 103-2628-B-006-003-MY3]; National Health Research Institutes grant from Taiwan [CA-102-PP-41, CA-103-PP-35, CA-104-SP-01, CA-104-PP-12, MOHW104-TDU-B-212-124-008]; Ministry of Health and Welfare, Taiwan [DOH101-TD-PB-111-NSC015, DOH 102-TD-C-111-004]; Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare grant from Taiwan [103TMU-SHH-26]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	National Science Council grant from Taiwan; National Health Research Institutes grant from Taiwan; Ministry of Health and Welfare, Taiwan; Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare grant from Taiwan; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Science Council grant from Taiwan (NSC 99-2314-B-400-006-MY3, NSC 101-2320-B-400-016-MY3, NSC 102-2314-B-038-028-MY3, NSC 103-2314-B-038-059, MOST 103-2628-B-006-003-MY3); National Health Research Institutes grant from Taiwan (CA-102-PP-41, CA-103-PP-35, CA-104-SP-01, CA-104-PP-12, MOHW104-TDU-B-212-124-008); Ministry of Health and Welfare, Taiwan (DOH101-TD-PB-111-NSC015, DOH 102-TD-C-111-004); and Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare grant from Taiwan (103TMU-SHH-26). We thank Ms Fang-Yu Tsai and Dr I-Shou Chang of Taiwan Bioinformatics Institute Core Facility for assistance on using Oncomine (National Core Facility Program for Biotechnology, NSC-100-2319-B-400-001). We thank Dr Shiu-Feng Huang and Dr Yu-Ting Chiu of National Health Research Institutes pathology core lab for assistance in pathology services.	Bassermann F, 2014, BBA-MOL CELL RES, V1843, P150, DOI 10.1016/j.bbamcr.2013.02.028; Bedford L, 2011, NAT REV DRUG DISCOV, V10, P29, DOI 10.1038/nrd3321; Bertrand J, 2013, PROTEOMICS, V13, P3284, DOI 10.1002/pmic.201300082; CARLSSON L, 1983, P NATL ACAD SCI-BIOL, V80, P4664, DOI 10.1073/pnas.80.15.4664; Chan CH, 2012, CELL, V149, P1098, DOI 10.1016/j.cell.2012.02.065; Chang YW, 2014, ONCOTARGET, V5, P10558, DOI 10.18632/oncotarget.2510; Chang YJ, 2010, ANN SURG ONCOL, V17, P1703, DOI 10.1245/s10434-010-0912-8; Chen B, 2006, P NATL ACAD SCI USA, V103, P341, DOI 10.1073/pnas.0506618103; Chiu CC, 2008, MOL CANCER THER, V7, P2788, DOI 10.1158/1535-7163.MCT-08-0172; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950; Dong DZ, 2011, CANCER RES, V71, P2848, DOI 10.1158/0008-5472.CAN-10-3151; Fairbank M, 2009, MOL BIOSYST, V5, P793, DOI 10.1039/b820820b; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; Festing Michael F W, 2002, ILAR J, V43, P244; Floriano-Sanchez E, 2014, ASIAN PAC J CANCER P, V15, P3805, DOI 10.7314/APJCP.2014.15.8.3805; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; Fujimura T, 2012, CANCER SCI, V103, P176, DOI 10.1111/j.1349-7006.2011.02143.x; Gazit G, 1999, BREAST CANCER RES TR, V54, P135, DOI 10.1023/A:1006102411439; Haga A, 2006, LEUKEMIA LYMPHOMA, V47, P2234, DOI 10.1080/10428190600773263; Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; Hesling C, 2004, J INVEST DERMATOL, V122, P369, DOI 10.1046/j.0022-202X.2004.22212.x; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hirono Y, 1996, BRIT J CANCER, V74, P2003, DOI 10.1038/bjc.1996.667; His M, 2014, EUR J EPIDEMIOL, V29, P119, DOI 10.1007/s10654-014-9884-5; Jo Y, 2010, CRIT REV BIOCHEM MOL, V45, P185, DOI 10.3109/10409238.2010.485605; Joshi B, 2010, J BIOL CHEM, V285, P8830, DOI 10.1074/jbc.M109.074344; Joukov V, 2006, CELL, V127, P539, DOI 10.1016/j.cell.2006.08.053; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Kundrat L, 2010, J MOL BIOL, V395, P587, DOI 10.1016/j.jmb.2009.11.017; Lecker SH, 2006, J AM SOC NEPHROL, V17, P1807, DOI 10.1681/ASN.2006010083; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lee AS, 2006, CANCER BIOL THER, V5, P721, DOI 10.4161/cbt.5.7.3120; Li M, 2013, CANCER CELL, V23, P693, DOI 10.1016/j.ccr.2013.03.025; Liang JS, 2003, J BIOL CHEM, V278, P23984, DOI 10.1074/jbc.M302683200; Lopitz-Otsoa F, 2012, J PROTEOMICS, V75, P2998, DOI 10.1016/j.jprot.2011.12.001; Luo SZ, 2006, MOL CELL BIOL, V26, P5688, DOI 10.1128/MCB.00779-06; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; McFadyen MCE, 2004, MOL CANCER THER, V3, P363; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Pootrakul L, 2006, CLIN CANCER RES, V12, P5987, DOI 10.1158/1078-0432.CCR-06-0133; Rao R, 2008, BLOOD, V112, P1886, DOI 10.1182/blood-2008-03-143644; Rao R, 2010, MOL CANCER THER, V9, P942, DOI 10.1158/1535-7163.MCT-09-0988; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Sakurai K, 2011, SURG TODAY, V41, P674, DOI 10.1007/s00595-009-4328-7; SATOH M, 1993, EXP CELL RES, V205, P76, DOI 10.1006/excr.1993.1060; Schointuch MN, 2014, GYNECOL ONCOL, V134, P346, DOI 10.1016/j.ygyno.2014.05.015; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Sommer T, 2014, BBA-MOL CELL RES, V1843, P1, DOI 10.1016/j.bbamcr.2013.09.009; Song BL, 2005, MOL CELL, V19, P829, DOI 10.1016/j.molcel.2005.08.009; Su JL, 2010, CANCER RES, V70, P5096, DOI 10.1158/0008-5472.CAN-09-4148; Sun Y, 2006, NEOPLASIA, V8, P645, DOI 10.1593/neo.06376; Tsai YC, 2007, NAT MED, V13, P1504, DOI 10.1038/nm1686; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wang Q, 2005, CANCER DETECT PREV, V29, P544, DOI 10.1016/j.cdp.2005.09.010; Wang X, 2015, MOL CELL PROTEOMICS, V14, P686, DOI 10.1074/mcp.M114.042697; Wang YL, 2012, SOFT POWER STUDY FROM CULTURE, EDUCATION AND SOCIAL SYSTEM PERSPECTIVE, P478; Wang YQ, 2015, J BIOL CHEM, V290, P3308, DOI 10.1074/jbc.M114.611525; Wong CSF, 2013, CANCER RES, V73, P2400, DOI 10.1158/0008-5472.CAN-12-4348; Xing XM, 2006, CLIN CHIM ACTA, V364, P308, DOI 10.1016/j.cca.2005.07.016; Yang YH, 2008, CANCER RES, V68, P4833, DOI 10.1158/0008-5472.CAN-08-0644; Ying Z, 2009, HUM MOL GENET, V18, P4268, DOI 10.1093/hmg/ddp380; Zhang J, 2006, CLIN EXP METASTAS, V23, P401, DOI 10.1007/s10585-006-9051-9; Zhang TP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118448; Zia H, 2015, INT J EXP PATHOL, V96, P81, DOI 10.1111/iep.12115	70	45	46	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1517	1528		10.1038/onc.2015.214	http://dx.doi.org/10.1038/onc.2015.214			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26119938				2022-12-17	WOS:000373063600005
J	Latina, A; Viticchie, G; Lena, AM; Piro, MC; Annicchiarico-Petruzzelli, M; Melino, G; Candi, E				Latina, A.; Viticchie, G.; Lena, A. M.; Piro, M. C.; Annicchiarico-Petruzzelli, M.; Melino, G.; Candi, E.			Delta Np63 targets cytoglobin to inhibit oxidative stress-induced apoptosis in keratinocytes and lung cancer	ONCOGENE			English	Article							DOWN-REGULATION; TUMOR-SUPPRESSOR; CELL-SURVIVAL; P53 HOMOLOG; P63; GENE; PROTEIN; EXPRESSION; OVEREXPRESSION; PROLIFERATION	During physiological aerobic metabolism, the epidermis undergoes significant oxidative stress as a result of the production of reactive oxygen species (ROS). To maintain a balanced oxidative state, cells have developed protective antioxidant systems, and preliminary studies suggest that the transcriptional factor p63 is involved in cellular oxidative defence. Supporting this hypothesis, the Delta Np63a isoform of p63 is expressed at high levels in the proliferative basal layer of the epidermis. Here we identify the CYGB gene as a novel transcriptional target of Delta Np63 that is involved in maintaining epidermal oxidative defence. The CYGB gene encodes cytoglobin, a member of the globin protein family, which facilitates the diffusion of oxygen through tissues and acts as a scavenger for nitric oxide or other ROS. By performing promoter activity assays and chromatin immunoprecipitation, reverse transcriptase quantitative PCR and western blotting analyses, we confirm the direct regulation of CYGB by Delta Np63a. We also demonstrate that CYGB has a protective role in proliferating keratinocytes grown under normal conditions, as well as in cells treated with exogenous hydrogen peroxide. These results indicate that Delta Np63, through its target CYGB has an important role in the cellular antioxidant system and protects keratinocytes from oxidative stress-induced apoptosis. The Delta Np63-CYGB axis is also present in lung and breast cancer cell lines, indicating that CYGB-mediated ROS-scavenging activity may also have a role in epithelial tumours. In human lung cancer data sets, the p63-CYGB interaction significantly predicts reduction of patient survival.	[Latina, A.; Viticchie, G.; Lena, A. M.; Piro, M. C.; Melino, G.; Candi, E.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy; [Annicchiarico-Petruzzelli, M.; Candi, E.] IDI IRCCS, Biochem Lab, Rome, Italy; [Melino, G.] Med Res Council Toxicol Unit, Leicester, Leics, England	University of Rome Tor Vergata; IRCCS Istituto Dermopatico dell'Immacolata (IDI); UK Research & Innovation (UKRI); Medical Research Council UK (MRC)	Melino, G; Candi, E (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy.	gerry.melino@uniroma2.it; candi@uniroma2.it	Annicchiarico-Petruzzelli, Margherita/AAG-7746-2020; Lena, Anna Maria/AAI-5042-2020; PIRO, MARIA CRISTINA/GVT-4380-2022	Annicchiarico-Petruzzelli, Margherita/0000-0002-4717-4740; PIRO, MARIA CRISTINA/0000-0003-3004-367X	AIRC grant [IG13387]; Min. Salute (Ric oncol) [26/07]; IDI-IRCCS [RF08 c.15, RF07 c.57]; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	AIRC grant(Fondazione AIRC per la ricerca sul cancro); Min. Salute (Ric oncol); IDI-IRCCS; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was mainly supported by the AIRC grant (IG13387) to EC and Min. Salute (Ric oncol 26/07) and IDI-IRCCS (RF08 c.15, RF07 c.57) to GM.	Adams PD, 2009, MOL CELL, V36, P2, DOI 10.1016/j.molcel.2009.09.021; Agrelo R, 2013, ONCOGENE, V32, P5492, DOI 10.1038/onc.2013.158; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Amelio I, 2014, ONCOGENE, V33, P5039, DOI 10.1038/onc.2013.456; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Bause AS, 2013, J BIOL CHEM, V288, P36484, DOI 10.1074/jbc.M113.472324; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Berkers CR, 2013, CELL METAB, V18, P617, DOI 10.1016/j.cmet.2013.06.019; Bickers DR, 2006, J INVEST DERMATOL, V126, P2565, DOI 10.1038/sj.jid.5700340; Borrelli S, 2010, CELL DEATH DIFFER, V17, P1896, DOI 10.1038/cdd.2010.59; Browne G, 2011, J CELL SCI, V124, P2200, DOI 10.1242/jcs.079327; Budanov AV, 2011, ANTIOXID REDOX SIGN, V15, P1679, DOI 10.1089/ars.2010.3530; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burnley P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.460; Candi E, 2008, CELL MOL LIFE SCI, V65, P3126, DOI 10.1007/s00018-008-8119-x; Candi E, 2006, CELL DEATH DIFFER, V13, P1037, DOI 10.1038/sj.cdd.4401926; Candi E, 2007, P NATL ACAD SCI USA, V104, P11999, DOI 10.1073/pnas.0703458104; Candi E, 2007, CELL CYCLE, V6, P274, DOI 10.4161/cc.6.3.3797; Candi E, 2006, J CELL SCI, V119, P4617, DOI 10.1242/jcs.03265; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Celardo I, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.175; Cervo PRD, 2012, P NATL ACAD SCI USA, V109, P1133, DOI 10.1073/pnas.1112257109; Crum CP, 2010, ANNU REV PATHOL-MECH, V5, P349, DOI 10.1146/annurev-pathol-121808-102117; DeYoung MP, 2006, CANCER RES, V66, P9362, DOI 10.1158/0008-5472.CAN-06-1619; Dhar A, 2002, MOL CELL BIOCHEM, V234, P185, DOI 10.1023/A:1015948505117; Dhar SK, 2006, J BIOL CHEM, V281, P21698, DOI 10.1074/jbc.M601083200; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Emara M, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-33; Fordel E, 2004, BIOCHEM BIOPH RES CO, V319, P342, DOI 10.1016/j.bbrc.2004.05.010; Fordel E, 2006, NEUROSCI LETT, V410, P146, DOI 10.1016/j.neulet.2006.09.027; Gao B, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.298; Genin O, 2008, NEOPLASIA, V10, P940, DOI 10.1593/neo.08456; Gorr TA, 2011, ACTA PHYSIOL, V202, P563, DOI 10.1111/j.1748-1716.2010.02205.x; Guo XM, 2006, BBA-GENE STRUCT EXPR, V1759, P208, DOI 10.1016/j.bbaexp.2006.04.002; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Italiano D, 2012, CELL CYCLE, V11, P4589, DOI 10.4161/cc.22853; John R, 2014, DNA REPAIR, V24, P107, DOI 10.1016/j.dnarep.2014.09.003; Katsuyama M, 2012, J CLIN BIOCHEM NUTR, V50, P9, DOI 10.3164/jcbn.11-06SR; Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Kouwenhoven EN, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001065; Laurikkala J, 2006, DEVELOPMENT, V133, P1553, DOI 10.1242/dev.02325; Leikam C, 2014, ONCOGENE, V33, P771, DOI 10.1038/onc.2012.641; Lena AM, 2010, BIOCHEM BIOPH RES CO, V401, P568, DOI 10.1016/j.bbrc.2010.09.102; Li C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.468; Liefer KM, 2000, CANCER RES, V60, P4016; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Massion PP, 2003, CANCER RES, V63, P7113; McRonald FE, 2006, HUM MOL GENET, V15, P1271, DOI 10.1093/hmg/ddl042; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nakanome A, 2013, ONCOGENE, V32, P3231, DOI 10.1038/onc.2012.336; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Ogawa E, 2008, ONCOGENE, V27, P848, DOI 10.1038/sj.onc.1210682; Oleksiewicz U, 2013, HUM MOL GENET, V22, P3207, DOI 10.1093/hmg/ddt174; Paris M, 2012, CELL DEATH DIFFER, V19, P186, DOI 10.1038/cdd.2011.181; Park Eun-sung, 2003, J Vet Sci, V4, P129; Patel A, 2015, ONCOGENE, V34, P2586, DOI 10.1038/onc.2014.195; Pinton P, 2007, SCIENCE, V315, P659, DOI 10.1126/science.1135380; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Presneau N, 2005, MOL CARCINOGEN, V43, P141, DOI 10.1002/mc.20096; Ramsey MR, 2013, J CLIN INVEST, V123, P3525, DOI 10.1172/JCI68899; Ramsey MR, 2011, CANCER RES, V71, P4373, DOI 10.1158/0008-5472.CAN-11-0046; Rinne T, 2008, HUM MOL GENET, V17, P1968, DOI 10.1093/hmg/ddn094; Rivera A, 2005, J BIOL CHEM, V280, P29346, DOI 10.1074/jbc.M504852200; Romano RA, 2012, DEVELOPMENT, V139, P772, DOI 10.1242/dev.071191; Rufini A, 2006, BIOCHEM BIOPH RES CO, V340, P737, DOI 10.1016/j.bbrc.2005.12.065; Rufini A, 2012, GENE DEV, V26, P2009, DOI 10.1101/gad.197640.112; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Schmidt M, 2004, J BIOL CHEM, V279, P8063, DOI 10.1074/jbc.M310540200; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Shalom-Feuerstein R, 2011, CELL DEATH DIFFER, V18, P887, DOI 10.1038/cdd.2010.159; Shaw RJ, 2009, BRIT J CANCER, V101, P139, DOI 10.1038/sj.bjc.6605121; Sommer M, 2006, CELL CYCLE, V5, P2005, DOI 10.4161/cc.5.17.3194; Stagner JI, 2005, TRANSPL P, V37, P3452, DOI 10.1016/j.transproceed.2005.10.001; Stambolsky P, 2006, CELL DEATH DIFFER, V13, P2140, DOI 10.1038/sj.cdd.4401965; Truong AB, 2006, GENE DEV, V20, P3185, DOI 10.1101/gad.1463206; Vanbokhoven H, 2011, J INVEST DERMATOL, V131, P1196, DOI 10.1038/jid.2011.84; Wajcman H, 2009, CR BIOL, V332, P273, DOI 10.1016/j.crvi.2008.07.026; Wansleben S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.365; Wiel C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.382; Wolyniec K, 2013, ONCOGENE, V32, P3510, DOI 10.1038/onc.2012.365; Xinarianos G, 2006, HUM MOL GENET, V15, P2038, DOI 10.1093/hmg/ddl128; Yan WS, 2006, J BIOL CHEM, V281, P7856, DOI 10.1074/jbc.M512655200; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu XL, 2013, NEURAL REGEN RES, V8, P2198, DOI 10.3969/j.issn.1673-5374.2013.23.010	88	45	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1493	1503		10.1038/onc.2015.222	http://dx.doi.org/10.1038/onc.2015.222			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26096935				2022-12-17	WOS:000373063600003
J	Sheikh, BN; Phipson, B; El-Saafin, F; Vanyai, HK; Downer, NL; Bird, MJ; Kueh, AJ; May, RE; Smyth, GK; Voss, AK; Thomas, T				Sheikh, B. N.; Phipson, B.; El-Saafin, F.; Vanyai, H. K.; Downer, N. L.; Bird, M. J.; Kueh, A. J.; May, R. E.; Smyth, G. K.; Voss, A. K.; Thomas, T.			MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway	ONCOGENE			English	Article							LEUKEMIA ZINC-FINGER; LEUCINE-ZIPPER KINASE; ACUTE MYELOID-LEUKEMIA; MONOCYTIC LEUKEMIA; GENE-EXPRESSION; TRANSLOCATION T(8/16)(P11,P13); GENOME EXPRESSION; CELL-DEATH; PROTEIN; PROLIFERATION	Cellular senescence is an important mechanism that restricts tumour growth. The Ink4a-Arf locus (also known as Cdkn2a), which encodes p16(INK4A) and p19(ARF), has a central role in inducing and maintaining senescence. Given the importance of cellular senescence in restraining tumour growth, great emphasis is being placed on the identification of novel factors that can modulate senescence. The MYST-family histone acetyltransferase MOZ (MYST3, KAT6A), first identified in recurrent translocations in acute myeloid leukaemia, has been implicated in both the promotion and inhibition of senescence. In this study, we investigate the role of MOZ in cellular senescence and show that MOZ is a potent inhibitor of senescence via the INK4A-ARF pathway. Primary mouse embryonic fibroblasts (MEFs) isolated from Moz-deficient embryos exhibit premature senescence, which was rescued on the Ink4a-Arf(-/-) background. Importantly, senescence resulting from the absence of MOZ was not accompanied by DNA damage, suggesting that MOZ acts independently of the DNA damage response. Consistent with the importance of senescence in cancer, expression profiling revealed that genes overexpressed in aggressive and highly proliferative cancers are expressed at low levels in Mozdeficient MEFs. We show that MOZ is required to maintain normal levels of histone 3 lysine 9 (H3K9) and H3K27 acetylation at the transcriptional start sites of at least four genes, Cdc6, Ezh2, E2f2 and Melk, and normal mRNA levels of these genes. CDC6, EZH2 and E2F2 are known inhibitors of the INK4A-ARF pathway. Using chromatin immunoprecipitation, we show that MOZ occupies the Cdc6, Ezh2 and Melk loci, thereby providing a direct link between MOZ, H3K9 and H3K27 acetylation, and normal transcriptional levels at these loci. This work establishes that MOZ is an upstream inhibitor of the INK4A-ARF pathway, and suggests that inhibiting MOZ may be one way to induce senescence in proliferative tumour cells.	[Sheikh, B. N.; El-Saafin, F.; Vanyai, H. K.; Downer, N. L.; Kueh, A. J.; May, R. E.; Voss, A. K.; Thomas, T.] Walter & Eliza Hall Inst Med Res, Div Dev & Canc, Melbourne, Vic 3052, Australia; [Sheikh, B. N.; El-Saafin, F.; Vanyai, H. K.; Voss, A. K.; Thomas, T.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; [Phipson, B.; Smyth, G. K.] Walter & Eliza Hall Inst Med Res, Div Bioinformat, Melbourne, Vic 3052, Australia; [Phipson, B.; Bird, M. J.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Bird, M. J.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Smyth, G. K.] Univ Melbourne, Dept Math & Stat, Melbourne, Vic, Australia	University of Melbourne; Murdoch Children's Research Institute; University of Melbourne; University of Melbourne	Thomas, T (corresponding author), Walter & Eliza Hall Inst Med Res, Div Dev & Canc, 1G Royal Parade, Melbourne, Vic 3052, Australia.	avoss@wehi.edu.au; tthomas@wehi.edu.au	Phipson, Belinda/AAP-2213-2020; Smyth, Gordon/B-5276-2008; Voss, Anne K/F-5110-2013	Phipson, Belinda/0000-0002-1711-7454; Smyth, Gordon/0000-0001-9221-2892; Voss, Anne K/0000-0002-3853-9381; Bird, Matthew/0000-0003-3185-0780; Thomas, Tim/0000-0002-7623-8344; Sheikh, Bilal/0000-0002-1970-6236	Australian National Health and Medical Research Council; Australian Mitochondrial Disease Foundation; Australian Postgraduate Awards; Australian Federal Government (IRISS); Victorian State Government	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Mitochondrial Disease Foundation; Australian Postgraduate Awards(Australian Government); Australian Federal Government (IRISS)(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government	We thank Carmen Gatt and Faye Dabrowski for technical support. We thank Andreas Strasser for helpful discussions and Liz Valente for the provision of the anti-p21<SUP>CIP1</SUP> antibody. This work was supported by the Australian National Health and Medical Research Council (senior research fellowships to AKV and TT; scholarship to BNS), the Australian Mitochondrial Disease Foundation (MJB), Australian Postgraduate Awards (to MJB, FE and HKV) and operational infrastructure grants from the Australian Federal Government (IRISS) and the Victorian State Government (OIS).	Agherbi H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005622; Azzam G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074297; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Camos M, 2006, CANCER RES, V66, P6947, DOI 10.1158/0008-5472.CAN-05-4601; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Champagne N, 2001, ONCOGENE, V20, P404, DOI 10.1038/sj.onc.1204114; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Dietrich N, 2007, EMBO J, V26, P1637, DOI 10.1038/sj.emboj.7601632; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Esteyries S, 2008, LEUKEMIA, V22, P663, DOI 10.1038/sj.leu.2404930; Gonzalez S, 2006, NATURE, V440, P702, DOI 10.1038/nature04585; Haferlach T, 2009, LEUKEMIA, V23, P934, DOI 10.1038/leu.2008.388; Hayama S, 2007, CANCER RES, V67, P4113, DOI 10.1158/0008-5472.CAN-06-4705; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Jaffe JD, 2013, NAT GENET, V45, P1386, DOI 10.1038/ng.2777; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Karakaidos P, 2004, AM J PATHOL, V165, P1351, DOI 10.1016/S0002-9440(10)63393-7; Katsumoto T, 2006, GENE DEV, V20, P1321, DOI 10.1101/gad.1393106; Kig C, 2013, J BIOL CHEM, V288, P24200, DOI 10.1074/jbc.M113.471433; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Lau E, 2006, EMBO REP, V7, P425, DOI 10.1038/sj.embor.7400624; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Liu BH, 2005, NAT MED, V11, P780, DOI 10.1038/nm1266; Lu T, 2008, EXP CELL RES, V314, P1918, DOI 10.1016/j.yexcr.2008.01.011; Maddika S, 2007, DRUG RESIST UPDATE, V10, P13, DOI 10.1016/j.drup.2007.01.003; Maertens GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006380; Muslimovic A, 2008, NAT PROTOC, V3, P1187, DOI 10.1038/nprot.2008.93; Nakano I, 2005, J CELL BIOL, V170, P413, DOI 10.1083/jcb.200412115; Nakano I, 2008, J NEUROSCI RES, V86, P48, DOI 10.1002/jnr.21471; Ohta S, 2001, ONCOL REP, V8, P1063; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Perez-Campo FM, 2014, STEM CELLS, V32, P1591, DOI 10.1002/stem.1606; Perez-Campo FM, 2009, BLOOD, V113, P4866, DOI 10.1182/blood-2008-04-152017; QUELLE DE, 1995, CELL, V83, P993; Reimann M, 2010, CANCER CELL, V17, P262, DOI 10.1016/j.ccr.2009.12.043; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rokudai S, 2013, P NATL ACAD SCI USA, V110, P3895, DOI 10.1073/pnas.1300490110; Rokudai S, 2009, J BIOL CHEM, V284, P237, DOI 10.1074/jbc.M805101200; Schwickert TA, 2014, NAT IMMUNOL, V15, P283, DOI 10.1038/ni.2828; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shi W, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq871; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; STARK B, 1995, LEUKEMIA RES, V19, P367, DOI 10.1016/0145-2126(94)00150-9; Sun T, 2001, AM J HEMATOL, V66, P207, DOI 10.1002/1096-8652(200103)66:3<207::AID-AJH1046>3.0.CO;2-Q; Tang X, 2007, ONCOGENE, V26, P7302, DOI 10.1038/sj.onc.1210542; Thomas T, 2006, GENE DEV, V20, P1175, DOI 10.1101/gad.1382606; Uchida F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056381; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vasseur Sophie, 2003, Mol Cancer, V2, P19, DOI 10.1186/1476-4598-2-19; Voss AK, 1998, DEV DYNAM, V212, P171, DOI 10.1002/(SICI)1097-0177(199806)212:2<171::AID-AJA3>3.0.CO;2-E; Voss AK, 2012, DEV CELL, V23, P652, DOI 10.1016/j.devcel.2012.07.010; Voss AK, 2012, METHODS MOL BIOL, V809, P335, DOI 10.1007/978-1-61779-376-9_23; Voss AK, 2009, DEV CELL, V17, P674, DOI 10.1016/j.devcel.2009.10.006; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wu D, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks461; Wu D, 2010, BIOINFORMATICS, V26, P2176, DOI 10.1093/bioinformatics/btq401; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603	75	45	48	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2015	34	47					5807	5820		10.1038/onc.2015.33	http://dx.doi.org/10.1038/onc.2015.33			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW5KV	25772242				2022-12-17	WOS:000365035200004
J	Fujii, S; Matsumoto, S; Nojima, S; Morii, E; Kikuchi, A				Fujii, S.; Matsumoto, S.; Nojima, S.; Morii, E.; Kikuchi, A.			Arl4c expression in colorectal and lung cancers promotes tumorigenesis and may represent a novel therapeutic target	ONCOGENE			English	Article							GASTRIC-CANCER; SIGNALING PATHWAYS; EXCHANGE FACTORS; TUMOR-CELLS; WNT; BINDING; ACTIVATION; INVASION; FAMILY; GROWTH	We recently demonstrated that expression of ADP-ribosylation factor (ARF)-like 4c (Arl4c) induced by a combination of Wnt/beta-catenin and epidermal growth factor/Ras signaling in normal epithelial cells grown in three-dimensional culture promotes cellular migration and proliferation, resulting in formation of tube-like structures, suggesting the involvement of Arl4c in epithelial morphogenesis. It is conceivable that there could be a common mechanism between epithelial morphogenesis and carcinogenesis. Therefore the current study was conducted to investigate whether Arl4c might be involved in tumorigenesis. Immunohistochemical analyses of tissue specimens obtained from colorectal and lung cancer patients revealed that Arl4c was not observed in non-tumor regions but was strongly expressed at high frequencies in tumor lesions. Inhibition of Wnt/beta-catenin or Ras/mitogen-activated protein kinase signaling reduced Arl4c mRNA levels in HCT116 colorectal cancer cells and A549 lung cancer cells. Knockdown of Arl4c inhibited Rac activity and also prevented nuclear localization of yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ) in these cancer cells. Arl4c-depleted cancer cells consistently showed decreased migration, invasion and proliferation capabilities both in vitro and in vivo. Furthermore, direct injection of Arl4c small interfering RNA (siRNA) into HCT116 cell-derived tumors (in vivo treatment with siRNA) inhibited tumor growth in immunodeficient mice. These results suggest that Arl4c is involved in tumorigenesis and might represent a novel therapeutic target for suppressing proliferation and invasion of colorectal and lung cancer cells.	[Fujii, S.; Matsumoto, S.; Kikuchi, A.] Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Suita, Osaka 5650871, Japan; [Fujii, S.] Osaka Univ, IPBS, Inst Acad Initiat, Suita, Osaka 5650871, Japan; [Nojima, S.; Morii, E.] Osaka Univ, Dept Pathol, Grad Sch Med, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Kikuchi, A (corresponding author), Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	akikuchi@molbiobc.med.osaka-u.ac.jp			Ministry of Education, Science and Culture of Japan [25250018, 26861547, 25860211, 23112004]; Uehara Memorial Foundation	Ministry of Education, Science and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Uehara Memorial Foundation(Uehara Memorial Foundation)	We thank Dr Y Shintani and Dr K Shojima for valuable discussions regarding Arl4c expression and their technical assistance. We also thank Dr T Kobayashi, Dr W Yasui and Dr K Matsumoto for donating cells. This work was supported by Grants-in-Aid for Scientific Research to AK (2013-2014) (No. 25250018), SF (2014) (No. 26861547) and SM (2013-2014) (No. 25860211) and for Scientific Research on Innovative Areas to AK (2011-2014) (No. 23112004) from the Ministry of Education, Science and Culture of Japan and by grants from the Uehara Memorial Foundation.	Barry ER, 2013, NATURE, V493, P106, DOI 10.1038/nature11693; Burd CG, 2004, TRENDS CELL BIOL, V14, P687, DOI 10.1016/j.tcb.2004.10.004; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Engel T, 2004, FEBS LETT, V566, P241, DOI 10.1016/j.febslet.2004.04.048; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Gon H, 2013, MOL BIOL CELL, V24, P3764, DOI 10.1091/mbc.E13-07-0357; Hanaki H, 2012, MOL CANCER THER, V11, P298, DOI 10.1158/1535-7163.MCT-11-0682; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Hofmann I, 2007, CURR BIOL, V17, P711, DOI 10.1016/j.cub.2007.03.007; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Jacobs S, 1999, FEBS LETT, V456, P384, DOI 10.1016/S0014-5793(99)00759-0; Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Kagawa Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083629; Kikuchi A, 2011, INT REV CEL MOL BIO, V291, P21, DOI 10.1016/B978-0-12-386035-4.00002-1; Krypuy M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-295; Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359; Li CC, 2007, MOL BIOL CELL, V18, P4420, DOI 10.1091/mbc.E07-02-0149; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Matsumoto S, 2014, EMBO J, V33, P702, DOI 10.1002/embj.201386942; Matsumoto S, 2010, EMBO J, V29, P1192, DOI 10.1038/emboj.2010.26; McCormick F, 1999, TRENDS BIOCHEM SCI, V24, pM53, DOI 10.1016/S0968-0004(99)01480-2; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Mori M, 2001, MODERN PATHOL, V14, P72, DOI 10.1038/modpathol.3880259; Nieto MA, 2013, SCIENCE, V342; O'Brien LE, 2002, NAT REV MOL CELL BIO, V3, P531, DOI 10.1038/nrm859; Pasqualato S, 2002, EMBO REP, V3, P1035, DOI 10.1093/embo-reports/kvf221; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Salhia B, 2005, CANCER RES, V65, P8792, DOI 10.1158/0008-5472.CAN-05-0160; Sato A, 2010, EMBO J, V29, P41, DOI 10.1038/emboj.2009.322; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Shitashige M, 2010, CANCER RES, V70, P5024, DOI 10.1158/0008-5472.CAN-10-0306; Sunaga N, 2011, MOL CANCER THER, V10, P336, DOI 10.1158/1535-7163.MCT-10-0750; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Wang LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065539; Wei SM, 2009, BIOCHEM BIOPH RES CO, V384, P352, DOI 10.1016/j.bbrc.2009.04.125; Yamamoto H, 2009, GASTROENTEROLOGY, V137, P242, DOI 10.1053/j.gastro.2009.02.003; Yang J, 2006, J BIOL CHEM, V281, P17751, DOI 10.1074/jbc.M600831200	46	45	47	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4834	4844		10.1038/onc.2014.402	http://dx.doi.org/10.1038/onc.2014.402			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25486429				2022-12-17	WOS:000361050000004
J	Gong, X; Yi, J; Carmon, KS; Crumbley, CA; Xiong, W; Thomas, A; Fan, X; Guo, S; An, Z; Chang, JT; Liu, QJ				Gong, X.; Yi, J.; Carmon, K. S.; Crumbley, C. A.; Xiong, W.; Thomas, A.; Fan, X.; Guo, S.; An, Z.; Chang, J. T.; Liu, Q. J.			Aberrant RSPO3-LGR4 signaling in Keap1-deficient lung adenocarcinomas promotes tumor aggressiveness	ONCOGENE			English	Article							TRANSCRIPTION FACTOR NRF2; PROTEIN-COUPLED RECEPTOR; COLORECTAL-CANCER; WNT/BETA-CATENIN; FUSION TRANSCRIPTS; IDENTIFIES GENES; KNOCKOUT MICE; METASTASIS; KEAP1; LGR4	The four R-spondins (RSPO1-4) and their three related receptors LGR4, 5 and 6 (LGR4-6) have emerged as a major ligand-receptor system with critical roles in development and stem cell survival through modulation of Wnt signaling. Recurrent, gain-of-expression gene fusions of RSPO2 (to EIF3E) and RSPO3 (to PTPRK) occur in a subset of human colorectal cancer. However, the exact roles and mechanisms of the RSPO-LGR system in oncogenesis remain largely unknown. We found that RSPO3 is aberrantly expressed at high levels in approximately half of Keap1-mutated lung adenocarcinomas (ADs). This high RSPO3 expression is driven by a combination of demethylation of its own promoter region and deficiency in Keap1 instead of gene fusion as in colon cancer. Patients with RSPO3-high tumors (similar to 9%, 36/412) displayed much poorer survival than the rest of the cohort (median survival of 28 vs 163 months, log-rank test P<0.0001). Knockdown (KD) of RSPO3, LGR4 or their signaling mediator IQGAP1 in lung cancer cell lines with Keap1 deficiency and high RSPO3-LGR4 expression led to reduction in cell proliferation and migration in vitro, and KD of LGR4 or IQGAP1 resulted in decrease in tumor growth and metastasis in vivo. These findings suggest that aberrant RSPO3-LGR4 signaling potentially acts as a driving mechanism in the aggressiveness of Keap1-deficient lung ADs.	[Gong, X.; Yi, J.; Carmon, K. S.; Crumbley, C. A.; Xiong, W.; Thomas, A.; Fan, X.; An, Z.; Chang, J. T.; Liu, Q. J.] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, Houston, TX 77030 USA; [Gong, X.; Yi, J.; Carmon, K. S.; Crumbley, C. A.; Xiong, W.; Thomas, A.; Fan, X.; An, Z.; Liu, Q. J.] Univ Texas Hlth Sci Ctr Houston, Texas Therapeut Inst, Houston, TX 77030 USA; [Guo, S.] Univ Texas Hlth Sci Ctr Houston, Div Oncol, Houston, TX 77030 USA; [Chang, J. T.] Univ Texas Hlth Sci Ctr Houston, Ctr Clin & Translat Sci, Houston, TX 77030 USA; [Chang, J. T.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Chang, J. T.] Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Liu, QJ (corresponding author), Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, 1825 Pressler St,Suite 530A, Houston, TX 77030 USA.	Qingyun.liu@uth.tmc.edu	Yi, Jing/S-2586-2016	Yi, Jing/0000-0001-5037-1924; An, Zhiqiang/0000-0001-9309-2335; Carmon, Kendra/0000-0002-3244-6096	Cancer Prevention and Research Institute of Texas (CPRIT) [RP100678]; US National Institute of Health-NIH [R01GM102485]; Texas Emerging Technology Fund; Janice D. Gordon endowment for bowel cancer research; NIH [R00LM009837, TL1TR000371]; CPRIT [R1006]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM102485] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R00LM009837] Funding Source: NIH RePORTER	Cancer Prevention and Research Institute of Texas (CPRIT); US National Institute of Health-NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Texas Emerging Technology Fund; Janice D. Gordon endowment for bowel cancer research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We thank TCGA for generating the genomics data, collecting the clinical information and making them available for analysis. We also thank cBioportal for providing data analysis and visualization tools and downloading capability. We thank Dr B Fang at the University of Texas MD Anderson Cancer for the cell lines A549, H460 and H2009 cells. This work was supported in part by the Cancer Prevention and Research Institute of Texas (CPRIT, RP100678), the US National Institute of Health-NIH (R01GM102485), the Texas Emerging Technology Fund and the Janice D. Gordon endowment for bowel cancer research (to QJL), by NIH (R00LM009837, TL1TR000371) and CPRIT (R1006; to JTC) and by the Texas Emerging Technology Fund (to ZA).	Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bell SM, 2008, DEVELOPMENT, V135, P1049, DOI 10.1242/dev.013359; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108; Chien AJ, 2009, J INVEST DERMATOL, V129, P1614, DOI 10.1038/jid.2008.445; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; de Lau WBM, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-3-242; Fujita PA, 2011, NUCLEIC ACIDS RES, V39, pD876, DOI 10.1093/nar/gkq963; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gattelli A, 2006, J VIROL, V80, P11409, DOI 10.1128/JVI.00234-06; Glinka A, 2011, EMBO REP, V12, P1055, DOI 10.1038/embor.2011.175; Gugger M, 2008, DIS MARKERS, V24, P41, DOI 10.1155/2008/857474; Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019; Hayashi H, 2010, INT J CANCER, V126, P2563, DOI 10.1002/ijc.24987; Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Jenkins DE, 2003, CLIN EXP METASTAS, V20, P733, DOI 10.1023/B:CLIN.0000006815.49932.98; Johnson M, 2009, CELL SIGNAL, V21, P1471, DOI 10.1016/j.cellsig.2009.02.023; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kato S, 2006, NEPHRON EXP NEPHROL, V104, pE63, DOI 10.1159/000093999; Ke N, 2011, METHODS MOL BIOL, V740, P33, DOI 10.1007/978-1-61779-108-6_6; Kim D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r72; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liu Y, 2011, HISTOPATHOLOGY, V59, P882, DOI 10.1111/j.1365-2559.2011.04013.x; Lowther W, 2005, J VIROL, V79, P10093, DOI 10.1128/JVI.79.15.10093-10096.2005; Malhotra D, 2010, NUCLEIC ACIDS RES, V38, P5718, DOI 10.1093/nar/gkq212; Mazieres J, 2005, CANCER LETT, V222, P1, DOI 10.1016/j.canlet.2004.08.040; McDonald T, 1998, BIOCHEM BIOPH RES CO, V247, P266, DOI 10.1006/bbrc.1998.8774; Mendive F, 2006, DEV BIOL, V290, P421, DOI 10.1016/j.ydbio.2005.11.043; Miyoshi T, 2005, PATHOL INT, V55, P419, DOI 10.1111/j.1440-1827.2005.01847.x; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakatani Y, 2003, METHOD ENZYMOL, V370, P430; Nam JS, 2007, GENE EXPR PATTERNS, V7, P306, DOI 10.1016/j.modgep.2006.08.006; Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030; Noritake J, 2005, J CELL SCI, V118, P2085, DOI 10.1242/jcs.02379; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Pacheco-Pinedo EC, 2011, J CLIN INVEST, V121, P1935, DOI 10.1172/JCI44871; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Shinmura K, 2014, MOL BIOL REP, V41, P5375, DOI 10.1007/s11033-014-3409-x; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Singh A, 2013, J CLIN INVEST, V123, P2921, DOI 10.1172/JCI66353; Solis LM, 2010, CLIN CANCER RES, V16, P3743, DOI 10.1158/1078-0432.CCR-09-3352; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Takahashi T, 2010, J SURG ONCOL, V101, P500, DOI 10.1002/jso.21520; Theodorou V, 2007, NAT GENET, V39, P759, DOI 10.1038/ng2034; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Weng JS, 2008, P NATL ACAD SCI USA, V105, P6081, DOI 10.1073/pnas.0708257105; White CD, 2012, CELL SIGNAL, V24, P826, DOI 10.1016/j.cellsig.2011.12.005; Yamada W, 2009, BIOCHEM BIOPH RES CO, V381, P453, DOI 10.1016/j.bbrc.2009.02.066; Yi J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078144	54	45	48	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4692	4701		10.1038/onc.2014.417	http://dx.doi.org/10.1038/onc.2014.417			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25531322	Green Accepted			2022-12-17	WOS:000360931500003
J	Dhillon, AS; Tulchinsky, E				Dhillon, A. S.; Tulchinsky, E.			FRA-1 as a driver of tumour heterogeneity: a nexus between oncogenes and embryonic signalling pathways in cancer	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; SQUAMOUS-CELL CARCINOMA; NEGATIVE FEEDBACK LOOP; BREAST-CANCER; TGF-BETA; STEM-CELLS; MIR-200 FAMILY; PROTEASOMAL DEGRADATION; E-CADHERIN; TRANSCRIPTIONAL ACTIVATION	Tumour heterogeneity is a major factor undermining the success of therapies targeting metastatic cancer. Two major theories are thought to explain the phenomenon of heterogeneity in cancer-clonal evolution and cell plasticity. In this review, we examine a growing body of work implicating the transcription factor FOS-related antigen 1 (FRA-1) as a central node in tumour cell plasticity networks, and discuss mechanisms regulating its activity in cancer cells. We also discuss evidence from the FRA-1 perspective supporting the notion that clonal selection and cell plasticity represent two sides of the same coin. We propose that FRA-1overexpressing clones featuring high plasticity undergo positive selection during consecutive stages of multistep tumour progression. This model underscores a potential mechanism through which tumour cells retaining elevated levels of plasticity acquire a selective advantage over other clonal populations within a tumour.	[Dhillon, A. S.] Peter MacCallum Canc Ctr, Melbourne, Vic 3002, Australia; [Tulchinsky, E.] Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE2 7LX, Leics, England	Peter Maccallum Cancer Center; University of Leicester	Dhillon, AS (corresponding author), Peter MacCallum Canc Ctr, Growth & Differentiat Program Res Div, St Andrews Pl, Melbourne, Vic 3002, Australia.	Amardeep.Dhillon@petermac.org; et32@le.ac.uk	Tulchinsky, Eugene/ABD-7070-2021	Dhillon, Amardeep/0000-0002-6065-663X	National Health and Medical Research Council of Australia; Cancer Research UK (CRUK); Association for International Cancer Research (AICR)	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Research UK (CRUK)(Cancer Research UK); Association for International Cancer Research (AICR)	We apologize to the colleagues whose relevant work we were unable to cite owing to space limitations. This work was supported by project grants from the National Health and Medical Research Council of Australia (to ASD), and Cancer Research UK (CRUK) and Association for International Cancer Research (AICR) (to ET).	Adiseshaiah P, 2003, J BIOL CHEM, V278, P47423, DOI 10.1074/jbc.M303505200; Ahn YH, 2012, J CLIN INVEST, V122, P3170, DOI 10.1172/JCI63608; Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Basbous J, 2008, BIOCHIMIE, V90, P296, DOI 10.1016/j.biochi.2007.07.016; Basbous J, 2007, MOL CELL BIOL, V27, P3936, DOI 10.1128/MCB.01776-06; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Belguise K, 2012, ONCOGENE, V31, P4889, DOI 10.1038/onc.2011.659; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Brabletz S, 2011, EMBO J, V30, P770, DOI 10.1038/emboj.2010.349; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Cha YH, 2012, CELL CYCLE, V11, P1273, DOI 10.4161/cc.19618; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Desmet CJ, 2013, P NATL ACAD SCI USA, V110, P5139, DOI 10.1073/pnas.1222085110; Diesch J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088950; Ding XM, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003884; Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; Gilan O, 2015, ONCOGENE, V34, P1340, DOI 10.1038/onc.2014.460; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Gu XX, 2013, P NATL ACAD SCI USA, V110, P14960, DOI 10.1073/pnas.1309110110; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; Hill L, 2013, INT J CANCER, V132, P745, DOI 10.1002/ijc.27708; Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janda E, 2006, ONCOGENE, V25, P7117, DOI 10.1038/sj.onc.1209701; Kahlert C, 2011, CLIN CANCER RES, V17, P7654, DOI 10.1158/1078-0432.CCR-10-2816; Kakumoto K, 2006, P NATL ACAD SCI USA, V103, P5490, DOI 10.1073/pnas.0601222103; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kim NH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001744; Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lamouille S, 2012, J CELL SCI, V125, P1259, DOI 10.1242/jcs.095299; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Li X, 2014, ONCOGENE, V33, P4077, DOI 10.1038/onc.2013.370; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Marusyk A, 2014, NATURE; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Matthews CP, 2007, CURR CANCER DRUG TAR, V7, P317, DOI 10.2174/156800907780809723; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Mejlvang J, 2007, MOL BIOL CELL, V18, P4615, DOI 10.1091/mbc.E07-05-0406; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Muraoka-Cook RS, 2004, CANCER RES, V64, P9002, DOI 10.1158/0008-5472.CAN-04-2111; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Nishimura G, 2006, DEV CELL, V11, P93, DOI 10.1016/j.devcel.2006.05.011; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Pakay JL, 2012, ONCOGENE, V31, P1817, DOI 10.1038/onc.2011.375; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pollock CB, 2005, CANCER RES, V65, P1244, DOI 10.1158/0008-5472.CAN-04-1911; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Postigo AA, 2003, EMBO J, V22, P2453, DOI 10.1093/emboj/cdg226; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Sayan AE, 2012, ONCOGENE, V31, P1493, DOI 10.1038/onc.2011.336; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Siemens H, 2011, CELL CYCLE, V10, P4256, DOI 10.4161/cc.10.24.18552; Signore M, 2013, CANCER LETT, V332, P374, DOI 10.1016/j.canlet.2011.01.013; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Sundqvist A, 2013, ONCOGENE, V32, P3606, DOI 10.1038/onc.2012.370; Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Treinies I, 1999, MOL CELL BIOL, V19, P321; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tulchinsky E, 2000, HISTOL HISTOPATHOL, V15, P921, DOI 10.14670/HH-15.921; Usui A, 2012, CANCER-AM CANCER SOC, V118, P3387, DOI 10.1002/cncr.26652; Van Grunsven LA, 2006, DEV DYNAM, V235, P1491, DOI 10.1002/dvdy.20727; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; Vikhanskaya F, 2007, NAT CELL BIOL, V9, P698, DOI 10.1038/ncb1598; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304; Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang PY, 2012, CANCER CELL, V22, P291, DOI 10.1016/j.ccr.2012.07.023; Yang S, 2013, ONCOGENE, V32, P4294, DOI 10.1038/onc.2012.432; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhang GN, 2011, CANCER LETT, V313, P137, DOI 10.1016/j.canlet.2011.05.030; Zhao CY, 2014, CANCER RES, V74, P3983, DOI 10.1158/0008-5472.CAN-13-3396; Zheng H, 2014, ONCOGENE, V33, P1755, DOI 10.1038/onc.2013.128; Zippo A, 2009, CELL, V138, P1122, DOI 10.1016/j.cell.2009.07.031	127	45	45	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4421	4428		10.1038/onc.2014.374	http://dx.doi.org/10.1038/onc.2014.374			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25381818	Green Accepted			2022-12-17	WOS:000360189200001
J	Zhang, Z; Liang, X; Gao, L; Ma, H; Liu, X; Pan, Y; Yan, W; Shan, H; Wang, Z; Chen, YH; Ma, C				Zhang, Z.; Liang, X.; Gao, L.; Ma, H.; Liu, X.; Pan, Y.; Yan, W.; Shan, H.; Wang, Z.; Chen, Y. H.; Ma, C.			TIPE1 induces apoptosis by negatively regulating Rac1 activation in hepatocellular carcinoma cells	ONCOGENE			English	Article							DEATH PATHWAYS; RHO-GTPASES; EXPRESSION; SCC-S2; CANCER; LIVER; PROLIFERATION; METASTASIS; MODULATION; IMMUNITY	TIPE1 (tumor necrosis factor-alpha-induced protein 8-like 1 or TNFAIP8L1) is a newly identified member of the TIPE (TNFAIP8) family, which play roles in regulating cell death. However, the biologic functions of TIPE1 in physiologic and pathologic conditions are largely unknown. Here, we report the roles of TIPE1 in hepatocellular carcinoma (HCC). Evaluated by immunohistochemical staining, HCC tissues showed significantly downregulated TIPE1 expression compared with adjacent non-tumor tissues, which positively correlated with tumor pathologic grades and patient survival. Using a homograft tumor model in Balb/c mice, we discovered that TIPE1 significantly diminished the growth and tumor weight of murine liver cancer homografts. Consistently, TIPE1 inhibited both cell growth and colony formation ability of cultured HCC cell lines, which was further identified to be due to TIPE1-inducing apoptosis in a caspase-independent, necrostatin-1 (Nec-1)-insensitive manner. Furthermore, mechanistic investigations revealed that TIPE1 interacted with Rac1, and inhibited the activation of Rac1 and its downstream p65 and c-Jun N-terminal kinase pathway. Moreover, overexpression of constitutively active Rac1 partially rescued the apoptosis induced by TIPE1, and Rac1 knockdown significantly restored the deregulated cell growth induced by TIPE1 small interfering RNA. Our findings revealed that TIPE1 induced apoptosis in HCC cells by negatively regulating Rac1 pathway, and loss of TIPE1 might be a new prognostic indicator for HCC patients.	[Zhang, Z.; Liang, X.; Gao, L.; Ma, H.; Liu, X.; Pan, Y.; Yan, W.; Shan, H.; Ma, C.] Shandong Univ, Sch Med, Key Lab Expt Teratol, Minist Educ, Jinan 250012, Shandong, Peoples R China; [Wang, Z.; Chen, Y. H.] Shandong Univ, Sch Med, Dept Immunol, Jinan 250012, Shandong, Peoples R China; [Wang, Z.; Chen, Y. H.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Shandong University; Shandong University; University of Pennsylvania	Chen, YH (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 713 Stellar Chance Labs,422 Curie Blvd, Philadelphia, PA 19104 USA.	yhc@mail.med.upenn.edu; machunhong@sdu.edu.cn	Chen, Youhai/AAJ-4031-2021; Wang, Zhaojun/GKS-9141-2022; ma, chunhong/C-6043-2008	Wang, Zhaojun/0000-0003-2853-1850; ma, chunhong/0000-0002-8121-4718	National Science Foundation of China [81172353, 81372211]; Cultivating Project, Major Research Plan of National Natural Science Foundation of China [91129704]; Shandong Provincial Nature Science Foundation [JQ200907]; Research Fund for the Doctoral Program of Higher Education of China (RFDP) [20110131110034];  [NCET-10-0524]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Cultivating Project, Major Research Plan of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Provincial Nature Science Foundation; Research Fund for the Doctoral Program of Higher Education of China (RFDP)(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); 	This work was supported by grants from the National Science Foundation of China (Nos. 81172353, 81372211), Cultivating Project, Major Research Plan of National Natural Science Foundation of China (91129704), Programme for NCET-10-0524, Research Fund for the Doctoral Program of Higher Education of China (RFDP) (20110131110034) and Shandong Provincial Nature Science Foundation for Distinguished Young Scholars JQ200907.	Brown JH, 2006, CIRC RES, V98, P730, DOI 10.1161/01.RES.0000216039.75913.9e; Chaigne-Delalande B, 2008, ONCOGENE, V27, P1876, DOI 10.1038/sj.onc.1210830; Cui J, 2011, MOL IMMUNOL, V48, P1548, DOI 10.1016/j.molimm.2011.04.023; Debidda M, 2006, J BIOL CHEM, V281, P38519, DOI 10.1074/jbc.M604607200; Delavallee L, 2011, IUBMB LIFE, V63, P221, DOI 10.1002/iub.432; Dong QZ, 2010, CANCER SCI, V101, P1562, DOI 10.1111/j.1349-7006.2010.01557.x; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Filmus Jorge, 2004, Mol Diagn, V8, P207, DOI 10.2165/00066982-200408040-00002; Gomez J, 1998, IMMUNOL CELL BIOL, V76, P125, DOI 10.1046/j.1440-1711.1998.00723.x; Gus-Brautbar Y, 2012, MOL CELL, V45, P610, DOI 10.1016/j.molcel.2012.01.006; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Ishak KG, 2000, AM J CLIN PATHOL, V113, P40, DOI 10.1309/42D6-W7PL-FX0A-LBXF; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Kumar D, 2004, ONCOGENE, V23, P612, DOI 10.1038/sj.onc.1207123; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Luan F, 2009, GUT, V58, P1528, DOI 10.1136/gut.2008.174029; Ma CH, 2004, WORLD J GASTROENTERO, V10, P2874; Mack NA, 2011, CELL CYCLE, V10, P1571, DOI 10.4161/cc.10.10.15612; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; Miao ZF, 2012, TUMOR BIOL, V33, P2099, DOI 10.1007/s13277-012-0469-1; Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x; Ozen C, 2013, NEW BIOTECHNOL, V30, P381, DOI 10.1016/j.nbt.2013.01.007; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sasi N, 2009, MOL CANCER THER, V8, P1421, DOI 10.1158/1535-7163.MCT-08-0895; Shi TY, 2013, CARCINOGENESIS, V34, P770, DOI 10.1093/carcin/bgt001; Shiraha H, 2013, INT J ONCOL, V42, P1133, DOI 10.3892/ijo.2013.1829; Sun HH, 2008, CELL, V133, P415, DOI 10.1016/j.cell.2008.03.026; Sun HH, 2012, J IMMUNOL, V189, P2768, DOI 10.4049/jimmunol.1103477; Wang ZJ, 2012, P NATL ACAD SCI USA, V109, P15413, DOI 10.1073/pnas.1204525109; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Wilson KD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002609; Woodward MJ, 2010, CELL DEATH DIFFER, V17, P316, DOI 10.1038/cdd.2009.125; Yue XT, 2012, GASTROENTEROLOGY, V142, P1559, DOI 10.1053/j.gastro.2012.02.049; Zhang CB, 2006, MOL THER, V13, P947, DOI 10.1016/j.ymthe.2005.11.020	37	45	51	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2566	2574		10.1038/onc.2014.208	http://dx.doi.org/10.1038/onc.2014.208			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25043299				2022-12-17	WOS:000354541300003
J	Vinnedge, LMP; Benight, NM; Wagh, PK; Pease, NA; Nashu, MA; Serrano-Lopez, J; Adams, AK; Cancelas, JA; Waltz, SE; Wells, SI				Vinnedge, L. M. Privette; Benight, N. M.; Wagh, P. K.; Pease, N. A.; Nashu, M. A.; Serrano-Lopez, J.; Adams, A. K.; Cancelas, J. A.; Waltz, S. E.; Wells, S. I.			The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; BETA-CATENIN; MAMMARY-GLAND; STEM-CELL; TYROSINE KINASE; ONCOPROTEIN DEK; TUMOR-FORMATION; BLADDER-CANCER; UP-REGULATION; FEMALE MICE	Disease progression and recurrence are major barriers to survival for breast cancer patients. Understanding the etiology of recurrent or metastatic breast cancer and underlying mechanisms is critical for the development of new treatments and improved survival. Here, we report that two commonly overexpressed breast cancer oncogenes, Ron (Recepteur d'Origine Nantaise) and DEK, cooperate to promote advanced disease through multipronged effects on beta-catenin signaling. The Ron receptor is commonly activated in breast cancers, and Ron overexpression in human disease stimulates beta-catenin nuclear translocation and is an independent predictor of metastatic dissemination. Dek is a chromatin-associated oncogene whose expression has been linked to cancer through multiple mechanisms, including beta-catenin activity. We demonstrate here that Dek is a downstream target of Ron receptor activation in murine and human models. The absence of Dek in the MMTV-Ron mouse model led to a significant delay in tumor development, characterized by decreased cell proliferation, diminished metastasis and fewer cells expressing mammary cancer stem cell markers. Dek complementation of cell lines established from this model was sufficient to promote cellular growth and invasion. Mechanistically, Dek expression stimulated the production and secretion of Wnt ligands to sustain an autocrine/paracrine canonical beta-catenin signaling loop. Finally, we show that Dek overexpression promotes tumorigenic phenotypes in immortalized human mammary epithelial MCF10A cells and, in the context of Ron receptor activation, correlates with disease recurrence and metastasis in patients. Overall, our studies demonstrate that DEK overexpression, due in part to Ron receptor activation, drives breast cancer progression through the induction of Wnt/beta-catenin signaling.	[Vinnedge, L. M. Privette; Pease, N. A.; Adams, A. K.; Wells, S. I.] Cincinnati Childrens Hosp Med Ctr, Div Oncol, Cincinnati, OH 45229 USA; [Benight, N. M.; Nashu, M. A.; Waltz, S. E.] Univ Cincinnati, Coll Med, Dept Canc Biol, Cincinnati, OH USA; [Wagh, P. K.] Cincinnati Childrens Hosp Med Ctr, Dept Pathol & Lab Med, Cincinnati, OH 45229 USA; [Serrano-Lopez, J.; Cancelas, J. A.] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Serrano-Lopez, J.] Univ Hosp Reina Sofia, UCO, IMIBIC, Cordoba, Spain; [Cancelas, J. A.] Univ Cincinnati, Coll Med, Hoxworth Blood Ctr, Cincinnati, OH USA; [Waltz, S. E.] Cincinnati Vet Affairs Med Ctr, Dept Res, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Wells, SI (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Oncol, MLC 7013,3333 Burnet Ave, Cincinnati, OH 45229 USA.	Lisa.Privette@cchmc.org; Susanne.Wells@cchmc.org	Cancelas, Jose/AAR-9324-2020; Vinnedge, Lisa Privette/H-5869-2019; Serano-Lopez, Juana/O-8874-2017	Vinnedge, Lisa Privette/0000-0003-2087-4920; Waltz, Susan/0000-0003-3572-4642; Benight, Nancy/0000-0001-7321-3187; Serrano Lopez, Juana/0000-0001-8140-9040	NIH [AR-47363]; Ride Cincinnati Foundation for Breast Cancer Research [F32CA139931, T32HL091805, K12HD051953]; Public Health Services [R01CA116316, R01HL875109, T32ES007250, T32CA117846-07, T32CA11784]; Department of Defense [W81XWH-12-1-0194]; Veteran's Administration [BX000803]; Government of the Spanish Junta de Andalucia; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD051953] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA117846, R01CA116316, F32CA189685, F32CA139931] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL091805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR047363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000803] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ride Cincinnati Foundation for Breast Cancer Research; Public Health Services(United States Department of Health & Human ServicesUnited States Public Health Service); Department of Defense(United States Department of Defense); Veteran's Administration(US Department of Veterans Affairs); Government of the Spanish Junta de Andalucia; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Veterans Affairs(US Department of Veterans Affairs)	We acknowledge James Lessard and Gerard Grosveld for reagents, Kathryn Wikenheiser-Brokamp for technical assistance and the Research Flow Cytometry Core at Cincinnati Children's, supported by NIH AR-47363. LMPV is supported by the Ride Cincinnati Foundation for Breast Cancer Research in honor of Marlene Harris and Public Health Service Grants F32CA139931, T32HL091805 and K12HD051953. Funding also was provided by Public Health Services Grants R01CA116316 (SIW), R01HL875109 (JAC), T32ES007250 (AKA), T32CA117846-07 (PKW) and T32CA11784 (SEW and NMB), Department of Defense Grant W81XWH-12-1-0194 (SIW and SEW) and the Veteran's Administration Grant BX000803 (SEW). JS-W is supported by the Government of the Spanish Junta de Andalucia.	ACS (American Cancer Society), 2011, BREAST CANC FACTS FI; Adams AK, 2015, ONCOGENE, V34, P868, DOI 10.1038/onc.2014.15; Alexiadis V, 2000, GENE DEV, V14, P1308; Benhaj K, 2006, ONCOL REP, V15, P701; Campillos M, 2003, NUCLEIC ACIDS RES, V31, P1571, DOI 10.1093/nar/gkg247; Carro MS, 2006, CELL CYCLE, V5, P1202, DOI 10.4161/cc.5.11.2801; Danilkovitch-Miagkova A, 2003, CURR CANCER DRUG TAR, V3, P31, DOI 10.2174/1568009033333745; Datta A, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-234; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Evans AJ, 2004, AM J PATHOL, V164, P285, DOI 10.1016/S0002-9440(10)63118-5; Florian MC, 2013, NATURE, V503, P392, DOI 10.1038/nature12631; Gamble MJ, 2007, NAT STRUCT MOL BIOL, V14, P548, DOI 10.1038/nsmb1248; Gao B, 2012, CURR TOP DEV BIOL, V101, P263, DOI 10.1016/B978-0-12-394592-1.00008-9; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Habib SJ, 2013, SCIENCE, V339, P1445, DOI 10.1126/science.1231077; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; HUGUET EL, 1994, CANCER RES, V54, P2615; Kappes F, 2011, GENE DEV, V25, P673, DOI 10.1101/gad.2036411; Karam M, 2014, NEOPLASIA, V16, P21, DOI 10.1593/neo.131658; Karner C, 2006, SEMIN CELL DEV BIOL, V17, P214, DOI 10.1016/j.semcdb.2006.05.007; Kavanaugh GM, 2011, NUCLEIC ACIDS RES, V39, P7465, DOI 10.1093/nar/gkr454; Khodadoust MS, 2009, CANCER RES, V69, P6405, DOI 10.1158/0008-5472.CAN-09-1063; Kim DW, 2010, MOL MED REP, V3, P877, DOI 10.3892/mmr.2010.346; Koleva RI, 2012, BLOOD, V119, P4878, DOI 10.1182/blood-2011-10-383083; Kondoh N, 1999, CANCER RES, V59, P4990; Krol M, 2010, J APPL GENET, V51, P37, DOI 10.1007/BF03195709; Kuorelahti A, 2007, ENDOCRINOLOGY, V148, P3694, DOI 10.1210/en.2007-0249; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; Leonis Mike A, 2007, Future Oncol, V3, P441, DOI 10.2217/14796694.3.4.441; Liu KR, 2012, BIOSCIENCE REP, V32, P323, DOI 10.1042/BSR20100141; Lossaint G, 2013, MOL CELL, V51, P678, DOI 10.1016/j.molcel.2013.07.023; Ma J, 2012, TUMOR BIOL, V33, P1983, DOI 10.1007/s13277-012-0458-4; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; McClaine RJ, 2010, NEOPLASIA, V12, P650, DOI 10.1593/neo.10476; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; Meier-Abt F, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3419; Soares LMM, 2006, SCIENCE, V312, P1961, DOI 10.1126/science.1128659; Miranda-Carboni GA, 2008, GENE DEV, V22, P3121, DOI 10.1101/gad.1692808; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Moll UM, 2004, MOL CANCER RES, V2, P371; Mor-Vaknin N, 2006, MOL CELL BIOL, V26, P9484, DOI 10.1128/MCB.01030-06; Mor-Vaknin N, 2011, ARTHRITIS RHEUM-US, V63, P556, DOI 10.1002/art.30138; Peace BE, 2005, CANCER RES, V65, P1285, DOI 10.1158/0008-5472.CAN-03-3580; Rajagopal J, 2008, DEVELOPMENT, V135, P1625, DOI 10.1242/dev.015495; Robinson GW, 2000, GENE DEV, V14, P889; Saha AK, 2013, P NATL ACAD SCI USA, V110, P6847, DOI 10.1073/pnas.1220751110; Sammons M, 2006, J BIOL CHEM, V281, P26802, DOI 10.1074/jbc.M600915200; Sanden C, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-440; Sawatsubashi S, 2010, GENE DEV, V24, P159, DOI 10.1101/gad.1857410; Schlessinger K, 2009, GENE DEV, V23, P265, DOI 10.1101/gad.1760809; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shibata T, 2010, ONCOGENE, V29, P4671, DOI 10.1038/onc.2010.217; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Veltmaat JM, 2004, DEV DYNAM, V229, P349, DOI 10.1002/dvdy.10441; Vinnedge LMP, 2011, ONCOGENE, V30, P2741, DOI 10.1038/onc.2011.2; Vinnedge LMP, 2013, CELL CYCLE, V12, P51, DOI 10.4161/cc.23121; Vinnedge LMP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046985; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Wagh PK, 2011, ONCOGENE, V30, P3694, DOI 10.1038/onc.2011.86; Wang JY, 2013, J HISTOCHEM CYTOCHEM, V61, P510, DOI 10.1369/0022155413488120; Wang MH, 2013, J BIOMED RES, V27, P345, DOI 10.7555/JBR.27.20130038; Wend P, 2013, EMBO MOL MED, V5, P264, DOI 10.1002/emmm.201201320; Wise-Draper TM, 2005, J VIROL, V79, P14309, DOI 10.1128/JVI.79.22.14309-14317.2005; Wise-Draper TM, 2006, MOL CELL BIOL, V26, P7506, DOI 10.1128/MCB.00430-06; Wise-Draper TM, 2009, CANCER RES, V69, P1792, DOI 10.1158/0008-5472.CAN-08-2304; Wise-Draper TM, 2009, AM J PATHOL, V174, P71, DOI 10.2353/ajpath.2009.080330; Wu BB, 2007, IMMUNITY, V26, P227, DOI 10.1016/j.immuni.2006.12.007; Yin YJ, 2006, CANCER RES, V66, P5224, DOI 10.1158/0008-5472.CAN-05-4234; Zhao H, 2014, ONCOGENE, V33, P1429, DOI 10.1038/onc.2013.84; Zinser GM, 2006, CANCER RES, V66, P11967, DOI 10.1158/0008-5472.CAN-06-2473	74	45	46	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2325	2336		10.1038/onc.2014.173	http://dx.doi.org/10.1038/onc.2014.173			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24954505	Green Accepted			2022-12-17	WOS:000353824800006
J	Mucaj, V; Lee, SS; Skuli, N; Giannoukos, DN; Qiu, B; Eisinger-Mathason, TSK; Nakazawa, MS; Shay, JES; Gopal, PP; Venneti, S; Lal, P; Minn, AJ; Simon, MC; Mathew, LK				Mucaj, V.; Lee, S. S.; Skuli, N.; Giannoukos, D. N.; Qiu, B.; Eisinger-Mathason, T. S. K.; Nakazawa, M. S.; Shay, J. E. S.; Gopal, P. P.; Venneti, S.; Lal, P.; Minn, A. J.; Simon, M. C.; Mathew, L. K.			MicroRNA-124 expression counteracts pro-survival stress responses in glioblastoma	ONCOGENE			English	Article							GENE-EXPRESSION; HYPOXIA; MIR-124; PROLIFERATION; PATHWAY; GLIOMA; RADIOTHERAPY; PROGRESSION	Glioblastomas are aggressive adult brain tumors, characterized by inadequately organized vasculature and consequent nutrient and oxygen (O-2)-depleted areas. Adaptation to low nutrients and hypoxia supports glioblastoma cell survival, progression and therapeutic resistance. However, specific mechanisms promoting cellular survival under nutrient and O-2 deprivation remain incompletely understood. Here, we show that miR-124 expression is negatively correlated with a hypoxic gene signature in glioblastoma patient samples, suggesting that low miR-124 levels contribute to pro-survival adaptive pathways in this disease. As miR-124 expression is repressed in various cancer types (including glioblastoma), we quantified miR-124 abundance in normoxic and hypoxic regions in glioblastoma patient tissue, and investigated whether ectopic miR-124 expression compromises cell survival during tumor ischemia. Our results indicate that miR-124 levels are further diminished in hypoxic/ischemic regions within individual glioblastoma patient samples, compared with regions replete in O-2 and nutrients. Importantly, we also show that increased miR-124 expression affects the ability of tumor cells to survive under O-2 and/or nutrient deprivation. Moreover, miR-124 re-expression increases cell death in vivo and enhances the survival of mice bearing intracranial xenograft tumors. miR-124 exerts this phenotype in part by directly regulating TEAD1, MAPK14/p38a and SERP1, factors involved in cell proliferation and survival under stress. Simultaneous suppression of these miR-124 targets results in similar levels of cell death as caused by miR-124 restoration. Importantly, we further demonstrate that SERP1 reintroduction reverses the hypoxic cell death elicited by miR-124, indicating the importance of SERP1 in promoting tumor cell survival. In support of our experimental data, we observed a significant correlation between high SERP1 levels and poor patient outcome in glioblastoma patients. Collectively, among the many pro-tumorigeneic properties of miR-124 repression in glioblastoma, we delineated a novel role in promoting tumor cell survival under stressful microenvironments, thereby supporting tumor progression.	[Mucaj, V.; Lee, S. S.; Skuli, N.; Giannoukos, D. N.; Qiu, B.; Eisinger-Mathason, T. S. K.; Nakazawa, M. S.; Shay, J. E. S.; Minn, A. J.; Simon, M. C.; Mathew, L. K.] Univ Penn, Abramson Family Canc Res Inst, Perelman Sch Med, Philadelphia, PA 19104 USA; [Lee, S. S.; Skuli, N.; Giannoukos, D. N.; Simon, M. C.; Mathew, L. K.] Univ Penn, Howard Hughes Med Inst, Perelman Sch Med, Philadelphia, PA 19104 USA; [Skuli, N.] Inst Claudius Regaud, INSERM U1037, Toulouse, France; [Gopal, P. P.; Venneti, S.; Lal, P.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Howard Hughes Medical Institute; University of Pennsylvania; Pennsylvania Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; University of Pennsylvania; Pennsylvania Medicine	Simon, MC (corresponding author), Univ Penn, Dept Cell & Dev Biol, Sch Med, Abramson Family Canc Res Inst,Howard Hughes Med I, 456 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	celeste2@mail.med.upenn.edu	Simon, Celeste/AAG-3941-2021	Shay, Jessica/0000-0001-7799-1349; Gopal, Pallavi/0000-0003-4708-8479; Minn, Andy/0000-0003-1418-0906; Qiu, Bo/0000-0003-4199-1659	Howard Hughes Medical Institute; National Institutes of Health [T32 GM-07229, F31CA174211]; NATIONAL CANCER INSTITUTE [F31CA174211, K08CA181475, R01CA172651, F30CA177106, P01CA104838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Hongwei Yu for assistance with histological preparations, Dr Jeremy Rich for providing the patient-derived tumor sphere cells, Dr Stephen Prouty for assistance with Laser-Capture Microdissection and the Simon laboratory for helpful discussions. This work was funded by the Howard Hughes Medical Institute and the National Institutes of Health (T32 GM-07229; F31CA174211). MCS is an investigator of the Howard Hughes Medical Institute.	Amberger-Murphy V, 2009, CURR CANCER DRUG TAR, V9, P381, DOI 10.2174/156800909788166637; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Ben-Hamo R, 2011, GENOME MED, V3, DOI 10.1186/gm293; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cloninger C, 2011, MOL CANCER THER, V10, P2244, DOI 10.1158/1535-7163.MCT-11-0478; Demuth T, 2007, MOL CANCER THER, V6, P1212, DOI 10.1158/1535-7163.MCT-06-0711; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Evans SM, 2010, TRANSL ONCOL, V3, P160, DOI 10.1593/tlo.09265; Gao FB, 2010, NEURAL DEV, V5, DOI 10.1186/1749-8104-5-25; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Hatziapostolou M, 2011, CELL, V147, P1233, DOI 10.1016/j.cell.2011.10.043; Hori O, 2006, MOL CELL BIOL, V26, P4257, DOI 10.1128/MCB.02055-05; Huang X, 2009, MOL CELL, V35, P856, DOI 10.1016/j.molcel.2009.09.006; Hunt S, 2011, FEBS LETT, V585, P187, DOI 10.1016/j.febslet.2010.11.038; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kang K, 2013, J BIOL CHEM, V288, P25414, DOI 10.1074/jbc.M113.460287; Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898; Krex D, 2007, BRAIN, V130, P2596, DOI 10.1093/brain/awm204; Lawson SK, 2013, MOL CELL BIOL, V33, P127, DOI 10.1128/MCB.00695-12; Li D, 2011, OMICS, V15, P673, DOI 10.1089/omi.2011.0064; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu XS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023461; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Makeyev EV, 2007, MOL CELL, V27, P435, DOI 10.1016/j.molcel.2007.07.015; Malt AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045498; Mathew LK, 2014, P NATL ACAD SCI USA, V111, P291, DOI 10.1073/pnas.1314341111; Nelson PT, 2006, RNA, V12, P187, DOI 10.1261/rna.2258506; Paillas S, 2012, AUTOPHAGY, V8, P1098, DOI 10.4161/auto.20268; Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Sonntag KC, 2012, EXP NEUROL, V235, P427, DOI 10.1016/j.expneurol.2011.11.035; Spence AM, 2008, CLIN CANCER RES, V14, P2623, DOI 10.1158/1078-0432.CCR-07-4995; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Visvanathan J, 2007, GENE DEV, V21, P744, DOI 10.1101/gad.1519107; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wu ZF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047270; Yamaguchi A, 1999, J CELL BIOL, V147, P1195, DOI 10.1083/jcb.147.6.1195; Yoo AS, 2011, NATURE, V476, P228, DOI 10.1038/nature10323; Zhao B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI 10.1016/j.ceb.2008.10.001	41	45	47	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2204	2214		10.1038/onc.2014.168	http://dx.doi.org/10.1038/onc.2014.168			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24954504	Green Accepted			2022-12-17	WOS:000353473000006
J	Sharif, GM; Schmidt, MO; Yi, C; Hu, Z; Haddad, BR; Glasgow, E; Riegel, AT; Wellstein, A				Sharif, G. M.; Schmidt, M. O.; Yi, C.; Hu, Z.; Haddad, B. R.; Glasgow, E.; Riegel, A. T.; Wellstein, A.			Cell growth density modulates cancer cell vascular invasion via Hippo pathway activity and CXCR2 signaling	ONCOGENE			English	Article							CONTACT INHIBITION; SIZE-CONTROL; TENASCIN-C; STEM-CELLS; METASTASIS; YAP; ANGIOGENESIS; ZEBRAFISH; BIOLOGY; PROGRESSION	Metastasis of cancer cells involves multiple steps, including their dissociation from the primary tumor and invasion through the endothelial cell barrier to enter the circulation and finding their way to distant organ sites where they extravasate and establish metastatic lesions. Deficient contact inhibition is a hallmark of invasive cancer cells, yet surprisingly the vascular invasiveness of commonly studied cancer cell lines is regulated by the density at which cells are propagated in culture. Cells grown at high density were less effective at invading an endothelial monolayer than cells grown at low density. This phenotypic difference was also observed in a zebrafish model of vascular invasion of cancer cells after injection into the yolk sac and extravasation of cancer cells into tissues from the vasculature. The vascular invasive phenotypes were reversible. A kinome-wide RNA interference screen was used to identify drivers of vascular invasion by panning small hairpin RNA (shRNA) library-transduced noninvasive cancer cell populations on endothelial monolayers. The selection of invasive subpopulations showed enrichment of shRNAs targeting the large tumor suppressor 1 (LATS1) kinase that inhibits the activity of the transcriptional coactivator yes-associated protein (YAP) in the Hippo pathway. Depletion of LATS1 from noninvasive cancer cells restored the invasive phenotype. Complementary to this, inhibition or depletion of YAP inhibited invasion in vitro and in vivo. The vascular invasive phenotype was associated with a YAP-dependent upregulation of the cytokines IL6, IL8 and C-X-C motif ligand 1, 2 and 3. Antibody blockade of cytokine receptors inhibited invasion and confirmed that they are rate-limiting drivers that promote cancer cell vascular invasiveness and could provide therapeutic targets.	[Sharif, G. M.; Schmidt, M. O.; Yi, C.; Hu, Z.; Haddad, B. R.; Glasgow, E.; Riegel, A. T.; Wellstein, A.] Georgetown Univ, Lombardi Canc Ctr, 3970 Reservoir Rd, Washington, DC 20057 USA	Georgetown University	Wellstein, A (corresponding author), Georgetown Univ, Lombardi Canc Ctr, 3970 Reservoir Rd, Washington, DC 20057 USA.	wellstea@georgetown.edu	Schmidt, Marcel/AAV-8054-2021	Schmidt, Marcel/0000-0002-3991-2766; Glasgow, Eric/0000-0001-7729-3954; Sharif, Ghada/0000-0001-5344-3575	NIH/NCI [CA71508, CA113477, CA51008]; NATIONAL CANCER INSTITUTE [R01CA071508, P30CA051008, R33CA177466, R01CA113477, R01CA108440, T32CA009686, P50CA058185, R01CA101811] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Dr Joan Massague kindly provided the MDA-MB-231 derivative cell lines used here. We thank Caroline E Laverriere for excellent assistance with the zebrafish experiments. Work was supported by NIH/NCI grant CA71508 (AW) and CA113477 (ATR) and CA51008 for zebrafish and mouse studies.	Abassi YA, 2009, CHEM BIOL, V16, P712, DOI 10.1016/j.chembiol.2009.05.011; Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Al-Otaiby M, 2012, AM J PATHOL, V180, P1474, DOI 10.1016/j.ajpath.2011.12.032; Bieche I, 2007, ENDOCR-RELAT CANCER, V14, P1039, DOI 10.1677/erc.1.01301; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Chen DH, 2012, NAT MED, V18, P1511, DOI 10.1038/nm.2940; Chen Q, 2014, GENE DEV, V28, P432, DOI 10.1101/gad.233676.113; Cross LM, 2003, ARTERIOSCL THROM VAS, V23, P911, DOI 10.1161/01.ATV.0000068685.72914.7E; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; Erez N, 2011, INT J CANCER, V128, P2536, DOI 10.1002/ijc.26032; Fereshteh MP, 2008, CANCER RES, V68, P3697, DOI 10.1158/0008-5472.CAN-07-6702; Fernando RI, 2011, CANCER RES, V71, P5296, DOI 10.1158/0008-5472.CAN-11-0156; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Greten FR, 2014, CELL, V158, P11, DOI 10.1016/j.cell.2014.06.021; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Huh SJ, 2010, CANCER RES, V70, P6071, DOI 10.1158/0008-5472.CAN-09-4442; Iorns E, 2012, BREAST CANCER RES TR, V135, P79, DOI 10.1007/s10549-012-2068-7; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Lau AN, 2014, EMBO J, V33, P468, DOI 10.1002/embj.201386082; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Melo SA, 2013, NAT CELL BIOL, V15, P139, DOI 10.1038/ncb2684; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Nallet-Staub F, 2014, J INVEST DERMATOL, V134, P123, DOI 10.1038/jid.2013.319; Nance J, 2014, J CELL BIOL, V206, P823, DOI 10.1083/jcb.201407064; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; O'Connell JT, 2011, P NATL ACAD SCI USA, V108, P16002, DOI 10.1073/pnas.1109493108; Oehlers SHB, 2010, DEV COMP IMMUNOL, V34, P352, DOI 10.1016/j.dci.2009.11.007; Oh A, 2004, CANCER RES, V64, P8299, DOI 10.1158/0008-5472.CAN-04-0354; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Park HW, 2013, TRENDS PHARMACOL SCI, V34, P581, DOI 10.1016/j.tips.2013.08.006; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Rasanen K, 2012, CANCER DISCOV, V2, P775, DOI 10.1158/2159-8290.CD-12-0312; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stoletov K, 2008, ONCOGENE, V27, P4509, DOI 10.1038/onc.2008.95; Stoletov K, 2010, J CELL SCI, V123, P2332, DOI 10.1242/jcs.069443; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tassi E, 2011, AM J PATHOL, V179, P2220, DOI 10.1016/j.ajpath.2011.07.043; van der Aa LM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012384; Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376; Varelas X, 2010, DEV CELL, V19, P831, DOI 10.1016/j.devcel.2010.11.012; Yagi H, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002221; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049	57	45	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	2015	34	48					5879	5889		10.1038/onc.2015.44	http://dx.doi.org/10.1038/onc.2015.44			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VC0NX	25772246	Green Accepted			2022-12-17	WOS:000426437000001
J	Huang, Z; Choi, BK; Mujoo, K; Fan, X; Fa, M; Mukherjee, S; Owiti, N; Zhang, N; An, Z				Huang, Z.; Choi, B-K; Mujoo, K.; Fan, X.; Fa, M.; Mukherjee, S.; Owiti, N.; Zhang, N.; An, Z.			The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; BREAST-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT ACTIVATION; PROSTATE-CANCER; ERBB RECEPTORS; BINDING-SITE; HER3; DEGRADATION	HER3/ErbB3, a member of the epidermal growth factor receptor (EGFR) family, has a pivotal role in cancer and is emerging as a therapeutic antibody target. In this study, we identified NEDD4 (neural precursor cell expressed, developmentally downregulated 4) as a novel interaction partner and ubiquitin E3 ligase of human HER3. Using molecular and biochemical approaches, we demonstrated that the C-terminal tail of HER3 interacted with the WW domains of NEDD4 and the interaction was independent of neuregulin-1. Short hairpin RNA knockdown of NEDD4 elevated HER3 levels and resulted in increased HER3 signaling and cancer cell proliferation in vitro and in vivo. A similar inverse relationship between HER3 and NEDD4 levels was observed in prostate cancer tumor tissues. More importantly, the upregulated HER3 expression by NEDD4 knockdown sensitized cancer cells for growth inhibition by an anti-HER3 antibody. Taken together, our results suggest that low NEDD4 levels may predict activation of HER3 signaling and efficacies of anti-HER3 antibody therapies.	[Huang, Z.; Choi, B-K; Mujoo, K.; Fan, X.; Fa, M.; Mukherjee, S.; Owiti, N.; Zhang, N.; An, Z.] Univ Texas Houston, Texas Therapeut Inst, Brown Fdn Inst Mol Med, Hlth Sci Ctr, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Zhang, N (corresponding author), Univ Texas Houston, Texas Therapeut Inst, Brown Fdn Inst Mol Med, Hlth Sci Ctr, Houston, TX 77030 USA.	Ningyan.zhang@uth.tmc.edu; Zhiqiang.an@uth.tmc.edu	Mujoo, Kalpana/S-9933-2019	Mujoo, Kalpana/0000-0002-4275-1051; Owiti, Norah/0000-0002-5061-7434; Zhang, Ningyan/0000-0002-4348-2180; An, Zhiqiang/0000-0001-9309-2335	Texas Emerging Technology Fund; Johnson and Johnson; Welch Foundation [AU00024]	Texas Emerging Technology Fund; Johnson and Johnson(Johnson & JohnsonJohnson & Johnson USA); Welch Foundation(The Welch Foundation)	We thank Dr Hui Deng for help on cell cultures; Professor Renping Zhou and Dr Kendra Carmon for critical comments on the manuscript; Dr Stephen Hewitt of NIH/ NCI for providing the prostate cancer clinical samples; and Dr Rabih Said for interpretation of immunohistochemistry experiments. The work was partially funded by grants from the Texas Emerging Technology Fund, Johnson and Johnson, and the Welch Foundation grant no. AU00024 to ZA.	Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Baselga J, 2010, ANN ONCOL, V21, P36, DOI 10.1093/annonc/mdq421; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Bouyain S, 2007, PROTEIN SCI, V16, P654, DOI 10.1110/ps.062700307; Carraway KL, 2010, SEMIN CELL DEV BIOL, V21, P936, DOI 10.1016/j.semcdb.2010.09.006; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chaib H, 2001, NEOPLASIA, V3, P43, DOI 10.1038/sj.neo.7900126; Choi BK, 2012, CANCER MED-US, V1, P28, DOI 10.1002/cam4.10; Choi BK, 2012, PROTEIN CELL, V3, P781, DOI 10.1007/s13238-012-2065-y; Diamonti AJ, 2002, P NATL ACAD SCI USA, V99, P2866, DOI 10.1073/pnas.052709799; Dornan D, 2004, CANCER RES, V64, P7226, DOI 10.1158/0008-5472.CAN-04-2601; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Feng SM, 2009, MOL CELL BIOL, V29, P892, DOI 10.1128/MCB.00595-08; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hsieh AC, 2007, BRIT J CANCER, V97, P453, DOI 10.1038/sj.bjc.6603910; Huang QQ, 2010, J BIOL CHEM, V285, P42130, DOI 10.1074/jbc.M110.143412; Huang X, 2000, NATURE, P7634; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Jaiswal BS, 2013, CANCER CELL, V23, P603, DOI 10.1016/j.ccr.2013.04.012; Koumakpayi IH, 2006, CLIN CANCER RES, V12, P2730, DOI 10.1158/1078-0432.CCR-05-2242; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Li Z, 2006, CARCINOGENESIS, V27, P1054, DOI 10.1093/carcin/bgi324; Lipkowitz S, 2003, BREAST CANCER RES, V5, P8, DOI 10.1186/bcr541; Lyne JC, 1997, CANCER J SCI AM, V3, P21; Maspero E, 2011, EMBO REP, V12, P342, DOI 10.1038/embor.2011.21; Menendez JA, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1773; Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509; Omerovic J, 2007, FASEB J, V21, P2849, DOI 10.1096/fj.06-7925com; Persaud A, 2011, EMBO J, V30, P3259, DOI 10.1038/emboj.2011.234; Persaud A, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.85; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Qiu XB, 2002, P NATL ACAD SCI USA, V99, P14843, DOI 10.1073/pnas.232580999; Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690; Schaefer G, 2011, CANCER CELL, V20, P472, DOI 10.1016/j.ccr.2011.09.003; Schoeberl B, 2010, CANCER RES, V70, P2485, DOI 10.1158/0008-5472.CAN-09-3145; Schoeberl B, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000352; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; Sithanandam G, 2008, CANCER GENE THER, V15, P413, DOI 10.1038/cgt.2008.15; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Sweeney C, 2004, BRIT J CANCER, V90, P289, DOI 10.1038/sj.bjc.6601500; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Tsang RY, 2012, BRIT J CANCER, V106, P6, DOI 10.1038/bjc.2011.516; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Vijapurkar U, 1998, J BIOL CHEM, V273, P20996, DOI 10.1074/jbc.273.33.20996; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Zeng FH, 2009, FASEB J, V23, P1935, DOI 10.1096/fj.08-121947	56	45	46	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1105	1115		10.1038/onc.2014.56	http://dx.doi.org/10.1038/onc.2014.56			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662824				2022-12-17	WOS:000350122100004
J	Kwon, Y; Smith, BD; Zhou, Y; Kaufman, MD; Godwin, AK				Kwon, Y.; Smith, B. D.; Zhou, Y.; Kaufman, M. D.; Godwin, A. K.			Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment	ONCOGENE			English	Article						ovarian cancer; human ovarian fibroblast; c-MET; hepatocyte growth factor; DCC-2701	TUMOR-ASSOCIATED FIBROBLASTS; HEPARAN-SULFATE; KINASE; MATRIX; OLIGOSACCHARIDES; TRANSFORMATION; STROMAGENESIS; RESISTANCE	The signaling mediated by c-MET and its ligand, hepatocyte growth factor (HGF), has been implicated in malignant progression of cancer involving stimulation of proliferation, invasion and metastasis. We studied the c-MET/HGF axis as a mediator of tumor-stromal interaction in ovarian cancer and the value of targeting c-MET for the treatment of ovarian cancer. To assess c-MET signaling, we established in vitro models of the microenvironment using primary and immortalized human fibroblasts from normal ovary and tumor samples and epithelial ovarian cancer cell lines. We found that fibroblast from normal ovaries secreted high levels of HGF (1500-3800 pg/ml) as compared with tumor-derived fibroblasts (undetectable level) and could elicit cellular biological responses on c-MET-expressing ovarian cancer cells including increase of cell proliferation and migration (2- to 140-fold increase). HGF secreted by fibroblasts was also found sequestered within extracellular matrices (ECMs) and when degraded this ECM-derived HGF stimulated cancer cell migration (1.5- to 24-fold). In cells containing constitutive c-MET phosphorylation, recombinant HGF and fibroblast-derived HGF negligibly affect c-MET phosphorylation on Tyr(1234) and Tyr(1003). However, both sources of HGF increased the phosphorylation of c-MET on Tyr(1349), the multi-substrate docking site, by more than sixfold and led to activation of downstream signaling transducers. DCC-2701 (Deciphera Pharmaceuticals, LLC), a novel c-MET/TIE-2/VEGFR inhibitor was able to effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro. Importantly, DCC-2701's anti-proliferative activity was dependent on c-MET activation induced by stromal human fibroblasts and to a lesser extent exogenous HGF. Our data suggest for the first time that DCC-2701 may be superior to HGF antagonists that are in clinical trials and that pTyr(134)(levels might be a good indicator of c-MET activation and likely response to targeted therapy as a result of signals from the microenvironment.	[Kwon, Y.; Godwin, A. K.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA; [Kwon, Y.] Ewha Womans Univ, Dept Food Sci & Engn, Seoul, South Korea; [Smith, B. D.; Kaufman, M. D.] Deciphera Pharmaceut LLC, Lawrence, KS USA; [Zhou, Y.] Fox Chase Canc Ctr, Biostat & Bioinformat Facil, Philadelphia, PA 19111 USA; [Godwin, A. K.] Univ Kansas, Ctr Canc, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; Ewha Womans University; Fox Chase Cancer Center; University of Kansas	Godwin, AK (corresponding author), Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Mail Stop 3040,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	AGodwin@kumc.edu		Kwon, Youngjoo/0000-0003-3582-4192	Ovarian Cancer Research Fund; NCI [R01 CA140323]; University of Kansas Cancer Center's CCSG [P30 CA168524]; Kansas Bioscience Authority Eminent Scholar Program; NATIONAL CANCER INSTITUTE [P30CA168524, R01CA140323] Funding Source: NIH RePORTER	Ovarian Cancer Research Fund; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Kansas Cancer Center's CCSG; Kansas Bioscience Authority Eminent Scholar Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Ziyan Pessetto for her expertise in the cell viability assays and Dr Daniel Flynn for his helpful comments and guidance in regards the biology and activity of DCC-2701. The study was supported in part by a program project grant from Ovarian Cancer Research Fund (http://www.ocrf.org) and a grant from the NCI (R01 CA140323) to AKG. We would also like to acknowledge support from the University of Kansas Cancer Center's CCSG (P30 CA168524), the Kansas Bioscience Authority Eminent Scholar Program. AKG is the Chancellors Distinguished Chair in Biomedical Sciences endowed Professor.	Amatangelo MD, 2005, AM J PATHOL, V167, P475, DOI 10.1016/S0002-9440(10)62991-4; ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; Ayhan A, 2005, INT J GYNECOL CANCER, V15, P618, DOI 10.1111/j.1525-1438.2005.00117.x; Beacham DA, 2005, SEMIN CANCER BIOL, V15, P329, DOI 10.1016/j.semcancer.2005.05.003; Beacham Dorothy A, 2007, Curr Protoc Cell Biol, VChapter 10, DOI 10.1002/0471143030.cb1009s33; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Castello-Cros Remedios, 2009, V522, P275, DOI 10.1007/978-1-59745-413-1_19; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Corps AN, 1997, INT J CANCER, V73, P151, DOI 10.1002/(SICI)1097-0215(19970926)73:1<151::AID-IJC23>3.0.CO;2-I; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Flynn DL, 2013, ACS NAT M NEW ORL 8; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Gordon MS, 2010, CLIN CANCER RES, V16, P699, DOI 10.1158/1078-0432.CCR-09-1365; HAMILTON TC, 1983, CANCER RES, V43, P5379; Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009; Kwon Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018872; LANGDON SP, 1988, CANCER RES, V48, P6166; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Liu XD, 2010, TRENDS MOL MED, V16, P37, DOI 10.1016/j.molmed.2009.11.005; LYON M, 1994, J BIOL CHEM, V269, P11216; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Marchand-Adam S, 2003, AM J RESP CRIT CARE, V168, P1156, DOI 10.1164/rccm.200212-1514OC; Matsumoto K, 2006, INT J CANCER, V119, P477, DOI 10.1002/ijc.21808; Matsuoka H, 2006, AM J RESP CELL MOL, V35, P705, DOI 10.1165/rcmb.2006-0006OC; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; Miyata Y, 2006, CLIN CANCER RES, V12, P4876, DOI 10.1158/1078-0432.CCR-06-0362; Nayeri F, 2008, GROWTH FACTORS, V26, P163, DOI 10.1080/08977190802128083; Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9; Pan BS, 2010, CANCER RES, V70, P1524, DOI 10.1158/0008-5472.CAN-09-2541; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Quiros RM, 2008, GYNECOL ONCOL, V110, P99, DOI 10.1016/j.ygyno.2008.03.006; Sawada K, 2007, CANCER RES, V67, P1670, DOI 10.1158/0008-5472.CAN-06-1147; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sierra J Rafael, 2011, Ther Adv Med Oncol, V3, pS21, DOI 10.1177/1758834011422557; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Tatsumi R, 2004, MUSCLE NERVE, V30, P654, DOI 10.1002/mus.20114; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Zillhardt M, 2011, CLIN CANCER RES, V17, P4042, DOI 10.1158/1078-0432.CCR-10-3387; Zillhardt M, 2010, NEOPLASIA, V12, P1, DOI 10.1593/neo.09948; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	41	45	46	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					144	153		10.1038/onc.2013.539	http://dx.doi.org/10.1038/onc.2013.539			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24362531	Green Accepted			2022-12-17	WOS:000347790500002
J	Hirsch, E; Ciraolo, E; Franco, I; Ghigo, A; Martin, M				Hirsch, E.; Ciraolo, E.; Franco, I.; Ghigo, A.; Martin, M.			PI3K in cancer-stroma interactions: bad in seed and ugly in soil	ONCOGENE			English	Review						PI3K; tumorigenesis; microenvironment	EPITHELIAL-MESENCHYMAL TRANSITION; ENDOTHELIAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAY; CELL-SURVIVAL; PHOSPHATIDYLINOSITOL 3'-KINASE; PROSTATE-CANCER; BREAST-CANCER; TRASTUZUMAB RESISTANCE; INHIBITOR NVP-BEZ235; ONCOGENIC MUTATIONS	Over the past decade the phosphoinositide-3 kinase (PI3K) signaling pathway emerged as an important player for tumor initiation and growth and, currently, PI3K inhibition constitutes a promising therapeutic approach for solid and hematological tumors. Beside its role in tumor cell evolution, PI3K signaling also provides integral functions for noncancerous cells that reside in healthy tissues surrounding the tumor, also referred as tumor microenvironment (TME). This review will address how PI3K signaling participates to the tumorigenic process and discuss the interaction between tumor cells and the surrounding TME, with particular focus on the role of PI3Ks in tumor-associated immune responses, tumor angiogenesis and metastasis formation.	[Hirsch, E.; Ciraolo, E.; Franco, I.; Ghigo, A.; Martin, M.] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Ctr Mol Biotechnol, I-10126 Turin, Italy	University of Turin	Hirsch, E (corresponding author), Univ Turin, Dept Mol Biotechnol & Hlth Sci, Via Nizza 52, I-10126 Turin, Italy.	emilio.hirsch@unito.it	Franco, Irene/AAA-9170-2022; Ciraolo, Elisa/AAA-3430-2022; Martini, Miriam/K-3053-2016; Hirsch, Emilio/F-4848-2013	Franco, Irene/0000-0002-4272-239X; Martini, Miriam/0000-0002-4262-946X; Ghigo, Alessandra/0000-0002-1193-5296; Hirsch, Emilio/0000-0002-9073-6024; Ciraolo, Elisa/0000-0002-5601-1695	Fondazione Cariplo; Associazione Italiana Ricerca Cancro (AIRC); Italian Foundation for Cancer Research (FIRC)	Fondazione Cariplo(Fondazione Cariplo); Associazione Italiana Ricerca Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Foundation for Cancer Research (FIRC)(Fondazione AIRC per la ricerca sul cancro)	We thank MC Schmid for critical reading of the manuscript. This work was supported by a grant from Fondazione Cariplo and Associazione Italiana Ricerca Cancro (AIRC). AG is recipient of a fellowship from Italian Foundation for Cancer Research (FIRC).	Adamo B, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3071; Awad AE, 2010, AM J PHYSIOL-CELL PH, V298, pC679, DOI 10.1152/ajpcell.00351.2009; Barber DF, 2005, NAT MED, V11, P933, DOI 10.1038/nm1291; Bartholomeusz C, 2012, EXPERT OPIN THER TAR, V16, P121, DOI 10.1517/14728222.2011.644788; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Beer-Hammer S, 2010, J LEUKOCYTE BIOL, V87, P1083, DOI 10.1189/jlb.0809585; Benistant C, 2000, ONCOGENE, V19, P5083, DOI 10.1038/sj.onc.1203871; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Blajecka K, 2011, CURR DRUG TARGETS, V12, P1056, DOI 10.2174/138945011795677773; Burke JE, 2012, P NATL ACAD SCI USA, V109, P15259, DOI 10.1073/pnas.1205508109; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carvalho S, 2010, VIRCHOWS ARCH, V456, P235, DOI 10.1007/s00428-010-0881-0; Castillo JJ, 2012, EXPERT OPIN INV DRUG, V21, P15, DOI 10.1517/13543784.2012.640318; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chavakis E, 2008, CIRC RES, V102, P942, DOI 10.1161/CIRCRESAHA.107.164376; Chen JS, 2009, HEPATOL RES, V39, P177, DOI 10.1111/j.1872-034X.2008.00449.x; Cheng GZ, 2008, CANCER RES, V68, P957, DOI 10.1158/0008-5472.CAN-07-5067; Ciraolo E, 2011, CURR MED CHEM, V18, P2674, DOI 10.2174/092986711796011193; Ciraolo E, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1161577; Clark AS, 2002, MOL CANCER THER, V1, P707; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Crawford Y, 2009, CANCER CELL, V15, P21, DOI 10.1016/j.ccr.2008.12.004; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Damilano F, 2011, CIRCULATION, V123, P391, DOI 10.1161/CIRCULATIONAHA.110.950543; Dbouk HA, 2010, P NATL ACAD SCI USA, V107, P19897, DOI 10.1073/pnas.1008739107; De Wever O, 2004, FASEB J, V18, P1016, DOI 10.1096/fj.03-1110fje; Edling CE, 2010, CLIN CANCER RES, V16, P4928, DOI 10.1158/1078-0432.CCR-10-1210; Falasca M, 2010, CURR PHARM DESIGN, V16, P1410, DOI 10.2174/138161210791033950; Fang J, 2007, CELL SIGNAL, V19, P2487, DOI 10.1016/j.cellsig.2007.07.025; Fougerat A, 2008, CIRCULATION, V117, P1310, DOI 10.1161/CIRCULATIONAHA.107.720466; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Garlich JR, 2008, CANCER RES, V68, P206, DOI 10.1158/0008-5472.CAN-07-0669; Geng L, 2004, CANCER RES, V64, P4893, DOI 10.1158/0008-5472.CAN-03-3955; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Ghigo A, 2010, BIOESSAYS, V32, P185, DOI 10.1002/bies.200900150; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Gonzalez-Garcia A, 2010, GASTROENTEROLOGY, V138, P1374, DOI 10.1053/j.gastro.2009.12.001; Grassian AR, 2011, COLD SH Q B, V76, P313, DOI 10.1101/sqb.2011.76.010967; Graupera M, 2008, NATURE, V453, P662, DOI 10.1038/nature06892; Grille SJ, 2003, CANCER RES, V63, P2172; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heller R, 2008, CARDIOVASC RES, V80, P96, DOI 10.1093/cvr/cvn159; Hill KM, 2010, PROSTATE, V70, P755, DOI 10.1002/pros.21108; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hoellenriegel J, 2011, BLOOD, V118, P3603, DOI 10.1182/blood-2011-05-352492; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Hu LM, 2005, CLIN CANCER RES, V11, P8208, DOI 10.1158/1078-0432.CCR-05-0206; Hutti JE, 2012, CANCER RES, V72, P3260, DOI 10.1158/0008-5472.CAN-11-4141; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Jia SD, 2008, NATURE, V454, P776, DOI 10.1038/nature07091; Jones GE, 2003, EXP CELL RES, V290, P120, DOI 10.1016/S0014-4827(03)00318-5; Kim A, 2012, LEUKEMIA RES, V36, P912, DOI 10.1016/j.leukres.2012.02.010; Kim D, 2005, FRONT BIOSCI-LANDMRK, V10, P975, DOI 10.2741/1592; Kim S, 2010, BIOCHIM BIOPHYS ACTA, V1803, P1287; Knobbe CB, 2003, BRAIN PATHOL, V13, P507; Kong D, 2009, EUR J CANCER, V45, P857, DOI 10.1016/j.ejca.2008.12.007; Lau MT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059083; Lee H, 2013, CANCER LETT, V328, P152, DOI 10.1016/j.canlet.2012.08.020; Lee JH, 2013, CANCER LETT, V329, P99, DOI 10.1016/j.canlet.2012.10.028; Lelievre E, 2005, BLOOD, V105, P3935, DOI 10.1182/blood-2004-10-3955; Li H, 2011, ADV MED SCI-POLAND, V56, P275, DOI 10.2478/v10039-011-0043-x; Li SY, 2006, BREAST CANCER RES TR, V96, P91, DOI 10.1007/s10549-005-9048-0; Littlepage LE, 2005, CANCER CELL, V7, P499, DOI 10.1016/j.ccr.2005.05.019; Liu D, 2009, J IMMUNOL, V183, P1921, DOI 10.4049/jimmunol.0901099; Lorusso G, 2008, HISTOCHEM CELL BIOL, V130, P1091, DOI 10.1007/s00418-008-0530-8; Lu PF, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005058; Madeddu P, 2008, ARTERIOSCL THROM VAS, V28, P68, DOI 10.1161/ATVBAHA.107.145573; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marshall NA, 2012, CANCER RES, V72, P581, DOI 10.1158/0008-5472.CAN-11-0307; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Mizoguchi M, 2004, BRAIN PATHOL, V14, P372, DOI 10.1111/j.1750-3639.2004.tb00080.x; Morgan SC, 2011, NAT REV CLIN ONCOL, V8, P504, DOI 10.1038/nrclinonc.2011.88; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nombela-Arrieta C, 2004, IMMUNITY, V21, P429, DOI 10.1016/j.immuni.2004.07.012; PAGET S, 1989, CANCER METAST REV, V8, P98; Palucka K, 2012, NAT REV CANCER, V12, P265, DOI 10.1038/nrc3258; Patrucco E, 2004, CELL, V118, P375, DOI 10.1016/j.cell.2004.07.017; Philp AJ, 2001, CANCER RES, V61, P7426; Putz EM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040852; Qayum N, 2012, CLIN CANCER RES, V18, P161, DOI 10.1158/1078-0432.CCR-11-1413; Rommel C, 2007, NAT REV IMMUNOL, V7, P191, DOI 10.1038/nri2036; Salvesen HB, 2009, P NATL ACAD SCI USA, V106, P4834, DOI 10.1073/pnas.0806514106; Sampaio NG, 2011, J CELL SCI, V124, P2021, DOI 10.1242/jcs.075309; Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Schmid MC, 2007, CANCER LETT, V250, P1, DOI 10.1016/j.canlet.2006.09.002; Schmid MC, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0060226, 10.1371/journal.pone.0061623]; Schmid MC, 2011, CANCER CELL, V19, P715, DOI 10.1016/j.ccr.2011.04.016; Schmid MC, 2010, J ONCOL, V2010, DOI 10.1155/2010/201026; Schnell CR, 2008, CANCER RES, V68, P6598, DOI 10.1158/0008-5472.CAN-08-1044; Shoman N, 2005, MODERN PATHOL, V18, P250, DOI 10.1038/modpathol.3800296; So L, 2012, BIOCHEM J, V442, P465, DOI 10.1042/BJ20112092; Soond DR, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00244; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224; Torsvik A, 2013, CANCER TREAT REV, V39, P180, DOI 10.1016/j.ctrv.2012.03.005; Tsutsui S, 2005, ONCOLOGY-BASEL, V68, P398, DOI 10.1159/000086981; Urick ME, 2011, CANCER RES, V71, P4061, DOI 10.1158/0008-5472.CAN-11-0549; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Vogt PK, 2007, TRENDS BIOCHEM SCI, V32, P342, DOI 10.1016/j.tibs.2007.05.005; Wallin JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036402; Wang W, 2009, CLIN CANCER RES, V15, P6630, DOI 10.1158/1078-0432.CCR-09-1001; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Wik E, 2013, CLIN CANCER RES, V19, P1094, DOI 10.1158/1078-0432.CCR-12-3039; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Xia C, 2006, J CELL PHYSIOL, V209, P56, DOI 10.1002/jcp.20707; Xing F, 2010, FRONT BIOSCI-LANDMRK, V15, P166, DOI 10.2741/3613; Xue GD, 2012, CANCER DISCOV, V2, P248, DOI 10.1158/2159-8290.CD-11-0270; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yoshimoto M, 2006, CANCER GENET CYTOGEN, V169, P128, DOI 10.1016/j.cancergencyto.2006.04.003; Yoshioka K, 2012, NAT MED, V18, P1560, DOI 10.1038/nm.2928; Yu Q, 2000, GENE DEV, V14, P163; Yuan TL, 2008, P NATL ACAD SCI USA, V105, P9739, DOI 10.1073/pnas.0804123105; Zarrabi K, 2011, J BIOL CHEM, V286, P33167, DOI 10.1074/jbc.M111.256644; Zebedin E, 2008, BLOOD, V112, P4655, DOI 10.1182/blood-2008-02-139105; Zhang L, 2012, BLOOD, V120, P3783, DOI 10.1182/blood-2012-04-424630; Zhang T, 2010, ONCOL REP, V24, P1683, DOI 10.3892/or_00001034; Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244; Zhong H, 2000, CANCER RES, V60, P1541	127	45	46	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3083	3090		10.1038/onc.2013.265	http://dx.doi.org/10.1038/onc.2013.265			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23893246				2022-12-17	WOS:000338410000001
J	Liu, L; Xu, HX; Wang, WQ; Wu, CT; Chen, T; Qin, Y; Liu, C; Xu, J; Long, J; Zhang, B; Xu, YF; Ni, QX; Li, M; Yu, XJ				Liu, L.; Xu, H-X; Wang, W-Q; Wu, C-T; Chen, T.; Qin, Y.; Liu, C.; Xu, J.; Long, J.; Zhang, B.; Xu, Y-F; Ni, Q-X; Li, M.; Yu, X-J			Cavin-1 is essential for the tumor-promoting effect of caveolin-1 and enhances its prognostic potency in pancreatic cancer	ONCOGENE			English	Article						cavin-1; caveolin-1; pancreatic cancer; metastatic potential; prognostic potency	TRANSCRIPT-RELEASE FACTOR; I OVEREXPRESSION; CELL-MIGRATION; POOR-PROGNOSIS; POLYMERASE-I; EXPRESSION; CARCINOMA; GENE; PROGRESSION; INVASION	Caveolin-1 exhibits a stage-dependent, functional fluctuation during pancreatic cancer development, but the underlying mechanisms remain unclear. Here, we report that cavin-1, a structural protein of caveolae, modulates the oncogenic function of caveolin-1 and cooperates with caveolin-1 to enhance pancreatic cancer aggressiveness. Cavin-1 expression is associated with caveolin-1 in pancreatic cancer tissue samples and cell lines, and predicts the metastatic potential of pancreatic cancer. Interactome analyses further revealed the physical interaction of cavin-1 and caveolin-1 and their colocalization in pancreatic cancer cells. Cavin-1 stabilizes caveolin-1 expression or activity by inhibiting its internalization and subsequent lysosomal degradation. More in-depth functional experiments showed that caveolin-1-enhanced aggressiveness of pancreatic cancer cells is dependent on the presence of cavin-1. In contrast, cavin-1 depletion inhibited the invasion and metastasis of pancreatic cancer cells, which could not be restored by caveolin-1-rescue construct. Tissue microarray analyses in two independent clinic cohorts also supported the augment of cavin-1 on the prognostic potency of caveolin-1, and showed that combination of cavin-1 with caveolin-1 predicted worse survival in pancreatic cancer patients. Of note, the phenotypes because of cavin-1 could not be achieved by other cavins such as cavin-2, and the tumor-promoting role of cavin-1 in pancreatic cancer was found to be largely dependent on caveolin-1 expression, which highlights the critical role of cavin-1/caveoin-1 in pancreatic cancer progression, and suggests that the interruption of cavin-1/caveolin-1 interaction is a promising therapeutic strategy for pancreatic cancer.	[Liu, L.; Xu, H-X; Wang, W-Q; Wu, C-T; Chen, T.; Qin, Y.; Liu, C.; Xu, J.; Long, J.; Zhang, B.; Xu, Y-F; Ni, Q-X; Li, M.; Yu, X-J] Fudan Univ, Pancreat Canc Inst, Shanghai 200032, Peoples R China; [Liu, L.; Xu, H-X; Wang, W-Q; Wu, C-T; Chen, T.; Qin, Y.; Liu, C.; Xu, J.; Long, J.; Zhang, B.; Xu, Y-F; Ni, Q-X; Li, M.; Yu, X-J] Fudan Univ, Dept Pancreat & Hepatobiliary Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Liu, L.; Xu, H-X; Wang, W-Q; Wu, C-T; Chen, T.; Qin, Y.; Liu, C.; Xu, J.; Long, J.; Zhang, B.; Xu, Y-F; Ni, Q-X; Li, M.; Yu, X-J] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Li, M.] Univ Texas Houston, Sch Med, Vivian L Smith Dept Neurosurg, Houston, TX USA	Fudan University; Fudan University; Fudan University; University of Texas System; University of Texas Health Science Center Houston	Yu, XJ (corresponding author), Fudan Univ, Pancreat Canc Inst, 270 DongAn Rd, Shanghai 200032, Peoples R China.	Min.Li@uth.tmc.edu; yuxianjun88@hotmail.com		yu, xianjun/0000-0002-6697-7143	National Natural Science Foundation of China [81172005, 81172276]; National Natural Science Foundation of Shanghai [11ZR1407000]; PhD Programs Foundation of Ministry of Education of China [20110071120096]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of Shanghai; PhD Programs Foundation of Ministry of Education of China(Ministry of Education, China)	We thank Zhi-Qiang Meng for providing the pancreatic cancer cells SW1990HM and Huan-Yu Xia for assistance in collecting the patient data. This research project was supported by grants from the National Natural Science Foundation of China (81172005 and 81172276), the National Natural Science Foundation of Shanghai (11ZR1407000) and PhD Programs Foundation of Ministry of Education of China (20110071120096).	Aung CS, 2011, EUR J CELL BIOL, V90, P136, DOI 10.1016/j.ejcb.2010.06.004; Bastiani M, 2009, J CELL BIOL, V185, P1259, DOI 10.1083/jcb.200903053; Bender FC, 2000, CANCER RES, V60, P5870; Bruns Christiane J., 1999, Neoplasia (New York), V1, P50, DOI 10.1038/sj.neo.7900005; Burgermeister E, 2007, CANCER RES, V67, P8519, DOI 10.1158/0008-5472.CAN-07-1125; Chen ST, 2004, INT J MOL MED, V14, P577; Chiu WT, 2011, CANCER RES, V71, P4932, DOI 10.1158/0008-5472.CAN-10-4249; Fong A, 2003, AM J CLIN PATHOL, V120, P93, DOI 10.1309/292NHAYNWAVREJ37; Gamez-Pozo A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033752; Goetz JG, 2008, CANCER METAST REV, V27, P715, DOI 10.1007/s10555-008-9160-9; Hansen CG, 2010, TRENDS CELL BIOL, V20, P177, DOI 10.1016/j.tcb.2010.01.005; Hansen CG, 2009, NAT CELL BIOL, V11, P807, DOI 10.1038/ncb1887; Harris J, 2002, IMMUNOLOGY, V105, P190, DOI 10.1046/j.1365-2567.2002.01362.x; Hasegawa T, 2000, BIOCHEM J, V347, P55, DOI 10.1042/0264-6021:3470055; Hill MM, 2008, CELL, V132, P113, DOI 10.1016/j.cell.2007.11.042; Ho CC, 2008, LUNG CANCER, V59, P105, DOI 10.1016/j.lungcan.2007.07.024; Huang C, 2012, CANCER RES, V72, P655, DOI 10.1158/0008-5472.CAN-11-3102; Ito Y, 2002, BRIT J CANCER, V86, P912, DOI 10.1038/sj.bjc.6600172; Jansa P, 1998, EMBO J, V17, P2855, DOI 10.1093/emboj/17.10.2855; Joshi B, 2008, CANCER RES, V68, P8210, DOI 10.1158/0008-5472.CAN-08-0343; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Karam JA, 2007, PROSTATE, V67, P614, DOI 10.1002/pros.20557; Kato K, 2002, CANCER, V94, P929, DOI 10.1002/cncr.10329.abs; Li LK, 2001, CANCER RES, V61, P4386; Lin M, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-21; Liu LA, 2010, CLIN CANCER RES, V16, P2740, DOI 10.1158/1078-0432.CCR-09-2610; Liu L, 2010, CANCER SCI, V101, P120, DOI 10.1111/j.1349-7006.2009.01363.x; Liu LB, 2008, J BIOL CHEM, V283, P4314, DOI 10.1074/jbc.M707890200; McMahon KA, 2009, EMBO J, V28, P1001, DOI 10.1038/emboj.2009.46; Murakami S, 2003, BRIT J CANCER, V88, P1234, DOI 10.1038/sj.bjc.6600878; Nabi IR, 2009, NAT CELL BIOL, V11, P789, DOI 10.1038/ncb0709-789; Quest AFG, 2008, J CELL MOL MED, V12, P1130, DOI 10.1111/j.1582-4934.2008.00331.x; Rao X, 2013, ONCOGENE, V32, P4519, DOI 10.1038/onc.2012.474; Shi WD, 2009, CANCER LETT, V283, P84, DOI 10.1016/j.canlet.2009.03.030; Terris B, 2002, AM J PATHOL, V160, P1745, DOI 10.1016/S0002-9440(10)61121-2; Thomas S, 2004, MOL IMMUNOL, V41, P399, DOI 10.1016/j.molimm.2004.03.022; Wiechen K, 2001, AM J PATHOL, V158, P833, DOI 10.1016/S0002-9440(10)64031-X	37	45	46	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2728	2736		10.1038/onc.2013.223	http://dx.doi.org/10.1038/onc.2013.223			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23770857				2022-12-17	WOS:000337231700006
J	Chandrakesan, P; Roy, B; Jakkula, LUMR; Ahmed, I; Ramamoorthy, P; Tawfik, O; Papineni, R; Houchen, C; Anant, S; Umar, S				Chandrakesan, P.; Roy, B.; Jakkula, L. U. M. R.; Ahmed, I.; Ramamoorthy, P.; Tawfik, O.; Papineni, R.; Houchen, C.; Anant, S.; Umar, S.			Utility of a bacterial infection model to study epithelial-mesenchymal transition, mesenchymal-epithelial transition or tumorigenesis	ONCOGENE			English	Article						bacterial infection; Wnt; Notch; EMT; MET; hyperplasia; inflammation; colon cancer	NF-KAPPA-B; HYPERPLASIA AND/OR COLITIS; TRANSCRIPTION FACTOR SNAIL; BETA-CATENIN EXPRESSION; FUNCTIONAL CROSS-TALK; E-CADHERIN; CITROBACTER-RODENTIUM; STEM-CELLS; TRANSEPITHELIAL MIGRATION; TUMOR PROGRESSION	DCLK1 and Lgr5 have recently been identified as markers of quiescent and cycling stem cells in the small intestinal crypts, respectively. Epithelial-mesenchymal transition (EMT) is a key development program that is often activated during cancer invasion and metastasis, and also imparts a self-renewal capability to disseminating cancer cells. Utilizing the Citrobacter rodentium (CR)-induced transmissible murine colonic hyperplasia (TMCH) model, we observed a relative decrease in DCLK1 expression in the colonic crypts, with significant shift towards stromal staining at peak (12 days post infection) hyperplasia, whereas staining for Lgr5 and Msi-1 increased several fold. When hyperplasia was regressing (days 20-34), an expansion of DCLK1 + ve cells in the CR-infected crypts compared with that seen in uninfected control was recorded. Purified colonic crypt cells exhibiting epigenetic modulation of the transforming growth factor-beta (TGF beta), Wnt and Notch pathways on 12 or 34 days post infection formed monolayers in vitro, and underwent trans-differentiation into fibroblast-like cells that stained positive for vimentin, fibronectin and DCLK1. These cells when trypsinized and regrown in soft agar, formed colonospheres/organoids that developed into crypt-like structures (colonoids) in Matrigel and stained positive for DCLK1. Mice exhibiting 12 or 34 days of TMCH were given azoxymethane once for 8 h (Gp1) or weekly for 3 weeks (Gp2), and subjected to crypt isolation. Crypt cells from Gp1 animals formed monolayers as well as colonospheres in soft agar and nodules/tumors in nude mice. Crypt cells isolated from Gp2 animals failed to form the monolayers, but developed into colonospheres in soft agar and nodules/tumors in nude mice. Thus, both hyperplasia and increased presence of DCLK1 + ve cells promote cellular transformation in response to a second hit. The TMCH model, therefore, provides an excellent template to study how alterations in intestinal stem cells promote trans-differentiation, crypt regeneration or colon carcinogenesis following bacterial infection.	[Chandrakesan, P.; Houchen, C.] Dept Internal Med, Div Gastroenterol, Oklahoma City, OK USA; [Roy, B.; Jakkula, L. U. M. R.; Ahmed, I.; Ramamoorthy, P.; Anant, S.; Umar, S.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; [Tawfik, O.] Univ Kansas, Med Ctr, Dept Anat & Surg Pathol, Kansas City, KS 66160 USA; [Papineni, R.] Carestream Mol Imaging, Woodbridge, CT USA; [Anant, S.; Umar, S.] Univ Kansas, Med Ctr, Ctr Canc, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Umar, S (corresponding author), Univ Kansas, Med Ctr, Ctr Canc, 3901 Rainbow Blvd,4028 Wahl Hall East, Kansas City, KS 66160 USA.	sumar@kumc.edu	Anant, Shrikant/AAF-8020-2020; Chandrakesan, Parthasarathy/AAB-9136-2020	Chandrakesan, Parthasarathy/0000-0002-7587-9553	National Institutes of Health [R01 CA131413]; NIDDK's [U01DK085508-04S1]; University of Kansas Medical Center, Kansas City, KS, USA; NATIONAL CANCER INSTITUTE [R01CA131413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK085508] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK's; University of Kansas Medical Center, Kansas City, KS, USA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the National Institutes of Health Grant R01 CA131413 (to SU), NIDDK's U01DK085508-04S1 (to CWH) and start-up funds from the University of Kansas Medical Center, Kansas City, KS, USA.	Ahmed I, 2013, AM J PHYSIOL-GASTR L, V304, pG356, DOI 10.1152/ajpgi.00372.2012; Ahmed I, 2012, INFECT IMMUN, V80, P3107, DOI 10.1128/IAI.00236-12; Ali N, 2011, J VIROL, V85, P12292, DOI 10.1128/JVI.05920-11; BARTHOLD SW, 1978, VET PATHOL, V15, P223, DOI 10.1177/030098587801500209; BARTHOLD SW, 1977, CANCER RES, V37, P4352; Bataille F, 2008, INFLAMM BOWEL DIS, V14, P1514, DOI 10.1002/ibd.20590; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Betis F, 2003, INFECT IMMUN, V71, P1774, DOI 10.1128/IAI.71.4.1774-1783.2003; Betis F, 2003, INFECT IMMUN, V71, P1068, DOI 10.1128/IAI.71.3.1068-1074.2003; Bierne H, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a010272; Borenshtein D, 2008, CURR OPIN GASTROEN, V24, P32, DOI 10.1097/MOG.0b013e3282f2b0fb; Brabletz S, 2011, EMBO J, V30, P770, DOI 10.1038/emboj.2010.349; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Brown JB, 2011, INFECT IMMUN, V79, P1863, DOI 10.1128/IAI.01025-10; Cane G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001359; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chandrakesan P, 2012, INFECT IMMUN, V80, P753, DOI 10.1128/IAI.06101-11; Chandrakesan P, 2010, J BIOL CHEM, V285, P33485, DOI 10.1074/jbc.M110.129353; Colgan SP, 2010, NAT REV GASTRO HEPAT, V7, P281, DOI 10.1038/nrgastro.2010.39; Cun DM, 2011, EUR J PHARM BIOPHARM, V77, P26, DOI 10.1016/j.ejpb.2010.11.008; Deng WY, 2005, INFECT IMMUN, V73, P2135, DOI 10.1128/IAI.73.4.2135-2146.2005; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Flier SN, 2010, J BIOL CHEM, V285, P20202, DOI 10.1074/jbc.M110.102012; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Franci C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005595; Gilles C, 2003, CANCER RES, V63, P2658; Hamon MA, 2008, CELL HOST MICROBE, V4, P100, DOI 10.1016/j.chom.2008.07.009; Hofman P, 2012, GUT MICROBES, V3, P1; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Hongpaisan J, 2000, CELL BIOL INT, V24, P1, DOI 10.1006/cbir.1999.0448; Humphries A, 2008, NAT REV CANCER, V8, P415, DOI 10.1038/nrc2392; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Kwatra D, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/702869; Liu XW, 2012, HEPATOL RES, V42, P1024, DOI 10.1111/j.1872-034X.2012.01011.x; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; May R, 2009, STEM CELLS, V27, P2571, DOI 10.1002/stem.193; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Mukherjee T, 2011, SCIENCE, V332, P1210, DOI 10.1126/science.1199643; Mundy R, 2005, CELL MICROBIOL, V7, P1697, DOI 10.1111/j.1462-5822.2005.00625.x; Newman JV, 2001, J INFECT DIS, V184, P227, DOI 10.1086/321998; Niessen K, 2008, J CELL BIOL, V182, P315, DOI 10.1083/jcb.200710067; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pilpilidis I, 2011, J SURG RES, V166, P255, DOI 10.1016/j.jss.2010.02.012; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Ponnurangam S, 2012, MOL CANCER THER, V11, P963, DOI 10.1158/1535-7163.MCT-11-0999; Radisky DC, 2008, CELL STEM CELL, V2, P511, DOI 10.1016/j.stem.2008.05.007; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rubio D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001398; Saito Y, 2010, J EXP MED, V207, P2157, DOI 10.1084/jem.20100602; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Sellin JH, 2001, CANCER RES, V61, P2899; Sellin JH, 2009, EXP CELL RES, V315, P97, DOI 10.1016/j.yexcr.2008.10.019; Sipos F, 2011, WORLD J GASTROENTERO, V17, P2981, DOI 10.3748/wjg.v17.i25.2981; Subramaniam D, 2011, MOL CANCER THER, V10, P2146, DOI 10.1158/1535-7163.MCT-11-0399; SUN NC, 1979, P NATL ACAD SCI USA, V76, P1819, DOI 10.1073/pnas.76.4.1819; Sureban SM, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-40; Sureban SM, 2009, GASTROENTEROLOGY, V137, P649, DOI 10.1053/j.gastro.2009.05.004; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Umar S, 2008, ONCOGENE, V27, P5599, DOI 10.1038/onc.2008.169; Umar S, 2005, ONCOGENE, V24, P6709, DOI 10.1038/sj.onc.1208820; Umar S, 2003, CELL PROLIFERAT, V36, P361, DOI 10.1046/j.1365-2184.2003.00291.x; Umar S, 2007, AM J PHYSIOL-GASTR L, V292, pG599, DOI 10.1152/ajpgi.00343.2006; Umar S, 2009, J BIOL CHEM, V284, P22274, DOI 10.1074/jbc.M109.020941; van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145; Wang Y, 2006, BRIT J PHARMACOL, V148, P814, DOI 10.1038/sj.bjp.0706784; Whitehead RH, 1999, GASTROENTEROLOGY, V117, P858, DOI 10.1016/S0016-5085(99)70344-6; Wu MZ, 2011, MOL CELL, V43, P811, DOI 10.1016/j.molcel.2011.07.012; Xi Y, 2013, ONCOGENE, V32, P5048, DOI 10.1038/onc.2012.530; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yin YF, 2010, GUT, V59, P1037, DOI 10.1136/gut.2009.199794; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zhang Q, 2013, CARCINOGENESIS, V34, P962, DOI 10.1093/carcin/bgt027; Zhao LJ, 2011, J SURG RES, V171, P819, DOI 10.1016/j.jss.2010.04.059	77	45	46	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2639	2654		10.1038/onc.2013.210	http://dx.doi.org/10.1038/onc.2013.210			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23752178	Green Accepted			2022-12-17	WOS:000336502700010
J	Viotti, J; Duplan, E; Caillava, C; Condat, J; Goiran, T; Giordano, C; Marie, Y; Idbaih, A; Delattre, JY; Honnorat, J; Checler, F; Alves Da Costa, C				Viotti, J.; Duplan, E.; Caillava, C.; Condat, J.; Goiran, T.; Giordano, C.; Marie, Y.; Idbaih, A.; Delattre, J-Y; Honnorat, J.; Checler, F.; Alves Da Costa, C.			Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity	ONCOGENE			English	Article						human brain glioma; glioblastoma cells; tumor grade; parkin; p53; transcription	SUPPRESSOR GENE; HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; BRAIN-TUMORS; BAX GENE; IN-VITRO; MUTATIONS; PROTEIN; CANCER; EXPRESSION	Gliomas represent the most frequent form of primary brain tumors in adults, the prognosis of which remains extremely poor. Inactivating mutations on the tumor suppressor TP53 were proposed as a key etiological trigger of glioma development. p53 has been recently identified as a transcriptional target of parkin. Interestingly, somatic mutations on parkin have also been linked to glioma genesis. We examined the possibility that a disruption of a functional interaction between p53 and parkin could contribute to glioma development in samples devoid of somatic parkin mutations or genetic allele deletion. We show here that parkin levels inversely correlate to brain tumor grade and p53 levels in oligodendrogliomas, mixed gliomas and glioblastomas. We demonstrate that p53 levels negatively and positively correlate to bax and Bcl2 respectively, underlying a loss of p53 transcriptional activity in all types of glial tumors. Using various cell models lacking p53 or harboring either transcriptionally inactive or dominant negative p53, as well as in p53 knockout mice brain, we establish that p53 controls parkin promoter transactivation, mRNA and protein levels. Furthermore, we document an increase of parkin expression in mice brain after p53-bearing viral infection. Finally, both cancer-related p53 inactivating mutations and deletion of a consensus p53 binding sequence located on parkin promoter abolish p53-mediated control of parkin transcription, demonstrating that p53 regulates parkin transcription via its DNA binding properties. In conclusion, our work delineates a functional interplay between mutated p53 and parkin in glioma genesis that is disrupted by cancer-linked pathogenic mutations. It also allows envisioning parkin as a novel biomarker of glioma biopsies enabling to follow the progression of this type of cancers.	[Viotti, J.; Duplan, E.; Caillava, C.; Condat, J.; Goiran, T.; Giordano, C.; Checler, F.; Alves Da Costa, C.] CNRS, Inst Pharmacol Mol & Cellulaire, UNSA, Team Labeled Fdn,Rech Med & Lab Excellemce LABEX, F-06560 Valbonne, France; [Marie, Y.; Idbaih, A.; Delattre, J-Y] Univ Paris 06, AP HP, Grp Hosp Pitie Salpetriere,UMR 975, Ctr Rech,Inst Cerveau & Moelle Epiniere,Serv Neur, Paris, France; [Honnorat, J.] Hop Neurol, Hosp Civils Lyon, Ctr Reference Maladies Rares Syndromes Neurol Par, Lyon, France; [Honnorat, J.] Ctr Rech Neurosci Lyon, Inserm U1028, CNRS UMR 5292, Lyon, France; [Honnorat, J.] Univ Lyon 1, Univ Lyon, F-69365 Lyon, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Jean Monnet; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Checler, F (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UNSA, Team Labeled Fdn,Rech Med & Lab Excellemce LABEX, Valbonne,PACA, F-06560 Valbonne, France.	checler@ipmc.cnrs.fr; acosta@ipmc.cnrs.fr	Duplan, Eric/AAK-8224-2020; da Costa, Cristine Alves/G-8075-2011; Checler, Frederic/C-1241-2009; Honnorat, jerome/G-6394-2017; Idbaih, Ahmed/N-8746-2017	Duplan, Eric/0000-0002-1348-1507; da Costa, Cristine Alves/0000-0002-7777-005X; Checler, Frederic/0000-0003-2098-1750; Honnorat, jerome/0000-0002-4721-5952; goiran, thomas/0000-0001-5838-8798; Giordano, Cecile/0000-0003-3641-8647; Idbaih, Ahmed/0000-0001-5290-1204	Fondation pour la Recherche Medicale; Conseil General des Alpes Maritimes; LABEX (excellence laboratory, program investment for the future) DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to Alzheimer's disease); AMPA (Association Monegasque Pour la recherche sur la Maladie d'Alzheimer); ARC ("Association pour la recherche contre le cancer")	Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Conseil General des Alpes Maritimes(Region Provence-Alpes-Cote d'Azur); LABEX (excellence laboratory, program investment for the future) DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to Alzheimer's disease); AMPA (Association Monegasque Pour la recherche sur la Maladie d'Alzheimer); ARC ("Association pour la recherche contre le cancer")(Fondation ARC pour la Recherche sur le Cancer)	Drs Roussel, Bourdon and Serrano are thanked for providing us with p53 knockout cells, MCF-7 cells and mice brains. Drs West and Oren are acknowledged for providing us with parkin-luciferase and PG13 constructs. JV was supported by AMPA (Association Monegasque Pour la recherche sur la Maladie d'Alzheimer) and ARC ("Association pour la recherche contre le cancer"). This work was supported by the 'Fondation pour la Recherche Medicale' and by the 'Conseil General des Alpes Maritimes'. This work has been developed and supported through the LABEX (excellence laboratory, program investment for the future) DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to Alzheimer's disease). Cristine Alves da Costa is recipient of a Hospital Contract for Translational Research (CHRT) between INSERM and the Hospices Civils de Lyon.	Agirre X, 2006, INT J CANCER, V118, P1945, DOI 10.1002/ijc.21584; Asker C, 1999, BIOCHEM BIOPH RES CO, V265, P1, DOI 10.1006/bbrc.1999.1446; Basu A, 1998, MOL HUM REPROD, V4, P1099, DOI 10.1093/molehr/4.12.1099; Bourdon JC, 2003, CELL DEATH DIFFER, V10, P397, DOI 10.1038/sj.cdd.4401243; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Costa SL, 2001, EUR J CANCER, V37, P520, DOI 10.1016/S0959-8049(00)00430-5; da Costa CA, 2006, J NEUROSCI, V26, P6377, DOI 10.1523/JNEUROSCI.0651-06.2006; da Costa CA, 2009, NAT CELL BIOL, V11, P1370, DOI 10.1038/ncb1981; Deguin-Chambon V, 2000, ONCOGENE, V19, P5831, DOI 10.1038/sj.onc.1203960; Edlund K, 2012, P NATL ACAD SCI USA, V109, P9551, DOI 10.1073/pnas.1200019109; Fujiwara M, 2008, ONCOGENE, V27, P6002, DOI 10.1038/onc.2008.199; Fulci G, 1998, BRAIN PATHOL, V8, P599, DOI 10.1111/j.1750-3639.1998.tb00187.x; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; GINSBERG D, 1990, ONCOGENE, V5, P1285; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hemann MT, 2006, CELL DEATH DIFFER, V13, P1256, DOI 10.1038/sj.cdd.4401962; Henn IH, 2005, J NEUROCHEM, V92, P114, DOI 10.1111/j.1471-4159.2004.02854.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Idbaih A, 2005, ANN NEUROL, V58, P483, DOI 10.1002/ana.20607; Idbaih A, 2008, INT J CANCER, V122, P1778, DOI 10.1002/ijc.23270; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Letessier A, 2007, ONCOGENE, V26, P298, DOI 10.1038/sj.onc.1209772; Lim YP, 2007, ONCOGENE, V26, P1517, DOI 10.1038/sj.onc.1209952; Maintz D, 1997, J NEUROPATH EXP NEUR, V56, P1098, DOI 10.1097/00005072-199710000-00003; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Nayak A, 2004, NEUROL INDIA, V52, P228; Nozaki M, 1999, Neuro Oncol, V1, P124, DOI 10.1093/neuonc/1.2.124; OHGAKI H, 1991, CANCER RES, V51, P6202; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Picchio MC, 2004, CLIN CANCER RES, V10, P2720, DOI 10.1158/1078-0432.CCR-03-0086; Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107; ROTTER V, 1983, P NATL ACAD SCI-BIOL, V80, P2613, DOI 10.1073/pnas.80.9.2613; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2010, HUM MUTAT, V31, P1020, DOI 10.1002/humu.21313; Veeriah S, 2010, NAT GENET, V42, P77, DOI 10.1038/ng.491; Wang F, 2004, GENE CHROMOSOME CANC, V40, P85, DOI 10.1002/gcc.20020; Watanabe K, 1997, CLIN CANCER RES, V3, P523; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Weller M, 2009, J CLIN ONCOL, V27, P5743, DOI 10.1200/JCO.2009.23.0805; West AB, 2003, J MOL BIOL, V326, P11, DOI 10.1016/S0022-2836(02)01376-1; Yeo CWS, 2012, CANCER RES, V72, P2543, DOI 10.1158/0008-5472.CAN-11-3060; Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108; Zinkel S, 2006, CELL DEATH DIFFER, V13, P1351, DOI 10.1038/sj.cdd.4401987	53	45	46	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1764	1775		10.1038/onc.2013.124	http://dx.doi.org/10.1038/onc.2013.124			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23644658				2022-12-17	WOS:000334345500003
J	Yan, L; Singh, LS; Zhang, L; Xu, Y				Yan, L.; Singh, L. S.; Zhang, L.; Xu, Y.			Role of OGR1 in myeloid-derived cells in prostate cancer	ONCOGENE			English	Article						adoptive transfer; MDSC; macrophages; OGR1; ovarian cancer G protein coupled receptor-1	PROTEIN-COUPLED RECEPTOR; CD8(+) T-CELLS; SUPPRESSOR-CELLS; TUMOR; MOUSE; MACROPHAGES; EXPRESSION; GROWTH; MODEL; DIFFERENTIATION	Ovarian cancer G-protein-coupled-receptor-1 (OGR1) is a tumor metastasis suppressor in prostate cancer (PCa). OGR1 knockout mice (ogr1(-/-)) are grossly normal under physiological conditions, however, reduced melanoma tumorigenesis has been observed, with the mechanisms of this reduction completely unknown. In this work, we demonstrated that OGR1 deficiency in host cells significantly reduced tumorigenesis of PCa in mice. Adoptive transfer of WT CD11b(+) Gr1(+) double positive (DP) cells, but not T cells, was sufficient to allow tumor development in ogr1(-/-) mice. The expression of an M1 macrophage marker, inducible nitric oxide synthase (iNOS) was higher and expression of an M2 macrophage marker, arginase-1 (Arg 1) was lower in tumors from ogr1(-/-) mice compared with WT mice. Furthermore, coinjection of transgenic adenocarcinoma mouse prostate (TRAMP)-C2 cells with WT, but not ogr1(-/-) macrophages, increased tumor incidence in ogr1(-/-) mice. T-cell depletion experiments suggested that T cells were required for tumor rejection in ogr1(-/-) mice, although OGR1 expression in T cells may not be necessary. In summary, the expression of OGR1 in myeloid-derived cells, especially in DP cells, was required for PCa tumor cell-induced immunosuppression.	[Yan, L.; Singh, L. S.; Xu, Y.] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46234 USA; [Singh, L. S.] Manipur Univ, Dept Biotechnol, Imphal, Manipur, India; [Zhang, L.] Univ Toronto, Univ Hlth Net Work, Toronto Gen Res Inst, Dept Lab Med, Toronto, ON, Canada; [Zhang, L.] Univ Toronto, Univ Hlth Net Work, Toronto Gen Res Inst, Dept Pathobiol, Toronto, ON, Canada	Indiana University System; Indiana University Bloomington; Manipur University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Xu, Y (corresponding author), Indiana Univ Sch Med, Dept Obstet & Gynecol, 975 W Walnut St,IB 355A, Indianapolis, IN 46234 USA.	lzhang@uhnresearch.ca; xu2@iupui.edu			National Institutes of Health [RO1 155145]; Mary Fendrich-Hulman Charitable Trust Fund; NATIONAL CANCER INSTITUTE [R01CA155145] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mary Fendrich-Hulman Charitable Trust Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Mrs Helen Jan Chin-Sinex from Dr Marc S. Mendonca's lab at Indiana University School of Medicine for technical assistance in the preparation of irradiated TRAMP-C2 tumor cells. We thank Mrs Huiying Gu from Dr Yansheng Du's lab for technical assistance in the preparation of tumor frozen sections. We also thank Dr Caryl Antalis and Dr Cheryl Dsouza for critical reading and editing of the manuscript. This work was supported in part by the National Institutes of Health (RO1 155145 to YX and LZ); and the Mary Fendrich-Hulman Charitable Trust Fund to YX.	Babiarova K, 2012, J IMMUNOTHER, V35, P478, DOI 10.1097/CJI.0b013e3182618381; BALEY PA, 1995, J STEROID BIOCHEM, V52, P403, DOI 10.1016/0960-0760(95)00001-G; Biswas SK, 2008, J IMMUNOL, V180, P2011, DOI 10.4049/jimmunol.180.4.2011; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; Elkabets M, 2010, EUR J IMMUNOL, V40, P3347, DOI 10.1002/eji.201041037; Eruslanov E, 2010, J LEUKOCYTE BIOL, V88, P839, DOI 10.1189/jlb.1209821; Fasso M, 2008, P NATL ACAD SCI USA, V105, P3509, DOI 10.1073/pnas.0712269105; Foster BA, 1997, CANCER RES, V57, P3325; Fricke I, 2007, CLIN CANCER RES, V13, P4840, DOI 10.1158/1078-0432.CCR-07-0409; Gingrich JR, 1996, CANCER RES, V56, P4096; Grossmann ME, 2001, WORLD J UROL, V19, P365, DOI 10.1007/PL00007104; Hasita H, 2010, CANCER SCI, V101, P1913, DOI 10.1111/j.1349-7006.2010.01614.x; Hong DS, 2007, CANCER-AM CANCER SOC, V110, P1911, DOI 10.1002/cncr.22999; Im DS, 2005, ACTA PHARMACOL SIN, V26, P1435, DOI 10.1111/j.1745-7254.2005.00237.x; Koide N, 2004, AM J GASTROENTEROL, V99, P1667, DOI 10.1111/j.1572-0241.2004.30733.x; LaTulippe E, 2002, CANCER RES, V62, P4499; Li H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005705; Luczynski W, 2008, POSTEP HIG MED DOSW, V62, P18; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Nagaraj S, 2010, CLIN CANCER RES, V16, P1812, DOI 10.1158/1078-0432.CCR-09-3272; Nagaraj S, 2010, J IMMUNOL, V184, P3106, DOI 10.4049/jimmunol.0902661; Nefedova Y, 2007, CANCER RES, V67, P11021, DOI 10.1158/0008-5472.CAN-07-2593; Ostrand-Rosenberg S, 2012, SEMIN CANCER BIOL, V22, P275, DOI 10.1016/j.semcancer.2012.01.011; Ostrand-Rosenberg S, 2010, CANCER IMMUNOL IMMUN, V59, P1593, DOI 10.1007/s00262-010-0855-8; PEARSON TC, 1993, TRANSPLANTATION, V55, P361, DOI 10.1097/00007890-199302000-00025; Rauhala HE, 2008, INT J CANCER, V123, P1601, DOI 10.1002/ijc.23658; Silliman CC, 1996, TRANSFUSION, V36, P133, DOI 10.1046/j.1537-2995.1996.36296181925.x; Singh LS, 2007, JNCI-J NATL CANCER I, V99, P1313, DOI 10.1093/jnci/djm107; Talmadge JE, 2007, CLIN CANCER RES, V13, P5243, DOI 10.1158/1078-0432.CCR-07-0182; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Umemura N, 2008, J LEUKOCYTE BIOL, V83, P1136, DOI 10.1189/jlb.0907611; Xu Y, 1996, GENOMICS, V35, P397, DOI 10.1006/geno.1996.0377; Yin DP, 2002, TRANSPLANTATION, V74, P1236, DOI 10.1097/00007890-200211150-00007; Zhang Q, 2005, CANCER RES, V65, P1761, DOI 10.1158/0008-5472.CAN-04-3169	34	45	46	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					157	164		10.1038/onc.2012.566	http://dx.doi.org/10.1038/onc.2012.566			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23222714				2022-12-17	WOS:000329440700003
J	Das, TK; Sangodkar, J; Negre, N; Narla, G; Cagan, RL				Das, T. K.; Sangodkar, J.; Negre, N.; Narla, G.; Cagan, R. L.			Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors	ONCOGENE			English	Article						Sin3a; Ret; Src; Rho; wingless; Drosophila	GENE-EXPRESSION PATTERNS; HISTONE DEACETYLASE; BETA-CATENIN; TRANSCRIPTIONAL REPRESSION; LUNG ADENOCARCINOMA; FUNCTIONAL-ROLE; CANCER; COMPLEX; GROWTH; PROGRESSION	Chromatin remodeling proteins regulate multiple aspects of cell homeostasis, making them ideal candidates for misregulation in transformed cells. Here, we explore Sin3A, a member of the Sin3 family of proteins linked to tumorigenesis that are thought to regulate gene expression through their role as histone deacetylases (HDACs). We identified Drosophila Sin3a as an important mediator of oncogenic Ret receptor in a fly model of Multiple Endocrine Neoplasia Type 2. Reducing Drosophila Sin3a activity led to metastasis-like behavior and, in the presence of Diap1, secondary tumors distant from the site of origin. Genetic and Chip-Seq analyses identified previously undescribed Sin3a targets including genes involved in cell motility and actin dynamics, as well as signaling pathways including Src, Jnk and Rho. A key Sin3a oncogenic target, PP1B, regulates stability of beta-Catenin/Armadillo: the outcome is to oppose T-cell factor (TCF) function and Wg/Wnt pathway signaling in both fly and mammalian cancer cells. Reducing Sin3A strongly increased the invasive behavior of A549 human lung adenocarcinoma cells. We show that Sin3A is downregulated in a variety of human tumors and that Src, JNK, RhoA and PP1B/beta-Catenin are regulated in a manner analogous to our Drosophila models. Our data suggest that Sin3A influences a specific step of tumorigenesis by regulating a module of genes involved in cell invasion. Tumor progression may commonly rely on such 'modules of invasion' under the control of broad transcriptional regulators.	[Das, T. K.; Cagan, R. L.] Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY 10029 USA; [Sangodkar, J.; Narla, G.] Mt Sinai Sch Med, Dept Genet, New York, NY 10029 USA; [Negre, N.] Univ Chicago, Inst Genom & Syst Biol, Chicago, IL 60637 USA; [Narla, G.] Mt Sinai Sch Med, Div Hematol Oncol, Dept Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Chicago; Icahn School of Medicine at Mount Sinai	Cagan, RL (corresponding author), Mt Sinai Sch Med, Dept Dev & Regenerat Biol, Box 1020,1 Gustave Levy Pl, New York, NY 10029 USA.	Ross.Cagan@mssm.edu	Narla, Goutham/AAZ-5710-2020; Cagan, Ross Leigh/AAV-9528-2021	Narla, Goutham/0000-0003-4098-4203; Cagan, Ross/0000-0001-5297-450X; Negre, Nicolas/0000-0001-9727-3416	NIH/NCI [R01-CA084309, R01-CA109730]; American Cancer Society [120886-PFM-11-137-01-DDC]; NATIONAL CANCER INSTITUTE [R01CA109730, R01CA170495, R01CA084309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM082773] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank members of the Cagan Lab for sharing reagents, information, and helpful advice and Justin Graves for providing help mapping UAS-dRet<SUP>MEN2</SUP> transgenic flies. This work was supported by NIH/NCI grants R01-CA084309 and R01-CA109730 to RC and American Cancer Society Fellowship grant 120886-PFM-11-137-01-DDC to TD.	Ahn YH, 2011, MOL CELL BIOL, V31, P4270, DOI 10.1128/MCB.05562-11; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Blauwkamp TA, 2008, EMBO J, V27, P1436, DOI 10.1038/emboj.2008.80; Brachmann CB, 2000, CURR BIOL, V10, P547, DOI 10.1016/S0960-9822(00)00474-7; Cadigan KM, 2012, CURR TOP DEV BIOL, V98, P1, DOI 10.1016/B978-0-12-386499-4.00001-X; Castellone MD, 2009, CANCER RES, V69, P1867, DOI 10.1158/0008-5472.CAN-08-1982; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Chen X, 2003, MOL BIOL CELL, V14, P3208, DOI 10.1091/mbc.E02-12-0833; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905; David G, 2008, P NATL ACAD SCI USA, V105, P4168, DOI 10.1073/pnas.0710285105; Difeo A, 2008, CANCER RES, V68, P965, DOI 10.1158/0008-5472.CAN-07-2604; Duman-Scheel M, 2004, P NATL ACAD SCI USA, V101, P3857, DOI 10.1073/pnas.0400526101; Ellison-Zelski SJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-263; Farias EF, 2010, P NATL ACAD SCI USA, V107, P11811, DOI 10.1073/pnas.1006737107; Foglietti C, 2006, J BIOL CHEM, V281, P17968, DOI 10.1074/jbc.M511945200; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Geuking P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007709; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hasegawa T, 2008, ONCOGENE, V27, P5684, DOI 10.1038/onc.2008.182; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4; Hurst DR, 2009, CLIN EXP METASTAS, V26, P89, DOI 10.1007/s10585-008-9216-9; Iwashita T, 1996, ONCOGENE, V12, P481; Janic A, 2010, SCIENCE, V330, P1824, DOI 10.1126/science.1195481; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lafon-Hughes L, 2008, MUTAT RES-REV MUTAT, V658, P191, DOI 10.1016/j.mrrev.2008.01.008; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; Lilien J, 2005, CURR OPIN CELL BIOL, V17, P459, DOI 10.1016/j.ceb.2005.08.009; Luo W, 2007, EMBO J, V26, P1511, DOI 10.1038/sj.emboj.7601607; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Meehan WJ, 2004, J BIOL CHEM, V279, P1562, DOI 10.1074/jbc.M307969200; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nascimento EM, 2011, NAT CELL BIOL, V13, P1395, DOI 10.1038/ncb2385; Negre N, 2011, NATURE, V471, P527, DOI 10.1038/nature09990; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pile LA, 2003, J BIOL CHEM, V278, P37840, DOI 10.1074/jbc.M305996200; Pile LA, 2002, MOL CELL BIOL, V22, P4965, DOI 10.1128/MCB.22.14.4965-4976.2002; Plaza-Menacho I, 2006, TRENDS GENET, V22, P627, DOI 10.1016/j.tig.2006.09.005; Polette M, 2007, CELLS TISSUES ORGANS, V185, P61, DOI 10.1159/000101304; Rao G, 1996, ONCOGENE, V12, P1165; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; Read RD, 2005, GENETICS, V171, P1057, DOI 10.1534/genetics.104.038018; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Samant RS, 2006, CANCER LETT, V235, P260, DOI 10.1016/j.canlet.2005.04.032; Sancho R, 2009, EMBO J, V28, P1843, DOI 10.1038/emboj.2009.153; Sangodkar J, 2009, EUR J CANCER, V45, P666, DOI 10.1016/j.ejca.2008.11.009; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Smith-Hicks CL, 2000, EMBO J, V19, P612, DOI 10.1093/emboj/19.4.612; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Suzuki H, 2008, LUNG CANCER, V59, P24, DOI 10.1016/j.lungcan.2007.08.002; Teng DHF, 1997, CANCER RES, V57, P4177; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; van Oevelen C, 2008, MOL CELL, V32, P359, DOI 10.1016/j.molcel.2008.10.015; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733; Zhang YX, 2005, NUCLEIC ACIDS RES, V33, P6024, DOI 10.1093/nar/gki903	67	45	45	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2013	32	26					3184	3197		10.1038/onc.2012.326	http://dx.doi.org/10.1038/onc.2012.326			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22890320	Green Accepted			2022-12-17	WOS:000321004600009
J	Mihlan, S; Reiss, C; Thalheimer, P; Herterich, S; Gaetzner, S; Kremerskothen, J; Pavenstadt, HJ; Lewandrowski, U; Sickmann, A; Butt, E				Mihlan, S.; Reiss, C.; Thalheimer, P.; Herterich, S.; Gaetzner, S.; Kremerskothen, J.; Pavenstaedt, H. J.; Lewandrowski, U.; Sickmann, A.; Butt, E.			Nuclear import of LASP-1 is regulated by phosphorylation and dynamic protein-protein interactions	ONCOGENE			English	Article						LASP-1; nucleo-cytoplasmatic shuttling; phosphatase 2B; ZO-2; LPP	BINDING-PROTEINS; CELL-MIGRATION; OVARIAN-CANCER; ACTIN-BINDING; LIM; DOMAIN; TRANSCRIPTION; LOCALIZATION; ZO-2; CAMP	LASP-1 is a multidomain protein predominantly localized at focal contacts, where it regulates cytoskeleton dynamics and cell migration. However, in different tumor entities, a nuclear LASP-1 accumulation is observed, thought to have an important role in cancer progression. Until now, the molecular mechanisms that control LASP-1 nuclear import were not elucidated. Here, we identified a novel LASP-1-binding partner, zona occludens protein 2 (ZO-2), and established its role in the signal transduction pathway of LASP-1 nucleo-cytoplasmatic shuttling. Phosphorylation of LASP-1 by PKA at serine 146 induces translocation of the LASP-1/ZO-2 complex from the cytoplasm to the nucleus. Interaction occurs within the carboxyterminal proline-rich motif of ZO-2 and the SH3 domain in LASP-1. In situ proximity ligation assay confirmed the direct binding between LASP-1 and ZO-2 and visualized the shuttling. Nuclear export is mediated by Crm-1 and a newly identified nuclear export signal in LASP-1. Finally, dephosphorylation of LASP-1 by phosphatase PP2B is suggested to relocalize the protein back to focal contacts. In summary, we define a new pathway for LASP-1 in tumor progression. Oncogene (2013) 32, 2107-2113; doi:10.1038/onc.2012.216; published online 4 June 2012	[Mihlan, S.; Reiss, C.; Thalheimer, P.; Herterich, S.; Gaetzner, S.; Butt, E.] Univ Clin Wuerzburg, Inst Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; [Kremerskothen, J.; Pavenstaedt, H. J.] Univ Hosp Muenster, Div Mol Nephrol, Dept Internal Med D, Munster, Germany; [Lewandrowski, U.; Sickmann, A.] Leibniz Inst Analyt Wissensch ISAS eV, Dept Bioanalyt, Dortmund, Germany; [Sickmann, A.] Ruhr Univ Bochum, Med Proteome Ctr, Bochum, Germany	University of Wurzburg; University of Munster; Dortmund University of Technology; Leibniz Institut fur Analytische Wissenschaften (ISAS); Ruhr University Bochum	Butt, E (corresponding author), Univ Clin Wuerzburg, Inst Clin Biochem & Pathobiochem, Grombuehlstr 12, D-97080 Wurzburg, Germany.	butt@klin-biochem.uni-wuerzburg.de	Sickmann, Albert/A-1010-2011	Sickmann, Albert/0000-0002-2388-5265	DFG [BU 740/6-2, RE 3183/1-1, SFB 688 A2]; Innovative Medizinische Forschung, University Hospital Munster [KR110904]; Ministerium fur Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen	DFG(German Research Foundation (DFG)); Innovative Medizinische Forschung, University Hospital Munster; Ministerium fur Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen	We thank Dr Viacheslav Nikolaev for his help with confocal microscopy. This work was supported by grants from the DFG (BU 740/6-2 to EB, RE 3183/1-1 to CR, SFB 688 A2 to SG) the Innovative Medizinische Forschung, University Hospital Munster (KR110904 to JK) and the Ministerium fur Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen (UL and AS).	Balda MS, 2009, BBA-BIOMEMBRANES, V1788, P761, DOI 10.1016/j.bbamem.2008.11.024; Betanzos A, 2004, EXP CELL RES, V292, P51, DOI 10.1016/j.yexcr.2003.08.007; Butt E, 2003, J BIOL CHEM, V278, P15601, DOI 10.1074/jbc.M209009200; Call GS, 1942, BIOCHEM BIOPH RES CO, V404, P780; Chew CS, 2002, J CELL SCI, V115, P4787, DOI 10.1242/jcs.00174; Chew CS, 2008, AM J PHYSIOL-GASTR L, V288, pG376; CHIYOMARU T, 2010, UROL ONCOL; Dimova I, 2009, TUMORI, V95, P357; Ferraro E, 2007, NUCLEIC ACIDS RES, V35, pW451, DOI 10.1093/nar/gkm296; Frietsch JJ, 2010, BRIT J CANCER, V102, P1645, DOI 10.1038/sj.bjc.6605685; Grunewald TGP, 2007, BRIT J CANCER, V96, P296, DOI 10.1038/sj.bjc.6603545; Grunewald TGP, 2006, EXP CELL RES, V312, P974, DOI 10.1016/j.yexcr.2005.12.016; Grunewald TGP, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-31; Grunewald TGP, 2007, BMC CANCER, V7, P1, DOI 10.1186/1471-2407-7-198; Hammarstrom A, 1996, BIOCHEMISTRY-US, V35, P12723, DOI 10.1021/bi961149j; Huerta M, 2007, MOL BIOL CELL, V18, P4826, DOI 10.1091/mbc.E07-02-0109; Keicher C, 2004, BIOCHEM BIOPH RES CO, V324, P308, DOI 10.1016/j.bbrc.2004.08.235; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; LEREA KM, 1991, BIOCHEMISTRY-US, V30, P6819, DOI 10.1021/bi00242a003; Li B, 2004, J BIOL CHEM, V279, P20401, DOI 10.1074/jbc.M310304200; Lin YH, 2004, J CELL BIOL, V165, P421, DOI 10.1083/jcb.200311045; Merkle D, 2011, CELL SIGNAL, V23, P507, DOI 10.1016/j.cellsig.2010.08.017; Nakagawa H, 2006, FEBS LETT, V580, P3223, DOI 10.1016/j.febslet.2006.04.082; Oka T, 2002, BIOCHEM J, V432, P461; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Traenka C, 2010, CANCER RES, V70, P8003, DOI 10.1158/0008-5472.CAN-10-0592; Traenka J, 2009, THROMB HAEMOSTASIS, V102, P520, DOI 10.1160/TH09-03-0143; Traweger A, 2003, J BIOL CHEM, V278, P2692, DOI 10.1074/jbc.M206821200; Viticchie G, 2011, CELL CYCLE, V10, P1121, DOI 10.4161/cc.10.7.15180; Zhang H, 2009, PHYSIOL GENOMICS, V38, P372, DOI 10.1152/physiolgenomics.00048.2009; Zhao LA, 2010, GUT, V59, P1226, DOI 10.1136/gut.2009.202739; Zheng B, 2009, FEBS J, V276, P2669, DOI 10.1111/j.1742-4658.2009.06986.x	34	45	48	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2107	2113		10.1038/onc.2012.216	http://dx.doi.org/10.1038/onc.2012.216			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22665060				2022-12-17	WOS:000317919900012
J	Saito, R; Shirakawa, R; Nishiyama, H; Kobayashi, T; Kawato, M; Kanno, T; Nishizawa, K; Matsui, Y; Ohbayashi, T; Horiguchi, M; Nakamura, T; Ikeda, T; Yamane, K; Nakayama, E; Nakamura, E; Toda, Y; Kimura, T; Kita, T; Ogawa, O; Horiuchi, H				Saito, R.; Shirakawa, R.; Nishiyama, H.; Kobayashi, T.; Kawato, M.; Kanno, T.; Nishizawa, K.; Matsui, Y.; Ohbayashi, T.; Horiguchi, M.; Nakamura, T.; Ikeda, T.; Yamane, K.; Nakayama, E.; Nakamura, E.; Toda, Y.; Kimura, T.; Kita, T.; Ogawa, O.; Horiuchi, H.			Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer	ONCOGENE			English	Article						RaIGAP alpha 2; Ral small GTPase; bladder cancer; invasion; metastasis	TRANSITIONAL-CELL-CARCINOMA; IN-VITRO; PROSTATE-CANCER; EXPRESSION; GROWTH; PROLIFERATION; TUMORIGENESIS; CHEMOTHERAPY; TISSUE; GENES	The small GTPase Ral is known to be highly activated in several human cancers, such as bladder, colon and pancreas cancers. It is reported that activated Ral is involved in cell proliferation, migration and metastasis of bladder cancer. This protein is activated by Ral guanine nucleotide exchange factors (RaIGEFs) and inactivated by Rat GTPase-activating proteins (RaIGAPs), the latter of which consist of heterodimers containing a catalytic alpha 1 or alpha 2 subunit and a common beta subunit. In Ras-driven cancers, such as pancreas and colon cancers, constitutively active Ras mutant activates Ral through interaction with RaIGEFs, which contain the Ras association domain. However, little is known with regard to the mechanism that governs aberrant activation of Ral in bladder cancer, in which Ras mutations are relatively infrequent. Here, we show that Ral was highly activated in invasive bladder cancer cells due to reduced expression of RaIGAP alpha 2, the dominant catalytic subunit in bladder, rather than increased expression of RaIGEFs. Exogenous expression of wild-type RaIGAP alpha 2 in KU7 bladder cancer cells with invasive phenotype, but not mutant RaIGAID alpha 2-N1742K lacking RaIGAP activity, resulted in attenuated cell migration in vitro and lung metastasis in vivo. Furthermore, genetic ablation of Ralgapa2 promoted tumor invasion in a chemically-induced murine bladder cancer model. Importantly, immunohistochennical analysis of human bladder cancer specimens revealed that lower expression of RaIGAP alpha 2 was associated with advanced clinical stage and poor survival of patients. Collectively, these results are highly indicative that attenuated expression of RaIGAP alpha 2 leads to disease progression of bladder cancer through enhancement of Ral activity. Oncogene (2013) 32, 894-902; doi:10.1038/onc.2012.101; published online 26 March 2012	[Saito, R.; Kobayashi, T.; Kanno, T.; Nishizawa, K.; Matsui, Y.; Nakamura, E.; Ogawa, O.] Kyoto Univ, Dept Urol, Grad Sch Med, Kyoto, Japan; [Shirakawa, R.; Horiuchi, H.] Tohoku Univ, Dept Mol & Cellular Biol, Inst Dev Aging & Canc, Sendai, Miyagi 9808575, Japan; [Nishiyama, H.] Univ Tsukuba, Dept Urol, Fac Med, Tsukuba, Ibaraki 3058575, Japan; [Kawato, M.; Horiguchi, M.; Ikeda, T.; Yamane, K.; Nakayama, E.; Kimura, T.; Kita, T.] Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto, Japan; [Ohbayashi, T.] Tottori Univ, Div Lab Anim Sci, Res Ctr Biosci & Technol, Yonago, Tottori, Japan; [Nakamura, T.] Kansai Med Univ, Dept Pharmacol, Moriguchi, Osaka 570, Japan; [Toda, Y.] Kyoto Univ, Grad Sch Med, Ctr Anat Studies, Kyoto, Japan	Kyoto University; Tohoku University; University of Tsukuba; Kyoto University; Tottori University; Kansai Medical University; Kyoto University	Nishiyama, H (corresponding author), Univ Tsukuba, Dept Urol, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	nishiuro@md.tsukuba.ac.jp; horiuchi@idac.tohoku.ac.jp	MATSUI, Yoshiyuki/I-2323-2019		Ministry of Education, Culture, Sports, Science and Technology, Japan [22591766, 22890015, 22501009, 20013201, 23113702]; Uehara Memorial Foundation; Takeda Science Foundation; Suzuken Memorial Foundation; Daiichi-Sankyo Foundation of Life-Science; Kurokawa Cancer Research Foundation; Novartis Foundation for the Promotion of Science; Grants-in-Aid for Scientific Research [22501009] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Uehara Memorial Foundation(Uehara Memorial Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF)); Suzuken Memorial Foundation; Daiichi-Sankyo Foundation of Life-Science; Kurokawa Cancer Research Foundation(Kurokawa Cancer Research Foundation); Novartis Foundation for the Promotion of Science; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We would like to thank Aaron Mathew Coutts for proofreading of the manuscript. We appreciate all members of the Cancer Research Course for Integrated Research Training in Kyoto University Graduate School of Medicine for their helpful advice and discussion. This study was supported by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan (No. 22591766 to HN and OO, 22890015, 22501009, 20013201 and 23113702 to R Shirakawa and HH) as well as grants from Uehara Memorial Foundation (to T Kobayashi and 00), Takeda Science Foundation, the Suzuken Memorial Foundation, Daiichi-Sankyo Foundation of Life-Science, Kurokawa Cancer Research Foundation (to R Shirakawa), and Novartis Foundation for the Promotion of Science (to HH).	Adhim Z, 2011, BRIT J CANCER, V105, P393, DOI 10.1038/bjc.2011.262; Badea L, 2008, HEPATO-GASTROENTEROL, V55, P2016; Blaveri E, 2005, CLIN CANCER RES, V11, P4044, DOI 10.1158/1078-0432.CCR-04-2409; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; Copeland NG, 2001, NAT REV GENET, V2, P769, DOI 10.1038/35093556; Cordon-Cardo C, 2008, SCAND J UROL NEPHROL, V42, P154, DOI 10.1080/03008880802291915; Ding ST, 2010, J UROLOGY, V184, P1175, DOI 10.1016/j.juro.2010.04.073; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Gaspar C, 2008, AM J PATHOL, V172, P1363, DOI 10.2353/ajpath.2008.070851; Hadaschik BA, 2008, CLIN CANCER RES, V14, P1510, DOI 10.1158/1078-0432.CCR-07-4475; Hsieh JL, 2003, BRIT J CANCER, V88, P1492, DOI 10.1038/sj.bjc.6600908; Hurst RE, 2003, ANTICANCER RES, V23, P3119; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Kawato M, 2008, J BIOL CHEM, V283, P166, DOI 10.1074/jbc.M705340200; Knowles MA, 2006, CARCINOGENESIS, V27, P361, DOI 10.1093/carcin/bgi310; Kobayashi T, 2010, MOL ENDOCRINOL, V24, P722, DOI 10.1210/me.2009-0326; Konety BR, 2001, J UROLOGY, V165, P253, DOI 10.1097/00005392-200101000-00074; Korkola JE, 2006, CANCER RES, V66, P820, DOI 10.1158/0008-5472.CAN-05-2445; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Martin TD, 2011, CANCER RES, V71, P206, DOI 10.1158/0008-5472.CAN-10-1517; MASTERS JRW, 1986, CANCER RES, V46, P3630; Matsui Y, 2010, BJU INT, V105, P558, DOI 10.1111/j.1464-410X.2009.08732.x; Nishiyama H, 1999, GENE CHROMOSOME CANC, V26, P171, DOI 10.1002/(SICI)1098-2264(199910)26:2<171::AID-GCC10>3.3.CO;2-2; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375; Shao HP, 2000, J BIOL CHEM, V275, P26914; SHIBAYAMA T, 1991, J UROLOGY, V146, P1136, DOI 10.1016/S0022-5347(17)38025-4; Shirakawa R, 2009, J BIOL CHEM, V284, P21580, DOI 10.1074/jbc.M109.012112; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Smith SC, 2007, CLIN CANCER RES, V13, P3803, DOI 10.1158/1078-0432.CCR-06-2419; Su LJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-140; Vigil D, 2010, J BIOL CHEM, V285, P34729, DOI 10.1074/jbc.M110.116756; Wallace TA, 2008, CANCER RES, V68, P927, DOI 10.1158/0008-5472.CAN-07-2608; Wang H, 2010, CANCER RES, V70, P8760, DOI 10.1158/0008-5472.CAN-10-0952; Williams SV, 2002, GENE CHROMOSOME CANC, V34, P86, DOI 10.1002/gcc.10050; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	44	45	45	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2013	32	7					894	902		10.1038/onc.2012.101	http://dx.doi.org/10.1038/onc.2012.101			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22450745	Green Submitted			2022-12-17	WOS:000316581100009
J	Calhabeu, F; Hayashi, S; Morgan, JE; Relaix, F; Zammit, PS				Calhabeu, F.; Hayashi, S.; Morgan, J. E.; Relaix, F.; Zammit, P. S.			Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells	ONCOGENE			English	Article						alveolar rhabdomyosarcoma; PAX3/FOXO1A; PAX7/FOXO1A; MyoD; myogenin; satellite cell	PAX3-FKHR FUSION PROTEIN; SKELETAL-MUSCLE; SATELLITE CELLS; PROGENITOR CELLS; MYOGENIC DIFFERENTIATION; TERMINAL DIFFERENTIATION; FAMILY-MEMBERS; IN-VIVO; PAX3; EXPRESSION	Rhabdomyosarcoma (RMS) is the commonest soft-tissue sarcoma in childhood and is characterized by expression of myogenic proteins, including the transcription factors MyoD and myogenin. There are two main subgroups, embryonal RMS and alveolar RMS (ARMS). Most ARMS are associated with chromosomal translocations that have breakpoints in introns of either PAX3 or PAX7, and FOXO1A. These translocations create chimeric transcription factors termed PAX3/FOXO1A and PAX7/FOXO1A respectively. Upon ectopic PAX3/FOXO1A expression, together with other genetic manipulation in mice, both differentiating myoblasts and satellite cells (the resident stem cells of postnatal muscle) can give rise to tumours with ARMS characteristics. As PAX3 and PAX7 are part of transcriptional networks that regulate muscle stem cell function in utero and during early postnatal life, PAX3/FOXO1A and PAX7/FOXO1A may subvert normal PAX3 and PAX7 functions. Here we examined how PAX3/FOXO1A and PAX7/FOXO1A affect myogenesis in satellite cells. PAX3/FOXO1A or PAX7/FOXO1A inhibited myogenin expression and prevented terminal differentiation in nnurine satellite cells: the same effect as dominant-negative (DN) Pax3 or Pax7 constructs. The transcription of MyoD-target genes myogenin and muscle creatine kinase were suppressed by PAX3/FOXO1A or PAX7/FOXO1A in C2C12 myogenic cells again as seen with Pax3/7DN. PAX3/FOXO1A or PAX7/FOXO1A did not inhibit the transcriptional activity of MyoD by perturbing MyoD expression, localization, phosphorylation or interaction with E-proteins. Chromatin immunoprecipitation on the myogenin promoter showed that PAX3/FOXO1A or PAX7/FOXO1A did not prevent MyoD from binding. However, PAX3/FOXO1A or PAX7/FOXO1A reduced occupation of the myogenin promoter by RNA polynnerase II and decreased acetylation of histone H4, but did not directly bind to the myogenin promoter. Together, these observations reveal that PAX3/FOXO1A and PAX7/FOXO1A act to prevent myogenic differentiation via suppression of the transcriptional activation of MyoD-target genes. Oncogene (2013) 32, 651-662; doi:10.1038/onc.2012.73; published online 18 June 2012	[Calhabeu, F.; Zammit, P. S.] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; [Hayashi, S.; Relaix, F.] Univ Paris 06, INSERM, UMR S 787,Fac Med Pitie Salpetriere, Myol Grp,Avenir Team Mouse Mol Genet, Paris, France; [Morgan, J. E.] UCL Inst Child Hlth, Dubowitz Neuromuscular Ctr, London, England	University of London; King's College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of London; University College London	Zammit, PS (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, New Hunts House,Guys Campus, London SE1 1UL, England.	peter.zammit@kcl.ac.uk	Zammit, peter/GXV-7746-2022	Hayashi, Shinichiro/0000-0001-5553-7698; zammit, peter/0000-0001-9562-3072; Relaix, Frederic/0000-0003-1270-1472	Association of International Cancer Research [07-0151]; Wellcome Trust [085137/Z/08/Z]; Medical Research Council; OPTISTEM European Commission [223098]; Wellcome Trust; INSERM Avenir Program; AFM; INCa; LNCC; ARC; FP7 ENDOSTEM [241440]	Association of International Cancer Research; Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); OPTISTEM European Commission; Wellcome Trust(Wellcome Trust); INSERM Avenir Program(Institut National de la Sante et de la Recherche Medicale (Inserm)); AFM(Association Francaise contre les Myopathies); INCa(Institut National du Cancer (INCA) France); LNCC; ARC(Australian Research Council); FP7 ENDOSTEM	We thank Frederic Barr for PAX3-FOXO1A and PAX7-FOXO1A, and Stephen Tapscott for pcIBabe-MyoD similar to E12 and pC52-MCK-luciferase. We acknowledge colleagues who shared antibodies through the Developmental Studies Hybridoma Bank maintained by the University of Iowa. FC was funded by the Association of International Cancer Research (07-0151). The laboratory of PSZ is also supported by The Wellcome Trust (085137/Z/08/Z), The Medical Research Council and OPTISTEM (Grant 223098) from the European Commission FP7. JEM is supported by a Wellcome Trust University Award. The laboratory of FR is supported by the INSERM Avenir Program, AFM, INCa, LNCC, ARC and FP7 ENDOSTEM (Grant 241440).	Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; Bajard L, 2006, GENE DEV, V20, P2450, DOI 10.1101/gad.382806; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Begum S, 2005, ONCOGENE, V24, P1860, DOI 10.1038/sj.onc.1208315; Bennicelli JL, 1999, ONCOGENE, V18, P4348, DOI 10.1038/sj.onc.1202812; Berkes CA, 2005, SEMIN CELL DEV BIOL, V16, P585, DOI 10.1016/j.semcdb.2005.07.006; Buckingham M, 2007, ANNU REV CELL DEV BI, V23, P645, DOI 10.1146/annurev.cellbio.23.090506.123438; Cao LA, 2010, CANCER RES, V70, P6497, DOI 10.1158/0008-5472.CAN-10-0582; Collins CA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004475; Cui S, 1999, PATHOL INT, V49, P62, DOI 10.1046/j.1440-1827.1999.00825.x; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; Dilworth FJ, 2004, P NATL ACAD SCI USA, V101, P11593, DOI 10.1073/pnas.0404192101; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Finckenstein FG, 2008, ONCOGENE, V27, P2004, DOI 10.1038/sj.onc.1210835; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Gnocchi VF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005205; GUO K, 1995, MOL CELL BIOL, V15, P3823; Gurney JG, 1999, CANC INCIDENCE SURVI, P111; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hettmer S, 2010, NAT MED, V16, P171, DOI 10.1038/nm0210-171; Horst D, 2006, INT J DEV BIOL, V50, P47, DOI 10.1387/ijdb.052111dh; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Kelly KM, 1997, J CLIN ONCOL, V15, P1831, DOI 10.1200/JCO.1997.15.5.1831; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; L'honore A, 2007, MOL BIOL CELL, V18, P1992, DOI 10.1091/mbc.E06-09-0867; Lagha M, 2008, GENE DEV, V22, P1828, DOI 10.1101/gad.477908; Lepper C, 2009, NATURE, V460, P627, DOI 10.1038/nature08209; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; Miller PJ, 2007, BBA-GEN SUBJECTS, V1770, P1450, DOI 10.1016/j.bbagen.2007.06.016; Montarras D, 2005, SCIENCE, V309, P2064, DOI 10.1126/science.1114758; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nishijo K, 2009, FASEB J, V23, P2681, DOI 10.1096/fj.08-128116; Ono Y, 2010, DEV BIOL, V337, P29, DOI 10.1016/j.ydbio.2009.10.005; Ornatsky OI, 1997, J BIOL CHEM, V272, P33271, DOI 10.1074/jbc.272.52.33271; Otten AD, 1997, CELL GROWTH DIFFER, V8, P1151; Relaix F, 2005, NATURE, V435, P948, DOI 10.1038/nature03594; Relaix F, 2006, J CELL BIOL, V172, P91, DOI 10.1083/jcb.200508044; Relaix F, 2004, GENE DEV, V18, P1088, DOI 10.1101/gad.301004; Relaix F, 2003, GENE DEV, V17, P2950, DOI 10.1101/gad.281203; Russo S, 1998, J CELL SCI, V111, P691; Saccone V, 2010, ORGANOGENESIS, V6, P48, DOI 10.4161/org.6.1.11293; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Scuoppo C, 2007, EXP CELL RES, V313, P2308, DOI 10.1016/j.yexcr.2007.02.037; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Spitz F, 1998, P NATL ACAD SCI USA, V95, P14220, DOI 10.1073/pnas.95.24.14220; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Tapscott SJ, 2005, DEVELOPMENT, V132, P2685, DOI 10.1242/dev.01874; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Wei Q, 2001, FEBS LETT, V490, P171, DOI 10.1016/S0014-5793(01)02120-2; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; Weintraub M, 1997, Sarcoma, V1, P135, DOI 10.1080/13577149778218; Yang ZH, 2009, GENE DEV, V23, P694, DOI 10.1101/gad.1765109; Zammit PS, 2006, J CELL SCI, V119, P1824, DOI 10.1242/jcs.02908; Zammit PS, 2004, J CELL BIOL, V166, P347, DOI 10.1083/jcb.200312007; Zhang L, 2007, ONCOGENE, V26, P1595, DOI 10.1038/sj.onc.1209958	58	45	47	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2013	32	5					651	662		10.1038/onc.2012.73	http://dx.doi.org/10.1038/onc.2012.73			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22710712				2022-12-17	WOS:000316164700012
J	Lorca, T; Castro, A				Lorca, T.; Castro, A.			The Greatwall kinase: a new pathway in the control of the cell cycle	ONCOGENE			English	Review						Greatwall; PP2A; cyclin B-Cdc2; mitosis; mRNA; checkpoint	PROTEIN PHOSPHATASE 2A; XENOPUS EGG EXTRACTS; IN-VIVO; MITOSIS; DROSOPHILA; ENTRY; MASTL; EXIT; THROMBOCYTOPENIA; PROGRESSION	New data have recently established that protein phosphorylation during mitosis is the result of a controlled balance between kinase and phosphatase activities and that, as for mitotic kinases, phosphatases are also regulated during cell division. This regulation is at least in part induced by the activation of the Greatwall (Gwl) kinase at mitotic entry. Activated Gwl phosphorylates its substrates cAMP-regulated phospho protein 19 (Arpp19) and alpha-endosulfine (ENSA), promoting their binding to and the inhibition of PP2A. Interestingly, besides the role of the Gwl-Arpp19/ENSA in the control of mitotic division, new data in yeast support the involvement of this pathway in mRNA stabilization during G(o) program initiation, although in this case the phosphatase PP2A appears not to be implicated. Finally, Gwl activity has been shown to be required for DNA checkpoint recovery. These new findings support the view that Gwl, Arpp19 and ENSA could function as the core of a new signalization pathway that, by targeting different final substrates, could participate in a variety of physiological functions. Oncogene (2013) 32, 537-543; doi:10.1038/onc.2012.79; published online 2 April 2012	Univ Montpellier 2, Ctr Rech Biochim Macromol, CNRS UMR 5237, F-34293 Montpellier 5, France; Univ Montpellier I, Ctr Rech Biochim Macromol, CNRS UMR 5237, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Castro, A (corresponding author), Univ Montpellier 2, Ctr Rech Biochim Macromol, CNRS UMR 5237, IFR 122, 1919 Route Mende, F-34293 Montpellier 5, France.	thierry.lorca@crbm.cnrs.fr; anna.castro@crbm.cnrs.fr	CASTRO, ANNA/F-4350-2010	CASTRO, ANNA/0000-0002-3655-1352; Lorca, Thierry/0000-0003-2007-8924	'Agence Nationale de la Recherche' (Programme Blanc); Ligue Nationale Contre le Cancer' (Equipe Labelissee)	'Agence Nationale de la Recherche' (Programme Blanc)(French National Research Agency (ANR)); Ligue Nationale Contre le Cancer' (Equipe Labelissee)	We thank A Burgess and K Hached for comments and suggestions on the manuscript. Research in the laboratory of TL and AC has received funding from the 'Agence Nationale de la Recherche' (Programme Blanc) and from The Ligue Nationale Contre le Cancer' (Equipe Labelissee).	Archambault V, 2007, PLOS GENET, V3, P2163, DOI 10.1371/journal.pgen.0030200; Bettencourt-Dias M, 2004, NATURE, V432, P980, DOI 10.1038/nature03160; Burgess A, 2010, P NATL ACAD SCI USA, V107, P12564, DOI 10.1073/pnas.0914191107; Castilho PV, 2009, MOL BIOL CELL, V20, P4777, DOI 10.1091/mbc.E09-07-0643; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Galvin JE, 2001, ARCH NEUROL-CHICAGO, V58, P186, DOI 10.1001/archneur.58.2.186; Gandhi MJ, 2003, HUM HERED, V55, P66, DOI 10.1159/000071812; Gharbi-Ayachi A, 2010, SCIENCE, V330, P1673, DOI 10.1126/science.1197048; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Johnson HJ, 2009, EXP HEMATOL, V37, P901, DOI 10.1016/j.exphem.2009.05.005; Lorca T, 2010, J CELL SCI, V123, P2281, DOI 10.1242/jcs.064527; Manchado E, 2010, CANCER CELL, V18, P641, DOI 10.1016/j.ccr.2010.10.028; Mochida S, 2010, SCIENCE, V330, P1670, DOI 10.1126/science.1195689; Mochida S, 2009, EMBO J, V28, P2777, DOI 10.1038/emboj.2009.238; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Peng AM, 2011, J BIOL CHEM, V286, P28996, DOI 10.1074/jbc.M111.257121; Peng AM, 2010, CELL CYCLE, V9, P4364, DOI 10.4161/cc.9.21.13632; Rangone H, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002225; Schmitz MHA, 2010, NAT CELL BIOL, V12, P886, DOI 10.1038/ncb2092; Steegmaier M, 2007, CURR BIOL, V17, P316, DOI 10.1016/j.cub.2006.12.037; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Talarek N, 2010, MOL CELL, V38, P345, DOI 10.1016/j.molcel.2010.02.039; Vigneron S, 2011, MOL CELL BIOL, V31, P2262, DOI 10.1128/MCB.00753-10; Vigneron S, 2009, EMBO J, V28, P2786, DOI 10.1038/emboj.2009.228; Voets E, 2010, CELL CYCLE, V9, P3591, DOI 10.4161/cc.9.17.12832; Von Stetina JR, 2008, DEVELOPMENT, V135, P3697, DOI 10.1242/dev.025114; Wang P, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002227; WhiteCooper H, 1996, GENETICS, V144, P1097, DOI 10.1534/genetics.112.1097.test; Woods WS, 2007, J BIOL CHEM, V282, P34555, DOI 10.1074/jbc.M705283200; Yamamoto TM, 2011, MOL BIOL CELL, V22, P2157, DOI 10.1091/mbc.E11-01-0008; Yong Z, 2008, MOL BIOL CELL, V19, P1317, DOI 10.1091/mbc.E07-11-1099; Yu JT, 2006, MOL CELL, V22, P83, DOI 10.1016/j.molcel.2006.02.022; Yu JT, 2004, J CELL BIOL, V164, P487, DOI 10.1083/JCB.200310059	33	45	45	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2013	32	5					537	543		10.1038/onc.2012.79	http://dx.doi.org/10.1038/onc.2012.79			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22469975	Green Published			2022-12-17	WOS:000316164700001
J	Geutjes, EJ; Bajpe, PK; Bernards, R				Geutjes, E-J; Bajpe, P. K.; Bernards, R.			Targeting the epigenome for treatment of cancer	ONCOGENE			English	Review						cancer epigenetics; epigenetic therapy; DNA methylation; histone modifications; nucleosome remodelling	HISTONE-DEACETYLASE INHIBITOR; TUMOR-SUPPRESSOR GENE; PHASE-II TRIAL; POLYCOMB-GROUP PROTEIN; CHROMATIN-REMODELING FACTOR; SUBEROYLANILIDE HYDROXAMIC ACID; DEMETHYLASE JMJD3 CONTRIBUTES; TRANSITIONAL-CELL CARCINOMA; CONVENTIONAL CARE REGIMENS; MESSENGER-RNA EXPRESSION	Cancer genome analyses have revealed that the enzymes involved in epigenetic gene regulation are frequently deregulated in cancer. Here we describe the enzymes that control the epigenetic state of the cell, how they are affected in cancer and how this knowledge can be exploited to treat cancer with a new arsenal of selective therapies. Oncogene (2012) 31, 3827-3844; doi: 10.1038/onc.2011.552; published online 5 December 2011	[Bernards, R.] Netherlands Canc Inst, Div Mol Carcinogenesis, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; [Bernards, R.] Netherlands Canc Inst, Canc Genom Ctr, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Ctr Biomed Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl		Bernards, Rene/0000-0001-8677-3423				Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809; Andersen JB, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001338; Nguyen AT, 2011, BLOOD, V117, P6912, DOI 10.1182/blood-2011-02-334359; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aribi A, 2007, CANCER-AM CANCER SOC, V109, P713, DOI 10.1002/cncr.22457; Arif M, 2010, CHEM BIOL, V17, P903, DOI 10.1016/j.chembiol.2010.06.014; Arisan S, 2005, UROL INT, V75, P252, DOI 10.1159/000087804; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Baek SH, 2011, MOL CELL, V42, P274, DOI 10.1016/j.molcel.2011.03.022; Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Balasubramanian S, 2008, LEUKEMIA, V22, P1026, DOI 10.1038/leu.2008.9; Balasubramanyam K, 2003, J BIOL CHEM, V278, P19134, DOI 10.1074/jbc.M301580200; Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Bea S, 2001, CANCER RES, V61, P2409; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Berdasco M, 2009, P NATL ACAD SCI USA, V106, P21830, DOI 10.1073/pnas.0906831106; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Bhaskara S, 2010, CANCER CELL, V18, P436, DOI 10.1016/j.ccr.2010.10.022; Biegel JA, 2000, CLIN CANCER RES, V6, P2759; Biegel JA, 2000, GENE CHROMOSOME CANC, V28, P31, DOI 10.1002/(SICI)1098-2264(200005)28:1<31::AID-GCC4>3.0.CO;2-Y; Biegel Jaclyn A., 2002, Cancer Research, V62, P323; Biegel Jaclyn A, 2004, Curr Oncol Rep, V6, P445, DOI 10.1007/s11912-004-0075-5; Blum KA, 2009, BRIT J HAEMATOL, V147, P507, DOI 10.1111/j.1365-2141.2009.07881.x; Blum W, 2007, J CLIN ONCOL, V25, P3884, DOI 10.1200/JCO.2006.09.4169; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Boumber Y, 2011, ONCOLOGY-NY, V25, P220; Bradley D, 2009, CANCER-AM CANCER SOC, V115, P5541, DOI 10.1002/cncr.24597; Bradner JE, 2010, NAT CHEM BIOL, V6, P238, DOI 10.1038/NCHEMBIO.313; Braiteh F, 2008, CLIN CANCER RES, V14, P6296, DOI 10.1158/1078-0432.CCR-08-1247; Brueckner B, 2005, CANCER RES, V65, P6305, DOI 10.1158/0008-5472.CAN-04-2957; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664; Buszczak M, 2009, SCIENCE, V323, P248, DOI 10.1126/science.1165678; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806; Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497; Chang YQ, 2009, NAT STRUCT MOL BIOL, V16, P312, DOI 10.1038/nsmb.1560; Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833; Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399; Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Clapier CR, 2009, ANNU REV BIOCHEM, V78, P273, DOI 10.1146/annurev.biochem.77.062706.153223; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Coste A, 2006, EMBO J, V25, P2453, DOI 10.1038/sj.emboj.7601106; Crump M, 2008, ANN ONCOL, V19, P964, DOI 10.1093/annonc/mdn031; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Datta J, 2009, CANCER RES, V69, P4277, DOI 10.1158/0008-5472.CAN-08-3669; Dawson MR, 2009, NATURE, V461, pE4, DOI 10.1038/nature08254; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dickinson M, 2009, BRIT J HAEMATOL, V147, P97, DOI 10.1111/j.1365-2141.2009.07837.x; Drost J, 2010, NAT CELL BIOL, V12, P380, DOI 10.1038/ncb2038; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Ehrbrecht A, 2006, J PATHOL, V208, P554, DOI 10.1002/path.1925; Eliazer S, 2011, P NATL ACAD SCI USA, V108, P7064, DOI 10.1073/pnas.1015874108; Eliseeva ED, 2007, MOL CANCER THER, V6, P2391, DOI 10.1158/1535-7163.MCT-07-0159; Epping MT, 2005, CELL, V122, P835, DOI 10.1016/j.cell.2005.07.003; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875; Fenaux P, 2010, J CLIN ONCOL, V28, P562, DOI 10.1200/JCO.2009.23.8329; Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8; Ferrari R, 2008, SCIENCE, V321, P1086, DOI 10.1126/science.1155546; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496; Frescas D, 2008, CELL CYCLE, V7, P3539, DOI 10.4161/cc.7.22.7062; Fujita T, 2008, JNCI-J NATL CANCER I, V100, P940, DOI 10.1093/jnci/djn176; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; Galanis E, 2009, J CLIN ONCOL, V27, P2052, DOI 10.1200/JCO.2008.19.0694; Garcia-Manero G, 2006, BLOOD, V108, P3271, DOI 10.1182/blood-2006-03-009142; Gazin C, 2007, NATURE, V449, P1073, DOI 10.1038/nature06251; Geutjes EJ, 2011, BREAST CANC RES TREA; Giaccone G, 2011, J CLIN ONCOL, V29, P2052, DOI 10.1200/JCO.2010.32.4467; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Glaros S, 2008, CANCER RES, V68, P3689, DOI 10.1158/0008-5472.CAN-07-6652; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Grand F, 1999, CANCER RES, V59, P3870; Griffiths DS, 2011, NAT CELL BIOL, V13, P13, DOI 10.1038/ncb2135; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Haberland M, 2009, P NATL ACAD SCI USA, V106, P7751, DOI 10.1073/pnas.0903139106; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022; Hamada S, 2010, J MED CHEM, V53, P5629, DOI 10.1021/jm1003655; Hauschild A, 2008, MELANOMA RES, V18, P274, DOI 10.1097/CMR.0b013e328307c248; He LS, 1998, CANCER RES, V58, P4238; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102; Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588; Huang Y, 2011, BREAST CANC RES TREA; Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104; Huang Y, 2009, CLIN CANCER RES, V15, P7217, DOI 10.1158/1078-0432.CCR-09-1293; Issa JPJ, 2009, CLIN CANCER RES, V15, P3938, DOI 10.1158/1078-0432.CCR-08-2783; Issa JPJ, 2005, J CLIN ONCOL, V23, P3948, DOI 10.1200/JCO.2005.11.981; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Jackson EM, 2009, CLIN CANCER RES, V15, P1923, DOI 10.1158/1078-0432.CCR-08-2091; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jaju RJ, 2001, BLOOD, V98, P1264, DOI 10.1182/blood.V98.4.1264; Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019; Jin Ke Long, 2008, J Gynecol Oncol, V19, P185, DOI 10.3802/jgo.2008.19.3.185; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Joo HY, 2007, NATURE, V449, P1068, DOI 10.1038/nature06256; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Kaminskas E, 2005, CLIN CANCER RES, V11, P3604, DOI 10.1158/1078-0432.CCR-04-2135; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678; Kilpivaara O, 2008, LEUKEMIA, V22, P1813, DOI 10.1038/leu.2008.229; Kirschbaum M, 2011, J CLIN ONCOL, V29, P1198, DOI 10.1200/JCO.2010.32.1398; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 2001, LEUKEMIA, V15, P89, DOI 10.1038/sj.leu.2401983; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Knapper S, 2006, BLOOD, V108, P3262, DOI 10.1182/blood-2006-04-015560; Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586; Kondo Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002037; Koontz JI, 2001, P NATL ACAD SCI USA, V98, P6348, DOI 10.1073/pnas.101132598; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; Kuck D, 2010, MOL CANCER THER, V9, P3015, DOI 10.1158/1535-7163.MCT-10-0609; Kung AL, 2000, GENE DEV, V14, P272; Kurotaki N, 2002, NAT GENET, V30, P365, DOI 10.1038/ng863; Lahusen T, 2009, BREAST CANCER RES TR, V116, P225, DOI 10.1007/s10549-009-0405-2; Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291; Langemeijer SMC, 2009, NAT GENET, V41, P838, DOI 10.1038/ng.391; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Leary RJ, 2008, P NATL ACAD SCI USA, V105, P16224, DOI 10.1073/pnas.0808041105; Lee YS, 2008, CANCER RES, V68, P7561, DOI 10.1158/0008-5472.CAN-08-0188; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297; Liu H, 2009, CANCER BIOL THER, V8, P1204, DOI 10.4161/cbt.8.13.8924; Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633; Luu TH, 2008, CLIN CANCER RES, V14, P7138, DOI 10.1158/1078-0432.CCR-08-0122; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Marschalek R, 2011, BRIT J HAEMATOL, V152, P141, DOI 10.1111/j.1365-2141.2010.08459.x; Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x; McGarvey KM, 2008, CANCER RES, V68, P5753, DOI 10.1158/0008-5472.CAN-08-0700; Medina PP, 2004, GENE CHROMOSOME CANC, V41, P170, DOI 10.1002/gcc.20068; Mesa RA, 2011, CANCER-AM CANCER SOC, V117, P4869, DOI 10.1002/cncr.26129; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Miller CT, 2003, CLIN CANCER RES, V9, P4819; Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013; Modesitt SC, 2008, GYNECOL ONCOL, V109, P182, DOI 10.1016/j.ygyno.2008.01.009; Molife LR, 2010, ANN ONCOL, V21, P109, DOI 10.1093/annonc/mdp270; Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Mulero-Navarro S, 2008, EPIGENETICS-US, V3, P210, DOI 10.4161/epi.3.4.6610; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Namdar M, 2010, P NATL ACAD SCI USA, V107, P20003, DOI 10.1073/pnas.1013754107; Nicassio F, 2007, CURR BIOL, V17, P1972, DOI 10.1016/j.cub.2007.10.034; Niesvizky R, 2011, CANCER-AM CANCER SOC, V117, P336, DOI 10.1002/cncr.25584; Niu X, 2012, ONCOGENE, V31, P776, DOI 10.1038/onc.2011.266; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Nowell PC, 2002, SEMIN CANCER BIOL, V12, P261, DOI 10.1016/S1044-579X(02)00012-3; Oehme I, 2009, CLIN CANCER RES, V15, P91, DOI 10.1158/1078-0432.CCR-08-0684; Oki Y, 2008, BLOOD, V111, P2382, DOI 10.1182/blood-2007-07-103960; Otterson GA, 2010, J THORAC ONCOL, V5, P1644, DOI 10.1097/JTO.0b013e3181ec1713; Palakurthy RK, 2009, MOL CELL, V36, P219, DOI 10.1016/j.molcel.2009.10.009; Pardanani A, 2011, J CLIN ONCOL, V29, P789, DOI 10.1200/JCO.2010.32.8021; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730; Pedersen MT, 2010, TRENDS CELL BIOL, V20, P662, DOI 10.1016/j.tcb.2010.08.011; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Piekarz RL, 2009, J CLIN ONCOL, V27, P5410, DOI 10.1200/JCO.2008.21.6150; Piekarz RL, 2009, CLIN CANCER RES, V15, P3918, DOI 10.1158/1078-0432.CCR-08-2788; Quintas-Cardama A, 2008, LEUKEMIA, V22, P965, DOI 10.1038/leu.2008.91; Quintas-Cardama A, 2010, NAT REV CLIN ONCOL, V7, P433, DOI 10.1038/nrclinonc.2010.87; Quivoron C, 2011, CANCER CELL, V20, P25, DOI 10.1016/j.ccr.2011.06.003; Rahman N, 2005, CURR OPIN GENET DEV, V15, P227, DOI 10.1016/j.gde.2005.04.007; Ramalingam SS, 2009, J THORAC ONCOL, V4, P97, DOI 10.1097/JTO.0b013e318191520c; Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047; Rambaldi A, 2010, BRIT J HAEMATOL, V150, P446, DOI 10.1111/j.1365-2141.2010.08266.x; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Reisman DN, 2003, CANCER RES, V63, P560; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Rodriguez-Nieto S, 2011, HUM MUTAT, V32, pE1999, DOI 10.1002/humu.21415; Roesch A, 2005, MODERN PATHOL, V18, P1249, DOI 10.1038/modpathol.3800413; Rousseau-Merck MF, 1999, CANCER RES, V59, P3152; Rubio-Moscardo F, 2005, BLOOD, V105, P4445, DOI 10.1182/blood-2004-10-3907; Rui LX, 2010, CANCER CELL, V18, P590, DOI 10.1016/j.ccr.2010.11.013; Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646; Sakakura C, 2000, INT J CANCER, V89, P217; Santos FPS, 2010, BLOOD, V115, P1131, DOI 10.1182/blood-2009-10-246363; Schaefer EW, 2009, HAEMATOL-HEMATOL J, V94, P1375, DOI 10.3324/haematol.2009.009217; Schrump DS, 2008, CLIN CANCER RES, V14, P188, DOI 10.1158/1078-0432.CCR-07-0135; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Song J, 2005, APMIS, V113, P264, DOI 10.1111/j.1600-0463.2005.apm_04.x; Sonpavde G, 2007, CLIN GENITOURIN CANC, V5, P457, DOI 10.3816/CGC.2007.n.036; Stadler WM, 2006, CLIN GENITOURIN CANC, V5, P57, DOI 10.3816/CGC.2006.n.018; Stathis A, 2011, CLIN CANCER RES, V17, P1582, DOI 10.1158/1078-0432.CCR-10-1893; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Steine EJ, 2011, J CLIN INVEST, V121, P1748, DOI 10.1172/JCI43169; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Traynor AM, 2009, J THORAC ONCOL, V4, P522, DOI 10.1097/JTO.0b013e3181952478; van der Knaap JA, 2005, MOL CELL, V17, P695, DOI 10.1016/j.molcel.2005.02.013; van der Knaap JA, 2010, MOL CELL BIOL, V30, P736, DOI 10.1128/MCB.01121-09; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Vansteenkiste J, 2008, INVEST NEW DRUG, V26, P483, DOI 10.1007/s10637-008-9131-6; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/NCHEMBIO.599, 10.1038/nchembio.599]; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Verstovsek S, 2010, NEW ENGL J MED, V363, P1117, DOI 10.1056/NEJMoa1002028; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Voso MT, 2009, CLIN CANCER RES, V15, P5002, DOI 10.1158/1078-0432.CCR-09-0494; Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4; Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036; Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268; Wang JK, 2010, GENE DEV, V24, P327, DOI 10.1101/gad.1882610; Wang L, 2011, SCIENCE, V333, P765, DOI 10.1126/science.1201662; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Wartman LD, 2011, J CLIN INVEST, V121, P1445, DOI 10.1172/JCI45284; Wei XM, 2011, NAT GENET, V43, P442, DOI 10.1038/ng.810; Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990; Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4; Weichert W, 2009, CANCER LETT, V280, P168, DOI 10.1016/j.canlet.2008.10.047; Weikert S, 2005, INT J MOL MED, V16, P349; Whitehead RP, 2009, INVEST NEW DRUG, V27, P469, DOI 10.1007/s10637-008-9190-8; Whittaker SJ, 2010, J CLIN ONCOL, V28, P4485, DOI 10.1200/JCO.2010.28.9066; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wijermans PW, 2008, LEUKEMIA RES, V32, P587, DOI 10.1016/j.leukres.2007.08.004; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Woyach JA, 2009, J CLIN ENDOCR METAB, V94, P164, DOI 10.1210/jc.2008-1631; Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763; Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716; Yan XJ, 2011, NAT GENET, V43, P309, DOI 10.1038/ng.788; Yang ZQ, 2000, CANCER RES, V60, P4735; Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208; Yoo CB, 2007, CANCER RES, V67, P6400, DOI 10.1158/0008-5472.CAN-07-0251; Yuge M, 2000, CANCER GENET CYTOGEN, V122, P37, DOI 10.1016/S0165-4608(00)00274-0; Zeng JP, 2010, GASTROENTEROLOGY, V138, P981, DOI 10.1053/j.gastro.2009.10.004; Zhang ZH, 2005, BREAST CANCER RES TR, V94, P11, DOI 10.1007/s10549-005-6001-1; Zhu P, 2007, MOL CELL, V27, P609, DOI 10.1016/j.molcel.2007.07.024; Zhu Q, 2011, NATURE, V477, P179, DOI 10.1038/nature10371; Zhu WG, 2001, CANCER RES, V61, P1327; Zimmermann S, 2007, CANCER RES, V67, P9047, DOI 10.1158/0008-5472.CAN-07-0312; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	257	45	47	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	34					3827	3844		10.1038/onc.2011.552	http://dx.doi.org/10.1038/onc.2011.552			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IV	22139071				2022-12-17	WOS:000307925000001
J	Zagorodna, O; Martin, SM; Rutkowski, DT; Kuwana, T; Spitz, DR; Knudson, CM				Zagorodna, O.; Martin, S. M.; Rutkowski, D. T.; Kuwana, T.; Spitz, D. R.; Knudson, C. M.			2-Deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines	ONCOGENE			English	Article						2-deoxyglucose (2DG); apoptosis; Bcl-2; Bax; BH3 mimetics; oncogenesis	MOUSE B-CELL; MITOCHONDRIAL APOPTOSIS; BH3-ONLY PROTEINS; BH3 DOMAINS; IN-VITRO; 2-DEOXY-D-GLUCOSE; STRESS; BAX; METABOLISM; ACTIVATION	Targeting altered cancer cell metabolism with the glycolysis inhibitor, 2-deoxyglucose (2DG), is a viable therapeutic strategy, but the effects of 2DG on lymphoma cells and the mechanism of action are unknown. Five T-cell lymphoma lines and two B-cell lymphoma lines were shown to be highly sensitive to 2DG. Examination of the cell death pathway demonstrated pro-apoptotic protein Bax 'activation' and caspase cleavage in 2DG-treated cells. However, Q-VD-OPh, a potent inhibitor of caspase activity provided minimal protection from death. In contrast, overexpressing the anti-apoptotic protein Bcl-2 dramatically enhanced the survival of 2DG-treated cells that was negated by a Bcl-2 antagonist. BH3-only members, Bim and Bmf, were upregulated by 2DG, and shRNAs targeting Bim protected from 2DG toxicity demonstrating that Bim is a critical mediator of 2DG toxicity. 2DG also induced GADD153/CHOP expression, a marker of endoplasmic reticulum (ER) stress and a known activator of Bim. Mannose, a reagent known to alleviate ER stress, transiently protected from 2DG-induced cell death. Examination of the effects of 2DG on energy metabolism showed a drop in ATP levels by 30 min that was not affected by either Bcl-2 or mannose. These results demonstrate that ER stress appears to be rate limiting in 2DG-induced cell death in lymphoma cells, and this cell killing is regulated by the Bcl-2 family of proteins. Bcl-2 inhibition combined with 2DG may be an effective therapeutic strategy for lymphoma. Oncogene (2012) 31, 2738-2749; doi: 10.1038/onc.2011.454; published online 10 October 2011	[Zagorodna, O.; Martin, S. M.; Kuwana, T.; Knudson, C. M.] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; [Zagorodna, O.; Spitz, D. R.; Knudson, C. M.] Univ Iowa, Free Radical & Radiat Biol Program, Dept Radiat Oncol, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA; [Rutkowski, D. T.] Univ Iowa, Dept Anat & Cell Biol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Knudson, CM (corresponding author), Univ Iowa, Dept Pathol, 200 Hawkins Dr,1171 ML, Iowa City, IA 52242 USA.	c-knudson@uiowa.edu		Knudson, Charles Michael/0000-0003-3964-5466; Spitz, Douglas/0000-0002-1254-8765; Rutkowski, Thomas/0000-0001-6586-4449	 [CA104695];  [CA133114];  [DK084058];  [GM086389.]; NATIONAL CANCER INSTITUTE [R01CA104695, R01CA133114, P50CA097274, T32CA078586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK084058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM086389] Funding Source: NIH RePORTER	; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by RO1 no. CA104695, RO1 no. CA133114, R01 no. DK084058, and R01 no. GM086389. We thank Dr Chris van de Wetering for assistance in generating lymphoma cell lines, Dr Siegfried Janz and Dr SS Han for B-cell neoplasms, Dr Agshin Taghiyev and Dr Van Tompkins for their advice and assistance with TCL transduction experiments, Dr Craig Kuder and Dr Ray Hohl for antibodies and assistance with ER-stress markers, Heather Tyra for assistance with RT-PCR, Han Du for advice with the Bcl-2 IP experiments, Rebecca Glover and Jacob Wolf for their technical advice on western blotting and Dr Craig Thompson (The Sloan-Kettering Cancer Center) for Bax/Bak double-knockout cells.	Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aykin-Burns N, 2009, BIOCHEM J, V418, P29, DOI 10.1042/BJ20081258; Ben Sahra I, 2010, CANCER RES, V70, P2465, DOI 10.1158/0008-5472.CAN-09-2782; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; CRANE RK, 1954, J BIOL CHEM, V210, P597; Dasmahapatra G, 2009, CANCER BIOL THER, V8, P808, DOI 10.4161/cbt.8.9.8131; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; El Mjiyad N, 2011, ONCOGENE, V30, P253, DOI 10.1038/onc.2010.466; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han SS, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-22; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; Kang MH, 2007, BLOOD, V110, P2057, DOI 10.1182/blood-2007-03-080325; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Kurtoglu M, 2007, MOL CANCER THER, V6, P3049, DOI 10.1158/1535-7163.MCT-07-0310; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Ma YJ, 2004, J CHEM NEUROANAT, V28, P51, DOI 10.1016/j.jchemneu.2003.08.007; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Raden D, 2005, IEE P SYST BIOL, V152, P285, DOI 10.1049/ip-syb:20050048; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Rutkowski DT, 2006, PLOS BIOL, V4, P2024, DOI 10.1371/journal.pbio.0040374; Saeki K, 2000, CELL DEATH DIFFER, V7, P1263, DOI 10.1038/sj.cdd.4400759; Shoemaker AR, 2006, CANCER RES, V66, P8731, DOI 10.1158/0008-5472.CAN-06-0367; Simons AL, 2007, CANCER RES, V67, P3364, DOI 10.1158/0008-5472.CAN-06-3717; Smaili SS, 2003, BRAZ J MED BIOL RES, V36, P183, DOI 10.1590/S0100-879X2003000200004; TOWER DB, 1958, J NEUROCHEM, V3, P185, DOI 10.1111/j.1471-4159.1958.tb12625.x; van de Wetering CI, 2007, CANCER RES, V67, P8081, DOI 10.1158/0008-5472.CAN-07-1666; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Zhang XD, 2006, ANTICANCER RES, V26, P3561	43	45	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	22					2738	2749		10.1038/onc.2011.454	http://dx.doi.org/10.1038/onc.2011.454			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	952DB	21986940	Green Accepted			2022-12-17	WOS:000304769000004
J	de Andrea, CE; Reijnders, CMA; Kroon, HM; de Jong, D; Hogendoorn, PCW; Szuhai, K; Bovee, JVMG				de Andrea, C. E.; Reijnders, C. M. A.; Kroon, H. M.; de Jong, D.; Hogendoorn, P. C. W.; Szuhai, K.; Bovee, J. V. M. G.			Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT	ONCOGENE			English	Article						chondrosarcoma; osteochondroma; EXT1; array-CGH; FISH; bone tumors	HEREDITARY MULTIPLE EXOSTOSES; HEPARAN-SULFATE; MOUSE MODEL; HETEROZYGOSITY; BONE; EXPRESSION; TUMORS; CHROMOSOME-11; INACTIVATION; PROGRESSION	Secondary peripheral chondrosarcoma is the result of malignant transformation of a pre-existing osteochondroma, the most common benign bone tumor. Osteochondromas are caused by genetic abnormalities in EXT1 or EXT2: homozygous deletion of EXT1 characterizes sporadic osteochondromas (non-familial/solitary), and germline mutations in EXT1 or EXT2 combined with loss of heterozygosity define hereditary multiple osteochondromas. While cells with homozygous inactivation of EXT and wild-type cells shape osteochondromas, the cellular composition of secondary peripheral chondrosarcomas and the role of EXT in their formation have remained unclear. We report using a targeted-tiling-resolution oligo-array-CGH (array comparative genomic hybridization) that homozygous deletions of EXT1 or EXT2 are much less frequently detected (2/17, 12%) in sporadic secondary peripheral chondrosarcomas than expected based on the assumption that they originate in sporadic osteochondromas, in which homozygous inactivation of EXT1 is found in similar to 80% of our cases. FISH with an EXT1 probe confirmed that, unlike sporadic osteochondromas, cells from sporadic secondary peripheral chondrosarcomas predominantly retained one (hemizygous deleted loci) or both copies (wild-type) of the EXT1 locus. By immunohistochemistry, we confirm the presence of cells with dysfunctional EXT1 in sporadic osteochondromas and show cells with functional EXT1 in sporadic secondary peripheral chondrosarcomas. These immuno results were verified in osteochondromas and secondary peripheral chondrosarcomas in the setting of hereditary multiple osteochondromas. Our data therefore point to a model of oncogenesis in which the osteochondroma creates a niche in which wild-type cells with functional EXT are predisposed to acquire other mutations giving rise to secondary peripheral chondrosarcoma, indicating that EXT-independent mechanisms are involved in the pathogenesis of secondary peripheral chondrosarcoma. Oncogene (2012) 31, 1095-1104; doi:10.1038/onc.2011.311; published online 1 August 2011	[de Andrea, C. E.; Reijnders, C. M. A.; Hogendoorn, P. C. W.; Bovee, J. V. M. G.] Leiden Univ, Dept Pathol, Med Ctr, NL-2300 RC Leiden, Netherlands; [Kroon, H. M.] Leiden Univ, Dept Radiol, Med Ctr, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Bovee, JVMG (corresponding author), Leiden Univ, Dept Pathol, Med Ctr, POB 9600,L1-Q, NL-2300 RC Leiden, Netherlands.	j.v.m.g.bovee@lumc.nl	Hogendoorn, Pancras/O-6494-2019; Szuhai, Karoly/A-1100-2008; Hogendoorn, Pancras C.W./H-5859-2015	Hogendoorn, Pancras/0000-0002-1513-8104; Szuhai, Karoly/0000-0002-1228-4245; Hogendoorn, Pancras C.W./0000-0002-1513-8104; de Jong, Danielle/0000-0003-4003-5593; Bovee, Judith/0000-0003-1155-0481	Netherlands Organization for Scientific Research [917-76-315]; EuroBoNeT [LSHC-CT-2006-018814]	Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); EuroBoNeT(European CommissionEuropean Commission Joint Research Centre)	We acknowledge the expert technical work of Marja van der Burg, Inge Briaire-de Bruijn, Maayke van Ruler and Pauline M Wijers-Koster (Leiden University Medical Center, Leiden, The Netherlands). We also thank the Netherlands Committee on Bone Tumors. Professor E Bakker is acknowledged for EXT mutation analysis. This study was supported by Netherlands Organization for Scientific Research (917-76-315 to CMAR and JVMGB) and by EuroBoNeT (a European Commission-granted European Network of Excellence for studying the pathology and genetics of bone tumors; grant number: LSHC-CT-2006-018814 (to CEA, JVMGB, DJ, KS and PCWH).	Bernard SA, 2010, RADIOLOGY, V255, P857, DOI 10.1148/radiol.10082120; Bertoni F., 2002, WHO CLASSIFICATION T, P247; Bovee JVMG, 2010, NAT REV CANCER, V10, P481, DOI 10.1038/nrc2869; Bovee JVMG, 2000, AM J PATHOL, V157, P1587, DOI 10.1016/S0002-9440(10)64796-7; Bovee JVMG, 1999, GENE CHROMOSOME CANC, V26, P237; Bulow HE, 2006, ANNU REV CELL DEV BI, V22, P375, DOI 10.1146/annurev.cellbio.22.010605.093433; Clement A, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000136; de Andrea CE, 2011, J PATHOL, V224, P160, DOI 10.1002/path.2886; de Andrea CE, 2010, LAB INVEST, V90, P1091, DOI 10.1038/labinvest.2010.81; Dorfman HD, 2002, WHO CLASSIFICATION T, P226; EVANS HL, 1977, CANCER-AM CANCER SOC, V40, P818, DOI 10.1002/1097-0142(197708)40:2<818::AID-CNCR2820400234>3.0.CO;2-B; Hallor KH, 2009, CLIN CANCER RES, V15, P2685, DOI 10.1158/1078-0432.CCR-08-2330; Hameetman L, 2007, J PATHOL, V211, P399, DOI 10.1002/path.2127; Hameetman L, 2007, JNCI-J NATL CANCER I, V99, P396, DOI 10.1093/jnci/djk067; HECHT JT, 1995, AM J HUM GENET, V56, P1125; Jones KB, 2010, P NATL ACAD SCI USA, V107, P2054, DOI 10.1073/pnas.0910875107; Khurana J, 2002, WHO CLASSIFICATION T, V4, P234; Matsumoto K, 2010, P NATL ACAD SCI USA, V107, P10932, DOI 10.1073/pnas.0914642107; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Mohseny AB, 2010, GENE CHROMOSOME CANC, V49, P1095, DOI 10.1002/gcc.20817; Pansuriya TC, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-2; Raaijmakers MHGP, 2011, HAEMATOL-HEMATOL J, V96, P1041, DOI 10.3324/haematol.2010.028035; Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851; RASKIND WH, 1995, AM J HUM GENET, V56, P1132; Reijmers RM, 2010, BLOOD, V115, P601, DOI 10.1182/blood-2009-02-204396; Reijnders CMA, 2010, AM J PATHOL, V177, P1946, DOI 10.2353/ajpath.2010.100296; Szuhai K, 2011, HUM MUTAT, V32, pE2036, DOI 10.1002/humu.21423; Szuhai K, 2009, CLIN CANCER RES, V15, P2259, DOI 10.1158/1078-0432.CCR-08-2184; van den Berg H, 2008, J PEDIATR ORTHOPED, V28, P29, DOI 10.1097/BPO.0b013e3181558cb5; Ventura RA, 2006, J MOL DIAGN, V8, P141, DOI 10.2353/jmoldx.2006.050083; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6; Zuntini M, 2010, ONCOGENE, V29, P3827, DOI 10.1038/onc.2010.135	32	45	45	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	9					1095	1104		10.1038/onc.2011.311	http://dx.doi.org/10.1038/onc.2011.311			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21804604	Green Published			2022-12-17	WOS:000300945900003
J	Eppinga, RD; Krueger, EW; Weller, SG; Zhang, L; Cao, H; McNiven, MA				Eppinga, R. D.; Krueger, E. W.; Weller, S. G.; Zhang, L.; Cao, H.; McNiven, M. A.			Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma	ONCOGENE			English	Article						dynamin 2 (Dyn2); pancreatic ductal adenocarcinoma (PDAC); cell migration; invasion; metastasis; Src	ACTIN-BINDING PROTEIN; FOCAL ADHESION; TYROSINE PHOSPHORYLATION; CELL-MIGRATION; SRC; ENDOCYTOSIS; CANCER; CYTOSKELETON; ACTIVATION; INHIBITORS	Pancreatic ductal tumors invade local parenchyma and metastasize to distant organs. Src-mediated tyrosine kinase signaling pathways promote pancreatic ductal adenocarcinoma (PDAC) metastasis, though the molecular mechanisms supporting this invasive process are poorly understood and represent important and novel therapeutic targets. The large GTPase Dynamin 2 (Dyn2), a Src-kinase substrate, regulates membrane-cytoskeletal dynamics although it is yet to be defined if it contributes to tumor cell migration and invasion. Therefore, the goal of this study was to test if Dyn2 is upregulated in human pancreatic tumors and to define its role in cell migration and metastatic invasion using in vitro assays and nude mouse models. Histological analysis showed that 81% of 85 patients had elevated Dyn2 in PDAC. To test if Dyn2 overexpression alters metastatic properties of human pancreatic tumor cells, stable clones of BxPC-3 cells overexpressing either wild-type Dyn2 or a phosphorylation-deficient mutant Dyn2Y(231/597) F known to attenuate Dyn2 function, were generated and analyzed. Importantly, tumor cells overexpressing Dyn2 protruded lamellipodia at twice the rate, migrated faster (180%) and farther (2.5-fold greater distance) on glass and through transwell chambers (2-3-fold more cells through the filter) compared with cells expressing Dyn2Y(231/597) F or vector alone. Further, depletion of Dyn2 and dynamin inhibitors Myristyl trimethyl ammonium bromides and Dynasore significantly reduced cell migration, wound healing and invasion in transwell assays compared with controls. To test the metastatic potential conferred by increased Dyn2 expression, the BxPC-3 cell lines were implanted orthotopically into the pancreas of nude mice. Cells expressing Dyn2-green fluorescent protein exhibited a threefold increase in large distal tumors compared with cells expressing Dyn2Y(231/597) F or vector alone. Finally, histological analysis revealed that Dyn2 is upregulated in 60% of human metastatic pancreatic tumors. These findings are the first to implicate dynamin in any neoplastic condition and to directly demonstrate a role for this mechanoenzyme in invasive cell migration. Oncogene (2012) 31, 1228-1241; doi:10.1038/onc.2011.329; published online 15 August 2011	[Eppinga, R. D.; Krueger, E. W.; Weller, S. G.; Cao, H.; McNiven, M. A.] Mayo Clin, Dept Biochem & Mol Biol, Ctr Digest Dis, Rochester, MN 55905 USA; [Zhang, L.] Mayo Clin, Dept Lab Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	McNiven, MA (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, Ctr Digest Dis, 200 1st St SW,Guggenheim 1637, Rochester, MN 55905 USA.	mcniven.mark@mayo.edu			National Institutes of Health NCI [R01-CA104125, T32-DK007198]; Mayo Clinic Center for Cell Signaling in Gastroenterology (NIDDK) [P30DK084567]; Mayo Clinic SPORE in Pancreatic Cancer [P50 CA 102701]; Lustgarten Foundation for Pancreatic Cancer Research; Fraternal Order of the Eagles; NATIONAL CANCER INSTITUTE [R01CA104125, P50CA102701, P20CA102701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK084567, T32DK007198] Funding Source: NIH RePORTER	National Institutes of Health NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Mayo Clinic Center for Cell Signaling in Gastroenterology (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Mayo Clinic SPORE in Pancreatic Cancer; Lustgarten Foundation for Pancreatic Cancer Research; Fraternal Order of the Eagles; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful for support from the National Institutes of Health NCI R01-CA104125 (MAM), T32-DK007198 (RDE), the Mayo Clinic Center for Cell Signaling in Gastroenterology (NIDDK P30DK084567), the Mayo Clinic SPORE in Pancreatic Cancer (P50 CA 102701), the Lustgarten Foundation for Pancreatic Cancer Research and the Fraternal Order of the Eagles.	Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Alves F, 2001, PANCREAS, V23, P227, DOI 10.1097/00006676-200110000-00002; Bloomston M, 2006, DIGEST SURG, V23, P74, DOI 10.1159/000093497; Bouvet M, 2000, CLIN EXP METASTAS, V18, P213, DOI 10.1023/A:1006767405609; Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Cao H, 2010, MOL CELL BIOL, V30, P781, DOI 10.1128/MCB.00330-09; Chao WT, 2009, FEBS LETT, V583, P1337, DOI 10.1016/j.febslet.2009.03.037; Dancer J, 2007, ONCOL REP, V18, P151; Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Ezratty EJ, 2009, J CELL BIOL, V187, P733, DOI 10.1083/jcb.200904054; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Giannone G, 2004, CELL, V116, P431, DOI 10.1016/S0092-8674(04)00058-3; Gomez TS, 2005, NAT IMMUNOL, V6, P261, DOI 10.1038/ni1168; Hakam A, 2003, DIGEST DIS SCI, V48, P1972, DOI 10.1023/A:1026122421369; Hansen CG, 2009, J CELL SCI, V122, P1713, DOI 10.1242/jcs.033951; Harada T, 2008, ONCOGENE, V27, P1951, DOI 10.1038/sj.onc.1210832; Hasegawa K, 2006, CLIN CANCER RES, V12, P6170, DOI 10.1158/1078-0432.CCR-06-0992; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hill TA, 2004, BIOORG MED CHEM LETT, V14, P3275, DOI 10.1016/j.bmcl.2004.03.096; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Joshi S, 2010, MOL CANCER THER, V9, P1995, DOI 10.1158/1535-7163.MCT-10-0161; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Kim DJ, 2006, J BIOL CHEM, V281, P617, DOI 10.1074/jbc.M504450200; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kim Y, 2005, J NEUROSCI, V25, P9515, DOI 10.1523/JNEUROSCI.1643-05.2005; Kruchten AE, 2006, J CELL SCI, V119, P1683, DOI 10.1242/jcs.02963; Krueger EW, 2003, MOL BIOL CELL, V14, P1085, DOI 10.1091/mbc.E02-08-0466; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; Machesky LM, 2008, FEBS LETT, V582, P2102, DOI 10.1016/j.febslet.2008.03.039; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Mihaljevic AL, 2010, LANGENBECK ARCH SURG, V395, P295, DOI 10.1007/s00423-010-0622-5; Mooren OL, 2009, J BIOL CHEM, V284, P23995, DOI 10.1074/jbc.M109.024398; Morton JP, 2010, GASTROENTEROLOGY, V139, P292, DOI 10.1053/j.gastro.2010.03.034; Muders MH, 2006, CANCER RES, V66, P10264, DOI 10.1158/0008-5472.CAN-06-2321; Newton AJ, 2006, P NATL ACAD SCI USA, V103, P17955, DOI 10.1073/pnas.0606212103; Nieto J, 2008, ONCOLOGIST, V13, P562, DOI 10.1634/theoncologist.2007-0181; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Quan A, 2007, MOL PHARMACOL, V72, P1425, DOI 10.1124/mol.107.034207; Schafer DA, 2004, TRAFFIC, V5, P463, DOI 10.1111/j.1600-0854.2004.00199.x; Schlunck G, 2004, MOL BIOL CELL, V15, P256, DOI 10.1091/mbc.E03-01-0019; Shajahan AN, 2004, J BIOL CHEM, V279, P20392, DOI 10.1074/jbc.M308710200; Thybusch-Bernhardt A, 2001, Int J Surg Investig, V2, P393; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang Y, 2011, MOL BIOL CELL, V22, P1529, DOI 10.1091/mbc.E10-09-0785; Weller SG, 2010, P NATL ACAD SCI USA, V107, P5863, DOI 10.1073/pnas.0915123107; Wu M, 2010, NAT CELL BIOL, V12, P902, DOI 10.1038/ncb2094; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yoo JY, 2005, BIOCHEM BIOPH RES CO, V328, P424, DOI 10.1016/j.bbrc.2004.12.179	63	45	45	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	10					1228	1241		10.1038/onc.2011.329	http://dx.doi.org/10.1038/onc.2011.329			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21841817	Green Accepted			2022-12-17	WOS:000301344600003
J	Gu, L; Zhang, H; He, J; Li, J; Huang, M; Zhou, M				Gu, L.; Zhang, H.; He, J.; Li, J.; Huang, M.; Zhou, M.			MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells	ONCOGENE			English	Article						MYCN; MDM2; neuroblastoma	DIRECT TRANSCRIPTIONAL TARGET; RING FINGER DOMAIN; N-MYC; BINDING PROTEIN; IN-VIVO; EXPRESSION; P53; HUD; AMPLIFICATION; INDUCTION	The MYCN gene has a critical role in determining the clinical behavior of neuroblastoma. Although it is known that genomic amplification occurs in high-risk subsets, it remains unclear how MYCN expression is regulated in the pathogenesis of neuroblastomas. Here, we report that MYCN expression was regulated by the oncoprotein MDM2 at the post-transcriptional level and was associated with neuroblastoma cell growth. Increasing MDM2 by ectopic overexpression in the cytoplasm enhanced both mRNA and protein expression of MYCN. Mechanistic studies found that the C-terminal RING domain of the MDM2 protein bound to the MYCN mRNA's AREs within the 3 ' UTR and increased MYCN 3 ' UTR-mediated mRNA stability and translation. Conversely, MDM2 silencing by specific siRNA rendered the MYCN mRNA unstable and reduced the abundance of the MYCN protein in MYCN-amplified neuroblastoma cell lines. Importantly, this MDM2 silencing resulted in a remarkable inhibition of neuroblastoma cell growth and induction of cell death through a p53-independent pathway. Our results indicate that MDM2 has a p53-independent role in the regulation of both MYCN mRNA stabilization and its translation, suggesting that MDM2-mediated MYCN expression is one mechanism associated with growth of MYCN-associated neuroblastoma and disease progression. Oncogene (2012) 31, 1342-1353; doi:10.1038/onc.2011.343; published online 8 August 2011	[Zhou, M.] Emory Univ, Div Pediat Hematol Oncol, Sch Med, Dept Pediat,Aflac Canc Ctr, Atlanta, GA 30322 USA; Emory Univ, Blood Disorders Serv, Sch Med, Atlanta, GA 30322 USA	Emory University; Emory University	Zhou, M (corresponding author), Emory Univ, Div Pediat Hematol Oncol, Sch Med, Dept Pediat,Aflac Canc Ctr, 2015 Uppergate Dr, Atlanta, GA 30322 USA.	mzhou@emory.edu			National Institutes of Health [R01 CA123490, R01CA143107]; CURE; NATIONAL CANCER INSTITUTE [R01CA123490, R01CA143107] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CURE; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health (R01 CA123490 and R01CA143107 to MZ) and CURE (MZ and LG).	Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; Anderson JJ, 2007, INT J ONCOL, V31, P545; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770; Carr J, 2006, CANCER RES, V66, P2138, DOI 10.1158/0008-5472.CAN-05-2623; Cattelani S, 2008, CLIN CANCER RES, V14, P3248, DOI 10.1158/1078-0432.CCR-07-4725; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen LD, 2010, CANCER RES, V70, P1377, DOI 10.1158/0008-5472.CAN-09-2598; Chen ZW, 2009, NEOPLASIA, V11, P753, DOI 10.1593/neo.09466; Cobbold LC, 2008, MOL CELL BIOL, V28, P40, DOI 10.1128/MCB.01298-07; CORVI R, 1995, ONCOGENE, V10, P1081; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Fornaro M, 2007, ANN ANAT, V189, P223, DOI 10.1016/j.aanat.2006.11.004; Gu LB, 2009, CANCER CELL, V15, P363, DOI 10.1016/j.ccr.2009.03.002; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hogarty MD, 2003, CANCER LETT, V197, P173, DOI 10.1016/S0304-3835(03)00103-4; Horvilleur E, 2008, NUCLEIC ACIDS RES, V36, P4222, DOI 10.1093/nar/gkn394; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Lai ZH, 1998, BIOCHEMISTRY-US, V37, P17005, DOI 10.1021/bi980596r; Lazarova DL, 1999, ONCOGENE, V18, P2703, DOI 10.1038/sj.onc.1202621; Manohar CF, 2002, J BIOL CHEM, V277, P1967, DOI 10.1074/jbc.M106966200; Matthay KK, 2000, J CLIN ONCOL, V18, P3591, DOI 10.1200/JCO.2000.18.21.3591; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meek DW, 2003, MOL CANCER RES, V1, P1017; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Peirce SK, 2009, INT J ONCOL, V34, P1395, DOI 10.3892/ijo_00000267; Poyurovsky MV, 2003, MOL CELL, V12, P875, DOI 10.1016/S1097-2765(03)00400-3; Ross RA, 1997, EUR J CANCER, V33, P2071, DOI 10.1016/S0959-8049(97)00331-6; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Sivak LE, 1997, ONCOGENE, V15, P1937, DOI 10.1038/sj.onc.1201363; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; Tang XX, 2006, CANCER RES, V66, P2826, DOI 10.1158/0008-5472.CAN-05-0854; Thompson J, 1997, CLIN CANCER RES, V3, P423; Wang XQ, 2001, NAT STRUCT BIOL, V8, P141, DOI 10.1038/84131; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Zhang Z, 2005, CURR CANCER DRUG TAR, V5, P9, DOI 10.2174/1568009053332618	39	45	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	11					1342	1353		10.1038/onc.2011.343	http://dx.doi.org/10.1038/onc.2011.343			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21822304	Green Accepted			2022-12-17	WOS:000301780000002
J	Zaric, J; Joseph, JM; Tercier, S; Sengstag, T; Ponsonnet, L; Delorenzi, M; Ruegg, C				Zaric, J.; Joseph, J-M; Tercier, S.; Sengstag, T.; Ponsonnet, L.; Delorenzi, M.; Rueegg, C.			Identification of MAGI1 as a tumor-suppressor protein induced by cyclooxygenase-2 inhibitors in colorectal cancer cells	ONCOGENE			English	Article						COX-2; Wnt signaling; metastasis; colorectal cancer; tumor suppressor	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; INTEGRIN-MEDIATED ADHESION; GUANYLATE KINASE; SCAFFOLDING MOLECULE; TISSUE POLARITY; BETA-CATENIN; PDZ DOMAIN; PREVENTION; CELECOXIB; GROWTH	Cyclooxyganase-2 (COX-2), a rate-limiting enzyme in the prostaglandin synthesis pathway, is overexpressed in many cancers and contributes to cancer progression through tumor cell-autonomous and paracrine effects. Regular use of non-steroidal anti-inflammatory drugs or selective COX-2 inhibitors (COXIBs) reduces the risk of cancer development and progression, in particular of the colon. The COXIB celecoxib is approved for adjunct therapy in patients with Familial adenomatous polyposis at high risk for colorectal cancer (CRC) formation. Long-term use of COXIBs, however, is associated with potentially severe cardiovascular complications, which hampers their broader use as preventive anticancer agents. In an effort to better understand the tumor-suppressive mechanisms of COXIBs, we identified MAGUK with Inverted domain structure-1 (MAGI1), a scaffolding protein implicated in the stabilization of adherens junctions, as a gene upregulated by COXIB in CRC cells and acting as tumor suppressor. Overexpression of MAGI1 in CRC cell lines SW480 and HCT116 induced an epithelial-like morphology; stabilized E-cadherin and beta-catenin localization at cell-cell junctions; enhanced actin stress fiber and focal adhesion formation; increased cell adhesion to matrix proteins and suppressed Wnt signaling, anchorage-independent growth, migration and invasion in vitro. Conversely, MAGI1 silencing decreased E-cadherin and beta-catenin localization at cell-cell junctions; disrupted actin stress fiber and focal adhesion formation; and enhanced Wnt signaling, anchorage-independent growth, migration and invasion in vitro. MAGI1 overexpression suppressed SW480 and HCT116 subcutaneous primary tumor growth, attenuated primary tumor growth and spontaneous lung metastasis in an orthotopic model of CRC, and decreased the number and size of metastatic nodules in an experimental model of lung metastasis. Collectively, these results identify MAG1 as a COXIB-induced inhibitor of the Wnt/beta-catenin signaling pathway, with tumor-suppressive and anti-metastatic activity in experimental colon cancer. Oncogene (2012) 31, 48-59; doi: 10.1038/onc.2011.218; published online 13 June 2011	[Zaric, J.; Ponsonnet, L.; Rueegg, C.] Univ Fribourg UNIFR, Dept Med, Fac Sci, CH-1700 Fribourg, Switzerland; [Zaric, J.; Ponsonnet, L.; Rueegg, C.] Univ Lausanne UNIL, Univ Med Ctr CHUV, Multidisciplinary Oncol Ctr CePO, Div Expt Oncol, Lausanne, Switzerland; [Zaric, J.; Delorenzi, M.; Rueegg, C.] Ecole Polytech Fed Lausanne EPFL, Swiss Inst Expt Canc Res ISREC, Natl Ctr Competence Res NCCR, Lausanne, Switzerland; [Joseph, J-M; Tercier, S.] Univ Lausanne UNIL, Univ Med Ctr CHUV, Dept Pediat Surg, Lausanne, Switzerland; [Sengstag, T.; Delorenzi, M.] Swiss Inst Bioinformat SIB, Lausanne, Switzerland	University of Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; University of Lausanne; Swiss Institute of Bioinformatics	Ruegg, C (corresponding author), Univ Fribourg UNIFR, Dept Med, Fac Sci, 1 Rue Albert Gockel, CH-1700 Fribourg, Switzerland.	curzio.ruegg@unifr.ch			Medic Foundation; National Center for Competence in Research (NCCR, Molecular Oncology, a research instrument of the Swiss National Science Foundation); European Union [HEALTH-F2-2008-201662]; Swiss Cancer League [OCS 020020-02-2007]	Medic Foundation; National Center for Competence in Research (NCCR, Molecular Oncology, a research instrument of the Swiss National Science Foundation); European Union(European Commission); Swiss Cancer League	We thank Drs M Aguet, Y Hata, L Naldini, A Follenzi and R Iggo for sharing reagents; F Derouet and D Uldry for invaluable technical assistance; N Rives for proof reading the paper and Pfizer for providing celecoxib. This work was supported by grants from the Medic Foundation, the National Center for Competence in Research (NCCR, Molecular Oncology, a research instrument of the Swiss National Science Foundation), the European Union under the auspices of the FP7 collaborative project TuMIC (contract number HEALTH-F2-2008-201662) and by the Swiss Cancer League (OCS 020020-02-2007).	Abassi YA, 2009, CHEM BIOL, V16, P712, DOI 10.1016/j.chembiol.2009.05.011; Araki Y, 2003, CANCER RES, V63, P728; Bertagnolli MM, 2009, CANCER PREV RES, V2, P310, DOI 10.1158/1940-6207.CAPR-08-0206; Bieler G, 2007, ONCOGENE, V26, P5722, DOI 10.1038/sj.onc.1210354; Buchanan FG, 2006, CANCER CELL, V9, P6, DOI 10.1016/j.ccr.2005.12.029; Cabodi S, 2010, ADV EXP MED BIOL, V674, P43; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Cha YI, 2007, ANNU REV MED, V58, P239, DOI 10.1146/annurev.med.57.121304.131253; Chastre E, 2009, FASEB J, V23, P916, DOI 10.1096/fj.08-106344; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cuzick J, 2009, LANCET ONCOL, V10, P501, DOI 10.1016/S1470-2045(09)70035-X; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Futaki N, 1997, INFLAMM RES, V46, P496, DOI 10.1007/s000110050232; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Howe LR, 1999, CANCER RES, V59, P1572; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Ilyas M, 1999, EUR J CANCER, V35, P1986, DOI 10.1016/S0959-8049(99)00298-1; Jacoby RF, 2000, CANCER RES, V60, P5040; Jones MK, 1999, NAT MED, V5, P1418; Kawajiri A, 2000, BIOCHEM BIOPH RES CO, V273, P712, DOI 10.1006/bbrc.2000.3002; Koch A, 2004, J PATHOL, V204, P546, DOI 10.1002/path.1662; Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje; Laura RP, 2002, EXP CELL RES, V275, P155, DOI 10.1006/excr.2002.5475; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Mino A, 2000, GENES CELLS, V5, P1009, DOI 10.1046/j.1365-2443.2000.00385.x; Monnier Y, 2008, CANCER RES, V68, P7323, DOI 10.1158/0008-5472.CAN-08-0841; Noda M, 2002, J GASTROENTEROL, V37, P896, DOI 10.1007/s005350200151; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; Shao JY, 2003, CANCER RES, V63, P5218; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stolfi C, 2008, BIOCHEM PHARMACOL, V75, P668, DOI 10.1016/j.bcp.2007.09.020; Swamy MV, 2006, CANCER RES, V66, P7370, DOI 10.1158/0008-5472.CAN-05-4619; Taylor J, 1998, GENETICS, V150, P199; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Tuynman JB, 2008, CANCER RES, V68, P1213, DOI 10.1158/0008-5472.CAN-07-5172; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Cespedes MV, 2007, AM J PATHOL, V170, P1077, DOI 10.2353/ajpath.2007.060773; Wang D, 2006, GUT, V55, P115, DOI 10.1136/gut.2004.047100; Wang DZ, 2004, CELL CYCLE, V3, P1512, DOI 10.4161/cc.3.12.1288; Wolff T, 1998, DEVELOPMENT, V125, P1149; Yao R, 2004, ONCOGENE, V23, P6023, DOI 10.1038/sj.onc.1207817; Zaric J, 2005, J BIOL CHEM, V280, P1077, DOI 10.1074/jbc.M410006200	51	45	47	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	1					48	59		10.1038/onc.2011.218	http://dx.doi.org/10.1038/onc.2011.218			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21666716	Green Published, Green Submitted			2022-12-17	WOS:000299176200005
J	Tanizaki, J; Okamoto, I; Fumita, S; Okamoto, W; Nishio, K; Nakagawa, K				Tanizaki, J.; Okamoto, I.; Fumita, S.; Okamoto, W.; Nishio, K.; Nakagawa, K.			Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification	ONCOGENE			English	Article						BIM; survivin; HER2 amplification; PIK3CA mutation; apoptosis; breast cancer	MAMMARY EPITHELIAL-CELLS; DUAL PI3K/MTOR INHIBITOR; PIK3CA MUTATIONS; NVP-BEZ235; RESISTANCE; GENE; EXPRESSION; ONCOGENE; EFFICACY; THERAPY	Lapatinib, a dual tyrosine kinase inhibitor of the epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2), is clinically active in patients with breast cancer positive for HER2 amplification. The mechanism of this anti-tumor action has remained unclear, however. We have now investigated the effects of lapatinib in HER2 amplification-positive breast cancer cells with or without an activating PIK3CA mutation. Lapatinib induced apoptosis in association with upregulation of the pro-apoptotic protein Bcl-2 interacting mediator of cell death (BIM) through inhibition of the MEK-ERK signaling pathway in breast cancer cells with HER2 amplification. RNA interference (RNAi)-mediated depletion of BIM inhibited lapatinib-induced apoptosis, implicating BIM induction in this process. The proapoptotic effect of lapatinib was less pronounced in cells with a PIK3CA mutation than in those without one. Lapatinib failed to inhibit AKT phosphorylation in PIK3CA mutant cells, likely because of hyperactivation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway by the mutation. Depletion of PIK3CA (a catalytic subunit of PI3K) revealed that survivin expression is regulated by the PI3K pathway in these cells, suggesting that insufficient inhibition of PI3K-survivin signaling is responsible for the limited pro-apoptotic effect of lapatinib in HER2 amplification-positive cells with a PIK3CA mutation. Consistent with this notion, depletion of survivin by RNAi or treatment with a PI3K inhibitor markedly increased the level of apoptosis in PIK3CA mutant cells treated with lapatinib. Our results thus suggest that inhibition of both PI3K-survivin and MEK-ERK-BIM pathways is required for effective induction of apoptosis in breast cancer cells with HER2 amplification. Oncogene (2011) 30, 4097-4106; doi:10.1038/onc.2011.111; published online 18 April 2011	[Tanizaki, J.; Okamoto, I.; Fumita, S.; Okamoto, W.; Nakagawa, K.] Kinki Univ, Dept Med Oncol, Fac Med, Osaka, Japan; [Nishio, K.] Kinki Univ, Dept Genome Biol, Fac Med, Osaka, Japan	Kindai University (Kinki University); Kindai University (Kinki University)	Okamoto, I (corresponding author), Kinki Univ, Dept Med Oncol, Fac Med, 377-2 Ohno Higashi, Osaka, Japan.	chi-okamoto@dotd.med.kindai.ac.jp	Okamoto, Wataru/AIE-0808-2022	Fumita, Soichi/0000-0003-0253-0681				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Brachmann SM, 2009, P NATL ACAD SCI USA, V106, P22299, DOI 10.1073/pnas.0905152106; Burris HA, 2009, CLIN CANCER RES, V15, P6702, DOI 10.1158/1078-0432.CCR-09-0369; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; Cragg MS, 2008, J CLIN INVEST, V118, P3651, DOI 10.1172/JCI35437; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Di Leo A, 2008, J CLIN ONCOL, V26, P5544, DOI 10.1200/JCO.2008.16.2578; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gomez HL, 2008, J CLIN ONCOL, V26, P2999, DOI 10.1200/JCO.2007.14.0590; Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Kanwar JR, 2001, J NATL CANCER I, V93, P1541, DOI 10.1093/jnci/93.20.1541; Kataoka Y, 2010, ANN ONCOL, V21, P255, DOI 10.1093/annonc/mdp304; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; LoRusso PM, 2008, J CLIN ONCOL, V26, P3051, DOI 10.1200/JCO.2007.14.9633; McKenzie JA, 2010, CANCER RES, V70, P7927, DOI 10.1158/0008-5472.CAN-10-0194; Olie RA, 2000, CANCER RES, V60, P2805; PEIRCE SK, 2010, CANCER CHEMOTH PHARM, DOI DOI 10.1007/S00280-1010-1486-7; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Slamon D J, 1990, Cancer Invest, V8, P253, DOI 10.3109/07357909009017573; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Tanaka K, 2000, CLIN CANCER RES, V6, P127; Toi M, 2009, BRIT J CANCER, V101, P1676, DOI 10.1038/sj.bjc.6605343; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Zhang HJ, 2008, BREAST CANCER RES TR, V112, P217, DOI 10.1007/s10549-007-9847-6; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102	37	45	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	39					4097	4106		10.1038/onc.2011.111	http://dx.doi.org/10.1038/onc.2011.111			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	826ME	21499301				2022-12-17	WOS:000295357500005
J	Palmieri, D; Valentino, T; D'Angelo, D; De Martino, I; Postiglione, I; Pacelli, R; Croce, CM; Fedele, M; Fusco, A				Palmieri, D.; Valentino, T.; D'Angelo, D.; De Martino, I.; Postiglione, I.; Pacelli, R.; Croce, C. M.; Fedele, M.; Fusco, A.			HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents	ONCOGENE			English	Article						HMGA; ATM; DNA repair	DNA-DAMAGE RESPONSE; GROUP-A PROTEINS; ATAXIA-TELANGIECTASIA; RADIOSENSITIZING AGENT; IONIZING-RADIATION; KINASE; GENE; P53; TARGET; TUMORIGENESIS	DNA-damaging therapies represent a keystone in cancer treatment. Unfortunately, many tumors often relapse because of a group of cancer cells, which are resistant to conventional therapies. High-mobility group A (HMGA) proteins has a key role in cell transformation, and their overexpression is a common feature of human malignant neoplasias, representing a poor prognostic index often correlated to anti-cancer drug resistance. Our previous results demonstrated that HMGA1 is a substrate of ataxia-telangiectasia mutated (ATM), the main cellular sensor of genotoxic stress. Here we also report that HMGA2, the other member of the HMGA family, is a novel substrate of ATM. Interestingly, we found that HMGA proteins positively regulate ATM gene expression. Moreover, induction of ATM kinase activity by DNA-damaging agents enhances HMGA-dependent transcriptional activation of ATM promoter, suggesting that ATM expression is modulated by a DNA-damage-and HMGA-dependent positive feedback loop. Finally, inhibition of HMGA expression in mouse embryonic fibroblasts and in cancer cells strongly reduces ATM protein levels, impairing the cellular DNA-damage response and enhancing the sensitivity to DNA-damaging agents. These findings indicate this novel HMGA-ATM pathway as a new potential target to improve the effectiveness of conventional anti-neoplastic treatments on the genotoxic-drug resistant cancer cells. Oncogene (2011) 30, 3024-3035; doi: 10.1038/onc.2011.21; published online 21 February 2011	[Palmieri, D.; Valentino, T.; D'Angelo, D.; De Martino, I.; Postiglione, I.; Fedele, M.; Fusco, A.] Univ Naples Federico II, CNR, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale,Fac Med & Chi, Naples, Italy; [Pacelli, R.] CNR, Ist Biostrutture & Bioimmagini, I-80125 Naples, Italy; [Palmieri, D.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA; [Fusco, A.] NOGEC Naples Oncogenom Ctr CEINGE, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR); James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Fusco, A (corresponding author), CNR, Ist Oncol & Endocrinol Sperimentale G Salvatore, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	D'Angelo, Daniela/GVT-9143-2022; Pacelli, Roberto/AFS-0333-2022; Young, Richard A/F-6495-2012; Fedele, Monica/C-1417-2015	Young, Richard A/0000-0001-8855-8647; Fedele, Monica/0000-0002-9171-1312; Pacelli, Roberto/0000-0002-2048-7675; Fusco, Alfredo/0000-0003-3332-5197; Palmieri, Dario/0000-0002-0797-4268	Associazione Italiana Ricerca sul Cancro (AIRC); Fondazione Italiana per la Ricerca sul Cancro (FIRC)	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Italiana per la Ricerca sul Cancro (FIRC)(Fondazione AIRC per la ricerca sul cancro)	We thank V Costanzo for revision of the paper and I Pellegrino for technical support. We are grateful to MB Kastan for providing the pFLAG-ATM expression construct and to D Ginsberg for the pLuc-ATM reporter vector. This work was supported by grants from the Associazione Italiana Ricerca sul Cancro (AIRC). DP is recipient of a fellowship from Fondazione Italiana per la Ricerca sul Cancro (FIRC).	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; Berlingieri MT, 2002, ONCOGENE, V21, P2971, DOI 10.1038/sj.onc.1205368; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chiappetta G, 1996, ONCOGENE, V13, P2439; Crescenzi E, 2008, CLIN CANCER RES, V14, P1877, DOI 10.1158/1078-0432.CCR-07-4298; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Fedele M, 2001, CANCER RES, V61, P4583; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; Fedele M, 2006, CANCER CELL, V9, P459, DOI 10.1016/j.ccr.2006.04.024; Fedele M, 2010, BBA-GENE REGUL MECH, V1799, P48, DOI 10.1016/j.bbagrm.2009.11.007; Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271; Gueven N, 2003, GENE CHROMOSOME CANC, V38, P157, DOI 10.1002/gcc.10261; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hoyos JM, 2004, CANCER RES, V64, P5728, DOI 10.1158/0008-5472.CAN-04-1410; Jackson SP, 2009, BIOCHEM SOC T, V37, P483, DOI 10.1042/BST0370483; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Kuhne M, 2004, CANCER RES, V64, P500, DOI 10.1158/0008-5472.CAN-03-2384; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Lavin MF, 2007, CELL CYCLE, V6, P931, DOI 10.4161/cc.6.8.4180; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MEYN MS, 1994, INT J RADIAT BIOL, V66, pS141; Nagpal S, 1999, J BIOL CHEM, V274, P22563, DOI 10.1074/jbc.274.32.22563; Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Pentimalli F, 2008, EUR J CANCER, V44, P2668, DOI 10.1016/j.ejca.2008.07.033; Pierantoni GM, 2007, J CLIN INVEST, V117, P693, DOI 10.1172/JCI29852; Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635; PIERANTONI GM, 2006, CELL DEATH DIFFER, V5, P2045; Reeves R, 2005, DNA REPAIR, V4, P926, DOI 10.1016/j.dnarep.2005.04.010; REEVES R, 1990, J BIOL CHEM, V265, P8573; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 2001, SEMIN RADIAT ONCOL, V11, P316, DOI 10.1053/srao.2001.26030; Sarkaria JN, 1998, CANCER RES, V58, P4375; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Viale A, 2009, NATURE, V457, P51, DOI 10.1038/nature07618; Wood LJ, 2000, CANCER RES, V60, P4256; Xu Y, 1998, MOL CELL BIOL, V18, P4385, DOI 10.1128/MCB.18.7.4385; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	41	45	47	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	27					3024	3035		10.1038/onc.2011.21	http://dx.doi.org/10.1038/onc.2011.21			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	789IW	21339738				2022-12-17	WOS:000292510100003
J	Albasri, A; Al-Ghamdi, S; Fadhil, W; Aleskandarany, M; Liao, YC; Jackson, D; Lobo, DN; Lo, SH; Kumari, R; Durrant, L; Watson, S; Kindle, KB; Ilyas, M				Albasri, A.; Al-Ghamdi, S.; Fadhil, W.; Aleskandarany, M.; Liao, Y-C; Jackson, D.; Lobo, D. N.; Lo, S. H.; Kumari, R.; Durrant, L.; Watson, S.; Kindle, K. B.; Ilyas, M.			Cten signals through integrin-linked kinase (ILK) and may promote metastasis in colorectal cancer	ONCOGENE			English	Article						Cten; integrin-linked kinase; metastasis	MESSENGER-RNA EXPRESSION; E-CADHERIN EXPRESSION; UP-REGULATION; TUMOR PROGRESSION; TENSIN; OVEREXPRESSION; MIGRATION; MARKER	CTEN/TNS4 is an oncogene in colorectal cancer (CRC), which can induce cell motility although its mechanistic basis of activity and the clinical implications of Cten expression are unknown. As Cten is in complex with integrins at focal adhesions, we hypothesised that it may interact with integrin-linked kinase (ILK). Through forced expression and knockdown of Cten in HCT116 and SW620 (respectively, showing low and high Cten expression), we showed that Cten could regulate ILK. However, inhibition of ILK after forced expression of Cten abrogated the motility-inducing effects of Cten, thereby demonstrating that the Cten-ILK interaction was functionally relevant. Combined knockdown of Cten and ILK had no additive effects on cell motility compared with knockdown of each individually. In order to investigate the clinical implications of Cten expression, a series of 462 CRCs were evaluated by immunohistochemistry. High expression of Cten was associated with advanced Dukes' stage (P < 0.001), poor prognosis (P < 0.001) and distant metastasis (P = 0.008). The role of Cten in metastasis was tested by (a) intrasplenic injection of CRC cells stably transfected with a Cten expression vector into nude mice and (b) testing a series of primary human CRCs and their metastases by immunohistochemistry. Compared with controls, mice injected with cells expressing Cten developed larger tumours in the spleen (P < 0.05) and liver (P < 0.05). In the human cases, compared with primary tumours, the metastatic deposits had a significantly higher frequency of nuclear localisation of Cten (P = 0.002). We conclude that Cten expression is of prognostic significance in CRC, and we delineate a Cten-ILK pathway controlling cell motility and possibly promoting metastasis. Oncogene (2011) 30, 2997-3002; doi:10.1038/onc.2011.26; published online 21 February 2011	[Ilyas, M.] Univ Nottingham, Queens Med Ctr, Sch Mol Med Sci, Div Pathol, Nottingham NG7 2UH, Notts, England; [Liao, Y-C; Lo, S. H.] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Lobo, D. N.] Univ Nottingham, Div Gastrointestinal Surg, Nottingham NG7 2UH, Notts, England; [Lobo, D. N.; Watson, S.; Ilyas, M.] Nottingham Univ Hosp NHS Trust, Queens Med Ctr, NIHR Biomed Res Unit, Nottingham Digest Dis Ctr, Nottingham, England; [Kumari, R.; Watson, S.] Univ Nottingham, Div Preclin Oncol, Nottingham NG7 2UH, Notts, England; [Durrant, L.] Univ Nottingham, Div Acad Oncol, Nottingham NG7 2UH, Notts, England	University of Nottingham; University of California System; University of California Davis; University of Nottingham; Nottingham University Hospital NHS Trust; University of Nottingham; University of Nottingham; University of Nottingham	Ilyas, M (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Mol Med Sci, Div Pathol, Nottingham NG7 2UH, Notts, England.	mohammad.ilyas@nottingham.ac.uk	AlGhamdi, Saleh/S-2515-2019; Liao, Yi-Chun/H-2383-2014; Lobo, Dileep/AAC-6207-2020; Hsiao, Wei-Hung/B-9931-2013; Aleskandarany, Mohammed/X-8585-2019; Aleskandarany, Mohammed/D-9162-2018	Lobo, Dileep/0000-0003-1187-5796; Aleskandarany, Mohammed/0000-0001-5538-5946; Albasri, Abdulkader/0000-0002-1824-4025; Lo, Su Hao/0000-0002-2675-9387; Garrie, Karin/0000-0003-2204-9975; Liao, Yi-Chun/0000-0002-0399-0201; Fadhil, Wakkas/0000-0002-0529-0460	University of Nottingham and Cancer Research Nottingham; National Association for Colitis and Crohn's Disease (NACC)	University of Nottingham and Cancer Research Nottingham; National Association for Colitis and Crohn's Disease (NACC)	Funding: The study was funded by the University of Nottingham and Cancer Research Nottingham. KBK is funded by the National Association for Colitis and Crohn's Disease (NACC).	Ahmed MAH, 2009, J CLIN PATHOL, V62, P1117, DOI 10.1136/jcp.2009.069310; Albasri A, 2011, BREAST CANCER RES TR, V126, P47, DOI 10.1007/s10549-010-0890-3; Albasri A, 2009, J PATHOL, V218, P57, DOI 10.1002/path.2508; Barbieri I, 2010, CANCER RES, V70, P2558, DOI 10.1158/0008-5472.CAN-09-2840; Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Chen HY, 2000, BIOCHEM J, V351, P403, DOI 10.1042/0264-6021:3510403; Katz M, 2007, NAT CELL BIOL, V9, P961, DOI 10.1038/ncb1622; Liao YC, 2009, CANCER RES, V69, P4563, DOI 10.1158/0008-5472.CAN-09-0117; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; Lo SH, 2004, INT J BIOCHEM CELL B, V36, P31, DOI 10.1016/S1357-2725(03)00171-7; Lo SH, 2002, CANCER RES, V62, P4217; McPhee TR, 2008, DEV DYNAM, V237, P2737, DOI 10.1002/dvdy.21685; Oloumi A, 2004, BBA-MOL CELL RES, V1691, P1, DOI 10.1016/j.bbamcr.2003.12.002; Sakashita K, 2008, ANN SURG ONCOL, V15, P2606, DOI 10.1245/s10434-008-9989-8; Sasaki H, 2003, TUMOR BIOL, V24, P271, DOI 10.1159/000076141; Sasaki H, 2003, LUNG CANCER, V40, P151, DOI 10.1016/S0169-5002(03)00037-0; Somasiri A, 2001, J CELL SCI, V114, P1125; Ullenhag GJ, 2007, CLIN CANCER RES, V13, P5070, DOI 10.1158/1078-0432.CCR-06-2547	18	45	49	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	26					2997	3002		10.1038/onc.2011.26	http://dx.doi.org/10.1038/onc.2011.26			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21339732	Bronze			2022-12-17	WOS:000292245100010
J	Dettman, EJ; Simko, SJ; Ayanga, B; Carofino, BL; Margolin, JF; Morse, HC; Justice, MJ				Dettman, E. J.; Simko, S. J.; Ayanga, B.; Carofino, B. L.; Margolin, J. F.; Morse, H. C., III; Justice, M. J.			Prdm14 initiates lymphoblastic leukemia after expanding a population of cells resembling common lymphoid progenitors	ONCOGENE			English	Article						leukemia; Prdm14; leukemia-initiating cell; pluripotency; common lymphoid progenitor; acute lymphoblastic leukemia	BREAST-CANCER; STEM-CELLS; RETROVIRAL INSERTIONS; MEIOTIC RECOMBINATION; BONE-MARROW; IN-VITRO; C-KIT; GENE; MICE; EXPRESSION	Understanding the heterogeneous genetic mechanisms of tumor initiation in lymphoid leukemias (LL) will lead to improvements in prognostic classification and treatment regimens. In previous studies of mouse leukemias, we showed that retroviral insertion at the ecotropic viral insertion site 32 locus leads to increased expression of Prdm14, a pluripotency gene implicated in the self-renewal capacity of embryonic stem cells and the early stages of breast cancer. Here, we show that PRDM14 is also overexpressed in similar to 25% of human lymphoid neoplasms, with increased frequencies in T-cell acute LL and hyperdiploid precursor B-cell acute LL. To test if Prdm14 overexpression could initiate leukemia, mice were transduced with bone marrow cells transfected with a Prdm14 expression vector. LLs developed in 96% of female mice and 42% of male mice. Before the onset of leukemia, differentiation of transduced cells was biased up to 1000-fold toward cells with features of common lymphoid progenitors (CLPs), and lymphoid differentiation showed a relative block at the pro-B stage. Microarray gene expression analysis of expanded CLP-like cells before the onset of leukemia demonstrated upregulation of genes involved in pluripotency, tumor initiation, early B-lineage commitment, Wnt/Ras signaling and the epithelial-to-mesenchymal transition. Among the dysregulated genes were imprinted genes and non-coding RNAs including Dlk1 and Meg3, which are also key pluripotency mediators. Heightened expression of the estrogen-dependent oncogene, Myb, in tumors suggests a basis for the increased frequency of cancer in female mice. These data provide the first direct evidence for the association of Prdm14 with cancer initiation in an in vivo mouse model and in human lymphoid malignancies, while suggesting mechanisms for Prdm14's mode of action. Oncogene (2011) 30, 2859-2873; doi:10.1038/onc.2011.12; published online 21 February 2011	[Dettman, E. J.; Ayanga, B.; Carofino, B. L.; Justice, M. J.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Simko, S. J.; Margolin, J. F.] Baylor Coll Med, Sect Hematol & Oncol, Dept Pediat, Houston, TX 77030 USA; [Morse, H. C., III] NIAID, Immunopathol Lab, NIH, Rockville, MD USA; [Justice, M. J.] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Baylor College of Medicine	Justice, MJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, MS227,1 Baylor Plaza R804, Houston, TX 77030 USA.	mjustice@bcm.edu	liang, yan/H-3894-2011	Morse, Herbert/0000-0002-9331-3705; Carofino, Brandi/0000-0003-0717-6917; Dettman, E.J./0000-0002-0059-836X; Simko, Stephen/0000-0002-4790-4117	NIH [R01 CA63229, R01 CA15530]; Baylor College of Medicine; NIH National Research Service [3 T32 CA115303-04]; NIH, National Institute of Allergy and Infectious Diseases; NATIONAL CANCER INSTITUTE [R01CA115503, R01CA063229, T32CA115303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001024, ZIAAI000858] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Baylor College of Medicine; NIH National Research Service(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The work by MJJ was supported by NIH R01 CA63229, R01 CA15530 and a Baylor College of Medicine Interim funding award. SJS was supported by an NIH National Research Service Award Institutional Training Grant 3 T32 CA115303-04, 'Pediatric Oncology Research Training Program.' HCM was supported by the Intramural Research Program of the NIH, National Institute of Allergy and Infectious Diseases. We thank John Belmont and Molly Bray at the Laboratory for Translational Genomics at BCM for microarray data production; Jill Crowe for excellent technical assistance; and Frank Probst for the critical reading of the paper.	Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Baudat F, 2010, SCIENCE, V327, P836, DOI 10.1126/science.1183439; BESMER P, 1993, DEVELOPMENT, P125; Bhojwani D, 2006, BLOOD, V108, P711, DOI 10.1182/blood-2006-02-002824; Boles MK, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000759; Castor A, 2005, NAT MED, V11, P630, DOI 10.1038/nm1253; Chia NY, 2010, NATURE, V468, P316, DOI 10.1038/nature09531; Davi F, 1996, BLOOD, V88, P609, DOI 10.1182/blood.V88.2.609.bloodjournal882609; Davidsson J, 2010, LEUKEMIA, V24, P924, DOI 10.1038/leu.2010.39; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dettman EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003823; DOWNING JR, 2006, HEMATOL-AM SOC HEMAT, V508, P118; Drabsch Y, 2007, P NATL ACAD SCI USA, V104, P13762, DOI 10.1073/pnas.0700104104; Ford AM, 2001, BLOOD, V98, P558, DOI 10.1182/blood.V98.3.558; Fredrickson T N, 1995, Curr Top Microbiol Immunol, V194, P109; Fumasoni I, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-187; Greig KT, 2010, BLOOD, V115, P2796, DOI 10.1182/blood-2009-08-239210; GUERIN M, 1990, ONCOGENE, V5, P131; Hansen GM, 2000, GENOME RES, V10, P237, DOI 10.1101/gr.10.2.237; Hao XP, 2006, LEUKEMIA RES, V30, P397, DOI 10.1016/j.leukres.2005.08.021; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; Hayashi K, 2005, NATURE, V438, P374, DOI 10.1038/nature04112; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jiang GL, 2000, HISTOL HISTOPATHOL, V15, P109, DOI 10.14670/HH-15.109; JONKERS S, 1996, BIOCHIM BIOPHYS ACTA, V1287, P29; Jordan CT, 2006, CANCER CELL, V10, P253, DOI 10.1016/j.ccr.2006.09.010; Khoury H, 2010, BLOOD, V115, P2260, DOI 10.1182/blood-2009-03-212746; Kim KC, 2003, CANCER BIOL THER, V2, P491, DOI 10.4161/cbt.2.5.629; Kim KC, 2003, CANCER RES, V63, P7619; Kinameri E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003859; Ko CD, 2003, CLIN EXP METASTAS, V20, P593, DOI 10.1023/A:1027323210736; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Kurimoto K, 2008, CELL CYCLE, V7, P3514, DOI 10.4161/cc.7.22.6979; Liu L, 2010, J BIOL CHEM, V285, P19483, DOI 10.1074/jbc.M110.131995; Lossos IS, 2003, LEUKEMIA, V17, P789, DOI 10.1038/sj.leu.2402880; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Moelans CB, 2010, MODERN PATHOL, V23, P1029, DOI 10.1038/modpathol.2010.84; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; Mullighan CG, 2005, CANCER J, V11, P268, DOI 10.1097/00130404-200507000-00003; Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Mullighan CG, 2009, NEW ENGL J MED, V360, P470, DOI 10.1056/NEJMoa0808253; Myers S, 2010, SCIENCE, V327, P876, DOI 10.1126/science.1182363; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Nishikawa N, 2007, CANCER RES, V67, P9649, DOI 10.1158/0008-5472.CAN-06-4111; Ohinata Y, 2009, CELL, V137, P571, DOI 10.1016/j.cell.2009.03.014; Palmu S, 2002, ANTICANCER RES, V22, P411; PARVANOV ED, 2010, SCIENCE, P327; Pasqualucci L, 2006, J EXP MED, V203, P311, DOI 10.1084/jem.20052204; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; Pizzo PA, 2006, PRINCIPLES PRACTICE; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Sakajiri S, 2005, LEUKEMIA, V19, P1404, DOI 10.1038/sj.leu.2403832; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Sorich MJ, 2008, PLOS MED, V5, P646, DOI 10.1371/journal.pmed.0050083; Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017; Surani MA, 2007, CELL, V128, P747, DOI 10.1016/j.cell.2007.02.010; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tremblay M, 2010, GENE DEV, V24, P1093, DOI 10.1101/gad.1897910; Tsuda H, 2005, CANCER SCI, V96, P333, DOI 10.1111/j.1349-7006.2005.00060.x; Tsuneyoshi N, 2008, BIOCHEM BIOPH RES CO, V367, P899, DOI 10.1016/j.bbrc.2007.12.189; Villadsen R, 2007, J CELL BIOL, V177, P87, DOI 10.1083/jcb.200611114; Weiser KC, 2007, MAMM GENOME, V18, P709, DOI 10.1007/s00335-007-9060-2; Yamaji M, 2008, NAT GENET, V40, P1016, DOI 10.1038/ng.186; Yan XQ, 1996, BLOOD, V88, P402, DOI 10.1182/blood.V88.2.402.bloodjournal882402	69	45	46	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	25					2859	2873		10.1038/onc.2011.12	http://dx.doi.org/10.1038/onc.2011.12			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	781ZV	21339739	Green Accepted			2022-12-17	WOS:000291977800006
J	Henry, LA; Johnson, DA; Sarrio, D; Lee, S; Quinlan, PR; Crook, T; Thompson, AM; Reis, JS; Isacke, CM				Henry, L. A.; Johnson, D. A.; Sarrio, D.; Lee, S.; Quinlan, P. R.; Crook, T.; Thompson, A. M.; Reis-Filho, J. S.; Isacke, C. M.			Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome	ONCOGENE			English	Article						endoglin; CD105; breast cancer; TGF-beta; MCF10A; ErbB2	GROWTH-FACTOR-BETA; MOUSE SKIN CARCINOGENESIS; TGF-BETA; ENDOTHELIAL-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; RECEPTOR; CANCER; MIGRATION; PROLIFERATION; ACTIVATION	Tumor growth factor-beta (TGF-beta) signaling in cancer has been implicated in growth suppression of early lesions and enhancing tumor cell invasion and metastasis. However, the cellular mechanisms that determine this signaling output in individual tumors are still largely unknown. In endothelial cells, TGF-beta signaling is modulated by the TGF-beta co-receptor endoglin (CD105). Here we demonstrate that endoglin is expressed in a subset of invasive breast cancers and cell lines and is subject to epigenetic silencing by gene methylation. Endoglin downregulation in non-tumorigenic MCF10A breast cells leads to the formation of abnormal acini in 3D culture, but does not promote cell migration or transformation. In contrast, in the presence of activated ErbB2, endoglin downregulation in MCF10A cells leads to enhanced invasion into a 3D matrix. Consistent with these data, ectopic expression of endoglin in MDA-MB-231 cells blocks TGF-beta-enhanced cell motility and invasion and reduces lung colonization in an in vivo metastasis model. Unlike endothelial cells, endoglin does not modulate Smad-mediated TGF-beta signaling in breast cells but attenuates the cytoskeletal remodeling to impair cell migration and invasion. Importantly, in a large cohort of invasive breast cancers, lack of endoglin expression in the tumor cell compartment correlates with ENG gene methylation and poor clinical outcome. Oncogene (2011) 30, 1046-1058; doi:10.1038/onc.2010.488; published online 1 November 2010	[Henry, L. A.; Johnson, D. A.; Sarrio, D.; Lee, S.; Crook, T.; Reis-Filho, J. S.; Isacke, C. M.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Quinlan, P. R.; Thompson, A. M.] Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Dundee	Isacke, CM (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	clare.isacke@icr.ac.uk	SARRIO, DAVID/Y-8903-2019	Isacke, Clare/0000-0002-9222-3345; Sarrio, David/0000-0003-4886-8290; Quinlan, Philip/0000-0002-3012-6646	Breakthrough Breast Cancer; NHS; Marie Curie Intra-European Fellowship [PIEF-GA-2008-221083]; Breast Cancer Research Scotland; Tayside Tissue Bank	Breakthrough Breast Cancer; NHS; Marie Curie Intra-European Fellowship(European Commission); Breast Cancer Research Scotland; Tayside Tissue Bank	We thank Kay Savage and Suzanne Parry for immunohistochemical staining, Reshma Shah for help with the methylation analysis, Caterina Marchio for microdissection, Senthil Muthuswamy for the MCF10A.ErbB2 cells and Ariad Pharmaceuticals (www.ariad.com/regulationkits) for the AP1510 reagent. This project was funded by Breakthrough Breast Cancer and from NHS funding to the NIHR Biomedical Research Centre, a Marie Curie Intra-European Fellowship (PIEF-GA-2008-221083) and Breast Cancer Research Scotland with support from the Tayside Tissue Bank.	Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Bernabeu C, 2007, J CELL BIOCHEM, V102, P1375, DOI 10.1002/jcb.21594; Bernabeu C, 2009, BBA-MOL BASIS DIS, V1792, P954, DOI 10.1016/j.bbadis.2009.07.003; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Conley BA, 2004, J BIOL CHEM, V279, P27440, DOI 10.1074/jbc.M312561200; Craft CS, 2007, ONCOGENE, V26, P7240, DOI 10.1038/sj.onc.1210533; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Illingworth RS, 2009, FEBS LETT, V583, P1713, DOI 10.1016/j.febslet.2009.04.012; Ishibashi O, 2010, J CELL PHYSIOL, V222, P465, DOI 10.1002/jcp.21968; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Klingbeil P, 2010, BREAST CANCER RES TR, V120, P95, DOI 10.1007/s10549-009-0380-7; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Lee NY, 2007, J BIOL CHEM, V282, P21507, DOI 10.1074/jbc.M700176200; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Mythreye K, 2009, P NATL ACAD SCI USA, V106, P8221, DOI 10.1073/pnas.0812879106; Oxmann D, 2008, ONCOGENE, V27, P3567, DOI 10.1038/sj.onc.1211025; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Perez-Gomez E, 2007, CANCER RES, V67, P10268, DOI 10.1158/0008-5472.CAN-07-1348; Quintanilla M, 2003, ONCOGENE, V22, P5976, DOI 10.1038/sj.onc.1206841; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Rodriguez-Barbero A, 2006, CELL PHYSIOL BIOCHEM, V18, P135, DOI 10.1159/000095181; Romero D, 2010, CARCINOGENESIS, V31, P359, DOI 10.1093/carcin/bgp217; Sanz-Rodriguez F, 2004, J BIOL CHEM, V279, P32858, DOI 10.1074/jbc.M400843200; Scharpfenecker M, 2007, J CELL SCI, V120, P964, DOI 10.1242/jcs.002949; Scherner O, 2007, J BIOL CHEM, V282, P13934, DOI 10.1074/jbc.M611062200; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; ten Dijke P, 2008, ANGIOGENESIS, V11, P79, DOI 10.1007/s10456-008-9101-9; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Wong VCL, 2008, INT J CANCER, V123, P2816, DOI 10.1002/ijc.23882; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	40	45	49	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1046	1058		10.1038/onc.2010.488	http://dx.doi.org/10.1038/onc.2010.488			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	21042283				2022-12-17	WOS:000287964100004
J	Rokaeus, N; Shen, J; Eckhardt, I; Bykov, VJN; Wiman, KG; Wilhelm, MT				Rokaeus, N.; Shen, J.; Eckhardt, I.; Bykov, V. J. N.; Wiman, K. G.; Wilhelm, M. T.			PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73	ONCOGENE			English	Article						PRIMA-1(MET); APR-246; reactivation; mutant p63; mutant p73; apoptosis	TUMOR-SUPPRESSOR FUNCTIONS; DNA-BINDING ACTIVITY; EEC-SYNDROME; HOMOLOG P63; APOPTOSIS; GENE; ACTIVATION; INDUCTION; CELLS; LIMB	The low molecular weight compound PRIMA-1 and the structural analog PRIMA-1(MET), also named APR-246, reactivate mutant p53 through covalent binding to the core domain and induce apoptosis in tumor cells. Here, we asked whether PRIMA-1(MET)/APR-246 can rescue mutant forms of the p53 family members p63 and p73 that share high sequence homology with p53. We found that PRIMA-1(MET)/APR-246 can restore the pro-apoptotic function to mutant TAp63 gamma and TAp73 beta in tumor cells but has less effect on TAp73 alpha. Moreover, PRIMA-1(MET)/APR-246-stimulated DNA binding of mutant TAp63 gamma and induced expression of the p53/p63/p73 downstream targets p21 and Noxa. The reactivation of mutant p53, p63 and p73 by PRIMA-1(MET)/APR-246 indicates a common mechanism, presumably involving homologous structural elements in the p53 family proteins. Our findings may open avenues for therapeutic intervention in human developmental disorders with mutations in p63. Oncogene (2010) 29, 6442-6451; doi:10.1038/onc.2010.382; published online 6 September 2010	[Wiman, K. G.] Karolinska Inst, CCK, Dept Oncol Pathol, Karolinska Univ Hosp R8 04, SE-17176 Stockholm, Sweden; [Wilhelm, M. T.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Inst, CCK, Dept Oncol Pathol, Karolinska Univ Hosp R8 04, SE-17176 Stockholm, Sweden.	Klas.Wiman@ki.se	Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Nakade Bykov, Vladimir/0000-0002-7199-8942; Wilhelm, Margareta/0000-0002-0516-9724	EU [LSHB-CT-2005-019067]	EU(European Commission)	We thank Dr Jiandong Chen, H Lee Moffitt Cancer Center, for the ts mutant p63/p73-expressing cells, and Dr Bert Vogelstein, Johns Hopkins Oncology Center, for the HCT116 cells. This work was supported by EU 6th Framework Program within the EPISTEM Integrated Project (LSHB-CT-2005-019067).	Bernassola F, 2005, ONCOGENE, V24, P6982, DOI 10.1038/sj.onc.1208843; Buhlmann S, 2008, BBA-REV CANCER, V1785, P207, DOI 10.1016/j.bbcan.2008.01.002; Bykov VJN, 2005, J BIOL CHEM, V280, P30384, DOI 10.1074/jbc.M501664200; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Bykov VJN, 2002, CARCINOGENESIS, V23, P2011, DOI 10.1093/carcin/23.12.2011; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cam H, 2006, CANCER CELL, V10, P281, DOI 10.1016/j.ccr.2006.08.024; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Chan WM, 2004, MOL CELL BIOL, V24, P3536, DOI 10.1128/MCB.24.8.3536-3551.2004; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Corn PG, 1999, CANCER RES, V59, P3352; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Demma MJ, 2004, J BIOL CHEM, V279, P45887, DOI 10.1074/jbc.M401854200; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Gonzalez S, 2005, CANCER RES, V65, P2186, DOI 10.1158/0008-5472.CAN-04-3047; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Guo XC, 2009, NAT CELL BIOL, V11, P1451, DOI 10.1038/ncb1988; Helton ES, 2006, J BIOL CHEM, V281, P2533, DOI 10.1074/jbc.M507964200; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kawano S, 1999, BLOOD, V94, P1113; Lambert JMR, 2010, ONCOGENE, V29, P1329, DOI 10.1038/onc.2009.425; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Ozaki T, 1999, CANCER RES, V59, P5902; Pochampally R, 2000, BIOCHEM BIOPH RES CO, V279, P1001, DOI 10.1006/bbrc.2000.4056; Rinne T, 2007, CELL CYCLE, V6, P262, DOI 10.4161/cc.6.3.3796; Rokaeus N, 2007, ONCOGENE, V26, P982, DOI 10.1038/sj.onc.1209858; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Scoumanne A, 2005, CANCER BIOL THER, V4, P1178, DOI 10.4161/cbt.4.11.2254; Shen J, 2008, ONCOGENE, V27, P6571, DOI 10.1038/onc.2008.249; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Strano S, 2001, FEBS LETT, V490, P163, DOI 10.1016/S0014-5793(01)02119-6; Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003; Suh EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; van Bokhoven H, 2001, AM J HUM GENET, V69, P481, DOI 10.1086/323123; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zache N, 2008, CELL ONCOL, V30, P411, DOI 10.3233/CLO-2008-0440; Zeng XY, 2001, CARCINOGENESIS, V22, P215, DOI 10.1093/carcin/22.2.215	48	45	47	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2010	29	49					6442	6451		10.1038/onc.2010.382	http://dx.doi.org/10.1038/onc.2010.382			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP	20818419				2022-12-17	WOS:000285138900004
J	Zenvirt, S; Kravchenko-Balasha, N; Levitzki, A				Zenvirt, S.; Kravchenko-Balasha, N.; Levitzki, A.			Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents	ONCOGENE			English	Article						CHK1; checkpoint; cancer; p53	DNA-DAMAGE; S-PHASE; CHECKPOINT KINASES; MITOTIC CATASTROPHE; G(2)/M TRANSITION; PATHWAY; THERAPY; ARREST; ABROGATION; ATM	DNA damage checkpoints cause cell cycle arrest, allowing DNA repair before resumption of the cell cycle. These checkpoints can be activated through several signaling pathways. Checkpoint activators include p53, checkpoint kinase 1 (CHK1), checkpoint kinase 2 and/or MAPKAP kinase 2 (MK2). Many cancer cells lack p53 activity and, therefore, depend on alternative checkpoint activators to arrest the cell cycle following DNA damage. Inhibition of these pathways is expected to specifically sensitize these p53-deficient cells to DNA damage caused by chemotherapy. Using isogenic p53-proficient and p53-deficient cancer cell lines, we show that inactivation of CHK1, but not MK2, abrogates cell cycle arrest following chemotherapy, specifically in p53-deficient cells. However, we show that CHK1 is required to maintain genome integrity and cell viability, and that p53-proficient cells are no less sensitive than p53-deficient cells to CHK1 inhibition in the presence of DNA damage. Thus, combining CHK1 inhibition with DNA damage does not lead to preferential killing of p53-deficient over p53-proficient cells, and inhibiting CHK1 does not appear to be a promising approach for potentiation of cancer chemotherapy. Oncogene (2010) 29, 6149-6159; doi:10.1038/onc.2010.343; published online 23 August 2010	[Zenvirt, S.; Kravchenko-Balasha, N.; Levitzki, A.] Hebrew Univ Jerusalem, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel.	Levitzki@vms.huji.ac.il	Kravchenko-Balasha, Nataly/D-7683-2016	Kravchenko-Balasha, Nataly/0000-0001-6943-7479	Lady Davis Fellowship Trust; Algen Biopharmaceuticals, Ltd.	Lady Davis Fellowship Trust; Algen Biopharmaceuticals, Ltd.	We would like to thank Dr Shoshana Klein for discussions and editing. This work was partially supported by the Lady Davis Fellowship Trust and by Algen Biopharmaceuticals, Ltd.	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ashwell S, 2008, EXPERT OPIN INV DRUG, V17, P1331, DOI [10.1517/13543784.17.9.1331, 10.1517/13543784.17.9.1331 ]; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bucher N, 2008, BRIT J CANCER, V98, P523, DOI 10.1038/sj.bjc.6604208; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen ZH, 2006, INT J CANCER, V119, P2784, DOI 10.1002/ijc.22198; Cho SH, 2005, CELL CYCLE, V4, P131, DOI 10.4161/cc.4.1.1299; Dai J, 2005, GENE DEV, V19, P472, DOI 10.1101/gad.1267105; DENT MF, 1995, CYTOTECHNOLOGY, V17, P27, DOI 10.1007/BF00749218; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Finkel E, 1999, SCIENCE, V286, P2256, DOI 10.1126/science.286.5448.2256; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hirose Y, 2001, CANCER RES, V61, P5843; Karisson-Rosenthal C, 2006, TRENDS CELL BIOL, V16, P285, DOI 10.1016/j.tcb.2006.04.002; Kawabe T, 2004, MOL CANCER THER, V3, P513; Kravchenko-Balasha N, 2009, J BIOL CHEM, V284, P11717, DOI 10.1074/jbc.M900217200; Levesque AA, 2008, MOL CANCER THER, V7, P252, DOI 10.1158/1535-7163.MCT-07-2066; Lieberman HB, 2008, CURR MED CHEM, V15, P360, DOI 10.2174/092986708783497328; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; O'Connor MJ, 2007, ONCOGENE, V26, P7816, DOI 10.1038/sj.onc.1210879; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Petermann E, 2006, CELL CYCLE, V5, P2203, DOI 10.4161/cc.5.19.3256; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Senderowicz AM, 2003, CANCER CHEMOTH PHARM, V52, pS61, DOI 10.1007/s00280-003-0624-x; Shao RG, 1997, CANCER RES, V57, P4029; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stark GR, 2006, MOL BIOTECHNOL, V32, P227, DOI 10.1385/MB:32:3:227; Tao YG, 2009, CELL CYCLE, V8, P1196, DOI 10.4161/cc.8.8.8203; Tse AN, 2004, CANCER RES, V64, P6635, DOI 10.1158/0008-5472.CAN-04-0841; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Xiao Z, 2006, MOL CANCER THER, V5, P1935, DOI 10.1158/1535-7163.MCT-06-0077; Zhang WH, 2008, CELL CYCLE, V7, P1668, DOI 10.4161/cc.7.11.5982; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zhou BBS, 2003, CANCER BIOL THER, V2, pS16; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	42	45	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	46					6149	6159		10.1038/onc.2010.343	http://dx.doi.org/10.1038/onc.2010.343			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20729914	Bronze			2022-12-17	WOS:000284356500007
J	Herrero-Gonzalez, S; Gangoso, E; Giaume, C; Naus, CC; Medina, JM; Tabernero, A				Herrero-Gonzalez, S.; Gangoso, E.; Giaume, C.; Naus, C. C.; Medina, J. M.; Tabernero, A.			Connexin43 inhibits the oncogenic activity of c-Src in C6 glioma cells	ONCOGENE			English	Article						cell cycle; CNS; gap junctions; glia; proliferation	GAP-JUNCTION PROTEIN; INTERCELLULAR COMMUNICATION; TYROSINE PHOSPHORYLATION; CULTURED ASTROCYTES; CYCLIN D1; GROWTH; EXPRESSION; PROLIFERATION; GENE; TRANSCRIPTION	One of the characteristics of gliomas is a decrease in the expression of connexin43, a protein that forms gap junctions. Restoring connexin43 expression in glioma cells reduces their exacerbated rate of cell growth, although it is not yet known how connexin43 modifies the expression of genes involved in cell proliferation. Here, we show that restoring connexin43 to C6 glioma cells impedes their progression from G0/G1 to the S phase of the cell cycle by reducing retinoblastoma phosphorylation and cyclin E expression through the upregulation of p21 and p27. Interestingly, connexin43 diminishes the oncogenic activity of c-Src exhibited by glioma cells. By studying a Tyr247 and Tyr265 mutant connexin43, we show that these residues are required for connexin43 to inhibit c-Src activity and cell proliferation. In conclusion, by acting as a substrate of c-Src, connexin43 reduces its oncogenic activity and decreases the rate of glioma cell proliferation, potentially an early step in the antiproliferative effects of connexin43. Although c-Src is known to phosphorylate connexin43, this study provides the first evidence that connexin43 can also inhibit c-Src activity. Oncogene (2010) 29, 5712-5723; doi:10.1038/onc.2010.299; published online 2 August 2010	[Herrero-Gonzalez, S.; Gangoso, E.; Medina, J. M.; Tabernero, A.] Univ Salamanca, Dept Bioquim & Biol Mol, INCYL, Salamanca 37007, Spain; [Giaume, C.] Coll France, INSERM, U840, F-75231 Paris, France; [Naus, C. C.] Univ British Columbia, Inst Life Sci, Dept Cellular & Physiol Sci, Vancouver, BC V5Z 1M9, Canada	University of Salamanca; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; University of British Columbia	Tabernero, A (corresponding author), Univ Salamanca, Dept Bioquim & Biol Mol, INCYL, C Pintor Fernando Gallego 1, Salamanca 37007, Spain.	ataber@usal.es	Tabernero, Arantxa/K-5950-2014; IBSAL, Secretaría/H-3719-2011; Gangoso, Ester/B-4825-2016; Gangoso, Ester/J-2604-2019	Tabernero, Arantxa/0000-0001-6302-6134; Gangoso, Ester/0000-0003-4851-9680; Gangoso, Ester/0000-0003-4851-9680	Ministerio de Educacion y Ciencia [SAF2007-64161]; Junta de Castilla y Leon [SA043A09]	Ministerio de Educacion y Ciencia(Spanish Government); Junta de Castilla y Leon(Junta de Castilla y Leon)	This work was supported by the Ministerio de Educacion y Ciencia, FEDER SAF2007-64161, the Junta de Castilla y Leon SA043A09. S Herrero-Gonzalez and E Gangoso were recipient of a fellowship from the Ministerio de Educacion y Ciencia. We are grateful for the technical assistance of T del Rey and we thank M Sefton for help in preparing the paper.	Bates DC, 2007, GLIA, V55, P1554, DOI 10.1002/glia.20569; Bennett MVL, 2003, TRENDS NEUROSCI, V26, P610, DOI 10.1016/j.tins.2003.09.008; Campbell EJ, 2008, BRIT J CANCER, V99, P1769, DOI 10.1038/sj.bjc.6604768; Cavalla P, 1998, ACTA NEUROPATHOL, V95, P131, DOI 10.1007/s004010050776; Chakrabarty A, 1996, NEUROPATH APPL NEURO, V22, P311, DOI 10.1111/j.1365-2990.1996.tb01109.x; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Cina C, 2009, J NEUROSCI, V29, P2009, DOI 10.1523/JNEUROSCI.5025-08.2009; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; Dang XT, 2003, MOL CELL BIOCHEM, V242, P35, DOI 10.1023/A:1021152709313; DAVIDPFEUTY T, 1993, J CELL SCI, V105, P613; Du JY, 2009, NAT BIOTECHNOL, V27, P77, DOI 10.1038/nbt.1513; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; Fu CT, 2004, J BIOL CHEM, V279, P36943, DOI 10.1074/jbc.M403952200; Geng Y, 1996, ONCOGENE, V12, P1173; Giepmans BNG, 2006, ADV CARDIOL, V42, P41, DOI 10.1159/000092561; Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200; Gilleron J, 2008, J CELL SCI, V121, P4069, DOI 10.1242/jcs.033373; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Herrero-Gonzalez S, 2009, GLIA, V57, P222, DOI 10.1002/glia.20748; Herve JC, 2007, PROG BIOPHYS MOL BIO, V94, P29, DOI 10.1016/j.pbiomolbio.2007.03.010; Huang RP, 1998, CANCER RES, V58, P5089; Huang RP, 1999, J SURG ONCOL, V70, P21, DOI 10.1002/(SICI)1096-9098(199901)70:1<21::AID-JSO4>3.3.CO;2-S; Kanemitsu MY, 1998, CELL GROWTH DIFFER, V9, P13; Kardami E, 2007, PROG BIOPHYS MOL BIO, V94, P245, DOI 10.1016/j.pbiomolbio.2007.03.009; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Koffler L, 2000, J CELL BIOCHEM, V79, P347, DOI 10.1002/1097-4644(20001201)79:3<347::AID-JCB10>3.0.CO;2-2; Krutovskikh VA, 2000, ONCOGENE, V19, P505, DOI 10.1038/sj.onc.1203340; Lai CPK, 2009, ONCOGENE, V28, P4402, DOI 10.1038/onc.2009.283; Lai CPK, 2007, CANCER RES, V67, P1545, DOI 10.1158/0008-5472.CAN-06-1396; Lampe PD, 2004, INT J BIOCHEM CELL B, V36, P1171, DOI 10.1016/S1357-2725(03)00264-4; Li W, 2005, J BIOL CHEM, V280, P7941, DOI 10.1074/jbc.M410548200; Lin R, 2001, J CELL BIOL, V154, P815, DOI 10.1083/jcb.200102027; Lin R, 2006, CELL COMMUN ADHES, V13, P199, DOI 10.1080/15419060600848516; LOEWENSTEIN WR, 1966, NATURE, V209, P1248, DOI 10.1038/2091248a0; Naus CCG, 2002, CAN J PHYSIOL PHARM, V80, P136, DOI 10.1139/Y02-009; Naus CCG, 1997, J NEUROSCI RES, V49, P528, DOI 10.1002/(SICI)1097-4547(19970901)49:5<528::AID-JNR3>3.0.CO;2-D; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Pahujaa M, 2007, EXP CELL RES, V313, P4083, DOI 10.1016/j.yexcr.2007.09.010; Penuela S, 2007, J CELL SCI, V120, P3772, DOI 10.1242/jcs.009514; Prochnow N, 2008, HISTOCHEM CELL BIOL, V130, P71, DOI 10.1007/s00418-008-0434-7; Pu PY, 2004, CLIN NEUROL NEUROSUR, V107, P49, DOI 10.1016/j.clineuro.2004.03.006; Rouach N, 2008, SCIENCE, V322, P1551, DOI 10.1126/science.1164022; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shinoura N, 1996, J NEUROSURG, V84, P839, DOI 10.3171/jns.1996.84.5.0839; Sin WC, 2008, J CELL BIOCHEM, V103, P1772, DOI 10.1002/jcb.21571; Solan JL, 2009, BIOCHEM J, V419, P261, DOI 10.1042/BJ20082319; Soroceanu L, 2001, GLIA, V33, P107, DOI 10.1002/1098-1136(200102)33:2<107::AID-GLIA1010>3.0.CO;2-4; Suadicani SO, 2009, ASN NEURO, V1, DOI 10.1042/AN20090001; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; Tabernero A, 2006, J NEUROCHEM, V96, P973, DOI 10.1111/j.1471-4159.2005.03623.x; Tabernero A, 1996, GLIA, V16, P187, DOI 10.1002/(SICI)1098-1136(199603)16:3<187::AID-GLIA1>3.0.CO;2-#; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Warn-Cramer BJ, 2003, CELL COMMUN ADHES, V10, P299, DOI 10.1080/714040443; Weissenberger J, 1997, ONCOGENE, V14, P2005, DOI 10.1038/sj.onc.1201168; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamasaki H, 1999, CR ACAD SCI III-VIE, V322, P151, DOI 10.1016/S0764-4469(99)80038-9; Zhang X, 2005, J CLIN NEUROSCI, V12, P166, DOI 10.1016/j.jocn.2004.03.036; Zhang YW, 2001, ONCOGENE, V20, P4138, DOI 10.1038/sj.onc.1204563; Zhang YW, 2003, CANCER RES, V63, P1623; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	60	45	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5712	5723		10.1038/onc.2010.299	http://dx.doi.org/10.1038/onc.2010.299			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20676131				2022-12-17	WOS:000283262500007
J	Shang, X; Vasudevan, SA; Yu, Y; Ge, N; Ludwig, AD; Wesson, CL; Wang, K; Burlingame, SM; Zhao, YJ; Rao, PH; Lu, X; Russell, HV; Okcu, MF; Hicks, MJ; Shohet, JM; Donehower, LA; Nuchtern, JG; Yang, J				Shang, X.; Vasudevan, S. A.; Yu, Y.; Ge, N.; Ludwig, A. D.; Wesson, C. L.; Wang, K.; Burlingame, S. M.; Zhao, Y-j; Rao, P. H.; Lu, X.; Russell, H. V.; Okcu, M. F.; Hicks, M. J.; Shohet, J. M.; Donehower, L. A.; Nuchtern, J. G.; Yang, J.			Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma	ONCOGENE			English	Article						neuroblastoma; DUSP26; MKP8; doxorubicin; p53; phosphatase	IN-VIVO; PATHWAY; PROTEIN; CANCER; PHOSPHORYLATION; TARGET; MDM2; THERAPY; KINASE; GROWTH	Chemoresistance is a major cause of treatment failure and poor outcome in neuroblastoma. In this study, we investigated the expression and function of dual-specificity phosphatase 26 (DUSP26), also known as mitogen-activated protein kinase phophatase-8, in human neuroblastoma. We found that DUSP26 was expressed in a majority of neuroblastoma cell lines and tissue specimens. Importantly, we found that DUSP26 promotes the resistance of human neuroblastoma to doxorubicin-induced apoptosis by acting as a p53 phosphatase to downregulate p53 tumor suppressor function in neuroblastoma cells. Inhibiting DUSP26 expression in the IMR-32 neuroblastoma cell line enhanced doxorubicin-induced p53 phosphorylation at Ser20 and Ser37, p21, Puma, Bax expression as well as apoptosis. In contrast, DUSP26 overexpression in the SK-N-SH cell line inhibited doxorubicin-induced p53 phosphorylation at Ser20 and Ser37, p21, Puma, Bax expression and apoptosis. Using in vitro and in vivo assays, we found that DUSP26 binds to p53 and dephosphorylates p53 at Ser20 and Ser37. In this report, we show that DUSP26 functions as a p53 phosphatase, which suppresses downstream p53 activity in response to genotoxic stress. This suggests that inhibition of this phosphatase may increase neuroblastoma chemosensitivity and DUSP26 is a novel therapeutic target for this aggressive pediatric malignancy. Oncogene (2010) 29, 4938-4946; doi: 10.1038/onc.2010.244; published online 21 June 2010	[Shang, X.; Vasudevan, S. A.; Wesson, C. L.; Burlingame, S. M.; Nuchtern, J. G.] Baylor Coll Med, Michael E DeBakey Dept Surg, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Shang, X.; Yu, Y.; Ge, N.; Ludwig, A. D.; Wang, K.; Burlingame, S. M.; Zhao, Y-j; Rao, P. H.; Russell, H. V.; Okcu, M. F.; Shohet, J. M.; Nuchtern, J. G.; Yang, J.] Baylor Coll Med, Texas Childrens Canc Ctr, Dept Pediat, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Lu, X.] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA; [Hicks, M. J.] Baylor Coll Med, Dept Pathol, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Donehower, L. A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Texas Children's Cancer Center; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Baylor College of Medicine; Baylor College of Medicine	Nuchtern, JG (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Surg, Dan L Duncan Canc Ctr, 6621 Fannin,CC650-00, Houston, TX 77030 USA.	nuchtern@bcm.edu; jianhuay@bcm.edu			Hope Street Kids Foundation; Bear Necessities Pediatric Cancer Foundation; American Cancer Society [RSG-06-070-01-TBE]; Society of University Surgeons; NIH/NCI-NRSA [1F32CA113059-01A1]; NATIONAL CANCER INSTITUTE [F32CA113059] Funding Source: NIH RePORTER	Hope Street Kids Foundation; Bear Necessities Pediatric Cancer Foundation; American Cancer Society(American Cancer Society); Society of University Surgeons; NIH/NCI-NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Xiangwei Wu for providing GFP-p53 expression plasmid and Mdm2-Luc reporter. The work was supported in part by the grants from the Hope Street Kids Foundation (to JY), the Bear Necessities Pediatric Cancer Foundation (to JY), the American Cancer Society Grant RSG-06-070-01-TBE (to JY), the Society of University Surgeons Ethicon Resident Scholarship (SAV) and the NIH/NCI-NRSA training grant 1F32CA113059-01A1 (SAV).	Amano T, 2009, J NEURO-ONCOL, V92, P357, DOI 10.1007/s11060-009-9844-1; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen L, 2007, CELL CYCLE, V6, P2685, DOI 10.4161/cc.6.21.4853; Eischen CM, 2009, CANCER CELL, V15, P161, DOI 10.1016/j.ccr.2009.02.004; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Goldman SC, 1996, AM J PATHOL, V148, P1381; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Jeffrey KL, 2007, NAT REV DRUG DISCOV, V6, P391, DOI 10.1038/nrd2289; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li DWC, 2006, ONCOGENE, V25, P3006, DOI 10.1038/sj.onc.1209334; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; London WB, 2005, J CLIN ONCOL, V23, P6459, DOI 10.1200/JCO.2005.05.571; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; MARUTA H, 1991, J BIOL CHEM, V266, P11661; Matthay KK, 1998, J CLIN ONCOL, V16, P1256, DOI 10.1200/JCO.1998.16.4.1256; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Patterson KI, 2009, BIOCHEM J, V418, P475, DOI 10.1042/BJ20082234; Pestell KE, 2000, ONCOGENE, V19, P6607, DOI 10.1038/sj.onc.1204084; Shang XY, 2009, MOL CANCER THER, V8, P2461, DOI 10.1158/1535-7163.MCT-08-0857; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tweddle DA, 2003, CANCER LETT, V197, P93, DOI 10.1016/S0304-3835(03)00088-0; Tweddle DA, 2001, CANCER RES, V61, P8; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Vasudevan SA, 2005, BIOCHEM BIOPH RES CO, V330, P511, DOI 10.1016/j.bbrc.2005.03.028; Vasudevan SA, 2009, MOL CANCER THER, V8, P2478, DOI 10.1158/1535-7163.MCT-08-1132; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yu W, 2007, ONCOGENE, V26, P1178, DOI 10.1038/sj.onc.1209899; Yu Y, 2008, J BIOL CHEM, V283, P24497, DOI 10.1074/jbc.M802825200	34	45	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	35					4938	4946		10.1038/onc.2010.244	http://dx.doi.org/10.1038/onc.2010.244			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20562916	Green Accepted			2022-12-17	WOS:000281578700008
J	Kim, M; Williamson, CT; Prudhomme, J; Bebb, DG; Riabowol, K; Lee, PWK; Lees-Miller, SP; Mori, Y; Rahman, MM; McFadden, G; Johnston, RN				Kim, M.; Williamson, C. T.; Prudhomme, J.; Bebb, D. G.; Riabowol, K.; Lee, P. W. K.; Lees-Miller, S. P.; Mori, Y.; Rahman, M. M.; McFadden, G.; Johnston, R. N.			The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status	ONCOGENE			English	Article						reovirus; myxoma virus; tumor suppressor; oncolytic virus; anticancer therapy	ACTIVATED RAS PATHWAY; SIGNALING PATHWAY; CANCER-THERAPY; PHASE-I; CELLS; P53; INFECTION; INTERFERON; REPLICATION; VIROTHERAPY	Replication-competent oncolytic viruses hold great potential for the clinical treatment of many cancers. Importantly, many oncolytic virus candidates, such as reovirus and myxoma virus, preferentially infect cancer cells bearing abnormal cellular signaling pathways. Reovirus and myxoma virus are highly responsive to activated Ras and Akt signaling pathways, respectively, for their specificity for viral oncolysis. However, considering the complexity of cancer cell populations, it is possible that other tumor-specific signaling pathways may also contribute to viral discrimination between normal versus cancer cells. Because carcinogenesis is a multistep process involving the accumulation of both oncogene activations and the inactivation of tumor suppressor genes, we speculated that not only oncogenes but also tumor suppressor genes may have an important role in determining the tropism of these viruses for cancer cells. It has been previously shown that many cellular tumor suppressor genes, such as p53, ATM and Rb, are important for maintaining genomic stability; dysfunction of these tumor suppressors may disrupt intact cellular antiviral activity due to the accumulation of genomic instability or due to interference with apoptotic signaling. Therefore, we speculated that cells with dysfunctional tumor suppressors may display enhanced susceptibility to challenge with these oncolytic viruses, as previously seen with adenovirus. We report here that both reovirus and myxoma virus preferentially infect cancer cells bearing dysfunctional or deleted p53, ATM and Rb tumor suppressor genes compared to cells retaining normal counterparts of these genes. Thus, oncolysis by these viruses may be influenced by both oncogenic activation and tumor suppressor status. Oncogene (2010) 29, 3990-3996; doi:10.1038/onc.2010.137; published online 17 May 2010	[Kim, M.; Williamson, C. T.; Prudhomme, J.; Riabowol, K.; Lees-Miller, S. P.; Mori, Y.; Johnston, R. N.] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; [Kim, M.; Rahman, M. M.; McFadden, G.] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL USA; [Bebb, D. G.] Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada; [Lee, P. W. K.] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada	University of Calgary; State University System of Florida; University of Florida; University of Calgary; Dalhousie University	Johnston, RN (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Room HMRB 307,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	rnjohnst@ucalgary.ca	Johnston, Randal/B-9247-2009	McFadden, Grant/0000-0002-2556-3526; Lees-Miller, Susan/0000-0001-5809-2516	Canadian Institutes of Health Research; Canadian Breast Cancer Foundation; University of Florida College of Medicine; NIH [R01 CA138541]; NATIONAL CANCER INSTITUTE [R01CA138541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI080607] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); University of Florida College of Medicine(University of Florida); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by funding from the Canadian Institutes of Health Research and the Canadian Breast Cancer Foundation (to RNJ) and a start-up grant from the University of Florida College of Medicine and NIH grant R01 CA138541 (to GM). GM is an International Scholar of the Howard Hughes Medical Institute.	Abou El Hassan MAI, 2004, J VIROL, V78, P12243, DOI 10.1128/JVI.78.22.12243-12251.2004; Alain T, 2002, BLOOD, V100, P4146, DOI 10.1182/blood-2002-02-0503; Bea S, 2009, BLOOD, V113, P3059, DOI 10.1182/blood-2008-07-170183; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Dharel N, 2008, HEPATOLOGY, V47, P1136, DOI 10.1002/hep.22176; DUNCAN MR, 1978, J VIROL, V28, P444, DOI 10.1128/JVI.28.2.444-449.1978; Duursma AM, 2003, SEMIN CANCER BIOL, V13, P267, DOI 10.1016/S1044-579X(03)00040-3; Forsyth P, 2008, MOL THER, V16, P627, DOI 10.1038/sj.mt.6300403; HASHIRO G, 1977, ARCH VIROL, V54, P307, DOI 10.1007/BF01314776; Huang S, 2004, CELL CYCLE, V3, P1043; Johnston JB, 2003, J VIROL, V77, P5877, DOI 10.1128/JVI.77.10.5877-5888.2003; Kim M, 2007, ONCOGENE, V26, P4124, DOI 10.1038/sj.onc.1210189; Kim M, 2009, LEUKEMIA, V23, P2313, DOI 10.1038/leu.2009.219; KIM M, 2007, AM SOC VIR ASV 2007; Kitagawa R, 2005, COLD SH Q B, V70, P99, DOI 10.1101/sqb.2005.70.002; Kozlov S, 2003, J BIOL CHEM, V278, P9309, DOI 10.1074/jbc.M300003200; Li DWC, 2006, ONCOGENE, V25, P3006, DOI 10.1038/sj.onc.1209334; Lun XQ, 2005, CANCER RES, V65, P9982, DOI 10.1158/0008-5472.CAN-05-1201; Lun XQ, 2007, CANCER RES, V67, P8818, DOI 10.1158/0008-5472.CAN-07-1214; McCormick F, 2005, ONCOGENE, V24, P7817, DOI 10.1038/sj.onc.1209064; McFadden G, 2005, NAT REV MICROBIOL, V3, P201, DOI 10.1038/nrmicro1099; Morris SM, 2002, MUTAT RES-REV MUTAT, V511, P45, DOI 10.1016/S1383-5742(01)00075-8; Munoz-Fontela C, 2008, J EXP MED, V205, P1929, DOI 10.1084/jem.20080383; Norman KL, 2005, DRUG DISCOV TODAY, V10, P847, DOI 10.1016/S1359-6446(05)03483-5; Norman KL, 2004, P NATL ACAD SCI USA, V101, P11099, DOI 10.1073/pnas.0404310101; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; REID TW, 1974, J NATL CANCER I, V53, P347, DOI 10.1093/jnci/53.2.347; Royds JA, 2006, ONCOGENE, V25, P1509, DOI 10.1038/sj.onc.1209185; Shmulevitz M, 2010, CANCER GENE THER, V17, P69, DOI 10.1038/cgt.2009.46; Song L, 2009, CANCER GENE THER, V16, P382, DOI 10.1038/cgt.2008.84; Stanford MM, 2008, MOL THER, V16, P52, DOI 10.1038/sj.mt.6300348; Stanford MM, 2007, EXPERT OPIN BIOL TH, V7, P1415, DOI 10.1517/14712598.7.9.1415; Strong JE, 1996, J VIROL, V70, P612, DOI 10.1128/JVI.70.1.612-616.1996; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; STRONG JE, 1993, VIROLOGY, V197, P405, DOI 10.1006/viro.1993.1602; Sypula J., 2004, GENE THER MOL BIOL, V8, P103; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Tucker CA, 2006, LEUKEMIA RES, V30, P449, DOI 10.1016/j.leukres.2005.08.016; Vidal L, 2008, CLIN CANCER RES, V14, P7127, DOI 10.1158/1078-0432.CCR-08-0524; Wang F, 2009, J VIROL, V83, P5928, DOI 10.1128/JVI.02587-08; Wang G, 2006, P NATL ACAD SCI USA, V103, P4640, DOI 10.1073/pnas.0509341103; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0	44	45	47	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	2010	29	27					3990	3996		10.1038/onc.2010.137	http://dx.doi.org/10.1038/onc.2010.137			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20473328	Green Accepted			2022-12-17	WOS:000279603200011
J	Kim, TH; Franco, HL; Jung, SY; Qin, J; Broaddus, RR; Lydon, JP; Jeong, JW				Kim, T. H.; Franco, H. L.; Jung, S. Y.; Qin, J.; Broaddus, R. R.; Lydon, J. P.; Jeong, J-W			The synergistic effect of Mig-6 and Pten ablation on endometrial cancer development and progression	ONCOGENE			English	Article						Mig-6; Pten; uterus; endometrial cancer	APOPTOSIS-INHIBITORY PROTEIN; ESTROGEN-RECEPTOR-ALPHA; TUMOR-SUPPRESSOR GENE; PROGESTERONE-RECEPTOR; AKT-PHOSPHORYLATION; SIGNAL-TRANSDUCTION; EXPRESSION; CARCINOMA; ACTIVATION; STRESS	Ablation of Mig-6 in the murine uterus leads to the development of endometrial hyperplasia and estrogen-induced endometrial cancer. An additional endometrial cancer mouse model is generated by the ablation of phosphatase and tensin homolog deleted from chromosome 10 (Pten) (either as heterozygotes or by conditional uterine ablation). To determine the interplay between Mig-6 and the PTEN/phosphoinositide 3-kinase signaling pathway during endometrial tumorigenesis, we generated mice with Mig-6 and Pten conditionally ablated in progesterone receptor-positive cells (PR(cre/+)Mig-6(f/f)Pten(f/f); Mig-6(d/d)Pten(d/d)). The ablation of both Mig-6 and Pten dramatically accelerated the development of endometrial cancer compared with the single ablation of either gene. The epithelium of Mig-6(d/d)Pten(d/d) mice showed a significant decrease in the number of apoptotic cells compared with Pten(d/d) mice. The expression of the estrogen-induced apoptotic inhibitors Birc1 was significantly increased in Mig-6(d/d)Pten(d/d) mice. We identified extracellular signal-regulated kinase 2 (ERK2) as an MIG-6 interacting protein by coimmunoprecipitation and demonstrated that the level of ERK2 phosphorylation was increased upon Mig-6 ablation either singly or in combination with Pten ablation. These results suggest that Mig-6 exerts a tumor-suppressor function in endometrial cancer by promoting epithelial cell apoptosis through the downregulation of the estrogen-induced apoptosis inhibitors Birc1 and the inhibition of ERK2 phosphorylation. Oncogene (2010) 29, 3770-3780; doi: 10.1038/onc.2010.126; published online 26 April 2010	[Kim, T. H.; Franco, H. L.; Jung, S. Y.; Qin, J.; Lydon, J. P.; Jeong, J-W] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Jung, S. Y.; Qin, J.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Broaddus, R. R.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Jeong, JW (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza,M725, Houston, TX 77030 USA.	jjeong@bcm.edu		Jung, Sung Yun/0000-0003-1521-7977	Reproductive Biology Training [T32HD007165]; Baylor Research Advocates for Student Scientists; NIH [R01CA77530, P50CA098258, R01HD057873]; Dan Duncan Cancer Center in Baylor College of Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007165, R01HD057873] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA098258, R01CA077530, P30CA016672] Funding Source: NIH RePORTER	Reproductive Biology Training; Baylor Research Advocates for Student Scientists; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dan Duncan Cancer Center in Baylor College of Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Francesco J DeMayo for fruitful discussion; Jinghua Li for technical assistance; Cory A Rubel, MS and Michael J Large for manuscript preparation. We also thank Dr Hong Wu for the floxed Pten mice. This work was supported by the Reproductive Biology Training Grant T32HD007165 and a scholarship from Baylor Research Advocates for Student Scientists (to HLF), NIH R01CA77530 (to JPL), NIH P50CA098258 (to RRB) and NIH R01HD057873 (to J-WJ). We thank the support of the pathway discovery core of the Dan Duncan Cancer Center in Baylor College of Medicine for proteomic work.	Acconcia F, 2006, CANCER LETT, V238, P1, DOI 10.1016/j.canlet.2005.06.018; Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; Bhat-Nakshatri P, 2008, MOL CELL BIOL, V28, P7487, DOI 10.1128/MCB.00799-08; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Boland R, 2008, STEROIDS, V73, P859, DOI 10.1016/j.steroids.2007.12.027; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Chambliss KL, 2002, MOL ENDOCRINOL, V16, P938, DOI 10.1210/me.16.5.938; Cheskis BJ, 2008, STEROIDS, V73, P901, DOI 10.1016/j.steroids.2007.12.028; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; Davoodi J, 2004, J BIOL CHEM, V279, P40622, DOI 10.1074/jbc.M405963200; DELIGDISCH L, 1987, CANCER DETECT PREV, V10, P237; Di Cristofano A, 2007, ANNU REV PATHOL-MECH, V2, P57, DOI 10.1146/annurev.pathol.2.010506.091905; Ejskjaer K, 2007, GYNECOL ONCOL, V104, P158, DOI 10.1016/j.ygyno.2006.07.015; ELDREDGE ER, 1994, MOL CELL BIOL, V14, P7527, DOI 10.1128/MCB.14.11.7527; Endrizzi MG, 2000, GENOME RES, V10, P1095, DOI 10.1101/gr.10.8.1095; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Ferby I, 2006, NAT MED, V12, P568, DOI 10.1038/nm1401; Franco HL, 2008, SEMIN CELL DEV BIOL, V19, P178, DOI 10.1016/j.semcdb.2007.12.001; Freeman D, 2006, CANCER RES, V66, P6492, DOI 10.1158/0008-5472.CAN-05-4143; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Gesty-Palmer D, 2005, J BIOL CHEM, V280, P32157, DOI 10.1074/jbc.M507460200; Ito K, 2007, ENDOCR J, V54, P667, DOI 10.1507/endocrj.KR-114; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jeong JW, 2009, P NATL ACAD SCI USA, V106, P8677, DOI 10.1073/pnas.0903632106; Jiang BH, 2008, BBA-PROTEINS PROTEOM, V1784, P150, DOI 10.1016/j.bbapap.2007.09.008; Jin N, 2007, GENESIS, V45, P716, DOI 10.1002/dvg.20348; Jung SY, 2008, ANAL CHEM, V80, P1721, DOI 10.1021/ac7021025; Jung SY, 2005, MOL ENDOCRINOL, V19, P2451, DOI 10.1210/me.2004-0476; Kakinuma N, 2008, J CELL BIOL, V181, P537, DOI 10.1083/jcb.200707022; Kanamori Y, 2001, CLIN CANCER RES, V7, P892; KHALIFA MA, 1994, GYNECOL ONCOL, V53, P84, DOI 10.1006/gyno.1994.1092; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Levine RL, 1998, CANCER RES, V58, P3254; Lian ZL, 2006, J CELL PHYSIOL, V208, P255, DOI 10.1002/jcp.20681; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; Malathi K, 2005, P NATL ACAD SCI USA, V102, P14533, DOI 10.1073/pnas.0507551102; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Saarikoski ST, 2002, FEBS LETT, V530, P186, DOI 10.1016/S0014-5793(02)03475-0; Sivridis E, 2004, INT J SURG PATHOL, V12, P99, DOI 10.1177/106689690401200202; Slaets H, 2008, PROTEOMICS, V8, P1237, DOI 10.1002/pmic.200700641; SMITH WL, 2000, ANNU REV BIOCHEM, V145, P182; Song RXD, 2003, APOPTOSIS, V8, P55, DOI 10.1023/A:1021649019025; Soyal SM, 2005, GENESIS, V41, P58, DOI 10.1002/gene.20098; Spyridopoulos I, 1997, CIRCULATION, V95, P1505; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun HB, 2001, AM J CLIN PATHOL, V115, P32; Tashker JS, 2002, MOL BIOL CELL, V13, P393, DOI 10.1091/mbc.01-06-0291; Thomas RS, 2008, J MOL ENDOCRINOL, V40, P173, DOI 10.1677/JME-07-0165; Vilgelm A, 2006, CANCER RES, V66, P3375, DOI 10.1158/0008-5472.CAN-05-4019; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yin Y, 2008, MOL ENDOCRINOL, V22, P113, DOI 10.1210/me.2007-0295; Zhang YW, 2007, ONCOGENE, V26, P269, DOI 10.1038/sj.onc.1209790; Zhang YW, 2007, CELL CYCLE, V6, P507, DOI 10.4161/cc.6.5.3928	61	45	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	2010	29	26					3770	3780		10.1038/onc.2010.126	http://dx.doi.org/10.1038/onc.2010.126			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20418913	Bronze, Green Accepted			2022-12-17	WOS:000279385200005
J	Xu, Y; Chen, Q; Li, W; Su, X; Chen, T; Liu, Y; Zhao, Y; Yu, C				Xu, Y.; Chen, Q.; Li, W.; Su, X.; Chen, T.; Liu, Y.; Zhao, Y.; Yu, C.			Overexpression of transcriptional coactivator AIB1 promotes hepatocellular carcinoma progression by enhancing cell proliferation and invasiveness	ONCOGENE			English	Article						amplified in breast cancer 1; hepatocellular carcinoma; cell proliferation; cell invasion	STEROID-RECEPTOR COACTIVATOR-3; BREAST-CANCER CELLS; SIGNALING PATHWAY; GROWTH; SRC-3; EXPRESSION; MICE; GENE; ACTIVATION; AMPLIFICATION	Amplified in breast cancer 1 (AIB1) is a transcriptional coactivator for nuclear receptors and other transcription factors. AIB1 has an important role in malignancy of several cancers such as breast and prostate cancers. However, its involvement in human hepatocellular carcinoma (HCC) progression remains unclear. Here, we found that AIB1 protein was overexpressed in 23 of 34 human HCC specimens (68%). Down-regulation of AIB1 reduced HCC cell proliferation, migration, invasion, colony formation ability and tumorigenic potential in nude mice. These phenotypic changes caused by AIB1 knockdown correlated with increased expression of the cell cycle inhibitor p21(Cip1/Waf1) and decreased Akt activation and the expression of proliferating cell nuclear antigen (PCNA) and matrix metallopeptidase MMP-9. In agreement with these findings, clinical AIB1-positive HCC expressed higher levels of PCNA than AIB1-negative HCC. A positive correlation was established between the levels of AIB1 protein and PCNA protein in HCC, suggesting that AIB1 may contribute to HCC cell proliferation. In addition, MMP-9 expression in AIB1-postive HCC was significantly higher than that in AIB1-negative HCC, suggesting that AIB1-postive HCC may be more invasive. Collectively, our results show that overexpression of AIB1 promotes human HCC progression by enhancing cell proliferation and invasiveness. Therefore, AIB1 is a master regulator of human HCC growth and might be a useful molecular target for HCC prognosis and treatment. Oncogene (2010) 29, 3386-3397; doi:10.1038/onc.2010.90; published online 22 March 2010	[Xu, Y.; Su, X.; Chen, T.; Liu, Y.; Zhao, Y.; Yu, C.] Xiamen Univ, Sch Life Sci, Key Lab Minist Educ Cell Biol & Tumor Cell Engn, Xiamen 361005, Fujian, Peoples R China; [Chen, Q.; Li, W.; Su, X.] Xiamen Univ, Affiliated Hosp 1, Xiamen 361005, Fujian, Peoples R China	Xiamen University; Xiamen University	Yu, C (corresponding author), Xiamen Univ, Sch Life Sci, Key Lab Minist Educ Cell Biol & Tumor Cell Engn, Xiamen 361005, Fujian, Peoples R China.	cdyu@xmu.edu.cn	xu, yixiang/J-4297-2017	xu, yixiang/0000-0001-5793-7783	National Basic Research Program of China [2008CB517311, 2009CB522200]; National Natural Science Foundation of China [30600566, 30770455]; 111 Project [06016]; Science Planning Program of Fujian Province [2009J1010]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 111 Project(Ministry of Education, China - 111 Project); Science Planning Program of Fujian Province	We thank Dr Li Qin for the MMP-9-promoter/reporter plasmid and Dr Jianming Xu for critical reading of the article. This work was supported by Grants from National Basic Research Program of China (973 Program, 2008CB517311 and 2009CB522200), National Natural Science Foundation of China (30600566 and 30770455), 111 Project (06016), and the Science Planning Program of Fujian Province (2009J1010).	Adams BD, 2009, MOL ENDOCRINOL, V23, P1215, DOI 10.1210/me.2009-0062; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Arii S, 1996, HEPATOLOGY, V24, P316; Bouras T, 2001, CANCER RES, V61, P903; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chung ACK, 2007, CANCER RES, V67, P5965, DOI 10.1158/0008-5472.CAN-06-3168; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Henke RT, 2004, CLIN CANCER RES, V10, P6134, DOI 10.1158/1078-0432.CCR-04-0561; Hossain A, 2006, MOL CELL BIOL, V26, P8191, DOI 10.1128/MCB.00242-06; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Kajiro M, 2009, NAT CELL BIOL, V11, P312, DOI 10.1038/ncb1839; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; KITAMOTO M, 1993, CANCER, V72, P1859, DOI 10.1002/1097-0142(19930915)72:6<1859::AID-CNCR2820720612>3.0.CO;2-A; Kuang SQ, 2005, CANCER RES, V65, P7993, DOI 10.1158/0008-5472.CAN-05-1179; Kuang SQ, 2004, CANCER RES, V64, P1875, DOI 10.1158/0008-5472.CAN-03-3745; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liang JA, 2009, MOL PHARMACOL, V75, P151, DOI 10.1124/mol.108.049502; Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; Ma CL, 2008, GASTROENTEROLOGY, V135, P947, DOI 10.1053/j.gastro.2008.05.046; Mussi P, 2006, MOL ENDOCRINOL, V20, P3105, DOI 10.1210/me.2005-0522; Nakanishi K, 2005, CANCER-AM CANCER SOC, V103, P307, DOI 10.1002/cncr.20774; Oh A, 2004, CANCER RES, V64, P8299, DOI 10.1158/0008-5472.CAN-04-0354; Qin L, 2008, MOL CELL BIOL, V28, P5937, DOI 10.1128/MCB.00579-08; Sakakura C, 2000, INT J CANCER, V89, P217; SATO H, 1993, ONCOGENE, V8, P395; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tan JA, 2000, ENDOCRINOLOGY, V141, P3440, DOI 10.1210/en.141.9.3440; Thaler S, 2009, CANCER RES, V69, P1748, DOI 10.1158/0008-5472.CAN-08-1377; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Wang Y, 2002, CANCER-AM CANCER SOC, V95, P2346, DOI 10.1002/cncr.10963; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Xie D, 2005, HUM PATHOL, V36, P777, DOI 10.1016/j.humpath.2005.05.007; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yan J, 2008, CANCER RES, V68, P5460, DOI 10.1158/0008-5472.CAN-08-0955; Yan J, 2006, CANCER RES, V66, P11039, DOI 10.1158/0008-5472.CAN-06-2442; Yu CD, 2003, AM J PATHOL, V163, P1653, DOI 10.1016/S0002-9440(10)63522-5; Zhou G, 2003, MOL CELL BIOL, V23, P7742, DOI 10.1128/MCB.23.21.7742-7755.2003; Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076	44	45	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2010	29	23					3386	3397		10.1038/onc.2010.90	http://dx.doi.org/10.1038/onc.2010.90			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20305690				2022-12-17	WOS:000278622700007
J	Markova, B; Albers, C; Breitenbuecher, F; Melo, JV; Brummendorf, TH; Heidel, F; Lipka, D; Duyster, J; Huber, C; Fischer, T				Markova, B.; Albers, C.; Breitenbuecher, F.; Melo, J. V.; Bruemmendorf, T. H.; Heidel, F.; Lipka, D.; Duyster, J.; Huber, C.; Fischer, T.			Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma 1-driven activation of mTOR/p70S6-kinase pathway	ONCOGENE			English	Article						Bcr-Abl; CML; PLC-gamma 1; signaling; mTOR; p70S6-kinase	PHOSPHOLIPASE-C-GAMMA; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; RIBOSOMAL-PROTEIN S6; MAMMALIAN TARGET; TYROSINE KINASE; POSITIVE CELLS; PHOSPHATIDYLINOSITOL-3 KINASE; HEMATOPOIETIC-CELLS; IMATINIB MESYLATE	In chronic myeloid leukemia, activation of the phosphoinositide 3-kinase (PI3K)/Akt pathway is crucial for survival and proliferation of leukemic cells. Essential downstream molecules involve mammalian target of rapamycin (mTOR) and S6-kinase. Here, we present a comprehensive analysis of the molecular events involved in activation of these key signaling pathways. We provide evidence for a previously unrecognized phospholipase C-gamma 1 (PLC-gamma 1)-controlled mechanism of mTOR/p70S6-kinase activation, which operates in parallel to the classical Akt-dependent machinery. Short-term imatinib treatment of Bcr-Abl-positive cells caused dephosphorylation of p70S6K and S6-protein without inactivation of Akt. Suppression of Akt activity alone did not affect phosphorylation of p70-S6K and S6. These results suggested the existence of an alternative mechanism for mTOR/p70S6-K activation. In Bcr-Abl-expressing cells, we detected strong PLC-gamma 1 activation, which was suppressed by imatinib. Pharmacological inhibition and siRNA knockdown of PLC-gamma 1 blocked p70S6-K and S6 phosphorylation. By inhibiting the Ca-signaling, CaMK and PKCs we demonstrated participation of these molecules in the pathway. Suppression of PLC-gamma 1 led to inhibition of cell proliferation and enhanced apoptosis. The novel pathway proved to be essential for survival and proliferation of leukemic cells and almost complete cell death was observed upon combined PLC-gamma 1 and Bcr-Abl inhibition. The pivotal role of PLC-gamma 1 was further confirmed in a mouse leukemogenesis model. Oncogene (2010) 29, 739-751; doi: 10.1038/onc.2009.374; published online 2 November 2009	[Heidel, F.; Lipka, D.; Fischer, T.] Otto von Guericke Univ, Dept Hematol Oncol, Med Ctr, Magdeburg, Germany; [Markova, B.; Breitenbuecher, F.] Univ Hosp, W German Canc Ctr, Dept Med Canc Res, Essen, Germany; [Albers, C.; Duyster, J.] Tech Univ Munich, Dept Internal Med 3, Munich, Germany; [Melo, J. V.] Inst Med & Vet Sci, Dept Haematol, Adelaide, SA 5000, Australia; [Bruemmendorf, T. H.] UCCH, Dept Oncol & Hematol, Hamburg, Germany; [Markova, B.; Breitenbuecher, F.; Heidel, F.; Lipka, D.; Huber, C.; Fischer, T.] Johannes Gutenberg Univ Mainz, Dept Med 3, Mainz, Germany	Otto von Guericke University; University of Duisburg Essen; Technical University of Munich; University of Munich; Institute Medical & Veterinary Science Australia; University of Hamburg; University Medical Center Hamburg-Eppendorf; Johannes Gutenberg University of Mainz	Fischer, T (corresponding author), Univ Magdeburg, Dept Hematol Oncol, Univ Med Ctr, Leipziger Str 44, D-39120 Magdeburg, Saxony Anhalt, Germany.	thomas.fischer@med.ovgu.de		Heidel, Florian/0000-0003-2438-1955				Arvisais EW, 2006, J BIOL CHEM, V281, P26904, DOI 10.1074/jbc.M605371200; Bartolovic K, 2004, BLOOD, V103, P523, DOI 10.1182/blood-2003-05-1535; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burchert A, 2005, LEUKEMIA, V19, P1774, DOI 10.1038/sj.leu.2403898; Copland M, 2008, BLOOD, V111, P2843, DOI 10.1182/blood-2007-09-112573; Dengler J, 2005, LEUKEMIA, V19, P1835, DOI 10.1038/sj.leu.2403848; DRUKER BJ, 2001, NEW ENGL J MED, V344, P1037; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Giles FJ, 2005, CURR MOL MED, V5, P653, DOI 10.2174/156652405774641034; GOTOH A, 1994, LEUKEMIA, V8, P115; Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Heidel F, 2006, BLOOD, V107, P293, DOI 10.1182/blood-2005-06-2469; Kharas NG, 2005, CANCER RES, V65, P2047, DOI 10.1158/0008-5472.CAN-04-3888; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; Kindler T, 2003, LEUKEMIA, V17, P999, DOI 10.1038/sj.leu.2402940; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; Liao HJ, 2002, J BIOL CHEM, V277, P9335, DOI 10.1074/jbc.M109955200; Ly C, 2003, CANCER RES, V63, P5716; Maffucci T, 2007, BIOCHEM SOC T, V35, P229, DOI 10.1042/BST0350229; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Marley SB, 2005, CLIN SCI, V109, P13, DOI 10.1042/CS20040336; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; Miething C, 2006, LEUKEMIA, V20, P650, DOI 10.1038/sj.leu.2404151; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Ren SY, 2005, EXP HEMATOL, V33, P1222, DOI 10.1016/j.exphem.2005.06.030; RHEE S, 2000, BIOL PHOSPHOINOSITID, V27; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Richardson CJ, 2004, SEMIN CELL DEV BIOL, V15, P147, DOI 10.1016/j.semcdb.2003.12.023; Saglio G, 2004, CELL MOL LIFE SCI, V61, P2897, DOI 10.1007/s00018-004-4271-0; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Si JT, 2008, CANCER RES, V68, P3733, DOI 10.1158/0008-5472.CAN-07-2509; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Van Etten RA, 2002, ONCOGENE, V21, P8643, DOI 10.1038/sj.onc.1206091; Walz C, 2006, CRIT REV ONCOL HEMAT, V57, P145, DOI 10.1016/j.critrevonc.2005.06.007; Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898-6568(01)00191-7; Wing LYC, 2005, J BIOL CHEM, V280, P19937, DOI 10.1074/jbc.M411865200; Wlodarski P, 2005, CANCER RES, V65, P7800, DOI 10.1158/0008-5472.CAN-04-4180; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	46	45	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					739	751		10.1038/onc.2009.374	http://dx.doi.org/10.1038/onc.2009.374			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19881535				2022-12-17	WOS:000274223700010
J	Cohen, SB; Ma, W; Valova, VA; Algie, M; Harfoot, R; Woolley, AG; Robinson, PJ; Braithwaite, AW				Cohen, S. B.; Ma, W.; Valova, V. A.; Algie, M.; Harfoot, R.; Woolley, A. G.; Robinson, P. J.; Braithwaite, A. W.			Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing	ONCOGENE			English	Article						YB-1; oncoprotein; proteolysis; nuclear; translocation	BOX-BINDING-PROTEIN; MDR1 GENE-EXPRESSION; COLD SHOCK DOMAIN; P-GLYCOPROTEIN; DISEASE; CELLS; BINDING-PROTEIN-1; PROGRESSION; RESISTANCE; CISPLATIN	Y-box-binding protein 1 (YB-1) is an oncogenic transcription factor whose overexpression and nuclear localization is associated with tumor progression and drug resistance. Transcriptional activation of YB-1 in response to genotoxic stress is believed to occur in the cytoplasm through sequence-specific endoproteolytic cleavage by the 20S Proteasome, followed by nuclear translocation of cleaved YB-1. To study the proteolysis model, we developed a two-step affinity purification of endogenous YB-1 protein species and characterized the products using mass spectrometry. Whereas full-length YB-1 was readily identified, the smaller protein band thought to be activated YB-1 was identified as hnRNP A1. An antibody specific for YB-1 was generated, which revealed only one YB-1 species, even after genotoxic stress-induced nuclear YB-1 translocation. These findings warrant re-evaluation of the mechanism of YB-1 nuclear translocation and transcriptional activation. The relationship between nuclear YB-1 and tumor progression may also have to re-evaluated in some cases. Oncogene (2010) 29, 403-410; doi:10.1038/onc.2009.321; published online 19 October 2009	[Cohen, S. B.; Ma, W.; Braithwaite, A. W.] Childrens Med Res Inst, Cell Transformat Unit, Westmead, NSW 2145, Australia; [Cohen, S. B.; Robinson, P. J.; Braithwaite, A. W.] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; [Valova, V. A.; Robinson, P. J.] Childrens Med Res Inst, Cell Signalling Unit, Westmead, NSW 2145, Australia; [Algie, M.; Harfoot, R.; Woolley, A. G.; Braithwaite, A. W.] Univ Otago, Dunedin Sch Med, Dept Pathol, Cell Transformat Grp, Dunedin, New Zealand	Children's Medical Research Institute - Australia; University of Sydney; Children's Medical Research Institute - Australia; University of Otago	Braithwaite, AW (corresponding author), Childrens Med Res Inst, Cell Transformat Unit, 214 Hawkesbury Rd, Westmead, NSW 2145, Australia.	abraithwaite@cmri.org.au	Robinson, Phillip J/G-4008-2011	Robinson, Phillip J/0000-0002-7878-0313; Algie, Michael/0000-0002-0568-331X	National Health & Medical Research Council of Australia [423405, 477100]; Cancer Institute NSW [05/RLP/1-01]; Health Research Council of New Zealand [07/284A]; Children's Medical Research Institute Jeans-for-Genes Campaign	National Health & Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW; Health Research Council of New Zealand(Health Research Council of New Zealand); Children's Medical Research Institute Jeans-for-Genes Campaign	We thank Professor H-D Royer (CASEAR, Bonn, Germany) for a generous gift of the C-terminal YB-1 antibody. This research was supported by the National Health & Medical Research Council of Australia (SBC, 423405; PJP, 477100), the Cancer Institute NSW (AWB, WM, 05/RLP/1-01), the Health Research Council of New Zealand (AWB, AMW, RH, MA 07/284A) and the Children's Medical Research Institute Jeans-for-Genes Campaign (VAV).	ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Berquin IM, 2005, ONCOGENE, V24, P3177, DOI 10.1038/sj.onc.1208504; Chatterjee M, 2008, BLOOD, V111, P3714, DOI 10.1182/blood-2007-05-089151; Fujita T, 2005, CLIN CANCER RES, V11, P8837, DOI 10.1158/1078-0432.CCR-05-0945; Gimenez-Bonafe P, 2004, PROSTATE, V59, P337, DOI 10.1002/pros.20023; Guay D, 2008, INT J BIOCHEM CELL B, V40, P2492, DOI 10.1016/j.biocel.2008.04.011; HORWITZ EM, 1994, J BIOL CHEM, V269, P14130; Ito Y, 2003, PATHOL INT, V53, P429, DOI 10.1046/j.1440-1827.2003.01494.x; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Lee SM, 2006, NEUROSCI LETT, V401, P188, DOI 10.1016/j.neulet.2006.03.016; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Oda Y, 2003, J PATHOL, V199, P251, DOI 10.1002/path.1282; Ohga T, 1996, CANCER RES, V56, P4224; Raffetseder U, 2003, J BIOL CHEM, V278, P18241, DOI 10.1074/jbc.M212518200; Shibahara K, 2001, CLIN CANCER RES, V7, P3151; Sorokin AV, 2005, EMBO J, V24, P3602, DOI 10.1038/sj.emboj.7600830; Stenina OI, 2000, J CLIN INVEST, V106, P579, DOI 10.1172/JCI9075; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	20	45	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					403	410		10.1038/onc.2009.321	http://dx.doi.org/10.1038/onc.2009.321			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19838214				2022-12-17	WOS:000273793200009
J	Lee, JJ; Lee, JH; Ko, YG; Hong, SI; Lee, JS				Lee, J-J; Lee, J-H; Ko, Y-G; Hong, S. I.; Lee, J-S			Prevention of premature senescence requires JNK regulation of Bcl-2 and reactive oxygen species	ONCOGENE			English	Article						premature senescence; JNK; Bcl-2; ROS; DNA damage	CELL-CYCLE PROGRESSION; PROTEIN-KINASE; KAPPA-B; PHOSPHORYLATION; APOPTOSIS; INHIBITION; CANCER; ACTIVATION; INDUCTION; ARREST	Premature senescence is considered as a cellular defense mechanism to prevent tumorigenesis. Although recent evidences show that c-Jun N-terminal kinase (JNK) is involved in the senescence process, the mechanism for this regulation is not fully understood. Here, we examined the role of JNK in premature senescence of tumor cells. Treatment of cells with the JNK-specific inhibitor SP600125 caused phenotypical changes of senescence and triggered a rapid increase in mitochondrial reactive oxygen species (ROS) production and DNA-damage response (DDR) in MCF7 breast carcinoma cells. ROS generation was attributed to the suppression of B-cell lymphoma-2 (Bcl-2) phosphorylation, and resulted in DNA damage and p53 activation. Bax did not change their localization to the mitochondria, which is required for apoptosis. The essential roles of JNK and phosphorylated Bcl-2 in preventing premature senescence were confirmed using RNA interference and ectopic expression of mutants of Bcl-2, including phosphomimetic and nonphosphorylatable forms. These findings were evidenced in H460 lung carcinoma cells and primary human embryonic fibroblasts. Altogether, our results showed that loss of JNK activity triggers a Bcl-2/ROS/DDR signaling cascade that ultimately leads to premature senescence, indicating that basal JNK activity is essential in preventing premature senescence. Oncogene (2010) 29, 561-575; doi: 10.1038/onc.2009.355; published online 26 October 2009	[Lee, J-J; Lee, J-S] Korea Inst Radiol & Med Sci, Div Radiat Canc Res, Seoul 139706, South Korea; [Lee, J-J; Ko, Y-G] Korea Univ, Grad Sch Life Sci & Biotechnol, Seoul, South Korea; [Lee, J-H] Catholic Univ, Coll Med, Dept Biochem, Seoul, South Korea; [Hong, S. I.] Korea Inst Radiol & Med Sci, Dept Lab Med & Clin Pathol, Seoul 139706, South Korea	Korea Institute of Radiological & Medical Sciences; Korea University; Catholic University of Korea; Korea Institute of Radiological & Medical Sciences	Lee, JS (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Canc Res, 75 Nowongil, Seoul 139706, South Korea.	jaeslee@kcch.re.kr			Korean government (MEST)	Korean government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	We thank Professor WS May of the University of Florida, USA for the kind gift of Bcl-2 mutant constructs and Professor J-Y Lee of the Hallym University, Korea for the kind supply of HEF cells. This work was supported by the Nuclear Research & Development Program of the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korean government (MEST).	Autret A, 2007, J VIROL, V81, P7504, DOI 10.1128/JVI.02690-06; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bihani T, 2007, J BIOL CHEM, V282, P2666, DOI 10.1074/jbc.M608127200; Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936; Bulgin D, 2006, THYROID, V16, P217, DOI 10.1089/thy.2006.16.217; Byun HO, 2009, CANCER RES, V69, P4638, DOI 10.1158/0008-5472.CAN-08-4042; Campisi J, 2005, SCIENCE, V309, P886, DOI 10.1126/science.1116801; Chan SHH, 2006, FREE RADICAL BIO MED, V40, P2028, DOI 10.1016/j.freeradbiomed.2006.01.032; Crescenzi E, 2003, BIOCHEM J, V375, P263, DOI 10.1042/BJ20030868; Das M, 2007, P NATL ACAD SCI USA, V104, P15759, DOI 10.1073/pnas.0707782104; Deng XM, 2006, MOL CELL BIOL, V26, P4421, DOI 10.1128/MCB.01647-05; Deng XM, 2004, P NATL ACAD SCI USA, V101, P153, DOI 10.1073/pnas.2533920100; Deng XM, 2003, BLOOD, V102, P3179, DOI 10.1182/blood-2003-04-1027; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Du LH, 2005, ONCOGENE, V24, P107, DOI 10.1038/sj.onc.1208189; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; GEWIRTZ DA, 2008, BIOCHEM PHARMACOL, V76, P957; GOLETZ TJ, 1994, COLD SPRING HARB SYM, V59, P59, DOI 10.1101/SQB.1994.059.01.009; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Huang STJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0852com; Jones KR, 2005, INT J RADIAT BIOL, V81, P445, DOI 10.1080/09553000500168549; Kerr LE, 2007, ONCOGENE, V26, P2554, DOI 10.1038/sj.onc.1210044; Kim HS, 2005, MECH AGEING DEV, V126, P1255, DOI 10.1016/j.mad.2005.07.002; Kramer DL, 2001, CANCER RES, V61, P7754; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; MacLaren A, 2004, MOL CELL BIOL, V24, P9006, DOI 10.1128/MCB.24.20.9006-9018.2004; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Marchetti A, 2004, CELL DEATH DIFFER, V11, P596, DOI 10.1038/sj.cdd.4401368; Mates J M, 1999, Front Biosci, V4, pD339; Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147; Muller IM, 2005, MOL PHARMACOL, V67, P1684, DOI 10.1124/mol.104.004234; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Oliva JL, 2008, J BIOL CHEM, V283, P5466, DOI 10.1074/jbc.M707576200; Oruetxebarria I, 2004, J BIOL CHEM, V279, P3807, DOI 10.1074/jbc.M309333200; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Qian YJ, 2008, J BIOL CHEM, V283, P2896, DOI 10.1074/jbc.M708624200; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Roninson IB, 2003, CANCER RES, V63, P2705; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Ruas M, 2007, MOL CELL BIOL, V27, P4273, DOI 10.1128/MCB.02286-06; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Schmitt Estelle, 2007, Journal of Zhejiang University-Science B, V8, P377, DOI 10.1631/jzus.2007.B0377; Sharpless NE, 2004, EXP GERONTOL, V39, P1751, DOI 10.1016/j.exger.2004.06.025; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sunayama J, 2005, J CELL BIOL, V170, P295, DOI 10.1083/jcb.200409117; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tafani M, 2002, J BIOL CHEM, V277, P49569, DOI 10.1074/jbc.M208915200; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Tombor B, 2003, BIOCHEM BIOPH RES CO, V303, P800, DOI 10.1016/S0006-291X(03)00402-9; Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Turjanski AG, 2007, ONCOGENE, V26, P3240, DOI 10.1038/sj.onc.1210415; Vigneron A, 2005, CANCER RES, V65, P8927, DOI 10.1158/0008-5472.CAN-05-0461; Wada T, 2004, NAT CELL BIOL, V6, P215, DOI 10.1038/ncb1098; Xia HHX, 2006, CANCER LETT, V241, P268, DOI 10.1016/j.canlet.2005.10.031; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zhang P, 2006, ONCOGENE, V25, P7758, DOI 10.1038/sj.onc.1209744; Zimmermann AK, 2007, J BIOL CHEM, V282, P29296, DOI 10.1074/jbc.M702853200	67	45	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					561	575		10.1038/onc.2009.355	http://dx.doi.org/10.1038/onc.2009.355			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19855432				2022-12-17	WOS:000274084600009
J	Yamagata, H; Shimizu, S; Nishida, Y; Watanabe, Y; Craigen, WJ; Tsujimoto, Y				Yamagata, H.; Shimizu, S.; Nishida, Y.; Watanabe, Y.; Craigen, W. J.; Tsujimoto, Y.			Requirement of voltage-dependent anion channel 2 for pro-apoptotic activity of Bax	ONCOGENE			English	Article						apoptosis; Bax; VDAC; mitochondria	OUTER MITOCHONDRIAL-MEMBRANE; CYTOCHROME-C RELEASE; CELL-DEATH; PROTEINS; FAMILY; VDAC; LIFE; OLIGOMERIZATION; ACTIVATION; MICE	Mitochondrial membrane permeabilization is central to apoptotic signaling and is directly regulated by the Bcl-2 family of proteins, consisting of anti-apoptotic members and pro-apoptotic members, although the precise mechanisms involved remain elusive. When cells are deficient in both pro-apoptotic multidomain members of this family (Bax and Bak), mitochondrial membrane permeabilization does not occur in response to various apoptotic stimuli. We have previously reported that the voltage-dependent anion channel (VDAC or porin) plays a role in apoptotic mitochondrial membrane permeabilization by interacting with Bcl-2 family members. Here, we have provided additional evidence that VDAC2 is required for pro-apoptotic activity of Bax in the absence of Bak. In the absence of Bak, VDAC2-deficient cells showed strong resistance to various apoptotic stimuli, whereas reintroduction of the Vdac2 gene restored their apoptotic response. Consistently, silencing of VDAC2 in Bak-deficient cells, but not Bax-deficient cells, also conferred resistance to various apoptotic stimuli. In the absence of VDAC2 and Bak, the activation of Bax (assessed by mitochondrial membrane integration, conformational changes and oligomerization) was markedly impaired. Taken together, these findings indicate that VDAC2 is required for pro-apoptotic activity of Bax in the absence of Bak. Oncogene (2009) 28, 3563-3572; doi: 10.1038/onc.2009.213; published online 20 July 2009	[Yamagata, H.; Shimizu, S.; Nishida, Y.; Tsujimoto, Y.] Osaka Univ, Dept Med Genet, Sch Med, Suita, Osaka 5650871, Japan; [Yamagata, H.; Watanabe, Y.] Yamaguchi Univ, Sch Med, Dept Neuropsychiat, Yamaguchi, Japan; [Shimizu, S.; Nishida, Y.] Tokyo Med & Dent Univ, Med Res Inst, Dept Pathol Cell Biol, Tokyo, Japan; [Craigen, W. J.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Craigen, W. J.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Osaka University; Yamaguchi University; Tokyo Medical & Dental University (TMDU); Baylor College of Medicine; Baylor College of Medicine	Tsujimoto, Y (corresponding author), Osaka Univ, Dept Med Genet, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tsujimot@gene.med.osaka-u.ac.jp			SORST of the Japan Science and Technology Corporation (JST); Japan Society for the Promotion of Science; Ministry of Education, Science, Sports and Culture; Ministry of Health, Labor and Welfare, Japan	SORST of the Japan Science and Technology Corporation (JST)(Japan Science & Technology Agency (JST)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Science, Sports and Culture(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan)	We are grateful to Dr Kitamura for providing of Plat-E cells. This study was supported in part by SORST of the Japan Science and Technology Corporation (JST), a grant for Creative Scientific Research from Japan Society for the Promotion of Science, a grant for the 21st Century COE Program from the Ministry of Education, Science, Sports and Culture, and a grant for Comprehensive Research on Aging and Health from the Ministry of Health, Labor and Welfare, Japan.	Abu-Hamad S, 2006, P NATL ACAD SCI USA, V103, P5787, DOI 10.1073/pnas.0600103103; Abu-Hamad S, 2008, J BIOL CHEM, V283, P13482, DOI 10.1074/jbc.M708216200; Anflous K, 2001, J BIOL CHEM, V276, P1954, DOI 10.1074/jbc.M006587200; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Baehrecke EH, 2002, NAT REV MOL CELL BIO, V3, P779, DOI 10.1038/nrm931; Baines CP, 2007, NAT CELL BIOL, V9, P550, DOI 10.1038/ncb1575; Bellot G, 2007, CELL DEATH DIFFER, V14, P785, DOI 10.1038/sj.cdd.4402055; Blachly-Dyson E, 2001, IUBMB LIFE, V52, P113; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Neise D, 2008, ONCOGENE, V27, P1387, DOI 10.1038/sj.onc.1210773; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Ott M, 2007, J BIOL CHEM, V282, P27633, DOI 10.1074/jbc.M703155200; Rapaport D, 2003, EMBO REP, V4, P948, DOI 10.1038/sj.embor.embor937; Sampson MJ, 2001, J BIOL CHEM, V276, P39206, DOI 10.1074/jbc.M104724200; Sampson MJ, 1997, J BIOL CHEM, V272, P18966, DOI 10.1074/jbc.272.30.18966; Sampson MJ, 1996, GENOMICS, V33, P283, DOI 10.1006/geno.1996.0193; Setoguchi K, 2006, EMBO J, V25, P5635, DOI 10.1038/sj.emboj.7601438; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Shoshan-Barmatz V, 2006, CURR PHARM DESIGN, V12, P2249, DOI 10.2174/138161206777585111; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	32	45	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2009	28	40					3563	3572		10.1038/onc.2009.213	http://dx.doi.org/10.1038/onc.2009.213			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KI	19617898	Bronze			2022-12-17	WOS:000270851700005
J	Sarangi, A; Valadez, JG; Rush, S; Abel, TW; Thompson, RC; Cooper, MK				Sarangi, A.; Valadez, J. G.; Rush, S.; Abel, T. W.; Thompson, R. C.; Cooper, M. K.			Targeted inhibition of the Hedgehog pathway in established malignant glioma xenografts enhances survival	ONCOGENE			English	Article						brain tumor; glioma; Hedgehog; xenotransplantation; cyclopamine	NEURAL STEM-CELLS; MOUSE MODELS; BRAIN-TUMORS; GROWTH; MEDULLOBLASTOMA; CLASSIFICATION; IDENTIFICATION; CYCLOPAMINE; DRIVEN	Hedgehog pathway activity has been demonstrated in malignant glioma. However, its role in tumor growth has not been determined. Here we demonstrate that pharmacological inhibition of the Hedgehog pathway in established orthotopic malignant glioma xenografts confers a survival advantage. Pathway inhibition is measured in transplanted human tumor cells and not in host mouse brain. Correspondingly, survival benefit is observed only in tumors with an operational Hedgehog pathway. These data indicate that Hedgehog signaling regulates the growth of select malignant gliomas. We also demonstrate that Hedgehog pathway component and gene target expression segregate to CD133(+) tumor initiating cells. Treated mice eventually succumb to disease, thus, targeting the Hedgehog pathway in CD133(+) cells produces significant, but incomplete tumor regression. Therefore, our studies suggest that more complete tumor regression may require the inclusion of other therapeutic targets, including CD133(-) cells. Oncogene (2009) 28, 3468-3476; doi: 10.1038/onc.2009.208; published online 20 July 2009	[Sarangi, A.; Valadez, J. G.; Cooper, M. K.] Vanderbilt Univ Sch Med, Dept Neurol, Nashville, TN 37232 USA; [Sarangi, A.; Cooper, M. K.] Vanderbilt Univ Sch Med, Vanderbilt Neurosci Grad Program, Nashville, TN 37232 USA; [Rush, S.] Vanderbilt Univ Sch Med, Dept Pediat, Nashville, TN 37232 USA; [Abel, T. W.] Vanderbilt Univ Sch Med, Dept Pathol, Nashville, TN 37232 USA; [Thompson, R. C.] Vanderbilt Univ Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Thompson, R. C.] Vanderbilt Univ Sch Med, Dept Neurol Surg, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Cooper, MK (corresponding author), Vanderbilt Univ Sch Med, Dept Neurol, MRB3,Rm 6160,465 21st Ave S, Nashville, TN 37232 USA.	michael.cooper@vanderbilt.edu	Rush, Sarah/AAA-1701-2020		Vanderbilt Ingram Cancer Center [P30 CA68485]; Vanderbilt Digestive Disease Research Center [DK058404]; MKC from the NINDS [K02 NS053614]; Burroughs Wellcome Fund; Doris Duke Charitable Foundation; VMC development funds; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K02NS053614] Funding Source: NIH RePORTER	Vanderbilt Ingram Cancer Center; Vanderbilt Digestive Disease Research Center; MKC from the NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Burroughs Wellcome Fund(Burroughs Wellcome Fund); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); VMC development funds; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We are grateful to Infinity Pharmaceuticals for supplying cyclopamine. Histological services were performed, in part, by the Vanderbilt Medical Center (VMC) Human Tissue Acquisition and Pathology Shared Resource (supported by the Vanderbilt Ingram Cancer Center, P30 CA68485). Flow cytometry experiments were performed in the VMC Flow Cytometry Shared Resource (supported by the Vanderbilt Ingram Cancer Center, P30 CA68485, and the Vanderbilt Digestive Disease Research Center, DK058404). This work was supported by grants to MKC from the NINDS (K02 NS053614), the Burroughs Wellcome Fund and the Doris Duke Charitable Foundation (for human tissues) and VMC development funds (for animal studies).	Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Ehtesham M, 2007, ONCOGENE, V26, P5752, DOI 10.1038/sj.onc.1210359; Fomchenko EI, 2006, CLIN CANCER RES, V12, P5288, DOI 10.1158/1078-0432.CCR-06-0438; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; Gutmann David H, 2006, Cancer Res, V66, P10, DOI 10.1158/0008-5472.CAN-05-3180; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; KLEIHUES P, 1995, GLIA, V15, P211, DOI 10.1002/glia.440150303; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Ligon KL, 2007, NEURON, V53, P503, DOI 10.1016/j.neuron.2007.01.009; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Ogden AT, 2008, NEUROSURGERY, V62, P505, DOI 10.1227/01.neu.0000316019.28421.95; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Rohatgi R, 2007, NAT CELL BIOL, V9, P1005, DOI 10.1038/ncb435; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Sanchez P, 2005, MECH DEVELOP, V122, P223, DOI 10.1016/j.mod.2004.10.002; Shu Q, 2008, STEM CELLS, V26, P1414, DOI 10.1634/stemcells.2007-1009; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Suggitt M, 2005, CLIN CANCER RES, V11, P971; Trowbridge JJ, 2006, P NATL ACAD SCI USA, V103, P14134, DOI 10.1073/pnas.0604568103; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Weinstein IB, 2008, CANCER RES, V68, P3086; Xu QJ, 2008, STEM CELLS, V26, P3018, DOI 10.1634/stemcells.2008-0459; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Zhang XM, 2001, CELL, V105, P781, DOI 10.1016/S0092-8674(01)00385-3; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	37	45	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	39					3468	3476		10.1038/onc.2009.208	http://dx.doi.org/10.1038/onc.2009.208			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	502RR	19617900	Green Accepted			2022-12-17	WOS:000270478300004
J	Kiessling, A; Hogrefe, C; Erb, S; Bobach, C; Fuessel, S; Wessjohann, L; Seliger, B				Kiessling, A.; Hogrefe, C.; Erb, S.; Bobach, C.; Fuessel, S.; Wessjohann, L.; Seliger, B.			Expression, regulation and function of the ISGylation system in prostate cancer	ONCOGENE			English	Article						ISG15; prostate cancer; androgen receptor; androgen-regulated genes	UBIQUITIN-LIKE PROTEIN; ANDROGEN RECEPTOR EXPRESSION; RESPONSIVE FINGER PROTEIN; RAT VENTRAL PROSTATE; HUMAN BREAST-CANCER; ISG15 E3 LIGASE; NEGATIVE REGULATION; EPITHELIAL-CELLS; GENE-EXPRESSION; LUNG-CANCER	The androgen receptor (AR) plays a crucial role in the modulation of prostate cell proliferation and is involved in the development and progression of prostate cancer (PCa). An understanding of the complex regulation of AR provides novel treatment options for PCa. Here, we show (i) that the ubiquitin-like modifier, interferon-stimulated gene 15 (ISG15), and most enzymes involved in ISG15 conjugation were upregulated in tumor samples versus in non-malignant tissues of PCa patients and (ii) that the expression of these components significantly differed between tumors in patients treated with and without androgen ablation. Using PCa cell lines as in vitro models, the specific androgen-mediated, AR-dependent regulation of the ISGylation components was confirmed. In addition, the ISGylation system controls AR mRNA and protein expressions, as overexpression of Ube1L as a limiting ISGylation factor in the AR(+) androgen-sensitive PCa cell line, LNCaP, results in significant AR upregulation, accompanied by an increased proliferation even under androgen deprivation. Accordingly, Ube1L knockdown decreased the AR expression. Thus, this study describes for the. first time the modulation of AR expression by ISGylation components, which affects the proliferation of PCa cells, thereby providing evidence for a novel function of the ISGylation system in malignant transformation. Oncogene (2009) 28, 2606-2620; doi: 10.1038/onc.2009.115; published online 11 May 2009	[Kiessling, A.; Hogrefe, C.; Erb, S.; Seliger, B.] Univ Halle Wittenberg, Inst Med Immunol, Fac Med, D-06112 Halle, Germany; [Bobach, C.; Wessjohann, L.] Leibniz Inst Plant Biochem, Dept Bioorgan Chem, Halle, Germany; [Fuessel, S.] Tech Univ Dresden, Dept Urol, Med Fac Carl Gustav Carus, Dresden, Germany	Martin Luther University Halle Wittenberg; Leibniz Institut fur Pflanzenbiochemie; Technische Universitat Dresden; Carl Gustav Carus University Hospital	Seliger, B (corresponding author), Univ Halle Wittenberg, Inst Med Immunol, Fac Med, Magdeburger Str 2, D-06112 Halle, Germany.	Andrea.Kiessling@novartis.com; Barbara.Seliger@medizin.uni-halle.de	Wessjohann, Ludger/AAZ-3838-2021	Wessjohann, Ludger A./0000-0003-2060-8235; Seliger, Barbara/0000-0002-5544-4958				Andersen JB, 2006, BRIT J CANCER, V94, P1465, DOI 10.1038/sj.bjc.6603099; Andersen JB, 2006, CYTOKINE GROWTH F R, V17, P411, DOI 10.1016/j.cytogfr.2006.10.001; Asirvatham AJ, 2006, ENDOCRINOLOGY, V147, P257, DOI 10.1210/en.2005-0942; Basrawala Z, 2006, ONCOGENE, V25, P2812, DOI 10.1038/sj.onc.1209304; Bektas N, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2117; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315; Callewaert L, 2004, MOL ENDOCRINOL, V18, P1438, DOI 10.1210/me.2003-0313; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Culig Z, 1998, BRIT J CANCER, V78, P1004, DOI 10.1038/bjc.1998.619; Dastur A, 2006, J BIOL CHEM, V281, P4334, DOI 10.1074/jbc.M512830200; Desai KV, 2004, MOL ENDOCRINOL, V18, P2895, DOI 10.1210/me.2004-0033; Desai SD, 2006, CANCER RES, V66, P921, DOI 10.1158/0008-5472.CAN-05-1123; Desai SD, 2008, MOL CANCER THER, V7, P1430, DOI 10.1158/1535-7163.MCT-07-2345; Edwards J, 2003, BRIT J CANCER, V89, P552, DOI 10.1038/sj.bjc.6601127; Feng Q, 2008, MOL CANCER THER, V7, P3780, DOI 10.1158/1535-7163.MCT-08-0753; Giannakopoulos NV, 2005, BIOCHEM BIOPH RES CO, V336, P496, DOI 10.1016/j.bbrc.2005.08.132; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; GONG YW, 1995, ENDOCRINOLOGY, V136, P2172, DOI 10.1210/en.136.5.2172; Gregory CW, 2001, CANCER RES, V61, P2892; Gregory CW, 2001, CANCER RES, V61, P4315; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Ikeda K, 2000, FEBS LETT, V472, P9, DOI 10.1016/S0014-5793(00)01421-6; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jung D, 1999, SCAND J IMMUNOL, V50, P242; Kalvakolanu DV, 2000, HISTOL HISTOPATHOL, V15, P523, DOI 10.14670/HH-15.523; Khodarev NN, 2007, CANCER RES, V67, P9214, DOI 10.1158/0008-5472.CAN-07-1019; Kim KI, 2004, MOL CELL BIOL, V24, P9592, DOI 10.1128/MCB.24.21.9592-9600.2004; Ko S, 2008, MOL ENDOCRINOL, V22, P273, DOI 10.1210/me.2007-0332; KORANT BD, 1984, J BIOL CHEM, V259, P4835; Li R, 2004, AM J SURG PATHOL, V28, P928, DOI 10.1097/00000478-200407000-00013; Lin DL, 2001, CLIN CANCER RES, V7, P1773; Linja MJ, 2001, CANCER RES, V61, P3550; Liu MJ, 2004, J INTERF CYTOK RES, V24, P647, DOI 10.1089/jir.2004.24.647; Maggiolini M, 2004, J MOL ENDOCRINOL, V32, P777, DOI 10.1677/jme.0.0320777; Malakhov MP, 2003, J BIOL CHEM, V278, P16608, DOI 10.1074/jbc.M208435200; Malakhova OA, 2008, J BIOL CHEM, V283, P8783, DOI 10.1074/jbc.C800030200; Mitsui K, 1999, BIOCHEM BIOPH RES CO, V266, P115, DOI 10.1006/bbrc.1999.1777; Nakajima A, 2007, BIOCHEM BIOPH RES CO, V357, P245, DOI 10.1016/j.bbrc.2007.03.134; Nantermet PV, 2004, J BIOL CHEM, V279, P1310, DOI 10.1074/jbc.M310206200; Okumura F, 2007, GENE DEV, V21, P255, DOI 10.1101/gad.1521607; Olshavsky NA, 2008, ONCOGENE, V27, P3111, DOI 10.1038/sj.onc.1210981; Pitterle DM, 1998, IN VIVO, V12, P643; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Reddy GPV, 2006, J CELL BIOCHEM, V98, P1408, DOI 10.1002/jcb.20927; Rokhlin OW, 2005, ONCOGENE, V24, P6773, DOI 10.1038/sj.onc.1208833; Sakuma M, 2005, GYNECOL ONCOL, V99, P664, DOI 10.1016/j.ygyno.2005.07.103; SICA G, 1994, UROL RES, V22, P33, DOI 10.1007/BF00431546; Stanbrough M, 2001, P NATL ACAD SCI USA, V98, P10823, DOI 10.1073/pnas.191235898; Suzuki T, 2005, CLIN CANCER RES, V11, P6148, DOI 10.1158/1078-0432.CCR-05-0040; Takahashi Y, 2007, MOL CARCINOGEN, V46, P117, DOI 10.1002/mc.20254; Takeuchi T, 2005, J BIOCHEM, V138, P711, DOI 10.1093/jb/mvi172; Takeuchi T, 2005, BIOCHEM BIOPH RES CO, V336, P9, DOI 10.1016/j.bbrc.2005.08.034; Takeuchi T, 2006, FEBS LETT, V580, P4521, DOI 10.1016/j.febslet.2006.07.032; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105; Yeap BB, 1999, ENDOCRINOLOGY, V140, P3282, DOI 10.1210/en.140.7.3282; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; Zhao C, 2004, P NATL ACAD SCI USA, V101, P7578, DOI 10.1073/pnas.0402528101; Zhao C, 2005, P NATL ACAD SCI USA, V102, P10200, DOI 10.1073/pnas.0504754102; Zou WG, 2007, BIOCHEM BIOPH RES CO, V354, P321, DOI 10.1016/j.bbrc.2006.12.210; Zou WG, 2006, J BIOL CHEM, V281, P3989, DOI 10.1074/jbc.M510787200	65	45	47	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2009	28	28					2606	2620		10.1038/onc.2009.115	http://dx.doi.org/10.1038/onc.2009.115			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	471LJ	19430494				2022-12-17	WOS:000268058900006
J	Mateo, F; Vidal-Laliena, M; Canela, N; Busino, L; Martinez-Balbas, MA; Pagano, M; Agell, N; Bachs, O				Mateo, F.; Vidal-Laliena, M.; Canela, N.; Busino, L.; Martinez-Balbas, M. A.; Pagano, M.; Agell, N.; Bachs, O.			Degradation of cyclin A is regulated by acetylation	ONCOGENE			English	Article						acetylation; cyclin A; degradation; P/CAF; ubiquitylation	SPINDLE ASSEMBLY CHECKPOINT; DEPENDENT KINASES; DNA-DAMAGE; CELL-CYCLE; S-PHASE; MITOSIS; CDC20; UBIQUITINATION; DESTRUCTION; COMPLEX	Cyclin A accumulates at the onset of S phase, remains high during G(2) and early mitosis and is degraded at prometaphase. Here, we report that the acetyltransferase P/CAF directly interacts with cyclin A that as a consequence becomes acetylated at lysines 54,68, 95 and 112. Maximal acetylation occurs simultaneously to ubiquitylation at mitosis, indicating importance of acetylation on cyclin A stability. This was further confirmed by the observation that the pseudoacetylated cyclin A mutant can be ubiquitylated whereas the nonacetylatable mutant cannot. The nonacetylatable mutant is more stable than cyclin A WT (cycA WT) and arrests cell cycle at mitosis. Moreover, in cells treated with histone deacetylase inhibitors cyclin A acetylation increases and its stability decreases, thus supporting the function of acetylation on cyclin A degradation. Although the nonacetylatable mutant cannot be ubiquitylated, it interacts with the proteins needed for its degradation (cdks, Cks, Cdc 20, Cdh1 and APC/C). In fact, its association with cdks is increased and its complexes with these kinases display higher activity than control cycA WT-cdk complexes. All these results indicate that cyclin A acetylation at specific lysines is crucial for cyclin A stability and also has a function in the regulation of cycA-cdk activity. Oncogene (2009) 28, 2654-2666; doi: 10.1038/onc.2009.127; published online 1 June 2009	[Mateo, F.; Vidal-Laliena, M.; Canela, N.; Agell, N.; Bachs, O.] Univ Barcelona, Dept Pathol & Cell Biol, Fac Med, E-08036 Barcelona, Spain; [Busino, L.; Pagano, M.] NYU, Sch Med, Dept Pathol, NYU Canc Inst,Smilow Res Ctr, New York, NY USA; [Martinez-Balbas, M. A.] CSIC, Inst Biol Mol Barcelona, Barcelona, Spain; [Pagano, M.] NYU, Sch Med, Howard Hughes Med Inst, New York, NY USA	University of Barcelona; New York University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Howard Hughes Medical Institute; New York University	Bachs, O (corresponding author), Univ Barcelona, Dept Pathol & Cell Biol, Fac Med, Casanova 143, E-08036 Barcelona, Spain.	obachs@ub.edu	Mateo, Francesca/K-7746-2015; Agell, Neus/E-9640-2016; Canela, Núria/I-5401-2015	Mateo, Francesca/0000-0002-2342-7010; Agell, Neus/0000-0002-1205-6074; Canela, Núria/0000-0003-0261-2396; Martinez-Balbas, Marian/0000-0003-0173-0964; pagano, michele/0000-0003-3210-2442	Ministerio de Educacion y Ciencia of Spain [SAF2006-05212, SAF2007-60491]; RETICS [RD06/0020/0010]; Instituto de Salud Carlos III; National Institutes of Health [R01-GM57587, R37-CA76584, R21-CA125173]; Multiple Myeloma Research foundation to Michele Pagano; Michele Pagano is an Investigator with the Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [R21CA125173, R21CA161108, R37CA076584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER	Ministerio de Educacion y Ciencia of Spain(Spanish Government); RETICS; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Multiple Myeloma Research foundation to Michele Pagano; Michele Pagano is an Investigator with the Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported by grants SAF2006-05212 and SAF2007-60491 from the Ministerio de Educacion y Ciencia of Spain and RETICS RD06/0020/0010 from the Instituto de Salud Carlos III. It was also supported by grants from the National Institutes of Health (R01-GM57587, R37-CA76584, and R21-CA125173) and the Multiple Myeloma Research foundation to Michele Pagano. Michele Pagano is an Investigator with the Howard Hughes Medical Institute.	Abramova MV, 2006, J BIOL CHEM, V281, P21040, DOI 10.1074/jbc.M511059200; Baek SY, 2006, NEUROSCI LETT, V396, P230, DOI 10.1016/j.neulet.2005.11.041; Bloom J, 2007, NAT REV MOL CELL BIO, V8, P149, DOI 10.1038/nrm2105; Canela N, 2006, J BIOL CHEM, V281, P35942, DOI 10.1074/jbc.M603511200; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fung TK, 2005, CELL CYCLE, V4, P1411, DOI 10.4161/cc.4.10.2046; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Galbiati L, 2005, CELL CYCLE, V4, P930, DOI 10.4161/cc.4.7.1784; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gong DQ, 2007, CURR BIOL, V17, P85, DOI 10.1016/j.cub.2006.11.066; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Klotzbucher A, 1996, EMBO J, V15, P3053, DOI 10.1002/j.1460-2075.1996.tb00668.x; Leduc C, 2006, ONCOGENE, V25, P4147, DOI 10.1038/sj.onc.1209446; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Linares LK, 2007, NAT CELL BIOL, V9, P331, DOI 10.1038/ncb1545; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nagy Z, 2007, ONCOGENE, V26, P5341, DOI 10.1038/sj.onc.1210604; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; PAGANO M, 1991, Progress in Growth Factor Research, V3, P267, DOI 10.1016/0955-2235(91)90004-N; Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4; Patel JH, 2004, MOL CELL BIOL, V24, P10826, DOI 10.1128/MCB.24.24.10826-10834.2004; Ramachandran V, 2007, CELL CYCLE, V6, P171, DOI 10.4161/cc.6.2.3716; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; Sadoul K, 2008, BIOCHIMIE, V90, P306, DOI 10.1016/j.biochi.2007.06.009; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schiltz RL, 2000, BBA-REV CANCER, V1470, pM37, DOI 10.1016/S0304-419X(99)00037-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimazu T, 2006, ONCOGENE, V25, P7391, DOI 10.1038/sj.onc.1209731; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Sullivan M, 2007, NAT REV MOL CELL BIO, V8, P894, DOI 10.1038/nrm2276; van Leuken R, 2008, BBA-REV CANCER, V1786, P49, DOI 10.1016/j.bbcan.2008.05.002; Wolthuis R, 2008, MOL CELL, V30, P290, DOI 10.1016/j.molcel.2008.02.027	42	45	48	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	29					2654	2666		10.1038/onc.2009.127	http://dx.doi.org/10.1038/onc.2009.127			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19483727	Green Submitted, Green Accepted			2022-12-17	WOS:000268211200004
J	Tilman, G; Loriot, A; Van Beneden, A; Arnoult, N; Londono-Vallejo, JA; De Smet, C; Decottignies, A				Tilman, G.; Loriot, A.; Van Beneden, A.; Arnoult, N.; Londono-Vallejo, J. A.; De Smet, C.; Decottignies, A.			Subtelomeric DNA hypomethylation is not required for telomeric sister chromatid exchanges in ALT cells	ONCOGENE			English	Article						telomeres; DNA methylation; T-SCE; ALT; subtelomeric D4Z4 and DNF92	FACIOSCAPULOHUMERAL MUSCULAR-DYSTROPHY; HUMAN-CHROMOSOMES; REVERSE-TRANSCRIPTASE; EPIGENETIC REGULATION; MAMMALIAN TELOMERES; MELANOMA-CELLS; HUMAN CANCER; TUMOR-CELLS; RECOMBINATION; EXPRESSION	Most human tumor cells acquire immortality by activating the expression of telomerase, a ribonucleoprotein that maintains stable telomere lengths at chromosome ends throughout cell divisions. Other tumors use an alternative mechanism of telomere lengthening (ALT), characterized by high frequencies of telomeric sister chromatid exchanges (T-SCEs). Mechanisms of ALT activation are still poorly understood, but recent studies suggest that DNA hypomethylation of chromosome ends might contribute to the process by facilitating T-SCEs. Here, we show that ALT/T-SCEhigh tumor cells display low DNA-methylation levels at the D4Z4 and DNF92 subtelomeric sequences. Surprisingly, however, the same sequences retained high methylation levels in ALT/T-SCEhigh SV40-immortalized fibroblasts. Moreover, T-SCE rates were efficiently reduced by ectopic expression of active telomerase in ALT tumor cells, even though subtelomeric sequences remained hypomethylated. We also show that hypomethylation of subtelomeric sequences in ALT tumor cells is correlated with genome-wide hypomethylation of Alu repeats and pericentromeric Sat2 DNA sequences. Overall, this study suggests that, although subtelomeric DNA hypomethylation is often coincident with the ALT process in human tumor cells, it is not required for T-SCE.	[Tilman, G.; Loriot, A.; Van Beneden, A.; De Smet, C.; Decottignies, A.] Catholic Univ Louvain, de Duve Inst, Genet & Epigenet Alterat Genome Grp, Fac Med, Brussels, Belgium; [Arnoult, N.; Londono-Vallejo, J. A.] Inst Curie, Telomeres & Canc Lab, Paris, France	Universite Catholique Louvain; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Decottignies, A (corresponding author), Catholic Univ Louvain, de Duve Inst, Genet & Epigenet Alterat Genome Grp, Fac Med, 74 Ave Hippocrate,ICP Tower, Brussels, Belgium.	anabelle.decottignies@uclouvain.be	Londono-Vallejo, Arturo/ABH-5555-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563; Arnoult, Nausica/0000-0003-2633-0270	Fonds National de la Recherche Scientifique (FNRS), Belgium; Televie/FNRS; ANR; ARC; INCa; La Ligue	Fonds National de la Recherche Scientifique (FNRS), Belgium(Fonds de la Recherche Scientifique - FNRS); Televie/FNRS(Fonds de la Recherche Scientifique - FNRS); ANR(French National Research Agency (ANR)); ARC(Australian Research Council); INCa(Institut National du Cancer (INCA) France); La Ligue	We are grateful to M Swinarska, F Brasseur, W Wright, F Fuks, J Lingner, F d'Adda di Fagagna, F Journe, H Id Boufker and C Heirman for the generous gifts of cell lines and plasmids. We thank all the members of the GENEPI group for their constant support and help. This study was supported by the Fonds National de la Recherche Scientifique (FNRS), Belgium. GT is supported by a PhD fellowship grant from Televie/FNRS. AL is supported by a post-doctoral grant from the FNRS. Work in the 'Telomere- &Cancer' laboratory is supported by grants from ANR, ARC, INCa and La Ligue.	Bailey SM, 2004, NUCLEIC ACIDS RES, V32, P3743, DOI 10.1093/nar/gkh691; Bechter OE, 2004, CELL CYCLE, V3, P547; Benetti R, 2007, J CELL BIOL, V178, P925, DOI 10.1083/jcb.200703081; Benetti R, 2007, NAT GENET, V39, P243, DOI 10.1038/ng1952; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 2007, NAT REV GENET, V8, P299, DOI 10.1038/nrg2047; Brock GJR, 1999, GENE, V240, P269, DOI 10.1016/S0378-1119(99)00442-4; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cacurri S, 1998, AM J HUM GENET, V63, P181, DOI 10.1086/301906; Cadieux B, 2006, CANCER RES, V66, P8469, DOI 10.1158/0008-5472.CAN-06-1547; Cerone MA, 2005, ONCOGENE, V24, P7893, DOI 10.1038/sj.onc.1208934; Cerone MA, 2001, HUM MOL GENET, V10, P1945, DOI 10.1093/hmg/10.18.1945; Cornforth MN, 2001, MUTAGENESIS, V16, P85, DOI 10.1093/mutage/16.1.85; De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; Der-Sarkissian H, 2002, GENOME RES, V12, P1673, DOI 10.1101/gr.322802; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Ehrlich M, 2006, CURR TOP MICROBIOL, V310, P251; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Flint J, 1997, HUM MOL GENET, V6, P1305, DOI 10.1093/hmg/6.8.1305; Ford LP, 2001, J BIOL CHEM, V276, P32198, DOI 10.1074/jbc.M104469200; Gonzalo S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Kholmanskikh O, 2008, INT J CANCER, V122, P777, DOI 10.1002/ijc.23140; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Londono-Vallejo JA, 2004, CANCER RES, V64, P2324, DOI 10.1158/0008-5472.CAN-03-4035; Loriot A, 2006, J BIOL CHEM, V281, P10118, DOI 10.1074/jbc.M510469200; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736; Monfouilloux S, 1998, GENOMICS, V51, P165, DOI 10.1006/geno.1998.5358; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Riethman H, 2005, CHROMOSOME RES, V13, P505, DOI 10.1007/s10577-005-0998-1; Riethman H, 2008, ANNU REV GENOM HUM G, V9, P1, DOI 10.1146/annurev.genom.8.021506.172017; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shimojima M, 2004, HEPATOL RES, V29, P31, DOI 10.1016/j.hepres.2004.02.005; Siedlecki P, 2006, ACTA BIOCHIM POL, V53, P245; Tilman G, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-80; TRAVERSARI C, 1992, IMMUNOGENETICS, V35, P145, DOI 10.1007/BF00185107; van Overveld PGM, 2003, NAT GENET, V35, P315, DOI 10.1038/ng1262; Vera E, 2008, ONCOGENE, V27, P6817, DOI 10.1038/onc.2008.289; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987; WILSON V L, 1983, Science (Washington D C), V220, P1055, DOI 10.1126/science.6844925; Yehezkel S, 2008, HUM MOL GENET, V17, P2776, DOI 10.1093/hmg/ddn177; Young JI, 2003, J BIOL CHEM, V278, P19904, DOI 10.1074/jbc.M301685200	49	45	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2009	28	14					1682	1693		10.1038/onc.2009.23	http://dx.doi.org/10.1038/onc.2009.23			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430WQ	19252523				2022-12-17	WOS:000265022000003
J	Fukuzawa, R; Anaka, MR; Weeks, RJ; Morison, IM; Reeve, AE				Fukuzawa, R.; Anaka, M. R.; Weeks, R. J.; Morison, I. M.; Reeve, A. E.			Canonical WNT signalling determines lineage specificity in Wilms tumour	ONCOGENE			English	Article						WTX; cancer stem cell; nephrogenic rest; mesenchymal stem cell; multiplex ligation-dependent probe amplification	GROWTH-FACTOR-II; BETA-CATENIN; STEM-CELLS; NEPHROGENIC RESTS; CTNNB1 MUTATIONS; TARGET GENES; WT1; CANCER; OVEREXPRESSION; PATHOGENESIS	Wilms tumours (WTs) have two distinct types of histology with or without ectopic mesenchymal elements, suggesting that WTs arise from either the mesenchymal or epithelial nephrogenic lineages. Regardless of the presence or absence of CTNNB1 mutations, nuclear accumulation of beta-catenin is often observed in WTs with ectopic mesenchymal elements. Here, we addressed the relationship between the WNT-signalling pathway and lineage in WTs by examining CTNNB1 and WT1 mutations, nuclear accumulation of beta-catenin, tumour histology and gene expression profiles. In addition, we screened for mutations in WTX, which has been proposed to be a negative regulator of the canonical WNT-signalling pathway. Unsupervised clustering analysis identified two classes of tumours: mesenchymal lineage WNT-dependent tumours, and epithelial lineage WNT-independent tumours. In contrast to the mesenchymal lineage specificity of CTNNB1 mutations, WTX mutations were surprisingly observed in both lineages. WTX-mutant WTs with ectopic mesenchymal elements had nuclear accumulation of beta-catenin, upregulation of WNT target genes and an association with CTNNB1 mutations in exon 7 or 8. However, epithelial lineage WTs with WTX mutations had no indications of active WNT signalling, suggesting that the involvement of WTX in the WNT-signalling pathway may be lineage dependent, and that WTX may have an alternative function to its role in the canonical WNT-signalling pathway.	[Fukuzawa, R.; Anaka, M. R.; Weeks, R. J.; Morison, I. M.; Reeve, A. E.] Univ Otago, Dept Biochem, Canc Genet Lab, Dunedin, New Zealand	University of Otago	Fukuzawa, R (corresponding author), Univ Otago, Dept Biochem, Canc Genet Lab, POB 56, Dunedin, New Zealand.	ryuji.fukuzawa@otago.ac.nz	Weeks, Robert J/A-6876-2012; Morison, Ian M/A-1236-2008	Weeks, Robert J/0000-0003-0474-9089; Morison, Ian M/0000-0003-3616-0025	Health Research Council of New Zealand	Health Research Council of New Zealand(Health Research Council of New Zealand)	This study was supported by the Health Research Council of New Zealand.	Barberi T, 2005, PLOS MED, V2, P554, DOI 10.1371/journal.pmed.0020161; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; Beckwith JB, 1998, AM J MED GENET, V79, P268, DOI 10.1002/(SICI)1096-8628(19981002)79:4<268::AID-AJMG7>3.0.CO;2-I; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Breslow NE, 2006, PEDIATR BLOOD CANCER, V47, P260, DOI 10.1002/pbc.20891; Bunting KD, 2002, STEM CELLS, V20, P11, DOI 10.1002/stem.200011; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Eberhart CG, 2001, PEDIATR DEVEL PATHOL, V4, P351, DOI 10.1007/s10024001-0037-y; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22-5-849; Fodde R, 2003, NAT CELL BIOL, V5, P190, DOI 10.1038/ncb0303-190; Fukuzawa R, 2008, J PATHOL, V215, P377, DOI 10.1002/path.2366; Fukuzawa R, 2004, PEDIATR DEVEL PATHOL, V7, P125, DOI 10.1007/s10024-003-3023-8; Fukuzawa R, 2004, LANCET, V363, P446, DOI 10.1016/S0140-6736(04)15491-3; Fukuzawa R, 2007, J CLIN PATHOL, V60, P1013, DOI 10.1136/jcp.2006.043083; Grohmann A, 2007, J CELL SCI, V120, P3738, DOI 10.1242/jcs.011320; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; JENKINS ZA, NAT GENET IN PRESS; Koesters R, 1999, CANCER RES, V59, P3880; Koesters R, 2003, J PATHOL, V199, P68, DOI 10.1002/path.1248; Li CM, 2004, AM J PATHOL, V165, P1943, DOI 10.1016/S0002-9440(10)63246-4; Lindsley RC, 2006, DEVELOPMENT, V133, P3787, DOI 10.1242/dev.02551; Maiti S, 2000, CANCER RES, V60, P6288; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; Mishra L, 2005, SCIENCE, V310, P68, DOI 10.1126/science.1118389; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Perotti D, 2008, ONCOGENE, V27, P4625, DOI 10.1038/onc.2008.93; Ridgeway AG, 2001, J BIOL CHEM, V276, P19033, DOI 10.1074/jbc.M011491200; Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509; Ruteshouser EC, 2008, GENE CHROMOSOME CANC, V47, P461, DOI 10.1002/gcc.20553; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Wang YJ, 2005, J BONE MINER RES, V20, P1624, DOI 10.1359/JBMR.050516; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zirn B, 2006, GENE CHROMOSOME CANC, V45, P565, DOI 10.1002/gcc.20319	39	45	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2009	28	8					1063	1075		10.1038/onc.2008.455	http://dx.doi.org/10.1038/onc.2008.455			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137020				2022-12-17	WOS:000263722900002
J	Segditsas, S; Rowan, AJ; Howarth, K; Jones, A; Leedham, S; Wright, NA; Gorman, P; Chambers, W; Domingo, E; Roylance, RR; Sawyer, EJ; Sieber, OM; Tomlinson, IPM				Segditsas, S.; Rowan, A. J.; Howarth, K.; Jones, A.; Leedham, S.; Wright, N. A.; Gorman, P.; Chambers, W.; Domingo, E.; Roylance, R. R.; Sawyer, E. J.; Sieber, O. M.; Tomlinson, I. P. M.			APC and the three-hit hypothesis	ONCOGENE			English	Article						two hits; tumour suppressor; APC; Wnt; copy number change; 'just right'	FAMILIAL ADENOMATOUS POLYPOSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CHROMOSOMAL INSTABILITY; COLORECTAL ADENOMAS; SOMATIC MUTATIONS; GERMLINE MUTATION; BETA-CATENIN; CANCERS; ALLELES; MODEL	The seminal 'two-hit hypothesis' implicitly assumes that bi-allelic tumour suppressor gene (TSG) mutations cause loss of protein function. All subsequent events in that tumour therefore take place on an essentially null background for that TSG protein. We have shown that the two-hit model requires modi. cation for the APC TSG, because mutant APC proteins probably retain some function and the two hits are co-selected to produce an optimal level of Wnt activation. We wondered whether the optimal Wnt level might change during tumour progression, leading to selection for more than two hits at the APC locus. Comprehensive screening of a panel of colorectal cancer (CRC) cell lines and primary CRCs showed that some had indeed acquired third hits at APC. These third hits were mostly copy number gains or deletions, but could be protein-truncating mutations. Third hits were significantly less common when the second hit at APC had arisen by copy-neutral loss of heterozygosity. Both polyploid and near-diploid CRCs had third hits, and the third hits did not simply arise as a result of acquiring a polyploid karyotype. The third hits affected mRNA and protein levels, with potential functional consequences for Wnt signalling and tumour growth. Although some third hits were probably secondary to genomic instability, others did appear specifically to target APC. Whilst it is generally believed that tumours develop and progress through stepwise accumulation of mutations in different functional pathways, it also seems that repeated targeting of the same pathway and/or gene is selected in some cancers.	[Segditsas, S.; Rowan, A. J.; Howarth, K.; Jones, A.; Gorman, P.; Chambers, W.; Domingo, E.; Roylance, R. R.; Sawyer, E. J.; Sieber, O. M.; Tomlinson, I. P. M.] Canc Res UK, London Res Inst, Mol & Populat Genet Lab, London, England; [Leedham, S.; Wright, N. A.] Canc Res UK, London Res Inst, Histopathol Lab, London, England; [Chambers, W.] Oxford Radcliffe Hosp, Dept Colorectal Surg & Genet Knowledge Pk, Oxford, England	Cancer Research UK; Cancer Research UK; University of Oxford	Tomlinson, IPM (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.	iant@well.ox.ac.uk	Domingo, Enric/A-9099-2018; Sieber, Oliver/M-9473-2015; Sieber, Oliver/ABA-9211-2021	Domingo, Enric/0000-0003-4390-8767; Sieber, Oliver/0000-0001-9480-0786; Sieber, Oliver/0000-0001-9480-0786; Wright, Nicholas/0000-0002-5525-3457	Medical Research Council [G84/6549] Funding Source: Medline; MRC [G84/6549] Funding Source: UKRI; National Institute for Health Research [03/DHCS/03/G121/51] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research(National Institute for Health Research (NIHR))		Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Fodde R, 2001, TRENDS MOL MED, V7, P369, DOI 10.1016/S1471-4914(01)02050-0; Gaasenbeek M, 2006, CANCER RES, V66, P3471, DOI 10.1158/0008-5472.CAN-05-3285; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jones AM, 2007, J PATHOL, V213, P249, DOI 10.1002/path.2234; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; Leslie A, 2006, GENE CHROMOSOME CANC, V45, P126, DOI 10.1002/gcc.20271; Michor F, 2005, SEMIN CANCER BIOL, V15, P43, DOI 10.1016/j.semcancer.2004.09.007; Schneikert J, 2007, HUM MOL GENET, V16, P199, DOI 10.1093/hmg/ddl464; Sieber OM, 2006, GUT, V55, P1440, DOI 10.1136/gut.2005.087106; Sieber OM, 2005, NAT REV CANCER, V5, P649, DOI 10.1038/nrc1674; Sieber OM, 2002, P NATL ACAD SCI USA, V99, P16910, DOI 10.1073/pnas.012679099; Spirio LN, 1998, NAT GENET, V20, P385, DOI 10.1038/3865; Su LK, 2000, AM J HUM GENET, V67, P582, DOI 10.1086/303058; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720	17	45	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					146	155		10.1038/onc.2008.361	http://dx.doi.org/10.1038/onc.2008.361			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18836487				2022-12-17	WOS:000262294100015
J	Kump, E; Ji, J; Wernli, M; Hausermann, P; Erb, P				Kump, E.; Ji, J.; Wernli, M.; Haeusermann, P.; Erb, P.			Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis	ONCOGENE			English	Article						Gli2; cFlip; apoptosis; basal cell carcinoma; gene silencing	HEDGEHOG SIGNALING PATHWAY; SKIN-CANCER; HUMAN EPIDERMIS; TUMOR-GROWTH; IN-VIVO; ACTIVATION; EXPRESSION; PROTEINS; INHIBITION; PROMOTER	Mutations in the Hedgehog signaling pathway is responsible for the formation of various cancers, including some forms of basal cell carcinoma (BCC). Uncontrolled Hedgehog signaling leads to overexpression of the zinc finger Gli transcription factors, among which Gli2 plays a central role. We found that high Gli2 expression induced the concomitant high expression of the caspase 8 inhibitor, cFlip, and thereby counteracts death-ligand-mediated apoptosis. By investigating the cFlip promoter, Gli2 binding sites were identified and confirmed. Gli2 gene silencing by RNA interference broke the apoptosis resistance via cFlip downregulation. The direct functional connection between Gli2 and cFlip was not only demonstrated in a keratinocytic cell line but also in BCC tissue. As cFlip and Bcl-2 are highly expressed in BCCs, as a consequence of high Gli2 expression, this may explain the marked resistance of the tumor to the extrinsic and intrinsic apoptotic pathway. We could now demonstrate that Gli2 gene silencing in BCC tissues made the tumor sensitive to TRAIL ( tumor necrosis factor-related apoptosis-inducing ligand)- mediated cell death by downregulating cFlip. As Gli2 silencing does not only downregulate cFlip, but also Bcl-2, Gli2 could be a key target for a novel therapeutic approach in tumors with dysregulated Hedgehog signaling.	[Kump, E.; Ji, J.; Wernli, M.; Erb, P.] Univ Basel, Dept Biomed, Inst Med Microbiol, CH-4003 Basel, Switzerland; [Haeusermann, P.] Univ Basel Hosp, Dept Dermatol, CH-4031 Basel, Switzerland	University of Basel; University of Basel	Erb, P (corresponding author), Univ Basel, Dept Biomed, Inst Med Microbiol, Peterspl 10, CH-4003 Basel, Switzerland.	peter.erb@unibas.ch						Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Bachmann F, 2001, J INVEST DERMATOL, V117, P59, DOI 10.1046/j.0022-202x.2001.01380.x; Bai CB, 2002, DEVELOPMENT, V129, P4753; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Buechner SA, 1997, J CLIN INVEST, V100, P2691, DOI 10.1172/JCI119814; Callahan CA, 2001, CURR OPIN GENET DEV, V11, P541, DOI 10.1016/S0959-437X(00)00230-6; Cohen MM, 2003, AM J MED GENET A, V123A, P5, DOI 10.1002/ajmg.a.20495; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Daya-Grosjean L, 2005, CANCER LETT, V225, P181, DOI 10.1016/j.canlet.2004.10.003; Delehedde M, 1999, CANCER, V85, P1514, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1514::AID-CNCR12>3.3.CO;2-H; Diepgen TL, 2002, BRIT J DERMATOL, V146, P1, DOI 10.1046/j.1365-2133.146.s61.2.x; Eichberger T, 2004, J INVEST DERMATOL, V122, P1180, DOI 10.1111/j.0022-202X.2004.22505.x; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; Erb P, 2005, IMMUNOL LETT, V100, P68, DOI 10.1016/j.imlet.2005.06.008; Hutchin ME, 2005, GENE DEV, V19, P214, DOI 10.1101/gad.1258705; Igney FH, 2005, CANCER IMMUNOL IMMUN, V54, P1127, DOI 10.1007/s00262-005-0680-7; Ikram MS, 2004, J INVEST DERMATOL, V122, P1503, DOI 10.1111/j.0022-202X.2004.22612.x; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Ji J, 2005, GENE THER, V12, P678, DOI 10.1038/sj.gt.3302453; Ji J, 2008, INT J CANCER, V122, P50, DOI 10.1002/ijc.23023; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103; Miller KL, 2006, CARCINOGENESIS, V27, P1670, DOI 10.1093/carcin/bgi376; Nguyen V, 2005, DEVELOPMENT, V132, P3267, DOI 10.1242/dev.01905; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Park HL, 2000, DEVELOPMENT, V127, P1593; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; Regl G, 2004, CANCER RES, V64, P7724, DOI 10.1158/0008-5472.CAN-04-1085; Regl G, 2004, ONCOGENE, V23, P1263, DOI 10.1038/sj.onc.1207240; Trisciuoglio D, 2005, J CELL PHYSIOL, V205, P414, DOI 10.1002/jcp.20413; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	33	45	49	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3856	3864		10.1038/onc.2008.5	http://dx.doi.org/10.1038/onc.2008.5			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18264131				2022-12-17	WOS:000256904700009
J	Baldwin, RM; Parolin, DAE; Lorimer, IAJ				Baldwin, R. M.; Parolin, D. A. E.; Lorimer, I. A. J.			Regulation of glioblastoma cell invasion by PKC iota and RhoB	ONCOGENE			English	Article						atypical PKC; RhoB; PI 3-kinase; PTEN; glioblastoma	PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN CYTOSKELETON; LUNG-CANCER; GROWTH; LAMBDA; PHOSPHORYLATION; SUPPRESSOR; EXPRESSION; MIGRATION	Glioblastoma multiforme is the most aggressive form of primary brain tumor and remains largely incurable, in large part, due to its highly invasive nature. The phosphoinositide (PI) 3-kinase pathway is often constitutively active in these tumors due to activating mutations in the epidermal growth factor receptor, or deletion/loss of function of the tumor suppressor PTEN. Protein kinase C type iota (PKC iota), a member of the atypical protein kinase C family, is activated by the PI 3-kinase pathway and is an important downstream mediator. Here, we have assessed the role of PKC iota in glioblastoma cell invasion. Depletion of PKC iota with RNA interference caused an increase in actin stress fibers and a decrease in cell motility and invasion. Gene expression microarray analysis of U87MG cells showed that PKC iota repressed expression of mRNA for RhoB, which has previously been shown to have a role in actin stress fiber formation. Western blot analysis showed that both PKC iota depletion and pharmacological inhibition of PKC iota caused an increase in the protein levels of RhoB, as did inhibition of PI 3-kinase. Expression of RhoB from a constitutive promoter caused changes in actin stress fibers and cell invasion that were similar to those seen with PKC iota depletion. These data show that PKC iota, activated as a consequence of aberrant upstream PI 3-kinase signaling, mediates glioblastoma cell motility and invasion, and that repression of RhoB is key downstream event in PKC iota signaling leading to enhanced cell motility. In addition, constitutive expression of RhoB repressed PKC iota activity, as assessed by its phosphorylation status on Thr555. PKC iota and RhoB are, therefore, mutually antagonistic, potentially creating a sensitive switch between invasive and non-invasive phenotypes.	[Baldwin, R. M.; Parolin, D. A. E.; Lorimer, I. A. J.] Ottawa Hlth Res Inst, Ottawa, ON, Canada; [Baldwin, R. M.; Lorimer, I. A. J.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [Lorimer, I. A. J.] Univ Ottawa, Dept Med, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa	Lorimer, IAJ (corresponding author), Ottawa Hosp, Reg Canc Ctr, Ctr Canc Therapeut, 501 Smyth Rd,3rd Floor, Ottawa, ON K1H 8L6, Canada.	ilorimer@ohri.ca						Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Baldwin RM, 2006, ONCOGENE, V25, P2909, DOI 10.1038/sj.onc.1209312; Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Cai XM, 2005, INT J CANCER, V117, P905, DOI 10.1002/ijc.21251; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Forget MA, 2002, CLIN EXP METASTAS, V19, P9, DOI 10.1023/A:1013884426692; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Gerhard R, 2005, J BIOL CHEM, V280, P1499, DOI 10.1074/jbc.M406014200; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Gustafson WC, 2004, J BIOL CHEM, V279, P9400, DOI 10.1074/jbc.M312840200; Huang M, 2006, HISTOL HISTOPATHOL, V21, P213, DOI 10.14670/HH-21.213; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Jin ZJ, 2005, J BIOL CHEM, V280, P16045, DOI 10.1074/jbc.M413488200; Kanzaki M, 2004, J CELL BIOL, V164, P279, DOI 10.1083/jcb.200306152; Lambrechts A, 2004, INT J BIOCHEM CELL B, V36, P1890, DOI 10.1016/j.biocel.2004.01.024; Lavictoire SJ, 2003, J BIOL CHEM, V278, P5292, DOI 10.1074/jbc.M209494200; Liu AX, 2000, FEBS LETT, V481, P205, DOI 10.1016/S0014-5793(00)02003-2; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; Messerschmidt A, 2005, J MOL BIOL, V352, P918, DOI 10.1016/j.jmb.2005.07.060; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Sang RL, 2007, CHEM BIOL DRUG DES, V69, P240, DOI 10.1111/j.1747-0285.2007.00502.x; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Soloff RS, 2004, J IMMUNOL, V173, P3250, DOI 10.4049/jimmunol.173.5.3250; Tamura M, 1999, CANCER RES, V59, P442; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Xu LJ, 2006, J BIOL CHEM, V281, P4457, DOI 10.1074/jbc.M510721200; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527	37	45	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2008	27	25					3587	3595		10.1038/sj.onc.1211027	http://dx.doi.org/10.1038/sj.onc.1211027			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18212741				2022-12-17	WOS:000256468500010
J	Humphries, MJ; Ohm, AM; Schaack, J; Adwan, TS; Reyland, ME				Humphries, M. J.; Ohm, A. M.; Schaack, J.; Adwan, T. S.; Reyland, M. E.			Tyrosine phosphorylation regulates nuclear translocation of PKC delta	ONCOGENE			English	Article						protein kinase C; tyrosine phosphorylation; apoptosis; nuclear localization; salivary gland	PROTEIN-KINASE-C; INDUCED APOPTOSIS; ACINAR-CELLS; ACTIVATION; CONSTRUCTION; SUPPRESSION; ETOPOSIDE; VECTORS	PKC delta is essential for apoptosis, but regulation of the proapoptotic function of this ubiquitous kinase is not well understood. Nuclear translocation of PKC delta is necessary and sufficient to induce apoptosis and is mediated via a C-terminal bipartite nuclear localization sequence. However, PKC delta is found predominantly in the cytoplasm of nonapoptotic cells, and the apoptotic signal that activates its nuclear translocation is not known. We show that in salivary epithelial cells, phosphorylation at specific tyrosine residues in the N-terminal regulatory domain directs PKC delta to the nucleus where it induces apoptosis. Analysis of each tyrosine residue in PKC delta by site-directed mutagenesis identified two residues, Y64 and Y155, as essential for nuclear translocation. Suppression of apoptosis correlated with suppressed nuclear localization of the Y -> F mutant proteins. Moreover, a phosphomimetic PKC delta Y64D/Y155D mutant accumulated in the nucleus in the absence of an apoptotic signal. Forced nuclear accumulation of PKC delta-Y64F and Y155F mutant proteins, by attachment of an SV40 nuclear localization sequence, fully reconstituted their ability to induce apoptosis, indicating that tyrosine phosphorylation per se is not required for apoptosis, but for targeting PKC delta to the nucleus. We propose that phosphorylation/dephosphorylation of PKC delta in the regulatory domain functions as a switch to promote cell survival or cell death.	[Humphries, M. J.; Ohm, A. M.; Schaack, J.; Adwan, T. S.; Reyland, M. E.] Hlth Sci Ctr, Aurora, CO 80045 USA; [Humphries, M. J.; Ohm, A. M.; Adwan, T. S.; Reyland, M. E.] Univ Colorado Denver, Sch Dent, Dept Craniofacial Biol, Program Cell & Dev Biol, Aurora, CO 80045 USA; [Schaack, J.] Univ Colorado Denver, Sch Med, Dept Microbiol, Aurora, CO USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Reyland, ME (corresponding author), Univ Colorado Denver, Sch Dent, Dept Craniofacial Biol, Program Cell & Dev Biol, 12801 E 17th Ave,Mail Stop 8120,POB 6511, Aurora, CO 80045 USA.	Mary.Reyland@uchsc.edu			NICHD NIH HHS [P01 HD038129, P0I HD038129] Funding Source: Medline; NIDCR NIH HHS [R01 DE015648, R01 DE015648-01, R01 DE015648-05, R01 DE015648-04] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD038129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015648] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Acs P, 2000, CARCINOGENESIS, V21, P887, DOI 10.1093/carcin/21.5.887; Anderson SM, 1999, CELL DEATH DIFFER, V6, P454, DOI 10.1038/sj.cdd.4400507; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Collazos A, 2006, MOL CELL BIOL, V26, P2247, DOI 10.1128/MCB.26.6.2247-2261.2006; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; DeVries-Seimon TA, 2007, J BIOL CHEM, V282, P22307, DOI 10.1074/jbc.M703661200; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; Humphries MJ, 2006, J BIOL CHEM, V281, P9728, DOI 10.1074/jbc.M507851200; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Limesand KH, 2003, CELL DEATH DIFFER, V10, P345, DOI 10.1038/sj.cdd.4401153; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Okhrimenko H, 2005, J BIOL CHEM, V280, P23643, DOI 10.1074/jbc.M501374200; Schaack J, 2001, VIROLOGY, V291, P101, DOI 10.1006/viro.2001.1211; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; Tolcher AW, 2002, CLIN CANCER RES, V8, P2530; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zrachia A, 2002, J BIOL CHEM, V277, P23693, DOI 10.1074/jbc.M111658200	24	45	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2008	27	21					3045	3053		10.1038/sj.onc.1210967	http://dx.doi.org/10.1038/sj.onc.1210967			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059334	Green Accepted			2022-12-17	WOS:000255681700011
J	Nakayama, T; Hieshima, K; Arao, T; Jin, Z; Nagakubo, D; Shirakawa, AK; Yamada, Y; Fujii, M; Oiso, N; Kawada, A; Nishio, K; Yoshie, O				Nakayama, T.; Hieshima, K.; Arao, T.; Jin, Z.; Nagakubo, D.; Shirakawa, A-K; Yamada, Y.; Fujii, M.; Oiso, N.; Kawada, A.; Nishio, K.; Yoshie, O.			Aberrant expression of Fra-2 promotes CCR4 expression and cell proliferation in adult T-cell leukemia	ONCOGENE			English	Article						adult T-cell leukemia; CCR4; Fra-2; JunD; c-Myb; MDM2; BCL-6	VIRUS TYPE-I; TRANSCRIPTIONAL ACTIVITY; CONSTITUTIVE ACTIVATION; CHEMOKINE RECEPTORS; NONCODING REGION; ATL CELLS; C-MYB; LYMPHOMA; GROWTH; GENE	Adult T-cell leukemia (ATL) is a mature CD4(+) T-cell malignancy etiologically associated with human T-cell leukemia virus type 1 (HTLV-1). Primary ATL cells frequently express CCR4 at high levels. Since HTLV-1 Tax does not induce CCR4 expression, transcription factor(s) constitutively active in ATL may be responsible for its strong expression. We identified an activator protein-1 (AP-1) site in the CCR4 promoter as the major positive regulatory element in ATL cells. Among the AP-1 family members, Fra-2, JunB and JunD are highly expressed in fresh primary ATL cells. Consistently, the Fra-2/JunB and Fra-2/JunD heterodimers strongly activated the CCR4 promoter in Jurkat cells. Furthermore, Fra-2 small interfering RNA (siRNA) or JunD siRNA, but not JunB siRNA, effectively reduced CCR4 expression and cell growth in ATL cells. Conversely, Fra-2 or JunD overexpression promoted cell growth in Jurkat cells. We identified 49 genes, including c-Myb, BCL-6 and MDM2, which were downregulated by Fra-2 siRNA in ATL cells. c-Myb, BCL-6 and MDM2 were also downregulated by JunD siRNA. As Fra-2, these proto-oncogenes were highly expressed in primary ATL cells but not in normal CD4(+) T cells. Collectively, aberrantly expressed Fra-2 in association with JunD may play a major role in CCR4 expression and oncogenesis in ATL.	[Nakayama, T.; Hieshima, K.; Jin, Z.; Nagakubo, D.; Shirakawa, A-K; Yoshie, O.] Kinki Univ, Sch Med, Dept Microbiol, Osaka 5898511, Japan; [Arao, T.; Nishio, K.] Kinki Univ, Sch Med, Dept Genome Sci, Osaka 5898511, Japan; [Yamada, Y.] Nagasaki Univ, Grad Sch Biomed Sci, Dept Lab Med, Nagasaki 852, Japan; [Fujii, M.] Niigata Univ, Grad Sch Med & Dent Sci, Div Virol, Niigata, Japan; [Oiso, N.; Kawada, A.] Kinki Univ, Sch Med, Dept Dermatol, Osaka 5898511, Japan	Kindai University (Kinki University); Kindai University (Kinki University); Nagasaki University; Niigata University; Kindai University (Kinki University)	Yoshie, O (corresponding author), Kinki Univ, Sch Med, Dept Microbiol, 377-2 Ohono Higashi, Osaka 5898511, Japan.	o.yoshie@med.kindai.ac.jp	Oiso, Naoki/H-6540-2019; Hieshima, Kunio/AAF-7040-2019; Nagakubo, Daisuke/AAW-3621-2021; Kawada, Akira/AAQ-3460-2020	Oiso, Naoki/0000-0001-5593-6496; Hieshima, Kunio/0000-0002-7786-4646; Nagakubo, Daisuke/0000-0003-1213-1246; Yoshie, Osamu/0000-0003-4353-5809				Basbous J, 2003, J BIOL CHEM, V278, P43620, DOI 10.1074/jbc.M307275200; CESARMAN E, 1992, BLOOD, V80, P3205; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen F, 1999, INT IMMUNOL, V11, P677, DOI 10.1093/intimm/11.5.677; Dang CV, 1999, MOL CELL BIOL, V19, P1; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Ferenczi K, 2002, J INVEST DERMATOL, V119, P1405, DOI 10.1046/j.1523-1747.2002.19610.x; Galonek HL, 2006, NAT CELL BIOL, V8, P1317, DOI 10.1038/ncb1206-1317; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; Hata T, 1999, LEUKEMIA, V13, P215, DOI 10.1038/sj.leu.2401271; Hess JL, 2006, BLOOD, V108, P297, DOI 10.1182/blood-2005-12-5014; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Iellem A, 2001, J EXP MED, V194, P847, DOI 10.1084/jem.194.6.847; Igarashi T, 2007, ONCOGENE, V26, P4749, DOI 10.1038/sj.onc.1210289; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Ishida T, 2003, CLIN CANCER RES, V9, P3625; Iwai K, 2001, VIROLOGY, V279, P38, DOI 10.1006/viro.2000.0669; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; Jones D, 2000, BLOOD, V96, P685; Karreth F, 2004, DEVELOPMENT, V131, P5717, DOI 10.1242/dev.01414; Karube K, 2004, BRIT J HAEMATOL, V126, P81, DOI 10.1111/j.1365-2141.2004.04999.x; Kerl K, 2001, LAB INVEST, V81, P1693, DOI 10.1038/labinvest.3780382; Kim EJ, 2005, J CLIN INVEST, V115, P798, DOI 10.1172/JCI200524826; Matsubara Y, 2005, LEUKEMIA, V19, P482, DOI 10.1038/sj.leu.2403628; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; Mori N, 1999, BLOOD, V93, P2360; Mori N, 2000, BLOOD, V95, P3915; Nagakubo D, 2007, INT J CANCER, V120, P1591, DOI 10.1002/ijc.22483; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Pasqualucci L, 2003, LEUKEMIA LYMPHOMA, V44, pS5, DOI 10.1080/10428190310001621588; Ramsay RG, 2003, EXPERT OPIN THER TAR, V7, P235; Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073/pnas.0507631103; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shetzline SE, 2004, BLOOD, V104, P1833, DOI 10.1182/blood-2003-10-3577; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; Thebault S, 2004, FEBS LETT, V562, P165, DOI 10.1016/S0014-5793(04)00225-X; Vargas DA, 2003, ADV CANCER RES, V89, P1, DOI 10.1016/S0065-230X(03)01001-7; Yamada Y, 1996, LEUKEMIA LYMPHOMA, V21, P443, DOI 10.3109/10428199609093442; YAMAMOTO N, 1985, J GEN VIROL, V66, P1641, DOI 10.1099/0022-1317-66-8-1641; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Yoshie O, 2002, BLOOD, V99, P1505, DOI 10.1182/blood.V99.5.1505; Yoshie O, 2001, ADV IMMUNOL, V78, P57, DOI 10.1016/S0065-2776(01)78002-9	47	45	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	23					3221	3232		10.1038/sj.onc.1210984	http://dx.doi.org/10.1038/sj.onc.1210984			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18071306				2022-12-17	WOS:000256111400001
J	Colo, GP; Rubio, MF; Nojek, IM; Werbajh, SE; Echeverria, PC; Alvarado, CV; Nahmod, VE; Galigniana, MD; Costas, MA				Colo, G. P.; Rubio, M. F.; Nojek, I. M.; Werbajh, S. E.; Echeverria, P. C.; Alvarado, C. V.; Nahmod, V. E.; Galigniana, M. D.; Costas, M. A.			The p160 nuclear receptor co-activator RAC3 exerts an anti-apoptotic role through a cytoplasmatic action	ONCOGENE			English	Article						apoptosis; NF-kappa B; peroxides; nuclear receptor co-activators; MAP kinases	NF-KAPPA-B; TRANSCRIPTIONAL COACTIVATOR; EXPRESSION; AIB1; PROTEIN; BREAST; ACTIVATION; PATHWAY; GROWTH; STRESS	The p160 nuclear receptor co- activators represent a family of molecules, which are recruited by steroid nuclear receptors as well as other transcription factors that are overexpressed in several tumors. We investigated the role of one member of this family on the sensitivity of cells to apoptosis. We observed that overexpression of the RAC3 ( receptor- associated co- activator- 3) p160 co- activator inhibits hydrogen peroxide- induced cell death in human embryonic kidney 293 ( HEK293) cells. The mechanism involves the activation of anti- apoptotic pathways mediated through enhanced nuclear factor kappa B ( NF-kappa B) activity, inhibition of caspase- 9 activation, diminished apoptotic- inducing factor ( AIF) nuclear localization and a change in the activation pattern of several kinases, including an increase in both AKT and p38 kinase activities, and inhibition of ERK2. Moreover, RAC3 has been found associated with a protein complex containing AIF, Hsp90 and dynein, suggesting a role for the coactivator in the cytoplasmatic nuclear transport of these proteins associated with cytoskeleton. These results demonstrate that there are several molecular pathways that could be affected by their overexpression, including those not restricted to steroid regulation or the nuclear action of co- activators, which results in diminished sensitivity to apoptosis. Furthermore, this could represent one mechanism by which co- activators contribute to tumor development.	[Colo, G. P.; Rubio, M. F.; Nojek, I. M.; Werbajh, S. E.; Echeverria, P. C.; Alvarado, C. V.; Nahmod, V. E.; Costas, M. A.] Univ Buenos Aires, CONICET, Argentine Natl Res Council, Inst Invest Med Alfredo Lanari IDIM,Lab Biol Mol, Buenos Aires, DF, Argentina; [Galigniana, M. D.] Fdn Inst Leloir, Lab Receptores Nucl & Arquitectura Nucl, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Leloir Institute	Costas, MA (corresponding author), Univ Buenos Aires, CONICET, Argentine Natl Res Council, Inst Invest Med Alfredo Lanari IDIM,Lab Biol Mol, Combatientes Malvinas 3150,Cuerpo 2-Piso 1, Buenos Aires, DF, Argentina.	mcostas@lanari.fmed.uba.ar	Echeverria, Pablo Christian/A-9098-2010	Echeverria, Pablo Christian/0000-0003-1367-9692; Costas, Monica/0000-0002-4773-3389; GALIGNIANA, MARIO/0000-0002-9130-8574; Alvarado, Cecilia/0000-0003-3147-747X	FIC NIH HHS [R03TW007162-01A2] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW007162] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Cavarretta ITR, 2002, MOL ENDOCRINOL, V16, P253, DOI 10.1210/me.16.2.253; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; Costas MA, 2000, BBA-MOL CELL RES, V1499, P122, DOI 10.1016/S0167-4889(00)00113-0; Coste A, 2006, EMBO J, V25, P2453, DOI 10.1038/sj.emboj.7601106; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Franco D, 2002, CELL DEATH DIFFER, V9, P1090, DOI 10.1038/sj.cdd.4401074; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Glaeser M, 2001, HORM METAB RES, V33, P121, DOI 10.1055/s-2001-14938; Glass CK, 2000, GENE DEV, V14, P121; Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Iwase H, 2003, BREAST CANCER RES TR, V80, P339, DOI 10.1023/A:1024916126532; Katoh I, 2004, J BIOL CHEM, V279, P15515, DOI 10.1074/jbc.M311819200; Kultz D, 1998, J EXP BIOL, V201, P3015; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; List HJ, 2001, BREAST CANCER RES TR, V68, P21, DOI 10.1023/A:1017910924390; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; ONATE SA, 1995, SCIENCE, V270, P1354; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Park BG, 2005, TOXICOLOGY, V215, P115, DOI 10.1016/j.tox.2005.07.003; Peterson CL, 2000, J CELL BIOCHEM, V78, P179, DOI 10.1002/(SICI)1097-4644(20000801)78:2<179::AID-JCB1>3.0.CO;2-E; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Rubio MF, 2006, ONCOGENE, V25, P1367, DOI 10.1038/sj.onc.1209176; Sakakura C, 2000, INT J CANCER, V89, P217; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yan J, 2006, ACTA PHARMACOL SIN, V27, P387, DOI 10.1111/j.1745-7254.2006.00315.x; Zhang L, 2001, CELL DEATH DIFFER, V8, P528, DOI 10.1038/sj.cdd.4400838; Zhou G, 2003, MOL CELL BIOL, V23, P7742, DOI 10.1128/MCB.23.21.7742-7755.2003	50	45	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2430	2444		10.1038/sj.onc.1210900	http://dx.doi.org/10.1038/sj.onc.1210900			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17968310				2022-12-17	WOS:000254844900008
J	Ferreira, BI; Alonso, J; Carrillo, J; Acquadro, F; Largo, C; Suela, J; Teixeira, MR; Cerveira, N; Molares, A; Gomez-Lopez, G; Pestana, A; Sastre, A; Garcia-Miguel, P; Cigudosa, JC				Ferreira, B. I.; Alonso, J.; Carrillo, J.; Acquadro, F.; Largo, C.; Suela, J.; Teixeira, M. R.; Cerveira, N.; Molares, A.; Gomez-Lopez, G.; Pestana, A.; Sastre, A.; Garcia-Miguel, P.; Cigudosa, J. C.			Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing's sarcoma	ONCOGENE			English	Article						Ewing's sarcoma; arrayCGH; expression profile; genomic instability	TUMORS; HYBRIDIZATION; TRANSLOCATION; PREDICTION; FUSION	Ewing's sarcoma (ES) is characterized by specific chromosome translocations, the most common being t(11; 22)(q24; q12). Additionally, other type of genetic abnormalities may occur and be relevant for explaining the variable tumour biology and clinical outcome. We have carried out a high-resolution array CGH and expression profiling on 25 ES tumour samples to characterize the DNA copy number aberrations (CNA) occurring in these tumours and determine their association with gene-expression profiles and clinical outcome. CNA were observed in 84% of the cases. We observed a median number of three aberrations per case. Besides numerical chromosome changes, smaller aberrations were found and defined at chromosomes 5p, 7q and 9p. All CNA were compiled to define the smallest overlapping regions of imbalance (SORI). A total of 35 SORI were delimited. Bioinformatics analyses were conducted to identify subgroups according to the pattern of genomic instability. Unsupervised and supervised clustering analysis (using SORI as variables) segregated the tumours in two distinct groups: one genomically stable (<= 3 CNA) and other genomically unstable (> 3 CNA). The genomic unstable group showed a statistically significant shorter overall survival and was more refractory to chemotherapy. Expression pro. le analysis revealed significant differences between both groups. Genes related with chromosome segregation, DNA repair pathways and cell-cycle control were upregulated in the genomically unstable group. This report elucidates, for the first time, data about genomic instability in ES, based on CNA and expression pro. ling, and shows that a genomically unstable group of Ewing's tumours is correlated with a significant poor prognosis.	[Ferreira, B. I.; Acquadro, F.; Largo, C.; Suela, J.; Cigudosa, J. C.] CNIO, Mol Cytogenet Grp, Madrid 28089, Spain; [Ferreira, B. I.; Acquadro, F.; Largo, C.; Suela, J.; Cigudosa, J. C.] CIBERER, Madrid, Spain; [Alonso, J.; Carrillo, J.; Pestana, A.] UAM, CSIC, Inst Invest Biomed A Sols, Dept Biol Mol & Celular Canc, Madrid, Spain; [Teixeira, M. R.; Cerveira, N.] Portuguese Oncol Inst & Biomed Sci Inst ICBAS, Dept Genet, Oporto, Portugal; [Molares, A.; Gomez-Lopez, G.] Hosp Rebullon, CHUVI, Fdn Biomed, Vigo, Pontevedra, Spain; [Gomez-Lopez, G.] CNIO, Unidad Bioinformat, Madrid, Spain; [Sastre, A.; Garcia-Miguel, P.] Hosp Infantil La Paz, Unidad Oncohematol Infantil, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Universidade do Porto; Complexo Hospitalario Universitario de Vigo; Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitario La Paz	Cigudosa, JC (corresponding author), CNIO, Mol Cytogenet Grp, 3 C Melchor Fernandez Almagro, Madrid 28089, Spain.	jalonso@iib.uam.es; jccigudosa@cnio.es	SUELA, JAVIER/K-3968-2016; Teixeira, Manuel AC/AAZ-7251-2020; Teixeira, Manuel António Rodrigues/E-4885-2011; Molares-Vila, Alberto/AAA-3140-2021; García, Jaime Carrillo/AAC-5144-2020; Gomez-Lopez, Gonzalo/D-9123-2016; Cigudosa, Juan C/E-4105-2016; Alonso, Javier/B-6012-2013	Teixeira, Manuel AC/0000-0002-1959-0624; Teixeira, Manuel António Rodrigues/0000-0002-4896-5982; Gomez-Lopez, Gonzalo/0000-0002-4146-0551; Alonso, Javier/0000-0002-6287-8391; Cerveira, Nuno/0000-0001-5098-3840; Carrillo Garcia, Jaime/0000-0002-2861-3015; ferreira, Bibiana/0000-0003-4772-9395				Armengol G, 1997, BRIT J CANCER, V75, P1403, DOI 10.1038/bjc.1997.242; AURIAS A, 1984, CANCER GENET CYTOGEN, V12, P21, DOI 10.1016/0165-4608(84)90003-7; Bandres E, 2005, J PEDIAT HEMATOL ONC, V27, P537, DOI 10.1097/01.mph.0000184576.38835.e2; Blaveri E, 2005, CLIN CANCER RES, V11, P7012, DOI 10.1158/1078-0432.CCR-05-0177; Brisset S, 2001, CANCER GENET CYTOGEN, V130, P57, DOI 10.1016/S0165-4608(01)00454-X; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Eilers PHC, 2005, BIOINFORMATICS, V21, P1146, DOI 10.1093/bioinformatics/bti148; Hattinger CM, 2002, BRIT J CANCER, V86, P1763, DOI 10.1038/sj.bjc.6600332; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; Mendiola M, 2006, INT J CANCER, V118, P1381, DOI 10.1002/ijc.21578; MUGNERET F, 1988, CANCER GENET CYTOGEN, V32, P239, DOI 10.1016/0165-4608(88)90286-5; Ohali A, 2004, ONCOGENE, V23, P8997, DOI 10.1038/sj.onc.1208060; Ozaki T, 2001, GENE CHROMOSOME CANC, V32, P164, DOI 10.1002/gcc.1178; Pinkel D, 2005, ANNU REV GENOM HUM G, V6, P331, DOI 10.1146/annurev.genom.6.080604.162140; Rouveirol C, 2006, BIOINFORMATICS, V22, P849, DOI 10.1093/bioinformatics/btl004; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thompson PM, 2001, CANCER RES, V61, P679; Ushigome U, 2002, PATHOLOGY GENETICS T, P298; Wu W, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-309; Zielenska M, 2001, CANCER, V91, P2156, DOI 10.1002/1097-0142(20010601)91:11<2156::AID-CNCR1244>3.0.CO;2-I	21	45	61	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2008	27	14					2084	2090		10.1038/sj.onc.1210845	http://dx.doi.org/10.1038/sj.onc.1210845			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17952124				2022-12-17	WOS:000254359100013
J	Joo, CK; Kim, HS; Park, JY; Seomun, Y; Son, MJ; Kim, JT				Joo, C-K; Kim, H-S; Park, J-Y; Seomun, Y.; Son, M-J; Kim, J-T			Ligand release-independent transactivation of epidermal growth factor receptor by transforming growth factor-beta involves multiple signaling pathways	ONCOGENE			English	Article						TGF-beta; EGFR; Src; ROS; NADPH oxidase; E-cadherin	PROTEIN-KINASE INHIBITORS; SMOOTH-MUSCLE-CELLS; TGF-BETA; EGF RECEPTOR; MESENCHYMAL TRANSITION; HYDROGEN-PEROXIDE; TYROSINE KINASES; GENE-EXPRESSION; MESANGIAL CELLS; C-SRC	Many of the signaling responses induced by transforming growth factor-beta (TGF-beta) are mediated by Smad proteins, but there is evidence that it can also signal independently of Smads. Here, we provide evidence that multiple signal pathways induced by TGF-beta 1-including Src family tyrosine kinases (SFKs), generation of reactive oxygen species (ROS), de novo protein synthesis and E-cadherin-dependent cell-cell interactions-transactivate the epidermal growth factor receptor (EGFR), which in turn regulates expression of c-Fos and c-Jun. Immunoprecipitation and immunofluorescence staining showed that EGFR was phosphorylated on tyrosine in response to TGF-beta 1. EGFR transactivation required the activation of SFKs and the production of ROS via NADPH oxidase, but was not dependent on metalloproteases or the release of EGF-like ligands. In addition, the production of ROS was dependent on signaling by specific SFKs as well as de novo protein synthesis. Stable transfection of E-cadherin into MDA-MB-231 cells as well as E-cadherin-blocking assays revealed that E-cadherin-mediated cell-cell interactions were also essential for EGFR transactivation. Finally, EGFR transactivation was involved in the expression of c-Fos and c-Jun via the extracellular signal-regulated kinase signaling cascade. Taken together our data suggest that ligand release-independent transactivation of EGFR may diversify early TGF-beta signaling and represent a novel pathway leading to TGF-beta-mediated gene expression.	[Joo, C-K; Kim, H-S; Park, J-Y; Seomun, Y.; Son, M-J; Kim, J-T] Catholic Univ Korea, Lab Visual Sci, Coll Med, Korea Eye Tissue & Gene Bank, Seoul 137040, South Korea; [Kim, J-T] KOCAT Inc, Bio Div, Seoul, South Korea	Catholic University of Korea	Kim, JT (corresponding author), Catholic Univ Korea, Lab Ophthalmol & Visual Sci, Coll Med, 505 Banpo Dong, Seoul 137040, South Korea.	superbio@kocat.com						Bahk YY, 2004, PROTEOMICS, V4, P3299, DOI 10.1002/pmic.200400980; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; CARMONOCUENCA I, 2005, J CELL PHYSL, V207, P322; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen HY, 1997, J CELL SCI, V110, P345; Chiu C, 2001, INT J MOL MED, V8, P251; Cucoranu I, 2005, CIRC RES, V97, P900, DOI 10.1161/01.RES.0000187457.24338.3D; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; FAN Z, 1994, J BIOL CHEM, V269, P27595; Ferguson KM, 2004, BIOCHEM SOC T, V32, P742, DOI 10.1042/BST0320742; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Frank GD, 2001, BIOCHEM BIOPH RES CO, V280, P1116, DOI 10.1006/bbrc.2001.4251; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hua H, 2003, J BIOL CHEM, V278, P33951, DOI 10.1074/jbc.M302823200; Iwamoto R, 2000, CYTOKINE GROWTH F R, V11, P335, DOI 10.1016/S1359-6101(00)00013-7; Kim JT, 2002, J BIOL CHEM, V277, P31938, DOI 10.1074/jbc.M201178200; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; LAFON C, 1995, BBA-MOL CELL RES, V1266, P288, DOI 10.1016/0167-4889(95)00023-L; Lecuit M, 1999, EMBO J, V18, P3956, DOI 10.1093/emboj/18.14.3956; Levy DE, 1998, J MED CHEM, V41, P199, DOI 10.1021/jm970494j; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Murillo MM, 2005, ONCOGENE, V24, P4580, DOI 10.1038/sj.onc.1208664; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Park SK, 2001, BIOCHEM BIOPH RES CO, V284, P966, DOI 10.1006/bbrc.2001.5058; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RHEE SG, 2000, SCI STKE, pE1; Rocic P, 2005, CIRC RES, V97, P850, DOI 10.1161/01.RES.0000190403.87462.bf; Samarakoon R, 2005, J CELL PHYSIOL, V204, P236, DOI 10.1002/jcp.20279; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; Sorescu D, 2001, FREE RADICAL BIO MED, V30, P603, DOI 10.1016/S0891-5849(00)00507-4; Takeda S, 2006, EMBO J, V25, P2388, DOI 10.1038/sj.emboj.7601131; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Uchiyama-Tanaka Y, 2002, KIDNEY INT, V62, P799, DOI 10.1046/j.1523-1755.2002.00537.x; Vinals F, 2001, MOL CELL BIOL, V21, P7218, DOI 10.1128/MCB.21.21.7218-7230.2001; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zuo X, 2001, ELECTROPHORESIS, V22, P1603, DOI 10.1002/1522-2683(200105)22:9<1603::AID-ELPS1603>3.0.CO;2-I; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	58	45	45	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					614	628		10.1038/sj.onc.1210649	http://dx.doi.org/10.1038/sj.onc.1210649			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17637750				2022-12-17	WOS:000252674900006
J	Gibbs, J; Liebermann, D; Hoffman, B				Gibbs, Jd; Liebermann, Da; Hoffman, B.			Egr-1 abrogates the E2F-1 block in terminal myeloid differentiation and suppresses leukemia	ONCOGENE			English	Article						Egr-1; E2F-1; myeloid differentiation; leukemia; tumor suppressor	TRANSCRIPTION FACTOR EGR-1; C-MYC; MACROPHAGE DIFFERENTIATION; CELLS; LEUKEMOGENESIS; TRANSFORMATION; EXPRESSION; INDUCTION; ACTIVATOR; LINEAGE	Deregulated growth and blocks in differentiation collaborate in the multistage process of leukemogenesis. Previously, we have shown that ectopic expression of the zinc finger transcription factor Egr-1 in M1 myeloblastic leukemia cells promotes terminal differentiation with interleukin-6 (IL-6). In addition, we have shown that deregulated expression of the oncogene E2F-1 blocks the myeloid terminal differentiation program, resulting in proliferation of immature cells in the presence of IL-6. Here it is shown that the positive regulator of differentiation Egr-1 abrogates the E2F-1-driven block in myeloid terminal differentiation. The M1E2F-1/Egr-1 cells underwent G(0)/G(1) arrest and functional macrophage maturation following treatment with IL-6. Furthermore, Egr-1 diminished the aggressiveness of M1E2F-1 leukemias and abrogated the leukemic potential of IL-6-treated M1E2F-1 cells. Previously, we reported that Egr-1 abrogated the block in terminal myeloid differentiation imparted by deregulated c-myc, which blocks differentiation at a later stage than E2F-1, resulting in cells that have the characteristics of functionally mature macrophages that did not undergo G(0)/G(1) arrest. Taken together, this work extends and highlights the tumor suppressor role of Egr-1, with Egr-1 behaving as a tumor suppressor against two oncogenes, each blocking myeloid differentiation by a different mechanism. These findings suggest that Egr-1 and/or Egr-1 target genes may be useful tools to treat or suppress oncogene-driven hematological malignancies.	[Gibbs, Jd; Liebermann, Da; Hoffman, B.] Temple Univ, Fels Inst Canc Res & Mol Biol, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Hoffman, B (corresponding author), Temple Univ, Fels Inst Canc Res & Mol Biol, Dept Biochem, 3307 N Broad St,AHB 331, Philadelphia, PA 19140 USA.	hoffman@temple.edu			NATIONAL CANCER INSTITUTE [R01CA081168] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA081168] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amanullah A, 2000, BLOOD, V96, P475; Baron V, 2003, ONCOGENE, V22, P4194, DOI 10.1038/sj.onc.1206560; Beckmann AM, 1997, NEUROCHEM INT, V31, P477, DOI 10.1016/S0197-0186(96)00136-2; Bram S, 2004, CANCER GENET CYTOGEN, V155, P74, DOI 10.1016/j.cancergencyto.2004.03.003; Carter JH, 2007, J IMMUNOL, V178, P3038, DOI 10.4049/jimmunol.178.5.3038; Chen F, 2004, CANCER RES, V64, P5425, DOI 10.1158/0008-5472.CAN-04-0806; Giagounidis AAN, 2004, LEUKEMIA, V18, P113, DOI 10.1038/sj.leu.2403189; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; Krishnaraju K, 2001, BLOOD, V97, P1298, DOI 10.1182/blood.V97.5.1298; Laslo P, 2006, CELL, V126, P755, DOI 10.1016/j.cell.2006.06.052; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; McMahon SB, 1996, J LEUKOCYTE BIOL, V60, P159, DOI 10.1002/jlb.60.2.159; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Shafarenko M, 2005, BLOOD, V106, P871, DOI 10.1182/blood-2004-08-3056; STEINKAMP JA, 1982, SCIENCE, V215, P64, DOI 10.1126/science.7053559	19	45	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2008	27	1					98	106		10.1038/sj.onc.1210627	http://dx.doi.org/10.1038/sj.onc.1210627			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599039				2022-12-17	WOS:000252118700010
J	Inoue, K; Mallakin, A; Frazier, DP				Inoue, K.; Mallakin, A.; Frazier, D. P.			Dmp1 and tumor suppression	ONCOGENE			English	Review						Dmp1; cyclin D; arf; p53; Ras; haplo-insufficiency	D-TYPE CYCLINS; TRANSCRIPTION FACTOR DMP1; DEPENDENT-KINASE; GENE-EXPRESSION; LEUKEMIC-CELLS; BREAST-CANCER; PROTEIN HDMP1; ARF; P53; MYB	Dmp1 (cyclin D binding myb-like protein 1; also called Dmtf1) is a transcription factor that was isolated in a yeast two-hybrid screen through its binding property to cyclin D2. Although it was initially predicted to be involved in the cyclin D-Rb pathway, overexpression of Dmp1 in primary cells induces cell cycle arrest in an Arf, p53-dependent fashion. Dmp1 is a unique Arf regulator, the promoter of which is activated by oncogenic Ras-Raf signaling. Dmp1 expression is repressed by physiological mitogenic stimuli as well as by overexpressed E2F proteins; thus, it is a novel marker of cells that have exited from the cell cycle. Spontaneous and oncogene-induced tumor formation is accelerated in both Dmp1(+/-) and Dmp1(-/-) mice; the Dmp1(+/-) tumors often retain and express the wild-type allele; thus, Dmp1 is haplo-insufficient for tumor suppression. Tumors from Dmp1(+/-) and Dmp1(+/-) mice often retain wild-type Arf and p53, suggesting that Dmp1 is a physiological regulator of the Arf-p53 pathway. The human DMP1 (hDMP1) gene is located on chromosome 7q21, the locus of which is often deleted in myeloid leukemia and also in some types of solid tumors. Post-translational modication of Dmp1 and its role in human malignancy remain to be investigated.	Wake Forest Univ Hlth Sci, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ Hlth Sci, Dept Canc Biol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine	Inoue, K (corresponding author), Wake Forest Univ Hlth Sci, Dept Pathol, 2102 Gray Bldg,Med Ctr Blvd, Winston Salem, NC 27157 USA.	kinoue@wfubmc.edu			NATIONAL CANCER INSTITUTE [R01CA106314] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106314-01, R01 CA106314, R01 CA106314-02, 5R01CA106314, R01 CA106314-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Bernards R, 1999, BBA-REV CANCER, V1424, pM17, DOI 10.1016/S0304-419X(99)00024-4; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Bodner SM, 1999, GENE, V229, P223, DOI 10.1016/S0378-1119(98)00591-5; Brooksbank C, 2001, NAT REV CANCER, V1, P174, DOI 10.1038/35106021; Calin GA, 2006, SEMIN ONCOL, V33, P167, DOI 10.1053/j.seminoncol.2006.01.010; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Elmaagacli AH, 2005, HAEMATOLOGICA, V90, P326; EVERS R, 1995, P NATL ACAD SCI USA, V92, P5827, DOI 10.1073/pnas.92.13.5827; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302; Inoue K, 1997, BLOOD, V89, P1405, DOI 10.1182/blood.V89.4.1405; Inoue K, 1998, BLOOD, V91, P2969, DOI 10.1182/blood.V91.8.2969.2969_2969_2976; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Inoue K, 2000, GENE DEV, V14, P1797; Inoue K, 1998, J BIOL CHEM, V273, P29188, DOI 10.1074/jbc.273.44.29188; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Kamijo T, 1999, CANCER RES, V59, P2217; Kerr J, 1996, ONCOGENE, V13, P1815; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lu Z, 2006, ONCOGENE, V25, P230, DOI 10.1038/sj.onc.1209025; Mallakin A, 2006, ONCOGENE, V25, P7703, DOI 10.1038/sj.onc.1209750; McMahon M, 2001, BBA-REV CANCER, V1471, pM63, DOI 10.1016/S0304-419X(00)00027-5; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sreeramaneni R, 2005, MOL CELL BIOL, V25, P220, DOI 10.1128/MCB.25.1.220-232.2005; Trovato M, 2004, ENDOCR-RELAT CANCER, V11, P365, DOI 10.1677/erc.0.0110365; Tschan MP, 2003, J BIOL CHEM, V278, P42750, DOI 10.1074/jbc.M307067200; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	49	45	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2007	26	30					4329	4335		10.1038/sj.onc.1210226	http://dx.doi.org/10.1038/sj.onc.1210226			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17237816	Green Accepted			2022-12-17	WOS:000247620000001
J	Mitchell, DC; Stafford, LJ; Li, D; Bar-Eli, M; Liu, M				Mitchell, D. C.; Stafford, L. J.; Li, D.; Bar-Eli, M.; Liu, M.			Transcriptional regulation of KiSS-1 gene expression in metastatic melanoma by specificity protein-1 and its coactivator DRIP-130	ONCOGENE			English	Article						KiSS1; GPR54; Sp1; CRSP3; cancer metastasis	ENDOTHELIAL GROWTH-FACTOR; PANCREATIC-CANCER CELLS; COFACTOR COMPLEX CRSP; HUMAN GASTRIC-CANCER; COUPLED RECEPTOR; SUPPRESSOR GENE; FACTOR SP1; ACTIVATOR PROTEIN-2-ALPHA; FACTOR FAMILY; I-RECEPTOR	Loss of the metastasis suppressor gene, KiSS-1 has been strongly correlated to the progression of metastases in numerous types of cancers. The mechanism through which KiSS-1 is lost during metastasis, however, is still not completely known. Previous studies have shown that genetic material on human chromosome 6q16.3-q23 is essential for KiSS-1 expression in normal tissues. Additionally, microcell-mediated transfer of this chromosome in cancerous tissue results in rescued expression of KiSS-1 and reduced metastatic phenotype. Here, we show that loss of Sp1-coactivator protein DRIP-130, which is encoded by human chromosome 6q16.3-q23, results in reduced KiSS-1 promoter activation in highly malignant melanoma cells. Co-expression of Sp1 and DRIP-130 not only rescues KiSS-1 expression, but also induces an inhibition of the invasive and migratory behavior in highly metastatic melanoma cells, similar to the overexpression of KiSS-1 metastasis suppressor gene in those cells. Furthermore, we demonstrate that KiSS-1 expression is regulated by Sp1 elements within the first 100-bp region of the KiSS-1 promoter and that targeted deletion of a single GC-rich region spanning -93 to -58 interrupts Sp1- and DRIP-130-modulated transcriptional control of KiSS-1 expression. Our results thus suggest that DRIP-130 is a key regulator in KiSS-1 transactivation in normal tissue, and that the loss of DRIP-130 expression, as a result of the gross loss of human chromosome 6q16.3-q23, provokes increased tumor metastasis.	Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Dept Mol & Cellular Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; UTMD Anderson Cancer Center	Liu, M (corresponding author), Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamhsc.edu			NCI NIH HHS [1R01CA106479] Funding Source: Medline; NHLBI NIH HHS [5R01HL064792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106479] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdelrahim M, 2004, CANCER RES, V64, P6740, DOI 10.1158/0008-5472.CAN-04-0713; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Goldberg SF, 2003, CANCER RES, V63, P432; Ikeguchi M, 2004, CLIN CANCER RES, V10, P1379, DOI 10.1158/1078-0432.CCR-1519-02; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; Jiang Y, 2005, CLIN EXP METASTAS, V22, P369, DOI 10.1007/s10585-005-8186-4; Jiang YX, 2004, CLIN EXP METASTAS, V21, P755, DOI 10.1007/s10585-005-1198-2; Kotani M, 2001, J BIOL CHEM, V276, P34631, DOI 10.1074/jbc.M104847200; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lee JH, 1997, CANCER RES, V57, P2384; Lee JH, 1997, INT J CANCER, V71, P1035, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1035::AID-IJC20>3.3.CO;2-T; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; Masui T, 2004, BIOCHEM BIOPH RES CO, V315, P85, DOI 10.1016/j.bbrc.2004.01.021; Miele ME, 2000, INT J CANCER, V86, P524, DOI 10.1002/(SICI)1097-0215(20000515)86:4<524::AID-IJC13>3.0.CO;2-W; Mitchell DC, 2006, J BIOL CHEM, V281, P51, DOI 10.1074/jbc.M506245200; Muir AI, 2001, J BIOL CHEM, V276, P28969, DOI 10.1074/jbc.M102743200; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Ryu SJ, 1999, P NATL ACAD SCI USA, V96, P7137, DOI 10.1073/pnas.96.13.7137; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Sanchez-Carbayo M, 2003, AM J PATHOL, V162, P609, DOI 10.1016/S0002-9440(10)63854-0; Shi Q, 2001, CANCER RES, V61, P4143; Shirasaki F, 2001, CANCER RES, V61, P7422; Stafford LJ, 2002, CANCER RES, V62, P5399; Steeg Patricia S, 2003, Clin Breast Cancer, V4, P51, DOI 10.3816/CBC.2003.n.012; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Taatjes DJ, 2004, MOL CELL, V14, P675, DOI 10.1016/j.molcel.2004.05.014; Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200; Wang J, 2005, J NEUROCHEM, V93, P474, DOI 10.1111/j.1471-4159.2005.03051.x; Wang LW, 2003, CLIN CANCER RES, V9, P6371; Yao JC, 2004, CLIN CANCER RES, V10, P4109, DOI 10.1158/1078-0432.CCR-03-0628; Zhu GH, 2002, ONCOGENE, V21, P8477, DOI 10.1038/sj.onc.1206030	36	45	52	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	12					1739	1747		10.1038/sj.onc.1209963	http://dx.doi.org/10.1038/sj.onc.1209963			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964286				2022-12-17	WOS:000244955600008
J	Singh, AP; Chauhan, SC; Andrianifahanana, M; Moniaux, N; Meza, JL; Copin, MC; van Seuningen, I; Hollingsworth, MA; Aubert, JP; Batra, SK				Singh, A. P.; Chauhan, S. C.; Andrianifahanana, M.; Moniaux, N.; Meza, J. L.; Copin, M. C.; van Seuningen, I.; Hollingsworth, M. A.; Aubert, J. P.; Batra, S. K.			MUC4 expression is regulated by cystic fibrosis transmembrane conductance regulator in pancreatic adenocarcinoma cells via transcriptional and post-translational mechanisms	ONCOGENE			English	Article						MUC4; CFTR; pancreatic adenocarcinoma	KAPPA-B ACTIVATION; GENE-EXPRESSION; MUC4/SIALOMUCIN COMPLEX; SIALOMUCIN COMPLEX; SIGNALING PATHWAY; EPITHELIAL-CELLS; CANCER-CELLS; TUMOR-CELLS; DUCT CELLS; T84 CELLS	MUC4 mucin is a high molecular weight transmembrane glycoprotein that plays important roles in tumour biology. It is aberrantly expressed in pancreatic adenocarcinoma, while not being detectable in the normal pancreas. Previous studies have demonstrated that the cystic. brosis transmembrane conductance regulator (CFTR), a chloride channel that is defective in CF, is implicated in multiple cellular functions, including gene regulation. In the present study, using a CFTR-defective pancreatic cancer cell line and its derived subline expressing functional CFTR, we report that MUC4 expression is negatively regulated by CFTR. Short-interfering RNA (siRNA)mediated silencing of CFTR also leads to an increased expression of MUC4. Additionally, our results suggest that CFTR-mediated regulation of MUC4 is cell density-dependent and is achieved by transcriptional and post-translational mechanisms. Moreover, in a panel of pancreatic cancer cell lines and normal pancreas, we observed that CFTR was downregulated in pancreatic cancer cells and negatively correlated with MUC4 in most cases. An aberrant expression of MUC4 was also detected in the CF pancreas. Downregulation of CFTR in pancreatic adenocarcinoma and its inverse association with the tumour-linked mucin, MUC4, indicate novel function(s) of CFTR in pancreatic tumour biology and suggest the implication of new signalling pathway(s) in MUC4 regulation.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Prevent & Societal Med, Biostat Sect, Omaha, NE 68198 USA; INSERM, U560, F-59045 Lille, France	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm)	Batra, SK (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.	sbatra@unmc.edu	Moniaux, Nicolas/Y-3243-2018; Singh, Ajay/AAF-4414-2020; VAN SEUNINGEN, Isabelle/N-6176-2016	Moniaux, Nicolas/0000-0001-9718-1386; VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; Singh, Ajay/0000-0003-3492-6330	NCI NIH HHS [R01 CA78590] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham EH, 1996, NAT MED, V2, P593, DOI 10.1038/nm0596-593; Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; BREUER W, 1993, J BIOL CHEM, V268, P13935; Buisine MP, 1998, GUT, V43, P519, DOI 10.1136/gut.43.4.519; Buisine MP, 2000, J HISTOCHEM CYTOCHEM, V48, P1667, DOI 10.1177/002215540004801210; Cafferata EG, 2000, BBA-MOL BASIS DIS, V1500, P241, DOI 10.1016/S0925-4439(99)00105-2; Cafferata EGA, 2001, J BIOL CHEM, V276, P15441, DOI 10.1074/jbc.M010061200; Chen R, 2004, BIOCHEM BIOPH RES CO, V324, P1087, DOI 10.1016/j.bbrc.2004.09.157; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Davenport SE, 1996, BIOCHEM BIOPH RES CO, V229, P663, DOI 10.1006/bbrc.1996.1861; Debailleul V, 1998, J BIOL CHEM, V273, P881, DOI 10.1074/jbc.273.2.881; Dhakshinamoorthy S, 2002, ONCOGENE, V21, P5301, DOI 10.1038/sj.onc.1205642; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Estell K, 2003, MOL CELL BIOL, V23, P594, DOI 10.1128/MCB.23.2.594-606.2003; Gonzalez-Guerrico AM, 2002, J BIOL CHEM, V277, P17239, DOI 10.1074/jbc.M112456200; Guo RJ, 2004, J BIOL CHEM, V279, P36865, DOI 10.1074/jbc.M405213200; Hinojosa-Kurtzberg AM, 2003, AM J PHYSIOL-GASTR L, V284, pG853, DOI 10.1152/ajpgi.00326.2002; Hokari R, 2005, AM J PHYSIOL-GASTR L, V289, pG949, DOI 10.1152/ajpgi.00142.2005; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Iacobuzio-Donahue CA, 2003, CANCER RES, V63, P8614; Jepson S, 2002, ONCOGENE, V21, P7524, DOI 10.1038/sj.onc.1205970; Karan D, 2003, BIOCHEM BIOPH RES CO, V305, P598, DOI 10.1016/S0006-291X(03)00823-4; Komatsu M, 2001, ONCOGENE, V20, P461, DOI 10.1038/sj.onc.1204106; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Malats N, 2001, GUT, V48, P70, DOI 10.1136/gut.48.1.70; MALMBERG EK, 2006, IN PRESS AM J PHYSL; Mariette C, 2004, BIOCHEM J, V377, P701, DOI 10.1042/BJ20031132; McWilliams R, 2005, GUT, V54, P1661, DOI 10.1136/gut.2005.074534; Namkung W, 2003, J BIOL CHEM, V278, P200, DOI 10.1074/jbc.M207199200; NEGLIA JP, 1995, NEW ENGL J MED, V332, P494, DOI 10.1056/NEJM199502233320803; Park Hee-Ug, 2003, Pancreas, V26, pe48, DOI 10.1097/00006676-200304000-00022; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SHELDON CD, 1993, BRIT J CANCER, V68, P1025, DOI 10.1038/bjc.1993.474; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Soto P, 2003, J BIOL CHEM, V278, P20338, DOI 10.1074/jbc.M301886200; Steagall WK, 2000, AM J RESP CELL MOL, V22, P45, DOI 10.1165/ajrcmb.22.1.3789; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Tabary O, 1999, AM J PATHOL, V155, P473, DOI 10.1016/S0002-9440(10)65143-7; Thomsson KA, 2002, BIOCHEM J, V367, P609, DOI 10.1042/BJ20020371; Uribe JM, 2002, AM J PHYSIOL-GASTR L, V283, pG923, DOI 10.1152/ajpgi.00237.2002; WARREN N, 1991, BRIT MED J, V302, P760, DOI 10.1136/bmj.302.6779.760; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WINPENNY JP, 1995, AM J PHYSIOL-CELL PH, V268, pC823, DOI 10.1152/ajpcell.1995.268.4.C823; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	49	45	45	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 4	2007	26	1					30	41		10.1038/sj.onc.1209764	http://dx.doi.org/10.1038/sj.onc.1209764			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799633				2022-12-17	WOS:000243236500004
J	Lallemand, C; Blanchard, B; Palmieri, M; Lebon, P; May, E; Tovey, MG				Lallemand, C.; Blanchard, B.; Palmieri, M.; Lebon, P.; May, E.; Tovey, M. G.			Single-stranded RNA viruses inactivate the transcriptional activity of p53 but induce NOXA-dependent apoptosis via post-translational modifications of IRF-1, IRF-3 and CREB	ONCOGENE			English	Article						NOXA; p53; IRF-1; IRF-3; virus	INDEPENDENT PHOSPHOLIPASE A(2); OXIDE SYNTHASE EXPRESSION; REGULATORY FACTOR-I; GENE-EXPRESSION; ANTIVIRAL RESPONSE; BH3-ONLY PROTEINS; FACTOR DRAF1; INTERFERON; CELLS; ACTIVATION	To characterize the mechanisms underlying apoptosis induced by viral infection, transcriptional activation of genes encoding members of the 'BH3-only' family of proteins was analysed during the course of virus infection. Among these genes, only NOXA is transcriptionally activated by vesicular stomatitis virus (VSV), sendai virus (SV), measles virus, herpes simplex virus, or dsRNA and required for efficient apoptosis of cells. Transcriptional activation of NOXA by VSV or SV is independent of p53, but requires the presence of interferon regulatory factor 1 (IRF-1), IRF-3 and cAMP-responsive element binding protein (CREB). Binding to and transactivation of the NOXA promoter by each of these transcription factors is governed by post-translational modi. cation involving different pathways for each factor. Thus, SV infection activates IRF-3and CREB by phosphorylation triggered by Toll like receptor 3 signalling, and a pathway involving calcium-independent phopholipase A2, respectively. In addition transactivation induced by IRF-1 during viral infection correlates with a 10 kDa increase in its molecular weight, suggesting a covalent linkage with a previously unknown regulatory polypeptide.	Inst Andre Lwoff, Lab Viral Oncol, UPR 9045, CNRS, F-94801 Villejuif, France; Univ Verona, Sez Chim Biol, Dipartimento Sci Morfol Biomed, I-37100 Verona, Italy; Univ Paris 05, Hop Cochin, Virol Lab, Paris, France	Centre National de la Recherche Scientifique (CNRS); University of Verona; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Lallemand, C (corresponding author), Inst Andre Lwoff, Lab Viral Oncol, UPR 9045, CNRS, 7 Rue Guy Moquet, F-94801 Villejuif, France.	lalleman@vjf.cnrs.fr		lallemand, christophe/0000-0001-5965-2482; Tovey, Michael/0000-0002-3058-0494				Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; Bouker KB, 2004, CANCER RES, V64, P4030, DOI 10.1158/0008-5472.CAN-03-3602; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; Chow WA, 2000, J IMMUNOL, V164, P3512, DOI 10.4049/jimmunol.164.7.3512; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Geiss G, 2001, J BIOL CHEM, V276, P30178, DOI 10.1074/jbc.C100137200; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Licata JM, 2003, INT REV IMMUNOL, V22, P451, DOI 10.1080/08830180305217; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lyles DS, 2000, MICROBIOL MOL BIOL R, V64, P709, DOI 10.1128/MMBR.64.4.709-724.2000; Maggi LB, 2002, J BIOL CHEM, V277, P38449, DOI 10.1074/jbc.M206247200; Marques JT, 2005, J VIROL, V79, P11105, DOI 10.1128/JVI.79.17.11105-11114.2005; Martinson BD, 2003, J LIPID RES, V44, P1686, DOI 10.1194/jlr.M300018-JLR200; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Miro-Mur F, 2003, ONCOGENE, V22, P5451, DOI 10.1038/sj.onc.1206538; Moehler M, 2001, CANCER GENE THER, V8, P158, DOI 10.1038/sj.cgt.7700288; Moran JM, 2005, J BIOL CHEM, V280, P28162, DOI 10.1074/jbc.M500013200; Moro A, 2000, BIOCHEM BIOPH RES CO, V269, P31, DOI 10.1006/bbrc.2000.2256; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Nakagawa K, 2000, EUR J BIOCHEM, V267, P1680, DOI 10.1046/j.1432-1327.2000.01163.x; Nakagawa K, 2002, FEBS LETT, V530, P204, DOI 10.1016/S0014-5793(02)03486-5; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998; Ruiz-Ruiz C, 2004, J BIOL CHEM, V279, P19712, DOI 10.1074/jbc.M313023200; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Sun YP, 2005, J BIOL CHEM, V280, P15561, DOI 10.1074/jbc.m412630200; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Tanaka N, 1998, GENES CELLS, V3, P29, DOI 10.1046/j.1365-2443.1998.00164.x; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Weaver BK, 2001, FASEB J, V15, P501, DOI 10.1096/fj.00-0222com; Williams SD, 2001, AM J PHYSIOL-HEART C, V281, pH168, DOI 10.1152/ajpheart.2001.281.1.H168; Xie RL, 2001, J BIOL CHEM, V276, P18624, DOI 10.1074/jbc.M010391200; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yoneyama Mitsutoshi, 2004, Uirusu, V54, P161, DOI 10.2222/jsv.54.161	41	45	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					328	338		10.1038/sj.onc.1209795	http://dx.doi.org/10.1038/sj.onc.1209795			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832344				2022-12-17	WOS:000243544000002
J	Benoit, V; de Moraes, E; Dar, NA; Taranchon, E; Bours, V; Hautefeuille, A; Taniere, P; Chariot, A; Scoazec, JY; Gallo, CVD; Merville, MP; Hainaut, P				Benoit, V.; de Moraes, E.; Dar, N. A.; Taranchon, E.; Bours, V.; Hautefeuille, A.; Taniere, P.; Chariot, A.; Scoazec, J-Y; Gallo, C. V. de Moura; Merville, M-P; Hainaut, P.			Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB	ONCOGENE			English	Article						p53; NF-kappaB; cyclooxygenase-2 esophageal cancer; Barrett's metaplasia	SQUAMOUS-CELL CARCINOMA; BARRETTS-ESOPHAGUS; GENE-EXPRESSION; UP-REGULATION; COLON-CANCER; B ACTIVATION; COX-2; INHIBITION; PROTEIN; INDUCTION	Overexpression of cyclooxygenase-2 (Cox-2) is thought to exert antiapoptotic effects in cancer. Here we show that the tumor suppressor p53 upregulated Cox-2 in esophageal and colon cancer cell lines by inducing the binding of nuclear factor-kappaB (NF-kappaB) to its response element in the COX-2 promoter. Inhibition of NF-kappaB prevented p53 induction of Cox-2 expression. Cooperation between p53 and NF-kappaB was required for activation of COX-2 promoter in response to daunomycin, a DNA-damaging agent. Pharmacological inhibition of Cox-2 enhanced apoptosis in response to daunomycin, in particular in cells containing active p53. In esophageal cancer, there was a correlation between Cox-2 expression and wild-type TP53 in Barrett's esophagus (BE) and in adenocarcinoma, but not in squamous cell carcinoma (P < 0.01). These results suggest that p53 and NF-kappaB cooperate in upregulating Cox-2 expression, promoting cell survival in inflammatory precursor lesions such as BE.	Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon, France; Univ Liege, Lab Med Chem & Human Genet, Ctr Biomed Integrated Genoproteom, Liege, Belgium; Hop Edouard Herriot, Dept Pathol, Lyon, France; State Uni Rio de Janeiro, Dept Cellular Biol & Genet, Rio De Janeiro, Brazil	World Health Organization; International Agency for Research on Cancer (IARC); University of Liege; CHU Lyon; Universidade do Estado do Rio de Janeiro	Hainaut, P (corresponding author), Int Agcy Res Canc, Grp Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon, France.	hainaut@iarc.fr	Dar, NAZIR AHMAD/AAX-2763-2020; Hainaut, Pierre/B-6018-2012	Dar, NAZIR AHMAD/0000-0002-9517-9458; Hainaut, Pierre/0000-0002-1303-1610; Chariot, Alain/0000-0002-1691-4347; BENOIT, Valerie/0000-0002-1098-9452				Barnas C, 1997, INT J CANCER, V71, P79, DOI 10.1002/(SICI)1097-0215(19970328)71:1<79::AID-IJC14>3.0.CO;2-4; Beltrami E, 2004, J BIOL CHEM, V279, P2077, DOI 10.1074/jbc.M309479200; Benoit V, 2000, ONCOGENE, V19, P4787, DOI 10.1038/sj.onc.1203831; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bentires-Alj M, 2001, ONCOGENE, V20, P2805, DOI 10.1038/sj.onc.1204343; Bentires-Alj M, 1999, DRUG RESIST UPDATE, V2, P274, DOI 10.1054/drup.1999.0093; Birkenkamp-Demtroder K, 2005, GUT, V54, P374, DOI 10.1136/gut.2003.036848; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Buskens CJ, 2003, GUT, V52, P1678, DOI 10.1136/gut.52.12.1678; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Corcoran CA, 2005, ONCOGENE, V24, P1634, DOI 10.1038/sj.onc.1208353; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Gilroy DW, 2001, FASEB J, V15, P288; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Han JH, 2004, MECH AGEING DEV, V125, P359, DOI 10.1016/j.mad.2004.02.002; Harris RE, 2000, CANCER RES, V60, P2101; Hla T, 1999, INT J BIOCHEM CELL B, V31, P551, DOI 10.1016/S1357-2725(98)00152-6; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jiang XH, 2002, ONCOGENE, V21, P6113, DOI 10.1038/sj.onc.1205778; Jobin C, 1998, IMMUNOLOGY, V95, P537; Kaur BS, 2002, AM J PHYSIOL-GASTR L, V283, pG327, DOI 10.1152/ajpgi.00543.2001; Kaur BS, 2002, GASTROENTEROLOGY, V123, P60, DOI 10.1053/gast.2002.34244; Konturek PC, 2004, DIGEST DIS SCI, V49, P1075, DOI 10.1023/B:DDAS.0000037790.11724.70; Krysan K, 2004, FASEB J, V18, P205, DOI 10.1096/fj.03-0369fje; Krysan K, 2004, CANCER RES, V64, P6359, DOI 10.1158/0008-5472.CAN-04-1681; Kuo KT, 2003, ANN THORAC SURG, V76, P909, DOI 10.1016/S0003-4975(03)00717-3; Lagorce C, 2003, HISTOPATHOLOGY, V42, P457, DOI 10.1046/j.1365-2559.2003.01627.x; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; Oshima M, 2001, CANCER RES, V61, P1733; Rockwell P, 2004, CELL SIGNAL, V16, P343, DOI 10.1016/j.cellsig.2003.08.006; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Sepehr A, 2001, ONCOGENE, V20, P7368, DOI 10.1038/sj.onc.1204912; Shamma A, 2000, CLIN CANCER RES, V6, P1229; Shirvani VN, 2000, GASTROENTEROLOGY, V118, P487, DOI 10.1016/S0016-5085(00)70254-X; Siewert JR, 1998, BRIT J SURG, V85, P1457; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Smith GV, 2005, AM J CLIN PATHOL, V123, P415, DOI 10.1309/263A4PQ83R9OCRUF; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Swamy MV, 2003, CANCER RES, V63, P5239; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; Tsuji S, 2001, J EXP CLIN CANC RES, V20, P117; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wu KK, 2005, ARTERIOSCL THROM VAS, V25, P679, DOI 10.1161/01.ATV.0000157899.35660.61; Yang D, 2004, P NATL ACAD SCI USA, V101, P15100, DOI 10.1073/pnas.0406665101; Yu HP, 2003, CANCER LETT, V198, P193, DOI 10.1016/S0304-3835(03)00340-9; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200; Zimmermann KC, 1999, CANCER RES, V59, P198	56	45	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5708	5718		10.1038/sj.onc.1209579	http://dx.doi.org/10.1038/sj.onc.1209579			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16682957	Green Published			2022-12-17	WOS:000240765800002
J	Caracciolo, V; Reiss, K; Khalili, K; De Falco, G; Giordano, A				Caracciolo, V.; Reiss, K.; Khalili, K.; De Falco, G.; Giordano, A.			Role of the interaction between large T antigen and Rb family members in the oncogenicity of JC virus	ONCOGENE			English	Review						JCV T antigen; retinoblastoma family proteins; cell cycle	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETINOBLASTOMA GENE FAMILY; TUMOR-SUPPRESSOR PROTEIN; GROWTH IN-VIVO; CELL-CYCLE; HISTONE DEACETYLASE; DNA-SEQUENCES; E2F FAMILY; PRB-FAMILY; REPRESS TRANSCRIPTION	Human polyomaviruses (JC virus, BK virus and simian virus 40) are causative agents of some human diseases and, interestingly, are involved in processes of cell transformation and oncogenesis. These viruses need the cell cycle machinery of the host cell to complete their replication; so they evolved mechanisms that can interfere with the growth control of infected cells and force them into DNA replication. The retinoblastoma family of proteins (pRb), which includes pRb/p105, p107 and pRb2/p130, acts as one of the most important regulators of the G1/S transition of the cell cycle. Rb proteins represent an important target for viral oncoproteins. Early viral T antigens can bind all members of the pRb family, promoting the activation of the E2F family of transcription factors, thus inducing the expression of genes required for the entry to the S phase. The interaction between early viral antigens and cell cycle regulators represents an important mechanism through which viruses deregulate cell cycle and lead to cell transformation. In this review, we will discuss the effects of the interaction between large T antigen and Rb proteins in JC virus-mediated oncogenesis.	Temple Univ, Sbarro Inst Canc Res & Mol Med, Dept Biol, Philadelphia, PA 19122 USA; Temple Univ, Ctr Neurovirol, Dept Neurosci, Philadelphia, PA 19122 USA; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena	Giordano, A (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, Dept Biol, 1900 N 12th St,BioLife Sci Bldg, Philadelphia, PA 19122 USA.	giordano@temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				ARIZA A, 1994, HUM PATHOL, V25, P1341, DOI 10.1016/0046-8177(94)90095-7; Balciunaite E, 2005, MOL CELL BIOL, V25, P8166, DOI 10.1128/MCB.25.18.8166-8178.2005; Barbanti-Brodano G, 1998, ADV VIRUS RES, V50, P69, DOI 10.1016/S0065-3527(08)60806-4; Berger JR, 1998, ANN NEUROL, V44, P341, DOI 10.1002/ana.410440309; Boldorini R, 1998, J NEUROVIROL, V4, P242, DOI 10.3109/13550289809114524; BOLLAG B, 1989, J VIROL, V63, P863, DOI 10.1128/JVI.63.2.863-872.1989; Bollag B, 2000, VIROLOGY, V274, P165, DOI 10.1006/viro.2000.0451; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Caldarelli-Stefano R, 2000, HUM PATHOL, V31, P394, DOI 10.1016/S0046-8177(00)80256-7; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Casini B, 2005, ANTICANCER RES, V25, P1079; Chestukhin A, 2002, MOL CELL BIOL, V22, P453, DOI 10.1128/MCB.22.2.453-468.2002; CINATL J, 2001, MECH DNA TUMOR VIRUS; Cinti C, 2000, CANCER RES, V60, P383; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2000, CANCER RES, V60, P8; Croul S, 2003, J NEUROVIROL, V9, P173, DOI 10.1080/13550280390194055; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Del Valle L, 2000, ANN NEUROL, V48, P932, DOI 10.1002/1531-8249(200012)48:6<932::AID-ANA15>3.0.CO;2-E; Del Valle L, 2005, CANCER-AM CANCER SOC, V103, P516, DOI 10.1002/cncr.20806; Del Valle L, 2002, CLIN CANCER RES, V8, P3332; Del Valle L, 2001, CANCER RES, V61, P4287; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dorries K, 1998, DEV BIOLOGICALS, V94, P71; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Frisque RJ, 2003, J NEUROVIROL, V9, P15, DOI 10.1080/13550280390195270; Frisque RJ, 2001, J NEUROVIROL, V7, P293, DOI 10.1080/13550280152537120; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; Frisque RJ, 1992, MOL NEUROVIROLOGY PA, P25; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; GJOERUP OV, 1994, P NATL ACAD SCI USA, V91, P12125; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; HOLMAN PS, 1994, J VIROL, V68, P668, DOI 10.1128/JVI.68.2.668-673.1994; Howard CM, 1998, J NATL CANCER I, V90, P1451, DOI 10.1093/jnci/90.19.1451; Howard CM, 2000, CANCER RES, V60, P2737; Howes SH, 1996, J VIROL, V70, P3581, DOI 10.1128/JVI.70.6.3581-3588.1996; Khalili K, 1999, LANCET, V353, P1152, DOI 10.1016/S0140-6736(99)00357-8; Klucky B, 2004, ONCOGENE, V23, P4707, DOI 10.1038/sj.onc.1207640; Knudsen ES, 1998, ONCOGENE, V16, P1655, DOI 10.1038/sj.onc.1201682; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; Lin JY, 2003, J BIOL CHEM, V278, P46482, DOI 10.1074/jbc.M307044200; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; LONDON WT, 1978, SCIENCE, V201, P1246, DOI 10.1126/science.211583; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Maiti B, 2005, J BIOL CHEM, V280, P18211, DOI 10.1074/jbc.M501410200; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nemethova M, 2004, MOL CELL BIOL, V24, P10986, DOI 10.1128/MCB.24.24.10986-10994.2004; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Rencic A, 1996, P NATL ACAD SCI USA, V93, P7352, DOI 10.1073/pnas.93.14.7352; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Ross JF, 2001, GENE DEV, V15, P392, DOI 10.1101/gad.858501; Seth P, 2003, J NEUROVIROL, V9, P236, DOI 10.1080/13550280390194019; Sheng Q, 1997, J VIROL, V71, P9410, DOI 10.1128/JVI.71.12.9410-9416.1997; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SIMA AAF, 1983, ANN NEUROL, V14, P183, DOI 10.1002/ana.410140205; Simmons DT, 2000, ADV VIRUS RES, V55, P75, DOI 10.1016/S0065-3527(00)55002-7; Stiegler P, 1998, J CELL BIOCHEM, P30; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Trojanek J, 2006, J CELL PHYSIOL, V206, P35, DOI 10.1002/jcp.20425; TROJANEK J, 2006, INT J CANC      0329; TROWBRIDGE PW, 1995, J NEUROVIROL, V1, P195, DOI 10.3109/13550289509113966; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White MK, 2004, VIROLOGY, V324, P1, DOI 10.1016/j.virol.2004.03.025; WHITE MK, 2006, IN PRESS ONCOGENE; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; ZURHEIN GM, 1983, POLYOMAVIRUSES HUMAN, P205	90	45	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5294	5301		10.1038/sj.onc.1209681	http://dx.doi.org/10.1038/sj.onc.1209681			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936750				2022-12-17	WOS:000240064100015
J	White, MK; Khalili, K				White, M. K.; Khalili, K.			Interaction of retinoblastoma protein family members with large T-antigen of primate polyomaviruses	ONCOGENE			English	Review						polyomavirus; retinoblastoma; cell cycle; transformation; oncogenesis	SV40 LARGE-T; SUSCEPTIBILITY GENE-PRODUCT; TUMOR-SUPPRESSOR PROTEINS; CELL-CYCLE CONTROL; E2F TRANSCRIPTION FACTOR; ADENOVIRUS E1A PROTEINS; VIRAL-DNA REPLICATION; PRB-RELATED PROTEINS; JC-VIRUS; BK VIRUS	The retinoblastoma gene product pRb and other members of the Rb family of pocket proteins have a central role in the regulation of cell cycle progression. Soon after its discovery, p Rb was found to interact with the transforming oncoproteins of DNA tumor viruses and this led to rapid advances in our understanding of the mechanisms of viral transformation and cell cycle progression. DNA viruses of the polyomavirus family have small, circular, double-stranded DNA genomes contained within non-enveloped icosahedral capsids and are highly tumorigenic in experimental animals. At least three types of polyomavirus infect humans: JC virus (JCV), BK virus (BKV) and Simian Vacuolating virus-40. The early region of these viruses encodes the transforming proteins large T-antigen and small t-antigen, which are involved in viral replication and also promote transformation of cells in culture and oncogenesis in vivo. Binding of T-antigen to pRb promotes the activation of the E2F family of transcription factors, which induce the expression of cellular genes required for S phase. In the context of lytic infection, this cell cycle progression is necessary for viral replication because polyomaviruses rely on S phase-specific host factors for their DNA synthesis. In the context of cellular transformation and tumorigenesis, T-antigen/pRB interaction is an indispensable event.	Temple Univ, Sch Med, Ctr Neurovirol, Dept Neurosci, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Sch Med, Ctr Neurovirol, Dept Neurosci, 1900 12th St,015-96,Room 203, Philadelphia, PA 19122 USA.	kamel.khalili@temple.edu						Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, CELL, V65, P1053; Blais A, 2004, CURR OPIN GENET DEV, V14, P527, DOI 10.1016/j.gde.2004.07.003; Bollag B, 2000, VIROLOGY, V274, P165, DOI 10.1006/viro.2000.0451; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Cantalupo P, 2005, J VIROL, V79, P13094, DOI 10.1128/JVI.79.20.13094-13104.2005; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, COLD SPRING HARB SYM, V56, P187; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Cole Charles N., 1996, P917; Corallini A, 2001, HUMAN POLYOMAVIRUSES, P431; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Del Valle L, 2001, J CLIN PATHOL-MOL PA, V54, P331, DOI 10.1136/mp.54.5.331; DELVALLE L, 2001, HUMAN POLYOMAVIRUSES, P409; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Frisque RJ, 2005, J NEUROVIROL, V14, P65; Frisque RJ, 2003, J NEUROVIROL, V9, P15, DOI 10.1080/13550280390195270; Frisque RJ, 2001, J NEUROVIROL, V7, P293, DOI 10.1080/13550280152537120; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; Garcea RL, 2003, J VIROL, V77, P5039, DOI 10.1128/JVI.77.9.5039-5045.2003; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; Harris KF, 1996, J VIROL, V70, P2378, DOI 10.1128/JVI.70.4.2378-2386.1996; Hirsch HH, 2005, CLIN INFECT DIS, V41, P354, DOI 10.1086/431488; Howard CM, 1998, J NATL CANCER I, V90, P1451, DOI 10.1093/jnci/90.19.1451; Howard CM, 2000, CANCER RES, V60, P2737; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; Kelley WL, 1997, MOL MICROBIOL, V25, P913, DOI 10.1111/j.1365-2958.1997.mmi527.x; KHALILI K, 2005, POLYOMAVIRUSES HUMAN; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1997, J CELL BIOCHEM, V67, P223, DOI 10.1002/(SICI)1097-4644(19971101)67:2<223::AID-JCB7>3.0.CO;2-Z; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lin JY, 2003, J BIOL CHEM, V278, P46482, DOI 10.1074/jbc.M307044200; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; Ludlow JW, 1996, J VIROL METHODS, V59, P105, DOI 10.1016/0166-0934(96)02027-7; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANDL C, 1987, J VIROL, V61, P755, DOI 10.1128/JVI.61.3.755-763.1987; MAYOL X, 1993, ONCOGENE, V8, P2561; NEVINS JR, 1991, COLD SH Q B, V56, P157; ONEILL FJ, 1995, ONCOGENE, V10, P1131; PAGNANI M, 1988, INT J CANCER, V42, P405, DOI 10.1002/ijc.2910420317; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Prins C, 2001, J NEUROVIROL, V7, P250; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; REICHEL R, 1987, CELL, V48, P501, DOI 10.1016/0092-8674(87)90200-5; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Sullivan CS, 2004, VIROLOGY, V320, P218, DOI 10.1016/j.virol.2003.10.035; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; TAVIS JE, 1994, VIROLOGY, V199, P384, DOI 10.1006/viro.1994.1136; Tevethia MJ, 1997, J VIROL, V71, P1888, DOI 10.1128/JVI.71.3.1888-1896.1997; Tognon M, 2003, ONCOGENE, V22, P5192, DOI 10.1038/sj.onc.1206550; TRIFILLIS P, 1990, J VIROL, V64, P1345, DOI 10.1128/JVI.64.3.1345-1347.1990; TROWBRIDGE PW, 1995, J NEUROVIROL, V1, P195, DOI 10.3109/13550289509113966; Tyagarajan SK, 2005, J NEUROVIROL, V14, P43; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White MK, 2004, VIROLOGY, V324, P1, DOI 10.1016/j.virol.2004.03.025; White MK, 2005, BRAIN RES REV, V50, P69, DOI 10.1016/j.brainresrev.2005.04.007; White MK, 2005, EUR J CANCER, V41, P2537, DOI 10.1016/j.ejca.2005.08.019; WHITE MK, 2004, GENE THER MOL BIOL, V8, P19; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WOLF DA, 1995, ONCOGENE, V10, P2067; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408	89	45	45	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5286	5293		10.1038/sj.onc.1209618	http://dx.doi.org/10.1038/sj.onc.1209618			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936749				2022-12-17	WOS:000240064100014
J	Stevens, TA; Meech, R				Stevens, T. A.; Meech, R.			BARX2 and estrogen receptor-alpha (ESR1) coordinatelyregulate the production of alternatively spliced ESR1 isoforms and control breast cancer cell growth and invasion	ONCOGENE			English	Article						homeobox; estrogen; breast cancer; invasion; splicing	ANCHORAGE INDEPENDENT GROWTH; HOMEODOMAIN PROTEIN BARX2; SERUM RESPONSE FACTOR; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; BRANCHING MORPHOGENESIS; NUCLEAR RECEPTOR; TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; GENE-EXPRESSION	The estrogen receptor-alpha gene (ESR1) was previously identified as a direct target of the homeobox transcription factor BARX2 in MCF7 cells. Here, we show that BARX2 and ESR1 proteins bind to different ESR1 gene promoters and regulate the expression of alternatively spliced mRNAs that encode 66 and 46 kDa ESR1 protein isoforms. BARX2 increases the expression of both ESR1 isoforms; however, it has a greater effect on the 46 kDa isoform, leading to an increased ratio between the 46 and 66 kDa proteins. BARX2 also influences estrogen-dependent processes such as anchorage-independent growth and modulates the expression of the estrogen-responsive genes SOX5, RBM15, Dynein and Mortalin. In addition, BARX2 expression promotes cellular invasion and increases the expression of active matrix metalloproteinase-9 (MMP9). BARX2 also increases the expression of the tissue inhibitor of metalloproteinase (TIMP) genes, TIMP1 and TIMP3, in cooperation with estrogen signaling. Overall, these data indicate that BARX2 and ESR1 may coordinately regulate cell growth, survival and invasion pathways that are critical to breast cancer progression.	Scripps Res Inst, Dept Neurobiol, La Jolla, CA 92037 USA	Scripps Research Institute	Meech, R (corresponding author), Scripps Res Inst, Dept Neurobiol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rmeech@scripps.edu		Meech, Robyn/0000-0002-6831-0801				Auboeuf D, 2005, MOL CELL BIOL, V25, P5307, DOI 10.1128/MCB.25.13.5307-5316.2005; Auboeuf D, 2004, MOL CELL BIOL, V24, P442, DOI 10.1128/MCB.24.1.442-453.2004; Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Balduyck M, 2000, CLIN EXP METASTAS, V18, P171, DOI 10.1023/A:1006762425323; Care A, 2001, CANCER RES, V61, P6532; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Denger S, 2001, MOL ENDOCRINOL, V15, P2064, DOI 10.1210/me.15.12.2064; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fasco MJ, 2000, MOL CELL ENDOCRINOL, V162, P167, DOI 10.1016/S0303-7207(00)00194-5; Fata JE, 1999, DEV BIOL, V211, P238, DOI 10.1006/dbio.1999.9313; FIENBERG AA, 1987, CURR TOP DEV BIOL, V23, P23; Flouriot G, 2000, EMBO J, V19, P4688, DOI 10.1093/emboj/19.17.4688; Flouriot G, 1998, MOL ENDOCRINOL, V12, P1939, DOI 10.1210/me.12.12.1939; Gill SE, 2003, DEV BIOL, V261, P313, DOI 10.1016/S0012-1606(03)00318-X; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Herring BP, 2001, J BIOL CHEM, V276, P14482, DOI 10.1074/jbc.M011585200; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Jones FS, 1997, P NATL ACAD SCI USA, V94, P2632, DOI 10.1073/pnas.94.6.2632; Krasner A, 2000, GENE, V250, P171, DOI 10.1016/S0378-1119(00)00169-4; Lambertini E, 2003, BIOCHEM J, V372, P831, DOI 10.1042/BJ20021633; Lelongt B, 1997, J CELL BIOL, V136, P1363, DOI 10.1083/jcb.136.6.1363; Li GY, 1999, CANCER RES, V59, P6267; Liu D, 2001, EUR J CANCER, V37, P268, DOI 10.1016/S0959-8049(00)00392-0; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; Mark M, 1997, PEDIATR RES, V42, P421, DOI 10.1203/00006450-199710000-00001; McDowell N, 1999, SEMIN CELL DEV BIOL, V10, P311, DOI 10.1006/scdb.1999.0307; Meech R, 2003, J BIOL CHEM, V278, P8269, DOI 10.1074/jbc.M207617200; Meech R, 2005, DEVELOPMENT, V132, P2135, DOI 10.1242/dev.01811; Metivier R, 2004, EMBO J, V23, P3653, DOI 10.1038/sj.emboj.7600377; Nguyen M, 1998, J BIOL CHEM, V273, P5400, DOI 10.1074/jbc.273.9.5400; Nothnick WB, 2004, BIOL REPROD, V70, P500, DOI 10.1095/biolreprod.103.020834; O'Doherty A, 2002, BRIT J CANCER, V86, P282, DOI 10.1038/sj.bjc.6600028; PENOT G, 2005, ENDOCRINOLOGY, V8, P8; Rayala SK, 2005, EMBO REP, V6, P538, DOI 10.1038/sj.embor.7400417; Samady L, 2004, CANCER BIOL THER, V3, P317, DOI 10.4161/cbt.3.3.698; Satoh K, 2004, J MAMMARY GLAND BIOL, V9, P195, DOI 10.1023/B:JOMG.0000037162.84758.b5; Schratt G, 2002, J CELL BIOL, V156, P737, DOI 10.1083/jcb.200106008; Sellar GC, 2001, CANCER RES, V61, P6977; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Sivak JM, 2004, MOL CELL BIOL, V24, P245, DOI 10.1128/MCB.24.1.245-257.2004; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; Stevens TA, 2004, J BIOL CHEM, V279, P14520, DOI 10.1074/jbc.M310259200; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Yoshiji H, 1996, INT J CANCER, V69, P131, DOI 10.1002/(SICI)1097-0215(19960422)69:2<131::AID-IJC11>3.0.CO;2-C; Zhao YG, 2004, CANCER RES, V64, P590, DOI 10.1158/0008-5472.CAN-03-1932; ZUGMAIER G, 1991, J STEROID BIOCHEM, V39, P681, DOI 10.1016/0960-0760(91)90367-E	52	45	46	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	39					5426	5435		10.1038/sj.onc.1209529	http://dx.doi.org/10.1038/sj.onc.1209529			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16636675				2022-12-17	WOS:000240144900007
J	Cerda, SR; Mustafi, R; Little, H; Cohen, G; Khare, S; Moore, C; Majumder, P; Bissonnette, M				Cerda, S. R.; Mustafi, R.; Little, H.; Cohen, G.; Khare, S.; Moore, C.; Majumder, P.; Bissonnette, M.			Protein kinase C delta inhibits Caco-2 cell proliferation by selective changes in cell cycle and cell death regulators	ONCOGENE			English	Review						pKC; cyclins; p21(Waf1); Bcl-2; Bax; colon cancer cells	COLON-CANCER CELLS; PKC-DELTA; INDUCED APOPTOSIS; BREAST-CANCER; UP-REGULATION; 1,25-DIHYDROXYVITAMIN D-3; P21(WAF1/CIP1) EXPRESSION; RETINOBLASTOMA PROTEIN; TRANSFORMED PHENOTYPE; ACTIVATION MECHANISMS	PKC-delta is a serine/threonine kinase that mediates diverse signal transduction pathways. We previously demonstrated that overexpression of PKC-delta slowed the G1 progression of Caco-2 colon cancer cells, accelerated apoptosis, and induced cellular differentiation. In this study, we further characterized the PKC-delta dependent signaling pathways involved in these tumor suppressor actions in Caco-2 cells overexpressing PKC-delta using a Zn2+ inducible expression vector. Consistent with a G1 arrest, increased expression of PKC-delta caused rapid and significant downregulation of cyclin D1 and cyclin E proteins (50% decreases, P < 0.05), while mRNA levels remained unchanged. The PKC agonist, phorbol 12-myristate 13-acetate (TPA, 100 nM, 4 h), induced two-fold higher protein and mRNA levels of p21(Waf1), a cyclin-dependent kinase (cdk) inhibitor in PKC-delta transfectants compared with empty vector (EV) transfected cells, whereas the PKC-delta specific inhibitor rottlerin (3 mu M) or knockdown of this isoenzyme with specific siRNA oligonucleotides blocked p21(Waf1) expression. Concomitantly, compared to EV control cells, PKC-delta upregulation decreased cyclin D1 and cyclin E proteins co-immunoprecipitating with cdk6 and cdk2, respectively. In addition, overexpression of PKC-delta increased binding of cdk inhibitor p27(Kip1) to cdk4. These alterations in cyclin-cdks and their inhibitors are predicted to decrease G1 cyclin kinase activity. As an independent confirmation of the direct role PKC-delta plays in cell growth and cell cycle regulation, we knocked down PKC-delta using specific siRNA oligonucleotides. PKC-delta specific siRNA oligonucleotides, but not irrelevant control oligonucleotides, inhibited PKC-delta protein by more than 80% in Caco-2 cells. Moreover, PKC-delta knockdown enhanced cell proliferation (similar to 1.4-2-fold, P < 0.05) and concomitantly increased cyclin D1 and cyclin E expression (similar to 1.7-fold, P < 0.05). This was a specific effect, as nontargeted PKC-zeta was not changed by PKC-delta siRNA oligonucleotides. Consistent with accelerated apoptosis in PKC-delta transfectants, compared to EV cells, PKC-delta upregulation increased proapoptotic regulator Bax two-fold at mRNA and protein levels, while antiapoptotic Bcl-2 protein was decreased by 50% at a post-transcriptional level. PKC-delta specific siRNA oligonucleotides inhibited Bax protein expression by more than 50%, indicating that PKC-delta regulates apoptosis through Bax. Taken together, these results elucidate two critical mechanisms regulated by PKC-delta that inhibit cell cycle progression and enhance apoptosis in colon cancer cells. We postulate these antiproliferative pathways mediate an important tumor suppressor function for PKC-delta in colonic carcinogenesis.	Univ Chicago, Dept Med, Div Gastroenterol, Chicago, IL 60637 USA; Loyola Univ, Med Ctr, Dept Med, Div Gastroenterol, Maywood, IL 60153 USA	University of Chicago; Loyola University Chicago	Cerda, SR (corresponding author), Univ Chicago, Dept Med, Div Gastroenterol, MC 4076,5841 S Maryland Ave, Chicago, IL 60637 USA.	scerda@medicine.bsd.uchicago.edu		Cerda, Sandra/0000-0002-7779-6110	NCI NIH HHS [2R01CA36745] Funding Source: Medline; NIDDK NIH HHS [P30DK42086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036745] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham C, 1998, GASTROENTEROLOGY, V114, P503, DOI 10.1016/S0016-5085(98)70533-5; Acevedo-Duncan M, 2002, CELL PROLIFERAT, V35, P23, DOI 10.1046/j.1365-2184.2002.00220.x; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; Andre F, 1999, GASTROENTEROLOGY, V116, P64, DOI 10.1016/S0016-5085(99)70230-1; Arber N, 1997, CANCER RES, V57, P1569; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Arita Y, 1998, EXP CELL RES, V242, P381, DOI 10.1006/excr.1997.3911; Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; Assert R, 1999, INT J CANCER, V80, P47, DOI 10.1002/(SICI)1097-0215(19990105)80:1<47::AID-IJC10>3.3.CO;2-A; Atten MJ, 2005, INVEST NEW DRUG, V23, P111, DOI 10.1007/s10637-005-5855-8; Avazeri N, 2004, J CELL SCI, V117, P4969, DOI 10.1242/jcs.01375; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Banan A, 2002, J PHARMACOL EXP THER, V303, P17, DOI 10.1124/jpet.102.037218; Barrett CM, 2002, MOL CANCER THER, V1, P469; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; Black JD, 2001, GASTROENTEROLOGY, V120, P1868, DOI 10.1053/gast.2001.25287; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BOSARI S, 1995, HUM PATHOL, V26, P534, DOI 10.1016/0046-8177(95)90250-3; Brasitus TA, 1998, GASTROENTEROLOGY, V115, P225, DOI 10.1016/S0016-5085(98)70387-7; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; BRONNER MP, 1995, AM J PATHOL, V146, P20; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Cerda SR, 2001, GASTROENTEROLOGY, V120, P1700, DOI 10.1053/gast.2001.24843; Chen AP, 1999, J BIOL CHEM, V274, P35505, DOI 10.1074/jbc.274.50.35505; Clark JA, 2004, J BIOL CHEM, V279, P9233, DOI 10.1074/jbc.M312268200; CRAVEN PA, 1992, CANCER RES, V52, P2216; CRAVEN PA, 1994, DIGEST DIS SCI, V39, P481, DOI 10.1007/BF02088331; DARZYNKIEWICZ Z, 1994, CELL BIOL LAB HDB, P261; DAVIDSON LA, 1994, ARCH BIOCHEM BIOPHYS, V312, P547, DOI 10.1006/abbi.1994.1344; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Di Mari JF, 2005, GASTROENTEROLOGY, V128, P2131, DOI 10.1053/j.gastro.2004.09.078; Ding QM, 1998, AM J PHYSIOL-CELL PH, V275, pC1193, DOI 10.1152/ajpcell.1998.275.5.C1193; Djelloul S, 1997, FEBS LETT, V406, P234, DOI 10.1016/S0014-5793(97)00208-1; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fikaris AJ, 2005, J BIOL CHEM, V280, P32107, DOI 10.1074/jbc.M504432200; Fima E, 2001, ONCOGENE, V20, P6794, DOI 10.1038/sj.onc.1204885; Fishman DD, 1998, INT J ONCOL, V12, P181; Frey MR, 2000, J CELL BIOL, V151, P763, DOI 10.1083/jcb.151.4.763; Frey MR, 1997, J BIOL CHEM, V272, P9424; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; Gartel AL, 2000, ONCOGENE, V19, P961, DOI 10.1038/sj.onc.1203411; Gartel AL, 2000, ONCOGENE, V19, P5182, DOI 10.1038/sj.onc.1203900; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; Gavrielides MV, 2004, CURR DRUG TARGETS, V5, P431, DOI 10.2174/1389450043345380; GEIGES D, 1995, EXP CELL RES, V219, P299, DOI 10.1006/excr.1995.1231; Goerke A, 2002, J BIOL CHEM, V277, P32054, DOI 10.1074/jbc.M203734200; GOLDSTEIN DR, 1995, CARCINOGENESIS, V16, P1121, DOI 10.1093/carcin/16.5.1121; Graham MA, 2000, INVEST OPHTH VIS SCI, V41, P4124; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5; Irie N, 2002, BIOCHEM BIOPH RES CO, V298, P738, DOI 10.1016/S0006-291X(02)02531-7; Jackson DN, 2004, FASEB J, V18, P627, DOI 10.1096/fj.03-0979rev; Jang SJ, 1999, EUR J SURG ONCOL, V25, P157, DOI 10.1053/ejso.1998.0619; Jones SM, 2001, FEBS LETT, V490, P110, DOI 10.1016/S0014-5793(01)02113-5; KAHLRAINER P, 1994, CARCINOGENESIS, V15, P779, DOI 10.1093/carcin/15.4.779; KahlRainer P, 1996, GASTROENTEROLOGY, V110, P1753, DOI 10.1053/gast.1996.v110.pm8964400; Khare S, 1999, AM J PHYSIOL-GASTR L, V276, pG993, DOI 10.1152/ajpgi.1999.276.4.G993; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kitamura K, 2003, GENES CELLS, V8, P311, DOI 10.1046/j.1365-2443.2003.00635.x; Klein IK, 2000, CANCER RES, V60, P2077; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; La Porta CAM, 2002, MELANOMA RES, V12, P297, DOI 10.1097/00008390-200208000-00001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee YJ, 2002, CELL GROWTH DIFFER, V13, P237; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Lewis AE, 2005, CELL SIGNAL, V17, P253, DOI 10.1016/j.cellsig.2004.07.005; Li WQ, 1996, ONCOGENE, V13, P731; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Li WQ, 1997, J BIOL CHEM, V272, P24550, DOI 10.1074/jbc.272.39.24550; Lin SY, 2002, MOL CARCINOGEN, V35, P21, DOI 10.1002/mc.10070; LIPKIN M, 1971, CANCER-AM CANCER SOC, V28, P38, DOI 10.1002/1097-0142(197107)28:1<38::AID-CNCR2820280108>3.0.CO;2-W; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Mandal M, 2001, GASTROENTEROLOGY, V120, P71, DOI 10.1053/gast.2001.20897; McCracken MA, 2003, MOL CANCER THER, V2, P273; MCGARRITY TJ, 1994, DIGEST DIS SCI, V39, P458, DOI 10.1007/BF02088328; McMillan L, 2003, BRIT J CANCER, V88, P748, DOI 10.1038/sj.bjc.6600793; Meyer E, 2005, CANCER RES, V65, P4261, DOI 10.1158/0008-5472.CAN-04-2908; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; Moss SF, 1996, GASTROENTEROLOGY, V111, P1425, DOI 10.1016/S0016-5085(96)70003-3; Nabha SM, 2005, ONCOGENE, V24, P3166, DOI 10.1038/sj.onc.1208502; Nakagawa M, 2005, J BIOL CHEM, V280, P33926, DOI 10.1074/jbc.M505748200; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ogura E, 1999, ONCOL REP, V6, P365; Page K, 2002, AM J RESP CELL MOL, V27, P204, DOI 10.1165/ajrcmb.27.2.20010016oc; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Perletti G, 2004, J CELL MOL MED, V8, P563, DOI 10.1111/j.1582-4934.2004.tb00481.x; Perletti G, 2005, INT J CANCER, V113, P42, DOI 10.1002/ijc.20535; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; Perletti GP, 1998, ONCOGENE, V16, P3345, DOI 10.1038/sj.onc.1201871; PINTO M, 1983, BIOL CELL, V47, P323; Polyak K, 1996, AM J PATHOL, V149, P381; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; Potten CS, 1997, STEM CELLS, V15, P82, DOI 10.1002/stem.150082; Qiao L, 1996, CANCER LETT, V107, P83, DOI 10.1016/0304-3835(96)04346-7; Ruemmele FM, 1999, CELL DEATH DIFFER, V6, P729, DOI 10.1038/sj.cdd.4400545; Rybin VO, 2003, J BIOL CHEM, V278, P14555, DOI 10.1074/jbc.M212644200; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; Sauma S, 1996, CELL GROWTH DIFFER, V7, P587; Savickiene J, 1999, CELL DEATH DIFFER, V6, P698, DOI 10.1038/sj.cdd.4400541; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; Scaglione-Sewell B, 1998, CANCER RES, V58, P1074; Scaglione-Sewell BA, 2000, ENDOCRINOLOGY, V141, P3931, DOI 10.1210/en.141.11.3931; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Seki T, 2005, GENES CELLS, V10, P225, DOI 10.1111/j.1365-2443.2005.00830.x; Shanmugam M, 2001, CANCER LETT, V172, P43, DOI 10.1016/S0304-3835(01)00602-4; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sitailo LA, 2004, J INVEST DERMATOL, V123, P434, DOI 10.1111/j.0022-202X.2004.23403.x; Soh JW, 2003, J BIOL CHEM, V278, P34709, DOI 10.1074/jbc.M302016200; Srivastava J, 2002, BIOCHEM J, V368, P349, DOI 10.1042/BJ20020737; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tillman DM, 2003, CANCER RES, V63, P5118; Toyoda M, 1998, BIOCHEM BIOPH RES CO, V250, P430, DOI 10.1006/bbrc.1998.9332; Umar S, 2000, AM J PHYSIOL-GASTR L, V278, pG765, DOI 10.1152/ajpgi.2000.278.5.G765; Verstovsek G, 1998, GASTROENTEROLOGY, V115, P75, DOI 10.1016/S0016-5085(98)70367-1; Villalba M, 1998, NEUROREPORT, V9, P2381, DOI 10.1097/00001756-199807130-00042; Wakino S, 2001, J BIOL CHEM, V276, P47650, DOI 10.1074/jbc.M108719200; WALI RK, 1995, CANCER RES, V55, P5257; Wang QD, 2006, INT J CANCER, V118, P326, DOI 10.1002/ijc.21373; Wang QD, 2003, J BIOL CHEM, V278, P51091, DOI 10.1074/jbc.M306541200; Wang XF, 2004, ONCOGENE, V23, P1885, DOI 10.1038/sj.onc.1207312; Watters D, 1998, BIOCHEM PHARMACOL, V55, P1691, DOI 10.1016/S0006-2952(97)00680-1; Weinstein I B, 1991, Princess Takamatsu Symp, V22, P277; Weller SG, 1999, GASTROENTEROLOGY, V117, P848, DOI 10.1016/S0016-5085(99)70343-4; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; Yin LH, 2005, J BIOL CHEM, V280, P5533, DOI 10.1074/jbc.M405266200; Yokoyama G, 2005, BIOCHEM BIOPH RES CO, V327, P720, DOI 10.1016/j.bbrc.2004.12.070; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; Zeng YX, 1996, ONCOGENE, V12, P1557; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967; Zhu GH, 2000, GASTROENTEROLOGY, V118, P507, DOI 10.1016/S0016-5085(00)70256-3	152	45	48	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3123	3138		10.1038/sj.onc.1209360	http://dx.doi.org/10.1038/sj.onc.1209360			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16434969				2022-12-17	WOS:000237951000004
J	Kondo, S; Kubota, S; Mukudai, Y; Moritani, N; Nishida, T; Matsushita, H; Matsumoto, S; Sugahara, T; Takigawa, M				Kondo, S; Kubota, S; Mukudai, Y; Moritani, N; Nishida, T; Matsushita, H; Matsumoto, S; Sugahara, T; Takigawa, M			Hypoxic regulation of stability of connective tissue growth factor/CCN2 mRNA by 3 '-untranslated region interacting with a cellular protein in human chondrosarcoma cells	ONCOGENE			English	Article						hypoxia; connective tissue growth factor; CCN family; mRNA stability; 3 '-UTR; post-transcriptional regulation	VASCULAR ENDOTHELIAL-CELLS; INDUCIBLE FACTOR-I; GENE-EXPRESSION; CTGF/HCS24 GENE; RICH SEQUENCE; BINDING; ANGIOGENESIS; IDENTIFICATION; ELEMENT; VITRO	Connective tissue growth factor (CTGF/CCN2) can be induced by various forms of stress such as exposure to high glucose, mechanical load, or hypoxia. Here, we investigated the molecular mechanism involved in the induction of ctgf/ccn2 by hypoxia in a human chondrosarcoma cell line, HCS-2/8. Hypoxia increased the ctgf/ccn2 mRNA level by altering the 3'-untranslated region (UTR)-mediated mRNA stability without requiring de novo protein synthesis. After a series of extensive analyses, we eventually found that the cis-repressive element of 84 bases within the 3'-UTR specifically bound to a cytoplasmic/nuclear protein. By conducting a UV crosslinking assay, we found the cytoplasmic/nuclear protein to be a 35 kDa molecule that bound to the cis-element in a hypoxia-inducible manner. These results suggest that a cis-element in the 3'-UTR of ctgf/ccn2 mRNA and trans-factor counterpart(s) play an important role in the post-transcriptional regulation by determining the stability of ctgf/ccn2 mRNA.	Okayama Univ, Grad Sch Med & Dent, Dept Biochem & Mol Biol, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008525, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Oral & Maxillofacial Reconstruct Surg, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008525, Japan; Nichirei Corp, Biosci Business Div, Chuo Ku, Tokyo, Japan	Okayama University; Okayama University; Nichirei Corporation	Takigawa, M (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Biochem & Mol Biol, Grad Sch Med Dent & Pharmaceut Sci, 2-5-1 Shikata Cho, Okayama 7008525, Japan.	takigawa@md.okayama-u.ac.jp	Kondo, Seiji/ABD-3982-2020; Kondo, Seiji/I-4332-2017; Mukudai, Yoshiki/L-4459-2019	Kondo, Seiji/0000-0001-9341-5069; Kondo, Seiji/0000-0001-9341-5069; Mukudai, Yoshiki/0000-0002-9600-4430				Babic AM, 1999, MOL CELL BIOL, V19, P2958; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Eguchi T, 2001, J BIOCHEM, V130, P79, DOI 10.1093/oxfordjournals.jbchem.a002965; FAN XC, 1998, P NATL ACAD SCI US, V95; Ford LP, 1999, METHODS, V17, P21, DOI 10.1006/meth.1998.0703; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; Hew Y, 1999, J BIOL CHEM, V274, P14415, DOI 10.1074/jbc.274.20.14415; Hew Y, 2000, J BIOL CHEM, V275, P24857, DOI 10.1074/jbc.M002776200; Higgins DF, 2004, AM J PHYSIOL-RENAL, V287, pF1223, DOI 10.1152/ajprenal.00245.2004; Kondo S, 2002, CARCINOGENESIS, V23, P769, DOI 10.1093/carcin/23.5.769; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Kubota S, 2000, ONCOGENE, V19, P4773, DOI 10.1038/sj.onc.1203835; Kubota S, 2005, FEBS LETT, V579, P3751, DOI 10.1016/j.febslet.2005.05.068; Kubota S, 1999, FEBS LETT, V450, P84, DOI 10.1016/S0014-5793(99)00480-9; Kubota S, 2003, BONE, V33, P694, DOI 10.1016/S8756-3282(03)00227-8; Kumar S, 1999, J BIOL CHEM, V274, P17123, DOI 10.1074/jbc.274.24.17123; Kunz M, 2003, J BIOL CHEM, V278, P45651, DOI 10.1074/jbc.M301373200; KUNZ M, 2003, MOL CANCER, V2, P1, DOI DOI 10.1186/1476-4598-2-1.PUBMED:12537587; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MACDONALD LE, 1994, J MOL BIOL, V238, P145, DOI 10.1006/jmbi.1994.1277; Mukudai Y, 2005, J BIOL CHEM, V280, P3166, DOI 10.1074/jbc.M411632200; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; Ratnam S, 2002, J BIOL CHEM, V277, P42912, DOI 10.1074/jbc.M206588200; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Shih SC, 1998, INT J EXP PATHOL, V79, P347, DOI 10.1046/j.1365-2613.1998.00088.x; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; Takigawa M, 2003, DRUG NEWS PERSPECT, V16, P11, DOI 10.1358/dnp.2003.16.1.829302; TAKIGAWA M, 1989, CANCER RES, V49, P3996; Takigawa M, 2003, J CELL PHYSIOL, V194, P256, DOI 10.1002/jcp.10206; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	45	45	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1099	1110		10.1038/sj.onc.1209129	http://dx.doi.org/10.1038/sj.onc.1209129			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247469				2022-12-17	WOS:000235361000014
J	Sakai, M; Shimokawa, T; Kobayashi, T; Matsushima, S; Yamada, Y; Nakamura, Y; Furukawa, Y				Sakai, M; Shimokawa, T; Kobayashi, T; Matsushima, S; Yamada, Y; Nakamura, Y; Furukawa, Y			Elevated expression of C10orf3 (chromosome 10 open reading frame 3) is involved in the growth of human colon tumor	ONCOGENE			English	Article						colon; cancer; C10orf3; TSG101	GENOME-WIDE ANALYSIS; METASTATIC COLORECTAL-CANCER; GENE-EXPRESSION; TSG101 PROTEIN; BREAST-CANCER; CDNA MICROARRAY; CELL-GROWTH; PROFILES; CARCINOGENESIS; IDENTIFICATION	After analysing gene-expression profiles of colon cancers on a cDNA microarray containing cDNAs corresponding to 23 040 human genes, we focused on a gene annotated as C10orf3 ( chromosome 10 open reading frame 3), whose expression was elevated in colorectal cancers (CRC) as well as in tumors arising in the stomach, lung, pancreas, and breast. The gene encodes a putative 464-amino-acid protein containing a domain known as AAA ( ATPases associated witha variety of cellular activities). Western blot analysis using an antibody to the gene product confirmed that the protein was overexpressed in nine of the 15 clinical cancer tissues examined, compared to corresponding noncancerous epithelial cells. A subsequent proteomics analysis revealed that C10orf3 product associated with the product of tumor susceptibility gene 101 (TSG101), and that C10orf3 downregulated TSG101 in a post-transcriptional manner. Expression of short interfering RNA in cells derived from CRC caused significant decreases in C10orf3 expression and inhibited growth of the transfected cells, which was associated with increased apoptotic cells. These data suggest that elevated C10orf3 expression might play an essential role in the growth of cancer cells, and that suppression of C10orf3-mediated signal transduction may be a novel therapeutic strategy to a wide range of human tumors.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Promot Genome Based Med Project,Minato Ku, Tokyo 1088639, Japan; Yokohama City Univ, Sch Med, Dept Anesthesiol, Kanagawa, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,, Tokyo 1088639, Japan	University of Tokyo; Yokohama City University; University of Tokyo	Furukawa, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Promot Genome Based Med Project,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	furukawa@ims.u-tokyo.ac.jp	Sakai, Michihiro/B-8755-2011; Shimokawa, Takashi/AAA-5870-2020	Shimokawa, Takashi/0000-0001-6549-9277				Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gridelli C, 2003, ONCOGENE, V22, P6629, DOI 10.1038/sj.onc.1206957; Hasegawa S, 2002, CANCER RES, V62, P7012; Jessberger R, 2002, NAT REV MOL CELL BIO, V3, P767, DOI 10.1038/nrm930; Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; Molina MA, 2001, CANCER RES, V61, P4744; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Neuwald AF, 1999, GENOME RES, V9, P27; Nishidate T, 2004, INT J ONCOL, V25, P797; O'Dwyer ME, 2000, CURR OPIN ONCOL, V12, P594, DOI 10.1097/00001622-200011000-00013; Obama K, 2005, HEPATOLOGY, V41, P1339, DOI 10.1002/hep.20718; Okabe H, 2001, CANCER RES, V61, P2129; Okabe H, 2003, CANCER RES, V63, P3043; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Shimokawa T, 2003, CANCER RES, V63, P6116; Sun ZJ, 1997, ONCOGENE, V15, P3121, DOI 10.1038/sj.onc.1201521; Wagner KU, 2003, MOL CELL BIOL, V23, P150, DOI 10.1128/MCB.23.1.150-162.2003; Walt G, 2004, BRIT MED J, V328, P6, DOI 10.1136/bmj.328.7430.6; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Zhong Q, 1998, CANCER RES, V58, P2699; Zhu G, 2004, INT J CANCER, V109, P541, DOI 10.1002/ijc.20014	27	45	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					480	486		10.1038/sj.onc.1209051	http://dx.doi.org/10.1038/sj.onc.1209051			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16170351				2022-12-17	WOS:000234714100016
J	Ware, MD; DeSilva, D; Sinilnikova, OM; Stoppa-Lyonnet, D; Tavtigian, SV; Mazoyer, S				Ware, MD; DeSilva, D; Sinilnikova, OM; Stoppa-Lyonnet, D; Tavtigian, SV; Mazoyer, S			Does nonsense-mediated mRNA decay explain the ovarian cancer cluster region of the BRCA2 gene?	ONCOGENE			English	Article						BRCA2; ovarian cancer cluster region; nonsense-mediated mRNA decay; genotype-phenotype correlation	PREMATURE TERMINATION CODONS; DNA-REPAIR; PROTEIN; TRANSCRIPTS; BREAST; SUSCEPTIBILITY; RECOMBINATION; TRANSLATION; EXPRESSION; MUTATIONS	BRCA2 (BReast CAncer susceptibility gene 2) germline mutation carriers are at increased risk for breast and ovarian cancers. Mutations occurring in the ovarian cancer cluster region (OCCR) are linked to higher ovarian cancer and/or lower breast cancer risk(s) than mutations occurring elsewhere in BRCA2. Most BRCA2 germline mutations introduce premature termination codons (PTCs), making their mRNAs likely targets of nonsense-mediated mRNA decay (NMD), a mechanism that eliminates PTC-bearing transcripts to prevent expression of truncated proteins. Contradictory evidence exists regarding whether NMD can be triggered by PTCs located far upstream of the nearest exon-exon junction (EEJ). Since the OCCR comprises a major portion of the 4.9 kb exon 11 of BRCA2, we investigated if transcripts bearing PTCs in this large exon are unable to trigger NMD, and if this might contribute to the phenotypic difference associated with the OCCR. We examined cDNA from 18 carriers of PTC-introducing germline mutations located throughout BRCA2, and found that PTC-bearing transcripts were 1.4-3.3-fold less prevalent than their nonmutated counterparts irregardless of PTC position. We conclude that NMD can recognize PTCs up to 4.5 kb upstream of the nearest EEJ, demonstrating that a general inability of NMD to recognize PTCs in exon 11 is unlikely to explain the genotype-phenotype correlation associated with the OCCR.	Univ Lyon 1, CNRS, UMR 5201, Fac Med Rockefeller,Lab Genet Mol Signalisat & Ca, F-69373 Lyon 08, France; Int Agcy Res Canc, F-69372 Lyon, France; Hosp Civils Lyon, Ctr Leon Berard, Plate Forme Mixte Genet Constitut Canc Frequents, Lyon, France; Inst Curie, Serv Genet Oncol, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; World Health Organization; International Agency for Research on Cancer (IARC); CHU Lyon; UNICANCER; Centre Leon Berard; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Mazoyer, S (corresponding author), Univ Lyon 1, CNRS, UMR 5201, Fac Med Rockefeller,Lab Genet Mol Signalisat & Ca, 8 Ave Rockefeller, F-69373 Lyon 08, France.	sylvie.mazoyer@sante.univ-lyon1.fr	Mazoyer, Sylvie/N-7559-2017	Mazoyer, Sylvie/0000-0002-2135-0160				Chatr-aryamontri A, 2004, HUM MUTAT, V24, P526, DOI 10.1002/humu.20117; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Cowles CR, 2002, NAT GENET, V32, P432, DOI 10.1038/ng992; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Gayther SA, 1997, NAT GENET, V15, P103, DOI 10.1038/ng0197-103; Gismondi V, 1998, GENE CHROMOSOME CANC, V22, P278, DOI 10.1002/(SICI)1098-2264(199808)22:4<278::AID-GCC3>3.3.CO;2-Q; Harries LW, 2004, DIABETES, V53, P500, DOI 10.2337/diabetes.53.2.500; Holbrook JA, 2004, NAT GENET, V36, P801, DOI 10.1038/ng1403; Lubinski Jan, 2004, Fam Cancer, V3, P1; Maquat LE, 2001, RNA, V7, P445, DOI 10.1017/S1355838201002229; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Neu-Yilik G, 2001, EMBO J, V20, P532, DOI 10.1093/emboj/20.3.532; Perrin-Vidoz L, 2002, HUM MOL GENET, V11, P2805, DOI 10.1093/hmg/11.23.2805; Rodningen OK, 1999, HUM MUTAT, V13, P186, DOI 10.1002/(SICI)1098-1004(1999)13:3<186::AID-HUMU2>3.0.CO;2-K; Thompson D, 2001, AM J HUM GENET, V68, P410, DOI 10.1086/318181; Thompson D, 2004, J MAMMARY GLAND BIOL, V9, P221, DOI 10.1023/B:JOMG.0000048770.90334.3b; Tournier I, 2004, HUM MUTAT, V23, P379, DOI 10.1002/humu.20008; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yang HJ, 2005, NATURE, V433, P653, DOI 10.1038/nature03234; Yoshida K, 2004, CANCER SCI, V95, P866, DOI 10.1111/j.1349-7006.2004.tb02195.x; Zhang J, 1998, MOL CELL BIOL, V18, P5272, DOI 10.1128/MCB.18.9.5272	25	45	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					323	328		10.1038/sj.onc.1209033	http://dx.doi.org/10.1038/sj.onc.1209033			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170354				2022-12-17	WOS:000234583600018
J	Zalcenstein, A; Weisz, L; Stambolsky, P; Bar, J; Rotter, V; Oren, M				Zalcenstein, A; Weisz, L; Stambolsky, P; Bar, J; Rotter, V; Oren, M			Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53	ONCOGENE			English	Article						p53; MSP; MST-1; apoptosis; RON	RECEPTOR TYROSINE KINASE; MACROPHAGE-STIMULATING PROTEIN; WILD-TYPE P53; EXPRESSION PATTERNS; TUMOR-SUPPRESSOR; OF-FUNCTION; TRANSCRIPTIONAL REPRESSION; HUMAN MDR1; RON; CELLS	Tumor-associated mutant forms of p53 can exert an antiapoptotic gain of function activity, which confers a selective advantage upon tumor cells harboring such mutations. We report that mutant p53 suppresses the expression of the MSP ( MST-1/HGFL) gene, encoding the ligand of the receptor tyrosine kinase RON, implicated in a variety of cellular responses. Mutant p53 associates with the MSP gene promoter and represses its transcriptional activity, leading to a decrease in mRNA levels and a subsequent decrease in the levels of secreted MSP protein. Forced downregulation of MSP expression in H1299 cells, derived from a large-cell lung carcinoma, confers increased resistance against etoposide-induced cell death. These antiapoptotic consequences of MSP downregulation seemingly conflict with the well-documented ability of the RON receptor to promote cell survival and tumor progression when aberrantly hyperactive. Yet, they are consistent with the fact that reduced MSP expression was observed in many types of human cancer, including large-cell lung carcinoma. Thus, repression of MSP gene expression by mutant p53 may contribute to oncogenesis in a cell type-specific manner.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, 300 Herzl St, IL-76100 Rehovot, Israel.	moshe.oren@weizmann.ac.il	Bar, Jair/AAS-5743-2021	Bar, Jair/0000-0002-1224-3646; Oren, Moshe/0000-0003-4311-7172	NCI NIH HHS [R37 CA40099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albor A, 1998, CANCER RES, V58, P2091; Bardella C, 2004, CANCER RES, V64, P5154, DOI 10.1158/0008-5472.CAN-04-0600; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bezerra JA, 1998, J CLIN INVEST, V101, P1175, DOI 10.1172/JCI1744; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Camp ER, 2005, ANN SURG ONCOL, V12, P273, DOI 10.1245/ASO.2005.08.013; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Chen YQ, 2002, CARCINOGENESIS, V23, P1811, DOI 10.1093/carcin/23.11.1811; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Correll Pamela H., 1997, Genes and Function, V1, P69; Danilkovitch-Miagkova A, 2001, APOPTOSIS, V6, P183, DOI 10.1023/A:1011384609811; Demidenko ZN, 2005, FEBS LETT, V579, P2231, DOI 10.1016/j.febslet.2005.03.012; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; DIPPOLD W, 1993, Z GASTROENTEROL, V31, P24; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gohler T, 2005, NUCLEIC ACIDS RES, V33, P1087, DOI 10.1093/nar/gki252; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Gurova KV, 2003, CANCER RES, V63, P2905; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Kim E, 2004, J CELL BIOCHEM, V93, P878, DOI 10.1002/jcb.20271; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; Miller AD, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-64; Muraoka RS, 1999, J CLIN INVEST, V103, P1277, DOI 10.1172/JCI6091; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; O'Farrell TJ, 2004, CANCER RES, V64, P8199, DOI 10.1158/0008-5472.CAN-03-3639; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sakamoto O, 1997, J CLIN INVEST, V99, P701, DOI 10.1172/JCI119214; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Scian MJ, 2004, CANCER RES, V64, P7447, DOI 10.1158/0008-5472.CAN-04-1568; Scian MJ, 2004, ONCOGENE, V23, P4430, DOI 10.1038/sj.onc.1207553; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Sigal A, 2000, CANCER RES, V60, P6788; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; Storz MN, 2003, J INVEST DERMATOL, V120, P865, DOI 10.1046/j.1523-1747.2003.12142.x; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang D, 2005, CARCINOGENESIS, V26, P27, DOI 10.1093/carcin/bgh284; Wang D, 2004, ONCOGENE, V23, P1668, DOI 10.1038/sj.onc.1207282; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; WANG MH, 1994, J BIOL CHEM, V269, P3436; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	65	45	47	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					359	369		10.1038/sj.onc.1209061	http://dx.doi.org/10.1038/sj.onc.1209061			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16170349				2022-12-17	WOS:000234714100004
J	Song, SM; Lippman, SM; Zou, YY; Ye, XF; Ajani, JA; Xu, XC				Song, SM; Lippman, SM; Zou, YY; Ye, XF; Ajani, JA; Xu, XC			Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta(2) expression	ONCOGENE			English	Article						RAR-beta(2); COX-2; Erk1/2; AP-1; BPDE; esophageal cancer	ACID RECEPTOR-BETA; RETINOIC ACID; UP-REGULATION; LUNG-CANCER; RAR-BETA; PROMOTER HYPERMETHYLATION; DIFFERENTIAL EXPRESSION; BRONCHIAL EPITHELIUM; 13-CIS-RETINOIC ACID; CELL-PROLIFERATION	Benzo[a] pyrene diol epoxide (BPDE, a carcinogen present in tobacco smoke and environmental pollution) has been shown to suppress retinoic acid receptor-beta2 (RAR-beta(2)) and induce cyclooxygenase-2 (COX-2) expression. Restoration of RAR-beta 2 inhibited growth and colony formation of esophageal cancer cells, which was correlated with COX-2 suppression. In this study, we investigated the molecular mechanisms for RAR-beta(2)-mediated suppression of COX-2 expression using BPDE as a tool. We found that BPDE-induced COX-2 expression was through inhibition of RAR-beta 2 and consequently, induction of epidermal growth factor receptor (EGFR), extracellular signal-regulated protein kinases 1/2 (Erk1/2) phosphorylation, and c-Jun expression. Esophageal cancer cells that do not express RAR-beta 2 did not respond to BPDE for induction of COX-2. BPDE was also unable to induce COX-2 expression after RAR-beta 2 expression was manipulated in these esophageal cancer cells. Furthermore, BPDE induced time-dependent methylation of RAR-beta 2 gene promoter in esophageal cancer cells. Transfection of RAR-beta 2 expression vector into esophageal cancer cells suppressed expression of EGFR, Erk1/2 phosphorylation, c-Jun, and COX-2. In addition, co-treatment of RAR-beta 2-positive cells with BPDE and the MEK1/2 inhibitor U0126 caused little change in c-Jun and COX-2 expression. This study demonstrated that BPDE-suppressed expression of RAR-beta 2 results in COX-2 induction and restoration of RAR-beta 2 expression reduces COX-2 protein in esophageal cancer cells, thereby further supporting our previous finding that RAR-beta 2 plays an important role in suppressing esophageal carcinogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, Houston, TX 77030 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10461 USA; Univ Texas, MD Anderson Canc Ctr, Dept Med Oncol GI, Unit 1360, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Yeshiva University; Albert Einstein College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Xu, XC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, 1515 Holcombe Blvd, Houston, TX 77030 USA.	xxu@mdanderson.org						Alberts D, 2004, CLIN CANCER RES, V10, P1875, DOI 10.1158/1078-0432.CCR-03-0188; Ayoub J, 1999, J CLIN ONCOL, V17, P3546, DOI 10.1200/JCO.1999.17.11.3546; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Berg WJ, 1999, CLIN CANCER RES, V5, P1671; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; DeVita VT, 1997, CANC PRINCIPLES PRAC; Dragnev KH, 2003, CANCER BIOL THER, V2, pS150; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; GEBERT JF, 1991, ONCOGENE, V6, P1859; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Khuri FR, 2001, CLIN CANCER RES, V7, P861; Kim YT, 2005, ANN THORAC SURG, V79, P1180, DOI 10.1016/j.athoracsur.2004.09.060; Koch Timothy R, 2003, Curr Gastroenterol Rep, V5, P187, DOI 10.1007/s11894-003-0018-6; Kong G, 2005, CANCER RES, V65, P3462, DOI 10.1158/0008-5472.CAN-03-2912; Kurie JM, 2003, J NATL CANCER I, V95, P206, DOI 10.1093/jnci/95.3.206; Kurie JM, 2000, CLIN CANCER RES, V6, P2973; Kuroki T, 2003, CANCER RES, V63, P3724; Lam S, 2003, INT J ONCOL, V23, P1607; Lango M, 2003, CLIN CANCER RES, V9, P4205; Li M, 2002, ONCOGENE, V21, P411, DOI 10.1038/sj.onc.1205106; Lin BZ, 2000, MOL CELL BIOL, V20, P957, DOI 10.1128/MCB.20.3.957-970.2000; Lin F, 2000, CANCER RES, V60, P3271; Liu ZM, 2004, WORLD J GASTROENTERO, V10, P771; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; Lotan Y, 2000, J CLIN ONCOL, V18, P116, DOI 10.1200/JCO.2000.18.1.116; Mayne ST, 2002, J NUTR, V132, p3467S, DOI 10.1093/jn/132.11.3467S; McCann J, 1999, J NATL CANCER I, V91, P497, DOI 10.1093/jnci/91.6.497; McGregor F, 2002, CANCER RES, V62, P4757; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; POSNER MC, 2002, CANC UPPER GASTROINT; Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3; Qiu HM, 2000, GENE CHROMOSOME CANC, V28, P196, DOI 10.1002/(SICI)1098-2264(200006)28:2<196::AID-GCC8>3.0.CO;2-L; RICHTER JE, 1999, CLIN PRACTICE GASTRO, V1, P1; Sah JF, 2002, J BIOL CHEM, V277, P9728, DOI 10.1074/jbc.M110897200; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Song SM, 2001, BIOCHEM BIOPH RES CO, V281, P872, DOI 10.1006/bbrc.2001.4433; Su H, 2003, CANCER RES, V63, P3872; Toulouse A, 2000, FASEB J, V14, P1224, DOI 10.1096/fasebj.14.9.1224; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Wang XD, 1999, J NATL CANCER I, V91, P60, DOI 10.1093/jnci/91.1.60; Wang YM, 2003, CLIN CANCER RES, V9, P5257; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Xu M, 2002, WORLD J GASTROENTERO, V8, P200; Xu X.-C., 1999, HANDB EXP PHARM, P323; Xu XC, 1999, CANCER RES, V59, P2477; Xu XC, 1999, J NATL CANCER I, V91, P1317, DOI 10.1093/jnci/91.15.1317; Xu XC, 2002, CANCER EPIDEM BIOMAR, V11, p1148S; Xu XC, 2002, ANTI-CANCER DRUG, V13, P127, DOI 10.1097/00001813-200202000-00003; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Zhang W, 2001, J CANCER RES CLIN, V127, P237, DOI 10.1007/s004320000183; Zhuang Y, 2003, MOL CANCER RES, V1, P619; 2004, US SURG GEN REPORT	56	45	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8268	8276		10.1038/sj.onc.1208992	http://dx.doi.org/10.1038/sj.onc.1208992			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16170369				2022-12-17	WOS:000233956500006
J	Mullan, PB; Hosey, AM; Buckley, NE; Quinn, JE; Kennedy, RD; Johnston, PG; Harkin, DP				Mullan, PB; Hosey, AM; Buckley, NE; Quinn, JE; Kennedy, RD; Johnston, PG; Harkin, DP			The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1-and interferon-gamma-mediated apoptosis	ONCOGENE			English	Article						BRCA1; 2,5 OAS; RNaseL; IFN-gamma; apoptosis	SUSCEPTIBILITY GENE BRCA1; BREAST-CANCER; PROSTATE-CANCER; RIBONUCLEASE-L; RNASEL GENE; DNA-REPAIR; IFN-GAMMA; EXPRESSION; INTERACTS; MUTATION	BRCA1 has been reported to have roles in DNA damage repair, cell cycle checkpoint control, transcriptional regulation and ubiquitination. We have previously demonstrated that BRCA1 is a potent activator of a subset of interferon (IFN)-regulated genes and that BRCA1 synergistically activated a number of these genes in the presence of IFN-gamma, but not type I IFNs. Here we report that one of these targets, 2,5 oligoadenylate synthetase (2,5 OAS), is a mediator of BRCA1/IFN-gamma-induced apoptosis. We show that the induction of 2,5 OAS in response to IFN-gamma is BRCA1 and STAT1 dependent. Consistent with a role as a negative regulator of proliferation, transient transfection of 2,5 OAS into breast cancer cell lines results in decreased colony growth and apoptosis. Furthermore we show that IFN-gamma-induced apoptosis is dependent on functional BRCA1 and STAT1 and we demonstrate that IFN-gamma-induced apoptosis is dependent on 2,5 OAS induction. 2,5 OAS is the only known upstream regulator of RNaseL. a recently identified hereditary prostate tumour suppressor gene implicated in apoptosis. We propose that BRCA1 may be an upstream regulator of RNaseL, acting in concert with IFN-gamma to transcriptionally activate 2,5 OAS, leading to the downstream activation of RNaseL and apoptosis.	Queens Univ Belfast, Belfast City Hosp, Ctr Canc Res & Cell Biol, Belfast BT9 7AB, Antrim, North Ireland	Belfast City Hospital; Queens University Belfast	Harkin, DP (corresponding author), Queens Univ Belfast, Belfast City Hosp, Ctr Canc Res & Cell Biol, Univ Floor,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.harkin@qub.ac.uk	Kennedy, Richard/J-3489-2012	Kennedy, Richard/0000-0003-4737-6163; Buckley, Niamh/0000-0001-9326-8513				Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Andrews HN, 2002, J BIOL CHEM, V277, P26225, DOI 10.1074/jbc.M201316200; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; Castelli JC, 1998, CELL DEATH DIFFER, V5, P313, DOI 10.1038/sj.cdd.4400352; Gilmore PM, 2004, CANCER RES, V64, P4148, DOI 10.1158/0008-5472.CAN-03-4080; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; Kennedy RD, 2004, JNCI-J NATL CANCER I, V96, P1659, DOI 10.1093/jnci/djh312; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li HC, 2002, J BIOL CHEM, V277, P20965, DOI 10.1074/jbc.M112231200; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moos PJ, 1998, P NATL ACAD SCI USA, V95, P3896, DOI 10.1073/pnas.95.7.3896; Moynahan ME, 2001, CANCER RES, V61, P4842; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Quinn JE, 2003, CANCER RES, V63, P6221; Rennert H, 2002, AM J HUM GENET, V71, P981, DOI 10.1086/342775; Rokman A, 2002, AM J HUM GENET, V70, P1299, DOI 10.1086/340450; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Silverman RH, 2003, BIOCHEMISTRY-US, V42, P1805, DOI 10.1021/bi027147i; STARK GR, 1979, NATURE, V278, P471, DOI 10.1038/278471a0; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	32	45	47	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5492	5501		10.1038/sj.onc.1208698	http://dx.doi.org/10.1038/sj.onc.1208698			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15940267				2022-12-17	WOS:000231222300009
J	Bhatia, B; Tang, SH; Yang, PY; Doll, A; Aumueller, G; Newman, RA; Tang, DG				Bhatia, B; Tang, SH; Yang, PY; Doll, A; Aumueller, G; Newman, RA; Tang, DG			Cell-autonomous induction of functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) contributes to replicative senescence of human prostate progenitor cells	ONCOGENE			English	Article						15-lipoxygenase 2; replicative cell senescence; stem cells; prostate progenitor cells; cell cycle; gene regulation	OLIGODENDROCYTE PRECURSOR CELLS; EPITHELIAL STEM-CELLS; BASAL-CELLS; IN-VITRO; EXPRESSION; CULTURE; CANCER; 15S-LIPOXYGENASE; IDENTIFICATION; HYPERPLASIA	Normal human prostatic (NHP) epithelial cells undergo senescence in vitro and in vivo, but little is known about the tissue-specific molecular mechanisms. Here we first characterize young primary NHP cells as CK5(+)/CK18(+) intermediate basal cells that also express several other putative stem/progenitor cell markers including p63, CD44, alpha 2 beta 1, and hTERT. When cultured in serum- and androgen-free medium, NHP cells gradually lose the expression of these markers, slow down in proliferation, and enter senescence. Several pieces of evidence implicate 15-lipoxygenase 2 (15-LOX2), a molecule with a restricted tissue expression and most abundantly expressed in adult human prostate, in the replicative senescence of NHP cells. First, the 15-LOX2 promoter activity and the mRNA and protein levels of 15-LOX2 and its multiple splice variants are upregulated in serially passaged NHP cells, which precede replicative senescence and occur in a cell-autonomous manner. Second, all immortalized prostate epithelial cells and prostate cancer cells do not express 15-LOX2. Third, PCa cells stably transfected with 15-LOX2 or 15-LOX2sv-b, a splice variant that does not possess arachidonate-metabolizing activity, show a passage-related senescence-like phenotype. Fourth, infection of early-passage NHP cells with retroviral vectors encoding 15-LOX2 or 15-LOX2sv-b induces partial cell-cycle arrest and big and. at senescence-like phenotype. Finally, 15-LOX2 protein expression in human prostate correlates with age. Together, these data suggest that 15-LOX2 may represent an endogenous prostate senescence gene and its tumor-suppressing functions might be associated with its ability to induce cell senescence.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Marburg, Dept Anat & Cell Biol, D-3550 Marburg, Germany	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Philipps University Marburg	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, 1808 Pk Rd 1C, Smithville, TX 78957 USA.	dtang@sprd1.mdacc.tmc.edu	Tang, Dean/AAI-3457-2020; Doll, Andreas/I-1449-2012	Tang, Dean/0000-0001-5029-1174; Doll, Andreas/0000-0001-8965-8682	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA090297, P01CA106451] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023374] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA90297, P01 CA106451] Funding Source: Medline; NIA NIH HHS [AG023374] Funding Source: Medline; NIEHS NIH HHS [P50 ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bhatia B, 2003, J BIOL CHEM, V278, P25091, DOI 10.1074/jbc.M301920200; BONKHOFF H, 1994, PROSTATE, V24, P42; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Castro P, 2003, PROSTATE, V55, P30, DOI 10.1002/pros.10204; Choi J, 2000, UROLOGY, V56, P160, DOI 10.1016/S0090-4295(00)00538-0; Collins AT, 2001, J CELL SCI, V114, P3865; Cristofalo VJ, 1998, P NATL ACAD SCI USA, V95, P10614, DOI 10.1073/pnas.95.18.10614; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Garraway LA, 2003, PROSTATE, V55, P206, DOI 10.1002/pros.10244; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Hudson DL, 2000, LAB INVEST, V80, P1243, DOI 10.1038/labinvest.3780132; Jarrard DF, 1999, CANCER RES, V59, P2957; Kilty I, 1999, EUR J BIOCHEM, V266, P83, DOI 10.1046/j.1432-1327.1999.00818.x; Kinbara H, 1996, PROSTATE, V29, P107; Kuhn H, 1999, ADV EXP MED BIOL, V447, P5; Liu AY, 1997, P NATL ACAD SCI USA, V94, P10705, DOI 10.1073/pnas.94.20.10705; Raff M, 2003, ANNU REV CELL DEV BI, V19, P1, DOI 10.1146/annurev.cellbio.19.111301.143037; RICHARDSON GD, 2004, J CELL SCI      0629; Robinson EJ, 1998, PROSTATE, V37, P149, DOI 10.1002/(SICI)1097-0045(19981101)37:3<149::AID-PROS4>3.0.CO;2-E; Ruijter E, 1999, ENDOCR REV, V20, P22, DOI 10.1210/er.20.1.22; Sandhu C, 2000, CANCER RES, V60, P2616; Schalken JA, 2003, UROLOGY, V62, P11, DOI 10.1016/S0090-4295(03)00758-1; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schwarze SR, 2001, ONCOGENE, V20, P8184, DOI 10.1038/sj.onc.1205049; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; Shou JY, 2001, CANCER RES, V61, P7291; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Tang DG, 2000, J CELL BIOL, V148, P971, DOI 10.1083/jcb.148.5.971; Tang DG, 2001, SCIENCE, V291, P868, DOI 10.1126/science.1056780; Tang SH, 2004, ONCOGENE, V23, P6942, DOI 10.1038/sj.onc.1207913; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; Tran CP, 2002, MOL CANCER RES, V1, P113; Untergasser G, 2002, CANCER RES, V62, P6255; van Leenders G, 2000, LAB INVEST, V80, P1251, DOI 10.1038/labinvest.3780133; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; Wright WE, 2001, CURR OPIN GENET DEV, V11, P98, DOI 10.1016/S0959-437X(00)00163-5	37	45	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3583	3595		10.1038/sj.onc.1208406	http://dx.doi.org/10.1038/sj.onc.1208406			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15750631				2022-12-17	WOS:000229221800006
J	Stein, U; Bergmann, S; Scheffer, GL; Scheper, RJ; Royer, HD; Schlag, PM; Walther, W				Stein, U; Bergmann, S; Scheffer, GL; Scheper, RJ; Royer, HD; Schlag, PM; Walther, W			YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene	ONCOGENE			English	Article						YB-1; MVP; 5-fluorouracil; drug resistance	BOX-BINDING-PROTEIN; RESISTANCE-RELATED PROTEIN; CANCER-CELL-LINES; TRANSCRIPTION FACTOR YB-1; SHORT-TERM EXPOSURE; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; BREAST-CANCER; MDR1 GENE; COLORECTAL CARCINOMAS	Vaults have been suggested to play a direct role in multidrug resistance ( MDR) to anticancer drugs. The human major vault protein ( MVP) also known as lung resistance- related protein ( LRP) represents the predominant component of vaults that may be involved in the defense against xenobiotics. Here, we demonstrate that besides MDR- related cytostatics, also the non- MDR-related drug 5-fluorouracil ( 5- FU) was able to induce MVP mRNA and protein expression. Treatment with 5- FU amplified the binding activity and interaction of the transcription factor Y- box binding protein- 1 ( YB- 1) with the Y- box of the human MVP gene promoter in a time-dependent manner. 5- FU also induced reporter expressions driven by a panel of newly generated MVP promoter deletion mutants. Interestingly, stably YB- 1 overexpressing cell clones showed enhanced binding of YB- 1 to the Y- box motif, associated with enhanced basal as well as 5- FU- inducible MVP promoter- driven reporter expressions. Moreover, transduction of YB- 1 cDNA led to increased expression of endogenous MVP protein. Under physiological conditions, we observed a strong coexpression of MVP and YB- 1 in human colon carcinoma specimen. In summary, our data demonstrate a direct involvement of YB- 1 in controlling basal and 5- FU-induced MVP promoter activity. Therefore, YB- 1 is directly linked to MVP- mediated drug resistance.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Free Univ Amsterdam, Dept Pathol, NL-1007 MB Amsterdam, Netherlands; Ctr Adv European Studies & Res, D-53175 Bonn, Germany; Humboldt Univ, Charite, Div Surg & Surg Oncol, D-13122 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Vrije Universiteit Amsterdam; Center of Advanced European Studies & Research (CAESAR); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Stein, U (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	ustein@mdc-berlin.de	Royer, Hans-dieter/AAH-6293-2019	Stein, Ulrike/0000-0001-7006-282X; Walther, Wolfgang/0000-0003-2360-1370				ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Berger W, 2000, INT J CANCER, V88, P293, DOI 10.1002/1097-0215(20001015)88:2<293::AID-IJC23>3.0.CO;2-S; Cheng SH, 2000, TOXICOL APPL PHARM, V164, P134, DOI 10.1006/taap.2000.8903; Comerford KM, 2002, CANCER RES, V62, P3387; Emre N, 2004, BBA-GENE STRUCT EXPR, V1678, P33, DOI 10.1016/j.bbaexp.2004.01.005; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; Holm PS, 2002, J BIOL CHEM, V277, P10427, DOI 10.1074/jbc.M106955200; Hu Y, 2002, INT J CANCER, V97, P149, DOI 10.1002/ijc.1590; Ise T, 1999, CANCER RES, V59, P342; Izquierdo MA, 1996, AM J PATHOL, V148, P877; Izquierdo MA, 1996, INT J CANCER, V65, P230; Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kickhoefer VA, 1998, J BIOL CHEM, V273, P8971, DOI 10.1074/jbc.273.15.8971; Kitazono M, 1999, JNCI-J NATL CANCER I, V91, P1647, DOI 10.1093/jnci/91.19.1647; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; Komarov PG, 1998, ONCOL RES, V10, P185; Kumar A, 2001, GENE, V270, P221, DOI 10.1016/S0378-1119(01)00473-5; Kuwano M, 2003, CANCER SCI, V94, P9, DOI 10.1111/j.1349-7006.2003.tb01344.x; Labialle S, 2002, BIOCHEM PHARMACOL, V64, P943, DOI 10.1016/S0006-2952(02)01156-5; Lange C, 2000, BIOCHEM BIOPH RES CO, V278, P125, DOI 10.1006/bbrc.2000.3782; Lasham A, 2003, J BIOL CHEM, V278, P35516, DOI 10.1074/jbc.M303920200; Laurencot CM, 1997, INT J CANCER, V72, P1021; Meijer GA, 1999, J CLIN PATHOL, V52, P450, DOI 10.1136/jcp.52.6.450; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; Meschini S, 2002, TOXICOL IN VITRO, V16, P389, DOI 10.1016/S0887-2333(02)00035-8; Midgley R, 1999, LANCET, V353, P391, DOI 10.1016/S0140-6736(98)07127-X; Mossink MH, 2003, ONCOGENE, V22, P7458, DOI 10.1038/sj.onc.1206947; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Pohl G, 1999, ANTICANCER RES, V19, P5051; Pohl G, 2001, ANTICANCER RES, V21, P201; Scheffer GL, 2000, CURR OPIN ONCOL, V12, P550, DOI 10.1097/00001622-200011000-00007; SCHEFFER GL, 1995, NAT MED, V1, P578, DOI 10.1038/nm0695-578; SCHEPER RJ, 1993, CANCER RES, V53, P1475; Schneider J, 2001, BREAST CANCER RES, V3, P183, DOI 10.1186/bcr293; Schroeijers AB, 2001, J HISTOCHEM CYTOCHEM, V49, P1379, DOI 10.1177/002215540104901106; Scotto KW, 2003, ONCOGENE, V22, P7496, DOI 10.1038/sj.onc.1206950; Shibao K, 1999, INT J CANCER, V83, P732; Stein U, 2002, J CLIN ONCOL, V20, P3282, DOI 10.1200/JCO.2002.01.003; Stein U, 1997, JNCI-J NATL CANCER I, V89, P807, DOI 10.1093/jnci/89.11.807; Stein U, 2001, J BIOL CHEM, V276, P28562, DOI 10.1074/jbc.M100311200; Steiner E, 2004, BIOCHEM BIOPH RES CO, V317, P235, DOI 10.1016/j.bbrc.2004.03.029; Tebbutt NC, 2002, EUR J CANCER, V38, P1000, DOI 10.1016/S0959-8049(02)00062-X; Wyler B, 1997, BRIT J HAEMATOL, V97, P65, DOI 10.1046/j.1365-2141.1997.52649.x; Zhang YF, 2003, ONCOGENE, V22, P2782, DOI 10.1038/sj.onc.1206357; ZIJLSTRA JG, 1987, CANCER RES, V47, P1780	51	45	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 19	2005	24	22					3606	3618		10.1038/sj.onc.1208386	http://dx.doi.org/10.1038/sj.onc.1208386			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15750632				2022-12-17	WOS:000229221800008
J	Lin, H; Monaco, G; Sun, T; Ling, XY; Stephens, C; Xie, SH; Belmont, J; Arlinghaus, A				Lin, H; Monaco, G; Sun, T; Ling, XY; Stephens, C; Xie, SH; Belmont, J; Arlinghaus, A			Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia	ONCOGENE			English	Article						BCR-ABL; lipocalin 2; leukemia; hematopoiesis; apoptosis	NORMAL GRANULOPOIESIS INVITRO; HUMAN NEUTROPHIL GELATINASE; CHRONIC MYELOID-LEUKEMIA; INHIBITOR LAI; PROTEIN; LIPOCALIN; MOUSE; CELLS; FIBROBLASTS; INDUCTION	A variety of experimental evidence including findings in various mouse models indicates that the BCR-ABL oncogene is the cause of chronic myeloid leukemia (CML). Since normal hematopoietic cells in marrow and spleen are replaced with proliferating leukemic blasts, we determined whether this is an active process mediated by the leukemia cells. The lipocalin 24p3 was reported to be secreted by mouse hematopoietic cells deprived of IL-3, resulting in apoptosis induction in a variety of hematopoietic cells including bone marrow cells. Here, we show that BCR-ABL + mouse hematopoietic cells induced persistent expression and secretion of 24p3. Importantly, BCR-ABL + hematopoietic cells were resistant to the apoptotic effects of 24p3. The expression of the Bcr-Abl oncoprotein and its tyrosine kinase were required for induction of 24p3 expression. Co-culture studies showed that BCR-ABL + cells induced apoptosis in BCR-ABL negative cells. Antisense 24p3/siRNA expression reduced the level of 24p3 protein in both BCR-ABL + cells and in conditioned medium ( CM) obtained from these cells. CM from BCR-ABL + cells expressing antisense 24p3/siRNA had reduced apoptotic activity for target cells; 24p3 antibody also reduced the apoptotic activity of the CM. Leukemic mice induced by BCR-ABL + cells expressing either antisense 24p3 or 24p3 siRNA had increased levels of normal hematopoiesis and reduced invasion of leukemia cells in marrow and spleen tissues. These findings indicate that suppression of normal hematopoiesis in BCR-ABL-induced leukemia is an active process involving secretion of the cell death-inducing factor 24p3 by mouse leukemia cells, raising the possibility that similar factors are involved in BCR-ABL + CML.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, A (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rarlingh@mdanderson.org	Belmont, John W/AAI-2494-2019; Belmont, John/AAH-6084-2021	Belmont, John W/0000-0001-7409-3578; 	NATIONAL CANCER INSTITUTE [P01CA049639, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA49639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DAVIS TR, 1991, BIOCHIM BIOPHYS ACTA, V1095, P145, DOI 10.1016/0167-4889(91)90077-B; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Eaves C, 1998, LEUKEMIA RES, V22, P1085, DOI 10.1016/S0145-2126(98)00113-1; El Ouriaghli F, 2003, BLOOD, V102, P3786; FLOWER DR, 1991, BIOCHEM BIOPH RES CO, V180, P69, DOI 10.1016/S0006-291X(05)81256-2; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; Guo JQ, 2002, LEUKEMIA, V16, P2447, DOI 10.1038/sj.leu.2402730; Kjeldsen L, 2000, BBA-PROTEIN STRUCT M, V1482, P272, DOI 10.1016/S0167-4838(00)00152-7; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; Lin F, 2001, ONCOGENE, V20, P1873, DOI 10.1038/sj.onc.1204409; Ling XY, 2003, CANCER RES, V63, P298; Liu QS, 1997, MOL REPROD DEV, V46, P507, DOI 10.1002/(SICI)1098-2795(199704)46:4&lt;507::AID-MRD9&gt;3.0.CO;2-S; MATULONIS UA, 1995, BLOOD, V85, P2507, DOI 10.1182/blood.V85.9.2507.bloodjournal8592507; MCCUBREY JA, 1993, ONCOGENE, V8, P2905; OLOFSSON T, 1980, BLOOD, V55, P983; OLOFSSON T, 1980, BLOOD, V55, P975; Salomoni P, 2000, BLOOD, V96, P676; Skold S, 1999, BLOOD, V93, P849, DOI 10.1182/blood.V93.3.849.403k07_849_856; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Xie SH, 2002, ONCOGENE, V21, P7137, DOI 10.1038/sj.onc.1205942; Yousefi S, 2002, CELL DEATH DIFFER, V9, P595, DOI 10.1038/sj.cdd.4401037	23	45	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3246	3256		10.1038/sj.onc.1208500	http://dx.doi.org/10.1038/sj.onc.1208500			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735695				2022-12-17	WOS:000228881800003
J	Le Pera, I; Iuliano, R; Florio, T; Susini, C; Trapasso, F; Santoro, M; Chiariotti, L; Schettini, G; Viglietto, G; Fusco, A				Le Pera, I; Iuliano, R; Florio, T; Susini, C; Trapasso, F; Santoro, M; Chiariotti, L; Schettini, G; Viglietto, G; Fusco, A			The rat tyrosine phosphatase eta increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue	ONCOGENE			English	Article						protein tyrosine phosphatases; r-PTP eta; HPTP eta/DEP-1; c-Src; cell adhesion	THYROID EPITHELIAL-CELLS; MATRIX ADHESION; FAMILY KINASES; SOMATOSTATIN INHIBITION; SIGNAL-TRANSDUCTION; COLORECTAL-CANCER; FOCAL ADHESIONS; SARCOMA-VIRUS; IN-VITRO; PROTEIN	The expression of the receptor protein tyrosine phosphatase r-PTP eta is drastically reduced in rat and human malignant thyroid cells, whereas its restoration reverts the neoplastic phenotype of retrovirally transformed rat thyroid cells. Moreover, reduced levels and loss of heterozygosity of DEP-1, the human homolog of r-PTP eta, have been found in many human neoplasias. Here, we report that the r-PTP eta protein binds to c-Src in living cells and dephosphorylates the c-Src inhibitory tyrosine phosphorylation site (Tyr 529), thereby increasing c-Src tyrosine kinase activity in malignant rat thyroid cells stably transfected with r-PTP eta. Tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin was enhanced in r-PTP eta-expressing cells. This was associated with increased adhesion of malignant r-PTP eta-transfected thyroid cells vs both untransfected cells and cells stably transfected with an inactive r-PTP eta mutant. Treatment of rat thyroid cells with the c-Src inhibitor PP2 decreased cell adhesion to a higher extent in r-PTP eta-transfected cells than in mock-transfected or stably transfected cells with the inactive r-PTP eta mutant, indicating that r-PTP eta regulates cell - substratum adhesion by activating c-Src. Interestingly, the extent of both c-Src dephosphorylation at Tyr 529, FAK and paxillin phosphorylation, and the increased cell adhesion were associated with the degree of r-PTP eta expression.	Univ Naples Federico II, Sch Med, CNR,Dept Biol & Mol & Cellular Pathol, Endocrinol & Expt Oncol Ctr, I-80131 Naples, Italy; Magna Graecia Univ Catanzaro, Med Sch Catanzaro, Dept Expt & Clin Med, I-88100 Catanzaro, Italy; Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy; CHU Rangueil, IFR 31, INSERM, U531, F-31403 Toulouse, France; Univ Molise, Dept SpeS, I-86100 Campobasso, Italy; NOGEC, CEINGE, I-80145 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; University of Genoa; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Molise; CEINGE Biotecnologie Avanzate	Fusco, A (corresponding author), Univ Naples Federico II, Sch Med, CNR,Dept Biol & Mol & Cellular Pathol, Endocrinol & Expt Oncol Ctr, I-80131 Naples, Italy.	afusco@napoli.com	Chiariotti, Lorenzo/AAC-5262-2022; Viglietto, Giuseppe/AAC-2852-2019; Florio, Tullio/A-2211-2012; FLORIO, TULLIO/ABG-3182-2020	Viglietto, Giuseppe/0000-0003-2327-7515; Florio, Tullio/0000-0002-2394-996X; Fusco, Alfredo/0000-0003-3332-5197; CHIARIOTTI, Lorenzo/0000-0001-6097-4171				Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Baker JE, 2001, MOL CELL BIOL, V21, P2393, DOI 10.1128/MCB.21.7.2393-2403.2001; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chiang GG, 2000, J BIOL CHEM, V275, P6055, DOI 10.1074/jbc.275.9.6055; de la Fuente-Garcia MA, 1998, BLOOD, V91, P2800, DOI 10.1182/blood.V91.8.2800.2800_2800_2809; Florio T, 2001, MOL ENDOCRINOL, V15, P1838, DOI 10.1210/me.15.10.1838; FUSCO A, 1985, J VIROL, V56, P284, DOI 10.1128/JVI.56.1.284-292.1985; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; Iuliano R, 2004, ONCOGENE, V23, P8432, DOI 10.1038/sj.onc.1207766; Iuliano R, 2003, CANCER RES, V63, P882; Iuliano R, 2001, FEBS LETT, V500, P41, DOI 10.1016/S0014-5793(01)02580-7; Jandt E, 2003, ONCOGENE, V22, P4175, DOI 10.1038/sj.onc.1206652; Jones RJ, 2002, BRIT J CANCER, V87, P1128, DOI 10.1038/sj.bjc.6600594; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Keane MM, 1996, CANCER RES, V56, P4236; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Li LM, 2002, MOL CELL BIOL, V22, P1203, DOI 10.1128/MCB.22.4.1203-1217.2002; Martelli ML, 1998, EXP CELL RES, V245, P195, DOI 10.1006/excr.1998.4257; Massa A, 2004, J BIOL CHEM, V279, P29004, DOI 10.1074/jbc.M403573200; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Petrone A, 2000, J CELL SCI, V113, P2345; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; Ruivenkamp C, 2003, ONCOGENE, V22, P3472, DOI 10.1038/sj.onc.1206246; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; Tangye SG, 1998, J IMMUNOL, V161, P3803; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Trapasso F, 2004, CARCINOGENESIS, V25, P2107, DOI 10.1093/carcin/bgh224; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zhang L, 1997, EXP CELL RES, V235, P62, DOI 10.1006/excr.1997.3659; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; Zimmermann P, 2001, MOL BIOL CELL, V12, P339, DOI 10.1091/mbc.12.2.339	45	45	48	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3187	3195		10.1038/sj.onc.1208510	http://dx.doi.org/10.1038/sj.onc.1208510			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735685				2022-12-17	WOS:000228728100012
J	Jackson, D; Zheng, Y; Lyo, DG; Shen, YJ; Nakayama, K; Nakayama, KI; Humphries, MJ; Reyland, ME; Foster, DA				Jackson, D; Zheng, Y; Lyo, DG; Shen, YJ; Nakayama, K; Nakayama, KI; Humphries, MJ; Reyland, ME; Foster, DA			Suppression of cell migration by protein kinase C delta	ONCOGENE			English	Article						protein kinase C delta; cell migration; metastasis; breast cancer cells	GROWTH-FACTOR RECEPTOR; TUMOR PROMOTION; PLASMINOGEN-ACTIVATOR; DOWN-REGULATION; NIH 3T3-CELLS; CANCER; TUMORIGENICITY; BRYOSTATIN-1; MOTILITY; EPSILON	The ability of cancer cells to migrate is strongly correlated with malignant progression and metastasis. Survival signals that suppress apoptosis have also been linked to increased cell motility. We previously reported that suppression of protein kinase C delta (PKC delta) provided survival signals in a rat fibroblast model system. These studies have been extended to human breast cancer cells with differential cell motilities and PKC delta levels. BT-549 cells, which lack detectable expression of PKC delta, migrate very efficiently, whereas MCF-7 cells, which express high levels of PKC delta, migrate very poorly. Ectopic expression of PKC delta suppressed cell migration in the BT-549 cells, and downregulation of PKC delta enhanced cell migration in the MCF-7 cells. Downregulation of PKC delta in the MCF-7 cells also led to increased secretion of the matrix metalloprotease MMP-9. The migration of mouse embryo fibroblasts (MEFs) from wild type and PKC delta knockout mice was also examined and MEFs from PKC delta knockout mice had a five-fold increase in cell migration relative to the wild-type MEFs. These data provide evidence that PKC delta suppresses cell migration in both human breast cancer cells and in primary mouse fibroblasts, and indicate that the loss of PKC delta in human cancers could contribute to both cell survival and metastasis.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA; Kyushu Univ, Med Inst Bioregulat, Dept Mol Genet, Fukuoka 8128582, Japan; Univ Colorado, Sch Dent, Dept Craniofacial Biol, Denver, CO 80262 USA	City University of New York (CUNY) System; Hunter College (CUNY); Kyushu University; University of Colorado System; University of Colorado Denver	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edu			NCI NIH HHS [R01-CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [SO6-GM60654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbas T, 2004, J BIOL CHEM, V279, P9970, DOI 10.1074/jbc.M306979200; Acs P, 1997, J BIOL CHEM, V272, P28793, DOI 10.1074/jbc.272.45.28793; Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Bartucci M, 2001, CANCER RES, V61, P6747; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Clamp A, 2002, ANTI-CANCER DRUG, V13, P673, DOI 10.1097/00001813-200208000-00001; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; HATA A, 1993, J BIOL CHEM, V268, P9122; HENNINGS H, 1987, CARCINOGENESIS, V8, P1343, DOI 10.1093/carcin/8.9.1343; Hornia A, 1999, MOL CELL BIOL, V19, P7672; HUPPI K, 1994, GENOMICS, V19, P161, DOI 10.1006/geno.1994.1028; Jackson DN, 2004, FASEB J, V18, P627, DOI 10.1096/fj.03-0979rev; Johnson MD, 1999, EXP CELL RES, V247, P105, DOI 10.1006/excr.1998.4336; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Kiley SC, 1999, CANCER RES, V59, P3230; Kruger JS, 2003, MOL CANCER RES, V1, P801; Liu JF, 2002, BIOCHEM BIOPH RES CO, V293, P1174, DOI 10.1016/S0006-291X(02)00350-9; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Marshall JL, 2002, CANCER BIOL THER, V1, P409, DOI 10.4161/cbt.1.4.17; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z; OHNO S, 1994, J BIOL CHEM, V269, P17495; Reddig PJ, 1999, CANCER RES, V59, P5710; Sevignani C, 2003, CANCER RES, V63, P1183; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Sugatani T, 2003, J BIOL CHEM, V278, P5001, DOI 10.1074/jbc.M209299200; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; YANG Q, 2000, J HUM GENET, V47, P453; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zhong MH, 2002, ONCOGENE, V21, P1071, DOI 10.1038/sj/onc/1205165; Zhong MH, 2001, CELL GROWTH DIFFER, V12, P187	36	45	48	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3067	3072		10.1038/sj.onc.1208465	http://dx.doi.org/10.1038/sj.onc.1208465			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735725				2022-12-17	WOS:000228649500018
J	Song, ZY; Wu, M				Song, ZY; Wu, M			Identification of a novel nucleolar localization signal and a degradation signal in Survivin-deltaEx3: a potential link between nucleolus and protein degradation	ONCOGENE			English	Article						Survivin-deltaEx3; subcellular localization; antiapoptosis; nucleolus; ubiquitination	NUCLEAR-LOCALIZATION; SPLICE VARIANTS; SURVIVIN; APOPTOSIS; UBIQUITIN; DOMAINS; HERPESVIRUS; EXPRESSION; DISRUPT; CANCER	For a long time, as the most prominent subnuclear structure, nucleolus has been recognized as a main site where rRNA processing and ribosomal subunit assemblies take place. It has not been until recently that additional functions of nucleolus have begun to be proposed. In this study, we for the first time demonstrate that Survivin-deltaEx3, a novel functionally splice variant of Survivin localizes in the nucleoli where it degrades rapidly through ubiquitin-proteosome pathway. Several lines of evidences provided in this report support this finding (i) a novel nucleolar localization sequence (NoLS, MQRKPTIRRKNLRLRRK) and a novel degradation signal (aa92 - aa137) within Survivin-deltaEx3 were identified (ii) proteasome inhibitors MG132 or ALLN greatly inhibits degradation of Survivin-deltaEx3 and polyubiquitination of Survivin-deltaEx3 was detected (iii) heterologous proteins such as TAT-PTD or p14ARF, when fused to this putative degradation signal, result in a significant degradation within the nucleolus. In addition, the nucleolar localization and degradation of Survivin-deltaEx3 appear to be required for its antiapoptotic function, since neither NoLS-deleted nor degradation signal-deleted Survivin-deltaEx3 retains protective effect against Doxorubicin-induced apoptosis. Thus, our results have provided evidences to suggest that besides cytosol, nucleus, endoplsmic reticulum (ER) or lysosomes, nucleolus may also operate important protein degradation pathway, which has been overlooked previously.	Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Wu, M (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.	wumian88@yahoo.com	Wu, Mian/H-2494-2018	Wu, Mian/0000-0002-2714-0500				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475; Arabi A, 2003, J CELL SCI, V116, P1707, DOI 10.1242/jcs.00370; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; CREANCIER L, 1993, MOL BIOL CELL, V4, P1239, DOI 10.1091/mbc.4.12.1239; Everett RD, 1997, EMBO J, V16, P566, DOI 10.1093/emboj/16.3.566; Galcheva-Gargova Z, 1998, MOL BIOL CELL, V9, P2963, DOI 10.1091/mbc.9.10.2963; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Krieg A, 2002, BRIT J CANCER, V86, P737, DOI 10.1038/sj.bjc.6600153; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Latonen L, 2003, CELL SIGNAL, V15, P95, DOI 10.1016/S0898-6568(02)00044-X; Lenk U, 2000, J BIOL CHEM, V275, P39403, DOI 10.1074/jbc.M006949200; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Lindsten K, 2003, NAT BIOTECHNOL, V21, P897, DOI 10.1038/nbt851; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Mahotka C, 1999, CANCER RES, V59, P6097; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Olson MOJ, 2002, INT REV CYTOL, V219, P199; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Pederson T, 1998, J CELL BIOL, V143, P279, DOI 10.1083/jcb.143.2.279; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Pokrovskaja K, 2001, J GEN VIROL, V82, P345, DOI 10.1099/0022-1317-82-2-345; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Rudin CM, 1997, ANNU REV MED, V48, P267; Satyamoorthy K, 2001, TRENDS MOL MED, V7, P191, DOI 10.1016/S1471-4914(01)02013-5; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Song ZY, 2004, MOL BIOL CELL, V15, P1287, DOI 10.1091/mbc.E03-07-0512; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wang HW, 2002, EMBO J, V21, P2602, DOI 10.1093/emboj/21.11.2602; Wurm T, 2001, J VIROL, V75, P9345, DOI 10.1128/JVI.75.19.9345-9356.2001; Yamada Y, 2003, J NEUROSURG, V99, P738, DOI 10.3171/jns.2003.99.4.0738; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhao J, 2000, J CELL SCI, V113, P4363	44	45	48	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2723	2734		10.1038/sj.onc.1208097	http://dx.doi.org/10.1038/sj.onc.1208097			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735764				2022-12-17	WOS:000228356700014
J	King, TJ; Gurley, KE; Prunty, J; Shin, JL; Kemp, CJ; Lampe, PD				King, TJ; Gurley, KE; Prunty, J; Shin, JL; Kemp, CJ; Lampe, PD			Deficiency in the gap junction protein Connexin32 alters p27(Kip1) tumor suppression and MAPK activation in a tissue-specific manner	ONCOGENE			English	Article						gap junction; connexin; p27(Kip1); radiation; lung; liver; carcinogenesis; Connexin32; mouse; knock-out (KO)	DEPENDENT KINASE INHIBITOR; INTERCELLULAR COMMUNICATION; INDUCIBLE EXPRESSION; EPITHELIAL-CELLS; MICE DEFICIENT; BETA-CATENIN; LUNG-TUMORS; MOUSE; LIVER; TUMORIGENESIS	Connexin32 knockout mice (Cx32-KO) exhibit increased chemical- and radiation-induced liver and lung tumor formation with many lung tumors demonstrating decreased levels of the tumor suppressor p27(KIP1). To determine if p27 deficiency alters Cx32-influenced tumorigenesis, we have generated a Cx32/p27 double-deficient mouse strain (DKO) and show here that exposure of these mice to X-ray radiation resulted in an increase or decrease in tumorigenesis depending on the tissue. Several tissues were highly sensitive to loss of p27 tumor suppressor function ( intestine, adrenal, pituitary) resulting in an increased overall tumor burden in DKO mice compared to both wild-type (P<0.005) and Cx32-KO mice ( P = 0.066). However, additional deletion of p27 in a Cx32-KO background resulted in a statistically significant decrease in the liver tumor incidence suggesting that Cx32 and p27 pathways mechanistically interact. Immunohistochemical analysis revealed an increased percentage of Cx32-KO liver and lung tumors harboring active mitogen-activated protein kinase (Erk1, Erk2) pathways in contrast to lower percentages of activated wild-type (P<0.005) and DKO tumors ( P = 0.027). Increased MAPK activation in liver tumors did not correlate with Ha-ras codon-61 mutation status. This study demonstrates that tissues dependent on Cx32 tumor suppression, such as the liver and lung, exhibit altered tumorigenesis and tumor biology (MAPK pathway activation) related to p27 status.	Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Canc Prevent Res Progam, Seattle, WA USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Canc Biol, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	King, TJ (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Canc Prevent Res Progam, 1100 Fairview Ave N,M5-C800, Seattle, WA USA.	tking@fhcrc.org			NIAID NIH HHS [T32-AI07509] Funding Source: Medline; NIAMS NIH HHS [AR47963] Funding Source: Medline; NIGMS NIH HHS [R01 GM055632, GM55632] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055632] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham V, 2001, AM J PHYSIOL-LUNG C, V280, pL1085, DOI 10.1152/ajplung.2001.280.6.L1085; Avanzo JL, 2004, CARCINOGENESIS, V25, P1973, DOI 10.1093/carcin/bgh193; Aydinlik H, 2001, ONCOGENE, V20, P7812, DOI 10.1038/sj.onc.1204982; Defamie N, 2003, LAB INVEST, V83, P449, DOI 10.1097/01.LAB.0000059928.82702.6D; Evert M, 2002, CARCINOGENESIS, V23, P697, DOI 10.1093/carcin/23.5.697; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Hanna EA, 1999, CARCINOGENESIS, V20, P1369, DOI 10.1093/carcin/20.7.1369; King TJ, 2000, CARCINOGENESIS, V21, P1097, DOI 10.1093/carcin/21.6.1097; King TJ, 2004, CARCINOGENESIS, V25, P669, DOI 10.1093/carcin/bgh071; King TJ, 2004, CANCER RES, V64, P7191, DOI 10.1158/0008-5472.CAN-04-0624; King TJ, 2002, MOL CARCINOGEN, V35, P29, DOI 10.1002/mc.10071; Koffler L, 2000, J CELL BIOCHEM, V79, P347, DOI 10.1002/1097-4644(20001201)79:3<347::AID-JCB10>3.0.CO;2-2; Koval M, 2002, AM J PHYSIOL-LUNG C, V283, pL875, DOI 10.1152/ajplung.00078.2002; Krutovskikh V, 2000, MUTAT RES-REV MUTAT, V462, P197, DOI 10.1016/S1383-5742(00)00037-5; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Lo CW, 1999, DEV GENET, V24, P1, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<1::AID-DVG1>3.0.CO;2-U; Lumniczky K, 1998, MOL CARCINOGEN, V21, P100, DOI 10.1002/(SICI)1098-2744(199802)21:2<100::AID-MC4>3.3.CO;2-Z; Maronpot R, 1999, PATHOLOGY MOUSE; Mehta P, 1999, DEV GENET, V24, P91, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<91::AID-DVG10>3.0.CO;2-#; Mesnil M, 2002, BIOL CELL, V94, P493, DOI 10.1016/S0248-4900(02)00025-4; Moennikes O, 1999, CARCINOGENESIS, V20, P1379, DOI 10.1093/carcin/20.7.1379; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Nelles E, 1996, P NATL ACAD SCI USA, V93, P9565, DOI 10.1073/pnas.93.18.9565; Philipp-Staheli J, 2004, ONCOGENE, V23, P905, DOI 10.1038/sj.onc.1207220; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Ramakrishna G, 2002, TOXICOL APPL PHARM, V179, P21, DOI 10.1006/taap.2001.9344; Richard G, 2001, Adv Dermatol, V17, P243; Ruch RJ, 1998, EXP LUNG RES, V24, P523, DOI 10.3109/01902149809087384; Scherer SS, 1998, GLIA, V24, P8, DOI 10.1002/(SICI)1098-1136(199809)24:1<8::AID-GLIA2>3.0.CO;2-3; Schwarz M, 2003, TOXICOL PATHOL, V31, P99, DOI 10.1080/01926230390173932; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Temme A, 1997, CURR BIOL, V7, P713, DOI 10.1016/S0960-9822(06)00302-2; Temme A, 2001, PFLUG ARCH EUR J PHY, V442, P961, DOI 10.1007/s004240100623; Trosko James E., 1998, Frontiers in Bioscience, V3, pD208; Upham BL, 2003, INT J CANCER, V104, P12, DOI 10.1002/ijc.10899; Warn-Cramer BJ, 1998, J BIOL CHEM, V273, P9188, DOI 10.1074/jbc.273.15.9188; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Yao RS, 2003, NEOPLASIA, V5, P41, DOI 10.1016/S1476-5586(03)80016-7; Zhang YW, 2001, ONCOGENE, V20, P4138, DOI 10.1038/sj.onc.1204563; Zhang YW, 2003, CANCER RES, V63, P1623	43	45	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1718	1726		10.1038/sj.onc.1208355	http://dx.doi.org/10.1038/sj.onc.1208355			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15608667				2022-12-17	WOS:000227345100008
J	Huh, JI; Calvo, A; Stafford, J; Cheung, M; Kumar, R; Philp, D; Kleinman, HK; Green, JE				Huh, JI; Calvo, A; Stafford, J; Cheung, M; Kumar, R; Philp, D; Kleinman, HK; Green, JE			Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and nonantiangiogenic mechanisms	ONCOGENE			English	Article						antiangiogenesis; VEGFR tyrosine kinase inhibitor; mammary cancer; C3(1)/Tag transgenic mice	BONE-MARROW MICROENVIRONMENT; MULTIPLE-MYELOMA CELLS; TYROSINE KINASE; MOUSE MODEL; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; BREAST-CANCER; THERAPY; ANTIGEN; ENDOSTATIN	Cancer growth and progression is often critically influenced by the production of vascular endothelial growth factor ( VEGF), a key mediator of angiogenesis. VEGF produced by tumor cells stimulates endothelial cell growth through the binding and activation of the KDR/Flk-1 receptor (VEGFR-2) on endothelial cells. Recently, some human breast cancer epithelial cells have been shown to express VEGF receptors, suggesting a potential autocrine-mediated growth stimulation of a subset of cancers by VEGF. We demonstrate that mammary tumors in the C3(1)/Tag transgenic model express VEGF and VEGF receptors and tumor growth is stimulated by this autocrine mechanism. GW654652, an indazolylpyrimidine, is a VEGFRs tyrosine kinase inhibitor that dramatically reduces both angiogenesis and tumor cell growth in this model, as demonstrated using both in vitro and in vivo assays. GW654652 significantly decreased cell proliferation and induced apoptosis in human umbilical vein endothelial cells and M6 mammary tumor cells derived from C3(1)/Tag ( Tag: simian virus 40 T-antigen) transgenic mice. A 75% reduction in VEGF-induced angiogenesis was observed with GW654652 using the chick chorioallantoic membrane assay, whereas GW654652 produced an approximately 85% reduction in angiogenesis as assessed by the Matrigel(TM) plug assay. A profound inhibitory effect on tumor growth in the C3(1)/Tag transgenic model of human breast cancer was observed with oral administration of GW654652 as measured by delayed tumor onset, decreased multiplicity, reduced tumor volume, and extended animal survival. The antitumor effects of GW654652 were associated with reduced tumor vascularization and no apparent toxicity. Tumor growth, however, rapidly advanced following cessation of treatment. This is the first demonstration that a VEGF receptor inhibitor, GW654652, has a strong inhibitory effect on angiogenesis and tumor progression in a transgenic model of mammary cancer, suggesting that this is a useful approach for preclinical testing of such agents.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Cell Biol Sect, NIH, Bethesda, MD USA; GlaxoSmithKline, Res Triangle Pk, NC USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); GlaxoSmithKline	Green, JE (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bldg 41,Room C629,41 Medlars Dr, Bethesda, MD 20892 USA.	jegreen@nih.gov	Calvo, Alfonso/V-7945-2017	Calvo, Alfonso/0000-0003-4074-4242	NATIONAL CANCER INSTITUTE [Z01BC005740, ZIABC005740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000482] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Calvo A, 2002, CANCER RES, V62, P3934; Calvo A, 2002, INT J CANCER, V101, P224, DOI 10.1002/ijc.10589; Chen YL, 2003, ACTA BOT SIN, V45, P40; Ciardiello F, 2002, EXPERT OPIN INV DRUG, V11, P755; DEV I, 2003, P AM ASSOC CANC RES, V45, P4695; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Heer K, 2001, CLIN CANCER RES, V7, P3491; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Holzer RG, 2003, BREAST CANCER RES TR, V77, P65, DOI 10.1023/A:1021175931177; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Itokawa T, 2002, MOL CANCER THER, V1, P295; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; KUMAR R, 2003, P AM ASSOC CANC RES, V45, P39; Laird AD, 2002, FASEB J, V16, DOI 10.1096/fj.01-0700com; Lin B, 2002, CANCER RES, V62, P5019; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Nakopoulou L, 2002, HUM PATHOL, V33, P863, DOI 10.1053/hupa.2002.126879; Parry TJ, 1999, NUCLEIC ACIDS RES, V27, P2569, DOI 10.1093/nar/27.13.2569; Podar K, 2004, BLOOD, V103, P3474, DOI 10.1182/blood-2003-10-3527; Ponce ML, 2001, FASEB J, V15, P1389, DOI 10.1096/fj.00-0736com; Presta LG, 1997, CANCER RES, V57, P4593; Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Qanungo S, 2002, ONCOGENE, V21, P4149, DOI 10.1038/sj.onc.1205508; Reich S, 2003, MOL VIS, V9, P210; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Shibata MA, 1996, CANCER RES, V56, P2998; Spiekermann K, 2002, EXP HEMATOL, V30, P767, DOI 10.1016/S0301-472X(02)00837-8; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Traxler P, 2003, EXPERT OPIN THER TAR, V7, P215, DOI 10.1517/14728222.7.2.215; Xie B, 1999, BRIT J CANCER, V81, P1335, DOI 10.1038/sj.bjc.6692206; Yokoyama Y, 2000, CANCER RES, V60, P4362; Zhu Z, 2003, LEUKEMIA, V17, P604, DOI 10.1038/sj.leu.2402831	38	45	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					790	800		10.1038/sj.onc.1208221	http://dx.doi.org/10.1038/sj.onc.1208221			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592523				2022-12-17	WOS:000226577100005
J	Sadasivam, S; Gupta, S; Radha, V; Batta, K; Kundu, TK; Swarup, G				Sadasivam, S; Gupta, S; Radha, V; Batta, K; Kundu, TK; Swarup, G			Caspase-1 activator Ipaf is a p53-inducible gene involved in apoptosis	ONCOGENE			English	Article						p53; ipaf; caspase-1; apoptosis; transcriptional activation; gene expression	PROTEIN TYROSINE PHOSPHATASE; CELL-DEATH; P53; CANCER; PUMA; ASC; INFLAMMASOME; EXPRESSION; GENERATION; MECHANISM	The tumor suppressor protein p53 regulates transcription of many genes that mediate cell cycle arrest, apoptosis, DNA repair and other cellular responses. Here we show that Ipaf, a human CED-4 homologue and an activator of caspase-1, is induced by p53. Overexpression of p53 by transfection in U2OS and A549 cells increased Ipaf mRNA levels. Treatment of p53-positive cell lines U2OS and MCF-7 with the DNA damaging drug, doxorubicin, which increases p53 protein level, induced expression of Ipaf mRNA but similar treatment of MCF-7-mp53 ( a clone of MCF-7 cells expressing mutant p53) and p53-negative K562 cells showed much less induction of Ipaf gene expression. Expression analysis for Ipaf mRNA in doxorubicin-treated human tumor cell lines suggests that p53-dependent as well as p53-independent mechanisms are involved in the regulation of Ipaf gene expression in a cell-type-specific manner. The Ipaf promoter was activated by normal p53 but not by His(273) mutant of p53. A functional p53-binding site was identified in the Ipaf promoter. A dominant-negative mutant of Ipaf inhibited p53-induced and doxorubicin-induced apoptosis by about 50%. Ipaf-directed small hairpin RNA downregulated p53-induced Ipaf gene expression and also reduced p53-induced apoptosis. Doxorubicin-induced apoptosis was also inhibited by Ipaf-directed small hairpin RNA. Our results show that p53 can directly induce Ipaf gene transcription, which contributes to p53-dependent apoptosis in at least some human cells.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India; Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bangalore 560064, Karnataka, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Swarup, G (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	gshyam@ccmb.res.in	gupta, sanjeev/B-2824-2008; Gupta, Sanjeev/AAG-9749-2020	gupta, sanjeev/0000-0002-4691-6853; Gupta, Sanjeev/0000-0002-4691-6853; Swarup, Ghanshyam/0000-0002-8098-0509; Sadasivam, Subhashini/0000-0002-7875-7180; Kundu, Tapas/0000-0001-7790-214X				Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Burns K, 2003, CURR OPIN IMMUNOL, V15, P26, DOI 10.1016/S0952-7915(02)00017-1; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Damiano JS, 2001, GENOMICS, V75, P77, DOI 10.1006/geno.2001.6579; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Druilhe A, 2001, CELL DEATH DIFFER, V8, P649, DOI 10.1038/sj.cdd.4400881; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Geddes BJ, 2001, BIOCHEM BIOPH RES CO, V284, P77, DOI 10.1006/bbrc.2001.4928; Gupta S, 2002, FEBS LETT, V532, P61, DOI 10.1016/S0014-5793(02)03628-1; Gupta S, 2001, J BIOL CHEM, V276, P10585, DOI 10.1074/jbc.C100025200; Gutierrez O, 2004, FEBS LETT, V568, P79, DOI 10.1016/j.febslet.2004.04.095; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; Kamatkar S, 1996, J BIOL CHEM, V271, P26755, DOI 10.1074/jbc.271.43.26755; King AR, 2003, LAB INVEST, V83, P1497, DOI 10.1097/01.LAB.0000093096.62765.85; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Liedtke C, 2003, J BIOL CHEM, V278, P27593, DOI 10.1074/jbc.M304077200; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; MacLachan TK, 2002, P NATL ACAD SCI USA, V99, P9492, DOI 10.1073/pnas.132241599; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masumoto J, 2003, BIOCHEM BIOPH RES CO, V303, P69, DOI 10.1016/S0006-291X(03)00309-7; Matsuda K, 2002, CANCER RES, V62, P2883; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Radha V, 1999, FEBS LETT, V453, P308, DOI 10.1016/S0014-5793(99)00734-6; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Shivakrupa R, 2003, J BIOL CHEM, V278, P52188, DOI 10.1074/jbc.M310656200; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zhang WH, 2003, P NATL ACAD SCI USA, V100, P16012, DOI 10.1073/pnas.2534856100; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	40	45	47	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					627	636		10.1038/sj.onc.1208201	http://dx.doi.org/10.1038/sj.onc.1208201			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580302				2022-12-17	WOS:000226420400010
J	Irimia, M; Fraga, MF; Sanchez-Cespedes, M; Esteller, M				Irimia, M; Fraga, MF; Sanchez-Cespedes, M; Esteller, M			CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer	ONCOGENE			English	Article						K-ras; methylation; NORE1A; lung cancer	TUMOR-SUPPRESSOR GENE; COLORECTAL-CANCER; EPIGENETIC INACTIVATION; CELL-LINES; MUTATIONS; METHYLATION; RASSF1A; IDENTIFICATION; TUMORIGENESIS; PROTEIN	Imbalance of the Ras signaling pathway is a major hallmark of human cancer. In this context, activating point mutations of the K-ras oncogene are a common feature of many tumor types. The discovery of methylation-mediated silencing of the Ras-effector homologue RASSF1A has revealed another way by which this cellular pathway may be altered. Inactivation by hypermethylation of a RASSF1A homologue, NORE1A, has recently been observed in human cancers. If both K-ras and NORE1A act in the same pathway, simultaneous molecular lesions in the two genes in the same tumor should be a rare event. To test whether this inverse association exists, we have analysed the K-ras mutational status and NORE1A CpG island hypermethylation of 61 non-small-cell lung carcinomas and the methylation status of the two other Ras effectors, RASSF1A and HRASLS. No association was found between the methylation status of NORE1A, RASSF1A and HRASLS or the status of K-ras with respect to the latter two genes. However, our results demonstrate that the epigenetic alteration of NORE1A is confined to lung tumors with a wild-type K-ras: 88% (15 of 17) of the tumors with NORE1 hypermethylation did not harbor a K-ras mutation (P=0.008, Fisher's exact test). Thus, the mutual exclusivity of the epigenetic and genetic alterations in the two genes of the Ras pathway suggests that they play a critical and cooperative role in human tumorigenesis.	Spanish Natl Canc Ctr CNIO, Canc Epigenet Lab, Mol Pathol Program, Madrid 28029, Spain; Spanish Natl Canc Ctr CNIO, Lung Canc Res Grp, Mol Pathol Program, Madrid 28029, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO)	Esteller, M (corresponding author), Spanish Natl Canc Ctr CNIO, Canc Epigenet Lab, Mol Pathol Program, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	mesteller@cnio.es	Sanchez-Cespedes, Montse/H-8485-2012; Irimia, Manuel/E-3040-2010; Esteller, Manel/L-5956-2014; Fraga, Mario F/H-7824-2017	Sanchez-Cespedes, Montse/0000-0002-6045-5627; Irimia, Manuel/0000-0002-2179-2567; Esteller, Manel/0000-0003-4490-6093; Fraga, Mario F/0000-0001-8450-2603				Akiyama H, 1999, J BIOL CHEM, V274, P32192, DOI 10.1074/jbc.274.45.32192; AOYAMA Y, 2004, ONCOGENE        0308; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Chen H, 2003, J BIOL CHEM, V278, P3121, DOI 10.1074/jbc.M208230200; Dammann R, 2003, ONCOGENE, V22, P3806, DOI 10.1038/sj.onc.1206582; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Esteller M, 2001, CANCER RES, V61, P2816; Esteller M, 2000, CANCER RES, V60, P129; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Ito H, 2001, CYTOGENET CELL GENET, V93, P36, DOI 10.1159/000056944; Kaneda A, 2002, CANCER RES, V62, P6645; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kim DH, 2003, CANCER RES, V63, P6206; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Morris MR, 2003, ONCOGENE, V22, P6794, DOI 10.1038/sj.onc.1206914; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Ramirez JL, 2003, CANCER LETT, V193, P207, DOI 10.1016/S0304-3835(02)00740-1; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; Schimanski CC, 1999, CANCER RES, V59, P5169; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Sparks AB, 1998, CANCER RES, V58, P1130; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Xing MZ, 2004, CANCER RES, V64, P1664, DOI 10.1158/0008-5472.CAN-03-3242; Zhu Kuichun, 2003, Curr Opin Investig Drugs, V4, P1428	37	45	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8695	8699		10.1038/sj.onc.1207914	http://dx.doi.org/10.1038/sj.onc.1207914			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15378027				2022-12-17	WOS:000224988800016
J	Zhang, AJ; Wang, JL; Zheng, BY; Fang, XL; Angstrom, T; Liu, C; Li, XD; Erlandsson, F; Bjorkholm, M; Nordenskjord, M; Gruber, A; Wallin, KL; Xu, DW				Zhang, AJ; Wang, JL; Zheng, BY; Fang, XL; Angstrom, T; Liu, C; Li, XD; Erlandsson, F; Bjorkholm, M; Nordenskjord, M; Gruber, A; Wallin, KL; Xu, DW			Telomere attrition predominantly occurs in precursor lesions during in vivo carcinogenic process of the uterine cervix	ONCOGENE			English	Article						cervical cancer; HPV; genomic instability; telomere erosion; telomerase	SQUAMOUS INTRAEPITHELIAL LESIONS; HUMAN-PAPILLOMAVIRUS TYPE-16; COMPARATIVE GENOMIC HYBRIDIZATION; REVERSE-TRANSCRIPTASE GENE; HTERT GENE; CHROMOSOME INSTABILITY; HUMAN CANCER; AMPLIFICATION; DYSFUNCTION; ACTIVATION	Although human papillomavirus (HPV) has been defined as the pathogen for cervical carcinomas, molecular events underlying the oncogenic process are unclear. As telomere dysfunction-mediated chromosomal instability and telomerase activation have been suggested as key events in carcinogenesis, we dissected the dynamic changes in telomere length, checkpoint response, and temporal pro. le of telomerase expression during the evolution from precursor lesions ( cervical intraepithelial neoplasia, CINs) to invasive cancers of the uterine cervix in sequential samples from 16 patients. Telomeres were significantly shortened in all CIN samples and no further substantial attritions occurred in most cases with the acquisition of malignant phenotype. Very short telomeres were coupled with constitutive activation of the DNA damage response pathway (Chk2 phosphorylation) and increased cellular proliferation in those cervical specimens. Telomerase reverse transcriptase ( hTERT) expression was preferably induced at advanced CINs or invasive cancers. The present finding demonstrates that excessive telomere shortening predominantly occurs in the early carcinogenesis of the uterine cervix largely prior to telomerase activation. Widespread over-erosion of telomeres or telomere dysfunction in very early stages of cervical tumorigenesis might fuel transformation processes by driving chromosomal instability.	Karolinska Univ Hosp, Karolinska Inst, Dept Mol Med, CMM, SE-17176 Stockholm, Sweden; Univ Umea Hosp, Cytol Lab, SE-90187 Umea, Sweden; Karolinska Univ Hosp, Karolinska Inst, Dept Med, Div Hematol, SE-17176 Stockholm, Sweden; Karolinska Univ Hosp, Karolinska Inst, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Peking Univ, Peoples Hosp, Dept Gynecol, Beijing 100083, Peoples R China; Shandong Univ, Qilu Hosp, Dept Urol, Jinan 250108, Peoples R China; Karolinska Univ Hosp, Karolinska Inst, Dept Urol, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Umea University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Peking University; Shandong University; Karolinska Institutet; Karolinska University Hospital	Wallin, KL (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Dept Mol Med, CMM, SE-17176 Stockholm, Sweden.	Keng-Ling.Wallin@cmm.ki.se; Dawei.Xu@cmm.ki.se		Xu, Dawei/0000-0003-3141-4524; Wang, Jianliu/0000-0003-0338-0427				Anderson S, 1997, AM J PATHOL, V151, P25; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Aubele M, 1998, CANCER CYTOPATHOL, V84, P375, DOI 10.1002/(SICI)1097-0142(19981225)84:6<375::AID-CNCR10>3.0.CO;2-1; Burd EM, 2003, CLIN MICROBIOL REV, V16, P1, DOI 10.1128/CMR.16.1.1-17.2003; Chang S, 2001, SEMIN CANCER BIOL, V11, P227, DOI 10.1006/scbi.2000.0374; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; der-Sarkissian H, 2004, ONCOGENE, V23, P1221, DOI 10.1038/sj.onc.1207152; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Evans MF, 1998, ONCOGENE, V16, P2557, DOI 10.1038/sj.onc.1202039; FAGAGNA FF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; Fehrmann F, 2003, ONCOGENE, V22, P5201, DOI 10.1038/sj.onc.1206554; Ferber MJ, 2003, ONCOGENE, V22, P3813, DOI 10.1038/sj.onc.1206528; Giannoudis A, 2000, BRIT J CANCER, V82, P424, DOI 10.1054/bjoc.1999.0937; Hackett JA, 2002, ONCOGENE, V21, P619, DOI 10.1038/sj.onc.1205061; Hahn WC, 2003, J CLIN ONCOL, V21, P2034, DOI 10.1200/JCO.2003.06.018; Heselmeyer-Haddad K, 2003, AM J PATHOL, V163, P1405, DOI 10.1016/S0002-9440(10)63498-0; Jarboe EA, 2002, ONCOGENE, V21, P664, DOI 10.1038/sj.onc.1205073; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kyo S, 1997, CANCER RES, V57, P1863; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; McMurray HR, 2003, J VIROL, V77, P9852, DOI 10.1128/JVI.77.18.9852-9861.2003; Meeker AK, 2002, CANCER RES, V62, P6405; O'Hagan RC, 2002, CANCER CELL, V2, P149, DOI 10.1016/S1535-6108(02)00094-6; Oh H, 2003, P NATL ACAD SCI USA, V100, P5378, DOI 10.1073/pnas.0836098100; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Pihan GA, 2003, CANCER RES, V63, P1398; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Snijders PJF, 1998, CANCER RES, V58, P3812; Southern SA, 1997, CANCER RES, V57, P4210; Takakura M, 1998, CANCER RES, V58, P1558; Umayahara K, 2002, GENE CHROMOSOME CANC, V33, P98, DOI 10.1002/gcc.1215; van Heek NT, 2002, AM J PATHOL, V161, P1541, DOI 10.1016/S0002-9440(10)64432-X; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Vukovic B, 2003, ONCOGENE, V22, P1978, DOI 10.1038/sj.onc.1206227; Zhang AJ, 2002, GENE CHROMOSOME CANC, V34, P269, DOI 10.1002/gcc.10071; Zhang AJ, 2000, CANCER RES, V60, P6230; Zhang AJ, 2003, AM J HUM GENET, V72, P940, DOI 10.1086/374565; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	40	45	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7441	7447		10.1038/sj.onc.1207527	http://dx.doi.org/10.1038/sj.onc.1207527			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15318175				2022-12-17	WOS:000224021400015
J	Wotton, SF; Blyth, K; Kilbey, A; Jenkins, A; Terry, A; Bernardin-Fried, F; Friedman, AD; Baxter, EW; Neil, JC; Cameron, ER				Wotton, SF; Blyth, K; Kilbey, A; Jenkins, A; Terry, A; Bernardin-Fried, F; Friedman, AD; Baxter, EW; Neil, JC; Cameron, ER			RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53	ONCOGENE			English	Article						RUNX1; oncogene; MEF; p53; TGF beta	ACUTE LYMPHOBLASTIC-LEUKEMIA; DOMAIN TRANSCRIPTION FACTOR; T(8/21) FUSION PROTEIN; ACUTE MYELOID-LEUKEMIA; GROWTH-FACTOR BETA-1; T-CELL DEVELOPMENT; TGF-BETA; OSTEOBLAST DIFFERENTIATION; NEOPLASTIC TRANSFORMATION; NIH3T3 CELLS	The mammalian Runx gene family (Runx1-3) are transcription factors that play essential, lineage-specific roles in development. A growing body of evidence implicates these genes as mutational targets in cancer where, in different contexts, individual family members have been reported to act as tumour suppressors, dominant oncogenes or mediators of metastasis. We are exploring these paradoxical observations by ectopic expression of RUNX genes in primary murine embryonic fibroblasts where, in common with a number of other dominant oncogenes, RUNX1 induces senescence-like growth arrest in the presence of an intact p19(ARF)-p53 pathway. We now report that, in MEFs lacking functional p53, RUNX1 has apparently prooncogenic effects on cell growth that include cytoskeletal reorganization, reduced contact inhibition at confluence and accelerated tumour expansion in vivo. On the other hand, RUNX1 conferred no obvious growth advantage at low cell density and actually delayed entry of primary MEFs into S phase. We also found that ectopic RUNX1 interferes with the morphological and growth responses of p53-null MEFs to TGFbeta indicating that these effects are mediated by overlapping pathways. These observations help to elucidate the context-dependent consequences of loss and gain of Runx activity.	Univ Glasgow, Mol Oncol Lab, Inst Comparat Med, Fac Vet Med, Glasgow G61 1QH, Lanark, Scotland; Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21231 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	University of Glasgow; Johns Hopkins University; Fred Hutchinson Cancer Center	Wotton, SF (corresponding author), Univ Glasgow, Mol Oncol Lab, Inst Comparat Med, Fac Vet Med, Bearsdon Rd, Glasgow G61 1QH, Lanark, Scotland.	S.Wotton@vet.gla.ac.uk		Blyth, Karen/0000-0002-9304-439X				Bae SC, 2001, J BONE JOINT SURG AM, V83A, pS48; Baxter EW, 2001, J VIROL, V75, P9790, DOI 10.1128/JVI.75.20.9790-9798.2001; Bernardin F, 2002, ONCOGENE, V21, P3247, DOI 10.1038/sj.onc.1205447; Blyth K, 2001, ONCOGENE, V20, P295, DOI 10.1038/sj.onc.1204090; Blyth K, 2000, ONCOGENE, V19, P773, DOI 10.1038/sj.onc.1203321; Brubaker KD, 2003, PROSTATE, V56, P13, DOI 10.1002/pros.10233; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; Chow M, 2000, P NATL ACAD SCI USA, V97, P174, DOI 10.1073/pnas.97.1.174; Chow M, 2000, CANCER RES, V60, P6510; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Dal Cin P, 2001, GENE CHROMOSOME CANC, V30, P407, DOI 10.1002/1098-2264(2001)9999:9999<::AID-GCC1107>3.0.CO;2-C; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Frank R, 1995, ONCOGENE, V11, P2667; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Harewood L, 2003, LEUKEMIA, V17, P547, DOI 10.1038/sj.leu.2402849; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; Kurokawa M, 1996, ONCOGENE, V12, P883; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Mikhail FM, 2002, LEUKEMIA, V16, P658, DOI 10.1038/sj.leu.2402399; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moustakas A, 1999, J CELL SCI, V112, P1169; Nelson PJ, 2002, KIDNEY INT S1, V61, P99, DOI DOI 10.1046/J.1523-1755.2002.0610S1099.X; Niini T, 2000, HAEMATOLOGICA, V85, P362; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Sakamoto Y, 1999, CANCER LETT, V136, P159, DOI 10.1016/S0304-3835(98)00318-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Sun LX, 2001, CANCER RES, V61, P4994; Vaillant F, 2002, J IMMUNOL, V169, P2866, DOI 10.4049/jimmunol.169.6.2866; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wotton S, 2002, CANCER RES, V62, P7181; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yeung F, 2002, J BIOL CHEM, V277, P2468, DOI 10.1074/jbc.M105947200; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	52	45	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2004	23	32					5476	5486		10.1038/sj.onc.1207729	http://dx.doi.org/10.1038/sj.onc.1207729			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15133495				2022-12-17	WOS:000222588400007
J	Kaeser, MD; Iggo, RD				Kaeser, MD; Iggo, RD			Promoter-specific p53-dependent histone acetylation following DNA damage	ONCOGENE			English	Article						chromatin immunoprecipitation; p53; p21; MDM2; PUMA; histone acetyltransferase	CELL-CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; CANCER CELLS; P53 PROTEIN; BINDING; EXPRESSION; COMPLEX; GENE; PHOSPHORYLATION	We have used chromatin immunoprecipitation (ChIP) to measure p53-dependent histone acetylation at the p21, MDM2, and PUMA promoters. The pattern of histone acetylation was different at each promoter. H3 and H4 acetylation increased at both the p21 and PUMA promoters in response to p53 activation, whereas there was only a minimal increase in H4 acetylation and no increase in H3 acetylation at the MDM2 promoter. The high p53 occupancy of the p21, MDM2 and PUMA promoters has been attributed to the presence of two p53 binding sites in these promoters, but mutation of the p53 binding sites in integrated p21 promoter constructs showed that the two sites in the p21 promoter do not cooperate to stabilize p53 binding. Despite 10-fold higher p53 binding to the proximal than the distal site in the p21 promoter, both sites showed similar patterns of H3 and H4 acetylation. Mutation of the binding sites showed that acetylation of the proximal, low-affinity site requires p53 binding to that site but not to the distal, high-affinity site. Since low-affinity p53 binding sites can confer strong acetylation, the DNA binding affinity in vitro is an unreliable guide to the likely importance of p53 in regulating candidate target genes in vivo.	Swiss Inst Expt Canc Res, Oncogene Grp, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Iggo, RD (corresponding author), Swiss Inst Expt Canc Res, Oncogene Grp, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.	richard.iggo@isrec.unil.ch	Iggo, Richard/G-3546-2014	Kaeser, Matthias/0000-0003-0050-9408				Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; ANDERSON CW, 2003, HDB CELL SIGNALING, V3, P237; Ard PG, 2002, MOL CELL BIOL, V22, P5650, DOI 10.1128/MCB.22.16.5650-5661.2002; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jackson P, 1998, ONCOGENE, V16, P283, DOI 10.1038/sj.onc.1201491; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Klein C, 2001, J BIOL CHEM, V276, P49020, DOI 10.1074/jbc.M107516200; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Winkler GS, 2002, P NATL ACAD SCI USA, V99, P3517, DOI 10.1073/pnas.022042899; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; Zhao RB, 2000, GENE DEV, V14, P981; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	41	45	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					4007	4013		10.1038/sj.onc.1207536	http://dx.doi.org/10.1038/sj.onc.1207536			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15007388	Bronze			2022-12-17	WOS:000221382000013
J	Chauhan, D; Li, GL; Hideshima, T; Podar, K; Shringarpure, R; Mitsiades, C; Munshi, N; Yew, PR; Anderson, KC				Chauhan, D; Li, GL; Hideshima, T; Podar, K; Shringarpure, R; Mitsiades, C; Munshi, N; Yew, PR; Anderson, KC			Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341	ONCOGENE			English	Article						Bortezomib/PS-341; multiple myeloma; apoptosis; 2-Methoxyestradiol; dexamethasone	MULTIPLE-MYELOMA; INDUCED APOPTOSIS; POLY(ADP-RIBOSE) POLYMERASE; OLIGONUCLEOTIDE ARRAYS; MITOCHONDRIAL PROTEIN; DRUG-RESISTANCE; CELL-CYCLE; MM CELLS; INTERLEUKIN-6; DEXAMETHASONE	The ubiquitin-conjugating enzyme CDC34 (UBC3) is linked to cell cycle progression in diverse cell types; however, its role in multiple myeloma ( MM) pathogenesis is unclear. Here, we show that CDC34 is highly expressed in patient MM cells and MM cell lines versus normal cells. Blocking CDC34 using a dominant-negative strategy enhances the anti-MM activity of Bortezomib/ Proteasome inhibitor PS-341, dexamethasone (Dex) and 2-Methoxyestradiol (2ME2). The expression of wild-type CDC34 reduces Dex-induced cytotoxicity in MM cells. Moreover, inhibition of CDC34 enzymatic activity abrogates interleukin-6-induced protection against Dex-induced apoptosis. Together, these findings provide evidence that ( 1) CDC34 expression is associated with growth and survival of MM cells and ( 2) blocking CDC34 activity not only enhances anti-MM activity of Bortezomib and 2ME2 but also overcomes IL-6-triggered Dex-resistance.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Texas System; University of Texas Health San Antonio	Anderson, KC (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Munshi, Nikhil/ABE-2338-2021; Podar, Klaus/ABD-1112-2020	Podar, Klaus/0000-0002-7414-3632	NCI NIH HHS [R01 CA50947, P01 CA 78373, IP50 CA 10070] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Block K, 2001, J BIOL CHEM, V276, P41049, DOI 10.1074/jbc.M106453200; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 2003, BLOOD, V102, P3379, DOI 10.1182/blood-2003-05-1417; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chauhan D, 2003, BLOOD, V101, P3606, DOI 10.1182/blood-2002-10-3146; Chauhan D, 2002, BLOOD, V100, P2187, DOI 10.1182/blood-2002-02-0376; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Chen YH, 1996, BLOOD, V87, P314, DOI 10.1182/blood.V87.1.314.bloodjournal871314; De Vos J, 2002, ONCOGENE, V21, P6848, DOI 10.1038/sj.onc.1205868; DESNOYERS S, 1994, ANAL BIOCHEM, V218, P470, DOI 10.1006/abio.1994.1212; Eliseeva E, 2001, CELL GROWTH DIFFER, V12, P427; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HARDIN J, 1994, BLOOD, V84, P3063; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hwang GW, 2002, FASEB J, V16, P709, DOI 10.1096/fj.01-0899fje; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Li YZ, 1999, MOL MED, V5, P232, DOI 10.1007/BF03402120; MOALLI PA, 1992, BLOOD, V79, P213; Rowley M, 2000, BLOOD, V96, P3175, DOI 10.1182/blood.V96.9.3175.h8003175_3175_3180; Tanaka K, 2001, BBA-MOL BASIS DIS, V1536, P1, DOI 10.1016/S0925-4439(01)00026-6; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672	25	45	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3597	3602		10.1038/sj.onc.1207458	http://dx.doi.org/10.1038/sj.onc.1207458			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15094775				2022-12-17	WOS:000221101700011
J	Yan, J; Yu, YL; Wang, N; Chang, YC; Ying, H; Liu, WZ; He, J; Li, SQ; Jiang, WL; Li, YL; Liu, HM; Wang, HY; Xu, YH				Yan, J; Yu, YL; Wang, N; Chang, YC; Ying, H; Liu, WZ; He, J; Li, SQ; Jiang, WL; Li, YL; Liu, HM; Wang, HY; Xu, YH			LFIRE-1/HFREP-1, a liver-specific gene, is frequently downregulated and has growth suppressor activity in hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma (HCC); 8p22; fibrinogen-related domain; liver-specific expression; differentiation	CANCER EPIGENETICS; CHROMOSOME 8P; CLONING; PROGRESSION; STAGE; ARM	We have previously identified several novel genes, which are differentially expressed among human normal liver and hepatocellular carcinomas (HCCs). The full-length liver fibrinogen-related gene-1 (LFIRE-1) cDNA was cloned from the human normal liver cDNA library. LFIRE-1 is highly homologous to HFREP-1 with discrepancy at 50 untranslated region (UTR) and encodes the same fibrinogen-related protein, which suggest that these two sequences might be alternative splicing forms of the same gene, LFIRE-1/HFREP-1, located at human chromosome 8p22. The LFIRE-1 and HFREP-1 are specifically expressed in normal human liver tissue, but reduced or undetectable in most of HCC specimens at both RNA and protein level. Furthermore, the reduction or nonexpression of LFIRE-1/HFREP-1 is significantly associated with the degree of tumor differentiation. Loss of heterozygosity (LOH) analysis revealed allelic loss of LFIRE-1/HFREP-1 on chromosome 8p22 in 57.1% (24/42) of HCC specimens. We detected three inactivation mutations among 45 cases of HCC specimens examined, two of which lost the remaining allele and the third had a replacement of conserved cysteine residue with glycine residue. Notably, the downregulation of LFIRE-1/HFREP-1 expression is frequently associated with allelic loss. The reduction of LFIRE-1/HFREP-1 expression by antisense approach enhances cancer cell proliferation and colony formation in soft agar. Moreover, restoration of exogenous wild-type LFIRE-1/HFREP-1 expression but not LFIRE-1/HFREP-1 missense mutations in human HCC cells inhibited their anchorage-dependent or independent growth in vitro, and suppressed their tumorigenicity in nude mice. In conclusion, our data demonstrated that liver-specific gene LFIRE-1/HFREP-1 was frequently downregulated and might possess growth suppressor activity in HCC.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Lab Mol & Cellular Oncol, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China; Second Mil Med Univ, Changzheng Hosp, Shanghai, Peoples R China; Eastern Hepatobiliary Surg Hosp, Int Cooperat Lab Signal Transduct, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Naval Medical University; Naval Medical University	Xu, YH (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Lab Mol & Cellular Oncol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	yhxu@sunm.shcnc.ac.cn	Yan, Jun/Q-3031-2017	Yan, Jun/0000-0002-1303-1952				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Chan KL, 2002, CANCER, V94, P3179, DOI 10.1002/cncr.10612; Chang Y C, 2001, Shi Yan Sheng Wu Xue Bao, V34, P319; CHEN CJ, 1997, J GASTROEN HEPATOL, V12, P294; CHEN R, 1980, SCI SINICA, V23, P236; COLOMBO M, 1992, J HEPATOL, V15, P225, DOI 10.1016/0168-8278(92)90041-M; EMI M, 1993, GENE CHROMOSOME CANC, V7, P152, DOI 10.1002/gcc.2870070307; FARRELL DH, 1994, J BIOL CHEM, V269, P226; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Feinberg AP, 2001, P NATL ACAD SCI USA, V98, P392, DOI 10.1073/pnas.98.2.392; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HAYDON GH, 1995, BRIT J HOSP MED, V53, P74; Hermann S, 2001, INT J CANCER, V92, P805, DOI 10.1002/ijc.1284; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KUROKI T, 1995, GENE CHROMOSOME CANC, V13, P163, DOI 10.1002/gcc.2870130305; Mironov AA, 1999, GENOME RES, V9, P1288, DOI 10.1101/gr.9.12.1288; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Nagai H, 1998, HEPATITIS B VIRUS, P182; Pineau P, 1999, ONCOGENE, V18, P3127, DOI 10.1038/sj.onc.1202648; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; Qiang S, 1997, INT J ARTIF ORGANS, V20, P119, DOI 10.1177/039139889702000213; Qin LX, 1999, CANCER RES, V59, P5662; Sherman M, 1995, Gastroenterologist, V3, P55; YAMAMOTO T, 1993, BIOCHEM BIOPH RES CO, V193, P681, DOI 10.1006/bbrc.1993.1678; Yan J, 2002, CELL RES, V12, P353, DOI 10.1038/sj.cr.7290137; Ying H, 2001, ONCOL RES, V12, P485, DOI 10.3727/096504001108747495; Ying H, 2001, BIOCHEM BIOPH RES CO, V286, P394, DOI 10.1006/bbrc.2001.5390; ZHU H, 1981, ZHONGHUA ZHONGLIU ZA, V3, P241	32	45	49	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1939	1949		10.1038/sj.onc.1207306	http://dx.doi.org/10.1038/sj.onc.1207306			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14981537				2022-12-17	WOS:000220129500016
J	Kim, M; Tezuka, T; Tanaka, K; Yamamoto, T				Kim, M; Tezuka, T; Tanaka, K; Yamamoto, T			Cbl-c suppresses v-Src-induced transformation through ubiquitin-dependent protein degradation	ONCOGENE			English	Article						Cbl family; v-Src; transformation; ubiquitination	MEDIATED TYROSINE PHOSPHORYLATION; D-ASPARTATE RECEPTOR; DOWN-REGULATION; NEGATIVE REGULATOR; LIGASE ACTIVITY; KINASE; ACTIVATION; ZAP-70; CELLS; PROLIFERATION	The Cbl family proteins Cbl, Cbl- b, and Cbl-c/Cbl-3 are thought to regulate signaling through protein-tyrosine kinases, positively as scaffold proteins and negatively as ubiquitin ligases. However, the precise signaling pathways and target proteins for each Cbl family member are not well understood. Here we show that Src is a preferential target of Cbl- c for degradation. Although exogenous expression of all Cbl family proteins suppressed the anchorage-independent growth of v-Src-transformed NIH3T3 cells, only Cbl- c caused reversion of the refractile morphology. The level of v-Src protein was reduced by Cbl- c, possibly through a lysosome-dependent pathway. The TKB domain and RING finger of Cbl- c were important for its antioncogenic activity. Wild-type Cbl- c promoted ubiquitination of Src in 293T cells, whereas a RING finger mutant did not. Cbl- c bound specifically to Src phosphorylated at Tyr419. Furthermore, Cbl- c together with UbcH5 induced ubiquitination of Src in vitro. Importantly, the Tyr419 nonphosphorylated form of Src was not ubiquitinated by Cbl- c. Therefore, activated Src may be a direct target of Cbl- c in vivo. Our results suggest that Cbl and Cbl- b suppress v-Src-induced transformation through mechanisms distinct from that of Cbl- c.	Univ Tokyo, Inst Med Sci, Div Oncol, Dept Canc Biol,Minato Ku, Tokyo 1088639, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138613, Japan	University of Tokyo; Tokyo Metropolitan Institute of Medical Science	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Oncol, Dept Canc Biol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp		Kim, Minsoo/0000-0001-8536-8653				Astarie-Dequeker C, 2002, J CELL SCI, V115, P81; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Howlett CJ, 2002, ONCOGENE, V21, P1707, DOI 10.1038/sj.onc.1205228; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; ODAJIMA J, 2000, J BIOL CHEM, V11, P11; Panigada M, 2002, J EXP MED, V195, P1585, DOI 10.1084/jem.20020047; Paolini R, 2001, P NATL ACAD SCI USA, V98, P9611, DOI 10.1073/pnas.161298098; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yasuda T, 2002, J EXP MED, V196, P51, DOI 10.1084/jem.20020068; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200	33	45	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1645	1655		10.1038/sj.onc.1207298	http://dx.doi.org/10.1038/sj.onc.1207298			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14661060				2022-12-17	WOS:000220029300001
J	Langley, B; Thomas, M; McFarlane, C; Gilmour, S; Sharma, M; Kambadur, R				Langley, B; Thomas, M; McFarlane, C; Gilmour, S; Sharma, M; Kambadur, R			Myostatin inhibits rhabdomyosarcoma cell proliferation through an Rb-independent pathway	ONCOGENE			English	Article						myostatin; NPAT; rhabdomyosarcoma; retinoblastoma; histone	TRANSFORMING-GROWTH-FACTOR; HISTONE GENE-TRANSCRIPTION; CYCLIN-DEPENDENT KINASES; PAX3-FKHR FUSION PROTEIN; BETA SUPERFAMILY MEMBER; ALVEOLAR RHABDOMYOSARCOMA; EMBRYONAL RHABDOMYOSARCOMA; MUSCLE GROWTH; MYOD FAMILY; S-PHASE	Rhabdomyosarcoma (RMS) tumors are the most common soft-tissue sarcomas in childhood. In this investigation, we show that myostatin, a skeletal muscle-specific inhibitor of growth and differentiation is expressed and translated in the cultured RMS cell line, RD. The addition of exogenous recombinant myostatin inhibits the proliferation of RD cells cultured in growth media, consistent with the role of myostatin in normal myoblast proliferation inhibition. However, unlike normal myoblasts, upregulation of p21 was not observed. Rather, myostatin signalling resulted in the specific downregulation of both Cdk2 and its cognate partner, cyclin-E. The analysis of Rb reveals that there was no change in its phosphorylation status with myostatin treatment, consistent with D-type-cyclin-Cdk4/6 complexes being active in the absence of p21. Moreover, the activity of Rb appeared to be unchanged between treated and nontreated RD cells, as determined by the ability of Rb to bind E2F1. The examination of NPAT, a substrate of cyclin-E-Cdk2 involved in the transcriptional activation of replication-dependent histone gene expression, revealed that it undergoes a loss of phosphorylation with myostatin treatment. Supporting this, a downregulation in H4-histone gene expression was observed. These results suggest that myostatin could potentially be used as an inhibitor of RMS proliferation and define a previously uncharacterized, Rb-independent mechanism for the inhibition of muscle precursor cell proliferation by myostatin.	AgRes, Anim Genom, Hamilton, New Zealand; Univ Auckland, Fac Med & Hlth Sci, Auckland 1, New Zealand	AgResearch - New Zealand; University of Auckland	Kambadur, R (corresponding author), AgRes, Anim Genom, Private Bag 3123,East St, Hamilton, New Zealand.	Ravi.Kambadur@agresearch.co.nz	McFarlane, Craig/R-2968-2019; Langley, Brett C/P-7207-2017	McFarlane, Craig/0000-0002-7056-8887; Langley, Brett C/0000-0003-4009-2109				AGUANNO S, 1990, CANCER RES, V50, P3377; Albig W, 1997, HUM GENET, V101, P284, DOI 10.1007/s004390050630; Arthur PF, 1995, AUST J AGR RES, V46, P1493, DOI 10.1071/AR9951493; BENNICELLI JL, 1995, ONCOGENE, V11, P119; Bouche M, 2000, FASEB J, V14, P1147, DOI 10.1096/fasebj.14.9.1147; BOUCHE M, 1993, EXP CELL RES, V208, P209, DOI 10.1006/excr.1993.1239; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; Dagher R, 1999, Oncologist, V4, P34; DAVIS RJ, 1994, CANCER RES, V54, P2869; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Ewen ME, 2000, GENE DEV, V14, P2265, DOI 10.1101/gad.842100; Feinberg AP, 1999, CANCER RES, V59, p1743S; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Grobet L, 1998, MAMM GENOME, V9, P210, DOI 10.1007/s003359900727; HEINTZ N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P327, DOI 10.1016/0167-4781(91)90122-3; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; HOUGHTON JA, 1981, INT J CANCER, V28, P409, DOI 10.1002/ijc.2910280403; Hu XT, 2001, J HEMATOTH STEM CELL, V10, P67, DOI 10.1089/152581601750098255; Ji SQ, 1998, AM J PHYSIOL-REG I, V275, pR1265, DOI 10.1152/ajpregu.1998.275.4.R1265; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; Megeney LA, 1995, BIOCHEM CELL BIOL, V73, P723, DOI 10.1139/o95-080; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; NIGGLI FK, 1994, BRIT J CANCER, V69, P1106, DOI 10.1038/bjc.1994.217; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OLIVER MH, 1989, J CELL SCI, V92, P513; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.bi.60.070191.004143; Otten AD, 1997, CELL GROWTH DIFFER, V8, P1151; Owa T, 2001, CURR MED CHEM, V8, P1487, DOI 10.2174/0929867013371996; Pandita Ajay, 1999, Neoplasia (New York), V1, P262, DOI 10.1038/sj.neo.7900036; PAPPO AS, 1993, J CLIN ONCOL, V11, P1901, DOI 10.1200/JCO.1993.11.10.1901; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Puri PL, 2000, GENE DEV, V14, P574; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SHAPIRO DN, 1991, J CLIN ONCOL, V9, P159, DOI 10.1200/JCO.1991.9.1.159; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Sharma M, 1999, J CELL PHYSIOL, V180, P1; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEIN G S, 1992, Current Opinion in Cell Biology, V4, P166, DOI 10.1016/0955-0674(92)90028-B; Szabo G, 1998, MAMM GENOME, V9, P671, DOI 10.1007/s003359900843; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Thies RS, 2001, GROWTH FACTORS, V18, P251; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; Yang JZ, 2001, MOL REPROD DEV, V60, P351, DOI 10.1002/mrd.1097; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456; Zhu XL, 2000, FEBS LETT, V474, P71, DOI 10.1016/S0014-5793(00)01570-2	61	45	50	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					524	534		10.1038/sj.onc.1207144	http://dx.doi.org/10.1038/sj.onc.1207144			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724580				2022-12-17	WOS:000188098300023
J	Wu, YZ; Zhang, XP; Zehner, ZE				Wu, YZ; Zhang, XP; Zehner, ZE			c-Jun and the dominant-negative mutant, TAM67, induce vimentin gene expression by interacting with the activator Sp1	ONCOGENE			English	Article						c-Jun; coactivator; Sp1; vimentin; dominantnegative TAM67	CANCER CELL-LINES; NF-KAPPA-B; BREAST-CANCER; TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; TUMOR-CELLS; PROMOTER; OVEREXPRESSION; PHENOTYPE; MECHANISMS	Vimentin exhibits a complex pattern of developmental- and tissue-specific expression. Since it is aberrantly expressed in metastatic tumors, which have progressed through the epithelial-mesenchymal transition, it has been cited as a marker for tumor progression. Previous studies have indicated that the transcription factor activator protein (AP1) is important in tumor progression. The stable transformation of the MCF7 cell line with the oncogene c-Jun resulted in a cell line (MCF7Jun), which displayed a change in morphology, enhanced migratory and invasive properties, and metastatic behavior. Of the 21 genes whose expression levels were altered in the MCF7Jun cell line, the greatest change in expression occurred for the vimentin gene. Previously, tandem AP1 sites in the promoter were reported to be important for the serum and TPA inducibility of the vimentin gene. However, we find that the AP1 elements only contribute in part to c-Jun activation. Moreover, this activation can be duplicated in COS-1 or S2 cells by expression of c-Jun or TAM67, and is dependent only on the leucine-zipper region of c-Jun. Transient transfection analyses, electrophoretic mobility shift assays, DNA precipitation assays, and coimmunoprecipitation studies suggest that c-Jun is able to synergize with the activator protein Sp1 in binding to GC-box1 to enhance vimentin gene expression.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Zehner, ZE (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045422] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45422] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bakovic M, 2000, J LIPID RES, V41, P583; Blaine SA, 2001, J BIOL CHEM, V276, P42737, DOI 10.1074/jbc.M107773200; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chen JH, 1996, ONCOGENE, V13, P1667; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GILLES C, 1996, BREAST J, V2, P83; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Izmailova ES, 1999, GENE, V235, P69, DOI 10.1016/S0378-1119(99)00209-7; Izmailova ES, 1999, GENE, V230, P111, DOI 10.1016/S0378-1119(99)00046-3; Izmailova ES, 2000, J INTERF CYTOK RES, V20, P13, DOI 10.1089/107999000312694; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; LILIENBAUM A, 1993, J BIOL CHEM, V268, P2180; Melnikova IN, 2001, J BIOL CHEM, V276, P19040, DOI 10.1074/jbc.M010735200; Milde-Langosch K, 2001, BREAST CANCER RES TR, V67, P61, DOI 10.1023/A:1010623308275; Mitchell RA, 2000, SEMIN CANCER BIOL, V10, P359, DOI 10.1006/scbi.2000.0328; Rahmsdorf HJ, 1996, J MOL MED, V74, P725, DOI 10.1007/s001090050077; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; RITTLING SR, 1989, NUCLEIC ACIDS RES, V17, P1619, DOI 10.1093/nar/17.4.1619; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Schneider I, 1972, J EMBRYOL EXP MORPH, V27, P363; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SOMMERS CL, 1994, CELL GROWTH DIFFER, V5, P839; SOMMERS CL, 1989, CANCER RES, V49, P4258; STOVER DM, 1994, CANCER RES, V54, P3092; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wieczorek E, 2000, J BIOL CHEM, V275, P12879, DOI 10.1074/jbc.275.17.12879; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; ZHANG X, 2003, NUCLEIC ACIDS RES, V31, P1	33	45	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8891	8901		10.1038/sj.onc.1206898	http://dx.doi.org/10.1038/sj.onc.1206898			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654785				2022-12-17	WOS:000186982200010
J	Del Bufalo, D; Trisciuoglio, D; Scarsella, M; Zangemeister-Wittke, U; Zupi, G				Del Bufalo, D; Trisciuoglio, D; Scarsella, M; Zangemeister-Wittke, U; Zupi, G			Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity	ONCOGENE			English	Article						bcl-2; antisense oligonucleotides; vascular endothelial growth factor; angiogenesis; melanoma	GROWTH-FACTOR EXPRESSION; PROTEIN-KINASE-A; BCL-2 OVEREXPRESSION; CARCINOMA-CELLS; IN-VIVO; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; TYROSINE KINASE; FACTOR RECEPTOR; TUMOR-GROWTH	We have recently reported that bcl-2 overexpression and hypoxia synergistically interact to modulate vascular endothelial growth factor (VEGF) and in vivo angiogenesis in tumour cells through VEGF mRNA stabilization and hypoxia-inducible factor 1-mediated transcriptional activity. Bcl-2 antisense treatment has shown promising clinical results in patients with malignant melanoma. In the present study, we demonstrated that the bcl-2/bcl-xL bispecific antisense oligonucleotide 4625 inhibits bcl-2 expression and angiogenesis in two bcl-2 overexpressing clones derived from the M14 human melanoma cell line. The antiangiogenic effect was determined in in vitro and in vivo angiogenesis assays. In particular, a reduction of hypoxia-induced VEGF secretion was observed after 4625 treatment, and the conditioned medium (CM) of bcl-2 overexpressing clones treated with 4625 and exposed to hypoxic conditions resulted in decreased endothelial cell proliferation when compared to CM of untreated control cells. In addition, we found that CM of 4625 antisense-treated bcl-2 transfectants inhibited in vivo vessel formation in matrigel plugs implanted subcutaneously in C57/B16 mice. Our findings confirm that bcl-2 plays a crucial role in melanoma angiogenesis and demonstrate for the first time that downregulation of bcl-2 by antisense treatment has potential to inhibit angiogenesis independent of its effect on cell survival. The use of 4625 in cancer therapy is suggested as an approach to facilitate simultaneously tumour cell apoptosis and inhibit tumour angiogenesis.	Regina Elena Inst Canc Res, Expt Chemotherapy Lab, I-00158 Rome, Italy; Univ Zurich Hosp, Dept Oncol, CH-8091 Zurich, Switzerland	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Zurich; University Zurich Hospital	Zupi, G (corresponding author), Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Via Messi dOro 156, I-00158 Rome, Italy.	zupi@ifo.it	Del Bufalo, Donatella/AAC-1594-2021; trisciuoglio, daniela/AAL-4002-2021; trisciuoglio, Daniela/H-2131-2016; Del Bufalo, Donatella/K-8673-2016	Del Bufalo, Donatella/0000-0002-3148-6096; trisciuoglio, Daniela/0000-0002-7007-7914; Del Bufalo, Donatella/0000-0002-3148-6096; Scarsella, Marco/0000-0002-3386-9664				Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Biroccio A, 2000, FASEB J, V14, P652, DOI 10.1096/fasebj.14.5.652; Biroccio A, 1999, INT J CANCER, V82, P125, DOI 10.1002/(SICI)1097-0215(19990702)82:1<125::AID-IJC21>3.0.CO;2-Q; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Cristofanilli M, 2002, NAT REV DRUG DISCOV, V1, P415, DOI 10.1038/nrd819; Del Bufalo D, 2002, EUR J CANCER, V38, P2455, DOI 10.1016/S0959-8049(02)00391-X; Del Bufalo D, 2002, MOL PHARMACOL, V61, P524, DOI 10.1124/mol.61.3.524; Del Bufalo D, 2001, J CELL BIOCHEM, V83, P473, DOI 10.1002/jcb.1245; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; DelBufalo D, 1996, J CLIN INVEST, V98, P1165, DOI 10.1172/JCI118900; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Fernandez A, 2001, J NATL CANCER I, V93, P208, DOI 10.1093/jnci/93.3.208; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Folkman J, 2000, JNCI-J NATL CANCER I, V92, P94, DOI 10.1093/jnci/92.2.94; FOLKMAN J, 1986, CANCER RES, V46, P467; Fong TAT, 1999, CANCER RES, V59, P99; Gautschi O, 2001, J NATL CANCER I, V93, P463, DOI 10.1093/jnci/93.6.463; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Iervolino A, 2002, FASEB J, V16, P1453, DOI 10.1096/fj.02-0122fje; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Kinoshita M, 2001, INT J CANCER, V91, P322, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1064>3.0.CO;2-P; Klagsbrun M, 1999, CHEM BIOL, V6, pR217, DOI 10.1016/S1074-5521(99)80081-7; Koty PP, 2002, MOL CELL BIOCHEM, V234, P125, DOI 10.1023/A:1015932615769; McCarthy M, 2001, LANCET, V357, P1593, DOI 10.1016/S0140-6736(00)04782-6; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Moses MA, 1997, STEM CELLS, V15, P180, DOI 10.1002/stem.150180; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nam NH, 2003, CURR DRUG TARGETS, V4, P159, DOI 10.2174/1389450033346966; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; Nor JE, 2001, CANCER RES, V61, P2183; Olie RA, 2002, J INVEST DERMATOL, V118, P505, DOI 10.1046/j.0022-202x.2001.01677.x; Olie RA, 2002, BBA-GENE STRUCT EXPR, V1576, P101, DOI 10.1016/S0167-4781(02)00300-7; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Presta LG, 1997, CANCER RES, V57, P4593; Rak J, 2002, CANCER RES, V62, P1931; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Simoes-Wust AP, 2002, BREAST CANCER RES TR, V76, P157, DOI 10.1023/A:1020543004400; Tortora G, 2003, CLIN CANCER RES, V9, P1566; Tortora G, 2001, CLIN CANCER RES, V7, P2537; Wang JH, 2002, CANCER-AM CANCER SOC, V94, P2745, DOI 10.1002/cncr.10520; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; Zangemeister-Wittke U, 2000, CLIN CANCER RES, V6, P2547	46	45	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8441	8447		10.1038/sj.onc.1206999	http://dx.doi.org/10.1038/sj.onc.1206999			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627985				2022-12-17	WOS:000186650300008
J	Kim, E; Gunther, W; Yoshizato, K; Meissner, H; Zapf, S; Nusing, RM; Yamamoto, H; Van Meir, EG; Deppert, W; Giese, A				Kim, E; Gunther, W; Yoshizato, K; Meissner, H; Zapf, S; Nusing, RM; Yamamoto, H; Van Meir, EG; Deppert, W; Giese, A			Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1	ONCOGENE			English	Article						invasion genes; glioma; p53; ets-1; thromboxane synthase; transcription	HUMAN COLON-CANCER; GROWTH-FACTOR; CELL-GROWTH; PLASMINOGEN-ACTIVATOR; GLIOBLASTOMA CELLS; INDUCE APOPTOSIS; EPITHELIAL-CELLS; DOWN-REGULATION; BREAST-CANCER; HUMAN GLIOMAS	Cancer formation and progression is a complex process determined by several mechanisms that promote cell growth, invasiveness, neo-angiogenesis, and render neoplastic cells resistant to apoptosis. The tumor suppressor p53 and the proto-oncogenic factor ets-1 are important regulators of such mechanisms. While it is well established that p53 and ets-1 influence various aspects of cell behavior by regulating the transcription of specific genes, little is known about the functional relationship between these transcription factors. We found that the gene encoding thromboxane synthase (TXSA), which we recently identified as a factor promoting invasion and resistance to apoptosis in gliomas, is a novel target gene for both p53 and ets-1. We demonstrate that p53 and ets-1 coregulate TXSA in an antagonistic and interrelated manner, with ets-1 being a potent transcriptional activator and p53 inhibiting ets-1-dependent transcription. Negative interference with ets-1 transcription requires functional p53 and is lost in mutant p53 proteins. We show that ets-1 and p53 associate physically in vitro and in vivo and that their interaction, rather than a direct binding of p53 to the TXSA promoter, is required for transcriptional repression of TXSA by wild-type p53. An important implication of our findings is that the loss of p53-mediated negative control over ets-1-dependent transcription may lead to the acquisition of an invasive phenotype in tumor cells.	Univ Hosp Lubeck, Dept Neurosurg, D-23538 Lubeck, Germany; Univ Hosp Eppendorf, Dept Neurosurg, Hamburg, Germany; Univ Childrens Hosp, Ctr Sci Res, Marburg, Germany; Inst Neurosurg & Neurores, Chicago, IL USA; Emory Univ, Sch Med, Winship Canc Inst, Dept Neurosurg, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol Oncol, Atlanta, GA 30322 USA; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Dept Tumor Virol, D-2000 Hamburg, Germany	University of Lubeck; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Emory University; Emory University; Heinrich Pette Institute; University of Hamburg	Giese, A (corresponding author), Univ Hosp Lubeck, Dept Neurosurg, Ratzeburger Allee 160, D-23538 Lubeck, Germany.			Van Meir, Erwin G./0000-0003-2444-7707				Albertoni M, 1998, ONCOGENE, V16, P321, DOI 10.1038/sj.onc.1201544; Albertoni M, 2002, ONCOGENE, V21, P4212, DOI 10.1038/sj.onc.1205610; ANKER L, 1993, INT J CANCER, V55, P982, DOI 10.1002/ijc.2910550618; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; BENNETT A, 1986, PROG LIPID RES, V25, P539, DOI 10.1016/0163-7827(86)90109-8; BENNETT A, 1977, LANCET, V2, P624; BENNETT A, 1987, GUT, V28, P315, DOI 10.1136/gut.28.3.315; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; CASTELLI MG, 1989, CANCER RES, V49, P1505; Daniel TO, 1999, CANCER RES, V59, P4574; Deininger MH, 1999, ACTA NEUROPATHOL, V98, P240, DOI 10.1007/s004010051075; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fritsche M, 1998, MOL CELL ENDOCRINOL, V143, P143, DOI 10.1016/S0303-7207(98)00140-3; Giese A, 1999, Neuro Oncol, V1, P3, DOI 10.1093/neuonc/1.1.3; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; Gohler T, 2002, J BIOL CHEM, V277, P41192, DOI 10.1074/jbc.M202344200; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Hong TM, 2001, J BIOL CHEM, V276, P1510, DOI 10.1074/jbc.M008231200; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Jayaraman G, 1999, J BIOL CHEM, V274, P17869, DOI 10.1074/jbc.274.25.17869; Jiang Y, 2001, BIOCHEM BIOPH RES CO, V286, P1123, DOI 10.1006/bbrc.2001.5521; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kim E, 1999, ONCOGENE, V18, P7310, DOI 10.1038/sj.onc.1203139; Kim E, 2003, BIOCHEM CELL BIOL, V81, P141, DOI 10.1139/o03-046; Kita D, 2001, CANCER RES, V61, P7985; Kitange G, 2000, CANCER, V89, P2292, DOI 10.1002/1097-0142(20001201)89:11<2292::AID-CNCR18>3.0.CO;2-0; Kurzel F, 2002, ACTA NEUROCHIR, V144, P71, DOI 10.1007/s701-002-8276-9; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; McDonough W, 1998, J NEUROPATH EXP NEUR, V57, P449, DOI 10.1097/00005072-199805000-00008; MIYATA A, 1994, EUR J BIOCHEM, V224, P273, DOI 10.1111/j.1432-1033.1994.00273.x; Modugno M, 2002, ONCOGENE, V21, P7478, DOI 10.1038/sj.onc.1205957; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nakada M, 1999, J NEUROPATH EXP NEUR, V58, P329, DOI 10.1097/00005072-199904000-00003; Nie DT, 2000, BIOCHEM BIOPH RES CO, V267, P245, DOI 10.1006/bbrc.1999.1840; Pastorcic M, 2000, J BIOL CHEM, V275, P34938, DOI 10.1074/jbc.M005411200; Pica F, 1996, J PHARMACOL EXP THER, V277, P1793; Pradono P, 2002, CANCER RES, V62, P63; Reisdorff J, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015617.39974.FB; Ristimaki A, 1997, CANCER RES, V57, P1276; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; SANO H, 1995, CANCER RES, V55, P3785; Sato Y, 2001, ANN NY ACAD SCI, V947, P117; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Surette ME, 1999, CARCINOGENESIS, V20, P757, DOI 10.1093/carcin/20.5.757; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Valter MM, 1999, CANCER RES, V59, P5608; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang XJ, 1997, J RADIAT RES, V38, P179, DOI 10.1269/jrr.38.179; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Xu DK, 2002, EMBO J, V21, P4081, DOI 10.1093/emboj/cdf413; Yamamoto H, 2000, CANCER RES, V60, P134; Yoshizato K, 2002, NEUROSURGERY, V50, P343, DOI 10.1097/00006123-200202000-00021; ZHOU Y, 2002, J BIOL CHEM, V25, P25	70	45	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7716	7727		10.1038/sj.onc.1207155	http://dx.doi.org/10.1038/sj.onc.1207155			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586398				2022-12-17	WOS:000186240200002
J	Kasid, U; Dritschilo, A				Kasid, U; Dritschilo, A			RAF antisense oligonucleotide as a tumor radiosensitizer	ONCOGENE			English	Review						radioresistance; RAF-1; radiation response; antisense; liposomal oligonucleotide drug; in vivo potency; clinical relevance	ENDOTHELIAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; FACTOR-KAPPA-B; PHASE-I TRIAL; IONIZING-RADIATION; FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ISIS 5132; GENE-EXPRESSION	The RAF-1 serine-threonine kinase plays a central role in signal transduction pathways involved in cell survival and proliferation. The concept of RAF-1-targeted disruption of cell signaling for therapeutic purposes was first advanced in 1989 with the demonstration of tumor growth inhibition in athymic mice and radiosensitization of human squamous carcinoma cells transfected with a vector expressing antisense cDNA. However, the clinical application of antisense strategies has awaited the development of improved antisense oligonucleotide technologies and drug delivery methods. Nuclease-resistant phosphorothioated antisense oligonucleotides have been the focus of pharmaceutical industry attention. In vivo delivery of nuclease-sensitive, natural backbone/phosphodiester oligonucleotides has remained a formidable challenge. Liposomal encapsulation of antisense oligonucleotides protects them from degradation and enhances drug delivery. Here, we review the importance of targeting RAF-1 signaling in cancer therapy and the preclinical and clinical experiences with a liposomal formulation of a nuclease-sensitive, ends-modified antisense RAF oligonucleotide.	Georgetown Univ, Dept Radiat Med, Lombardi Canc Ctr, Med Ctr, Washington, DC 20007 USA	Georgetown University	Dritschilo, A (corresponding author), Georgetown Univ, Dept Radiat Med, Lombardi Canc Ctr, Med Ctr, E202,Res Bldg, Washington, DC 20007 USA.	dritscha@georgetown.edu			NCI NIH HHS [CA74175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal S, 1999, ANTISENSE NUCLEIC A, V9, P371; Agrawal S, 1996, TRENDS BIOTECHNOL, V14, P376, DOI 10.1016/0167-7799(96)10053-6; Aplin AE, 1998, PHARMACOL REV, V50, P197; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; AWADA A, 2001, P AACR NCI EORTC INT, P116; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; Bianco C, 2002, CLIN CANCER RES, V8, P3250; Broustas CG, 2002, J BIOL CHEM, V277, P3053, DOI 10.1074/jbc.M106343200; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; Cunningham CC, 2000, CLIN CANCER RES, V6, P1626; Dai Y, 2001, CANCER RES, V61, P5106; DAngelo G, 1997, J CELL BIOCHEM, V67, P353, DOI 10.1002/(SICI)1097-4644(19971201)67:3<353::AID-JCB7>3.3.CO;2-2; DEL PL, 1997, SCIENCE, V278, P687; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; DRITSCHILO A, 2002, P AN M AM SOC CLIN, V21, pA28; Dumaz N, 2002, MOL CELL BIOL, V22, P3717, DOI 10.1128/MCB.22.11.3717-3728.2002; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Fuhrmann G, 2001, ONCOGENE, V20, P4542, DOI 10.1038/sj.onc.1204499; Garcia-Chaumont C, 2000, PHARMACOL THERAPEUT, V87, P255, DOI 10.1016/S0163-7258(00)00062-0; Geng L, 2001, CANCER RES, V61, P2413; Gokhale PC, 2002, CLIN CANCER RES, V8, P3611; Gokhale PC, 1999, ANTISENSE NUCLEIC A, V9, P191, DOI 10.1089/oli.1.1999.9.191; Gokhale PC, 1997, GENE THER, V4, P1289, DOI 10.1038/sj.gt.3300543; Gorski DH, 1999, CANCER RES, V59, P3374; Grana TM, 2002, CANCER RES, V62, P4142; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Gupta AK, 2001, CANCER RES, V61, P4278; Gupta AK, 2002, CLIN CANCER RES, V8, P885; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; HALLAHAN DE, 1991, CANCER RES, V51, P4565; Henry SP, 1997, J PHARMACOL EXP THER, V281, P810; HOLMLUND J, 1998, P AN M AM SOC CLIN, V17, P811; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Huang SM, 1999, CANCER RES, V59, P1935; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Janosch P, 2000, FASEB J, V14, P2008, DOI 10.1096/fj.99-0883com; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KASID U, 1991, INT C RAD RES, V1, P242; Kasid Usha, 1998, P85; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; Khatib AM, 2002, CANCER RES, V62, P5393; Khodarev NN, 2001, P NATL ACAD SCI USA, V98, P12665, DOI 10.1073/pnas.211443698; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Koller E, 2000, TRENDS PHARMACOL SCI, V21, P142, DOI 10.1016/S0165-6147(00)01448-6; Kozin SV, 2001, CANCER RES, V61, P39; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lammering G, 2001, CLIN CANCER RES, V7, P682; Lau QC, 1998, ONCOGENE, V16, P1899, DOI 10.1038/sj.onc.1201709; Leonetti C, 2001, CANCER GENE THER, V8, P459, DOI 10.1038/sj.cgt.7700326; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; Meighan-Mantha RL, 1999, MOL CELL BIOCHEM, V199, P209, DOI 10.1023/A:1006958217143; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Milas L, 2000, CLIN CANCER RES, V6, P701; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; Monia BP, 2000, CANCER INVEST, V18, P635, DOI 10.3109/07357900009032830; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; Monteith DK, 1998, TOXICOL SCI, V46, P365, DOI 10.1093/toxsci/46.2.365; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586; O'Dwyer PJ, 1999, CLIN CANCER RES, V5, P3977; Pagnan G, 2000, J NATL CANCER I, V92, P253, DOI 10.1093/jnci/92.3.253; Pandey SK, 1999, BIOCHEMISTRY-US, V38, P14667, DOI 10.1021/bi9911886; Patel S, 1997, MOL MED, V3, P674, DOI 10.1007/BF03401706; PETERS LJ, 1982, INT J RADIAT ONCOL, V8, P101, DOI 10.1016/0360-3016(82)90392-3; Pfeifer A, 1998, BIOCHEM BIOPH RES CO, V252, P481, DOI 10.1006/bbrc.1998.9660; Pirollo KF, 1997, BIOCHEM BIOPH RES CO, V230, P196, DOI 10.1006/bbrc.1996.5922; PIROLLO KF, 1989, INT J RADIAT BIOL, V55, P783, DOI 10.1080/09553008914550831; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Poggi MM, 2001, CURR PROB CANCER, V25, P334, DOI 10.1067/mcn.2001.120122; Rasouli-Nia A, 1998, CLIN CANCER RES, V4, P1111; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rosenzweig KE, 1997, CLIN CANCER RES, V3, P1149; RUDIN C, 2002, P AN M AM SOC CLIN, V21, pB9; RUDIN C, 2001, P AN M AM SOC CLIN, V20, pA322; Rudin CM, 2001, CLIN CANCER RES, V7, P1214; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; SKORSKI T, 1995, CANCER RES, V55, P2275; Soldatenkov VA, 1997, CANCER J SCI AM, V3, P13; Stein CA, 2001, J CLIN INVEST, V108, P641, DOI 10.1172/JCI13885; Stevenson JP, 1999, J CLIN ONCOL, V17, P2227, DOI 10.1200/JCO.1999.17.7.2227; STRUMBERG D, 2001, P AN M AM SOC CLIN, V20, pA83; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Suy S, 1997, ONCOGENE, V15, P53, DOI 10.1038/sj.onc.1201165; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Tari AM, 1998, J LIPOSOME RES, V8, P251, DOI 10.3109/08982109809035530; Tenzer A, 2001, CANCER RES, V61, P8203; Tortora G, 2002, ANN NY ACAD SCI, V968, P139, DOI 10.1111/j.1749-6632.2002.tb04332.x; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; Veikkola T, 2000, CANCER RES, V60, P203; Virdee K, 2000, CURR BIOL, V10, P1151, DOI 10.1016/S0960-9822(00)00702-8; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; WEICHSELBAUM RR, 1991, J NATL CANCER I, V83, P480, DOI 10.1093/jnci/83.7.480; WEICHSELBAUM RR, 1988, INT J RADIAT ONCOL, V15, P575, DOI 10.1016/0360-3016(88)90297-0; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Xu XXS, 1998, J BIOL CHEM, V273, P33230, DOI 10.1074/jbc.273.50.33230; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; Zhong J, 2001, ONCOGENE, V20, P4807, DOI 10.1038/sj.onc.1204614; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	142	45	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5876	5884		10.1038/sj.onc.1206700	http://dx.doi.org/10.1038/sj.onc.1206700			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947394				2022-12-17	WOS:000185086100014
J	Zhong, SP; Goto, H; Inagaki, M; Dong, ZG				Zhong, SP; Goto, H; Inagaki, M; Dong, ZG			Phosphorylation at serine 28 and acetylation at lysine 9 of histone H3 induced by trichostatin A	ONCOGENE			English	Article						histone H3; trichostatin A; phosphorylation; acetylation; ultraviolet; MAP kinase	ACTIVATED PROTEIN-KINASE; MITOTIC CHROMOSOME CONDENSATION; B-INDUCED PHOSPHORYLATION; P38 MAP KINASE; GENE ACTIVATION; CYCLIC TETRAPEPTIDE; CHROMATIN STRUCTURE; IN-VITRO; DEACETYLASE; EXPRESSION	Trichostatin A (TSA), a histone deacetylase inhibitor, strongly increases acetylation of the N-terminal tails of histone H3. Many studies have correlated the function of TSA with the hyperacetylation of histone. Although histone H3 is known to be phosphorylated, the effect of acetylation on phosphorylation is not known. Here, we report that in JB6 cells, TSA induces both acetylation at lysine 9 and phosphorylation at serine 28 of histone H3. UVB irradiation, which is known to induce phosphorylation at serine 28, did not significantly affect phosphorylation of histone H3 in TSA-pretreated JB6 cells. In contrast, TSA markedly increased phosphorylation and acetylation of histone H3 in UVB-pretreated JB6 cells. TSA strongly activated MAP kinases. Moreover, PD98059 and SB202190 inhibited TSA-induced phosphorylation but not acetylation of histone H3. Dominant negative mutant ERK2 and dominant negative mutant p38 kinase blocked TSA-stimulated phosphorylation of histone H3 at serine 28. The results indicate that TSA-induced phosphorylation of histone H3 at serine 28 occurs through activation of the MAP kinase pathway and phosphorylated histone H3 is more sensitive to TSA-induced hyperacetylation. The facilitation of phosphorylation and acetylation of histone H3 induced by TSA may play a critical regulatory role in chromatin remodeling and gene expression.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Aichi Canc Ctr, Res Inst, Biochem Lab, Chikusa Ku, Aichi 4648681, Japan	University of Minnesota System; Aichi Cancer Center	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	Inagaki, Masaki/B-9920-2016	Goto, Hidemasa/0000-0002-6796-4467	NATIONAL CANCER INSTITUTE [R01CA077646, P01CA027502] Funding Source: NIH RePORTER; NCI NIH HHS [CA77646, CA27502] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chen WY, 2000, P NATL ACAD SCI USA, V97, P377, DOI 10.1073/pnas.97.1.377; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Dangond F, 1998, BIOCHEM BIOPH RES CO, V247, P833, DOI 10.1006/bbrc.1998.8891; Davie JR, 1999, J CELL BIOCHEM, P141; Davie JR, 1998, J CELL BIOCHEM, P203; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; HONDA BM, 1975, J BIOL CHEM, V250, P8681; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Medina V, 1997, CANCER RES, V57, P3697; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Salvador LM, 2001, J BIOL CHEM, V276, P40146, DOI 10.1074/jbc.M106710200; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; She QB, 2002, J BIOL CHEM, V277, P24039, DOI 10.1074/jbc.M109907200; Smalley KSM, 1999, BIOCHEM BIOPH RES CO, V263, P239, DOI 10.1006/bbrc.1999.1351; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200; Zhong SP, 2001, J BIOL CHEM, V276, P12932, DOI 10.1074/jbc.M010931200	49	45	46	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5291	5297		10.1038/sj.onc.1206507	http://dx.doi.org/10.1038/sj.onc.1206507			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917630				2022-12-17	WOS:000184734900008
J	Molton, SA; Todd, DE; Cook, SJ				Molton, SA; Todd, DE; Cook, SJ			Selective activation of the c-Jun N-terminal kinase (JNK) pathway fails to elicit Bax activation or apoptosis unless the phosphoinositide 3 '-kinase (PI3K) pathway is inhibited	ONCOGENE			English	Article						apoptosis; Bcl-2; JNK; MEKK1; PI3K; PKB	KAPPA-B KINASE; FORKHEAD TRANSCRIPTION FACTOR; PROGRAMMED CELL-DEATH; BCL-2 FAMILY MEMBER; PROTEIN-KINASE; FAS LIGAND; SIGNAL-TRANSDUCTION; MAP KINASES; MEK KINASE; NH2-TERMINAL KINASE	c-Jun N-terminal kinase (JNK) is activated when cells are exposed to noxious stimuli. The role of JNK in apoptosis is subject to considerable debate; for example, JNK activation may promote or inhibit apoptosis depending on the cell type and stimulus involved. These conflicting results have arisen in part because few studies have successfully separated JNK activation from the primary stress-induced damage or from other stress-induced signalling pathways. Here we describe a conditional mutant, DeltaMEKK1:ER*, which allows selective activation of the JNK cascade in the absence of any cellular stress. Activation of DeltaMEKK1:ER* in CC139 fibroblasts resulted in the rapid and sustained activation of JNK without activating ERK or p38 or promoting IkappaBalpha phosphorylation. Activation of AMEKK1:ER* caused a reversible halt in cell growth but failed to induce apoptosis. In contrast, treatment of cells with LY294002, to inhibit phosphoinositide 3-kinase (PI3K), caused downregulation of Bcl-2 and Mcl-1 and allowed AMEKK1:ER* to elicit a robust apoptotic response characterized by activation of Bax and caspases. This PI3K-inhibitable, JNK-induced death response was not impeded, but actually accelerated, by cycloheximide. This suggests that JNK-induced activation of Bax and cell death does not require the upregulation of pro-death genes such as Bim or FasL, but rather proceeds through preexisting components. However, if the PI3K cell survival pathway is not inhibited, even sustained activation of JNK exerts no overt proapoptotic effect in CC139 cells.	Babraham Inst, Signalling Programme, Inositide Lab, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Cook, SJ (corresponding author), Babraham Inst, Signalling Programme, Inositide Lab, Cambridge CB2 4AT, England.				Biotechnology and Biological Sciences Research Council [BBS/E/B/0000H457, BBS/E/B/0000C199] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ADLER V, 1992, J BIOL CHEM, V267, P17001; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Bonvin C, 2002, CELL SIGNAL, V14, P123, DOI 10.1016/S0898-6568(01)00219-4; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Garner AP, 2002, ONCOGENE, V21, P8089, DOI 10.1038/sj.onc.1206000; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Levresse V, 2000, J NEUROSCI RES, V62, P799; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Pinkoski MJ, 1999, CELL DEATH DIFFER, V6, P1174, DOI 10.1038/sj.cdd.4400611; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schubert KM, 2001, BIOCHEM J, V356, P473, DOI 10.1042/0264-6021:3560473; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; Torcia M, 2001, J BIOL CHEM, V276, P39027, DOI 10.1074/jbc.M102970200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; YAN MH, 1994, NATURE, V372, P798; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	62	45	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4690	4701		10.1038/sj.onc.1206692	http://dx.doi.org/10.1038/sj.onc.1206692			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879014				2022-12-17	WOS:000184157000010
J	Llorca, O; Rivera-Calzada, A; Grantham, J; Willison, KR				Llorca, O; Rivera-Calzada, A; Grantham, J; Willison, KR			Electron microscopy and 3D reconstructions reveal that human ATM kinase uses an arm-like domain to clamp around double-stranded DNA	ONCOGENE			English	Article						ATM; electron microscopy reconstruction; DNA repair	DEPENDENT PROTEIN-KINASE; CONFORMATIONAL-CHANGES; ATAXIA-TELANGIECTASIA; BREAST-CANCER; SUSCEPTIBILITY; PURIFICATION; MUTATIONS; BREAKS/; DAMAGE; SITES	The human tumor suppressor gene ataxia telangiectasia mutated (ATM) encodes a 3056 amino-acid protein kinase that regulates cell cycle checkpoints. ATM is defective in the neurodegenerative and cancer predisposition syndrome ataxia-telangiectasia. ATM protein kinase is activated by DNA damage and responds by phosphorylating downstream effectors involved in cell cycle arrest and DNA repair, such as p53, MDM2, CHEK2, BRCA1 and H2AX. ATM is probably a component of, or in close proximity to, the double-stranded DNA break-sensing machinery. We have observed purified human ATM protein, ATM-DNA and ATM-DNA-avidin bound complexes by single-particle electron microscopy and obtained three-dimensional reconstructions which show that ATM is composed of two main domains comprising a head and an arm. DNA binding to ATM induces a large conformational movement of the arm-like domain. Taken together, these three structures suggest that ATM is capable of interacting with DNA, using its arm to clamp around the double helix.	Canc Res UK, Canc Res Inst, Ctr Cell & Mol Biol, Chester Beatty Labs, London SW3 6JB, England; CSIC, Ctr Invest Biol, Madrid 28040, Spain	Cancer Research UK; University of London; Institute of Cancer Research - UK; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Willison, KR (corresponding author), Canc Res UK, Canc Res Inst, Ctr Cell & Mol Biol, Chester Beatty Labs, 237 Fulham Rd, London SW3 6JB, England.		Llorca, Oscar/K-1144-2014; Rivera-Calzada, Angel/K-3617-2014; Llorca, Oscar/P-2784-2019; Grantham, Julie/A-5002-2009	Llorca, Oscar/0000-0001-5705-0699; Rivera-Calzada, Angel/0000-0003-2472-5535; Llorca, Oscar/0000-0001-5705-0699; 				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chiu CY, 1998, J MOL BIOL, V284, P1075, DOI 10.1006/jmbi.1998.2212; Concannon P, 2002, NAT GENET, V32, P89, DOI 10.1038/ng0902-89; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Ellison V, 2001, CELL, V106, P655, DOI 10.1016/S0092-8674(01)00498-6; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Llorca O, 1999, NATURE, V402, P693, DOI 10.1038/45294; Llorca O, 2001, EMBO J, V20, P4065, DOI 10.1093/emboj/20.15.4065; Llorca O, 1997, J STRUCT BIOL, V118, P31, DOI 10.1006/jsbi.1996.3832; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Rhodes N, 2001, PROTEIN EXPRES PURIF, V22, P462, DOI 10.1006/prep.2001.1459; Rosano C, 1999, BIOMOL ENG, V16, P5, DOI 10.1016/S1050-3862(99)00047-9; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; Scott SP, 2002, P NATL ACAD SCI USA, V99, P925, DOI 10.1073/pnas.012329699; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Spring K, 2002, NAT GENET, V32, P185, DOI 10.1038/ng958; Stroud JC, 2002, NAT STRUCT BIOL, V9, P90, DOI 10.1038/nsb749; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; VanLoock MS, 2002, CURR BIOL, V12, P472, DOI 10.1016/S0960-9822(02)00696-6; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098	30	45	45	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3867	3874		10.1038/sj.onc.1206649	http://dx.doi.org/10.1038/sj.onc.1206649			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813460				2022-12-17	WOS:000183612000006
J	Teramoto, H; Malek, RL; Behbahani, B; Castellone, MD; Lee, NH; Gutkind, JS				Teramoto, H; Malek, RL; Behbahani, B; Castellone, MD; Lee, NH; Gutkind, JS			Identification of H-Ras, RhoA, Rac1 and Cdc42 responsive genes	ONCOGENE			English	Article						foci formation; small GTPases; microarray	GTP-BINDING PROTEINS; SIGNAL-TRANSDUCTION; CELLS; GTPASES; EXPRESSION; CANCER; TRANSFORMATION; TRANSCRIPTION; ACTIVATION; RECEPTOR	The superfamily of small GTP-binding proteins has expanded dramatically in recent years. The Ras family has long been associated with signaling pathways contributing to normal and aberrant cell growth, while Rho-related protein function is to integrate extracellular signals with specific targets regulating cell morphology, cell aggregation, tissue polarity, cell motility and cytokinesis. Recent findings suggest that certain Rho proteins, including RhoA, Rac1 and Cdc42, can also play a role in signal transduction to the nucleus and cell growth control. However, the nature of the genes regulated by Ras and Rho GTPases, as well as their contribution to their numerous biological effects is still largely unknown. To approach these questions, we investigated the global gene expression pattern induced by activated forms of H-Ras, RhoA, Rac1 and Cdc42 using cDNA microarrays comprising 19 117 unique elements. Using this approach, we identified 1184 genes that were up- or downregulated by at least twofold. Hierarchical cluster analysis revealed the existence of patterns of gene regulation both unique and common to H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL activation. For example, H-Ras V12 upregulated osteopontin and Akt 1, and H-Ras and RhoA stimulated cyclin G1, cyclin-dependent kinase 8, cyclin A2 and HMGI-C, while Rac1 QL and Cdc42 QL upregulated extracellular matrix and cell adhesion proteins such as alpha-actinin 4, procollagen type I and V and neuropilin. Furthermore, H-Ras V12 downregulated by >eightfold 52 genes compared to only three genes by RhoA QL, Rac1 QL and Cdc42 QL. These results provide key information to begin unraveling the complexity of the molecular mechanisms underlying the transforming potential of Ras and Rho proteins, as well as the numerous morphological and cell cycle effects induced by these small GTPases.	NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Inst Genom Res, Dept Funct Genom, Rockville, MD 20850 USA; George Washington Univ, Med Ctr, Dept Pharmacol, Washington, DC 20037 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); J. Craig Venter Institute; George Washington University	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, 9000 Rockville Pike,Bldg 30,Room 212, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BOS JL, 1989, CANCER RES, V49, P4682; Brenner KA, 2000, ONCOGENE, V19, P3156, DOI 10.1038/sj.onc.1203626; Chen H, 1998, NAT NEUROSCI, V1, P436, DOI 10.1038/2154; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Liu CT, 2000, J BIOL CHEM, V275, P20315, DOI 10.1074/jbc.M909046199; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PERONA R, 1993, ONCOGENE, V8, P1285; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Prasad MVVSV, 1999, ONCOGENE, V18, P1639, DOI 10.1038/sj.onc.1202461; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; YANG IV, 2002, GENOME BIOL, V3; Zentner MD, 2001, J BIOL CHEM, V276, P29805, DOI 10.1074/jbc.M103153200; Zhang J, 2001, CANCER LETT, V171, P215, DOI 10.1016/S0304-3835(01)00607-3	27	45	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2689	2697		10.1038/sj.onc.1206364	http://dx.doi.org/10.1038/sj.onc.1206364			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730683				2022-12-17	WOS:000182569000017
J	Kamiguti, AS; Harris, RJ; Slupsky, JR; Baker, PK; Cawley, JC; Zuzel, M				Kamiguti, AS; Harris, RJ; Slupsky, JR; Baker, PK; Cawley, JC; Zuzel, M			Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways	ONCOGENE			English	Article						cell survival; hairy-cell leukemia; MAPK; PKC; Src	P38 MAP KINASE; GROWTH-FACTOR; RAF-1; APOPTOSIS; LEUKEMIA; PHOSPHORYLATION; ERK; RECEPTORS; STRESS; JNK	The hairy cells (HCs) of hairy-cell leukemia are intrinsically activated mature clonal B cells. The aims of this study were to gain further insights into the nature of this activation and to assess its importance for the prolonged HC survival in this chronic disease. We show that HCs contain phosphorylated/activated p38 MAPK, JNK and ERK1/ERK2 (ERK1/2). PKC inhibitors increased the activation of p38 and JNK, but reduced the phosphorylation of ERK1/2. Moreover, PKC inhibition resulted in cell death; cell death was also observed when the activation of ERK1/2 in HCs was abrogated with an inhibitor of MEK1/2 activation. In addition to PKC, active Src kinase was also shown to be involved in the maintenance of Raf-independent ERK activation in HCs. During cell culture on a nonadherent surface, ERK phosphorylation was sustained, while phosphorylation of p38 and JNK decreased. This decrease was not observed in HCs cultured on vitronectin (VN), indicating that p38/JNK activation is probably a consequence of in vivo HC interaction with VN present in abundance in the red pulp of the spleen. Taken together, these results suggest that active p38/JNK make HCs susceptible to apoptosis, but the cells are effectively rescued by ERK activation involving constitutively active PKC and Src. These findings are relevant for the understanding of the prolonged cell survival of HCs and their selective sensitivity to some chemotherapeutic agents.	Univ Liverpool, Royal Liverpool Hosp, Dept Haematol, Liverpool L69 3GA, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Kamiguti, AS (corresponding author), Univ Liverpool, Royal Liverpool Hosp, Dept Haematol, Daulby St, Liverpool L69 3GA, Merseyside, England.	aurakami@liverpool.ac.uk	Slupsky, Joseph/H-2843-2019	Slupsky, Joseph/0000-0002-7410-9004				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Avdi NJ, 1996, J BIOL CHEM, V271, P33598, DOI 10.1074/jbc.271.52.33598; Baines CP, 2002, CIRC RES, V90, P390, DOI 10.1161/01.RES.0000012702.90501.8D; Baker PK, 2002, BLOOD, V100, P647, DOI 10.1182/blood.V100.2.647; Bastie JN, 1999, LEUKEMIA LYMPHOMA, V35, P555, DOI 10.1080/10428199909169620; Behrens MM, 1999, NEUROSCIENCE, V94, P917, DOI 10.1016/S0306-4522(99)00212-2; Birkenkamp KU, 1999, LEUKEMIA, V13, P1037, DOI 10.1038/sj.leu.2401447; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; BURTHEM J, 1994, BLOOD, V84, P873; BURTHEM J, 1996, HAIRY CELL LEUKAEMIA; Busuttil V, 2002, ONCOGENE, V21, P3213, DOI 10.1038/sj.onc.1205433; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CALIGARISCAPPIO F, 1985, BLOOD, V66, P1035; Carlomagno F, 2002, CANCER RES, V62, P1077; CAWLEY JC, 2000, ADV BLOOD DISORD, V5, P9; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen HJ, 1999, BRIT J HAEMATOL, V105, P87; Chen J, 2001, J BIOL CHEM, V276, P47901, DOI 10.1074/jbc.M107574200; Clarke H, 2000, EXP CELL RES, V261, P239, DOI 10.1006/excr.2000.5035; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; CORDINGLEY FT, 1988, LANCET, V1, P969; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREXLER HG, 1989, BLOOD, V74, P1747; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GENOT EM, 1993, J IMMUNOL, V151, P71; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Gruber G, 1999, BLOOD, V94, P1077, DOI 10.1182/blood.V94.3.1077.415k06_1077_1085; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Harris RJ, 2000, J IMMUNOL, V164, P3887, DOI 10.4049/jimmunol.164.7.3887; Herrmann C, 1998, ONCOGENE, V17, P1769, DOI 10.1038/sj.onc.1202085; Hindley A, 2002, J CELL SCI, V115, P1575; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kreitman RJ, 2001, NEW ENGL J MED, V345, P241, DOI 10.1056/NEJM200107263450402; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LYNCH SA, 1993, LEUKEMIA, V7, P1416; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; Nadal-Wollbold F, 2002, FEBS LETT, V531, P475, DOI 10.1016/S0014-5793(02)03587-1; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; Pettitt AR, 1999, BRIT J HAEMATOL, V106, P2; PING P, 1999, AM J PHYSIOL, V276, P468; PIRO LD, 1990, NEW ENGL J MED, V322, P1117, DOI 10.1056/NEJM199004193221605; REUTER CWM, 1992, BLOOD, V96, P655; Savoie L, 2001, Curr Treat Options Oncol, V2, P217, DOI 10.1007/s11864-001-0035-3; SIMONTON SC, 1985, LAB INVEST, V52, pA63; SOUTHERN C, 1995, IMMUNOLOGY, V84, P326; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAM LT, 1971, NEW ENGL J MED, V284, P357, DOI 10.1056/NEJM197102182840704; Zhang Z, 1999, J NEUROCHEM, V73, P1502, DOI 10.1046/j.1471-4159.1999.0731502.x	62	45	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2272	2284		10.1038/sj.onc.1206398	http://dx.doi.org/10.1038/sj.onc.1206398			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700663				2022-12-17	WOS:000182231500006
J	Rabbitt, E; Ayuk, J; Boelaert, K; Sheppard, MC; Hewison, M; Stewart, PM; Gittoes, NJL				Rabbitt, E; Ayuk, J; Boelaert, K; Sheppard, MC; Hewison, M; Stewart, PM; Gittoes, NJL			Abnormal expression of 11 beta-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation	ONCOGENE			English	Article						pituitary adenoma; 11 beta-hydroxysteroid dehydrogenase; proliferation	APPARENT MINERALOCORTICOID EXCESS; CYCLE INHIBITOR P27(KIP1); RECEPTOR EXPRESSION; MICE LACKING; TUMORS; ARREST; GROWTH; TUMORIGENESIS; HYPERPLASIA; PROGRESSION	The physiological effects of glucocorticoids (GCs) are, at least in part, mediated by inhibition of cell proliferation. Two isozymes of 11beta-hydroxysteroid dehydrogenase (11beta-HSD) interconvert cortisol (F) and inactive cortisone (E), and are thus able to modulate GC action at an autocrine level. Previously, we have demonstrated absent expression of 11beta-HSD2 in normal pituitaries; however, in a small number of pituitary tumors analysed, 11beta-HSD2 was readily demonstrable. Here we have used real-time RT-PCR to quantify expression of mRNA for 11beta-HSD1 and 2 in 105 human pituitary tumors and have performed enzyme expression and activity studies in primary pituitary cultures. Overall, pituitary tumors expressed lower levels of 11beta-HSD1 mRNA compared with normals (0.2-fold, P<0.05). In contrast, expression of 11beta-HSD2 mRNA was 9.8-fold greater in tumors than in normals (P < 0.001). Enzyme assays showed significant 11beta-HSD2 activity (71.9+/-22.3pmol/h/mg protein (mean+/-s.d.)) but no detectable 11beta-HSD1 activity. Proliferation assays showed that addition of glycyrrhetinic acid (an 11beta-HSD2 inhibitor) resulted in a 30.3+/-7.7% inhibition of cell proliferation. In summary, we describe a switch in expression from 11beta-HSD1 to 11beta-HSD2 in neoplastic pituitary tissue. We propose that abnormal expression of 11beta-HSD2 acts as a proproliferative prereceptor determinant of pituitary cell growth, and may provide a novel target for future tumor therapy.	Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England	University of Birmingham	Stewart, PM (corresponding author), Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England.							Bamberger CM, 1999, EUR J ENDOCRINOL, V140, P250, DOI 10.1530/eje.0.1400250; Bland R, 1999, J ENDOCRINOL, V161, P455, DOI 10.1677/joe.0.1610455; Cooper MS, 2000, BONE, V27, P375, DOI 10.1016/S8756-3282(00)00344-6; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Gingras MC, 2000, EXP HEMATOL, V28, P350, DOI 10.1016/S0301-472X(00)00149-1; Gittoes NJL, 1997, J CLIN ENDOCR METAB, V82, P1960, DOI 10.1210/jc.82.6.1960; Hundertmark S, 1997, J ENDOCRINOL, V155, P171, DOI 10.1677/joe.0.1550171; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Korbonits M, 2001, J CLIN ENDOCR METAB, V86, P2728, DOI 10.1210/jc.86.6.2728; Koyama K, 2001, J STEROID BIOCHEM, V76, P153, DOI 10.1016/S0960-0760(00)00157-6; Labrie F, 2000, TRENDS ENDOCRIN MET, V11, P421, DOI 10.1016/S1043-2760(00)00342-8; Lidhar K, 1999, J CLIN ENDOCR METAB, V84, P3823, DOI 10.1210/jc.84.10.3823; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; McTernan CL, 2001, J CLIN ENDOCR METAB, V86, P4979, DOI 10.1210/jc.86.10.4979; MOTOO Y, 1994, CANCER LETT, V86, P91, DOI 10.1016/0304-3835(94)90184-8; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nawrocki AR, 2002, J BIOL CHEM, V277, P14647, DOI 10.1074/jbc.M111549200; Rabbitt EH, 2002, FASEB J, V16, P36, DOI 10.1096/fj.01-0582com; Robson AC, 1998, MOL BRAIN RES, V61, P1, DOI 10.1016/S0169-328X(98)00161-2; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; Samuelsson MKR, 1999, MOL ENDOCRINOL, V13, P1811, DOI 10.1210/me.13.11.1811; SANCHEZ I, 1993, CELL GROWTH DIFFER, V4, P215; Shiota G, 1999, CARCINOGENESIS, V20, P59, DOI 10.1093/carcin/20.1.59; Stewart PM, 1999, VITAM HORM, V57, P249; Stewart PM, 1996, LANCET, V347, P88, DOI 10.1016/S0140-6736(96)90211-1; STEWART PM, 1987, LANCET, V2, P821; Stewart PM, 2002, TRENDS ENDOCRIN MET, V13, P94, DOI 10.1016/S1043-2760(02)00566-0; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; WHORWOOD CB, 1993, ENDOCRINOLOGY, V132, P2287, DOI 10.1210/en.132.6.2287	32	45	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1663	1667		10.1038/sj.onc.1206293	http://dx.doi.org/10.1038/sj.onc.1206293			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642869				2022-12-17	WOS:000181580500008
J	Hampton, R; Walker, M; Marshall, J; Juhl, H				Hampton, R; Walker, M; Marshall, J; Juhl, H			Differential expression of carcinoembryonic antigen (CEA) splice variants in whole blood of colon cancer patients and healthy volunteers: implication for the detection of circulating colon cancer cells	ONCOGENE			English	Article						minimal residual disease; circulating cancer cells; colon cancer; CEA; CK20	POLYMERASE-CHAIN-REACTION; DISSEMINATED TUMOR-CELLS; BONE-MARROW; REVERSE-TRANSCRIPTASE; PERIPHERAL-BLOOD; PERITONEAL-CAVITY; CARCINOMA-CELLS; CYTOKINES; DISEASE; FAMILY	Quantification of circulating cancer cells in whole blood samples by real time quantitative RT-PCR might be of clinical value for monitoring therapeutic effectiveness. In colon cancer patients, carcinoembrynic antigen (CEA) and cytokeratin 20 (CK20) have been frequently used for RTPCR based tumor cell detection, but the specificity in particular for CEA has been questioned. In this study, we compared real-time RT-PCR for CEA. and CK20 and analysed patients with metastatic disease (n = 32) and healthy volunteers (n = 17). CK20 mean values were elevated in cancer patients (P < 0.001) and defined a subgroup (38%) who showed CK20 levels at least 100-fold above the highest value of the healthy control group. In contrast, only two cancer patients (6%) showed elevated CEA levels. Samples of the healthy control group showed exclusively a CEA-PCR product of 79degreesC melting temperature. Thirty per cent of the colon cancer patients showed an additional product of 82degreesC melting temperature. The 82degreesC product was identical with the amplification product of CEA-cDNA and cDNA from different colon cancer cell fines. Colon cancer cells were spiked into normal blood in 10-fold dilutions that resulted in a dose dependent shift of the melt curve from 79degreesC to the 82degreesC. Sequencing of the PCR products showed that white blood cells express a splice variant of CEA, which hinders detection of tumor cell cDNA in whole blood samples. Our findings have implications for the use of CEA as a diagnostic molecule (e.g. by RT - PCR). The discovery of a physiologically expressed CEA splice variant might lead to a better understanding of the biological function of CEA and its family members.	Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University	Juhl, H (corresponding author), INDIVUMED, Ctr Canc Res, Israelit Krankenhaus, Orchideenstieg 14, D-22297 Hamburg, Germany.	juhl@indivumed.com			NATIONAL CANCER INSTITUTE [R01CA088972, P30CA051008] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA088972, 2P30-CA-51008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BURCHILL SA, 1995, BRIT J CANCER, V71, P278, DOI 10.1038/bjc.1995.56; Castells A, 1998, BRIT J CANCER, V78, P1368, DOI 10.1038/bjc.1998.686; ENGELL H, 1955, ACTA CHIR SCAND    S, V210, pS10; Gangopadhyay A, 1998, CLIN EXP METASTAS, V16, P703, DOI 10.1023/A:1006576627429; GERHARD M, 1994, J CLIN ONCOL, V12, P725, DOI 10.1200/JCO.1994.12.4.725; Goeminne JC, 2000, ANN ONCOL, V11, P785, DOI 10.1023/A:1008398228018; Grem Jean, 1997, Current Opinion in Oncology, V9, P380, DOI 10.1097/00001622-199709040-00012; Guadagni F, 2001, CANCER RES, V61, P2523; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; JUHL H, 1994, INT J CANCER, V57, P330, DOI 10.1002/ijc.2910570307; Jung R, 1998, BRIT J CANCER, V78, P1194, DOI 10.1038/bjc.1998.653; Ko Y, 1998, CLIN CANCER RES, V4, P2141; Liefers GJ, 1998, NEW ENGL J MED, V339, P223, DOI 10.1056/NEJM199807233390403; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; Mori M, 1996, INT J CANCER, V68, P739; REDDING WH, 1983, LANCET, V2, P1271; SCHLIMOK G, 1987, P NATL ACAD SCI USA, V84, P8672, DOI 10.1073/pnas.84.23.8672; Schott A, 1998, ANN SURG, V227, P372, DOI 10.1097/00000658-199803000-00009; SCHREWE H, 1990, MOL CELL BIOL, V10, P2738, DOI 10.1128/MCB.10.6.2738; Soeth E, 1996, INT J CANCER, V69, P278, DOI 10.1002/(SICI)1097-0215(19960822)69:4<278::AID-IJC7>3.0.CO;2-U; Soeth E, 2001, CLIN CANCER RES, V7, P2022; Soeth E, 1997, CANCER RES, V57, P3106; THOMPSON J, 1994, J BIOL CHEM, V269, P32924; Vogel I, 2001, AM J SURG, V181, P188, DOI 10.1016/S0002-9610(00)00555-9; Wirth T, 2002, CLIN EXP METASTAS, V19, P155, DOI 10.1023/A:1014566127493	26	45	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7817	7823		10.1038/sj.onc.1205906	http://dx.doi.org/10.1038/sj.onc.1205906			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420218				2022-12-17	WOS:000178946000006
J	Yao, RS; Wang, Y; Lubet, RA; You, M				Yao, RS; Wang, Y; Lubet, RA; You, M			Differentially expressed genes associated with mouse lung tumor progression	ONCOGENE			English	Article						mouse; lung; adenoma; adenocarcinoma; lung tumor progression gene; gene expression	CELL-CYCLE ARREST; CANCER-CELLS; RETINOBLASTOMA PROTEIN; PRENEOPLASTIC LESIONS; CDK INHIBITORS; BETA; ADENOCARCINOMA; ACTIVATION; NEOPLASIA; MUTATIONS	To detect altered gene expression associated with mouse lung tumor progression, we compared the gene expression profile of lung adenocarcinomas with that of lung adenomas and normal lungs. Autoradiographic analysis showed that among the 588 genes surveyed, 152 genes were detected and the remaining 436 genes did not give any signals. A gene-specific semiquantitative reverse transcription polymerase chain reaction method was used to confirm the expression profile. A total of 29 genes was found to be differentially expressed in mouse lung tumors when compared to normal lungs. The pattern of expression, either underexpression or overexpression, was the same for 10 genes between adenocarcinomas and adenomas. Among them, seven genes were over-expressed, two genes were underexpressed and one gene was lost. Interestingly, 19 genes showed differential expression or increased incidence or difference in level of change between lung adenomas and adenocarcinomas, including Stat1, ADAP, IGFBP-6, PDGF-A, TGF-beta2, Int-3, VEGFR2, BAX, BAG-1, c-Jun, FasL, TRAIL, YB-1, CD31, Cdc42, B-raf, Rab-2, Abi-1, and ACE. These,genes can be designated as candidate 'lung tumor progression' (LTP) genes because their expression changes may specifically affect lung tumor progression in mice. Further analyses of these candidate LTP genes may provide new leads for elucidation of lung tumor progression in mice.	Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Med Res Facil 514, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Sch Publ Hlth, Columbus, OH 43210 USA; NCI, Chemoprevent Branch, Bethesda, MD 20892 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Med Res Facil 514, 420 W 12th Ave, Columbus, OH 43210 USA.				DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005113] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA058554, R01CA078797, R29CA058554] Funding Source: NIH RePORTER; NCI NIH HHS [CA58554, CA78797, CN05113] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT WP, 1993, CANCER RES, V53, P4817; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHIBA I, 1990, ONCOGENE, V5, P1603; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DeRisi J, 1996, NAT GENET, V14, P457; Frank DA, 1999, MOL MED, V5, P432; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; Gemma A, 2001, EUR J CANCER, V37, P1554, DOI 10.1016/S0959-8049(01)00154-X; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Herzog CR, 1997, J CELL BIOCHEM, P49; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; KISHIMOTO Y, 1995, JNCI-J NATL CANCER I, V87, P1224, DOI 10.1093/jnci/87.16.1224; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kleeff J, 1998, J BIOL CHEM, V273, P7495, DOI 10.1074/jbc.273.13.7495; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Lin L, 2001, EXP LUNG RES, V27, P217, DOI 10.1080/019021401300053966; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mielnicki LM, 1996, BIOCHEM BIOPH RES CO, V228, P586, DOI 10.1006/bbrc.1996.1702; Minna JD, 1989, CANCER PRINCIPLES PR, P591; OITVAI ZN, 1993, CELL, V74, P609; Palmisano W. A., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P94; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rhee CH, 1999, ONCOGENE, V18, P2711, DOI 10.1038/sj.onc.1202623; RODENHUIS S, 1988, CANCER RES, V48, P5738; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; SHISEKI M, 1994, CANCER RES, V54, P5643; Sneath RJS, 1998, J CLIN PATHOL-MOL PA, V51, P191, DOI 10.1136/mp.51.4.191; SOZZI G, 1992, CANCER RES, V52, P6079; Sriuranpong V, 2001, CANCER RES, V61, P3200; Sueoka N, 2000, ONCOGENE, V19, P4432, DOI 10.1038/sj.onc.1203813; Tisdale EJ, 1998, J BIOL CHEM, V273, P17269, DOI 10.1074/jbc.273.27.17269; Volm M, 2000, BRIT J CANCER, V82, P1747; XU HJ, 1991, CANCER RES, V51, P2735; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032	38	45	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5814	5821		10.1038/sj.onc.1205422	http://dx.doi.org/10.1038/sj.onc.1205422			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173053				2022-12-17	WOS:000177463400018
J	Scelfo, RAM; Schwienbacher, C; Veronese, A; Gramantieri, L; Bolondi, L; Querzoli, P; Nenci, I; Calin, GA; Angioni, A; Barbanti-Brodano, G; Negrini, M				Scelfo, RAM; Schwienbacher, C; Veronese, A; Gramantieri, L; Bolondi, L; Querzoli, P; Nenci, I; Calin, GA; Angioni, A; Barbanti-Brodano, G; Negrini, M			Loss of methylation at chromosome 11p15.5 is common in human adult tumors	ONCOGENE			English	Article						chromosome 11p15.5; DNA hypomethylation	BECKWITH-WIEDEMANN-SYNDROME; DNA METHYLATION; IMPRINTED GENE; WILMS-TUMOR; SUPPRESSOR REGIONS; H19; LOCUS; IGF2; EXPRESSION; DISRUPTION	Chromosome 11p15 deletion is frequent in human tumors, suggesting the presence of at least one tumor suppressor gene within this region. While mutation analyses of local genes revealed only rare mutations, we have previously described a mechanism, gain of imprinting, that leads to loss of expression of genes located on the maternal 11p15 chromosome in human hepatocarcinomas. Loss of expression was often associated with loss of maternal-specific methylation at the KvDMR1 locus. Here, we show that loss of the maternal KvDMR1 methylation is common, ranging from 30 to 50%, to a variety of adult neoplasms, including liver, breast, cervical and gastric carcinomas. We found that other 11p15.5 loci were concomitantly hypomethylated, indicating that loss of KvDMR1 methylation occurred in the context of a common mechanism affecting the methylation of a large 11p15 subchromosomal domain. These epigenetic abnormalities were not detected in any normal somatic tissue. Therefore, it seems possible that, contrary to the repression of promoter activity caused by hypermethylation, loss of gene expression at 11p15.5 may result from the activation, by hypomethylation, of one or more negative regulatory elements.	Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, Sez Microbiol, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Interdipartmentale Ric Canc, I-44100 Ferrara, Italy; Int Canc Ctr, Mol Biol Labs, Rovigo, Italy; Univ Bologna, Dipartimento Med Interna & Gastroenterol, Bologna, Italy; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Osped Pediat, Serv Immunotrasfus, Bambino Gesu IRCCS, Rome, Italy	University of Ferrara; University of Ferrara; University of Bologna; Jefferson University; IRCCS Bambino Gesu	Negrini, M (corresponding author), Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, Sez Microbiol, Via Luigi Borsari 46, I-44100 Ferrara, Italy.	ngm@unife.it	Veronese, Angelo/I-4292-2019; Negrini, Massimo/J-2377-2016; angioni, adriano/G-1160-2014; Calin, George/E-9390-2011; Gramantieri, Laura/J-3862-2019; Gramantieri, Laura/K-8603-2016	Negrini, Massimo/0000-0002-0007-1920; angioni, adriano/0000-0003-0862-2456; Gramantieri, Laura/0000-0002-5187-9559; Calin, George/0000-0001-6704-5615; Veronese, Angelo/0000-0002-1451-1392; QUERZOLI, Patrizia/0000-0003-2873-8894				Baffa R, 1996, CANCER RES, V56, P268; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; Brown KW, 1996, HUM MOL GENET, V5, P2027, DOI 10.1093/hmg/5.12.2027; Catchpoole D, 1997, J MED GENET, V34, P353, DOI 10.1136/jmg.34.5.353; Cleary MA, 2001, NAT GENET, V29, P78, DOI 10.1038/ng715; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Ehrlich Melanie, 2000, P273; Engel JR, 2000, J MED GENET, V37, P921, DOI 10.1136/jmg.37.12.921; Frevel MAE, 1999, J BIOL CHEM, V274, P29331, DOI 10.1074/jbc.274.41.29331; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; Horike S, 2000, HUM MOL GENET, V9, P2075, DOI 10.1093/hmg/9.14.2075; KIECHLESCHWARZ M, 1993, CANCER, V72, P2423, DOI 10.1002/1097-0142(19931015)72:8<2423::AID-CNCR2820720821>3.0.CO;2-P; KOUFOS A, 1989, AM J HUM GENET, V44, P711; Lee MP, 1998, CANCER RES, V58, P4155; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; Mitsuya K, 1999, HUM MOL GENET, V8, P1209, DOI 10.1093/hmg/8.7.1209; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; OBriant KC, 1997, GENE CHROMOSOME CANC, V18, P111, DOI 10.1002/(SICI)1098-2264(199702)18:2<111::AID-GCC5>3.0.CO;2-5; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Sabbioni S, 1999, CYTOGENET CELL GENET, V86, P214, DOI 10.1159/000015341; Sambrook J., 1982, MOL CLONING; Schwienbacher C, 1998, P NATL ACAD SCI USA, V95, P3873, DOI 10.1073/pnas.95.7.3873; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; Schwienbacher C, 2000, CANCER RES, V60, P1521; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; Webber AL, 1998, NATURE, V391, P711, DOI 10.1038/35655; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143	36	45	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2564	2572		10.1038/sj.onc.1205336	http://dx.doi.org/10.1038/sj.onc.1205336			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971191				2022-12-17	WOS:000174918400013
J	Yamada, Y; Pannell, R; Forster, A; Rabbitts, TH				Yamada, Y; Pannell, R; Forster, A; Rabbitts, TH			The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target	ONCOGENE			English	Article						transcriptional regulation; tumour angiogenesis; chromosomal translocation; endothelium; cancer; neo-vascularization	T-CELL LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; CANCER; TRANSCRIPTION; ONCOGENES; RBTN2	The growth of solid tumours requires a blood supply provided by re-modeling of existing blood vessel endothelium (angiogenesis). Little is known about transcription regulators which are specific for the control of tumour angiogenesis. The proto-oncogene LM02 encodes a LIM domain transcription regulator which controls angiogenesis during mouse embryogenesis where it regulates remodelling of the capillary network into mature vessels. We now show that Lmo2 expression is augmented in tumour endothelium such as mouse thymomas and human lung tumours. The functional significance of this Lmo2 expression was assessed in teratocarcinomas induced in nude mice by subcutaneous implantation of Lmo2-lacZ targeted ES cells. CD31-positive, sprouting endothelium of ES-cell origin occurred in teratocarcinomas from heterozygous Lmo2-lacZ ES cells but none occurred from null Lmo2-lacZ ES cells. Therefore, in this model Lmo2 is an obligatory regulator of neo-vascularization of tumours. These data suggest that LM02 function may be a drug target in cancer and other conditions characterized by neo-vascularization.	Med Res Council Lab Mol Biol, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology; UK Research & Innovation (UKRI); Medical Research Council UK (MRC)	Rabbitts, TH (corresponding author), Med Res Council Lab Mol Biol, Hills Rd, Cambridge CB2 2QH, England.	thr@mrc.lmb.cam.ac.uk	Mordwinkin, Nicholas M/A-4347-2010; Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Taniere P, 2001, AM J PATHOL, V158, P33, DOI 10.1016/S0002-9440(10)63941-7; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yamada Y, 2000, P NATL ACAD SCI USA, V97, P320, DOI 10.1073/pnas.97.1.320	23	45	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1309	1315		10.1038/sj.onc.1205285	http://dx.doi.org/10.1038/sj.onc.1205285			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857074	Bronze			2022-12-17	WOS:000173861000001
J	Jarboe, EA; Liaw, KL; Thompson, LC; Heinz, DE; Baker, PL; McGregor, JA; Dunn, T; Woods, JE; Shroyer, KR				Jarboe, EA; Liaw, KL; Thompson, LC; Heinz, DE; Baker, PL; McGregor, JA; Dunn, T; Woods, JE; Shroyer, KR			Analysis of telomerase as a diagnostic biomarker of cervical dysplasia and carcinoma	ONCOGENE			English	Article						telomerase; hTR; hTERT; TRAP; cervix neoplasia	SQUAMOUS-CELL CARCINOMA; CATALYTIC SUBUNIT GENE; HUMAN PAPILLOMAVIRUS TYPE-16; INTRAEPITHELIAL NEOPLASIA; RNA COMPONENT; PRECANCEROUS LESIONS; PAPANICOLAOU SMEARS; UTERINE CERVIX; ACETIC-ACID; CANCER	Telomerase expression is a potentially important marker of high-grade cervical dysplasia and squamous cell carcinoma (SCC). The routine practice of cervical cytology is limited by problems of false negative diagnoses as well as by poor specificity for clinically significant lesions in patients with low-grade cytologic abnormalities. Telomerase is widely expressed in most SCCs as well as in a high proportion of high-grade squamous intraepithelial lesions. Histochemical studies have confirmed that telomerase is expressed in the lower portions of normal or metaplastic squamous mucosa but that telomerase positive cells extend into the upper epithelial layers in cases of high-grade dysplasia. Since the cervical smear samples the uppermost cell layers of the cervical mucosa, but does not normally include cells derived from the lower layers of the squamous mucosa, the detection of telomerase in exfoliated cells of the cervical smear may have specificity for clinically significant lesions. The analysis of hTR, hTERT, and telomerase activity are complicated by a number of technical factors that may lead to either false negative or false positive test results. Thus, the practical application of telomerase analysis as a diagnostic adjunct for cervical cytopathology may depend on the development of more reliable and sensitive assay systems, possibly formatted for cytochemical applications.	Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Obstet & Gynecol, Denver, CO 80262 USA; Merck Res Labs, Dept Epidemiol, West Point, PA 19486 USA; Denver Hlth Med Ctr, Dept Obstet & Gynecol, Denver, CO 80204 USA; Denver Hlth Med Ctr, Dept Pathol, Denver, CO 80204 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Merck & Company; Denver Health Medical Center; Denver Health Medical Center	Shroyer, KR (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pathol, 4200 E 9th Ave, Denver, CO 80262 USA.	Ken.Shroyer@UCHSC.edu			NCI NIH HHS [R01 CA78442-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078442] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM CANC SOC, 2001, CANC FACTS FIG 2001; Anderson S, 1997, AM J PATHOL, V151, P25; BENOIT AG, 1984, AM J OBSTET GYNECOL, V148, P690, DOI 10.1016/0002-9378(84)90775-0; BERKELEY AS, 1980, LANCET, V2, P375; BIRLEY HDL, 1995, ANN TROP MED PARASIT, V89, P453, DOI 10.1080/00034983.1995.11812977; Brien TP, 1997, CANCER RES, V57, P2760; ChangChien CC, 1998, GYNECOL ONCOL, V71, P99, DOI 10.1006/gyno.1998.5143; Colgin LM, 2000, NEOPLASIA, V2, P426, DOI 10.1038/sj.neo.7900112; DeMay RM, 1996, AM J OBSTET GYNECOL, V175, P1110, DOI 10.1016/S0002-9378(96)70013-3; DEMAY RM, 1996, EXFOLIATIVE CYTOLOGY, P61; ENOMOTO T, 1997, INT J CANCER, V73, P1; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Frost M, 2000, AM J CLIN PATHOL, V114, P726, DOI 10.1309/XWFE-ARMN-HG2D-AJYV; GAY JD, 1985, ACTA CYTOL, V29, P1043; Gorham H, 1997, J CLIN PATHOL, V50, P501, DOI 10.1136/jcp.50.6.501; Guidozzi F, 1996, Obstet Gynecol Surv, V51, P247; Gullu IH, 1999, BRIT J CANCER, V81, P186, DOI 10.1038/sj.bjc.6690674; HATCH KD, 1995, AM J OBSTET GYNECOL, V172, P1150, DOI 10.1016/0002-9378(95)91473-0; Hiyama E, 2001, NEOPLASIA, V3, P17, DOI 10.1038/sj.neo.7900134; Iwasaka T, 1998, OBSTET GYNECOL, V91, P260, DOI 10.1016/S0029-7844(97)00595-4; Kawai K, 1998, EUR J CANCER, V34, P2082, DOI 10.1016/S0959-8049(98)00242-1; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KRIEGER P, 1994, ACTA CYTOL, V38, P291; Kyo S, 1996, CLIN CANCER RES, V2, P2023; Kyo S, 1997, CANCER RES, V57, P610; Kyo S, 1998, INT J CANCER, V79, P66, DOI 10.1002/(SICI)1097-0215(19980220)79:1<66::AID-IJC13>3.0.CO;2-F; Manos MM, 1999, JAMA-J AM MED ASSOC, V281, P1605, DOI 10.1001/jama.281.17.1605; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mutirangura A, 1998, BRIT J CANCER, V78, P933, DOI 10.1038/bjc.1998.604; Nagai N, 1999, ONCOL REP, V6, P325; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakano K, 1998, AM J PATHOL, V153, P857, DOI 10.1016/S0002-9440(10)65627-1; Naryshkin S, 1997, ARCH PATHOL LAB MED, V121, P270; Oh ST, 2001, J VIROL, V75, P5559, DOI 10.1128/JVI.75.12.5559-5566.2001; PAIRWUTI S, 1991, ACTA CYTOL, V35, P40; Pao CC, 1997, J CLIN ONCOL, V15, P1932, DOI 10.1200/JCO.1997.15.5.1932; Park TW, 1996, J NATL CANCER I, V88, P355, DOI 10.1093/jnci/88.6.355; PARK TW, 1995, CANCER-AM CANCER SOC, V76, P1902, DOI 10.1002/1097-0142(19951115)76:10+<1902::AID-CNCR2820761306>3.0.CO;2-0; Reddy VG, 2001, INT J GYNECOL CANCER, V11, P100; RICHART RM, 1993, PATHOL ANNU, V8, P301; Riethdorf S, 2001, INT J GYNECOL PATHOL, V20, P177, DOI 10.1097/00004347-200104000-00011; ROBERTSON JH, 1993, J CLIN PATHOL, V46, P700, DOI 10.1136/jcp.46.8.700; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Shroyer KR, 1998, AM J CLIN PATHOL, V109, P153, DOI 10.1093/ajcp/109.2.153; Shroyer KR, 1997, INT J GYNECOL PATHOL, V16, P225, DOI 10.1097/00004347-199707000-00006; Snijders PJF, 1998, CANCER RES, V58, P3812; Solomon D, 2001, J NATL CANCER I, V93, P293, DOI 10.1093/jnci/93.4.293; Solomon D, 1994, BETHESDA SYSTEM REPO, P9; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; Tabbara SO, 1996, DIAGN CYTOPATHOL, V14, P84, DOI 10.1002/(SICI)1097-0339(199602)14:1<84::AID-DC17>3.0.CO;2-9; Takakura M, 1998, CANCER RES, V58, P1558; Tkeshelashvili V. T., 1993, European Journal of Gynaecological Oncology, V14, P89; Ulaner GA, 1998, CANCER RES, V58, P4168; VANDERGRAAF Y, 1987, ACTA CYTOL, V31, P434; VANDERGRAAF Y, 1987, J CLIN PATHOL, V40, P438, DOI 10.1136/jcp.40.4.438; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wisman GBA, 2000, HUM PATHOL, V31, P1304, DOI 10.1053/hupa.2000.19299; Wisman GBA, 1998, J CLIN ONCOL, V16, P2238, DOI 10.1200/JCO.1998.16.6.2238; Wisman GBA, 2001, INT J CANCER, V91, P658, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1099>3.0.CO;2-7; Wolf JK, 2001, CANCER INVEST, V19, P621, DOI 10.1081/CNV-100104290; WRIGHT TC, 1995, OBSTET GYNECOL, V85, P202, DOI 10.1016/0029-7844(94)00373-L; Wright TC, 1994, BLAUSTEINS PATHOLOGY, P229; WRIGHT TC, 1994, BLAUSTEINS PATHOLOGY, P287; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Wu YY, 2000, CLIN CHIM ACTA, V293, P199, DOI 10.1016/S0009-8981(99)00238-7; Yahata N, 1999, INT J ONCOL, V14, P709; Yashima K, 1998, CANCER, V82, P1319; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Yokoyama Y, 1998, GYNECOL ONCOL, V68, P145, DOI 10.1006/gyno.1997.4921; Zhang DK, 1999, EUR J CANCER, V35, P154, DOI 10.1016/S0959-8049(98)00303-7; Zheng PS, 1997, GYNECOL ONCOL, V66, P222, DOI 10.1006/gyno.1997.4757; zur Hausen H, 1999, P ASSOC AM PHYSICIAN, V111, P581, DOI 10.1046/j.1525-1381.1999.99723.x; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	75	45	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					664	673		10.1038/sj.onc.1205073	http://dx.doi.org/10.1038/sj.onc.1205073			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850794				2022-12-17	WOS:000173390500021
J	Grant, SL; Hammacher, A; Douglas, AM; Goss, GA; Mansfield, RK; Heath, JK; Begley, CG				Grant, SL; Hammacher, A; Douglas, AM; Goss, GA; Mansfield, RK; Heath, JK; Begley, CG			An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells	ONCOGENE			English	Article						breast cancer; oncostatin M; epidermal growth factor; ErbB; gp130; receptors	EPIDERMAL GROWTH-FACTOR; LEUKEMIA INHIBITORY FACTOR; ONCOSTATIN-M RECEPTOR; SIGNAL-TRANSDUCTION; ESTROGEN-RECEPTOR; TYROSINE KINASES; GENE-EXPRESSION; CARCINOMA-CELLS; DIFFERENTIATION; INTERLEUKIN-6	Oncostatin M (OSM), an interleukin-6 type cytokine, acts via the gp130 signaling receptor to inhibit proliferation and induce differentiation of breast cancer cells. EGF, a mitogen for breast cells, signals via EGFR/ErbB tyrosine kinase receptors which are implicated in breast cancer pathogenesis. Here we show paradoxically that EGF enhanced the OSM-induced inhibition of proliferation and induction of cellular differentiation in both estrogen receptor positive and negative breast cancer cells. This functional synergism was also seen with heregulin but not SCF, PDGF or IGF-1, indicating that it was specific to EGF-related growth factors. Immunoprecipitation experiments revealed that gp130 was constitutively associated with ErbB-2 and ErbB-3. There was a similar association between the OSMRbeta and ErbB-2. Furthermore, EGF unexpectedly induced tyrosine phosphorylation of gp130. We show that OSM induced phosphorylation of STAT3. Both OSM and EGF activated the p42/44 MAP kinases, but while the MEK inhibitor, PD98059, ablated the OSM-induced inhibition, it only partially ablated the inhibitory effects of OSM plus EGF. Thus, we have demonstrated that the receptors and signalling pathways of two apparently unrelated growth factors were intimately linked, resulting in an unexpected biological effect. This provides a new mechanism for generating signalling diversity and has potential clinical implications in breast cancer.	Rotary Bone Marrow Res Labs, Parkville, Vic 3050, Australia; Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Melbourne Tumour Biol Branch, Ludwig Inst Canc Res, Parkville, Vic 3050, Australia; Univ Birmingham, Sch Biochem, Growth Factors Grp, Canc Res Campaign, Birmingham B15 2TT, W Midlands, England; Univ Western Australia, TVW Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA, Australia; Western Australian Inst Med Res, Perth, WA, Australia	Walter & Eliza Hall Institute; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; University of Birmingham; Telethon Kids Institute; University of Western Australia; University of Western Australia	Grant, SL (corresponding author), Inst Child Htlh Res, Subiaco, WA 6008, Australia.	suzieg@ichr.uwa.edu.au						Aubert J, 1999, J BIOL CHEM, V274, P24965, DOI 10.1074/jbc.274.35.24965; Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; Baselga J, 2000, SEMIN ONCOL, V27, P20; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; De Leon DD, 1992, GROWTH FACTORS, V6, P327, DOI 10.3109/08977199209021544; DICKSON RB, 1988, BREAST CANCER CELLUL, P119; Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; FIDDES RJ, 1995, CELL GROWTH DIFFER, V6, P1567; FITZPATRICK SL, 1984, CANCER RES, V44, P3448; FITZPATRICK SL, 1984, CANCER RES, V44, P3442; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357-4310(99)01540-3; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Halfter H, 1999, Mol Cell Biol Res Commun, V1, P109, DOI 10.1006/mcbr.1999.0117; Hammacher A, 1998, J BIOL CHEM, V273, P22701, DOI 10.1074/jbc.273.35.22701; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; Hibi M, 1996, J MOL MED-JMM, V74, P1, DOI 10.1007/BF00202068; HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769; Hoffmann M, 1998, CANCER IMMUNOL IMMUN, V47, P167, DOI 10.1007/s002620050517; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; Klapper LN, 2000, ADV CANCER RES, V77, P25; KOGA M, 1987, BIOCHEM BIOPH RES CO, V146, P739, DOI 10.1016/0006-291X(87)90591-2; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; METCALF D, 1988, LEUKEMIA, V2, P216; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; Murakami-Mori K, 1999, BIOCHEM BIOPH RES CO, V264, P676, DOI 10.1006/bbrc.1999.1574; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; OSBORNE CK, 1980, CANCER RES, V40, P2361; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; RAO KVS, 1987, CANCER RES, V47, P5888; ROSE TM, 1994, CYTOKINE, V6, P48, DOI 10.1016/1043-4666(94)90007-8; SARUP JC, 1988, CANCER RES, V48, P5071; SEYMOUR L, 1994, BREAST CANCER RES TR, V32, P229, DOI 10.1007/BF00665774; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Taga T, 1996, J NEUROCHEM, V67, P1; Taylor ML, 2000, HEMATOL ONCOL CLIN N, V14, P517, DOI 10.1016/S0889-8588(05)70294-X; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	50	45	48	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					460	474		10.1038/sj.onc.1205100	http://dx.doi.org/10.1038/sj.onc.1205100			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821958				2022-12-17	WOS:000173311200014
J	Fukuyama, T; Sueoka, E; Sugio, Y; Otsuka, T; Niho, Y; Akagi, K; Kozu, T				Fukuyama, T; Sueoka, E; Sugio, Y; Otsuka, T; Niho, Y; Akagi, K; Kozu, T			MTG8 proto-oncoprotein interacts with the regulatory subunit of type II cyclic AMP-dependent protein kinase in lymphocytes	ONCOGENE			English	Article						AKAP; AML1 (RUNX-1); lymphocyte; MTG8 (ETO); PKA RII alpha	ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; TRANSCRIPTION FACTOR; FUSION PARTNER; SIGNALING ENZYMES; MOLECULAR-BASIS; RUNT DOMAIN; AML1 GENE; T(8-21); ETO	AML1-MTG8 chimeric oncogene is generated in acute myelogenous leukemia with t(8;21), and seems to be responsible for the pathogenesis of the disease. However, the role of MTG8 is ambiguous. Here we found that MTG8 interacted with the regulatory subunit of type II cyclic AMP-dependent protein kinase (PKA RII alpha). The binding site of MTG8 was NHR3 domain, and that of RII alpha was the N-terminus for interacting with PKA anchoring proteins (AKAPs). NHR3 contains a putative alpha -amphipathic helix which is characteristic in binding of AKAPs with RII. Indirect immunofluorescence microscopy showed that MTG8 and RII alpha were overlapped at the centrosome-Golgi area in lymphocytes. These findings suggest that MTG8 may function as an AKAP at the Centrosome-Golgi area in lymphocytes.	Saitama Canc Ctr, Res Inst, Ina, Saitama 3620806, Japan; Kyushu Univ Hosp, Ctr Canc, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Fac Med, Dept Med & Biosyst Sci, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Kozu, T (corresponding author), Saitama Canc Ctr, Res Inst, Ina, Saitama 3620806, Japan.		Kozu, Tomoko/R-3087-2019	Fukuyama, Tomofusa/0000-0002-0709-3188				Calabi F, 1998, GENOMICS, V52, P332, DOI 10.1006/geno.1998.5429; CARR DW, 1991, J BIOL CHEM, V266, P14188; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Davis JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/sj.onc.1202412; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; ERICKSON P, 1992, BLOOD, V80, P1825; Erickson PF, 1996, BLOOD, V88, P1813; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FEINSTEIN PG, 1995, GENETICS, V140, P573; Fracchiolla NS, 1998, BLOOD, V92, P3481, DOI 10.1182/blood.V92.9.3481.splL6_3481_3484; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Keryer G, 1999, EXP CELL RES, V249, P131, DOI 10.1006/excr.1999.4447; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Komori A, 1999, JPN J CANCER RES, V90, P60, DOI 10.1111/j.1349-7006.1999.tb00666.x; KOZU T, 1993, BLOOD, V82, P1270; Le XF, 1998, EUR J HAEMATOL, V60, P217; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sacchi N, 1998, ONCOGENE, V16, P2609, DOI 10.1038/sj.onc.1201824; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sueoka E, 1998, BRIT J HAEMATOL, V101, P737, DOI 10.1046/j.1365-2141.1998.00757.x; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Tasken K, 1997, ADV SEC MESS PHOSPH, V31, P191; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang JX, 1997, CANCER RES, V57, P2951; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3	48	45	47	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6225	6232		10.1038/sj.onc.1204794	http://dx.doi.org/10.1038/sj.onc.1204794			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593431				2022-12-17	WOS:000171206300014
J	DiNardo, DNM; Butcher, DT; Robinson, DP; Archer, TK; Rodenhiser, DI				DiNardo, DNM; Butcher, DT; Robinson, DP; Archer, TK; Rodenhiser, DI			Functional analysis of CpG methylation in the BRCA1 promoter region	ONCOGENE			English	Article						BRCA1; methylation; expression; CREB	CANCER SUSCEPTIBILITY GENE; SPORADIC BREAST-CANCER; TUMOR-SUPPRESSOR GENE; OVARIAN-CANCER; DNA METHYLATION; MESSENGER-RNA; ISLAND; ESTROGEN; BINDING; TRANSCRIPTION	Understanding the role for DNA methylation in tumorigenesis has evolved from defining the location and extent of methylation in a variety of cancer-related genes to clarifying the functional and site-specific effects of aberrant methylation on gene expression, Our objectives were to characterize the functional effects of DNA methylation in the BRCA1 promoter and to clarify the functional status of the BRCA1 CRE (cAMP response element) motif Luciferase reporter assays confirm that an intact CRE is important for BRCA1 expression in transient transfections. Luciferase activities were decreased in constructs where the CRE recognition sequence was altered and when constructs were methylated in vitro. Gel mobility shift and competition assays identified a DNA-protein complex recognizing the CRE motif that we were able to supershift using CREB-specific antibody. Furthermore this CRE is methylation sensitive, and we localized this methylation effect to a CpG dinucleotide within the BRCA1 CRE motif. The consequences of aberrant DNA methylation at specific transcription factor motifs, along with the multiple mutational events that can occur in a variety of essential genes such as BRCA1, paint a complex picture where both genetic and epigenetic changes contribute to tumour formation.	Univ Western Ontario, London Reg Canc Ctr, London, ON N6A 4L6, Canada; Univ Western Ontario, Child Hlth Res Inst, London, ON, Canada; Univ Western Ontario, Dept Biochem, London, ON, Canada; Univ Western Ontario, Dept Paediat, London, ON, Canada; NIEHS, Reprod & Dev Toxicol Lab, Res Triangle Pk, NC 27709 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Rodenhiser, DI (corresponding author), Univ Western Ontario, London Reg Canc Ctr, Room 4068,790 Commissioners Rd E, London, ON N6A 4L6, Canada.		Archer, Trevor K/E-5191-2019	Archer, Trevor K/0000-0001-7651-3644	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071007] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; Atlas E, 2000, ONCOGENE, V19, P1933, DOI 10.1038/sj.onc.1203516; Baldwin RL, 2000, CANCER RES, V60, P5329; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Dobrovic A, 1997, CANCER RES, V57, P3347; Ferguson AT, 1998, ONCOGENE, V17, P577, DOI 10.1038/sj.onc.1201961; Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hwu WL, 1997, DNA CELL BIOL, V16, P449, DOI 10.1089/dna.1997.16.449; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Issa JPJ, 1996, CANCER RES, V56, P973; Issa JPJ, 1996, CANCER RES, V56, P3655; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; Maesawa C, 1996, CANCER RES, V56, P3875; Magdinier F, 2000, FASEB J, V14, P1585, DOI 10.1096/fj.14.11.1585; Mancini D, 1997, AM J HUM GENET, V61, P80, DOI 10.1086/513898; Mancini DN, 1999, ONCOGENE, V18, P4108, DOI 10.1038/sj.onc.1202764; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Okuse K, 1997, MOL BRAIN RES, V46, P197, DOI 10.1016/S0169-328X(96)00302-6; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761; Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Rodenhiser D, 1996, ONCOGENE, V12, P2623; Rodenhiser DI, 1997, MUTAT RES-FUND MOL M, V373, P185, DOI 10.1016/S0027-5107(96)00171-6; SAKAI T, 1991, AM J HUM GENET, V48, P888; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SHATTUCKEIDENS E, 1995, JAMA-J AM MED ASSOC, V273, P535; Suen TC, 1999, J BIOL CHEM, V274, P31297, DOI 10.1074/jbc.274.44.31297; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994	38	45	46	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5331	5340		10.1038/sj.onc.1204697	http://dx.doi.org/10.1038/sj.onc.1204697			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536045				2022-12-17	WOS:000170575500008
J	Galy, B; Creancier, L; Prado-Lourenco, L; Prats, AC; Prats, H				Galy, B; Creancier, L; Prado-Lourenco, L; Prats, AC; Prats, H			p53 directs conformational change and translation initiation blockade of human fibroblast growth factor 2 mRNA	ONCOGENE			English	Article						FGF; p53; translational control; RNA-protein interactions; RNA structure	WILD-TYPE P53; ALTERNATIVE TRANSLATION; NUCLEIC-ACIDS; MESSENGER-RNA; PROTEIN; GROWTH-FACTOR-2; RIBOSOMES; DOMAIN; ENTRY; CELLS	Tumour suppressor p53 has been shown to inhibit fibroblast growth factor 2 expression post-transcriptionally in cultured cells. Here we have investigated the mechanism responsible for this post-transcriptional blockade. Deletion mutagenesis of the FGF-2 mRNA leader revealed the requirement of at least four RNA cis-acting elements to mediate the inhibitory effect of p53 in SK-Hep-1 transfected cells, suggesting the involvement of RNA secondary or tertiary structures. Recombinant wild-type, but not Ala(143) mutant p53, was able to specifically repress FGF-2 mRNA translation in rabbit reticulocyte lysate, in a dose dependent manner. Sucrose gradient experiments showed that p53 blocks translation initiation by preventing 80S ribosome formation on an mRNA bearing the FGF-2 mRNA leader sequence. Interaction of wild-type and mutant p53 with different RNAs showed no significant correlation between p53 RNA binding activity and its translational inhibiting effect. However, by checking the accessibility of the FGF-2 mRNA leader to complementary oligonucleotide probes, we showed that the binding to RNA of wild-type, but not mutant p53, induced RNA conformational changes that might be responsible for the translational blockade. This strongly suggests that p53 represses FGF-2 mRNA translation by a direct mechanism involving its nucleic acid unwinding-annealing activity.	CHU Rangueil, INSERM, U397, Inst Fed Rech Louis Bugnard, F-31403 Toulouse 04, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Prats, AC (corresponding author), CHU Rangueil, INSERM, U397, Inst Fed Rech Louis Bugnard, F-31403 Toulouse 04, France.		Prats, Anne-Catherine/E-5051-2016	Prats, Anne-Catherine/0000-0002-5282-3776; Galy, Bruno/0000-0002-0501-6357; Prats, Herve/0000-0002-4861-2167				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; Galy B, 1999, CANCER RES, V59, P165; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497	18	45	45	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4613	4620		10.1038/sj.onc.1204630	http://dx.doi.org/10.1038/sj.onc.1204630			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498784				2022-12-17	WOS:000170208600002
J	Ibarra-Sanchez, MD; Wagner, J; Ong, MT; Lampron, C; Tremblay, ML				Ibarra-Sanchez, MD; Wagner, J; Ong, MT; Lampron, C; Tremblay, ML			Murine embryonic fibroblasts lacking TC-PTP display delayed G1 phase through defective NF-kappa B activation	ONCOGENE			English	Article						T-cell protein tyrosine phosphatase; G1 phase; cyclin D1; NF-kappa B; IKK	PROTEIN-TYROSINE-PHOSPHATASE; CELL-CYCLE PROGRESSION; DEPENDENT KINASE; NEGATIVE REGULATORS; PROLIFERATION; P27(KIP1); EXPRESSION; GROWTH; TRANSCRIPTION; D1	Previous results suggested a potential role for T-cell protein tyrosine phosphatase (TC-PTP) in cell proliferation. However, no conclusive data has supported such a function in the modulation of this process. In order to clarify this issue, we isolated TC-PTP-/- murine embryonic fibroblasts (MEFs) as well as cell lines to characterize the role of TC-PTP in the control of cell proliferation and cell cycle. Both TC-PTP-/- primary MEFs and cell lines proliferate slower than TC-PTP+/+ cells. We also demonstrated that TC-PTP-/- cells have a slow progression through the G1 phase of the cell cycle. Further characterization of the G1 defect indicates that the kinetics of cyclin D1 induction was delayed and that p27(KIP1) remains at higher levels for an extended period of time. Moreover, cells lacking TC-PTP showed a delayed activation of CDK2. This slow progression through the early G1-phase resulted in decreased phosphorylation of the RB protein and subsequent delay into the S phase transition. In contrast, no further defects were detected in other phases of the cell cycle. Survey of the potential signaling pathways leading to this delayed cyclin D1 expression indicated that NF-kappaB activation was compromised and that IKK beta activity was also reduced following PDGF stimulation. Reintroduction of wild-type TC-PTP into the TC-PTP-/- cells rescued the defective proliferation, cyclin D1 expression, NF-kappaB, activation as well as I kappaB phosphorylation. Together, these results confirm that TC-PTP plays a positive role in the progression of early G1 phase of the cell cycle through the NF-kappaB pathway.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Kinetek Pharmaceut Inc, Vancouver, BC V6P 6G5, Canada	McGill University; McGill University	Tremblay, ML (corresponding author), McGill Univ, McGill Canc Ctr, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.		Ong, Ming Thong/R-4045-2018; Ibarra-Sánchez, María de Jesús/C-4722-2008	Ong, Ming Thong/0000-0002-6639-9718; Ibarra-Sánchez, María de Jesús/0000-0003-3623-1903				BARGOU RC, 1997, J CLIN INVEST, V100, P405; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; Ferreira V, 1999, J IMMUNOL, V162, P6442; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Ibarra-Sanchez MD, 2000, SEMIN IMMUNOL, V12, P379, DOI 10.1006/smim.2000.0220; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Liou HC, 1999, INT IMMUNOL, V11, P361, DOI 10.1093/intimm/11.3.361; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; LORENZEN J, 1995, J BIOL CHEM, V14, P631; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; NAMBIRAJAN S, 1995, J BIOSCIENCE, V20, P461, DOI 10.1007/BF02703529; Nambirajan S, 2000, J BIOSCIENCE, V25, P33, DOI 10.1007/BF02985179; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Radha V, 1997, FEBS LETT, V409, P33, DOI 10.1016/S0014-5793(97)00471-7; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Snapper CM, 1996, J IMMUNOL, V156, P183; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; TILLMANN U, 1994, MOL CELL BIOL, V14, P3030, DOI 10.1128/MCB.14.5.3030; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101; YouTen KE, 1997, J EXP MED, V186, P683, DOI 10.1084/jem.186.5.683	47	45	47	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4728	4739		10.1038/sj.onc.1204648	http://dx.doi.org/10.1038/sj.onc.1204648			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498795				2022-12-17	WOS:000170208600013
J	Demeret, C; Vassetzky, Y; Mechali, M				Demeret, C; Vassetzky, Y; Mechali, M			Chromatin remodelling and DNA replication: from nucleosomes to loop domains	ONCOGENE			English	Review						chromatin remodelling; DNA replication; DNA loop domains	YEAST SWI/SNF COMPLEX; SIMIAN VIRUS-40 DNA; TRANSCRIPTIONAL ACTIVATION DOMAIN; ASSEMBLY FACTOR-I; XENOPUS-LAEVIS; TOPOISOMERASE-II; DEVELOPMENTAL REGULATION; CHROMOSOME-REPLICATION; HISTONE DEACETYLASE; REPLICON CLUSTERS	Organization of DIVA into chromatin is likely to participate in the control of the timing and selection of DNA replication origins. Reorganization of the chromatin is carried out by chromatin remodelling machines, which may affect the choice of replication origins and efficiency of replication. Replication itself causes a profound rearrangement in the chromatin structure, from nucleosomes to DNA loop domains, allowing to retain or switch an epigenetic state. The present review considers the effects of chromatin remodelling on replication and vice versa.	CNRS, Inst Human Genet, F-34396 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Mechali, M (corresponding author), CNRS, Inst Human Genet, 141 Rue Cardonille, F-34396 Montpellier 5, France.		Vassetzky, Yegor S/C-6447-2008; Vassetzky, Yegor/M-3383-2019	Vassetzky, Yegor S/0000-0003-3101-7043; Vassetzky, Yegor/0000-0003-3101-7043; Demeret, caroline/0000-0002-1103-6805				Alexiadis V, 2000, GENE DEV, V14, P1308; Alexiadis V, 1998, EMBO J, V17, P3428, DOI 10.1093/emboj/17.12.3428; Benham C, 1997, J MOL BIOL, V274, P181, DOI 10.1006/jmbi.1997.1385; Berezney R, 2000, CHROMOSOMA, V108, P471, DOI 10.1007/s004120050399; Biggar SR, 1999, EMBO J, V18, P2254, DOI 10.1093/emboj/18.8.2254; Bochar DA, 2000, P NATL ACAD SCI USA, V97, P1038, DOI 10.1073/pnas.97.3.1038; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; BUONGIORNONARDELLI M, 1982, NATURE, V298, P100, DOI 10.1038/298100a0; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P4553, DOI 10.1093/nar/18.15.4553; CHENG LZ, 1992, P NATL ACAD SCI USA, V89, P589, DOI 10.1073/pnas.89.2.589; COCKERILL PN, 1990, NUCLEIC ACIDS RES, V18, P2643, DOI 10.1093/nar/18.9.2643; COOK PR, 1976, J CELL SCI, V22, P287; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DePamphilis ML, 1999, BIOESSAYS, V21, P5, DOI 10.1002/(SICI)1521-1878(199901)21:1<5::AID-BIES2>3.0.CO;2-6; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; EDENBERG HJ, 1975, ANNU REV GENET, V9, P245, DOI 10.1146/annurev.ge.09.120175.001333; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; Flanagan JF, 1999, NUCLEIC ACIDS RES, V27, P2022, DOI 10.1093/nar/27.9.2022; Francon P, 1999, FEBS LETT, V452, P87, DOI 10.1016/S0014-5793(99)00585-2; Friedman KL, 1996, GENE DEV, V10, P1595, DOI 10.1101/gad.10.13.1595; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gomez M, 1999, EMBO J, V18, P5683, DOI 10.1093/emboj/18.20.5683; Halmer L, 1998, J BIOL CHEM, V273, P34792, DOI 10.1074/jbc.273.52.34792; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; HYRIEN O, 1995, SCIENCE, V270, P994, DOI 10.1126/science.270.5238.994; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; ISHIMI Y, 1992, MOL CELL BIOL, V12, P4007, DOI 10.1128/MCB.12.9.4007; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; JACKSON DA, 1990, BIOESSAYS, V12, P87, DOI 10.1002/bies.950120207; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Kamakaka RT, 1996, MOL CELL BIOL, V16, P810; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lagarkova MA, 1998, J CELL BIOCHEM, V69, P13, DOI 10.1002/(SICI)1097-4644(19980401)69:1<13::AID-JCB2>3.0.CO;2-Y; Leach TJ, 2000, MOL CELL BIOL, V20, P6308, DOI 10.1128/MCB.20.17.6308-6316.2000; Lee CH, 1999, P NATL ACAD SCI USA, V96, P12311, DOI 10.1073/pnas.96.22.12311; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Lemaitre JM, 1998, J CELL BIOL, V142, P1159, DOI 10.1083/jcb.142.5.1159; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LI R, 1994, P NATL ACAD SCI USA, V91, P7051, DOI 10.1073/pnas.91.15.7051; Logie C, 1999, METHOD ENZYMOL, V304, P726; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; MAJUMDER S, 1994, J CELL BIOCHEM, V55, P59, DOI 10.1002/jcb.240550107; Maric C, 1999, J MOL BIOL, V291, P775, DOI 10.1006/jmbi.1999.3017; MARILLEY M, 1989, EXP CELL RES, V180, P475, DOI 10.1016/0014-4827(89)90074-8; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; MEISSNER B, 1991, CHROMOSOMA, V101, P222, DOI 10.1007/BF00365154; MICHELI G, 1993, CHROMOSOMA, V102, P478, DOI 10.1007/BF00357103; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Mizushima T, 2000, GENE DEV, V14, P1631; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; POMMIER Y, 1991, J MOL BIOL, V222, P909, DOI 10.1016/0022-2836(91)90585-T; RAZIN SV, 1986, NUCLEIC ACIDS RES, V14, P8189, DOI 10.1093/nar/14.20.8189; REITMAN M, 1990, MOL CELL BIOL, V10, P2774, DOI 10.1128/MCB.10.6.2774; Ridgway P, 2000, J CELL SCI, V113, P2647; Sasaki T, 1999, MOL CELL BIOL, V19, P547; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; SMITH HC, 1984, J CELL BIOL, V99, P1794, DOI 10.1083/jcb.99.5.1794; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Travers A, 1999, CELL, V96, P311, DOI 10.1016/S0092-8674(00)80543-7; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; VANDERVELDEN HMW, 1984, FEBS LETT, V171, P13, DOI 10.1016/0014-5793(84)80451-2; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Vassetzky Y, 2000, GENE DEV, V14, P1541; Vestner B, 1998, J BIOL CHEM, V273, P9409, DOI 10.1074/jbc.273.16.9409; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; VOGELSTEIN B, 1980, CELL, V22, P79, DOI 10.1016/0092-8674(80)90156-7; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WOLFFE AP, 1986, CELL, V47, P217, DOI 10.1016/0092-8674(86)90444-7; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Wolffe AP., 1998, CHROMATIN STRUCTURE; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601	96	45	46	1	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3086	3093		10.1038/sj.onc.1204333	http://dx.doi.org/10.1038/sj.onc.1204333			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420724				2022-12-17	WOS:000169308500012
J	Sharma, SV; Oneyama, C; Yamashita, Y; Nakano, H; Sugawara, K; Hamada, M; Kosaka, N; Tamaoki, T				Sharma, SV; Oneyama, C; Yamashita, Y; Nakano, H; Sugawara, K; Hamada, M; Kosaka, N; Tamaoki, T			UCS15A, a non-kinase inhibitor of Src signal transduction	ONCOGENE			English	Article						Src; UCS15A; bone resorption inhibitor; protein-protein interaction	PP60C-SRC PROTEIN-KINASE; FOCAL ADHESION KINASE; RESORPTION IN-VITRO; C-SRC; BONE-RESORPTION; SH3 DOMAIN; OSTEOCLAST FUNCTION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; GROWTH-FACTOR	Src tyrosine kinase plays key roles in signal transduction following growth factor stimulation and integrin-mediated cell-substrate adhesion. Since src-signal transduction defects are implicated in a multitude of human diseases, we have sought to develop new ways to identify small molecule inhibitors using a yeast-based, activated-src over-expression system, In the present study, we describe the identification of a unique src-signal transduction inhibitor, UCS15A, UCS15A was found to inhibit the src specific tyrosine phosphorylation of numerous proteins in v-src-transformed cells, Two of these phosphoproteins were identified as bona-fide src substrates, cortactin and Sam68, UCS15A differed from conventional src-inhibitors in that it did not inhibit the tyrosine kinase activity of src, In addition, UCS15A appeared to differ from src-destabilizing agents such as herbimycin and radicicol that destabilize src by interfering with Hsp90. Our studies suggest that UCS15A exerted its src-inhibitory effects by a novel mechanism that involved disruption of protein-protein interactions mediated by src, One of the biological consequences of src-inhibition by UCS15A was its ability to inhibit the bone resorption activity of osteoclasts in vitro, These data suggest that UCS15A may inhibit the bone resorption activity of osteoclasts, not by inhibiting src tyrosine kinase activity, but by disrupting the interaction of proteins associated with src, thereby modulating downstream events in the src signal transduction pathway.	Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 194, Japan; Kyowa Hakko Kogyo Co Ltd, Pharmaceut Res Labs, Nagaizumi, Shizuoka 411, Japan; Natl Inst Basic Biol, Okazaki Natl Res Inst, Div Morphogenesis, Okazaki, Aichi 4448585, Japan	Kyowa Kirin Ltd; Kyowa Kirin Ltd; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Okazaki Institute for Integrative Bioscience (OIIB)	Sharma, SV (corresponding author), Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, 3-6-6 Asahimachi, Machida, Tokyo 194, Japan.							AKATSU T, 1992, J BONE MINER RES, V7, P1297; Blair HC, 1996, J CELL BIOCHEM, V61, P629, DOI 10.1002/(SICI)1097-4644(19960616)61:4<629::AID-JCB17>3.0.CO;2-A; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUGGE JS, 1987, MOL CELL BIOL, V7, P2180, DOI 10.1128/MCB.7.6.2180; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHENG HC, 1992, J BIOL CHEM, V267, P9248; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; Fischer RS, 2000, VIROLOGY, V269, P404, DOI 10.1006/viro.2000.0232; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; HALL GE, 1987, CALCIFIED TISSUE INT, V40, P212, DOI 10.1007/BF02556624; HALL TJ, 1994, BIOCHEM BIOPH RES CO, V199, P1237, DOI 10.1006/bbrc.1994.1363; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Huang JQ, 1999, ONCOGENE, V18, P4099, DOI 10.1038/sj.onc.1202779; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JACOBS C, 1983, CANCER RES, V43, P1696; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo-126-5-2733; KWON HJ, 1995, J BIOCHEM-TOKYO, V118, P221, DOI 10.1093/oxfordjournals.jbchem.a124882; KWON HJ, 1992, CANCER RES, V52, P6926; KWON HJ, 1992, BIOSCI BIOTECH BIOCH, V56, P538; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Missbach M, 1999, BONE, V24, P437, DOI 10.1016/S8756-3282(99)00020-4; Miyazaki T, 2000, J BONE MINER RES, V15, P41, DOI 10.1359/jbmr.2000.15.1.41; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OKAMURA H, 1994, ONCOGENE, V9, P2293; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; Sharma SV, 1998, ONCOGENE, V16, P2639, DOI 10.1038/sj.onc.1201790; Shen ZW, 1999, ONCOGENE, V18, P4647, DOI 10.1038/sj.onc.1203079; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; Sugawara K, 1998, ANAL BIOCHEM, V255, P204, DOI 10.1006/abio.1997.2474; SUZUKI G, 1983, Patent No. 58116686; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; UEHARA Y, 1988, J ANTIBIOT, V41, P831, DOI 10.7164/antibiotics.41.831; Viola R, 1999, KNEE SURG SPORT TR A, V7, P25, DOI 10.1007/s001670050116; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; YONEDA T, 1993, J CLIN INVEST, V91, P2791, DOI 10.1172/JCI116521; ZHAO JF, 1995, ONCOGENE, V11, P161; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864	69	45	48	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2068	2079		10.1038/sj.onc.1204296	http://dx.doi.org/10.1038/sj.onc.1204296			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360191				2022-12-17	WOS:000168116700002
J	Galy, B; Creancier, L; Zanibellato, C; Prats, AC; Prats, H				Galy, B; Creancier, L; Zanibellato, C; Prats, AC; Prats, H			Tumour suppressor p53 inhibits human fibroblast growth factor 2 expression by a post-transcriptional mechanism	ONCOGENE			English	Article						FGF; p53; p73; post-transcriptional control; growth factor; tumour suppressor	INTERNAL RIBOSOME ENTRY; FACTOR MESSENGER-RNA; ALTERNATIVE TRANSLATION; HUMAN CANCERS; FIBROBLAST-GROWTH-FACTOR-2; INITIATION; PROTEIN; CELLS; GROWTH-FACTOR-2; LOCALIZATION	Fibroblast growth factor-2 (FGF-2) is a powerful mitogen and angiogenic factor whose expression is strongly regulated at the translational level. The constitutive upregulation of FGF-2 isoforms in transformed cells prompted us to investigate the posttranscriptional effects of a tumour suppressor, p53, on FGF-2 expression. We show here in human primary skin fibroblasts that the cell density-dependent variation of FGF-2 mRNA translatability was inversely correlated with endogenous p53 expression. Transient cell transfection revealed an inhibitory effect of wild-type p53 on the expression of chimeric FGF-CAT proteins. RNAse mapping experiments ruled out any effect of p53 on FGF-CAT mRNA accumulation, suggesting a translational inhibition. This inhibition was mediated by the FGF-2 mRNA leader, but not by vascular endothelial growth factor or platelet derived growth factor mRNA leaders. Neither p53-like protein p73, nor p21/waf had any inhibitory activity. Furthermore a set of hot spot mutants of p53 bearing mutations in the DNA binding domain had no post-transcriptional inhibitory effect. In contrast a p53 mutant of the transactivating domain was still able to block FGF - CAT expression, indicating that the post-transcriptional activity of p53 described here was independent of the trans-activation of target genes. Such data reveal a novel mechanism by which p53 efficiently blocks the expression of a major proliferating, anti-apoptotic and angiogenic gene.	CHU Rangueil, Inst Federat Rech Louis Bugnard, INSERM U397, F-31403 Toulouse 04, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Prats, H (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Prats, Anne-Catherine/E-5051-2016	Prats, Anne-Catherine/0000-0002-5282-3776; Prats, Herve/0000-0002-4861-2167; Galy, Bruno/0000-0002-0501-6357				Arnaud E, 1999, MOL CELL BIOL, V19, P505; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bernstein J, 1997, J BIOL CHEM, V272, P9356; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Bouck N, 1996, BBA-REV CANCER, V1287, P63, DOI 10.1016/0304-419X(96)00005-4; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ewen ME, 1996, BBA-REV CANCER, V1242, P181, DOI 10.1016/0304-419X(95)00010-D; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FUKS Z, 1994, CANCER RES, V54, P2582; Galy B, 1999, CANCER RES, V59, P165; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Nishimura T, 1999, BBA-GENE STRUCT EXPR, V1444, P148, DOI 10.1016/S0167-4781(98)00255-3; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696	33	45	47	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1669	1677		10.1038/sj.onc.1204271	http://dx.doi.org/10.1038/sj.onc.1204271			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313915				2022-12-17	WOS:000167750900001
J	Shah, N; Thomas, TJ; Lewis, JS; Klinge, CM; Shirahata, A; Gelinas, C; Thomas, T				Shah, N; Thomas, TJ; Lewis, JS; Klinge, CM; Shirahata, A; Gelinas, C; Thomas, T			Regulation of estrogenic and nuclear factor kappa B functions by polyamines and their role in polyamine analog-induced apoptosis of breast cancer cells	ONCOGENE			English	Review						polyamines; nuclear factor kappa B; estrogen receptor; breast cancer	SPERMIDINE SPERMINE N1-ACETYLTRANSFERASE; CREB-BINDING PROTEIN; ORNITHINE DECARBOXYLASE; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASES; INDUCIBLE CHEMORESISTANCE; GROWTH-INHIBITION; RESPONSE ELEMENT; CARCINOMA-CELLS; GENE-EXPRESSION	The natural polyamines -putrescine, spermidine, and spermine- are essential for cell growth and differentiation. Polyamines are involved in several gene regulatory functions, although their mechanism(s) of action has not been elucidated. We investigated the role of polyamines in the function of NF-kappaB and estrogen receptor-alpha (ER alpha), two transcription factors implicated in breast cancer cell proliferation and cell survival, using MCF-7 breast cancer cells. We found that spermine facilitated the binding of ER alpha and NF-kappaB to estrogen response element (ERE)- and NF-kappaB response element (NRE), respectively, and enhanced ER alpha -mediated transcriptional activation in transient transfection experiments. We also found that the association of the co-regulatory protein CBP/p300 with ER alpha and NF-kappaB was increased by spermine treatment of MCF-7 cells. Spermine also increased the nuclear translocation of NF-kappaB compared to the control. In contrast, treatment of MCF-7 cells with polyamine analogs, BE-3-4-3 and BE-3-3-3, resulted in transcriptional inhibition of both ERE- and NRE-driven reporter plasmids, in addition, polyamine analogs inhibited the association of ER alpha and NF-kappaB with CBP/p300 and were unable to facilitate nuclear translocation of NF-kappaB, APO-BRDU assay demonstrated that polyamine analogs induced apoptosis, with a loss of the anti-apoptotic protein Bcl-2, These data show a gene regulatory function of polyamines involving transcriptional activation of ER alpha and NF-kappaB, potentially leading to the up-regulation of genes involved in breast cancer cell proliferation. Our results with BE-3-4-3 and BE-3-3-3 suggest that down-regulation of ER alpha- and NF-kappaB-regulated genes is a possible mechanism for the action of polyamine analogs in inducing apoptosis of breast cancer cells.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Environm & Community Med, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Environm & Occupat Hlth Sci Inst, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, New Brunswick, NJ 08903 USA; Rutgers State Univ, Nutr Sci Grad Program, New Brunswick, NJ 08903 USA; Univ Louisville, Dept Biochem & Mol Biol, Sch Med, Louisville, KY 40292 USA; Josai Univ, Fac Pharmaceut Sci, Sakado, Saitama 35002, Japan	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; University of Louisville; Josai University	Thomas, T (corresponding author), 125 Paterson St,Clin Acad Bldg,Room 7090, New Brunswick, NJ 08901 USA.			Klinge, Carolyn/0000-0002-3358-4378; Shah, Neha/0000-0002-9286-3801	NCI NIH HHS [CA 42439, CA 80163, CA 73058] Funding Source: Medline; NIDDK NIH HHS [DK 53220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R23CA042439, R01CA080163, R01CA042439, R01CA073058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berchtold CM, 1998, J CELL PHYSIOL, V174, P380, DOI 10.1002/(SICI)1097-4652(199803)174:3<380::AID-JCP12>3.0.CO;2-D; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BISWAD SK, 2000, P NATL ACAD SCI USA, V97, P8542; Boland MP, 1998, J BIOL CHEM, V273, P15494, DOI 10.1074/jbc.273.25.15494; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bryans M, 1996, BIOCHEM BIOPH RES CO, V226, P618, DOI 10.1006/bbrc.1996.1405; Canizares F, 1999, CLIN CANCER RES, V5, P2035; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; CELANO P, 1989, J BIOL CHEM, V264, P8922; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Cohen S, 1998, GUIDE POLYAMINES; Cusack JC, 2000, CANCER RES, V60, P2323; DAVIDSON NE, 1993, CANCER RES, V53, P2071; Davidson NE, 1999, ENDOCR-RELAT CANCER, V6, P69, DOI 10.1677/erc.0.0060069; DAVIS RH, 1992, MICROBIOL REV, V56, P280, DOI 10.1128/MMBR.56.2.280-290.1992; Delzenne NM, 2000, J NUTR, V130, P2456, DOI 10.1093/jn/130.10.2456; Desiderio MA, 1999, FEBS LETT, V455, P149, DOI 10.1016/S0014-5793(99)00873-X; Doerre S, 1999, J IMMUNOL, V163, P269; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Faaland CA, 2000, BIOCHEM CELL BIOL, V78, P415, DOI 10.1139/bcb-78-4-415; FAALAND CA, 1995, CELL GROWTH DIFFER, V6, P115; FEUERSTEIN BG, 1990, NUCLEIC ACIDS RES, V18, P1271, DOI 10.1093/nar/18.5.1271; Gabrielson EW, 1999, CLIN CANCER RES, V5, P1638; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; HIBSHOOSH H, 1991, ONCOGENE, V6, P739; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hu RH, 1997, BIOCHEM J, V328, P307, DOI 10.1042/bj3280307; Huang Y, 1997, BREAST CANCER RES TR, V42, P73, DOI 10.1023/A:1005777219997; IGARASHI K, 1995, CANCER RES, V55, P2615; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Klinge CM, 1997, J BIOL CHEM, V272, P31465, DOI 10.1074/jbc.272.50.31465; Kramer DL, 1997, CANCER RES, V57, P5521; Krappmann D, 1997, IMMUNOBIOLOGY, V198, P3, DOI 10.1016/S0171-2985(97)80022-8; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kurebayashi S, 1997, J STEROID BIOCHEM, V60, P11, DOI 10.1016/S0960-0760(96)00175-6; Leveque J, 1999, ANTICANCER RES, V19, P2275; Leveque J, 2000, BREAST CANCER RES TR, V60, P99, DOI 10.1023/A:1006319818530; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; MANNI A, 1995, CANCER LETT, V92, P49, DOI 10.1016/0304-3835(95)03763-M; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; Matsushita H, 2000, CIRC RES, V86, P974, DOI 10.1161/01.RES.86.9.974; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McCloskey DE, 1996, CLIN CANCER RES, V2, P441; MCCLOSKEY DE, 1995, CANCER RES, V55, P3233; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MUNOZ E, 1994, J VIROL, V68, P8035; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; OBRIEN MJ, 1992, CANCER-AM CANCER SOC, V70, P1317, DOI 10.1002/1097-0142(19920901)70:3+<1317::AID-CNCR2820701519>3.0.CO;2-X; OBrien TG, 1997, CANCER RES, V57, P2630; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PANAGIOTIDIS CA, 1995, NUCLEIC ACIDS RES, V23, P1800, DOI 10.1093/nar/23.10.1800; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PERA PJ, 1986, CANCER RES, V46, P1148; Porter C W, 1988, Adv Exp Med Biol, V250, P677; PORTER CW, 1994, CANCER RES, V54, P5917; PORTER CW, 1990, BIOCHEM J, V268, P207, DOI 10.1042/bj2680207; Rauch BH, 2000, FEBS LETT, V481, P3, DOI 10.1016/S0014-5793(00)01957-8; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Rouet-Benzineb P, 2000, J MOL CELL CARDIOL, V32, P1767, DOI 10.1006/jmcc.2000.1211; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SCALABRINO G, 1991, MOL CELL ENDOCRINOL, V77, P37, DOI 10.1016/0303-7207(91)90057-Y; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; Shah N, 1999, BIOCHEMISTRY-US, V38, P14763, DOI 10.1021/bi991291v; Sharma A, 1997, CLIN CANCER RES, V3, P1239; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Smith MK, 1998, CARCINOGENESIS, V19, P1409, DOI 10.1093/carcin/19.8.1409; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEIN B, 1995, MOL CELL BIOL, V15, P4971; TABIB A, 1994, BIOCHEM BIOPH RES CO, V202, P720, DOI 10.1006/bbrc.1994.1990; Tabib A, 1999, INT J BIOCHEM CELL B, V31, P1289, DOI 10.1016/S1357-2725(99)00098-9; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; THOMAS T, 1995, J STEROID BIOCHEM, V54, P89, DOI 10.1016/0960-0760(95)00126-K; Thomas T, 1999, J MOL ENDOCRINOL, V22, P131, DOI 10.1677/jme.0.0220131; Thomas T, 1997, NUCLEIC ACIDS RES, V25, P2396, DOI 10.1093/nar/25.12.2396; THOMAS T, 1993, BREAST CANCER RES TR, V29, P189; Thomas TJ, 1998, BREAST CANCER RES TR, V47, P181, DOI 10.1023/A:1005925931215; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WATANABE S, 1991, J BIOL CHEM, V266, P20803; Zhang GJ, 1999, CLIN CANCER RES, V5, P2971; Zhang GJ, 1998, ONCOL REP, V5, P1211; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	112	45	46	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1715	1729		10.1038/sj.onc.1204247	http://dx.doi.org/10.1038/sj.onc.1204247			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313919				2022-12-17	WOS:000167750900005
J	Chai, YL; Chipitsyna, G; Cui, JQ; Liao, BS; Liu, S; Aysola, K; Yezdani, M; Reddy, ESP; Rao, VN				Chai, YL; Chipitsyna, G; Cui, JQ; Liao, BS; Liu, S; Aysola, K; Yezdani, M; Reddy, ESP; Rao, VN			c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells	ONCOGENE			English	Article						c-Fos; BRCA1/BRCA1a/1b; Elk-1; growth suppression; breast cancer; protein-protein interaction	ETS TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR; DNA-BINDING; PROTEIN ELK-1; IN-VIVO; EXPRESSION; ACTIVATION; GENE; DOMAINS; COMPLEX	Elk-1, a c-Fos protooncogene regulator, which belongs to the ETS-domain family of transcriptional factors, plays an important role in the induction of immediate early gene expression in response to a variety of extracellular signals. In this study, we demonstrate for the first time the in, vitro and in vivo interaction of Elk-1 with BRCA1 splice variants BRCA1a and BRCA1b using GST-pull down assays, co-imunoprecipitations/Western blot analysis of cell extracts from breast cancer cells and mammalian two-hybrid assays. We have localized the BRCA1 interaction domain of Elk-1 protein to the conserved ETS domain, a motif involved in DNA binding and protein-protein interactions. We also observed binding of BRCA1 proteins to other ETS-domain transcription factors SAP1, ETS-1, ERG-2 and Fli-1 but not to Elk-1 splice variant Delta Elk-1 and c-Fos protooncogene, Both BRCA1a and BRCA1b splice variants function as growth suppressors of human breast cancer cells. interestingly, our studies reveal that although both Elk-1 and SAP-1 are highly homologous members of a subfamily of ETS domain proteins called ternary complex factors, it is only Elk-1 but not SAP-I that can augment the growth suppressive function of BRCA1a/1b proteins in breast cancer cells, Thus Elk-1 could be a potential downstream target of BRCA1 in its growth control pathway, Furthermore, we hare observed inhibition of c-Fos promoter activity in BRCA1a transfected stable breast cancer cells and over expression of BRCA1a/1b attenuates MEK-induced SRE activation in vivo. These results demonstrate for the first time a link between the growth suppressive function of BRCA1a/1b proteins and signal transduction pathway involving Elk-1 protein, All these results taken together suggest that one of the mechanisms by which BRCA1a/1b proteins function as growth/tumor suppressors is through inhibition of the expression of Elk-1 target genes like c-Fos.	Med Coll Penn & Hahnemann Univ, Ctr Canc, Dept Med, Program Canc Genet, Philadelphia, PA 19102 USA	Drexel University	Rao, VN (corresponding author), Med Coll Penn & Hahnemann Univ, Ctr Canc, Dept Med, Program Canc Genet, 245 N 15th St,New Coll Bldg,MS 481, Philadelphia, PA 19102 USA.				NATIONAL CANCER INSTITUTE [R01CA085343, R01CA058642, R01CA057322] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1CA58642, 1RO1CA85343, 1RO1CA57322] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Cui JQ, 1998, ONCOL REP, V5, P585; Cui JQ, 1998, ONCOL REP, V5, P591; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Drewett V, 2000, J BIOL CHEM, V275, P1757, DOI 10.1074/jbc.275.3.1757; EASTON DF, 1995, AM J HUM GENET, V56, P265; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; FORD D, 1995, AM J HUM GENET, V57, P1457; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Katsama A, 2000, CANCER LETT, V150, P165, DOI 10.1016/S0304-3835(99)00386-9; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; Lu ML, 1996, CANCER RES, V56, P4578; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nozaki M, 1996, DNA CELL BIOL, V15, P855, DOI 10.1089/dna.1996.15.855; Ozcelik H, 1998, INT J CANCER, V77, P1; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; Rao VN, 1996, ONCOGENE, V12, P523; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; Shao NS, 1998, ONCOGENE, V17, P527, DOI 10.1038/sj.onc.1201931; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; SHYAM E, 1990, CANCER RES, V50, P5013; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	59	45	48	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1357	1367		10.1038/sj.onc.1204256	http://dx.doi.org/10.1038/sj.onc.1204256			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313879				2022-12-17	WOS:000167495000009
J	Kim, SG; Kim, SN; Jong, HS; Kim, NK; Hong, SH; Kim, SJ; Bang, YJ				Kim, SG; Kim, SN; Jong, HS; Kim, NK; Hong, SH; Kim, SJ; Bang, YJ			Caspase-mediated Cdk2 activation is a critical step to execute transforming growth factor-beta 1-induced apoptosis in human gastric cancer cells	ONCOGENE			English	Article						TGF-beta 1; apoptosis; caspase-3; cyclin-dependent kinase-2; p21(cip1); p27(kip1)	DEPENDENT PROTEIN-KINASES; FACTOR-BETA; TGF-BETA; CYCLE ARREST; RETINOBLASTOMA PROTEIN; EPITHELIAL-CELLS; THYMOCYTE APOPTOSIS; HEPATOMA-CELLS; INHIBITION; DEATH	Although TGF-beta1, a growth inhibitor, is known to also induce apoptosis, the molecular mechanism of this apoptosis is largely undefined, Here, we identify the mechanism of TGF-beta1-induced apoptosis in SNU-16 human gastric cancer cells. Cell cycle and TUNEL analysis showed that, upon TGF-beta1 treatment, cells mere initially arrested at the G1 phase and then driven into apoptosis, Of note, caspase-3 was activated in accordance with TGF-beta1-induced G1 arrest, Activated caspase-3 is targeted to cleave p21(cip1), p27(kip1), and Rb, which play important roles in TGF-beta -induced G1 arrest, into;inactive fragments. Subsequently, Cdk2 was aberrantly activated due to the cleavage of p21 and p27, We found that the inhibition of Cdk2 activity efficiently blocks TGF-beta1-induced apoptosis, whereas it did; not prevent caspase-3 activation or the subsequent cleavage of target proteins, In contrast, the suppression of caspase-3 activity inhibited the cleavage of target proteins, the activation of Cdk2, and the induction of apoptosis. Taken together, our results suggest that activation of caspase-3 by TGF-beta1 may initiate the conversion from G1 cell cycle arrest to apoptosis via the cleavage of p21, p27 and Rb, which in turn causes Cdk2 activation and, most significantly, Cdk2 activation as a downstream effector of caspase is a critical step for the execution TGF-beta1-induced apoptosis.	Seoul Natl Univ, Coll Med, Dept Internal Med, Canc Res Inst, Seoul 110744, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bang, YJ (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, Canc Res Inst, 28 Yongon Dong, Seoul 110744, South Korea.		Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Fan GS, 1996, ONCOGENE, V12, P1909; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; GIRARD F, 1991, CELL, V67, P1; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KO TC, 1995, ONCOGENE, V10, P177; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Mgbonyebi OP, 1999, CANCER RES, V59, P1903; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; PARK JG, 1990, CANCER RES, V50, P2773; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Schrantz N, 1999, ONCOGENE, V18, P3511, DOI 10.1038/sj.onc.1202718; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785	45	45	46	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1254	1265		10.1038/sj.onc.1204203	http://dx.doi.org/10.1038/sj.onc.1204203			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313870				2022-12-17	WOS:000167570100013
J	Ahomadegbe, JC; Tourpin, S; Kaghad, M; Zelek, L; Vayssade, M; Mathieu, MC; Rochard, F; Spielmann, M; Tursz, T; Caput, D; Riou, G; Benard, J				Ahomadegbe, JC; Tourpin, S; Kaghad, M; Zelek, L; Vayssade, M; Mathieu, MC; Rochard, F; Spielmann, M; Tursz, T; Caput, D; Riou, G; Benard, J			Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: Prevalence of alterations in inflammatory breast cancers	ONCOGENE			English	Article						p73; monoallelic expression; inflammatory breast carcinoma	TUMOR-SUPPRESSOR GENE; P53; MUTATION; OVEREXPRESSION; PROTEIN; NEUROBLASTOMA; CARCINOMA; DELETION	The p73 gene is a p53 homologue located at 1p36-33, a region submitted to deletions in breast cancer (BC) and putatively imprinted. To study whether p73 was associated with breast carcinogenesis, loss of heterozygosity (LOH), allele expression and transcript levels were assessed in 59 BC, including 39 BC presenting no inflammatory symptoms (NBC) and 20 inflammatory BC (IBC). IBC is a rare but aggressive form of cancer with a very Door prognosis. Normal breast epithelium (BE) and lymphocytes from patients were used as controls. StyI polymorphism generating GC and/or AT alleles was used to select 22 heterozygous patients, p73 LOH was significantly higher in IBC than in NBC [five of eight cases (62%) versus two of 14 cases (14%); Fisher's exact test, P = 0.05]. p73 was biallelically expressed in all BE. In contrast, 12 of 16 (75%) BC were monoallelically expressed, showing that allele silencing was significantly associated with breast carcinogenesis (P = 0.012), AT being the preferential silent allele (10 out of 12 tumours). p73 mRNA levels in NBC and IBC were two- and threefold lower than in BE, respectively, suggesting that decreased expression could be related to tumour aggressiveness. In conclusion, LOH, allele silencing and decreased expression of the p73 gene may play a role in breast carcinogenesis.	Inst Gustave Roussy, Dept Biol Clin, Unite Marqueurs Genet Canc, F-94800 Villejuif, France; Inst Gustave Roussy, Dept Med, F-94800 Villejuif, France; Inst Gustave Roussy, Dept Anatomopathol, F-94800 Villejuif, France; Inst Gustave Roussy, Dept Chirurg, F-94800 Villejuif, France; Sanofi Rech, F-31676 Labege, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Sanofi-Aventis; Sanofi France	Benard, J (corresponding author), Inst Gustave Roussy, Dept Biol Clin, Unite Marqueurs Genet Canc, Rue Camille Desmoulins, F-94800 Villejuif, France.		Laurent, Zelek/F-2906-2017	Laurent, Zelek/0000-0001-7455-2009				AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; BEAHRS OH, 1992, AM JOINT COMMITTEE C, P149; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; BIECHE I, 1994, CANCER RES, V54, P4274; Cordon-Cardo C, 1999, J EXP MED, V190, P1367, DOI 10.1084/jem.190.10.1367; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195; Han S, 1999, EUR J SURG ONCOL, V25, P194, DOI 10.1053/ejso.1998.0626; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Mai M, 1998, CANCER RES, V58, P2347; Mai M, 1998, ONCOGENE, V17, P1739, DOI 10.1038/sj.onc.1202099; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; PETER M, 1992, INT J CANCER, V52, P544, DOI 10.1002/ijc.2910520408; RIOU G, 1993, J NATL CANCER I, V85, P1765, DOI 10.1093/jnci/85.21.1765; Shishikura T, 1999, INT J CANCER, V84, P321, DOI 10.1002/(SICI)1097-0215(19990621)84:3<321::AID-IJC21>3.0.CO;2-S; SHITTOOR SR, 1998, BREAST COMPREHENSIVE, V2, P1260; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Zaika AI, 1999, CANCER RES, V59, P3257	22	45	46	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5413	5418		10.1038/sj.onc.1203914	http://dx.doi.org/10.1038/sj.onc.1203914			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103943				2022-12-17	WOS:000165302300013
J	Canhoto, AJ; Chestukhin, A; Litovchick, L; DeCaprio, JA				Canhoto, AJ; Chestukhin, A; Litovchick, L; DeCaprio, JA			Phosphorylation of the retinoblastoma-related protein p130 in growth-arrested cells	ONCOGENE			English	Article						p130; G0; growth arrest; pRb	LARGE-T-ANTIGEN; PHOSPHOAMINO ACID ANALYSIS; LAYER CELLULOSE PLATES; PRB-RELATED PROTEINS; GENE-PRODUCT; SUSCEPTIBILITY GENE; TRANSCRIPTIONAL REPRESSOR; FUNCTIONAL INACTIVATION; TUMOR-SUPPRESSOR; FAMILY PROTEINS	The retinoblastoma family of proteins including pRB, p107 and p130 undergoes cell cycle dependent phosphorylation during the mid-G1 to S phase transition. This phosphorylation is dependent upon the activity of cyclin D/cdk4. In contrast to pRB and p107, p130 is phosphorylated during G0 and the early GT phase of the cell cycle, We observed that p130 is specifically phosphorylated on serine and threonine residues in T98G cells arrested in G0 by serum deprivation or density arrest. Identification of the phospho-serine and phosphothreonine residues revealed that most were clustered within a short co-linear region unique to p130, defined as the Loop, Deletion of the Loop region resulted in a change in the phosphorylation status of p130 under growth arrest conditions. Notably, deletion of the Loop did not affect the ability of p130 to bind to E2F-4 or SV40 Large T antigen, to induce growth arrest in Saos-2 cells, and to become hyperphosphorylated during the proliferative phase of the cell cycle. p130 undergoes specific G0 phosphorylation in a manner that distinguishes it from pRB and p107.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	DeCaprio, JA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Mayer 457,44 Binney St, Boston, MA 02115 USA.			Litovchick, Larisa/0000-0002-9540-597X	NATIONAL CANCER INSTITUTE [R01CA063113, T32CA009031, T32CA009361] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09031, R01-CA63113, 2T32CA09361] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; Cinti C, 2000, CANCER RES, V60, P383; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2000, CANCER RES, V60, P8; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Furukawa Y, 1999, ONCOGENE, V18, P2003, DOI 10.1038/sj.onc.1202500; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hansen K, 1999, ELECTROPHORESIS, V20, P372, DOI 10.1002/(SICI)1522-2683(19990201)20:2<372::AID-ELPS372>3.0.CO;2-R; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; HERZINGER T, 1995, ONCOGENE, V10, P2079; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Lai A, 1999, ONCOGENE, V18, P2091, DOI 10.1038/sj.onc.1202520; Laj A, 1999, MOL CELL BIOL, V19, P6632; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MAYOL X, 1993, ONCOGENE, V8, P2561; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Moberg K, 1996, MOL CELL BIOL, V16, P1436; POLLACK IF, 1990, J NEUROSURG, V73, P106, DOI 10.3171/jns.1990.73.1.0106; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Starborg M, 1996, J CELL SCI, V109, P143; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Thomas NSB, 1998, J BIOL CHEM, V273, P23659, DOI 10.1074/jbc.273.37.23659; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WOLF DA, 1995, ONCOGENE, V10, P2067; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	61	45	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2000	19	44					5116	5122		10.1038/sj.onc.1203893	http://dx.doi.org/10.1038/sj.onc.1203893			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042701				2022-12-17	WOS:000089930100010
J	Yuasa, M; Masutani, C; Eki, T; Hanaoka, F				Yuasa, M; Masutani, C; Eki, T; Hanaoka, F			Genomic structure, chromosomal localization and identification of mutations in the xeroderma pigmentosum variant (XPV) gene	ONCOGENE			English	Article						xeroderma pigmentosum variant (XPV); DNA polymerase eta; genomic structure; chromosome 6; mutation analysis; TATA-less promoter; translesion synthesis	DNA-POLYMERASE-ZETA; THYMINE DIMER; ULTRAVIOLET-LIGHT; MAMMALIAN-CELLS; MOUSE HOMOLOGS; REPLICATION; TRANSCRIPTION; EXTRACTS; BYPASS; HYPERMUTABILITY	The xeroderma pigmentosum variant (XP-V) is one of the most common forms of this cancer-prone syndrome. XP groups A through G are characterized by defective nucleotide excision repair, whereas the XP-V phenotype is proficient in this pathway. The XPV gene encodes DNA polymerase eta, which catalyzes an accurate translesion synthesis, indicating that the XPV gene contributes tumor suppression in normal individuals. Here me describe the genomic structure and chromosomal localization of the XPV gene, which includes 11 exons covering the entire coding sequence, lacks a TATA sequence in the upstream region of the transcription-initiation, and is located at the chromosome band 6p21.1-6p12, Analyses of patient-derived XP-V cell lines strongly suggested that three of four cell lines carried homozygous mutations in the XPV gene, The fourth cell line, XP1RO, carried heterozygous point mutations in the XPV gene, one of which was located at the splice acceptor site of exon 2, resulting in the omission of exon 2 from the mature mRNA, These findings provide a basis for diagnosis and therapy of XP-V patients.	Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	Osaka University; Japan Science & Technology Agency (JST); RIKEN	Hanaoka, F (corresponding author), Osaka Univ, Inst Mol & Cellular Biol, 1-3 Yamadaoka, Suita, Osaka 5650871, Japan.		Masutani, Chikahide/I-6160-2014	Masutani, Chikahide/0000-0002-8600-8227				BrayWard P, 1996, GENOMICS, V32, P1, DOI 10.1006/geno.1996.0070; Carty MP, 1996, J BIOL CHEM, V271, P9637, DOI 10.1074/jbc.271.16.9637; CLEAVER JE, 1972, J INVEST DERMATOL, V58, P124, DOI 10.1111/1523-1747.ep12538913; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; Ensch-Simon I, 1998, BIOCHEMISTRY-US, V37, P8218, DOI 10.1021/bi972460j; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; LIM SK, 1992, EMBO J, V11, P3271, DOI 10.1002/j.1460-2075.1992.tb05405.x; Lin WS, 1999, MUTAT RES-DNA REPAIR, V433, P89, DOI 10.1016/S0921-8777(98)00065-2; Lin WS, 1999, NUCLEIC ACIDS RES, V27, P4468, DOI 10.1093/nar/27.22.4468; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; MISRA RR, 1993, MOL CELL BIOL, V13, P1002, DOI 10.1128/MCB.13.2.1002; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; OKUMURA K, 1995, GENOMICS, V25, P274, DOI 10.1016/0888-7543(95)80135-9; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Svoboda DL, 1998, CANCER RES, V58, P2445; TAKAHASHI E, 1990, HUM GENET, V86, P14; WANG YC, 1991, P NATL ACAD SCI USA, V88, P7810, DOI 10.1073/pnas.88.17.7810; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; WATERS HL, 1993, J INVEST DERMATOL, V101, P744, DOI 10.1111/1523-1747.ep12371686; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; Xiao W, 1998, CARCINOGENESIS, V19, P945, DOI 10.1093/carcin/19.5.945; Yamada A, 2000, NUCLEIC ACIDS RES, V28, P2473, DOI 10.1093/nar/28.13.2473; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823	40	45	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4721	4728		10.1038/sj.onc.1203842	http://dx.doi.org/10.1038/sj.onc.1203842			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032022				2022-12-17	WOS:000089528800006
J	Ge, NL; Rudikoff, S				Ge, NL; Rudikoff, S			Expression of PTEN in PTEN-deficient multiple mgeloma cells abolishes tumor growth in vivo	ONCOGENE			English	Article						multiple myeloma; PTEN; AKT; OPM-2 cells	SUPPRESSOR GENE; FACTOR-I; GERMLINE MUTATIONS; CARCINOMA-CELLS; MYELOMA; INSULIN; BREAST; CANCER; APOPTOSIS; LINES	Biochemical abnormalities associated with the development of multiple myeloma hale been difficult to define especially in terms of demonstrating an irt vivo effect of suspected lesions. Herein, we have identified such a defect associated with lack of expression of PTEN, a cellular phosphatase involved in the regulation of phosphatidylinositol phosphates (PIP's), In myeloma cells, PIP's are required for phosphorylation of Akt, a key event leading to inhibition of apoptosis, Loss of PTEN results in a failure to de-phosphorylate PIP's and a corresponding increase in Akt phosphorylation. OPM-2 cells lacking PTEN expression have the highest level of Akt phosphorylation of eight lines examined. Loss of PTEN was found to be associated with a 630 bp deletion corresponding to amino acids 56-267, Ectopic expression of wild type PTEN in OPM-2 cells inhibited Akt phosphorylation which was correlated with an increase in apoptosis, The in vivo relevance of loss of PTEN expression was demonstrated by injecting control and wild type PTEN transfected OPM-2 cells into SCID mice. Tumors arose at an incidence of 100% in controls, but only 50% (and of smaller size and longer latency) in lon PTEN expressing clones. Importantly, clones expressing high le,els of PTEN failed to produce tumors even at five times the latency period of controls. These results demonstrate that PTEN deletion/mutation is responsible for in vivo growth of this tumor and suggests that PTEN regulation may play an important role in turner development in a subset of multiple myeloma patients.	NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rudikoff, S (corresponding author), NCI, Cellular & Mol Biol Lab, NIH, Bldg 37, Bethesda, MD 20892 USA.				DIVISION OF BASIC SCIENCES - NCI [Z01BC005553] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KC, 1999, SEMIN HEMATOL, V36, P3; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; Boni R, 1998, MELANOMA RES, V8, P300; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Davies MA, 1999, CANCER RES, V59, P2551; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; FREUND GG, 1994, CANCER RES, V54, P3179; Gabrea A, 1999, MOL CELL, V3, P119, DOI 10.1016/S1097-2765(00)80180-X; GE NL, 2000, IN PRESS BLOOD; GeorgiiHemming P, 1996, BLOOD, V88, P2250, DOI 10.1182/blood.V88.6.2250.bloodjournal8862250; Ghosh AK, 1999, GENE, V235, P85, DOI 10.1016/S0378-1119(99)00206-1; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Jelinek DF, 1997, J IMMUNOL, V159, P487; KLEIN B, 1992, HEMATOL ONCOL CLIN N, V6, P273, DOI 10.1016/S0889-8588(18)30344-7; Klein B, 1990, Eur Cytokine Netw, V1, P193; KYLE RA, 1992, HEMATOL ONCOL CLIN N, V6, P347, DOI 10.1016/S0889-8588(18)30348-4; LADANYI M, 1992, AM J PATHOL, V141, P949; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Munshi NC, 1999, SEMIN ONCOL, V26, P28; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PORTIER M, 1992, ONCOGENE, V7, P2539; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Risinger JI, 1997, CANCER RES, V57, P4736; Seiden Michael V., 1994, Current Opinion in Oncology, V6, P41, DOI 10.1097/00001622-199401000-00006; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Uddin S, 1996, EXP HEMATOL, V24, P622; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YASUGA Y, 1995, INT J HEMATOL, V62, P91	32	45	47	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4091	4095		10.1038/sj.onc.1203801	http://dx.doi.org/10.1038/sj.onc.1203801			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962569				2022-12-17	WOS:000088955100002
J	Adryan, B; Decker, HJH; Papas, TS; Hsu, T				Adryan, B; Decker, HJH; Papas, TS; Hsu, T			Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila	ONCOGENE			English	Article						Drosophila; tracheal development; VHL; vascularization	BIOLOGICALLY-ACTIVE PRODUCT; ENDOTHELIAL GROWTH-FACTOR; UBIQUITIN LIGASE COMPLEX; GENETIC INTERFERENCE; RENAL-CARCINOMA; CELL-MIGRATION; PROTEIN; ANGIOGENESIS; TRANSCRIPTION; HYPOXIA	von Hippel-Lindau disease is a hereditary cancer syndrome, Mutations in the VHL tumor suppressor gene predispose individuals to highly vascularized tumors. However, VHL-deficient mice die in utero due to a lack of vascularization in the placenta. To resolve the contradiction, we cloned the Drosophila VHL homologue (d-VHL) and studied its function. It showed an overall 50% similarity to the human counterpart and 76% similarity in the crucial functional domain: the elongin C binding site. The putative d-VHL protein can bind Drosophila elongin C in vitro. During embryogenesis, d-VHL is expressed in the developing tracheal regions where tube outgrowth no longer occurs, Reduced d-VHL activity (using RNA interference methodology) caused breakage of the main vasculature accompanied by excessive looping of smaller branches, whereas overexpression caused a general lack of vasculature. Importantly, human VHL can induce the same gain-of-function phenotypes, VHL is likely involved in halting cell migration at the end of vascular tube outgrowth. Loss of VHL activity can therefore lead to disruption of major vasculature las in the mouse embryo), which requires precise cell movement and tube fusion, or ectopic outgrowth from existing secondary vascular branches las in the adult tumors).	Med Univ S Carolina, Ctr Mol & Struct Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA; Johannes Gutenberg Univ Mainz, Dept Hematol & Oncol, D-55131 Mainz, Germany	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Johannes Gutenberg University of Mainz	Hsu, T (corresponding author), Med Univ S Carolina, Ctr Mol & Struct Biol, HCC 334,86 Jonathan Lucas St, Charleston, SC 29425 USA.			Adryan, Boris/0000-0003-4588-7867; Hsu, Tien/0000-0003-2308-4297	NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057843] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA78582] Funding Source: Medline; NIGMS NIH HHS [GM57843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aso T, 1997, BIOCHEM BIOPH RES CO, V241, P334, DOI 10.1006/bbrc.1997.7819; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P256, DOI 10.1093/nar/26.1.256; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Gnarra JR, 1996, BBA-REV CANCER, V1242, P201, DOI 10.1016/0304-419X(95)00012-5; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; Isaac DD, 1996, GENE DEV, V10, P103, DOI 10.1101/gad.10.1.103; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jarecki J, 1999, CELL, V99, P211, DOI 10.1016/S0092-8674(00)81652-9; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Liu YR, 1999, DEVELOPMENT, V126, P1869; Mantrova EY, 1998, GENE DEV, V12, P1166; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Okuda H, 1999, BIOCHEM BIOPH RES CO, V263, P491, DOI 10.1006/bbrc.1999.1347; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; Pause A, 1999, P NATL ACAD SCI USA, V96, P9533, DOI 10.1073/pnas.96.17.9533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; TanakaMatakatsu M, 1996, DEVELOPMENT, V122, P3697; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8	44	45	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2000	19	24					2803	2811		10.1038/sj.onc.1203611	http://dx.doi.org/10.1038/sj.onc.1203611			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851083				2022-12-17	WOS:000087403600001
J	Shoemaker, AR; Haigis, KM; Baker, SM; Dudley, S; Liskay, RM; Dove, WF				Shoemaker, AR; Haigis, KM; Baker, SM; Dudley, S; Liskay, RM; Dove, WF			Mlh1 deficiency enhances several phenotypes of Apc(Min/+) mice	ONCOGENE			English	Article						Apc; Mlh1; Min; mutation; tumor	DNA MISMATCH REPAIR; NONPOLYPOSIS COLON-CANCER; INTESTINAL TUMORIGENESIS; MIN MICE; CHROMOSOME SYNAPSIS; MUTANT MICE; MOUSE; GENE; NEOPLASIA; MSH2	Defects in APC and DNA mismatch repair genes are associated with a strong predisposition to colon cancer in humans, and numerous mouse strains with mutations in these genes have been generated. In this report we describe the phenotype of Min/+ Mlh1(-/-) mice. We find that these doubly mutant mice develop more than three times the number of intestinal adenomas compared to Min/+ Mlh1(+/+) or (+/-) mice but that these tumors do not show advanced progression in terms of tumor size or histological appearance. Full length Apc protein was not detected in the tumor cells from Min/+ Mlh1(-/-) mice. Molecular analyses indicated that in many tumors from Min/+ Mlh1(-/-) mice, Apc was inactivated by intragenic mutation. Mlh1 deficiency in Min/+ mice also led to an increase in cystic intestinal crypt multiplicity as well as enhancing desmoid tumorigenesis and epidermoid cyst development. Thus, Mlh1 deficiency influences the somatic events involved in the development of most of the phenotypes associated with the Min mutation.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Genet Lab, Madison, WI 53706 USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Oregon Health & Science University	Dove, WF (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA.		Dudley, Samuel C/A-7085-2009		NATIONAL CANCER INSTITUTE [R01CA063677, R37CA063677] Funding Source: NIH RePORTER; NCI NIH HHS [CA07075, CA63677, CA58085] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; Baker SM, 1998, CANCER RES, V58, P1087; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CLARKE AR, 1995, ONCOGENE, V11, P1913; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; de Vries SS, 1999, GENE DEV, V13, P523, DOI 10.1101/gad.13.5.523; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 1999, CANCER RES, V59, P1301; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Gong JG, 1999, NATURE, V399, P806; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Halberg RB, 2000, P NATL ACAD SCI USA, V97, P3461, DOI 10.1073/pnas.050585597; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LEVY DB, 1994, CANCER RES, V54, P5953; Luongo C, 1996, GENE CHROMOSOME CANC, V17, P194, DOI 10.1002/1098-2264(199611)17:3<194::AID-GCC2870170302>3.0.CO;2-E; LUONGO C, 1994, CANCER RES, V54, P5947; Peckham M., 1995, OXFORD TXB ONCOLOGY; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; POTTEN CS, 1988, J CELL SCI, P45; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Reitmair AH, 1996, CANCER RES, V56, P2922; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; SHOEMAKER AR, 1995, CANCER RES, V55, P4479; Shoemaker AR, 1997, CANCER RES, V57, P1999; Shoemaker AR, 1998, P NATL ACAD SCI USA, V95, P10826, DOI 10.1073/pnas.95.18.10826; Shoemaker AR, 1997, BBA-REV CANCER, V1332, pF25, DOI 10.1016/S0304-419X(96)00041-8; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850; Zhang H, 1999, CANCER RES, V59, P3021	42	45	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2000	19	23					2774	2779		10.1038/sj.onc.1203574	http://dx.doi.org/10.1038/sj.onc.1203574			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851078				2022-12-17	WOS:000087318500006
J	Conforti, G; Nardo, T; D'Incalci, H; Stefanini, M				Conforti, G; Nardo, T; D'Incalci, H; Stefanini, M			Proneness to UV-induced apoptosis in human fibroblasts defective in transcription coupled repair is associated with the lack of Mdm2 transactivation	ONCOGENE			English	Article						UV-sensitivity DNA repair; xeroderma pigmentosum; Cockayne syndrome; p53	NUCLEOTIDE EXCISION-REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; COCKAYNE-SYNDROME CELLS; DNA-REPAIR; P53 RESPONSE; PROTEIN STABILITY; ITALIAN PATIENTS; RNA-POLYMERASE; GENE; TRICHOTHIODYSTROPHY	The apoptotic response and the level of expression of p53 and of three genes transcriptionally activated by p53 (Mdm2, p21 and bar) were investigated in UV-sensitive cells from patients with xeroderma pigmentosum (XP) or Cockayne syndome (CS), These disorders are due to different genetic defects affecting transcription-coupled repair (TCR) and/or global genome repair (GGR), the nucleotide excision repair subpathways which remove UV-induced lesions from the transcribed strand of active genes or from the rest of the genome, respectively. After 20 J/m(2) UV light, normal and GGR-defective XP-C fibroblasts showed rapid increase in p53, late induction of Mdm2 and no evidence of apoptosis even 96 h after irradiation. In contrast, in XP-A (defective in GGR and TCR), CS-A and CS-B (defective only in TCR) fibroblasts, the p53 increase was not followed by Mdm2 induction and the persistence of high levels of p53, due to the lack of its degradation by Mdm2, was associated with the appearance of apoptosis, Besides indicating that the persistence of DNA damage in the transcribed strand of active genes leads to apoptosis, these findings provide the first evidence that the lack of activation of Mdm2 plays a key role in the cascade of events leading to apoptosis.	CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy; Ist Ric Farmacol Mario Negri, Dipartimento Oncol, I-20157 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Stefanini, M (corresponding author), CNR, Ist Genet Biochim & Evoluzionist, Via Abbiategrasso 207, I-27100 Pavia, Italy.		D'Incalci, Maurizio/AAA-9021-2020	D'Incalci, Maurizio/0000-0001-8784-1360				BARRETT SF, 1991, MUTAT RES, V255, P281, DOI 10.1016/0921-8777(91)90032-K; Blattner C, 1998, ONCOGENE, V16, P2827, DOI 10.1038/sj.onc.1201827; Bootsma D., 1998, GENETIC BASIS HUMAN, P245; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; CLAVANNE F, 2000, CANCER RES, V60, P1974; Colella S, 1999, HUM MOL GENET, V8, P935, DOI 10.1093/hmg/8.5.935; CONFORTI G, 1989, BLOOD, V73, P1576; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Dumaz N, 1998, CARCINOGENESIS, V19, P1701, DOI 10.1093/carcin/19.9.1701; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; EVANS MK, 1994, MUTAT RES, V314, P221, DOI 10.1016/0921-8777(94)90067-1; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leadon SA, 1999, AM J HUM GENET, V64, P1259, DOI 10.1086/302390; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PARRIS CN, 1993, P NATL ACAD SCI USA, V90, P7260, DOI 10.1073/pnas.90.15.7260; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEFANINI M, 1986, HUM GENET, V74, P107, DOI 10.1007/BF00282072; STEFANINI M, 1992, MUTAT RES, V273, P119, DOI 10.1016/0921-8777(92)90073-C; STEFANINI M, 1993, CARCINOGENESIS, V14, P1101, DOI 10.1093/carcin/14.6.1101; Stefanini M, 1996, HUM GENET, V97, P418; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775	42	45	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2000	19	22					2714	2720		10.1038/sj.onc.1203583	http://dx.doi.org/10.1038/sj.onc.1203583			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851071				2022-12-17	WOS:000087193000007
J	Kao, SY; Lemoine, FJ; Marriott, SJ				Kao, SY; Lemoine, FJ; Marriott, SJ			HTLV-1 Tax protein sensitizes cells to apoptotic cell death induced by DNA damaging agents	ONCOGENE			English	Article						HTLV-1; Tax; apoptosis; nucleotide excision repair; DNA damage	VIRUS TYPE-I; NF-KAPPA-B; TRANSFORMS RAT FIBROBLASTS; LEUKEMIA-VIRUS; INDUCTION; GENE; ACTIVATION; EXPRESSION; TRANSACTIVATOR; INTEGRATION	Transient HTLV-1 Tax expression suppresses cellular nucleotide excision repair, and this effect correlates with Tax transactivation of the proliferating cell nuclear antigen promoter. The inability to repair DNA damage typically induces apoptotic cell death, Therefore, we in investigated the effect of Tax-mediated suppression of DIVA repair on apoptosis in stable Tax-expressing cells. Constitutive Tax expression reduced cellular nucleotide excision repair activity compared with parental and control cells. Tax-expressing cells were also more sensitive to apoptosis induced by DNA damaging agents than control cells. Even though Tax-expressing cells displayed reduced DNA repair, they showed increased DNA replication following UV damage. These results suggest that Tax suppresses the cell's ability to repair DNA damage and stimulates DIVA replication even in the presence of damage. The inability to repair DNA damage is likely to stimulate apoptotic cell death in the majority of Tax-expressing cells while the ability to promote DNA replication may also allow the survival of a small population of cells. We propose that together these effects contribute to the monoclonal nature and low efficiency of HTLV-1 transformation.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Marriott, SJ (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA077371] Funding Source: NIH RePORTER; NCI NIH HHS [CA09197, CA-77371] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; Chen XL, 1997, J GEN VIROL, V78, P3277, DOI 10.1099/0022-1317-78-12-3277; Chlichlia K, 1997, ONCOGENE, V14, P2265, DOI 10.1038/sj.onc.1201070; CHLICHLIA K, 1995, ONCOGENE, V10, P269; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; FUJITA M, 1995, ONCOGENE, V11, P15; GESSAIN A, 1985, LANCET, V2, P407; Hall AP, 1998, J PATHOL, V186, P209; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KAMADA N, 1992, CANCER RES, V52, P1481; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; KELLAND LR, 1993, CRIT REV ONCOL HEMAT, V15, P191, DOI 10.1016/1040-8428(93)90042-3; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kitajima I, 1996, J BONE MINER RES, V11, P200; LENO M, 1995, J EXP MED, V181, P1575, DOI 10.1084/jem.181.4.1575; Los M, 1998, J IMMUNOL, V161, P3050; Lydy SL, 1998, VIROLOGY, V250, P60, DOI 10.1006/viro.1998.9378; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; POIESZ BJ, 1980, J VIROL, V64, P5682; PROSPERI E, 1994, EXP CELL RES, V215, P257, DOI 10.1006/excr.1994.1341; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Ressler S, 1996, FEMS MICROBIOL LETT, V140, P99, DOI 10.1016/0378-1097(96)00166-8; Ressler S, 1997, J VIROL, V71, P1181, DOI 10.1128/JVI.71.2.1181-1190.1997; SAGGIORO D, 1994, LEUKEMIA LYMPHOMA, V12, P281; SANDBERG AA, 1991, CHROMOSOMES HUMAN CA; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534	43	45	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2000	19	18					2240	2248		10.1038/sj.onc.1203559	http://dx.doi.org/10.1038/sj.onc.1203559			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822374				2022-12-17	WOS:000086974100009
J	Kasus-Jacobi, A; Bereziat, V; Perdereau, D; Girard, J; Burnol, AF				Kasus-Jacobi, A; Bereziat, V; Perdereau, D; Girard, J; Burnol, AF			Evidence for an interaction between the insulin receptor and Grb7. A role for two of its binding domains, PIR and SH2	ONCOGENE			English	Article						Grb7; SH2 domain; PIR/BPS; signal transduction; adapter protein; insulin receptor	ADAPTER PROTEIN GRB10; TYROSINE KINASE; I RECEPTOR; GROWTH; CLONING; FAMILY; ASSOCIATION; EXPRESSION; SUBSTRATE; REVEALS	The molecular adapter Grb7 is likely to be implicated in the development of certain cancer types. In this study we show that Grb7 binds the insulin receptors, when they are activated and tyrosine phosphorylated. This interaction is documented by two-hybrid experiments, GST pull-down assays and in vivo coimmunoprecipitations. In addition, our results argue in favor of a preferential association between Grb7 and the insulin receptors when compared to other tyrosine kinase receptors like the EGF receptor, the FGF receptor and Ret, Interestingly, Grb7 is not a substrate of the insulin receptor tyrosine kinase activity. Grb7 binds the activated tyrosine kinase loop of the insulin receptors. Two domains of Grb7 are implicated in the insulin receptor binding: the SH2 domain and the PIR (phosphotyrosine interacting region). The role of these two domains in the interaction,vith the insulin receptor was already reported for Grb10 and Grb14, the other members of the Grb7 family of proteins. However, the relative importance of these domains varies, considering the receptor and the Grb protein. These differences should be a determinant of the specificity of the receptor tyrosine kinase-Grbs binding, and thus of the implication of Grb7/10/14 in signal transduction.	CNRS, UPR 1524, F-92190 Meudon, France	Centre National de la Recherche Scientifique (CNRS)	Burnol, AF (corresponding author), CNRS, UPR 1524, 9 Rue Jules Hetzel, F-92190 Meudon, France.		Burnol, Anne-Francoise/P-2181-2017; KASUS-JACOBI, Anne/V-7799-2019	KASUS-JACOBI, Anne/0000-0003-3844-0450; BEREZIAT, Veronique/0000-0002-9795-549X				Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; KasusJacobi A, 1997, J BIOL CHEM, V272, P17166, DOI 10.1074/jbc.272.27.17166; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; Leavey SF, 1998, AM J PHYSIOL-RENAL, V275, pF770, DOI 10.1152/ajprenal.1998.275.5.F770; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Mano H, 1998, GENES CELLS, V3, P431, DOI 10.1046/j.1365-2443.1998.00201.x; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MORRIONE A, 1997, J BIOL CHEM, V272, P26282; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wang J, 1999, MOL CELL BIOL, V19, P6217; White MF, 1998, CURR TOP MICROBIOL, V228, P179; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942	36	45	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					2052	2059		10.1038/sj.onc.1203469	http://dx.doi.org/10.1038/sj.onc.1203469			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803466				2022-12-17	WOS:000086613200009
J	Brembeck, FH; Opitz, OG; Libermann, TA; Rustgi, AK				Brembeck, FH; Opitz, OG; Libermann, TA; Rustgi, AK			Dual function of the epithelial specific ets transcription factor, ELF3, in modulating differentiation	ONCOGENE			English	Article						ets transcription factors; epithelial cell; differentiation	DNA-BINDING; PROTEIN DOMAINS; GENE-EXPRESSION; FAMILY PROTEINS; ACTIVATION; PROMOTER; MEMBER; PHOSPHORYLATION; PROTOONCOGENE; KERATIN-4	The ets family of transcription factors comprises many members which contribute to diverse cellular functions that vary depending upon the cell- and tissue-type context, Recently, different groups have identified a novel member of the ets family that is epithelial-specific. Variably called ESE-1, ERT, jen, ESX, this gene is designated currently as ELF3, In order to understand transcriptional regulatory mechanisms mediated by ELF3, we investigated its effect on the human keratin 4 gene promoter based upon the role of keratin 4 in early differentiation of the esophageal squamous epithelium, Interestingly, ELF3 suppressed basal keratin 4 promoter activity in both esophageal and cervical epithelial cancer cell Lines, a novel result, while simultaneously activating the late-differentiation linked SPRR2A promoter. Furthermore, serial deletion constructs of the keratin 4 promoter continued to be suppressed by ELF3, a phenomenon that was only partially rescued by ELF3 ets domain mutants, but completely abrogated by deletion of the ELF3 pointed domain. These results suggest that ELF3 may have dual functions in the transcriptional regulation of genes involved in squamous epithelial differentiation. One of these functions may not be exclusively mediated through DNA binding in the context of transcriptional suppression of the keratin 4 promoter.	Univ Penn, Div Gastroenterol, Philadelphia, PA 19014 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19014 USA; Univ Penn, Dept Genet, Philadelphia, PA 19014 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rustgi, AK (corresponding author), Univ Penn, Div Gastroenterol, 415 Curie Blvd,600A CRB, Philadelphia, PA 19014 USA.		Libermann, Towia/F-9866-2010	Libermann, Towia/0000-0002-4006-8179	NIDCR NIH HHS [P01-DE12467] Funding Source: Medline; NIDDK NIH HHS [R01-DK53377, P30 DK50306] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306, R01DK053377] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; Arlotta P, 1997, J BIOL CHEM, V272, P29904, DOI 10.1074/jbc.272.47.29904; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Buttice G, 1996, ONCOGENE, V13, P2297; Chang CH, 1999, ONCOGENE, V18, P3682, DOI 10.1038/sj.onc.1202674; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; JOHN S, 1995, MOL CELL BIOL, V15, P1786; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Mantovani F, 1998, NUCLEIC ACIDS RES, V26, P1433, DOI 10.1093/nar/26.6.1433; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; Ness SL, 1998, J BIOL CHEM, V273, P23904, DOI 10.1074/jbc.273.37.23904; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, GENOMICS, V55, P358, DOI 10.1006/geno.1998.5681; Oettgen P, 1997, GENOMICS, V45, P456, DOI 10.1006/geno.1997.4974; Opitz OG, 1998, J BIOL CHEM, V273, P23912, DOI 10.1074/jbc.273.37.23912; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; REEVES R, 1990, J BIOL CHEM, V265, P8573; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; WERNERT N, 1992, AM J PATHOL, V140, P119	33	45	48	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 6	2000	19	15					1941	1949		10.1038/sj.onc.1203441	http://dx.doi.org/10.1038/sj.onc.1203441			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773884				2022-12-17	WOS:000086424300010
J	D'Errico, M; Calcagnile, A; Canzona, F; Didona, B; Posteraro, P; Cavalieri, R; Corona, R; Vorechovsky, I; Nardo, T; Stefanini, M; Dogliotti, E				D'Errico, M; Calcagnile, A; Canzona, F; Didona, B; Posteraro, P; Cavalieri, R; Corona, R; Vorechovsky, I; Nardo, T; Stefanini, M; Dogliotti, E			UV mutation signature in tumor suppressor genes involved in skin carcinogenesis in xeroderma pigmentosum patients	ONCOGENE			English	Article						skin cancer; XP; p53; PATCHED; UV light	BASAL-CELL CARCINOMAS; HUMAN HOMOLOG; P53 MUTATIONS; SONIC HEDGEHOG; NEVUS SYNDROME; PATCHED GENE; CANCER; REPAIR; SPECTRA; PTCH	Molecular analysis of p53 and patched (PTCH), two candidate tumor suppressor genes for non-melanocytic skin cancer, was performed in skin tumors from six patients affected by the cancer-prone disease xeroderma pigmentosum (XP), UV-specific p53 mutations were detected at a frequency of 38-50% in all the tumor types analysed, including melanomas, Additional analysis of PTCH mutations in the subset of eight basal call carcinomas (BCC) revealed a very high mutation frequency of this gene (90%) which exceeded that detected in the p53 gene in the same tumors (38%), PTCH mutations were predominantly UV-specific C > T transitions, This mutation pattern is different from that reported in BCC from normal donors where PTCH mutation frequency is 27% and mutations are frequently deletions and insertions. These findings suggest that PTCH mutations represent an earlier event in BCC development than p53 alterations and that the inability of XP patients to repair UV-induced PTCH mutations might significantly contribute to the early and frequent appearance of BCC observed in these patients.	Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, I-00161 Rome, Italy; Ist Dermopat Immacolata, I-00167 Rome, Italy; Karolinska Inst, Dept Biosci Novum, Ctr Nutr & Toxicol, S-14157 Huddinge, Sweden; CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy	Istituto Superiore di Sanita (ISS); IRCCS Istituto Dermopatico dell'Immacolata (IDI); Karolinska Institutet; Consiglio Nazionale delle Ricerche (CNR)	Dogliotti, E (corresponding author), Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, Viale Regina Elens 299, I-00161 Rome, Italy.			Didona, Biagio/0000-0001-6635-0490				Aszterbaum M, 1998, J INVEST DERMATOL, V110, P885, DOI 10.1046/j.1523-1747.1998.00222.x; Bodak N, 1999, P NATL ACAD SCI USA, V96, P5117, DOI 10.1073/pnas.96.9.5117; Chidambaram A, 1996, CANCER RES, V56, P4599; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DErrico M, 1997, CANCER RES, V57, P747; Dogliotti E, 1998, RECENT RES CANCER, V154, P97; DUMAZ N, 1993, P NATL ACAD SCI USA, V90, P10529, DOI 10.1073/pnas.90.22.10529; Eklund LK, 1998, MOL CARCINOGEN, V21, P87, DOI 10.1002/(SICI)1098-2744(199802)21:2<87::AID-MC2>3.0.CO;2-L; Gailani MR, 1997, JNCI-J NATL CANCER I, V89, P1103, DOI 10.1093/jnci/89.15.1103; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Giglia G, 1998, CANCER RES, V58, P4402; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; LUBBE J, 1994, J INVEST DERMATOL, V102, P819, DOI 10.1111/1523-1747.ep12381544; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McGregor WG, 1999, MOL CELL BIOL, V19, P147; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; Papp T, 1996, J CANCER RES CLIN, V122, P541, DOI 10.1007/BF01213550; STEFANINI M, 1993, CARCINOGENESIS, V14, P1101, DOI 10.1093/carcin/14.6.1101; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; Unden AB, 1996, CANCER RES, V56, P4562; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; Wicking C, 1997, AM J HUM GENET, V60, P21; Wolter M, 1997, CANCER RES, V57, P2581; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	28	45	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					463	467		10.1038/sj.onc.1203313	http://dx.doi.org/10.1038/sj.onc.1203313			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656695				2022-12-17	WOS:000084873700018
J	Takahashi, T; Suwabe, N; Dai, P; Yamamoto, M; Ishii, S; Nakano, T				Takahashi, T; Suwabe, N; Dai, P; Yamamoto, M; Ishii, S; Nakano, T			Inhibitory interaction of c-Myb and GATA-1 via transcriptional co-activator CBP	ONCOGENE			English	Article						c-Myb; GATA-1; CBP; cell differentiation; hematopoiesis	MURINE HEMATOPOIETIC-CELLS; EMBRYONIC STEM-CELLS; NUCLEAR-PROTEIN CBP; ERYTHROID-DIFFERENTIATION; ONCOGENE PRODUCT; COACTIVATOR CBP; GENE; EXPRESSION; BINDING; PROMOTER	Gene targeting experiments have revealed that transcription factors such as c-Myb and GATA-1 play crucial roles during hematopoietic differentiation. c-Myb is necessary in the immature cells of almost every hematopoietic lineage and GATA-1 is essential for the development of the ervthroid lineage. In addition, CREB-binding protein (CBP) acts as a transcriptional adapter for various transcription factors, including c-Myc and GATA-1. In this paper,,ve show that the transcription factors c-Myb and GATA-1 each inhibit the transcriptional activity of the other and that any possible bipartite complexes c-Myb, GATA-1, and CBP could be formed, but the tripartite complex was hardly formed, The exclusive binding of GATA-1 and c-Myb to CBP is probably the molecular basis for the mutual inhibition of their transcriptional activity. Our data suggest that cross-talk between these three factors might be important for hematopoietic differentiation and that CBP functions as a hey molecule during the process.	Osaka Univ, Dept Mol Cell Biol, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan; RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan	Osaka University; University of Tsukuba; University of Tsukuba; RIKEN	Nakano, T (corresponding author), Osaka Univ, Dept Mol Cell Biol, Microbial Dis Res Inst, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.		Yamamoto, Masayuki/A-4873-2010; Ishii, Shunsuke/A-5271-2016	Yamamoto, Masayuki/0000-0002-9073-9436; Ishii, Shunsuke/0000-0002-6530-2478				Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cross MA, 1997, CIBA F SYMP, V204, P3; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; FERRAO P, 1995, ONCOGENE, V11, P1631; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HIGUCHI R, 1990, PCR TECHNOLOGY PRINC; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; Lipsick JS, 1996, ONCOGENE, V13, P223; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V9, P1123; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOMURA T, 1993, J BIOL CHEM, V268, P21914; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Orita T, 1997, J BIOL CHEM, V272, P23216, DOI 10.1074/jbc.272.37.23216; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; Takahashi S, 1997, J BIOL CHEM, V272, P12611, DOI 10.1074/jbc.272.19.12611; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	43	45	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2000	19	1					134	140		10.1038/sj.onc.1203228	http://dx.doi.org/10.1038/sj.onc.1203228			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644988				2022-12-17	WOS:000084844300015
J	Baldassarre, G; Barone, MV; Belletti, B; Sandomenico, C; Bruni, P; Spiezia, S; Boccia, A; Vento, MT; Romano, A; Pepe, S; Fusco, A; Viglietto, G				Baldassarre, G; Barone, MV; Belletti, B; Sandomenico, C; Bruni, P; Spiezia, S; Boccia, A; Vento, MT; Romano, A; Pepe, S; Fusco, A; Viglietto, G			Key role of the cyclin-dependent kinase inhibitor p27(kip1) for embryonal carcinoma cell survival and differentiation	ONCOGENE			English	Article						embryonal carcinoma; p27; HMBA; differentiation; apoptosis	HEXAMETHYLENE BISACETAMIDE; NEURONAL DIFFERENTIATION; TERMINAL DIFFERENTIATION; POTENTIAL MEDIATOR; GENE-EXPRESSION; CDK INHIBITORS; RETINOIC ACID; G1 PHASE; APOPTOSIS; P21(CIP1/WAF1)	Hexamethylen-bisacetamide (HMBA) represents the prototype of a group of hybrid polar compounds, which induce differentiation in a variety of transformed cells including human embryonal carcinoma cells, Therefore, HMBA has been used in the differentiation therapy of cancer for patients with both hematological and solid malignancies. Upon HMBA treatment, the embryonal carcinoma cell line NTERA-2 clone D1 (NT2/D1) accumulates in G1 and undergoes terminal differentiation. Here we demonstrate that growth arrest and differentiation of NT2/D1 cells induced by HMBA involve increased expression of the cyclin-dependent kinase inhibitor p27, enhanced association of p27 with cyclin E/CDK2 complexes and suppression of kinase activity associated to cyclin E/CDK2 (but not to cyclin D3/CDK4), When HMBA differentiation was induced in the presence of p27 antisense oligonucleotides, NT2/D1 cells failed to arrest growth properly and, in parallel with the reduction of the anti-apoptotic Bcl-2 gene expression, cells underwent massive programmed cell death. Conversely, constitutive expression of p27 into NT2/D1 cells induced a marked reduction in the growth potential of these cells and partially reproduced HMBA-induced modification of surface antigen expression (down-regulation of SSEA-3 expression and up-regulation of VINIS-3 expression). Expression of p21 induced growth arrest but not differentiation. Likewise, inhibition of CDK2 by transfection of a dominant negative CDK2 in NT2/D1 cells or treatment with the kinase inhibitor olomucine induced growth arrest but not differentiation, Therefore, we propose that p27 represents a crucial molecule in HMBA signaling that cannot be replaced by p21, Furthermore, the results obtained with CDK2 inhibitors demonstrate that the block of CDK2; activity is sufficient for growth arrest but not for cell differentiation and suggest that, at least in these cells, growth arrest and differentiation are regulated by two overlapping but different pathways.	Ist Nazl Tumori, Serv Oncol Sperimentale E, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Oncol & Endocrinol Mol & Clin, Cattedra Oncol Med, I-80131 Naples, Italy; Univ Reggio Calabria, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria	Viglietto, G (corresponding author), Ist Nazl Tumori, Serv Oncol Sperimentale E, Via M Semmola, I-80131 Naples, Italy.		Belletti, Barbara/J-2028-2018; Baldassarre, Gustavo/K-1350-2016; Viglietto, Giuseppe/AAC-2852-2019	Belletti, Barbara/0000-0003-2249-0285; Baldassarre, Gustavo/0000-0002-9750-8825; Viglietto, Giuseppe/0000-0003-2327-7515; Fusco, Alfredo/0000-0003-3332-5197; Sandomenico, Claudia/0000-0003-3709-0807; BARONE, Maria Vittoria/0000-0001-6190-4917				Alessi F, 1998, EXP CELL RES, V245, P8, DOI 10.1006/excr.1998.4216; ANDREEFF M, 1992, BLOOD, V80, P2604; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; CONLEY BA, 1992, CANCER CHEMOTH PHARM, V31, P37, DOI 10.1007/BF00695992; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; GUO K, 1995, MOL CELL BIOL, V15, P3823; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KRANENBURG O, 1995, FEBS LETT, V367, P103, DOI 10.1016/0014-5793(95)00587-Y; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Liu JB, 1997, J IMMUNOL, V159, P812; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MARKS PA, 1987, CANCER RES, V47, P659; MIEKRANTZ W, 1995, J CELL BIOCHEM, V58, P160; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Poluha W, 1996, MOL CELL BIOL, V16, P1335; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; SAMBROOK J, 1992, MOL CLONING LAB MANU; Schutte B, 1997, EXP CELL RES, V236, P4, DOI 10.1006/excr.1997.3700; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YOUNG CW, 1988, CANCER RES, V48, P7304	43	45	45	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6241	6251		10.1038/sj.onc.1203031	http://dx.doi.org/10.1038/sj.onc.1203031			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597222				2022-12-17	WOS:000083934100007
J	Jiang, YX; Rom, WN; Yie, TA; Chi, CX; Tchou-Wong, KM				Jiang, YX; Rom, WN; Yie, TA; Chi, CX; Tchou-Wong, KM			Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor	ONCOGENE			English	Article						IGF-IR; glandular differentiation; lung carcinoma cells	GROWTH-FACTOR-I; MOUSE EMBRYO FIBROBLASTS; SIGNAL-TRANSDUCTION; INSULIN; APOPTOSIS; CANCER; TRANSFORMATION; TUMORIGENESIS; INHIBITION; VIVO	Overexpression or activation of insulin-like growth factor I receptor (IGF-IR) has been observed in many human cancers including breast, lung, colon and gastric carcinomas, We demonstrate that inhibition of the endogenous insulin-like growth factor I receptor by stable expression of a dominant-negative IGF-IR represses the transforming activity in vitro and tumorigenicity of human lung carcinoma cells A549 in vivo, The suppression of tumorigenicity in nude mice is correlated with the induction of glandular differentiation. In addition, functional inhibition of the endogenous receptor dramatically increases the sensitivity of A549 cells to a variety of apoptotic signals including UV irradiation and proteasome inhibitors. These effects are due to the formation of a stable heterocomplex of the dominant-negative receptor with the endogenous wild type receptor which reduces the kinase activity of the latter by twofold. Thus, inhibition of the IGF-IR signaling pathway not only suppresses tumorigenicity but also enhances sensitivity to apoptosis-inducing agents. Antagonizing IGF-IR signaling by promoting tumor differentiation and enhancing sensitivity to apoptotic death are potential cancer therapeutic approaches.	NYU, Med Ctr, Dept Med, Div Pulm & Crit Care Med, New York, NY 10016 USA; NYU, Med Ctr, Dept Environm Med, Div Pulm & Crit Care Med, New York, NY 10016 USA; NYU, Dept Pathol, Div Pulm & Crit Care Med, New York, NY 10016 USA; NYU, Med Ctr, Dept Microbiol, Div Pulm & Crit Care Med, New York, NY 10016 USA	New York University; New York University; New York University; New York University	Tchou-Wong, KM (corresponding author), NYU, Med Ctr, Dept Med, Div Pulm & Crit Care Med, 550 1st Ave,MSB 147, New York, NY 10016 USA.			Rom, William/0000-0002-8793-7028	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062055, R01HL059832] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00096] Funding Source: Medline; NHLBI NIH HHS [R01-HL62055, R01-HL59832] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DAmbrosio C, 1997, CANCER RES, V57, P3264; DAmbrosio C, 1996, CANCER RES, V56, P4013; FREED KA, 1989, J MOL ENDOCRINOL, V3, P183, DOI 10.1677/jme.0.0030183; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LEE TC, 1993, CANCER RES, V53, P2858; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LEROITH D, 1995, ANN INTERN MED, V122, P54, DOI 10.7326/0003-4819-122-1-199501010-00009; LIU DL, 1993, J VIROL, V67, P9, DOI 10.1128/JVI.67.1.9-18.1993; MACAULY VM, 1988, BRIT J CANCER, V57, P91, DOI 10.1038/bjc.1988.16; Nakamura S, 1997, EXP CELL RES, V235, P287, DOI 10.1006/excr.1997.3683; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; RANDAZZO PA, 1990, EXP CELL RES, V190, P25, DOI 10.1016/0014-4827(90)90139-2; Resnicoff M, 1996, J Exp Ther Oncol, V1, P385; RESNICOFF M, 1994, CANCER RES, V54, P4848; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; RUBIN R, 1995, LAB INVEST, V73, P311; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHIMIHARA K, 1996, BIOCHEM J, V317, P385; Singleton JR, 1996, CANCER RES, V56, P4522; SPEIRS V, 1991, BRIT J CANCER, V64, P693, DOI 10.1038/bjc.1991.383; Turner BC, 1997, CANCER RES, V57, P3079; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; Zong CS, 1997, J BIOL CHEM, V272, P1500, DOI 10.1074/jbc.272.3.1500	36	45	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					6071	6077		10.1038/sj.onc.1202984	http://dx.doi.org/10.1038/sj.onc.1202984			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557096				2022-12-17	WOS:000083359100013
J	Collavin, L; Lazarevic, D; Utrera, R; Marzinotto, S; Monte, M; Schneider, C				Collavin, L; Lazarevic, D; Utrera, R; Marzinotto, S; Monte, M; Schneider, C			wt p53 dependent expression of a membrane-associated isoform of adenylate kinase	ONCOGENE			English	Article						p53 tumor suppressor; adenylate kinase; Va15 fibroblasts	NUCLEOSIDE-DIPHOSPHATE KINASE; WILD-TYPE P53; G-PROTEIN; GROWTH SUPPRESSION; DNA-DAMAGE; ARREST; NM23; PHOSPHOTRANSFERASE; FIBROBLASTS; INDUCTION	Six novel p53-inducible transcripts were recently cloned from Val5, a murine cell line stably expressing a temperature-sensitive p53 allele. One of the isolated clones represented a novel isoform of cytosolic adenylate kinase (AK1), a highly conserved monomeric enzyme involved in cellular homeostasis of adenine nucleotides. The corresponding protein, which we named AK1 beta, was specifically induced upon activation of wt p53 in Val5 cells. The AK1 beta protein differs from cytoplasmic AK1 by having 18 extra amino acids at the N-terminus. The extra residues in AK1 beta provide a consensus signal for N-terminal myristoylation; as expected, AK1 beta was shown to localize to the plasma membrane. The human AK1 gene contains several consensus p53 binding sites and we report that p53-dependent induction of the alternative AK1 beta transcript also occurs in human cells. By using antisense ablation experiments in Val5 fibroblasts we show that AK1 beta plays a relevant role in the establishment of reversible cell-cycle arrest as induced by p53 in these cells. These findings suggest that within a p53-dependent genetic program, a specific isoform of adenylate kinase has a previously undescribed growth regulatory function, which might not necessarily require its best characterized biochemical activity.	Lab Nazl Consorzio Interuniv Biotecnol, I-34012 Trieste, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Schneider, C (corresponding author), Lab Nazl Consorzio Interuniv Biotecnol, AREA Sci Pk,Padriciano 99, I-34012 Trieste, Italy.		Collavin, Licio/A-5312-2010; Lazarevic, Dejan/AAN-1861-2020	Collavin, Licio/0000-0001-6815-5381; Monte, Martin/0000-0002-5068-563X; lazarevic, dejan/0000-0003-4527-290X				Bates GD, 1996, J MANAGE ENG, V12, P12; Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; Boyer P.D, 1973, ENZYMES, P279; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; BYEON IJL, 1995, BIOCHEMISTRY-US, V34, P3172, DOI 10.1021/bi00010a006; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DelSal G, 1996, ONCOGENE, V12, P177; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Engel M, 1998, J BIOL CHEM, V273, P20058, DOI 10.1074/jbc.273.32.20058; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GUTIERREZ JA, 1995, J BACTERIOL, V177, P390, DOI 10.1128/jb.177.2.390-400.1995; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Kaufman M, 1996, BIOCHEM J, V316, P35, DOI 10.1042/bj3160035; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LASCU I, 1992, J BIOL CHEM, V267, P12775; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lu Q, 1996, P NATL ACAD SCI USA, V93, P5720, DOI 10.1073/pnas.93.12.5720; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUURA S, 1989, J BIOL CHEM, V264, P10148; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Ohnishi T, 1996, J BIOL CHEM, V271, P14510, DOI 10.1074/jbc.271.24.14510; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RENZING J, 1995, ONCOGENE, V10, P1865; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SCHULZ GE, 1974, NATURE, V250, P142, DOI 10.1038/250142a0; Shankar S, 1996, J BACTERIOL, V178, P1777, DOI 10.1128/jb.178.7.1777-1781.1996; TANABE T, 1993, J BIOCHEM-TOKYO, V113, P200, DOI 10.1093/oxfordjournals.jbchem.a124026; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VIKHANSKAYA F, 1994, NUCLEIC ACIDS RES, V22, P1012, DOI 10.1093/nar/22.6.1012; WATANABE K, 1986, BIOCHEM BIOPH RES CO, V134, P527, DOI 10.1016/S0006-291X(86)80452-1; XIONG Y, 1993, NATURE, V366, P704; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	59	45	46	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5879	5888		10.1038/sj.onc.1202970	http://dx.doi.org/10.1038/sj.onc.1202970			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557075				2022-12-17	WOS:000083270700005
J	Kitareewan, S; Spinella, MJ; Allopenna, J; Reczek, PR; Dmitrovsky, E				Kitareewan, S; Spinella, MJ; Allopenna, J; Reczek, PR; Dmitrovsky, E			4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RAR gamma independent pathway	ONCOGENE			English	Article						retinoic acid; retinoid receptors; teratocarcinomas; 4HPR	HUMAN BREAST-CARCINOMA; RECEPTOR-GAMMA; PROMYELOCYTIC LEUKEMIA; ACID RECEPTORS; F9 CELLS; 4-HYDROXYPHENYL RETINAMIDE; HUMAN TERATOCARCINOMAS; HISTONE DEACETYLASE; GROWTH SUPPRESSION; NUCLEAR RECEPTOR	Retinoids signal biological effects through retinoic acid receptors (RAR) and retinoid X receptors (RXR) and their co-regulators. We previously reported that all-trans retinoic acid (RA) triggers terminal differentiation in the human embryonal carcinoma cell line NTERA-2 clone D1 (NT2/D1), through an RAR gamma dependent pathway. RAR gamma repression in NT2/D1-R1 cells accounts for RA resistance in this line. This report finds RAR gamma repression is due to selective repression of RAR gamma but not RAR beta transcription in NT2/D1-R1 cells. The repression is neither due to mutations in RAR gamma nor its promoter containing the RA response element. Prior work was confirmed and extended by demonstrating that an RAR gamma selective agonist preferentially signals differentiation of NT2/D1 cells, while RAR alpha/beta, RAR beta, RXR agonists and an RAR pan-antagonist do not even when NT2/D1 cells are treated with these retinoids at 10 mu M dosages. None of these examined retinoids induced differentiation of the RA resistant NT2/D1-R1 cells. In contrast, N-(4-hydroxyphenyl)retinamide (4HPR), a reported transcriptional activator of RAR gamma was shown to potently induce growth inhibition and apoptosis in both NT2/D1 and NT2/D1-R1 cells. 4HPR-induced apoptosis was unaffected by co-treatment of both cell lines with equimolar RAR antagonist. Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) assays of total RNA from 4HPR-treated NT2/D1 and NT2/D1-R1 cells did not reveal RAR gamma induction. Since 4HPR signals in RA-resistant NT2/D1-R1 cells having an RAR; transcriptional block, these results indicate that 4HPR triggers apoptosis but not differentiation through an RAR gamma independent pathway. Taken together, these findings implicate a therapeutic role for 4HPR mediated apoptosis in germ cell tumors even when a maturation block is present.	Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Dept Med, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Hanover, NH 03755 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Buffalo, NY 14213 USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Memorial Sloan Kettering Cancer Center; Bristol-Myers Squibb	Kitareewan, S (corresponding author), Dartmouth Med Sch, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.		Spinella, Michael/B-7210-2014		NCI NIH HHS [K01 CA75154] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075154] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; BHATNAGAR R, 1991, BIOCHEM PHARMACOL, V41, P1471, DOI 10.1016/0006-2952(91)90563-K; Bosl George J., 1997, P1397; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CLIFFORD JL, 1990, MOL ENDOCRINOL, V4, P1546, DOI 10.1210/mend-4-10-1546; Clifford JL, 1999, CANCER RES, V59, P14; De Palo G, 1997, TUMORI, V83, P884, DOI 10.1177/030089169708300603; DELIA D, 1993, CANCER RES, V53, P6036; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DOWLATSHAHI K, 1989, CANCER LETT, V47, P187, DOI 10.1016/0304-3835(89)90089-X; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; FONTANA JA, 1986, CANCER RES, V46, P2468; Formelli F, 1996, FASEB J, V10, P1014, DOI 10.1096/fasebj.10.9.8801162; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Gudas Lorraine J., 1994, P443; Kastner P, 1997, DEVELOPMENT, V124, P313; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kazmi SMI, 1996, CANCER RES, V56, P1056; KURIE JM, 1993, DIFFERENTIATION, V54, P123; LEHMANN JM, 1991, NUCLEIC ACIDS RES, V19, P573, DOI 10.1093/nar/19.3.573; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; MOASSER MM, 1995, CANCER, V76, P680, DOI 10.1002/1097-0142(19950815)76:4<680::AID-CNCR2820760423>3.0.CO;2-9; Monzon RI, 1997, MOL PHARMACOL, V51, P377; MOON RC, 1992, ANTICANCER RES, V12, P1147; MOON RC, 1979, CANCER RES, V39, P1339; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nason-Burchenal K, 1998, BLOOD, V92, P1758, DOI 10.1182/blood.V92.5.1758.417k28_1758_1767; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; Park DJ, 1998, BIOTECHNIQUES, V24, P558, DOI 10.2144/98244bm07; PETKOVICH M, 1987, NATURE, V330, P44; POLLARD M, 1991, CANCER LETT, V59, P159, DOI 10.1016/0304-3835(91)90181-G; SHEIKH MS, 1995, CARCINOGENESIS, V16, P2477, DOI 10.1093/carcin/16.10.2477; Spanjaard RA, 1997, J BIOL CHEM, V272, P18990, DOI 10.1074/jbc.272.30.18990; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Subbarayan V, 1997, MECH DEVELOP, V66, P131, DOI 10.1016/S0925-4773(97)00098-1; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452	50	45	46	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5747	5755		10.1038/sj.onc.1202981	http://dx.doi.org/10.1038/sj.onc.1202981			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523855				2022-12-17	WOS:000083095100003
J	Naishiro, Y; Adachi, M; Okuda, H; Yawata, A; Mitaka, T; Takayama, S; Reed, JC; Hinoda, Y; Imai, K				Naishiro, Y; Adachi, M; Okuda, H; Yawata, A; Mitaka, T; Takayama, S; Reed, JC; Hinoda, Y; Imai, K			BAG-1 accelerates cell motility of human gastric cancer cells	ONCOGENE			English	Article						BAG-1; gastric adenocarcinoma; cell migration; membrane ruffles; cytoskeleton	HEAT-SHOCK PROTEINS; INTERMEDIATE FILAMENTS; INDUCED APOPTOSIS; MELANOMA-CELLS; DEATH ACTIVITY; HGF RECEPTOR; EXPRESSION; VIMENTIN; COEXPRESSION; ASSOCIATION	BAG-1 is a Hsp70/Hsc70-binding protein that interacts with Bcl-2, Raf-1, steroid hormone receptors, Siah-1, and hepatocyte growth factor (HGF) receptors, implying multiple functions for the BAG-1 protein, Here, we provide evidence that gene transfer-mediated overexpression of BAG-1 markedly enhances the motility of human gastric cancer cells, Two independent in vitro migration assays showed that the BAG-1-expressing MKN74 cells exhibited more active migration compared with control transfectants or parent MKN74 cells, In MKN74 cells, the overexpression of BAG-1 affected neither cell adhesion capability nor migration responses to HGF, The promotive effect of BAG-1 on cell migration was similarly observed in transfectants of another human gastric cancer MKN45 cell line, In BAG-1 transfected gastric cancer MKN74 cells, BAG-1 colocalized with cytokeratin as well as actin filaments, and was concentrated at membrane ruffles induced by lysophosphatidic acid (LPA), Taken together, these studies demonstrate that BAG-1 has a novel function as promoter of cell migration in human gastric cancer cells, possibly through cooperation with cytoskeletal proteins.	Sapporo Med Univ, Sch Med, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan; Sapporo Med Univ, Sch Med, Dept Pathol, Inst Canc Res, Sapporo, Hokkaido 0608543, Japan; Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Sapporo Medical University; Sapporo Medical University; Sanford Burnham Prebys Medical Discovery Institute	Adachi, M (corresponding author), Sapporo Med Univ, Sch Med, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan.		Mitaka, Toshihiro/K-9424-2013	Mitaka, Toshihiro/0000-0001-9467-4871				Adachi M, 1996, BLOOD, V88, P4118, DOI 10.1182/blood.V88.11.4118.bloodjournal88114118; ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; ASAO T, 1994, CANCER LETT, V78, P57, DOI 10.1016/0304-3835(94)90031-0; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Chu YW, 1996, AM J PATHOL, V148, P63; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; DIRENZO MF, 1991, ONCOGENE, V6, P1997; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRIX MJC, 1992, JNCI-J NATL CANCER I, V84, P165, DOI 10.1093/jnci/84.3.165; Hohfeld J, 1998, BIOL CHEM, V379, P269; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; LIAO J, 1995, J BIOL CHEM, V270, P915, DOI 10.1074/jbc.270.2.915; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; MASTERS DB, 1992, BIOTECHNIQUES, V12, P902; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; OSHIMA RG, 1988, GENE DEV, V2, P505, DOI 10.1101/gad.2.5.505; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SHARON LS, 1998, CELL DEATH DIFFER, V5, P372; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STUART J, 1998, IN PRESS J BIOL CHEM; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TAKAYAMA S, 1998, IN PRESS CANC RES; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; [No title captured]	34	45	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3244	3251		10.1038/sj.onc.1202661	http://dx.doi.org/10.1038/sj.onc.1202661			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359530				2022-12-17	WOS:000080523800007
J	Plass, C; Yu, F; Yu, L; Strout, MP; El-Rifai, W; Elonen, E; Knuutila, S; Marcucci, G; Young, DC; Held, WA; Bloomfield, CD; Caligiuri, MA				Plass, C; Yu, F; Yu, L; Strout, MP; El-Rifai, W; Elonen, E; Knuutila, S; Marcucci, G; Young, DC; Held, WA; Bloomfield, CD; Caligiuri, MA			Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene	ONCOGENE			English	Article						RLGS; DNA methylation; WIT-1; acute myeloid leukemia	MOUSE-LIVER TUMORS; DNA METHYLATION; WILMS-TUMOR; HEMATOPOIETIC NEOPLASMS; CALCITONIN-GENE; CELL-LINE; WT1; HYPERMETHYLATION; IDENTIFICATION; PATTERNS	There is substantial evidence to suggest that aberrant DNA methylation in the regulatory regions of expressed genes may play a role in hematologic malignancy, In the current report, the Restriction Landmark Genomic Scanning (RLGS) method was used to detect aberrant DNA methylation (M) in acute myeloid leukemia (AML), RLGS-M profiles were initially performed using DNA from diagnostic, remission, and relapse samples from a patient with AML, Rp18, one of the eight spots found that was absent in the relapse sample, was cloned. Sequence analysis showed that the spot represented a portion of the WIT-1 gene on human chromosome 11p13, Rp18 was missing in the relapse sample due to a distinct DNA methylation pattern of the WIT-I gene. Twenty-seven AML patients that entered CR after therapy (i.e., chemosensitive) were studied and only 10 (37%) of the diagnostic bone marrow (BM) samples showed methylation of WIT-I, However, seven of eight (87.5%) diagnostic BM samples from primary refractory AML (chemosensitive) showed methylation of WIT-I. The incidence of WIT-I methylation in primary refractory AML was significantly higher than that noted in chemosensitive AML (P=0.018), Together, these results indicate that RLGS-M can be used to find novel epigenetic alterations in human cancer that are undetectable by standard methods, In addition, these results underline the potential importance of WIT-I methylation in chemoresistant AML.	Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Dept Microbiol & Immunol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Div Hematol Oncol, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Biostat Unit, Columbus, OH 43210 USA; Univ Helsinki, Cent Hosp, Med Genet Lab, FIN-00290 Helsinki, Finland; Roswell Pk Canc Inst, Div Med, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Helsinki; Helsinki University Central Hospital; Roswell Park Cancer Institute; Roswell Park Cancer Institute	Plass, C (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Dept Microbiol & Immunol, 420 W 12th St, Columbus, OH 43210 USA.		Plass, Christoph/H-7192-2014		NCI NIH HHS [2RO1CA68612, P30 CA16058] Funding Source: Medline; NIGMS NIH HHS [1RO1GM58269] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058, R01CA068612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058269] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akama TO, 1997, CANCER RES, V57, P3294; BAYLIN SB, 1986, CANCER RES, V46, P2917; Baylin SB, 1998, ADV CANCER RES, V72, P141; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BERGMANN L, 1997, BLOOD, V90, pA5611; Caligiuri MA, 1997, SEMIN ONCOL, V24, P32; CHESON BD, 1990, J CLIN ONCOL, V8, P813, DOI 10.1200/JCO.1990.8.5.813; Costello JF, 1997, CANCER RES, V57, P1250; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; GESSLER M, 1993, GENOMICS, V17, P499, DOI 10.1006/geno.1993.1355; Gonzalgo ML, 1997, CANCER RES, V57, P594; Herman JG, 1997, CANCER RES, V57, P837; Hiltunen MO, 1997, BRIT J CANCER, V76, P1124, DOI 10.1038/bjc.1997.522; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; Inoue K, 1997, BLOOD, V89, P1405, DOI 10.1182/blood.V89.4.1405; Issa JPJ, 1997, LEUKEMIA, V11, pS7; Issa JPJ, 1996, CANCER RES, V56, P973; Issa JPJ, 1997, CANCER RES, V57, P1678; JINNO Y, 1994, NAT GENET, V6, P305, DOI 10.1038/ng0394-305; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; OKAZAKI Y, 1995, ELECTROPHORESIS, V16, P197, DOI 10.1002/elps.1150160134; PALUMBO A, 1984, BLOOD, V64, P1059; Plass C, 1997, DNA Res, V4, P253, DOI 10.1093/dnares/4.3.253; Plass C, 1996, NAT GENET, V14, P106, DOI 10.1038/ng0996-106; Sambrook J, 1989, MOL CLONING LAB MANU; TAOKA T, 1992, BLOOD, V80, P46; TYCKO B, 1994, AM J PATHOL, V144, P431; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878	29	45	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3159	3165		10.1038/sj.onc.1202651	http://dx.doi.org/10.1038/sj.onc.1202651			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340388				2022-12-17	WOS:000080388000012
J	Gerbitz, A; Mautner, J; Geltinger, C; Hortnagel, K; Christoph, B; Asenbauer, H; Klobeck, G; Polack, A; Bornkamm, GW				Gerbitz, A; Mautner, J; Geltinger, C; Hortnagel, K; Christoph, B; Asenbauer, H; Klobeck, G; Polack, A; Bornkamm, GW			Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma	ONCOGENE			English	Article						c-myc; lambda enhancer; gene regulation; Burkitt's lymphoma; Na-Butyrate	LOCUS-CONTROL REGION; EPSTEIN-BARR-VIRUS; IMMUNOGLOBULIN-KAPPA-ENHANCERS; HEAVY-CHAIN LOCUS; PROMOTER SHIFT; CHROMOSOMAL TRANSLOCATIONS; HYPERSENSITIVE SITES; GENE-EXPRESSION; SODIUM-BUTYRATE; DOWN-REGULATION	In Burkitt's lymphoma (BL) cells the proto-oncogene c-myc is juxtaposed to one of the immunoglobulin (Ig) loci on chromosomes 2, 14, or 22, The c-myc gene becomes transcriptionally activated as a consequence of the chromosomal translocation and shows preferential usage of promoter P1 over P2, a phenomenon referred to as promoter shift. In order to define the responsible regulatory elements within the Ig lambda locus, we studied the effect of the human Ig lambda enhancer (HuE lambda) on c-myc expression after stable transfection into BL cells. A 12 kb genomic fragment encompassing HuE lambda, but not HuE lambda alone, strongly activated c-myc expression and induced the promoter shift. To identify additional elements involved in c-myc deregulation, we mapped DNaseI hypersensitive sites within the 12 kb lambda fragment on the construct. Besides one hypersensitive site corresponding to HuE lambda, three additional sites were detected, Two of these elements displayed enhancer activity after transient transfection. The third element did not activate c-myc transcription, but was required for full c-myc activation and promoter shift. Deletion analyses of the c-myc promoter identified the immediate promoter region as sufficient for activation by the Ig lambda locus, but also revealed that induction of the promoter shift requires additional upstream elements.	Dana Farber Canc Inst, Boston, MA 02115 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumor Genet, D-81377 Munich, Germany; Univ Munich, Genet Inst, D-80336 Munich, Germany; Adolf Butenandt Inst Physiol Chem, D-80336 Munich, Germany	Harvard University; Dana-Farber Cancer Institute; Johns Hopkins University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich	Gerbitz, A (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.							ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ANISIMOVA E, 1982, J GEN VIROL, V58, P163, DOI 10.1099/0022-1317-58-1-163; ARONOW BJ, 1995, MOL CELL BIOL, V15, P1123; Asenbauer H, 1996, EUR J IMMUNOL, V26, P142, DOI 10.1002/eji.1830260122; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BLASQUEZ VC, 1989, J BIOL CHEM, V264, P21183; BLOMBERG BB, 1991, J IMMUNOL, V147, P2354; BORNKAMM GW, 1988, G KLEIN, P223; BREZNICK EH, 1997, P NATL ACAD SCI USA, V94, P4566; BURKITT D, 1958, BRIT J SURG, V46, P218, DOI 10.1002/bjs.18004619704; COMBRIATO G, 1991, EUR J IMMUNOL, V21, P1513, DOI 10.1002/eji.1830210627; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; Geltinger C, 1996, GENE EXPRESSION, V6, P113; Glozak MA, 1996, MOL IMMUNOL, V33, P427, DOI 10.1016/0161-5890(95)00146-8; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; HOLLIS GF, 1984, NATURE, V307, P752, DOI 10.1038/307752a0; HORTNAGEL K, 1995, ONCOGENE, V10, P1393; HUG BA, 1992, NUCLEIC ACIDS RES, V20, P5771, DOI 10.1093/nar/20.21.5771; JOOS S, 1992, CANCER RES, V52, P6547; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; MAGRATH I, 1990, ADV CANCER RES, V55, P134; Mautner J, 1996, ONCOGENE, V12, P1299; MAUTNER J, 1995, NUCLEIC ACIDS RES, V23, P72, DOI 10.1093/nar/23.1.72; NOWELL PC, 1960, SCIENCE, V132, P1497; NOWELL PC, 1990, AM J CLIN PATHOL, V94, P229, DOI 10.1093/ajcp/94.2.229; POLACK A, 1991, ONCOGENE, V6, P2033; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; POLACK A, 1987, EMBO J, V6, P2959, DOI 10.1002/j.1460-2075.1987.tb02601.x; PULVERTAFT RJV, 1964, LANCET, V1, P238; QUEEN C, 1984, MOL CELL BIOL, V4, P1042, DOI 10.1128/MCB.4.6.1042; RABBITTS TH, 1983, NATURE, V306, P806, DOI 10.1038/306806a0; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROTTLEB C, 1995, INT J CANCER, V62, P697, DOI 10.1002/ijc.2910620609; ROTTLEB C, 1996, INT J CANCER, V67, P1; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STIEF A, 1989, NATURE, V341, P341; STROBL LJ, 1993, ONCOGENE, V8, P1437; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; ZEIDLER R, 1994, GENE CHROMOSOME CANC, V9, P282, DOI 10.1002/gcc.2870090408; ZIMBERSTROBL U, 1993, EMBO J, V12, P167, DOI 10.1002/j.1460-2075.1993.tb05642.x	55	45	50	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1745	1753		10.1038/sj.onc.1202468	http://dx.doi.org/10.1038/sj.onc.1202468			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208435				2022-12-17	WOS:000079025000009
J	Zhan, QM; Kontny, U; Iglesias, M; Alamo, I; Yu, K; Hollander, MC; Woodworth, CD; Fornace, AJ				Zhan, QM; Kontny, U; Iglesias, M; Alamo, I; Yu, K; Hollander, MC; Woodworth, CD; Fornace, AJ			Inhibitory effect of Bcl-2 on p53-mediated transactivation following genotoxic stress	ONCOGENE			English	Article						BCL-2; GADD45; p21(CIPI/WAF1); p53; apoptosis; ionizing radiation; methylmethane sulfonate; UV radiation	PROGRAMMED CELL-DEATH; DNA-DAMAGING AGENTS; NUCLEAR ANTIGEN; GENE-EXPRESSION; P53; PROTEIN; APOPTOSIS; INDUCTION; GROWTH; GADD45	In the cellular response to genotoxic stress, cell cycle checkpoint and apoptosis are considered to be two of the major biological events in maintaining genomic stability. The tumor suppressor p53 has been shown to play critical roles in these stress-induced cellular responses at least in part through the activation of its down-stream genes, such as p21(ClPl/WAFl), GADD45 and BAX. In addition, p53 has been found to down-regulate the expression of BCL-2, which is able to block apoptosis induced by both p53-dependent and independent signaling events. In this report,,ve have found that increased expression of Bcl-2 protein in the human Burkitt's lymphoma WMN cell line suppressed apoptosis induced by different DNA-damaging agents. The induction of p53-regulated genes including GADDIS, p21(ClPl/WAFl) and BAX by genotoxic stress was substantially reduced in cells expressing high levels of Bcl-2 protein. Furthermore, Bcl-2 protein was shown to specifically suppress the p53-mediated transactivation of p21(ClPl/WAFl) and PG13-CAT, which is a typical p53-binding-site reporter construct, Similarly, the inhibitory effect of Bcl-2 protein was seen in a GADD45 promoter reporter construct after treatment with methylmethane sulfonate or UV-radiation, These results indicate that in addition to its apoptosis-suppressing activity, Bcl-2 protein is able to inhibit transactivation of p53-regulated genes, which function in multiple important cellular responses to genotoxic stress, including the control of cell cycle checkpoints, cell growth suppression and DNA repair.	NCI, Biol Chem Lab, Bethesda, MD 20892 USA; NCI, Div Basic Sci, Biol Lab, Bethesda, MD 20892 USA; NCI, Pediat Oncol Branch, Div Clin Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhan, QM (corresponding author), NCI, Biol Chem Lab, Room 5CO9,Bldg 37, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HALDAR S, 1994, CANCER RES, V54, P2095; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HOLLANDER MC, 1989, CANCER RES, V49, P1687; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LAROCCA RV, 1990, J STEROID BIOCHEM, V37, P893, DOI 10.1016/0960-0760(90)90439-R; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1995, CELL, V80, P293; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OCONNOR PM, 1993, CANCER RES, V53, P4776; OCONNOR PM, 1991, CANCER RES, V51, P6550; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1992, CELL, V70, P526; WOODWORTH CD, 1992, ONCOGENE, V7, P619; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHAN QM, 1995, INT J ONCOL, V6, P937	46	45	56	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					297	304		10.1038/sj.onc.1202310	http://dx.doi.org/10.1038/sj.onc.1202310			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927186				2022-12-17	WOS:000078166500002
J	Kim, SK; Ro, JY; Kemp, BL; Lee, JS; Kwon, TJ; Hong, WK; Mao, L				Kim, SK; Ro, JY; Kemp, BL; Lee, JS; Kwon, TJ; Hong, WK; Mao, L			Identification of two distinct tumor-suppressor loci on the long arm of chromosome 10 in small cell lung cancer	ONCOGENE			English	Article						SCLC chromosome 10; LOH; tumor suppressor	PROSTATE-CANCER; HOMOZYGOUS DELETION; HUMAN GLIOBLASTOMAS; HUMAN GLIOMAS; GENE; HETEROZYGOSITY; CARCINOMA; PROTEIN; MXI1; LOCALIZATION	Recent cytogenetic studies indicated that loss of the long arm of chromosome 10 is a frequent event in small cell lung cancer (SCLC) and that a common region of the deletion is at 10q24-qter, which suggests the presence of a tumor-suppressor gene there. To map precise tumor-suppressor loci on the chromosome arm for further positional cloning efforts, we tested 46 primary SCLCs using microsatellite analysis, By analysing 11 highly polymorphic microsatellite markers located in 10q23-q26, we found that at least 78% (36/46) of the tumors exhibited loss of heterozygosity (LOH) at 10q with at least two distinct minimally deleted regions, LOH at one region (10q24) was found in at least 74% (32/43) of informative cases with a minimally deleted region between D10S198 and D10S192 (about 2 cM); LOH at another region (10q24-q25) was observed in at least 66% (29/44) of informative tumors with a minimally deleted region between D10S221 and D10S587 (about 11 cM), LOH at both regions or across both regions was observed in at least 52% (24/46) of the tumors tested, However, no mutations or homozygous deletions were found in the coding region of MXI1, a candidate tumor suppressor gene at 10q24-q25, in a panel of SCLC cell lines. Our data demonstrate that at least two tumor-suppressor loci exist on 10q and that they may play an important role in SCLC tumorigenesis.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mao, L (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358	NATIONAL CANCER INSTITUTE [P50CA070907, U19CA068437, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, CA 70907, U19 CA 68437] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albarosa R, 1996, AM J HUM GENET, V58, P1260; AYER DE, 1993, CELL, V72, P1; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GARDNER E, 1991, GENOMICS, V11, P475, DOI 10.1016/0888-7543(91)90162-8; GRAY IC, 1995, CANCER RES, V55, P4800; HERBST RA, 1994, CANCER RES, V54, P3111; HOSOE S, 1994, CANCER RES, V54, P1787; Kim SK, 1997, CANCER RES, V57, P400; Kim SK, 1998, ONCOGENE, V16, P89, DOI 10.1038/sj.onc.1201512; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MERLO A, 1994, CANCER RES, V54, P2322; MILLER CW, 1992, CANCER RES, V52, P1695; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MORI N, 1990, ONCOGENE, V5, P1713; MORITA R, 1991, CANCER RES, V51, P5817; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PEIFFER SL, 1995, CANCER RES, V55, P1922; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RASHEED BKA, 1995, ONCOGENE, V10, P2243; REMPEL SA, 1993, CANCER RES, V53, P2386; RIED T, 1994, CANCER RES, V54, P1801; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SPEAKS SL, 1992, GENE CHROMOSOME CANC, V5, P239, DOI 10.1002/gcc.2870050311; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; WECHSLER DS, 1994, GENOMICS, V21, P669, DOI 10.1006/geno.1994.1336; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	33	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1749	1753		10.1038/sj.onc.1202073	http://dx.doi.org/10.1038/sj.onc.1202073			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796705				2022-12-17	WOS:000076200100014
J	Schwahn, DJ; Medina, D				Schwahn, DJ; Medina, D			p96, a MAPK-related protein, is consistently downregulated during mouse mammary carcinogenesis	ONCOGENE			English	Article						mammary carcinogenesis; p96; mammary epithelium; hyperplasia	PHOSPHOTYROSINE INTERACTION DOMAIN; COLONY-STIMULATING FACTOR-1; GROWTH-FACTOR RECEPTOR; DIFFERENTIAL DISPLAY; GENE-EXPRESSION; MESSENGER-RNA; PRODUCT; BINDING; CSF-1; PROTOONCOGENE	Differential display PCR [DD-PCR] was applied to identify mRNAs differentially expressed between two consecutive stages of an in vivo model of mouse mammary carcinogenesis. The extended life 12 [EL12] and transformed mammary 12 [TM12] outgrowths differ in morphology, ovarian hormone dependence, and tumorigenicity, yet the TM12 outgrowth arose spontaneously from the EL12 outgrowth. A fragment of the mouse p96 gene was identified using DD-PCR. The differential expression of p96 was confirmed using RNase protection assays. Examination of the RNA expression patterns of the p96 isoforms during normal mammary gland development showed high levels in the involuting mammary gland and in preneoplastic hyperplasias. In contrast, p96 isoform mRNA levels were consistently decreased in mammary tumors derived from the in vivo hyperplasias. Examination of p96 protein levels revealed a decrease in p96 protein in a number of mammary tumors as compared to their hyperplastic precursors further supporting the observations that p96 gene expression is consistently downregulated in mammary tumors. The functional activity of p96 protein has not been resolved, however the observation that p96 gene expression is downregulated in two different tumor systems (human ovarian tumors and mouse mammary tumors) warrants more extensive investigation on its role in normal and neoplastic cell growth.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	Medina, D (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NCI NIH HHS [CA63137] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063137] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BORYCKI AG, 1995, ONCOGENE, V10, P1799; CALLARD D, 1994, BIOTECHNIQUES, V16, P1096; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P15; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; Jackowski S, 1997, MOL REPROD DEV, V46, P24; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MEDINA D, 1993, CANCER RES, V53, P668; MEDINA D, 1993, CARCINOGENESIS, V14, P25, DOI 10.1093/carcin/14.1.25; MEDINA D, 1993, CANCER RES, V53, P663; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Nowicki A, 1996, INT J CANCER, V65, P112, DOI 10.1002/(SICI)1097-0215(19960103)65:1<112::AID-IJC19>3.3.CO;2-R; POLLARD JW, 1994, P NATL ACAD SCI USA, V91, P9312, DOI 10.1073/pnas.91.20.9312; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; ZHANG LX, 1993, MOL CARCINOGEN, V8, P123, DOI 10.1002/mc.2940080209	24	45	46	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1173	1178		10.1038/sj.onc.1202038	http://dx.doi.org/10.1038/sj.onc.1202038			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764828				2022-12-17	WOS:000075598400013
J	FitzGerald, MG; Marsh, DJ; Wahrer, D; Bell, D; Caron, S; Shannon, KE; Ishioka, C; Isselbacher, KJ; Garber, JE; Eng, C; Haber, DA				FitzGerald, MG; Marsh, DJ; Wahrer, D; Bell, D; Caron, S; Shannon, KE; Ishioka, C; Isselbacher, KJ; Garber, JE; Eng, C; Haber, DA			Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer	ONCOGENE			English	Article						PTEN/MMAC1; Cowden syndrome; breast cancer; genetic predisposition; yeast truncation assay		Heterozygous germline mutations in PTEN are responsible for most cases of Cowden Syndrome, a rare familial trait characterized by hamartomas and by predisposition to cancer of the breast and thyroid. The variable and often subtle clinical findings that characterize Cowden Syndrome are frequently unrecognized, raising the possibility that germline PTEN mutations may confer susceptibility to breast cancer in women who have not been diagnosed with this syndrome. To determine whether such mutations contribute to genetic predisposition to breast cancer within the general population, we analysed a cohort of women with early-onset breast cancer (<age 40), a subset of the population at increased risk for genetic susceptibility, Lymphoblast cell lines were analysed using either direct nucleotide sequencing (28 cases), denaturing gradient gel electrophoresis (DGGE) (34 cases) or a yeast-based truncation assay (110 cases). No definitive, truncating mutations were observed in 172 patients, Missense changes were noted in the germline of 2/60 patients analysed by direct nucleotide sequencing or DGGE, including a non-conservative amino acid substitution within the phosphatase domain, but neither showed loss of the wild-type allele in the corresponding breast tumor specimen, We conclude that germline mutations in PTEN are an uncommon cause of genetic predisposition to breast cancer within the general population.	Massachusetts Gen Hosp, Ctr Canc Risk Anal, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Boston, MA 02114 USA; Univ Cambridge, CRC, Human Canc Genet Res Grp, Cambridge, England; Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol, Sendai, Miyagi 980, Japan; Harvard Univ, Sch Med, Dana Farber Canc Inst, Program Populat Sci, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Cambridge; Tohoku University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Haber, DA (corresponding author), Massachusetts Gen Hosp, Ctr Canc Risk Anal, Charlestown, MA 02129 USA.		Marsh, Deborah J/I-1491-2014	Marsh, Deborah J/0000-0001-5899-4931; Ishioka, Chikashi/0000-0002-3023-1227; Eng, Charis/0000-0002-3693-5145				CLAUS EB, 1991, AM J HUM GENET, V48, P232; Dahia PLM, 1997, CANCER RES, V57, P4710; DAHIA PLM, 1998, IN PRESS ONCOGENE; DURR WM, 1998, IN PRESS ONCOGENE; Eng C, 1997, J Genet Couns, V6, P181, DOI 10.1023/A:1025664119494; FEILOTTER HE, 1998, IN PRESS ONCOGENE; FEILOTTER HE, 1998, IN PRESS BR J CANC; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; Guldberg P, 1997, CANCER RES, V57, P3660; Ishioka C, 1997, P NATL ACAD SCI USA, V94, P2449, DOI 10.1073/pnas.94.6.2449; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Longy M, 1996, ANN GENET-PARIS, V39, P35; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Rasheed BKA, 1997, CANCER RES, V57, P4187; Rhei E, 1997, CANCER RES, V57, P3657; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tashiro H, 1997, CANCER RES, V57, P3935; Wang SI, 1997, CANCER RES, V57, P4183	25	45	46	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					727	731		10.1038/sj.onc.1201984	http://dx.doi.org/10.1038/sj.onc.1201984			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715274				2022-12-17	WOS:000075337200007
J	Gum, R; Juarez, J; Allgayer, H; Mazar, A; Wang, Y; Boyd, D				Gum, R; Juarez, J; Allgayer, H; Mazar, A; Wang, Y; Boyd, D			Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules	ONCOGENE			English	Review						urokinase receptor; proteolysis; JNK; MAPK	PROTEIN-KINASE-C; PHORBOL-MYRISTATE ACETATE; HUMAN OVARIAN-CANCER; TERMINAL PHOSPHORYLATION; TRANSDUCTION PATHWAYS; BOUND UROKINASE; CELL-MIGRATION; MESSENGER-RNA; GROWTH-FACTOR; U937 CELLS	The urokinase-type plasminogen activator receptor (u-PAR) has been implicated in tumor progression, and previous studies have shown that the expression of this gene is strongly up-regulated by PMA, Although the signaling mechanism by which PMA modulates u-PAR expression is not known, the effect of this phorbol ester on the expression of other genes has been ascribed to activation of the c-Raf-1-ERK signaling pathway. However, in the current study we examined an alternate possibility that the inductive effect of PMA on u-PAR expression also required a JNK1-dependent signaling cascade usually associated with stress-inducing stimuli. PMA treatment of the u-PAR-deficient OVCAR-3 ovarian cancer cells, which contain low JNK activities, resulted in a rapid (5 min) increase in JNK activity, Maximal JNK activity (12-fold induction) occurred after 30 min; this preceding the earliest detected rise in u-PAR protein (2 h), Dose-response studies with PMA also indicated that the increased JNK activity was tightly correlated with elevated u-PAR protein levels. The stimulation of u-PAR promoter activity by PMA required an intact upstream AP-1 motif (- 184) and in PMA-treated cells this motif was bound with c-Jun as indicated from mobility shift assays, PMA up-regulated the c-Jun trans acting activity as indicated by the higher activity of a GAL4-regulated luciferase reporter in phorbol-ester-treated cells co-transfected with an expression vector encoding the c-Jun transactivation domain fused to the GAL4 DNA-binding domain, The ability of PMA to stimulate u-PAR promoter activity was effectively titrated out by the co-expression of either a kinase-defective JNK1 or a dominant negative MEKK1 the latter being an upstream activator of JNK1, Conversely, u-PAR promoter activity was stimulated by the co-expression of a constitutively active MEKK1 and this induction was antagonized by the inclusion of the kinase-defective JNK1 plasmid, We also determined the biological significance of the JNK1-dependent signaling cascade in regulating u-PAR promoter activity by c-Ha-ras since this oncogene is activated and/or overexpressed in a variety of tumors including ovarian cancer. Transfection of an activated c-Ha-ras into OVCAR-3 cells stimulated u-PAR promoter activity over 20-fold and this could be countered by the individual expression of dominant negative expression constructs to Rac-1, MEKK1 or JNK1, Taken together, these data suggest that the PMA- or c-Ha-Ras-dependent stimulation of u-PAR gene expression requires a JNK1-dependent signaling module and that, at least for PMA, the concurrent stimulation of a JNK1-independent signaling module is also required. Thus, caution should be exercised in invoking linear signaling modules to account for the regulation of inducible gene expression.	Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol Head & Neck Surg, Houston, TX 77030 USA; Angstrom Pharmaceut, San Diego, CA USA; Univ Sydney, Westmead Hosp, Dept Renal Med, Westmead, NSW 2145, Australia; SmithKline Beecham, Dept Mol Immunol, King Of Prussia, PA 19406 USA	University of Texas System; UTMD Anderson Cancer Center; University of Sydney; GlaxoSmithKline	Boyd, D (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, 1515 Holcombe Blvd,Box 108, Houston, TX 77030 USA.				NCI NIH HHS [R01CA58311] Funding Source: Medline; NIDCR NIH HHS [P50 DE11906-01, R01DE10845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011906, R01DE010845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABDELHAFIZ H, 1996, MOL ENDOCRINOL, V6, P2079; ADLER V, 1994, J BIOL CHEM, V269, P11186; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Allgayer H, 1997, CANCER RES, V57, P1394; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BIANCHI E, 1994, CANCER RES, V54, P861; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BOS JL, 1989, CANCER RES, V49, P4682; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CANO E, 1995, J CELL SCI, V108, P3599; CASEY JR, 1994, BLOOD, V84, P1151; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHIEN CH, 1993, DNA CELL BIOL, V12, P623, DOI 10.1089/dna.1993.12.623; CONESE M, 1994, J BIOL CHEM, V269, P17886; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DENG T, 1995, NATURE, V371, P171; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVRIES TJ, 1994, AM J PATHOL, V144, P70; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELLIS V, 1991, J BIOL CHEM, V266, P12752; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; HEISS MM, 1995, NAT MED, V1, P1035, DOI 10.1038/nm1095-1035; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; JONES LG, 1994, J BIOL CHEM, V269, P23790; KARIKO K, 1993, CANCER RES, V53, P3109; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lengyel E, 1997, ONCOGENE, V14, P2563, DOI 10.1038/sj.onc.1201098; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; LUND LR, 1991, J BIOL CHEM, V266, P5177; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; MARQUARDT B, 1994, ONCOGENE, V9, P3213; Masuelli L, 1996, MOL CELL BIOL, V16, P5466; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Min HY, 1996, CANCER RES, V56, P2428; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; NEAD MA, 1995, J INVEST DERMATOL, V105, P668, DOI 10.1111/1523-1747.ep12324367; NICOLSON GL, 1990, ONCOGENE, V5, P747; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; OHagan RC, 1996, ONCOGENE, V13, P1323; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PALEJWALA S, 1996, P AM ASSOC CANC RES, V37, pA1429; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PICONE R, 1989, J CELL BIOL, V108, P693, DOI 10.1083/jcb.108.2.693; PULVERER BJ, 1993, ONCOGENE, V8, P407; PYKE C, 1993, FEBS LETT, V326, P69, DOI 10.1016/0014-5793(93)81763-P; QUATTRONE A, 1995, CANCER RES, V55, P90; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; RAO VN, 1993, CANCER RES, V53, P3449; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Riittinen L, 1996, FEBS LETT, V381, P1, DOI 10.1016/0014-5793(96)00033-6; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Sauma S, 1996, J BIOL CHEM, V271, P11422, DOI 10.1074/jbc.271.19.11422; Scambia G, 1997, BRIT J CANCER, V75, P1547, DOI 10.1038/bjc.1997.264; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Silberman S, 1997, J BIOL CHEM, V272, P5927, DOI 10.1074/jbc.272.9.5927; Sillaber C, 1997, J BIOL CHEM, V272, P7824, DOI 10.1074/jbc.272.12.7824; SOZERI O, 1992, ONCOGENE, V7, P2259; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; VAGNARELLI P, 1992, CYTOGENET CELL GENET, V60, P197, DOI 10.1159/000133335; VANDAM PA, 1994, J CLIN PATHOL, V47, P914, DOI 10.1136/jcp.47.10.914; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WANG Y, 1995, EUR J BIOCHEM, V227, P116, DOI 10.1111/j.1432-1033.1995.tb20366.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WILHELM O, 1994, FEBS LETT, V337, P131, DOI 10.1016/0014-5793(94)80259-9; Xing RH, 1997, CANCER RES, V57, P3585; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	109	45	46	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					213	225		10.1038/sj.onc.1201917	http://dx.doi.org/10.1038/sj.onc.1201917			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674706				2022-12-17	WOS:000074706700010
J	Varley, JM; Chapman, P; McGown, G; Thorncroft, M; White, GRM; Greaves, MJ; Scott, D; Spreadborough, A; Tricker, KJ; Birch, JM; Evans, DGR; Reddel, R; Camplejohn, RS; Burn, J; Boyle, JM				Varley, JM; Chapman, P; McGown, G; Thorncroft, M; White, GRM; Greaves, MJ; Scott, D; Spreadborough, A; Tricker, KJ; Birch, JM; Evans, DGR; Reddel, R; Camplejohn, RS; Burn, J; Boyle, JM			Genetic and functional studies of a germline TP53 splicing mutation in a Li-Fraumeni-like family	ONCOGENE			English	Article						Li-Fraumeni; TP53; splicing	CANCER-PRONE FAMILY; P53 MUTATIONS; BREAST-CANCER; IRRADIATION; POLYMORPHISM; GENOME; BLOOD; ASSAY	We report an extensive Li-Fraumeni-like family in which there is an unusual spectrum of tumours at relatively late onset. A germline TP53 splice donor mutation in exon 4 is present in all affected family members available for testing. The mutation abolishes correct splicing of intron 4 and techniques of RT-PCR have identified three different aberrant transcripts from the mutant TP53 allele. Using the yeast functional assay to analyse transcripts in cells from a number of family members with the mutant allele, TP53 appears wild-type, Functional studies have been carried out on cells from patients with and without cancer who carry the germline mutation, and on cells from unaffected individuals from the same family who do not carry the mutation. Using a number of functional endpoints known to distinguish between cells carrying mutant or wild-type TP53 alleles, we were unable to discriminate normal (wt/wt) from heterozygous (wt/mut) cells by lymphocyte apoptosis and fibroblast survival following low dose rate ionising radiation exposure. However germline mutation carriers show increased sensitivity to radiation-induced chromosome damage in the G(2) phase of the cell cycle, and decreased transient and permanent G(1) arrest. These studies demonstrate the importance of fully characterising the effects of TP53 germline mutations, and may explain some of the phenotypic features of this family.	Paterson Inst Canc Res, CRC, Mol Genet Sect, Manchester M20 9BX, Lancs, England; Univ Newcastle Upon Tyne, Dept Human Genet, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Paterson Inst Canc Res, CRC, Paediat & Familial Canc Res Grp, Manchester M20 9BX, Lancs, England; St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England; Childrens Med Res Inst, Sydney, NSW 2145, Australia; St Thomas Hosp, Richard Dimbleby Dept Canc Res, London SE1 7EH, England	Paterson Institute for Cancer Research; Newcastle University - UK; Paterson Institute for Cancer Research; University of Manchester; Children's Medical Research Institute - Australia; University of Sydney; Guy's & St Thomas' NHS Foundation Trust	Varley, JM (corresponding author), Paterson Inst Canc Res, CRC, Mol Genet Sect, Wilmslow Rd, Manchester M20 9BX, Lancs, England.		Reddel, Roger R/A-6635-2014; Evans, D Gareth/AAB-4308-2022	Reddel, Roger R/0000-0002-6302-6107; Evans, D Gareth/0000-0002-8482-5784; Burn, John/0000-0002-9823-2322				BIRCH JM, 1994, CANCER RES, V54, P1298; BOYLE JM, 1998, IN PRESS BR J CANC; CAMPLEJOHN RS, 1995, BRIT J CANCER, V72, P654, DOI 10.1038/bjc.1995.390; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FREBOURG T, 1995, AM J HUM GENET, V56, P608; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; Heineman EF, 1996, CANCER, V77, P549, DOI 10.1002/(SICI)1097-0142(19960201)77:3<549::AID-CNCR18>3.0.CO;2-4; HOGGARD N, 1995, GENE CHROMOSOME CANC, V12, P24, DOI 10.1002/gcc.2870120105; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Lomax ME, 1997, ONCOGENE, V14, P1869, DOI 10.1038/sj.onc.1201133; MACGEOCH C, 1995, J MED GENET, V32, P186, DOI 10.1136/jmg.32.3.186; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mitchell ELD, 1997, INT J RADIAT BIOL, V72, P435, DOI 10.1080/095530097143202; PARSHAD R, 1993, RADIAT RES, V136, P236, DOI 10.2307/3578616; SCOTT D, 1993, NATO ASI SERIES H, V77, P101; Sproston ARM, 1996, INT J RADIAT BIOL, V70, P145, DOI 10.1080/095530096145139; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; WARNEFORD S, 1991, CELL GROWTH DIFFER, V2, P439; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; Williams KJ, 1997, ONCOGENE, V14, P277, DOI 10.1038/sj.onc.1200838	27	45	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3291	3298		10.1038/sj.onc.1201878	http://dx.doi.org/10.1038/sj.onc.1201878			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681828				2022-12-17	WOS:000074343600010
J	Ottini, L; Falchetti, M; D'Amico, C; Amorosi, A; Saieva, C; Masala, G; Frati, L; Cama, A; Palli, D; Mariani-Costantini, R				Ottini, L; Falchetti, M; D'Amico, C; Amorosi, A; Saieva, C; Masala, G; Frati, L; Cama, A; Palli, D; Mariani-Costantini, R			Mutations at coding mononucleotide repeats in gastric cancer with the microsatellite mutator phenotype	ONCOGENE			English	Article						gastric cancer; microsatellite instability; TGF beta-RII; IGFIIR; BAX; hMSH3; hMSH6; BRCA2; mutation	II RECEPTOR GENE; BETA RECEPTOR; INSTABILITY; COLON; CELLS; BAX	We analysed 50 gastric carcinomas (GCs) to verify whether mutations at coding repeats were associated with microsatellite instability (MSI), The tumors included: ten cases with no MSI, 14 cases with MSI=1 locus, 13 cases with MSI=two loci and 13 cases with MSI greater than or equal to 3 loci, We investigated coding repeats within the TGF-beta RII, IGFIIR, BAX, hMSH6, AMSH3 and BRCA2 genes. The TGF-beta RII, IGIIR, BAX, hMSH6 and hMSH3 repeats were altered in 11 (22%), five (10%), four (8%), 16 (32%) and five (10%) cases respectively. Mutations occurred only in MSI-positive (MSI+) tumors and correlated with increasing MSI levels. No alterations of the BRCA2 repeat were found. Mutations in genes other than hMSH6 were strongly associated to kMSH6 mutations, suggesting a key role of this gene. The non-coding BAT-26 and E-Cadherin 3' UTR poly(A)8/(T)15 repeats were analysed in 44 of the 50 cases. Novel tumor-associated alleles were observed only in MSI-positive GCs and were in most cases associated with mutations at coding repeats. Further investigations with BAT-40 confirmed that four cases manifested mononucleotide repeat alterations restricted to hMSH6 and one case to TGF-beta XII. A subset of tumors,vith MSI at two or more dinucleotide loci resulted negative for mutations at coding and non-coding mononucleotide repeats.	Univ Gabriele DAnnunzio, Dept Oncol & Neurosci, I-66013 Chieti, Italy; Univ La Sapienza, Dept Expt Med & Pathol, Rome, Italy; Careggi Hosp, CSPO, Epidemiol Unit, Florence, Italy; Univ Florence, Dept Pathol, Florence, Italy; CSPO, IST, Epidemiol Satellite Unit, Florence, Italy; IMNS, Isernia, Italy	G d'Annunzio University of Chieti-Pescara; Sapienza University Rome; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence	Mariani-Costantini, R (corresponding author), Univ Gabriele DAnnunzio, Dept Oncol & Neurosci, I-66013 Chieti, Italy.		Mariani-Costantini, Renato/B-6637-2012; CAMA, Alessandro/J-3964-2018; Frati, Luigi/ABI-7437-2020; Saieva, Calogero/AAC-2611-2019; Masala, Giovanna/AAC-5474-2022	Mariani-Costantini, Renato/0000-0002-4440-1848; CAMA, Alessandro/0000-0003-3647-1368; Saieva, Calogero/0000-0002-0117-1608; Masala, Giovanna/0000-0002-5758-9069; PALLI, Domenico/0000-0002-5558-2437; OTTINI, LAURA/0000-0001-8030-0449; tumino, rosario/0000-0003-2666-414X				Akiyama Y, 1997, CANCER RES, V57, P3920; Arnheim N, 1997, CURR OPIN GENET DEV, V7, P364, DOI 10.1016/S0959-437X(97)80150-5; BUIATTI E, 1991, INT J CANCER, V48, P369, DOI 10.1002/ijc.2910480310; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Chung YJ, 1996, CANCER RES, V56, P4662; Chung YJ, 1997, ONCOGENE, V15, P1719, DOI 10.1038/sj.onc.1201343; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; Hoang JM, 1997, CANCER RES, V57, P300; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MIYASHITA T, 1995, CELL, V80, P293; MYEROFF LL, 1995, CANCER RES, V55, P5545; Ohue M, 1996, INT J CANCER, V68, P203, DOI 10.1002/(SICI)1097-0215(19961009)68:2<203::AID-IJC11>3.0.CO;2-B; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTTINI L, 1995, CANCER RES, V55, P5677; Ottini L, 1997, CANCER RES, V57, P4523; Ouyang H, 1997, CANCER RES, V57, P1851; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, CANCER RES, V55, P5548; Perucho M, 1996, NAT MED, V2, P630, DOI 10.1038/nm0696-630; Prolla TA, 1996, SEMIN CANCER BIOL, V7, P241, DOI 10.1006/scbi.1996.0032; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Stratton MR, 1996, CURR OPIN GENET DEV, V6, P93, DOI 10.1016/S0959-437X(96)90017-9; Takahashi H, 1996, CANCER RES, V56, P2738; Zhou XP, 1997, ONCOGENE, V15, P1713, DOI 10.1038/sj.onc.1201337	28	45	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2767	2772		10.1038/sj.onc.1201816	http://dx.doi.org/10.1038/sj.onc.1201816			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652743	Green Published			2022-12-17	WOS:000073812200008
J	Noe, V; Alemany, C; Chasin, LA; Ciudad, CJ				Noe, V; Alemany, C; Chasin, LA; Ciudad, CJ			Retinoblastoma protein associates with Sp1 and activates the hamster dihydrofolate reductase promoter	ONCOGENE			English	Article						DHFR; Sp1; Rb	TRANSCRIPTION FACTOR E2F; SUSCEPTIBILITY GENE-PRODUCT; CELL-CYCLE; SP1-MEDIATED TRANSCRIPTION; GROWTH-REGULATION; BINDING PROTEIN; EXPRESSION; REPRESSION; ELEMENT; CLONING	The dihydrofolate reductase (dhfr) promoter is powerfully activated by the transcription factor Sp1. It has been suggested that Sp1 is a potential target for transcriptional regulation by the cell cycle regulator retinoblastoma protein (Rb), and so we have explored this possibility using the hamster dhfr gene as a model. By the use of DNA probes from the hamster dhfr gene promoter, containing the most proximal GC box (minimal promoter), and nuclear extracts from cultured hamster cells (CHO K1), we show that polyclonal and monoclonal antibodies against Rb supershift the binding of Sp1. Nuclear extract immunoprecipitation with anti- Rb followed by Western analysis using anti-Sp1 also shows that Rb is complexed to Sp1. Complementary Immunoprecipitation/WB analysis shows both forms of Rh protein in the anti-Sp1 immunoprecipitates. Moreover, nuclear extract immunodepletion of Rb abolishes Sp1 gel-shift. The interaction between Rb and Sp1 is maintained in all the phases of the cell cycle. Transient overexpression of Rb in dhfr negative cells co-transfected with a dhfr minigene driven by its minimal promoter increases DHFR activity and potentiates transcription when overexpressing Sp1. Both effects are severely reduced when the co-transfections are performed with a homologous dhfr minigene containing a single point mutation in the GC box. Thus, the activation by Rb of the dhfr gene may be exerted through Sp1. Stable transfectants of pCMVRb in K1 cells show an increase in both mRNA and DHFR activity. It is concluded that Sp1 is physically associated with Rb, and that this association increases Sp1-mediated transcription of the hamster dhfr gene.	Univ Barcelona, Sch Pharm, Biochem Unit, E-08028 Barcelona, Spain; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	University of Barcelona; Columbia University	Ciudad, CJ (corresponding author), Univ Barcelona, Sch Pharm, Biochem Unit, E-08028 Barcelona, Spain.		Noe, Veronique/K-3615-2014; Ciudad, Carlos J./D-7917-2014	Noe, Veronique/0000-0001-7937-8038; Ciudad, Carlos J./0000-0002-7855-392X	NIGMS NIH HHS [GM-22529] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CIUDAD CJ, 1988, J BIOL CHEM, V263, P16274; CIUDAD CJ, 1992, J BIOL CHEM, V267, P3650; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P365, DOI 10.1128/MCB.6.2.365; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Noe V, 1997, EUR J BIOCHEM, V249, P13, DOI 10.1111/j.1432-1033.1997.00013.x; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Rohde M, 1996, ONCOGENE, V12, P2393; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; URLAUB G, 1985, SOMAT CELL MOLEC GEN, V11, P71, DOI 10.1007/BF01534736; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; YU DH, 1992, J BIOL CHEM, V267, P10203	42	45	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					1931	1938		10.1038/sj.onc.1201718	http://dx.doi.org/10.1038/sj.onc.1201718			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591776				2022-12-17	WOS:000073079400004
J	Sun, ZJ; Pan, J; Bubley, G; Balk, SP				Sun, ZJ; Pan, J; Bubley, G; Balk, SP			Frequent abnormalities of TSG101 transcripts in human prostate cancer	ONCOGENE			English	Article						prostate cancer; tumor suppressor; aberrant RNA splicing; TSG101	DEPENDENT PROTEIN-KINASE; FHIT GENE; STATHMIN; CELLS; PHOSPHORYLATION; PHOSPHOPROTEIN; EXPRESSION; 3P14.2	TSG101 has been identified as a candidate tumor suppressor gene and abnormal transcripts have been identified in a substantial fraction of breast cancers, To determine whether TSG101 expression is commonly altered in other tumors, a series of 15 primary and metastatic prostate cancers were analysed by reverse transcriptase-PCR amplification, Abnormal transcripts with extensive deletions in the coding region were found in nine of these tumors, while only the normal transcript was found in control and benign prostatic hypertrophy tissues, More than one abnormal transcript was found in four of these nine cases and distinct abnormal TSG101 transcripts were found in separate biopsies taken from one tumor, Importantly, the normal TSG101 transcript was undetectable in two metastatic prostate cancers, indicating the absence of TSG101 protein, Sequence analysis demonstrated that there were at least sh distinct deletions, with four of these deletions found in more than one tumor sample, The most commonly identified deletion, from bp 153 to 1055, was identical to a deletion reported previously in breast cancer, These results demonstrate that TSG101 transcripts are frequently abnormal in prostate cancer and suggest that loss of TSG101 protein contributes to disease development or progression.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Sun, ZJ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA065647, R01CA070297, R29CA070297] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA070297-03, R29 CA070297, R01 CA070297, CA65647, R01 CA070297-12, CA70297] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERETTA L, 1993, J BIOL CHEM, V268, P20076; CHNEIWEISS H, 1989, J NEUROCHEM, V53, P856, DOI 10.1111/j.1471-4159.1989.tb11783.x; DURAJ J, 1995, LEUKEMIA RES, V19, P457, DOI 10.1016/0145-2126(94)00154-3; EUSTACE W, 1995, FEBS LETT, V364, P309, DOI 10.1016/0014-5793(95)00416-7; GUSSOW D, 1987, J IMMUNOL, V139, P3132; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LEIGHTON IA, 1993, MOL CELL BIOCHEM, V128, P151, DOI 10.1007/BF01076766; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAMURA K, 1995, ELECTROPHORESIS, V16, P1530, DOI 10.1002/elps.11501601253; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8	16	45	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	1997	15	25					3121	3125		10.1038/sj.onc.1201521	http://dx.doi.org/10.1038/sj.onc.1201521			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444960				2022-12-17	WOS:000070968000012
J	Chattopadhyay, P; Rathore, A; Mathur, M; Sarkar, C; Mahapatra, AK; Sinha, S				Chattopadhyay, P; Rathore, A; Mathur, M; Sarkar, C; Mahapatra, AK; Sinha, S			Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours	ONCOGENE			English	Article						glioma, genetics; chromosomes, human, pair 17; gene, suppressor, tumour	POLYMERASE CHAIN-REACTION; SUPPRESSOR GENE; MUTATIONS; CHROMOSOME-17; PATHWAYS; GLIOMAS; TUMORS	Amongst the human astrocytic tumours, the commonest of primary brain tumours, the clinical outcome of astrocytoma (AS) is significantly better than anaplastic astrocytoma (AA) and glioblastoma multiforme (GEM), Often, low grade tumours can progress to or recur with a more malignant phenotype, Recent loss of heterozygosity (LOH) reports suspect the involvement of a suppressor gene, different from p53, in the region of the human chromosome, However, the effect of LOH of 17p13.3 region on tumour histology at presentation and prognosis is as yet undefined, As a first step to define the role of this putative oncogene in astrocytic tumour progression, we correlated the LOH of a locus, D17S379, in 17p13.3 region and the p53 locus in 17p13.1 region with the histopathology of astrocytic tumours by PCR based microsatellite and restriction fragment length polymorphism of DNA extracted from microdissected paraffin sections of 45 astrocytic tumours of different histopathological grades, LOH of D17S379 was significantly associated (P=0.02) with AA and GBM (high grade malignancy), while no such preferential association was found with LOH of p53. There were no mutations in the exons 5 to 9 of p53 gene in the five tumours with LOH of D17S379 but not of p53 region, In a case of AA with a heterogenous microscopic appearance, heterozygosity of D17S379 was lost only in the area with a more malignant histology while both areas had no LOH or mutation of p53, A locus at the 17p13.3 region, independent of the p53 locus, is involved in a large subset of astrocytic tumours during transformation into a more malignant phenotype, and thus may be a link in the chain of genetic events occurring in astrocytic tumour progression.	ALL INDIA INST MED SCI,DEPT BIOCHEM,NEW DELHI 110029,INDIA; ALL INDIA INST MED SCI,DEPT PATHOL,NEW DELHI 110029,INDIA; ALL INDIA INST MED SCI,DEPT NEUROSURG,NEW DELHI 110029,INDIA	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi								CARROZZO R, 1993, HUM MOL GENET, V2, P615, DOI 10.1093/hmg/2.5.615; FRANKEL RH, 1992, CANCER RES, V52, P1427; FULTS D, 1992, CANCER RES, V52, P674; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HAHN M, 1993, CLIN CHEM, V39, P549; Hermanson M, 1996, CANCER RES, V56, P164; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LARGEY JS, 1993, CANCER, V71, P1933, DOI 10.1002/1097-0142(19930315)71:6<1933::AID-CNCR2820710602>3.0.CO;2-D; LEDBETTER SA, 1992, AM J HUM GENET, V50, P182; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; SAXENA A, 1992, CANCER RES, V52, P6716; Schultz DC, 1996, CANCER RES, V56, P1997; SHAPIRO WR, 1986, SEMIN ONCOL, V13, P38; SHAW EG, 1989, INT J RADIAT ONCOL, V16, P663, DOI 10.1016/0360-3016(89)90482-3; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570	16	45	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					871	874		10.1038/sj.onc.1201238	http://dx.doi.org/10.1038/sj.onc.1201238			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266974				2022-12-17	WOS:A1997XQ11700014
J	Huff, SY; Quilliam, LA; Cox, AD; Der, CJ				Huff, SY; Quilliam, LA; Cox, AD; Der, CJ			R-Ras is regulated by activators and effectors distinct from those that control Ras function	ONCOGENE			English	Article						GDP; GTP regulation; Raf kinases; dominant negative mutants	NUCLEOTIDE EXCHANGE FACTORS; SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE KINASE; PROTEIN-KINASE; TYPE-1 NEUROFIBROMATOSIS; CELL-TRANSFORMATION; MAMMALIAN-CELLS; GENE-PRODUCT; GROWTH; EXPRESSION	Like Ras, constitutively activated mutants of the Ras-related protein R-Ras cause tumorigenic transformation of NIH3T3 cells. However, since R-Ras causes a transformed phenotype distinct from that induced by Ras, it is likely that R-Ras controls signaling pathways and cellular processes distinct from those regulated by Ras. To address this possibility, we determined if R-Ras is regulated by activators and effecters distinct from those that regulate Ras function, We observed that Ras guanine nucleotide exchange factors failed to activate R-Ras in vivo, indicating that R-Ras is activated by distinct GEFs. Consistent with this, mutants of R-Ras with mutations analogous to the Ras(15A)/(17N) dominant negative proteins did not antagonize Ras GEF function and lacked the growth inhibitory activity seen with these mutant Ras proteins, Thus, R-Ras, but not Ras, is dispensable for the viability of MIH3T3 cells. Finally, whereas constitutively activated Ras can overcome the growth inhibitory action of the Ras(17N) dominant negative protein via Raf-dependent and -independent activities, transforming mutants of R-Ras failed to do so. This inability was consistent with our observation that Ras-, but not R-Ras-transformed, NIH3T3 cells possessed constitutively upregulated Raf kinase activities. Thus, R-Ras and Ras are regulators of distinct signaling pathways and cellular processes.	UNIV N CAROLINA, CHAPEL HILL, NC 27514 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, DEPT RADIAT ONCOL, CHAPEL HILL, NC 27599 USA; INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute			Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019	Der, Channing/0000-0002-7751-2747; Cox, Adrienne D./0000-0002-4901-2454	NATIONAL CANCER INSTITUTE [R01CA055008, R01CA052072, R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978, CA52072, CA55008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHEN SY, 1994, ONCOGENE, V9, P2691; Clark GJ, 1996, ONCOGENE, V12, P169; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1995, METHOD ENZYMOL, V255, P195; COX AD, 1994, ONCOGENE, V9, P3281; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FASANO O, 1988, EMBO J, V7, P3375, DOI 10.1002/j.1460-2075.1988.tb03210.x; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; GRAHAM SM, 1996, IN PRESS MOL CELL BI; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HAUSER CA, 1994, METHOD ENZYMOL, V238, P271; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LOWE DG, 1988, P NATL ACAD SCI USA, V85, P1015, DOI 10.1073/pnas.85.4.1015; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MOODIE SA, 1994, TRENDS GENET, V10, P14; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; REY I, 1994, ONCOGENE, V9, P685; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SAEZ R, 1994, ONCOGENE, V9, P2977; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Williams Lewis T., 1992, Current Biology, V2, P601, DOI 10.1016/0960-9822(92)90169-B; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	77	45	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	1997	14	2					133	143		10.1038/sj.onc.1200815	http://dx.doi.org/10.1038/sj.onc.1200815			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010215				2022-12-17	WOS:A1997WC81800001
J	Caligo, MA; Ghimenti, C; Cipollini, G; Ricci, S; Brunetti, I; Marchetti, V; Olsen, R; Neuhausen, S; ShattuckEidens, D; Conte, PF; Skolnick, MH; Bevilacqua, G				Caligo, MA; Ghimenti, C; Cipollini, G; Ricci, S; Brunetti, I; Marchetti, V; Olsen, R; Neuhausen, S; ShattuckEidens, D; Conte, PF; Skolnick, MH; Bevilacqua, G			BRCA1 germline mutational spectrum in Italian families from Tuscany: A high frequency of novel mutations	ONCOGENE			English	Article						hereditary breast ovarian cancer; BRCA1; mutation	CANCER SUSCEPTIBILITY GENE; OVARIAN-CANCER; BREAST-CANCER; LINKAGE; TUMORS; MAP	BRCA1 germline mutations confer susceptibility to familial breast and ovarian cancer, Mutational hot spots have never been detected in BRCA1 cDNA, Some mutations have been reported several times whereas some others appear to be population-related. In this study a group of 36 Italian families were analysed for BRCA1 germline mutations, All of them mere screened by allele-specific oligonucleotide hybridization (ASO) for three recurrent mutations (185delAG, 5382insC, nt332T>G), Twenty families, selected because of their high risk of carrying BRCA1 mutations, were subjected to analysis of the entire coding sequence of the gene, A total of eight mutations were found, ASO screening demonstrated only one known mutation in one patient, whereas cycle sequencing revealed five new mutations, Three of these new mutations were frameshifts: one occurred in exon 11 (1499insA), one in exon 16 (4873delCA) and one in the splice site of exon 3 (252delAAgt). Two were missense mutations (Cys64Arg; Asn158Tyr. The same frameshift mutation, 1499insA, was detected in three unrelated families, Haplotype analysis supported the hypothesis that two of these families may have had common ancestors, whereas in the third family the analysis was uninformative, BRCA1 germ line mutations mere found in one out of two families with ovarian cancer, in five out of eight families with breast-ovarian cancer, and in two out of 11 families with breast canter, All three families with 1499insA mutations included at least one case of ovarian cancer, The majority of the ovarian cancers (4/5) associated with detectable BRCA1 germline mutations were of serous histotype.	MYRIAD GENET, SALT LAKE CITY, UT USA; UNIV UTAH, DEPT MED INFORMAT, SALT LAKE CITY, UT 84112 USA; SANTA CHIARA HOSP, DEPT MED ONCOL, PISA, ITALY	Myriad Genetics, Inc; Utah System of Higher Education; University of Utah; Santa Chiara Hospital	Caligo, MA (corresponding author), UNIV PISA, INST PATHOL, PISA, ITALY.		Conte, PierFranco/F-7418-2014; Caligo, Adelaide Maria/K-4289-2018	Conte, PierFranco/0000-0002-5210-5344; Caligo, Adelaide Maria/0000-0003-0589-1829; BEVILACQUA, GENEROSO/0000-0001-8857-2609				BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; EASTON DF, 1995, AM J HUM GENET, V56, P265; EASTON DF, 1993, AM J HUM GENET, V52, P678; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1995, BRIT J CANCER, V72, P805, DOI 10.1038/bjc.1995.417; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; GOLDGAR DE, 1994, J NATL CANCER I, V86, P200, DOI 10.1093/jnci/86.3.200; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1995, AM J HUM GENET, V56, P254; NAROD SA, 1991, LANCET, V338, P82; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; NEUHAUSEN SL, 1994, HUM MOL GENET, V3, P1919, DOI 10.1093/hmg/3.11.1919; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P582; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; TAKAHASHI H, 1995, CANCER RES, V55, P2998; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	26	45	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1483	1488						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875986				2022-12-17	WOS:A1996VL38400013
J	Smit, L; vanderHorst, G; Borst, J				Smit, L; vanderHorst, G; Borst, J			Formation of Shc/Grb2- and Crk adaptor complexes containing tyrosine phosphorylated Cbl upon stimulation of the B-cell antigen receptor	ONCOGENE			English	Article						B-cell antigen receptor; adaptor protein; Cbl; Shc/Grb2; Crk; Ras activation	NUCLEOTIDE EXCHANGE FACTOR; GTPASE-ACTIVATING PROTEIN; PROTOONCOGENE C-CBL; PHOSPHATIDYLINOSITOL 3-KINASE; LYMPHOCYTES-B; GRB2 ADAPTER; KINASE LYN; T-CELLS; SIGNAL TRANSDUCTION; EGF STIMULATION	B-cell antigen receptor (BCR) stimulation induces tyrosine phosphorylation of the She adaptor protein and its association with Grb2. The Shc/Grb2 complex may be involved in Ras activation, since Grb2 interacts with the guanine nucleotide exchange factor Sos. We reveal here an additional complexity of the BCR-induced Shc/Grb2 complex: it contains tyrosine phosphorylated proteins of 130, 110 and 75 kDa. The 130 kDa molecule inducibly associates with She, while the 75 kDa protein interacts with the carboxy-terminal SH3 domain of Grb2. The 110 kDa molecule is defined as Cbl, the product of the c-cbl oncogene, which is strongly phosphorylated on tyrosine upon BCR stimulation. Cbl constitutively interacts with the SH3 domains of Grb2, with a preference for the amino-terminal domain, and is in this way recruited to She upon BCR stimulation. Immunodepletion studies showed that Grb2-associated Cbl can be phosphorylated by BCR-induced tyrosine kinases independent of a Shc/Grb2 interaction. This indicates that the BCR can also couple to a Grb2 complex without the involvement of She. Cbl not only interacts with Grb2, but also with the adaptor protein Crk. In contrast to its constitutive interaction with Grb2, tyrosine-phosphorylated Cbl only associates with Crk after BCR stimulation. In summary, we observe that the BCR activates Shc/Grb2-, Grb2- and Crk adaptor complexes of distinct composition, which may allow selective coupling to different signal transduction cascades. Cbl participates in all three adaptor complexes and is tyrosine phosphorylated upon BCR stimulation, pointing to a central role for this molecule in the regulation of antigen receptor-induced B cell responses.	NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Smit, Linda/0000-0003-0025-269X; Borst, Jannie/0000-0002-8043-5009				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; BAUMANN G, 1994, EUR J IMMUNOL, V24, P1799, DOI 10.1002/eji.1830240812; BLAKE TJ, 1991, ONCOGENE, V6, P653; BORST J, 1993, IMMUNOL REV, V132, P49, DOI 10.1111/j.1600-065X.1993.tb00837.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKUZAWA T, 1995, J BIOL CHEM, V270, P19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOLD MR, 1993, J IMMUNOL, V150, P377; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLD MR, 1992, J IMMUNOL, V148, P2012; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REIF K, 1994, J BIOL CHEM, V269, P14081; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SAXTON TM, 1994, J IMMUNOL, V153, P623; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SMIT L, 1994, J BIOL CHEM, V269, P20209; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; VANNOESEL CJM, 1993, INT IMMUNOL, V5, P699; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	61	45	46	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					381	389						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710377				2022-12-17	WOS:A1996VA25200017
J	Farrington, SM; Cunningham, C; Boyle, SM; Wyllie, AH; Dunlop, MG				Farrington, SM; Cunningham, C; Boyle, SM; Wyllie, AH; Dunlop, MG			Detailed physical and deletion mapping of 8p with isolation of YAC clones from tumour suppressor loci involved in colorectal cancer	ONCOGENE			English	Article						chromosome 8p; colorectal cancer; mapping; YAC isolation; TSG	HEPATOCELLULAR-CARCINOMA; ALLELIC LOSS; SHORT ARM; CHROMOSOME-8; MUTATIONS; GENE	Loss of heterozygosity (LOH) of markers at chromosome 8p is frequently noted in many different tumour types, including colorectal cancer, Numerous investigations indicate the presence of more than one tumour suppressor gene (TSG) located on 8p. In this study, we describe a detailed LOH map in colorectal cancer and relate this to physical mapping data from reduced radiation 8p hybrids, yeast artificial chromosome (YAC) co-localisation of markers and fluorescence in situ hybridisation data,;These data indicate the presence of two regions harbouring putative TSG's between the polymorphic markers for the LPL gene-D8S298 (similar to 4 Mb) and the markers D8S136-D8S137 (similar to 8 Mb), Yeast Artificial Chromosomes (YAC) have been isolated from these regions of interest to aid the localisation of the putative TSG's.	UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANC RES CAMPAIGN LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,ROYAL INFIRM,DEPT SURG,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Farrington, SM (corresponding author), MRC,HUMAN GENET UNIT,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Farrington, Susan M/C-7319-2013; Farrington, Susan M/Q-2710-2019; Dunlop, Malcolm G/F-1973-2011	Farrington, Susan M/0000-0001-5955-7389; Dunlop, Malcolm G/0000-0002-3033-5851				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BOOKSTEIN R, 1994, GENOMICS, V24, P317, DOI 10.1006/geno.1994.1622; BOVA GS, 1993, CANCER RES, V53, P3869; CHER ML, 1994, GENE CHROMOSOME CANC, V11, P153, DOI 10.1002/gcc.2870110304; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; CUNNINGHAM C, 1994, BRIT J CANCER, V70, P18, DOI 10.1038/bjc.1994.243; EMI M, 1992, CANCER RES, V52, P5368; EMI M, 1993, GENE CHROMOSOME CANC, V7, P152, DOI 10.1002/gcc.2870070307; FANTES J, 1995, HUM MOL GENET, V4, P415, DOI 10.1093/hmg/4.3.415; FANTES JA, 1992, AM J HUM GENET, V51, P1286; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; FUJIWARA Y, 1993, CANCER RES, V53, P1172; FUJIWARA Y, 1995, ONCOGENE, V10, P891; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; ICHIKAWA T, 1994, CANCER RES, V54, P2299; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KELEMEN PR, 1994, GENE CHROMOSOME CANC, V11, P195, DOI 10.1002/gcc.2870110308; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; MACOSKA JA, 1994, CANCER RES, V54, P3824; Maniatis T., 1982, MOL CLONING; MATSUYAMA H, 1994, ONCOGENE, V9, P3071; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; PYKETT MJ, 1994, CANCER GENET CYTOGEN, V76, P23, DOI 10.1016/0165-4608(94)90064-7; Rogaev E., 1992, Human Molecular Genetics, V1, P781, DOI 10.1093/hmg/1.9.781; SADAKANE Y, 1994, BIOCHEM BIOPH RES CO, V200, P219, DOI 10.1006/bbrc.1994.1437; SAPRU M, 1994, GENOMICS, V21, P208, DOI 10.1006/geno.1994.1244; SCHOENBERG M, 1995, GENE CHROMOSOME CANC, V12, P76, DOI 10.1002/gcc.2870120115; SENGUPTA DN, 1993, SCIENCE, V260, P816; STEINBRUECK T, 1992, SCIENCE, V258, P67; TRAPMAN J, 1994, CANCER RES, V54, P6061; VANDERBOSCH K, 1992, GENE CHROMOSOME CANC, V5, P91, DOI 10.1002/gcc.2870050114; WAGNER MJ, 1991, GENOMICS, V10, P114, DOI 10.1016/0888-7543(91)90491-V; WANG LM, 1992, CANCER RES, V52, P4824; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; Wood S, 1993, Cytogenet Cell Genet, V64, P134; YAREMKO ML, 1994, GENE CHROMOSOME CANC, V10, P1, DOI 10.1002/gcc.2870100102	38	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1803	1808						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622901				2022-12-17	WOS:A1996UG45800023
J	Smits, PHM; deWit, L; vanderEb, AJ; Zantema, A				Smits, PHM; deWit, L; vanderEb, AJ; Zantema, A			The adenovirus E1A-associated 300 kDa adaptor protein counteracts the inhibition of the collagenase promoter by E1A and represses transformation	ONCOGENE			English	Article						adenovirus E1A; CBP; cJun; collagenase promoter; p300	E2F TRANSCRIPTION FACTOR; CELL-CYCLE; 5 DNA; REGION; GENE; COMPLEXES; BINDING; PRODUCT; JUN; TRANSACTIVATION	Adenovirus E1A proteins modulate the expression of a large variety of genes in transformed cells by either stimulating or repressing their promoters. For example, the E1A proteins inhibit the collagenase promoter, whereas they activate the c-jun promoter. Both effects are mediated through AP-1/ATF-binding sites. Repression of transcription of the collagenase gene requires the amino-terminus and conserved region 1 (CR1) of Ad5 E1A, two regions that are also crucial for interaction of E1A with the recently isolated transcriptional adaptor protein p300. We show here that overexpressed p300 can counteract the repressive effect of E1A on the collagenase promoter. Using the CREB-binding protein (CBP), which is highly homologous to p300, the same results were obtained. The domains in E1A required for binding to p300 are also essential for E1A-mediated cell transformation. We therefore tested the effect of p300 and CBP on the transforming potential of Ad5 El in baby rat kidney (BRK) cells. It was found that E1A-induced focus formation was strongly inhibited by overexpression of p300 or CBP. Moreover the BRK cell colonies, obtained after cotransfection with Ad5E1 and p300, could not be established. These results indicate that one of the mechanisms by which E1A modulates transcription and transforms cells is via transcriptional adaptors like p300 and CBP.			Smits, PHM (corresponding author), LEIDEN STATE UNIV,SYLVIUS LAB,MOLEC CARCINOGENESIS LAB,WASSENAARSEWEG 72,2333 AL LEIDEN,NETHERLANDS.							ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARBEAU D, 1994, ONCOGENE, V9, P359; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DORMAN JC, 1995, J VIROL, V69, P2962; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAGMEYER BM, 1995, BIOESSAYS, V17, P621, DOI 10.1002/bies.950170708; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Maniatis T, 1989, DECONTAMINATION DILU; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NEVINS J, 1992, SCIENCE, V258, P242; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1989, ONCOGENE, V4, P1207; VANDENELSEN P, 1983, VIROLOGY, V128, P377; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988	40	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1529	1535						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622869				2022-12-17	WOS:A1996UF07600017
J	Tangir, J; Muto, MG; Berkowitz, RS; Welch, WR; Bell, DA; Mok, SC				Tangir, J; Muto, MG; Berkowitz, RS; Welch, WR; Bell, DA; Mok, SC			A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer	ONCOGENE			English	Article						ovary; cancer; borderline; BRCA1; loss of heterozygosity	HETEROZYGOSITY; TUMORS	Allelic deletions on chromosome 17q21 in sporadic ovarian cancer are common, suggesting that inactivation of a tumor suppressor gene(s) in that region may be important for the etiology of these tumors. The recently identified BRCA1 gene on 17q21, involved in the development of familial breast/ovarian cancer, could be a candidate. However, inactivating mutations on BRCA1 in sporadic ovarian cancer has been rarely described. Furthermore, the potential relationship of BRCA1 gene to ovarian tumors of borderline malignancy remains also unclear. We constructed a highly detailed deletion map of chromosome 17q21 based on PCR amplification of eight polymorphic tandem repeat markers in a 650 kb area including three BRCA1 intragenic markers. DNA from 52 sporadic ovarian cancers and 26 borderline tumors, together with their corresponding normal control tissues were used. Only one borderline tumor showed loss of heterozygosity at one marker, whereas 65% of invasive ovarian cancers displayed allelic loss in at least one of the markers studied. A common deletion unit, located approximately 60 kb centromeric to BRCA1, was revealed. These results suggest that inactivation of the BRCA1 gene may not be responsible for the development of borderline ovarian tumors and that another tumor suppressor gene, located centromeric to the BRCA1 gene, may play a role in sporadic ovarian cancer development.	BRIGHAM & WOMENS HOSP, DEPT OBSTET GYNECOL & REPROD BIOL, LAB GYNECOL ONCOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital					NATIONAL CANCER INSTITUTE [R01CA063381] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA63381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1987, Am J Obstet Gynecol, V156, P263; BEWTRA C, 1992, INT J GYNECOL PATHOL, V11, P180, DOI 10.1097/00004347-199207000-00003; BOYD J, 1995, NAT GENET, V9, P335, DOI 10.1038/ng0495-335; COUCH FJ, 1994, GENOMICS, V24, P419, DOI 10.1006/geno.1994.1647; CROOP CS, 1995, CANCER LETT, V90, P51, DOI 10.1016/0304-3835(94)03677-B; CROPP CS, 1994, CANCER RES, V54, P2548; DODSON MK, 1993, CANCER RES, V53, P4456; EASTON DF, 1994, LANCET, V344, P761, DOI 10.1016/S0140-6736(94)92256-X; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FRIEDMAN LS, 1995, GENOMICS, V25, P256, DOI 10.1016/0888-7543(95)80133-7; FRIEDMAN LS, 1994, CANCER RES, V54, P6374; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GODWIN AK, 1994, AM J HUM GENET, V55, P666; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; JACOB ANK, 1995, ONCOGENE, V11, P981; JACOBS IJ, 1993, CANCER RES, V53, P1218; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOK CH, 1992, CANCER RES, V52, P5119; MOK SCH, 1993, CANCER RES, V53, P1489; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; NEUHAUSEN SL, 1994, HUM MOL GENET, V3, P1919, DOI 10.1093/hmg/3.11.1919; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; TAKAHASHI H, 1995, CANCER RES, V55, P2998; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X; WERTHEIM I, 1994, J NATL CANCER I, V86, P1549, DOI 10.1093/jnci/86.20.1549; 1995, CANCER FACTS FIGURES, P6	27	45	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					735	740						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632895				2022-12-17	WOS:A1996TW68600004
J	Rodewald, HR; Sato, TN				Rodewald, HR; Sato, TN			Tie1, a receptor tyrosine kinase essential for vascular endothelial cell integrity, is not critical for the development of hematopoietic cells	ONCOGENE			English	Article						Tie1; receptor tyrosine kinase; hematopoietic stem cells; lymphocyte development; recombination-activating-gene (RAG)-2-deficient mice; colony-forming cells	MOLECULAR-CLONING; PROGENITOR CELLS; STEM-CELLS; C-KIT; EXPRESSION; MOUSE; FAMILY; GENES; MEMBER; DIFFERENTIATION	The receptor tyrosine kinase Tiel is expressed in both vascular endothelial cells and immature hematopoietic cells. Expression of a common signaling molecule in distinct cellular Lineages may suggest common ancestry of these lineages in ontogeny and/or utilization of shared signaling pathways, Tie l-deficient mice carrying a targeted insertional mutation in germ line show defects in endothelial cell integrity resulting in edema and hemorrhage. To analyse the potential role of this kinase in hematopoietic cells, we have now compared hematopoietic compartments in wildtype and Tiel-deficient mice, The results show: (1) Total cellularity is mildly reduced comparing Tie1(-/-) and wildtype fetal liver from day 15.5 of gestation, (2) In vitro colony assays and cell transfer experiments of fetal liver cells into lymphocyte-deficient recombination-activating-gene-2(-/-) mice reveal that Tie1(-/-) hematopoietic progenitor cells can generate myeloid lineages as well as T and B lymphocytes, (3) Tie1(-/-) fetal liver cells contain long-term (at least 4 months) bone marrow-reconstituting hematopoietic stem cells suggesting that this kinase is not critical for stem cell-engraftment nor self-renewal.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND; ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110	Roche Holding								ARMSTRONG E, 1993, LEUKEMIA, V7, P1585; AUGUSTIN HG, 1994, BIOESSAYS, V16, P901, DOI 10.1002/bies.950161208; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; ERA T, 1994, IMMUNOL REV, V137, P35, DOI 10.1111/j.1600-065X.1994.tb00658.x; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GULLEY ML, 1988, J IMMUNOL, V140, P3751; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NICOLA NA, 1981, BLOOD, V58, P376; NIENHUIS AW, 1985, CELL, V42, P421, DOI 10.1016/0092-8674(85)90099-6; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OGAWA M, 1993, DEVELOPMENT, V117, P1089; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PAUL WE, 1989, CELL, V57, P521, DOI 10.1016/0092-8674(89)90121-9; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; RAJEWSKY K, 1992, SCIENCE, V256, P483, DOI 10.1126/science.1570513; RISAU W, 1988, DEVELOPMENT, V102, P471; RODEWALD HR, 1994, EMBO J, V13, P4229, DOI 10.1002/j.1460-2075.1994.tb06743.x; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROSNET O, 1991, ONCOGENE, V6, P1641; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Shortman K, 1990, Semin Immunol, V2, P3; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; UCHIDA N, 1993, CURR OPIN IMMUNOL, V5, P177, DOI 10.1016/0952-7915(93)90002-A; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ZIEGLER SF, 1993, ONCOGENE, V8, P663	41	45	46	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					397	404						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570217				2022-12-17	WOS:A1996TR53800019
J	RUSCIANO, D; LORENZONI, P; BURGER, MM				RUSCIANO, D; LORENZONI, P; BURGER, MM			EXPRESSION OF CONSTITUTIVELY ACTIVATED HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR-RECEPTOR (C-MET) IN B16 MELANOMA-CELLS SELECTED FOR ENHANCED LIVER COLONIZATION	ONCOGENE			English	Article						B16 MELANOMA; C-MET; LIVER; METASTASIS	TYROSINE KINASE; B-16 MELANOMA; HOST ORGAN; PROTOONCOGENE; METASTASIS; MOTILITY; LINES	The murine melanoma B16-LS9 cell line was obtained after repeated passages in vivo through the liver of syngeneic mice, and shows an enhanced ability to colonize the liver after intravenous inoculation when compared to its parental, unselected counterpart B16-F1. We have previously shown that paracrine growth effects mainly account for better growth of B16-LS9 in the liver than at other sites, and more recently we reported hepatic transferrin as a factor contributing to efficient growth in the liver. Here we show that increased expression of constitutively activated c-met (the receptor for Hepatocyte Growth Factor/Scatter Factor) consistently occurs during selection of B16 cells through the liver. Constitutive activation of c-met seems to follow its own overexpression and not to depend on an autocrine mechanism. As a consequence, liver-selected B16 melanoma cells have higher tyrosine-kinase activity and higher amounts of tyrosine-phosphorylated proteins than parental B16-F1 or lung-specific B16-F10 cells. Overexpression of constitutively activated c-met enhances motility and invasiveness of B16-LS9 cells, presumably favoring their colonization efficiency in vivo. However, whether levels of c-met expression also determine the organ-specificity of B16 melanoma cells needs further clarification.			RUSCIANO, D (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.			RUSCIANO, DARIO/0000-0002-9577-2585				BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRUNSON KW, 1979, J SUPRAMOL STR CELL, V11, P517, DOI 10.1002/jss.400110410; CHANG JH, 1993, ONCOGENE, V8, P959; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GIORDANO S, 1989, ONCOGENE, V4, P1383; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HALABAN R, 1992, ONCOGENE, V7, P2195; KOMADA M, 1993, ONCOGENE, V8, P2381; MINER KM, 1982, CANCER RES, V42, P4631; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MIZUNO K, 1993, HEPATOCYTE GROWTH FA, P1; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; POSTE G, 1980, CANCER RES, V40, P1636; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RUSCIANO D, 1994, INVAS METAST, V14, P349; RUSCIANO D, 1993, INVAS METAST, V13, P212; SARGENT NSE, 1988, P NATL ACAD SCI USA, V85, P7251, DOI 10.1073/pnas.85.19.7251; TAO T, 1979, INT J CANCER, V23, P854, DOI 10.1002/ijc.2910230618; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; YANAGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P802, DOI 10.1016/0006-291X(92)91803-X; ZHEN Z, 1994, ONCOGENE, V9, P1691	30	45	46	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					1979	1987						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478516				2022-12-17	WOS:A1995TF29700007
J	NEVILLE, EM; STEWART, M; MYSKOW, M; DONNELLY, RJ; FIELD, JK				NEVILLE, EM; STEWART, M; MYSKOW, M; DONNELLY, RJ; FIELD, JK			LOSS OF HETEROZYGOSITY AT 9P23 DEFINES A NOVEL LOCUS IN NONSMALL CELL LUNG-CANCER	ONCOGENE			English	Article						LUNG CANCER; NONSMALL CELL; LOSS OF HETEROZYGOSITY; CHROMOSOME 9P; 9P23	REGION	Genetic studies have previously demonstrated cytogenetic deletions and allelic imbalance or loss of heterozygosity (LOH) on the p arm of chromosome 9, in a number of tumour types. We have analysed 45 Non-Small Cell Lung Cancers (NSCLC) with a panel of highly polymorphic microsatellite markers on chromosome 9. Our results indicate that loss on 9p is concentrated within the D9S156-D9S161 region with 44% (20/45) LOH, however the area with minimal loss in this set of lung tumours was found at D9S157 (9p23), with 30% LOH (10/33), whereas loss at the IFNA locus was only found in 6% (2/34) tumours. Five of the lung tumours in this study which demonstrated LOH at D9S157 retained heterozygosity at the adjacent informative markers lying centromeric and telomeric to D9S157. No correlations were found between any of the clinico-pathological parameters and LOH on 9p or at the D9S157 locus. The results of this study indicates the presence of a further putative tumour suppressor gene on 9p at the D9S157 locus (9p23) to be most likely involved in the pathogenesis of non-small cell lung cancer.	UNIV LIVERPOOL,DEPT CLIN DENT SCI,MOLEC GENET & ONCOL GRP,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; BROADGREEN HOSP,DEPT PATHOL,LIVERPOOL L14 3LB,MERSEYSIDE,ENGLAND; BROADGREEN HOSP,CTR CARDIOTHORAC,LIVERPOOL L14 3LB,MERSEYSIDE,ENGLAND	University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust			Field, John K./AAD-5674-2020	Field, John K./0000-0003-3951-6365				CAIRNS P, 1993, CANCER RES, V53, P1230; CENTER R, 1993, GENE CHROMOSOME CANC, V7, P47, DOI 10.1002/gcc.2870070108; COLEMAN A, 1994, CANCER RES, V54, P344; DEVLIN J, 1994, ONCOGENE, V9, P2757; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; HARMER EM, 1978, GENEVA UNION INT CAN, P41; HOLLAND EA, 1994, ONCOGENE, V9, P1361; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEEN AJ, 1994, ONCOGENE, V9, P2083; KNOWLES MA, 1994, CANCER RES, V54, P531; MEAD LJ, 1994, CANCER RES, V54, P2307; MERLO A, 1994, CANCER RES, V54, P640; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1993, CANCER RES, V53, P2410; ORLOW I, 1994, CANCER RES, V54, P2848; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; TARMIN L, 1994, CANCER RES, V54, P6094; VANDERRIET P, 1994, CANCER RES, V54, P1156; WHITEHOUSE JMA, 1994, MANAGEMENT LUNG CANC	20	45	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					581	585						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630642				2022-12-17	WOS:A1995RN53000019
J	LORENZO, MJ; ENG, C; MULLIGAN, LM; STONEHOUSE, TJ; HEALEY, CS; PONDER, BAJ; SMITH, DP				LORENZO, MJ; ENG, C; MULLIGAN, LM; STONEHOUSE, TJ; HEALEY, CS; PONDER, BAJ; SMITH, DP			MULTIPLE MESSENGER-RNA ISOFORMS OF THE HUMAN RET PROTOONCOGENE GENERATED BY ALTERNATE SPLICING	ONCOGENE			English	Article						RET; RECEPTOR TYROSINE KINASE; ALTERNATE SPLICING	TYROSINE KINASE; TRANSFORMING GENE; SOLUBLE RECEPTOR; II ONCOGENE; CELL-LINE; PROTOONCOGENE; SEQUENCE; CLONING; RNA; CARCINOMAS	The RET proto-oncogene encodes a receptor tyrosine kinase. We and others have recently shown that distinct germline mutations of the BET proto-oncogene account for the majority of cases of the dominantly inherited multiple endocrine neoplasia (MEN) type 2 syndromes, and can cause a dominantly inherited form of Hirschsprung disease, a disorder of development of the autonomic innervation of the gut. RET is also oncogenically activated in some sporadic thyroid and adrenal tumours. Here we report the characterisation of multiple mRNA isoforms of RET generated by alternate splicing. Two isoforms are predicted to encode membrane-spanning receptors with a truncated extracellular ligand-binding domain. A third isoform is predicted to encode a soluble, secreted form of the receptor, These mRNA isoforms are expressed in both normal and tumour tissues.	UNIV CAMBRIDGE, DEPT PATHOL, CRC, HUMAN CANC GENET RES GRP, CAMBRIDGE CB2 1QP, ENGLAND; HARVARD UNIV, SCH MED,DEPT MED,DANA FARBER CANC INST, DIV MED ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED,DEPT MED,DANA FARBER CANC INST, DIV CANC EPIDEMIOL & CONTROL, BOSTON, MA 02115 USA; QUEENS UNIV, DEPT PATHOL, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT PAEDIAT, KINGSTON, ON K7L 3N6, CANADA	University of Cambridge; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Queens University - Canada; Queens University - Canada				Lorenzo, Maria Jesus/0000-0003-4416-0615; Eng, Charis/0000-0002-3693-5145				BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DELANEY SJ, 1993, NAT GENET, V4, P426, DOI 10.1038/ng0893-426; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; EISEMANN A, 1991, ONCOGENE, V6, P1195; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; ENGG C, 1995, IN PRESS GENES CHROM; Favaloro J, 1980, Methods Enzymol, V65, P718; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; KODA T, 1988, Hokkaido Journal of Medical Science, V63, P913; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUMABE T, 1992, ONCOGENE, V7, P627; KWOK JBJ, 1983, ONCOGENE, V8, P2575; LANZI C, 1992, ONCOGENE, V7, P2189; Leong S, 1981, ADV THYROID NEOPLASI, P95; Maniatis T., 1982, MOL CLONING; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, HUM MOL GENET, V3, P1007, DOI 10.1093/hmg/3.6.1007; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROSS RA, 1983, J NATL CANCER I, V71, P741; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404	42	45	46	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1377	1383						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731689				2022-12-17	WOS:A1995QR65100015
J	LAUREYS, G; SPELEMAN, F; VERSTEEG, R; VANDERDRIFT, P; CHAN, A; LEROY, J; FRANCKE, U; OPDENAKKER, G; VANROY, N				LAUREYS, G; SPELEMAN, F; VERSTEEG, R; VANDERDRIFT, P; CHAN, A; LEROY, J; FRANCKE, U; OPDENAKKER, G; VANROY, N			CONSTITUTIONAL TRANSLOCATION T(1-17)(P36.31-P36.13-Q11.2Q12.1) IN A NEUROBLASTOMA PATIENT. ESTABLISHMENT OF SOMATIC-CELL HYBRIDS AND IDENTIFICATION OF PND/A12M2 ON CHROMOSOME-1 AND NF1/SCYA7 ON CHROMOSOME-17 AS BREAKPOINT FLANKING SINGLE-COPY MARKERS	ONCOGENE			English	Article						NEUROBLASTOMA; SOMATIC CELL HYBRIDS; PRONATRIODILATIN; MONOCYTE CHEMOTACTIC PROTEIN; ADENOVIRUS INTEGRATION SITE; NEUROFIBROMATOSIS; SUPPRESSOR GENE	TUMOR-NECROSIS-FACTOR; CUTANEOUS MALIGNANT-MELANOMA; SHORT ARM; LINKAGE MAP; RNA GENES; N-MYC; REGION; 1P36; CANCER; EXPRESSION	Cytogenetic and molecular studies in neuroblastoma suggest the presence of a tumor suppressor gene at the distal band p36 of human chromosome 1, We described a constitutional translocation t(1;17)(p36;q12-q21), involving the critical region 1p36, in a patient with neuroblastoma, and hypothesized that the translocation predisposed the patient to tumor development, Here we report the molecular delineation of the translocation breakpoints, Somatic cell hybrids were generated by fusion of the patient's fibroblasts with the thymidine kinase deficient hamster cell line, a3, In hybrid cell lines which retained the human derivative chromosomes, the position of chromosome 1p and 17q DNA probes respective to the translocation breakpoints was determined by fluorescence in situ hybridization and Southern blot analysis, The chromosome Ip breakpoint was localized within a repetitive region encoding t-RNA genes, with 12A-2 (PND) as most distal and pHE2.6 (A12M2) as most proximal single-copy breakpoint flanking markers, For the chromosome 17 breakpoint, the proximal and distal flanking markers were identified as 7G4 (NF1) and cMCP-3 (SCYA7), respectively, In this study, cMCP-3 (SCYA7), encoding the human monocyte chemotactic protein-3, was mapped between NF1 and ERBB2, As a pivotal step towards breakpoint cloning, at present these flanking markers optimally delineate the breakpoint regions of both chromosomes 1 and 17 at the molecular level.	STATE UNIV GHENT HOSP, DEPT MED GENET, B-9000 GHENT, BELGIUM; STATE UNIV GHENT HOSP, DEPT PEDIAT, B-9000 GHENT, BELGIUM; UNIV AMSTERDAM, ACAD MED CTR, DEPT HUMAN GENET, 1105 AZ AMSTERDAM, NETHERLANDS; STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT GENET, STANFORD, CA 94305 USA; CATHOLIC UNIV LEUVEN, REGA INST MED RES, LOUVAIN, BELGIUM	Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Howard Hughes Medical Institute; Stanford University; KU Leuven	LAUREYS, G (corresponding author), STATE UNIV GHENT HOSP, DEPT PEDIAT ONCOL, B-9000 GHENT, BELGIUM.		Opdenakker, Ghislain/V-8562-2019; laureys, genevieve/AAG-2390-2021; Versteeg, Rogier/AAQ-1765-2020; Opdenakker, Ghislain/Q-3130-2017	Opdenakker, Ghislain/0000-0003-1714-2294; Opdenakker, Ghislain/0000-0003-1714-2294; Versteeg, Rogier/0000-0001-7172-0388				BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BARKER PE, 1993, ONCOGENE, V8, P3353; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BOYD E, 1989, HUM GENET, V81, P153, DOI 10.1007/BF00293892; BRODEUR GM, 1981, CANCER RES, V41, P4678; BUCKLAND RA, 1992, CYTOGENET CELL GENET, V61, P1, DOI 10.1159/000133358; CARON H, 1994, AM J HUM GENET, V55, P341; CHENG NC, 1995, ONCOGENE, V10, P291; CORSARO CM, 1978, SOMAT CELL GENET, V4, P541, DOI 10.1007/BF01542925; DRACOPOLI NC, 1991, GENOMICS, V9, P686, DOI 10.1016/0888-7543(91)90362-I; DRIESEN MS, 1991, GENOMICS, V11, P1079, DOI 10.1016/0888-7543(91)90035-D; ELLMEIER W, 1992, EMBO J, V11, P2563, DOI 10.1002/j.1460-2075.1992.tb05321.x; FAIN P R, 1987, Genomics, V1, P340, DOI 10.1016/0888-7543(87)90034-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FOUNTAIN JW, 1989, AM J HUM GENET, V44, P58; GEFTER ML, 1977, SOMAT CELL GENET, V3, P231, DOI 10.1007/BF01551818; GILBERT F, 1984, CANCER RES, V44, P5444; GOILLOT E, 1992, CANCER RES, V52, P3194; GREENE MH, 1983, P NATL ACAD SCI-BIOL, V80, P6071, DOI 10.1073/pnas.80.19.6071; HARNETT PR, 1991, CANCER GENET CYTOGEN, V54, P109, DOI 10.1016/0165-4608(91)90037-U; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; JORDE LB, 1993, AM J HUM GENET, V53, P1038; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1966, CANCER, V19, P1032, DOI 10.1002/1097-0142(196607)19:7<1032::AID-CNCR2820190719>3.0.CO;2-7; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LEDBETTER SA, 1992, AM J HUM GENET, V50, P182; LEISTER I, 1990, CANCER RES, V50, P7232; LEMONS RS, 1990, GENE CHROMOSOME CANC, V2, P79, DOI 10.1002/gcc.2870020202; LENGAUER C, 1992, CANCER RES, V52, P2590; LINDGREN V, 1985, MOL CELL BIOL, V5, P2172, DOI 10.1128/MCB.5.9.2172; LINDGREN V, 1985, NATURE, V314, P115, DOI 10.1038/314115a0; LUND E, 1983, MOL CELL BIOL, V3, P2211, DOI 10.1128/MCB.3.12.2211; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; MCBRIDE OW, 1989, GENOMICS, V5, P561, DOI 10.1016/0888-7543(89)90024-4; MCDOUGALL JK, 1971, J GEN VIROL, V12, P43, DOI 10.1099/0022-1317-12-1-43; MICHALSKI AJ, 1992, ONCOGENE, V7, P1595; OCONNELL P, 1993, GENOMICS, V15, P38, DOI 10.1006/geno.1993.1007; OPDENAKKER G, 1994, GENOMICS, V21, P403, DOI 10.1006/geno.1994.1283; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PONZONI M, 1992, CANCER RES, V52, P931; ROMANI M, 1990, GENE, V95, P231, DOI 10.1016/0378-1119(90)90366-Y; ROSEN ST, 1987, LAB INVEST, V56, P302; Sambrook J., 1989, MOL CLONING LAB MANU; SAVELYEVA L, 1994, AM J HUM GENET, V55, P334; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SHAPIRO DN, 1993, GENOMICS, V17, P767, DOI 10.1006/geno.1993.1404; SOLOMON E, 1991, CYTOGENET CELL GENET, V58, P1, DOI 10.1159/000133157; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; TANAKA K, 1993, ONCOGENE, V8, P2253; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; VANDERDRIFT P, 1994, HUM MOL GENET, V3, P2131, DOI 10.1093/hmg/3.12.2131; VANROY N, 1994, GENE CHROMOSOME CANC, V10, P103, DOI 10.1002/gcc.2870100205; VANROY N, 1993, GENOMICS, V18, P71, DOI 10.1006/geno.1993.1427; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160; WAYE JS, 1986, NUCLEIC ACIDS RES, V14, P6915, DOI 10.1093/nar/14.17.6915; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WESTERVELD A, 1971, NATURE-NEW BIOL, V234, P20, DOI 10.1038/newbio234020a0; WITZLEBEN CL, 1974, CANCER-AM CANCER SOC, V34, P786, DOI 10.1002/1097-0142(197409)34:3<786::AID-CNCR2820340339>3.0.CO;2-9	66	45	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	1995	10	6					1087	1093						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700633				2022-12-17	WOS:A1995QN35300008
J	FOLETTA, VC; SONOBE, MH; SUZUKI, T; ENDO, T; IBA, H; COHEN, DR				FOLETTA, VC; SONOBE, MH; SUZUKI, T; ENDO, T; IBA, H; COHEN, DR			CLONING AND CHARACTERIZATION OF THE MOUSE FRA-2 GENE	ONCOGENE			English	Article							C-FOS; MESSENGER-RNAS; JUN COMPLEXES; TRANSCRIPTION; PROTEINS; AP-1; EXPRESSION; FAMILY; SERUM; DNA	Transcription factor AP-1 is comprised of multiple protein complexes that include members of a family of genes related to the proto-oncogene c-fos. In this report, we have extended the analysis of one member of this family, fos-related antigen-2 (fra-2), by isolating and characterising genomic and cDNA clones encoding:the mouse fra-2 homolog. The overall gene structure (number and positions of introns) was similar to that of both the chicken fra-2 gene and other members of the fos family, and the relative positions of putative enhancers in the 5' regulatory region were well conserved between the mouse and chicken fra-2 genes. High levels of fra-2 mRNA were detected in ovary, stomach, small and large intestine, brain, lung and heart. The mouse Fra-2 protein showed 94% and 87.5% conservation with human and chicken Fra-2, respectively, and mouse Fra-2, like the chicken homolog, induced transformation of chicken embryo fibroblasts. The characterisation of the mouse fra-2 gene provides a basis for analysis of Fra-2 function in the whole animal.	AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CANBERRA,ACT 2601,AUSTRALIA; UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO,JAPAN	Australian National University; John Curtin School of Medical Research; University of Tokyo			Sonobe, Martha/I-2877-2015	Cohen, Donna/0000-0002-0419-9542				ALEXANDERBRIDGES M, 1992, J CELL BIOCHEM, V48, P129, DOI 10.1002/jcb.240480204; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; COHEN DR, 1993, ONCOGENE, V8, P443; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1994, P NATL ACAD SCI USA, V91, P4372, DOI 10.1073/pnas.91.10.4372; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FUJIWARA K, 1987, J VIROL, V61, P4021; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; HADMAN M, 1993, ONCOGENE, V8, P1895; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MATSUI M, 1990, ONCOGENE, V5, P249; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; MOLDERS H, 1987, ONCOGENE, V1, P377; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; THOMPSON JA, 1979, J VIROL, V31, P437, DOI 10.1128/JVI.31.2.437-446.1979; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715	38	45	48	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3305	3311						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936655				2022-12-17	WOS:A1994PM65800024
J	KAMPS, MP; WRIGHT, DD				KAMPS, MP; WRIGHT, DD			ONCOPROTEIN E2A-PBX1 IMMORTALIZES A MYELOID PROGENITOR IN PRIMARY MARROW CULTURES WITHOUT ABROGATING ITS FACTOR-DEPENDENCE	ONCOGENE			English	Article							T-CELL LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; GROWTH-FACTOR-INDEPENDENCE; HOMEOBOX GENE; PRE-B; CHROMOSOMAL TRANSLOCATIONS; TRANSGENIC MICE; PROTEIN; EXPRESSION	E2A-PBX1 is a chimeric homeobox oncogene formed by the t(1;19) translocation of human pre-B cell acute lymphoblastic leukemia (ALL). Tn a previous study, we found that retroviral expression of E2A-Phx1 in the marrow of reconstituted mice induced the formation of acute myeloid leukemia (AML) in vivo. Here, we report that E2A-Pbx1 can also immortalize myeloid progenitors in vitro, and that the outgrowth of immortalized myeloblasts is evident only in the presence of the myeloid lymphokine, granulocyte-macrophage colony stimulating factor (GM-CSF). When cultured in the presence of GM-CSP, responsive myeloblasts from normal marrow exhibit concurrent proliferation and differentiation, and undergo terminal differentiation into non-mitotic neutrophils and macrophages within 4 weeks. Infection of identical cultures with a retrovirus encoding E2A-Pbx1 produces a rapid outgrowth of myeloid progenitors that express high levels of E2A-Pbx1 protein. A small fraction of myeloblasts in each population exhibited limited differentiation to neutrophils, and all populations of myeloblasts retained a strict dependence on GM-CSF for both survival and proliferation. This data suggests that the function of E2A-Pbx1 in leukemias is to strongly retard differentiation without affecting growth-factor dependence.			KAMPS, MP (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,LA JOLLA,CA 92093, USA.				NATIONAL CANCER INSTITUTE [R01CA056876] Funding Source: NIH RePORTER; NCI NIH HHS [5 RO1 CA 56876-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLACKWOOD EM, 1991, COLD SPRING HARB SYM, V56, P109; BLATT C, 1992, CELL GROWTH DIFFER, V3, P671; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL AJ, 1984, BLOOD, V63, P721; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DUBE ID, 1991, BLOOD, V78, P2996; ERICKSON P, 1992, BLOOD, V80, P1825; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MOUTHON MA, 1993, BLOOD, V81, P647; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OVAL J, 1992, LEUKEMIA, V6, P446; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; READING CL, 1993, BLOOD, V81, P3083; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VOGT M, 1986, MOL CELL BIOL, V6, P3545, DOI 10.1128/MCB.6.10.3545; VOGT M, 1987, ONCOGENE RES, V2, P49; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; WRIGHT CVE, 1989, TRENDS BIOCHEM SCI, V14, P52, DOI 10.1016/0968-0004(89)90043-1	39	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3159	3166						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936638				2022-12-17	WOS:A1994PM65800007
J	SAVOYSKY, E; MIZUNO, T; SOWA, Y; WATANABE, H; SAWADA, J; NOMURA, H; OHSUGI, Y; HANDA, H; SAKAI, T				SAVOYSKY, E; MIZUNO, T; SOWA, Y; WATANABE, H; SAWADA, J; NOMURA, H; OHSUGI, Y; HANDA, H; SAKAI, T			THE RETINOBLASTOMA BINDING-FACTOR-1 (RBF-1) SITE IN RB GENE PROMOTER BINDS PREFERENTIALLY E4TF1, A MEMBER OF THE ETS TRANSCRIPTION FACTORS FAMILY	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; DNA-BINDING; AFFINITY PURIFICATION; C-FOS; PROTEIN; EXPRESSION; SEQUENCE; DIFFERENTIATION; ACTIVATION; ONCOGENE	The tumor suppressor retinoblastoma gene product, pRB, is a well known regulator of G1/S cell cycle progression. Moreover, mutational inactivations within the retinoblastoma gene (RB) are found in many human malignant tumors, and thus, believed to be an essential step in tumor formation. The human RB gene is considered as a housekeeping gene with no characteristic TATA or CAAT elements in its promoter region, but the sequence between 206 and 185 bases upstream of the initiation codon, essential for RB promoter activity, contains putative Sp1 and ATF recognition sites. We have previously reported that point mutations in this region, causing low penetrance retinoblastomas, completely reduced RB promoter activity, and that a nuclear factor, named RBF-1 (retinoblastoma binding factor 1), could specifically bind to this sequence, overlapping Sp1 recognition sequence. We show here, that RBF-1 can recognize a specific DNA sequence, 5'-GGCGGAAGT-3', overlapping the Sp1 and ATF sites and corresponding to the consensus DNA binding site for members of Ets transcription factors family. When RBF-1 site was used for sequence specific DNA affinity purification from erythroleukemia cells, reconstitution assays, immunoblotting analysis and peptide mapping show that the two major co-purified proteins are identical to human E4TF1-60 and -53 proteins. This reveals that E4TF1 can bind to the RBF-1 site of RB gene promoter, which, thus, constitutes a new target for this member of Ets transcription factors family.	KYOTO PREFECTURAL UNIV MED,DEPT PREVENT MED,KAMIKYO KU,KYOTO 602,JAPAN; CHUGAI PHARMACEUT CO LTD,FUJI GOTEMBA RES LABS,GOTEMBA,SHIZUOKA 412,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	Kyoto Prefectural University of Medicine; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Tokyo Institute of Technology								BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUPRIEZ VJ, 1993, P NATL ACAD SCI USA, V90, P8224, DOI 10.1073/pnas.90.17.8224; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; FISHER RJ, 1991, ONCOGENE, V6, P2249; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; GABRIELSEN OS, 1989, NUCLEIC ACIDS RES, V17, P6253, DOI 10.1093/nar/17.15.6253; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MURAKAMI K, 1993, ONCOGENE, V8, P1559; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; SAKAI T, 1991, AM J HUM GENET, V48, P880; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SLACK RS, 1993, ONCOGENE, V8, P1585; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATANABE H, 1990, EMBO J, V9, P841, DOI 10.1002/j.1460-2075.1990.tb08181.x; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WATANABE H, 1988, MOL CELL BIOL, V8, P190; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; YOO WD, 1991, J VIROL, V65, P5391, DOI 10.1128/JVI.65.10.5391-5400.1991; ZACKSENHAUS E, 1993, ONCOGENE, V8, P2343	41	45	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1839	1846						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208529				2022-12-17	WOS:A1994NR68500005
J	DELGADO, MD; HALLIER, M; MENECEUR, P; TAVITIAN, A; MOREAUGACHELIN, F				DELGADO, MD; HALLIER, M; MENECEUR, P; TAVITIAN, A; MOREAUGACHELIN, F			INHIBITION OF FRIEND-CELLS PROLIFERATION BY SPI-1 ANTISENSE OLIGODEOXYNUCLEOTIDES	ONCOGENE			English	Note							ETS GENE FAMILY; VIRUS-INDUCED ERYTHROLEUKEMIA; PUTATIVE ONCOGENE SPI-1; WILD-TYPE P53; TRANSCRIPTION FACTOR; C-MYB; ERYTHROPOIETIN RECEPTOR; OLIGOMER COMPLEMENTARY; TUMORIGENIC CELLS; LEUKEMIA-VIRUS	The spi-1 proto-oncogene encodes the transcription factor PU.1 which is normally expressed in all hematopoietic cell lineages except in T cell lines. During the murine acute erythroleukemia induced by the Friend retrovirus, SFFV, spi-1 deregulation by insertional mutagenesis results in the overexpression of Spi-1/PU.1 in the malignant proerythroblastic cell. To assess the Spi-1 role in the proliferation and the differentiation arrest of the Friend tumor cells we inhibited spi-1 gene expression in two Friend cell lines by using antisense oligodeoxyribonucleotides. Proliferation and cloning efficiency of both cell lines were significantly inhibited by spi1 antisense. This antiproliferative effect was not related to an apparent maturation of erythroleukemic cells demonstrating that repression of spi-1 expression is not sufficient per se to restore the ability of the proerythroblastic cells to spontaneously differentiate in mature erythroblasts. These data suggest that the spi-1 gene would be involved in the Friend leukemic process by promoting the proerythroblast to proliferate.	FAC MED PARIS,INSERM,U248,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Delgado, M. Dolores/K-9056-2014	Delgado, M. Dolores/0000-0003-4682-4040				ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOWARD JC, 1993, ONCOGENE, V8, P2721; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SHEN DW, 1983, P NATL ACAD SCI-BIOL, V80, P5919, DOI 10.1073/pnas.80.19.5919; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKESHITA K, 1993, P NATL ACAD SCI USA, V90, P3535, DOI 10.1073/pnas.90.8.3535; WANG YL, 1993, J VIROL, V67, P1322, DOI 10.1128/JVI.67.3.1322-1327.1993; WENDLING F, 1981, P NATL ACAD SCI-BIOL, V78, P3614, DOI 10.1073/pnas.78.6.3614; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	43	45	45	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1723	1727						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183568				2022-12-17	WOS:A1994NL81500025
J	WONG, WT; KRAUS, MH; CARLOMAGNO, F; ZELANO, A; DRUCK, T; CROCE, CM; HUEBNER, K; DIFIORE, PP				WONG, WT; KRAUS, MH; CARLOMAGNO, F; ZELANO, A; DRUCK, T; CROCE, CM; HUEBNER, K; DIFIORE, PP			THE HUMAN EPS15 GENE, ENCODING A TYROSINE KINASE SUBSTRATE, IS CONSERVED IN EVOLUTION AND MAPS TO 1P31-P-32	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; FACTOR RECEPTOR KINASE; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; SH3 DOMAINS; RAS; GRB2; CLONING; SOS	Employing an expression cloning approach for tyrosine kinase substrates, we have previously isolated the coding sequence for a novel putative EGFR substrate, eps15, from NIH3T3 fibroblasts. Eps15 displayed a receptor-specific pattern of tyrosine phosphorylation in vivo and was able to transform NIH3T3 cells upon overexpression. To gain understanding of eps15 function as well as its role in normal and neoplastic proliferation, we cloned the human eps15 coding sequence and studied expression of the human RNA and protein, evolutionary conservation, and chromosomal location. The close structural similarity of human eps15 with the murine homologue is indicated by 89% and 90% identity of nucleotide and predicted amino acid sequences, respectively. Using the human eps15 coding sequence as probe, we demonstrate that eps15 is member of a gene family that is highly conserved during evolution. An essential function of eps15 in cell growth regulation is underscored by our observation of ubiquitous expression at the transcript and the protein level in normal and malignant human cells. The human EPS15 locus maps to chromosome 1p31-p32, a region involved in deletion in neuroblastoma, translocations in acute lymphoblastic leukemia, and exhibiting a fragile site.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON INST MOLEC MED, PHILADELPHIA, PA 19107 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Jefferson University			Di Fiore, Pier Paolo/K-2130-2012; Young, Richard A/F-6495-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950; Young, Richard A/0000-0001-8855-8647	NCI NIH HHS [CA51083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BRUNS GA, 1993, CHROMOSOME COORDINAT, V1, P143; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CIMINO G, 1991, CANCER RES, V51, P6712; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FAZIOLI F, 1993, ONCOGENE, V8, P1335; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1991, METHOD ENZYMOL, V196, P65; HALUSKA FG, 1988, P NATL ACAD SCI USA, V85, P2215, DOI 10.1073/pnas.85.7.2215; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUEBNER K, 1991, AM J HUM GENET, V48, P726; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Katz Wendy S., 1992, Current Opinion in Cell Biology, V4, P939, DOI 10.1016/0955-0674(92)90122-S; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAUS MH, 1991, METHOD ENZYMOL, V200, P546; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LI N, 1993, NATURE, V363, P86; LINNENBACH AJ, 1993, MOL CELL BIOL, V13, P1507, DOI 10.1128/MCB.13.3.1507; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAKELA TP, 1991, MOL CELL BIOL, V11, P4015; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MITELMAN F, 1993, CHROMOSOME COORDINAT, V1, P700; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; MORRIS SW, 1993, GENOMICS, V15, P677, DOI 10.1006/geno.1993.1124; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUFF JS, 1993, SCIENCE, V261, P1733; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHILO BZ, 1992, FASEB J, V6, P2915, DOI 10.1096/fasebj.6.11.1322852; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TWEARDY DJ, 1992, BLOOD, V79, P1148, DOI 10.1182/blood.V79.5.1148.bloodjournal7951148; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	49	45	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1591	1597						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183552				2022-12-17	WOS:A1994NL81500009
J	HOGG, D; GUIDOS, C; BAILEY, D; AMENDOLA, A; GROVES, T; DAVIDSON, J; SCHMANDT, R; MILLS, G				HOGG, D; GUIDOS, C; BAILEY, D; AMENDOLA, A; GROVES, T; DAVIDSON, J; SCHMANDT, R; MILLS, G			CELL-CYCLE DEPENDENT REGULATION OF THE PROTEIN-KINASE TTK	ONCOGENE			English	Article							TYROSINE PHOSPHATASE; ACTIVATES P34CDC2; CDC25 PROTEIN; S-PHASE; PHOSPHORYLATION; DEPHOSPHORYLATION; IDENTIFICATION; TRANSITIONS; COMPLEX; G1	TTK is a novel protein kinase detectable in all proliferating human cells and tissues. Expression of the TTK gene is markedly reduced or absent in resting cells and in tissues with a low proliferative index. In view of the apparent association between TTK gene expression and cell proliferation, we examined the regulation of this protein kinase during transit of the cell cycle. We found very low levels of TTK mRNA and protein in starved cells. When cells are induced to enter the cell cycle, levels of TTK mRNA, protein and kinase activity increase at the G1/S phase of the cell cycle and peak in G2/M. TTK mRNA levels, as well as kinase activity, drop sharply in early G1, whereas protein levels are largely maintained. TTK may play a role in cell cycle control.	TORONTO HOSP, DEPT PATHOL, TORONTO M5T 2S8, ON, CANADA; HOSP SICK CHILDREN, DIV IMMUNOL & CANC, TORONTO M5G 1X8, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								ADAMS RLP, 1967, J BIOL CHEM, V242, P1314; BASERGA R, 1990, CANCER RES, V50, P6769; Bauer K D, 1990, Methods Cell Biol, V33, P235; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DOUVILLE EMJ, 1992, MOL CELL BIOL, V12, P2681, DOI 10.1128/MCB.12.6.2681; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; JOLOMON M, 1993, EMBO J, V12, P3133; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LINDBERG RA, 1993, ONCOGENE, V8, P351; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MILLS GB, 1992, J BIOL CHEM, V267, P16000; MORIA AO, 1989, CELL, V58, P193; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	44	45	48	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					89	96						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302607				2022-12-17	WOS:A1994MW24700011
J	CALLAGHAN, T; ANTCZAK, M; FLICKINGER, T; RAINES, M; MYERS, M; KUNG, HJ				CALLAGHAN, T; ANTCZAK, M; FLICKINGER, T; RAINES, M; MYERS, M; KUNG, HJ			A COMPLETE DESCRIPTION OF THE EGF-RECEPTOR EXON STRUCTURE - IMPLICATIONS IN ONCOGENIC ACTIVATION AND DOMAIN EVOLUTION	ONCOGENE			English	Article							GROWTH-FACTOR-RECEPTOR; AVIAN-LEUKOSIS VIRUS; TYROSINE KINASE-ACTIVITY; HUMAN-BRAIN TUMORS; C-ERBB ACTIVATION; INDUCED ERYTHROBLASTOSIS; SIGNAL TRANSDUCTION; SELF-PHOSPHORYLATION; CATALYTIC DOMAINS; PHOSPHOLIPASE-C	In this paper, we report that the chicken Epidermal Growth Factor Receptor (EGF-R), encoded by the proto-oncogene c-erbB, is comprised of 28 exons and spans over 75 Kb. The four previously identified domains which make up the extracellular ligand binding region of the receptor are coded for by two copies of a 300 amino acid repeat. We have demonstrated that the 3' end of each repeat coincides with the 3' end of the last exon making up the repeat. This alignment suggests that an exon-duplication may have occurred in the ligand-binding region of the gene. The transmembrane domain is encoded within a single exon and the exon boundaries of the catalytic domain closely match those defined by structural homology with other kinases. Along with the 54 chicken splice sites, the region 5' to the first exon was also sequenced. The proposed promoter region is greater than 70% GC, contains five repeats of the consensus Spl binding sequence and does not have a CCATT or TATA box. In addition to the presence of these characteristic housekeeping features, expression analysis confirms the promoter activity of this region and four sets of TCC repeats similar to those found in the human EGF-R promoter have been identified. To our knowledge this represents the first complete description of the exon-intron structure of the EGF-receptor family. The elucidation of the EGF-R exon structure provides insight into the domain evolution of the receptor-kinases and the mechanisms for the oncogenic conversion of EGF-R in erythroleukemias and glioblastomas.			CALLAGHAN, T (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, CLEVELAND, OH 44106 USA.		Kung, Hsing-Jien/C-7651-2013		NCI NIH HHS [P-30 CA43703, NCI CA 39207] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039207, R37CA039207, P30CA043703] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANDRE C, 1992, ONCOGENE, V7, P685; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BEUG H, 1982, J CELL PHYSIOL, P195; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOKKEL E, 1992, ONCOGENE, V7, P1423; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GOODWIN RG, 1986, MOL CELL BIOL, V6, P3128, DOI 10.1128/MCB.6.9.3128; HALEY J, 1987, ONCOGENE RES, V1, P375; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MAIHLE NJ, 1989, BIOCHIM BIOPHYS ACTA, V948, P287, DOI 10.1016/0304-419X(89)90003-6; MAIHLE NJ, 1991, P NATL ACAD SCI USA, V88, P1825, DOI 10.1073/pnas.88.5.1825; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MEINSENHELDER J, 1989, CELL, V57, P1109; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; Partanen A M, 1990, Curr Top Dev Biol, V24, P31, DOI 10.1016/S0070-2153(08)60083-6; PAWSON T, 1988, ONCOGENE, V3, P491; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALIER JP, 1989, BIOTECHNIQUES, V7, P30; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEJTER ED, 1986, CELL, V46, P1091, DOI 10.1016/0092-8674(86)90709-9; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SERGEANT A, 1982, EMBO J, V1, P237, DOI 10.1002/j.1460-2075.1982.tb01153.x; STECK PA, 1988, CANCER RES, V48, P5433; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; TOH H, 1985, NATURE, V314, P199, DOI 10.1038/314199a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WHITE MRA, 1992, ONCOGENE, V7, P677; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816	70	45	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					2939	2948						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414496				2022-12-17	WOS:A1993MC09300007
J	DUTERQUECOQUILLAUD, M; NIEL, C; PLAZA, S; STEHELIN, D				DUTERQUECOQUILLAUD, M; NIEL, C; PLAZA, S; STEHELIN, D			NEW HUMAN ERG ISOFORMS GENERATED BY ALTERNATIVE SPLICING ARE TRANSCRIPTIONAL ACTIVATORS	ONCOGENE			English	Article							PUTATIVE ONCOGENE SPI-1; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; ETS PROTO-ONCOGENE; DNA-BINDING; C-ETS; V-ETS; CHROMOSOMAL LOCALIZATION; GENE FAMILY; PROTEINS	The erg gene is a member of the ets gene family. ETS proteins have been shown to bind specifically the (GGAA/T) motif and to transactivate via this consensus sequence. The human erg products exhibit almost-equal-to 70% homology with ETS proteins in their DNA-binding domain. We have isolated three erg cDNAs from a human fetal liver library. Two of them are different from the previously described erg-1 and erg-2 cDNAs (Rao et al., Science, 1987, 237, 635-639), in the middle of their coding sequence and in their 5' part where a novel initiation codon is introduced. These isoforms are generated by alternative RNA splicing from a single gene that leads to the inclusion or exclusion of different exon sequences. The three cDNAs expressed by an in vitro transcription-translation system direct the synthesis of proteins of almost-equal-to 38, 49 and 55 kDa. These in vitro erg products were tested for their DNA-binding activity by gel mobility-shift assays with different probes containing the ETS-specific binding site. The results indicated that all these erg isoforms are able to bind the ETS binding site in a specific manner. Our data using transient transfection assays indicate that erg protein isoforms function as transcriptional activators.			DUTERQUECOQUILLAUD, M (corresponding author), INST PASTEUR,CNRS,URA 1160,1 RUE CALMETTE,F-59019 LILLE,FRANCE.		plaza, serge/F-5290-2015; Niel, Christian/G-3712-2013	Duterque-Coquillaud, Martine/0000-0003-3943-5629				ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JORCYK CL, 1991, ONCOGENE, V6, P523; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MESSING J, 1983, METHOD ENZYMOL, V101, P20; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SACCHI N, 1988, Genomics, V3, P110, DOI 10.1016/0888-7543(88)90140-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SPEGELAERE P, 1991, J VIROL, V65, P4919, DOI 10.1128/JVI.65.9.4919-4928.1991; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	62	45	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1865	1873						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510931				2022-12-17	WOS:A1993LG68200019
J	SCHWEIGHOFFER, F; FAURE, M; FATH, I; CHEVALLIERMULTON, MC; APIOU, F; DUTRILLAUX, B; STURANI, E; JACQUET, M; TOCQUE, B				SCHWEIGHOFFER, F; FAURE, M; FATH, I; CHEVALLIERMULTON, MC; APIOU, F; DUTRILLAUX, B; STURANI, E; JACQUET, M; TOCQUE, B			IDENTIFICATION OF A HUMAN GUANINE NUCLEOTIDE-RELEASING FACTOR (H-GRF55) SPECIFIC FOR RAS PROTEINS	ONCOGENE			English	Article							GTPASE ACTIVATING PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; MAMMALIAN-CELLS; CDC25 GENE; PRODUCT; DOMAIN; EXCHANGE; MUTANTS; SCD25	A critical step in the activation of cellular Ras is the release of bound GDP. Oligonucleotide primers derived from a mouse cDNA sequence homologous to the Sac-charomyces cerevisiae CDC25 gene product were used to screen a human brain cDNA library. The cloning led to the isolation of a 2.8-kb cDNA predicted to encode a protein of 488 amino acids. This protein was produced in Escherichia coli as a glutathione S-transferase fusion protein and functioned in vitro as a specific guanine nucleotide-releasing factor. Polyclonal antibodies raised against the last 281 amino acids of the protein allowed a protein in the molecular weight range of 55 kDa to be identified in human cortex homogenates. Analysis by Northern blotting led to the identification of a 5.5-kb mRNA in brain poly(A)+ RNA. The functionality of the encoded protein was evaluated after expression in different cells: (i) in Saccharomyces cerevisiae the effects of the cdc25.5 and RAS2 Ala-22 mutations were reversed; (ii) in chinese hamster ovary cells, a RAS-responsive element was transactivated as demonstrated by the expression of a CAT reporter gene under the control of the polyomavirus enhancer. Finally, in situ hybridization on of human chromosomes revealed a localization on band 15q2.4.	RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,13 QUAI JULES GUESDE,BP 14,F-94403 VITRY,FRANCE; UNIV PARIS 11,INST GENET & MICROBIOL,F-91405 ORSAY,FRANCE; INST CURIE,BIOL SECT,F-75231 PARIS 05,FRANCE; UNIV MILAN,DIPARTIMENTO FISIOL & BIOCHIM GEN,SEZ BIOCHIM COMPARATA,I-20133 MILAN,ITALY	Sanofi-Aventis; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Milan								ADAMS JM, 1992, ONCOGENE, V7, P611; BARLAT I, 1993, ONCOGENE, V8, P215; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CAMONIS JH, 1990, GENE, V86, P263, DOI 10.1016/0378-1119(90)90288-3; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; REY I, 1991, ONCOGENE, V6, P347; Sambrook J., 1989, MOL CLONING LAB MANU; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SHERMAN F, 1986, LABORATORY COURSE MA; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SKOLNIK EY, 1991, CELL, V65, P833; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SMITH DB, 1988, GENE, V67, P131; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122; WASYLYK B, 1988, P NATL ACAD SCI USA, V85, P7952, DOI 10.1073/pnas.85.21.7952	34	45	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1477	1485						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	7684828				2022-12-17	WOS:A1993LE06400010
J	FILMUS, J; SHI, W; SPENCER, T				FILMUS, J; SHI, W; SPENCER, T			ROLE OF TRANSFORMING GROWTH FACTOR-ALPHA (TGF-ALPHA) IN THE TRANSFORMATION OF RAS-TRANSFECTED RAT INTESTINAL EPITHELIAL-CELLS	ONCOGENE			English	Article							HUMAN-COLON; FACTOR-RECEPTOR; AUTOCRINE GROWTH; HA-RAS; CARCINOMA-CELLS; TRANSGENIC MICE; EXPRESSION; CANCER; GENE; INDUCTION	Most intestinal tumors express transforming growth factor alpha (TGF-alpha) while normal immature crypt cells, the targets for tumor initiation, do not. We have used a rat intestinal cell line derived from immature epithelial crypt cells (IEC-18) to investigate the role of this growth factor in intestinal tumorigenesis. ras transformation of IEC-18 cells induces expression and secretion of TGF-alpha. By studying several independently derived IEC-ras clones, we have established that the amount of TGF-alpha secreted is proportional to the level of activated ras expressed by each clone. The growth of all ras-transformed IEC clones is significantly inhibited by neutralizing antibodies against TGF-alpha and by an antisense TGF-alpha expression vector, indicating a mitogenic role for this growth factor through an autocrine loop. To determine whether TGF-alpha itself can transform intestinal cells, IEC-18 clones transfected with TGF-alpha expression vectors were isolated and characterized. None of the TGF-alpha-expressing clones show any signs of tumorigenic transformation even when they secrete as much TGF-alpha as the IEC-ras clones. It seems, therefore, that TGF-alpha per se does not have the capacity to transform rat epithelial intestinal cells and that its role is mostly related to autocrine growth stimulation.	UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto	FILMUS, J (corresponding author), SUNNYBROOK HLTH SCI CTR,DIV CANC RES,REICHMANN RES BLDG,2075 BAYVIEW AVE,TORONTO M4N 3M5,ON,CANADA.							ANZANO MA, 1989, CANCER RES, V49, P2898; BARNARD JA, 1991, AM J PHYSIOL, V261, pC994, DOI 10.1152/ajpcell.1991.261.6.C994; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; CIARDIELLO F, 1990, J CELL BIOCHEM, V42, P45, DOI 10.1002/jcb.240420105; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; CIARDIELLO F, 1989, FEBS LETT, V250, P474, DOI 10.1016/0014-5793(89)80779-3; CIARDIELLO F, 1988, MOL ENDOCRINOL, V2, P1202, DOI 10.1210/mend-2-12-1202; COLLETTA G, 1991, ONCOGENE, V6, P583; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DERNYCK R, 1992, ADV CANCER RES, V58, P27; DIMARCO E, 1989, ONCOGENE, V4, P831; FILMUS J, 1992, ONCOGENE, V7, P521; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; FINZI E, 1988, MOL CARCINOGEN, V1, P7, DOI 10.1002/mc.2940010105; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GOUSTIN AS, 1986, CANCER RES, V46, P1015; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; HELDIN CH, 1989, EUR J BIOCHEM, V184, P487, DOI 10.1111/j.1432-1033.1989.tb15041.x; HOFER DR, 1991, CANCER RES, V51, P2780; IMANISHI K, 1989, J NATL CANCER I, V81, P220, DOI 10.1093/jnci/81.3.220; KARNES WE, 1992, GASTROENTEROLOGY, V102, P474, DOI 10.1016/0016-5085(92)90093-E; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LIU C, 1990, BRIT J CANCER, V62, P425, DOI 10.1038/bjc.1990.311; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MORISHIGE K, 1991, CANCER RES, V51, P5951; MURTHY U, 1989, INT J CANCER, V44, P110, DOI 10.1002/ijc.2910440120; QUARONI A, 1981, J NATL CANCER I, V67, P1353; REISS M, 1991, CANCER RES, V51, P6254; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SALOMON DS, 1990, CANCER CELL-MON REV, V2, P389; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STROMBERG K, 1992, CANCER RES, V52, P341; TANAKA S, 1991, AM J PATHOL, V139, P123; THOMAS DM, 1992, GUT, V33, P628, DOI 10.1136/gut.33.5.628; TRICOLI JV, 1986, CANCER RES, V46, P6169; WATANABE S, 1987, P NATL ACAD SCI USA, V84, P1258, DOI 10.1073/pnas.84.5.1258; YASUI W, 1988, CANCER RES, V48, P137; YOSHIDA K, 1990, JPN J CANCER RES, V81, P43, DOI 10.1111/j.1349-7006.1990.tb02505.x	48	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1017	1022						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455929				2022-12-17	WOS:A1993KT22000025
J	AUWERX, J; SASSONECORSI, P				AUWERX, J; SASSONECORSI, P			AP-1 (FOS-JUN) REGULATION BY IP-1 - EFFECT OF SIGNAL TRANSDUCTION PATHWAYS AND CELL-GROWTH	ONCOGENE			English	Article							NF-KAPPA-B; DNA-BINDING PROTEINS; TRANSCRIPTION FACTOR AP-1; C-JUN; PROTO-ONCOGENE; GENE-EXPRESSION; KINASE-C; V-JUN; RAPIDLY DISSOCIATE; LEUCINE ZIPPERS	Transcription factor AP-1 is constituted by the various products of the fos and jun proto-oncogene family members, which associate as dimers to bind with variable efficiency to 12-O-tetradecanoyl phorbol 13-acetate (TPA)-responsive promoter elements (TREs). We have recently shown that DNA binding of AP-1 is regulated by an inhibitory protein, IP-1, whose activity is modulated by phosphorylation. Here it is shown that although AP-1 has a very high affinity for its recognition sequence, its binding to the TRE can be quickly inhibited by the addition of IP-1. IP-1 is more active on AP-1 complexes formed during a shorter period of time. IP-1 activity is blocked by stimulation of the protein kinase C (PKC) signal transducation pathway, achieved by treating HeLa cells with phorbol esters or with a diacylglycerol analog. We observed an increase in AP-1-DNA, binding after treatment of the cells with either the calcium ionophore A-23187 or dibutyryl cAMP; this could be ascribed to inhibition of IP-1 activity. A decreased IP-1 activity also correlates with the increase in AP-1-DNA binding after stimulating cells with serum. This suggests that IP-1 is an important target of the various signal transduction pathways. No effect on AP-1 and IP-1 was detected in cells transformed by Ki-ras or v-raf; nor could an effect of inhibition of protein synthesis be observed. We also analysed IP-1 regulation upon differentiation of P19 embryonal carcinoma cells by retinoic acid. We conclude that IP-1 regulation has a pivotal role in the final modulation of Fos-Jun by signal transduction pathways.	CATHOLIC UNIV LEUVEN,DEPT DEV BIOL,EXPTL MED & ENDOCRINOL LAB,B-3000 LOUVAIN,BELGIUM; CNRS,UMR 134,CTR BIOCHEM,F-06108 NICE,FRANCE; FAC MED STRASBOURG,GENET MOLEC EUCARYOTES LAB,CNRS,U184,INSERM,F-67085 STRASBOURG,FRANCE	KU Leuven; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Auwerx, Johan/0000-0002-5065-5393				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CAMBIER JC, 1987, NATURE, V327, P619; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MURAKAMI Y, 1990, ONCOGENE, V5, P5; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NARANJO JR, 1991, NEURON, V6, P307; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1986, TRENDS GENET, V2, P215, DOI 10.1016/0168-9525(86)90233-7; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YANG-YEN H-F, 1990, New Biologist, V2, P351; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	74	45	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2271	2280						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437149				2022-12-17	WOS:A1992JW66500020
J	NEUMANN, M; TSAPOS, K; SCHEPPLER, JA; ROSS, J; FRANZA, BR				NEUMANN, M; TSAPOS, K; SCHEPPLER, JA; ROSS, J; FRANZA, BR			IDENTIFICATION OF COMPLEX-FORMATION BETWEEN 2 INTRACELLULAR TYROSINE KINASE SUBSTRATES - HUMAN C-REL AND THE P105 PRECURSOR OF P50 NF-KAPPA-B	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENHANCER-BINDING-PROTEIN; LONG TERMINAL REPEAT; DNA-BINDING; V-REL; TRANSCRIPTION FACTORS; CELLULAR PROTEINS; STRAIN-T; ACTIVATION; CELLS	Immune complexes of the product of the c-rel protooncogene and of p105, the p50 NF-kappaB precursor, isolated from human T-lymphoblastoid cell lines are comprised of multiple proteins. Only p105 and human c-Rel (hc-Rel) are common to complexes precipitated with antiserum directed against either p105 or hc-Rel. Both proteins are inducible by phytohemagglutinin (PHA) and phorbol 12-myristate 13-acetate (PMA) and their subcellular distribution is affected by this induction. We demonstrate that the Rel immune complex contains a protein with a molecular weight in the 40 kDa range (p40) which apparently is exclusively cytoplasmic. We were not able to detect p40 in the p105 immune complex, though hc-Rel is present. This indicates that hc-Rel exists in different multi-protein complexes and fits a model of functional regulation mediated by differential protein-protein interaction. We also demonstrate considerable isoform diversity of both hc-Rel and p105. We show that this heterogeneity is, in part, the result of phosphorylation. Furthermore, we demonstrate that p105 and hc-Rel are tyrosine kinase substrates. This finding indicates a role for both proteins in intracellular signal transduction pathways which are modulated by modification of their phosphorylation status.	COLD SPRING HARBOR LAB, FREEMAN LAB CANC CELL BIOL, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory					NIAID NIH HHS [NIAID 32028] Funding Source: Medline; NCPDCID CDC HHS [NCI 40512] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032028] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCPDCID CDC HHS; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DAVIS JN, 1990, ONCOGENE, V5, P1109; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINTER H, 1987, EMBO J, V6, P4067, DOI 10.1002/j.1460-2075.1987.tb02752.x; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANZA BR, 1990, UCLA SYM BI, V119, P181; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; GARRELS JI, 1989, J BIOL CHEM, V264, P5283; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90421-L; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; IP YT, 1991, CELL, V64, P439; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOCHEL T, 1991, ONCOGENE, V6, P615; KOCHEL T, 1992, ONCOGENE, V7, P567; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JH, 1991, ONCOGENE, V6, P665; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LI YC, 1991, MOL CELL BIOL, V11, P1883, DOI 10.1128/MCB.11.4.1883; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MORRISON LE, 1989, ONCOGENE, V4, P677; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NSRURTLR PS, 1988, DVIRNVR, V242, P540; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RICE NR, 1988, ONCOGENE HDB, P495; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; ROBINSON FR, 1974, AVIAN DIS, V18, P278, DOI 10.2307/1589142; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	61	45	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2095	2104						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437141				2022-12-17	WOS:A1992JW66500001
J	HATTORI, S; MAEKAWA, M; NAKAMURA, S				HATTORI, S; MAEKAWA, M; NAKAMURA, S			IDENTIFICATION OF NEUROFIBROMATOSIS TYPE-I GENE-PRODUCT AS AN INSOLUBLE GTPASE-ACTIVATING PROTEIN TOWARD RAS P21	ONCOGENE			English	Article							GAP; PURIFICATION; ENCODES; CLONING; DOMAIN; LOCUS; BRAIN; CELLS	The neurofibromatosis type I (NF1) gene was cloned as a gene whose structural change is closely related to the onset of a neurocutaneous disorder, neurofibromatosis type I. The predicted amino acid sequence of the NF1 gene product shows significant similarity to the catalytic domain of GTPase-activating protein (GAP) for ras p21. This GAP-related domain has been shown to have GAP activity when expressed by recombinant DNA technique, however little is known about the NF1 gene product expressed in tissues. Antibodies against the carboxy terminus and the GAP-related domain of the NF1 gene product were made to identify and characterize NF1 protein expressed in vivo. Both antibodies specifically reacted with a polypeptide with apparent molecular weight of 235 kDa in immunoblot and immunoprecipitation analyses. This 235 kDa protein is detected in brain but not in spleen, thymus, kidney, liver, lung and heart. The subcellular distribution of NF1 and GAP was studied using rat brain extract and was identified by the activity which was inhibited by antibodies against GAP-related domain of NF1 and anti-GAP respectively. The results show that NF1 protein mainly resides in the particulate fraction, in contrast to GAP, which is a soluble protein. We also found that a GAP activity which is not inhibited by anti-NF1 and anti-GAP exists in both the soluble and particulate fractions. The result suggests that there may be another GAP molecule.			HATTORI, S (corresponding author), NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,4-1-1 OGAWAHIGASHI,TOKYO 187,JAPAN.							BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BORISY GG, 1975, ANN NY ACAD SCI, V253, P107, DOI 10.1111/j.1749-6632.1975.tb19196.x; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; GLENNEY JR, 1982, CELL, V28, P845; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HATTORI S, 1991, BIOCHEM BIOPH RES CO, V177, P83, DOI 10.1016/0006-291X(91)91951-8; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WANG K, 1977, BIOCHEMISTRY-US, V16, P1857, DOI 10.1021/bi00628a015; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	21	45	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					481	485						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549362				2022-12-17	WOS:A1992HK00500012
J	OKA, T; RAIRKAR, A; CHEN, JH				OKA, T; RAIRKAR, A; CHEN, JH			STRUCTURAL AND FUNCTIONAL-ANALYSIS OF THE REGULATORY SEQUENCES OF THE ETS-1 GENE	ONCOGENE			English	Article							LONG TERMINAL REPEAT; ONCOGENE C-ETS; TRANSCRIPTION FACTOR; EXPRESSION SYSTEM; ENHANCER; LEUKEMIA; PROMOTER; BINDING; LOCALIZATION; CLONING	The ets-1 gene is a human homolog of the oncogene v-ets of avian acute leukemia virus E26. The ets-1 gene is preferentially expressed in lymphoid cells. To understand the regulation of the ets-1 gene expression the regulatory sequences of this gene were identified and isolated. The promoter is found to be functioning in the lymphoid cell line Daudi and the erythromyeloid cell line K562 but not in the promyelocytic cell line HL60. Sequence analysis indicates that the ets-1 promoter does not contain the TATA or CAT box. It contains multiple transcription initiation sites in a tight cluster. The promoter contains one binding site each for AP1 and AP2. It has one definitive and five presumptive sp1-binding sites. In addition, the ets-1 promoter contains one ets-1 protein-binding site. Functional analysis has shown that c-jun enhances the activity of the ets-1 promoter, whereas the combination of c-fos and c-jun expressions has no synergistic effect. The expression of exogenous AP2 and ets-1 also enhances the activity of the ets-1 promoter. These results suggest that the AP1, AP2 and ets-1 proteins have a positive regulatory effect. The presence of the ets-I protein-binding site indicates the existence of an autoregulatory mechanism for the expression of the ets-1 gene. Our results suggested that the presence of a negative regulatory element upstream of the region where most of the positive regulators are located.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL PEDIATR,BOX 88,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center								Abate C, 1990, Semin Cancer Biol, V1, P19; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOULUKOS KD, 1989, MOL CELL BIOL, V95, P5718; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JH, 1990, ONCOGENE RES, V5, P277; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; FUJIWARA S, 1988, ONCOGENE, V2, P99; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KANEKO Y, 1986, BLOOD, V67, P484; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MAJERUS MA, 1990, 6TH ANN M ON FRED, P193; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WOOD WM, 1989, J BIOL CHEM, V264, P14840	27	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2077	2083						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945412				2022-12-17	WOS:A1991GX11900019
J	AVIVI, A; LAX, I; ULLRICH, A; SCHLESSINGER, J; GIVOL, D; MORSE, B				AVIVI, A; LAX, I; ULLRICH, A; SCHLESSINGER, J; GIVOL, D; MORSE, B			COMPARISON OF EGF RECEPTOR SEQUENCES AS A GUIDE TO STUDY THE LIGAND-BINDING SITE	ONCOGENE			English	Note							EPIDERMAL GROWTH-FACTOR; LOCALIZATION; EXPRESSION; CELLS	While murine and human EGF-receptor (EGF-R) bind mammalian EGF with high affinity their chicken counterpart has approximately 300 fold reduced binding affinity towards mammalian EGF. We now cloned and sequenced the extracellular ligand binding domain of murine EGF-R in order to define the amino-acids which comprise the binding site for EGF. Comparison of human, murine and chicken EGF-R allows the identification of amino acid substitutions which are conservative and would not affect EGF binding, substitutions which are responsible for the low affinity binding of EGF to chicken EGF-R and those responsible for the high affinity binding of EGF to mammalian EGF-R. This analysis will enable future design of point mutations in the EGF-R which will restore the high affinity binding for EGF typical of human or murine EGF-R.	NYU MED CTR,DEPT PHARMACOL,550 1ST AVE,NEW YORK,NY 10016; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; RORER GRP INC,KING OF PRUSSIA,PA 19406; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	New York University; Weizmann Institute of Science; Max Planck Society								LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LAX I, 1991, UNPUB; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WU DG, 1989, J BIOL CHEM, V264, P17469	6	45	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					673	676						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	2030916				2022-12-17	WOS:A1991FR93900026
J	STEIN, J; RETTENMIER, CW				STEIN, J; RETTENMIER, CW			PROTEOLYTIC PROCESSING OF A PLASMA MEMBRANE-BOUND PRECURSOR TO HUMAN MACROPHAGE COLONY-STIMULATING FACTOR (CSF-1) IS ACCELERATED BY PHORBOL ESTER	ONCOGENE			English	Article							FACTOR-I RECEPTOR; HUMAN-MONOCYTES; GROWTH-FACTOR; INDEPENDENT MECHANISMS; MOLECULAR-CLONING; EXPRESSION; CELLS; BINDING; PROTEIN; GENE	A transmembrane precursor to human macrophage colony-stimulating factor (M-CSF, CSF-1) is stably expressed at the cell surface where it is slowly and inefficiently cleaved to yield a soluble form of the growth factor. Incubation in the presence of phorbol ester resulted in rapid cleavage of the plasma membrane-bound precursor and release of soluble CSF-1. Within 60 min after phorbol treatment the quantity of growth factor recovered in the medium was more than 30-fold greater than that observed in the absence of the agent. The growth factor released in the presence of phorbol was biologically active and exhibited the same electrophoretic mobility as that obtained in the absence of the drug. Phorbol ester-accelerated processing of the cell surface CSF-1 precursor was abrogated by long-term exposure to phorbol, but was not inhibited by pretreatment with cycloheximide or incubation in serum-free medium. These results suggest that the enhanced post-translational processing of the CSF-1 precursor resulted from activation of a pre-existing cellular protease via a mechanism involving phorbol ester-mediated stimulation of protein kinase C.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital					NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040603] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NHLBI NIH HHS [HL40603] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHEN BDM, 1983, J CELL PHYSIOL, V116, P207, DOI 10.1002/jcp.1041160212; COCHET C, 1984, J BIOL CHEM, V259, P2553; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; ERNST TJ, 1989, J BIOL CHEM, V264, P5700; GUILBERT LJ, 1983, J CELL PHYSIOL, V115, P276, DOI 10.1002/jcp.1041150310; HALENBECK R, 1988, J BIOTECHNOL, V8, P45, DOI 10.1016/0168-1656(88)90067-3; HEARD JM, 1987, ONCOGENE RES, V1, P423; HORIGUCHI J, 1986, BIOCHEM BIOPH RES CO, V141, P924, DOI 10.1016/S0006-291X(86)80131-0; HORIGUCHI J, 1987, BLOOD, V69, P1259; HORIGUCHI J, 1988, MOL CELL BIOL, V8, P3951, DOI 10.1128/MCB.8.9.3951; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; MANOS MM, 1988, MOL CELL BIOL, V8, P5035, DOI 10.1128/MCB.8.11.5035; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; OSTER W, 1987, BLOOD, V70, P1700; RALPH P, 1986, BLOOD, V68, P633; RAMBALDI A, 1988, J CLIN INVEST, V81, P1030, DOI 10.1172/JCI113413; RAMBALDI A, 1987, BLOOD, V69, P1409; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; RETTENMIER CW, 1989, HEMATOL ONCOL CLIN N, V3, P479, DOI 10.1016/S0889-8588(18)30543-4; RETTENMIER CW, 1986, J CLIN INVEST, V77, P1740, DOI 10.1172/JCI112496; RETTENMIER CW, 1988, MOL CELL BIOL, V8, P5026, DOI 10.1128/MCB.8.11.5026; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; SACCA R, 1986, P NATL ACAD SCI USA, V83, P3331, DOI 10.1073/pnas.83.10.3331; SHADLE PJ, 1989, J CELL BIOCHEM, V40, P91, DOI 10.1002/jcb.240400110; SHERR CJ, 1990, HDB EXPT PHARM, V95, P667; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; STANLEY ER, 1986, METHOD ENZYMOL, V116, P563; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529	32	45	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					601	605						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	2030912				2022-12-17	WOS:A1991FR93900015
J	SOZZI, G; PIEROTTI, MA; MIOZZO, M; DONGHI, R; RADICE, P; DEBENEDETTI, V; GRIECO, M; SANTORO, M; FUSCO, A; VECCHIO, G; MATHEW, CGP; PONDER, BAJ; SPURR, NK; DELLAPORTA, G				SOZZI, G; PIEROTTI, MA; MIOZZO, M; DONGHI, R; RADICE, P; DEBENEDETTI, V; GRIECO, M; SANTORO, M; FUSCO, A; VECCHIO, G; MATHEW, CGP; PONDER, BAJ; SPURR, NK; DELLAPORTA, G			REFINED LOCALIZATION TO CONTIGUOUS REGIONS ON CHROMOSOME-10Q OF THE 2 GENES (H4 AND RET) THAT FORM THE ONCOGENIC SEQUENCE PTC	ONCOGENE			English	Note							THYROID PAPILLARY CARCINOMAS; HUMAN-MOUSE HYBRIDS; PROTO-ONCOGENE; ASSIGNMENT; ACTIVATION	In this report we confirm the localization of the human RET proto-oncogene to chromosome 10q11.2, both by Southern blot analysis of a panel of human-rodent somatic cell hybrids and by in situ hybridization on human metaphase chromosomes. Previously, we had assigned to the same chromosome region the gene termed H4. In about 25% of papillary thyroid carcinomas, this gene was shown to rearrange with RET to give rise to the transforming sequence PTC. The analysis of different cell hybrids containing subfragments of chromosome 10, in conjunction with pulse field gel electrophoresis, established that H4 is mapped distally to RET at a distance not less than 280 kb. These findings suggest that intrachromosomal rearrangements are responsible for PTC activation in papillary thyroid carcinomas.	IST NAZL TUMORI,DIV ONCOL SPERIMENTALE A,VIA G VENEZIAN,I-20133 MILAN,ITALY; NAPLES UNIV,FAC MED & CHIRURG 2,CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; GUYS HOSP,PEDIAT RES UNIT,LONDON SE1 9RT,ENGLAND; INST CANC RES,CANC RES CAMPAIGN,HUMAN CANC GENET RES GRP,SUTTON SM2 5PX,SURREY,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE,ENGLAND; CLARE HALL LABS,IMPERIAL CANC RES FUND,S MIMMS EN6 3LID,HERTS,ENGLAND	Fondazione IRCCS Istituto Nazionale Tumori Milan; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Guy's & St Thomas' NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Cambridge			Mathew, Christopher G/G-3434-2015; Radice, Paolo/O-3119-2013; sozzi, gabriella/G-8259-2011	Mathew, Christopher G/0000-0003-4178-1838; Radice, Paolo/0000-0001-6298-4111; sozzi, gabriella/0000-0001-9360-6914; Grieco, Michele/0000-0002-4212-7814; Fusco, Alfredo/0000-0003-3332-5197; Pierotti, Marco Alessandro/0000-0002-7431-8332; Miozzo, Monica/0000-0002-6523-4575				ANAND R, 1986, TRENDS GENET, V2, P278, DOI 10.1016/0168-9525(86)90269-6; BAI Y, 1982, ANN HUM GENET, V46, P337, DOI 10.1111/j.1469-1809.1982.tb01584.x; BONGARZONE I, 1989, ONCOGENE, V4, P1457; DONGHI R, 1989, ONCOGENE, V4, P521; EDWARDS YH, 1985, ANN HUM GENET, V49, P101, DOI 10.1111/j.1469-1809.1985.tb01681.x; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; JONES EA, 1976, SOMAT CELL GENET, V2, P483, DOI 10.1007/BF01542686; MATHEW CGP, 1990, ANN HUM GENET, V54, P121, DOI 10.1111/j.1469-1809.1990.tb00368.x; MAYALL BH, 1975, AUTOMATION CYTOGENET; NABHOLZ M, 1969, NATURE, V223, P358, DOI 10.1038/223358a0; NARUM RA, 1988, AM J HUM GENET, V43, pA154; POVEY S, 1980, ANN HUM GENET, V43, P241, DOI 10.1111/j.1469-1809.1980.tb01557.x; RADICE P, 1988, NUCLEIC ACIDS RES, V18, P5062; SOLOMON E, 1976, SOMAT CELL GENET, V2, P125, DOI 10.1007/BF01542626; SOLOMON E, 1979, ANN HUM GENET, V42, P273, DOI 10.1111/j.1469-1809.1979.tb00661.x; SWALLOW DM, 1977, CYTOGENET CELL GENET, V18, P136, DOI 10.1159/000130758; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; WHITEHEAD AS, 1982, P NATL ACAD SCI-BIOL, V79, P5021, DOI 10.1073/pnas.79.16.5021; 1989, CYTOGENET CELL GENET, V51, P1	21	45	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					339	342						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	2000227				2022-12-17	WOS:A1991FZ13400022
J	MURAKAMI, Y; KATAHIRA, M; MAKINO, R; HAYASHI, K; HIROHASHI, S; SEKIYA, T				MURAKAMI, Y; KATAHIRA, M; MAKINO, R; HAYASHI, K; HIROHASHI, S; SEKIYA, T			INACTIVATION OF THE RETINOBLASTOMA GENE IN A HUMAN LUNG-CARCINOMA CELL-LINE DETECTED BY SINGLE-STRAND CONFORMATION POLYMORPHISM ANALYSIS OF THE POLYMERASE CHAIN-REACTION PRODUCT OF CDNA	ONCOGENE			English	Article							SUSCEPTIBILITY GENE; HUMAN DNA; C-MYC; EXPRESSION; AMPLIFICATION; MUTATIONS; SEQUENCE; CANCER; IDENTIFICATION; ORGANIZATION	Combined use of a simple, sensitive method of DNA analysis of nucleotide substitutions, namely, single-strand conformation polymorphism analysis of polymerase chain reation products (PCR-SSCP), and the reverse transcriptase reaction (RT) is an effective method for mRNA analysis. We used this RT-PCR-SSCP method to detect abnormal retinoblastoma (RB) gene transcripts in human tumor cell lines. Results showed the presence of two types of RB gene transcripts in a giant cell lung carcinoma cell line Lu65: a minor mRNA species with a base substitution that created a stop codon in the nucleotide sequence corresponding to exon 2 of the gene, and a major species of mRNA without the nucleotide sequence corresponding to that of exon 2. PCR-SSCP analysis of the genomic DNA also revealed that Lu65 cells contained the mutated RB allele, but not the normal allele. These results suggested that in Lu65 cells, both RB alleles were inactivated. The transcript without the exon 2 sequence, probably due to alternative splicing, was also found in all the other human cells examined, as a very minor species.	NATL CANC CTR,RES INST,DIV ONCOGENE,1-1 TSUKIJI 5 CHOME,CHUO KU,TOKYO 104,JAPAN; NATL CANC CTR,RES INST,DIV PATHOL,TOKYO 104,JAPAN	National Cancer Center - Japan; National Cancer Center - Japan								CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P3605, DOI 10.1093/nar/17.9.3605; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE EYHP, 1988, P NATL ACAD SCI USA, V85, P6017, DOI 10.1073/pnas.85.16.6017; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; TANG A, 1989, ONCOGENE, V4, P401; TAYA Y, 1984, EMBO J, V3, P2943, DOI 10.1002/j.1460-2075.1984.tb02236.x; XU HJ, 1989, ONCOGENE, V4, P807; YAMADA H, 1986, BIOCHEM BIOPH RES CO, V140, P167, DOI 10.1016/0006-291X(86)91072-7; YAMADA T, 1985, JPN J CANCER RES, V76, P967; YOKOTA J, 1988, ONCOGENE, V3, P471; YOSHIMOTO K, 1986, JPN J CANCER RES, V77, P540	30	45	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					37	42						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1992444				2022-12-17	WOS:A1991EY03900005
J	BONNIEU, A; ROUX, P; MARTY, L; JEANTEUR, P; PIECHACZYK, M				BONNIEU, A; ROUX, P; MARTY, L; JEANTEUR, P; PIECHACZYK, M			AUUA MOTIFS ARE DISPENSABLE FOR RAPID DEGRADATION OF THE MOUSE C-MYC RNA	ONCOGENE			English	Note									UNIV MONTPELLIER 2,BIOL MOLEC LAB,CNRS,URA 1191,BIOL MOLEC LAB,F-34060 MONTPELLIER,FRANCE; CTR PAUL LAMARQUE,BIOCHIM LAB,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier			Bonnieu, Anne/ABA-7182-2020; PIECHACZYK, Marc/E-7896-2013; Roux, Pierre/D-8833-2017	PIECHACZYK, Marc/0000-0003-1367-2597; 				BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BEUTLER E, 1989, P NATL ACAD SCI USA, V86, P192, DOI 10.1073/pnas.86.1.192; BONNIEU A, 1988, ONCOGENE RES, V3, P155; BONNIEU A, 1989, ONCOGENE, V4, P881; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1665; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; EICK D, 1985, EMBO J, V4, P3725; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GREENBERG JR, 1972, NATURE, V240, P102, DOI 10.1038/240102a0; HAYASHI K, 1987, NUCLEIC ACIDS RES, V15, P6419, DOI 10.1093/nar/15.16.6419; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; NAKAMAYE K, 1985, NUCLEIC ACIDS RES, V13, P8764; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PIECHACZYK M, 1986, CURR TOP MICROBIOL, V132, P331; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RAYMOND V, 1989, ONCOGENE RES, V5, P1; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	27	45	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1990	5	10					1585	1588						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2250915				2022-12-17	WOS:A1990EK50200020
J	LUO, K; SEFTON, BM				LUO, K; SEFTON, BM			ANALYSIS OF THE SITES IN P56LCK WHOSE PHOSPHORYLATION IS INDUCED BY TETRADECANOYL PHORBOL ACETATE	ONCOGENE			English	Article											LUO, K (corresponding author), SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92138, USA.				NATIONAL CANCER INSTITUTE [P30CA014195, R01CA042350] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42350, CA-14195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACRES RB, 1986, J BIOL CHEM, V261, P6210; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CASNELLIE JE, 1984, P NATL ACAD SCI-BIOL, V81, P6676, DOI 10.1073/pnas.81.21.6676; CASNELLIE JE, 1982, J BIOL CHEM, V257, P3877; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; GLYNN JP, 1964, CANCER RES, V24, P502; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; HOXIE JA, 1988, J IMMUNOL, V140, P786; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HURLEY TR, 1989, ONCOGENE, V4, P265; HURLEY TR, 1989, SCIENCE, V245, P407, DOI 10.1126/science.2787934; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUO K, 1990, ONCOGENE, V5, P921; MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PATSCHINSKY T, 1986, J VIROL, V59, P73, DOI 10.1128/JVI.59.1.73-81.1986; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PURCHIO AF, 1985, SCIENCE, V229, P1393, DOI 10.1126/science.2994221; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; TREVILLYAN JM, 1986, BIOCHIM BIOPHYS ACTA, V888, P286, DOI 10.1016/0167-4889(86)90228-4; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; WEYAND CM, 1987, J IMMUNOL, V138, P1351	41	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					803	808						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	2359619				2022-12-17	WOS:A1990DP55300004
J	RON, D; GRAZIANI, G; AARONSON, SA; EVA, A				RON, D; GRAZIANI, G; AARONSON, SA; EVA, A			THE N-TERMINAL REGION OF PROTO-DBL DOWN REGULATES ITS TRANSFORMING ACTIVITY	ONCOGENE			English	Article											RON, D (corresponding author), NCI, CELLULAR & MOLEC BIOL LAB, BLDG 37, ROOM 1E24, BETHESDA, MD 20892 USA.		Eva, Alessandra/J-8268-2016; Graziani, Grazia/G-5747-2012	Eva, Alessandra/0000-0003-2949-078X; Graziani, Grazia/0000-0002-0221-768X				ARVUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334; BALMAIN A, 1985, BRIT J CANCER, V51, P1, DOI 10.1038/bjc.1985.1; Barbacid M, 1986, Important Adv Oncol, P3; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1987, ONCOGENE, V1, P355; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GRAZIANI G, 1989, IN PRESS ONCOGENE; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KINGSTON RE, 1985, CELL, V41, P3, DOI 10.1016/0092-8674(85)90049-2; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; RADKE K, 1983, J CELL BIOL, V97, P1601, DOI 10.1083/jcb.97.5.1601; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STOLZENBACH F, 1966, METHOD ENZYMOL, V9, P278; TAHARA SM, 1982, EUR J BIOCHEM, V126, P395; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WANG JYJ, 1984, CELL, V36, P349; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WIDNELL CC, 1968, P NATL ACAD SCI USA, V61, P1050, DOI 10.1073/pnas.61.3.1050; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	40	45	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1989	4	9					1067	1072						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2674851				2022-12-17	WOS:A1989AM53100002
J	BIGNAMI, M; ROSA, S; LAROCCA, SA; FALCONE, G; TATO, F				BIGNAMI, M; ROSA, S; LAROCCA, SA; FALCONE, G; TATO, F			DIFFERENTIAL INFLUENCE OF ADJACENT NORMAL-CELLS ON THE PROLIFERATION OF MAMMALIAN-CELLS TRANSFORMED BY THE VIRAL ONCOGENES MYC, RAS AND SRC	ONCOGENE			English	Article									UNIV ROME LA SAPIENZA,DIPARTIMENTO BIOL CELLULARE & SVILUPPO,VIA APULI,I-00185 ROME,ITALY; IST SUPER SANITA,TOSSICOL APPLICATA LAB,I-00161 ROME,ITALY	Sapienza University Rome; Istituto Superiore di Sanita (ISS)			Falcone, Germana/A-3735-2016; la rocca, severina anna/D-8028-2011	Falcone, Germana/0000-0002-3508-7623				ATKINSON MM, 1981, J CELL BIOL, V91, P573, DOI 10.1083/jcb.91.2.573; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P191, DOI 10.1007/BF01871629; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BERTRAM JS, 1979, CANCER RES, V39, P3502; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CHANG CC, 1985, P NATL ACAD SCI USA, V82, P5360, DOI 10.1073/pnas.82.16.5360; CONNAN G, 1985, NATURE, V314, P277, DOI 10.1038/314277a0; DAVIDSON JS, 1985, CARCINOGENESIS, V6, P1353, DOI 10.1093/carcin/6.9.1353; Diamond L, 1980, Adv Cancer Res, V32, P1, DOI 10.1016/S0065-230X(08)60360-7; DOTTO GP, 1985, NATURE, V318, P472; FALCONE G, 1987, EXP CELL RES, V168, P273, DOI 10.1016/0014-4827(87)90435-6; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HSIAO WLW, 1986, MOL CELL BIOL, V6, P1943, DOI 10.1128/MCB.6.6.1943; HSU YM, 1984, P NATL ACAD SCI-BIOL, V81, P2107, DOI 10.1073/pnas.81.7.2107; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEHTA PP, 1986, CELL, V44, P187, DOI 10.1016/0092-8674(86)90497-6; MONDAL S, 1976, NATURE, V260, P710, DOI 10.1038/260710a0; MONDAL S, 1976, CANCER RES, V36, P2254; MORDAN LJ, 1983, CANCER RES, V43, P4062; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PONTEN J, 1968, J CELL SCI, V3, P603; PONTEN J, 1971, SPONTANEOUS VIRUS IN; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; REZNIKOFF CA, 1973, CANCER RES, V33, P3239; SHAW J, 1985, J VIROL, V56, P943, DOI 10.1128/JVI.56.3.943-950.1985; STOKER MGP, 1966, J CELL SCI, V1, P297; STOKER MGP, 1967, J CELL SCI, V2, P293; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; WEISS RA, 1970, EXP CELL RES, V63, P1, DOI 10.1016/0014-4827(70)90326-5; WHITTENBERGER B, 1977, P NATL ACAD SCI USA, V74, P2251, DOI 10.1073/pnas.74.6.2251; WIESER RJ, 1985, EXP CELL RES, V158, P493, DOI 10.1016/0014-4827(85)90472-0	37	45	45	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					509	514						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	3287279				2022-12-17	WOS:A1988N434800013
J	CHAN, AML; KING, HWS; TEMPEST, PR; DEAKIN, EA; COOPER, CS; BROOKES, P				CHAN, AML; KING, HWS; TEMPEST, PR; DEAKIN, EA; COOPER, CS; BROOKES, P			PRIMARY STRUCTURE OF THE MET PROTEIN TYROSINE KINASE DOMAIN	ONCOGENE			English	Article											CHAN, AML (corresponding author), INST CANC RES,CHESTER BEATTY LABS,CHEM CARCINOGENESIS SECT,FULHAM RD,LONDON SW3 6JB,ENGLAND.		Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020	Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464				BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; COOPER CS, 1984, CANCER RES, V44, P1; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; Favaloro J, 1980, Methods Enzymol, V65, P718; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; KIENY MP, 1983, GENE, V26, P91, DOI 10.1016/0378-1119(83)90039-2; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; TEMPEST PR, 1986, CARCINOGENESIS, V7, P2051, DOI 10.1093/carcin/7.12.2051; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	21	45	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1987	1	2					229	233						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6352	3325883				2022-12-17	WOS:A1987J635200016
J	IGARASHI, H; RAO, CD; SIROFF, M; LEAL, F; ROBBINS, KC; AARONSON, SA				IGARASHI, H; RAO, CD; SIROFF, M; LEAL, F; ROBBINS, KC; AARONSON, SA			DETECTION OF PDGF-2 HOMODIMERS IN HUMAN-TUMOR CELLS	ONCOGENE			English	Article									NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1E24,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Leal, Fernando/J-3182-2015	Leal, Fernando/0000-0002-9298-470X				BARRETT TB, 1984, P NATL ACAD SCI-BIOL, V81, P6772, DOI 10.1073/pnas.81.21.6772; BOWENPOPE DF, 1982, J BIOL CHEM, V257, P5161; CHIU IM, 1984, CELL, V37, P123; COLLINS T, 1985, NATURE, V316, P748, DOI 10.1038/316748a0; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORESTIN AS, 1985, CELL, V41, P301; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAVES DT, 1984, SCIENCE, V226, P972, DOI 10.1126/science.6209798; GRAVES DT, 1986, P NATL ACAD SCI USA, V83, P4636, DOI 10.1073/pnas.83.13.4636; HANNINK M, 1984, SCIENCE, V226, P1197, DOI 10.1126/science.6095451; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HUANG JS, 1982, J BIOL CHEM, V257, P8130; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JOHNSSON A, 1984, EMBO J, V3, P921, DOI 10.1002/j.1460-2075.1984.tb01908.x; JOSEPHS SF, 1984, SCIENCE, V225, P636, DOI 10.1126/science.6740330; JOSEPHS SF, 1984, SCIENCE, V223, P487, DOI 10.1126/science.6318322; KING CR, 1985, P NATL ACAD SCI USA, V82, P5295, DOI 10.1073/pnas.82.16.5295; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; PANTAZIS P, 1986, P NATL ACAD SCI USA, V83, P5526, DOI 10.1073/pnas.83.15.5526; PANTAZIS P, 1985, P NATL ACAD SCI USA, V82, P2404, DOI 10.1073/pnas.82.8.2404; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; RAO CD, 1986, P NATL ACAD SCI USA, V83, P2392, DOI 10.1073/pnas.83.8.2392; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; ROBBINS KC, 1982, SCIENCE, V218, P1131, DOI 10.1126/science.6293053; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	38	45	45	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1987	1	1					79	85						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6351	3325876				2022-12-17	WOS:A1987J635100009
J	EICK, D; BERGER, R; POLACK, A; BORNKAMM, GW				EICK, D; BERGER, R; POLACK, A; BORNKAMM, GW			TRANSCRIPTION OF C-MYC IN HUMAN MONONUCLEAR-CELLS IS REGULATED BY AN ELONGATION BLOCK	ONCOGENE			English	Note											EICK, D (corresponding author), UNIV FREIBURG,INST MED MIKROBIOL & HYG,VIROL ABT,HERMANN HERDER STR 11,D-7800 FREIBURG,FED REP GER.							ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1983, P NATL ACAD SCI US, V80, P6966; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BLANCHARD JM, 1985, NATURE, V317, P343; BOYD AW, 1984, LEUKEMIA RES, V8, P27, DOI 10.1016/0145-2126(84)90029-8; BOYM A, 1968, SCAND J CLIN LAB S97, V21, P77; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DALLAFAVERA R, 1982, NATURE, V299, P61; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; FAHRLANDER PD, 1985, EMBO J, V4, P3195, DOI 10.1002/j.1460-2075.1985.tb04065.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GROSSO LE, 1985, CANCER RES, V45, P847; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KNIGHT E, 1985, P NATL ACAD SCI USA, V82, P1151, DOI 10.1073/pnas.82.4.1151; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MARTIN P, 1986, EMBO J, V5, P1529, DOI 10.1002/j.1460-2075.1986.tb04393.x; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MOOS M, 1983, EMBO J, V2, P757, DOI 10.1002/j.1460-2075.1983.tb01496.x; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PAYNE GS, 1982, NATURE, V295, P209, DOI 10.1038/295209a0; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; SCHUBACH W, 1984, NATURE, V307, P702, DOI 10.1038/307702a0; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; WALDMANN TA, 1982, ADV IMMUNOL, V32, P1, DOI 10.1016/S0065-2776(08)60720-8; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7	43	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	2	1					61	65						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	L4813	3438086				2022-12-17	WOS:A1987L481300009
J	Liu, JH; He, DH; Cheng, LJ; Huang, CK; Zhang, YQ; Rao, XJ; Kong, YF; Li, CH; Zhang, ZZ; Liu, JP; Jones, K; Napier, D; Lee, EY; Wang, C; Liu, XQ				Liu, Jinghui; He, Daheng; Cheng, Lijun; Huang, Changkun; Zhang, Yanquan; Rao, Xiongjian; Kong, Yifan; Li, Chaohao; Zhang, Zhuangzhuang; Liu, Jinpeng; Jones, Karrie; Napier, Dana; Lee, Eun Y.; Wang, Chi; Liu, Xiaoqi			p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer	ONCOGENE			English	Article							ANTITUMOR IMMUNITY; ANDROGEN RECEPTOR; PD-L1; EXPRESSION; MECHANISMS; DOCETAXEL	Blockade of programmed death-ligand 1 (PD-L1) by therapeutic antibodies has shown to be a promising strategy in cancer therapy, yet clinical response in many types of cancer, including prostate cancer (PCa), is limited. Tumor cells secrete PD-L1 through exosomes or splice variants, which has been described as a new mechanism for the resistance to PD-L1 blockade therapy in multiple cancers, including PCa. This suggests that cutting off the secretion or expression of PD-L1 might improve the response rate of PD-L1 blockade therapy in PCa treatment. Here we report that p300/CBP inhibition by a small molecule p300/CBP inhibitor dramatically enhanced the efficacy of PD-L1 blockade treatment in a syngeneic model of PCa by blocking both the intrinsic and IFN-gamma-induced PD-L1 expression. Mechanistically, p300/CBP could be recruited to the promoter of CD274 (encoding PD-L1) by the transcription factor IRF-1, which induced the acetylation of Histone H3 at CD274 promoter followed by the transcription of CD274. A485, a p300/CBP inhibitor, abrogated this process and cut off the secretion of exosomal PD-L1 by blocking the transcription of CD274, which combined with the anti-PD-L1 antibody to reactivate T cells function for tumor attack. This finding reports a new mechanism of how cancer cells regulate PD-L1 expression through epigenetic factors and provides a novel therapeutic approach to enhance the efficacy of immune checkpoint inhibitors treatment.	[Liu, Jinghui; Huang, Changkun; Zhang, Yanquan; Rao, Xiongjian; Kong, Yifan; Li, Chaohao; Zhang, Zhuangzhuang; Liu, Xiaoqi] Univ Kentucky, Dept Toxicol & Canc Biol, Lexington, KY 40536 USA; [He, Daheng; Liu, Jinpeng; Wang, Chi] Univ Kentucky, Dept Biostat, Lexington, KY 40536 USA; [Cheng, Lijun] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA; [Jones, Karrie; Napier, Dana; Lee, Eun Y.; Wang, Chi; Liu, Xiaoqi] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA; [Lee, Eun Y.] Univ Kentucky, Dept Pathol & Lab Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University System of Ohio; Ohio State University; University of Kentucky; University of Kentucky	Liu, XQ (corresponding author), Univ Kentucky, Dept Toxicol & Canc Biol, Lexington, KY 40536 USA.; Liu, XQ (corresponding author), Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA.	Xiaoqi.Liu@uky.edu	He, Daheng/AAR-1813-2021; Zhang, Yanquan/D-5615-2017	Zhang, Yanquan/0000-0003-3527-9972; Zhang, Zhuangzhuang/0000-0003-2578-7375	NIH [R01 CA157429, R01 CA192894, R01 CA196835, R01 CA196634]; Biospecimen Procurement and Translational Pathology, Biostatistics and Bioinformatics, Flow Cytometry and Immune Monitoring Shared Resources of the University of Kentucky Markey Cancer Center [P30CA177558]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Biospecimen Procurement and Translational Pathology, Biostatistics and Bioinformatics, Flow Cytometry and Immune Monitoring Shared Resources of the University of Kentucky Markey Cancer Center	This work was supported by NIH grants R01 CA157429 (XL), R01 CA192894 (XL), R01 CA196835 (XL), and R01 CA196634 (XL). The work was also supported by Biospecimen Procurement and Translational Pathology, Biostatistics and Bioinformatics, Flow Cytometry and Immune Monitoring Shared Resources of the University of Kentucky Markey Cancer Center (P30CA177558). We thank Heather Russell-Simmons at Research Communications Office of Markey Cancer Center for proof-reading of the paper.	Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Calagua C, 2017, CLIN CANCER RES, V23, P6812, DOI 10.1158/1078-0432.CCR-17-0807; Chen G, 2018, NATURE, V560, P382, DOI 10.1038/s41586-018-0392-8; Chen LP, 2015, J CLIN INVEST, V125, P3384, DOI 10.1172/JCI80011; Claessens F, 2014, NAT REV UROL, V11, P712, DOI 10.1038/nrurol.2014.243; Coelho MA, 2017, IMMUNITY, V47, P1083, DOI 10.1016/j.immuni.2017.11.016; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Drazic A, 2016, BBA-PROTEINS PROTEOM, V1864, P1372, DOI 10.1016/j.bbapap.2016.06.007; Eckschlager T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071414; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Gevensleben H, 2016, CLIN CANCER RES, V22, P1969, DOI 10.1158/1078-0432.CCR-15-2042; Gong B, 2019, J EXP MED, V216, P982, DOI 10.1084/jem.20180870; Haeussler M, 2019, NUCLEIC ACIDS RES, V47, pD853, DOI 10.1093/nar/gky1095; Jin LY, 2017, CANCER RES, V77, P5564, DOI 10.1158/0008-5472.CAN-17-0314; Kaushik D, 2015, THER ADV UROL, V7, P388, DOI 10.1177/1756287215597637; Lasko LM, 2017, NATURE, V550, P128, DOI 10.1038/nature24028; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Li Y, 2016, COLD SPRING HARB PER, V6, P1; Liu JH, 2016, CHEMOSPHERE, V163, P14, DOI 10.1016/j.chemosphere.2016.08.002; Mahoney KM, 2019, CANCER IMMUNOL IMMUN, V68, P421, DOI 10.1007/s00262-018-2282-1; Martin AM, 2015, PROSTATE CANCER P D, V18, P325, DOI 10.1038/pcan.2015.39; Massari F, 2016, TARGET ONCOL, V11, P345, DOI 10.1007/s11523-015-0396-3; Michaelis M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019705; Nebbioso A, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007362; Poggio M, 2019, CELL, V177, P414, DOI 10.1016/j.cell.2019.02.016; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Seruga B, 2011, NAT REV CLIN ONCOL, V8, P12, DOI 10.1038/nrclinonc.2010.136; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smithy JW, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0229-2; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Zhong J, 2014, CANCER RES, V74, P1870, DOI 10.1158/0008-5472.CAN-13-2485; Zhu HR, 2016, CELL REP, V16, P2829, DOI 10.1016/j.celrep.2016.08.032	35	44	44	1	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3939	3951		10.1038/s41388-020-1270-z	http://dx.doi.org/10.1038/s41388-020-1270-z		MAR 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32203167	Green Accepted			2022-12-17	WOS:000520950900001
J	Majem, B; Parrilla, A; Jimenez, C; Suarez-Cabrera, L; Barber, M; Marin, A; Castellvi, J; Tamayo, G; Moreno-Bueno, G; Ponce, J; Matias-Guiu, X; Alameda, F; Romero, I; Sanchez, JL; Perez-Benavente, A; Moran, S; Esteller, M; Reventos, J; Rigau, M; Gil-Moreno, A; Segura, MF; Santamaria, A				Majem, Blanca; Parrilla, Alfonso; Jimenez, Carlos; Suarez-Cabrera, Leticia; Barber, Marta; Marin, Andrea; Castellvi, Josep; Tamayo, Gabriel; Moreno-Bueno, Gema; Ponce, Jordi; Matias-Guiu, Xavier; Alameda, Francesc; Romero, Ignacio; Luis Sanchez, Jose; Perez-Benavente, Asuncion; Moran, Sebastian; Esteller, Manel; Reventos, Jaume; Rigau, Marina; Gil-Moreno, Antonio; Segura, Miguel F.; Santamaria, Anna			MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways	ONCOGENE			English	Article							SPHEROID FORMATION; DNA METHYLATION; ELEVATED CDCP1; EXPRESSION; PLAGL2; CELLS; PROGRESSION; CARCINOMA; SURVIVAL; LEUKEMIA	Ovarian cancer is the most lethal gynecological malignancy due to the silent nature on its early onset and the rapid acquisition of drug resistance. Histologically heterogeneous, it includes several subtypes with different mutational landscapes, hampering the development of effective targeted therapies. Non-coding RNAs are emerging as potential new therapeutic targets in cancer. To search for a microRNA signature related to ovarian carcinomas and study its potential as effective targeted therapy, we examined the expression of 768 miRNA in a large collection of tumor samples and found miR-654-5p to be infraexpressed in ovarian serous carcinomas, the most common and aggressive type. Restoration of miR654-5p levels reduced tumor cell viability in vitro and in vivo and impaired sphere formation capacity and viability of ovarian cancer patient-derived ascitic cells ex vivo. CDCP1 and PLAGL2 oncogenes were found to be the most relevant direct miR-654-5p targets and both genes convey in a molecular signature associated with key cancer pathways relevant to ovarian tumorigenesis, such as MYC, WNT and AKT pathways. Together, we unveiled the tumor suppressor function of miR-654-5p, suggesting that its restoration or co-targeting of CDCP1 and PLAGL2 may be an effective therapeutic approach for ovarian cancer.	[Majem, Blanca; Parrilla, Alfonso; Suarez-Cabrera, Leticia; Barber, Marta; Marin, Andrea; Tamayo, Gabriel; Santamaria, Anna] UAB, Cell Cycle & Canc Lab, Grp Biomed Res Urol, Vall Hebron Res Inst VHIR, Barcelona 08035, Spain; [Jimenez, Carlos; Segura, Miguel F.] UAB, Grp Translat Res Child & Adolescent Canc, Vall Hebron Res Inst VHIR, Barcelona 08035, Spain; [Castellvi, Josep] Vall Hebron Univ Hosp, Dept Pathol, Barcelona 08035, Spain; [Moreno-Bueno, Gema] UAM, Dept Biochem, Inst Invest Biomed Alberto Sols, CIBERONC,IdiPaz,CSIC, Madrid 28029, Spain; [Moreno-Bueno, Gema] Fdn MD Anderson Int, Madrid 28033, Spain; [Ponce, Jordi] Univ Barcelona, Univ Hosp Bellvitge IDIBELL, Dept Gynaecol, Barcelona 08908, Spain; [Matias-Guiu, Xavier] Univ Lleida, Dept Pathol, Hosp Univ Arnau de Vilanova, IRB Lleida, Lleida 25198, Spain; [Matias-Guiu, Xavier; Reventos, Jaume] Hosp Univ Bellvitge, CIBERONC, IDIBELL, Dept Pathol, Barcelona 08908, Spain; [Alameda, Francesc] Hosp del Mar, Pathol Dept, Barcelona 08003, Spain; [Romero, Ignacio] IVO, Dept Med Oncol, Valencia 46009, Spain; [Luis Sanchez, Jose; Perez-Benavente, Asuncion; Gil-Moreno, Antonio] UAB, Dept Gynecol Oncol, Vall Hebron Univ Hosp, Barcelona 08035, Spain; [Luis Sanchez, Jose; Perez-Benavente, Asuncion; Gil-Moreno, Antonio] UAB, CIBERONC, Grp Biomed Res Gynecol, Vall Hebron Res Inst VHIR, Barcelona 08035, Spain; [Moran, Sebastian; Esteller, Manel] Bellvitge Biomed Res Inst IDIBELL, CIBERONC, Canc Epigenet & Biol Program PEBC, Barcelona 08908, Spain; [Esteller, Manel] UB, Physiol Sci Dept, Sch Med & Hlth Sci, Barcelona 08036, Spain; [Esteller, Manel] ICREA, Barcelona 08010, Spain; [Reventos, Jaume] Univ Int Catalunya, Dept Basic Sci, Barcelona 08017, Spain; [Rigau, Marina] Bellvitge Biomed Res Inst IDIBELL, Barcelona 08908, Spain; [Majem, Blanca] Bellvitge Biomed Res Inst IDIBELL, Cell Death Regulat Grp, Oncobell Program, Barcelona 08908, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Hospital Universitari Vall d'Hebron; Autonomous University of Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Texas System; UTMD Anderson Cancer Center; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Universitat de Lleida; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Instituto Valenciano De Oncologia; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; ICREA; Universitat Internacional de Catalunya (UIC); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)	Santamaria, A (corresponding author), UAB, Cell Cycle & Canc Lab, Grp Biomed Res Urol, Vall Hebron Res Inst VHIR, Barcelona 08035, Spain.	anna.santamaria@vhir.org	Esteller, Manel/L-5956-2014; Castellvi, Josep/C-5092-2014; Majem, Blanca/AAN-6687-2021; matias-guiu, xavier/C-3039-2009; Segura, Miguel F/J-4749-2013; /AAD-2326-2020; Moreno-Bueno, Gema/K-9354-2016; PEREZ BENAVENTE, ASUNCION/J-8272-2016	Esteller, Manel/0000-0003-4490-6093; Castellvi, Josep/0000-0001-5745-9996; matias-guiu, xavier/0000-0002-7201-6605; Segura, Miguel F/0000-0003-0916-3618; /0000-0001-9219-3492; Moreno-Bueno, Gema/0000-0002-5030-6687; PEREZ BENAVENTE, ASUNCION/0000-0003-1872-9003	Instituto de la Mujer Dexeus [DEXEUSB29/012]; CIBER [CB16/12/00328]; SGR [2017 SGR 1661]; Fondos FEDER [RTC-2015-3821-1]; Instituto Carlos III [PI15/00238, PI17/00564]; Miguel Servet Program [CP13/00158, CPII18/00027, CPII16/00006]; predoctoral VHIR fellowships [VHIR: PRED-VHIR-2014-11, PRED-VHIR-2017]; AGAUR predoctoral fellowship [AGAUR: 2017FI_ B_ 00095]; Ministerio de Economia y Competitividad	Instituto de la Mujer Dexeus; CIBER; SGR; Fondos FEDER(European Commission); Instituto Carlos III(Instituto de Salud Carlos III); Miguel Servet Program; predoctoral VHIR fellowships; AGAUR predoctoral fellowship; Ministerio de Economia y Competitividad(Spanish Government)	We are thankful to Drs. Diego Arango and Agueda Martinez, Dr. Sung Goo Park and Dr. Rosanna Paciucci for 9E10 c-Myc, anti-HAX1 and anti-RB and anti-p-RB antibodies, respectively. We thank Dr. Francesc Vinals, Dr. Barbara Vanderhyden, Dr. Antonio Rosato, Dr. Erich A. Nigg and the Ovarian Cancer Research Team for cell lines. We are grateful to Drs. Aroa Soriano and Luz Jubierre for experimental help. We acknowledge technical support from the Flow Cytometry Facility at Center of Genomic Regulation (CRG) and the Unitat d'Estadistica i Bioinformatica (UEB) and the Unitat d'Alta Tecnologia (UAT) at VHIR. We thank all our lab members for support and helpful discussions. This work was supported in part by grants from Instituto de la Mujer Dexeus (DEXEUSB29/012), CIBER (CB16/12/00328), SGR (2017 SGR 1661), the Ministerio de Economia y Competitividad and Fondos FEDER (RTC-2015-3821-1), Instituto Carlos III (PI15/00238 to A. S. and PI17/00564 to M. F. S) and the Miguel Servet Program (CP13/00158 and CPII18/00027 to AS. and CPII16/00006 to MFS). AP and LS were supported by predoctoral VHIR fellowships and CJ by an AGAUR predoctoral fellowship (VHIR: PRED-VHIR-2014-11 and PRED-VHIR-2017; AGAUR: 2017FI_ B_ 00095, respectively).	Adair SJ, 2009, CANCER IMMUNOL IMMUN, V58, P589, DOI 10.1007/s00262-008-0582-6; Banerjee S, 2013, CLIN CANCER RES, V19, P961, DOI 10.1158/1078-0432.CCR-12-2243; Beg MS, 2017, INVEST NEW DRUG, V35, P180, DOI 10.1007/s10637-016-0407-y; Bi LL, 2016, ONCOL REP, V36, P2563, DOI 10.3892/or.2016.5055; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chen MW, 2017, CANCER RES, V77, P1955, DOI 10.1158/0008-5472.CAN-16-1115; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; George A, 2017, NAT REV CLIN ONCOL, V14, P284, DOI 10.1038/nrclinonc.2016.191; Harrington BS, 2016, BRIT J CANCER, V114, P417, DOI 10.1038/bjc.2015.471; He Y, 2016, ONCOGENE, V35, P468, DOI 10.1038/onc.2015.101; Hensen K, 2002, CANCER RES, V62, P1510; Honkoop AH, 1997, AM J CLIN PATHOL, V107, P211, DOI 10.1093/ajcp/107.2.211; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Jaco F, 2014, BMC MOL BIOL, V15, DOI 10.1186/1471-2199-15-24; Ji WD, 2017, GENES-BASEL, V8, DOI 10.3390/genes8010021; Jubierre L, 2016, ONCOGENE, V35, P5179, DOI 10.1038/onc.2016.50; Karnezis AN, 2017, NAT REV CANCER, V17, P65, DOI 10.1038/nrc.2016.113; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Kircher M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-346; Klinkebiel D, 2016, MOL CANCER RES, V14, P787, DOI 10.1158/1541-7786.MCR-16-0097; Landrette SF, 2011, LEUKEMIA, V25, P655, DOI 10.1038/leu.2010.301; Landrette SF, 2005, BLOOD, V105, P2900, DOI 10.1182/blood-2004-09-3630; Li Jianqi, 2015, Zhonghua Zhong Liu Za Zhi, V37, P324; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maire G, 2011, CANCER GENET-NY, V204, P138, DOI 10.1016/j.cancergen.2010.12.012; Mateescu B, 2011, NAT MED, V17, P1627, DOI 10.1038/nm.2512; Matulonis UA, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.61; Moran S, 2014, EPIGENETICS-US, V9, P829, DOI 10.4161/epi.28790; Ostling P, 2011, CANCER RES, V71, P1956, DOI 10.1158/0008-5472.CAN-10-2421; Paydas S, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0749-5; Poole CJ, 2017, GENES-BASEL, V8, DOI 10.3390/genes8050142; Prahm KP, 2016, APMIS, V124, P337, DOI 10.1111/apm.12514; Reyes-Gonzalez JM, 2015, MOL CANCER THER, V14, P2260, DOI 10.1158/1535-7163.MCT-14-0801; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Sehouli J, 2016, GEBURTSH FRAUENHEILK, V76, P164, DOI 10.1055/s-0035-1558185; Shepherd TG, 2006, NAT PROTOC, V1, P2643, DOI 10.1038/nprot.2006.328; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Soriano A, 2016, ONCOTARGET, V7, P9271, DOI 10.18632/oncotarget.7005; Takahashi M, 2016, CANCER SCI, V107, P417, DOI 10.1111/cas.12892; Tan YY, 2016, AM J CANCER RES, V6, P522; Ueland FR, 2017, DIAGNOSTICS, V7, DOI 10.3390/diagnostics7010014; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Wang YP, 2017, ONCOL REP, V37, P1961, DOI 10.3892/or.2017.5485; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Zehavi L, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-44; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105; Zheng HW, 2010, CANCER CELL, V17, P497, DOI 10.1016/j.ccr.2010.03.020	49	44	47	1	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2019	38	32					6035	6050		10.1038/s41388-019-0860-0	http://dx.doi.org/10.1038/s41388-019-0860-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IP8XH	31278368	Green Published			2022-12-17	WOS:000480329900003
J	Wang, LN; Yu, T; Li, W; Li, MM; Zuo, QF; Zou, QM; Xiao, B				Wang, Lina; Yu, Ting; Li, Wei; Li, Mengmeng; Zuo, Qianfei; Zou, Quanming; Xiao, Bin			The miR-29c-KIAA1199 axis regulates gastric cancer migration by binding with WBP11 and PTP4A3	ONCOGENE			English	Article							PRL-3 PROMOTES; MESENCHYMAL TRANSITION; SIGNALING PATHWAY; SPLICING FACTOR; UP-REGULATION; METASTASIS; KIAA1199; PROTEIN; EXPRESSION; INVASION	Gastric cancer (GC) is the second leading cause of death among patients with cancer in China. The primary reason of GC treatment failure is metastasis. Therefore, identifying metastatic biomarkers and clarifying the regulatory mechanisms involved in the GC metastatic process are important. Here, we found that KIAA1199, a cell migration-inducing protein, was significantly overexpressed in GC and correlated with lymph node metastasis and poorer patient survival. Additionally, the introduction of KIAA1199 dramatically promoted GC cell proliferation and migration in vitro and in vivo, and the inhibition of KIAA1199 suppressed GC cell growth and migration and induced GC cell apoptosis. Cell migration is a functional consequence of the epithelial-mesenchymal transition (EMT). In this study, we found that KIAA1199 inhibition or overexpression regulated the expression of E-cadherin and N-cadherin through KIAA1199 binding to WW domain binding protein 11 (WBP11) and protein tyrosine phosphatase type IVA, member 3 (PTP4A3) and through the subsequent activation of the FGFR4/Wnt/beta-catenin and EGFR signaling pathways. More importantly, ectopic expression of WBP11 or PTP4A3 blocked the stimulatory effects of KIAA1199 on GC cell proliferation and migration. Meanwhile, we illustrated that KIAA1199 was a target gene of miR-29c-3p and that miR-29c-3p overexpression led to decreased migration of GC cells in vitro and in vivo by suppressing the expression of KIAA1199 and several key proteins in the Wnt/beta-catenin and EGFR signaling pathways (e.g., WBP11, FGFR4, and PTP4A3). Taken together, these data demonstrate that KIAA1199 promotes GC metastasis by activating EMT-related signaling pathways and that miR-29c-3p regulates GC cell migration in vitro and in vivo by regulating KIAA1199 expression and activating the FGFR4/Wnt/beta-catenin and EGFR signaling pathways. These findings provide a new understanding of GC development and progression and may provide novel therapeutic strategies for GC.	[Wang, Lina; Yu, Ting; Li, Mengmeng; Zuo, Qianfei; Zou, Quanming; Xiao, Bin] Third Mil Med Univ, Natl Engn Res Ctr Immunol Prod, Dept Microbiol & Biochem Pharm, Coll Pharm, Chongqing 400038, Peoples R China; [Li, Wei] Third Mil Med Univ, Southwest Hosp, Dept Pharm, Chongqing 400038, Peoples R China	Army Medical University; Army Medical University	Zuo, QF; Zou, QM; Xiao, B (corresponding author), Third Mil Med Univ, Natl Engn Res Ctr Immunol Prod, Dept Microbiol & Biochem Pharm, Coll Pharm, Chongqing 400038, Peoples R China.	zqfzqma@163.com; qmzoutmmu@yeah.net; binxiaotmmu@163.com			Chongqing Youth Science and Technology Talent Training Project [cstc2014kjrc-qnrc10008]; National Science Foundation of China (NSFC) [81872392]	Chongqing Youth Science and Technology Talent Training Project; National Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was supported by the Chongqing Youth Science and Technology Talent Training Project (cstc2014kjrc-qnrc10008) and National Science Foundation of China (NSFC) (81872392).	Abe S, 2003, J HUM GENET, V48, P564, DOI 10.1007/s10038-003-0079-2; Al-aidaroos AQO, 2013, J CLIN INVEST, V123, P3459, DOI 10.1172/JCI66824; Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bessette DC, 2008, CANCER METAST REV, V27, P231, DOI 10.1007/s10555-008-9121-3; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cheng XB, 2016, ONCOTARGET, V7, P4829, DOI 10.18632/oncotarget.6617; Da N, 2009, WORLD J GASTROENTERO, V15, P1499, DOI 10.3748/wjg.15.1499; Diepenbruck M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01197-w; Dong Q, 2016, J ORAL PATHOL MED, V45, P111, DOI 10.1111/jop.12331; Evensen NA, 2015, ONCOTARGET, V6, P20723, DOI 10.18632/oncotarget.3978; Evensen NA, 2013, JNCI-J NATL CANCER I, V105, P1402, DOI 10.1093/jnci/djt224; Guo K, 2004, CANCER BIOL THER, V3, P945, DOI 10.4161/cbt.3.10.1111; Han TS, 2015, GUT, V64, P203, DOI 10.1136/gutjnl-2013-306640; He X, 2005, CELL, V120, P156, DOI 10.1016/j.cell.2005.01.006; Iwasaki Y, 2014, DEVELOPMENT, V141, P3740, DOI 10.1242/dev.106658; Jia SQ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175058; Ju JY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00988-5; Kato H, 2004, CLIN CANCER RES, V10, P7318, DOI 10.1158/1078-0432.CCR-04-0485; Kohi S, 2017, ONCOTARGET, V8, P17156, DOI 10.18632/oncotarget.15052; Li BS, 2015, ONCOGENE, V34, P2556, DOI 10.1038/onc.2014.214; Li L, 2017, J CANCER, V8, P2238, DOI 10.7150/jca.19295; Liu R, 2013, CANCER RES, V73, P5926, DOI 10.1158/0008-5472.CAN-12-4718; Llorian M, 2004, BIOCHEM J, V378, P229, DOI 10.1042/BJ20030950; Matsuo M, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-15; Matsuzaki S, 2009, ANN SURG ONCOL, V16, P2042, DOI 10.1245/s10434-009-0469-6; Mendell JT, 2005, CELL CYCLE, V4, P1179, DOI 10.4161/cc.4.9.2032; Michishita E, 2006, CANCER LETT, V239, P71, DOI 10.1016/j.canlet.2005.07.028; Mitra R, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01781-0; Nagase T, 1999, DNA Res, V6, P337, DOI 10.1093/dnares/6.5.337; Natsuizaka M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01500-9; Pencheva N, 2013, NAT CELL BIOL, V15, P546, DOI 10.1038/ncb2769; Rizzolio S, 2018, CANCER RES, V78, P1058, DOI 10.1158/0008-5472.CAN-17-2020; Ruedel A, 2015, INT J CLIN EXP PATHO, V8, P4953; Shostak K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6232; Thrumurthy SG, 2015, NAT REV CLIN ONCOL, V12, P676, DOI 10.1038/nrclinonc.2015.132; Tiwari A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069473; Wang YX, 2015, CANCER RES, V75, P1332, DOI 10.1158/0008-5472.CAN-14-0787; Wrighton KH, 2015, NAT REV MOL CELL BIO, V16, P518, DOI 10.1038/nrm4045; Xiong JB, 2016, ONCOL REP, V36, P1819, DOI 10.3892/or.2016.5030; Yanaka Y, 2015, CARCINOGENESIS, V36, P1363, DOI 10.1093/carcin/bgv106; Ye GD, 2016, GASTROENTEROLOGY, V150, P659, DOI 10.1053/j.gastro.2015.11.041; Ye YW, 2011, CANCER-AM CANCER SOC, V117, P5304, DOI 10.1002/cncr.26207; Yoshida H, 2013, P NATL ACAD SCI USA, V110, P5612, DOI 10.1073/pnas.1215432110; Yu BQ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3096-9; Yu T, 2018, CANCER SCI, V109, P1393, DOI 10.1111/cas.13583; Zaravinos A., 2015, J ONCOL, V2015, DOI DOI 10.1155/2015/865816; Zhang DJ, 2017, INT J CANCER, V140, P2298, DOI 10.1002/ijc.30656; Zhang YS, 2014, ONCOL REP, V31, P1503, DOI 10.3892/or.2014.3038; Zuo QF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.297; Zuo QF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.573	52	44	45	5	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3134	3150		10.1038/s41388-018-0642-0	http://dx.doi.org/10.1038/s41388-018-0642-0			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30626935				2022-12-17	WOS:000465557200003
J	Su, F; Ahn, S; Saha, A; DiGiovanni, J; Kolonin, MG				Su, Fei; Ahn, Songyeon; Saha, Achinto; DiGiovanni, John; Kolonin, Mikhail G.			Adipose stromal cell targeting suppresses prostate cancer epithelial-mesenchymal transition and chemoresistance	ONCOGENE			English	Article							TUMOR PROGRESSION; TISSUE; OBESITY	Fat tissue, overgrowing in obesity, promotes the progression of various carcinomas. Clinical and animal model studies indicate that adipose stromal cells (ASC), the progenitors of adipocytes, are recruited by tumors and promote tumor growth as tumor stromal cells. Here, we investigated the role of ASC in cancer chemoresistance and invasiveness, the attributes of tumor aggressiveness. By using human cell co-culture models, we demonstrate that ASC induce epithelial-mesenchymal transition (EMT) in prostate cancer cells. Our results for the first time demonstrate that ASC interaction renders cancer cells more migratory and resistant to docetaxel, cabazitaxel, and cisplatin chemotherapy. To confirm these findings in vivo, we compared cancer aggressiveness in lean and obese mice grafted with prostate tumors. We show that obesity promotes EMT in cancer cells and tumor invasion into the surrounding fat tissue. A hunter-killer peptide D-CAN, previously developed for targeted ASC ablation, suppressed the obesity-associated EMT and cancer progression. Importantly, cisplatin combined with D-CAN was more effective than cisplatin alone in suppressing growth of mouse prostate cancer allografts and xenografts even in non-obese mice. Our data demonstrate that ASC promote tumor aggressiveness and identify them as a target of combination cancer therapy.	[Su, Fei; Kolonin, Mikhail G.] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med Prevent Dis, Brown Fdn, Houston, TX 77030 USA; [Ahn, Songyeon; Saha, Achinto; DiGiovanni, John] Univ Texas Austin, Dell Pediat Res Inst, Div Pharmacol & Toxicol, Austin, TX 78723 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Austin	Kolonin, MG (corresponding author), Univ Texas Hlth Sci Ctr Houston, Inst Mol Med Prevent Dis, Brown Fdn, Houston, TX 77030 USA.	mikhail.g.kolonin@uth.tmc.edu		Kolonin, Mikhail/0000-0002-3743-7869; SU, FEI/0000-0001-5834-4074	NIH [R01 CA196259, R21 CA216745]; Harry E. Bovay, Jr. Foundation; NATIONAL CANCER INSTITUTE [R01CA196259, R21CA216745] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harry E. Bovay, Jr. Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH grant R01 CA196259 (to JD and MK), R21 CA216745 (to MK) and the Harry E. Bovay, Jr. Foundation.	Daquinag AC, 2015, CELL DEATH DIFFER, V22, P351, DOI 10.1038/cdd.2014.148; Daquinag AC, 2017, MOL THER-ONCOLYTICS, V6, P1, DOI 10.1016/j.omto.2017.05.003; Daquinag AC, 2016, MOL THER, V24, P34, DOI 10.1038/mt.2015.155; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Eheman C, 2012, CANCER-AM CANCER SOC, V118, P2338, DOI 10.1002/cncr.27514; Jung YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2766; Kandul NP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13100; Lengyel E, 2018, TRENDS CANCER, V4, P374, DOI 10.1016/j.trecan.2018.03.004; Lu YS, 2017, BIOCHEM BIOPH RES CO, V494, P719, DOI 10.1016/j.bbrc.2017.10.118; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Duong MN, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0569-0; Nowicka A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081859; Orecchioni S, 2013, CANCER RES, V73, P5880, DOI 10.1158/0008-5472.CAN-13-0821; Park J, 2014, NAT REV ENDOCRINOL, V10, P455, DOI 10.1038/nrendo.2014.94; Rowan BG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089595; Saha A, 2017, CANCER RES, V77, P5158, DOI [10.1158/0008-5472.can-17-0284, 10.1158/0008-5472.CAN-17-0284]; Saha A, 2016, ONCOTARGET, V7, P25194, DOI 10.18632/oncotarget.7535; Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887; Tan EHP, 2018, ONCOGENE, V37, P2067, DOI 10.1038/s41388-017-0109-8; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Zhang Y, 2012, CANCER RES, V72, P5198, DOI 10.1158/0008-5472.CAN-12-0294; Zhang Y, 2009, CANCER RES, V69, P5259, DOI 10.1158/0008-5472.CAN-08-3444	22	44	45	5	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1979	1988		10.1038/s41388-018-0558-8	http://dx.doi.org/10.1038/s41388-018-0558-8			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30361686	Green Accepted			2022-12-17	WOS:000461164400014
J	Meng, J; Chen, S; Lei, YY; Han, JX; Zhong, WL; Wang, XR; Liu, YR; Gao, WF; Zhang, Q; Tan, Q; Liu, HJ; Zhou, HG; Sun, T; Yang, C				Meng, Jing; Chen, Shuang; Lei, Yue-yang; Han, Jing-xia; Zhong, Wei-long; Wang, Xiao-rui; Liu, Yan-rong; Gao, Wan-feng; Zhang, Qiang; Tan, Qiang; Liu, Hui-juan; Zhou, Hong-gang; Sun, Tao; Yang, Cheng			Hsp90 beta promotes aggressive vasculogenic mimicry via epithelial-mesenchymal transition in hepatocellular carcinoma	ONCOGENE			English	Article							HUMAN-MELANOMA CELLS; FUNCTIONAL-SIGNIFICANCE; VASCULAR MIMICRY; CANCER; TWIST1; EXPRESSION; PATHWAYS; PROTEIN; USP19	Hepatocellular carcinoma (HCC) is a typical hypervascular solid tumor. Vasculogenic mimicry (VM) formed by aggressive tumor cells to mimic vasculogenic networks plays an important role in the tumor malignancy of HCC. Hsp90 beta promotes endothelial cell-dependent angiogenesis in HCC. However, the relationship between Hsp90 beta and VM formation is unclear. In this study, we found that Hsp90 beta is positively correlated with VM and EMT marker proteins in HCC tissues and promotes tube formation, cell migration, and invasion in vitro. Hsp90 beta interacts with Twistl and promotes its deubiquitination and stabilization to nuclear translocation and enhances the VE-cadherin promoter activity. Results of in vitro analysis indicate that Hsp90 beta enhances the tumor VM in tumor-burdened mice, and the Hsp90 inhibitor NVP-BEP800 suppresses VM formation by releasing Hsp90 beta and Twistl interaction. This study provides a potential antitumor therapy for inhibiting VM by targeting Hsp90 beta in HCC.	[Meng, Jing; Lei, Yue-yang; Han, Jing-xia; Zhong, Wei-long; Gao, Wan-feng; Zhang, Qiang; Tan, Qiang; Zhou, Hong-gang; Sun, Tao; Yang, Cheng] Nankai Univ, State Key Lab Med Chem Biol, Tianjin, Peoples R China; [Meng, Jing; Lei, Yue-yang; Han, Jing-xia; Zhong, Wei-long; Gao, Wan-feng; Zhang, Qiang; Tan, Qiang; Zhou, Hong-gang; Sun, Tao; Yang, Cheng] Nankai Univ, Coll Pharm, Tianjin, Peoples R China; [Chen, Shuang; Liu, Yan-rong; Tan, Qiang; Liu, Hui-juan; Sun, Tao; Yang, Cheng] Tianjin Int Joint Acad Biomed, Tianjin Key Lab Mol Drug Res, Tianjin, Peoples R China; [Wang, Xiao-rui; Liu, Hui-juan] Nankai Univ, Coll Life Sci, Tianjin, Peoples R China	Nankai University; Nankai University; Tianjin International Joint Academy of Biomedicine; Nankai University	Sun, T; Yang, C (corresponding author), Nankai Univ, State Key Lab Med Chem Biol, Tianjin, Peoples R China.; Sun, T; Yang, C (corresponding author), Nankai Univ, Coll Pharm, Tianjin, Peoples R China.; Sun, T; Yang, C (corresponding author), Tianjin Int Joint Acad Biomed, Tianjin Key Lab Mol Drug Res, Tianjin, Peoples R China.	tao.sun@nankai.edu.cn; cheng.yang@nankai.edu.cn		Chen, Shuang/0000-0001-5254-6353	National Natural Science Foundation of China [81572838, 81402973, 81703581]; Tianjin Natural Science and Technology Fund [15JCYBJC26400]; Tianjin Science and Technology Project [15PTGCCX00140]; National Science and Technology Major Project [2017ZX09306007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Natural Science and Technology Fund; Tianjin Science and Technology Project; National Science and Technology Major Project	This study was supported by the National Natural Science Foundation of China (Grant nos. 81572838, 81402973 and 81703581), Tianjin Natural Science and Technology Fund (Grant no. 15JCYBJC26400), Tianjin Science and Technology Project (grant no. 15PTGCCX00140), and the National Science and Technology Major Project (grant no. 2017ZX09306007).	Cao ZF, 2013, EUR J CANCER, V49, P3914, DOI 10.1016/j.ejca.2013.07.148; Cao Z, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030500; Chang SX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065895; Delgado-Bellido D, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0631-x; Fan YL, 2013, ONCOL LETT, V6, P1174, DOI 10.3892/ol.2013.1555; He WT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147515; Hendrix MJC, 2016, PHARMACOL THERAPEUT, V159, P83, DOI 10.1016/j.pharmthera.2016.01.006; Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798; Hess AR, 2006, CELL CYCLE, V5, P478, DOI 10.4161/cc.5.5.2518; Hess AR, 2003, CANCER RES, V63, P4757; Hess AR, 2001, CANCER RES, V61, P3250; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kirschmann DA, 2012, CLIN CANCER RES, V18, P2726, DOI 10.1158/1078-0432.CCR-11-3237; Lee JG, 2014, J BIOL CHEM, V289, P3510, DOI 10.1074/jbc.M113.538934; Li X, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14866; Liu X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113921; Liu ZY, 2012, CANCER SCI, V103, P813, DOI 10.1111/j.1349-7006.2011.02199.x; Mabjeesh NJ, 2002, CANCER RES, V62, P2478; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Massey AJ, 2010, MOL CANCER THER, V9, P906, DOI 10.1158/1535-7163.MCT-10-0055; Mei Yide, 2011, J Biol Chem, V286, P35380, DOI 10.1074/jbc.M111.282020; Meng J, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0640-9; Su M, 2008, INT J GYNECOL CANCER, V18, P476, DOI 10.1111/j.1525-1438.2007.01034.x; Sun BC, 2004, INT J ONCOL, V25, P1609; Sun T, 2011, HEPATOLOGY, V54, P1690, DOI 10.1002/hep.24543; Sun T, 2010, HEPATOLOGY, V51, P545, DOI 10.1002/hep.23311; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Williamson SC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13322; Wu JY, 2014, EXP THER MED, V8, P893, DOI 10.3892/etm.2014.1800; Yang ZH, 2015, EXP MOL PATHOL, V98, P352, DOI 10.1016/j.yexmp.2015.03.030; Zhang H, 2004, J MOL MED, V82, P488, DOI 10.1007/s00109-004-0549-9; Zhang SW, 2007, CANCER LETT, V254, P157, DOI 10.1016/j.canlet.2006.12.036; Zhong WL, 2017, ONCOTARGET, V8, P16829, DOI 10.18632/oncotarget.15166; Zhou Y, 2015, MED SCI MONITOR, V21, P4039, DOI 10.12659/MSM.896712; Zhu QQ, 2016, TUMOR BIOL, V37, P185, DOI 10.1007/s13277-015-4450-7	36	44	45	1	45	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					228	243		10.1038/s41388-018-0428-4	http://dx.doi.org/10.1038/s41388-018-0428-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30087438				2022-12-17	WOS:000455366700006
J	Li, A; Chen, P; Leng, Y; Kang, JH				Li, Ang; Chen, Ping; Leng, Ye; Kang, Jiuhong			Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway	ONCOGENE			English	Article							TUMOR-STROMA; HDAC6; MICROENVIRONMENT; CELLS; INFLAMMATION; INHIBITORS; CHEMOTHERAPY; METASTASES; PROMOTION; FIBROSIS	Cancer-associated fibroblasts (CAFs) are important components in breast tumors and essential for tumor progression and metastasis. However, the role of epigenetic modification in driving the function of CAFs within breast tumors is only marginally known. Herein, we reported that histone deacetylase 6 (HDAC6), one of class II histone deacetylases, was frequently upregulated in the CAFs of breast tumor and promotes an immunosuppressive microenvironment. The genetic or pharmacologic disruption of HDAC6 in CAFs delays tumor growth, inhibits the tumor recruitment of myeloid-derived suppressor cells and regulatory T cells, alters the macrophage phenotype switch, and increases the CD8+ and CD4+ T-cell activation in vivo. Mechanistically, we identified prostaglandin E2/cyclooxygenase-2 (COX2) as a major target of HDAC6 in CAFs by regulating STAT3 activation. Overexpressing COX2 in HDAC6-knockdown CAFs can completely restore the immunosuppressive properties of the fibroblasts. Clinically, a positive correlation among the stromal expression levels of HDAC6, p-STAT3, and COX2 in human breast cancer was observed. High-stromal expression of HDAC6 was markedly associated with poor survival outcome. Overall, our findings indicated that fibroblastic HDAC6 was a vital epigenetic mediator involved in programming an immunosuppressive tumor microenvironment that dampens antitumor immunity. Thus, HDAC6 may be a good potential target to improve breast cancer immunotherapy.	[Li, Ang; Chen, Ping; Leng, Ye; Kang, Jiuhong] Tongji Univ, Clin & Translat Res Ctr, Shanghai Matern & Infant Hlth Hosp 1, Shanghai Key Lab Signaling & Dis Res,Sch Life Sci, 1239 Siping Rd, Shanghai 200092, Peoples R China	Tongji University	Kang, JH (corresponding author), Tongji Univ, Clin & Translat Res Ctr, Shanghai Matern & Infant Hlth Hosp 1, Shanghai Key Lab Signaling & Dis Res,Sch Life Sci, 1239 Siping Rd, Shanghai 200092, Peoples R China.	jhkang@tongji.edu.cn			Ministry of Science and Technology of China [2016YFA0101300]; Science and Technology Commission of Shanghai Municipality [16PJ1410200]; Fundamental Research Funds for the Central Universities [1501219171, 22120170068]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by grants obtained from the Ministry of Science and Technology of China (grant #2016YFA0101300), Science and Technology Commission of Shanghai Municipality (grant #16PJ1410200), and the Fundamental Research Funds for the Central Universities (grant #1501219171, 22120170068).	Chang AL, 2016, CANCER RES, V76, P5671, DOI 10.1158/0008-5472.CAN-16-0144; Cheng F, 2014, J IMMUNOL, V193, P2850, DOI 10.4049/jimmunol.1302778; Cheng F, 2014, MOL IMMUNOL, V60, P44, DOI 10.1016/j.molimm.2014.02.019; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Cohen N, 2017, ONCOGENE, V36, P4457, DOI 10.1038/onc.2017.65; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Fanelli A, 2017, THER ADV DRUG SAF, V8, P173, DOI 10.1177/2042098617690485; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Frangogiannis NG, 2017, J CLIN INVEST, V127, P1600, DOI 10.1172/JCI87491; Fulton AM, 2006, CANCER RES, V66, P9794, DOI 10.1158/0008-5472.CAN-06-2067; Guerriero JL, 2017, NATURE, V543, P428, DOI 10.1038/nature21409; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Jacobetz MA, 2013, GUT, V62, P112, DOI 10.1136/gutjnl-2012-302529; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Karavitis J, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23129; Kim K, 2014, P NATL ACAD SCI USA, V111, P11774, DOI 10.1073/pnas.1410626111; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Lee HJ, 2017, CELL SIGNAL, V38, P1, DOI 10.1016/j.cellsig.2017.06.012; Li L, 2016, ONCOGENE, V35, P4048, DOI 10.1038/onc.2015.476; Loeffler M, 2006, J CLIN INVEST, V116, P1955, DOI 10.1172/JCI26532; Lyssiotis CA, 2017, TRENDS CELL BIOL, V27, P873, DOI 10.1016/j.tcb.2017.06.003; Marsh T, 2013, BBA-MOL BASIS DIS, V1832, P1070, DOI 10.1016/j.bbadis.2012.10.013; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Nakasone ES, 2012, CANCER CELL, V21, P488, DOI 10.1016/j.ccr.2012.02.017; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Palijan A, 2009, J BIOL CHEM, V284, P30264, DOI 10.1074/jbc.M109.045526; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Putcha P, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0658-0; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Reader J, 2011, CANCER METAST REV, V30, P449, DOI 10.1007/s10555-011-9303-2; Regulski M, 2016, DRUG DISCOV TODAY, V21, P598, DOI 10.1016/j.drudis.2015.12.003; Scherz-Shouval R, 2014, CELL, V158, P564, DOI 10.1016/j.cell.2014.05.045; Schoepp M, 2017, CANCERS, V9, DOI 10.3390/cancers9060054; Schuetze KB, 2014, J MOL CELL CARDIOL, V70, P100, DOI 10.1016/j.yjmcc.2014.02.015; Schwartz H, 2016, CANCER RES, V76, P4359, DOI 10.1158/0008-5472.CAN-16-0485; Shalapour S, 2015, NATURE, V521, P94, DOI 10.1038/nature14395; Sharma S, 2005, CANCER RES, V65, P5211, DOI 10.1158/0008-5472.CAN-05-0141; Sharon Y, 2015, CANCER RES, V75, P963, DOI 10.1158/0008-5472.CAN-14-1990; Smith MP, 2016, CLIN CANCER RES, V22, P5966, DOI 10.1158/1078-0432.CCR-16-0954; Su CW, 2016, CRIT REV ONCOL HEMAT, V107, P33, DOI 10.1016/j.critrevonc.2016.08.010; Terranova-Barberio M, 2016, IMMUNOTHERAPY-UK, V8, P705, DOI 10.2217/imt-2016-0014; Wang HP, 2017, TRENDS CANCER, V3, P583, DOI 10.1016/j.trecan.2017.06.005; Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43; Williams L, 2004, J IMMUNOL, V172, P567, DOI 10.4049/jimmunol.172.1.567; Yan HL, 2012, CELL SIGNAL, V24, P961, DOI 10.1016/j.cellsig.2011.12.019; Yang XG, 2016, CANCER RES, V76, P4124, DOI 10.1158/0008-5472.CAN-15-2973; Youn GS, 2015, GLIA, V63, P1953, DOI 10.1002/glia.22865; Zheng H, 2016, CLIN CANCER RES, V22, P4119, DOI 10.1158/1078-0432.CCR-15-2584	50	44	47	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2018	37	45					5952	5966		10.1038/s41388-018-0379-9	http://dx.doi.org/10.1038/s41388-018-0379-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GZ6PQ	29980788				2022-12-17	WOS:000449562500004
J	Chan, JSK; Sng, MK; Teo, ZQ; Chong, HC; Twang, JS; Tan, NS				Chan, J. S. K.; Sng, M. K.; Teo, Z. Q.; Chong, H. C.; Twang, J. S.; Tan, N. S.			Targeting nuclear receptors in cancer-associated fibroblasts as concurrent therapy to inhibit development of chemoresistant tumors	ONCOGENE			English	Article							METASTATIC COLORECTAL-CANCER; RESISTANT PROSTATE-CANCER; PHASE-II TRIAL; RETINOIC ACID; CELL; PROGRESSION; TRANILAST; MICROENVIRONMENT; HYPOXIA; DISEASE	Most anticancer therapies to date focus on druggable features of tumor epithelia. Despite the increasing repertoire of treatment options, patient responses remain varied. Moreover, tumor resistance and relapse remain persistent clinical challenges. These observations imply an incomplete understanding of tumor heterogeneity. The tumor microenvironment is a major determinant of disease progression and therapy outcome. Cancer-associated fibroblasts (CAFs) are the dominant cell type within the reactive stroma of tumors. They orchestrate paracrine pro-tumorigenic signaling with adjacent tumor cells, thus exacerbating the hallmarks of cancer and accelerating tumor malignancy. Although CAF-derived soluble factors have been investigated for tumor stroma-directed therapy, the underlying transcriptional programs that enable the oncogenic functions of CAFs remain poorly understood. Nuclear receptors (NRs), a large family of ligand-responsive transcription factors, are pharmacologically viable targets for the suppression of CAF-facilitated oncogenesis. In this study, we defined the expression profiles of NRs in CAFs from clinical cutaneous squamous cell carcinoma (SCC) biopsies. We further identified a cluster of driver NRs in CAFs as important modifiers of CAF function with profound influence on cancer cell invasiveness, proliferation, drug resistance, energy metabolism and oxidative stress status. Importantly, guided by the NR profile of CAFs, retinoic acid receptor beta and androgen receptor antagonists were identified for concurrent therapy with cisplatin, resulting in the inhibition of chemoresistance in recurred SCC: CAF xenografts. Our work demonstrates that treatments targeting both the tumor epithelia and the surrounding CAFs can extend the efficacy of conventional chemotherapy.	[Chan, J. S. K.; Sng, M. K.; Teo, Z. Q.; Chong, H. C.; Twang, J. S.; Tan, N. S.] Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore; [Sng, M. K.; Tan, N. S.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore; [Tan, N. S.] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore; [Tan, N. S.] KK Womens & Children Hosp, Singapore, Singapore; [Chong, H. C.] DeNova Sci Pte Ltd, 16 Nanyang Dr, Singapore 637722, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); KK Women's & Children's Hospital	Chan, JSK; Tan, NS (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	CHAN0693@e.ntu.edu.sg; nstan@ntu.edu.sg	Tan, Nguan Soon/A-2220-2011; Sng, Ming Keat/J-7266-2013	Tan, Nguan Soon/0000-0003-0136-7341; Sng, Ming Keat/0000-0002-5529-4371	Singapore Ministry of Education [MOE2014-T2-1-012]; Singapore Ministry of Education (AcRF Tier 1) [RG134/15]; Nanyang President Graduate Scholarship	Singapore Ministry of Education(Ministry of Education, Singapore); Singapore Ministry of Education (AcRF Tier 1)(Ministry of Education, Singapore); Nanyang President Graduate Scholarship	The work was supported by grants from the Singapore Ministry of Education (MOE2014-T2-1-012 and AcRF Tier 1 RG134/15) to NST. JSKC is a recipient of the Nanyang President Graduate Scholarship.	Bhagwat AS, 2015, TRENDS CANCER, V1, P53, DOI 10.1016/j.trecan.2015.07.001; Bizzarri M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/934038; Byun JS, 2013, AM J PATHOL, V182, P1055, DOI 10.1016/j.ajpath.2013.01.009; Chen YY, 2007, BIOMED CHROMATOGR, V21, P628, DOI 10.1002/bmc.798; Darby IA, 2016, CELL MOL LIFE SCI, V73, P1145, DOI 10.1007/s00018-015-2110-0; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Dvorak HF, 2015, CANCER IMMUNOL RES, V3, P1, DOI 10.1158/2326-6066.CIR-14-0209; Eruslanov E, 2010, METHODS MOL BIOL, V594, P57, DOI 10.1007/978-1-60761-411-1_4; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Ghandadi M, 2016, CURR PHARM DESIGN, V22, P518, DOI 10.2174/1381612822666151124234417; Hofheinz RD, 2003, ONKOLOGIE, V26, P44, DOI 10.1159/000069863; Hong K, 2014, IMMUNOL LETT, V162, P34, DOI 10.1016/j.imlet.2014.06.011; Hong LZ, 2013, ONCOL LETT, V6, P1595, DOI 10.3892/ol.2013.1590; Izumi K, 2010, ANTICANCER RES, V30, P3077; Izumi K, 2009, PROSTATE, V69, P1222, DOI 10.1002/pros.20975; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; Lam CRI, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.339; Lisanti MP, 2010, CANCER BIOL THER, V10, P537, DOI 10.4161/cbt.10.6.13370; Marshall J, 2011, METHODS MOL BIOL, V769, P97, DOI 10.1007/978-1-61779-207-6_8; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3256, DOI 10.4161/cc.9.16.12553; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Narra K, 2007, CANCER BIOL THER, V6, P1691, DOI 10.4161/cbt.6.11.4874; Ohshio Y, 2014, SCAND J IMMUNOL, V80, P408, DOI 10.1111/sji.12242; Paulsson J, 2014, FUTURE ONCOL, V10, P1695, DOI [10.2217/FON.14.83, 10.2217/fon.14.83]; Redmond Aisling M, 2009, Genome Biol, V10, P311, DOI 10.1186/gb-2009-10-7-311; Rieger S, 2015, CELL BIOCHEM FUNCT, V33, P1, DOI 10.1002/cbf.3086; Rio DC., 2010, COLD SPRING HARB PRO, V2010, ppdb.prot5439, DOI [DOI 10.1101/PDB.PROT5439, 10.1101/pdb.prot5439]; Rothaeusler K, 2007, CURR PROTOC CYTOM, V7, P31; Santos AM, 2009, J CLIN INVEST, V119, P3613, DOI 10.1172/JCI38988; Sherman MH, 2014, CELL, V159, P80, DOI 10.1016/j.cell.2014.08.007; Shi YF, 2017, NAT REV DRUG DISCOV, V16, P35, DOI 10.1038/nrd.2016.193; Simkova D, 2016, BIOMED PAP, V160, P467, DOI 10.5507/bp.2016.037; Sladek FM, 2003, EXPERT OPIN THER TAR, V7, P679; Sonnenschein C, 2016, PROG BIOPHYS MOL BIO, V122, P70, DOI 10.1016/j.pbiomolbio.2016.07.004; Spaw M, 2017, MOL CARCINOGEN, V56, P1199, DOI 10.1002/mc.22583; SUZAWA H, 1992, JPN J PHARMACOL, V60, P91, DOI 10.1254/jjp.60.91; Tan NS, 2016, PROG LIPID RES, V64, P98, DOI 10.1016/j.plipres.2016.09.001; Tesei A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062657; Thomas C, 2013, MOL CANCER THER, V12, P2342, DOI 10.1158/1535-7163.MCT-13-0032; Togo Shinsaku, 2013, Cancers (Basel), V5, P149, DOI 10.3390/cancers5010149; van de Pavert SA, 2009, NAT IMMUNOL, V10, P1193, DOI 10.1038/ni.1789; Vazquez-Villa F, 2015, TUMOR BIOL, V36, P2213, DOI 10.1007/s13277-015-3295-4; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Wang YB, 2017, EBIOMEDICINE, V17, P45, DOI 10.1016/j.ebiom.2017.02.019; Yan CH, 2013, BBA-REV CANCER, V1835, P76, DOI 10.1016/j.bbcan.2012.11.002; Yin K, 2016, CELL MOL LIFE SCI, V73, P3789, DOI 10.1007/s00018-016-2329-4; Zou CH, 2005, J BIOCHEM BIOPH METH, V64, P207, DOI 10.1016/j.jbbm.2005.08.001	50	44	44	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					160	173		10.1038/onc.2017.319	http://dx.doi.org/10.1038/onc.2017.319			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28892046	Green Published, hybrid			2022-12-17	WOS:000422631700003
J	Thewes, V; Simon, R; Hlevnjak, M; Schlotter, M; Schroeter, P; Schmidt, K; Wu, Y; Anzeneder, T; Wang, W; Windisch, P; Kirchgassner, M; Melling, N; Kneisel, N; Buttner, R; Deuschle, U; Sinn, HP; Schneeweiss, A; Heck, S; Kaulfuss, S; Hess-Stumpp, H; Okun, JG; Sauter, G; Lykkesfeldt, AE; Zapatka, M; Radlwimmer, B; Lichter, P; Tonjes, M				Thewes, V.; Simon, R.; Hlevnjak, M.; Schlotter, M.; Schroeter, P.; Schmidt, K.; Wu, Y.; Anzeneder, T.; Wang, W.; Windisch, P.; Kirchgaessner, M.; Melling, N.; Kneisel, N.; Buettner, R.; Deuschle, U.; Sinn, H. P.; Schneeweiss, A.; Heck, S.; Kaulfuss, S.; Hess-Stumpp, H.; Okun, J. G.; Sauter, G.; Lykkesfeldt, A. E.; Zapatka, M.; Radlwimmer, B.; Lichter, P.; Toenjes, M.			The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ER alpha-negative breast cancer	ONCOGENE			English	Article							TAMOXIFEN RESISTANCE; CELL-LINES; EXPRESSION; ESTROGEN; AMINOTRANSFERASE; PROLIFERATION; GENES; MICROARRAYS; ACTIVATION; SIGNATURES	Antiestrogen-resistant and triple-negative breast tumors pose a serious clinical challenge because of limited treatment options. We assessed global gene expression changes in antiestrogen-sensitive compared with antiestrogen-resistant (two tamoxifen resistant and two fulvestrant resistant) MCF-7 breast cancer cell lines. The branched-chain amino acid transaminase 1 (BCAT1), which catalyzes the first step in the breakdown of branched-chain amino acids, was among the most upregulated transcripts in antiestrogen-resistant cells. Elevated BCAT1 expression was confirmed in relapsed tamoxifen-resistant breast tumor specimens. High intratumoral BCAT1 levels were associated with a reduced relapse-free survival in adjuvant tamoxifen-treated patients and overall survival in unselected patients. On a tissue microarray (n = 1421), BCAT1 expression was detectable in 58% of unselected primary breast carcinomas and linked to a higher Ki-67 proliferation index, as well as histological grade. Interestingly, BCAT1 was predominantly expressed in estrogen receptor-a-negative/human epidermal growth factor receptor-2-positive (ER alpha-negative/HER-2- positive) and triple-negative breast cancers in independent patient cohorts. The inverse relationship between BCAT1 and ER alpha was corroborated in various breast cancer cell lines and pharmacological long-term depletion of ERa induced BCAT1 expression in vitro. Mechanistically, BCAT1 indirectly controlled expression of the cell cycle inhibitor p27(Kip1) thereby affecting pRB. Correspondingly, phenotypic analyses using a lentiviral-mediated BCAT1 short hairpin RNA knockdown revealed that BCAT1 sustains proliferation in addition to migration and invasion and that its overexpression enhanced the capacity of antiestrogen-sensitive cells to grow in the presence of antiestrogens. Importantly, silencing of BCAT1 in an orthotopic triple-negative xenograft model resulted in a massive reduction of tumor volume in vivo, supporting our findings that BCAT1 is necessary for the growth of hormone-independent breast tumors.	[Thewes, V.; Hlevnjak, M.; Schlotter, M.; Schroeter, P.; Wu, Y.; Wang, W.; Windisch, P.; Kirchgaessner, M.; Kneisel, N.; Heck, S.; Zapatka, M.; Radlwimmer, B.; Lichter, P.; Toenjes, M.] German Canc Res Ctr, German Canc Consortium DKTK, Div Mol Genet, D-69120 Heidelberg, Germany; [Simon, R.; Melling, N.; Sauter, G.] Univ Med Ctr Hamburg Eppendorf, Inst Pathol, Hamburg, Germany; [Schmidt, K.; Okun, J. G.] Univ Childrens Hosp, Div Inherited Metab Dis, Heidelberg, Germany; [Anzeneder, T.] PATH Fdn Biobank Patients Tumor Bank Hope, Munich, Germany; [Buettner, R.] Univ Hosp Cologne, Inst Pathol, Cologne, Germany; [Deuschle, U.] Phenex Pharmaceut AG, Heidelberg, Germany; [Sinn, H. P.] Heidelberg Univ, Inst Pathol, Heidelberg, Germany; [Schneeweiss, A.] Heidelberg Univ, Natl Ctr Tumor Dis, Gynecol Oncol, Heidelberg, Germany; [Kaulfuss, S.; Hess-Stumpp, H.] Bayer Pharma AG, Berlin, Germany; [Lykkesfeldt, A. E.] Danish Canc Soc, Res Ctr, Breast Canc Grp, Copenhagen, Denmark	Helmholtz Association; German Cancer Research Center (DKFZ); University of Hamburg; University Medical Center Hamburg-Eppendorf; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Cologne; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Bayer AG; Bayer Healthcare Pharmaceuticals; Danish Cancer Society	Lichter, P (corresponding author), German Canc Res Ctr, German Canc Consortium DKTK, Div Mol Genet, D-69120 Heidelberg, Germany.	peter.lichter@dkfz-heidelberg.de	Zapatka, Marc/G-9896-2013; Radlwimmer, Bernhard F/I-3229-2013; Sinn, Hans-Peter/C-5661-2008; Wu, Yonghe/N-2269-2019	Zapatka, Marc/0000-0001-8287-5967; Radlwimmer, Bernhard F/0000-0002-4553-7800; Sinn, Hans-Peter/0000-0003-2836-6699; Wu, Yonghe/0000-0001-9667-8198	Strategic Alliance of Bayer Healthcare and the German Cancer Research Center (DKFZ); Helmholtz-Graduate School for Cancer Research	Strategic Alliance of Bayer Healthcare and the German Cancer Research Center (DKFZ); Helmholtz-Graduate School for Cancer Research	We highly appreciate the excellent technical assistance of Karin Pfleger and Achim Stephan. Further, we thank Nicolas Hafner and Yashna Paul for experimental and computational support and appreciate the help and constructive discussions from Martina Seiffert, and Michael Fletcher. Moreover, we thank the patients, pathologists and gynecologists associated with the PATH Biobank (http://pathbiobank.org/index.php/en/) for their support. This work was supported by the Strategic Alliance of Bayer Healthcare and the German Cancer Research Center (DKFZ). VT was supported by a scholarship from the Helmholtz-Graduate School for Cancer Research.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Al Saleh S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020610; Ananieva EA, 2014, J BIOL CHEM, V289, P18793, DOI 10.1074/jbc.M114.554113; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; BRIAND P, 1984, CANCER RES, V44, P1114; Castro F, 2013, INT J CANCER, V132, P308, DOI 10.1002/ijc.27675; Chang IW, 2016, HISTOPATHOLOGY, V68, P520, DOI 10.1111/his.12778; Chaumeil MM, 2014, CANCER RES, V74, P4247, DOI 10.1158/0008-5472.CAN-14-0680; Coser KR, 2009, P NATL ACAD SCI USA, V106, P14536, DOI 10.1073/pnas.0907560106; DeSantiago S, 2001, ADV EXP MED BIOL, V501, P93; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Frogne T, 2009, BREAST CANCER RES TR, V114, P263, DOI 10.1007/s10549-008-0011-8; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Gonzalez-Malerva L, 2011, P NATL ACAD SCI USA, V108, P2058, DOI 10.1073/pnas.1018157108; Harvell DME, 2008, BREAST CANCER RES TR, V112, P475, DOI 10.1007/s10549-008-9897-4; Heck S, 2009, CANCER RES, V69, P5184, DOI 10.1158/0008-5472.CAN-08-3062; Hull J, 2012, J NEUROCHEM, V123, P997, DOI 10.1111/jnc.12044; Hutson S, 2001, PROG NUCLEIC ACID RE, V70, P175, DOI 10.1016/S0079-6603(01)70017-7; Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886; Ju W, 2009, ONCOL RES, V18, P47, DOI 10.3727/096504009789954672; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lu XS, 2008, BREAST CANCER RES TR, V108, P191, DOI 10.1007/s10549-007-9596-6; LYKKESFELDT AE, 1994, CANCER RES, V54, P1587; LYKKESFELDT AE, 1995, INT J CANCER, V61, P529, DOI 10.1002/ijc.2910610417; Mayer IA, 2014, CLIN CANCER RES, V20, P782, DOI 10.1158/1078-0432.CCR-13-0583; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Mishra P, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.992217; Nagaraja GM, 2006, ONCOGENE, V25, P2328, DOI 10.1038/sj.onc.1209265; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Peyton KJ, 2012, J PHARMACOL EXP THER, V342, P827, DOI 10.1124/jpet.112.194712; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Prest SJ, 1999, CLIN EXP METASTAS, V17, P389, DOI 10.1023/A:1006657109866; Rimawi MF, 2015, ANNU REV MED, V66, P111, DOI 10.1146/annurev-med-042513-015127; Robertson JFR, 2001, BRIT J CANCER, V85, P11, DOI 10.1054/bjoc.2001.1982; Rodriguez S, 2003, ONCOGENE, V22, P1880, DOI 10.1038/sj.onc.1206302; Ruiz C, 2006, INT J CANCER, V118, P2190, DOI 10.1002/ijc.21581; Shajahan-Haq AN, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-239; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Thewes V, 2015, CANCER RES, V75, P720, DOI 10.1158/0008-5472.CAN-14-0652; Thrane S, 2013, BREAST CANCER RES TR, V139, P71, DOI 10.1007/s10549-013-2485-2; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; Tonjes M, 2013, NAT MED, V19, P901, DOI 10.1038/nm.3217; Waldmann A, 2014, GEBURTSH FRAUENHEILK, V74, P361, DOI 10.1055/s-0033-1360263; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Yoshikawa R, 2006, WORLD J GASTROENTERO, V12, P5884, DOI 10.3748/wjg.v12.i36.5884; Zhang Y, 2009, BREAST CANCER RES TR, V116, P303, DOI 10.1007/s10549-008-0183-2; Zhou W, 2007, ONCOL RES, V16, P405, DOI 10.3727/000000007783980873; Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011; Zschocke J, 2004, VADEMECUM METABOLICU	51	44	45	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4124	4134		10.1038/onc.2017.32	http://dx.doi.org/10.1038/onc.2017.32			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28319069				2022-12-17	WOS:000405835800004
J	Yang, M; Schiapparelli, P; Nguyen, HN; Igarashi, A; Zhang, Q; Abbadi, S; Amzel, LM; Sesaki, H; Quinones-Hinojosa, A; Iijima, M				Yang, Jr-M; Schiapparelli, P.; Nguyen, H-N; Igarashi, A.; Zhang, Q.; Abbadi, S.; Amzel, L. M.; Sesaki, H.; Quinones-Hinojosa, A.; Iijima, M.			Characterization of PTEN mutations in brain cancer reveals that pten mono-ubiquitination promotes protein stability and nuclear localization	ONCOGENE			English	Article							MESENCHYMAL STEM-CELLS; TUMOR-SUPPRESSOR; PHOSPHATASE-ACTIVITY; MIGRATION; GENE; PHOSPHORYLATION; ACTIVATION; SURVIVAL; BINDING	PTEN is a PIP3 phosphatase that antagonizes oncogenic PI3-kinase signalling. Due to its critical role in suppressing the potent signalling pathway, it is one of the most mutated tumour suppressors, especially in brain tumours. It is generally thought that PTEN deficiencies predominantly result from either loss of expression or enzymatic activity. By analysing PTEN in malignant glioblastoma primary cells derived from 16 of our patients, we report mutations that block localization of PTEN at the plasma membrane and nucleus without affecting lipid phosphatase activity. Cellular and biochemical analyses as well as structural modelling revealed that two mutations disrupt intramolecular interaction of PTEN and open its conformation, enhancing polyubiquitination of PTEN and decreasing protein stability. Moreover, promoting mono-ubiquitination increases protein stability and nuclear localization of mutant PTEN. Thus, our findings provide a molecular mechanism for cancer-associated PTEN defects and may lead to a brain cancer treatment that targets PTEN mono-ubiquitination.	[Yang, Jr-M; Nguyen, H-N; Igarashi, A.; Zhang, Q.; Sesaki, H.; Iijima, M.] Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725N Wolfe St,107 Hunterian, Baltimore, MD 21205 USA; [Schiapparelli, P.; Abbadi, S.; Quinones-Hinojosa, A.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA; [Schiapparelli, P.; Amzel, L. M.; Quinones-Hinojosa, A.] Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD USA; [Schiapparelli, P.; Quinones-Hinojosa, A.] Mayo Clin, Coll Med, Dept Neurosurg, 4500 San Pablo Rd, Jacksonville, FL 32224 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Mayo Clinic	Iijima, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725N Wolfe St,107 Hunterian, Baltimore, MD 21205 USA.; Quinones-Hinojosa, A (corresponding author), Mayo Clin, Coll Med, Dept Neurosurg, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	Quinones-Hinojosa.Alfredo@mayo.edu; miijima@jhmi.edu		Yang, Jr-Ming/0000-0002-6296-8987; schiapparelli, paula/0000-0003-4551-6337	NIH [GM084015, GM089853, NS070024]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS070024] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by NIH grants to Miho Iijima (GM084015), Hiromi Sesaki (GM089853) and Alfredo Quinones-Hinojosa (NS070024).	Abbadi S, 2014, MOL CANCER RES, V12, P1547, DOI 10.1158/1541-7786.MCR-14-0106-T; Al-Khouri AM, 2005, J BIOL CHEM, V280, P35195, DOI 10.1074/jbc.M503045200; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Bassi C, 2013, SCIENCE, V341, P395, DOI 10.1126/science.1236188; Bolduc D, 2013, ELIFE, V2, DOI 10.7554/eLife.00691; Chaichana KL, 2014, NEURO-ONCOLOGY, V16, P113, DOI 10.1093/neuonc/not137; Chaichana KL, 2011, J NEUROSURG, V114, P587, DOI 10.3171/2010.8.JNS1081; Chaichana KL, 2009, J NEUROSCI METH, V180, P116, DOI 10.1016/j.jneumeth.2009.02.014; Chen CL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002446; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Endersby R, 2008, ONCOGENE, V27, P5416, DOI 10.1038/onc.2008.239; Ermoian RP, 2002, CLIN CANCER RES, V8, P1100; Feng Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.521; Garzon-Muvdi T, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001320; Gil A, 2007, CELL DEATH DIFFER, V14, P395, DOI 10.1038/sj.cdd.4402073; Guerrero-Cazares H, 2011, J COMP NEUROL, V519, P1165, DOI 10.1002/cne.22566; Nguyen HN, 2015, SCI REP-UK, V5, DOI 10.1038/srep12600; Nguyen HN, 2014, P NATL ACAD SCI USA, V111, pE2684, DOI 10.1073/pnas.1409433111; Kamimura Y, 2008, CURR BIOL, V18, P1034, DOI 10.1016/j.cub.2008.06.068; Kim DH, 2009, BIOMATERIALS, V30, P5433, DOI 10.1016/j.biomaterials.2009.06.042; Kim DH, 2009, ADV FUNCT MATER, V19, P1579, DOI 10.1002/adfm.200801174; Kondapalli KC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7289; Lang V, 2015, METHODS, V77-78, P112, DOI 10.1016/j.ymeth.2014.09.001; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Levy AF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092165; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li Q, 2014, CLIN CANCER RES, V20, P2375, DOI 10.1158/1078-0432.CCR-13-1415; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Liu FH, 2005, J CELL BIOCHEM, V96, P221, DOI 10.1002/jcb.20525; Maccario H, 2007, BIOCHEM J, V405, P439, DOI 10.1042/BJ20061837; Nguyen HN, 2014, ONCOGENE, V33, P5688, DOI 10.1038/onc.2013.507; Nguyen HN, 2015, ONCOGENE, V34, P3737, DOI 10.1038/onc.2014.293; Papa A, 2014, CELL, V157, P595, DOI 10.1016/j.cell.2014.03.027; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Ravin R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039421; Riddick G, 2011, NAT REV NEUROL, V7, P439, DOI 10.1038/nrneurol.2011.100; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Smith CL, 2016, CELL REP, V15, P2616, DOI 10.1016/j.celrep.2016.05.042; Smith CL, 2015, STEM CELL TRANSL MED, V4, P239, DOI 10.5966/sctm.2014-0149; Song MS, 2011, CELL, V144, P187, DOI 10.1016/j.cell.2010.12.020; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Tzeng SY, 2011, BIOMATERIALS, V32, P5402, DOI 10.1016/j.biomaterials.2011.04.016; Wang XJ, 2008, BIOCHEM J, V414, P221, DOI 10.1042/BJ20080674; Wang Y, 2011, MOL BIOL CELL, V22, P2270, DOI 10.1091/mbc.E10-11-0926; Yang JM, 2015, METHODS, V77-78, P119, DOI 10.1016/j.ymeth.2014.10.018; Zhang P, 2010, P NATL ACAD SCI US; Zhang PB, 2010, P NATL ACAD SCI USA, V107, P11829, DOI 10.1073/pnas.1006153107; Zhu MX, 2015, STEM CELLS DEV, V24, P160, DOI 10.1089/scd.2014.0076	50	44	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3673	3685		10.1038/onc.2016.493	http://dx.doi.org/10.1038/onc.2016.493			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28263967	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000404349700003
J	Berthenet, K; Bokhari, A; Lagrange, A; Marcion, G; Boudesco, C; Causse, S; De Thonel, A; Svrcek, M; Goloudina, AR; Dumont, S; Hammann, A; Biard, DS; Demidov, ON; Seigneuric, R; Duval, A; Collura, A; Jego, G; Garrido, C				Berthenet, K.; Bokhari, A'dem; Lagrange, A.; Marcion, G.; Boudesco, C.; Causse, S.; De Thonel, A.; Svrcek, M.; Goloudina, A. R.; Dumont, S.; Hammann, A.; Biard, D. S.; Demidov, O. N.; Seigneuric, R.; Duval, A.; Collura, A.; Jego, G.; Garrido, C.			HSP110 promotes colorectal cancer growth through STAT3 activation	ONCOGENE			English	Article							MICROSATELLITE INSTABILITY; EXPRESSION; HSP70; GENE; PROTEINS; SURVIVAL; CELLS; CD1D; RNA	Heat shock protein 110 (HSP110) is induced by different stresses and, through its anti-apoptotic and chaperoning properties, helps cells survive these adverse situations. In colon cancers, HSP110 is abnormally abundant. We have recently shown that colorectal cancer patients with microsatellite instability (MSI) had an improved response to chemotherapy because they harbor an HSP110-inactivating mutation (HSP110DE9). In this work, we used patient biopsies, human colorectal cancer cells grown in vitro and in vivo (xenografts), and intestinal crypts to demonstrate that HSP110 is also involved in colon cancer growth. We showed that HSP110 induces colon cancer cell proliferation and that this effect is associated with STAT3 activation, specifically an increase in STAT3 phosphorylation, nuclear translocation and transcription factor activity. STAT3 inhibition blocks the proliferative effect of HSP110. From a molecular standpoint, we demonstrated that HSP110 directly binds to STAT3, thereby facilitating its phosphorylation by JAK2. Finally, we showed a correlation between HSP110 expression and STAT3 phosphorylation in colon cancer patient samples. Thus, the expression of HSP110 in colon cancer contributes to STAT3-dependent tumor growth and the frequent inactivating mutation of this chaperone is probably an important event underlying the improved prognosis in colon cancer displaying MSI.	[Berthenet, K.; Marcion, G.; Boudesco, C.; Causse, S.; Goloudina, A. R.; Hammann, A.; Demidov, O. N.; Seigneuric, R.; Jego, G.; Garrido, C.] Univ Bourgogne Franche Comte, INSERM, UMR866, Fac Sci Sante, 7 Blvd Jeanne dArc, F-21079 Dijon, France; [Berthenet, K.; Marcion, G.; Boudesco, C.; Causse, S.; Goloudina, A. R.; Hammann, A.; Demidov, O. N.; Seigneuric, R.; Jego, G.; Garrido, C.] Equipe Labellisee Ligue Natl Canc, INSERM, LNC UMR866, Dijon, France; [Bokhari, A'dem; Lagrange, A.; Svrcek, M.; Duval, A.; Collura, A.] Equipe Labellisee Ligue Natl Canc, INSERM, UMR 938, Dijon, France; [Bokhari, A'dem; Lagrange, A.; Svrcek, M.; Duval, A.; Collura, A.] Univ Pierre & Marie Curie Paris 6, Paris, France; [De Thonel, A.] CNRS, Epigenet & Cell Fate UMR7216, Paris, France; [Dumont, S.] Hop St Antoine, AP HP, Serv Anat Pathol, Paris, France; [Biard, D. S.] Ctr Etude Atom, Paris, France; [Garrido, C.] CGFL, Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Jego, G; Garrido, C (corresponding author), Univ Bourgogne Franche Comte, INSERM, UMR866, Fac Sci Sante, 7 Blvd Jeanne dArc, F-21079 Dijon, France.	gaetan.jego@u-bourgogne.fr; cgarrido@u-bourgogne.fr	Garrido, carmen/G-1633-2018; Garrido, Carolina/GWM-5557-2022; Causse, Sebastien Zwe/AAZ-7365-2021; Goloudina, Anastasia/T-4989-2019; jego, gaetan/N-7226-2018; Demidov, Oleg/U-2050-2017; Demidov, Oleg/AAC-4462-2021	Garrido, carmen/0000-0003-1368-1493; jego, gaetan/0000-0003-0376-9299; Demidov, Oleg/0000-0003-4323-7174; Demidov, Oleg/0000-0003-4323-7174; Causse, Sebastien/0000-0003-3246-3491; Berthenet, Kevin/0000-0001-7345-4837; BIARD, Denis Serge Francois/0000-0001-9697-4392; de Thonel, Aurelie/0000-0003-0405-0745; Marcion, Guillaume/0000-0002-3634-6316	Institut National du Cancer, Agence Nationale de la Recherche, Ligue Nationale Contre le Cancer; Association pour la Recherche sur le Cancer (ARC); Conseil Regional de Bourgogne; program 'Investissements d'Avenir' [ANR-11-LABX-0021-01-LipSTIC LabEx]; FEDER; La Ligue Nationale Contre le Cancer; La Foundation pour la Recherche Medicale	Institut National du Cancer, Agence Nationale de la Recherche, Ligue Nationale Contre le Cancer(French National Research Agency (ANR)); Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Conseil Regional de Bourgogne(Region Bourgogne-Franche-Comte); program 'Investissements d'Avenir'(French National Research Agency (ANR)); FEDER(European Commission); La Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); La Foundation pour la Recherche Medicale	This work was supported by grants from the Institut National du Cancer, Agence Nationale de la Recherche, Ligue Nationale Contre le Cancer ('Labeled teams' to CG and AD), the Association pour la Recherche sur le Cancer (ARC), the Conseil Regional de Bourgogne, the program 'Investissements d'Avenir' ANR-11-LABX-0021-01-LipSTIC LabEx. We thank the FEDER for their support. KB and SC have a doctoral fellowship from La Ligue Nationale Contre le Cancer and KB from La Foundation pour la Recherche Medicale. We thank Prof. Dr Ibrahim M. Adham, Institut fur Humangenetik, University of Gottingen for kindly providing the HSP110 KO mice and P Bastable (CHU, Dijon) for the English correction of the manuscript.	Berthenet K, ONCOIMMUNOL IN PRESS; Biard DSF, 2005, MOL CANCER RES, V3, P519, DOI 10.1158/1541-7786.MCR-05-0044; Boissiere-Michot F, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.29256; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Colgan SP, 2003, J CLIN INVEST, V112, P745, DOI 10.1172/JC1200317241; Collura A, 2014, GASTROENTEROLOGY, V146, P401, DOI 10.1053/j.gastro.2013.10.054; Dorard C, 2011, NAT MED, V17, P1283, DOI 10.1038/nm.2457; Duval A, 2011, ONCOTARGET, V2, P826, DOI 10.18632/oncotarget.353; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; Jego G, 2014, LEUKEMIA, V28, P1676, DOI 10.1038/leu.2014.63; Jego G, 2013, CANCER LETT, V332, P275, DOI 10.1016/j.canlet.2010.10.014; Lanneau D, 2008, J CELL MOL MED, V12, P743, DOI 10.1111/j.1582-4934.2008.00273.x; Mattoo RUH, 2013, J BIOL CHEM, V288, P21399, DOI 10.1074/jbc.M113.479253; Olszak T, 2014, NATURE, V509, P497, DOI 10.1038/nature13150; Prinsloo E, 2012, IUBMB LIFE, V64, P266, DOI 10.1002/iub.607; Saibil H, 2013, NAT REV MOL CELL BIO, V14, P630, DOI 10.1038/nrm3658; Sato N, 2003, BIOCHEM BIOPH RES CO, V300, P847, DOI 10.1016/S0006-291X(02)02941-8; Shaner L, 2007, CELL STRESS CHAPERON, V12, P1, DOI 10.1379/CSC-245R.1; Slaby O, 2009, ONCOL REP, V21, P1235, DOI 10.3892/or_00000346; Waldner MJ, 2012, INT J BIOL SCI, V8, P1248, DOI 10.7150/ijbs.4614; Yamagishi N, 2009, FEBS J, V276, P5870, DOI 10.1111/j.1742-4658.2009.07311.x; Yu N, 2015, MOL CELL BIOL, V35, P1390, DOI 10.1128/MCB.01307-14; Zappasodi R, 2015, BLOOD, V125, P1768, DOI 10.1182/blood-2014-07-590034; Zappasodi R, 2011, BLOOD, V118, P4421, DOI 10.1182/blood-2011-06-364570	25	44	45	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2328	2336		10.1038/onc.2016.403	http://dx.doi.org/10.1038/onc.2016.403			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27819670				2022-12-17	WOS:000399782700013
J	Kang, MH; Jeong, KJ; Kim, WY; Lee, HJ; Gong, G; Suh, N; Gyorffy, B; Kim, S; Jeong, SY; Mills, GB; Park, YY				Kang, M-H; Jeong, K. J.; Kim, W. Y.; Lee, H. J.; Gong, G.; Suh, N.; Gyorffy, B.; Kim, S.; Jeong, S-Y; Mills, G. B.; Park, Y-Y			Musashi RNA- binding protein 2 regulates estrogen receptor 1 function in breast cancer	ONCOGENE			English	Article							HUR; ALPHA; EXPRESSION; STABILITY; SUBSETS; REVEALS	Musashi RNA-binding protein 2 (MSI2) has important roles in human cancer. However, the regulatory mechanisms by which MSI2 alters breast cancer pathophysiology have not been clearly identified. Here we demonstrate that MSI2 directly regulates estrogen receptor 1 (ESR1), which is a well-known therapeutic target and has been shown to reflect clinical outcomes in breast cancer. Based on gene expression data analysis, we found that MSI2 expression was highly enriched in estrogen receptor (ER)-positive breast cancer and that MSI2 expression was significantly correlated with ESR1 expression, including expression of ESR1 downstream target genes. In addition, MSI2 levels were associated with clinical outcomes. MSI2 influenced breast cancer cell growth by altering ESR1 function. MSI2 alters ESR1 by binding specific sites in ESR1 RNA and by increasing ESR1 protein stability. Taken together, our findings identified a novel regulatory mechanism of MSI2 as an upstream regulator of ESR1 and revealed the clinical relevance of the RNA-binding protein MSI2 in breast cancer.	[Kang, M-H; Park, Y-Y] Ulsan Coll Med, Dep Convergence Med, Seoul, South Korea; [Jeong, K. J.; Mills, G. B.] MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77001 USA; [Kim, W. Y.] Korea Univ, Dept Surg, Seoul, South Korea; [Lee, H. J.; Gong, G.] ASAN Med Ctr, Dept Pathol, Seoul, South Korea; [Suh, N.] Chun Hyang Univ, Coll Med Sci, Dept Med Engn, Asan, South Korea; [Gyorffy, B.] Semmelweis Univ, 2 Dept Pediat, MTA TTK lendulet Canc biomarker Res Group, Budapest, Hungary; [Kim, S.] Anging Res Inst, Korea Res Inst Biosci & Biotechnol, Dacjeon, Hungary; [Jeong, S-Y; Park, Y-Y] ASAN Inst Life Sci, ASAN Med Ctr, Seoul, South Korea; [Park, Y-Y] Univ Ulsan Coll Med, Dept Convergence Med, 88 Olympic, Seoul 05505, South Korea	University of Ulsan; University of Texas System; UTMD Anderson Cancer Center; Korea University; University of Ulsan; Asan Medical Center; Semmelweis University; University of Ulsan	Park, YY (corresponding author), Ulsan Coll Med, Dep Convergence Med, Seoul, South Korea.	yypark@amc.seoul.kr	Jeong, Kangjin/HGT-9268-2022; Gyorffy, Balazs/AAA-9135-2021	Gyorffy, Balazs/0000-0002-5772-3766; Mills, Gordon/0000-0002-0144-9614	Ministry of Education [NRF-2014R1A1A2053529, NRF-2013R1A1A2064367]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea [HI15C0972]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Ministry of Education; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Ministry of Education (NRF-2014R1A1A2053529 to Y-YP; NRF-2013R1A1A2064367 to M-HK) and by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (HI15C0972 to Y-YP).	Anji A, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6010004; Bennett CG, 2016, NUCLEIC ACIDS RES, V44, P3788, DOI 10.1093/nar/gkw207; Calaluce R, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-126; Carroll JS, 2006, MOL ENDOCRINOL, V20, P1707, DOI 10.1210/me.2005-0334; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Gerstberger S, 2014, NAT REV GENET, V15, P829, DOI 10.1038/nrg3813; Heinonen M, 2007, CLIN CANCER RES, V13, P6959, DOI 10.1158/1078-0432.CCR-07-1432; Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207; Katz Y, 2014, ELIFE, V3, DOI 10.7554/eLife.03915; Lee HJ, 2014, ANN SURG ONCOL, V21, P1561, DOI 10.1245/s10434-013-3456-x; Licata LA, 2010, BREAST CANCER RES TR, V122, P55, DOI 10.1007/s10549-009-0517-8; Morrow PKH, 2009, ANNU REV MED, V60, P153, DOI 10.1146/annurev.med.60.061107.145152; Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755; Okano H, 2002, J CELL SCI, V115, P1355; Park YY, 2012, CARCINOGENESIS, V33, P1843, DOI 10.1093/carcin/bgs167; Park YY, 2012, EMBO MOL MED, V4, P52, DOI 10.1002/emmm.201100187; Wang MH, 2015, AM J CANCER RES, V5, P1089; Wang S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7517; Wolff AC, 2014, ARCH PATHOL LAB MED, V138, P241, DOI 10.5858/arpa.2013-0953-SA; Woo HH, 2009, ONCOGENE, V28, P1176, DOI 10.1038/onc.2008.469; Wurth L, 2015, BBA-GENE REGUL MECH, V1849, P881, DOI 10.1016/j.bbagrm.2014.10.001; Zhao ZB, 2015, CHEM BIOL, V22, P1608, DOI 10.1016/j.chembiol.2015.10.011	24	44	45	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1745	1752		10.1038/onc.2016.327	http://dx.doi.org/10.1038/onc.2016.327			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27593929				2022-12-17	WOS:000397460600013
J	Tominaga, K; Shimamura, T; Kimura, N; Murayama, T; Matsubara, D; Kanauchi, H; Niida, A; Shimizu, S; Nishioka, K; Tsuji, EI; Yano, M; Sugano, S; Shimono, Y; Ishii, H; Saya, H; Mori, M; Akashi, K; Tada, KI; Ogawa, T; Tojo, A; Miyano, S; Gotoh, N				Tominaga, K.; Shimamura, T.; Kimura, N.; Murayama, T.; Matsubara, D.; Kanauchi, H.; Niida, A.; Shimizu, S.; Nishioka, K.; Tsuji, E-I; Yano, M.; Sugano, S.; Shimono, Y.; Ishii, H.; Saya, H.; Mori, M.; Akashi, K.; Tada, K-I; Ogawa, T.; Tojo, A.; Miyano, S.; Gotoh, N.			Addiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells	ONCOGENE			English	Article							NF-KAPPA-B; SIGNALING PATHWAYS; HUMAN MAMMARY; ID PROTEINS; EXPRESSION; INSULIN; INFLAMMATION; POPULATIONS; METASTASIS; REGULATORS	The transcription factor nuclear factor-kappa B (NF-kappa B) has important roles for tumorigenesis, but how it regulates cancer stem cells (CSCs) remains largely unclear. We identified insulin-like growth factor 2 (IGF2) is a key target of NF-kappa B activated by HER2/HER3 signaling to form tumor spheres in breast cancer cells. The IGF2 receptor, IGF1 R, was expressed at high levels in CSC-enriched populations in primary breast cancer cells. Moreover, IGF2-PI3K (IGF2-phosphatidyl inositol 3 kinase) signaling induced expression of a stemness transcription factor, inhibitor of DNA-binding 1 (ID1), and IGF2 itself. ID1 knockdown greatly reduced IGF2 expression, and tumor sphere formation. Finally, treatment with anti-IGF1/2 antibodies blocked tumorigenesis derived from the IGF1R(high) CSC-enriched population in a patient-derived xenograft model. Thus, NF-kappa B may trigger IGF2-ID1-IGF2-positive feedback circuits that allow cancer stem-like cells to appear. Then, they may become addicted to the circuits. As the circuits are the Achilles' heels of CSCs, it will be critical to break them for eradication of CSCs.	[Tominaga, K.; Kimura, N.; Murayama, T.; Tojo, A.; Gotoh, N.] Univ Tokyo, Inst Med Sci, Div Mol Therapy, Minato Ku, 4-6-1 Shirokanedai, Tokyo, Japan; [Tominaga, K.] Japan Soc Promot Sci, Tokyo, Japan; [Shimamura, T.; Niida, A.; Miyano, S.] Univ Tokyo, Inst Med Sci, Lab DNA informat Anal, Minato Ku, Tokyo, Japan; [Murayama, T.; Gotoh, N.] Kanazawa Univ, Canc Res Inst, Div Canc Cell Biol, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan; [Murayama, T.; Sugano, S.] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Lab Funct Genom,Minato Ku, Tokyo, Japan; [Matsubara, D.] Univ Tokyo, Inst Med Sci, Div Mol Pathol, Minato Ku, Tokyo, Japan; [Kanauchi, H.] Showa Gen Hosp, Dept Breast & Endocrine Surg, Kodaira, Tokyo, Japan; [Shimizu, S.] Showa Gen Hosp, Dept Pathol Diag, Kodaira, Tokyo, Japan; [Nishioka, K.; Tsuji, E-I; Tada, K-I; Ogawa, T.] Univ Tokyo, Grad Sch Med, Dept Breast & Endocrine Surg, Bunkyo Ku, Tokyo, Japan; [Yano, M.] Minami Machida Hosp, Dept Surg, Machida, Tokyo, Japan; [Shimono, Y.] Kobe Univ, Grad Sch Med, Div Mol & Cellular Biol, Kobe, Hyogo, Japan; [Ishii, H.] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Suita, Osaka, Japan; [Saya, H.] Keio Univ, Grad Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, Tokyo, Japan; [Mori, M.] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Osaka, Japan; [Akashi, K.] Kyushu Univ, Grad Sch Med, Dept Med & Biosyst Sci, Fukuoka, Japan	University of Tokyo; Japan Society for the Promotion of Science; University of Tokyo; Kanazawa University; University of Tokyo; University of Tokyo; University of Tokyo; Kobe University; Osaka University; Keio University; Osaka University; Kyushu University	Gotoh, N (corresponding author), Univ Tokyo, Inst Med Sci, Div Mol Therapy, Minato Ku, 4-6-1 Shirokanedai, Tokyo, Japan.; Gotoh, N (corresponding author), Kanazawa Univ, Canc Res Inst, Div Canc Cell Biol, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan.	ngotoh@ims.u-tokyo.ac.jp	Ishii, Hideshi/AAV-5317-2020; GOTOH, Noriko/D-8430-2015; Saya, Hideyuki/J-4325-2013	Shimono, Yohei/0000-0002-6256-4704; Shimamura, Teppei/0000-0003-2994-872X; Saya, Hideyuki/0000-0001-6610-1902; Gotoh, Noriko/0000-0003-3733-260X; Murayama, Takahiko/0000-0003-0764-8646; Miyano, Satoru/0000-0002-1753-6616; Tominaga, Kana/0000-0001-5136-5091	MEXT [22130009]; JSPS [15H04294]; Ministry of Health, Labor and Welfare of Japan for the Third term Comprehensive 10-year Strategy for Cancer Control; JSPS; Grants-in-Aid for Scientific Research [15K14381] Funding Source: KAKEN	MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Health, Labor and Welfare of Japan for the Third term Comprehensive 10-year Strategy for Cancer Control(Ministry of Health, Labour and Welfare, Japan); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank H Nakauchi, Y Ishii and A Fujita for their help with flow cytometry. We are grateful to A Umezawa for his kind gift of DHMEQ. We are grateful to S Akinaga and N Shiraishi in Kyowa Hakko Kirin Co. Ltd for their kind gift of KM1468. This work was supported by a Grant-in-Aid for Scientific Research on Innovative Areas from MEXT (22130009), a Grant-in-Aid for Scientific Research (B) from JSPS (15H04294) and a research grant from the Ministry of Health, Labor and Welfare of Japan for the Third term Comprehensive 10-year Strategy for Cancer Control (to NG). This work was supported by Grant-in-Aid for JSPS Fellows (to KT).	Ablett MP, 2012, EUR J CANCER, V48, P2104, DOI 10.1016/j.ejca.2012.03.019; AJCC, 2010, CANC STAGING MANUAL; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023; Badve S, 2012, LANCET ONCOL, V13, pE43, DOI 10.1016/S1470-2045(11)70191-7; Bair E, 2006, J AM STAT ASSOC, V101, P119, DOI 10.1198/016214505000000628; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gombos A, 2012, INVEST NEW DRUG, V30, P2433, DOI 10.1007/s10637-012-9811-0; Gotoh N, 2011, CANC STEM CELLS THEO, P261; Goya M, 2004, CANCER RES, V64, P6252, DOI 10.1158/0008-5472.CAN-04-0919; Heldin CH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-97; Hinohara K, 2012, P NATL ACAD SCI USA, V109, P6584, DOI 10.1073/pnas.1113271109; Hinohara K, 2010, CURR OPIN PHARMACOL, V10, P650, DOI 10.1016/j.coph.2010.08.003; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Lasorella A, 2014, NAT REV CANCER, V14, P77, DOI 10.1038/nrc3638; Lewitzky M, 2007, CURR OPIN BIOTECH, V18, P467, DOI 10.1016/j.copbio.2007.09.007; Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239; Miyamoto S, 2005, CLIN CANCER RES, V11, P3494, DOI 10.1158/1078-0432.CCR-04-1701; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Mukherjee D, 2013, AM J CANCER RES, V3, P46; Murayama T, 2016, CANCER RES, V76, P974, DOI 10.1158/0008-5472.CAN-15-2135; Murohashi M, 2010, BRIT J CANCER, V102, P206, DOI 10.1038/sj.bjc.6605468; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; O'Brien CA, 2012, CANCER CELL, V21, P777, DOI 10.1016/j.ccr.2012.04.036; Osuka S, 2013, STEM CELLS, V31, P627, DOI 10.1002/stem.1328; Ouyang WJ, 2011, ANNU REV IMMUNOL, V29, P71, DOI 10.1146/annurev-immunol-031210-101312; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Perk J, 2006, CANCER RES, V66, P10870, DOI 10.1158/0008-5472.CAN-06-2643; Perry SS, 2007, BLOOD, V110, P2351, DOI 10.1182/blood-2007-01-069914; Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sansone P, 2011, CURR OPIN GENET DEV, V21, P80, DOI 10.1016/j.gde.2010.11.001; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Sottoriva A, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001132; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Wee ZN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9746; Yamamoto M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3299; Yamauchi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043923; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309; Yi TF, 2014, P NATL ACAD SCI USA, V111, pE2182, DOI 10.1073/pnas.1404943111; Zardavas D, 2013, NAT REV CLIN ONCOL, V10, P191, DOI 10.1038/nrclinonc.2013.29	51	44	45	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1276	1286		10.1038/onc.2016.293	http://dx.doi.org/10.1038/onc.2016.293			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27546618	Green Published, hybrid			2022-12-17	WOS:000395861300011
J	Kesarwani, AK; Ramirez, O; Gupta, AK; Yang, X; Murthy, T; Minella, AC; Pillai, MM				Kesarwani, A. K.; Ramirez, O.; Gupta, A. K.; Yang, X.; Murthy, T.; Minella, A. C.; Pillai, M. M.			Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3 ' splice sites within RNA secondary structures	ONCOGENE			English	Article							EXPRESSION ANALYSIS; MUTATIONS; SELECTION; GENES; MYELODYSPLASIA; MITOFERRIN; UPSTREAM; BINDING; STEP	Recurrent mutations in core splicing factors have been reported in several clonal disorders, including cancers. Mutations in SF3B1, a component of the U2 splicing complex, are the most common. SF3B1 mutations are associated with aberrant pre-mRNA splicing using cryptic 3' splice sites (3' SSs), but the mechanism of their selection is not clear. To understand how cryptic 3' SSs are selected, we performed comprehensive analysis of transcriptome-wide changes to splicing and gene expression associated with SF3B1 mutations in patient samples as well as an experimental model of inducible expression. Hundreds of cryptic 3' SS were detectable across the genome in cells expressing mutant SF3B1. These 3' SS are typically sequestered within RNA secondary structures and poorly accessible compared with their corresponding canonical 3' SS. We hypothesized that these cryptic 3' SS are inaccessible during normal splicing catalysis and that this constraint is overcome in spliceosomes containing mutant SF3B1. This model of secondary structure-dependent selection of cryptic 3' SS was found across multiple clonal processes associated with SF3B1 mutations (myelodysplastic syndrome and chronic lymphocytic leukemia). We validated our model predictions in mini-gene splicing assays. Additionally, we found deregulated expression of proteins with relevant functions in splicing factor-related diseases both in association with aberrant splicing and without corresponding splicing changes. Our results show that SF3B1 mutations are associated with a distinct splicing program shared across multiple clonal processes and define a biochemical mechanism for altered 3' SS choice.	[Kesarwani, A. K.; Ramirez, O.; Gupta, A. K.; Yang, X.; Pillai, M. M.] Yale Canc Ctr, Sect Hematol, 300 George St, New Haven, CT 06511 USA; [Kesarwani, A. K.; Ramirez, O.; Gupta, A. K.; Yang, X.; Pillai, M. M.] Yale Univ, Sch Med, 300 George St, New Haven, CT 06511 USA; [Murthy, T.] Northwestern Univ, Feinberg Sch Med, Driskill Grad Program, Chicago, IL USA; [Minella, A. C.] BloodCtr Wisconsin, Blood Res Inst, Milwaukee, WI USA	Yale University; Yale University; Northwestern University; Feinberg School of Medicine; Versiti Blood Center of Wisconsin	Pillai, MM (corresponding author), Yale Canc Ctr, Sect Hematol, 300 George St, New Haven, CT 06511 USA.; Pillai, MM (corresponding author), Yale Univ, Sch Med, 300 George St, New Haven, CT 06511 USA.	Manoj.Pillai@Yale.edu	Gupta, Anjali/HCH-5986-2022	Minella, Alex/0000-0001-6693-3362	National Institutes of Health [R01 HL104070, R01 HL098608]; NATIONAL CANCER INSTITUTE [P30CA016359] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL098608, R01HL104070] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Work was funded in part by the National Institutes of Health (R01 HL104070 to MMP and R01 HL098608 to ACM). We thank Barry Paw (Boston Children's Hospital, Boston, MA, USA) for anti-Mitoferrin antibody, Thomas A Cooper (Baylor College of Medicine, Houston, TX, USA) for the RG6 plasmid and Karla Neugebauer (Yale University) for helpful suggestions. We also thank The Yale Center for Genome Analysis (YCGA) for high-throughput sequencing and the Yale University Biomedical High Performance Computing Center for use of compute clusters to run bioinformatics analysis.	Adiconis X, 2013, NAT METHODS, V10, P623, DOI 10.1038/nmeth.2483; Alsafadi S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10615; Balakrishnan I, 2014, STEM CELLS, V32, P662, DOI 10.1002/stem.1531; Bejar R, 2014, BLOOD, V124, P2793, DOI 10.1182/blood-2014-04-522136; Bevilacqua PC, 2008, ANNU REV PHYS CHEM, V59, P79, DOI 10.1146/annurev.physchem.59.032607.093743; Buratti E, 2004, MOL CELL BIOL, V24, P10505, DOI 10.1128/MCB.24.24.10505-10514.2004; Cameron JM, 2011, AM J HUM GENET, V89, P486, DOI 10.1016/j.ajhg.2011.08.011; Chua K, 2001, MOL CELL BIOL, V21, P1509, DOI 10.1128/MCB.21.5.1509-1514.2001; Cordin O, 2013, RNA BIOL, V10, P83, DOI 10.4161/rna.22547; Corvelo A, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001016; Darman RB, 2015, CELL REP, V13, P1033, DOI 10.1016/j.celrep.2015.09.053; DeBoever C, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004105; Dolatshad H, 2015, LEUKEMIA, V29, P1092, DOI [10.1038/leu.2014.331, 10.1038/leu.2015.178]; Floor SN, 2016, ELIFE, V5, DOI 10.7554/eLife.10921; Gerstein MB, 2014, NATURE, V512, P445, DOI 10.1038/nature13424; Gozani O, 1996, GENE DEV, V10, P233, DOI 10.1101/gad.10.2.233; Graubert TA, 2012, NAT GENET, V44, P53, DOI 10.1038/ng.1031; Greenberg Peter L, 2002, Hematology Am Soc Hematol Educ Program, P136; Gruber AR, 2008, NUCLEIC ACIDS RES, V36, pW70, DOI 10.1093/nar/gkn188; Harbour JW, 2013, NAT GENET, V45, P133, DOI 10.1038/ng.2523; Horowitz DS, 2012, WIRES RNA, V3, P331, DOI 10.1002/wrna.112; Ilagan JO, 2015, GENOME RES, V25, P14, DOI 10.1101/gr.181016.114; Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5; Kaganovich D, 2008, NATURE, V454, P1088, DOI 10.1038/nature07195; Kfir N, 2015, CELL REP, V11, P618, DOI 10.1016/j.celrep.2015.03.048; Kim E, 2015, CANCER CELL, V27, P617, DOI 10.1016/j.ccell.2015.04.006; Kontos CK, 2012, GENE, V505, P153, DOI 10.1016/j.gene.2012.04.084; Lai Y, 2006, HUM GENE THER, V17, P1036, DOI 10.1089/hum.2006.17.1036; Mahen EM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000307; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Mercer TR, 2015, GENOME RES, V25, P290, DOI 10.1101/gr.182899.114; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Meyer M, 2011, MOL CELL, V43, P1033, DOI 10.1016/j.molcel.2011.07.030; Min IM, 2008, CELL STEM CELL, V2, P380, DOI 10.1016/j.stem.2008.01.015; Moon YS, 2002, MOL CELL BIOL, V22, P5585, DOI 10.1128/MCB.22.15.5585-5592.2002; Mupo A, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.140.140; Obeng EA, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.828.828; Okeyo-Owuor T, 2015, LEUKEMIA, V29, P909, DOI 10.1038/leu.2014.303; Orengo JP, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl967; Papaemmanuil E, 2011, NEW ENGL J MED, V365, P1384, DOI 10.1056/NEJMoa1103283; Paradkar PN, 2009, MOL CELL BIOL, V29, P1007, DOI 10.1128/MCB.01685-08; Plass M, 2014, METHODS MOL BIOL, V1126, P341, DOI 10.1007/978-1-62703-980-2_25; Plass M, 2012, RNA, V18, P1103, DOI 10.1261/rna.030767.111; Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109; Polprasert C, 2015, CANCER CELL, V27, P658, DOI 10.1016/j.ccell.2015.03.017; Popp MWL, 2014, MOL CELLS, V37, P1, DOI 10.14348/molcells.2014.2193; Sakajiri S, 2005, LEUKEMIA, V19, P1404, DOI 10.1038/sj.leu.2403832; Shaw GC, 2006, NATURE, V440, P96, DOI 10.1038/nature04512; SMITH CWJ, 1993, MOL CELL BIOL, V13, P4939, DOI 10.1128/MCB.13.8.4939; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Visconte V, 2012, BLOOD, V120, P3173, DOI 10.1182/blood-2012-05-430876; Vorechovsky I, 2006, NUCLEIC ACIDS RES, V34, P4630, DOI 10.1093/nar/gkl535; Wang CY, 1998, GENE DEV, V12, P1409, DOI 10.1101/gad.12.10.1409; Wang LL, 2011, NEW ENGL J MED, V365, P2497, DOI 10.1056/NEJMoa1109016; Warf MB, 2010, TRENDS BIOCHEM SCI, V35, P169, DOI 10.1016/j.tibs.2009.10.004; Yoshida K, 2014, WIRES RNA, V5, P445, DOI 10.1002/wrna.1222; Yoshida K, 2011, NATURE, V478, P64, DOI 10.1038/nature10496; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	58	44	45	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1123	1133		10.1038/onc.2016.279	http://dx.doi.org/10.1038/onc.2016.279			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27524419	Green Accepted			2022-12-17	WOS:000395371500010
J	Qu, X; Sandmann, T; Frierson, H; Fu, L; Fuentes, E; Walter, K; Okrah, K; Rumpel, C; Moskaluk, C; Lu, S; Wang, Y; Bourgon, R; Penuel, E; Pirzkall, A; Amler, L; Lackner, MR; Tabernero, J; Hampton, GM; Kabbarah, O				Qu, X.; Sandmann, T.; Frierson, H., Jr.; Fu, L.; Fuentes, E.; Walter, K.; Okrah, K.; Rumpel, C.; Moskaluk, C.; Lu, S.; Wang, Y.; Bourgon, R.; Penuel, E.; Pirzkall, A.; Amler, L.; Lackner, M. R.; Tabernero, J.; Hampton, G. M.; Kabbarah, O.			Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter	ONCOGENE			English	Article							DNA METHYLATION; MUTATION STATUS; CETUXIMAB; EPIREGULIN; EXPRESSION; GROWTH; AMPHIREGULIN; KRAS; FLUOROURACIL; BEVACIZUMAB	Key molecular drivers that underlie transformation of colonic epithelium into colorectal adenocarcinoma (CRC) are well described. However, the mechanisms through which clinically targeted pathways are activated during CRC progression have yet to be elucidated. Here, we used an integrative genomics approach to examine CRC progression. We used laser capture microdissection to isolate colonic crypt cells, differentiated surface epithelium, adenomas, carcinomas and metastases, and used gene expression profiling to identify pathways that were differentially expressed between the different cell types. We identified a number of potentially important transcriptional changes in developmental and oncogenic pathways, and noted a marked upregulation of EREG in primary and metastatic cancer cells. We confirmed this pattern of gene expression by in situ hybridization and observed staining consistent with autocrine expression in the tumor cells. Upregulation of EREG during the adenoma-carcinoma transition was associated with demethylation of two key sites within its promoter, and this was accompanied by an increase in the levels of epidermal growth factor receptor (EGFR) phosphorylation, as assessed by reverse-phase protein analysis. In CRC cell lines, we demonstrated that EREG demethylation led to its transcriptional upregulation, higher levels of EGFR phosphorylation, and sensitization to EGFR inhibitors. Low levels of EREG methylation in patients who received cetuximab as part of a phase II study were associated with high expression of the ligand and a favorable response to therapy. Conversely, high levels of promoter methylation and low levels of EREG expression were observed in tumors that progressed after treatment. We also noted an inverse correlation between EREG methylation and expression levels in several other cancers, including those of the head and neck, lung and bladder. Therefore, we propose that upregulation of EREG expression through promoter demethylation might be an important means of activating the EGFR pathway during the genesis of CRC and potentially other cancers.	[Qu, X.; Fu, L.; Walter, K.; Lu, S.; Wang, Y.; Penuel, E.; Amler, L.; Lackner, M. R.; Hampton, G. M.; Kabbarah, O.] Genentech Inc, Oncol Biomarker Dev, 1 DNA Way, San Francisco, CA 94080 USA; [Sandmann, T.; Bourgon, R.] Genentech Inc, Bioinformat & Computat Biol, San Francisco, CA 94080 USA; [Frierson, H., Jr.; Rumpel, C.; Moskaluk, C.] Univ Virginia Hlth Syst, Dept Pathol, Charlottesville, VA USA; [Fuentes, E.] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA; [Okrah, K.] Genentech Inc, Dept Biostat, San Francisco, CA 94080 USA; [Pirzkall, A.] Genentech Inc, Dept Clin Sci, San Francisco, CA 94080 USA; [Tabernero, J.] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain	Roche Holding; Genentech; Roche Holding; Genentech; University of Virginia; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO)	Hampton, GM; Kabbarah, O (corresponding author), Genentech Inc, Oncol Biomarker Dev, 1 DNA Way, San Francisco, CA 94080 USA.	garreth@gene.com; kabbarao@gene.com	Miquel, Josep Maria/AAG-3508-2019; Tabernero, Josep/AAG-5026-2019	Tabernero, Josep/0000-0002-2495-8139; Wang, Yulei/0000-0002-9057-9786; Sandmann, Thomas/0000-0002-6601-8890; Bourgon, Richard/0000-0002-5890-4374				Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Auf G, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-597; Barbara PD, 2003, CELL MOL LIFE SCI, V60, P1322, DOI 10.1007/s00018-003-2289-3; Bourgon R, 2014, CLIN CANCER RES, V20, P2080, DOI 10.1158/1078-0432.CCR-13-3114; Busser B, 2011, BBA-REV CANCER, V1816, P119, DOI 10.1016/j.bbcan.2011.05.003; de Lau W, 2007, FRONT BIOSCI-LANDMRK, V12, P471, DOI 10.2741/2076; DeAngelo DJ, 2014, LEUKEMIA RES, V38, P430, DOI 10.1016/j.leukres.2013.10.026; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Grady WM, 2002, ANNU REV GENOM HUM G, V3, P101, DOI 10.1146/annurev.genom.3.022502.103043; Gryfe R, 1997, CURR PROB CANCER, V21, P238, DOI 10.1016/S0147-0272(97)80003-7; Hansen AR, 2013, J CLIN ONCOL, V31, P1381, DOI 10.1200/JCO.2012.47.9220; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Jonker DJ, 2014, BRIT J CANCER, V110, P648, DOI 10.1038/bjc.2013.753; Jover R, 2011, GASTROENTEROLOGY, V140, P1174, DOI 10.1053/j.gastro.2010.12.035; Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437; Kohsaka S, 2014, NEURO-ONCOLOGY, V16, P960, DOI 10.1093/neuonc/not315; Komurasaki T, 2002, GROWTH FACTORS, V20, P61, DOI 10.1080/08977190290024192; Lainey E, 2013, ONCOGENE, V32, P4331, DOI 10.1038/onc.2012.469; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; Luo YX, 2014, GASTROENTEROLOGY, V147, P418, DOI 10.1053/j.gastro.2014.04.039; Makky K, 2007, DEV BIOL, V303, P501, DOI 10.1016/j.ydbio.2006.11.030; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nathke IS, 2004, ANNU REV CELL DEV BI, V20, P337, DOI 10.1146/annurev.cellbio.20.012103.094541; Neufert C, 2013, J CLIN INVEST, V123, P1428, DOI 10.1172/JCI63748; Orre LM, 2013, ONCOGENE, V32, P5531, DOI 10.1038/onc.2013.213; Oshima G, 2012, J CANCER RES CLIN, V138, P491, DOI 10.1007/s00432-011-1127-5; Oving IM, 2002, EUR J CLIN INVEST, V32, P448, DOI 10.1046/j.1365-2362.2002.01004.x; Pasparakis M, 2012, IMMUNOL REV, V246, P346, DOI 10.1111/j.1600-065X.2012.01109.x; Peeters M, 2013, J CLIN ONCOL, V31, P759, DOI 10.1200/JCO.2012.45.1492; Pentheroudakis G, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-49; Price TJ, 2011, J CLIN ONCOL, V29, P2675, DOI 10.1200/JCO.2010.34.5520; Rebouissou S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008970; Revillion F, 2008, ANN ONCOL, V19, P73, DOI 10.1093/annonc/mdm431; Riese DJ, 2014, SEMIN CELL DEV BIOL, V28, P49, DOI 10.1016/j.semcdb.2014.03.005; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Seniski GG, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-80; Shen L, 2007, CLIN CANCER RES, V13, P6093, DOI 10.1158/1078-0432.CCR-07-1011; Skeen VR, 2012, CURR PHARM DESIGN, V18, P3874; Sun JZ, 2012, HEMATOL ONCOL, V30, P89, DOI 10.1002/hon.1002; Troiani T, 2013, CLIN CANCER RES, V19, P6751, DOI 10.1158/1078-0432.CCR-13-0423; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; van Es JH, 2005, TRENDS MOL MED, V11, P496, DOI 10.1016/j.molmed.2005.09.008; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Walter K, 2012, CLIN CANCER RES, V18, P2360, DOI 10.1158/1078-0432.CCR-11-2635-T; Walther A, 2009, NAT REV CANCER, V9, P489, DOI 10.1038/nrc2645; Watt FM, 2004, TRENDS MOL MED, V10, P577, DOI 10.1016/j.molmed.2004.10.008; Weng WH, 2016, ONCOL REP, V35, P107, DOI 10.3892/or.2015.4336; Yao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078086; Yonesaka K, 2008, CLIN CANCER RES, V14, P6963, DOI 10.1158/1078-0432.CCR-08-0957; Yun J, 2012, LAB INVEST, V92, P1033, DOI 10.1038/labinvest.2012.61; Zhang HT, 2007, J CLIN INVEST, V117, P2051, DOI 10.1172/JCI32278	56	44	44	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2016	35	50					6403	6415		10.1038/onc.2016.170	http://dx.doi.org/10.1038/onc.2016.170			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TP	27270421	Green Published, hybrid			2022-12-17	WOS:000390247600005
J	Li, Y; Bouchlaka, MN; Wolff, J; Grindle, KM; Lu, L; Qian, S; Zhong, X; Pflum, N; Jobin, P; Kahl, BS; Eickhoff, JC; Wuerzberger-Davis, SM; Miyamoto, S; Thomas, CJ; Yang, DT; Capitini, CM; Rui, L				Li, Y.; Bouchlaka, M. N.; Wolff, J.; Grindle, K. M.; Lu, L.; Qian, S.; Zhong, X.; Pflum, N.; Jobin, P.; Kahl, B. S.; Eickhoff, J. C.; Wuerzberger-Davis, S. M.; Miyamoto, S.; Thomas, C. J.; Yang, D. T.; Capitini, C. M.; Rui, L.			FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; BRUTONS TYROSINE KINASE; FACTOR-KAPPA-B; BAFF-R; IBRUTINIB; RECEPTOR; SURVIVAL; THERAPY; INHIBITION; MUTATIONS	Targeting Bruton tyrosine kinase (BTK) by ibrutinib is an effective treatment for patients with relapsed/refractory mantle cell lymphoma (MCL). However, both primary and acquired resistance to ibrutinib have developed in a significant number of these patients. A combinatory strategy targeting multiple oncogenic pathways is critical to enhance the efficacy of ibrutinib. Here, we focus on the BCL2 anti-apoptotic pathway. In a tissue microarray of 62 MCL samples, BCL2 expression positively correlated with BTK expression. Increased levels of BCL2 were shown to be due to a defect in protein degradation because of no or little expression of the E3 ubiquitin ligase FBXO10, as well as transcriptional upregulation through BTK-mediated canonical nuclear factor-kappa B activation. RNA-seq analysis confirmed that a set of anti-apoptotic genes (for example, BCL2, BCL-XL and DAD1) was downregulated by BTK short hairpin RNA. The downregulated genes also included those that are critical for B-cell growth and proliferation, such as BCL6, MYC, PIK3CA and BAFF-R. Targeting BCL2 by the specific inhibitor ABT-199 synergized with ibrutinib in inhibiting growth of both ibrutinib-sensitive and -resistant cancer cells in vitro and in vivo. These results suggest co-targeting of BTK and BCL2 as a new therapeutic strategy in MCL, especially for patients with primary resistance to ibrutinib.	[Li, Y.; Wolff, J.; Grindle, K. M.; Pflum, N.; Jobin, P.; Kahl, B. S.; Rui, L.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA; [Li, Y.; Bouchlaka, M. N.; Grindle, K. M.; Kahl, B. S.; Wuerzberger-Davis, S. M.; Miyamoto, S.; Yang, D. T.; Capitini, C. M.; Rui, L.] Univ Wisconsin, Carbone Canc Ctr, Sch Med & Publ Hlth, Madison, WI USA; [Bouchlaka, M. N.; Capitini, C. M.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA; [Lu, L.; Qian, S.; Zhong, X.] Univ Wisconsin, Wisconsin Inst Discovery, Madison, WI USA; [Lu, L.; Qian, S.; Zhong, X.] Univ Wisconsin, Genet Lab, Madison, WI USA; [Eickhoff, J. C.] Univ Wisconsin, Dept Biostat & Med Informat, Sch Med & Publ Hlth, Madison, WI USA; [Wuerzberger-Davis, S. M.; Miyamoto, S.] Univ Wisconsin, Dept Oncol, Sch Med & Publ Hlth, Madison, WI USA; [Thomas, C. J.] NIH, Div Preclin Innovat, Chem Genom Ctr, Natl Ctr Adv Translat Sci, Bldg 10, Bethesda, MD 20892 USA; [Yang, D. T.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI USA; [Kahl, B. S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS); University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL)	Yang, DT; Capitini, CM; Rui, L (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Div Hematol Oncol, Dept Med, 1111 Highland Ave, Madison, WI 53705 USA.	dtyang@wisc.edu; ccapitini@pediatrics.wisc.edu; lrui@medicine.wisc.edu	li, rui/GSD-4367-2022; rui, li/GYR-3791-2022; Capitini, Christian M/I-4288-2019	Capitini, Christian M/0000-0002-2276-6731; Thomas, Craig/0000-0001-9386-9001; Bouchlaka, Myriam/0000-0003-2865-0817	UW-Madison Start-up funds; KL2 Scholar Award [UL1TR0000427, KL2TR000428]; NIH [R01 CA187299]; MACC fund; National Institutes of Health/National Cancer Institute [K08 CA174750]; USDA National Institute of Food and Agriculture [Hatch 1002874]; UW Forward Lymphoma Fund; University of Wisconsin Carbone Cancer Center (UWCCC); NIH/NCI UW Comprehensive Cancer Center Support [P30 CA014520]; NATIONAL CANCER INSTITUTE [P30CA014520, R01CA187299, K08CA174750] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427, KL2TR000428] Funding Source: NIH RePORTER	UW-Madison Start-up funds; KL2 Scholar Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MACC fund; National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); USDA National Institute of Food and Agriculture(United States Department of Agriculture (USDA)); UW Forward Lymphoma Fund; University of Wisconsin Carbone Cancer Center (UWCCC); NIH/NCI UW Comprehensive Cancer Center Support(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank Dr Louis Staudt for providing the reagents, Dr Sameer Mathur for providing peripheral blood mononuclear cells, Dr Wei Huang for helping with analysis of immunohistochemical data, Drs Debra Bloom and Peiman Hematti for providing CD40, BAFF and BAFF receptor antibody, and Kirsti Walker for monitoring xenografted mice. This work was supported by the UW-Madison Start-up funds, KL2 Scholar Award (UL1TR0000427 and KL2TR000428), and NIH R01 CA187299 to LR, the MACC fund and the National Institutes of Health/National Cancer Institute (K08 CA174750) to CMC, the UW-Madison Start-up funds and USDA National Institute of Food and Agriculture (Hatch 1002874) to XZ, and the UW Forward Lymphoma Fund. We thank the University of Wisconsin Carbone Cancer Center (UWCCC) for the funds to complete this project. This work was also supported in part by NIH/NCI P30 CA014520- UW Comprehensive Cancer Center Support.	Abe M, 2006, LEUKEMIA, V20, P1313, DOI 10.1038/sj.leu.2404228; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Bea S, 2013, P NATL ACAD SCI USA, V110, P18250, DOI 10.1073/pnas.1314608110; Briones J, 2002, EXP HEMATOL, V30, P135, DOI 10.1016/S0301-472X(01)00774-3; Chiorazzi M, 2013, P NATL ACAD SCI USA, V110, P3943, DOI 10.1073/pnas.1217271110; Chiorazzi N, 2005, ANN NY ACAD SCI, V1062, P1, DOI 10.1196/annals.1358.002; Chiron D, 2015, ONCOTARGET, V6, P8750, DOI 10.18632/oncotarget.3275; Chiron D, 2014, CANCER DISCOV, V4, P1022, DOI 10.1158/2159-8290.CD-14-0098; Cinar M, 2013, LEUKEMIA RES, V37, P1271, DOI 10.1016/j.leukres.2013.07.028; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; de Leeuw RJ, 2004, HUM MOL GENET, V13, P1827, DOI 10.1093/hmg/ddh195; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Freedman AS, 2014, AM J HEMATOL, V89, P429, DOI 10.1002/ajh.23674; Griner LAM, 2014, P NATL ACAD SCI USA, V111, P2349, DOI 10.1073/pnas.1311846111; Hadzidimitriou A, 2011, BLOOD, V118, P3088, DOI 10.1182/blood-2011-03-343434; Hailfinger S, 2009, P NATL ACAD SCI USA, V106, P19946, DOI 10.1073/pnas.0907511106; Hendriks RW, 2014, NAT REV CANCER, V14, P219, DOI 10.1038/nrc3702; Herman SEM, 2013, LEUKEMIA, V27, P2311, DOI 10.1038/leu.2013.131; Hiddemann W, 2014, LEUKEMIA, V28, P1388, DOI 10.1038/leu.2014.91; Iqbal J, 2006, J CLIN ONCOL, V24, P961, DOI 10.1200/JCO.2005.03.4264; Jares P, 2012, J CLIN INVEST, V122, P3416, DOI 10.1172/JCI61272; Kenkre VP, 2012, CURR HEMATOL MALIG R, V7, P216, DOI 10.1007/s11899-012-0127-0; Knezevich S, 2005, LEUKEMIA, V19, P659, DOI 10.1038/sj.leu.2403661; Kuppers R, 2005, NAT REV CANCER, V5, P251, DOI 10.1038/nrc1589; Lam LT, 2008, BLOOD, V111, P3701, DOI 10.1182/blood-2007-09-111948; Lee MH, 2011, MOL CELL, V43, P180, DOI 10.1016/j.molcel.2011.06.017; Ma J, 2014, BRIT J HAEMATOL, V166, P849, DOI 10.1111/bjh.12974; Nagy B, 2003, BRIT J HAEMATOL, V120, P434, DOI 10.1046/j.1365-2141.2003.04121.x; Novak AJ, 2004, BLOOD, V104, P2247, DOI 10.1182/blood-2004-02-0762; O'Brien S, 2014, LANCET ONCOL, V15, P48, DOI 10.1016/S1470-2045(13)70513-8; Oberley MJ, 2013, HISTOPATHOLOGY, V63, P499, DOI 10.1111/his.12207; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Paterson JC, 2006, HAEMATOLOGICA, V91, P772; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Ponader S, 2012, BLOOD, V119, P1182, DOI 10.1182/blood-2011-10-386417; Rahal R, 2014, NAT MED, V20, P87, DOI 10.1038/nm.3435; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Rinaldi A, 2006, BRIT J HAEMATOL, V132, P303, DOI 10.1111/j.1365-2141.2005.05883.x; Schuetz JM, 2012, LEUKEMIA, V26, P1383, DOI 10.1038/leu.2011.378; Shinners NP, 2007, J IMMUNOL, V179, P3872, DOI 10.4049/jimmunol.179.6.3872; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Staudt LM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000109; Strasser A, 2011, EMBO J, V30, P3667, DOI 10.1038/emboj.2011.307; Sun SC, 2011, CELL RES, V21, P71, DOI 10.1038/cr.2010.177; Takahata H, 2010, J CLIN EXP HEMATOP, V50, P121, DOI 10.3960/jslrt.50.121; Tracey L, 2005, J PATHOL, V206, P123, DOI 10.1002/path.1768; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Tucker CA, 2008, MOL CANCER THER, V7, P749, DOI 10.1158/1535-7163.MCT-07-0302; Wada K, 2009, HISTOPATHOLOGY, V54, P221, DOI 10.1111/j.1365-2559.2008.03203.x; Wang ML, 2013, NEW ENGL J MED, V369, P507, DOI 10.1056/NEJMoa1306220; Yang YB, 2012, CANCER CELL, V21, P723, DOI 10.1016/j.ccr.2012.05.024; Young RM, 2013, NAT REV DRUG DISCOV, V12, P229, DOI 10.1038/nrd3937; Zhang J, 2014, BLOOD, V123, P2988, DOI 10.1182/blood-2013-07-517177; Zhao XX, 2015, BRIT J HAEMATOL, V168, P765, DOI 10.1111/bjh.13149	55	44	45	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6223	6234		10.1038/onc.2016.155	http://dx.doi.org/10.1038/onc.2016.155			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27157620	Green Accepted			2022-12-17	WOS:000388857700007
J	Paauwe, M; Heijkants, RC; Oudt, CH; van Pelt, GW; Cui, C; Theuer, CP; Hardwick, JCH; Sier, CFM; Hawinkels, LJAC				Paauwe, M.; Heijkants, R. C.; Oudt, C. H.; van Pelt, G. W.; Cui, C.; Theuer, C. P.; Hardwick, J. C. H.; Sier, C. F. M.; Hawinkels, L. J. A. C.			Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer	ONCOGENE			English	Article							TGF-BETA-RECEPTOR; MAMMARY-CARCINOMA; ENDOTHELIAL-CELLS; SOLID TUMORS; EXPRESSION; ANTIBODY; TRC105; BEVACIZUMAB; PROTEIN; NORMALIZATION	Endoglin, a transforming growth factor-beta co-receptor, is highly expressed on angiogenic endothelial cells in solid tumors. Therefore, targeting endoglin is currently being explored in clinical trials for anti-angiogenic therapy. In this project, the redundancy between endoglin and vascular endothelial growth factor (VEGF) signaling in angiogenesis and the effects of targeting both pathways on breast cancer metastasis were explored. In patient samples, increased endoglin signaling after VEGF inhibition was observed. In vitro TRC105, an endoglin-neutralizing antibody, increased VEGF signaling in endothelial cells. Moreover, combined targeting of the endoglin and VEGF pathway, with the VEGF receptor kinase inhibitor SU5416, increased antiangiogenic effects in vitro and in a zebrafish angiogenesis model. Next, in a mouse model for invasive lobular breast cancer, the effects of TRC105 and SU5416 on tumor growth and metastasis were explored. Although TRC105 and SU5416 decreased tumor vascular density, tumor volume was unaffected. Strikingly, in mice treated with TRC105, or TRC105 and SU5416 combined, a strong inhibition in the number of metastases was seen. Moreover, upon resection of the primary tumor, strong inhibition of metastatic spread by TRC105 was observed in an adjuvant setting. To confirm these data, we assessed the effects of endoglin-Fc (an endoglin ligand trap) on metastasis formation. Similar to treatment with TRC105 in the resection model, endoglin-Fc-expressing tumors showed strong inhibition of distant metastases. These results show, for the first time, that targeting endoglin, either with neutralizing antibodies or a ligand trap, strongly inhibits metastatic spread of breast cancer in vivo.	[Paauwe, M.; Heijkants, R. C.; Oudt, C. H.; Cui, C.; Hawinkels, L. J. A. C.] Leiden Univ, Med Ctr, Dept Mol Cell Biol, Leiden, Netherlands; [Paauwe, M.; Hardwick, J. C. H.; Sier, C. F. M.; Hawinkels, L. J. A. C.] Leiden Univ, Med Ctr, Dept Gastroenterol Hepatol, Leiden, Netherlands; [van Pelt, G. W.; Sier, C. F. M.] Leiden Univ, Med Ctr, Dept Surg, Leiden, Netherlands; [Theuer, C. P.] Tracon Pharmaceut, San Diego, CA USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Hawinkels, LJAC (corresponding author), Leiden Univ, Med Ctr, Dept Mol Cell Biol & Gastroenterol Hepatol, Bldg 1,C4-P,POB 9600, NL-2300 RC Leiden, Netherlands.	L.J.A.C.Hawinkels@LUMC.nl	Paauwe, Madelon/C-8244-2018; Sier, Cornelis/A-7664-2008; Hawinkels, Lukas/Q-5098-2019; Hardwick, James/J-4862-2013	Sier, Cornelis/0000-0002-4337-2758; Hawinkels, Lukas/0000-0002-2274-9325; Hardwick, James/0000-0002-9575-5099	Alpe d'huZes/Bas Mulder award [UL2011-5051]; Tracon Pharmaceuticals	Alpe d'huZes/Bas Mulder award; Tracon Pharmaceuticals	We thank Jos Jonkers (Netherlands Cancer Institute, Amsterdam) for providing the KEP1-11 mouse breast cancer cells, Midory Thorikay for generating Fc and endoglin-Fc lentiviral expression constructs, Henry Cheung and Gabri van der Pluijm for practical help in establishing the in vivo model and Peter ten Dijke, Hans van Dam and Marie-Jose Goumans (Leiden University Medical Center) for valuable discussions. This work was supported by the Alpe d'huZes/Bas Mulder award 2011 (UL2011-5051) to LJACH and MP and by a sponsored research grant from Tracon Pharmaceuticals.	Anderberg C, 2013, J EXP MED, V210, P563, DOI 10.1084/jem.20120662; Aristorena M, 2014, J CELL SCI, V127, P2723, DOI 10.1242/jcs.143644; Arjaans M, 2013, CANCER RES, V73, P3347, DOI 10.1158/0008-5472.CAN-12-3518; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Buijs JT, 2015, J PATHOL, V235, P745, DOI 10.1002/path.4488; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Charpin-Taranger C, 2003, B ACAD NAT MED PARIS, V187, P1129, DOI 10.1016/S0001-4079(19)33943-3; de Kruijf EM, 2013, ANN ONCOL, V24, P384, DOI 10.1093/annonc/mds333; Dekker TJA, 2013, BREAST CANCER RES TR, V139, P371, DOI 10.1007/s10549-013-2571-5; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; FOLKMAN J, 1966, ANN SURG, V164, P491, DOI 10.1097/00000658-196609000-00012; Fonsatti E, 2000, CLIN CANCER RES, V6, P2037; Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010; Gordon MS, 2014, CLIN CANCER RES, V20, P5918, DOI 10.1158/1078-0432.CCR-14-1143; Hawinkels L. J., 2015, CLIN CANC RES; Hawinkels LJAC, 2007, BRIT J CANCER, V97, P398, DOI 10.1038/sj.bjc.6603877; Hawinkels LJAC, 2014, ONCOGENE, V33, P97, DOI 10.1038/onc.2012.536; Hawinkels LJAC, 2008, EUR J CANCER, V44, P1904, DOI 10.1016/j.ejca.2008.06.031; Hawinkels LJAC, 2010, CANCER RES, V70, P4141, DOI 10.1158/0008-5472.CAN-09-4466; Henry LA, 2011, ONCOGENE, V30, P1046, DOI 10.1038/onc.2010.488; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Jerkic M, 2015, FASEB J, V29, P3678, DOI 10.1096/fj.14-269258; Karzai FH, 2015, BJU INT, V116, P546, DOI 10.1111/bju.12986; Khamis ZI, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/574025; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu YM, 2014, INVEST NEW DRUG, V32, P851, DOI 10.1007/s10637-014-0129-y; Liu YM, 2014, CANCER MED-US, V3, P580, DOI 10.1002/cam4.207; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Miller DW, 1999, INT J CANCER, V81, P568, DOI 10.1002/(SICI)1097-0215(19990517)81:4<568::AID-IJC11>3.3.CO;2-O; Nolan-Stevaux O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050920; Paauwe M, 2013, EXPERT OPIN THER TAR, V17, P421, DOI 10.1517/14728222.2013.758716; Pan CC, 2014, J BIOL CHEM, V289, P25486, DOI 10.1074/jbc.M114.578609; Perez-Gomez E, 2010, THESCIENTIFICWORLDJO, V10, P2367, DOI 10.1100/tsw.2010.230; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Romero D, 2011, CANCER RES, V71, P3482, DOI 10.1158/0008-5472.CAN-10-2665; Rosen LS, 2012, CLIN CANCER RES, V18, P4820, DOI 10.1158/1078-0432.CCR-12-0098; Seon BK, 2011, CURR DRUG DELIV, V8, P135; Sitohy B, 2012, CANCER RES, V72, P1909, DOI 10.1158/0008-5472.CAN-11-3406; Sounni NE, 2014, CELL METAB, V20, P280, DOI 10.1016/j.cmet.2014.05.022; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsujie M, 2008, INT J CANCER, V122, P2266, DOI 10.1002/ijc.23314; van Baardewijk LJ, 2013, INT ORTHOP, V37, P523, DOI 10.1007/s00264-012-1750-z; Zijlmans HJ, 2009, BRIT J CANCER, V100, P1617, DOI 10.1038/sj.bjc.6605009	48	44	48	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4069	4079		10.1038/onc.2015.509	http://dx.doi.org/10.1038/onc.2015.509			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26804178	Green Published			2022-12-17	WOS:000381020900005
J	Ying, M; Zhang, L; Zhou, Q; Shao, X; Cao, J; Zhang, N; Li, W; Zhu, H; Yang, B; He, Q				Ying, M.; Zhang, L.; Zhou, Q.; Shao, X.; Cao, J.; Zhang, N.; Li, W.; Zhu, H.; Yang, B.; He, Q.			The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid-induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RAR alpha	ONCOGENE			English	Article							MESENCHYMAL STEM-CELLS; MYELOID-LEUKEMIA CELLS; GENE AMPLIFICATION; RECEPTOR-ALPHA; CANCER-THERAPY; HUMAN SARCOMAS; P53; PHOSPHORYLATION; STABILIZATION; ACTIVATION	Retinoic acid receptor alpha (RAR alpha) has a critical role in the differentiation process of osteosarcoma cells induced by all-trans retinoic acid (ATRA). However, degradation of RAR alpha through ubiquitin proteasome pathway weakens the differentiation efficiency of osteosarcoma cells. In this study, we discover that murine double minute-2 (MDM2) acts as an E3 ubiquitin ligase to target RAR alpha for degradation. We observe that MDM2 is required for RAR alpha polyubiquitination and proteasomal degradation because downregulation of MDM2 by short hairpin RNA results in the accumulation of RAR alpha, and MDM2 overexpression promotes the degradation of RAR alpha. We also demonstrate that the N-terminal domain of MDM2 (amino acids 1-109) is the major RAR alpha-binding site. Importantly, endogenous MDM2 levels are not only upregulated in human primary osteosarcoma blasts but are also inversely correlated with the level of osteopontin, which is a marker of bone differentiation. Moreover, MDM2 impairs the ATRA-induced osteoblastic differentiation of osteosarcoma cells, whereas an inhibitor of the MDM2 ubiquitin ligase synergizes with ATRA to enhance the differentiation of osteosarcoma cells and primary osteosarcoma blasts. Therefore, our study indicates that MDM2 serves as an E3 ubiquitin ligase to regulate the degradation of RARa and suggests that MDM2 is a novel therapeutic target for ATRA-based differentiation therapeutic approaches in osteosarcoma.	[Ying, M.; Zhang, L.; Zhou, Q.; Shao, X.; Cao, J.; Zhu, H.; Yang, B.; He, Q.] Zhejiang Univ, Coll Pharmaceut Sci, Zhejiang Prov Key Lab Anticanc Drug Res, Hangzhou, Zhejiang, Peoples R China; [Zhang, N.; Li, W.] Zhejiang Univ, Affiliated Hosp 2, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Yang, B; He, Q (corresponding author), Zhejiang Univ, Coll Pharmaceut Sci, Inst Pharmacol & Toxicol, Room 113,866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.	yang924@zju.edu.cn; qiaojunhe@zju.edu.cn		Zhou, Qiong/0000-0002-8240-0440; Zhu, Hong/0000-0002-2575-4031	National Natural Science Foundation of China [81473227, 91029745, 81273536]; Zhejiang Provincial Program for Qianjiang Talents [2013R10025]; Zhejiang Provincial Natural Science Foundation of China [Y14H160124]; Fundamental Research Funds for Central Universities; NATIONAL CANCER INSTITUTE [P30CA046934, R01CA047135] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Program for Qianjiang Talents; Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province); Fundamental Research Funds for Central Universities(Fundamental Research Funds for the Central Universities); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81473227, 91029745 and 81273536), Zhejiang Provincial Program for Qianjiang Talents (2013R10025), Zhejiang Provincial Natural Science Foundation of China (No. Y14H160124) and the Fundamental Research Funds for the Central Universities.	BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Chai Z, 2009, IUBMB LIFE, V61, P670, DOI 10.1002/iub.212; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Dingwall M, 2011, DIFFERENTIATION, V82, P57, DOI 10.1016/j.diff.2011.05.003; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936; Gianni M, 2009, CANCER RES, V69, P1016, DOI 10.1158/0008-5472.CAN-08-2603; Haydon RC, 2002, CLIN CANCER RES, V8, P1288; Haydon RC, 2007, CLIN ORTHOP RELAT R, P237, DOI 10.1097/BLO.0b013e31802b683c; He BC, 2010, CLIN CANCER RES, V16, P2235, DOI 10.1158/1078-0432.CCR-09-2499; Hisada K, 2013, J BONE MINER METAB, V31, P53, DOI 10.1007/s00774-012-0385-x; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; LADANYI M, 1993, CANCER RES, V53, P16; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Luo P, 2010, ONCOGENE, V29, P2772, DOI 10.1038/onc.2010.50; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; McCoy MA, 2003, P NATL ACAD SCI USA, V100, P1645, DOI 10.1073/pnas.0334477100; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Moumen A, 2007, DEVELOPMENT, V134, P1443, DOI 10.1242/dev.02820; Niederreither K, 2008, NAT REV GENET, V9, P541, DOI 10.1038/nrg2340; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Poyurovsky MV, 2010, NAT STRUCT MOL BIOL, V17, P982, DOI 10.1038/nsmb.1872; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Steinman HA, 2004, J BIOL CHEM, V279, P4877, DOI 10.1074/jbc.M305966200; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Wallace M, 2006, MOL CELL, V23, P251, DOI 10.1016/j.molcel.2006.05.029; Wang WS, 2012, MED RES REV, V32, P1159, DOI 10.1002/med.20236; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Xiong L, 2007, J CELL BIOL, V178, P995, DOI 10.1083/jcb.200703044; Ying MD, 2013, MOL CANCER THER, V12, P195, DOI 10.1158/1535-7163.MCT-12-0433; Zhan CY, 2012, J AM CHEM SOC, V134, P6855, DOI 10.1021/ja301255n; Zhang L, 2014, CELL CYCLE, V13, P1277, DOI 10.4161/cc.28190; Zhang Z, 2005, CURR CANCER DRUG TAR, V5, P9, DOI 10.2174/1568009053332618; Zhou Q, 2014, FEBS J, V281, P3032, DOI 10.1111/febs.12840; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	39	44	45	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4358	4367		10.1038/onc.2015.503	http://dx.doi.org/10.1038/onc.2015.503			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26776160				2022-12-17	WOS:000382152100007
J	Babaian, A; Romanish, MT; Gagnier, L; Kuo, LY; Karimi, MM; Steidl, C; Mager, DL				Babaian, A.; Romanish, M. T.; Gagnier, L.; Kuo, L. Y.; Karimi, M. M.; Steidl, C.; Mager, D. L.			Onco-exaptation of an endogenous retroviral LTR drives IRF5 expression in Hodgkin lymphoma	ONCOGENE			English	Article							TRANSPOSABLE ELEMENTS; GENES; ISOFORM; TRANSCRIPTS; PROMOTERS; ALIGNMENT; BIOLOGY	The transcription factor interferon regulatory factor 5 (IRF5) is upregulated in Hodgkin lymphoma (HL) and is a key regulator of the aberrant transcriptome characteristic of this disease. Here we show that IRF5 upregulation in HL is driven by transcriptional activation of a normally dormant endogenous retroviral LOR1a long terminal repeat (LTR) upstream of IRF5. Specifically, through screening of RNA-sequencing libraries, we detected LTR-IRF5 chimeric transcripts in multiple HL cell lines but not in normal B-cell controls. In HL, the LTR was in an open and hypomethylated epigenetic state, and we further show the LTR is the site of transcriptional initiation. Among HL cell lines, usage of the LTR promoter strongly correlates with overall levels of IRF5 mRNA and protein, indicating that LTR transcriptional awakening is a major contributor to IRF5 upregulation in HL. Taken together, oncogenic IRF5 overexpression in HL is the result of a specific LTR transcriptional activation. We propose that such LTR derepression is a distinct mechanism of oncogene activation ('onco-exaptation'), and that such a mechanism warrants further investigation in molecular and cancer research.	[Babaian, A.; Romanish, M. T.; Gagnier, L.; Kuo, L. Y.; Mager, D. L.] British Columbia Canc Agcy, Terry Fox Lab, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada; [Babaian, A.; Romanish, M. T.; Gagnier, L.; Karimi, M. M.; Mager, D. L.] Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 1M9, Canada; [Karimi, M. M.] Univ British Columbia, Biomed Res Ctr, Vancouver, BC, Canada; [Steidl, C.] British Columbia Canc Agcy, Dept Lymphoid Canc Res, Vancouver, BC V5Z 1L3, Canada; [Steidl, C.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; British Columbia Cancer Agency; University of British Columbia	Mager, DL (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada.; Steidl, C (corresponding author), British Columbia Canc Agcy, Ctr Lymphoid Canc, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada.	CSteidl@bccancer.bc.ca; dmager@bccrc.ca		Mager, Dixie/0000-0002-5955-2550; Babaian, Artem/0000-0002-4315-6262; Karimi, Mohammad Mahdi/0000-0001-5017-1252	Leukemia and Lymphoma Society of Canada; British Columbia Cancer Agency; Natural Sciences and Engineering Research Council of Canada; Michael Smith Foundation for Health Research (MSFHR); MSFHR	Leukemia and Lymphoma Society of Canada; British Columbia Cancer Agency; Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Michael Smith Foundation for Health Research (MSFHR)(Michael Smith Foundation for Health Research); MSFHR(Michael Smith Foundation for Health Research)	This work was supported by a grant from the Leukemia and Lymphoma Society of Canada to DM and CS, with core support provided by the British Columbia Cancer Agency. AB is supported by a studentship award from the Natural Sciences and Engineering Research Council of Canada, MMK is supported by a postdoctoral fellowship from the Michael Smith Foundation for Health Research (MSFHR) and CS is supported by a scholarship award from MSFHR.	Chiaromonte F, 2002, Pac Symp Biocomput, P115; Clark DN, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00360; Davydov EV, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001025; De Smet Charles, 2010, Epigenetics, V5, P206; Faulkner GJ, 2009, NAT GENET, V41, P563, DOI 10.1038/ng.368; Hur K, 2014, GUT, V63, P635, DOI 10.1136/gutjnl-2012-304219; Jurka J, 2005, CYTOGENET GENOME RES, V110, P462, DOI 10.1159/000084979; Kapusta A, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003470; Karimi MM, 2011, CELL STEM CELL, V8, P676, DOI 10.1016/j.stem.2011.04.004; Kelley D, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-11-r107; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kreher S, 2014, P NATL ACAD SCI USA, V111, pE4513, DOI 10.1073/pnas.1406985111; Lamprecht B, 2010, NAT MED, V16, P571, DOI 10.1038/nm.2129; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lazzari E, 2014, CLIN IMMUNOL, V153, P343, DOI 10.1016/j.clim.2014.06.001; Liu Y, 2014, LEUKEMIA, V28, P2248, DOI 10.1038/leu.2014.201; Lock FE, 2014, P NATL ACAD SCI USA, V111, pE3534, DOI 10.1073/pnas.1405507111; Mancl ME, 2005, J BIOL CHEM, V280, P21078, DOI 10.1074/jbc.M500543200; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; PANGANIBAN AT, 1985, CELL, V42, P5, DOI 10.1016/S0092-8674(85)80092-1; Rebollo R, 2012, ANNU REV GENET, V46, P21, DOI 10.1146/annurev-genet-110711-155621; Rebollo R, 2012, MOBILE DNA-UK, V3, DOI 10.1186/1759-8753-3-9; Rebollo R, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002301; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Romanish MT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005761; Roullet MR, 2007, EXPERT REV MOL DIAGN, V7, P805, DOI 10.1586/14737159.7.6.805; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Slotkin RK, 2007, NAT REV GENET, V8, P272, DOI 10.1038/nrg2072; St Laurent G, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-7-r73; Steidl C, 2012, BLOOD, V120, P3530, DOI 10.1182/blood-2012-06-439570; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Weber B, 2010, ONCOGENE, V29, P5775, DOI 10.1038/onc.2010.227; Wolff EM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000917; Xie MC, 2013, NAT GENET, V45, P836, DOI 10.1038/ng.2649	35	44	45	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2542	2546		10.1038/onc.2015.308	http://dx.doi.org/10.1038/onc.2015.308			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26279299				2022-12-17	WOS:000376165500012
J	Hagenbuchner, J; Kiechl-Kohlendorfer, U; Obexer, P; Ausserlechner, MJ				Hagenbuchner, J.; Kiechl-Kohlendorfer, U.; Obexer, P.; Ausserlechner, M. J.			BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma	ONCOGENE			English	Article							SURVIVIN SUPPRESSANT; PANCREATIC-CANCER; PROTEIN SURVIVIN; OXIDATIVE STRESS; DRUG-RESISTANCE; CELL-CYCLE; IN-VITRO; BECLIN 1; APOPTOSIS; AUTOPHAGY	Adverse forms of neuroblastoma (NB), a childhood malignancy that develops from immature neuronal progenitor cells frequently carry a gain of chromosome 17q, which leads to overexpression of the antiapoptotic protein BIRC5/Survivin. We have recently shown that high Survivin expression shuts down mitochondrial complex I activity and shifts NB cells from oxidative phosphorylation to aerobic glycolysis, which further increases resistance to cell death induction. This increased glucose consumption sensitized tumor cells to glycolysis inhibitors. Interestingly, in Survivin-overexpressing cells 2-deoxy-D-glucose (2DG) treatment induces re-fusion of mitochondrial networks after 4 h, which coincides with Survivin repression. 2DG selectively acts on Survivin-expressing NB cells and induces autophagic degradation of Survivin via activation of the E3-ubiquitin ligase Parkin, a downstream target of PINK1. Survivin degradation further releases bound Beclin-1, which enhances autophagy and cell death induction. Knockdown of Parkin, however, reduces the sensitivity of Survivin-expressing NB cells to glycolysis inhibition. The selective activity of 2DG treatment on Survivin-overexpressing tumor cells was also confirmed in a xenograft mouse model, which further supports our hypothesis that glycolysis inhibitors might be useful drugs in the treatment of NB.	[Hagenbuchner, J.; Kiechl-Kohlendorfer, U.; Obexer, P.] Med Univ Innsbruck, Dept Pediat 2, Innrain 66, A-6020 Innsbruck, Austria; [Obexer, P.] Tyrolean Canc Res Inst, Innsbruck, Austria; [Ausserlechner, M. J.] Med Univ Innsbruck, Dept Pediat 1, A-6020 Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck	Hagenbuchner, J (corresponding author), Med Univ Innsbruck, Dept Pediat 2, Innrain 66, A-6020 Innsbruck, Austria.	judith.hagenbuchner@i-med.ac.at		Hagenbuchner, Judith/0000-0003-1396-3407; Ausserlechner, Michael/0000-0002-1015-2302	Medical University Innsbruck for young scientists MUI-START [P2012032014]; Provita Kinderleukamie Stiftung; Medizinische Forschungsfond Tirol; SVP-Frauen-Initiative; Tiroler Landeskrankenanstalten Ges.m.b.H. (TILAK); Tyrolean Cancer Society	Medical University Innsbruck for young scientists MUI-START; Provita Kinderleukamie Stiftung; Medizinische Forschungsfond Tirol; SVP-Frauen-Initiative; Tiroler Landeskrankenanstalten Ges.m.b.H. (TILAK); Tyrolean Cancer Society	We thank Dr Hermann Dietrich and his team for the animal care. This work was supported by the intramural funding program of the Medical University Innsbruck for young scientists MUI-START (P2012032014) and by grants from the 'Provita Kinderleukamie Stiftung', the 'Medizinische Forschungsfond Tirol' and 'SVP-Frauen-Initiative'. This study is supported by the 'Tiroler Landeskrankenanstalten Ges.m.b.H. (TILAK)' and the 'Tyrolean Cancer Society'.	Abe A, 2012, ONCOL REP, V29, P1333; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Ausserlechner MJ, 2006, MOL CANCER THER, V5, P1927, DOI 10.1158/1535-7163.MCT-05-0500; Bean JF, 2014, J PEDIATR SURG, V49, P981, DOI 10.1016/j.jpedsurg.2014.01.037; Blanc-Brude OP, 2003, CLIN CANCER RES, V9, P2683; Caldas H, 2006, J MED GENET, V43, P119, DOI 10.1136/jmg.2005.034686; Chang CC, 2004, P NATL ACAD SCI USA, V101, P13239, DOI 10.1073/pnas.0405407101; Cheng Y, 2013, INT J MED SCI, V10, P634, DOI 10.7150/ijms.5547; Chuang JH, 2013, INT J BIOCHEM CELL B, V45, P944, DOI 10.1016/j.biocel.2013.01.019; De Lena M, 2001, EUR J CANCER, V37, P364, DOI 10.1016/S0959-8049(00)00400-7; Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738; Denton D, 2015, IMMUNOL CELL BIOL, V93, P35, DOI 10.1038/icb.2014.85; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-152; Geiger K, 2012, MOL BIOL CELL, V23, P2226, DOI 10.1091/mbc.E11-06-0535; Grignani F, 1998, CANCER RES, V58, P14; Groner B, 2014, BIODRUGS, V28, P27, DOI 10.1007/s40259-013-0058-x; Gurbuxani S, 2005, P NATL ACAD SCI USA, V102, P11480, DOI 10.1073/pnas.0500303102; Hagenbuchner J, 2013, ONCOGENE, V32, P4748, DOI 10.1038/onc.2012.500; Hagenbuchner J, 2013, ONCOTARGET, V4, P1241, DOI 10.18632/oncotarget.1147; Hagenbuchner J, 2012, J CELL SCI, V125, P1191, DOI 10.1242/jcs.092098; Hagenbuchner J, 2010, J BIOL CHEM, V285, P6904, DOI 10.1074/jbc.M109.038331; Hoepken HH, 2007, NEUROBIOL DIS, V25, P401, DOI 10.1016/j.nbd.2006.10.007; Huang CY, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.149; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Kang BH, 2006, J BIOL CHEM, V281, P24721, DOI 10.1074/jbc.M603175200; Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191; Maher JC, 2004, CANCER CHEMOTH PHARM, V53, P116, DOI 10.1007/s00280-003-0724-7; Mesri M, 2001, AM J PATHOL, V158, P1757, DOI 10.1016/S0002-9440(10)64131-4; Michiorri S, 2010, CELL DEATH DIFFER, V17, P962, DOI 10.1038/cdd.2009.200; Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684; Nakahara T, 2007, CANCER RES, V67, P8014, DOI 10.1158/0008-5472.CAN-07-1343; Niu TK, 2010, FEBS LETT, V584, P3519, DOI 10.1016/j.febslet.2010.07.018; Novak I, 2012, ANTIOXID REDOX SIGN, V17, P794, DOI 10.1089/ars.2011.4407; Obexer P, 2009, MOL BIOL CELL, V20, P2041, DOI 10.1091/mbc.E08-07-0699; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Park E, 2011, BLOOD, V118, P2191, DOI 10.1182/blood-2011-04-351239; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Plescia J, 2005, CANCER CELL, V7, P457, DOI 10.1016/j.ccr.2005.03.035; Ramirez-Peinado S, 2013, J BIOL CHEM, V288, P30387, DOI 10.1074/jbc.M113.490581; Ramirez-Peinado S, 2011, CANCER RES, V71, P6796, DOI 10.1158/0008-5472.CAN-11-0759; Rodel F, 2008, INT J RADIAT ONCOL, V71, P247, DOI 10.1016/j.ijrobp.2008.02.011; Sachita K, 2015, J ORAL PATHOL MED, V44, P785, DOI 10.1111/jop.12299; Saita S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2400; Sandebring A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005701; Satoh T, 2009, CLIN CANCER RES, V15, P3872, DOI 10.1158/1078-0432.CCR-08-1946; Sheen JH, 2011, CANCER CELL, V19, P613, DOI 10.1016/j.ccr.2011.03.012; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Shutt DC, 2010, CANCER BIOL THER, V9, P853, DOI 10.4161/cbt.9.11.11632; Singh R, 2011, CELL METAB, V13, P495, DOI 10.1016/j.cmet.2011.04.004; Stein M, 2010, PROSTATE, V70, P1388, DOI 10.1002/pros.21172; Stern R, 2002, EXP CELL RES, V276, P24, DOI 10.1006/excr.2002.5508; Stock C, 2008, AM J PATHOL, V172, P203, DOI 10.2353/ajpath.2008.061263; Tolcher AW, 2012, ANN ONCOL, V23, P968, DOI 10.1093/annonc/mdr353; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Uchida H, 2004, MOL THER, V10, P162, DOI 10.1016/j.ymthe.2004.05.006; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Wang X, 2007, BRAIN RES, V1132, P1, DOI 10.1016/j.brainres.2006.11.032; Wobser M, 2006, CANCER IMMUNOL IMMUN, V55, P1294, DOI 10.1007/s00262-005-0102-x; Xing Z, 2004, J EXP MED, V199, P69, DOI 10.1084/jem.20031588; Yamamoto A, 2005, J BIOL CHEM, V280, P3390, DOI 10.1074/jbc.M407724200; Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108; Zhou W, 2014, SEMIN CELL DEV BIOL, V35, P14, DOI 10.1016/j.semcdb.2014.07.013	67	44	48	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2052	2061		10.1038/onc.2015.264	http://dx.doi.org/10.1038/onc.2015.264			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26148234				2022-12-17	WOS:000374505600005
J	Zhang, K; Zhao, H; Ji, Z; Zhang, C; Zhou, P; Wang, L; Chen, Q; Wang, J; Zhang, P; Chen, Z; Zhu, HH; Gao, WQ				Zhang, K.; Zhao, H.; Ji, Z.; Zhang, C.; Zhou, P.; Wang, L.; Chen, Q.; Wang, J.; Zhang, P.; Chen, Z.; Zhu, H. H.; Gao, W-Q			Shp2 promotes metastasis of prostate cancer by attenuating the PAR3/PAR6/aPKC polarity protein complex and enhancing epithelial-to-mesenchymal transition	ONCOGENE			English	Article							HEMATOPOIETIC STEM; TUMOR-SUPPRESSOR; NOONAN-SYNDROME; PHOSPHATASE; KINASE; GAB1; TUMORIGENESIS; PROGRESSION; ACTIVATION; MECHANISMS	Epithelial-to-mesenchymal transition (EMT), marked by the dissolution of cell-cell junctions, loss of cell polarity and increased cell motility, is one of the essential steps for prostate cancer metastasis. However, the underlying mechanism has not been fully explored. We report in this study that Shp2 is upregulated in prostate cancers and is associated with a poor disease outcome, namely tumor metastasis and shortened patient survival. Overexpression of wild-type Shp2 or an oncogenic Shp2 mutant leads to increased prostate cancer cell proliferation, colony and sphere formation, and in vivo tumor formation. Opposite effects are seen in Shp2-knockdown cells. Moreover, Shp2 promotes in vitro migration and in vivo metastasis of prostatic tumor cells. Mechanistically, Shp2 interacts with PAR3 (partitioning-defective 3) via its Src homology-2 domain. Ectopic expression of Shp2 attenuates the phosphorylation of PAR3 and the formation of the PAR3/PAR6/atypical protein kinase C polarity protein complex, resulting in disrupted cell polarity, dysregulated cell-cell junctions and increased EMT. These findings provide a novel mechanism by which oncogenic signal-transduction molecules regulate cell polarity and induction of EMT.	[Zhang, K.; Zhao, H.; Ji, Z.; Zhang, C.; Zhou, P.; Wang, L.; Chen, Q.; Wang, J.; Zhu, H. H.; Gao, W-Q] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji MedX Clin Stem Cell Res Ctr, Ren Ji Hosp,Sch Biomed Engn, 160 Pujian Rd, Shanghai 200127, Peoples R China; [Zhang, P.] Chinese Acad Sci, Key Lab Syst Biol, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, Shanghai, Peoples R China; [Chen, Z.] Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; ShanghaiTech University	Zhu, HH; Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji MedX Clin Stem Cell Res Ctr, Ren Ji Hosp,Sch Biomed Engn, 160 Pujian Rd, Shanghai 200127, Peoples R China.	zhuhecrane@shsmu.edu.cn; gao.weiqiang@sjtu.edu.cn	Gao, Wei/GXH-0380-2022	Wang, Jia/0000-0002-2343-4755	Chinese Ministry of Science and Technology [2012CB966800, 2013CB945600]; National Natural Science Foundation of China (NSFC) [81130038, 81372189]; Shanghai Health Bureau Key Discipline and Specialty Foundation; Shanghai Education Committee Key Discipline and Specialty Foundation [J50208]; KC Wong foundation; NSFC [81270627]; Science and Technology Commission of Shanghai Municipality (Pujiang program) [12PJ1406100]; Shanghai Education Committee [12CG16, 13YZ030]; Shanghai Institutions of Higher Learning	Chinese Ministry of Science and Technology(Ministry of Science and Technology, China); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Shanghai Health Bureau Key Discipline and Specialty Foundation; Shanghai Education Committee Key Discipline and Specialty Foundation; KC Wong foundation; NSFC(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality (Pujiang program); Shanghai Education Committee; Shanghai Institutions of Higher Learning	The study is supported by funds to W-Q Gao from the Chinese Ministry of Science and Technology (2012CB966800 and 2013CB945600), the National Natural Science Foundation of China (NSFC, 81130038 and 81372189), the Science and Technology Commission of Shanghai Municipality (Pujiang program), the Shanghai Health Bureau Key Discipline and Specialty Foundation, the Shanghai Education Committee Key Discipline and Specialty Foundation (J50208) and the KC Wong foundation, and by funds to HH Zhu from the NSFC (81270627), the Science and Technology Commission of Shanghai Municipality (Pujiang program 12PJ1406100) and the Shanghai Education Committee (Chenguang program12CG16, 13YZ030 and young investigator program) and Shanghai Institutions of Higher Learning (The Program for Professor of Special Appointment (Young Eastern Scholar)).	Aceto N, 2012, NAT MED, V18, P529, DOI 10.1038/nm.2645; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Bard-Chapeau EA, 2006, MOL CELL BIOL, V26, P4664, DOI 10.1128/MCB.02253-05; Bard-Chapeau EA, 2011, CANCER CELL, V19, P629, DOI 10.1016/j.ccr.2011.03.023; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Chan RJ, 2007, BLOOD, V109, P862, DOI 10.1182/blood-2006-07-028829; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Goldstein B, 2007, DEV CELL, V13, P609, DOI 10.1016/j.devcel.2007.10.007; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Hartman ZR, 2013, MOL CANCER RES, V11, P651, DOI 10.1158/1541-7786.MCR-12-0578; Huang L, 2010, CURR OPIN GENET DEV, V20, P41, DOI 10.1016/j.gde.2009.12.001; Iden S, 2012, CANCER CELL, V22, P389, DOI 10.1016/j.ccr.2012.08.004; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Knoblich JA, 2008, CELL, V132, P583, DOI 10.1016/j.cell.2008.02.007; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Li P, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-55; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Lu Y, 2011, P NATL ACAD SCI USA, V108, P2957, DOI 10.1073/pnas.1009395108; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Mali RS, 2012, BLOOD, V120, P2669, DOI 10.1182/blood-2011-08-375873; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; Saadat I, 2007, NATURE, V447, P330, DOI 10.1038/nature05765; Sausgruber N, 2015, ONCOGENE, V34, P2272, DOI 10.1038/onc.2014.170; Schneeberger VE, 2014, CARCINOGENESIS, V35, P1717, DOI 10.1093/carcin/bgu025; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Takahashi A, 2011, MOL CELL, V43, P45, DOI 10.1016/j.molcel.2011.05.014; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tartaglia M, 2005, ANNU REV GENOM HUM G, V6, P45, DOI 10.1146/annurev.genom.6.080604.162305; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wang FM, 2005, BREAST CANCER RES TR, V89, P5, DOI 10.1007/s10549-004-1002-z; Wang JJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4415; Wang YG, 2006, EMBO J, V25, P5058, DOI 10.1038/sj.emboj.7601384; Wohrle FU, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-22; Yang XQ, 2010, MOL CELL BIOL, V30, P5306, DOI 10.1128/MCB.00326-10; Yang ZQ, 2012, MOL CELL, V47, P469, DOI 10.1016/j.molcel.2012.06.037; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zhou XD, 2008, CELL DEATH DIFFER, V15, P988, DOI 10.1038/cdd.2008.54; Zhou ZC, 2014, GASTROENTEROLOGY, V147, P1043, DOI 10.1053/j.gastro.2014.07.021; Zhu HH, 2011, CELL CYCLE, V10, P2241, DOI 10.4161/cc.10.14.15861; Zhu HH, 2011, BLOOD, V117, P5350, DOI 10.1182/blood-2011-01-333476	44	44	46	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1271	1282		10.1038/onc.2015.184	http://dx.doi.org/10.1038/onc.2015.184			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26050620				2022-12-17	WOS:000371763100007
J	Ge, C; Zhao, G; Li, Y; Li, H; Zhao, X; Pannone, G; Bufo, P; Santoro, A; Sanguedolce, F; Tortorella, S; Mattoni, M; Papagerakis, S; Keller, ET; Franceschi, RT				Ge, C.; Zhao, G.; Li, Y.; Li, H.; Zhao, X.; Pannone, G.; Bufo, P.; Santoro, A.; Sanguedolce, F.; Tortorella, S.; Mattoni, M.; Papagerakis, S.; Keller, E. T.; Franceschi, R. T.			Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease	ONCOGENE			English	Article							SIGNAL-REGULATED KINASE; TRANSCRIPTION FACTOR; OSTEOBLAST DIFFERENTIATION; MOUSE MODEL; IN-VIVO; GENE; ACTIVATION; ANDROGEN; PROTEIN; EXPRESSION	The osteogenic transcription factor, Runx2, is abnormally expressed in prostate cancer (PCa) and associated with metastatic disease. During bone development, Runx2 is activated by signals known to be hyperactive in PCa including the RAS/MAP kinase pathway, which phosphorylates Runx2 on multiple serine residues including S301 and S319 (equivalent to S294 and S312 in human Runx2). This study examines the role of these phosphorylation sites in PCa. Runx2 was preferentially expressed in more invasive PCa cell lines (PC34C4-2B4LNCaP). Furthermore, analysis using a P-S319-Runx2-specific antibody revealed that the ratio of P-S319-Runx2/total Runx2 as well as P-ERK/total ERK was highest in PC3 followed by C4-2B and LNCaP cells. These results were confirmed by immunofluorescence confocal microscopy, which showed a higher percentage of PC3 cells staining positive for P-S319-Runx2 relative to C4-2B and LNCaP cells. Phosphorylated Runx2 had an exclusively nuclear localization. When expressed in prostate cell lines, wild-type Runx2 increased metastasis-associated gene expression, in vitro migratory and invasive activity as well as in vivo growth of tumor cell xenografts. In contrast, S301A/S319A phosphorylation site mutations greatly attenuated these Runx2 responses. Analysis of tissue microarrays from 129 patients revealed strong nuclear staining with the P-S319-Runx2 antibody in primary PCas and metastases. P-S319-Runx2 staining was positively correlated with Gleason score and occurrence of lymph node metastases while little or no Runx2 phosphorylation was seen in normal prostate, benign prostate hyperplasia or prostatitis indicating that Runx2 S319 phosphorylation is closely associated with PCa induction and progression towards an aggressive phenotype. These studies establish the importance of Runx2 phosphorylation in prostate tumor growth and highlight its value as a potential diagnostic marker and therapeutic target.	[Ge, C.; Zhao, G.; Li, Y.; Li, H.; Zhao, X.; Papagerakis, S.; Franceschi, R. T.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, 1011N Univ Ave, Ann Arbor, MI 48109 USA; [Pannone, G.; Bufo, P.; Santoro, A.; Sanguedolce, F.; Tortorella, S.; Mattoni, M.] Univ Foggia, Dept Clin & Expt Med, Sect Anat Pathol, Foggia, Italy; [Bufo, P.] RCCS Ctr Riferimento Oncol Basilicata Rionero Vul, Potenza, Italy; [Papagerakis, S.] Univ Michigan, Sch Med, Dept Otolaryngol Head & Neck Surg, Ann Arbor, MI 48109 USA; [Keller, E. T.] Univ Michigan, Sch Med, Lab Anim Med, Ann Arbor, MI 48109 USA; [Franceschi, R. T.] Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Foggia; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Franceschi, RT (corresponding author), Univ Michigan, Sch Dent, Dept Periodont & Oral Med, 1011N Univ Ave, Ann Arbor, MI 48109 USA.	rennyf@umich.edu	santoro, angela/AAC-2025-2019; FRANCESCHI, RENNY/K-3533-2019; Santoro, Angela/AAC-5833-2022; Keller, Evan T/M-1446-2016	santoro, angela/0000-0002-6964-5152; Keller, Evan T/0000-0002-7592-7535; Sanguedolce, Francesca/0000-0001-7459-3521	Department of Defense [W81XWH-11-1-0317]; National Institutes of Health [P01 CA093900]; I.R.C.C.S Centro di Riferimento Oncologico Della Basilicata Rionero in Vulture; NATIONAL CANCER INSTITUTE [R01CA108975, P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011723, K12DE023574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES010016] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); I.R.C.C.S Centro di Riferimento Oncologico Della Basilicata Rionero in Vulture; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by award number W81XWH-11-1-0317 from the Department of Defense (to RTF), and P01 CA093900 from the National Institutes of Health (EK) and I.R.C.C.S Centro di Riferimento Oncologico Della Basilicata Rionero in Vulture (PB). The pOPN-Luc plasmid was a generous gift from Dr. Martha Somerman (NIDCR).	AKECH J, 2009, ONCOGENE, V2009, P1; Aytes A, 2013, P NATL ACAD SCI USA, V110, pE3506, DOI 10.1073/pnas.1303558110; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Blyth K, 2010, BLOOD CELL MOL DIS, V45, P117, DOI 10.1016/j.bcmd.2010.05.007; Browne G, 2012, BRIT J CANCER, V107, P1714, DOI 10.1038/bjc.2012.455; Chang YM, 2007, NEOPLASIA, V9, P90, DOI 10.1593/neo.06694; Cho NY, 2006, INT J CANCER, V119, P1858, DOI 10.1002/ijc.22071; Chua CW, 2009, CLIN CANCER RES, V15, P4322, DOI 10.1158/1078-0432.CCR-08-3157; Fatherazi S, 2009, J DENT RES, V88, P39, DOI 10.1177/0022034508328072; Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046; Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561; Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980; Gioeli D, 1999, CANCER RES, V59, P279; Goh YM, 2010, J BIOL CHEM, V285, P10122, DOI 10.1074/jbc.M109.071381; Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285; Gupta A, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-66; Han B, 2009, MODERN PATHOL, V22, P1083, DOI 10.1038/modpathol.2009.69; Havens A, 2008, NEOPLASIA, V10, P371, DOI 10.1593/neo.08154; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jeong JH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003949; Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058; Kim HR, 2008, J CELL BIOCHEM, V105, P1048, DOI 10.1002/jcb.21906; Kwon TG, 2011, J CELL BIOCHEM, V112, P3582, DOI 10.1002/jcb.23289; Li Y, 2012, J BONE MINER RES, V27, P1263, DOI 10.1002/jbmr.1574; Li Y, 2010, J BONE MINER RES, V25, P154, DOI 10.1359/jbmr.090705; Lim M, 2010, LAB INVEST, V90, P222, DOI 10.1038/labinvest.2009.128; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pande S, 2013, J CELL PHYSIOL, V228, P1784, DOI 10.1002/jcp.24339; Pockwinse SM, 2006, J CELL PHYSIOL, V206, P354, DOI 10.1002/jcp.20469; Pratap J, 2006, CANCER METAST REV, V25, P589, DOI 10.1007/s10555-006-9032-0; Pratap J, 2008, CANCER RES, V68, P7795, DOI 10.1158/0008-5472.CAN-08-1078; Qiao M, 2006, J BIOL CHEM, V281, P7118, DOI 10.1074/jbc.M508162200; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037; Stewart M, 2007, CANCER RES, V67, P5126, DOI 10.1158/0008-5472.CAN-07-0433; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; THALMANN GN, 1994, CANCER RES, V54, P2577; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; van der Deen M, 2010, J CELL BIOCHEM, V109, P828, DOI 10.1002/jcb.22463; Wai PY, 2008, CANCER METAST REV, V27, P103, DOI 10.1007/s10555-007-9104-9; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; WARE JL, 1982, J UROLOGY, V128, P1064, DOI 10.1016/S0022-5347(17)53345-5; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xin L, 2006, P NATL ACAD SCI USA, V103, P7789, DOI 10.1073/pnas.0602567103; Yoshimi M, 2012, EUR J IMMUNOL, V42, P1044, DOI 10.1002/eji.201040746; Yun SJ, 2012, PROSTATE CANCER P D, V15, P369, DOI 10.1038/pcan.2012.31; Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925-4773(01)00428-2; Zhang HJ, 2011, CANCER RES, V71, P3257, DOI 10.1158/0008-5472.CAN-10-2603; Zhao M, 2005, J CELL BIOCHEM, V95, P1, DOI 10.1002/jcb.20411; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	54	44	44	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					366	376		10.1038/onc.2015.91	http://dx.doi.org/10.1038/onc.2015.91			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25867060	Green Accepted			2022-12-17	WOS:000369055300010
J	Cui, YH; Suh, Y; Lee, HJ; Yoo, KC; Uddin, N; Jeong, YJ; Lee, JS; Hwang, SG; Nam, SY; Kim, MJ; Lee, SJ				Cui, Y-H; Suh, Y.; Lee, H-J; Yoo, K-C; Uddin, N.; Jeong, Y-J; Lee, J-S; Hwang, S-G; Nam, S-Y; Kim, M-J; Lee, S-J			Radiation promotes invasiveness of non-small-cell lung cancer cells through granulocyte-colony-stimulating factor	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; NF-KAPPA-B; FACTOR G-CSF; SIGNALING PATHWAY; GM-CSF; FEEDBACK LOOP; BETA-CATENIN; METASTASIS; ACTIVATION; CARCINOMA	Despite ionizing radiation (IR) is being widely used as a standard treatment for lung cancer, many evidences suggest that IR paradoxically promotes cancer malignancy. However, its molecular mechanisms underlying radiation-induced cancer progression remain obscure. Here, we report that exposure to fractionated radiation (2 Gy per day for 3 days) induces the secretion of granulocyte-colony-stimulating factor (G-CSF) that has been commonly used in cancer therapies to ameliorate neutropenia. Intriguingly, radiation-induced G-CSF promoted the migratory and invasive properties by triggering the epithelial-mesenchymal cell transition (EMT) in non-small-cell lung cancer cells (NSCLCs). By irradiation, G-CSF was upregulated transcriptionally by beta-catenin/TCF4 complex that binds to the promoter region of G-CSF as a transcription factor. Importantly, irradiation increased the stability of beta-catenin through the activation of PI3K/AKT (phosphatidylinositol 3-kinase/AKT), thereby upregulating the expression of G-CSF. Radiation-induced G-CSF is recognized by G-CSFR and transduced its intracellular signaling JAK/STAT3 (Janus kinase/ signal transducers and activators of transcription), thereby triggering EMT program in NSCLCs. Taken together, our findings suggest that the application of G-CSF in cancer therapies to ameliorate neutropenia should be reconsidered owing to its effect on cancer progression, and G-CSF could be a novel therapeutic target to mitigate the harmful effect of radiotherapy for the treatment of NSCLC.	[Cui, Y-H; Suh, Y.; Yoo, K-C; Uddin, N.; Lee, S-J] Hanyang Univ, Lab Mol Biochem, Dept Life Sci, Res Inst Nat Sci, Seoul 133791, South Korea; [Lee, H-J; Jeong, Y-J] Korea Inst Radiol & Med Sci, Div Radiat Effect, Seoul 139706, South Korea; [Lee, J-S] Sungkyunkwan Univ, Dept Biol Sci, Coll Sci, Suwon, South Korea; [Hwang, S-G] Korea Inst Radiol & Med Sci, Div Radiat Canc Biol, Seoul 139706, South Korea; [Nam, S-Y] Korea Hydro & Nucl Power Co Ltd, Radiat Hlth Inst, Seoul, South Korea; [Kim, M-J] Korea Inst Radiol & Med Sci, Lab Radiat Exposure & Therapeut, Natl Radiat Emergency Med Ctr, Seoul 139706, South Korea	Hanyang University; Korea Institute of Radiological & Medical Sciences; Sungkyunkwan University (SKKU); Korea Institute of Radiological & Medical Sciences; Korea Hydro & Nuclear Power; Korea Institute of Radiological & Medical Sciences	Kim, MJ (corresponding author), Korea Inst Radiol & Med Sci, Lab Radiat Exposure & Therapeut, Natl Radiat Emergency Med Ctr, Seoul 139706, South Korea.	kimmj74@kirams.re.kr; sj0420@hanyang.ac.kr	Cui, Yanhong/ABB-1148-2021; Lee, Jae-Seong/H-6013-2015	Cui, Yanhong/0000-0002-4169-6521; Lee, Jae-Seong/0000-0003-0944-5172; Ud Din, Nizam/0000-0002-9845-3109	National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program [2012M2A2A7035878]; Ministry of Trade, Industry and Energy [20131610101840]	National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program; Ministry of Trade, Industry and Energy	This work was supported by the National Research Foundation (NRF) and Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program (2012M2A2A7035878), and the Ministry of Trade, Industry and Energy (Grant No: 20131610101840).	Acosta JC, 2012, TRENDS CELL BIOL, V22, P211, DOI 10.1016/j.tcb.2011.11.006; Bernier J, 2004, NAT REV CANCER, V4, P737, DOI 10.1038/nrc1451; BURGESS AW, 1980, BLOOD, V56, P947; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; DALE DC, 1995, J INFECT DIS, V172, P1061, DOI 10.1093/infdis/172.4.1061; DEMETRI GD, 1991, BLOOD, V78, P2791; Diederich K, 2009, J NEUROSCI, V29, P11572, DOI 10.1523/JNEUROSCI.0453-09.2009; Dirks PB, 2008, J CLIN ONCOL, V26, P2916, DOI 10.1200/JCO.2008.17.6792; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Jiang RC, 2011, MOL DIAGN THER, V15, P347, DOI 10.2165/11599190-000000000-00000; Jiang YG, 2007, INT J UROL, V14, P1034, DOI 10.1111/j.1442-2042.2007.01866.x; Kawamoto A, 2012, ONCOL REP, V27, P51, DOI 10.3892/or.2011.1485; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Liu RY, 2014, INT J ONCOL, V44, P1643, DOI 10.3892/ijo.2014.2310; Liu W, 2014, LAB INVEST, V94, P362, DOI 10.1038/labinvest.2013.153; Looyenga BD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030820; Marino VJ, 2008, J CELL BIOCHEM, V103, P1512, DOI 10.1002/jcb.21542; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; Mroczko B, 2004, CLIN CHEM LAB MED, V42, P1347, DOI 10.1515/CCLM.2004.253; Mroczko B, 2000, POL ARCH MED WEWN, V103, P163; Multhoff G, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00058; Novak U, 1996, GROWTH FACTORS, V13, P251, DOI 10.3109/08977199609003226; Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519; Prise KM, 2009, NAT REV CANCER, V9, P351, DOI 10.1038/nrc2603; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; Ross GM, 1999, ENDOCR-RELAT CANCER, V6, P41, DOI 10.1677/erc.0.0060041; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Squatrito M, 2010, CANCER CELL, V18, P619, DOI 10.1016/j.ccr.2010.10.034; Su SC, 2014, CANCER CELL, V25, P605, DOI 10.1016/j.ccr.2014.03.021; Teramachi M, 1992, Nihon Kyobu Shikkan Gakkai Zasshi, V30, P1327; Uemura Y, 2004, INT J CANCER, V109, P826, DOI 10.1002/ijc.20023; Uemura Y, 2007, ONCOL REP, V17, P955; Uemura Y, 2006, INT J MOL MED, V18, P365; Wang WC, 2011, J CELL BIOCHEM, V112, P1544, DOI 10.1002/jcb.23067; Wang ZW, 2010, CURR DRUG TARGETS, V11, P745, DOI 10.2174/138945010791170860; Watanabe M, 1998, JPN J CLIN ONCOL, V28, P559, DOI 10.1093/jjco/28.9.559; Wendt Michael K, 2014, JAKSTAT, V3, pe28975, DOI 10.4161/jkst.28975; Yan S, 2013, INT J ONCOL, V42, P1801, DOI 10.3892/ijo.2013.1852; YOUNG MRI, 1994, INT J CANCER, V56, P446, DOI 10.1002/ijc.2910560327; Zhang JN, 2013, NEURAL DEV, V8, DOI 10.1186/1749-8104-8-7	42	44	48	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5372	5382		10.1038/onc.2014.466	http://dx.doi.org/10.1038/onc.2014.466			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	25639867				2022-12-17	WOS:000363479200007
J	Qian, J; Pentz, K; Zhu, Q; Wang, Q; He, J; Srivastava, AK; Wani, AA				Qian, J.; Pentz, K.; Zhu, Q.; Wang, Q.; He, J.; Srivastava, A. K.; Wani, A. A.			USP7 modulates UV-induced PCNA monoubiquitination by regulating DNA polymerase eta stability	ONCOGENE			English	Article							NUCLEOTIDE EXCISION-REPAIR; PIGMENTOSUM VARIANT GENE; SENSITIVE SYNDROME; PROTEIN; UVSSA; PROTEOLYSIS; HAUSP; RAD18; P53	DNA polymerase eta (Pol eta) has unique and pivotal functions in several DNA damage-tolerance pathways. Steady-state level of this short-lived protein is tightly controlled by multiple mechanisms including proteolysis. Here, we have identified the deubiquitinating enzyme (DUB), ubiquitin-specific protease 7 (USP7), as a novel regulator of Pol eta stability. USP7 regulates Pol eta stability through both indirect and direct mechanisms. Knockout of USP7 increased the steady-state level of Pol eta and slowed down the turnover of both Pol eta and p53 proteins through destabilizing their E3 ligase murine double minute 2 (Mdm2). Also, USP7 physically binds Pol eta in vitro and in vivo. Overexpression of wild-type USP7 but not its catalytically-defective mutants deubiquitinates Pol eta and increases its cellular steady-state level. Thus, USP7 directly serves as a specific DUB for Pol eta. Furthermore, ectopic expression of USP7 promoted the UV-induced proliferating cell nuclear antigen (PCNA) monoubiquitination in Pol eta-proficient but not in Pol eta-deficient XPV (Xeroderma pigmentosum variant) cells, suggesting that USP7 facilitates UV-induced PCNA monoubiquitination by stabilizing Pol eta. Taken together, our findings reveal a modulatory role of USP7 in PCNA ubiquitination-mediated stress-tolerance pathways by fine-tuning Pol eta turnover.	[Qian, J.; Pentz, K.; Zhu, Q.; Wang, Q.; He, J.; Srivastava, A. K.; Wani, A. A.] Ohio State Univ, Dept Radiol, Columbus, OH 43210 USA; [Wani, A. A.] Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; [Wani, A. A.] Ohio State Univ, James Canc Hosp, Columbus, OH 43210 USA; [Wani, A. A.] Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Qian, J (corresponding author), Ohio State Univ, Dept Radiol, 1020 Biomed Res Tower,460W 12th Ave, Columbus, OH 43210 USA.	Qian.41@osu.edu; wani.2@osu.edu			National Institutes of Health [ES012991, ES023883]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002388, R01ES012991, R21ES023883] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We are thankful to Dr Bert Vogelstein for HCT116, HCT116 p53<SUP>-/-</SUP> and HCT116 USP7<SUP>-/-</SUP> cells; Dr Alan Lehmann for XP30RO and XP30RO-GFP-Pol eta cells; Drs Yanhui Xu and Yang Shi for FLAG-tagged WT and CS USP7 constructs; Dr Carol Prives for Myc-Mdm2 construct. This work was supported by grants from the National Institutes of Health (ES012991 and ES023883) to AAW.	Cummins JM, 2004, CELL CYCLE, V3, P689, DOI 10.4161/cc.3.6.924; Cummins JM, 2004, NATURE, V428, DOI 10.1038/nature02501; Durando M, 2013, NUCLEIC ACIDS RES, V41, P3079, DOI 10.1093/nar/gkt016; Faustrup H, 2009, J CELL BIOL, V184, P13, DOI 10.1083/jcb.200807137; Friedberg EC, 2005, MOL CELL, V18, P499, DOI 10.1016/j.molcel.2005.03.032; He JS, 2014, J BIOL CHEM, V289, P27278, DOI 10.1074/jbc.M114.589812; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Jung YS, 2012, DNA REPAIR, V11, P177, DOI 10.1016/j.dnarep.2011.10.017; Kim SH, 2008, MOL CELL, V32, P757, DOI 10.1016/j.molcel.2008.11.016; Lehmann AR, 2007, DNA REPAIR, V6, P891, DOI 10.1016/j.dnarep.2007.02.003; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Liu G, 2006, MOL CELL BIOL, V26, P1398, DOI 10.1128/MCB.26.4.1398-1413.2006; Ma HH, 2012, P NATL ACAD SCI USA, V109, P4828, DOI 10.1073/pnas.1116349109; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Sarasin A, 2012, GENOME MED, V4, DOI 10.1186/gm343; Schwertman P, 2012, NAT GENET, V44, P598, DOI 10.1038/ng.2230; Skoneczna A, 2007, J MOL BIOL, V366, P1074, DOI 10.1016/j.jmb.2006.11.093; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039; Zhang X, 2012, NAT GENET, V44, P593, DOI 10.1038/ng.2228	21	44	44	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4791	4796		10.1038/onc.2014.394	http://dx.doi.org/10.1038/onc.2014.394			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25435364	Green Accepted			2022-12-17	WOS:000360931500012
J	Chen, Y; Zhang, Z; Yang, K; Du, J; Xu, Y; Liu, S				Chen, Y.; Zhang, Z.; Yang, K.; Du, J.; Xu, Y.; Liu, S.			Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress	ONCOGENE			English	Article							MICRORNA EXPRESSION; FPN1 TRANSCRIPTION; C-MYB; CANCER; GENE; BINDING; RISK; AP4; OVEREXPRESSION; METASTASIS	Although previous studies suggest that myeloid zinc-finger 1 (MZF-1) is a multifaceted transcription factor that may function as either an oncogene or a tumor suppressor, the molecular bases determining its different traits remain elusive. Increasing evidence suggests that disorders in iron metabolism affect tumorigenesis and tumor behaviors, and that excess tumor iron stimulates tumor progression through various mechanisms such as enhancing DNA replication and energy metabolism. Ferroportin (FPN) is the only known iron exporter in mammalian cells, and it determines global iron egress out of cells. FPN reduction leads to decreased iron efflux and increased intracellular iron that consequentially aggravates the oncogenic effects of iron. MZF-1 was recently identified as a transcription factor that regulates FPN expression. Thus far, however, the molecular mechanisms underlying the MZF-1-FPN signaling in cancers are largely unknown. Here, we found a significant reduction of FPN levels in prostate tumors relative to adjacent tissues, and demonstrated a crucial role of FPN in tumor growth through controlling tumor iron concentration. Inhibition of MZF-1 expression led to reduced FPN concentration, coupled with resultant intracellular iron retention, increased iron-related cellular activities and enhanced tumor cell growth. In contrast, increase of MZF-1 expression restrained tumor cell growth by promoting FPN-driven iron egress. Importantly, we demonstrated that AP4 and c-Myb jointly modulated MZF-1 transcription, and that miR-492 was also directly involved in regulating MZF-1 concentration through binding to the 3' untranslated regions of its mRNA. These results correlate with reduced AP4 and c-Myb expression and elevated miR-492 expression found in prostate tumors as compared with adjacent tissues that resulted in diminished MZF-1 and FPN. Moreover, we demonstrated that alterations of AP4, c-Myb and miR-492 levels significantly affected tumor cell growth. Targeting molecules within the MZF-1-FPN signaling thus appears to be a promising approach to restrain prostate cancer.	[Chen, Y.; Zhang, Z.; Yang, K.; Xu, Y.] Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Dept Urol, Tianjin 300211, Peoples R China; [Chen, Y.; Liu, S.] Chinese Acad Sci, Res Ctr Ecoenvironm Sci, State Key Lab Environm Chem & Ecotoxicol, Beijing, Peoples R China; [Du, J.] Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China	Tianjin Medical University; Chinese Academy of Sciences; Research Center for Eco-Environmental Sciences (RCEES); Tsinghua University	Xu, Y (corresponding author), Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Dept Urol, Tianjin 300211, Peoples R China.	xuyong8816@sina.com; sjliu@rcees.ac.cn		Du, Jin/0000-0002-8224-250X	national '973' program [2014CB932000]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDB14000000]; National Natural Science Foundation of China [21377159, 81172451-H1620]; Tianjin Research Program of Application Foundation and Advanced Technology [12JCYBJC31400]	national '973' program(National Basic Research Program of China); Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Research Program of Application Foundation and Advanced Technology	This work was supported by a grant under the national '973' program (Grant Number: 2014CB932000), the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant No. XDB14000000) and grants from the National Natural Science Foundation of China (Grant Numbers: 21377159 and 81172451-H1620) and Tianjin Research Program of Application Foundation and Advanced Technology (Grant Number: 12JCYBJC31400). We thank all the laboratory members for their great assistance with experiments and reagents.	Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Brzoska K, 2006, ACTA BIOCHIM POL, V53, P685; Buschemeyer WC, 2007, EUR UROL, V52, P331, DOI 10.1016/j.eururo.2007.04.069; Choi JY, 2008, CARCINOGENESIS, V29, P964, DOI 10.1093/carcin/bgn056; Clapp Richard W., 2008, Reviews on Environmental Health, V23, P1; Cross AJ, 2011, CANCER PREV RES, V4, P1465, DOI 10.1158/1940-6207.CAPR-11-0103; Deng Y, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/868131; Donnianni RA, 2013, P NATL ACAD SCI USA, V110, P13475, DOI 10.1073/pnas.1309800110; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Donovan A, 2005, CELL METAB, V1, P191, DOI 10.1016/j.cmet.2005.01.003; Egawa T, 2011, P NATL ACAD SCI USA, V108, P14873, DOI 10.1073/pnas.1112293108; Gaboli M, 2001, GENE DEV, V15, P1625, DOI 10.1101/gad.902301; Gaedcke J, 2012, CLIN CANCER RES, V18, P4919, DOI 10.1158/1078-0432.CCR-12-0016; Greig KT, 2010, BLOOD, V115, P2796, DOI 10.1182/blood-2009-08-239210; Heath JL, 2013, NUTRIENTS, V5, P2836, DOI 10.3390/nu5082836; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; HROMAS R, 1991, J BIOL CHEM, V266, P14183; Hromas R, 1996, LEUKEMIA, V10, P1049; Hsieh YH, 2006, BIOCHEM BIOPH RES CO, V339, P217, DOI 10.1016/j.bbrc.2005.11.015; Huang X, 2008, LANCET ONCOL, V9, P803, DOI 10.1016/S1470-2045(08)70200-6; Hugo H, 2006, GENE CHROMOSOME CANC, V45, P1143, DOI 10.1002/gcc.20378; Jackstadt R, 2013, J EXP MED, V210, P1331, DOI 10.1084/jem.20120812; Jung P, 2009, CELL CYCLE, V8, P982, DOI 10.4161/cc.8.7.7949; Jung P, 2008, P NATL ACAD SCI USA, V105, P15046, DOI 10.1073/pnas.0801773105; KNEKT P, 1994, INT J CANCER, V56, P379, DOI 10.1002/ijc.2910560315; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lutwyche JK, 2006, BIOCHEM BIOPH RES CO, V344, P1300, DOI 10.1016/j.bbrc.2006.04.045; Marro S, 2010, HAEMATOL-HEMATOL J, V95, P1261, DOI 10.3324/haematol.2009.020123; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; Miller LD, 2011, CANCER RES, V71, P6728, DOI 10.1158/0008-5472.CAN-11-1870; Mudduluru G, 2010, MOL CANCER RES, V8, P159, DOI 10.1158/1541-7786.MCR-09-0326; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Ornstein DL, 2007, NUTR CANCER, V58, P115, DOI 10.1080/01635580701308265; PERROTTI D, 1995, MOL CELL BIOL, V15, P6075; Petersen CP, 2006, MOL CELL, V21, P533, DOI 10.1016/j.molcel.2006.01.031; Pinnix ZK, 2010, SCI TRANSL MED, V2, DOI [10.1126/scitranslmed.3001127, 10.1126/scisignal.3001127]; Rafn B, 2012, MOL CELL, V45, P764, DOI 10.1016/j.molcel.2012.01.029; Richardson DR, 2009, BBA-GEN SUBJECTS, V1790, P702, DOI 10.1016/j.bbagen.2008.04.003; Rouault TA, 2005, NAT REV MOL CELL BIO, V6, P345, DOI 10.1038/nrm1620; Schepeler T, 2008, CANCER RES, V68, P6416, DOI 10.1158/0008-5472.CAN-07-6110; Schultz NA, 2012, MODERN PATHOL, V25, P1609, DOI 10.1038/modpathol.2012.122; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; STEVENS RG, 1988, NEW ENGL J MED, V319, P1047, DOI 10.1056/NEJM198810203191603; Taylor M, 2011, GASTROENTEROLOGY, V140, P2044, DOI 10.1053/j.gastro.2011.03.007; Thorner AR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013073; Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495; Troadec MB, 2010, BLOOD, V116, P4657, DOI 10.1182/blood-2010-04-278614; Tsai SJ, 2012, BIOCHEM BIOPH RES CO, V425, P462, DOI 10.1016/j.bbrc.2012.07.125; von Frowein J, 2011, HEPATOLOGY, V53, P833, DOI 10.1002/hep.24125; Ward DM, 2012, BBA-MOL CELL RES, V1823, P1426, DOI 10.1016/j.bbamcr.2012.03.004; Wu YL, 2012, NUCLEIC ACIDS RES, V40, P4247, DOI 10.1093/nar/gks039; Yuan YN, 2011, J NUTRIGENET NUTRIGE, V4, P121, DOI 10.1159/000327902; Zhang SP, 2014, CELL SIGNAL, V26, P2539, DOI 10.1016/j.cellsig.2014.07.029	53	44	48	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3839	3847		10.1038/onc.2014.310	http://dx.doi.org/10.1038/onc.2014.310			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25284586				2022-12-17	WOS:000358001600009
J	Sarmento, LM; Povoa, V; Nascimento, R; Real, G; Antunes, I; Martins, LR; Moita, C; Alves, PM; Abecasis, M; Moita, LF; Parkhouse, RME; Meijerink, JPP; Barata, JT				Sarmento, L. M.; Povoa, V.; Nascimento, R.; Real, G.; Antunes, I.; Martins, L. R.; Moita, C.; Alves, P. M.; Abecasis, M.; Moita, L. F.; Parkhouse, R. M. E.; Meijerink, J. P. P.; Barata, J. T.			CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress	ONCOGENE			English	Article							DNA-DAMAGE; CROSS-TALK; CHECKPOINT; ATR; KINASE; PROGRESSION; ACTIVATION; INHIBITOR; MUTATIONS; PHOSPHORYLATION	Checkpoint kinase 1 (CHK1) is a key component of the ATR (ataxia telangiectasia-mutated and Rad3-related)-dependent DNA damage response pathway that protect cells from replication stress, a cell intrinsic phenomenon enhanced by oncogenic transformation. Here, we show that CHK1 is overexpressed and hyperactivated in T-cell acute lymphoblastic leukemia (T-ALL). CHEK1 mRNA is highly abundant in patients of the proliferative T-ALL subgroup and leukemia cells exhibit constitutively elevated levels of the replication stress marker phospho-RPA32 and the DNA damage marker gamma H2AX. Importantly, pharmacologic inhibition of CHK1 using PF-004777736 or CHK1 short hairpin RNA-mediated silencing impairs T-ALL cell proliferation and viability. CHK1 inactivation results in the accumulation of cells with incompletely replicated DNA, ensuing DNA damage, ATM/CHK2 activation and subsequent ATM-and caspase-3-dependent apoptosis. In contrast to normal thymocytes, primary T-ALL cells are sensitive to therapeutic doses of PF-004777736, even in the presence of stromal or interleukin-7 survival signals. Moreover, CHK1 inhibition significantly delays in vivo growth of xenotransplanted T-ALL tumors. We conclude that CHK1 is critical for T-ALL proliferation and viability by downmodulating replication stress and preventing ATM/caspase-3-dependent cell death. Pharmacologic inhibition of CHK1 may be a promising therapeutic alternative for T-ALL treatment.	[Sarmento, L. M.; Povoa, V.; Antunes, I.; Martins, L. R.; Moita, C.; Moita, L. F.; Barata, J. T.] Univ Lisbon, Inst Med Mol, Fac Med, P-1649028 Lisbon, Portugal; [Nascimento, R.; Parkhouse, R. M. E.] Inst Gulbenkian Ciencias, Infect & Immun Lab, Oeiras, Portugal; [Real, G.; Alves, P. M.] Inst Biol Expt & Tecnol, iBET, Oeiras, Portugal; [Real, G.; Alves, P. M.] Univ Nova Lisboa, Inst Tecnol Quim & Biol, Oeiras, Portugal; [Abecasis, M.] Hosp Sta Cruz, Cardiol Pediat Med Cirurg, Lisbon, Portugal; [Meijerink, J. P. P.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands	Universidade de Lisboa; Instituto Gulbenkian de Ciencia; Universidade Nova de Lisboa; Erasmus University Rotterdam; Erasmus MC	Barata, JT (corresponding author), Univ Lisbon, Inst Med Mol, Fac Med, Av Prof Egas Moniz, P-1649028 Lisbon, Portugal.	joao_barata@medicina.ulisboa.pt	Barata, João T./D-9181-2015; Alves, Paula M/C-1070-2008; Moita, Luis F./L-1296-2013; Meijerink, Jules P/D-4393-2017; Moita, Luis/HCI-2793-2022	Barata, João T./0000-0002-4826-8976; Alves, Paula M/0000-0003-1445-3556; Moita, Luis F./0000-0003-0707-315X; Meijerink, Jules P/0000-0002-6860-798X; Moita, Luis/0000-0003-0707-315X; Parkhouse, Michael/0000-0001-5967-3291; Afonso, Rute/0000-0002-4531-6581; Martins, Leila/0000-0002-5887-4734; Real, Goncalo/0000-0003-3157-4341; Ferreira Moita, Catarina/0000-0002-9910-2343	Fundacao para a Ciencia e a Tecnologia (FCT), Portugal [PTDC/SAU-ONC/113202/2009]; FCT	Fundacao para a Ciencia e a Tecnologia (FCT), Portugal(Portuguese Foundation for Science and Technology); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	This work was supported by the grant PTDC/SAU-ONC/113202/2009 from Fundacao para a Ciencia e a Tecnologia (FCT), Portugal. LMS, RN, IA, LRM and CM had postdoctoral fellowships, and VP a BI fellowship, all from FCT. We thank Dr J Ferreira for fruitful discussions and reagents. We also thank Dr O Fernandez-Capetillo and Centro Nacional de Investigaciones Oncologicas for providing the ATR inhibitor. We especially thank the generosity of patients and their families, and the collaboration of all the team from the Pediatrics Service of Instituto Portugues de Oncologia de Lisboa.	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Bains T, 2012, LEUKEMIA, V26, P2144, DOI 10.1038/leu.2012.74; Barata JT, 2004, BLOOD, V103, P1891, DOI 10.1182/blood-2002-12-3861; Barata JT, 2001, BLOOD, V98, P1524, DOI 10.1182/blood.V98.5.1524; Barde I, 2010, CURR PROTOC NEUROSCI, V53, P4211; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Brooks K, 2013, ONCOGENE, V32, P788, DOI 10.1038/onc.2012.72; Brown EJ, 2000, GENE DEV, V14, P397; Carrassa L, 2011, CELL CYCLE, V10, P2121, DOI 10.4161/cc.10.13.16398; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108; Dai Y, 2005, BLOOD, V105, P1706, DOI 10.1182/blood-2004-07-2767; Dohda T, 2007, EXP CELL RES, V313, P3141, DOI 10.1016/j.yexcr.2007.04.027; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Flex E, 2008, J EXP MED, V205, P751, DOI 10.1084/jem.20072182; Forment JV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023517; Gagou ME, 2010, MOL BIOL CELL, V21, P739, DOI 10.1091/mbc.E09-07-0618; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; Indraccolo S, 2009, CANCER RES, V69, P1314, DOI 10.1158/0008-5472.CAN-08-2791; Katsuno Y, 2009, P NATL ACAD SCI USA, V106, P3184, DOI 10.1073/pnas.0809350106; King B, 2013, CELL, V153, P1552, DOI 10.1016/j.cell.2013.05.041; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Liu QH, 2000, GENE DEV, V14, P1448; Liu SQ, 2012, NUCLEIC ACIDS RES, V40, P10780, DOI 10.1093/nar/gks849; Lonetti A, 2014, LEUKEMIA, V28, P1196, DOI 10.1038/leu.2013.369; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Lopez-Contreras AJ, 2012, J EXP MED, V209, P455, DOI 10.1084/jem.20112147; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Myers K, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000324; Niida H, 2005, J BIOL CHEM, V280, P39246, DOI 10.1074/jbc.M505009200; Petermann E, 2010, P NATL ACAD SCI USA, V107, P16090, DOI 10.1073/pnas.1005031107; Pui CH, 2008, LANCET, V371, P1030, DOI 10.1016/S0140-6736(08)60457-2; Real G, 2011, APPL MICROBIOL BIOT, V91, P1581, DOI 10.1007/s00253-011-3392-2; Ribeiro Daniel, 2013, Adv Biol Regul, V53, P211, DOI 10.1016/j.jbior.2012.10.005; Sarmento LM, 2011, EXPERT REV ANTICANC, V11, P1403, DOI [10.1586/ERA.11.73, 10.1586/era.11.73]; Sarmento LM, 2005, J EXP MED, V202, P157, DOI 10.1084/jem.20050559; Scupoli MT, 2007, HAEMATOLOGICA, V92, P264, DOI 10.3324/haematol.10356; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Silva A, 2008, J CLIN INVEST, V118, P3762, DOI 10.1172/JCI34616; Silva A, 2011, CANCER RES, V71, P4780, DOI 10.1158/0008-5472.CAN-10-3606; Smith J, 2010, ADV CANCER RES, V108, P73, DOI 10.1016/S0065.230X(10)08002.4; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Sugimoto K, 2008, ONCOGENE, V27, P3091, DOI 10.1038/sj.onc.1210978; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Toledo LI, 2011, MOL ONCOL, V5, P368, DOI 10.1016/j.molonc.2011.07.002; Toledo LI, 2011, NAT STRUCT MOL BIOL, V18, P721, DOI 10.1038/nsmb.2076; Verlinden L, 2007, CANCER RES, V67, P6574, DOI 10.1158/0008-5472.CAN-06-3545; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Xu J, 2013, ONCOGENE, V32, P976, DOI 10.1038/onc.2012.121; Zaugg K, 2007, P NATL ACAD SCI USA, V104, P3805, DOI 10.1073/pnas.0611584104; Zenatti PP, 2011, NAT GENET, V43, P932, DOI 10.1038/ng.924; Zhang C, 2009, CLIN CANCER RES, V15, P4630, DOI 10.1158/1078-0432.CCR-08-3272; Zhang YW, 2009, MOL CELL, V35, P442, DOI 10.1016/j.molcel.2009.06.030; Zhang YW, 2014, INT J CANCER, V134, P1013, DOI 10.1002/ijc.28226; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	60	44	47	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					2978	2990		10.1038/onc.2014.248	http://dx.doi.org/10.1038/onc.2014.248			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25132270	Bronze			2022-12-17	WOS:000356100500004
J	Zhang, J; Qin, X; Sun, Q; Guo, H; Wu, X; Xie, F; Xu, Q; Yan, M; Liu, J; Han, Z; Chen, W				Zhang, J.; Qin, X.; Sun, Q.; Guo, H.; Wu, X.; Xie, F.; Xu, Q.; Yan, M.; Liu, J.; Han, Z.; Chen, W.			Transcriptional control of PAX4-regulated miR-144/451 modulates metastasis by suppressing ADAMs expression	ONCOGENE			English	Article							B-CELL LYMPHOMAS; BREAST-CANCER; DIABETES-MELLITUS; DOWN-REGULATION; PAX4 GENE; INVASION; DISINTEGRIN; CARCINOMA; MIGRATION; MICRORNA	Paired box gene 4 (PAX4) is a transcriptional modulator located on chromosome 7q32, and its expression is dysregulated in a variety of human cancers, suggesting that PAX4 may be important in multiple tumors as a driver gene. Here, we show that PAX4 promoted migration and invasion in human epithelial cancers by decreasing miR-144 and miR-451 (miR-144/451) expression levels. Accordingly, miR-144/451 suppressed the migratory and invasive phenotypes, even in PAX4-expressing cells. Mechanistically, miR-144/451 inhibits cancer metastasis by targeting the A disintegrin and metalloproteinase (ADAM) protein family members ADAMTS5 and ADAM10. Their dysregulation is associated with increased tumor invasiveness and metastasis, then reduced patient prognosis in certain epithelial cancers. This discovery suggests that a PAX4-miR-144/451-ADAMs axis regulates human epithelial cancer metastasis, thus opening up therapeutic possibilities and predicting prognosis for those cancer types.	[Zhang, J.; Qin, X.; Sun, Q.; Wu, X.; Xie, F.; Xu, Q.; Yan, M.; Chen, W.] Shanghai Jiao Tong Univ, Sch Med, Dept Oral & Maxillofacial Head & Neck Oncol, Peoples Hosp 9, Shanghai 200011, Peoples R China; [Zhang, J.; Qin, X.; Sun, Q.; Wu, X.; Xie, F.; Xu, Q.; Yan, M.; Chen, W.] Shanghai Jiao Tong Univ, Sch Med, Fac Oral & Maxillofacial Surg, Peoples Hosp 9, Shanghai 200011, Peoples R China; [Guo, H.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 3, Dept Clin Lab, Shanghai 200011, Peoples R China; [Xu, Q.; Han, Z.; Chen, W.] Shanghai Key Lab Stomatol, Shanghai, Peoples R China; [Xu, Q.; Han, Z.; Chen, W.] Shanghai Res Inst Stomatol, Shanghai, Peoples R China; [Liu, J.] Fudan Univ, Zhongshan Hosp, Dept Integrat Med, Shanghai 200433, Peoples R China; [Han, Z.] Chinese Natl Human Genome Ctr Shanghai, Shanghai MOST Key Lab Dis & Hlth Genom, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Fudan University	Chen, W (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Oral & Maxillofacial Head & Neck Oncol, Peoples Hosp 9, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.	chenwantao196323@sjtu.edu.cn	建军, 张/R-3679-2019	Han, Ze-Guang/0000-0002-1018-1752	National Natural Science Foundation of China [91229103, 81101515, 81201912, 81272977]; Shanghai Municipal Education Commission [12YZ052, 12ZZ106]; Shanghai Science and Technology Committee [11DZ2291800, 10DZ1951300]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission(Shanghai Municipal Education Commission (SHMEC)); Shanghai Science and Technology Committee(Shanghai Science & Technology Committee)	This study was supported by the National Natural Science Foundation of China (grant no. 91229103, 81101515, 81201912 and 81272977), the Program of Shanghai Municipal Education Commission (12YZ052 and 12ZZ106) and Project of the Shanghai Science and Technology Committee (11DZ2291800 and 10DZ1951300). We appreciate Liu Jun and Shanghai Cancer Hospital affiliated to Fudan University for providing the 50 pairs of HNSCC tissues. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Akiyoshi S, 2012, BRIT J CANCER, V107, P1345, DOI 10.1038/bjc.2012.326; Benfey PN, 2003, NATURE, V425, P244, DOI 10.1038/425244a; Bergamaschi A, 2012, ONCOGENE, V31, P39, DOI 10.1038/onc.2011.223; Biason-Lauber A, 2005, DIABETOLOGIA, V48, P900, DOI 10.1007/s00125-005-1723-5; Brocker Chad N., 2009, Human Genomics, V4, P43; Cheng C, 2013, J BIOL CHEM, V288, P13748, DOI 10.1074/jbc.M112.381392; Cigudosa JC, 1999, GENE CHROMOSOME CANC, V25, P123, DOI 10.1002/(SICI)1098-2264(199906)25:2<123::AID-GCC8>3.0.CO;2-4; Cross NA, 2005, PROSTATE, V63, P269, DOI 10.1002/pros.20182; Dore LC, 2008, P NATL ACAD SCI USA, V105, P3333, DOI 10.1073/pnas.0712312105; FABBRO D, 1994, CANCER RES, V54, P4744; Gavert N, 2007, CANCER RES, V67, P7703, DOI 10.1158/0008-5472.CAN-07-0991; Guo HY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-77; Guo HY, 2012, INT J BIOCHEM CELL B, V44, P1465, DOI 10.1016/j.biocel.2012.05.015; Held-Feindt J, 2006, INT J CANCER, V118, P55, DOI 10.1002/ijc.21258; Iwaya T, 2012, CARCINOGENESIS, V33, P2391, DOI 10.1093/carcin/bgs288; Jeon HW, 2010, MOL CANCER THER, V9, P1361, DOI 10.1158/1535-7163.MCT-09-0717; Jerkeman M, 1999, EUR J HAEMATOL, V62, P184; Jones GC, 2006, CURR PHARM BIOTECHNO, V7, P25, DOI 10.2174/138920106775789656; Karan D, 2003, INT J ONCOL, V23, P1365; Kobayashi H, 2013, J BIOL CHEM, V288, P28620, DOI 10.1074/jbc.M113.452169; KOZMIK Z, 1995, P NATL ACAD SCI USA, V92, P5709, DOI 10.1073/pnas.92.12.5709; Kumar S, 2012, AM J PATHOL, V181, P1056, DOI 10.1016/j.ajpath.2012.05.022; Li YH, 2006, LEUKEMIA RES, V30, P1547, DOI 10.1016/j.leukres.2006.04.001; Liu PCC, 2006, CANCER BIOL THER, V5, P657, DOI 10.4161/cbt.5.6.2708; Lu XJ, 2008, CURR CANCER DRUG TAR, V8, P720, DOI 10.2174/156800908786733478; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; McCulloch DR, 2004, CLIN CANCER RES, V10, P314, DOI 10.1158/1078-0432.CCR-0846-3; Miller DJ, 2000, P NATL ACAD SCI USA, V97, P4475, DOI 10.1073/pnas.97.9.4475; Miyaki S, 2009, ARTHRITIS RHEUM-US, V60, P2723, DOI 10.1002/art.24745; Miyamoto T, 2001, BIOCHEM BIOPH RES CO, V282, P34, DOI 10.1006/bbrc.2001.4552; Murphy G, 2008, NAT REV CANCER, V8, P929, DOI 10.1038/nrc2459; Park SY, 2011, ONCOL REP, V25, P1677, DOI 10.3892/or.2011.1236; Rasmussen KD, 2010, J EXP MED, V207, P1351, DOI 10.1084/jem.20100458; Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.E03-05-0279; Shikata K, 2013, CANCER SCI, V104, P9, DOI 10.1111/cas.12043; Sosa-Pineda B, 2004, MOL CELLS, V18, P289; Sun Q, 2013, INT J BIOCHEM CELL B, V45, P513, DOI 10.1016/j.biocel.2012.12.004; TAMURA T, 1994, CYTOGENET CELL GENET, V66, P132, DOI 10.1159/000133684; Tian Y, 2012, INT J ONCOL, V40, P1105, DOI 10.3892/ijo.2011.1306; Tokuyama Y, 2006, METABOLISM, V55, P213, DOI 10.1016/j.metabol.2005.08.014; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Xu Q, 2013, CARCINOGENESIS, V34, P539, DOI 10.1093/carcin/bgs374; Yan M, 2013, MOL CELL PROTEOMICS, V12, P3271, DOI 10.1074/mcp.M112.025460; Yang S, 2013, ONCOGENE, V32, P4294, DOI 10.1038/onc.2012.432; Zhang J, 2013, ONCOGENE, V32, P61, DOI 10.1038/onc.2012.28; Zhang XW, 2010, J MOL CELL CARDIOL, V49, P841, DOI 10.1016/j.yjmcc.2010.08.007	46	44	45	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3283	3295		10.1038/onc.2014.259	http://dx.doi.org/10.1038/onc.2014.259			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25151965				2022-12-17	WOS:000356592300007
J	Lee, KH; Park, JW; Sung, HS; Choi, YJ; Kim, WH; Lee, HS; Chung, HJ; Shin, HW; Cho, CH; Kim, TY; Li, SH; Youn, HD; Kim, SJ; Chun, YS				Lee, K-H; Park, J-W; Sung, H-S; Choi, Y-J; Kim, W. H.; Lee, H. S.; Chung, H-J; Shin, H-W; Cho, C-H; Kim, T-Y; Li, S-H; Youn, H-D; Kim, S. J.; Chun, Y-S			PHF2 histone demethylase acts as a tumor suppressor in association with p53 in cancer	ONCOGENE			English	Article							PLANT HOMEODOMAIN; COLON-CANCER; TRANSCRIPTION; ACETYLATION; ACTIVATION; EXPRESSION; BINDING; GENES	Plant homeodomain finger 2 (PHF2) has a role in epigenetic regulation of gene expression by demethylating H3K9-Me2. Several genome-wide studies have demonstrated that the chromosomal region including the PHF2 gene is often deleted in some cancers including colorectal cancer, and this finding encouraged us to investigate the tumor suppressive role of PHF2. As p53 is a critical tumor suppressor in colon cancer, we tested the possibility that PHF2 is an epigenetic regulator of p53. PHF2 was associated with p53, and thereby, promoted p53-driven gene expression in cancer cells under genotoxic stress. PHF2 converted the chromatin that is favorable for transcription by demethylating the repressive H3K9-Me2 mark. In an HCT116 xenograft model, PHF2 was found to be required for the anticancer effects of oxaliplatin and doxorubicin. In PHF2-deficient xenografts, p53 expression was profoundly induced by both drugs, but its downstream product p21 was not, suggesting that p53 cannot be activated in the absence of PHF2. To find clinical evidence about the role of PHF2, we analyzed the expressions of PHF2, p53 and p21 in human colon cancer tissues and adjacent normal tissues from patients. PHF2 was downregulated in cancer tissues and PHF2 correlated with p21 in cancers expressing functional p53. Colon and stomach cancer tissue arrays showed a positive correlation between PHF2 and p21 expressions. Informatics analyses using the Oncomine database also supported our notion that PHF2 is downregulated in colon and stomach cancers. On the basis of these findings, we propose that PHF2 acts as a tumor suppressor in association with p53 in cancer development and ensures p53-mediated cell death in response to chemotherapy.	[Lee, K-H; Park, J-W; Shin, H-W; Youn, H-D; Kim, S. J.; Chun, Y-S] Seoul Natl Univ, Coll Med, Ischem Hypox Dis Inst, Seoul 110799, South Korea; [Park, J-W; Sung, H-S; Choi, Y-J; Chung, H-J; Cho, C-H; Li, S-H; Youn, H-D; Kim, S. J.; Chun, Y-S] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul 110799, South Korea; [Kim, W. H.; Lee, H. S.] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110799, South Korea; [Kim, T-Y] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110799, South Korea; [Kim, S. J.; Chun, Y-S] Seoul Natl Univ, Coll Med, Dept Physiol, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Chun, YS (corresponding author), Seoul Natl Univ, Coll Med, Dept Physiol, 103 Daehak Ro, Seoul 110799, South Korea.	chunys@snu.ac.kr	Lee, Kyoung-Hwa/AAJ-5213-2021	Kim, Sang Jeong/0000-0001-8931-3713	Korean Health Technology RD grant [A121106, A120476]; National Research Foundation grants of Korea [2009-0066985, 20110008634, 2011-0030737]; Seoul National University Hospital Research Fund [0320110180]	Korean Health Technology RD grant; National Research Foundation grants of Korea; Seoul National University Hospital Research Fund	This work was supported by a Korean Health Technology R&D grant (A121106, A120476), National Research Foundation grants of Korea (2009-0066985, 20110008634 and 2011-0030737) and by a grant from the Seoul National University Hospital Research Fund 2011 (0320110180).	Baba A, 2011, NAT CELL BIOL, V13, P668, DOI 10.1038/ncb2228; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Feng WJ, 2010, NAT STRUCT MOL BIOL, V17, P445, DOI 10.1038/nsmb.1778; Fortschegger K, 2011, EPIGENETICS-US, V6, P4, DOI 10.4161/epi.6.1.13297; Ghosh A, 2012, ANN SURG ONCOL, V19, pS528, DOI 10.1245/s10434-011-1991-x; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hasenpusch-Theil K, 1999, MAMM GENOME, V10, P294, DOI 10.1007/s003359900989; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; Jaskelioff M, 2003, NAT CELL BIOL, V5, P395, DOI 10.1038/ncb0503-395; Jin LH, 2013, BIOCHEM J, V449, P459, DOI 10.1042/BJ20121360; Kleine-Kohlbrecher D, 2010, MOL CELL, V38, P165, DOI 10.1016/j.molcel.2010.03.002; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Legube G, 2004, J BIOL CHEM, V279, P44825, DOI 10.1074/jbc.M407478200; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Liu W, 2010, NATURE, V466, P508, DOI 10.1038/nature09272; Mungamuri SK, 2012, NAT STRUCT MOL BIOL, V19, P478, DOI 10.1038/nsmb.2271; Munro AJ, 2005, BRIT J CANCER, V92, P434, DOI 10.1038/sj.bjc.6602358; Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451; Ogino S, 2009, CANCER EPIDEM BIOMAR, V18, P2513, DOI 10.1158/1055-9965.EPI-09-0451; Okuno Y, 2013, DIABETES, V62, P1426, DOI 10.2337/db12-0628; Qiu JH, 2010, CELL RES, V20, P908, DOI 10.1038/cr.2010.81; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schneider R, 2007, GENE DEV, V21, P3027, DOI 10.1101/gad.1604607; Shi XB, 2007, MOL CELL, V27, P636, DOI 10.1016/j.molcel.2007.07.012; Sinha S, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-84; Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091; Stender JD, 2012, MOL CELL, V48, P28, DOI 10.1016/j.molcel.2012.07.020; Wen H, 2010, J BIOL CHEM, V285, P9322, DOI 10.1074/jbc.C109.097667; Wiesner GL, 2003, P NATL ACAD SCI USA, V100, P12961, DOI 10.1073/pnas.2132286100; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Zirbes TK, 2000, INT J CANCER, V89, P14, DOI 10.1002/(SICI)1097-0215(20000120)89:1<14::AID-IJC3>3.0.CO;2-L	34	44	48	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2897	2909		10.1038/onc.2014.219	http://dx.doi.org/10.1038/onc.2014.219			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25043306				2022-12-17	WOS:000355324300009
J	Walker, SR; Liu, S; Xiang, M; Nicolais, M; Hatzi, K; Giannopoulou, E; Elemento, O; Cerchietti, L; Melnick, A; Frank, DA				Walker, S. R.; Liu, S.; Xiang, M.; Nicolais, M.; Hatzi, K.; Giannopoulou, E.; Elemento, O.; Cerchietti, L.; Melnick, A.; Frank, D. A.			The transcriptional modulator BCL6 as a molecular target for breast cancer therapy	ONCOGENE			English	Article							B-CELL LYMPHOMAS; HUMAN TUMORS; BTB DOMAIN; CHIP-SEQ; IN-VITRO; EXPRESSION; STAT5; DIFFERENTIATION; IDENTIFICATION; COREPRESSOR	Inappropriate expression or activation of transcription factors can drive patterns of gene expression, leading to the malignant behavior of breast cancer cells. We have found that the transcriptional repressor BCL6 is highly expressed in breast cancer cell lines, and its locus is amplified in about half of primary breast cancers. To understand how BCL6 regulates gene expression in breast cancer cells, we used chromatin immunoprecipitation followed by deep sequencing to identify the BCL6 binding sites on a genomic scale. This revealed that BCL6 regulates a unique cohort of genes in breast cancer cell lines compared with B-cell lymphomas. Furthermore, BCL6 expression promotes the survival of breast cancer cells, and targeting BCL6 with a peptidomimetic inhibitor leads to apoptosis of these cells. Finally, combining a BCL6 inhibitor and a signal transducer and activator of transcription3 inhibitor provided enhanced cell killing in triple-negative breast cancer cell lines, suggesting that combination therapy may be particularly useful. Thus, targeting BCL6 alone or in conjunction with other signaling pathways may be a useful therapeutic strategy for treating breast cancer.	[Walker, S. R.; Liu, S.; Xiang, M.; Nicolais, M.; Frank, D. A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Walker, S. R.; Liu, S.; Frank, D. A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Walker, S. R.; Liu, S.; Frank, D. A.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Hatzi, K.; Cerchietti, L.; Melnick, A.] Weill Cornell Med Coll, Dept Med & Pharmacol, New York, NY USA; [Giannopoulou, E.; Elemento, O.] Weill Cornell Med Coll, HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsa, New York, NY USA; [Giannopoulou, E.; Elemento, O.] Weill Cornell Med Coll, Dept Physiol & Biophys, New York, NY USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Cornell University; Cornell University; Cornell University	Frank, DA (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,M522B, Boston, MA 02215 USA.	david_frank@dfci.harvard.edu	Melnick, Ari/AAA-5763-2020; Giannopoulou, Evgenia/K-9576-2019	Cerchietti, Leandro/0000-0003-0608-1350	BCRF-AACR grant for Translational Breast Cancer Research; National Cancer Institute [R01-CA160979]; Susan G Komen for the Cure; Brent Leahey Fund; Friends of the Dana-Farber Cancer Institute; NATIONAL CANCER INSTITUTE [R01CA160979, R01CA104348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER	BCRF-AACR grant for Translational Breast Cancer Research; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); Brent Leahey Fund; Friends of the Dana-Farber Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by a BCRF-AACR grant for Translational Breast Cancer Research, and grants from the National Cancer Institute (R01-CA160979), Susan G Komen for the Cure, the Brent Leahey Fund and Friends of the Dana-Farber Cancer Institute.	Ahmad KF, 2003, MOL CELL, V12, P1551, DOI 10.1016/S1097-2765(03)00454-4; Alvarez JV, 2005, CANCER RES, V65, P5054, DOI 10.1158/0008-5472.CAN-04-4281; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Bos R, 2003, ONCOGENE, V22, P8948, DOI 10.1038/sj.onc.1206995; Cerchietti LC, 2010, CANCER CELL, V17, P400, DOI 10.1016/j.ccr.2009.12.050; Cerchietti LC, 2009, BLOOD, V113, P3397, DOI 10.1182/blood-2008-07-168773; Ci WM, 2009, BLOOD, V113, P5536, DOI 10.1182/blood-2008-12-193037; DiRenzo J, 2002, CANCER RES, V62, P89; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Ghetu AF, 2008, MOL CELL, V29, P384, DOI 10.1016/j.molcel.2007.12.026; Giannopoulou EG, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-277; He HSHS, 2010, NAT GENET, V42, P343, DOI 10.1038/ng.545; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kwon H, 2009, IMMUNITY, V31, P941, DOI 10.1016/j.immuni.2009.10.008; Lasho TL, 2008, LEUKEMIA, V22, P1790, DOI 10.1038/leu.2008.56; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Logarajah S, 2003, ONCOGENE, V22, P5572, DOI 10.1038/sj.onc.1206689; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Mendez LM, 2008, MOL CELL BIOL, V28, P2175, DOI 10.1128/MCB.01400-07; Nelson EA, 2004, J BIOL CHEM, V279, P54724, DOI 10.1074/jbc.M408464200; Nelson EA, 2008, BLOOD, V112, P5095, DOI 10.1182/blood-2007-12-129718; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Parekh S, 2007, BLOOD, V110, P2067, DOI 10.1182/blood-2007-01-069575; Polo JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134; Polo JM, 2008, BLOOD, V112, P644, DOI 10.1182/blood-2008-01-131813; Polo JM, 2007, P NATL ACAD SCI USA, V104, P3207, DOI 10.1073/pnas.0611399104; Shin HJ, 2009, BIOINFORMATICS, V25, P2605, DOI 10.1093/bioinformatics/btp479; Walker SR, 2007, ONCOGENE, V26, P224, DOI 10.1038/sj.onc.1209775; Walker SR, 2013, MOL CELL BIOL, V33, P2879, DOI 10.1128/MCB.01620-12; Walker SR, 2009, MOL CANCER RES, V7, P966, DOI 10.1158/1541-7786.MCR-08-0238; Wang X, 2002, P NATL ACAD SCI USA, V99, P15018, DOI 10.1073/pnas.232581199; Wang XZ, 2009, STUD FUZZ SOFT COMP, V245, P1; Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88; Werning G, 2008, CANCER CELL, V13, P311, DOI 10.1016/j.ccr.2008.02.009; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	38	44	46	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1073	1082		10.1038/onc.2014.61	http://dx.doi.org/10.1038/onc.2014.61			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662818	Green Accepted, Green Submitted			2022-12-17	WOS:000350122100001
J	Sulahian, R; Casey, F; Shen, J; Qian, ZR; Shin, H; Ogino, S; Weir, BA; Vazquez, F; Liu, XS; Hahn, WC; Bass, AJ; Chan, V; Shivdasani, RA				Sulahian, R.; Casey, F.; Shen, J.; Qian, Z. R.; Shin, H.; Ogino, S.; Weir, B. A.; Vazquez, F.; Liu, X. S.; Hahn, W. C.; Bass, A. J.; Chan, V.; Shivdasani, R. A.			An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric cancer	ONCOGENE			English	Article						transcriptional control of cancer; synexpression groups; somatic copy number alterations; ChIP-seq; GATA transcription factors	LINEAGE-SURVIVAL ONCOGENE; GENE-EXPRESSION; STEM-CELLS; PATTERNS; STOMACH; GENOME; DIFFERENTIATION; AMPLIFICATION; INTESTINE; FAMILY	Lineage-restricted transcription factors (TFs) are frequently mutated or overexpressed in cancer and contribute toward malignant behaviors; however, the molecular bases of their oncogenic properties are largely unknown. As TF activities are difficult to inhibit directly with small molecules, the genes and pathways they regulate might represent more tractable targets for drug therapy. We studied GATA6, a TF gene that is frequently amplified or overexpressed in gastric, esophageal and pancreatic adenocarcinomas. GATA6-overexpressing gastric cancer cell lines cluster in gene expression space, separate from non-overexpressing lines. This expression clustering signifies a shared pathogenic group of genes that GATA6 may regulate through direct cis-element binding. We used chromatin immunoprecipitation and sequencing (ChIP-seq) to identify GATA6-bound genes and considered TF occupancy in relation to genes that respond to GATA6 depletion in cell lines and track with GATA6 mRNA (synexpression groups) in primary gastric cancers. Among other cellular functions, GATA6-occupied genes control apoptosis and govern the M-phase of the cell cycle. Depletion of GATA6 reduced the levels of the latter transcripts and arrested cells in G2 and M phases of the cell cycle. Synexpression in human tumor samples identified likely direct transcriptional targets substantially better than consideration only of transcripts that respond to GATA6 loss in cultured cells. Candidate target genes responded to the loss of GATA6 or its homolog GATA4 and even more to the depletion of both proteins. Many GATA6-dependent genes lacked nearby binding sites but several strongly dependent, synexpressed and GATA6-bound genes encode TFs such as MYC, HES1, RARB and CDX2. Thus, many downstream effects occur indirectly through other TFs and GATA6 activity in gastric cancer is partially redundant with GATA4. This integrative analysis of locus occupancy, gene dependency and synexpression provides a functional signature of GATA6-overexpressing gastric cancers, revealing both limits and new therapeutic directions for a challenging and frequently fatal disease.	[Sulahian, R.; Qian, Z. R.; Ogino, S.; Weir, B. A.; Vazquez, F.; Hahn, W. C.; Bass, A. J.; Shivdasani, R. A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Sulahian, R.; Hahn, W. C.; Bass, A. J.; Shivdasani, R. A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Casey, F.; Shen, J.; Chan, V.] Novartis Inst Biomed Res, Emeryville, CA USA; [Qian, Z. R.; Ogino, S.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA; [Qian, Z. R.; Ogino, S.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Shin, H.; Liu, X. S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA; [Hahn, W. C.; Bass, A. J.; Shivdasani, R. A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Novartis; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital	Shivdasani, RA (corresponding author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.	ramesh_shivdasani@dfci.harvard.edu			Dana-Farber Cancer Institute-Novartis Drug Discovery Program; National Institutes of Health [R01CA151993, R01HG4069, K08CA134931]; SPORE program in GI cancers [P50 CA127003]; NATIONAL CANCER INSTITUTE [U01CA176058, K08CA134931, P50CA127003, R01CA151993] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004069] Funding Source: NIH RePORTER	Dana-Farber Cancer Institute-Novartis Drug Discovery Program; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SPORE program in GI cancers; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This study was supported by the Dana-Farber Cancer Institute-Novartis Drug Discovery Program and National Institutes of Health awards R01CA151993 (SO), R01HG4069 (XSL), K08CA134931 (AJB) and the SPORE program in GI cancers P50 CA127003. Data associated with this study are available in the GEO, GSE51936.	Abdi H, 2010, WIRES COMPUT STAT, V2, P433, DOI 10.1002/wics.101; Alvarez H, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001356; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Beuling E, 2011, GASTROENTEROLOGY, V140, P1219, DOI 10.1053/j.gastro.2011.01.033; Chen X, 2003, MOL BIOL CELL, V14, P3208, DOI 10.1091/mbc.E02-12-0833; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839; Dulak AM, 2012, CANCER RES, V72, P4383, DOI 10.1158/0008-5472.CAN-11-3893; Eeckhoute J, 2009, GENOME RES, V19, P372, DOI 10.1101/gr.084582.108; Fang RX, 2006, GENE EXPR PATTERNS, V6, P426, DOI 10.1016/j.modgep.2005.09.003; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fu BJ, 2008, CANCER BIOL THER, V7, P1593, DOI 10.4161/cbt.7.10.6565; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Guiu J, 2013, J EXP MED, V210, P71, DOI 10.1084/jem.20120993; Heng JCD, 2010, CELL STEM CELL, V6, P167, DOI 10.1016/j.stem.2009.12.009; Holtzinger A, 2005, DEVELOPMENT, V132, P4005, DOI 10.1242/dev.01978; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jang JH, 2001, CANCER RES, V61, P3541; Kageyama R, 2007, DEVELOPMENT, V134, P1243, DOI 10.1242/dev.000786; Kim TH, 2011, J EXP MED, V208, P677, DOI 10.1084/jem.20101737; Kunii K, 2008, CANCER RES, V68, P2340, DOI 10.1158/0008-5472.CAN-07-5229; Kwei KA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000081; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Lin L, 2012, P NATL ACAD SCI USA, V109, P4251, DOI 10.1073/pnas.1011989109; Liu T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r83; Matsuda A, 2012, JPN J CLIN ONCOL, V42, P154, DOI 10.1093/jjco/hys004; Nakajima M, 1999, CANCER, V85, P1894; Okines A, 2011, NAT REV CLIN ONCOL, V8, P492, DOI 10.1038/nrclinonc.2011.45; Redell MS, 2005, CURR PHARM DESIGN, V11, P2873, DOI 10.2174/1381612054546699; Robinson JT, 2012, GUT, V61, P673; Ross J, 2012, MOL CELL BIOL, V32, P3624, DOI 10.1128/MCB.00163-12; Schmidt PH, 1999, LAB INVEST, V79, P639; Shechter D, 2007, NAT PROTOC, V2, P1445, DOI 10.1038/nprot.2007.202; TAMURA S, 1994, P NATL ACAD SCI USA, V91, P4609, DOI 10.1073/pnas.91.10.4609; Verzi MP, 2011, MOL CELL BIOL, V31, P2026, DOI 10.1128/MCB.01250-10; Verzi MP, 2010, DEV CELL, V19, P713, DOI 10.1016/j.devcel.2010.10.006; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Welch JJ, 2004, BLOOD, V104, P3136, DOI 10.1182/blood-2004-04-1603; Yu M, 2009, MOL CELL, V36, P682, DOI 10.1016/j.molcel.2009.11.002; Zeitlinger J, 2007, GENE DEV, V21, P385, DOI 10.1101/gad.1509607; Zhao R, 2008, DEV BIOL, V317, P614, DOI 10.1016/j.ydbio.2008.03.013	49	44	46	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2014	33	49					5637	5648		10.1038/onc.2013.517	http://dx.doi.org/10.1038/onc.2013.517			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZW	24317510	Green Accepted, Green Submitted			2022-12-17	WOS:000346088700008
J	Sacco, JJ; Yau, TY; Darling, S; Patel, V; Liu, H; Urbe, S; Clague, MJ; Coulson, JM				Sacco, J. J.; Yau, T. Y.; Darling, S.; Patel, V.; Liu, H.; Urbe, S.; Clague, M. J.; Coulson, J. M.			The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells	ONCOGENE			English	Article						deubiquitinase; ATXN3; phosphatase and tensin homolog; PTENP1; ceRNA; MJD	DEUBIQUITINATING ENZYME ATAXIN-3; TUMOR-SUPPRESSOR PTEN; PROTEIN STABILITY; PROSTATE-CANCER; DISEASE PROTEIN; MESSENGER-RNAS; IN-VIVO; UBIQUITINATION; EXPRESSION; MICE	The phosphatidylinositol-3-kinase (PI3K) pathway is commonly hyperactivated in cancer. One mechanism by which this occurs is by silencing of the phosphatase and tensin homolog (PTEN), a tumor suppressor and major antagonist of the pathway, through genetic, epigenetic or posttranscriptional mechanisms. Here, we used an unbiased siRNA screen in non-small-cell lung cancer cells to identify deubiquitylases (DUBs) that have an impact on PI3K signaling by regulating the abundance of PTEN. We found that PTEN expression was induced by depleting any of three members of the Josephin family DUBs: ataxin 3 (ATXN3), ataxin 3-like (ATXN3L) and Josephin domain containing 1 (JOSD1). However, this effect is not mediated through altered PTEN protein stability. Instead, depletion of each DUB increases expression of both the PTEN transcript and its competing endogenous RNA, PTENP1. In ATXN3-depleted cells, under conditions of transcriptional inhibition, PTEN and PTENP1 mRNAs rapidly decay, suggesting that ATXN3 acts primarily by repressing their transcription. Importantly, the PTEN induction observed in response to ATXN3 siRNA is sufficient to downregulate Akt phosphorylation and hence PI3K signaling. Histone deacetylase inhibitors (HDACi) have been suggested as potential mediators of PTEN transcriptional reactivation in non-small-cell lung cancer. Although PTEN exhibits a very limited response to the broad-spectrum HDACi Vorinostat (SAHA) in A549 cells, we find that combination with ATXN3 depletion enhances PTEN induction in an additive manner. Similarly, these interventions additively decrease cell viability. Thus, ATXN3 provides an autonomous, complementary therapeutic target in cancers with epigenetic downregulation of PTEN.	[Sacco, J. J.; Yau, T. Y.; Darling, S.; Patel, V.; Liu, H.; Urbe, S.; Clague, M. J.; Coulson, J. M.] Univ Liverpool, Inst Translat Med, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Coulson, JM (corresponding author), Univ Liverpool, Inst Translat Med, Crown St, Liverpool L69 3BX, Merseyside, England.	j.m.coulson@liv.ac.uk	Urbe, Sylvie/S-1433-2018; Clague, Michael J/A-7199-2008	Urbe, Sylvie/0000-0003-4735-9814; Clague, Michael J/0000-0003-3355-9479; Coulson, Judy/0000-0003-2191-2001; Liu, Han/0000-0002-0014-4675	North-West Cancer Research; Clatterbridge Cancer Charity; Wellcome Trust	North-West Cancer Research; Clatterbridge Cancer Charity; Wellcome Trust(Wellcome TrustEuropean Commission)	This work was funded by a project grant from Clatterbridge Cancer Research (now incorporated into North-West Cancer Research) and Clatterbridge Cancer Charity. Sarah Darling is supported by a Wellcome Trust Prize studentship. We thank Paul Todd for his input into initial phospho-Akt experiments.	Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; Amodio N, 2010, AM J PATHOL, V177, P2622, DOI 10.2353/ajpath.2010.091075; Andersen CL, 2013, LEUKEMIA RES REPORTS, V2, P1; Buus R, 2009, CURR BIOL, V19, P1463, DOI 10.1016/j.cub.2009.07.040; Cai JC, 2013, CANCER RES, V73, P5402, DOI 10.1158/0008-5472.CAN-13-0297; Clague MJ, 2013, PHYSIOL REV, V93, P1289, DOI 10.1152/physrev.00002.2013; Clague MJ, 2012, J CELL SCI, V125, P277, DOI 10.1242/jcs.090985; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Evert BO, 2006, J NEUROSCI, V26, P11474, DOI 10.1523/JNEUROSCI.2053-06.2006; Gan YH, 2009, ORAL ONCOL, V45, pE150, DOI 10.1016/j.oraloncology.2009.05.563; Gorski JJ, 2007, EMBO J, V26, P1560, DOI 10.1038/sj.emboj.7601601; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Jin G, 2010, LUNG CANCER, V69, P279, DOI 10.1016/j.lungcan.2009.11.012; Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032; Leslie NR, 2011, TRENDS PHARMACOL SCI, V32, P131, DOI 10.1016/j.tips.2010.12.005; Li FS, 2002, J BIOL CHEM, V277, P45004, DOI 10.1074/jbc.M205259200; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maddika S, 2011, NAT CELL BIOL, V13, P728, DOI 10.1038/ncb2240; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mao JH, 2008, SCIENCE, V321, P1499, DOI 10.1126/science.1162981; Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204; Moss AC, 2009, CLIN CANCER RES, V15, P274, DOI 10.1158/1078-0432.CCR-08-1163; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Omerovic J, 2010, BIOCHEM J, V426, P65, DOI 10.1042/BJ20091413; Pan LN, 2007, CANCER, V109, P1676, DOI 10.1002/cncr.22585; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Rodriguez-Lebron E, 2013, MOL THER, V21, P1909, DOI 10.1038/mt.2013.152; Sacco JJ, 2010, IUBMB LIFE, V62, P140, DOI 10.1002/iub.300; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Seki T, 2013, J BIOL CHEM, V288, P17145, DOI 10.1074/jbc.M113.463406; Song EJ, 2010, GENE DEV, V24, P1434, DOI 10.1101/gad.1925010; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029; Todi SV, 2009, EMBO J, V28, P372, DOI 10.1038/emboj.2008.289; Van Themsche C, 2009, J BIOL CHEM, V284, P20462, DOI 10.1074/jbc.C109.009522; Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wang HL, 2013, NEUROPHARMACOLOGY, V70, P1, DOI 10.1016/j.neuropharm.2013.01.006; Weeks SD, 2011, J BIOL CHEM, V286, P4555, DOI 10.1074/jbc.M110.177360; Winborn BJ, 2008, J BIOL CHEM, V283, P26436, DOI 10.1074/jbc.M803692200; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Yang Y, 2009, J CELL BIOCHEM, V106, P1102, DOI 10.1002/jcb.22100; Yim EK, 2009, CANCER CELL, V15, P304, DOI 10.1016/j.ccr.2009.02.012	55	44	48	3	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2014	33	33					4265	4272		10.1038/onc.2013.512	http://dx.doi.org/10.1038/onc.2013.512			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MB	24292675	Green Published, hybrid			2022-12-17	WOS:000341155800008
J	Hu, C; Liu, D; Zhang, Y; Lou, G; Huang, G; Chen, B; Shen, X; Gao, M; Gong, W; Zhou, P; Dai, S; Zeng, Y; He, F				Hu, C.; Liu, D.; Zhang, Y.; Lou, G.; Huang, G.; Chen, B.; Shen, X.; Gao, M.; Gong, W.; Zhou, P.; Dai, S.; Zeng, Y.; He, F.			LXR alpha-mediated downregulation of FOXM1 suppresses the proliferation of hepatocellular carcinoma cells	ONCOGENE			English	Article						LXRs; FOXM1; cell proliferation; cell cycle; HCC	LIVER-X-RECEPTOR; FORKHEAD BOX M1B; PROSTATE-CANCER CELLS; TRANSCRIPTION FACTOR; BREAST-CANCER; NUCLEAR RECEPTORS; GENE-EXPRESSION; POOR-PROGNOSIS; TUMOR-GROWTH; TARGET GENE	Liver X receptors (LXRs), including LXR alpha and LXR beta isoforms, have important roles in the metabolic regulation of glucose, cholesterol and lipid. Moreover, activation of LXRs also represses the expression of cyclin D1 and cyclin B1, and thus suppresses the proliferation of multiple cancer cells, but the relevant mechanism is not well known. Forkhead box M1 ( FOXM1) is a proliferationspecific member of forkhead box family, which is highly expressed in proliferating normal cells and numerous cancer cells. FOXM1 directly activates transcription of cyclin D1 and cyclin B1, resulting in the enhancement of cell cycle progression and cell proliferation. However, it is unclear whether LXRs are involved in the regulation of FOXM1. In this study, we demonstrated that specific LXRs agonists downregulated expression of FOXM1, cyclin D1 and cyclin B1 in hepatocellular carcinoma ( HCC) cells, which led to cell cycle and cell proliferation arrest. Knockdown of FOXM1 significantly alleviated LXRs activation-mediated cell cycle arrest and cell growth suppression. Reporter assays showed that the activation of LXRs significantly reduced the transcriptional activity of FOXM1 promoter. Electrophoretic mobility shift assay and chromatin immunoprecipitation assays demonstrated that LXRa but not LXRb could bind to an inverted repeat IR2(-52CCGTCAcgTGACCT- 39) in the promoter region of FOXM1 gene. Moreover, the xenograft tumor growth and the corresponding FOXM1 expression in nude mice were dramatically repressed by LXRs agonists. Taken together, we conclude that LXRa but not LXRb functions as a transcriptional repressor for FOXM1 expression. The pathway ` LXRa- FOXM1- cyclin D1/ cyclin B1' is a novel mechanism by which LXRs suppress the proliferation of HCC cells, suggesting that the pathway may be a novel target for HCC treatment.	[Hu, C.; Liu, D.; Zhang, Y.; Lou, G.; Huang, G.; Chen, B.; Shen, X.; Gao, M.; Gong, W.; Zhou, P.; Dai, S.; Zeng, Y.; He, F.] Third Mil Med Univ, Coll Basic Med Sci, Dept Biochem & Mol Biol, Chongqing 400038, Peoples R China; [Liu, D.] Daping Hosp, Depeartment State Key Lab Trauma Burns & Combined, Chongqing, Peoples R China; [Liu, D.] Inst Surg Res, Chongqing, Peoples R China	Army Medical University; Army Medical University	He, F (corresponding author), Third Mil Med Univ, Coll Basic Med Sci, Dept Biochem & Mol Biol, 30 Gaotanyan, Chongqing 400038, Peoples R China.	hefengtian06@aliyun.com	HUANG, GANG/AAO-5503-2020		National Natural Science Foundation of China [81273226, 81102276]; Key Project of the Natural Science Foundation of Chongqing [cstc2013jjB10015]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Project of the Natural Science Foundation of Chongqing	This work was supported by the National Natural Science Foundation of China (nos. 81273226 and 81102276) and the Key Project of the Natural Science Foundation of Chongqing (no. cstc2013jjB10015).	Annicotte JS, 2004, ANAT REC PART A, V277A, P312, DOI 10.1002/ar.a.20015; Beaudet MJ, 2005, BIOCHEM J, V388, P407, DOI 10.1042/BJ20041556; Bensinger SJ, 2008, CELL, V134, P97, DOI 10.1016/j.cell.2008.04.052; Bhat UG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006593; Blaschke F, 2004, CIRC RES, V95, pE110, DOI 10.1161/01.RES.0000150368.56660.4f; Calvisi DF, 2009, GUT, V58, P679, DOI 10.1136/gut.2008.152652; Cha JY, 2007, J BIOL CHEM, V282, P743, DOI 10.1074/jbc.M605023200; Chen H, 2012, J GENE MED, V14, P231, DOI 10.1002/jgm.2614; Chen WD, 2010, HEPATOLOGY, V51, P953, DOI 10.1002/hep.23390; Chuu CP, 2007, J BIOMED SCI, V14, P543, DOI 10.1007/s11373-007-9160-8; Chuu CP, 2006, CANCER RES, V66, P6482, DOI 10.1158/0008-5472.CAN-06-0632; Chuu CP, 2010, ANTICANCER RES, V30, P3643; Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527; He FT, 2006, CIRC RES, V98, P192, DOI 10.1161/01.RES.0000200400.55539.85; Higuchi N, 2008, HEPATOL RES, V38, P1122, DOI 10.1111/j.1872-034X.2008.00382.x; Jakobsson T, 2012, TRENDS PHARMACOL SCI, V33, P394, DOI 10.1016/j.tips.2012.03.013; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Kalin TV, 2011, CELL CYCLE, V10, P396, DOI 10.4161/cc.10.3.14709; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kennedy MA, 2001, J BIOL CHEM, V276, P39438, DOI 10.1074/jbc.M105863200; Kim KH, 2010, J LIPID RES, V51, P3425, DOI 10.1194/jlr.M007989; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Korver W, 1997, IMMUNOBIOLOGY, V198, P157, DOI 10.1016/S0171-2985(97)80036-8; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Li YW, 2005, MOL CANCER THER, V4, P389; Littler DR, 2010, NUCLEIC ACIDS RES, V38, P4527, DOI 10.1093/nar/gkq194; Mak PA, 2002, J LIPID RES, V43, P2037, DOI 10.1194/jlr.C200014-JLR200; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Millour J, 2010, ONCOGENE, V29, P2983, DOI 10.1038/onc.2010.47; Pascual-Garcia M, 2011, J IMMUNOL, V186, P4656, DOI 10.4049/jimmunol.1000585; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Pommier AJC, 2010, ONCOGENE, V29, P2712, DOI 10.1038/onc.2010.30; Ratni H, 2010, CURR OPIN DRUG DISC, V13, P403; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Scoles DR, 2010, GYNECOL ONCOL, V116, P109, DOI 10.1016/j.ygyno.2009.09.034; Sun HC, 2011, ONCOL REP, V25, P1533, DOI 10.3892/or.2011.1230; Sun HC, 2011, CANCER LETT, V306, P214, DOI 10.1016/j.canlet.2011.03.009; Uddin S, 2011, AM J PATHOL, V178, P537, DOI 10.1016/j.ajpath.2010.10.020; Uno S, 2009, BIOCHEM PHARMACOL, V77, P186, DOI 10.1016/j.bcp.2008.10.007; Vedin LL, 2009, CARCINOGENESIS, V30, P575, DOI 10.1093/carcin/bgp029; Wang XH, 2002, J BIOL CHEM, V277, P44310, DOI 10.1074/jbc.M207510200; Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Wu QF, 2010, ACTA PHARMACOL SIN, V31, P361, DOI 10.1038/aps.2010.4; Xia JT, 2012, PANCREAS, V41, P629, DOI 10.1097/MPA.0b013e31823bcef2; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Zhao CY, 2010, J ENDOCRINOL, V204, P233, DOI 10.1677/JOE-09-0271	50	44	51	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2888	2897		10.1038/onc.2013.250	http://dx.doi.org/10.1038/onc.2013.250			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23812424				2022-12-17	WOS:000337231800008
J	Vascotto, C; Lirussi, L; Poletto, M; Tiribelli, M; Damiani, D; Fabbro, D; Damante, G; Demple, B; Colombo, E; Tell, G				Vascotto, C.; Lirussi, L.; Poletto, M.; Tiribelli, M.; Damiani, D.; Fabbro, D.; Damante, G.; Demple, B.; Colombo, E.; Tell, G.			Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology	ONCOGENE			English	Article						APE1/Ref-1; NPM1; acute myeloid leukemia; base excision repair	REDOX FACTOR-I; ACUTE MYELOID-LEUKEMIA; BASE EXCISION-REPAIR; N-TERMINAL DOMAIN; OXIDATIVE STRESS; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVITY; LYSINE RESIDUES; NPM1 MUTATIONS; GENE MUTATION	Nucleophosmin 1 (NPM1) is a nucleolar protein involved in ribosome biogenesis, stress responses and maintaining genome stability. One-third of acute myeloid leukemias (AMLs) are associated with aberrant localization of NPM1 to the cytoplasm (NPM1c +). This mutation is critical during leukemogenesis and constitutes a good prognostic factor for chemotherapy. At present, there is no clear molecular basis for the role of NPM1 in DNA repair and the tumorigenic process. We found that the nuclear apurinic/apyrimidinic endonuclease 1 (APE1), a core enzyme in base excision DNA repair (BER) of DNA lesions, specifically interacts with NPM1 within nucleoli and the nucleoplasm. Cytoplasmic accumulation of APE1 is associated with cancers including, as we show, NPM1c + AML. Here we show that NPM1 stimulates APE1 BER activity in cells. We provide evidence that expression of the NPM1c + variant causes cytoplasmic accumulation of APE1 in: (i) a heterologous cell system (HeLa cells); (ii) the myeloid cell line OCI/AML3 stably expressing NPM1c + ; and (iii) primary lymphoblasts of NPM1c + AML patients. Consistent with impaired APE1 localization, OCI/AML3 cells and blasts of AML patients have impaired BER activity. Cytoplasmic APE1 in NPM1c + myeloid cells is truncated due to proteolysis. Thus, the good prognostic response of NPM1c + AML to chemotherapy may result from the cytoplasmic relocalization of APE1 and the consequent BER deficiency. NPM1 thus has an indirect but significant role in BER in vivo that may also be important for NPM1c + tumorigenesis.	[Vascotto, C.; Lirussi, L.; Poletto, M.; Fabbro, D.; Damante, G.; Tell, G.] Univ Udine, Dept Med & Biol Sci, I-33100 Udine, Italy; [Tiribelli, M.; Damiani, D.] Univ Udine, Dept Expt & Clin Med Sci, I-33100 Udine, Italy; [Demple, B.] SUNY Stony Brook, Sch Med, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; [Colombo, E.] Univ Milan, Dept Med Surg & Dent, Milan, Italy	University of Udine; University of Udine; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Milan	Tell, G (corresponding author), Univ Udine, Dept Med & Biol Sci, Piazzale Kolbe 4, I-33100 Udine, Italy.	gianluca.tell@uniud.it	Colombo, Emanuela/AAO-7810-2020; Damante, Giuseppe/AAC-5200-2022; Tiribelli, Mario/G-7989-2018; Colombo, Emanuela/AAO-8113-2020; damiani, daniela/AAD-4629-2022	Tiribelli, Mario/0000-0001-9449-2621; Colombo, Emanuela/0000-0003-2079-7398; damiani, daniela/0000-0002-1663-4468; Damante, Giuseppe/0000-0003-2312-4009; vascotto, carlo/0000-0003-4431-029X; Tell, Gianluca/0000-0001-8845-6448	AIRC [IG10269]; MIUR [FIRB_RBRN07BMCT, PRIN2008_CCPKRP_003]; UICC Yamagiwa-Yoshida Memorial International Cancer Study Grant	AIRC(Fondazione AIRC per la ricerca sul cancro); MIUR(Ministry of Education, Universities and Research (MIUR)); UICC Yamagiwa-Yoshida Memorial International Cancer Study Grant	We greatly thank the National Center for Advancing Translational Sciences (NCATS) and Dr David M Wilson III for providing the APE1 specific inhibitor (compound 3). We also thank Dr Malgorzata M Kamocka from the Indiana University School of Medicine, Department of Medicine, Division of Nephrology, Indiana Center for Biological Microscopy, Indianapolis, IN, USA. for her helpful suggestions during IF analyses, Dr Laura Cesaratto for cell-viability assays and Sofia Tell for kind support. This work was supported by grants from: AIRC (IG10269) and MIUR (FIRB_RBRN07BMCT and PRIN2008_CCPKRP_003) to GT. This work has been also supported by a UICC Yamagiwa-Yoshida Memorial International Cancer Study Grant to GT.	Angkeow P, 2002, CELL DEATH DIFFER, V9, P717, DOI 10.1038/sj.cdd.4401025; Ballmaier D, 2006, TOXICOLOGY, V221, P166, DOI 10.1016/j.tox.2006.01.009; Barnes T, 2009, NUCLEIC ACIDS RES, V37, P3946, DOI 10.1093/nar/gkp275; Bhakat KK, 2003, EMBO J, V22, P6299, DOI 10.1093/emboj/cdg595; Bonetti P, 2008, J CELL BIOL, V182, P19, DOI 10.1083/jcb.200711040; Chen JY, 2005, NAT REV CANCER, V5, P102, DOI 10.1038/nrc1547; Cilloni D, 2008, LEUKEMIA, V22, P1234, DOI 10.1038/leu.2008.68; Colombo E, 2006, CANCER RES, V66, P3044, DOI 10.1158/0008-5472.CAN-05-2378; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2011, ONCOGENE, V30, P2595, DOI 10.1038/onc.2010.646; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; den Besten W, 2005, CELL CYCLE, V4, P1593; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Falini B, 2005, NEW ENGL J MED, V352, P740; Falini B, 2007, BLOOD, V109, P874, DOI 10.1182/blood-2006-07-012252; Falini B, 2006, BLOOD, V107, P4514, DOI 10.1182/blood-2005-11-4745; Falini B, 2011, BLOOD, V117, P1109, DOI 10.1182/blood-2010-08-299990; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Fantini D, 2010, NUCLEIC ACIDS RES, V38, P8239, DOI 10.1093/nar/gkq691; Fung H, 2005, MOL CELL, V17, P463, DOI 10.1016/j.molcel.2004.12.029; Fung H, 2011, J BIOL CHEM, V286, P4968, DOI 10.1074/jbc.M110.146498; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Guo YM, 2008, MOL IMMUNOL, V45, P2225, DOI 10.1016/j.molimm.2007.11.020; Gurumurthy M, 2008, J MOL BIOL, V378, P302, DOI 10.1016/j.jmb.2008.02.055; He TR, 2003, AM J PHYSIOL-HEART C, V285, pH804, DOI 10.1152/ajpheart.01080.2002; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Izumi T, 2005, P NATL ACAD SCI USA, V102, P5739, DOI 10.1073/pnas.0500986102; Jiang YL, 2009, DNA REPAIR, V8, P1273, DOI 10.1016/j.dnarep.2009.08.003; Kaina B, 2001, PROG NUCLEIC ACID RE, V68, P41; Kelley MR, 2011, ANTIOXID REDOX SIGN, V14, P1387, DOI 10.1089/ars.2010.3410; Lee C, 2005, CANCER RES, V65, P9834, DOI 10.1158/0008-5472.CAN-05-1759; Lirussi L, 2012, MOL BIOL CELL, V23, P4079, DOI 10.1091/mbc.E12-04-0299; Londero AP, EXPRESSION PRO UNPUB; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Mrozek K, 2007, BLOOD, V109, P431, DOI 10.1182/blood-2006-06-001149; Ozaki M, 2002, FASEB J, V16, P889, DOI 10.1096/fj.01-0664fje; Pianta A, 2010, HEMATOL ONCOL, V28, P151, DOI 10.1002/hon.906; Pitiot AS, 2007, LEUKEMIA, V21, P1564, DOI 10.1038/sj.leu.2404679; Poletto M, 2013, BIOCHEM J, V452, P545, DOI 10.1042/BJ20121277; Quentmeier H, 2005, LEUKEMIA, V19, P1760, DOI 10.1038/sj.leu.2403899; Rai G, 2012, J MED CHEM, V55, P3101, DOI 10.1021/jm201537d; Seemann S, 2005, ONCOGENE, V24, P3853, DOI 10.1038/sj.onc.1208549; Svilar D, 2011, ANTIOXID REDOX SIGN, V14, P2491, DOI 10.1089/ars.2010.3466; Szczesny B, 2008, J BIOL CHEM, V283, P26349, DOI 10.1074/jbc.M803491200; Szczesny B, 2010, MECH AGEING DEV, V131, P330, DOI 10.1016/j.mad.2010.03.009; Tell G, 2005, ANTIOXID REDOX SIGN, V7, P367, DOI 10.1089/ars.2005.7.367; Tell G, 2001, MUTAT RES-DNA REPAIR, V485, P143, DOI 10.1016/S0921-8777(00)00068-9; Tell G, 2010, CELL MOL LIFE SCI, V67, P3589, DOI 10.1007/s00018-010-0486-4; Tell G, 2010, MOL CELL BIOL, V30, P366, DOI 10.1128/MCB.01174-09; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Vascotto C, 2011, MOL BIOL CELL, V22, P3887, DOI 10.1091/mbc.E11-05-0391; Vascotto C, 2009, MOL CELL BIOL, V29, P1834, DOI 10.1128/MCB.01337-08; Vassiliou GS, 2011, NAT GENET, V43, P470, DOI 10.1038/ng.796; Wang HF, 2011, CANCER RES, V71, P68, DOI 10.1158/0008-5472.CAN-10-0030; Wanzel M, 2008, NAT CELL BIOL, V10, P1051, DOI 10.1038/ncb1764; Wei SJ, 2000, CANCER RES, V60, P6688; Weibrecht I, 2010, EXPERT REV PROTEOMIC, V7, P401, DOI 10.1586/EPR.10.10; Wilson DM, 2010, CELL MOL LIFE SCI, V67, P3621, DOI 10.1007/s00018-010-0488-2; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yoshida A, 2003, J BIOL CHEM, V278, P37768, DOI 10.1074/jbc.M304914200; Yu ET, 2011, MUTAT RES-GEN TOX EN, V722, P140, DOI 10.1016/j.mrgentox.2010.06.015; Ziel KA, 2004, FASEB J, V18, P986, DOI 10.1096/fj.03-1160fje	64	44	44	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2876	2887		10.1038/onc.2013.251	http://dx.doi.org/10.1038/onc.2013.251			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23831574				2022-12-17	WOS:000337231800007
J	Deming, DA; Leystra, AA; Nettekoven, L; Sievers, C; Miller, D; Middlebrooks, M; Clipson, L; Albrecht, D; Bacher, J; Washington, MK; Weichert, J; Halberg, RB				Deming, D. A.; Leystra, A. A.; Nettekoven, L.; Sievers, C.; Miller, D.; Middlebrooks, M.; Clipson, L.; Albrecht, D.; Bacher, J.; Washington, M. K.; Weichert, J.; Halberg, R. B.			PIK3CA and APC mutations are synergistic in the development of intestinal cancers	ONCOGENE			English	Article						colon cancer; APC; PI3K; PIK3CA; mouse models	COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; BETA-CATENIN; TUMOR-SUPPRESSOR; KINASE; GENE; PHOSPHORYLATION; PATHWAY; INSULIN; COLON	Human colorectal cancers are known to possess multiple mutations, though how these mutations interact in tumor development and progression has not been fully investigated. We have previously described the FCPIK3ca* murine colon cancer model, which expresses a constitutively activated phosphoinositide-3 kinase (PI3K) in the intestinal epithelium. The expression of this dominantly active form of PI3K results in hyperplasia and invasive mucinous adenocarcinomas. These cancers form via a non-canonical mechanism of tumor initiation that is mediated through activation of PI3K and not through aberrations in WNT signaling. Since the Adenomatous Polyposis Coli (APC) gene is mutated in the majority of human colon cancers and often occurs simultaneously with PIK3CA mutations, we sought to better understand the interaction between APC and PIK3CA mutations in the mammalian intestine. In this study, we have generated mice in which the expression of a constitutively active PI3K and the loss of APC occur simultaneously in the distal small intestine and colon. Here, we demonstrate that expression of a dominant active PI3K synergizes with loss of APC activity resulting in a dramatic change in tumor multiplicity, size, morphology and invasiveness. Activation of the PI3K pathway is not able to directly activate WNT signaling through the nuclear localization of CTNNB1 (beta-catenin) in the absence of aberrant WNT signaling. Alterations at the transcriptional level, including increased CCND1, may be the etiology of synergy between these activated pathways.	[Deming, D. A.] Univ Wisconsin, Dept Med, Div Hematol & Oncol, Madison, WI 53792 USA; [Leystra, A. A.; Clipson, L.] Univ Wisconsin, Dept Oncol, Madison, WI 53792 USA; [Nettekoven, L.; Miller, D.; Middlebrooks, M.; Albrecht, D.; Halberg, R. B.] Univ Wisconsin, Dept Med, Div Gastroenterol & Hepatol, Madison, WI 53792 USA; [Sievers, C.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53792 USA; [Bacher, J.] Promega Corp, Madison, WI USA; [Washington, M. K.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA; [Washington, M. K.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA; [Weichert, J.] Univ Wisconsin, Dept Radiol, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Promega Corporation; Vanderbilt University; Vanderbilt University; University of Wisconsin System; University of Wisconsin Madison	Halberg, RB (corresponding author), Univ Wisconsin, Dept Med, Ctr Clin Sci, 600 Highland Ave,K4-532, Madison, WI 53792 USA.	rbhalberg@medicine.wisc.edu		Sievers, Chelsie/0000-0003-0088-753X	Conquer Cancer Foundation of the American Society of Clinical Oncology through A Young Investigator Award; National Cancer Institute of the US National Institutes of Health [T32 CA009614, P50 CA095103, R01 CA123438, P30 CA014520]; UW Division of Gastroenterology and Hepatology; UW Department of Medicine; UW School of Medicine and Public Health; NATIONAL CANCER INSTITUTE [P30CA014520, R01CA123438, T32CA009614, T32CA009135, P50CA095103] Funding Source: NIH RePORTER	Conquer Cancer Foundation of the American Society of Clinical Oncology through A Young Investigator Award; National Cancer Institute of the US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UW Division of Gastroenterology and Hepatology; UW Department of Medicine; UW School of Medicine and Public Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ella Ward and Jane Weeks in Experimental Pathology at the UW Carbone Cancer Center for their technical assistance. This project was supported by the Conquer Cancer Foundation of the American Society of Clinical Oncology through A Young Investigator Award (DAD); the National Cancer Institute of the US National Institutes of Health through T32 CA009614 (DAD), P50 CA095103 (Gastrointestinal Specialized Program of Research Excellence Grant, Vanderbilt Ingram Cancer Center), R01 CA123438 (RBH), P30 CA014520 (Core Grant, University of Wisconsin Carbone Cancer Center); and start-up funds (RBH) from the UW Division of Gastroenterology and Hepatology, the UW Department of Medicine, and the UW School of Medicine and Public Health.	American Cancer Society, 2012, CANC FACTS FIG 2012; Armaghany Tannaz, 2012, Gastrointest Cancer Res, V5, P19; Bacher JW, 2005, MOL CARCINOGEN, V44, P285, DOI 10.1002/mc.20146; Boland CR, 1998, CANCER RES, V58, P5248; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Des Guetz G, 2009, EUR J CANCER, V45, P1890, DOI 10.1016/j.ejca.2009.04.018; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Hung KE, 2010, P NATL ACAD SCI USA, V107, P1565, DOI 10.1073/pnas.0908682107; Kinzler K.W., 2002, GENETIC BASIS HUMAN, V2, P583; Leystra AA, 2012, CANCER RES, V72, P2931, DOI 10.1158/0008-5472.CAN-11-4097; Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Naito AT, 2005, CIRC RES, V97, P144, DOI 10.1161/01.RES.0000175241.92285.f8; Ng SS, 2009, J BIOL CHEM, V284, P35308, DOI 10.1074/jbc.M109.078261; Nosho K, 2008, NEOPLASIA, V10, P534, DOI 10.1593/neo.08336; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Srinivasan L, 2009, CELL, V139, P573, DOI 10.1016/j.cell.2009.08.041; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Tanwar PS, 2011, CANCER RES, V71, P1584, DOI 10.1158/0008-5472.CAN-10-3166; Velho S, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-255; Whitehall VLJ, 2012, INT J CANCER, V131, P813, DOI 10.1002/ijc.26440; Zhao L, 2010, CELL CYCLE, V9, P596, DOI 10.4161/cc.9.3.10599	32	44	46	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2245	2254		10.1038/onc.2013.167	http://dx.doi.org/10.1038/onc.2013.167			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23708654	Green Accepted			2022-12-17	WOS:000334996000010
J	Hou, Y; Zhang, Z; Xu, Q; Wang, H; Xu, Y; Chen, K				Hou, Y.; Zhang, Z.; Xu, Q.; Wang, H.; Xu, Y.; Chen, K.			Inhibitor of growth 4 induces NF kappa B/p65 ubiquitin-dependent degradation	ONCOGENE			English	Article						ING4; NF kappa B/p65; ubiquitination; degradation	NF-KAPPA-B; TUMOR-SUPPRESSOR GENE; CELL-GROWTH; DOWN-REGULATION; ING4; ACTIVATION; APOPTOSIS; PROTEINS; BINDING; LIGASES	As a tumor suppressor protein, the inhibitor of growth 4 (ING4) has an important role in many cellular processes including cell cycle progression, proliferation, apoptosis, DNA damage response, tumor angiogenesis and contact inhibition. Here, we report that ING4 functions as an E3 ubiquitin ligase to induce nuclear factor-kappa B (NF kappa B)/p65 degradation. The plant homeodomain finger of ING4 interacted with p65 to undergo robust ubiquitination and degradation. ING4 bound to p65 and delivered the Lys-48-linked polyubiquitin to Lys-62 residue of p65, leading to ubiquitination of p65 and degradation. Lys-62 residue of p65 was required for ING4-mediated ubiquitination of p65 and degradation. Further analysis shows that C239 of ING4 was critical for ING4-induced p65 degradation. These findings demonstrate that ING4 acts as an E3 ubiquitin ligase to induce ubiquitination of p65 and degradation, which is critical to terminate NFkB activation.	[Hou, Y.; Zhang, Z.; Xu, Q.; Xu, Y.; Chen, K.] Jiangsu Univ, Inst Life Sci, Zhenjiang 2121300, Jiangsu, Peoples R China; [Wang, H.] Tianjin Univ Tradit Chinese Med, Tianjin, Peoples R China	Jiangsu University; Tianjin University of Traditional Chinese Medicine	Hou, Y (corresponding author), Jiangsu Univ, Inst Life Sci, Zhenjiang 2121300, Jiangsu, Peoples R China.	houyz@ujs.edu.cn	hou, YONGZHONG/K-7771-2013	xu, qinggang/0000-0002-8659-7041; Hou, Yongzhong/0000-0003-2019-8686	Start Fund of Jiangsu University [12JDG071]; National Natural Science Foundation of China [81173592]; Tianjin Applied Basic Research and Frontier Technological Program [11JCZDJC21100]	Start Fund of Jiangsu University; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Applied Basic Research and Frontier Technological Program	This work was supported by Start Fund of Jiangsu University (12JDG071). National Natural Science Foundation of China (81173592), Tianjin Applied Basic Research and Frontier Technological Program (11JCZDJC21100).	Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Byron SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046823; Cai LM, 2009, MELANOMA RES, V19, P1, DOI 10.1097/CMR.0b013e32831bc42f; Coles AH, 2010, P NATL ACAD SCI USA, V107, P11423, DOI 10.1073/pnas.0912116107; Coles AH, 2009, J CELL PHYSIOL, V218, P45, DOI 10.1002/jcp.21583; Coscoy L, 2003, TRENDS CELL BIOL, V13, P7, DOI 10.1016/S0962-8924(02)00005-3; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Gunduz M, 2005, GENE, V356, P109, DOI 10.1016/j.gene.2005.02.014; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hou YZ, 2007, J BIOL CHEM, V282, P9279, DOI 10.1074/jbc.M608523200; Hou YZ, 2010, J BIOL CHEM, V285, P35497, DOI 10.1074/jbc.M109.066035; Hung T, 2009, MOL CELL, V33, P248, DOI 10.1016/j.molcel.2008.12.016; Ivanov AV, 2007, MOL CELL, V28, P823, DOI 10.1016/j.molcel.2007.11.012; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim S, 2004, P NATL ACAD SCI USA, V101, P16251, DOI 10.1073/pnas.0407158101; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li XM, 2009, J CANCER RES CLIN, V135, P829, DOI 10.1007/s00432-008-0519-7; Natoli G, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.11pe1; Nozell S, 2008, MOL CELL BIOL, V28, P6632, DOI 10.1128/MCB.00697-08; Ozer A, 2005, P NATL ACAD SCI USA, V102, P7481, DOI 10.1073/pnas.0502716102; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Russell M, 2006, EXP CELL RES, V312, P951, DOI 10.1016/j.yexcr.2006.01.020; Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196; Shen JC, 2007, CANCER RES, V67, P2552, DOI 10.1158/0008-5472.CAN-06-3870; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Tanaka T, 2007, NAT IMMUNOL, V8, P584, DOI 10.1038/ni1464; Uchida D, 2004, J EXP MED, V199, P167, DOI 10.1084/jem.20031291; Unoki M, 2006, J BIOL CHEM, V281, P34677, DOI 10.1074/jbc.M606296200; Wang QS, 2010, HISTOPATHOLOGY, V57, P271, DOI 10.1111/j.1365-2559.2010.03623.x; Xie YF, 2008, CANCER LETT, V271, P105, DOI 10.1016/j.canlet.2008.05.050; Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041; Zhang X, 2005, BIOCHEM BIOPH RES CO, V331, P1032, DOI 10.1016/j.bbrc.2005.04.023; Zhang X, 2004, FEBS LETT, V570, P7, DOI 10.1016/j.febslet.2004.06.010	35	44	45	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1997	2003		10.1038/onc.2013.135	http://dx.doi.org/10.1038/onc.2013.135			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23624912				2022-12-17	WOS:000334346300012
J	Gao, M; Liang, J; Lu, Y; Guo, H; German, P; Bai, S; Jonasch, E; Yang, X; Mills, GB; Ding, Z				Gao, M.; Liang, J.; Lu, Y.; Guo, H.; German, P.; Bai, S.; Jonasch, E.; Yang, X.; Mills, G. B.; Ding, Z.			Site-specific activation of AKT protects cells from death induced by glucose deprivation	ONCOGENE			English	Article						glucose deprivation; site-specific AKT phosphorylation; substrate-specific AKT activation; cell survival	GROWTH-FACTORS; IN-VITRO; KINASE; PATHWAY; PHOSPHORYLATION; INHIBITOR; TARGET; SURVIVAL; IDENTIFICATION; PHOSPHATASE	The serine/threonine kinase AKT is a key mediator of cancer cell survival. We demonstrate that transient glucose deprivation modestly induces AKT phosphorylation at both Thr308 and Ser473. In contrast, prolonged glucose deprivation induces selective AKTThr308 phosphorylation and phosphorylation of a distinct subset of AKT downstream targets leading to cell survival under metabolic stress. Glucose-deprivation-induced AKTThr308 phosphorylation is dependent on PDK1 and PI3K but not EGF receptor or IGF1R. Prolonged glucose deprivation induces the formation of a complex of AKT, PDK1 and the GRP78 chaperone protein, directing phosphorylation of AKTThr308 but not AKTSer473. Our results reveal a novel mechanism of AKT activation under prolonged glucose deprivation that protects cells from metabolic stress. The selective activation of AKTThr308 phosphorylation that occurs during prolonged nutrient deprivation may provide an unexpected opportunity for the development and implementation of drugs targeting cell metabolism and aberrant AKT signaling.	[Gao, M.; Yang, X.] Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, Jinan 250100, Peoples R China; [Gao, M.; Liang, J.; Lu, Y.; Guo, H.; Mills, G. B.; Ding, Z.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [German, P.; Bai, S.; Jonasch, E.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA	Shandong University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mills, GB (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	gmills@mdanderson.org; zding@mdanderson.org			National Institutes of Health (NIH) [5R21CA126700]; University of Texas MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program; AstraZeneca; GlaxoSmithKline; NIH [CA016672];  [P01CA099031];  [P50CA083639];  [SU2C-AACR-DT0209]; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA098258, R21CA126700, P50CA083639, P01CA099031] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Texas MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program; AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Qinghua Yu and Nancy Shih for technical assistance for RPPA experiments. The work was supported by National Institutes of Health (NIH) grant 5R21CA126700, a grant from The University of Texas MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program and research support from AstraZeneca to ZD, and P01CA099031, P50CA083639, SU2C-AACR-DT0209 and research support from AstraZeneca and GlaxoSmithKline to GBM. RPPA was performed at the MD Anderson RPPA Core Facility (supported by NIH grant CA016672).	Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751; Ding ZY, 2006, P NATL ACAD SCI USA, V103, P15014, DOI 10.1073/pnas.0606917103; Ding ZY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009910; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Ericson K, 2010, P NATL ACAD SCI USA, V107, P2598, DOI 10.1073/pnas.0914018107; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Folkman J, 2003, SEMIN CANCER BIOL, V13, P159, DOI 10.1016/S1044-579X(02)00133-5; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Gewinner C, 2009, CANCER CELL, V16, P115, DOI 10.1016/j.ccr.2009.06.006; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hennessy BT, 2009, CLIN CANCER RES, V15, P417, DOI 10.1158/1078-0432.CCR-08-2620; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Higuchi M, 2008, NAT CELL BIOL, V10, P1356, DOI 10.1038/ncb1795; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Kim KY, 2009, CANCER RES, V69, P4018, DOI 10.1158/0008-5472.CAN-08-2641; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lu Y, 2011, ONCOGENE, V30, P4567, DOI 10.1038/onc.2011.164; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; MacDonald ML, 2006, NAT CHEM BIOL, V2, P329, DOI 10.1038/nchembio790; Macias AT, 2011, J MED CHEM, V54, P4034, DOI 10.1021/jm101625x; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732; Nakamura A, 2008, MOL CELL BIOL, V28, P5996, DOI 10.1128/MCB.00114-08; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Pelicano H, 2006, J CELL BIOL, V175, P913, DOI 10.1083/jcb.200512100; Pfaffenbach KT, 2011, CURR OPIN CELL BIOL, V23, P150, DOI 10.1016/j.ceb.2010.09.007; Roberts HR, 2011, CARCINOGENESIS, V32, P1741, DOI 10.1093/carcin/bgr210; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026; Tremblay F, 2007, P NATL ACAD SCI USA, V104, P14056, DOI 10.1073/pnas.0706517104; Vincent EE, 2011, BRIT J CANCER, V104, P1755, DOI 10.1038/bjc.2011.132; von der Crone S, 2000, EUR J CELL BIOL, V79, P943, DOI 10.1078/0171-9335-00118; Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97; Worster DT, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2001986; Zhong DS, 2008, MOL CANCER THER, V7, P809, DOI 10.1158/1535-7163.MCT-07-0559; Zhong DS, 2009, J BIOL CHEM, V284, P23225, DOI 10.1074/jbc.M109.005280	48	44	44	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					745	755		10.1038/onc.2013.2	http://dx.doi.org/10.1038/onc.2013.2			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23396361	Green Accepted			2022-12-17	WOS:000331129200009
J	Zheng, H; Chen, L; Pledger, WJ; Fang, J; Chen, J				Zheng, H.; Chen, L.; Pledger, W. J.; Fang, J.; Chen, J.			p53 promotes repair of heterochromatin DNA by regulating JMJD2b and SUV39H1 expression	ONCOGENE			English	Article						p53; JMJD2b; SUV39H1; heterochromatin; DNA damage; repair	DOUBLE-STRAND BREAKS; TELOMERIC REPEAT-LENGTH; RADIATION SENSITIVITY; H2AX PHOSPHORYLATION; MAMMALIAN-CELLS; ATM-DEFICIENT; CANCER; DAMAGE; P53-DEFICIENT; SENESCENCE	Constitutive heterochromatin (HC) is important for maintaining chromosome stability, but also delays the repair of DNA double-strand breaks (DSBs). DSB repair in complex mammalian genomes involves a fast phase (2-6 h) in which most of the breaks are rapidly repaired, and a slow phase (up to 24 h) in which the remaining damages in HC are repaired. We found that p53 deficiency delays the slow-phase DNA repair after ionizing irradiation. p53 deficiency prevents downregulation of histone H3K9 trimethylation at the pericentric HC after DNA damage. Moreover, p53 directly induces expression of the H3K9 demethylase Jumonji domain 2 family demethylase (JMJD2b) through promoter binding. The p53 activation also indirectly downregulates expression of the H3K9 methyltransferase SUV39H1. Depletion of JMJD2b or sustained expression of SUV39H1 delays the repair of HC DNA and reduces clonogenic survival after ionizing irradiation. The results suggest that by regulating JMJD2b and SUV39H1 expression, p53 not only controls transcription but also promotes HC relaxation to accelerate a rate-limiting step in the repair of complex genomes.	[Zheng, H.; Chen, L.; Pledger, W. J.; Fang, J.; Chen, J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute	Chen, J (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, MRC3057A,12902 Magnolia Dr, Tampa, FL 33612 USA.	Jiandong.chen@moffitt.org		Fang, Jia/0000-0001-8583-1652	Florida Department of Health James and Esther King Biomedical Research Program; National Institutes of Health [CA141244, CA109636]; NATIONAL CANCER INSTITUTE [R01CA141244, R01CA109636, P30CA076292] Funding Source: NIH RePORTER	Florida Department of Health James and Esther King Biomedical Research Program; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Moffitt Molecular Genomics Core for DNA sequence analyses, and Analytic Microscopy Core for image quantification. We also want to thank Dr. Savitha Sharma for providing the inducible p27 cell line. H Zheng is supported by a postdoctoral fellowship from the Florida Department of Health James and Esther King Biomedical Research Program. This work is supported by grants from the National Institutes of Health to J Chen (CA141244, CA109636).	Ayoub N, 2008, NATURE, V453, P682, DOI 10.1038/nature06875; Ayoub N, 2009, CELL CYCLE, V8, P2945; Banath JP, 2004, CANCER RES, V64, P7144, DOI 10.1158/0008-5472.CAN-04-1433; BATZER MA, 1994, GENET ANAL-BIOMOL E, V11, P34, DOI 10.1016/1050-3862(94)90058-2; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bertheau P, 2002, LANCET, V360, P852, DOI 10.1016/S0140-6736(02)09969-5; Bertheau P, 2007, PLOS MED, V4, P585, DOI 10.1371/journal.pmed.0040090; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; Bishop AJR, 2003, CANCER RES, V63, P5335; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Bosch-Presegue L, 2011, MOL CELL, V42, P210, DOI 10.1016/j.molcel.2011.02.034; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chen LH, 2010, EMBO J, V29, P2538, DOI 10.1038/emboj.2010.140; Cheng Q, 2009, EMBO J, V28, P3857, DOI 10.1038/emboj.2009.294; Chiolo I, 2011, CELL, V144, P732, DOI 10.1016/j.cell.2011.02.012; Cowell IG, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001057; Cuddihy AR, 2004, CANCER METAST REV, V23, P237, DOI 10.1023/B:CANC.0000031764.81141.e4; Dikomey E, 1998, INT J RADIAT BIOL, V73, P269, DOI 10.1080/095530098142365; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Finelli P, 1996, GENOMICS, V38, P325, DOI 10.1006/geno.1996.0635; Fodor BD, 2006, GENE DEV, V20, P1557, DOI 10.1101/gad.388206; Garcia-Cao M, 2004, NAT GENET, V36, P94, DOI 10.1038/ng1278; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Goodarzi AA, 2010, DNA REPAIR, V9, P1273, DOI 10.1016/j.dnarep.2010.09.013; Goodier JL, 2008, CELL, V135, P23, DOI 10.1016/j.cell.2008.09.022; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; HARVEY M, 1993, ONCOGENE, V8, P2457; Helton ES, 2007, J CELL BIOCHEM, V100, P883, DOI 10.1002/jcb.21091; HIYAMA K, 1995, ONCOGENE, V10, P937; Huang BY, 2009, MOL CANCER RES, V7, P1497, DOI 10.1158/1541-7786.MCR-09-0144; Jackson JG, 2012, CANCER CELL, V21, P793, DOI 10.1016/j.ccr.2012.04.027; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Kondo Y, 2003, J BIOL CHEM, V278, P27658, DOI 10.1074/jbc.M304072200; Kroger N, 2006, CLIN CANCER RES, V12, P159, DOI 10.1158/1078-0432.CCR-05-1340; Kuhne M, 2004, CANCER RES, V64, P500, DOI 10.1158/0008-5472.CAN-03-2384; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Luijsterburg MS, 2009, J CELL BIOL, V185, P577, DOI 10.1083/jcb.200810035; Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Mungamuri SK, 2012, NAT STRUCT MOL BIOL, V19, P478, DOI 10.1038/nsmb.2271; Murga M, 2007, J CELL BIOL, V178, P1101, DOI 10.1083/jcb.200704140; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Ohki S, 2003, INT J MOL MED, V11, P485; Palomera-Sanchez Z, 2010, J BIOL CHEM, V285, P31370, DOI 10.1074/jbc.M110.128462; Peng JC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000435; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Puerto S, 2001, MUTAGENESIS, V16, P291, DOI 10.1093/mutage/16.4.291; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Scott SL, 2003, CANCER RES, V63, P7190; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Sharma SS, 2012, ONCOGENE, V31, P3989, DOI 10.1038/onc.2011.550; Slee RB, 2012, ONCOGENE, V31, P3244, DOI 10.1038/onc.2011.502; TAKAHASHI K, 1985, INT J RADIAT BIOL, V48, P389, DOI 10.1080/09553008514551391; Taneja N, 2004, J BIOL CHEM, V279, P2273, DOI 10.1074/jbc.M310030200; Tjeertes JV, 2009, EMBO J, V28, P1878, DOI 10.1038/emboj.2009.119; Yan WS, 2010, J BIOL CHEM, V285, P14229, DOI 10.1074/jbc.M109.097253; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	65	44	44	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					734	744		10.1038/onc.2013.6	http://dx.doi.org/10.1038/onc.2013.6			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23376847	Green Accepted			2022-12-17	WOS:000331129200008
J	Dikshit, B; Irshad, K; Madan, E; Aggarwal, N; Sarkar, C; Chandra, PS; Gupta, DK; Chattopadhyay, P; Sinha, S; Chosdol, K				Dikshit, B.; Irshad, K.; Madan, E.; Aggarwal, N.; Sarkar, C.; Chandra, P. S.; Gupta, D. K.; Chattopadhyay, P.; Sinha, S.; Chosdol, K.			FAT1 acts as an upstream regulator of oncogenic and inflammatory pathways, via PDCD4, in glioma cells	ONCOGENE			English	Article						FAT1; inflammation; PDCD4; AP-1; COX-2; glioma	TUMOR-SUPPRESSOR GENE; INDEPENDENT PROGNOSTIC-FACTOR; HUMAN LUNG-CANCER; BREAST-CANCER; TRANSCRIPTION FACTOR; DEATH 4; C-JUN; DOWN-REGULATION; TRANSFORMATION SUPPRESSOR; FREQUENT LOSS	Glioblastoma multiforme (GBM) is the most aggressive and the commonest primary brain tumor with a tendency for local invasiveness. The pathways of neoplasia, invasion and inflammation are inextricably linked in cancer and aberrations in several regulatory pathways for these processes have been identified. Here we have studied the FAT1 (Homo sapiens FAT tumor-suppressor homolog 1 (Drosophila)) gene to identify its role in the tumorigenecity of the gliomas. The expression of FAT1 was found to be high in grade IV glioma cell lines (U87MG, A172, U373MG and T98G) but low in grade III glioma cell lines (GOS3 and SW1088). Two cell lines (U87MG and A172) with high FAT1 expression were chosen for in vitro FAT1-knockdown studies. FAT1 knockdown by small interfering RNA resulted in decreased migration and invasion of both the cell lines along with increased expression of the tumor-suppressor gene programmed cell death 4 (PDCD4). Increased PDCD4 expression led to the attenuation of activator protein-1 (AP-1) transcription by inhibiting c-Jun phosphorylation and resulted in concomitant decrease in the expression of AP-1-target genes like MMP3, VEGF-C and PLAU, the pro-inflammatory regulator COX-2 and cytokines IL1 beta and IL-6. Conversely, simultaneous silencing of PDCD4 and FAT1 in these cells significantly enhanced AP-1 activity and expression of its target genes, resulting in increase in mediators of inflammation and in enhanced migratory and invasive properties of the cells. We also observed a negative correlation between the expression of FAT1 and PDCD4 (P = 0.0145), a positive correlation between the expression of FAT1 and COX-2 (P = 0.048) and a similar positive trend between FAT1 and IL-6 expression in 35 primary human GBM samples studied. Taken together, this study identifies a novel signaling mechanism mediated by FAT1 in regulating the activity of PDCD4 and thereby the key transcription factor AP-1, which then affects known mediators of neoplasia and inflammation.	[Dikshit, B.; Irshad, K.; Madan, E.; Aggarwal, N.; Chattopadhyay, P.; Sinha, S.; Chosdol, K.] All India Inst Med Sci, Dept Biochem, New Delhi 110029, India; [Sarkar, C.] All India Inst Med Sci, Dept Pathol, New Delhi 110029, India; [Chandra, P. S.] All India Inst Med Sci, Dept Neurosurg, New Delhi 110029, India; [Sinha, S.] Natl Brain Res Ctr, Gurgaon, India	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC)	Sinha, S (corresponding author), Natl Brain Res Ctr, Near NSG Campus, Manesar 122050, Gurgaon, India.	sub_sinha@hotmail.com; kunzangchosdol@yahoo.com	Irshad, Khushboo/AAT-6842-2020; Aggarwal, Nupur/K-1296-2019	Irshad, Khushboo/0000-0002-1552-3686; Aggarwal, Nupur/0000-0002-7992-0023; chosdol, kunzang/0000-0002-7065-3395	Defense Research and Development Organization (DRDO), India [LSRB167-2008]; National Brain Research Center, India; Council of Scientific and Industrial Research (CSIR, India); Indian Council of Medical Research (ICMR, India)	Defense Research and Development Organization (DRDO), India(Defence Research & Development Organisation (DRDO)); National Brain Research Center, India; Council of Scientific and Industrial Research (CSIR, India)(Council of Scientific & Industrial Research (CSIR) - India); Indian Council of Medical Research (ICMR, India)(Indian Council of Medical Research (ICMR))	The work has been supported by grant from Defense Research and Development Organization (DRDO), India (no. LSRB167-2008) to KC and National Brain Research Center, India, core intramural grant to SS. RF (Research fellowship) to BD and EM from Council of Scientific and Industrial Research (CSIR, India) and RF to KI from Indian Council of Medical Research (ICMR, India). We would like to acknowledge Dr Miguel Iniguez for providing COX-2 promoter luciferase plasmid and Dr Shayamal Goswami, Dr Balaji and Dr Sandeep Saxena for their help during the progress of the work. We thank our Lab technician Ms Jyoti and Lab attendants Late Mathura Prasad, Mr Pappu, Mr Gopal and Mr Ajay for their assistance in routine lab work and cell-culture work.	Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; Aggarwal BB, 2009, CURR OPIN PHARMACOL, V9, P351, DOI 10.1016/j.coph.2009.06.020; Alves TR, 2011, LIFE SCI, V89, P532, DOI 10.1016/j.lfs.2011.04.022; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Balkwill F, 2010, CLIN PHARMACOL THER, V87, P401, DOI 10.1038/clpt.2009.312; Bendavid C, 2007, EUR J MED GENET, V50, P66, DOI 10.1016/j.ejmg.2006.09.003; Bennett FC, 2006, CURR BIOL, V16, P2101, DOI 10.1016/j.cub.2006.09.045; Bhattacharya A, 2001, CLIN CANCER RES, V7, P267; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Borrello MG, 2008, CANCER LETT, V267, P262, DOI 10.1016/j.canlet.2008.03.060; Braun GS, 2007, J BIOL CHEM, V282, P22823, DOI 10.1074/jbc.M701758200; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Chiu WT, 2010, NEUROBIOL DIS, V37, P118, DOI 10.1016/j.nbd.2009.09.015; Cho E, 2006, NAT GENET, V38, P1142, DOI 10.1038/ng1887; Chosdol K, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-5; Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535-6108(03)00310-6; de Bock CE, 2012, LEUKEMIA, V26, P918, DOI 10.1038/leu.2011.319; de la Iglesia N, 2008, GENE DEV, V22, P449, DOI 10.1101/gad.1606508; de Visser KE, 2009, CURR PHARM DESIGN, V15, P1844, DOI 10.2174/138161209788453239; Demaria S, 2010, J IMMUNOTHER, V33, P335, DOI 10.1097/CJI.0b013e3181d32e74; Deorukhkar A, 2010, BIOCHEM PHARMACOL, V80, P1904, DOI 10.1016/j.bcp.2010.06.039; Ding LL, 2012, MED ONCOL, V29, P1758, DOI 10.1007/s12032-011-0042-6; DUNNE J, 1995, GENOMICS, V30, P207, DOI 10.1006/geno.1995.9884; Eberstal S, 2012, CANCER IMMUNOL IMMUN, V61, P1191, DOI 10.1007/s00262-011-1196-y; Fleenor DL, 2003, INVEST OPHTH VIS SCI, V44, P3494, DOI 10.1167/iovs.02-0757; Fredlund E, 2008, P NATL ACAD SCI USA, V105, P14094, DOI 10.1073/pnas.0804455105; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Gao F, 2007, ONCOL REP, V17, P123; Gao F, 2009, J CELL MOL MED, V13, P4257, DOI 10.1111/j.1582-4934.2008.00497.x; Garodia Prachi, 2007, J Soc Integr Oncol, V5, P25, DOI 10.2310/7200.2006.029; Gaur AB, 2011, NEURO-ONCOLOGY, V13, P580, DOI 10.1093/neuonc/nor033; Goldbrunner RH, 1998, MICROSC RES TECHNIQ, V43, P250, DOI 10.1002/(SICI)1097-0029(19981101)43:3<250::AID-JEMT7>3.0.CO;2-C; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Grivennikov SI, 2010, CURR OPIN GENET DEV, V20, P65, DOI 10.1016/j.gde.2009.11.004; Hara A, 2004, ACTA NEUROPATHOL, V108, P43, DOI 10.1007/s00401-004-0860-0; Harris Randall E, 2007, Subcell Biochem, V42, P193; Harris Randall E, 2007, Subcell Biochem, V42, P93; Harris RE, 2007, INT J BIOL SCI, V3, P328; Herseth JI, 2009, TOXICOL IN VITRO, V23, P1342, DOI 10.1016/j.tiv.2009.06.031; Hou R, 2006, J CELL BIOL, V173, P417, DOI 10.1083/jcb.200508121; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Joki T, 2000, CANCER RES, V60, P4926; Karamouzis MV, 2007, MOL CANCER RES, V5, P109, DOI 10.1158/1541-7786.MCR-06-0311; Katoh Y, 2006, INT J MOL MED, V18, P523; Krakauer Teresa, 2004, Current Drug Targets - Inflammation and Allergy, V3, P317; Kwaepila N, 2006, PATHOLOGY, V38, P125, DOI 10.1080/00313020600559975; Lankat-Buttgereit B, 2003, BIOL CELL, V95, P515, DOI 10.1016/j.biolcel.2003.09.003; Lankat-Buttgereit B, 2009, BIOL CELL, V101, P309, DOI 10.1042/BC20080191; Leaner VD, 2003, ONCOGENE, V22, P5619, DOI 10.1038/sj.onc.1206644; Leaner VD, 2009, AM J PATHOL, V174, P265, DOI 10.2353/ajpath.2009.071006; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Lim SK, 2011, BMB REP, V44, P158, DOI 10.5483/BMBRep.2011.44.3.158; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Mandal RK, 2011, ARCH MED RES, V42, P620, DOI 10.1016/j.arcmed.2011.10.005; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mao YP, 2006, DEVELOPMENT, V133, P2539, DOI 10.1242/dev.02427; Moeller MJ, 2004, EMBO J, V23, P3769, DOI 10.1038/sj.emboj.7600380; Moore MM, 2010, CLIN PHARMACOL THER, V87, P504, DOI 10.1038/clpt.2009.254; Mudduluru G, 2007, CANCER-AM CANCER SOC, V110, P1697, DOI 10.1002/cncr.22983; Munshi A., 2009, Indian Journal of Cancer, V46, P127, DOI 10.4103/0019-509X.49150; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Nakaya K, 2007, ONCOGENE, V26, P5300, DOI 10.1038/sj.onc.1210330; New Pamela, 2004, Cancer Control, V11, P152; Nieves-Alicea R, 2009, BREAST CANCER RES TR, V114, P203, DOI 10.1007/s10549-008-9993-5; Nishikawa Y, 2011, ONCOL REP, V26, P587, DOI 10.3892/or.2011.1324; Noble M, 1997, J NEURO-ONCOL, V35, P193, DOI 10.1023/A:1005898228116; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; Reddy BVVG, 2008, DEVELOPMENT, V135, P2827, DOI 10.1242/dev.020974; Santhanam AN, 2010, ONCOGENE, V29, P3921, DOI 10.1038/onc.2010.158; Sareddy GR, 2012, J NEURO-ONCOL, V106, P99, DOI 10.1007/s11060-011-0662-x; Schmid T, 2011, CARCINOGENESIS, V32, P1427, DOI 10.1093/carcin/bgr131; SCHONTHAL A, 1992, P NATL ACAD SCI USA, V89, P4972, DOI 10.1073/pnas.89.11.4972; Sen E, 2011, DRUG DISCOV TODAY, V16, P1044, DOI 10.1016/j.drudis.2011.09.003; Sharma V, 2011, NEUROCHEM INT, V59, P567, DOI 10.1016/j.neuint.2011.06.018; Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Shono T, 2001, CANCER RES, V61, P4375; Silva E, 2006, CURR BIOL, V16, P2081, DOI 10.1016/j.cub.2006.09.004; Sinha S, 2011, CELL SIGNAL, V23, P1869, DOI 10.1016/j.cellsig.2011.06.024; Subbaramaiah K, 2002, CANCER RES, V62, P2522; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Tafani M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-32; Tanoue T, 2005, J CELL SCI, V118, P2347, DOI 10.1242/jcs.02398; Tanoue T, 2004, J CELL BIOL, V165, P517, DOI 10.1083/jcb.200403006; Teodorczyk M, 2010, J CELL PHYSIOL, V222, P1, DOI 10.1002/jcp.21901; Tewari R, 2012, J MOL MED, V90, P67, DOI 10.1007/s00109-011-0807-6; Tsuji F, 2007, INT IMMUNOPHARMACOL, V7, P1569, DOI 10.1016/j.intimp.2007.07.020; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Wang WQ, 2010, MOL DIAGN THER, V14, P155, DOI 10.2165/11536340-000000000-00000; Wang XY, 2008, ANTICANCER RES, V28, P2991; Waters LC, 2011, J BIOL CHEM, V286, P17270, DOI 10.1074/jbc.M110.166157; Wei ZT, 2009, CANCER SCI, V100, P1408, DOI 10.1111/j.1349-7006.2009.01210.x; Wen YH, 2007, ONCOL REP, V18, P1387; Willecke M, 2006, CURR BIOL, V16, P2090, DOI 10.1016/j.cub.2006.09.005; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yasuda M, 2010, MOL CARCINOGEN, V49, P837, DOI 10.1002/mc.20660; Zhang ZH, 2001, ONCOGENE, V20, P4450, DOI 10.1038/sj.onc.1204588	104	44	48	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3798	3808		10.1038/onc.2012.393	http://dx.doi.org/10.1038/onc.2012.393			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22986533				2022-12-17	WOS:000323210200002
J	Lai, KC; Liu, CJ; Chang, KW; Lee, TC				Lai, K. C.; Liu, C. J.; Chang, K. W.; Lee, T. C.			Depleting IFIT2 mediates atypical PKC signaling to enhance the migration and metastatic activity of oral squamous cell carcinoma cells	ONCOGENE			English	Article						IFIT2; oral squamous cell carcinoma; epithelial-mesenchymal transition; migration; invasion; atypical PKC	EPITHELIAL-MESENCHYMAL TRANSITION; GLYCOGEN-SYNTHASE KINASE-3; BREAST-CANCER; E-CADHERIN; HEAD; EXPRESSION; SURVIVAL; INVASION; GENES; CDC42	Interferon-induced protein with tetratricopeptide repeats 2 (IFIT2) is one of the most highly responsive interferon-stimulated genes, but its biological functions are poorly understood. In this study, we aimed to explore the underlying mechanisms by which depleting IFIT2 induces the migration of oral squamous cell carcinoma (OSCC) cells. Stable IFIT2-depleted cells underwent epithelial-mesenchymal transition (EMT) and exhibited enhanced cell motility and invasiveness compared with control cells. Furthermore, our results indicated that atypical protein kinase C (aPKC) was activated in IFIT2-depleted cells. Inhibition of aPKC using a specific myristoylated PKC zeta pseudosubstrate or aPKC-targeting small interfering RNA (siRNA) abolished IFIT2 depletion-induced EMT, migration and invasion, indicating that the activation of aPKC has an essential role in regulating the cellular responses induced by IFIT2 depletion. Following tail-vein injection, IFIT2-depleted OSCC cells colonized not only the lungs but also the heart, head and neck, retroperitoneal, and peritoneal cavities; whereas control cells predominantly localized in the lungs. IFIT2 mRNA and protein expression was positively associated with E-cadherin expression in OSCC patient specimens. The loss of E-cadherin and IFIT2 expression was observed at the invasive front of OSCC tumors, suggesting that the loss of IFIT2 may induce EMT and lead to the metastasis of OSCCs. OSCC patients possessing reduced IFIT2-expression levels (IFIT2 <50%) exhibited greater rates of distant metastasis and poor prognoses compared with OSCC patients who expressed greater levels of IFIT2 (IFIT2 >= 50%). These results demonstrate that IFIT2 depletion activates the aPKC pathway and consequently induces EMT, cell migration and invasion. Most importantly, depleting IFIT2 may participate in OSCC tumor progression, particularly during metastasis. Taken together, our study demonstrates that IFIT2, a protein responsible for interferon stimulation, may prevent OSCC metastasis and serve as a valuable prognostic marker.	[Lai, K. C.] Tzu Chi Univ, Dept Pharmacol, Hualien, Taiwan; [Lai, K. C.; Lee, T. C.] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; [Liu, C. J.] Mackay Mem Hosp, Dept Oral & Maxillofacial Surg, Taipei, Taiwan; [Chang, K. W.] Natl Yang Ming Univ, Sch Dent, Inst Oral Biol, Taipei 112, Taiwan	Tzu Chi University; Academia Sinica - Taiwan; Mackay Memorial Hospital; National Yang Ming Chiao Tung University	Lee, TC (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Sect 2,Acad Rd Nankang, Taipei 115, Taiwan.	bmtcl@ibms.sinica.edu.tw	Lee, Te-Chang/B-3245-2011	Lee, Te-Chang/0000-0003-4448-1507	Academia Sinica; National Science Council, Taiwan, ROC [NSC 93-3112-B-001-036, NSC 98-2320-B-001-002-MY3]	Academia Sinica(Academia Sinica - Taiwan); National Science Council, Taiwan, ROC(Ministry of Science and Technology, Taiwan)	We thank the Pathological Core Laboratory supported by Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, ROC for their excellent technical assistance on pathological examination. We also thank Dr Michael Hsiao (Genomics Research Center, Academia Sinica, Taipei, Taiwan, ROC) for providing lentiviral particles and experimental assistance. This work was also supported by the Academia Sinica and grants from the National Science Council, Taiwan, ROC (NSC 93-3112-B-001-036; NSC 98-2320-B-001-002-MY3).	ALBINI A, 1987, CANCER RES, V47, P3239; Bagan JV, 2009, ORAL ONCOL, V45, pE45, DOI 10.1016/j.oraloncology.2008.12.012; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Bell RB, 2007, J ORAL MAXIL SURG, V65, P229, DOI 10.1016/j.joms.2005.11.094; Chang SY, 2009, CYTOKINE, V45, P32, DOI 10.1016/j.cyto.2008.10.013; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Cooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Department of Health TEY, 2010, CANC REG ANN REP TAI; Doble BW, 2007, CELLS TISSUES ORGANS, V185, P73, DOI 10.1159/000101306; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Fan S, 2011, INT J ORAL SCI, V3, P180, DOI 10.4248/IJOS11068; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Ferlito A, 2001, ORL J OTO-RHINO-LARY, V63, P189, DOI 10.1159/000055738; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gonzalez-Garcia R, 2009, HEAD NECK-J SCI SPEC, V31, P1168, DOI 10.1002/hed.21088; Kim D W, 2001, Exp Mol Med, V33, P101; Korsching E, 2005, J PATHOL, V206, P451, DOI 10.1002/path.1797; Lai KC, 2008, MOL CANCER RES, V6, P1; Leon X, 1999, HEAD NECK-J SCI SPEC, V21, P204, DOI 10.1002/(SICI)1097-0347(199905)21:3<204::AID-HED4>3.0.CO;2-7; LEVY D, 1986, P NATL ACAD SCI USA, V83, P8929, DOI 10.1073/pnas.83.23.8929; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Lorusso G, 2012, SEMIN CANCER BIOL, V22, P226, DOI 10.1016/j.semcancer.2012.03.007; Lu X, 2007, J MAMMARY GLAND BIOL, V12, P153, DOI 10.1007/s10911-007-9047-3; Ma C, 2007, CANCER RES, V67, P7756, DOI 10.1158/0008-5472.CAN-06-4665; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Mishra R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-144; Ohira T, 2003, P NATL ACAD SCI USA, V100, P10429, DOI 10.1073/pnas.1734137100; Parkin DM, 2005, CA CANC J CLIN, V55, P74; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rao DN, 1998, BRIT J CANCER, V77, P1514, DOI 10.1038/bjc.1998.249; Rosse C, 2010, NAT REV MOL CELL BIO, V11, P103, DOI 10.1038/nrm2847; Saha S, 2006, J GEN VIROL, V87, P3285, DOI 10.1099/vir.0.82107-0; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Sanjiv K, 2012, INT J CANCER, V130, P1440, DOI 10.1002/ijc.26142; Sano D, 2007, CANCER METAST REV, V26, P645, DOI 10.1007/s10555-007-9082-y; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Shingaki S, 2003, AM J SURG, V185, P278, DOI 10.1016/S0002-9610(02)01378-8; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Taki M, 2003, CANCER SCI, V94, P593, DOI 10.1111/j.1349-7006.2003.tb01488.x; Terenzi F, 2006, J BIOL CHEM, V281, P34064, DOI 10.1074/jbc.M605771200; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yonezawa Tomo, 2009, Recent Pat DNA Gene Seq, V3, P96	52	44	48	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2013	32	32					3686	3697		10.1038/onc.2012.384	http://dx.doi.org/10.1038/onc.2012.384			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22986528				2022-12-17	WOS:000322904400004
J	Batlle, R; Alba-Castellon, L; Loubat-Casanovas, J; Armenteros, E; Franci, C; Stanisavljevic, J; Barderas, R; Martin-Caballero, J; Bonilla, F; Baulida, J; Casal, JI; Gridley, T; de Herreros, AG				Batlle, R.; Alba-Castellon, L.; Loubat-Casanovas, J.; Armenteros, E.; Franci, C.; Stanisavljevic, J.; Barderas, R.; Martin-Caballero, J.; Bonilla, F.; Baulida, J.; Casal, J. I.; Gridley, T.; Garcia de Herreros, A.			Snail1 controls TGF-beta responsiveness and differentiation of mesenchymal stem cells	ONCOGENE			English	Article						Snail1; mesenchymal stem cells; TGF-beta; Akt	TRANSCRIPTION FACTOR SNAIL; NF-KAPPA-B; EXPRESSION; REPRESSOR; TRANSITIONS; PROTEIN; STROMA; BINDS; PTEN; AKT1	The Snail1 transcriptional repressor plays a key role in triggering epithelial-to-mesenchymal transition. Although Snail1 is widely expressed in early development, in adult animals it is limited to a subset of mesenchymal cells where it has a largely unknown function. Using a mouse model with inducible depletion of Snail1, here we demonstrate that Snail1 is required to maintain mesenchymal stem cells (MSCs). This effect is associated to the responsiveness to transforming growth factor (TGF)-beta 1 that shows a strong Snail1 dependence. Snail1 depletion in conditional knockout adult animals causes a significant decrease in the number of bone marrow-derived MSCs. In culture, Snail1-deficient MSCs prematurely differentiate to osteoblasts or adipocytes and, in contrast to controls, are resistant to the TGF-beta 1-induced differentiation block. These results demonstrate a new role for Snail1 in TGF-beta response and MSC maintenance.	[Batlle, R.; Alba-Castellon, L.; Loubat-Casanovas, J.; Armenteros, E.; Franci, C.; Stanisavljevic, J.; Baulida, J.; Garcia de Herreros, A.] IMIM, Programa Recerca Cancer, Hosp Mar, Barcelona 08003, Spain; [Barderas, R.; Casal, J. I.] CSIC, Dept Med Mol, Ctr Invest Biol, Madrid, Spain; [Martin-Caballero, J.] Parc Recerca Biomed Barcelona, Anim Facil, Barcelona, Spain; [Bonilla, F.] Hosp Puerta Hierro, Serv Oncol Med, Majadahonda, Spain; [Gridley, T.] Maine Med Ctr Res Inst, Ctr Mol Med, Scarborough, ME USA; [Garcia de Herreros, A.] Univ Pompeu Fabra, Dept Ciencies Expt Salut, Barcelona, Spain	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Hospital Puerta de Hierro-Majadahonda; Maine Medical Center; Pompeu Fabra University	de Herreros, AG (corresponding author), IMIM, Programa Recerca Cancer, C Doctor Aiguader 88, Barcelona 08003, Spain.	agarcia@imim.es	Casal, Ignacio/M-2312-2014; Barderas, Rodrigo/K-3560-2014; Stanisavljević, Jelena/J-7152-2017; Stanisavljević, Jelena/ABG-8136-2020; de Herreros, A Garcia/H-3104-2014	Casal, Ignacio/0000-0003-1085-2840; Barderas, Rodrigo/0000-0003-3539-7469; Stanisavljević, Jelena/0000-0002-4880-4513; Stanisavljević, Jelena/0000-0002-4880-4513; de Herreros, A Garcia/0000-0001-5270-0808; Loubat Casanovas, Jordina/0000-0002-0158-3944; Alba-Castellon, Lorena/0000-0003-3449-7820	la Fundacion Cientifica de la Asociacion Espanola contra el Cancer; Ministerio de Ciencia y Tecnologia [SAF2006-00339, SAF2010-16089]; Fundacio La Marato de TV3; NIH [R01HD034883]; ISCIII/FEDER [RD06/0020/0109, RD06/0020/0040, RD06/0020/0020]; Generalitat de Catalunya [2009SGR867]; FPI; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034883] Funding Source: NIH RePORTER	la Fundacion Cientifica de la Asociacion Espanola contra el Cancer; Ministerio de Ciencia y Tecnologia(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Fundacio La Marato de TV3; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ISCIII/FEDER(Spanish Government); Generalitat de Catalunya(Generalitat de Catalunya); FPI(Spanish Government); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We thank M Massoumi for help in the preparation of MSCs, Td'Altri for assistance in the FACS analysis, N Garcia-Giralt and L Larue for reagents, L diCroce for comments and E Batlle for support and advice. This study was funded by a grant awarded by la Fundacion Cientifica de la Asociacion Espanola contra el Cancer to AGH, JIC and FB. Support from the Ministerio de Ciencia y Tecnologia (SAF2006-00339 and SAF2010-16089) and Fundacio La Marato de TV3 to AGH, and NIH R01HD034883 to TG is also appreciated. We also acknowledge support from ISCIII/FEDER (RD06/0020/0109, RD06/0020/0040, RD06/0020/0020), Generalitat de Catalunya (2009SGR867). RB and LA-C were recipients from FPI predoctoral fellowships.	Perez-Mancera PA, 2007, HUM MOL GENET, V16, P2972, DOI 10.1093/hmg/ddm278; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Byfield SD, 2004, MOL PHARMACOL, V65, P744, DOI 10.1124/mol.65.3.744; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Choudhury GG, 2004, CELL SIGNAL, V16, P31, DOI 10.1016/S0898-6568(03)00094-9; de Frutos CA, 2007, DEV CELL, V13, P872, DOI 10.1016/j.devcel.2007.09.016; de Frutos CA, 2009, EMBO J, V28, P686, DOI 10.1038/emboj.2009.23; Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364; Escriva M, 2008, MOL CELL BIOL, V28, P1528, DOI 10.1128/MCB.02061-07; Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519; Franci C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005595; de Herreros AG, 2010, J MAMMARY GLAND BIOL, V15, P135, DOI 10.1007/s10911-010-9179-8; Hill R, 2009, J BIOL CHEM, V284, P11755, DOI 10.1074/jbc.R800071200; IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361-11; Murray SA, 2006, GENESIS, V44, P7, DOI 10.1002/gene.20178; Murray SA, 2006, P NATL ACAD SCI USA, V103, P10300, DOI 10.1073/pnas.0602234103; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Peiro S, 2006, NUCLEIC ACIDS RES, V34, P2077, DOI 10.1093/nar/gkl141; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Rowe RG, 2009, J CELL BIOL, V184, P399, DOI 10.1083/jcb.200810113; Runyan CE, 2004, J BIOL CHEM, V279, P2632, DOI 10.1074/jbc.M310412200; Ryu JM, 2010, J CELL PHYSIOL, V224, P59, DOI [10.1002/jcp.2209, 10.1002/jcp.22091]; Sawyer JS, 2003, J MED CHEM, V46, P3953, DOI 10.1021/jm0205705; Solanas G, 2008, J CELL SCI, V121, P2224, DOI 10.1242/jcs.021667; Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221; Stanisavljevic J, 2011, J CELL SCI, V124, P4159, DOI 10.1242/jcs.078824; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Villagrasa P, 2011, ONCOGENE, V31, P4064; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Wu XH, 2011, J BIOL CHEM, V286, P13512, DOI 10.1074/jbc.M110.187351; Yi JY, 2005, J BIOL CHEM, V280, P10870, DOI 10.1074/jbc.M413223200	36	44	44	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2013	32	28					3381	3389		10.1038/onc.2012.342	http://dx.doi.org/10.1038/onc.2012.342			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	180TM	22869142	Green Accepted, Green Submitted			2022-12-17	WOS:000321620200008
J	Lin, PH; Lan, WM; Chau, LY				Lin, P-H; Lan, W-M; Chau, L-Y			TRC8 suppresses tumorigenesis through targeting heme oxygenase-1 for ubiquitination and degradation	ONCOGENE			English	Article						TRC8; heme oxygenase-1; tumor suppressor; ubiquitination	RENAL-CANCER CELLS; TUMOR-SUPPRESSOR; UP-REGULATION; GENE; EXPRESSION; OVEREXPRESSION; RESISTANCE; APOPTOSIS; PATHWAY; GROWTH	The TRC8 gene, which was previously shown to be disrupted by a 3; 8 chromosomal translocation in hereditary kidney cancer, encodes for an endoplasmic reticulum-resident E3 ligase. Studies have shown that TRC8 exhibits a tumor-suppressive effect through its E3-ligase activity. Therefore, the identification of its physiological substrates will provide important insights into the molecular mechanism underlying TRC8-mediated tumor suppression. Here we show that TRC8 targets heme oxygenase-1 (HO-1), an antioxidant enzyme highly expressed in various cancers, for ubiquitination and degradation. Ectopic TRC8 expression suppresses HO-1-induced cancer cell growth and migration/invasion. Conversely, HO-1 depletion reduced the tumorigenic and invasive capacities promoted by TRC8 knockdown. HO-1 downregulation in renal carcinoma cells induces a mitotic delay at G2/M phase by increasing the intracellular reactive oxygen species and the DNA-damage-induced checkpoint activation. These results highlight the tumorigenic role of HO-1 and the importance of TRC8-mediated HO-1 degradation in the control of cancer growth.	[Lin, P-H; Lan, W-M; Chau, L-Y] Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei 112, Taiwan; [Lin, P-H; Lan, W-M; Chau, L-Y] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Chau, LY (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.	lyc@ibms.sinica.edu.tw	Chau, Lee-Young/N-7659-2018	Chau, Lee-Young/0000-0002-6316-2328	Academia Sinica Investigatorship; National Science Council of Taiwan [NSC 100-2320-B-100-009MY3]	Academia Sinica Investigatorship(Academia Sinica - Taiwan); National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by an Academia Sinica Investigatorship to LYC and a grant from the National Science Council of Taiwan (NSC 100-2320-B-100-009MY3).	Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104; Alaoui-Jamali MA, 2009, CANCER RES, V69, P8017, DOI 10.1158/0008-5472.CAN-09-0419; Banerjee P, 2011, J BIOL CHEM, V286, P33580, DOI 10.1074/jbc.M111.248401; Berberat PO, 2005, CLIN CANCER RES, V11, P3790, DOI 10.1158/1078-0432.CCR-04-2159; Brauweiler A, 2007, ONCOGENE, V26, P2263, DOI 10.1038/sj.onc.1210017; Chen CY, 2005, BIOCHEM BIOPH RES CO, V331, P993, DOI 10.1016/j.bbrc.2005.03.237; Chen GG, 2004, J CELL BIOCHEM, V92, P1246, DOI 10.1002/jcb.20157; Datta D, 2010, J BIOL CHEM, V285, P36842, DOI 10.1074/jbc.M110.170324; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Fang YJ, 2011, CANCER LETT, V306, P10, DOI 10.1016/j.canlet.2011.02.019; Flad T, 2006, PROTEOMICS, V6, P364, DOI 10.1002/pmic.200500099; Gemmill RM, 2002, ONCOGENE, V21, P3507, DOI 10.1038/sj.onc.1205437; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Gimelli S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-52; Goodman AI, 1997, P SOC EXP BIOL MED, V214, P54; Hill-Kapturczak N, 2003, ARTERIOSCL THROM VAS, V23, P1416, DOI 10.1161/01.ATV.0000081656.76378.A7; Hirsch C, 2009, NATURE, V458, P453, DOI 10.1038/nature07962; Hwang HW, 2009, J BIOL CHEM, V284, P22672, DOI 10.1074/jbc.M109.028001; Irisawa M, 2009, J BIOL CHEM, V284, P28995, DOI 10.1074/jbc.M109.041376; Jozkowicz A, 2007, ANTIOXID REDOX SIGN, V9, P2099, DOI 10.1089/ars.2007.1659; Kocanova S, 2007, APOPTOSIS, V12, P731, DOI 10.1007/s10495-006-0016-x; Koizumi S, 2007, J BIOL CHEM, V282, P8715, DOI 10.1074/jbc.M609427200; Kweon MH, 2006, J BIOL CHEM, V281, P33761, DOI 10.1074/jbc.M604748200; Lee JP, 2010, MOL CANCER RES, V8, P93, DOI 10.1158/1541-7786.MCR-08-0491; Li MY, 2008, EUR RESPIR J, V32, P911, DOI 10.1183/09031936.00064508; Lin PH, 2008, BBA-MOL CELL RES, V1783, P1826, DOI 10.1016/j.bbamcr.2008.05.008; Liu PL, 2010, MOL NUTR FOOD RES, V54, pS196, DOI 10.1002/mnfr.200900550; Liu ZM, 2004, ONCOGENE, V23, P503, DOI 10.1038/sj.onc.1207173; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Mayerhofer M, 2004, CANCER RES, V64, P3148, DOI 10.1158/0008-5472.CAN-03-1200; Mayerhofer M, 2008, BLOOD, V111, P2200, DOI 10.1182/blood-2006-11-055723; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Otterbein LE, 2011, P NATL ACAD SCI USA, V108, P14491, DOI 10.1073/pnas.1102295108; Poland KS, 2007, GENE CHROMOSOME CANC, V46, P805, DOI 10.1002/gcc.20466; Pouponnot C, 2006, ONCOGENE, V25, P1299, DOI 10.1038/sj.onc.1209171; Sass G, 2008, INT J CANCER, V123, P1269, DOI 10.1002/ijc.23695; Shan Y, 2006, FASEB J, V20, P2651, DOI 10.1096/fj.06-6346fje; Stagg HR, 2009, J CELL BIOL, V186, P685, DOI 10.1083/jcb.200906110; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; Sunamura Makoto, 2003, Angiogenesis, V6, P15, DOI 10.1023/A:1025803600840; Tauber S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-200; Was H, 2006, AM J PATHOL, V169, P2181, DOI 10.2353/ajpath.2006.051365; Yang L, 2007, LEUKEMIA, V21, P868, DOI 10.1038/sj.leu.2404624; Yang ZZ, 2001, AM J PHYSIOL-RENAL, V281, pF900, DOI 10.1152/ajprenal.2001.281.5.F900	44	44	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2013	32	18					2325	2334		10.1038/onc.2012.244	http://dx.doi.org/10.1038/onc.2012.244			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22689053				2022-12-17	WOS:000318683600009
J	Gastaldi, S; Sassi, F; Accornero, P; Torti, D; Galimi, F; Migliardi, G; Molyneux, G; Perera, T; Comoglio, PM; Boccaccio, C; Smalley, MJ; Bertotti, A; Trusolino, L				Gastaldi, S.; Sassi, F.; Accornero, P.; Torti, D.; Galimi, F.; Migliardi, G.; Molyneux, G.; Perera, T.; Comoglio, P. M.; Boccaccio, C.; Smalley, M. J.; Bertotti, A.; Trusolino, L.			Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer	ONCOGENE			English	Article						Met tyrosine kinase receptor; mammary stem cells; mammary morphogenesis; basal-like breast cancer; cell-fate determination; mammary tumorigenesis	GLAND DEVELOPMENT; C-MET; DUCTAL MORPHOGENESIS; MOLECULAR PORTRAITS; TYROSINE KINASE; FACTOR RECEPTOR; EGF RECEPTOR; LUNG-CANCER; STEM-CELLS; EXPRESSION	Basal-like breast cancer is an aggressive subtype of mammary carcinoma. Despite expressing basal markers, typical of mammary stem cells, this tumor has been proposed to originate from luminal progenitors, which are downstream of stem cells along the mammary epithelial hierarchy. This suggests that committed luminal progenitors may reacquire basal, stem-like characteristics, but the mechanisms that regulate this transition remain unclear. Using mouse models, we found that luminal progenitors express high levels of the Met receptor for hepatocyte growth factor (HGF), as compared with the other mammary epithelial sub-populations. Constitutive activation of Met led luminal progenitors to attain stem cell properties, including enhanced clonogenic activity in vitro and de novo ability to reconstitute mammary glands in repopulation assays in vivo. Moreover, in response to Met signaling, luminal progenitors gave rise to hyperplastic ductal morphogenesis and preferentially underwent basal lineage commitment at the expense of luminal cell-fate specification. Opposite and symmetric results were produced by systemic pharmacological inhibition of Met. Hence, Met signaling targets luminal progenitors for expansion, impairs their differentiation toward the mature luminal phenotype and enables their commitment toward the basal lineage. These results emphasize a critical role for Met in promoting deregulated proliferation and basal plasticity of normal luminal progenitors in the mammary gland, a complex of events that may be required for sustaining the functional and phenotypic properties of basal-like breast tumors. Oncogene (2013) 32, 1428-1440; doi:10.1038/onc.2012.154; published online 7 May 2012	[Gastaldi, S.; Sassi, F.; Torti, D.; Galimi, F.; Migliardi, G.; Bertotti, A.; Trusolino, L.] Inst Canc Res & Treatment IRCC, Mol Pharmacol Lab, I-10060 Candiolo, Italy; [Gastaldi, S.; Sassi, F.; Torti, D.; Migliardi, G.; Comoglio, P. M.; Boccaccio, C.; Bertotti, A.; Trusolino, L.] Univ Turin, Sch Med, Dept Oncol Sci, Candiolo, Italy; [Accornero, P.] Univ Torino, Sch Vet Med, Dept Vet Morphophysiol, Grugliasco, Italy; [Molyneux, G.; Smalley, M. J.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Perera, T.] Janssen Res & Dev, Beerse, Belgium; [Comoglio, P. M.] Inst Canc Res & Treatment IRCC, Div Mol Clin Oncol, I-10060 Candiolo, Italy; [Boccaccio, C.] Inst Canc Res & Treatment IRCC, Lab Canc Stem Cell Biol, I-10060 Candiolo, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Turin; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Johnson & Johnson; Janssen Pharmaceuticals; IRCCS Fondazione del Piemonte per l'Oncologia; IRCCS Fondazione del Piemonte per l'Oncologia	Trusolino, L (corresponding author), Inst Canc Res & Treatment IRCC, Mol Pharmacol Lab, Str Prov 142,Km 3-95, I-10060 Candiolo, Italy.	SmalleyMJ@cardiff.ac.uk; livio.trusolino@ircc.it	Boccaccio, Carla/AHE-7875-2022; Smalley, Matthew J/M-7000-2015; Migliardi, Giorgia/AAB-6619-2020; sassi, francesco/AAB-6844-2020	Boccaccio, Carla/0000-0003-2620-9083; Smalley, Matthew J/0000-0001-9540-1146; sassi, francesco/0000-0002-4741-0408; Bertotti, Andrea/0000-0001-8196-7608; Comoglio, Paolo/0000-0002-7056-5328; Trusolino, Livio/0000-0002-6379-3365; GALIMI, Francesco/0000-0002-5939-6922; Migliardi, Giorgia/0000-0001-5770-8120	Janssen pharmaceutical companies; AIRC, Associazione Italiana per la Ricerca sul Cancro (IG project) [10116]; MIUR-FIRB, Fondo per gli Investimenti della Ricerca di Base - Futuro in Ricerca; FPRC, Fondazione Piemontese per la Ricerca sul Cancro; Breakthrough Breast Cancer; United Kingdom National Health Service	Janssen pharmaceutical companies; AIRC, Associazione Italiana per la Ricerca sul Cancro (IG project)(Fondazione AIRC per la ricerca sul cancro); MIUR-FIRB, Fondo per gli Investimenti della Ricerca di Base - Futuro in Ricerca(Ministry of Education, Universities and Research (MIUR)); FPRC, Fondazione Piemontese per la Ricerca sul Cancro; Breakthrough Breast Cancer; United Kingdom National Health Service	T Perera is an employee of Janssen pharmaceutical companies of Johnson & Johnson. PM Comoglio receives research grants from Janssen pharmaceutical companies. The other authors declare no potential conflicts of interest.; We thank Erica Lantelme for help with FACS sorting; Noemi Cavalera, Claudio Isella, Howard Kendrick, Simonetta Leto, Barbara Lupo, Paolo Luraghi, Fiona-Ann Magnay, Barbara Martinoglio, Enzo Medico, Roberta Porporato and Eugenia Zanella for help with experiments, discussion and sharing reagents; Fabrizio Maina, Laura Tarditi and Tuti Werdiningsih for animal husbandry; Raffaella Albano, Stefania Giove and Laura Palmas for technical assistance; Antonella Cignetto, Daniela Gramaglia and Francesca Natale for secretarial assistance. This work was supported by AIRC, Associazione Italiana per la Ricerca sul Cancro (IG project 10116 to LT); MIUR-FIRB, Fondo per gli Investimenti della Ricerca di Base - Futuro in Ricerca (AB); FPRC, Fondazione Piemontese per la Ricerca sul Cancro (LT); Breakthrough Breast Cancer and United Kingdom National Health Service funding to the National Institute for Health Research Biomedical Research Centre (MJS).	Andrechek ER, 2005, ONCOGENE, V24, P932, DOI 10.1038/sj.onc.1208230; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Bertotti A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000643; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Bozec A, 2007, BRIT J CANCER, V97, P65, DOI 10.1038/sj.bjc.6603791; Brisken C, 2000, GENE DEV, V14, P650; Bublil EM, 2007, CURR OPIN CELL BIOL, V19, P124, DOI 10.1016/j.ceb.2007.02.008; Cataldo VD, 2011, NEW ENGL J MED, V364, P947, DOI 10.1056/NEJMct0807960; Cepero V, 2010, CANCER RES, V70, P7580, DOI 10.1158/0008-5472.CAN-10-0436; Chaffer CL, 2010, CELL STEM CELL, V7, P271, DOI 10.1016/j.stem.2010.08.008; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Eder JP, 2009, CLIN CANCER RES, V15, P2207, DOI 10.1158/1078-0432.CCR-08-1306; Eirew P, 2008, NAT MED, V14, P1384, DOI 10.1038/nm.1791; Finkbeiner MR, 2009, ONCOGENE, V28, P1421, DOI 10.1038/onc.2008.485; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Galimi F, 2011, CLIN CANCER RES, V17, P3146, DOI 10.1158/1078-0432.CCR-10-3377; Garcia S, 2007, HUM PATHOL, V38, P830, DOI 10.1016/j.humpath.2006.11.015; Gastaldi S, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2617; Gjorevski N, 2011, NAT REV MOL CELL BIO, V12, P581, DOI 10.1038/nrm3168; Graveel CR, 2009, P NATL ACAD SCI USA, V106, P12909, DOI 10.1073/pnas.0810403106; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Jackson-Fisher AJ, 2004, P NATL ACAD SCI USA, V101, P17138, DOI 10.1073/pnas.0407057101; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Kendrick H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-591; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Mackay A, 2011, JNCI-J NATL CANCER I, V103, P662, DOI 10.1093/jnci/djr071; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; NIRANJAN B, 1995, DEVELOPMENT, V121, P2897; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ponzo MG, 2010, CELL CYCLE, V9, P1043, DOI 10.4161/cc.9.6.11033; Ponzo MG, 2009, P NATL ACAD SCI USA, V106, P12903, DOI 10.1073/pnas.0810402106; Regan JL, 2012, ONCOGENE, V31, P869, DOI 10.1038/onc.2011.289; Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1; Schroeder JA, 1997, J MAMMARY GLAND BIOL, V2, P119, DOI 10.1023/A:1026347629876; Sebastian J, 1998, CELL GROWTH DIFFER, V9, P777; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shimoyama T, 2006, LUNG CANCER, V53, P13, DOI 10.1016/j.lungcan.2006.03.014; Simian M, 2001, DEVELOPMENT, V128, P3117; Sleeman KE, 2007, J CELL BIOL, V176, P19, DOI 10.1083/jcb.200604065; Sleeman KE, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1371; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sternlicht MD, 2005, DEVELOPMENT, V132, P3923, DOI 10.1242/dev.01966; Stingl J, 2001, BREAST CANCER RES TR, V67, P93, DOI 10.1023/A:1010615124301; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212; Taddei I, 2008, NAT CELL BIOL, V10, P716, DOI 10.1038/ncb1734; Torti D, 2012, INT J CANCER, V130, P1357, DOI 10.1002/ijc.26137; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Villadsen R, 2007, J CELL BIOL, V177, P87, DOI 10.1083/jcb.200611114; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Wiesen JF, 1999, DEVELOPMENT, V126, P335; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215	60	44	45	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2013	32	11					1428	1440		10.1038/onc.2012.154	http://dx.doi.org/10.1038/onc.2012.154			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22562252	Green Submitted			2022-12-17	WOS:000316455600009
J	Heijmans, J; Buller, NVJA; Hoff, E; Dihal, AA; van der Poll, T; van Zoelen, MAD; Bierhaus, A; Biemond, I; Hardwick, JCH; Hommes, DW; Muncan, V; van den Brink, GR				Heijmans, J.; Buller, N. V. J. A.; Hoff, E.; Dihal, A. A.; van der Poll, T.; van Zoelen, M. A. D.; Bierhaus, A.; Biemond, I.; Hardwick, J. C. H.; Hommes, D. W.; Muncan, V.; van den Brink, G. R.			Rage signalling promotes intestinal tumourigenesis	ONCOGENE			English	Article						intestinal adenoma; ApcMin; Rage; MyD88	MOUSE MODEL; INFLAMMATION; COLON; COLITIS; PROTEIN; CANCER; RECEPTOR; HMGB1	Development of colon cancer is a multistep process that is regulated by intrinsic and extrinsic cellular signals. Extrinsic factors include molecular patterns that are derived from either pathogens (PAMPs) or cellular damage (DAMPs). These molecules can promote tumourigenesis by activation of the innate immune system, but the individual contribution of ligands and their receptors remains elusive. The receptor for advanced glycation end products (Rage) is a pattern recognition receptor that binds multiple ligands derived from a damaged cell environment such as Hmgb1 and S100 protein. Here we show that Rage signalling has a critical role in sporadic development of intestinal adenomas, as Apc(Min/+) Rage(-/-) mice are protected against tumourigenesis. Oncogene (2013) 32, 1202-1206; doi:10.1038/onc.2012.119; published online 2 April 2012	[Heijmans, J.; Buller, N. V. J. A.; Muncan, V.; van den Brink, G. R.] Univ Amsterdam, Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, NL-1105 BK Amsterdam, North Holland, Netherlands; [Heijmans, J.; Buller, N. V. J. A.; Hoff, E.; Dihal, A. A.; Biemond, I.; Hardwick, J. C. H.; Hommes, D. W.; Muncan, V.; van den Brink, G. R.] Leiden Univ, Dept Gastroenterol & Hepatol, Med Ctr, Leiden, Netherlands; [van der Poll, T.; van Zoelen, M. A. D.] Univ Amsterdam, Acad Med Ctr, Ctr Expt Mol Med, NL-1105 BK Amsterdam, North Holland, Netherlands; [Bierhaus, A.] Heidelberg Univ, Dept Med & Clin Chem 1, Heidelberg, Germany; [van den Brink, G. R.] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 BK Amsterdam, North Holland, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam; Ruprecht Karls University Heidelberg; University of Amsterdam; Academic Medical Center Amsterdam	Heijmans, J (corresponding author), Univ Amsterdam, Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, Meibergdreef 69-71, NL-1105 BK Amsterdam, North Holland, Netherlands.	j.heijmans@amc.nl; g.r.vandenbrink@amc.nl	Biemond, Izak/A-3540-2016; Hardwick, James/J-4862-2013	Biemond, Izak/0000-0002-3137-7527; Hardwick, James/0000-0002-9575-5099; Heijmans, Jarom/0000-0001-9615-7851				Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Cole AM, 2010, CANCER RES, V70, P8149, DOI 10.1158/0008-5472.CAN-10-0315; Constien R, 2001, GENESIS, V30, P36, DOI 10.1002/gene.1030; EKBOM A, 1990, LANCET, V336, P357, DOI 10.1016/0140-6736(90)91889-I; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; Fukata M, 2011, INFLAMM BOWEL DIS, V17, P1464, DOI 10.1002/ibd.21527; Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He M, 2011, EMBO REP, V12, P358, DOI 10.1038/embor.2011.28; Heijmans J. N.V., 2010, BIOCHIM BIOPHYS ACTA, V1822, P9; Heijmans J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022620; Kang HJ, 2009, LAB INVEST, V89, P948, DOI 10.1038/labinvest.2009.47; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Lee SH, 2010, NAT MED, V16, P665, DOI 10.1038/nm.2143; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Sakaguchi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023132; Salama I, 2008, EJSO-EUR J SURG ONC, V34, P357, DOI 10.1016/j.ejso.2007.04.009; Turovskaya O, 2008, CARCINOGENESIS, V29, P2035, DOI 10.1093/carcin/bgn188; van Zoelen MA, 2011, CRIT CARE, V15, DOI 10.1186/cc9990; Volp K, 2006, GUT, V55, P234, DOI 10.1136/gut.2004.062729; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296	26	44	45	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1202	1206		10.1038/onc.2012.119	http://dx.doi.org/10.1038/onc.2012.119			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22469986				2022-12-17	WOS:000316428800014
J	Zhang, S; Chen, H; Zhao, X; Cao, J; Tong, J; Lu, J; Wu, W; Shen, H; Wei, Q; Lu, D				Zhang, S.; Chen, H.; Zhao, X.; Cao, J.; Tong, J.; Lu, J.; Wu, W.; Shen, H.; Wei, Q.; Lu, D.			REV3L 3 ' UTR 460 T > C polymorphism in microRNA target sites contributes to lung cancer susceptibility	ONCOGENE			English	Article						genetic polymorphism; REV3L; lung cancer; microRNA	DNA-POLYMERASE-ZETA; CATALYTIC SUBUNIT; GENETIC-VARIANTS; BINDING-SITE; RISK; DISRUPTION; CHINESE; LEADS	REV3Lp, the catalytic subunit of DNA polymerase zeta, is the major participant in translesion DNA synthesis. Recent evidence suggests that REV3L has an important role in the maintenance of genome stability despite its mutagenic characteristics. Such a function makes it a cancer susceptibility candidate gene. To investigate association between REV3L polymorphisms and lung cancer risk in a Chinese population, we first genotyped 15 common polymorphisms of the REV3L gene and found that three single nucleotide polymorphisms (rs465646, rs459809 and rs1002481) were significantly associated with lung cancer risk. One of the strongest associations observed was for the 3'-terminal untranslated region (3'UTR) 460 T>C polymorphism (rs465646) (adjusted odds ratio (OR) = 0.69 for TC/CC; P = 0.007, compared with TT). Similar results were obtained in a subsequent replication study (adjusted OR = 0.72; P = 0.016). Combined data from the two studies of 1072 lung cancer patients and 1064 cancer-free controls generated an even stronger association (adjusted OR = 0.71; P = 3.04 x 10(-4)). This 3'UTR 460 T>C variant was predicted to modulate the binding of several micro RNAs. Surface plasmon resonance analysis and luciferase assays showed that the T allele demonstrated a stronger binding affinity for miR-25 and miR-32, resulting in significantly weaker reporter expression levels. Additional experiments revealed that miR-25/32 could downregulate endogenous REV3L. Furthermore, the tumor-suppressing role of REV3L was confirmed by the foci formation assay. These results support our hypothesis that the REV3L rs465646 variant modifies lung cancer susceptibility in Chinese Han population by affecting miRNA-mediated gene regulation. Oncogene (2013) 32, 242-250; doi:10.1038/onc.2012.32; published online 20 February 2012	[Zhang, S.; Chen, H.; Zhao, X.; Lu, J.; Wu, W.; Lu, D.] Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, Shanghai 200433, Peoples R China; [Zhang, S.; Chen, H.; Zhao, X.; Lu, J.; Wu, W.; Lu, D.] Fudan Univ, Sch Life Sci, Inst Genet, MOE Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China; [Zhang, S.; Cao, J.; Tong, J.] Soochow Univ, Coll Med, Sch Radiat Med & Protect, Suzhou, Peoples R China; [Shen, H.] Nanjing Med Univ, Ctr Canc, Dept Epidemiol & Biostat, Nanjing, Jiangsu, Peoples R China; [Wei, Q.] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	Fudan University; Fudan University; Soochow University - China; Nanjing Medical University; University of Texas System; UTMD Anderson Cancer Center	Lu, D (corresponding author), Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, 220 Handan Rd, Shanghai 200433, Peoples R China.	drlu@fudan.edu.cn	wu, wenting/Q-4979-2016	wu, wenting/0000-0003-0982-771X	Shanghai Science and Technology Research Program [09JC1402200, 10410709100]; Natural Science Foundation of China [30800622, 81001114, 81020108028]; Scientific Research Foundation for the Returned Overseas Chinese Scholars (State Education Ministry); Ministry of Education of China; Shanghai Key Subject Project for Public Health [08GWZX0301]	Shanghai Science and Technology Research Program; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific Research Foundation for the Returned Overseas Chinese Scholars (State Education Ministry)(Scientific Research Foundation for the Returned Overseas Chinese Scholars); Ministry of Education of China(Ministry of Education, China); Shanghai Key Subject Project for Public Health	This work was partially supported by the Shanghai Science and Technology Research Program (Grants 09JC1402200 and 10410709100), the Natural Science Foundation of China (Grants 30800622, 81001114 and 81020108028), the Scientific Research Foundation for the Returned Overseas Chinese Scholars (State Education Ministry), the Doctoral Fund of the Ministry of Education of China and the Shanghai Key Subject Project for Public Health (Grant 08GWZX0301).	Bemark M, 2000, CURR BIOL, V10, P1213, DOI 10.1016/S0960-9822(00)00724-7; Brondello JM, 2008, ONCOGENE, V27, P6093, DOI 10.1038/onc.2008.212; Chen D, 2008, CARCINOGENESIS, V29, P342, DOI 10.1093/carcin/bgm285; Clop A, 2006, NAT GENET, V38, P813, DOI 10.1038/ng1810; DATTA A, 1995, SCIENCE, V268, P1616, DOI 10.1126/science.7777859; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Esposito G, 2000, CURR BIOL, V10, P1221, DOI 10.1016/S0960-9822(00)00726-0; Friedberg EC, 2005, MOL CELL, V18, P499, DOI 10.1016/j.molcel.2005.03.032; Gan GN, 2008, CELL RES, V18, P174, DOI 10.1038/cr.2007.117; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Hoeijmakers JHJ, 2007, MECH AGEING DEV, V128, P460, DOI 10.1016/j.mad.2007.05.002; Hu ZB, 2007, HUM MUTAT, V28, P431, DOI 10.1002/humu.20462; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Kajiwara K, 1996, BIOCHEM BIOPH RES CO, V219, P795, DOI 10.1006/bbrc.1996.0313; Kim VN, 2006, TRENDS GENET, V22, P165, DOI 10.1016/j.tig.2006.01.003; Krieg AJ, 2006, MOL CELL BIOL, V26, P7030, DOI 10.1128/MCB.00322-06; Lawrence CW, 2001, PHILOS T R SOC B, V356, P41, DOI 10.1098/rstb.2000.0001; Lehmann AR, 2005, FEBS LETT, V579, P873, DOI 10.1016/j.febslet.2004.11.029; LEMONTT JF, 1972, MOL GEN GENET, V119, P27, DOI 10.1007/BF00270441; Lin WS, 1999, MUTAT RES-DNA REPAIR, V433, P89, DOI 10.1016/S0921-8777(98)00065-2; Lu J, 2009, FASEB J, V23, P3459, DOI 10.1096/fj.09-136549; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; Mishra PJ, 2007, P NATL ACAD SCI USA, V104, P13513, DOI 10.1073/pnas.0706217104; Nicoloso MS, 2010, CANCER RES, V70, P2789, DOI 10.1158/0008-5472.CAN-09-3541; Nojima K, 2005, CANCER RES, V65, P11704, DOI 10.1158/0008-5472.CAN-05-1214; Pan QR, 2005, CANCER LETT, V217, P139, DOI 10.1016/j.canlet.2004.07.021; Rockwell S, 2001, Novartis Found Symp, V240, P133; Rockwell S, 2001, NOVART FDN SYMP, V240, P142; Saunders MA, 2007, P NATL ACAD SCI USA, V104, P3300, DOI 10.1073/pnas.0611347104; Sonoda E, 2003, EMBO J, V22, P3188, DOI 10.1093/emboj/cdg308; Vatolin S, 2006, J MOL BIOL, V358, P983, DOI 10.1016/j.jmb.2006.02.063; Venkatesan RN, 2006, DNA REPAIR, V5, P294, DOI 10.1016/j.dnarep.2005.10.012; Wang G, 2008, AM J HUM GENET, V82, P283, DOI 10.1016/j.ajhg.2007.09.021; Wang HB, 2009, NEURO-ONCOLOGY, V11, P790, DOI 10.1215/15228517-2009-015; Wang QZ, 2009, CURR CANCER DRUG TAR, V9, P572, DOI 10.2174/156800909788486731; Wittschieben JP, 2006, CANCER RES, V66, P134, DOI 10.1158/0008-5472.CAN-05-2982; Yu ZB, 2007, NUCLEIC ACIDS RES, V35, P4535, DOI 10.1093/nar/gkm480; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000; Zhu F, 2003, WORLD J GASTROENTERO, V9, P888	40	44	48	0	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					242	250		10.1038/onc.2012.32	http://dx.doi.org/10.1038/onc.2012.32			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22349819				2022-12-17	WOS:000314075500012
J	Belguise, K; Milord, S; Galtier, F; Moquet-Torcy, G; Piechaczyk, M; Chalbos, D				Belguise, K.; Milord, S.; Galtier, F.; Moquet-Torcy, G.; Piechaczyk, M.; Chalbos, D.			The PKC theta pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells	ONCOGENE			English	Article						Fra-1; PKC theta; phosphorylation; protein stability; breast cancer cells	KINASE-C-THETA; PROTEASOMAL DEGRADATION; EXPRESSION; AP-1; TRANSFORMATION; RECEPTOR; TARGET; GENE; TUMORIGENESIS; ACTIVATION	Fra-1 is aberrantly expressed in a large number of cancer cells and tissues, and emerging evidence suggests an important role for this Fos family protein in both oncogenesis and the progression or maintenance of many tumour types. Here, we show that the concentration of Fra-1 is high in invasive oestrogen receptor (ER)-negative (ER-) breast cancer cell lines, regardless of their Ras pathway status. All of the ER-cells express high levels of activated PKC theta, and the inhibition of PKC theta activity using RNA interference or the expression of a dominant-negative mutant results in a dramatic reduction in Fra-1 abundance. Conversely, the ectopic expression of constitutively active PKC theta leads to Fra-1 phosphorylation and accumulation in poorly invasive ER+ cells. This accumulation is due to the stabilisation of the Fra-1 protein through PKC theta signalling, whereas other members of the PKC family are ineffective. Both Ste20-related proline-alanine-rich kinase (SPAK) and ERK1/2, whose activities are upregulated by PKC theta, participate in PKC theta-driven Fra-1 stabilisation. Interestingly, their relative contributions appear to be different depending on the cell line studied. ERK1/2 signalling has a major role in ER- MDA-MB-231 cells, whereas Fra-1 accumulation occurs mainly through SPAK signalling in ER- BT549 cells. Fra-1 mutational analysis shows that the phosphorylation of S265, T223 and T230 is critical for PKC theta-driven Fra-1 stabilisation. Phosphorylation of the protein was confirmed using specific antisera against Fra-1 phosphorylated on T223 or S265. In addition, Fra-1 participates in PKC theta-induced cell invasion and is necessary for PKC theta-induced cell migration. In summary, we identified PKC theta signalling as an important regulator of Fra-1 accumulation in ER- breast cancer cells. Moreover, our results suggest that PKC theta could participate in progression of some breast cancers and could be a new therapeutic target.	[Belguise, K.; Milord, S.; Galtier, F.; Chalbos, D.] IRCM, F-34298 Montpellier 5, France; [Belguise, K.; Milord, S.; Galtier, F.; Chalbos, D.] INSERM, U896, Montpellier, France; [Moquet-Torcy, G.; Piechaczyk, M.] Univ Montpellier I, CNRS, Inst Genet Mol Montpellier, Montpellier, France; [Belguise, K.; Milord, S.; Galtier, F.; Chalbos, D.] CRLC Val dAurelle Paul Lamarque, Montpellier, France; [Moquet-Torcy, G.; Piechaczyk, M.] Univ Montpellier 2, CNRS, Inst Genet Mol Montpellier, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Chalbos, D (corresponding author), IRCM, F-34298 Montpellier 5, France.	dany.chalbos@inserm.fr	PIECHACZYK, Marc/E-7896-2013	PIECHACZYK, Marc/0000-0003-1367-2597; Belguise, Karine/0000-0003-3426-8040	Institut National de la Sante et de la Recherche Medicale; University of Montpellier 1; Ligue Nationale Contre le Cancer-comite de l'Herault; Association pour la Recherche sur le Cancer; French Ministere de la Recherche et de l'Enseignement Superieur	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); University of Montpellier 1; Ligue Nationale Contre le Cancer-comite de l'Herault(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); French Ministere de la Recherche et de l'Enseignement Superieur	We are grateful to A Altman, J Pouyssegur and A Hipskind for providing plasmids and I Jariel-Encontre for critical reading of the manuscript. This work was supported by the 'Institut National de la Sante et de la Recherche Medicale', the University of Montpellier 1, the 'Ligue Nationale Contre le Cancer-comite de l'Herault', the 'Association pour la Recherche sur le Cancer' (fellowship to K. Belguise) and the French "Ministere de la Recherche et de l'Enseignement Superieur '(fellowship to S. Milord). M. Piechaczyk's laboratory was supported as an' Equipe Labellisee 'of the 'Ligue Nationale Contre le Cancer'.	BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Basbous J, 2007, MOL CELL BIOL, V27, P3936, DOI 10.1128/MCB.01776-06; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Belguise K, 2007, J CLIN INVEST, V117, P4009, DOI 10.1172/JCI32424; Blay P, 2004, CLIN CANCER RES, V10, P4089, DOI 10.1158/1078-0432.CCR-04-0630; BRUNET A, 1994, ONCOGENE, V9, P3379; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Chiappetta G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-17; Chuang HC, 2011, NAT IMMUNOL, V12, P1113, DOI 10.1038/ni.2121; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Debinski W, 2005, MOL CANCER RES, V3, P237; Delpire E, 2007, PHYSIOL GENOMICS, V28, P223, DOI 10.1152/physiolgenomics.00173.2006; Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Elsberger B, 2010, BRIT J CANCER, V103, P899, DOI 10.1038/sj.bjc.6605829; Harris TJR, 2010, NAT REV CLIN ONCOL, V7, P251, DOI 10.1038/nrclinonc.2010.41; Hayashi K, 2007, PHARMACOL RES, V55, P537, DOI 10.1016/j.phrs.2007.04.009; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Li YQ, 2004, EMBO J, V23, P1112, DOI 10.1038/sj.emboj.7600125; Logullo AF, 2011, HISTOPATHOLOGY, V58, P617, DOI 10.1111/j.1365-2559.2011.03785.x; Manicassamy S, 2006, CELL MOL IMMUNOL, V3, P263; Marsland BJ, 2008, TRENDS IMMUNOL, V29, P179, DOI 10.1016/j.it.2008.01.005; Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Milde-Langosch K, 2003, BREAST CANCER RES TR, V77, P265, DOI 10.1023/A:1021887100216; Mulloy R, 2003, ONCOGENE, V22, P5387, DOI 10.1038/sj.onc.1206839; Philips A, 1998, MOL ENDOCRINOL, V12, P973, DOI 10.1210/me.12.7.973; Piechotta K, 2002, J BIOL CHEM, V277, P50812, DOI 10.1074/jbc.M208108200; Polek TC, 2006, BIOCHEM BIOPH RES CO, V343, P125, DOI 10.1016/j.bbrc.2006.02.125; Risse-Hackl G, 1998, ONCOGENE, V16, P3057, DOI 10.1038/sj.onc.1201845; Sayan AE, 2012, ONCOGENE, V31, P1493, DOI 10.1038/onc.2011.336; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Song YH, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-298; Stinson S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001538; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Verde P, 2007, CELL CYCLE, V6, P2633, DOI 10.4161/cc.6.21.4850; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; Wang QS, 2010, CELL RES, V20, P701, DOI 10.1038/cr.2010.52; Wang XB, 2007, NAT CELL BIOL, V9, P470, DOI 10.1038/ncb1559; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Young MR, 2006, GENE, V379, P1, DOI 10.1016/j.gene.2006.05.001	45	44	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	47					4889	4897		10.1038/onc.2011.659	http://dx.doi.org/10.1038/onc.2011.659			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041VU	22286759	Green Submitted, Green Accepted			2022-12-17	WOS:000311430200001
J	Cornen, S; Adelaide, J; Bertucci, F; Finetti, P; Guille, A; Birnbaum, DJ; Birnbaum, D; Chaffanet, M				Cornen, S.; Adelaide, J.; Bertucci, F.; Finetti, P.; Guille, A.; Birnbaum, D. J.; Birnbaum, D.; Chaffanet, M.			Mutations and deletions of ARID1A in breast tumors	ONCOGENE			English	Letter							REMODELING GENE ARID1A; CARCINOMA		[Cornen, S.; Adelaide, J.; Bertucci, F.; Finetti, P.; Guille, A.; Birnbaum, D. J.; Birnbaum, D.; Chaffanet, M.] IPC, INSERM, UMR891, Marseille Canc Res Ctr CRCM,Dept Mol Oncol, Marseille, France; [Bertucci, F.] IPC, Dept Med Oncol, Marseille, France; [Bertucci, F.] Univ Aix Marseille, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite	Cornen, S (corresponding author), IPC, INSERM, UMR891, Marseille Canc Res Ctr CRCM,Dept Mol Oncol, Marseille, France.	chaffanetm@marseille.fnclcc.fr	Guille, Arnaud/GZG-1785-2022; CHAFFANET, Max/AAU-5743-2020; Birnbaum, David/Z-1563-2019; ADELAIDE, José JA/O-4390-2017; Finetti, Pascal/O-8669-2017	Guille, Arnaud/0000-0001-5747-562X; ADELAIDE, José JA/0000-0003-4364-9857; CHAFFANET, Max/0000-0002-2344-1488; Birnbaum, Daniel/0000-0001-7920-9883; Finetti, Pascal/0000-0002-2674-3123				Birnbaum DJ, 2011, NEW ENGL J MED, V364; Guan B, 2011, AM J SURG PATHOL, V35, P625, DOI 10.1097/PAS.0b013e318212782a; Jones S, 2012, HUM MUTAT, V33, P100, DOI 10.1002/humu.21633; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Mamo A, 2012, ONCOGENE, V31, P2090, DOI 10.1038/onc.2011.386; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433	6	44	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	38					4255	4256		10.1038/onc.2011.598	http://dx.doi.org/10.1038/onc.2011.598			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008SC	22249247				2022-12-17	WOS:000308975800008
J	Sasi, SP; Yan, X; Enderling, H; Park, D; Gilbert, HY; Curry, C; Coleman, C; Hlatky, L; Qin, G; Kishore, R; Goukassian, DA				Sasi, S. P.; Yan, X.; Enderling, H.; Park, D.; Gilbert, H-Y; Curry, C.; Coleman, C.; Hlatky, L.; Qin, G.; Kishore, R.; Goukassian, D. A.			Breaking the 'harmony' of TNF-alpha signaling for cancer treatment	ONCOGENE			English	Article						TNF-alpha; TNFR2/p75; cancer; angiogenesis; EPC; microenvironment	TUMOR-NECROSIS-FACTOR; ENDOTHELIAL PROGENITOR CELLS; ANGIOGENIC SWITCH; FACTOR-RECEPTOR; GROWTH-FACTOR; KAPPA-B; IN-VIVO; NEOVASCULARIZATION; ACTIVATION; APOPTOSIS	Tumor necrosis factor-alpha (TNF-alpha) binds to two distinct receptors, TNFR1/p55 and TNFR2/p75. TNF-alpha is implicated in the processes of tumor growth, survival, differentiation, invasion, metastases, secretion of cytokines and pro-angiogenic factors. We have shown that TNFR2/p75 signaling promotes ischemia-induced angiogenesis via modulation of several angiogenic growth factors. We hypothesized that TNFR2/p75 may promote tumor growth and angiogenesis. Growth of mouse Lewis lung carcinoma (LLC1) and/or mouse melanoma B16 cell was evaluated in wild type (WT), p75 knockout (KO) and double p55KO/p75KO mouse tumor xenograft models. Compared with WT and p55KO/p75KO mice, growth of tumors in p75KO mice was significantly decreased (twofold) in both LLC and B16 tumors. Tumor growth inhibition was correlated with decreases in vascular endothelial growth factor (VEGF) expression and capillary density, as well as bone marrow-derived endothelial progenitor cells incorporation into the functional capillary network, and an increase in apoptotic cells in LLC xenografts. Gene array analysis of tumor tissues showed a decrease in gene expression in pathways that promote tumor angiogenesis and cell survival. Blocking p75 by short-hairpin RNA in cultured LLCs led to increases in TNF-mediated apoptosis, as well as decreases in the constitutive and TNF-mediated expression of angiogenic growth factors (VEGF, HGF, PLGF), and SDF-1 alpha receptor CXCR4. In summary, p75 is essential for tumor angiogenesis and survival in highly vascularized murine lung tumor xenografts. Blocking p75 expression may lead to tumor regression. This may represent new and effective therapy against lung neoplasms and potentially tumors of other origin. Oncogene (2012) 31, 4117-4127; doi:10.1038/onc.2011.567; published online 12 December 2011	[Goukassian, D. A.] Tufts Univ, Sch Med, Ctr Canc Syst Biol, Brighton, MA 02135 USA; [Sasi, S. P.; Yan, X.; Park, D.; Gilbert, H-Y; Curry, C.; Coleman, C.; Goukassian, D. A.] Steward St Elizabeths Med Ctr, Cardiovasc Res Ctr, Brighton, MA USA; [Qin, G.; Kishore, R.] Northwestern Univ, Chicago, IL 60611 USA	Tufts University; St. Elizabeth's Medical Center; Northwestern University	Goukassian, DA (corresponding author), Tufts Univ, Sch Med, Ctr Canc Syst Biol, 736 Cambridge St,CBR 307, Brighton, MA 02135 USA.	david.goukassian@tufts.edu	Enderling, Heiko/AAA-2423-2021	Enderling, Heiko/0000-0002-9696-6410; Goukassian, David/0000-0001-5270-5270; Park, Daniel/0000-0001-5191-1371	NIH [HL091983]; NIH/NIA [5R21AG026777-02]; AHA SDG Award; NASA [NNX11AD22G]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL091983] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG026777] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHA SDG Award; NASA(National Aeronautics & Space Administration (NASA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Marcy Silver and Sharon Kunder for their valuable technical support. This work was supported in part by grants from the NIH HL091983 (to RK), NIH/NIA 5R21AG026777-02, the AHA SDG Award and the NASA NNX11AD22G (all three to DAG).	Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Barbara JAJ, 1996, IMMUNOL CELL BIOL, V74, P434, DOI 10.1038/icb.1996.73; Bhardwaj A, 2003, J CLIN IMMUNOL, V23, P317, DOI 10.1023/A:1025319031417; Coleman C, 2010, J ONCOL, V2010, DOI 10.1155/2010/928628; De Plaen IG, 2006, IMMUNOLOGY, V118, P153, DOI 10.1111/j.1365-2567.2006.02344.x; Eisenthal Avi, 2003, Sarcoma, V7, P57, DOI 10.1080/13577140310001607275; ELBAZ O, 1994, LEUKEMIA LYMPHOMA, V12, P191, DOI 10.3109/10428199409059589; FAJARDO LF, 1992, AM J PATHOL, V140, P539; Fiers W., 1995, Journal of Inflammation, V47, P67; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Gao DC, 2008, SCIENCE, V319, P195, DOI 10.1126/science.1150224; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; GOILLOT E, 1992, CANCER RES, V52, P3194; Goukassian DA, 2007, CIRCULATION, V115, P752, DOI 10.1161/CIRCULATIONAHA.106.647255; Gupta S, 2003, MECH AGEING DEV, V124, P503, DOI 10.1016/S0047-6374(03)00028-9; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hohenberger P, 2003, ANN SURG ONCOL, V10, P562, DOI 10.1245/ASO.2003.10.005; JACOBSEN SEW, 1994, STEM CELLS, V12, P111; Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198; Kohno K, 1998, CLIN IMMUNOL IMMUNOP, V86, P11, DOI 10.1006/clin.1997.4475; KOMORI A, 1993, CANCER RES, V53, P1982; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Li B, 2009, CANCER RES, V69, P338, DOI 10.1158/0008-5472.CAN-08-1565; Liu RY, 1998, CANCER RES, V58, P2217; Luo DH, 2006, AM J PATHOL, V169, P1886, DOI 10.2353/ajpath.2006.060603; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368; Meng YR, 2010, CANCER RES, V70, P1534, DOI 10.1158/0008-5472.CAN-09-2995; Montesano R, 2005, J CELL SCI, V118, P3487, DOI 10.1242/jcs.02467; Mukhopadhyay A, 2001, J BIOL CHEM, V276, P31906, DOI 10.1074/jbc.M105252200; Park CC, 2001, J IMMUNOL, V167, P1644, DOI 10.4049/jimmunol.167.3.1644; Peters BA, 2005, NAT MED, V11, P261, DOI 10.1038/nm1200; Rafii S, 2008, SCIENCE, V319, P163, DOI 10.1126/science.1153615; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Rivas MA, 2008, EXP CELL RES, V314, P509, DOI 10.1016/j.yexcr.2007.10.005; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Santarelli JG, 2006, NEUROSURGERY, V59, P374, DOI 10.1227/01.NEU.0000222658.66878.CC; SATO N, 1987, J NATL CANCER I, V79, P1383; Sethi G, 2008, FRONT BIOSCI-LANDMRK, V13, P5094, DOI 10.2741/3066; SLOWIK MR, 1993, AM J PATHOL, V143, P1724; Suganuma M, 1999, CANCER RES, V59, P4516; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; WONG GHW, 1994, J IMMUNOL, V152, P1751; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; Zhang R, 2003, J BIOL CHEM, V278, P51267, DOI 10.1074/jbc.M310678200	47	44	47	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	37					4117	4127		10.1038/onc.2011.567	http://dx.doi.org/10.1038/onc.2011.567			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NR	22158049	Green Accepted, hybrid			2022-12-17	WOS:000308688900004
J	Palermo, R; Checquolo, S; Giovenco, A; Grazioli, P; Kumar, V; Campese, AF; Giorgi, A; Napolitano, M; Canettieri, G; Ferrara, G; Schinina, ME; Maroder, M; Frati, L; Gulino, A; Vacca, A; Screpanti, I				Palermo, R.; Checquolo, S.; Giovenco, A.; Grazioli, P.; Kumar, V.; Campese, A. F.; Giorgi, A.; Napolitano, M.; Canettieri, G.; Ferrara, G.; Schinina, M. E.; Maroder, M.; Frati, L.; Gulino, A.; Vacca, A.; Screpanti, I.			Acetylation controls Notch3 stability and function in T-cell leukemia	ONCOGENE			English	Article						leukemia; Notch3; T-ALL; acetylation	HISTONE DEACETYLASE INHIBITORS; NF-KAPPA-B; ACUTE LYMPHOBLASTIC-LEUKEMIA; PRE-TCR; HDAC INHIBITORS; TRANSGENIC MICE; DNA-DAMAGE; EXPRESSION; TARGET; CANCER	Post-translational modifications of Notch3 and their functional role with respect to Notch3 overexpression in T-cell leukemia are still poorly understood. We identify here a specific novel property of Notch3 that is acetylated and deacetylated at lysines 1692 and 1731 by p300 and HDAC1, respectively, a balance impaired by HDAC inhibitors (HDACi) that favor hyperacetylation. By using HDACi and a non-acetylatable Notch3 mutant carrying K/R1692-1731 mutations in the intracellular domain, we show that Notch3 acetylation primes ubiquitination and proteasomal-mediated degradation of the protein. As a consequence, Notch3 protein expression and its transcriptional activity are decreased both in vitro and in vivo in Notch3 transgenic (tg) mice, thus impairing downstream signaling upon target genes. Consistently, Notch3-induced T-cell proliferation is inhibited by HDACi, whereas it is enhanced by the non-acetylatable Notch3-K/R1692-1731 mutant. Finally, HDACi-induced Notch3 hyperacetylation prevents in vivo growth of T-cell leukemia/lymphoma in Notch3 tg mice. Together, our findings suggest a novel level of Notch signaling control in which Notch3 acetylation/deacetylation process represents a key regulatory switch, thus representing a suitable druggable target for Notch3-sustained T-cell acute lymphoblastic leukemia therapy. Oncogene (2012) 31, 3807-3817; doi: 10.1038/onc.2011.533; published online 28 November 2011	[Palermo, R.; Giovenco, A.; Vacca, A.] Sapienza Univ, Dept Expt Med, I-00161 Rome, Italy; [Checquolo, S.; Maroder, M.] Sapienza Univ, Dept Biotechnol & Med Surg Sci, Latina, Italy; [Grazioli, P.; Kumar, V.; Campese, A. F.; Napolitano, M.; Canettieri, G.; Ferrara, G.; Frati, L.; Gulino, A.; Screpanti, I.] Sapienza Univ, Dept Mol Med, I-00161 Rome, Italy; [Giorgi, A.; Schinina, M. E.] Sapienza Univ, Dept Biochem Sci, I-00161 Rome, Italy; [Napolitano, M.] IRCCS OASI, Troina, Italy; [Frati, L.; Gulino, A.] Neuromed Inst, Pozzilli, Italy; [Screpanti, I.] Sapienza Univ, Inst Pasteur, Cenci Bolognetti Fdn, I-00161 Rome, Italy	Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; IRCCS Neuromed; Fondazione Cenci Bolognetti; Sapienza University Rome	Vacca, A (corresponding author), Sapienza Univ, Dept Expt Med, Viale Regina Elena 324, I-00161 Rome, Italy.	alessandra.vacca@uniroma1.it; isabella.screpanti@uniroma1.it	Campese, Antonio/A-9783-2015; Frati, Luigi/ABI-7437-2020; Palermo, Rocco/I-5140-2016	Palermo, Rocco/0000-0003-0134-9370; VACCA, Alessandra/0000-0002-0006-5379; CHECQUOLO, Saula/0000-0001-5109-8392; CAMPESE, Antonio Francesco/0000-0002-8535-6609; CANETTIERI, Gianluca/0000-0001-6694-2613	Italian Association for Cancer Research (AIRC); Italian Ministry of University and Research (MIUR); Italian Ministry of Health; European Union [FP7-MC-ITN 215761]; Eleonora Lorillard Spencer Cenci Foundation; Fondazione Roma	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR)); Italian Ministry of Health(Ministry of Health, Italy); European Union(European Commission); Eleonora Lorillard Spencer Cenci Foundation; Fondazione Roma(Fondazione RomaEuropean Commission)	We are grateful to Dr Sonia Coni for experimental support. This work was supported by the Italian Association for Cancer Research (AIRC), the Italian Ministry of University and Research (MIUR), PRIN and FIRB Programs, the Italian Ministry of Health, the European Union (NotchIT ITN Project; FP7-MC-ITN 215761), Eleonora Lorillard Spencer Cenci Foundation and the Fondazione Roma (fellowship to RP).	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Anastasi E, 2003, J IMMUNOL, V171, P4504, DOI 10.4049/jimmunol.171.9.4504; Barbarulo A, 2011, J IMMUNOL, V186, P6199, DOI 10.4049/jimmunol.1002136; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bellavia D, 2002, P NATL ACAD SCI USA, V99, P3788, DOI 10.1073/pnas.062050599; Bellavia D, 2007, EMBO J, V26, P1670, DOI 10.1038/sj.emboj.7601626; Beverly LJ, 2005, CANCER RES, V65, P7159, DOI 10.1158/0008-5472.CAN-05-1664; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bots M, 2009, CLIN CANCER RES, V15, P3970, DOI 10.1158/1078-0432.CCR-08-2786; Buchwald M, 2009, CANCER LETT, V280, P160, DOI 10.1016/j.canlet.2009.02.028; Canettieri G, 2010, NAT CELL BIOL, V12, P132, DOI 10.1038/ncb2013; Checquolo S, 2010, ONCOGENE, V29, P1463, DOI 10.1038/onc.2009.446; Clappier E, 2010, LEUKEMIA, V24, P2023, DOI 10.1038/leu.2010.205; Felli MP, 2005, ONCOGENE, V24, P992, DOI 10.1038/sj.onc.1208302; Galbiati L, 2005, CELL CYCLE, V4, P930, DOI 10.4161/cc.4.7.1784; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Guarani V, 2011, NATURE, V473, P234, DOI 10.1038/nature09917; Hernandez-Hernandez A, 2006, EMBO J, V25, P3264, DOI 10.1038/sj.emboj.7601228; Inari A, 2004, J BIOL CHEM, V279, P30830, DOI 10.1074/jbc.M402403200; Insinga A, 2005, CELL CYCLE, V4, P741, DOI 10.4161/cc.4.6.1717; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Kim MY, 2007, MOL CELL BIOL, V27, P6506, DOI 10.1128/MCB.01515-06; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Leduc C, 2006, ONCOGENE, V25, P4147, DOI 10.1038/sj.onc.1209446; Mateo F, 2009, ONCOGENE, V28, P2654, DOI 10.1038/onc.2009.127; Mercurio C, 2010, PHARMACOL RES, V62, P18, DOI 10.1016/j.phrs.2010.02.010; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mulligan P, 2011, MOL CELL, V42, P689, DOI 10.1016/j.molcel.2011.04.020; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Piekarz RL, 2007, CANCER J, V13, P30, DOI 10.1097/PPO.0b013e31803c73cc; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Screpanti I, 2003, TRENDS MOL MED, V9, P30, DOI 10.1016/S1471-4914(02)00003-5; Stockhausen MT, 2005, BRIT J CANCER, V92, P751, DOI 10.1038/sj.bjc.6602309; Talora C, 2006, BLOOD, V107, P3313, DOI 10.1182/blood-2005-07-2823; Talora C, 2003, EMBO REP, V4, P1067, DOI 10.1038/sj.embor.7400013; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Tsapis M, 2007, INT J BIOCHEM CELL B, V39, P1500, DOI 10.1016/j.biocel.2007.03.009; Vacca A, 2006, EMBO J, V25, P1000, DOI 10.1038/sj.emboj.7600996; Zhang B, 2010, CANCER CELL, V17, P427, DOI 10.1016/j.ccr.2010.03.011	41	44	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	33					3807	3817		10.1038/onc.2011.533	http://dx.doi.org/10.1038/onc.2011.533			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IU	22120716				2022-12-17	WOS:000307924900007
J	Claperon, A; Guedj, N; Mergey, M; Vignjevic, D; Desbois-Mouthon, C; Boissan, M; Saubamea, B; Paradis, V; Housset, C; Fouassier, L				Claperon, A.; Guedj, N.; Mergey, M.; Vignjevic, D.; Desbois-Mouthon, C.; Boissan, M.; Saubamea, B.; Paradis, V.; Housset, C.; Fouassier, L.			Loss of EBP50 stimulates EGFR activity to induce EMT phenotypic features in biliary cancer cells	ONCOGENE			English	Article						NHERF-1; EGFR; biliary carcinoma; adherens junctions; cell motility	MOESIN-BINDING PHOSPHOPROTEIN-50; SCAFFOLD PROTEINS; TUMOR-SUPPRESSOR; NHE-RF; RECEPTOR; EXPRESSION; NHERF1/EBP50; CONTRIBUTES; MEMBRANE; INHIBITION	Scaffold proteins form multiprotein complexes that are central to the regulation of intracellular signaling. The scaffold protein ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) is highly expressed at the plasma membrane of normal biliary epithelial cells and binds epidermal growth factor receptor (EGFR), a tyrosine kinase receptor with oncogenic properties. This study investigated EBP50-EGFR interplay in biliary cancer. We report that in a collection of 106 cholangio-carcinomas, EBP50 was delocalized to the cytoplasm of tumor cells in 66% of the cases. Ectopic expression of EBP50 was correlated with the presence of satellite nodules and with the expression of EGFR, which was at the plasma membrane, implying a loss of interaction with EBP50 in these cases. In vitro, loss of interaction between EBP50 and EGFR was mimicked by EBP50 depletion using a small interfering RNA approach in human biliary carcinoma cells co-expressing the two proteins at their plasma membrane, and in which interaction between EBP50 and EGFR was validated. EBP50 depletion caused an increase in EGFR expression at their surface, and a sustained activation of the receptor and of its downstream effectors (extracellular signal-regulated kinase 1/2, signal transducer and activator of transcription 3) in both basal and EGF-stimulated conditions. Cells lacking EBP50 showed epithelial-to-mesenchymal transition-associated features, including reduction in E-cadherin and cytokeratin-19 expression, induction of S100A4 and of the E-cadherin transcriptional repressor, Slug, and loss of cell polarity. Accordingly, depletion of EBP50 induced the disruption of adherens junctional complexes, the development of lamellipodia structures and the subsequent acquisition of motility properties. All these phenotypic changes were prevented upon inhibition of EGFR tyrosine kinase by gefitinib. These findings indicate that loss of EBP50 at the plasma membrane in tumor cells may contribute to biliary carcinogenesis through EGFR activation. Oncogene (2012) 31, 1376-1388; doi:10.1038/onc.2011.334; published online 8 August 2011	[Fouassier, L.] INSERM, Fac Med Pierre & Marie Curie, UMRS 938, F-75571 Paris, France; [Claperon, A.; Mergey, M.; Desbois-Mouthon, C.; Boissan, M.; Housset, C.; Fouassier, L.] Univ Paris 06, Paris, France; [Guedj, N.; Paradis, V.] Hop Beaujon, INSERM, UMRS U773, Clichy, France; [Guedj, N.; Paradis, V.] Hop Beaujon, AP HP, Serv Pathol, Clichy, France; [Vignjevic, D.] Inst Curie, CNRS, UMR 144, F-75231 Paris, France; [Boissan, M.] Hop Tenon, AP HP, Serv Biochim & Hormonol, F-75970 Paris, France; [Saubamea, B.] Univ Paris 05, INSERM, CNRS, U705,UMR 8206,Fac Pharm, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Fouassier, L (corresponding author), INSERM, Fac Med Pierre & Marie Curie, UMRS 938, Site St Antoine,27 Rue Chaligny, F-75571 Paris, France.	laura.fouassier@inserm.fr	vignjevic, Danijela Matic/R-5160-2019; Desbois-Mouthon, Christele/M-7076-2017; Fouassier, Laura/M-7556-2017; saubamea, bruno/H-6882-2017; Paradis, Valerie/X-9097-2019; Vignjevic, Danijela/L-9721-2017	vignjevic, Danijela Matic/0000-0003-4250-703X; Desbois-Mouthon, Christele/0000-0002-0772-1711; Fouassier, Laura/0000-0001-6377-5610; saubamea, bruno/0000-0002-6218-0460; guedj, nathalie/0000-0002-1421-6297; Paradis, Valerie/0000-0003-3142-3762	Institut National du Cancer; Association pour la Recherche sur le Cancer; Fonds CSP	Institut National du Cancer(Institut National du Cancer (INCA) France); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Fonds CSP	We thank Yves Chretien, UMRS_938, for statistical analysis, Anne-Marie Faussat, IFR65, for flow cytometry experiments and the Nikon Imaging Center, Institut Curie-CNRS Paris, for time-lapse microscopy. Confocal imaging was performed at the Cellular and Molecular Imaging facility of the IFR71-IMTCE (Faculty of Pharmacy, Paris Descartes University, Paris, France). This work was supported by grants from the Institut National du Cancer, Association pour la Recherche sur le Cancer and Fonds CSP (to CH). LF dedicates this work to RB Doctor and JG Fitz.	Bhattacharyya RP, 2006, ANNU REV BIOCHEM, V75, P655, DOI 10.1146/annurev.biochem.75.103004.142710; Cardone RA, 2007, MOL BIOL CELL, V18, P1768, DOI 10.1091/mbc.E06-07-0617; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Claperon A, 2007, ONCOGENE, V26, P3143, DOI 10.1038/sj.onc.1210408; Cortese MS, 2008, PROG BIOPHYS MOL BIO, V98, P85, DOI 10.1016/j.pbiomolbio.2008.05.007; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Dard N, 2006, BIOESSAYS, V28, P146, DOI 10.1002/bies.20351; Finzi L, 2009, J IMMUNOL, V182, P2269, DOI 10.4049/jimmunol.0801768; Fouassier L, 2001, HEPATOLOGY, V33, P166, DOI 10.1053/jhep.2001.21143; Fouassier L, 2009, AM J PATHOL, V174, P869, DOI 10.2353/ajpath.2009.080079; Georgescu MM, 2008, CURR MOL MED, V8, P459, DOI 10.2174/156652408785748031; Guedj N, 2009, J HEPATOL, V51, P93, DOI 10.1016/j.jhep.2009.03.017; Hayashi Y, 2010, NEOPLASIA, V12, P1013, DOI 10.1593/neo.10780; Henson ES, 2006, CELL SIGNAL, V18, P2089, DOI 10.1016/j.cellsig.2006.05.015; Hoque MT, 2008, CANCER RES, V68, P4802, DOI 10.1158/0008-5472.CAN-07-6778; KNUTH A, 1985, J HEPATOL, V1, P579, DOI 10.1016/S0168-8278(85)80002-7; Kreimann EL, 2007, ONCOGENE, V26, P5290, DOI 10.1038/sj.onc.1210336; Lambertini E, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-13; Lazar CS, 2004, MOL BIOL CELL, V15, P5470, DOI 10.1091/mbc.E04-03-0239; Lee CH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-64; Li M, 2010, J BIOL CHEM, V285, P19299, DOI 10.1074/jbc.M109.096081; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Masuda M, 2005, J BIOL CHEM, V280, P42164, DOI 10.1074/jbc.M507136200; Molina JR, 2010, CANCER RES, V70, P6697, DOI 10.1158/0008-5472.CAN-10-1271; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Sebastian S, 2006, BBA-REV CANCER, V1766, P120, DOI 10.1016/j.bbcan.2006.06.001; Shibata T, 2003, HEPATOLOGY, V38, P178, DOI 10.1053/jhep.2003.50270; Song J, 2007, HISTOPATHOLOGY, V51, P40, DOI 10.1111/j.1365-2559.2007.02730.x; Stemmer-Rachamimov AO, 2001, AM J PATHOL, V158, P57, DOI 10.1016/S0002-9440(10)63944-2; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Vondriska TM, 2004, J MOL CELL CARDIOL, V37, P391, DOI 10.1016/j.yjmcc.2004.04.021; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; Werneburg NW, 2003, AM J PHYSIOL-GASTR L, V285, pG31, DOI 10.1152/ajpgi.00536.2002; Yoon JH, 2004, J HEPATOL, V41, P808, DOI 10.1016/j.jhep.2004.07.016; Yoshikawa D, 2008, BRIT J CANCER, V98, P418, DOI 10.1038/sj.bjc.6604129	36	44	48	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	11					1376	1388		10.1038/onc.2011.334	http://dx.doi.org/10.1038/onc.2011.334			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21822312				2022-12-17	WOS:000301780000005
J	Dou, L; Zheng, D; Li, J; Li, Y; Gao, L; Wang, L; Yu, L				Dou, L.; Zheng, D.; Li, J.; Li, Y.; Gao, L.; Wang, L.; Yu, L.			Methylation-mediated repression of microRNA-143 enhances MLL-AF4 oncogene expression	ONCOGENE			English	Article						miR-143; MLL-AF4; methylation; leukemia	ACUTE MYELOID-LEUKEMIA; COLORECTAL-CANCER; MIR-143; PROGNOSIS; AND-145; GENE; TUMORIGENESIS; TRANSCRIPTION; DIAGNOSIS; PROFILES	Fusion proteins containing the amino terminus of mixed lineage leukemia (MLL) are common in acute lymphoblastic leukemia (ALL) due to translocations. The MLL-AF4 fusion protein is generated by the translocation t(4;11)(q21;q23), and t(4;11)-positive ALL patients (MLL-AF4 ALL), have a notoriously poorer prognosis compared with patients with other MLL-associated leukemias. The detailed role of this fusion protein in leukemogenesis is not well understood. MicroRNAs (miRNAs) targeting the AF4 3' untranslated regions may modulate MLL-AF4 fusion protein levels, raising the question of whether regulation of these miRNAs are involved in the progression of MLL-AF4 ALL. In this study, we show that miR-143 was identified as a regulator of MLL-AF4 expression in MLL-AF4 ALL samples. Restoration of miR-143 in MLL-AF4-positive RS4;11 and MV4-11 cells induced apoptosis, negatively contributing to leukemia cell growth by reducing MLL-AF4 fusion protein levels. Furthermore, miR-143 was epigenetically repressed by promoter hypermethylation in MLL-AF4-positive primary blasts and cell lines, but not in normal bone marrow cells and MLL-AF4-negative primary blasts, which was directly associated with expression of the MLL-AF4 oncogene. This is the first study to show that miR-143 functions as a tumor suppressor in MLL-AF4 B-cell ALL. These data reveal the therapeutic promise of upregulating miR-143 expression for MLL-AF4 B-cell ALL. Oncogene (2012) 31, 507-517; doi: 10.1038/onc.2011.248; published online 27 June 2011	[Dou, L.; Li, J.; Li, Y.; Gao, L.; Wang, L.; Yu, L.] Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing 100853, Peoples R China; [Zheng, D.] Chinese PLA 309th Hosp, Dept Hepatobiliary Surg, Organ Transplant Ctr, Beijing, Peoples R China	Chinese People's Liberation Army General Hospital	Yu, L (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Fuxing Rd 28th, Beijing 100853, Peoples R China.	daughter126@126.com; chunhuiliyu@yahoo.com		Yu, Li/0000-0001-6872-2665	National Natural Science Foundation of China [30800482, 30971297, 90919044]; Medical Capital Development Fund [2007-2040]; Beijing Natural Science Foundation of China [7102147]; National 973 Project of China [2005CB522400]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Capital Development Fund; Beijing Natural Science Foundation of China(Beijing Natural Science Foundation); National 973 Project of China(National Basic Research Program of China)	We are grateful to Professor Xiaofei Zheng for miRNA-expressing plasmids. We thank Wei Wang, Yi Ding, Yuanyuan Xu, Nan Wang, Chengwang Xu, Meng Li, Xufeng Luo, Huiyuan Kang, Xinrong Wang and Xiaoning Gao for excellent technical assistance. This work was supported by the National Natural Science Foundation of China (Nos. 30800482, 30971297 and 90919044), Medical Capital Development Fund (2007-2040), the Beijing Natural Science Foundation of China (No. 7102147) and the National 973 Project of China (No. 2005CB522400).	Akao Y, 2010, CANCER GENE THER, V17, P398, DOI 10.1038/cgt.2009.88; Akao Y, 2007, CANCER SCI, V98, P1914, DOI 10.1111/j.1349-7006.2007.00618.x; Akao Y, 2009, LEUKEMIA RES, V33, P1530, DOI 10.1016/j.leukres.2009.04.019; Bittner S, 2010, ANN NEUROL, V68, P58, DOI 10.1002/ana.22010; Chen X, 2009, ONCOGENE, V28, P1385, DOI 10.1038/onc.2008.474; Clape C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007542; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Erfurth FE, 2008, P NATL ACAD SCI USA, V105, P7517, DOI 10.1073/pnas.0800090105; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fazi F, 2007, CANCER CELL, V12, P457, DOI 10.1016/j.ccr.2007.09.020; Gao W, 2010, BIOMED PHARMACOTHER, V64, P399, DOI 10.1016/j.biopha.2010.01.018; Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006; Glas M, 2010, ANN NEUROL, V68, P264, DOI 10.1002/ana.22036; Langevin SM, 2011, CANCER-AM CANCER SOC, V117, P1454, DOI 10.1002/cncr.25689; Lin TC, 2011, LEUKEMIA, V25, P32, DOI 10.1038/leu.2010.222; Liu H, 2009, CANCER BIOL THER, V8, P1204, DOI 10.4161/cbt.8.13.8924; Liu Q, 2008, NUCLEIC ACIDS RES, V36, P5391, DOI 10.1093/nar/gkn522; Lowenberg B, 2008, NEW ENGL J MED, V358, P1960, DOI 10.1056/NEJMe0802379; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Luty AA, 2010, ANN NEUROL, V68, P639, DOI 10.1002/ana.22274; Metzler M, 2006, ONCOGENE, V25, P3093, DOI 10.1038/sj.onc.1209636; Meyer B, 2011, NUCLEIC ACIDS RES, V39, P1526, DOI 10.1093/nar/gkq931; RONCHI AE, 1995, J BIOL CHEM, V270, P21934, DOI 10.1074/jbc.270.37.21934; Santoro R, 2002, NAT GENET, V32, P393, DOI 10.1038/ng1010; Slaby O, 2007, ONCOLOGY-BASEL, V72, P397, DOI 10.1159/000113489; Takagi T, 2009, ONCOLOGY-BASEL, V77, P12, DOI 10.1159/000218166; Thomas M, 2005, BLOOD, V106, P3559, DOI 10.1182/blood-2005-03-1283; Walker BA, 2011, BLOOD, V117, P553, DOI 10.1182/blood-2010-04-279539; Wang CJ, 2009, DIS MARKERS, V26, P27, DOI [10.3233/DMA-2009-0601, 10.1155/2009/921907]; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521	32	44	54	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	4					507	517		10.1038/onc.2011.248	http://dx.doi.org/10.1038/onc.2011.248			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21706045				2022-12-17	WOS:000300219300009
J	Tomita, T; Sakurai, Y; Ishibashi, S; Maru, Y				Tomita, T.; Sakurai, Y.; Ishibashi, S.; Maru, Y.			Imbalance of Clara cell-mediated homeostatic inflammation is involved in lung metastasis	ONCOGENE			English	Article						Clara cell; lung metastasis; serum amyloid A3; Toll-like receptor 4	TUMOR-NECROSIS-FACTOR; ALLERGIC PULMONARY INFLAMMATION; SERUM AMYLOID A3; NF-KAPPA-B; TRANSENDOTHELIAL MIGRATION; NEGATIVE REGULATOR; EPITHELIAL-CELLS; DANGER SIGNAL; MYELOID CELLS; PROTEIN	We have previously shown that tumor necrosis factor (TNF)alpha produced from primary tumor-induced expression of two endogenous Toll-like receptor 4 (TLR4) ligands, S100A8 and serum amyloid A3 (SAA3), in pre-metastatic lungs. However, mechanistic details of the signaling network and relevance to pulmonary physiology are poorly understood. Here, we identify Clara cells as a control tower of the network. Clara cell ablation by naphthalene suppressed pulmonary recruitment of CD11b+ TLR4+ cells and spontaneous lung metastasis. Clara cells turned out to express TLR4 through which SAA3 was auto-amplified. Reciprocal bone marrow transplantation between wild-type and TLR4 knockout mice demonstrated that pulmonary TLR4+ Clara cells could be derived from bone marrow. SAA3-induced TNF alpha expression in both alveolar type II cells and macrophages. Primary co-cultures of alveolar type II cells and Clara cells revealed that the induction of TNF alpha in alveolar type II cells was dependent on the Clara cell-mediated amplification of SAA3. SAA3 induction by bacterial endotoxin also required both Clara cells and TLR4. Thus, pulmonary metastatic soil may feature deregulation of homeostatic inflammatory responses to constant assaults of microbes with endotoxin. Oncogene (2011) 30, 3429-3439; doi:10.1038/onc.2011.53; published online 14 March 2011	[Maru, Y.] Tokyo Womens Med Univ, Dept Pharmacol, Shinjuku Ku, Tokyo 1628666, Japan	Tokyo Women's Medical University	Maru, Y (corresponding author), Tokyo Womens Med Univ, Dept Pharmacol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	ymaru@research.twmu.ac.jp	Tomita, Taisuke/L-5427-2015	Tomita, Taisuke/0000-0002-0075-5943; Tomita, Takeshi/0000-0001-6815-2244	Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan [21117008, 21790330]; Sato Memorial Foundation for Cancer Research; Multidisciplinary Education and Research Center for Regenerative Medicine (MERCREM), from MEXT, Japan	Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Sato Memorial Foundation for Cancer Research; Multidisciplinary Education and Research Center for Regenerative Medicine (MERCREM), from MEXT, Japan	We thank Dr Shioko Kimura at National Institute of Health for providing resources including cell lines. This work was supported by Grant-in-Aid for Scientific Research from Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan, 21117008 (YM) and 21790330 (TT), Sato Memorial Foundation for Cancer Research (TT), and the Global COE program, Multidisciplinary Education and Research Center for Regenerative Medicine (MERCREM), from MEXT, Japan.	Armstrong L, 2004, AM J RESP CELL MOL, V31, P241, DOI 10.1165/rcmb.2004-0078OC; Arsalane K, 2000, AM J RESP CRIT CARE, V161, P1624, DOI 10.1164/ajrccm.161.5.9812157; Atkinson JJ, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-1; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Bing ZY, 2000, J BIOL CHEM, V275, P31616, DOI 10.1074/jbc.M005378200; DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018; Devoogdt N, 2003, P NATL ACAD SCI USA, V100, P5778, DOI 10.1073/pnas.1037154100; DOBBS LG, 1978, AM REV RESPIR DIS, V134, P141; Franklin GA, 2003, AM J SURG, V186, P493, DOI 10.1016/j.amjsurg.2003.07.012; Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198; Ghavami S, 2008, J LEUKOCYTE BIOL, V83, P1484, DOI 10.1189/jlb.0607397; Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768; Gilchrist M, 2008, J EXP MED, V205, P2349, DOI 10.1084/jem.20072254; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Kaplan RN, 2006, CANCER RES, V66, P11089, DOI 10.1158/0008-5472.CAN-06-2407; Kerkhoff C, 2005, FASEB J, V19, P467, DOI 10.1096/fj.04-2377fje; Kerkhoff C, 1999, PATHOBIOLOGY, V67, P230, DOI 10.1159/000028098; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Li JH, 2004, J IMMUNOL METHODS, V289, P211, DOI 10.1016/j.jim.2004.04.019; Maru Y, 2010, CELL MOL IMMUNOL, V7, P94, DOI 10.1038/cmi.2009.113; Maru Yoshiro, 2009, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V8, P337; Mata-Haro V, 2007, SCIENCE, V316, P1628, DOI 10.1126/science.1138963; Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830; Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589; Passey RJ, 1999, J IMMUNOL, V163, P2209; Raquil MA, 2008, J IMMUNOL, V180, P3366, DOI 10.4049/jimmunol.180.5.3366; Ryckman C, 2003, J IMMUNOL, V170, P3233, DOI 10.4049/jimmunol.170.6.3233; Saha A, 2010, J BIOL CHEM, V285, P10822, DOI 10.1074/jbc.M109.083550; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Son DS, 2004, ENDOCRINOLOGY, V145, P2245, DOI 10.1210/en.2003-1261; Taranova AG, 2008, CANCER RES, V68, P8582, DOI 10.1158/0008-5472.CAN-08-1673; Turovskaya O, 2008, CARCINOGENESIS, V29, P2035, DOI 10.1093/carcin/bgn188; van Zoelen MAD, 2009, J IMMUNOL, V182, P4349, DOI 10.4049/jimmunol.0801199; Vogl T, 2004, BLOOD, V104, P4260, DOI 10.1182/blood-2004-02-0446; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Wong AP, 2009, J CLIN INVEST, V119, P336, DOI 10.1172/JCI36882; Yang HA, 2010, P NATL ACAD SCI USA, V107, P11942, DOI 10.1073/pnas.1003893107; Yao XL, 1998, AM J RESP CELL MOL, V19, P629, DOI 10.1165/ajrcmb.19.4.3129; Yatera K, 2001, ENVIRON HEALTH PERSP, V109, P795, DOI 10.2307/3454821; Zhang XC, 2006, J CLIN INVEST, V116, P3050, DOI 10.1172/JCI28139; ZUGMAIER G, 1991, CANCER RES, V51, P3590	43	44	47	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	31					3429	3439		10.1038/onc.2011.53	http://dx.doi.org/10.1038/onc.2011.53			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	802KA	21399660				2022-12-17	WOS:000293508100004
J	Xu, S; Feng, Z; Zhang, M; Wu, Y; Sang, Y; Xu, H; Lv, X; Hu, K; Cao, J; Zhang, R; Chen, L; Liu, M; Yun, JP; Zeng, YX; Kang, T				Xu, S.; Feng, Z.; Zhang, M.; Wu, Y.; Sang, Y.; Xu, H.; Lv, X.; Hu, K.; Cao, J.; Zhang, R.; Chen, L.; Liu, M.; Yun, J-P; Zeng, Y-X; Kang, T.			hSSB1 binds and protects p21 from ubiquitin-mediated degradation and positively correlates with p21 in human hepatocellular carcinomas	ONCOGENE			English	Article						cell cycle; hSSB1; p21; ubiquitin; hepatocellular; carcinomas	HUMAN BREAST-CARCINOMA; P21(WAF1/CIP1) EXPRESSION; DNA-DAMAGE; CELL-CYCLE; GENOMIC STABILITY; INHIBITION; P53; PROTEASOME; APOPTOSIS; SURVIVAL	Downregulation of hSSB1, a single-stranded DNA-binding protein, causes increased radiosensitivity, defective checkpoint activation and genomic instability. However, the mechanisms of hSSB1 function in these responses remain to be uncovered. Here, we present evidence that hSSB1 directly binds p21 and this interaction may prevent p21 from ubiquitin-mediated degradation. Furthermore, both promotion of the G1/S transition and abrogation of the G2/M checkpoints induced by hSSB1 knockdown are partially dependent on p21. Most importantly, hSSB1 and p21 levels are positively correlated in human hepatocellular carcinomas (HCC), as determined by immuno-staining. Therefore, hSSB1 may positively modulate p21 to regulate cell cycle progression and DNA damage response, implicating hSSB1 as a novel, promising therapeutic target for cancers such as HCC. Oncogene (2011) 30, 2219-2229; doi:10.1038/onc.2010.596; published online 17 January 2011	[Xu, S.; Wu, Y.; Sang, Y.; Lv, X.; Hu, K.; Cao, J.; Zhang, R.; Chen, L.; Zeng, Y-X; Kang, T.] Sun Yat Sen Univ, Dept Expt Res, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China; [Xu, S.; Feng, Z.; Zhang, M.; Wu, Y.; Sang, Y.; Xu, H.; Lv, X.; Hu, K.; Cao, J.; Zhang, R.; Chen, L.; Liu, M.; Yun, J-P; Zeng, Y-X; Kang, T.] Sun Yat Sen Univ, State Key Lab Oncol S China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China; [Feng, Z.; Xu, H.; Liu, M.] Sun Yat Sen Univ, Dept Radiat Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China; [Zhang, M.; Yun, J-P] Sun Yat Sen Univ, Dept Pathol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Kang, T (corresponding author), Sun Yat Sen Univ, Dept Expt Res, Ctr Canc, 651 Dongfeng Rd E, Guangzhou 510060, Guangdong, Peoples R China.	kangtb@mail.sysu.edu.cn	Lv, Xiao-Bin/T-7607-2019; Feng, Zizhen/G-2322-2014	Feng, Zizhen/0000-0002-7763-1869; Sang, Yi/0000-0001-6534-0741	NSFC [30772492, 30973506, U0732005, 30930045]; 863 project [2006AA02A404]; 973 project [2010CB912201]	NSFC(National Natural Science Foundation of China (NSFC)); 863 project(National High Technology Research and Development Program of China); 973 project(National Basic Research Program of China)	We thank the members of the laboratory for their helpful comments on the manuscript. This work was supported by grants from NSFC (30772492 and 30973506 to J-PY, U0732005 to Y-XZ, and 30930045 to TK), from the 863 project (2006AA02A404 to Y-XZ), and from the 973 project (2010CB912201 to TK).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Brustmann H, 2005, GYNECOL ONCOL, V98, P396, DOI 10.1016/j.ygyno.2005.04.035; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; Child ES, 2006, CELL CYCLE, V5, P1313, DOI 10.4161/cc.5.12.2863; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferguson AM, 2005, MOL CELL BIOL, V25, P2853, DOI 10.1128/MCB.25.7.2853-2860.2005; Fukuchi K, 1999, BBA-MOL CELL RES, V1451, P206, DOI 10.1016/S0167-4889(99)00081-6; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 2006, MOL CANCER THER, V5, P1385, DOI 10.1158/1535-7163.MCT-06-0163; Huang J, 2009, MOL CELL, V35, P384, DOI 10.1016/j.molcel.2009.06.011; Inagaki Y, 2008, CANCER GENET CYTOGEN, V180, P30, DOI 10.1016/j.cancergencyto.2007.09.013; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Kang T, 2008, CANCER CELL, V13, P36, DOI 10.1016/j.ccr.2007.12.002; Kao JT, 2007, LIVER INT, V27, P772, DOI 10.1111/j.1478-3231.2007.01499.x; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Lee YH, 2009, MODERN PATHOL, V22, P1121, DOI 10.1038/modpathol.2009.76; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Li XS, 1996, CANCER RES, V56, P5055; Li YJ, 2009, J BIOL CHEM, V284, P23525, DOI 10.1074/jbc.C109.039586; Liu SX, 2003, DRUG RESIST UPDATE, V6, P183, DOI 10.1016/S1368-7646(03)00044-X; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MICHIELI P, 1994, CANCER RES, V54, P3391; Miyazaki M, 2004, CANCER RES, V64, P4155, DOI 10.1158/0008-5472.CAN-03-2750; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; O'Reilly MA, 2005, ANTIOXID REDOX SIGN, V7, P108, DOI 10.1089/ars.2005.7.108; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Qin LF, 1998, INT J CANCER, V79, P424, DOI 10.1002/(SICI)1097-0215(19980821)79:4<424::AID-IJC19>3.0.CO;2-4; Richard DJ, 2008, NATURE, V453, P677, DOI 10.1038/nature06883; Schoniger-Hekele M, 2005, LIVER INT, V25, P62, DOI 10.1111/j.1478-3231.2004.0997.x; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiohara M, 1996, J CELL PHYSIOL, V166, P568, DOI 10.1002/(SICI)1097-4652(199603)166:3<568::AID-JCP11>3.0.CO;2-3; Shiraki K, 2006, LIVER INT, V26, P1018, DOI 10.1111/j.1478-3231.2006.01320.x; Skaar JR, 2009, J CELL BIOL, V187, P25, DOI 10.1083/jcb.200907026; Tanaka H, 2002, J CELL BIOL, V158, P321, DOI 10.1083/jcb.200202071; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Xiao JY, 2009, CELL CYCLE, V8, P889, DOI 10.4161/cc.8.6.7898; Xu SB, 2009, J CANCER RES CLIN, V135, P1791, DOI 10.1007/s00432-009-0627-z; Zhang F, 2009, J BIOL CHEM, V284, P30408, DOI 10.1074/jbc.M109.039404; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	48	44	52	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	19					2219	2229		10.1038/onc.2010.596	http://dx.doi.org/10.1038/onc.2010.596			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21242961				2022-12-17	WOS:000290514600005
J	Low, JSW; Tao, Q; Ng, KM; Goh, HK; Shu, XS; Woo, WL; Ambinder, RF; Srivastava, G; Shamay, M; Chan, ATC; Popescu, NC; Hsieh, WS				Low, J. S. W.; Tao, Q.; Ng, K. M.; Goh, H. K.; Shu, X-S; Woo, W. L.; Ambinder, R. F.; Srivastava, G.; Shamay, M.; Chan, A. T. C.; Popescu, N. C.; Hsieh, W-S			A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors	ONCOGENE			English	Article						DLC1; RhoGAP; methylation; tumor suppressor gene; carcinoma; p53	GTPASE-ACTIVATING PROTEIN; STRESS-RESPONSIVE GENE; TRANSCRIPTIONAL REGULATION; HEPATOCELLULAR-CARCINOMA; MORPHOLOGICAL-CHANGES; RHOGAP PROTEIN; CELL-GROWTH; CANCER; NASOPHARYNGEAL; METHYLATION	The critical 8p22 tumor suppressor deleted in liver cancer 1 (DLC1) is frequently inactivated by aberrant CpG methylation and/or genetic deletion and implicated in tumorigeneses of multiple tumor types. Here, we report the identification and characterization of its new isoform, DLC1 isoform 4 (DLC1-i4). This novel isoform encodes an 1125-aa (amino acid) protein with distinct N-terminus as compared with other known DLC1 isoforms. Similar to other isoforms, DLC1-i4 is expressed ubiquitously in normal tissues and immortalized normal epithelial cells, suggesting a role as a major DLC1 transcript. However, differential expression of the four DLC1 isoforms is found in tumor cell lines: Isoform 1 (longest) and 3 (short thus probably nonfunctional) share a promoter and are silenced in almost all cancer and immortalized cell lines, whereas isoform 2 and 4 utilize different promoters and are frequently downregulated. DLC1-i4 is significantly downregulated in multiple carcinoma cell lines, including 2/4 nasopharyngeal, 8/16 (50%) esophageal, 4/16 (25%) gastric, 6/9 (67%) breast, 3/4 colorectal, 4/4 cervical and 2/8(25%) lung carcinoma cell lines. The functional DLC1-i4 promoter is within a CpG island and is activated by wild-type p53. CpG methylation of the DLC1-i4 promoter is associated with its silencing in tumor cells and was detected in 38-100% of multiple primary tumors. Treatment with 5-aza-20-deoxycytidine or genetic double knockout of DNMT1 and DNMT3B led to demethylation of the promoter and reactivation of its expression, indicating a predominantly epigenetic mechanism of silencing. Ectopic expression of DLC1-i4 in silenced tumor cells strongly inhibited their growth and colony formation. Thus, we identified a new isoform of DLC1 with tumor suppressive function. The differential expression of various DLC1 isoforms suggests interplay in modulating the complex activities of DLC1 during carcinogenesis. Oncogene (2011) 30, 1923-1935; doi: 10.1038/onc.2010.576; published online 10 January 2011	[Low, J. S. W.; Tao, Q.; Goh, H. K.; Woo, W. L.; Ambinder, R. F.; Shamay, M.; Hsieh, W-S] Johns Hopkins Singapore, Div Biomed Sci, Singapore, Singapore; [Low, J. S. W.; Goh, H. K.; Ambinder, R. F.; Hsieh, W-S] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117456, Singapore; [Tao, Q.; Ambinder, R. F.; Shamay, M.; Hsieh, W-S] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; [Tao, Q.; Ng, K. M.; Shu, X-S; Chan, A. T. C.] Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab Oncol S China, Sir YK Pao Ctr Canc,Hong Kong Canc Inst,Canc Epig, Shatin, Hong Kong, Peoples R China; [Tao, Q.] Chinese Univ Hong Kong, PWH, Ctr Canc, Dept Clin Oncol,Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; [Srivastava, G.] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Popescu, N. C.] NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; National University of Singapore; Johns Hopkins University; Johns Hopkins Medicine; Chinese University of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital; University of Hong Kong; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Tao, Q (corresponding author), Chinese Univ Hong Kong, PWH, Ctr Canc, Dept Clin Oncol,Li Ka Shing Inst Hlth Sci, Rm 315, Shatin, Hong Kong, Peoples R China.	qtao@clo.cuhk.edu.hk; whsieh1@jhem.jhmi.edu	Woo, Wai Lok/T-3662-2018; Tao, Qian/T-4743-2018; Chan, Anthony Tak Cheung/R-3940-2018	Woo, Wai Lok/0000-0002-8698-7605; Tao, Qian/0000-0001-5383-4808; Chan, Anthony Tak Cheung/0000-0002-6912-8091	A*STAR; Chinese University of Hong Kong; Singapore National Research Foundation; Ministry of Education; NATIONAL CANCER INSTITUTE [ZIABC010038, P50CA096888] Funding Source: NIH RePORTER	A*STAR(Agency for Science Technology & Research (A*STAR)); Chinese University of Hong Kong(Chinese University of Hong Kong); Singapore National Research Foundation(National Research Foundation, Singapore); Ministry of Education; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project was supported by an A*STAR grant (Johns Hopkins Singapore, QT/WS/RA), a Chinese University of Hong Kong grant (QT) and a grant from Singapore National Research Foundation and the Ministry of Education under the Research Center of Excellence Program (WS/RA). We thank Drs Bert Vogelstein, George Tsao, (Dolly Huang), Michael Obster and Guiyuan Li for some cell lines; and DSMZ (German Collection of Microorganisms & Cell Cultures) for the KYSE cell lines (Shimada et al., Cancer 69: 277-284, 1992). We also thank Drs Wenling Han, Thomas Putti, Luke Tan for some tumor samples.	AKIYAMA Y, 1995, TFSEARCH SEARC UNPUB; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bannai H, 2002, BIOINFORMATICS, V18, P298, DOI 10.1093/bioinformatics/18.2.298; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; CHEUNG WY, 1993, AM J CLIN PATHOL, V100, P502, DOI 10.1093/ajcp/100.5.502; Ching YP, 2003, J BIOL CHEM, V278, P10824, DOI 10.1074/jbc.M208310200; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Cui Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002990; Durkin ME, 2007, ONCOGENE, V26, P4580, DOI 10.1038/sj.onc.1210244; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Emanuelsson O, 2007, NAT PROTOC, V2, P953, DOI 10.1038/nprot.2007.131; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Flicek P, 2010, NUCLEIC ACIDS RES, V38, pD557, DOI 10.1093/nar/gkp972; Goodison S, 2005, CANCER RES, V65, P6042, DOI 10.1158/0008-5472.CAN-04-3043; Guda C, 2004, BIOINFORMATICS, V20, P1785, DOI 10.1093/bioinformatics/bth171; Guda C, 2004, NUCLEIC ACIDS RES, V32, pW372, DOI 10.1093/nar/gkh374; Hall T.A., 1999, NUCLC ACIDS S, V41, P95, DOI citeulike-article-id:691774; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; HORII A, 1993, HUM MOL GENET, V2, P283, DOI 10.1093/hmg/2.3.283; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Ko FCF, 2010, LIVER INT, V30, P139, DOI 10.1111/j.1478-3231.2009.02133.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Leung THY, 2005, P NATL ACAD SCI USA, V102, P15207, DOI 10.1073/pnas.0504501102; Lo AKF, 2006, NEOPLASIA, V8, P173, DOI 10.1593/neo.05625; Maglott D, 2007, NUCLEIC ACIDS RES, V35, pD26, DOI 10.1093/nar/gkl993; Martin G. Steven, 2003, Cancer Cell, V4, P167, DOI 10.1016/S1535-6108(03)00216-2; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Ng IOL, 2000, CANCER RES, V60, P6581; Pang JCS, 2005, HUM PATHOL, V36, P36, DOI 10.1016/j.humpath.2004.09.021; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Sabbir MG, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-17; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Seng TJ, 2007, ONCOGENE, V26, P934, DOI 10.1038/sj.onc.1209839; Small I, 2004, PROTEOMICS, V4, P1581, DOI 10.1002/pmic.200300776; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Takai Daiya, 2003, In Silico Biology, V3, P235; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 1998, BLOOD, V91, P1373, DOI 10.1182/blood.V91.4.1373; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; Wong CM, 2003, CANCER RES, V63, P7646; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yuan BZ, 2007, EXP CELL RES, V313, P3868, DOI 10.1016/j.yexcr.2007.08.009; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X; Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291; Zhou XL, 2004, ONCOGENE, V23, P1308, DOI 10.1038/sj.onc.1207246; Zhou XL, 1999, CANCER RES, V59, P843	66	44	49	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	16					1923	1935		10.1038/onc.2010.576	http://dx.doi.org/10.1038/onc.2010.576			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21217778	Green Accepted			2022-12-17	WOS:000289777700008
J	Chae, KS; Kang, MJ; Lee, JH; Ryu, BK; Lee, MG; Her, NG; Ha, TK; Han, J; Kim, YK; Chi, SG				Chae, K. S.; Kang, M. J.; Lee, J. H.; Ryu, B. K.; Lee, M. G.; Her, N. G.; Ha, T. K.; Han, J.; Kim, Y. K.; Chi, S. G.			Opposite functions of HIF-alpha isoforms in VEGF induction by TGF-beta 1 under non-hypoxic conditions	ONCOGENE			English	Article						TGF-beta 1; VEGF; Smad3; HIF-2 alpha; HuR; prostate cancer	ENDOTHELIAL GROWTH-FACTOR; HUMAN PROSTATE-CANCER; HYPOXIA-INDUCIBLE FACTOR-1; MESSENGER-RNA STABILITY; FACTOR GENE-EXPRESSION; RENAL-CELL CARCINOMA; FACTOR-BETA; CYCLOOXYGENASE-2 EXPRESSION; HIF-2-ALPHA EXPRESSION; FACTOR (HIF)-1-ALPHA	Transforming growth factor (TGF)-beta 1 has biphasic functions in prostate tumorigenesis, having a growth-inhibitory effect in the early stages, but in the late stages promoting tumor angiogenesis and metastasis. We demonstrate here that tumor-producing TGF-beta 1 induces vascular endothelial growth factor (VEGF) in prostate cancer cells, and hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha has opposite functions in TGF-beta 1 regulation of VEGF expression under non-hypoxic conditions. The promoter response of VEGF to TGF-beta 1 was upregulated by the transfection of HIF-2 alpha or siHIF-1 alpha but downregulated by HIF-1 alpha and siHIF-2 alpha. Both HIF-1 alpha and HIF-2 alpha were induced by TGF-beta 1 at mRNA and protein levels, however, their nuclear translocation was differentially regulated by TGF-beta 1, suggesting its association with their opposite effects. VEGF induction by TGF-beta 1 occurred in a Smad3-dependent manner, and the Smad-binding element 2 (SBE2, -992 to -986) and hypoxia response element (-975 to -968) in the VEGF promoter were required for the promoter response to TGF-beta 1. Smad3 cooperated with HIF-2 alpha in TGF-beta 1 activation of VEGF transcription and Smad3 binding to the SBE2 site was greatly impaired by knockdown of HIF-2 alpha expression. Moreover, the VEGF promoter response to TGF-beta 1 was synergistically elevated by co-transfection of Smad3 and HIF-2 alpha but attenuated by HIF-1 alpha in a dose-dependent manner. Additionally, TGF-beta 1 was found to increase the stability of VEGF transcript by facilitating the cytoplasmic translocation of a RNA-stabilizing factor HuR. Collectively, our data show that tumor-producing TGF-beta 1 induces VEGF at the both transcription and post-transcriptional levels through multiple routes including Smad3, HIF-2 alpha and HuR. This study thus suggests that autocrine TGF-beta 1 production may contribute to tumor angiogenesis via HIF-2 alpha signaling under non-hypoxic conditions, providing a selective growth advantage for prostate tumor cells. Oncogene (2011) 30, 1213-1228; doi:10.1038/onc.2010.498; published online 8 November 2010	[Chae, K. S.; Kang, M. J.; Lee, J. H.; Ryu, B. K.; Lee, M. G.; Her, N. G.; Ha, T. K.; Han, J.; Kim, Y. K.; Chi, S. G.] Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; [Chae, K. S.] Kyungpook Natl Univ, Dept Biol Educ, Teachers Coll, Taegu, South Korea	Korea University; Kyungpook National University	Chi, SG (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea.	chi6302@korea.ac.kr	Han, Jikhyon/L-7891-2014; Her, Nam-Gu/AGY-5470-2022; Kang, Min-Ju/AAY-8706-2021	Han, Jikhyon/0000-0002-7767-3305; Kim, Yoon Ki/0000-0003-1303-072X; KANG, MIN-JU/0000-0001-5040-1388	National Research Foundation of Korea [0000794, 0001197]; Korea Research Foundation [2008-314-C00247]; National Cancer Center, Republic of Korea [0820070]	National Research Foundation of Korea(National Research Foundation of Korea); Korea Research Foundation(National Research Foundation of Korea); National Cancer Center, Republic of Korea	This work was supported in part by grants from National Research Foundation of Korea (0000794 and 0001197), the Korea Research Foundation (2008-314-C00247) and the National Cancer Center (0820070), Republic of Korea.	Benckert C, 2003, CANCER RES, V63, P1083; Benjamin D, 2007, EXPERT OPIN BIOL TH, V7, P1515, DOI 10.1517/14712598.7.10.1515; Blancher C, 2000, CANCER RES, V60, P7106; Boddy JL, 2005, CLIN CANCER RES, V11, P7658, DOI 10.1158/1078-0432.CCR-05-0460; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI12973; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Fukuda R, 2003, CANCER RES, V63, P2330; Giatromanolaki A, 2003, MELANOMA RES, V13, P493, DOI 10.1097/00008390-200310000-00008; Goodyear SM, 2009, PROSTATE, V69, P982, DOI 10.1002/pros.20945; Helczynska K, 2008, CANCER RES, V68, P9212, DOI 10.1158/0008-5472.CAN-08-1135; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Jackson MW, 2002, CANCER RES, V62, P854; Jeon SH, 2007, J LEUKOCYTE BIOL, V81, P557, DOI 10.1189/jlb.0806517; Kang MJ, 2008, GASTROENTEROLOGY, V135, P2030, DOI 10.1053/j.gastro.2008.08.009; Kim IY, 1996, CLIN CANCER RES, V2, P1255; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lofstedt T, 2007, CELL CYCLE, V6, P919, DOI 10.4161/cc.6.8.4133; Loureiro RMB, 2005, CYTOKINE GROWTH F R, V16, P77, DOI 10.1016/j.cytogfr.2005.01.005; Lu S, 2007, CLIN CANCER RES, V13, P5692, DOI 10.1158/1078-0432.CCR-07-1078; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; McMahon S, 2006, J BIOL CHEM, V281, P24171, DOI 10.1074/jbc.M604507200; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nabors LB, 2001, CANCER RES, V61, P2154; Noguera R, 2009, CLIN CANCER RES, V15, P7130, DOI 10.1158/1078-0432.CCR-09-0223; Pallares J, 2006, HISTOL HISTOPATHOL, V21, P857, DOI 10.14670/HH-21.857; Park BJ, 2000, CANCER RES, V60, P3031; Park JI, 2003, ONCOGENE, V22, P4314, DOI 10.1038/sj.onc.1206478; Pietras A, 2008, J PATHOL, V214, P482, DOI 10.1002/path.2304; Pu H, 2009, CANCER RES, V69, P7366, DOI 10.1158/0008-5472.CAN-09-0758; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Stearns ME, 1999, CLIN CANCER RES, V5, P711; Sugano Y, 2003, ONCOGENE, V22, P2309, DOI 10.1038/sj.onc.1206305; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; TRUONG LD, 1993, HUM PATHOL, V24, P4, DOI 10.1016/0046-8177(93)90055-L; Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang L, 2004, J BIOL CHEM, V279, P33213, DOI 10.1074/jbc.M403758200; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; Williams RH, 1996, CLIN CANCER RES, V2, P635; Yoshimura H, 2004, CLIN CANCER RES, V10, P8554, DOI 10.1158/1078-0432.CCR-0946-03; Zhong H, 2004, CANCER DETECT PREV, V28, P88, DOI 10.1016/j.cdp.2003.12.009; Zhong H, 2000, CANCER RES, V60, P1541; Zhu B, 2005, CANC TREAT, V126, P157, DOI 10.1007/0-387-24361-5_7	55	44	46	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1213	1228		10.1038/onc.2010.498	http://dx.doi.org/10.1038/onc.2010.498			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21057546				2022-12-17	WOS:000288202400008
J	Monahan, KB; Rozenberg, GI; Krishnamurthy, J; Johnson, SM; Liu, W; Bradford, MK; Horner, J; DePinho, RA; Sharpless, NE				Monahan, K. B.; Rozenberg, G. I.; Krishnamurthy, J.; Johnson, S. M.; Liu, W.; Bradford, M. K.; Horner, J.; DePinho, R. A.; Sharpless, N. E.			Somatic p16(INK4a) loss accelerates melanomagenesis	ONCOGENE			English	Article						melanoma; RAS; p16(INK4a)	TUMOR-SUPPRESSOR PTEN; MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; CELL-MIGRATION; P53 GENE; GERMLINE MUTATIONS; MELANOCYTIC NEVI; ONCOGENIC RAS; SUN EXPOSURE; IN-VIVO	Loss of p16(INK4a)-RB and ARF-p53 tumor suppressor pathways, as well as activation of RAS-RAF signaling, is seen in a majority of human melanomas. Although heterozygous germline mutations of p16(INK4a) are associated with familial melanoma, most melanomas result from somatic genetic events: often p16(INK4a) loss and N-RAS or B-RAF mutational activation, with a minority possessing alternative genetic alterations such as activating mutations in K-RAS and/or p53 inactivation. To generate a murine model of melanoma featuring some of these somatic genetic events, we engineered a novel conditional p16(INK4a)-null allele and combined this allele with a melanocyte-specific, inducible CRE recombinase strain, a conditional p53-null allele and a loxP-stop-loxP activatable oncogenic K-Ras allele. We found potent synergy between melanocyte-specific activation of K-Ras and loss of p16(INK4a) and/or p53 in melanomagenesis. Mice harboring melanocyte-specific activated K-Ras and loss of p16(INK4a) and/or p53 developed invasive, unpigmented and nonmetastatic melanomas with short latency and high penetrance. In addition, the capacity of these somatic genetic events to rapidly induce melanomas in adult mice suggests that melanocytes remain susceptible to transformation throughout adulthood. Oncogene (2010) 29, 5809-5817; doi: 10.1038/onc.2010.314; published online 9 August 2010	[Monahan, K. B.; Rozenberg, G. I.; Krishnamurthy, J.; Johnson, S. M.; Liu, W.; Bradford, M. K.; Sharpless, N. E.] Univ N Carolina, Sch Med, Ctr Environm Hlth & Susceptibil, Dept Med,Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Monahan, K. B.; Rozenberg, G. I.; Krishnamurthy, J.; Johnson, S. M.; Liu, W.; Bradford, M. K.; Sharpless, N. E.] Univ N Carolina, Sch Med, Ctr Environm Hlth & Susceptibil, Dept Genet,Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Horner, J.; DePinho, R. A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Belfer Inst Appl Canc Sci,Dept Med Oncol, Boston, MA 02115 USA; [Horner, J.; DePinho, R. A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Belfer Inst Appl Canc Sci,Dept Med, Boston, MA 02115 USA; [Horner, J.; DePinho, R. A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Belfer Inst Appl Canc Sci,Dept Genet, Boston, MA 02115 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Sharpless, NE (corresponding author), Univ N Carolina, Sch Med, Lineberger Canc Ctr, Dept Med, CB 7295,Mason Farm Rd, Chapel Hill, NC 27599 USA.	nes@med.unc.edu		Sharpless, Norman/0000-0001-7078-9455; DePinho, Ronald/0000-0002-5625-577X	NIH [AG024379, ES14635]; American Federation of Aging; Golfers Against Cancer Foundation; Sidney Kimmel Foundation; National Cancer Center; NATIONAL CANCER INSTITUTE [R01CA163896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES014635, P30ES010126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG024379] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Federation of Aging; Golfers Against Cancer Foundation; Sidney Kimmel Foundation; National Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Eric Brown, Marcus Bosenberg, Vincent Hearing for advice and reagents. This work was supported by Grants from NIH (AG024379 and ES14635), as well as from the American Federation of Aging (to KJ), the Golfers Against Cancer Foundation, the Sidney Kimmel Foundation and the National Cancer Center (to KBM).	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Akslen LA, 1998, INT J CANCER, V79, P91; ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; BADER JL, 1985, AM J PEDIAT HEMATOL, V7, P341; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; BENNETT DC, 1989, DEVELOPMENT, V105, P379; Bosenberg M, 2006, GENESIS, V44, P262, DOI 10.1002/dvg.20205; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; English DR, 2005, CANCER EPIDEM BIOMAR, V14, P2873, DOI 10.1158/1055-9965.EPI-05-0520; Evan GI, 2009, CURR OPIN GENET DEV, V19, P25, DOI 10.1016/j.gde.2008.11.009; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Grafstrom E, 2005, CLIN CANCER RES, V11, P2991, DOI 10.1158/1078-0432.CCR-04-1731; HARRISON SL, 1994, LANCET, V344, P1529, DOI 10.1016/S0140-6736(94)90348-4; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Johansson P, 2007, PIGM CELL RES, V20, P216, DOI 10.1111/j.1600-0749.2007.00375.x; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kannan K, 2003, P NATL ACAD SCI USA, V100, P1221, DOI 10.1073/pnas.0336397100; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Marino S, 2002, DEVELOPMENT, V129, P3513; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Noonan FP, 2001, NATURE, V413, P271, DOI 10.1038/35095108; Pearson G, 2000, J BIOL CHEM, V275, P37303, DOI 10.1074/jbc.C000570200; Petermann KB, 2007, J CLIN INVEST, V117, P3922, DOI 10.1172/JCI32163; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Ramsey MR, 2007, CANCER RES, V67, P4732, DOI 10.1158/0008-5472.CAN-06-3437; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Ruzankina Y, 2007, CELL STEM CELL, V1, P113, DOI 10.1016/j.stem.2007.03.002; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2003, ONCOGENE, V22, P5055, DOI 10.1038/sj.onc.1206809; Sharpless NE, 2002, CANCER RES, V62, P2761; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shields JM, 2007, CANCER RES, V67, P1502, DOI 10.1158/0008-5472.CAN-06-3311; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; SPANAKIS E, 1992, DEVELOPMENT, V114, P675; SPARROW LE, 1995, MELANOMA RES, V5, P93, DOI 10.1097/00008390-199504000-00004; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N; Wiedemeyer R, 2008, CANCER CELL, V13, P355, DOI 10.1016/j.ccr.2008.02.010; Zerp SF, 1999, BRIT J CANCER, V79, P921, DOI 10.1038/sj.bjc.6690147; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	55	44	46	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	43					5809	5817		10.1038/onc.2010.314	http://dx.doi.org/10.1038/onc.2010.314			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20697345	Green Published, hybrid			2022-12-17	WOS:000283586200006
J	Chen, YC; Zhang, XW; Niu, XH; Xin, DQ; Zhao, WP; Na, YQ; Mao, ZB				Chen, Y. C.; Zhang, X. W.; Niu, X. H.; Xin, D. Q.; Zhao, W. P.; Na, Y. Q.; Mao, Z. B.			Macrophage migration inhibitory factor is a direct target of HBP1-mediated transcriptional repression that is overexpressed in prostate cancer	ONCOGENE			English	Article						HBP1; MIF; cancer	RETINOBLASTOMA PROTEIN; PROGENITOR CELLS; FACTOR HBP1; EXPRESSION; GROWTH; GENE; ADENOCARCINOMA; CARCINOMA; EFFECTORS; PATHWAY	Macrophage migration inhibitory factor (MIF) is a well-described proinflammatory mediator. MIF overexpression has been observed in many tumors and is implicated in oncogenic transformation and tumor progression. However, the molecular mechanisms responsible for regulating MIF expression remain poorly understood. In this study, we showed that the transcriptional repressor HBP1 (HMG box-containing protein 1) negatively regulates MIF expression. We first identified a large high-affinity HBP1 DNA-binding element at positions -811 to -792 from the transcriptional start site within the MIF promoter by computer analysis. Reporter analyses showed that this element was required for HBP1-mediated transcriptional repression. Furthermore, HBP1 associated with the MIF promoter in vivo and repressed endogenous MIF gene expression. Consistent with HBP1-mediated repression of MIF, low levels of HBP1 expression were associated with high levels of MIF expression in prostate cancer samples. Importantly, HBP1-mediated repression of MIF inhibited tumorigenic growth and invasion, and the repressive effect of HBP1 on tumorigenic growth and invasion could be partially rescued by the addition of recombinant MIF to the culture medium. Finally, prostate tumor samples with low HBP1 and high MIF expression were associated with a significant decrease in relapse-free survival. Taken together, these results indicated that HBP1 directly inhibited MIF gene transcription, and suggested that the loss of HBP1 expression or activity may contribute to the upregulation of MIF expression in prostate tumor tissue. Oncogene (2010) 29, 3067-3078; doi: 10.1038/onc.2010.97; published online 12 April 2010	[Zhang, X. W.; Mao, Z. B.] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China; [Chen, Y. C.; Niu, X. H.; Xin, D. Q.; Na, Y. Q.] Peking Univ, Peking Univ Hosp 1, Dept Urol, Beijing 100083, Peoples R China; [Chen, Y. C.; Niu, X. H.; Xin, D. Q.; Na, Y. Q.] Peking Univ, Inst Urol, Beijing 100083, Peoples R China; [Zhao, W. P.] Zhejiang Univ, Coll Med, Sir Run Run Shaw Hosp, Dept Urol, Hangzhou 310003, Zhejiang, Peoples R China	Peking University; Peking University; Peking University; Zhejiang University	Mao, ZB (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 38 XueyuanRd, Beijing 100083, Peoples R China.	zbmao@bjmu.edu.cn			National Science Foundation of China	National Science Foundation of China(National Natural Science Foundation of China (NSFC))	Our work has been funded by the National Science Foundation of China. Most parts of this research were completed in Dr Mao's laboratory. Dr Mao was the corresponding author.	Berasi SP, 2004, MOL CELL BIOL, V24, P3011, DOI 10.1128/MCB.24.7.3011-3024.2004; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Kamimura A, 2000, CANCER, V89, P334, DOI 10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.0.CO;2-N; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; Lemercier C, 2000, MOL CELL BIOL, V20, P6627, DOI 10.1128/MCB.20.18.6627-6637.2000; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lin KM, 2001, LEUKEMIA, V15, P601, DOI 10.1038/sj.leu.2402071; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Lu XF, 2005, J BIOL CHEM, V280, P22606, DOI 10.1074/jbc.M412073200; Meyer-Siegler KL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-34; MeyerSiegler K, 1996, UROLOGY, V48, P448, DOI 10.1016/S0090-4295(96)00207-5; Mitchell RA, 2004, CELL SIGNAL, V16, P13, DOI 10.1016/j.cellsig.2003.07.002; Paulson KE, 2007, CANCER RES, V67, P6136, DOI 10.1158/0008-5472.CAN-07-0567; Petrenko O, 2003, J BIOL CHEM, V278, P11078, DOI 10.1074/jbc.M211985200; Ren Y, 2003, INT J CANCER, V107, P22, DOI 10.1002/ijc.11287; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shih HH, 1998, MOL CELL BIOL, V18, P4732, DOI 10.1128/MCB.18.8.4732; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Walsh PC, 2002, CAMPBELLS UROLOGY; Yee AS, 2004, GENE, V336, P1, DOI 10.1016/j.gene.2004.04.004; Zhang XW, 2006, MOL CELL BIOL, V26, P8252, DOI 10.1128/MCB.00604-06; Zhuma T, 1999, EMBO J, V18, P6396, DOI 10.1093/emboj/18.22.6396	27	44	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	2010	29	21					3067	3078		10.1038/onc.2010.97	http://dx.doi.org/10.1038/onc.2010.97			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20383199				2022-12-17	WOS:000278133100004
J	Nicolas, L; Martinez, C; Baro, C; Rodriguez, M; Baroja-Mazo, A; Sole, F; Flores, JM; Ampurdanes, C; Dantzer, F; Martin-Caballero, J; Aparicio, P; Yelamos, J				Nicolas, L.; Martinez, C.; Baro, C.; Rodriguez, M.; Baroja-Mazo, A.; Sole, F.; Flores, J. M.; Ampurdanes, C.; Dantzer, F.; Martin-Caballero, J.; Aparicio, P.; Yelamos, J.			Loss of poly(ADP-ribose) polymerase-2 leads to rapid development of spontaneous T-cell lymphomas in p53-deficient mice	ONCOGENE			English	Article						Parp-2; p53; tumour development; thymocytes; V(D)J recombination; double-strand breaks	DOUBLE-STRAND BREAKS; DNA-DAMAGE; CHROMOSOMAL-ABERRATIONS; GENOMIC STABILITY; REPAIR; P53; RECOMBINATION; TUMORIGENESIS; INHIBITION; DEFICIENCY	Poly(ADP-ribose) polymerase-2 (Parp-2) belongs to a family of enzymes that catalyse poly(ADP-ribosyl) ation of proteins. Parp-2 deficiency in mice (Parp-2(-/-)) results in reduced thymic cellularity associated with increased apoptosis in thymocytes, defining Parp-2 as an important mediator of T-cell survival during thymopoiesis. To determine whether there is a link between Parp-2 and the p53 DNA-damage-dependent apoptotic response, we have generated Parp-2/p53-double-null mutant mice. We found that p53(-/-) backgrounds completely restored the survival and development of Parp-2(-/-) thymocytes. However, Parp-2-deficient thymocytes accumulated high levels of DNA double-strand breaks (DSB), independently of the p53 status, in line with a function of Parp-2 as a caretaker promoting genomic stability during thymocytes development. Although Parp-2(-/-) mice do not have spontaneous tumours, Parp-2 deficiency accelerated spontaneous tumour development in p53-null mice, mainly T-cell lymphomas. These data suggest a synergistic interaction between Parp-2 and p53 in tumour suppression through the role of Parp-2 in DNA-damage response and genome integrity surveillance, and point to the potential importance of examining human tumours for the status of both genes. Oncogene (2010) 29, 2877-2883; doi: 10.1038/onc.2010.11; published online 15 February 2010	[Nicolas, L.; Ampurdanes, C.; Martin-Caballero, J.; Yelamos, J.] IMIM Hosp Mar, Barcelona Biomed Res Pk PRBB, Dept Immunol, Barcelona 08003, Spain; [Nicolas, L.; Aparicio, P.] Univ Murcia, Dept Biochem Mol Biol & Immunol, Sch Med, Murcia, Spain; [Martinez, C.; Baroja-Mazo, A.] Univ Murcia, Dept Surg, CIBERehd, Univ Hosp Virgen de la Arrixaca, Murcia, Spain; [Baro, C.; Rodriguez, M.; Sole, F.] IMIM Hosp Mar, Barcelona Biomed Res Pk, Dept Pathol, Barcelona 08003, Spain; [Flores, J. M.] Univ Complutense, Dept Anim Surg & Med, Sch Vet, E-28040 Madrid, Spain; [Dantzer, F.] ESBS, IREBS FRE3211, Strasbourg, France	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; University of Murcia; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; Hospital Clinico Universitario Virgen de la Arrixaca; University of Murcia; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; Complutense University of Madrid	Yelamos, J (corresponding author), IMIM Hosp Mar, Barcelona Biomed Res Pk PRBB, Dept Immunol, C Dr Aiguader,88, Barcelona 08003, Spain.	jyelamos@imim.es	sole, francesc/A-2430-2011; Baroja-Mazo, Alberto/E-6270-2016; Dantzer, Françoise/O-2126-2016; Martinez, Carlos M./E-4986-2016; Solé, Francesc/K-8373-2012; Yelamos, Jose/N-2842-2016	Baroja-Mazo, Alberto/0000-0001-5212-5006; Martinez, Carlos M./0000-0003-3307-1326; Solé, Francesc/0000-0002-3251-2161; Aparicio, Pedro/0000-0001-9162-1563; Yelamos, Jose/0000-0003-1195-1496; Dantzer, Francoise/0000-0003-0945-8483	Spanish Ministerio de Ciencia e Innovacion [SAF2008-01572]; Generalitat de Catalunya [2009/SGR/524]; Instituto de Salud Carlos III [PI081150]; Fundacion Seneca [08643/PI/08]; Centre National de la Recherche Scientifique, Association pour la Recherche contre le Cancer, Electricite de France, Comite du Haut-Rhin de la Ligue Nationale Contre le Cancer and Commissariat a l'Energie Atomique; Spanish Ministerio de Ciencia e Innovacion; Instituto de Salud Carlos III (Madrid, Spain); FFIS (Murcia, Spain)	Spanish Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Generalitat de Catalunya(Generalitat de Catalunya); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Fundacion Seneca(Fundacion Seneca); Centre National de la Recherche Scientifique, Association pour la Recherche contre le Cancer, Electricite de France, Comite du Haut-Rhin de la Ligue Nationale Contre le Cancer and Commissariat a l'Energie Atomique(Centre National de la Recherche Scientifique (CNRS)); Spanish Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Instituto de Salud Carlos III (Madrid, Spain)(Instituto de Salud Carlos III); FFIS (Murcia, Spain)	We thank Katherine Papageorgiou for assistance with handling the mice and Sergi Mojal for statistical analysis support. This work was supported by Spanish Ministerio de Ciencia e Innovacion (Grant SAF2008-01572 to JY); Generalitat de Catalunya (Grant 2009/SGR/524 to JY); Instituto de Salud Carlos III (Grant PI081150 to PA); Fundacion Seneca (Grant 08643/PI/08 to PA); and funds from Centre National de la Recherche Scientifique, Association pour la Recherche contre le Cancer, Electricite de France, Comite du Haut-Rhin de la Ligue Nationale Contre le Cancer and Commissariat a l'Energie Atomique (VS, FD). LN is supported by the Spanish Ministerio de Ciencia e Innovacion and AB-M is supported by Instituto de Salud Carlos III (Madrid, Spain) and the FFIS (Murcia, Spain).	Bai P, 2007, J BIOL CHEM, V282, P37738, DOI 10.1074/jbc.M701021200; Bassing CH, 2008, BLOOD, V111, P2163, DOI 10.1182/blood-2007-08-104760; Beneke R, 2001, ONCOGENE, V20, P8136, DOI 10.1038/sj.onc.1205056; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Conde C, 2001, EMBO J, V20, P3535, DOI 10.1093/emboj/20.13.3535; Dantzer F, 2006, P NATL ACAD SCI USA, V103, P14854, DOI 10.1073/pnas.0604252103; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Hakem R, 2008, EMBO J, V27, P589, DOI 10.1038/emboj.2008.15; Hawwari A, 2005, NAT IMMUNOL, V6, P481, DOI 10.1038/ni1189; Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002; Lee GS, 2004, CELL, V117, P171, DOI 10.1016/S0092-8674(04)00301-0; Mak TW, 2000, NAT IMMUNOL, V1, P77, DOI 10.1038/76950; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PETRIE HT, 1993, J EXP MED, V178, P615, DOI 10.1084/jem.178.2.615; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Robert I, 2009, J EXP MED, V206, P1047, DOI 10.1084/jem.20082468; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rooney S, 2004, P NATL ACAD SCI USA, V101, P2410, DOI 10.1073/pnas.0308757101; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Tentori L, 2008, EUR J CANCER, V44, P1302, DOI 10.1016/j.ejca.2008.03.019; Tong WM, 2007, ONCOGENE, V26, P3857, DOI 10.1038/sj.onc.1210156; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; Tong WM, 2003, AM J PATHOL, V162, P343, DOI 10.1016/S0002-9440(10)63825-4; Tong WM, 2002, CANCER RES, V62, P6990; von Boehmer H, 1999, CURR OPIN IMMUNOL, V11, P135, DOI 10.1016/S0952-7915(99)80024-7; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Werlen G, 2003, SCIENCE, V299, P1859, DOI 10.1126/science.1067833; Xu M, 2008, MOL CELL BIOL, V28, P1713, DOI 10.1128/MCB.01360-07; Yelamos J, 2008, TRENDS MOL MED, V14, P169, DOI 10.1016/j.molmed.2008.02.003; Yelamos J, 2006, EMBO J, V25, P4350, DOI 10.1038/sj.emboj.7601301	39	44	45	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	19					2877	2883		10.1038/onc.2010.11	http://dx.doi.org/10.1038/onc.2010.11			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20154718				2022-12-17	WOS:000277591900012
J	Aktary, Z; Chapman, K; Lam, L; Lo, A; Ji, C; Graham, K; Cook, L; Li, L; Mackey, JR; Pasdar, M				Aktary, Z.; Chapman, K.; Lam, L.; Lo, A.; Ji, C.; Graham, K.; Cook, L.; Li, L.; Mackey, J. R.; Pasdar, M.			Plakoglobin interacts with and increases the protein levels of metastasis suppressor Nm23-H2 and regulates the expression of Nm23-H1	ONCOGENE			English	Article						plakoglobin; tumor suppressor; Nm23; cadherin; alpha-catenin	GAMMA-CATENIN EXPRESSION; SQUAMOUS CARCINOMA-CELLS; KIDNEY EPITHELIAL-CELLS; BETA-CATENIN; E-CADHERIN; ALPHA-CATENIN; C-MYC; SUBCELLULAR-LOCALIZATION; DESMOPLAKIN ORGANIZATION; SPATIAL REGULATION	Plakoglobin (gamma-catenin) is a homolog of beta-catenin with similar dual adhesive and signaling functions. The adhesive function of these proteins is mediated by their interactions with cadherins, whereas their signaling activity is regulated by association with various intracellular partners. In this respect, beta-catenin has a well-defined oncogenic activity through its role in the Wnt signaling pathway, whereas plakoglobin acts as a tumor/metastasis suppressor through mechanisms that remain unclear. We previously expressed plakoglobin in SCC9 squamous carcinoma cells (SCC9-P) and observed a mesenchymal-to-epidermoid transition. Comparison of the protein and RNA profiles of parental SCC9 cells and SCC9-P transfectants identified various differentially expressed proteins and transcripts, including the nonmetastatic protein 23 (Nm23). In this study, we show that Nm23-H1 mRNA and Nm23-H2 protein are increased after plakoglobin expression. Coimmunoprecipitation and confocal microscopy studies using SCC9-P and various epithelial cell lines with endogenous plakoglobin expression revealed that Nm23 interacts with plakoglobin, cadherins and alpha-catenin. Furthermore, Nm23-H2 is the primary isoform involved in these interactions, which occur prominently in the cytoskeleton-associated pool of cellular proteins. In addition, we show that plakoglobin-Nm23 interaction requires the N-terminal (alpha-catenin interacting) domain of plakoglobin. Our data suggest that by increasing the expression and stability of Nm23, plakoglobin has a role in regulating the metastasis suppressor activity of Nm23, which may further provide a potential mechanism for the tumor/metastasis suppressor function of plakoglobin itself. Oncogene (2010) 29, 2118-2129; doi: 10.1038/onc.2009.495; published online 25 January 2010	[Aktary, Z.; Chapman, K.; Lam, L.; Pasdar, M.] Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; [Lo, A.; Ji, C.; Li, L.] Univ Alberta, Dept Chem, Edmonton, AB T6G 2H7, Canada; [Graham, K.; Cook, L.; Mackey, J. R.] Univ Alberta, Dept Oncol, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta; University of Alberta	Pasdar, M (corresponding author), Univ Alberta, Dept Cell Biol, 6-24 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	mpasdar@ualberta.ca	Li, Liang/D-1822-2011	Aktary, Zackie/0000-0002-7238-3245	Alberta Cancer Research Institute; Canadian Breast Cancer Foundation-Prairies/NWT Chapter; Canadian Institutes of Health Research Frederick Banting; Charles Best Canada Graduate Scholarships; Canadian Research Chairs Program; Alberta Cancer Foundation; Killam Doctoral Award	Alberta Cancer Research Institute; Canadian Breast Cancer Foundation-Prairies/NWT Chapter; Canadian Institutes of Health Research Frederick Banting(Canadian Institutes of Health Research (CIHR)); Charles Best Canada Graduate Scholarships; Canadian Research Chairs Program(Canada Research Chairs); Alberta Cancer Foundation; Killam Doctoral Award	This work is supported by the Alberta Cancer Research Institute and the Canadian Breast Cancer Foundation-Prairies/NWT Chapter (MP) and Canadian Institutes of Health Research Frederick Banting and Charles Best Canada Graduate Scholarships award (ZA). LL is supported by the Canadian Research Chairs Program. JM is supported by the Alberta Cancer Research Institute and Alberta Cancer Foundation. ZA currently holds a Killam Doctoral Award.	Arnaud-Dabernat S, 2004, EXP CELL RES, V301, P293, DOI 10.1016/j.yexcr.2004.07.026; Ayabe Takanori, 2004, Ann Thorac Cardiovasc Surg, V10, P152; Bago R, 2009, MOL CARCINOGEN, V48, P779, DOI 10.1002/mc.20536; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Benjamin JM, 2008, SEMIN CANCER BIOL, V18, P53, DOI 10.1016/j.semcancer.2007.08.003; Bosnar MH, 2009, MOL CELL BIOCHEM, V329, P63, DOI 10.1007/s11010-009-0107-4; Bosnar MH, 2004, EXP CELL RES, V298, P275, DOI 10.1016/j.yexcr.2004.04.018; Che G, 2006, NEOPLASMA, V53, P530; Chen XF, 2005, LUNG CANCER, V48, P69, DOI 10.1016/j.lungcan.2004.09.009; Chidgey M, 2007, BRIT J CANCER, V96, P1783, DOI 10.1038/sj.bjc.6603808; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Garrod D, 2008, BIOCHEM SOC T, V36, P195, DOI 10.1042/BST0360195; Garrod D, 2008, BBA-BIOMEMBRANES, V1778, P572, DOI 10.1016/j.bbamem.2007.07.014; Gavert N, 2007, J CELL BIOCHEM, V102, P820, DOI 10.1002/jcb.21505; Green KJ, 2007, J INVEST DERMATOL, V127, P2499, DOI 10.1038/sj.jid.5701015; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Holthofer B, 2007, INT REV CYTOL, V264, P65, DOI 10.1016/S0074-7696(07)64003-0; Huang H, 2008, CURR OPIN CELL BIOL, V20, P119, DOI 10.1016/j.ceb.2008.01.009; Huber O, 2008, CELL CYCLE, V7, P1326, DOI 10.4161/cc.7.10.5926; IGAWA M, 1994, CANCER RES, V54, P1313; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Ji CJ, 2005, J PROTEOME RES, V4, P1419, DOI 10.1021/pr050094h; Jin L, 2009, LIFE SCI, V84, P458, DOI 10.1016/j.lfs.2009.01.010; Jin TR, 2008, CELL SIGNAL, V20, P1697, DOI 10.1016/j.cellsig.2008.04.014; Jung S, 2006, ANTICANCER RES, V26, P249; Kanazawa Y, 2008, ANTICANCER RES, V28, P655; Khan MH, 2001, AM J PATHOL, V158, P1785, DOI 10.1016/S0002-9440(10)64134-X; Kim HD, 2009, MOL CELL BIOCHEM, V329, P167, DOI 10.1007/s11010-009-0109-2; Kolligs FT, 2000, GENE DEV, V14, P1319; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; Lam L, 2009, BREAST CANCER RES TR, V118, P605, DOI 10.1007/s10549-008-0231-y; Lee HY, 1999, CANCER LETT, V145, P93, DOI 10.1016/S0304-3835(99)00236-0; Lee MY, 2009, CANCER LETT, V275, P221, DOI 10.1016/j.canlet.2008.10.018; Li LJ, 2007, MOL CARCINOGEN, V46, P824, DOI 10.1002/mc.20310; Li Z, 1998, J CELL SCI, V111, P1005; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; McDermott WG, 2008, CLIN EXP METASTAS, V25, P131, DOI 10.1007/s10585-007-9128-0; Miyazaki H, 1999, CLIN CANCER RES, V5, P4301; MORTON RA, 1993, CANCER RES, V53, P3585; Nakanishi K, 2006, ARCH PATHOL LAB MED, V130, P1330; Narkio-Makela M, 2009, ARCH OTOLARYNGOL, V135, P1035, DOI 10.1001/archoto.2009.132; Nelson WJ, 2008, BIOCHEM SOC T, V36, P149, DOI 10.1042/BST0360149; Niessen CM, 2008, BBA-BIOMEMBRANES, V1778, P562, DOI 10.1016/j.bbamem.2007.12.015; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Pantel K, 1998, J CLIN ONCOL, V16, P1407, DOI 10.1200/JCO.1998.16.4.1407; Parker HR, 1998, CELL MOTIL CYTOSKEL, V40, P87, DOI 10.1002/(SICI)1097-0169(1998)40:1<87::AID-CM8>3.0.CO;2-C; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; PASDAR M, 1988, J CELL BIOL, V106, P687, DOI 10.1083/jcb.106.3.687; PASDAR M, 1995, CELL MOTIL CYTOSKEL, V32, P258, DOI 10.1002/cm.970320403; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; Perez-Moreno M, 2006, DEV CELL, V11, P601, DOI 10.1016/j.devcel.2006.10.010; Postel EH, 2000, J BIOENERG BIOMEMBR, V32, P277, DOI 10.1023/A:1005541114029; Rieger-Christ KM, 2005, BRIT J CANCER, V92, P2153, DOI 10.1038/sj.bjc.6602651; SACCO PA, 1995, J BIOL CHEM, V270, P20201, DOI 10.1074/jbc.270.34.20201; Schuldiner O, 2002, GENE, V292, P91, DOI 10.1016/S0378-1119(02)00668-6; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Steeg PS, 2008, CLIN CANCER RES, V14, P5006, DOI 10.1158/1078-0432.CCR-08-0238; Steeg Patricia S, 2003, Clin Breast Cancer, V4, P51, DOI 10.3816/CBC.2003.n.012; STEEG PS, 1988, CANCER RES, V48, P6550; Stemmler MP, 2008, MOL BIOSYST, V4, P835, DOI 10.1039/b719215k; Suzuki E, 2004, INT J CANCER, V108, P207, DOI 10.1002/ijc.11546; Syed V, 2005, ONCOGENE, V24, P1774, DOI 10.1038/sj.onc.1207991; Tee Yi-Torng, 2006, Taiwan J Obstet Gynecol, V45, P107; Torlakovic E, 2002, HUM PATHOL, V33, P646, DOI 10.1053/hupa.2002.124033; van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963; Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020; Zhurinsky J, 2000, J CELL SCI, V113, P3127; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	74	44	45	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2010	29	14					2118	2129		10.1038/onc.2009.495	http://dx.doi.org/10.1038/onc.2009.495			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101217				2022-12-17	WOS:000276402800010
J	Kim, EY; Seo, JM; Cho, KJ; Kim, JH				Kim, E-Y; Seo, J-M; Cho, K-J; Kim, J-H			Ras-induced invasion and metastasis are regulated by a leukotriene B-4 receptor BLT2-linked pathway	ONCOGENE			English	Article						H-Ras; leukotriene B-4 receptor BLT2; ROS; metastasis; MMP-9	NF-KAPPA-B; PANCREATIC-CANCER; ONCOGENIC RAS; H-RAS; EXPRESSION; CYCLOOXYGENASE-2; PROLIFERATION; ACTIVATION; MIGRATION; MECHANISM	Ras signaling pathways are well-recognized for their involvement in cancer cell proliferation; however, considerably less is known regarding their contribution to invasion and metastasis. Here, we demonstrate that a novel BLT2, a low-affinity leukotriene B-4 receptor-linked signaling cascade involving the generation of reactive oxygen species (ROS) via Nox1, NF-kappa B stimulation and subsequent upregulation of matrix metalloproteinase-9 (MMP-9) is a potential mechanism by which Ras promotes invasion and metastasis. We found that inhibition of BLT2 signaling markedly suppressed Ras-evoked metastasis and reduced the associated mortality in mice. Consistent with the proposed role of BLT2 as a key downstream mediator of Ras signaling to metastasis, BLT2 expression alone resulted in the formation of numerous metastatic lung nodules and the nodules formation was significantly attenuated by the inhibition of MMP-9, a downstream component of BLT2. Together, our results reveal the previously unsuspected function of BLT2-linked cascade in driving oncogenic Ras-induced metastasis and would provide a valuable insight into invasion and metastasis. Oncogene (2010) 29, 1167-1178; doi: 10.1038/onc.2009.412; published online 23 November 2009	[Kim, E-Y; Seo, J-M; Cho, K-J; Kim, J-H] Korea Univ, Sch Life Sci & Biotechnol, Inflammatory Signaling Lab, Seoul 136701, South Korea	Korea University	Kim, JH (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, Inflammatory Signaling Lab, 5-1 Anam Dong, Seoul 136701, South Korea.	jhongkim@korea.ac.kr	Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208	Ministry of Education, Science, and Technology, Korea [M10751050001-08N5105-00110, 20090062880]	Ministry of Education, Science, and Technology, Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea)	We thank Dr Takao Shimizu (University of Tokyo, Tokyo, Japan) and Dr Takehiko Yokomizo (University of Kyushu, Fukuoka, Japan) for the BLT2 expression plasmids. This work was supported by the Diseases Network Research Program (M10751050001-08N5105-00110), and the SRC-Aging and Apoptosis Research program (20090062880) from the Ministry of Education, Science, and Technology, Korea.	Behrend L, 2003, BIOCHEM SOC T, V31, P1441; Bjorklund M, 2005, BBA-REV CANCER, V1755, P37, DOI 10.1016/j.bbcan.2005.03.001; BONDY GP, 1985, CANCER RES, V45, P6005; Bonfil RD, 2006, INT J CANCER, V118, P2721, DOI 10.1002/ijc.21645; Bortuzzo C, 1996, BBA-LIPID LIPID MET, V1300, P240, DOI 10.1016/0005-2760(96)00003-3; BOS JL, 1989, CANCER RES, V49, P4682; Brock TG, 2007, THESCIENTIFICWORLDJO, V7, P1273, DOI 10.1100/tsw.2007.180; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Cha YI, 2007, ANNU REV MED, V58, P239, DOI 10.1146/annurev.med.57.121304.131253; Choi JA, 2008, FREE RADICAL BIO MED, V44, P624, DOI 10.1016/j.freeradbiomed.2007.10.041; Choi JA, 2010, CARCINOGENESIS, V31, P543, DOI 10.1093/carcin/bgp203; Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Ding Xian-Zhong, 2003, Mol Cancer, V2, P10, DOI 10.1186/1476-4598-2-10; Ding XZ, 2005, ANTI-CANCER DRUG, V16, P467, DOI 10.1097/00001813-200506000-00001; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Harris Randall E, 2007, Subcell Biochem, V42, P93; Hennig R, 2008, BRIT J CANCER, V99, P1064, DOI 10.1038/sj.bjc.6604655; Hennig R, 2005, NEOPLASIA, V7, P417, DOI 10.1593/neo.04559; Heukamp I, 2006, PROSTAG LEUKOTR ESS, V74, P223, DOI 10.1016/j.plefa.2006.01.005; Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3; Iizuka Y, 2005, J BIOL CHEM, V280, P24816, DOI 10.1074/jbc.M413257200; Kim GY, 2009, ARTERIOSCL THROM VAS, V29, P915, DOI 10.1161/ATVBAHA.109.185793; Kruger A, 2005, CANCER RES, V65, P3523, DOI 10.1158/0008-5472.CAN-04-3570; KUMAR CC, 1992, CANCER RES, V52, P6877; Lee KW, 2006, INT J CANCER, V119, P1767, DOI 10.1002/ijc.22056; Mayoral R, 2005, CARCINOGENESIS, V26, P753, DOI 10.1093/carcin/bgi022; Nie DT, 2001, CANCER METAST REV, V20, P195, DOI 10.1023/A:1015579209850; Nikkola J, 2005, CLIN CANCER RES, V11, P5158, DOI 10.1158/1078-0432.CCR-04-2478; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Qiu H, 2006, P NATL ACAD SCI USA, V103, P6913, DOI 10.1073/pnas.0602208103; Rocconi RP, 2008, REPROD SCI, V15, P321, DOI 10.1177/1933719108316390; Romano M, 2003, FASEB J, V17, P1986, DOI 10.1096/fj.03-0053rev; Shin EH, 2006, BIOCHEM BIOPH RES CO, V348, P606, DOI 10.1016/j.bbrc.2006.07.084; SU ZZ, 1993, ONCOGENE, V8, P1211; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Tong WG, 2002, CLIN CANCER RES, V8, P3232; Van Putten V, 2001, J BIOL CHEM, V276, P1226, DOI 10.1074/jbc.M003581200; Wang MT, 2007, CANCER METAST REV, V26, P525, DOI 10.1007/s10555-007-9096-5; Woo CH, 2002, J BIOL CHEM, V277, P8572, DOI 10.1074/jbc.M104766200; Wu WS, 2006, CANCER METAST REV, V25, P695, DOI 10.1007/s10555-006-9037-8; Yang JQ, 2001, FREE RADICAL BIO MED, V31, P520, DOI 10.1016/S0891-5849(01)00613-X; YOKOMIZO T, 1995, J LIPID MEDIAT CELL, V12, P321, DOI 10.1016/0929-7855(95)00041-N; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200; Yoo MH, 2004, ONCOGENE, V23, P9259, DOI 10.1038/sj.onc.1208151; Yoo MH, 2001, J BIOL CHEM, V276, P24645, DOI 10.1074/jbc.M101975200; Zampetaki A, 2005, AM J PHYSIOL-HEART C, V288, pH2946, DOI 10.1152/ajpheart.00919.2004	50	44	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1167	1178		10.1038/onc.2009.412	http://dx.doi.org/10.1038/onc.2009.412			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935719				2022-12-17	WOS:000274912100008
J	Lin, Z; Yin, P; Reierstad, S; O'Halloran, M; Coon, JS; Pearson, EK; Mutlu, GM; Bulun, SE				Lin, Z.; Yin, P.; Reierstad, S.; O'Halloran, M.; Coon, J. S.; Pearson, E. K.; Mutlu, G. M.; Bulun, S. E.			Adenosine A1 receptor, a target and regulator of estrogen receptor-alpha action, mediates the proliferative effects of estradiol in breast cancer	ONCOGENE			English	Article						Adora1; ER alpha; estradiol; breast cancer; G protein-coupled receptors; cell proliferation	ADENOSINE A(1) RECEPTORS; CELL-PROLIFERATION; ENDOCRINE THERAPY; EXPRESSION; TRANSCRIPTION; ACTIVATION; INHIBITION; REVEALS; BINDING; PHOSPHORYLATION	Estrogen receptor-alpha (ER alpha) and its ligand estradiol (E2) has critical roles in breast cancer growth and are key therapeutic targets. In this study, we report a novel dual role of the adenosine A1 receptor (Adora1) as an E2/ER alpha target and a regulator of ER alpha transcriptional activity. In ER alpha-positive breast cancer cells, E2 upregulated Adora1 messenger RNA (mRNA) and protein levels, an effect that was reversed by the E2 antagonist ICI 182 780. Small interference RNA ablation of Adora1 in ER alpha-positive cells reduced basal and E2-dependent proliferation, whereas Adora1 over-expression in an ER alpha-negative cell line induced proliferation. The selective Adora1 antagonist, DPCPX, reduced proliferation, establishing Adora1 as a mediator of E2/ER alpha-dependent breast cancer growth. Intriguingly, Adora1 ablation decreased both mRNA and protein levels of ER alpha and, consequently, estrogen-responsive element-dependent ER alpha transcriptional activity. Moreover, Adora1 ablation decreased binding activity of ER alpha to the promoter of its target gene TFF1 and led to reduced TFF1 promoter activity and mRNA levels, suggesting that Adora1 is required for full transcriptional activity of ER alpha on E2 stimulation. Taken together, we showed a short feed-forward loop involving E2, ER alpha and Adora1 that favors breast cancer growth. These data suggest that Adora1 may represent an important target for therapeutic intervention in hormone-dependent breast cancer. Oncogene (2010) 29, 1114-1122; doi: 10.1038/onc.2009.409; published online 23 November 2009	[Lin, Z.; Yin, P.; Reierstad, S.; O'Halloran, M.; Coon, J. S.; Pearson, E. K.; Bulun, S. E.] Northwestern Univ, Dept Obstet & Gynecol, Feinberg Sch Med, Chicago, IL 60611 USA; [Mutlu, G. M.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Bulun, SE (corresponding author), Northwestern Univ, Dept Obstet & Gynecol, Feinberg Sch Med, Chicago, IL 60611 USA.	s-bulun@northwestern.edu			NIH [R01CA067167]; AVON Foundation; Lynn Sage Foundation; Northwestern Memorial Foundation; NATIONAL CANCER INSTITUTE [R01CA067167] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AVON Foundation; Lynn Sage Foundation; Northwestern Memorial Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by grants from the NIH (R01CA067167), AVON Foundation, Lynn Sage Foundation, and Northwestern Memorial Foundation. We thank Megha Reddi for expert technical assistance.	AITKEN SC, 1982, CANCER RES, V42, P1727; Alao JP, 2004, CLIN CANCER RES, V10, P8094, DOI 10.1158/1078-0432.CCR-04-1023; Albasanz JL, 2007, EUR J NEUROSCI, V26, P3501, DOI 10.1111/j.1460-9568.2007.05965.x; Altucci L, 1996, ONCOGENE, V12, P2315; Boulay A, 2005, CLIN CANCER RES, V11, P5319, DOI 10.1158/1078-0432.CCR-04-2402; Bourguignon LYW, 2005, J BIOL CHEM, V280, P11961, DOI 10.1074/jbc.M411985200; Brunsden AM, 1999, J PHYSIOL-LONDON, V521, P517, DOI 10.1111/j.1469-7793.1999.00517.x; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; CHALBOS D, 1982, J CLIN ENDOCR METAB, V55, P276, DOI 10.1210/jcem-55-2-276; DeNardo DG, 2005, MOL ENDOCRINOL, V19, P362, DOI 10.1210/me.2004-0267; Factor P, 2007, P NATL ACAD SCI USA, V104, P4083, DOI 10.1073/pnas.0601117104; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fu HJ, 2006, CANCER BIOL THER, V5, P842, DOI 10.4161/cbt.5.7.2840; HALEEN SJ, 1987, LIFE SCI, V40, P555, DOI 10.1016/0024-3205(87)90369-9; Hayashi S, 2005, CANCER CHEMOTH PHARM, V56, pS27, DOI 10.1007/s00280-005-0096-2; Howell A, 2005, J STEROID BIOCHEM, V93, P237, DOI 10.1016/j.jsbmb.2005.02.004; Huang Y, 2006, J BIOL CHEM, V281, P19055, DOI 10.1074/jbc.M600910200; Ilie A, 2009, NEUROSCIENCE, V159, P1070, DOI 10.1016/j.neuroscience.2009.01.025; Kenealy MR, 2000, ENDOCRINOLOGY, V141, P2805, DOI 10.1210/en.141.8.2805; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kun Y, 2003, HUM MOL GENET, V12, P3245, DOI 10.1093/hmg/ddg347; Kuske B, 2006, ENDOCR-RELAT CANCER, V13, P1121, DOI 10.1677/erc.1.01257; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lin ZH, 2007, CANCER RES, V67, P5017, DOI 10.1158/0008-5472.CAN-06-3696; Lu J, 2003, CANCER RES, V63, P6413; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; McPherson LA, 2007, J SURG RES, V138, P71, DOI 10.1016/j.jss.2006.07.002; Merighi S, 2003, PHARMACOL THERAPEUT, V100, P31, DOI 10.1016/S0163-7258(03)00084-6; Mirza A, 2005, CANCER BIOL THER, V4, P1355, DOI 10.4161/cbt.4.12.2196; Moosavi SMS, 2009, NEPHROLOGY, V14, P179, DOI 10.1111/j.1440-1797.2008.01024.x; Morrison RR, 2006, AM J PHYSIOL-HEART C, V291, pH1875, DOI 10.1152/ajpheart.00158.2005; Namba R, 2005, BREAST CANCER RES, V7, pR881, DOI 10.1186/bcr1317; Nonclercq D, 2007, J MOL ENDOCRINOL, V39, P105, DOI 10.1677/JME-07-0040; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; Osborne CK, 2005, J CLIN ONCOL, V23, P1616, DOI 10.1200/JCO.2005.10.036; Pettersson K, 2001, ANNU REV PHYSIOL, V63, P165, DOI 10.1146/annurev.physiol.63.1.165; Prest SJ, 2002, FASEB J, V16, P592, DOI 10.1096/fj.01-0498fje; Reid G, 2002, CELL MOL LIFE SCI, V59, P821, DOI 10.1007/s00018-002-8470-2; Shen Y, 2008, J NATL CANCER I, V100, P1448, DOI 10.1093/jnci/djn320; Snoj N, 2008, CURR OPIN ONCOL, V20, P627, DOI 10.1097/CCO.0b013e3283136770; Wendler CC, 2007, P NATL ACAD SCI USA, V104, P9697, DOI 10.1073/pnas.0703557104	43	44	48	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1114	1122		10.1038/onc.2009.409	http://dx.doi.org/10.1038/onc.2009.409			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935720	Green Accepted			2022-12-17	WOS:000274912100003
J	Yang, J; Parsons, J; Nicolay, NH; Caporali, S; Harrington, CF; Singh, R; Finch, D; D'Atri, S; Farmer, PB; Johnston, PG; McKenna, WG; Dianov, G; Sharma, RA				Yang, J.; Parsons, J.; Nicolay, N. H.; Caporali, S.; Harrington, C. F.; Singh, R.; Finch, D.; D'Atri, S.; Farmer, P. B.; Johnston, P. G.; McKenna, W. G.; Dianov, G.; Sharma, R. A.			Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy	ONCOGENE			English	Article						DNA repair; colorectal cancer; malignant melanoma	CANCER; LINES; OVEREXPRESSION; EXPRESSION; RESISTANT; CISPLATIN; APOPTOSIS; BREAKAGE; DAMAGE	A significant proportion of human cancers overexpress DNA polymerase beta (Pol beta), the major DNA polymerase involved in base excision repair. The underlying mechanism and biological consequences of overexpression of this protein are unknown. We examined whether Pol beta, expressed at levels found in tumor cells, is involved in the repair of DNA damage induced by oxaliplatin treatment and whether the expression status of this protein alters the sensitivity of cells to oxaliplatin. DNA damage induced by oxaliplatin treatment of HCT116 and HT29 colon cancer cells was observed to be associated with the stabilization of Pol beta protein on chromatin. In comparison with HCT116 colon cancer cells, isogenic oxaliplatin-resistant (HCT-OR) cells were found to have higher constitutive levels of Pol beta protein, faster in vitro repair of a DNA substrate containing a single nucleotide gap and faster repair of 1,2-GG oxaliplatin adduct levels in cells. In HCT-OR cells, small interfering RNA knockdown of Pol beta delayed the repair of oxaliplatin-induced DNA damage. In a different model system, Pol beta-deficient fibroblasts were less able to repair 1,2-GG oxaliplatin adducts and were hypersensitive to oxaliplatin treatment compared with isogenic Pol beta-expressing cells. Consistent with previous studies, Pol beta-deficient mouse fibroblasts were not hypersensitive to cisplatin treatment. These data provide the first link between oxaliplatin sensitivity and DNA repair involving Pol beta. They demonstrate that Pol beta modulates the sensitivity of cells to oxaliplatin treatment. Oncogene (2010) 29, 463-468; doi:10.1038/onc.2009.327; published online 19 October 2009	[Yang, J.; Parsons, J.; Nicolay, N. H.; Finch, D.; McKenna, W. G.; Dianov, G.; Sharma, R. A.] Univ Oxford, Canc Res UK Med Res Council, Gray Inst Radiat Oncol & Biol, Oxford OX3 7DQ, Oxon, England; [Caporali, S.; D'Atri, S.] IRCCS, Ist Dermopat Immacolata, Oncol Mol Lab, Rome, Italy; [Harrington, C. F.] Univ Surrey, Fac Hlth & Med Sci, Ctr Clin Sci & Measurement, Trace Element Lab, Surrey, England; [Singh, R.; Farmer, P. B.] Univ Leicester, Bioctr, Canc Biomarkers & Prevent Grp, Leicester, Leics, England; [Johnston, P. G.] Queens Univ Belfast, Inst Hlth Sci, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland	Cancer Research UK; University of Oxford; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Surrey; University of Leicester; Queens University Belfast	Sharma, RA (corresponding author), Univ Oxford, Churchill Hosp, Gray Inst Radiat Oncol & Biol, Old Rd Campus Res Bldg, Oxford OX3 7DQ, Oxon, England.	grigory.dianov@rob.ox.ac.uk; ricky.sharma@rob.ox.ac.uk	Harrington, Chris F/M-3453-2018; Singh, Raj/A-5398-2011; Singh, Raj/HDN-1244-2022; D'Atri, Stefania/K-6039-2016	Harrington, Chris F/0000-0003-4101-556X; Parsons, Jason/0000-0002-5052-1125; D'Atri, Stefania/0000-0001-9852-7377	Cancer Research UK; UK Medical Research Council; Higher Education Funding Council for England; UK Biotechnology and Biological Sciences Research Council; NIHR Biomedical Research Centre, Oxford, UK; Cancer Research UK [8971] Funding Source: researchfish; Medical Research Council [G0700730] Funding Source: researchfish; MRC [G0700730] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Higher Education Funding Council for England(UK Research & Innovation (UKRI)Higher Education Funding Council for England (HEFCE)); UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NIHR Biomedical Research Centre, Oxford, UK(National Institute for Health Research (NIHR)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Drs Tomas Lindahl and Peter McHugh for comments on the paper. This study was supported by Cancer Research UK, the UK Medical Research Council, the Higher Education Funding Council for England, the Research Equipment Initiative of the UK Biotechnology and Biological Sciences Research Council and the NIHR Biomedical Research Centre, Oxford, UK.	Albertella MR, 2005, DNA REPAIR, V4, P583, DOI 10.1016/j.dnarep.2005.01.005; Bergoglio V, 2001, ONCOGENE, V20, P6181, DOI 10.1038/sj.onc.1204743; Boyer J, 2004, CLIN CANCER RES, V10, P2158, DOI 10.1158/1078-0432.CCR-03-0362; Boyer J, 2006, CANCER RES, V66, P2765, DOI 10.1158/0008-5472.CAN-05-2693; Canitrot Y, 1999, FASEB J, V13, P1107, DOI 10.1096/fasebj.13.9.1107; Dianova II, 2001, BIOCHEMISTRY-US, V40, P12639, DOI 10.1021/bi011117i; Horton JK, 2002, DNA REPAIR, V1, P317, DOI 10.1016/S1568-7864(02)00008-3; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Le Pla RC, 2007, CHEM RES TOXICOL, V20, P1177, DOI 10.1021/tx700088j; Ochs K, 2002, CANCER RES, V62, P1524; Ochs K, 1999, CANCER RES, V59, P1544; Parsons JL, 2008, MOL CELL, V29, P477, DOI 10.1016/j.molcel.2007.12.027; Rixe O, 1996, BIOCHEM PHARMACOL, V52, P1855, DOI 10.1016/S0006-2952(97)81490-6; Servant L, 2002, J BIOL CHEM, V277, P50046, DOI 10.1074/jbc.M207101200; Shibuya K, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-37; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; Starcevic D, 2004, CELL CYCLE, V3, P998; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J; Vaisman A, 2000, J BIOL CHEM, V275, P13017, DOI 10.1074/jbc.275.17.13017; Woodhouse BC, 2008, DNA REPAIR, V7, P932, DOI 10.1016/j.dnarep.2008.03.017; ZMUDZKA BZ, 1988, NUCLEIC ACIDS RES, V16, P9587, DOI 10.1093/nar/16.20.9587	22	44	46	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					463	468		10.1038/onc.2009.327	http://dx.doi.org/10.1038/onc.2009.327			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19838217				2022-12-17	WOS:000273793200015
J	Grover, R; Candeias, MM; Fahraeus, R; Das, S				Grover, R.; Candeias, M. M.; Fahraeus, R.; Das, S.			p53 and little brother p53/47: linking IRES activities with protein functions	ONCOGENE			English	Article						p53; p53/47; IRES; translational control	TRACT BINDING-PROTEIN; RIBOSOME ENTRY SEGMENT; MESSENGER-RNA TRANSLATION; WILD-TYPE P53; SV40-TRANSFORMED CELLS; MEDIATED TRANSLATION; GENE-EXPRESSION; FEEDBACK LOOP; DNA-DAMAGE; ISOFORMS	The tumor suppressor p53 represents a paradigm for gene regulation. Its rapid induction in response to DNA damage conditions has been attributed to both increased half-life of p53 protein and also increased translation of p53 mRNA. Recent advances in our understanding of the post-transcriptional regulation of p53 include the discovery of internal ribosome entry sites (IRESs) within the p53 mRNA. These IRES elements regulate the translation of the full length as well as the N-terminally truncated isoform, p53/47. The p53/47 isoform is generated by alternative initiation at an internal AUG codon present within the p53 ORF. The aim of this review is to summarize the role of translational control mechanisms in regulating p53 functions. We discuss here in detail how diverse cellular stress pathways trigger alterations in the cap-dependent and cap-independent translation of p53 mRNA and how changes in the relative expression levels of p53 isoforms result in more differentiated p53 activity. Oncogene (2009) 28, 2766-2772; doi:10.1038/onc.2009.138; published online 1 June 2009	[Grover, R.; Das, S.] Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; [Candeias, M. M.; Fahraeus, R.] Hop St Louis, INSERM, Inst Genet Mol, U716, Paris, France; [Candeias, M. M.; Fahraeus, R.] Univ Paris 07, Paris, France	Indian Institute of Science (IISC) - Bangalore; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Das, S (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Sir CV Raman Ave, Bangalore 560012, Karnataka, India.	sdas@mcbl.iisc.ernet.in	fahraeus, robin/K-8726-2014		Council of Scientific and Industrial Research, India	Council of Scientific and Industrial Research, India(Council of Scientific & Industrial Research (CSIR) - India)	This study is supported by a research grant from the Indo-French (IFCPAR) to SD and RF. RG is supported by predoctoral fellowship from Council of Scientific and Industrial Research, India.	Anensen NA, 2006, LEUKEMIA, V20, P734, DOI 10.1038/sj.leu.2404117; Baird SD, 2006, RNA, V12, P1755, DOI 10.1261/rna.157806; Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Boldrup L, 2007, EUR J CANCER, V43, P617, DOI 10.1016/j.ejca.2006.10.019; Bourdon JC, 2007, BRIT J CANCER, V97, P277, DOI 10.1038/sj.bjc.6603886; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bushell M, 2006, MOL CELL, V23, P401, DOI 10.1016/j.molcel.2006.06.012; Candeias MM, 2006, ONCOGENE, V25, P6936, DOI 10.1038/sj.onc.1209996; Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770; Clemens MJ, 2001, J CELL MOL MED, V5, P221, DOI 10.1111/j.1582-4934.2001.tb00157.x; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Courtois S, 2004, ONCOGENE, V23, P631, DOI 10.1038/sj.onc.1206929; Ewen ME, 1996, BBA-REV CANCER, V1242, P181, DOI 10.1016/0304-419X(95)00010-D; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Goldschneider D, 2006, NUCLEIC ACIDS RES, V34, P5603, DOI 10.1093/nar/gkl619; Grover R, 2008, CELL CYCLE, V7, P2189, DOI 10.4161/cc.7.14.6271; Halaby MJ, 2007, GENE, V395, P1, DOI 10.1016/j.gene.2007.01.029; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hrstka R, 2008, ANTI-CANCER DRUG, V19, P369, DOI 10.1097/CAD.0b013e3282f7f500; Kim JH, 2003, MOL CELL BIOL, V23, P708, DOI 10.1128/MCB.23.2.708-720.2003; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Morley SJ, 2005, CELL DEATH DIFFER, V12, P571, DOI 10.1038/sj.cdd.4401591; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; Ohki R, 2007, CANCER SCI, V98, P189, DOI 10.1111/j.1349-7006.2006.00375.x; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Perry ME, 2004, MOL CANCER RES, V2, P9; Pfingsten JS, 2007, J MOL BIOL, V370, P856, DOI 10.1016/j.jmb.2007.04.076; Pickering BM, 2004, MOL CELL BIOL, V24, P5595, DOI 10.1128/MCB.24.12.5595-5605.2004; Pickering BM, 2003, NUCLEIC ACIDS RES, V31, P639, DOI 10.1093/nar/gkg146; Powell DJ, 2008, CELL CYCLE, V7, P950, DOI 10.4161/cc.7.7.5626; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Scrable H, 2005, INT J BIOCHEM CELL B, V37, P913, DOI 10.1016/j.biocel.2004.11.014; Spriggs KA, 2005, CELL DEATH DIFFER, V12, P585, DOI 10.1038/sj.cdd.4401642; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; TAUPIN JL, 1995, P NATL ACAD SCI USA, V92, P1629, DOI 10.1073/pnas.92.5.1629; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang DQ, 2006, ONCOGENE, V25, P4613, DOI 10.1038/sj.onc.1209483; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	54	44	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	30					2766	2772		10.1038/onc.2009.138	http://dx.doi.org/10.1038/onc.2009.138			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476OW	19483723				2022-12-17	WOS:000268452900007
J	Laner-Plamberger, S; Kaser, A; Paulischta, M; Hauser-Kronberger, C; Eichberger, T; Frischauf, AM				Laner-Plamberger, S.; Kaser, A.; Paulischta, M.; Hauser-Kronberger, C.; Eichberger, T.; Frischauf, A. M.			Cooperation between GLI and JUN enhances transcription of JUN and selected GLI target genes	ONCOGENE			English	Article						GLI1; GLI2; Hedgehog signaling; activated JUN; basal cell carcinoma; keratinocytes	BASAL-CELL CARCINOMAS; HEDGEHOG SIGNALING PATHWAY; SKIN TUMOR-DEVELOPMENT; HUMAN EPIDERMAL-CELLS; C-JUN; TERMINAL PHOSPHORYLATION; HUMAN KERATINOCYTES; PROTEIN-KINASE; AP-1 PROTEINS; HUMAN HOMOLOG	Sustained Hedgehog (HH) signaling is implicated in basal cell carcinoma of the skin and other types of cancer. Here we show that GLI1 and GLI2, the main transcriptional activators of the HH pathway, directly regulate expression of the activator protein 1 (AP-1) family member JUN, a transcription factor controlling keratinocyte proliferation and skin homeostasis. Activation of the JUN promoter by GLI is dependent on a GLI-binding site and the AP-1 sites known to be involved in self-activation of JUN. Transcription of JUN is greatly enhanced in the presence of GLI and requires activated JUN protein. GLI2act is a more potent activator than GLI1 in these experiments and physical interaction with phosphorylated JUN was only detected for GLI2act. The synergistic effect of GLI and JUN extends to the activation of further GLI target genes as shown by shRNA-mediated knockdown of JUN in human keratinocytes. Some of these cooperatively activated genes are involved in cell-cycle progression, which is consistent with a significant reduction of the proliferative potential of GLI in the absence of JUN. These results suggest a novel connection between HH/GLI pathway activity and JUN, which may contribute to the oncogenic activity of HH/GLI signaling in skin.	[Laner-Plamberger, S.; Kaser, A.; Paulischta, M.; Eichberger, T.; Frischauf, A. M.] Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria; [Hauser-Kronberger, C.] Paracelsus Med Univ Salzburg, St Johanns Hosp, Dept Pathol, Salzburg, Austria	Salzburg University; Paracelsus Private Medical University	Frischauf, AM (corresponding author), Salzburg Univ, Dept Mol Biol, Hellbrunnerstr 34, A-5020 Salzburg, Austria.	annemarie.frischauf@sbg.ac.at	Laner-Plamberger, Sandra/AFP-1191-2022	Laner-Plamberger, Sandra/0000-0002-1416-6023; Kaser-Eichberger, Alexandra/0000-0002-6115-5036	Austrian Genome Project GENAU Ultrasensitive Proteomics; Genomics II; University of Salzburg priority program Biosciences and Health	Austrian Genome Project GENAU Ultrasensitive Proteomics; Genomics II; University of Salzburg priority program Biosciences and Health	We thank Dr Fritz Aberger for stimulating discussions and critical reading of the paper, Mag. Stefan Klingler for advice on propagation ofhuman primary foreskin keratinocytes and Dr Martina Winklmayr for help with co- immunoprecipitations and cloning. We are particularly grateful to Dr Michael J Birrer for providing the JUN expression plasmid and Dr Rune Toftgard for a SUFU expression construct. This work was supported by the Austrian Genome Project GENAU Ultrasensitive Proteomics and Genomics II and the University ofSalzburg priority program Biosciences and Health.	Agren M, 2004, GENE, V330, P101, DOI 10.1016/j.gene.2004.01.010; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; Bannister AJ, 1995, ONCOGENE, V11, P2509; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bigelow RLH, 2005, J INVEST DERMATOL, V124, P457, DOI 10.1111/j.0022-202X.2004.23590.x; di Magliano MP, 2006, GENE DEV, V20, P3161, DOI 10.1101/gad.1470806; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eichberger T, 2008, J BIOL CHEM, V283, P12426, DOI 10.1074/jbc.M707117200; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; Evangelista M, 2006, CLIN CANCER RES, V12, P5924, DOI 10.1158/1078-0432.CCR-06-1736; Ghali L, 1999, J INVEST DERMATOL, V113, P595, DOI 10.1046/j.1523-1747.1999.00729.x; Giesecke AV, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100053; Ginsberg M, 2007, MOL CELL BIOL, V27, P6300, DOI 10.1128/MCB.00613-07; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Gramigni C, 1998, FEBS LETT, V440, P119, DOI 10.1016/S0014-5793(98)01443-4; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hallikas O, 2006, CELL, V124, P47, DOI 10.1016/j.cell.2005.10.042; Hayakawa J, 2004, MOL CELL, V16, P521, DOI 10.1016/j.molcel.2004.10.024; Hebrok M, 2003, MECH DEVELOP, V120, P45, DOI 10.1016/S0925-4773(02)00331-3; HERBER B, 1994, ONCOGENE, V9, P1295; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Huangfu D, 2006, DEVELOPMENT, V133, P3, DOI 10.1242/dev.02169; Ikram MS, 2004, J INVEST DERMATOL, V122, P1503, DOI 10.1111/j.0022-202X.2004.22612.x; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johnson GL, 2007, BBA-MOL CELL RES, V1773, P1341, DOI 10.1016/j.bbamcr.2006.12.009; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; Kasper M, 2006, MOL CELL BIOL, V26, P6283, DOI 10.1128/MCB.02317-05; Kasper Maria, 2007, V397, P67; Kim S, 2006, MOL CELL BIOL, V26, P2467, DOI 10.1128/MCB.26.7.2467-2478.2006; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Lauth M, 2007, ONCOGENE, V26, P5163, DOI 10.1038/sj.onc.1210321; Maeda S, 2003, CANCER CELL, V3, P102, DOI 10.1016/S1535-6108(03)00025-4; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; Martin KJ, 2001, P NATL ACAD SCI USA, V98, P2646, DOI 10.1073/pnas.041622398; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Mimeault M, 2007, MOL CANCER THER, V6, P967, DOI 10.1158/1535-7163.MCT-06-0648; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Neill GW, 2008, CARCINOGENESIS, V29, P738, DOI 10.1093/carcin/bgn037; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Panne D, 2008, CURR OPIN STRUC BIOL, V18, P236, DOI 10.1016/j.sbi.2007.12.002; Pearse RV, 1999, DEV BIOL, V212, P323, DOI 10.1006/dbio.1999.9335; Regl G, 2004, CANCER RES, V64, P7724, DOI 10.1158/0008-5472.CAN-04-1085; Regl G, 2004, ONCOGENE, V23, P1263, DOI 10.1038/sj.onc.1207240; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103; Riobo NA, 2006, CANCER RES, V66, P839, DOI 10.1158/0008-5472.CAN-05-2539; Roessler E, 2005, HUM MOL GENET, V14, P2181, DOI 10.1093/hmg/ddi222; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Ruiz i Altaba A, 2007, TRENDS CELL BIOL, V17, P438, DOI 10.1016/j.tcb.2007.06.007; Sasaki H, 1999, DEVELOPMENT, V126, P3915; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Sheng H, 2002, CANCER RES, V62, P5308; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Speek M, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-13; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Stecca Barbara, 2002, J Biol, V1, P9, DOI 10.1186/1475-4924-1-9; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; Toualbi K, 2007, ONCOGENE, V26, P3492, DOI 10.1038/sj.onc.1210133; Vezina Chad M, 2007, Curr Urol Rep, V8, P275, DOI 10.1007/s11934-007-0073-x; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yates S, 2002, WOUND REPAIR REGEN, V10, P5, DOI 10.1046/j.1524-475X.2002.10902.x; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zenz R, 2006, INT J BIOCHEM CELL B, V38, P1043, DOI 10.1016/j.biocel.2005.11.011; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8; Zhang G, 2006, ONCOGENE, V25, P7260, DOI 10.1038/sj.onc.1209726; Zhao M, 2006, MOL CELL BIOL, V26, P6197, DOI 10.1128/MCB.02214-05	83	44	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2009	28	13					1639	1651		10.1038/onc.2009.10	http://dx.doi.org/10.1038/onc.2009.10			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427LJ	19219074				2022-12-17	WOS:000264780500008
J	Yang, XY; Guan, M; Vigil, D; Der, CJ; Lowy, DR; Popescu, NC				Yang, X-Y; Guan, M.; Vigil, D.; Der, C. J.; Lowy, D. R.; Popescu, N. C.			p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities	ONCOGENE			English	Article						deleted in liver cancer; Ras-GAP; protein interaction; modulation of tumor cell proliferation; Rho-GAP; SH3	ACTIVATING PROTEIN; CELL-PROLIFERATION; GENE-EXPRESSION; RAS; CANCER; SH3; DOMAIN; CLONING; TUMORIGENICITY; TRANSFORMATION	DLC1 (deleted in liver cancer 1), which encodes a Rho GTPase-activating protein (Rho-GAP), is a potent tumor suppressor gene that is frequently inactivated in several human cancers. DLC1 is a multidomain protein that has been shown previously to bind members of the tensin gene family. Here we show that p120Ras-GAP (Ras-GAP; also known as RASA1) interacts and extensively colocalizes with DLC1 in focal adhesions. The binding was mapped to the SH3 domain located in the N terminus of Ras-GAP and to the Rho-GAP catalytic domain located in the C terminus of the DLC1. In vitro analyses with purified proteins determined that the isolated Ras-GAP SH3 domain inhibits DLC1 Rho-GAP activity, suggesting that Ras-GAP is a negative regulator of DLC1 Rho-GAP activity. Consistent with this possibility, we found that ectopic overexpression of Ras-GAP in a Ras-GAP-insensitive tumor line impaired the growth-suppressing activity of DLC1 and increased RhoA activity in vivo. Our observations expand the complexity of proteins that regulate DLC1 function and define a novel mechanism of the cross talk between Ras and Rho GTPases.	[Yang, X-Y; Guan, M.; Popescu, N. C.] NCI, Expt Carcinogenesis Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Vigil, D.; Der, C. J.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Lowy, D. R.] NCI, Cellular Oncol Lab, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Popescu, NC (corresponding author), NCI, Expt Carcinogenesis Lab, Ctr Canc Res, Bldg 37,Room 4128,37 Convent Dr,MSC4262, Bethesda, MD 20892 USA.	popescun@mail.nih.gov	yang, xuyu/D-1414-2012	Der, Channing/0000-0002-7751-2747	NIH [1R01CA129610]; American Cancer Society; NATIONAL CANCER INSTITUTE [ZIABC010038, ZIABC008905, R01CA129610] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The Intramural Research Program of the National Cancer Institute, Center for Cancer Research, NIH supported this work. CJD is also supported by an NIH grant (1R01CA129610), and DV was supported by a fellowship from the American Cancer Society.	Abdellatif M, 1998, MOL CELL BIOL, V18, P6729, DOI 10.1128/MCB.18.11.6729; Baselga J, 2008, J CLIN ONCOL, V26, P1582, DOI 10.1200/JCO.2007.15.3700; Bradley WD, 2006, MOL BIOL CELL, V17, P4827, DOI 10.1091/mbc.E06-02-0132; Bradshaw JM, 2003, ADV PROTEIN CHEM, V61, P161; Brouns MR, 2000, DEVELOPMENT, V127, P4891; BRYANT SS, 1995, J BIOL CHEM, V270, P17947, DOI 10.1074/jbc.270.30.17947; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Durkin ME, 2007, ONCOGENE, V26, P4580, DOI 10.1038/sj.onc.1210244; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; Durkin ME, 2005, FEBS LETT, V579, P1191, DOI 10.1016/j.febslet.2004.12.090; Ferraro E, 2007, NUCLEIC ACIDS RES, V35, pW451, DOI 10.1093/nar/gkm296; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; Gigoux V, 2002, J BIOL CHEM, V277, P23742, DOI 10.1074/jbc.C200121200; Guan M, 2008, CANCER GENE THER, V15, P371, DOI 10.1038/cgt.2008.13; Healy KD, 2008, MOL CARCINOGEN, V47, P326, DOI 10.1002/mc.20389; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Jin YL, 2008, ONCOL REP, V19, P669; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kawai K, 2007, BIOCHEM BIOPH RES CO, V364, P783, DOI 10.1016/j.bbrc.2007.10.052; Kennedy D, 2002, J CELL BIOCHEM, V84, P173, DOI 10.1002/jcb.1277; Kim TY, 2008, J BIOL CHEM, V283, P32762, DOI 10.1074/jbc.M800617200; Kim TY, 2007, BIOCHEM BIOPH RES CO, V355, P72, DOI 10.1016/j.bbrc.2007.01.121; Leblanc V, 1999, ONCOGENE, V18, P4884, DOI 10.1038/sj.onc.1202855; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; Leung THY, 2005, P NATL ACAD SCI USA, V102, P15207, DOI 10.1073/pnas.0504501102; Li SSC, 2005, BIOCHEM J, V390, P641, DOI 10.1042/BJ20050411; Liao YC, 2008, CANCER RES, V68, P7718, DOI 10.1158/0008-5472.CAN-08-2042; Liao YC, 2007, J CELL BIOL, V176, P43, DOI 10.1083/jcb.200608015; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Musacchio A, 2003, ADV PROTEIN CHEM, V61, P211; Pamonsinlapatham P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002902; Qian XL, 2007, P NATL ACAD SCI USA, V104, P9012, DOI 10.1073/pnas.0703033104; Ross B, 2007, BIOCHEM BIOPH RES CO, V353, P463, DOI 10.1016/j.bbrc.2006.12.044; Shang X, 2007, J BIOL CHEM, V282, P8801, DOI 10.1074/jbc.M609375200; Shankavaram UT, 2007, MOL CANCER THER, V6, P820, DOI 10.1158/1535-7163.MCT-06-0650; Shutes A, 2005, METHODS, V37, P183, DOI 10.1016/j.ymeth.2005.05.019; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; Ullmannova V, 2006, INT J ONCOL, V29, P1127; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; Wong CM, 2005, CANCER RES, V65, P8861, DOI 10.1158/0008-5472.CAN-05-1318; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Yam JWP, 2006, CANCER RES, V66, P8367, DOI 10.1158/0008-5472.CAN-05-2850; Yuan BZ, 1998, CANCER RES, V58, P2196; Yue YZ, 2004, J BIOL CHEM, V279, P12883, DOI 10.1074/jbc.M312308200; Zhou X, 2008, INT J ONCOL, V32, P1285; Zhou XL, 2004, ONCOGENE, V23, P1308, DOI 10.1038/sj.onc.1207246	48	44	47	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	11					1401	1409		10.1038/onc.2008.498	http://dx.doi.org/10.1038/onc.2008.498			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421JE	19151751	Green Submitted, Green Accepted			2022-12-17	WOS:000264354400001
J	Arscott, WT; LaBauve, AE; May, V; Wesley, UV				Arscott, W. T.; LaBauve, A. E.; May, V.; Wesley, U. V.			Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation	ONCOGENE			English	Article						DPPIV; neuroblastoma; apoptosis; chemokine; migration and invasion	PROSTATE-CANCER CELLS; DEAMINASE COMPLEXING PROTEIN; BONE-MARROW METASTASES; ADENOSINE-DEAMINASE; TUMOR-GROWTH; MALIGNANT PHENOTYPE; SURFACE PEPTIDASES; PROGENITOR CELLS; CARCINOMA CELLS; IN-VITRO	Imbalanced protease expression and activities may contribute to the development of cancers, including neuroblastoma (NB). NB is a fatal childhood cancer of the sympathetic nervous system that frequently overexpresses mitogenic peptides, chemokines and their receptors. Dipeptidyl peptidase IV (DPPIV), a cell surface serine protease, inactivates or degrades some of these bioactive peptides and chemokines, thereby regulating cell proliferation and survival. Our studies show that DPPIV is expressed in normal neural crest-derived structures, including superior cervical and dorsal root ganglion cells, sciatic nerve, and in adrenal glands, but its expression is greatly decreased or lost in cells derived from NB, their malignant counterpart. Restoration of DPPIV expression in NB cells led to their differentiation in association with increased expression of the neural marker MAP2 and decreased expression of chemokines, including stromal-derived factor 1 (SDF1) and its receptor CXCR4. Furthermore, DPPIV promoted apoptosis, and inhibited SDF1-mediated in vitro cell migration and angiogenic potential. These changes were accompanied by caspase activation and decreased levels of phospho-Akt and MMP9 activity, which are downstream effectors of SDF1-CXCR4 signaling. Importantly, DPPIV suppressed the tumorigenic potential of NB cells in a xenotransplantation mouse model. These data support a potential role for DPPIV in inhibiting NB growth and progression.	[Arscott, W. T.; LaBauve, A. E.; Wesley, U. V.] Univ Vermont, Vermont Canc Ctr, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA; [May, V.] Univ Vermont, Vermont Canc Ctr, Dept Anat & Neurobiol, Burlington, VT 05405 USA	University of Vermont; University of Vermont	Wesley, UV (corresponding author), Univ Vermont, Vermont Canc Ctr, Dept Microbiol & Mol Genet, 316A,HSRF,149 Beaumont Ave, Burlington, VT 05405 USA.	uwesley@uvm.edu		Arscott, William/0000-0003-0110-8569	National Center for Research Resources-National Institute of Health (NCRR) [COBRE 2 P20 RR016435-P4Y6]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016435] Funding Source: NIH RePORTER	National Center for Research Resources-National Institute of Health (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This study was supported by the Grant, Neuroscience COBRE 2 P20 RR016435-P4Y6 from the National Center for Research Resources-National Institute of Health (NCRR). We thank the Department of Microbiology and Molecular Genetics and the Vermont Cancer Center (VCC) for their support. We thank Drs Cynthia Forehand, Diane Jaworski, Rodney Parsons, Marcus Bosenberg, Rae Nishi and Cedric Wesley for helpful discussions and critical review of the paper. We thank the staff at the VCC and COBRE-Neuroscience core facilities for their technical help.	Abbott CA, 1997, ADV EXP MED BIOL, V421, P161; Airoldi I, 2006, CLIN CANCER RES, V12, P77, DOI 10.1158/1078-0432.CCR-05-1376; Airoldi I, 2008, CANCER IMMUNOL IMMUN, V57, P541, DOI 10.1007/s00262-007-0392-2; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Barbero S, 2003, CANCER RES, V63, P1969; Bauvois B, 2004, ONCOGENE, V23, P317, DOI 10.1038/sj.onc.1207124; Belmadani A, 2005, J NEUROSCI, V25, P3995, DOI 10.1523/JNEUROSCI.4631-04.2005; Bogenrieder T, 1997, PROSTATE, V33, P225; Bonfil RD, 2007, UROL ONCOL-SEMIN ORI, V25, P407, DOI 10.1016/j.urolonc.2007.05.008; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Carl-McGrath S, 2006, HISTOL HISTOPATHOL, V21, P1339, DOI 10.14670/HH-21.1339; Castel V, 2007, CLIN TRANSL ONCOL, V9, P478, DOI 10.1007/s12094-007-0091-7; Chinni SR, 2006, PROSTATE, V66, P32, DOI 10.1002/pros.20318; Christopherson KW, 2002, J IMMUNOL, V169, P7000, DOI 10.4049/jimmunol.169.12.7000; Dai J, 2001, CLIN CANCER RES, V7, P1370; DINJENS WNM, 1990, J PATHOL, V160, P195, DOI 10.1002/path.1711600303; Dobers J, 2000, EUR J BIOCHEM, V267, P5093, DOI 10.1046/j.1432-1327.2000.01571.x; Durinx C, 2000, EUR J BIOCHEM, V267, P5608, DOI 10.1046/j.1432-1327.2000.01634.x; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Fernandis AZ, 2004, ONCOGENE, V23, P157, DOI 10.1038/sj.onc.1206910; Gabrilovac J, 2003, LIFE SCI, V73, P151, DOI 10.1016/S0024-3205(03)00257-1; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Ghersi G, 2002, J BIOL CHEM, V277, P29231, DOI 10.1074/jbc.M202770200; Golubkov VS, 2007, CELL CYCLE, V6, P147, DOI 10.4161/cc.6.2.3706; Guyon A, 2007, J MOL ENDOCRINOL, V38, P365, DOI 10.1677/JME-06-0013; Havre PA, 2008, FRONT BIOSCI-LANDMRK, V13, P1634, DOI 10.2741/2787; Kajiyama H, 2006, ANN NY ACAD SCI, V1086, P233, DOI 10.1196/annals.1377.007; KENNY AJ, 1989, LANCET, V2, P785; Lambeir AM, 2001, J BIOL CHEM, V276, P29839, DOI 10.1074/jbc.M103106200; Li ZJ, 2007, EXPERT OPIN THER TAR, V11, P1611, DOI 10.1517/14728222.11.12.1611; Maris JM, 2008, LANCET, V371, P1142, DOI 10.1016/S0140-6736(08)60500-0; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matthay KK, 2008, LANCET ONCOL, V9, P195, DOI 10.1016/S1470-2045(08)70046-9; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; MORRISON ME, 1993, J EXP MED, V177, P1135, DOI 10.1084/jem.177.4.1135; Nakagawara A, 2004, PROG BRAIN RES, V146, P233, DOI 10.1016/S0079-6123(03)46015-9; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nanus DM, 2003, CLIN CANCER RES, V9, P6307; Nevo I, 2004, IMMUNOL LETT, V92, P163, DOI 10.1016/j.imlet.2003.10.019; Payne AS, 2002, J INVEST DERMATOL, V118, P915, DOI 10.1046/j.1523-1747.2002.01725.x; Pethiyagoda CL, 2001, CLIN EXP METASTAS, V18, P391, DOI 10.1023/A:1010930918055; PIAZZA GA, 1989, BIOCHEM J, V262, P327, DOI 10.1042/bj2620327; Proost P, 1998, FEBS LETT, V432, P73, DOI 10.1016/S0014-5793(98)00830-8; Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013; Ren Y, 2006, ONCOGENE, V25, P3501, DOI 10.1038/sj.onc.1209395; Rundhaug JE, 2005, J CELL MOL MED, V9, P267, DOI 10.1111/j.1582-4934.2005.tb00355.x; Russell HV, 2004, J PEDIATR SURG, V39, P1506, DOI 10.1016/j.jpedsurg.2004.06.019; SAKAMOTO J, 1993, J SURG ONCOL, V52, P124, DOI 10.1002/jso.2930520214; Scala S, 2006, CLIN CANCER RES, V12, P2427, DOI 10.1158/1078-0432.CCR-05-1940; Scharpe S, 2001, Verh K Acad Geneeskd Belg, V63, P5; SCHRADER WP, 1987, J HISTOCHEM CYTOCHEM, V35, P443, DOI 10.1177/35.4.3546489; Sedo A, 1994, Sb Lek, V95, P285; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; Singh S, 2007, CANCER METAST REV, V26, P453, DOI 10.1007/s10555-007-9068-9; Tanaka T, 2005, CANCER SCI, V96, P317, DOI 10.1111/j.1349-7006.2005.00059.x; Terauchi M, 2005, ONCOLOGY-BASEL, V69, P52, DOI 10.1159/000087476; Tran PB, 2004, J NEUROSCI RES, V76, P20, DOI 10.1002/jnr.20001; Tsuji T, 2004, INT J HEMATOL, V80, P254, DOI 10.1532/IJH97.04066; Tucker RP, 2004, INT J BIOCHEM CELL B, V36, P173, DOI 10.1016/S1357-2725(03)00243-7; Vasudevan SA, 2005, WORLD J SURG, V29, P317, DOI 10.1007/s00268-004-7820-7; Wesley UV, 2005, CANCER RES, V65, P1325, DOI 10.1158/0008-5472.CAN-04-1852; Wesley UV, 1999, J EXP MED, V190, P311, DOI 10.1084/jem.190.3.311; Wesley UV, 2004, INT J CANCER, V109, P855, DOI 10.1002/ijc.20091; Zigrino P, 2005, BIOCHIMIE, V87, P321, DOI 10.1016/j.biochi.2004.10.025	67	44	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					479	491		10.1038/onc.2008.402	http://dx.doi.org/10.1038/onc.2008.402			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18978811	Green Accepted			2022-12-17	WOS:000262866500002
J	Upadhyay, G; Goessling, W; North, TE; Xavier, R; Zon, LI; Yajnik, V				Upadhyay, G.; Goessling, W.; North, T. E.; Xavier, R.; Zon, L. I.; Yajnik, V.			Molecular association between beta-catenin degradation complex and Rac guanine exchange factor DOCK4 is essential for Wnt/beta-catenin signaling	ONCOGENE			English	Article						Wnt/beta-catenin; Rac; GSK3 beta; Axin; APC; DOCK4	NUCLEOTIDE EXCHANGE; PHOSPHORYLATION; GTPASE; MECHANISM; PATHWAY; EMBRYOS; MODEL; GEF; APC; RHO	The canonical Wnt/beta-catenin pathway is a highly conserved signaling cascade that is involved in development and stem cell renewal. The deregulation of this pathway is often associated with increased cell growth and neoplasia. The small GTPase Rac has been shown to influence canonical Wnt signaling by regulating beta-catenin stability through an unknown mechanism. We report that DOCK4, a guanine nucleotide exchange factor (GEF) for Rac and a member of the CDM family of unconventional GEFs, mediates Wnt-induced Rac activation in the canonical Wnt/beta-catenin pathway. DOCK4 expression regulates cellular beta-catenin levels in response to the Wnt signal, in vitro. Biochemical studies demonstrate that DOCK4 interacts with the beta-catenin degradation complex, consisting of the proteins adenomatosis polyposis coli, Axin and glycogen synthase kinase 3 beta (GSK3 beta). This molecular interaction enhances beta-catenin stability and Axin degradation. Furthermore, we observe that DOCK4 is phosphorylated by GSK3 beta, which enhances Wnt-induced Rac activation. Using a T-cell factor reporter zebrafish we confirm that DOCK4 is required for Wnt/beta-catenin activity, in vivo. These results elucidate a novel intracellular signaling mechanism in which a Rac GEF, DOCK4 acts as a scaffold protein in the Wnt/beta-catenin pathway.	[Upadhyay, G.; Goessling, W.; Xavier, R.; Yajnik, V.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Gastrointestinal Unit, Boston, MA 02114 USA; [Goessling, W.; North, T. E.; Zon, L. I.] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School	Yajnik, V (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Gastrointestinal Unit, 55 Fruit St,GRJ-825, Boston, MA 02114 USA.	gu6@georgetown.edu; vyajnik@partners.org	North, Trista/ABG-4789-2020; Upadhyay, Geeta/AEB-0203-2022	North, Trista/0000-0003-1249-563X; Goessling, Wolfram/0000-0001-9972-1569	NIH [DK 63933]; MGH GI unit; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK063933, P30DK040561] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MGH GI unit; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Lars von Buchholtz (NIH, MD, USA), Parool Meelu (MGH, MA, USA), Tiffany M Blake (Georgetown University, DC, USA) and Denver Matthew Lough (Georgetown University, DC, USA) for the help in the preparation of the paper. This study was supported by grant NIH DK 63933 (VY) and MGH GI unit startup funds (VY).	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Bhattacharyya R, 2007, ONCOGENE, V26, P7628, DOI 10.1038/sj.onc.1210576; Braga VMM, 2002, NAT CELL BIOL, V4, pE188, DOI 10.1038/ncb0802-e188; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cadigan KM, 2006, J CELL SCI, V119, P395, DOI 10.1242/jcs.02826; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cote JF, 2005, NAT CELL BIOL, V7, P797, DOI 10.1038/ncb1280; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Dorsky RI, 2002, DEV BIOL, V241, P229, DOI 10.1006/dbio.2001.0515; Esufali S, 2004, ONCOGENE, V23, P8260, DOI 10.1038/sj.onc.1208007; Gingerich JL, 2005, DEV BIOL, V286, P427, DOI 10.1016/j.ydbio.2005.07.031; Grimsley CM, 2004, J BIOL CHEM, V279, P6087, DOI 10.1074/jbc.M307087200; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Hagen T, 2004, BIOCHEM J, V379, P471, DOI 10.1042/BJ20031749; Harte D, 1998, J NONLINEAR SCI, V8, P581, DOI 10.1007/s003329900060; Hocevar BA, 2003, EMBO J, V22, P3084, DOI 10.1093/emboj/cdg286; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Link V, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-1; Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578; Liu XX, 2005, CURR BIOL, V15, P1989, DOI 10.1016/j.cub.2005.10.050; Lu MJ, 2005, CURR BIOL, V15, P371, DOI 10.1016/j.cub.2005.01.050; Luo W, 2007, EMBO J, V26, P1511, DOI 10.1038/sj.emboj.7601607; MacDonald BT, 2007, CELL, V131, DOI 10.1016/j.cell.2007.11.036; Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Schier AF, 2005, ANNU REV GENET, V39, P561, DOI 10.1146/annurev.genet.37.110801.143752; Thorpe CJ, 2005, DEVELOPMENT, V132, P1763, DOI 10.1242/dev.01733; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wu BB, 2007, IMMUNITY, V26, P227, DOI 10.1016/j.immuni.2006.12.007; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Xing Y, 2003, GENE DEV, V17, P2753, DOI 10.1101/gad.1142603; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; Yan D, 2006, J MOL BIOL, V357, P755, DOI 10.1016/j.jmb.2006.01.017; Yang J, 2006, J BIOL CHEM, V281, P17751, DOI 10.1074/jbc.M600831200; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185	44	44	45	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2008	27	44					5845	5855		10.1038/onc.2008.202	http://dx.doi.org/10.1038/onc.2008.202			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QC	18641688	Green Accepted			2022-12-17	WOS:000259722400008
J	Ishikawa, Y; Onoyama, I; Nakayama, KI; Nakayama, K				Ishikawa, Y.; Onoyama, I.; Nakayama, K. I.; Nakayama, K.			Notch-dependent cell cycle arrest and apoptosis in mouse embryonic fibroblasts lacking Fbxw7	ONCOGENE			English	Article						ubiquitin ligase; Fbxw7; Notch; mouse embryonic fibroblast; tumor suppressor; p53	F-BOX PROTEIN; GLYCOGEN-SYNTHASE KINASE-3; TUMOR-SUPPRESSOR; C-MYC; UBIQUITIN LIGASE; GROWTH ARREST; MICE LACKING; ACTIVATION; TRANSCRIPTION; DEGRADATION	The F-box protein Fbxw7 mediates the ubiquitylation and consequent degradation of proteins that regulate cell cycle progression, including cyclin E, c-Myc, c-Jun and Notch. Moreover, certain human cancer cell lines harbor loss-of-function mutations in FBXW7 that result in excessive accumulation of Fbxw7 substrates, implicating Fbxw7 in tumor suppression. To elucidate the physiological function of Fbxw7, we conditionally ablated Fbxw7 in mouse embryonic fibroblasts (MEFs). Unexpectedly, loss of Fbxw7 induced cell cycle arrest and apoptosis that were accompanied by abnormal accumulation of the intracellular domain of Notch1 (NICD1). Forced expression of NICD1 in wild-type MEFs recapitulated the phenotype of the Fbxw7-deficient (Fbxw7D/D) MEFs. Conversely, deletion of Rbpj normalized the phenotype of Fbxw7(Delta/Delta) MEFs, indicating that this phenotype is dependent on the Notch1 RBP-J signaling pathway. Deletion of the p53 gene prevented cell cycle arrest but not the induction of apoptosis in Fbxw7(Delta/Delta) cells. These observations suggest that Fbxw7 does not function as an oncosuppressor in MEFs. Instead, it promotes cell cycle progression and cell survival through degradation of Notch1, with loss of Fbxw7 resulting in NICD1 accumulation, cell cycle arrest and apoptosis.	[Ishikawa, Y.; Nakayama, K.] Tohoku Univ, Grad Sch Med, Dept Dev Genet, Ctr Translat & Adv Anim Res,Aoba Ku, Sendai, Miyagi 9808575, Japan; [Ishikawa, Y.; Onoyama, I.; Nakayama, K. I.; Nakayama, K.] Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama, Japan; [Onoyama, I.; Nakayama, K. I.] Kyushu Univ, Dept Mol & Cellular Biol, Med Inst Bioregulat, Fukuoka 812, Japan	Tohoku University; Japan Science & Technology Agency (JST); Kyushu University	Nakayama, K (corresponding author), Tohoku Univ, Grad Sch Med, Dept Dev Genet, Ctr Translat & Adv Anim Res,Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	nakayak2@mail.tains.tohoku.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan; 21st Century Center of Excellence Program	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); 21st Century Center of Excellence Program(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank T Honjo for Rbpj<SUP>F/F</SUP> mice; R Tsunematsu for an NICD1 plasmid; T Kitamura for pMX-puro and Plat-E cells; Y Ono and N Kobayashi for technical assistance; N Ishida and other laboratory members for helpful discussion. This study was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and by the 21st Century Center of Excellence Program.	Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Fujii Y, 2006, CANCER SCI, V97, P729, DOI 10.1111/j.1349-7006.2006.00239.x; Guentchev M, 2006, EUR J NEUROSCI, V23, P2289, DOI 10.1111/j.1460-9568.2006.04766.x; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030; Huang QH, 2004, P NATL ACAD SCI USA, V101, P3456, DOI 10.1073/pnas.0308562100; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Kato H, 1996, FEBS LETT, V395, P221, DOI 10.1016/0014-5793(96)01046-0; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Loeb KR, 2005, CANCER CELL, V8, P35, DOI 10.1016/j.ccr.2005.06.010; Lopez-Nieva P, 2004, CARCINOGENESIS, V25, P1299, DOI 10.1093/carcin/bgh124; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Mo JS, 2007, MOL CELL BIOL, V27, P5565, DOI 10.1128/MCB.02372-06; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Onoyama I, 2007, J EXP MED, V204, P2875, DOI 10.1084/jem.20062299; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Ramain P, 2001, CURR BIOL, V11, P1729, DOI 10.1016/S0960-9822(01)00562-0; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; Sarmento LM, 2005, J EXP MED, V202, P157, DOI 10.1084/jem.20050559; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; SUNDARAM M, 1993, GENETICS, V135, P765; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Tsunematsu R, 2004, J BIOL CHEM, V279, P9417, DOI 10.1074/jbc.M312337200; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yang XD, 2004, DEV BIOL, V269, P81, DOI 10.1016/j.ydbio.2004.01.014; Zweidler-McKay PA, 2005, BLOOD, V106, P3898, DOI 10.1182/blood-2005-01-0355	46	44	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	47					6164	6174		10.1038/onc.2008.216	http://dx.doi.org/10.1038/onc.2008.216			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18641686				2022-12-17	WOS:000260083100009
J	Iwanaga, R; Ozono, E; Fujisawa, J; Ikeda, MA; Okamura, N; Huang, Y; Ohtani, K				Iwanaga, R.; Ozono, E.; Fujisawa, J.; Ikeda, M. A.; Okamura, N.; Huang, Y.; Ohtani, K.			Activation of the cyclin D2 and cdk6 genes through NF-kappa B is critical for cell-cycle progression induced by HTLV-I Tax	ONCOGENE			English	Article						HTLV-I; Tax; cell cycle; E2F; cyclin D2; cdk6	VIRUS TYPE-I; ONCOGENE PRODUCT TAX; TYPE-1 TAX; PROTEIN; TRANSFORMATION; MECHANISMS	Human T-cell leukemia virus type I (HTLV-I) can infect a variety of cell types, so the cause of T-cell-specific oncogenesis remains to be elucidated. The trans-activator protein Tax of HTLV-I can promote cell-cycle progression in resting T cells along with induction of cyclin D2 and cyclin-dependent kinase (cdk6) gene expression. Here, we found that Tax cannot induce cell-cycle progression in resting fibroblasts and analysed the molecular basis of the cell-type specificity. Tax activated cyclin D2 and cdk6 promoters in T cells, but not in fibroblasts, depending on its ability to activate the transcription factor nuclear factor (NF)-kappa B. Expression of cyclin D2 and CDK6 activated the transcription factor E2F, which is essential for cell-cycle progression, in both T cells and fibroblasts. Short-hairpin RNA (shRNA)-mediated inhibition of cyclin D2 and CDK6 induction suppressed Tax-induced activation of E2F in T cells. Finally, shRNA-mediated downregulation of NF-kappa B p65 or p100 expression reduced Tax-induced activation of cyclin D2 and/or cdk6 promoters and cell-cycle progression in T cells. These results indicate that Tax-induced cell-cycle progression in T cells is mediated, at least in part, through cell-type-specific activation of the cyclin D2 and cdk6 genes through NF-kappa B and may be important for the cell-type-specific oncogenesis.	[Ohtani, K.] Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan; [Iwanaga, R.; Okamura, N.] Tokyo Med & Dent Univ, Grad Sch Hlth Sci, Lab Microbiol & Immunol, Tokyo 1138510, Japan; [Ozono, E.; Ikeda, M. A.] Tokyo Med & Dent Univ, Grad Sch, Sect Mol Embryol, Tokyo, Japan; [Fujisawa, J.] Kansai Med Univ, Dept Microbiol, Osaka, Japan; [Huang, Y.] E China Univ Sci & Technol, Sch Pharm, Dept Pharmaceut Sci, Shanghai 200237, Peoples R China	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Kansai Medical University; East China University of Science & Technology	Ohtani, K (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	kiyo.gene@cmn.tmd.ac.jp		Ozono, Eiko/0000-0002-3919-205X				Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198; Inoue J, 2007, CANCER SCI, V98, P268, DOI 10.1111/j.1349-7006.2007.00389.x; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; NAKAMURA M, 1989, J BIOL CHEM, V264, P20189; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; Ohtani K, 1998, J BIOL CHEM, V273, P14119, DOI 10.1074/jbc.273.23.14119; Schmitt I, 1998, J VIROL, V72, P633, DOI 10.1128/JVI.72.1.633-640.1998; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 2005, ONCOGENE, V24, P5931, DOI 10.1038/sj.onc.1208981	14	44	46	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2008	27	42					5635	5642		10.1038/onc.2008.174	http://dx.doi.org/10.1038/onc.2008.174			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18504428				2022-12-17	WOS:000259280800009
J	Rzymski, T; Paantjens, A; Bod, J; Harris, AL				Rzymski, T.; Paantjens, A.; Bod, J.; Harris, A. L.			Multiple pathways are involved in the anoxia response of SKIP3 including HuR-regulated RNA stability, NF-kappa B and ATF4	ONCOGENE			English	Article						ATF4; SKIP3; anoxia; RNA stability; NF-kappa B	MESSENGER-RNA; CYCLOOXYGENASE-2 EXPRESSION; GENE-EXPRESSION; HYPOXIA; ACTIVATION; BINDING; CELL; TRB3; PHOSPHORYLATION; STABILIZATION	Under anoxia a coordinated, cytoprotective program is induced, called the unfolded protein response (UPR). Activating transcription factor 4 (ATF4) is a mediator of the UPR and activates a gene expression program, promoting tumour growth and survival under anoxia. A key gene induced by ATF4 under normoxic conditions is SKIP3. We characterized the induction of SKIP3 during anoxic exposure to determine whether UPR alone was sufficient or there was a more complex regulatory response to anoxia. There was temporal separation of acute hypoxia-inducible factor (HIF)-1 alpha- and chronic ATF4-dependent gene expression programs. SKIP3 was regulated by chronic (48 h) rather than acute anoxia (< 24h) by a complex set of pathways and mechanisms, besides ATF4 induced by the classical UPR, there was transcriptional regulation by nuclear factor-kappa B (NF-kappa B)and RNA stabilization by HuR. Temporal activation of the NF-kappa B pathway under anoxia protected cells from negative consequences of the oxygen stress and involved the canonical signalling pathways that promote I kappa BA phosphorylation and degradation, and reduced mRNA level of the inhibitory protein I kappa BA followed by the translational repression of I kappa BA. We also show that SKIP3 acts as an inhibitor of NF-kappa B and ATF4-dependent transcription under anoxia and provides a regulatory feedback loop. Repression of the survival pathway NF-kappa B by SKIP3 sensitized cells to metabolic consequences of the anoxic stress. Thus, the response to anoxia is mediated by three pathways independently of HIF, suggesting that combined therapeutic approaches would be needed to maximize effects against this pathway.	[Rzymski, T.; Paantjens, A.; Bod, J.; Harris, A. L.] Univ Oxford, John Radcliffe Hosp, Mol Oncol Labs, Weatherall Inst Mol Med,Canc Res UK, Oxford OX3 9DS, England	Cancer Research UK; University of Oxford	Harris, AL (corresponding author), Univ Oxford, John Radcliffe Hosp, Mol Oncol Labs, Weatherall Inst Mol Med,Canc Res UK, Oxford OX3 9DS, England.	aharris.lab@cancer.org.uk	Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409	Cancer Research UK Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Ameri K, 2004, BLOOD, V103, P1876, DOI 10.1182/blood-2003-06-1859; Atasoy U, 1998, J CELL SCI, V111, P3145; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Bowers AJ, 2003, ONCOGENE, V22, P2823, DOI 10.1038/sj.onc.1206367; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Cummins EP, 2006, P NATL ACAD SCI USA, V103, P18154, DOI 10.1073/pnas.0602235103; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Erkinheimo TL, 2005, GYNECOL ONCOL, V99, P14, DOI 10.1016/j.ygyno.2005.04.047; Erkinheimo TL, 2003, CANCER RES, V63, P7591; Evans SM, 2003, CANCER LETT, V195, P1, DOI 10.1016/S0304-3835(03)00012-0; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jousse C, 2007, J BIOL CHEM, V282, P15851, DOI 10.1074/jbc.M611723200; Kiss-Toth E, 2004, J BIOL CHEM, V279, P42703, DOI 10.1074/jbc.M407732200; KOONG AC, 1994, CANCER RES, V54, P5273; Koritzinsky M, 2006, EMBO J, V25, P1114, DOI 10.1038/sj.emboj.7600998; Koritzinsky M, 2005, RADIOTHER ONCOL, V76, P177, DOI 10.1016/j.radonc.2005.06.036; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; Mouritzen P, 2003, EXPERT REV MOL DIAGN, V3, P27, DOI 10.1586/14737159.3.1.27; Nabors LB, 2001, CANCER RES, V61, P2154; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Ord D, 2005, BIOCHEM BIOPH RES CO, V330, P210, DOI 10.1016/j.bbrc.2005.02.149; Ord D, 2003, EXP CELL RES, V286, P308, DOI 10.1016/S0014-4827(03)00070-3; Pan YX, 2005, J BIOL CHEM, V280, P34609, DOI 10.1074/jbc.M507802200; Patel NS, 2005, CANCER RES, V65, P8690, DOI 10.1158/0008-5472.CAN-05-1208; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Royds JA, 1998, J CLIN PATHOL-MOL PA, V51, P55; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Sheflin LG, 2004, BIOCHEM BIOPH RES CO, V322, P644, DOI 10.1016/j.bbrc.2004.07.173; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Wu M, 2003, J BIOL CHEM, V278, P27072, DOI 10.1074/jbc.M209814200	38	44	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4532	4543		10.1038/onc.2008.100	http://dx.doi.org/10.1038/onc.2008.100			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18408768				2022-12-17	WOS:000258077300003
J	Zhou, G; Xie, TX; Zhao, M; Jasser, SA; Younes, MN; Sano, D; Lin, J; Kupferman, ME; Santillan, AA; Patel, V; Gutkind, JS; Ei-Naggar, AK; Emberley, ED; Watson, PH; Matsuzawa, SI; Reed, JC; Myers, JN				Zhou, G.; Xie, T-X; Zhao, M.; Jasser, S. A.; Younes, M. N.; Sano, D.; Lin, J.; Kupferman, M. E.; Santillan, A. A.; Patel, V.; Gutkind, J. S.; Ei-Naggar, A. K.; Emberley, E. D.; Watson, P. H.; Matsuzawa, S-I; Reed, J. C.; Myers, J. N.			Reciprocal negative regulation between S100A7/psoriasin and beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity	ONCOGENE			English	Article						S100A7; psoriasin; beta-catenin; oral squamous cell carcinoma; head and neck squamous cell carcinoma	F-BOX PROTEIN; DEGRADATION PATHWAY; COLORECTAL-CANCER; PSORIASIN S100A7; C-MYC; EXPRESSION; COMPLEX; ACTIVATION; CALCIUM; SIAH-1	Overexpression of S100A7 (psoriasin), a small calcium-binding protein, has been associated with the development of psoriasis and carcinomas in different types of epithelia, but its precise functions are still unknown. Using human tissue specimens, cultured cell lines, and a mouse model, we found that S100A7 is highly expressed in preinvasive, well-differentiated and early staged human squamous cell carcinoma of the oral cavity (SCCOC), but little or no expression was found in poorly differentiated, later-staged invasive tumors. Interestingly, our results showed that S100A7 inhibits both SCCOC cell proliferation in vitro and tumor growth/invasion in vivo. Furthermore, we demonstrated that S100A7 is associated with the beta-catenin complex, and inhibits beta-catenin signaling by targeting beta-catenin degradation via a noncanonical mechanism that is independent of GSK3 beta-mediated phosphorylation. More importantly, our results also indicated that beta-catenin signaling negatively regulates S100A7 expression. Thus, this reciprocal negative regulation between S100A7 and beta-catenin signaling implies their important roles in tumor development and progression. Despite its high levels of expression in early stage SCCOC tumorigenesis, S100A7 actually inhibits SCCOC tumor growth/invasion as well as tumor progression. Downregulation of S100A7 in later stages of tumorigenesis increases beta-catenin signaling, leading to promotion of tumor growth and tumor progression.	[Zhou, G.; Xie, T-X; Zhao, M.; Jasser, S. A.; Younes, M. N.; Sano, D.; Lin, J.; Kupferman, M. E.; Santillan, A. A.; Myers, J. N.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; [Patel, V.; Gutkind, J. S.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA; [Ei-Naggar, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Emberley, E. D.; Watson, P. H.] BC Canc Agcy, Deeley Res Ctr, Victoria, BC, Canada; [Matsuzawa, S-I; Reed, J. C.] Burnham Inst Med Res, La Jolla, CA USA; [Myers, J. N.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Texas System; UTMD Anderson Cancer Center; British Columbia Cancer Agency; Sanford Burnham Prebys Medical Discovery Institute; University of Texas System; UTMD Anderson Cancer Center	Myers, JN (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, 1515 Holcombe Blvd,Unit 441, Houston, TX 77030 USA.	jmyers@mdanderson.org	Gutkind, J. Silvio/A-1053-2009; Lin, Jing/I-3889-2013; Sano, Daisuke/R-6591-2018; Gutkind, J. Silvio/J-1201-2016	Lin, Jing/0000-0002-2563-5083; Sano, Daisuke/0000-0002-7686-4724; Gutkind, J. Silvio/0000-0002-5150-4482; Watson, Peter/0000-0002-1642-0638	NATIONAL CANCER INSTITUTE [P30CA016672, P01CA069381] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016672, CA16672, CA69381] Funding Source: Medline; NIDCR NIH HHS [R01DE01461301] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Alowami Salem, 2003, BMC Dermatol, V3, P1, DOI 10.1186/1471-5945-3-1; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Blanpain C, 2007, CELL, V128, P445, DOI 10.1016/j.cell.2007.01.014; Broome AM, 2003, J HISTOCHEM CYTOCHEM, V51, P675, DOI 10.1177/002215540305100513; Di Nuzzo S, 2000, PHOTOCHEM PHOTOBIOL, V72, P374; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Emberley ED, 2005, CANCER RES, V65, P5696, DOI 10.1158/0008-5472.CAN-04-3927; Emberley ED, 2003, CLIN CANCER RES, V9, P2627; Emberley ED, 2003, CANCER RES, V63, P1954; Enerback C, 2002, CANCER RES, V62, P43; Filipek A, 2002, J BIOL CHEM, V277, P28848, DOI 10.1074/jbc.M203602200; Fukushima T, 2006, IMMUNITY, V24, P29, DOI 10.1016/j.immuni.2005.12.002; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; HOFFMANN HJ, 1994, J INVEST DERMATOL, V103, P370, DOI 10.1111/1523-1747.ep12395202; Kennedy RD, 2005, CANCER RES, V65, P10265, DOI 10.1158/0008-5472.CAN-05-1841; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krop I, 2005, CANCER RES, V65, P11326, DOI 10.1158/0008-5472.CAN-05-1523; Leygue E, 1996, CANCER RES, V56, P4606; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Martinsson H, 2005, EXP DERMATOL, V14, P161, DOI 10.1111/j.0906-6705.2005.00239.x; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; MOOGLUTZ C, 1995, INT J CANCER, V63, P297, DOI 10.1002/ijc.2910630225; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin Patrice J, 2003, Cancer Treat Res, V115, P169; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Reischl J, 2007, J INVEST DERMATOL, V127, P163, DOI 10.1038/sj.jid.5700488; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; TAVAKKOL A, 1994, MOL BIOL REP, V20, P75, DOI 10.1007/BF00996356; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Watson PH, 1998, INT J BIOCHEM CELL B, V30, P567, DOI 10.1016/S1357-2725(97)00066-6; Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006; Yigitbasi OG, 2004, CANCER RES, V64, P7977, DOI 10.1158/0008-5472.CAN-04-1477	37	44	45	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3527	3538		10.1038/sj.onc.1211015	http://dx.doi.org/10.1038/sj.onc.1211015			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223693				2022-12-17	WOS:000256468500004
J	Colomba, A; Courilleau, D; Ramel, D; Billadeau, DD; Espinos, E; Delsol, G; Payrastre, B; Gaits-Iacovoni, F				Colomba, A.; Courilleau, D.; Ramel, D.; Billadeau, D. D.; Espinos, E.; Delsol, G.; Payrastre, B.; Gaits-Iacovoni, F.			Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas	ONCOGENE			English	Article						anaplastic large cell lymphomas; NPM-ALK; Rho GTPases; Vav3	RHO-GTPASES; TYROSINE KINASE; PROTEINS; EXPRESSION; IDENTIFICATION; PROLIFERATION; TRANSLOCATION; ASSOCIATION; INHIBITION; APOPTOSIS	The majority of anaplastic large cell lymphomas (ALCLs) express the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) fusion protein, which is oncogenic due to its constitutive tyrosine kinase activity. Transformation by NPM-ALK not only increases proliferation, but also modifies cell shape and motility in both lymphoid and fibroblastic cells. We report that the Rac1 GTPase, a known cytoskeletal regulator, is activated by NPM-ALK in ALCL cell lines (Karpas 299 and Cost) and transfected cells (lymphoid Ba/F3 cells, NIH-3T3 fibroblasts). We have identified Vav3 as one of the exchange factors involved in Rac1 activation. Stimulation of Vav3 and Rac1 by NPM-ALK is under the control of Src kinases. It involves formation of a signaling complex between NPM-ALK, pp60(c-src), Lyn and Vav3, in which Vav3 associates with tyrosine 343 of NPM-ALK via its SH2 domain. Moreover, Vav3 is phosphorylated in NPM-ALK positive biopsies from patients suffering from ALCL, demonstrating the pathological relevance of this observation. The use of Vav3-specific shRNA and a dominant negative Rac1 mutant demonstrates the central role of GTPases in NPM-ALK elicited motility and invasion.	[Colomba, A.; Courilleau, D.; Ramel, D.; Espinos, E.; Delsol, G.; Payrastre, B.; Gaits-Iacovoni, F.] CHU Purpan, Ctr Physiopathol Toulouse Purpan, INSERM,U563, Dpt Oncogenese Signalisat & Innovat Theraperut, F-31024 Toulouse 3, France; [Colomba, A.; Courilleau, D.; Ramel, D.; Espinos, E.; Delsol, G.; Payrastre, B.; Gaits-Iacovoni, F.] Univ Toulouse III Paul Sabatier, IFR30, Toulouse, France; [Billadeau, D. D.] Mayo Clin, Coll Med, Div Dev Oncol Res, Rochester, MN USA; [Billadeau, D. D.] Mayo Clin, Coll Med, Dept Immunol, Rochester, MN USA	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Mayo Clinic; Mayo Clinic	Gaits-Iacovoni, F (corresponding author), CHU Purpan, Ctr Physiopathol Toulouse Purpan, INSERM,U563, Dpt Oncogenese Signalisat & Innovat Theraperut, BP 3028, F-31024 Toulouse 3, France.	frgaits@toulouse.inserm.fr	Espinos, Estelle/A-4661-2015	Espinos, Estelle/0000-0002-5693-8941; , Bernard/0000-0002-8693-0190; Colomba, Audrey/0000-0002-5612-8519; Gaits-Iacovoni, Frederique/0000-0002-9853-0442				Ambrogio C, 2005, BLOOD, V106, P3907, DOI 10.1182/blood-2005-03-1204; Amin HM, 2003, ONCOGENE, V22, P5399, DOI 10.1038/sj.onc.1206849; Armstrong F, 2004, ONCOGENE, V23, P6071, DOI 10.1038/sj.onc.1207813; Aznar S, 2004, CANCER LETT, V206, P181, DOI 10.1016/j.canlet.2003.08.035; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Bassermann F, 2002, J BIOL CHEM, V277, P12437, DOI 10.1074/jbc.M112397200; Benard V, 2002, METHOD ENZYMOL, V345, P349; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Charvet C, 2005, J BIOL CHEM, V280, P15289, DOI 10.1074/jbc.M500275200; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Cho YJ, 2005, MOL CELL BIOL, V25, P5777, DOI 10.1128/MCB.25.13.5777-5785.2005; Contri A, 2005, J CLIN INVEST, V115, P369, DOI 10.1172/JC1200522094; Crockett DK, 2004, ONCOGENE, V23, P2617, DOI 10.1038/sj.onc.1207398; Cussac D, 2004, BLOOD, V103, P1464; Cussac D, 2006, PROTEOMICS, V6, P3210, DOI 10.1002/pmic.200500647; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Falini B, 1998, AM J PATHOL, V153, P875, DOI 10.1016/S0002-9440(10)65629-5; Fawal M, 2006, BLOOD, V108, P2780, DOI 10.1182/blood-2006-04-014902; Fritz G, 2006, CURR CANCER DRUG TAR, V6, P1, DOI 10.2174/156800906775471752; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Genth H, 2006, FEBS LETT, V580, P3565, DOI 10.1016/j.febslet.2006.04.100; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Honorat JF, 2006, BLOOD, V107, P4130, DOI 10.1182/blood-2005-06-2421; Hornstein I, 2004, CELL SIGNAL, V16, P1, DOI 10.1016/S0898-6568(03)00110-4; Lamant L, 2004, LEUKEMIA, V18, P1693, DOI 10.1038/sj.leu.2403464; Lamant L, 1996, BLOOD, V87, P284; Lamant L, 2007, BLOOD, V109, P2156, DOI 10.1182/blood-2006-06-028969; Lim MS, 2006, MOL CELL PROTEOMICS, V5, P1787, DOI 10.1074/mcp.R600005-MCP200; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Llorca O, 2005, EMBO J, V24, P1330, DOI 10.1038/sj.emboj.7600617; Marzec M, 2007, ONCOGENE, V26, P813, DOI 10.1038/sj.onc.1209843; Marzec M, 2005, LAB INVEST, V85, P1544, DOI 10.1038/labinvest.3700348; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Petit P, 2003, CELL MICROBIOL, V5, P761, DOI 10.1046/j.1462-5822.2003.00309.x; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Theodorescu D, 2004, CLIN CANCER RES, V10, P3800, DOI 10.1158/1078-0432.CCR-03-0653; Thompson MA, 2005, HUM PATHOL, V36, P494, DOI 10.1016/j.humpath.2005.03.004; Titus B, 2005, CRIT REV EUKAR GENE, V15, P103, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i2.20; Zakaria S, 2004, J EXP MED, V199, P429, DOI 10.1084/jem.20031228; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000	47	44	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2728	2736		10.1038/sj.onc.1210921	http://dx.doi.org/10.1038/sj.onc.1210921			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	17998938				2022-12-17	WOS:000255259500007
J	Choi, D; Lee, SJ; Hong, S; Kim, IH; Kang, S				Choi, D.; Lee, S-J; Hong, S.; Kim, I-H; Kang, S.			Prohibitin interacts with RNF2 and regulates E2F1 function via dual pathways	ONCOGENE			English	Article						prohibitin; RNF2; E2F1; p16; cell cycle	RB; REPRESSION; SUPPRESSOR; P53	Prohibitin, a tumor suppresser protein, plays an important role in the transcriptional regulation of various genes involved in cell-cycle control and proliferation. Recent studies have reported that the growth-suppressive property of the prohibitin protein is exhibited in its physical interaction with E2F family proteins and its subsequent repression of their transcriptional activity. Herein, we report that prohibitin interacts with RING finger protein 2 (RNF2), a member of the PcG (polycomb-group) family of proteins, and that the two proteins regulate the activity of E2F1 via dual pathways: the direct, prohibitin-mediated pathway and the indirect, p16-mediated pathway of E2F1 transcriptional regulation. Co-immunoprecipitation experiments showed that endogenous prohibitin interacts with endogenous RNF2. Interestingly, the expressed amounts of RNF2 and prohibitin were interdependently affected at the post-translational level. Furthermore, the depletion of either endogenous RNF2 or prohibitin using the RNA interference technique increased the level of p16 protein expression, resulting in a decrease in the transcriptional activity of E2F1 via the p16-CDK4-Rb pathway. In addition, chromatin immunoprecipitation assays showed that RNF2 was recruited to E2F1-response promoters along with prohibitin to inhibit the transcriptional activity of E2F1. Cell proliferation was also regulated by the prohibitin-RNF2 interaction. These results suggest that the RNF2-prohibitin complex regulates the activity of E2F1 via dual pathways.	[Choi, D.; Lee, S-J; Hong, S.; Kim, I-H; Kang, S.] Korea Univ, Grad Sch Life Sci & Biotechnol, Seoul 136701, South Korea	Korea University	Kang, S (corresponding author), Korea Univ, Grad Sch Life Sci & Biotechnol, Seoul 136701, South Korea.	skang@korea.ac.kr						Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Harbour JW, 2000, CURR OPIN CELL BIOL, V12, P685, DOI 10.1016/S0955-0674(00)00152-6; Kim H, 2004, J AM SOC NEPHROL, V15, P2042, DOI 10.1097/01.ASN.0000133490.00348.59; Lee SJ, 2005, BIOCHEM J, V389, P457, DOI 10.1042/BJ20041982; Lee SJ, 2001, FEBS LETT, V503, P61, DOI 10.1016/S0014-5793(01)02689-8; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; SATO T, 1993, GENOMICS, V17, P762, DOI 10.1006/geno.1993.1402; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sherr CJ, 2000, CANCER RES, V60, P3689; Voncken JW, 2003, P NATL ACAD SCI USA, V100, P2468, DOI 10.1073/pnas.0434312100; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Yoo YA, 2005, MOL CELL BIOL, V25, P6603, DOI 10.1128/MCB.25.15.6603-6616.2005; Zhu LA, 2005, EUR J CANCER, V41, P2415, DOI 10.1016/j.ejca.2005.08.009	18	44	47	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2008	27	12					1716	1725		10.1038/sj.onc.1210806	http://dx.doi.org/10.1038/sj.onc.1210806			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17873902				2022-12-17	WOS:000253962100007
J	Nieto-Miguel, T; Gajate, C; Gonzalez-Camacho, F; Mollinedo, F				Nieto-Miguel, T.; Gajate, C.; Gonzalez-Camacho, F.; Mollinedo, F.			Proapoptotic role of Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy	ONCOGENE			English	Article						Hsp90; JNK; lipid rafts; apoptosis; edelfosine; alkyl-lysophospholipid	HUMAN LEUKEMIC-CELLS; FAS/CD95 DEATH RECEPTOR; REGULATES AKT KINASE; COLON-CANCER CELLS; ET-18-OCH3 EDELFOSINE; INDUCED APOPTOSIS; HEAT-SHOCK-PROTEIN-90 FUNCTION; SELECTIVE INDUCTION; CYCLE ARREST; TUMOR-CELLS	Heat shock protein 90 (Hsp90) is a survival signaling chaperone and a cancer chemotherapeutic target. However, we have found that inhibitors of Hsp90 diminished the apoptotic response induced in leukemic cells by the antitumor alkyl-lysophospholipid analog edelfosine, which acts through lipid raft reorganization. Edelfosine treatment recruited Hsp90, c-Jun N-terminal kinase (JNK) and apoptotic molecules in lipid rafts, but not the JNK regulators apoptosis signal-regulating kinase 1 (ASK1) and Daxx, or the survival signaling molecules extracellular signal-regulated kinase (ERK) and Akt. Following edelfosine treatment, Hsp90 bound to JNK in lipid rafts and Hsp90-JNK clusters were identified at the plasma membrane by immunoelectron microscopy. Hsp90 inhibition reduced JNK protein level in lipid rafts and turned proapoptotic persistent JNK activation into a transient response in edelfosine-treated cells. Decrease in edelfosine-induced JNK activation and apoptosis by Hsp90 inhibition was prevented through proteasome inhibition, suggesting that Hsp90 inhibition diminishes apoptosis by promoting JNK protein degradation. Expression of ASK1 dominant negative mutant did not affect JNK activation and apoptosis following edelfosine treatment. These data indicate that lipid raft-recruited JNK is ASK1-independent and becomes a novel Hsp90 client protein. Our results reveal a new chaperoning role of Hsp90 on JNK-mediated apoptosis following its recruitment in lipid rafts.	[Nieto-Miguel, T.; Gajate, C.; Gonzalez-Camacho, F.; Mollinedo, F.] Univ Salamanca, Ctr Invest Canc, Inst Biol Mol & Celular Canc, CSIC, E-37007 Salamanca, Spain; [Gajate, C.] Hosp Univ Salamanca, Unidad Invest, Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca	Mollinedo, F (corresponding author), Univ Salamanca, Ctr Invest Canc, Inst Biol Mol & Celular Canc, CSIC, Campus Miguel Unamuno, E-37007 Salamanca, Spain.	fmollin@usal.es	2008, Ibsal/A-1268-2012; González-Camacho, Fernando/P-1610-2014; Nieto Miguel, Teresa/L-1496-2016	Gajate, Consuelo/0000-0003-0604-6459; Nieto Miguel, Teresa/0000-0002-8374-5379; Gonzalez-Camacho, Fernando/0000-0003-3175-9004				Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chiosis G, 2001, BIOORG MED CHEM LETT, V11, P909, DOI 10.1016/S0960-894X(01)00099-3; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z; Gajate C, 2005, J BIOL CHEM, V280, P11641, DOI 10.1074/jbc.M411781200; Gajate C, 2000, CANCER RES, V60, P2651; Gajate C, 2004, J EXP MED, V200, P353, DOI 10.1084/jem.20040213; Gajate C, 2002, CURR DRUG METAB, V3, P491, DOI 10.2174/1389200023337225; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Gajate C, 1998, MOL PHARMACOL, V53, P602, DOI 10.1124/mol.53.4.602; Gajate C, 2007, BLOOD, V109, P711, DOI 10.1182/blood-2006-04-016824; Georgakis GV, 2006, CLIN CANCER RES, V12, P584, DOI 10.1158/1078-0432.CCR-05-1194; George P, 2005, BLOOD, V105, P1768, DOI 10.1182/blood-2004-09-3413; Lacour S, 2004, CANCER RES, V64, P3593, DOI 10.1158/0008-5472.CAN-03-2787; Mollinedo F, 2003, J IMMUNOL, V170, P1034, DOI 10.4049/jimmunol.170.2.1034; Mollinedo F, 1997, CANCER RES, V57, P1320; Mollinedo F, 2004, CURR MED CHEM, V11, P3163, DOI 10.2174/0929867043363703; MOLLINEDO F, 1993, BIOCHEM BIOPH RES CO, V192, P603, DOI 10.1006/bbrc.1993.1458; MOLLINEDO F, 1994, BIOCHEM J, V302, P325, DOI 10.1042/bj3020325; Mollinedo F, 2006, DRUG RESIST UPDATE, V9, P51, DOI 10.1016/j.drup.2006.04.002; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Nieto-Miguel T, 2006, J BIOL CHEM, V281, P14833, DOI 10.1074/jbc.M511251200; Ruiter GA, 1999, CANCER RES, V59, P2457; Solit DB, 2003, CANCER RES, V63, P2139; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; van der Luit AH, 2002, J BIOL CHEM, V277, P39541, DOI 10.1074/jbc.M203176200; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zaremberg V, 2005, J BIOL CHEM, V280, P38047, DOI 10.1074/jbc.M502849200; Zhang H, 2004, J BIOL CHEM, V279, P19457, DOI 10.1074/jbc.M311377200; Zhao RM, 2005, CELL, V120, P715, DOI 10.1016/j.cell.2004.12.024	32	44	45	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2008	27	12					1779	1787		10.1038/sj.onc.1210816	http://dx.doi.org/10.1038/sj.onc.1210816			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891170				2022-12-17	WOS:000253962100013
J	Haraguchi, K; Ohsugi, M; Abe, Y; Semba, K; Akiyama, T; Yamamoto, T				Haraguchi, K.; Ohsugi, M.; Abe, Y.; Semba, K.; Akiyama, T.; Yamamoto, T.			Ajuba negatively regulates the Wnt signaling pathway by promoting GSK-3 beta-mediated phosphorylation of beta-catenin	ONCOGENE			English	Article						Wnt; beta-catenin; GSK-3 beta; Ajuba; phosphorylation	LIM PROTEIN FHL2; CYCLIN D1; AXIN; CANCER; EMBRYOGENESIS; FIBROBLASTS; ACTIVATION; INTERACTS; NUCLEUS; CELLS	The Wnt signaling pathway is essential for embryonic development and carcinogenesis. Upon Wnt stimulation, beta-catenin is stabilized and associates with T-cell factor or lymphoid enhancing factor, thereby activating transcription of target genes. In the absence of Wnt stimulation, the level of beta-catenin is reduced via glycogen synthase kinase (GSK)-beta b-mediated phosphorylation and subsequent proteasome-dependent degradation. Here, we report the identification of Ajuba as a negative regulator of the Wnt signaling pathway. Ajuba is a member of LIM domain-containing proteins that contribute to cell fate determination and regulate cell proliferation and differentiation. We found that enforced expression of Ajuba destabilized beta-catenin and suppressed target gene expression. Ajuba promoted GSK-3 beta-mediated phosphorylation of beta-catenin by reinforcing the association between beta-catenin and GSK-3 beta. Furthermore, Wnt stimulation induced both accumulation of beta-catenin and destabilization of Ajuba. Our findings suggest that Ajuba is important for regulation of the Wnt signaling pathway.	[Haraguchi, K.; Ohsugi, M.; Abe, Y.; Yamamoto, T.] Univ Tokyo, Inst Med Sci, Div Oncol, Tokyo 1088639, Japan; [Semba, K.] Univ Tokyo, Inst Med Sci, Div Cell & Mol Biol, Tokyo 1088639, Japan; [Akiyama, T.] Univ Tokyo, Inst Mol & Cell Biol, Lab Mol & Genet Informat, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Oncol, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp	Ohsugi, Miho/AAY-9339-2020	Ohsugi, Miho/0000-0003-0288-3428; Abe, Yoshinori/0000-0003-3894-494X				Adachi S, 2004, CANCER RES, V64, P8496, DOI 10.1158/0008-5472.CAN-04-2254; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; CADIGAM KM, 1998, GENE DEV, V14, P156; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Goyal RK, 1999, MOL CELL BIOL, V19, P4379; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kanungo J, 2000, MOL BIOL CELL, V11, P3299, DOI 10.1091/mbc.11.10.3299; Labalette C, 2004, MOL CELL BIOL, V24, P10689, DOI 10.1128/MCB.24.24.10689-10702.2004; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pratt SJ, 2005, J CELL BIOL, V168, P813, DOI 10.1083/jcb.200406083; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Shibamoto S, 1998, GENES CELLS, V3, P659; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tago K, 2000, GENE DEV, V14, P1741; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Wei Y, 2003, J BIOL CHEM, V278, P5188, DOI 10.1074/jbc.M207216200	26	44	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2008	27	3					274	284		10.1038/sj.onc.1210644	http://dx.doi.org/10.1038/sj.onc.1210644			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621269				2022-12-17	WOS:000252256000003
J	Gudmundsdottir, K; Lord, CJ; Ashworth, A				Gudmundsdottir, K.; Lord, C. J.; Ashworth, A.			The proteasome is involved in determining differential utilization of double-strand break repair pathways	ONCOGENE			English	Article						DSS1; BRCA2; proteasome; double-strand break	SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; USTILAGO-MAYDIS; DNA-REPAIR; DSS1; STABILITY; YEAST; BRCA2; RECOMBINATION; PROTEIN	The DSS1 protein interacts with the breast cancer susceptibility protein BRCA2 that plays an integral role in the repair of DNA double-strand breaks (DSBs). DSS1 has also been shown to interact with components of the 26S proteasome in Saccharomyces cerevisiae and in human tumour cells. This raises the possibility of functional interplay between the DNA repair machinery and the proteasome. We show here that human DSS1 interacts with the RPN3 and RPN7 proteasome subunits and de. ne regions of DSS1 important for the interactions with RPN3, RPN7 and BRCA2. We also show that BRCA2 interacts with RPN3 and RPN7 and that the BRCA2/RPN7 interaction is independent of DSS1. Finally, and most significantly, we demonstrate that the proteolytic activity of the proteasome is a determinant of the choice of DSB repair pathway; inhibition of proteasome proteolytic activity results in an increase in the utilization of potentially mutagenic single-strand annealing at the expense of a reduction in the level of error-free gene conversion. This confirms a functional link between DSB repair and proteasomal activity.	Canc Res Inst, Breakthrough Breast Canc Res Ctr, Gene Funct Lab, London, England	University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, Fulham Rd, London SW3 6JB, England.	alan.ashworth@icr.ac.uk	Lord, Christopher J/B-3295-2012; Lord, Christopher/AAX-7130-2021	Lord, Christopher J/0000-0002-3226-0515; 	Cancer Research UK [A8363] Funding Source: Medline; Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Cancer Research UK(Cancer Research UK); Breast Cancer Now		Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; Funakoshi M, 2004, J CELL SCI, V117, P6447, DOI 10.1242/jcs.01575; Gudmundsdottir K, 2004, EMBO REP, V5, P989, DOI 10.1038/sj.embor.7400255; Isono E, 2005, J BIOL CHEM, V280, P6537, DOI 10.1074/jbc.M409364200; Josse L, 2006, BIOCHEM J, V393, P303, DOI 10.1042/BJ20051238; Kojic M, 2005, MOL CELL BIOL, V25, P2547, DOI 10.1128/MCB.25.7.2547-2557.2005; Kojic M, 2003, MOL CELL, V12, P1043, DOI 10.1016/S1097-2765(03)00367-8; Krogan NJ, 2004, MOL CELL, V16, P1027, DOI 10.1016/j.molcel.2004.11.033; Li J, 2006, ONCOGENE, V25, P1186, DOI 10.1038/sj.onc.1209153; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Sin N, 1999, BIOORG MED CHEM LETT, V9, P2283, DOI 10.1016/S0960-894X(99)00376-5; Sone T, 2004, J BIOL CHEM, V279, P28807, DOI 10.1074/jbc.M403165200; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837	16	44	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2007	26	54					7601	7606		10.1038/sj.onc.1210579	http://dx.doi.org/10.1038/sj.onc.1210579			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17563742				2022-12-17	WOS:000251282100014
J	Pauleau, AL; Larochette, N; Giordanetto, F; Scholz, SR; Poncet, D; Zamzami, N; Goldmacher, VS; Kroemer, G				Pauleau, A-L; Larochette, N.; Giordanetto, F.; Scholz, S. R.; Poncet, D.; Zamzami, N.; Goldmacher, V. S.; Kroemer, G.			Structure-function analysis of the interaction between Bax and the cytomegalovirus-encoded protein vMIA	ONCOGENE			English	Article						cytomegalovirus; vMIA; mitochondria; Bak; Bax; apoptosis	CELL-DEATH; INDUCED APOPTOSIS; BCL-XL; MITOCHONDRIA; INHIBITOR; INFECTION; CANCER; LOCALIZATION; RECOGNITION; ACTIVATION	The viral mitochondrial inhibitor of apoptosis ( vMIA) encoded by the human cytomegalovirus exerts cytopathic effects and neutralizes the proapoptotic endogenous Bcl-2 family member Bax by recruiting it to mitochondria, inducing its oligomerization and membrane insertion. Using a combination of computational modeling and mutational analyses, we addressed the structure-function relationship of the molecular interaction between the protein Bax and the viral antiapoptotic protein vMIA. We propose a model in which vMIA exhibits an overall fold similar to Bcl-X-L. In contrast to Bcl-X-L, however, this predicted conformation of vMIA does not bind to the BH3 domain of Bax and rather engages in electrostatic interactions that involve a stretch of amino acids between the BH3 and BH2 domains of Bax and an alpha-helical domain located within the previously defined Bax-binding domain of vMIA, between the putative BH1-like and BH2-like domains. According to this model, vMIA is likely to bind Bax preferentially in its membrane-inserted conformation. The capacity of vMIA to cause fragmentation of the mitochondrial network and disorganization of the actin cytoskeleton is independent of its Bax-binding function. We found that Delta 131-147 vMIA mutant, which lacks both the Bax-binding function and cell-death suppression but has intact mitochondria-targeting capacity, is similar to vMIA in its ability to disrupt the mitochondrial network and to disorganize the actin cytoskeleton. vMIA Delta 131-147 is a dominant-negative inhibitor of the antiapoptotic function of wild-type vMIA. Our experiments with vMIA Delta 131-147 suggest that vMIA forms homo-oligomers, which may engage in cooperative and/or multivalent interactions with Bax, leading to its functional neutralization.	Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; Univ Paris 11, Fac Med, Villejuif, France; AstraZeneca R&D, Lead Generat, Molndal, Sweden; ImmunoGen Inc, Cambridge, MA USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; AstraZeneca; ImmunoGen, Inc.	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, PR1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Kroemer, Guido/AAY-9859-2020; Poncet, Delphine A/A-7190-2016; KROEMER, Guido/B-4263-2013; LAROCHETTE, Nathanael/R-4298-2017; Giordanetto, Fabrizio/E-2811-2012	Poncet, Delphine A/0000-0003-0446-5262; KROEMER, Guido/0000-0002-9334-4405; LAROCHETTE, Nathanael/0000-0002-7936-678X; Goldmakher, Viktor/0000-0001-6130-4436				ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Arnoult D, 2004, P NATL ACAD SCI USA, V101, P7988, DOI 10.1073/pnas.0401897101; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Day CL, 2005, J BIOL CHEM, V280, P4738, DOI 10.1074/jbc.M411434200; Froberg MK, 2004, ANN CLIN LAB SCI, V34, P123; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Garcia-Saez AJ, 2004, BIOCHEMISTRY-US, V43, P10930, DOI 10.1021/bi036044c; Goldmacher VS, 2005, APOPTOSIS, V10, P251, DOI 10.1007/s10495-005-0800-z; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Harkins L, 2002, LANCET, V360, P1557, DOI 10.1016/S0140-6736(02)11524-8; Hassan M, 1996, MOL DIVERS, V2, P64, DOI 10.1007/BF01718702; Hayajneh WA, 2001, VIROLOGY, V279, P233, DOI 10.1006/viro.2000.0726; Hoever G, 2005, BIOCHEM BIOPH RES CO, V326, P395, DOI 10.1016/j.bbrc.2004.11.042; Huang JH, 2005, CIRCULATION, V112, P76, DOI 10.1161/CIRCULATIONAHA.105.535740; Jackson RM, 1998, J MOL BIOL, V276, P265, DOI 10.1006/jmbi.1997.1519; Jurak I, 2006, EMBO J, V25, P2634, DOI 10.1038/sj.emboj.7601133; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Lang-Rollin I, 2005, APOPTOSIS, V10, P809, DOI 10.1007/s10495-005-0378-5; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Mavinakere MS, 2006, J VIROL, V80, P6771, DOI 10.1128/JVI.00492-06; McCormick AL, 2005, J VIROL, V79, P12205, DOI 10.1128/JVI.79.19.12205-12217.2005; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; McGuffin LJ, 2003, BIOINFORMATICS, V19, P874, DOI 10.1093/bioinformatics/btg097; McMartin C, 1997, J COMPUT AID MOL DES, V11, P333, DOI 10.1023/A:1007907728892; Michelson S, 2004, HUM IMMUNOL, V65, P465, DOI 10.1016/j.humimm.2004.02.002; Moont G, 1999, PROTEINS, V35, P364, DOI 10.1002/(SICI)1097-0134(19990515)35:3<364::AID-PROT11>3.0.CO;2-4; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Poncet D, 2006, J CELL BIOL, V174, P985, DOI 10.1083/jcb.200604069; Reboredo M, 2004, J GEN VIROL, V85, P3555, DOI 10.1099/vir.0.80379-0; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Samanta M, 2003, J UROLOGY, V170, P998, DOI 10.1097/01.ju.0000080263.46164.97; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Skaletskaya A, 2001, P NATL ACAD SCI USA, V98, P7829, DOI 10.1073/pnas.141108798; Smith MS, 2004, J LEUKOCYTE BIOL, V76, P65, DOI 10.1189/jlb.1203621; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Terrasson J, 2005, CANCER RES, V65, P2787, DOI 10.1158/0008-5472.CAN-04-2019; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281	47	44	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2007	26	50					7067	7080		10.1038/sj.onc.1210511	http://dx.doi.org/10.1038/sj.onc.1210511			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17496930				2022-12-17	WOS:000250715000001
J	Stang, MT; Armstrong, MJ; Watson, GA; Sung, KY; Liu, Y; Ren, B; Yim, JH				Stang, M. T.; Armstrong, M. J.; Watson, G. A.; Sung, K. Y.; Liu, Y.; Ren, B.; Yim, J. H.			Interferon regulatory factor-1-induced apoptosis mediated by a ligand-independent fas-associated death domain pathway in breast cancer cells	ONCOGENE			English	Article						apoptosis; IRF-1; breast cancer; FADD	TRAIL-INDUCED APOPTOSIS; FACTOR-I; GROWTH-INHIBITION; TUMOR-GROWTH; IRF-1; GAMMA; ACTIVATION; EXPRESSION; INDUCTION; CASPASE-8	Interferon (IFN) regulatory factor-1 (IRF-1) is a transcription factor that has apoptotic anti-tumor activity. In breast cancer cell types, IRF-1 is implicated in mediating apoptosis by both novel and established anti-tumor agents, including the anti-estrogens tamoxifen and faslodex. Here we demonstrate that in MDA468 breast cancer cells, apoptosis by IFN-gamma is mediated by IRF-1 and IFN-gamma, and IRF-1-induced apoptosis is caspase-mediated. IRF-1 induction results in cleavage of caspase-8, -3 and -7, and application of caspase inhibitors attenuate activated cleavage products. IRF-1-induced apoptosis involves caspase-8 since apoptosis is significantly decreased by the caspase-8-specific inhibitor IETD, c-FLIP expression and in caspase-8-deficient cancer cells. Furthermore, we demonstrate that IRF-1-induced apoptosis requires fas-associated death domain (FADD) since dominant-negative FADD expressing cells resist IRF-1-induced apoptosis and activated downstream products. Immunofluorescent studies demonstrate perinuclear colocalization of FADD and caspase-8. Despite the known role of FADD in mediating death-ligand induced apoptosis, neutralizing antibodies against classical death receptors do not inhibit IRF-1 induced apoptosis, and no secreted ligand appears to be involved since MDA468 coincubated with IRF-1 transfected cells do not apoptose. Therefore, we demonstrate that IRF-1 induces a ligand-independent FADD/caspase-8-mediated apoptosis in breast cancer cells.	Univ Pittsburgh, Pittsburgh Canc Inst, Dept Surg, Div Surg Oncol, Pittsburgh, PA 15261 USA; Catholic Univ Korea, Dept Surg, Seoul, South Korea	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Catholic University of Korea	Yim, JH (corresponding author), Univ Pittsburgh, Pittsburgh Canc Inst, Dept Surg, Div Surg Oncol, 497 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	yimjh@upmc.edu	Yim, John/R-7555-2019	Watson, Gregory/0000-0001-7729-4818	NCI NIH HHS [CA098403] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA098403] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Billecke CA, 2002, ONCOGENE, V21, P4481, DOI 10.1038/sj.onc.1205546; Bouker KB, 2004, CANCER RES, V64, P4030, DOI 10.1158/0008-5472.CAN-03-3602; Bowie ML, 2007, ONCOGENE, V26, P2017, DOI 10.1038/sj.onc.1210013; Bowie ML, 2004, ONCOGENE, V23, P8743, DOI 10.1038/sj.onc.1208120; Gupta V, 2005, P NATL ACAD SCI USA, V102, P3219, DOI 10.1073/pnas.0409709102; Keane MM, 1996, CANCER RES, V56, P4791; Kim EJ, 2002, J CELL BIOCHEM, V85, P369, DOI 10.1002/jcb.10142; Kim PKM, 2004, ONCOGENE, V23, P1125, DOI 10.1038/sj.onc.1207023; Kirchhoff S, 1999, ONCOGENE, V18, P3725, DOI 10.1038/sj.onc.1202704; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; Kirchhoff S, 2002, J IMMUNOL, V168, P1226, DOI 10.4049/jimmunol.168.3.1226; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Park SY, 2004, EUR J BIOCHEM, V271, P4222, DOI 10.1111/j.1432-1033.2004.04362.x; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Pizzoferrato E, 2004, CANCER RES, V64, P8381, DOI 10.1158/0008-5472.CAN-04-2223; Ruiz-Ruiz C, 2004, J BIOL CHEM, V279, P19712, DOI 10.1074/jbc.M313023200; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Shinoura N, 2000, HUM GENE THER, V11, P1123, DOI 10.1089/10430340050015185; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Wachter T, 2004, J BIOL CHEM, V279, P52824, DOI 10.1074/jbc.M409554200; Wang X, 2005, MOL CELL BIOL, V25, P4742, DOI 10.1128/MCB.25.11.4742-4751.2005; Yim JH, 2003, J INTERF CYTOK RES, V23, P501, DOI 10.1089/10799900360708623; Yim JH, 1997, J IMMUNOL, V158, P1284	27	44	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6420	6430		10.1038/sj.onc.1210470	http://dx.doi.org/10.1038/sj.onc.1210470			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452973				2022-12-17	WOS:000249737600006
J	Macpherson, IR; Hooper, S; Serrels, A; McGarry, L; Ozanne, BW; Harrington, K; Frame, MC; Sahai, E; Brunton, VG				Macpherson, I. R.; Hooper, S.; Serrels, A.; McGarry, L.; Ozanne, B. W.; Harrington, K.; Frame, M. C.; Sahai, E.; Brunton, V. G.			p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism	ONCOGENE			English	Article						p120; E-cadherin; invasion; phosphorylation	EPIDERMAL-GROWTH-FACTOR; MEDIATED TRANSCRIPTIONAL REPRESSION; E-CADHERIN EXPRESSION; RHO-FAMILY GTPASES; P120 CATENIN; NUCLEAR-LOCALIZATION; TYROSINE KINASES; COLON-CARCINOMA; BREAST-CANCER; TUMOR-CELLS	Loss of E-cadherin-mediated cell-cell junctions has been correlated with cancer cell invasion and poor patient survival. p120-catenin has emerged as a key player in promoting E-cadherin stability and adherens junction integrity and has been proposed as a potential invasion suppressor by preventing release of cells from the constraints imposed by cadherin-mediated cell-cell adhesion. However, it has been proposed that tyrosine phosphorylation of p120 may contribute to cadherin-dependent junction disassembly during invasion. Here, we use small interfering RNA ( siRNA) in A431 cells to show that knockdown of p120 promotes two-dimensional migration of cells. In contrast, p120 knockdown impairs epidermal growth factor-induced A431 invasion into three-dimensional matrix gels or in organotypic culture, whereas re-expression of siRNA-resistant p120, or a p120 isoform that cannot be phosphorylated on tyrosine, restores the collective mode of invasion employed by A431 cells in vitro. Thus, p120 promotes A431 cell invasion in a phosphorylation-independent manner. We show that the collective invasion of A431 cells depends on the presence of cadherin-mediated (P- and E-cadherin) cell-cell contacts, which are lost in cells where p120 expression is knocked down. Furthermore, membranous p120 is maintained in invasive squamous cell carcinomas in tumours suggesting that p120 may be important for the collective invasion of tumours cells in vivo.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Canc Res UK London Res Inst, London, England; Inst Canc Res, London SW3 6JB, England	Beatson Institute; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Brunton, VG (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	v.brunton@beatson.gla.ac.uk		Frame, Margaret/0000-0001-5882-1942; Harrington, Kevin/0000-0002-6014-348X; Macpherson, Iain/0000-0003-4295-8885; Sahai, Erik/0000-0002-3932-5086				Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Ardern H, 2006, CELL MOTIL CYTOSKEL, V63, P6, DOI 10.1002/cm.20101; Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829; Bellovin DI, 2005, CANCER RES, V65, P10938, DOI 10.1158/0008-5472.CAN-05-1947; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Brunton VG, 2004, BBA-MOL CELL RES, V1692, P121, DOI 10.1016/j.bbamcr.2004.04.010; Cozzolino M, 2003, MOL BIOL CELL, V14, P1964, DOI 10.1091/mbc.E02-08-0469; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; Davis MA, 2006, DEV CELL, V10, P21, DOI 10.1016/j.devcel.2005.12.004; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Friedl P, 2004, INT J DEV BIOL, V48, P441, DOI 10.1387/ijdb.041821pf; Grosheva I, 2001, J CELL SCI, V114, P695; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Ishizaki Y, 2004, J DERMATOL SCI, V34, P99, DOI 10.1016/j.jdermsci.2003.12.001; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; Jensen PJ, 1997, CELL TISSUE RES, V288, P307, DOI 10.1007/s004410050816; Keirsebilck A, 1998, GENOMICS, V50, P129, DOI 10.1006/geno.1998.5325; Kelly KF, 2004, J CELL SCI, V117, P2675, DOI 10.1242/jcs.01101; Kurokawa K, 2004, MOL BIOL CELL, V15, P1003, DOI 10.1091/mbc.E03-08-0609; Lim YP, 2003, MOL CANCER THER, V2, P1369; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Mariner DJ, 2004, J CELL SCI, V117, P1339, DOI 10.1242/jcs.01001; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; MCLEAN GW, 1991, J IMMUNOL METHODS, V137, P149, DOI 10.1016/0022-1759(91)90019-C; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Ozawa M, 2001, J CELL SCI, V114, P503; Park JI, 2005, DEV CELL, V8, P843, DOI 10.1016/j.devcel.2005.04.010; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Perez-Moreno M, 2006, CELL, V124, P631, DOI 10.1016/j.cell.2005.11.043; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; PLUMB JA, 1989, CANCER RES, V49, P4435; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; Scott LA, 2004, MOL CELL BIOL, V24, P1540, DOI 10.1128/MCB.24.4.1540-1559.2004; Shibata T, 2004, AM J PATHOL, V164, P2269, DOI 10.1016/S0002-9440(10)63783-2; Spring CM, 2005, EXP CELL RES, V305, P253, DOI 10.1016/j.yexcr.2005.01.007; Strathdee G, 2002, SEMIN CANCER BIOL, V12, P373, DOI 10.1016/S1044-579X(02)00057-3; Thelemann A, 2005, MOL CELL PROTEOMICS, V4, P356, DOI 10.1074/mcp.M400118-MCP200; Thoreson MA, 2002, DIFFERENTIATION, V70, P583, DOI 10.1046/j.1432-0436.2002.700911.x; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7; Xia XB, 2003, BIOCHEMISTRY-US, V42, P9195, DOI 10.1021/bi034597h; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Yanagisawa M, 2006, J CELL BIOL, V174, P1087, DOI 10.1083/jcb.200605022	50	44	45	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2007	26	36					5214	5228		10.1038/sj.onc.1210334	http://dx.doi.org/10.1038/sj.onc.1210334			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17334396				2022-12-17	WOS:000248674200005
J	de Cerio, ALD; Zabalegui, N; Rodriguez-Calvillo, M; Inoges, S; Bendandi, M				de Cerio, A. Lopez-Diaz; Zabalegui, N.; Rodriguez-Calvillo, M.; Inoges, S.; Bendandi, M.			Anti-idiotype antibodies in cancer treatment	ONCOGENE			English	Review						idiotype; lymphoma; solid tumors; immunotherapy	B-CELL LYMPHOMA; HUMORAL IMMUNE-RESPONSE; NON-HODGKINS-LYMPHOMA; COLONY-STIMULATING FACTOR; IDIOTYPE VACCINATION; DNA VACCINES; T-CELL; CLINICAL BENEFIT; DENDRITIC CELLS; HIGH-RISK	As a cancer immunotherapy tool, idiotypes (Ids) have been used in different ways over the last three decades, depending on the actual human tumor cell target. It all started with passive, monoclonal, anti-Id antibody treatment of B-cell lymphoma, a setting in which results were tantalizing, but logistics unsustainable. It then moved toward the development of anti-Id vaccines for the treatment of the same tumors, a setting in which we have recently provided the first formal proof of principle of clinical benefit associated with the use of a human cancer vaccine. Meanwhile, it also expanded in the direction of exploiting the antigenic mimicry of some Ids with Id-unrelated, tumor-associated antigens for the immunotherapy of a number of solid tumors, a setting in which clinical results are still far from being consolidated. All in all, over the years Id-based immunotherapy has paved the way for a number of seminal therapeutic improvements for cancer patients, including the development of most if not all Id-unrelated monoclonal antibodies that have recently revolutionized the field.	Univ Navarra, Unic Clin, Ctr Appl Med Res, Oncol Div,Lab Immunotherapy, Pamplona 31008, Spain; Univ Navarra, Unic Clin, Cell Therapy Area, Oncol Div,Lab Immunotherapy, Pamplona 31008, Spain	University of Navarra; University of Navarra	Bendandi, M (corresponding author), Univ Navarra, Unic Clin, Ctr Appl Med Res, Oncol Div,Lab Immunotherapy, Avda Pio XII,55 & 36, Pamplona 31008, Spain.	mbendandi@unav.es	Inogés, Susana/AAW-6785-2021					Alfonso M, 2002, J IMMUNOL, V168, P2523, DOI 10.4049/jimmunol.168.5.2523; ALLEBES W, 1991, LEUKEMIA RES, V15, P215, DOI 10.1016/0145-2126(91)90123-B; ALLEBES WA, 1990, SCAND J IMMUNOL, V32, P441, DOI 10.1111/j.1365-3083.1990.tb03184.x; Baral R, 2001, INT J CANCER, V92, P88, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1148>3.0.CO;2-9; Barrios Y, 2002, HAEMATOLOGICA, V87, P400; Bendandi M, 2006, LEUKEMIA LYMPHOMA, V47, P29, DOI 10.1080/10428190500272473; Bendandi M, 2001, Expert Rev Anticancer Ther, V1, P65, DOI 10.1586/14737140.1.1.65; Bendandi M, 1999, NAT MED, V5, P1171, DOI 10.1038/13928; Bendandi M, 2006, REV RECENT CLIN TRIA, V1, P67, DOI 10.2174/157488706775246120; Bendandi Maurizio, 2004, Expert Rev Vaccines, V3, P163, DOI 10.1586/14760584.3.2.163; Benvenuti F, 2000, GENE THER, V7, P605, DOI 10.1038/sj.gt.3301133; Bertinetti C, 2006, CANCER RES, V66, P4496, DOI 10.1158/0008-5472.CAN-05-4233; Bertinetti C, 2006, EUR J HAEMATOL, V77, P395, DOI 10.1111/j.1600-0609.2006.00740.x; Bhattacharya-Chatterjee M, 2002, EXPERT OPIN BIOL TH, V2, P869, DOI 10.1517/14712598.2.8.869; Birebent B, 2001, CRIT REV ONCOL HEMAT, V39, P107, DOI 10.1016/S1040-8428(01)00125-1; BIREBENT B, 2001, J CANCER RES CLIN, V2, P27; Caspar CB, 1997, BLOOD, V90, P3699, DOI 10.1182/blood.V90.9.3699; Chang CC, 2005, J BIOL CHEM, V280, P10164, DOI 10.1074/jbc.M409161200; Coscia M, 2004, LEUKEMIA, V18, P139, DOI 10.1038/sj.leu.2403181; Cull G, 1999, BRIT J HAEMATOL, V107, P648; Davis TA, 1998, BLOOD, V92, P1184, DOI 10.1182/blood.V92.4.1184.416k05_1184_1190; Diaz A, 2003, CLIN IMMUNOL, V107, P80, DOI 10.1016/S1521-6616(03)00036-6; Foon KA, 1997, CLIN CANCER RES, V3, P1267; Foon KA, 1999, J CLIN ONCOL, V17, P2889, DOI 10.1200/JCO.1999.17.9.2889; Guthmann MD, 2006, J IMMUNOTHER, V29, P215, DOI 10.1097/01.cji.0000188502.11348.34; Hawkins RE, 1997, HUM GENE THER, V8, P1287, DOI 10.1089/hum.1997.8.10-1287; Herlyn D, 1989, Viral Immunol, V2, P271, DOI 10.1089/vim.1989.2.271; Hsu FJ, 1997, BLOOD, V89, P3129, DOI 10.1182/blood.V89.9.3129; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Hurvitz SA, 2005, EXPERT OPIN BIOL TH, V5, P841, DOI 10.1517/14712598.5.6.841; Inoges S, 2003, HAEMATOLOGICA, V88, P1438; Inoges S, 2006, J NATL CANCER I, V98, P1292, DOI 10.1093/jnci/djj358; King CA, 1998, NAT MED, V4, P1281, DOI 10.1038/3266; Kwak LW, 1996, P NATL ACAD SCI USA, V93, P10972, DOI 10.1073/pnas.93.20.10972; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; Longo DL, 2006, JNCI-J NATL CANCER I, V98, P1263, DOI 10.1093/jnci/djj371; Lutzky J, 2002, SEMIN ONCOL, V29, P462, DOI 10.1053/sonc.2002.35241; MALONEY DG, 1992, BLOOD, V80, P1502; Massaia M, 1999, BLOOD, V94, P673, DOI 10.1182/blood.V94.2.673.414k30_673_683; MEEKER T, 1985, NEW ENGL J MED, V312, P1658, DOI 10.1056/NEJM198506273122602; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; MITTELMAN A, 1994, CANCER RES, V54, P415; Mittelman A, 1995, CLIN CANCER RES, V1, P705; MOHANTY K, 2006, BREAST CANC RES TREA; Mosolits S, 2004, CLIN CANCER RES, V10, P5391, DOI 10.1158/1078-0432.CCR-04-0425; Murray JL, 2004, CANCER RES, V64, P5481, DOI 10.1158/0008-5472.CAN-04-0517; Neelapu S, 2005, BONE MARROW TRANSPL, V36, P315, DOI 10.1038/sj.bmt.1705057; Neelapu Sattva S, 2005, Clin Lymphoma, V6, P61, DOI 10.3816/CLM.2005.n.031; Neelapu SS, 2005, NAT MED, V11, P986, DOI 10.1038/nm1290; Osterborg A, 1998, BLOOD, V91, P2459, DOI 10.1182/blood.V91.7.2459.2459_2459_2466; Pfisterer J, 2006, ANN ONCOL, V17, P1568, DOI 10.1093/annonc/mdl357; PIGNATARI GC, 2006, J BIOTECHNOL; RAFFELD M, 1985, NEW ENGL J MED, V312, P1653, DOI 10.1056/NEJM198506273122601; Rasmussen T, 2003, BLOOD, V101, P4607, DOI 10.1182/blood-2002-06-1925; Redfern CH, 2006, J CLIN ONCOL, V24, P3107, DOI 10.1200/JCO.2005.04.4289; Reece DE, 2000, BONE MARROW TRANSPL, V26, P729, DOI 10.1038/sj.bmt.1702607; REECE DE, 2001, CLIN BREAST CANCER, V1, P52; Reichardt VL, 1999, BLOOD, V93, P2411, DOI 10.1182/blood.V93.7.2411.407a24_2411_2419; Reichardt VL, 2003, HAEMATOLOGICA, V88, P1139; Reinartz S, 2004, CLIN CANCER RES, V10, P1580, DOI 10.1158/1078-0432.CCR-03-0056; Reinartz S, 2003, CANCER RES, V63, P3234; Sabbatini P, 2006, CLIN CANCER RES, V12, P5503, DOI 10.1158/1078-0432.CCR-05-2670; SAHA A, 2006, CANC IMMUNOL IMMUNOT; Saleh MN, 1998, J IMMUNOTHER, V21, P379, DOI 10.1097/00002371-199809000-00006; Savelyeva N, 2001, NAT BIOTECHNOL, V19, P760, DOI 10.1038/90816; SOMASUNDARAM R, 1995, J IMMUNOL, V155, P3253; STEVENSON FK, 1995, IMMUNOL REV, V145, P211, DOI 10.1111/j.1600-065X.1995.tb00083.x; STEVENSON FK, 1995, ANN NY ACAD SCI, V27, P212; SUGIYAMA T, 1991, J IMMUNOL, V146, P3097; Timmerman JM, 2002, BLOOD, V99, P1517, DOI 10.1182/blood.V99.5.1517; Timmerman John M, 2002, Curr Treat Options Oncol, V3, P307, DOI 10.1007/s11864-002-0030-3; Titzer S, 2000, BRIT J HAEMATOL, V108, P805, DOI 10.1046/j.1365-2141.2000.01958.x; ULLENHAG GJ, 2006, CLIN CANC RES; Weng WK, 2004, J CLIN ONCOL, V22, P4717, DOI 10.1200/JCO.2004.06.003; WENG WK, 2006, BLOOD; Zhu DL, 2001, TRENDS MOL MED, V7, P566, DOI 10.1016/S1471-4914(01)02126-8	76	44	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3594	3602		10.1038/sj.onc.1210371	http://dx.doi.org/10.1038/sj.onc.1210371			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530013				2022-12-17	WOS:000246816100002
J	Dabbeekeh, JTS; Faitar, SL; Dufresne, CP; Cowell, JK				Dabbeekeh, J. T. S.; Faitar, S. L.; Dufresne, C. P.; Cowell, J. K.			The EVI5 TBC domain provides the GTPase-activating protein motif for RAB11	ONCOGENE			English	Article						EVI5; TBC domain; GAP; RAB 11; GTPase	RECYCLING ENDOSOME; CLEAVAGE FURROW; CYTOKINESIS; FAMILY; RECEPTOR; COMPLEX; BINDS	The human EVI5 gene was originally isolated through its involvement with a constitutional chromosome translocation in a patient with stage 4S neuroblastoma. Recently, it has been shown that EVI5 is a centrosomal protein in interphase cells, which relocalizes to the midbody during late phases of mitosis. Disruption of its function leads to incomplete cell division and the formation of multinucleate cells. The EVI5 protein contains a TBC (TRE2/BUB/CDC16 homology) motif located in the N-terminal region. Proteins containing a TBC domain have been shown in some cases to act as GTPase-activating proteins (GAPs) and function through the interaction with Rab-like small G proteins. Despite the identification of over 50 TBC-containing proteins, and over 70 Rab-like proteins, only three combinations have been shown to have Rab/GAP activity to date. In this study, using linear ion trap mass spectroscopy, we have demonstrated that EVI5 exists in a protein complex with Rab11. Further, using a specific Rab-binding assay, we have shown that EVI5 preferentially interacts with the guanosine triphosphate-bound form of Rab11, and in a GAP activity assay, we have confirmed that EVI5 functions as a GAP for the Rab11 GTPase.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Cowell, JK (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.	John.Cowell@RoswellPark.org		Cowell, John/0000-0002-2079-5950				Bernards A, 2005, GROWTH FACTORS, V23, P143, DOI 10.1080/08977190500130480; Bottger G, 1996, J BIOL CHEM, V271, P29191, DOI 10.1074/jbc.271.46.29191; Cuif MH, 1999, EMBO J, V18, P1772, DOI 10.1093/emboj/18.7.1772; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Faitar SL, 2006, EXP CELL RES, V312, P2325, DOI 10.1016/j.yexcr.2006.03.032; Faitar SL, 2005, GENOMICS, V86, P594, DOI 10.1016/j.ygeno.2005.06.002; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; Haas AK, 2005, NAT CELL BIOL, V7, P887, DOI 10.1038/ncb1290; Horgan CP, 2004, BIOCHEM BIOPH RES CO, V319, P83, DOI 10.1016/j.bbrc.2004.04.157; Junutula JR, 2004, J BIOL CHEM, V279, P33430, DOI 10.1074/jbc.M404633200; Liu K, 1998, J BIOL CHEM, V273, P10087, DOI 10.1074/jbc.273.17.10087; Pereira-Leal JB, 2001, J MOL BIOL, V313, P889, DOI 10.1006/jmbi.2001.5072; RICHARDSON PM, 1995, ONCOGENE, V11, P1139; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Ward ES, 2005, MOL BIOL CELL, V16, P2028, DOI 10.1091/mbc.e04-08-0735; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Wilson GM, 2005, MOL BIOL CELL, V16, P849, DOI 10.1091/mbc.e04-10-0927; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	20	44	45	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2007	26	19					2804	2808		10.1038/sj.onc.1210081	http://dx.doi.org/10.1038/sj.onc.1210081			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17099728				2022-12-17	WOS:000246210600015
J	Barrier, A; Roser, F; Boelle, PY; Franc, B; Tse, C; Brault, D; Lacaine, F; Houry, S; Callard, P; Penna, C; Debuire, B; Flahault, A; Dudoit, S; Lemoine, A				Barrier, A.; Roser, F.; Boelle, P-Y; Franc, B.; Tse, C.; Brault, D.; Lacaine, F.; Houry, S.; Callard, P.; Penna, C.; Debuire, B.; Flahault, A.; Dudoit, S.; Lemoine, A.			Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling	ONCOGENE			English	Article						functional genomics; colon cancer; prognosis prediction; non neoplastic mucosa; cross validation; cDNA arrays	TRANSMEMBRANE-4 SUPERFAMILY; T-CELLS; TUMOR; METASTASIS; MICROARRAYS; PREDICTION; CD24	We have assessed the possibility to build a prognosis predictor (PP), based on non-neoplastic mucosa microarray gene expression measures, for stage II colon cancer patients. Non-neoplastic colonic mucosa mRNA samples from 24 patients (10 with a metachronous metastasis, 14 with no recurrence) were pro. led using the Affymetrix HGU133A GeneChip. Patients were repeatedly and randomly divided into 1000 training sets (TSs) of size 16 and validation sets (VS) of size 8. For each TS/VS split, a 70-gene PP, identified on the TS by selecting the 70 most differentially expressed genes and applying diagonal linear discriminant analysis, was used to predict the prognoses of VS patients. Mean prognosis prediction performances of the 70-gene PP were 81.8% for accuracy, 73.0% for sensitivity and 87.1% for specific city. Informative genes suggested branching signal-transduction pathways with possible extensive networks between individual pathways. They also included genes coding for proteins involved in immune surveillance. In conclusion, our study suggests that one can build an accurate PP for stage II colon cancer patients, based on non-neoplastic mucosa microarray gene expression measures.	Hop Paul Brousse, AP HP, Serv Biochim, F-94804 Villejuif, France; Hop Tenon, AP HP, Serv Chirurg Digest, F-75970 Paris, France; INSERM, UMR S707, Paris, France; Univ Paris 06, Fac Med, F-75252 Paris 05, France; Univ Calif Berkeley, Sch Publ Hlth, Div Biostat, Berkeley, CA 94720 USA; INSERM, UMR S602, Villejuif, France; Univ Paris 11, Fac Med, Villejuif, France; Hop Ambroise Pare, AP HP, Serv Anat Pathol, Boulogne, France; Univ Versailles, Fac Med, Boulogne, France; Hop Tenon, AP HP, Serv Biochim, F-75970 Paris, France; Hop Tenon, AP HP, Serv Anat Pathol, F-75970 Paris, France; Hop Ambroise Pare, AP HP, Serv Chirurg Digest, Boulogne, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of California System; University of California Berkeley; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	Lemoine, A (corresponding author), Hop Paul Brousse, AP HP, Serv Biochim, 12 Ave Paul Vaillant Couturier, F-94804 Villejuif, France.	antoinette.lemoine@pbr.ap-hop-paris.fr		Boelle, Pierre-Yves/0000-0002-5367-8232				Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Arango D, 2005, GASTROENTEROLOGY, V129, P874, DOI 10.1053/j.gastro.2005.06.066; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; Barrier A, 2005, ONCOGENE, V24, P6155, DOI 10.1038/sj.onc.1208984; BARRIER A, 2006, IN PRESS J CLIN ONCO, V24; Benson AB, 2004, J CLIN ONCOL, V22, P3408, DOI 10.1200/JCO.2004.05.063; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bolstad BM, 2005, STAT BIOL HEALTH, P13; Dudoit S, 2002, J AM STAT ASSOC, V97, P77, DOI 10.1198/016214502753479248; Dudoit S, 2005, STAT METHODOL, V2, P131, DOI [10.1016/j.stamet.2005.02.003, DOI 10.1016/J.STAMET.2005.02.003]; Figueredo A, 2004, J CLIN ONCOL, V22, P3395, DOI 10.1200/JCO.2004.03.087; Hashida H, 2003, BRIT J CANCER, V89, P158, DOI 10.1038/sj.bjc.6601015; Kanekura T, 2002, INT J CANCER, V99, P520, DOI 10.1002/ijc.10390; Kitahara O, 2001, CANCER RES, V61, P3544; Kristiansen G, 2004, J MOL HISTOL, V35, P255; Li O, 2004, J EXP MED, V200, P1083, DOI 10.1084/jem.20040779; Mazzocca A, 2002, J HEPATOL, V37, P322, DOI 10.1016/S0168-8278(02)00175-7; Michiels S, 2005, LANCET, V365, P488, DOI 10.1016/S0140-6736(05)17866-0; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Notterman DA, 2001, CANCER RES, V61, P3124; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Schindelmann S, 2002, TUMOR BIOL, V23, P139, DOI 10.1159/000064030; Tanaka T, 2004, ONCOGENE, V23, P3980, DOI 10.1038/sj.onc.1207555; Wang YX, 2004, J CLIN ONCOL, V22, P1564, DOI 10.1200/JCO.2004.08.186; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	26	44	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2642	2648		10.1038/sj.onc.1210060	http://dx.doi.org/10.1038/sj.onc.1210060			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043639				2022-12-17	WOS:000245831200011
J	Jacquel, A; Colosetti, P; Grosso, S; Belhacene, N; Puissant, A; Marchetti, S; Breittmayer, JP; Auberger, P				Jacquel, A.; Colosetti, P.; Grosso, S.; Belhacene, N.; Puissant, A.; Marchetti, S.; Breittmayer, J-P; Auberger, P.			Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition	ONCOGENE			English	Article						imatinib; PD166326; apoptosis; erythroid differentiation; caspases; CML	TYROSINE KINASE INHIBITOR; CHRONIC MYELOID-LEUKEMIA; SMALL-INTERFERING-RNA; IMATINIB MESYLATE STI571; K562 CELLS; MEGAKARYOCYTIC DIFFERENTIATION; GENE-EXPRESSION; C-KIT; ACTIVATION; CLEAVAGE	Imatinib targets the Bcr-Abl oncogene that causes chronic myelogenous leukemia (CML) in humans. Recently, we demonstrated that besides triggering apoptosis in K562 cells, imatinib also mediated their erythroid differentiation. Although both events appear to proceed concomitantly, it is not known at present whether or not imatinib-induced apoptosis and differentiation are interdependent processes. Hence, we investigated the requirements for Bcr-Abl inhibitor-mediated apoptosis and erythroid differentiation in several established and engineered CML cell lines. Imatinib triggered apoptosis and erythroid differentiation of different CML cell lines, but only apoptosis exhibited sensitivity to ZVAD-fmk inhibition. Conversely, the p38 mitogen-activated protein (MAP) kinase inhibitor, SB202190, significantly slowed down erythroid differentiation without affecting caspase activation. Furthermore, imatinib and PD166326, another Bcr-Abl inhibitory molecule, triggered erythroid differentiation of K562 cell clones, nevertheless resistant to Bcr-Abl inhibitor-induced apoptosis. Finally, short hairpin RNA inhibitor (shRNAi) silencing of caspase 3 efficiently inhibited caspase activity but had no effect on erythroid differentiation, whereas silencing of Bcr-Abl mimicked imatinib or PD166326 treatment, leading to increased apoptosis and erythroid differentiation of K562 cells. Taken together, our findings not only demonstrate that Bcr-Abl inhibitor-mediated apoptosis and differentiation are fully distinguishable events, but also that caspases are dispensable for erythroid differentiation of established CML cell lines.	Natl Contre Canc, INSERM U526, Equipe Labellisee Ligue, Cell Death Differentiat & Canc Team, F-06107 Nice, France; Univ Nice Sophia Antipolis, Nice, France; CHU Nice, Hop Archet, INSERM U576, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm)	Auberger, P (corresponding author), Natl Contre Canc, INSERM U526, Equipe Labellisee Ligue, Cell Death Differentiat & Canc Team, 28 Ave Valombrose, F-06107 Nice, France.	auberger@unice.fr	Jacquel, Arnaud/O-1928-2017; Puissant, Alexandre/AAF-3875-2021; Colosetti, Pascal/ABH-4585-2020; PUISSANT, ALEXANDRE/O-9575-2016; Jacquel, Arnaud/AAJ-4760-2021; Marchetti, Sandrine/P-6479-2016; AUBERGER, Patrick/G-1491-2013	Jacquel, Arnaud/0000-0001-5062-8048; Puissant, Alexandre/0000-0002-3997-9282; PUISSANT, ALEXANDRE/0000-0002-3997-9282; Jacquel, Arnaud/0000-0001-5062-8048; Marchetti, Sandrine/0000-0001-8326-5730; AUBERGER, Patrick/0000-0002-2481-8275				Belhacene N, 1998, FASEB J, V12, P531; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Carlile GW, 2004, BLOOD, V103, P4310, DOI 10.1182/blood-2003-09-3362; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Dorsey JF, 2002, BLOOD, V99, P1388, DOI 10.1182/blood.V99.4.1388; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Huron DR, 2003, CLIN CANCER RES, V9, P1267; Jacquel A, 2006, ONCOGENE, V25, P781, DOI 10.1038/sj.onc.1209119; Jacquel A, 2003, FASEB J, V17, P2160, DOI 10.1096/fj.03-0322fje; Kawano T, 2004, MOL CELL BIOCHEM, V258, P25, DOI 10.1023/B:MCBI.0000012830.96393.b9; Kohmura K, 2004, J CELL PHYSIOL, V198, P370, DOI 10.1002/jcp.10426; Kolbus A, 2002, J EXP MED, V196, P1347, DOI 10.1084/jem.20020562; Krauss SW, 2005, BLOOD, V106, P2200, DOI 10.1182/blood-2005-04-1357; Kuzelova K, 2005, J CELL BIOCHEM, V95, P268, DOI 10.1002/jcb.20407; Launay S, 2005, ONCOGENE, V24, P5137, DOI 10.1038/sj.onc.1208524; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Okada M, 2004, BLOOD, V103, P2299, DOI 10.1182/blood-2003-05-1605; Parmar S, 2004, J BIOL CHEM, V279, P25345, DOI 10.1074/jbc.M400590200; Perfettini JL, 2003, NAT IMMUNOL, V4, P308, DOI 10.1038/ni0403-308; Pettiford SM, 2003, LEUKEMIA, V17, P366, DOI 10.1038/sj.leu.2402767; Racke FK, 2001, J BIOL CHEM, V276, P522, DOI 10.1074/jbc.M005236200; Rangatia J, 2006, LEUKEMIA, V20, P68, DOI 10.1038/sj.leu.2403999; Roskoski R, 2003, BIOCHEM BIOPH RES CO, V309, P709, DOI 10.1016/j.bbrc.2003.08.055; Scherr M, 2003, BLOOD, V101, P1566, DOI 10.1182/blood-2002-06-1685; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; WITHEY JM, 2005, LEUKEMIA RES, V30, P553; Wohlbold L, 2003, BLOOD, V102, P2236, DOI 10.1182/blood-2002-12-3899; Wolff NC, 2005, BLOOD, V105, P3995, DOI 10.1182/blood-2004-09-3534; Wong S, 2004, ANNU REV IMMUNOL, V22, P247, DOI 10.1146/annurev.immunol.22.012703.104753; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247	32	44	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2007	26	17					2445	2458		10.1038/sj.onc.1210034	http://dx.doi.org/10.1038/sj.onc.1210034			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043649				2022-12-17	WOS:000245831000005
J	Liu, Z; Li, H; Wu, X; Yoo, BH; Yan, SR; Stadnyk, AW; Sasazuki, T; Shirasawa, S; LaCasse, EC; Korneluk, RG; Rosen, KV				Liu, Z.; Li, H.; Wu, X.; Yoo, B. H.; Yan, S. R.; Stadnyk, A. W.; Sasazuki, T.; Shirasawa, S.; LaCasse, E. C.; Korneluk, R. G.; Rosen, K. V.			Detachment-induced upregulation of XIAP and cIAP2 delays anoikis of intestinal epithelial cells	ONCOGENE			English	Article						apoptosis; anoikis; XIAP; cIAP2; intestinal epithelial cells	NF-KAPPA-B; EPIDERMAL-GROWTH-FACTOR; RAS-INDUCED TRANSFORMATION; HUMAN PROSTATE-CANCER; ACID PHENETHYL ESTER; BCL-2 PROTEIN FAMILY; DOWN-REGULATION; INDUCED APOPTOSIS; SERINE-PROTEASE; CYTOCHROME-C	Detachment of normal epithelial cells from the extracellular matrix triggers apoptosis, a phenomenon called anoikis. Conversely, carcinoma cells tend to be relatively more anoikis- resistant than their normal counterparts, and this increased resistance represents a critical feature of the malignant phenotype. Mechanisms that control susceptibilityand resistance to anoikis are not fully understood. It is now known that detachment of non-malignant epithelial cells triggers both pro- and antiapoptotic signals, and it is the balance between these signals and the duration of detachment that determine further fate of the cells. Detachment- induced antiapoptotic events delay anoikis and if cells reattach relativelysoo n after detachment they survive. Direct regulators of apoptosis responsible for this delay of anoikis are unknown. We found that detachment of non-malignant intestinal epithelial cells triggers upregulation of inhibitors of apoptosis protein (IAP) family, such as X- chromosome- linked inhibitor of apoptosis protein and cellular inhibitor of apoptosis- 2 (cIAP2). We demonstrated that this upregulation requires detachment-dependent activation of the transcription factor nuclear factor-kappa B. We further observed that various IAP antagonists accelerate anoikis, indicating that upregulation of the IAPs delays detachment- triggered apoptosis. We conclude that the IAPs are important regulators of the balance between detachment- triggered life and death signals. Perhaps, not by coincidence, these proteins are often upregulated in carcinomas, tumors composed of cells that tend to be anoikis- resistant.	Dalhousie Univ, Dept Pediat, CRC, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Biochem & Mol Biol, Atlantic Res Ctr, CRC, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 4H7, Canada; Int Med Ctr Japan, Dept Pathol, Inst Res, Shinjyuku Ku, Tokyo, Japan; Childrens Hosp Eastern Ontario, Inst Res, Aegera Oncol Inc, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Childrens Hosp Eastern Ontario, Inst Res, Solange Gauthier Karsh Mol Genet Lab, Ottawa, ON, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada	Dalhousie University; Dalhousie University; Dalhousie University; National Center for Global Health & Medicine - Japan; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa	Rosen, KV (corresponding author), Dalhousie Univ, Dept Pediat, CRC, Atlantic Res Ctr, Room C-302,5849 Univ Ave, Halifax, NS B3H 4H7, Canada.	kirill.rosen@dal.ca		Rosen, Kirill/0000-0002-4317-9907; Stadnyk, Andrew/0000-0002-1940-8036				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Berezovskaya O, 2005, CANCER RES, V65, P2378, DOI 10.1158/0008-5472.CAN-04-2649; Biswas DK, 2003, CANCER RES, V63, P290; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Coll MAL, 2005, ONCOGENE, V24, P1727, DOI 10.1038/sj.onc.1208379; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036; Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247; Farahani R, 1997, GENOMICS, V42, P514, DOI 10.1006/geno.1997.4742; Ferreira CG, 2001, CLIN CANCER RES, V7, P2468; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Gottfried Y, 2004, EMBO J, V23, P1627, DOI 10.1038/sj.emboj.7600155; Hofmann HS, 2002, J CANCER RES CLIN, V128, P554, DOI 10.1007/s00432-002-0364-z; Holcik M, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-5; Ikeda H, 1998, GUT, V42, P530, DOI 10.1136/gut.42.4.530; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Krajewska M, 2005, CLIN CANCER RES, V11, P5451, DOI 10.1158/1078-0432.CCR-05-0094; Krajewska M, 2003, CLIN CANCER RES, V9, P4914; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin MT, 2004, J BIOL CHEM, V279, P24015, DOI 10.1074/jbc.M402305200; Liu ZP, 2006, J BIOL CHEM, V281, P14738, DOI 10.1074/jbc.M508664200; Liu ZP, 2005, J BIOL CHEM, V280, P37383, DOI 10.1074/jbc.M503724200; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Olson AL, 2001, AMBUL PEDIATR, V1, P91, DOI 10.1367/1539-4409(2001)001<0091:PCPRAP>2.0.CO;2; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Rak Janusz, 1999, Neoplasia (New York), V1, P23, DOI 10.1038/sj.neo.7900001; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; RODENHUIS S, 1988, CANCER RES, V48, P5738; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Ruemmele FM, 2002, BIOCHEM BIOPH RES CO, V290, P1308, DOI 10.1006/bbrc.2002.6348; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; Scotlandi K, 2002, CANCER GENE THER, V9, P296, DOI 10.1038/sj.cgt.7700442; Shi Y, 2001, J UROLOGY, V166, P1514, DOI 10.1016/S0022-5347(05)65822-3; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Toruner M, 2006, J BIOL CHEM, V281, P8686, DOI 10.1074/jbc.M512178200; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Vachon PH, 2002, GASTROENTEROLOGY, V123, P1980, DOI 10.1053/gast.2002.37072; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang PB, 2003, J BIOL CHEM, V278, P19917, DOI 10.1074/jbc.M210337200; Watabe M, 2004, J BIOL CHEM, V279, P6017, DOI 10.1074/jbc.M306040200; Yamakita Y, 1999, J CELL BIOL, V144, P315, DOI 10.1083/jcb.144.2.315; Yan SR, 2005, ONCOGENE, V24, P6482, DOI 10.1038/sj.onc.1208810	69	44	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7680	7690		10.1038/sj.onc.1209753	http://dx.doi.org/10.1038/sj.onc.1209753			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16799641				2022-12-17	WOS:000242830800003
J	Yan, H; Thomas, J; Liu, T; Raj, D; London, N; Tandeski, T; Leachman, SA; Lee, RM; Grossman, D				Yan, H.; Thomas, J.; Liu, T.; Raj, D.; London, N.; Tandeski, T.; Leachman, S. A.; Lee, R. M.; Grossman, D.			Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable survivin antagonist	ONCOGENE			English	Article						survivin; apoptosis; melanoma; TAT; xenograft	PROTEIN TRANSDUCTION; MAMMALIAN-CELLS; IN-VIVO; CANCER; EXPRESSION; GENE; DIVISION; INTERFERENCE; CHECKPOINT; THERAPY	The inhibitor of apoptosis gene family member Survivin is highly expressed in most tumors, and appears to be a promising target for cancer therapy. Although a variety of Survivin antagonists have been shown to induce apoptosis in malignant cells, the potential utility of these agents is limited by inefficient delivery and cell impermeability. We generated recombinant fusion proteins containing the TAT protein transduction domain and either wild-type Survivin (TAT-Surv-WT) or a dominant-negative mutant (TAT-Surv-T34A). The TAT-Surv proteins were purified by sequential affinity and ion-exchange chromatography, and at 30 nM concentration demonstrated rapid entry into cells at 30 min. Whereas TAT-Surv-WT had minimal effect on YUSAC2 or WM793 melanoma cells, TAT-Surv-T34A induced cell detachment, DNA fragmentation, caspase-3 activation and mitochondrial release of apoptosis-inducing factor at low mu M concentrations. Intraperitoneal (i.p.)injection of mice bearing subcutaneous YUSAC2 xenografts with TAT-Surv-T34A (10 mg/ kg) was associated with rapid tumor accumulation at 1 h, and increased tumor cell apoptosis and aberrant nuclei formation in situ. Repeated i.p. injection of TAT- Surv-T34A resulted in a 40-50% reduction in growth and mass of established tumors, compared to those similarly injected with saline buffer or TAT-Surv-WT. These studies demonstrate the feasibility of systemic tumor treatment using a cell-permeable Survivin antagonist.	Univ Utah, Huntsman Canc Inst, Dept Dermatol & Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Dermatol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Grossman, D (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Dermatol & Oncol Sci, 2000 Circle Hope,Suite 5243, Salt Lake City, UT 84112 USA.	doug.grossman@hci.utah.edu			NIAMS NIH HHS [AR050102, R01 AR050102-03, R01 AR050102] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050102] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Azuhata T, 2001, J PEDIATR SURG, V36, P1785, DOI 10.1053/jpsu.2001.28839; Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Beltrami E, 2004, J BIOL CHEM, V279, P2077, DOI 10.1074/jbc.M309479200; Caldas H, 2005, ONCOGENE, V24, P1994, DOI 10.1038/sj.onc.1208350; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Kanwar JR, 2001, J NATL CANCER I, V93, P1541, DOI 10.1093/jnci/93.20.1541; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li FZ, 1999, CANCER RES, V59, P3143; Ling X, 2004, BIOTECHNIQUES, V36, P450, DOI 10.2144/04363RR01; Liu T, 2004, ONCOGENE, V23, P39, DOI 10.1038/sj.onc.1206978; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Muchmore SW, 2000, MOL CELL, V6, P173, DOI 10.1016/S1097-2765(00)00018-6; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Pennati M, 2002, J CLIN INVEST, V109, P285; Plescia J, 2005, CANCER CELL, V7, P457, DOI 10.1016/j.ccr.2005.03.035; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Shankar SL, 2001, J NEUROCHEM, V79, P426, DOI 10.1046/j.1471-4159.2001.00596.x; Takeuchi H, 2005, INT J CANCER, V117, P1032, DOI 10.1002/ijc.21267; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Vong QP, 2005, SCIENCE, V310, P1499, DOI 10.1126/science.1120160	30	44	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6968	6974		10.1038/sj.onc.1209676	http://dx.doi.org/10.1038/sj.onc.1209676			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16702945	Green Accepted			2022-12-17	WOS:000241732300007
J	Paruchuri, S; Mezhybovska, M; Juhas, M; Sjolander, A				Paruchuri, S.; Mezhybovska, M.; Juhas, M.; Sjolander, A.			Endogenous production of leukotriene D-4 mediates autocrine survival and proliferation via CysLT(1) receptor signalling in intestinal epithelial cells	ONCOGENE			English	Article						CysLT(1) receptor; apoptosis; caspase-3; epithelial cells	CANCER; DISRUPTION; INHIBITORS; APOPTOSIS; PROTEIN	The cysteinyl leukotriene(1) (CysLT(1)) receptor (CysLT(1)R) enhances survival and proliferation of intestinal cells via distinct pathways. Here, we have demonstrated that there is significant endogenous production of CysLTs from both non-tumour-and tumour-derived intestinal epithelial cells. Treatment of two non-tumour cell lines, Int 407 and IEC-6, with CysLT1R antagonists led to shrinkage and detachment of cells, confirmed as apoptotic cell death, and a dose-dependent reduction in proliferation. However, in the tumour intestinal cell lines Caco-2, SW480, HCT-116 and HT-29, treatment with CysLT1R antagonists significantly reduced proliferation, but had no effect on apoptosis. A unique characteristic of intestinal cancer cells is the presence of nuclear CysLT(1)Rs, which are inaccessible to receptor antagonists. In these cells, inhibition of the endogenous production of CysLTs indirectly, by 5-lipoxygenase inhibition, impaired CysLT1R signalling throughout the cell, and resulted in apoptosis of the tumour cells. These data reveal the existence of constitutive CysLT1R signalling that mediates both survival and proliferation in intestinal cells. Importantly, we propose that tumour-derived intestinal cells are resistant to CysLT(1)R antagonist-induced apoptosis, a phenomena that could be explained by nuclear CysLT1R signalling.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Sjolander, A (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, SE-20502 Malmo, Sweden.	anita.sjolander@exppat.mas.lu.se						Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Claesson HE, 1999, J INTERN MED, V245, P205, DOI 10.1046/j.1365-2796.1999.00418.x; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Ghosh J, 1998, P NATL ACAD SCI USA, V95, P13182, DOI 10.1073/pnas.95.22.13182; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hennig R, 2004, CANCER LETT, V210, P41, DOI 10.1016/j.canlet.2004.02.023; Lee E, 2000, AM J RESP CRIT CARE, V161, P1881, DOI 10.1164/ajrccm.161.6.9907054; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2002, J BIOL CHEM, V277, P20820, DOI 10.1074/jbc.M203163200; Mann JR, 2004, CANCER J, V10, P145, DOI 10.1097/00130404-200405000-00001; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Nielsen CK, 2005, CANCER RES, V65, P732; Ohd JF, 2000, GASTROENTEROLOGY, V119, P1007, DOI 10.1053/gast.2000.18141; Ohd JF, 2003, GASTROENTEROLOGY, V124, P57, DOI 10.1053/gast.2003.50011; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; Pachernik J, 2002, ARCH DERMATOL RES, V293, P626, DOI 10.1007/s00403-001-0288-5; Paruchuri S, 2003, J BIOL CHEM, V278, P45577, DOI 10.1074/jbc.M302881200; Paruchuri S, 2002, J CELL SCI, V115, P1883; Shi ZZ, 2001, MOL CELL BIOL, V21, P5389, DOI 10.1128/MCB.21.16.5389-5395.2001; Wkstrom K, 2003, BIOCHEM J, V371, P115; Wu X, 2003, CELL BIOL TOXICOL, V19, P135, DOI 10.1023/A:1024789810277	21	44	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6660	6665		10.1038/sj.onc.1209666	http://dx.doi.org/10.1038/sj.onc.1209666			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16715140				2022-12-17	WOS:000241569700010
J	Jin, A; Kurosu, T; Tsuji, K; Mizuchi, D; Arai, A; Fujita, H; Hattori, M; Minato, N; Miura, O				Jin, A.; Kurosu, T.; Tsuji, K.; Mizuchi, D.; Arai, A.; Fujita, H.; Hattori, M.; Minato, N.; Miura, O.			BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhesion	ONCOGENE			English	Article						BCR/ABL; IL-3; Rap1; B-Raf; Akt; adhesion	CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; HEMATOPOIETIC-CELL ADHESION; KINASE-ACTIVITY; BCR-ABL; ERYTHROPOIETIN RECEPTOR; PROGENITOR CELLS; EXCHANGE FACTOR; CYCLIC-AMP; PROTEINS	The Ras family small GTPase Rap1 is activated by hematopoietic cytokines, such as interleukin (IL)-3, to induce beta 1 integrin-mediated cell adhesion or by the BCR/ABL fusion tyrosine kinase to stimulate the MEK/Erk signaling pathway. Here, we demonstrate that the abrogation of Rap1 activation by SPA-1, a Rap1-specific GAP, inhibits activation of B-Raf, MEK, Erk, and Akt in a murine hematopoietic cell line, Ton.B210, stimulated with IL-3 or inducibly expressing BCR/ABL. Furthermore, Rap1 inactivation had an inhibitory effects on proliferation and survival of Ton.B210 cells, which were more remarkable when cells were stimulated by BCR/ABL than by IL-3. Induction of BCR/ABL expression increased adhesion of Ton.B210 cells to fibronectin in a manner at least partly dependent on its kinase activity, and Rap1 inhibition by SPA-1 partially inhibited BCR/ABL-induced adhesion of cells. Thus, IL-3- or BCR/ABL-induced activation of Rap1 may play important roles in regulation of cell proliferation and survival through activation of the B-Raf/MEK/Erk and Akt signaling pathways and in induction of integrin-mediated cell adhesion. Furthermore, as compared with IL-3, BCR/ABL is more dependent on Rap1-mediated signaling to induce cell proliferation and survival and, thus, Rap1 may represent an attractive target for novel therapies for leukemias caused by BCR/ABL.	Tokyo Med & Dent Univ, Dept Hematol, Bunkyo Ku, Tokyo 1138519, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Immunol & Cell Biol, Kyoto, Japan	Tokyo Medical & Dental University (TMDU); Kyoto University	Miura, O (corresponding author), Tokyo Med & Dent Univ, Dept Hematol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	miura.hema@tmd.ac.jp		Fujita, Harumi/0000-0003-2133-845X; Miura, Osamu/0000-0002-0981-3054				Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Barnes DJ, 2005, ONCOGENE, V24, P6432, DOI 10.1038/sj.onc.1208796; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Bhatia R, 2001, BRIT J HAEMATOL, V115, P845, DOI 10.1046/j.1365-2141.2001.03192.x; Bondzi C, 2000, ONCOGENE, V19, P5030, DOI 10.1038/sj.onc.1203862; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brummer T, 2002, EMBO J, V21, P5611, DOI 10.1093/emboj/cdf588; Christian SL, 2003, J BIOL CHEM, V278, P41756, DOI 10.1074/jbc.M303180200; Clarkson B, 2003, LEUKEMIA, V17, P1211, DOI 10.1038/sj.leu.2402912; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Garcia J, 2001, MOL CELL BIOL, V21, P2659, DOI 10.1128/MCB.21.8.2659-2670.2001; Goldman JM, 2003, NEW ENGL J MED, V349, P1451, DOI 10.1056/NEJMra020777; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; Hattori M, 2003, J BIOCHEM, V134, P479, DOI 10.1093/jb/mvg180; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ishida D, 2003, CANCER CELL, V4, P55, DOI 10.1016/S1535-6108(03)00163-6; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klein S, 2005, NAT REV CANCER, V5, P573, DOI 10.1038/nrc1651; Klejman A, 2002, ONCOGENE, V21, P5868, DOI 10.1038/sj.onc.1205724; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Kometani K, 2004, TRENDS MOL MED, V10, P401, DOI 10.1016/j.molmed.2004.06.004; Kramer A, 1999, P NATL ACAD SCI USA, V96, P2087, DOI 10.1073/pnas.96.5.2087; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; Lou LG, 2002, J BIOL CHEM, V277, P32799, DOI 10.1074/jbc.M201491200; Marley SB, 2004, BRIT J HAEMATOL, V125, P500, DOI 10.1111/j.1365-2141.2004.04933.x; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; Mizuchi D, 2005, BIOCHEM BIOPH RES CO, V326, P645, DOI 10.1016/j.bbrc.2004.11.086; Papin C, 1996, ONCOGENE, V12, P2213; PIZON V, 1988, ONCOGENE, V3, P201; Ramaraj P, 2004, CANCER RES, V64, P5322, DOI 10.1158/0008-5472.CAN-03-3656; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Stork PJS, 2005, BLOOD, V106, P2952, DOI 10.1182/blood-2005-03-1062; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wertheim JA, 2003, BLOOD, V102, P2220, DOI 10.1182/blood-2003-01-0062; Wertheim JA, 2002, BLOOD, V99, P4122, DOI 10.1182/blood.V99.11.4122	47	44	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2006	25	31					4332	4340		10.1038/sj.onc.1209459	http://dx.doi.org/10.1038/sj.onc.1209459			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518411				2022-12-17	WOS:000239240100008
J	Dolznig, H; Grebien, F; Deiner, EM; Stangl, K; Kolbus, A; Habermann, B; Kerenyi, MA; Kieslinger, M; Moriggl, R; Beug, H; Mullner, E				Dolznig, H.; Grebien, F.; Deiner, E. M.; Stangl, K.; Kolbus, A.; Habermann, B.; Kerenyi, M. A.; Kieslinger, M.; Moriggl, R.; Beug, H.; Muellner, E. W.			Erythroid progenitor renewal versus differentiation: genetic evidence for cell autonomous, essential functions of EpoR, Stat5 and the GR	ONCOGENE			English	Article						erythroid progenitor self-renewal; terminal erythropoiesis; Stat5; glucocorticoid receptor; erythropoietin receptor; Bcl-X-L	BCL-X-L; STEM-CELL; GLUCOCORTICOID-RECEPTOR; DNA-BINDING; C-KIT; ERYTHROPOIETIN; EXPRESSION; MECHANISMS; APOPTOSIS; BCL-X(L)	The balance between hematopoietic progenitor commitment and self- renewal versus differentiation is controlled by various transcriptional regulators cooperating with cytokine receptors. Disruption of this balance is increasingly recognized as important in the development of leukemia, by causing enhanced renewal and differentiation arrest. We studied regulation of renewal versus differentiation in primary murine erythroid progenitors that require cooperation of erythropoietin receptor ( EpoR), the receptor tyrosine kinase c- Kit and a transcriptional regulator ( glucocorticoid receptor; GR) for sustained renewal. However, mice defective for GR- ( GR(dim/ dim)), EpoR- ( EpoR(H)) or STAT5ab function ( Stat5ab (-/ -)) show no severe erythropoiesis defects in vivo. Using primary erythroblast cultures from these mutants, we present genetic evidence that functional GR, EpoR, and Stat5 are essential for erythroblast renewal in vitro. Cells from GRdim/ dim, Epo RH, and Stat5ab -/ - mice showed enhanced differentiation instead of renewal, causing accumulation of mature cells and gradual proliferation arrest. Stat5ab was additionally required for Epo- induced terminal differentiation: differentiating Stat5ab (-/ -) erythroblasts underwent apoptosis instead of erythrocyte maturation, due to absent induction of the antiapoptotic protein Bcl- X-L. This defect could be fully rescued by exogenous Bcl- X-L. These data suggest that signaling molecules driving leukemic proliferation may also be essential for prolonged self- renewal of normal erythroid progenitors.	Inst Mol Pathol, VBC, A-1030 Vienna, Austria; Med Univ Vienna, Div Mol Biol, Dept Med Biochem, Max F Perutz Labs, Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Beug, H (corresponding author), Inst Mol Pathol, VBC, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	beug@imp.univie; ernst.muellner@univie.ac.at	Moriggl, Richard/H-8118-2019; Grebien, Florian/H-9234-2019; Dolznig, Helmut/L-7005-2015; Habermann, Bianca/N-4886-2016	Moriggl, Richard/0000-0003-0918-9463; Grebien, Florian/0000-0003-4289-2281; Dolznig, Helmut/0000-0002-6063-3585; Habermann, Bianca/0000-0002-2457-7504	Austrian Science Fund FWF [F 2809, F 2807, F 2802, F 2801] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BAUER A, 2001, HEMATOPOIESIS DEV AP, P368; BEUG H, 1995, ONCOGENE, V11, P59; BEUG H, 1996, BIOCHIM BIOPHYS ACTA, V1128, pM35; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; Carotta S, 2004, BLOOD, V104, P1873, DOI 10.1182/blood-2004-02-0570; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; Dolznig H, 2004, METH MOLEC MED, V105, P323; Dolznig H, 2002, CURR BIOL, V12, P1076, DOI 10.1016/S0960-9822(02)00930-2; Dolznig H, 2001, FASEB J, V15, P1442, DOI 10.1096/fj.00-0705fje; Doppler W, 2000, ADV EXP MED BIOL, V480, P139; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Kieslinger M, 2000, GENE DEV, V14, P232; Kolbus A, 2002, J EXP MED, V196, P1347, DOI 10.1084/jem.20020562; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Li K, 2003, BLOOD, V102, P3147, DOI 10.1182/blood-2003-01-0078; MIKULITS W, 1995, NUCLEIC ACIDS RES, V23, P2342, DOI 10.1093/nar/23.12.2342; Moriggl R, 2005, CANCER CELL, V7, P87, DOI 10.1016/j.ccr.2004.12.010; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Onnebo SMN, 2005, EXP HEMATOL, V33, P182, DOI 10.1016/j.exphem.2004.10.019; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; SAWADA K, 1990, J CELL PHYSIOL, V142, P219, DOI 10.1002/jcp.1041420202; Schulte CE, 2002, EMBO J, V21, P4297, DOI 10.1093/emboj/cdf429; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Shet AS, 2002, LEUKEMIA, V16, P1402, DOI 10.1038/sj.leu.2402577; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; von Lindern M, 2004, CELL CYCLE, V3, P876; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; von Lindern M, 2001, ONCOGENE, V20, P3651, DOI 10.1038/sj.onc.1204494; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; YU H, 2004, NAT REV CANCER, V4, P655; Zang HS, 2001, EMBO J, V20, P3156, DOI 10.1093/emboj/20.12.3156	48	44	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2890	2900		10.1038/sj.onc.1209308	http://dx.doi.org/10.1038/sj.onc.1209308			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407844	Green Accepted			2022-12-17	WOS:000237448200007
J	Bernard, D; Gil, J; Dumont, P; Rizzo, S; Monte, D; Quatannens, B; Hudson, D; Visakorpi, T; Fuks, F; de Launoit, Y				Bernard, D; Gil, J; Dumont, P; Rizzo, S; Monte, D; Quatannens, B; Hudson, D; Visakorpi, T; Fuks, F; de Launoit, Y			The methyl-CpG- binding protein MECP2 is required for prostate cancer cell growth	ONCOGENE			English	Article						methyl-CpG-binding protein; epigenetic; cancer; prostate; growth	ANDROGEN DEPRIVATION THERAPY; HISTONE DEACETYLASE COMPLEX; DNA METHYLATION; NEUROENDOCRINE DIFFERENTIATION; MOLECULAR-GENETICS; C-MYC; EXPRESSION; CARCINOMA; RECEPTOR; METHYLTRANSFERASE	The incidence of prostate cancer is increasing in western countries because of population aging. Prostate cancer begins as an androgen-dependent disease, but it can become androgen independent at a later stage or in tumors recurring after an antihormonal treatment. Although many genetic events have been described to be involved in androgen-dependent and/or -independent prostate cancer growth, little is known about the contribution of epigenetic events. Here we have examined the possibility that the methyl-CpG-binding protein MECP2 might play a role in controlling the growth of prostate cancer cells. Inhibition of MECP2 expression by stable short hairpin RNA stopped the growth of both normal and cancer human prostate cells. In addition, ectopic expression of the MECP2 conferred a growth advantage to human prostate cancer cells. More importantly, this expression allowed androgen-dependent cells to grow independently of androgen stimulation and to retain tumorigenic properties in androgen-depleted conditions. Analysis of signaling pathways showed that this effect is independent of androgen receptor signaling. Instead, MECP2 appears to act by maintaining a constant c-myc level during antihormonal treatment. We further show that MECP2-expressing cells possess a functional p53 pathway and are still responsive to chemotherapeutic drugs.	ULB, Fac Med, Lab Virol Mol, B-1070 Brussels, Belgium; Imperial Coll Sch Med, MRC Clin Sci Ctr, London, England; Univ Sci & Technol, CNRS, UMR 8117, Inst Pasteur Lille,Inst Biol, Lille, France; Inst Canc Res, Prostate Stem Cell Lab, Sutton, Surrey, England; Tampere Univ Hosp, Tampere, Finland	Universite Libre de Bruxelles; Imperial College London; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; University of London; Institute of Cancer Research - UK; Tampere University; Tampere University Hospital	Bernard, D (corresponding author), ULB, Fac Med, Lab Virol Mol, CP 614,808 Route Lennik, B-1070 Brussels, Belgium.	dbernard@ulb.ac.be	Gil, Jesus/C-7739-2012; Bernard, David/D-6265-2018	Gil, Jesus/0000-0002-4303-6260; monte, didier/0000-0002-0613-6203; Visakorpi, Tapio/0000-0002-5004-0364; Bernard, David/0000-0002-1557-2074	MRC [MC_U120085810] Funding Source: UKRI; Medical Research Council [MC_U120085810] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; ABRAHAMSSON PA, 1989, PATHOL RES PRACT, V185, P373, DOI 10.1016/S0344-0338(89)80016-0; Ahlgren G, 2000, PROSTATE, V42, P274, DOI 10.1002/(SICI)1097-0045(20000301)42:4<274::AID-PROS4>3.0.CO;2-R; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bernard D, 2003, J CLIN INVEST, V112, P1724; Bernard D, 2001, CANCER RES, V61, P2656; Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7; Carlson CA, 2000, RADIAT RES, V154, P590, DOI 10.1667/0033-7587(2000)154[0590:LORPCW]2.0.CO;2; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023; COHEN RJ, 1990, BRIT J UROL, V66, P405, DOI 10.1111/j.1464-410X.1990.tb14963.x; Denmeade SR, 2002, NAT REV CANCER, V2, P389, DOI 10.1038/nrc801; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fojo T, 2003, ONCOGENE, V22, P7512, DOI 10.1038/sj.onc.1206951; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hirano D, 2004, EUR UROL, V45, P586, DOI 10.1016/j.eururo.2003.11.032; Hudson David L, 2003, Methods Mol Med, V81, P59; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KELLEN JA, 1994, ANTICANCER RES, V14, P433; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Kongkanuntn R, 1999, ONCOGENE, V18, P7219, DOI 10.1038/sj.onc.1203181; Kudo S, 2001, BRAIN DEV-JPN, V23, pS165, DOI 10.1016/S0387-7604(01)00345-X; Li LC, 2004, BBA-REV CANCER, V1704, P87, DOI 10.1016/j.bbcan.2004.06.001; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Miyoshi Y, 2001, BJU INT, V88, P982, DOI 10.1046/j.1464-4096.2001.00936.x; Nan X., 1998, NOVART FDN SYMP, V214, P16, DOI DOI 10.1002/9780470515501.CH2; Nan XS, 1998, CIBA F SYMP, V214, P6; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Porkka KP, 2004, EUR UROL, V45, P683, DOI 10.1016/j.eururo.2004.01.012; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; TETU B, 1987, CANCER, V59, P1803, DOI 10.1002/1097-0142(19870515)59:10<1803::AID-CNCR2820591019>3.0.CO;2-X; Valkov NI, 2003, DRUG RESIST UPDATE, V6, P27, DOI 10.1016/S1368-7646(02)00143-7; Visakorpi T, 2003, UROLOGY, V62, P3, DOI 10.1016/S0090-4295(03)00776-3; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WOLF DA, 1992, MOL ENDOCRINOL, V6, P753, DOI 10.1210/me.6.5.753; Wright ME, 2003, MOL ENDOCRINOL, V17, P1726, DOI 10.1210/me.2003-0031; Yeap BB, 1999, ENDOCRINOLOGY, V140, P3282, DOI 10.1210/en.140.7.3282; Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300; Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440	51	44	55	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1358	1366		10.1038/sj.onc.1209179	http://dx.doi.org/10.1038/sj.onc.1209179			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16331274				2022-12-17	WOS:000235708200009
J	Britschgi, C; Rizzi, M; Grob, TJ; Tschan, MP; Hugli, B; Reddy, VA; Andres, AC; Torbett, BE; Tobler, A; Fey, MF				Britschgi, C; Rizzi, M; Grob, TJ; Tschan, MP; Hugli, B; Reddy, VA; Andres, AC; Torbett, BE; Tobler, A; Fey, MF			Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1	ONCOGENE			English	Article						HIC1; p53; transcriptional target; HIC1.PRE; p73	HUMAN BREAST-CANCER; DNA-BINDING; COLORECTAL-CANCER; HIC-1; P73; EXPRESSION; CELLS; SITE; PCR; TUMORIGENESIS	The tumor suppressor gene hypermethylated in cancer 1 (HIC1), located on human chromosome 17p13.3, is frequently silenced in cancer by epigenetic mechanisms. Hypermethylated in cancer 1 belongs to the bric a brac/ poxviruses and zinc-finger family of transcription factors and acts by repressing target gene expression. It has been shown that enforced p53 expression leads to increased HIC1 mRNA, and recent data suggest that p53 and Hic1 cooperate in tumorigenesis. In order to elucidate the regulation of HIC1 expression, we have analysed the HIC1 promoter region for p53-dependent induction of gene expression. Using progressively truncated luciferase reporter gene constructs, we have identified a p53-responsive element (PRE) 500 bp upstream of the TATA-box containing promoter P0 of HIC1, which is sequence specifically bound by p53 in vitro as assessed by electrophoretic mobility shift assays. We demonstrate that this HIC1 p53-responsive element ( HIC1. PRE) is necessary and sufficient to mediate induction of transcription by p53. This result is supported by the observation that abolishing endogenous wild-type p53 function prevents HIC1 mRNA induction in response to UV-induced DNA damage. Other members of the p53 family, notably TAp73 beta and Delta Np63 alpha, can also act through this HIC1. PRE to induce transcription of HIC1, and finally, hypermethylation of the HIC1 promoter attenuates inducibility by p53.	Inselspital Bern, CH-3010 Bern, Switzerland; Univ Bern, Dept Clin Res, Bern, Switzerland; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA; Univ Bern, Dept Clin Res, Tiefenau Labs, Bern, Switzerland	University of Bern; Scripps Research Institute; University of Bern	Fey, MF (corresponding author), Inselspital Bern, CH-3010 Bern, Switzerland.	martin.fey@insel.ch	Rizzi, Mattia/AHE-4168-2022; Rizzi, Mattia/ABE-3996-2021	Britschgi, Christian/0000-0001-8831-1564; Tschan, Mario P./0000-0001-5897-3647; Rizzi, Mattia/0000-0001-6987-0678; Grob, Tobias/0000-0002-6298-9796	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049165] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49165] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahuja N, 1997, CANCER RES, V57, P3370; Arnold CN, 2003, INT J CANCER, V106, P66, DOI 10.1002/ijc.11176; Bahia H, 2002, INT J ONCOL, V20, P489; Beillard E, 2003, LEUKEMIA, V17, P2474, DOI 10.1038/sj.leu.2403136; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHEN W, 2005, P AM ASSOC CANC RES, V46, P114; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; de Almodovar CR, 2004, J BIOL CHEM, V279, P4093, DOI 10.1074/jbc.M311243200; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976; Galimi F, 2002, BLOOD, V100, P2732, DOI 10.1182/blood-2002-04-1245; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Issa JPJ, 1997, CANCER RES, V57, P1678; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Liu XG, 2004, CANCER RES, V64, P5078, DOI 10.1158/0008-5472.CAN-04-1195; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Moll UM, 2004, MOL CANCER RES, V2, P371; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Nicoll G, 2001, BRIT J CANCER, V85, P1878, DOI 10.1054/bjoc.2001.2163; Obad S, 2004, ONCOGENE, V23, P4050, DOI 10.1038/sj.onc.1207524; Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200; Pinte S, 2004, ONCOGENE, V23, P4023, DOI 10.1038/sj.onc.1207504; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Tschan MP, 2003, J BIOL CHEM, V278, P42750, DOI 10.1074/jbc.M307067200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wolcke J, 2003, J BIOL CHEM, V278, P32587, DOI 10.1074/jbc.M303615200; Wu GJ, 2005, CANCER RES, V65, P758	42	44	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2030	2039		10.1038/sj.onc.1209240	http://dx.doi.org/10.1038/sj.onc.1209240			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16301995				2022-12-17	WOS:000236359700006
J	Wu, D; Chen, B; Parihar, K; He, L; Fan, C; Zhang, J; Liu, L; Gillis, A; Bruce, A; Kapoor, A; Tang, D				Wu, D; Chen, B; Parihar, K; He, L; Fan, C; Zhang, J; Liu, L; Gillis, A; Bruce, A; Kapoor, A; Tang, D			ERK activity facilitates activation of the S-phase DNA damage checkpoint by modulating ATR function	ONCOGENE			English	Article						hydroxyurea; MEK1; Erk; ATR; S-phase checkpoint	ATAXIA TELANGIECTASIA CELLS; PROTEIN-KINASE KINASE; HISTONE H2AX; SUSTAINED ACTIVATION; CYCLIN D1; P53; INHIBITORS; REPAIR; TRANSFORMATION; INSTABILITY	Although Erk kinase has been recently reported to function in the DNA damage response, the mechanism governing this process is unknown. We report here that hydroxyurea (HU) activates Erk via MEK1, a process that is sensitized by a constitutively active MEK1 (MEK1Q56P) and attenuated by a dominant-negative MEK1 (MEK1K97M). While ectopic MEK1Q56P sensitized HU-induced S-phase arrest, inhibition of Erk activation via U0126, PD98059, and MEK1K97M attenuated the arrest, and thereby enhanced cells to HU-induced toxicity. Taken together, we demonstrate an important contribution of Erk to the activation of the S-phase DNA damage checkpoint. This can be attributed to Erk's regulatory role in modulating ATR function. Inhibition of Erk activation with U0126/PD98059 and MEK1K97M substantially reduced HU-induced ATR nuclear foci, leading to a dramatic reduction of gamma H2AX and its nuclear foci. Reduction of MEK1 function by a small interference RNA ( siRNA) MEK1 and ectopic MEK1K97M significantly decreased HU-induced gamma H2AX. Conversely, ectopic MEK1Q56P enhanced gamma H2AX foci. Furthermore, immunofluorescent and cell fractioning experiments revealed cytosolic and nuclear localization of ATR. HU treatment caused the redistribution of ATR from the cytosol to the nucleus, a process that is inhibited by U0126. Collectively, we show that Erk kinase modulates HU-initiated DNA damage response by regulating ATR function.	St Joseph Hosp, Father Sean Sullivan Res Inst, Hamilton, ON L8N 4A6, Canada; McMaster Univ, Dept Med, Div Nephrol, Hamilton, ON, Canada; McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada	McMaster University; McMaster University	Tang, D (corresponding author), St Joseph Hosp, Father Sean Sullivan Res Inst, T3310,50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	damut@mcmaster.ca	Tang, Damu/AAQ-1786-2021; Kapoor, Anil/AAQ-7184-2021	Tang, Damu/0000-0002-3282-9521; Kapoor, Anil/0000-0001-9180-8029				Ahn NG, 2001, METHOD ENZYMOL, V332, P417; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fernandez-Capetillo O, 2003, DEV CELL, V4, P497, DOI 10.1016/S1534-5807(03)00093-5; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Johns DG, 1998, BIOCHEM PHARMACOL, V55, P1551, DOI 10.1016/S0006-2952(97)00664-3; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Krepinsky J, 2002, EXPERT OPIN THER PAT, V12, P1795, DOI 10.1517/13543776.12.12.1795; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; LEHMANN AR, 1979, NUCLEIC ACIDS RES, V6, P1953, DOI 10.1093/nar/6.5.1953; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li YX, 2004, ONCOGENE, V23, P7355, DOI 10.1038/sj.onc.1207957; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Pippin JW, 2003, J CLIN INVEST, V111, P877, DOI 10.1172/JCI200315645; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schar P, 2001, CELL, V104, P329, DOI 10.1016/S0092-8674(01)00220-3; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; SHILOH Y, 1982, CARCINOGENESIS, V3, P815, DOI 10.1093/carcin/3.7.815; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Tang D, 2001, J BIOL CHEM, V276, P30461, DOI 10.1074/jbc.M102045200; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; TAYLOR AMR, 1979, CANCER RES, V39, P1046; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	49	44	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1153	1164		10.1038/sj.onc.1209148	http://dx.doi.org/10.1038/sj.onc.1209148			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16186792				2022-12-17	WOS:000235537500003
J	Linnerth, NM; Baldwin, M; Campbell, C; Brown, M; McGowan, H; Moorehead, RA				Linnerth, NM; Baldwin, M; Campbell, C; Brown, M; McGowan, H; Moorehead, RA			IGF-II induces CREB phosphorylation and cell survival in human lung cancer cells	ONCOGENE			English	Article						IGF-II; CREB; lung cancer; transformation	GROWTH-FACTOR-I; ELEMENT-BINDING PROTEIN; TRANSCRIPTION FACTOR CREB; HUMAN-MELANOMA CELLS; GENE-EXPRESSION; BREAST-CANCER; FACTOR FAMILY; FACTOR RECEPTOR; TUMOR-GROWTH; MICE	We have previously shown that lung tumors arising in MMTV-IGF-II transgenic mice displayed elevated levels of phospho rylated cAMP response element binding protein (CREB). To investigate the role that insulin-like growth factor II (IGF-II) and CREB play in human lung tumorigenesis, A549 and NCI-H358 cells were examined. In these cell lines, IGF-II administration enhances human tumor cell survival and CREB phosphorylation. Further, the effects of IGF-II on cell survival and CREB phosphorylation appeared to be mediated, at least in part, by activation of the Erk pathways, as inhibition of these signaling pathways reduced tumor cell survival and CREB phosphorylation. Specifi. cally, Erk5 appeared as the predominant mediator of CRE B phosporylation. To further verify the importance of CREB in human lung tumorigenesis, A549 and NCI-H358 cells were stably transfected with a vector containing a dominant negative CREB construct (KCREB). KCREB transfection significantly inhibited the soft agar growth of both human tumor cell lines. In contrast, overexpression of wild-type CREB in the normal human bronchial epithelial cell line, HBE135, enhanced soft agar growth. Therefore, our results indicate that CREB and its associated proteins play a significant role in lung adenocarcinoma and IGF-II induces CREB phosphorylation, at least in part, via the Erk5 signaling pathway.	Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada	University of Guelph	Moorehead, RA (corresponding author), Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada.	rmoorehe@uoguelph.ca		, Roger/0000-0001-9539-6295				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Alvarez-Lopez C, 2004, NEUROSCI LETT, V357, P223, DOI 10.1016/j.neulet.2003.12.099; Arteaga CL, 1996, CANCER RES, V56, P1098; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Fowden AL, 2003, PLACENTA, V24, P803, DOI 10.1016/S0143-4004(03)00080-8; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; Grothey A, 1999, J CANCER RES CLIN, V125, P166, DOI 10.1007/s004320050259; HABENER JF, 1989, HORM RES, V32, P61, DOI 10.1159/000181246; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; Jean D, 2000, MOL CELL BIOCHEM, V212, P19, DOI 10.1023/A:1007128101751; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Jiang YX, 1999, ONCOGENE, V18, P6071, DOI 10.1038/sj.onc.1202984; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kelemen BR, 2002, J BIOL CHEM, V277, P8741, DOI 10.1074/jbc.M108459200; Khachigian LM, 1998, J MOL MED-JMM, V76, P613, DOI 10.1007/s001090050258; Liu WL, 2001, ENDOCRINOLOGY, V142, P1710, DOI 10.1210/en.142.5.1710; Luciani P, 2003, EUR J ENDOCRINOL, V148, P579, DOI 10.1530/eje.0.1480579; MALKINSON AM, 1991, ENVIRON HEALTH PERSP, V93, P149, DOI 10.2307/3431183; Moorehead RA, 2003, ONCOGENE, V22, P853, DOI 10.1038/sj.onc.1206188; Moorehead RA, 2001, CELL DEATH DIFFER, V8, P16, DOI 10.1038/sj.cdd.4400762; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; OFIR R, 1991, GENE EXPRESSION, V1, P55; Pavelic J, 2002, MOL MED, V8, P149, DOI 10.1007/BF03402007; Pavelic K, 1999, J PATHOL, V188, P69; Peri A, 2002, EUR J ENDOCRINOL, V146, P759, DOI 10.1530/eje.0.1460759; Perissi V, 1999, P NATL ACAD SCI USA, V96, P3652, DOI 10.1073/pnas.96.7.3652; Petrich BG, 2004, TRENDS CARDIOVAS MED, V14, P50, DOI 10.1016/j.tcm.2003.11.002; Quinn KA, 1996, J BIOL CHEM, V271, P11477, DOI 10.1074/jbc.271.19.11477; Rabelo FLA, 2003, BIOCHEM BIOPH RES CO, V303, P968, DOI 10.1016/S0006-291X(03)00454-6; Reddy SPM, 2002, AM J RESP CELL MOL, V27, P64, DOI 10.1165/ajrcmb.27.1.20020003oc; REEVE JG, 1993, CANCER RES, V53, P4680; REEVE JG, 1992, J NATL CANCER I, V84, P628, DOI 10.1093/jnci/84.8.628; REHM S, 1991, EXP LUNG RES, V17, P181, DOI 10.3109/01902149109064410; Rosenberg D, 2002, ENDOCR RES, V28, P765, DOI 10.1081/ERC-120017071; Rosenberg D, 2002, ANN NY ACAD SCI, V968, P65, DOI 10.1111/j.1749-6632.2002.tb04327.x; ROTSCH M, 1992, J CANCER RES CLIN, V118, P502, DOI 10.1007/BF01225264; RUBIN R, 1995, LAB INVEST, V73, P311; Rubini M, 1999, EXP CELL RES, V251, P22, DOI 10.1006/excr.1999.4562; Saeki K, 2001, LEUKEMIA, V15, P238, DOI 10.1038/sj.leu.2402014; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; Scapoli L, 2004, ONCOGENE, V23, P805, DOI 10.1038/sj.onc.1207163; Shankar DB, 2004, LEUKEMIA LYMPHOMA, V45, P265, DOI 10.1080/1042819031000151095; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sung JY, 2001, J BIOL CHEM, V276, P13858, DOI 10.1074/jbc.M010610200; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; Takanami I, 1996, J SURG ONCOL, V61, P205, DOI 10.1002/(SICI)1096-9098(199603)61:3<205::AID-JSO8>3.0.CO;2-F; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358; Yan SF, 2000, J CLIN INVEST, V105, P553, DOI 10.1172/JCI9513; YOSHIDA K, 1995, J NEUROCHEM, V65, P1499	58	44	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7310	7319		10.1038/sj.onc.1208882	http://dx.doi.org/10.1038/sj.onc.1208882			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16158061				2022-12-17	WOS:000233142100007
J	Martin, NL; Saba-El-Leil, MK; Sadekova, S; Meloche, S; Sauvageau, G				Martin, NL; Saba-El-Leil, MK; Sadekova, S; Meloche, S; Sauvageau, G			EN2 is a candidate oncogene in human breast cancer	ONCOGENE			English	Article						Engrailed-2; homeobox; breast cancer; RNAi; transplantation	DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; HOMEOBOX GENES; IN-VIVO; C-MYC; MOUSE; CELLS; MICE; TRANSFORMATION; PHENOTYPE	Only a few critical oncogenes have been identified in the more commonly occurring cases of sporadic breast cancer. We provide evidence that EN2 is ectopically expressed in a subset of human breast cancer and may have a causal role in mammary tumorigenesis. Nontumorigenic mammary cell lines engineered to ectopically express En-2 have a marked reduction in their cycling time, lose cell contact inhibition, become sensitive to 17-AAG treatment, fail to differentiate when exposed to lactogenic hormones and induce mammary tumors when transplanted into cleared mammary glands of syngeneic hosts. RNA interference studies suggest that EN2 expression is required for the maintenance of the transformed phenotype of a human breast tumor cell line.	Inst Rech Immunol & Cancerol, Lab Mol Genet Hematopoiet Stem Cells, Montreal, PQ H3C 3J7, Canada; Inst Rech Immunol & Cancerol, Lab Signaling & Cell Growth, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 2B4, Canada; Hop Maison Neuve Rosemont, Dept Med, Montreal, PQ H1T 2M4, Canada; Hop Maison Neuve Rosemont, Div Hematol, Montreal, PQ H1T 2M4, Canada; Hop Maison Neuve Rosemont, Leukemia Cell Bank Quebec, Montreal, PQ H1T 2M4, Canada	Universite de Montreal; Universite de Montreal; McGill University; Universite de Montreal; Universite de Montreal; Universite de Montreal	Meloche, S (corresponding author), Inst Rech Immunol & Cancerol, Lab Mol Genet Hematopoiet Stem Cells, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	sylvain.meloche@umontreal.ca; guy.sauvageau@umontreal.ca		Sauvageau, Guy/0000-0002-4333-7266				Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Baselga J, 2002, CANCER CELL, V1, P319, DOI 10.1016/S1535-6108(02)00066-1; Bieche I, 1999, CANCER RES, V59, P2759; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DEOME K.B., 1959, JNCI-J NATL CANCER I, V78, P751; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HUGUET EL, 1994, CANCER RES, V54, P2615; Humphreys RC, 1997, CELL GROWTH DIFFER, V8, P839; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Ingvarsson S, 1999, SEMIN CANCER BIOL, V9, P277, DOI 10.1006/scbi.1999.0124; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; LAWRENCE HJ, 1995, EXP HEMATOL, V23, P1160; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lewis MT, 2000, BREAST CANCER RES, V2, P158, DOI 10.1186/bcr49; Liao DJ, 2000, ENDOCR-RELAT CANCER, V7, P143, DOI 10.1677/erc.0.0070143; LIZARDNACOL S, 1995, CANCER RES, V55, P4416; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; Neckers L, 2003, NATURE, V425, P357, DOI 10.1038/425357a; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAWLIUK R, 1994, BLOOD, V84, P2868, DOI 10.1182/blood.V84.9.2868.bloodjournal8492868; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; Ross JS, 2003, EXPERT REV MOL DIAGN, V3, P573, DOI 10.1586/14737159.3.5.573; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thorsteinsdottir U, 1999, MOL CELL BIOL, V19, P6355; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8	39	44	56	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6890	6901		10.1038/sj.onc.1208840	http://dx.doi.org/10.1038/sj.onc.1208840			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007149				2022-12-17	WOS:000232701700004
J	Ni, HH; Dydensborg, AB; Herring, FE; Basora, N; Gagne, D; Vachon, PH; Beaulieu, JF				Ni, HH; Dydensborg, AB; Herring, FE; Basora, N; Gagne, D; Vachon, PH; Beaulieu, JF			Upregulation of a functional form of the beta(4) integrin subunit in colorectal cancers correlates with c-Myc expression	ONCOGENE			English	Article						laminin receptor; integrin; colon; adenocarcinoma cells; epithelial cells	SUCRASE-ISOMALTASE EXPRESSION; HUMAN-COLON CARCINOMA; CRYPT-VILLUS AXIS; DIFFERENTIAL EXPRESSION; CYTOPLASMIC DOMAIN; ALPHA(6)BETA(4) INTEGRIN; ADHESION; LAMININ-5; MECHANISM; SEQUENCE	The integrin beta(4) subunit has been shown to be involved in various aspects of cancer progression. The aim of the present work was to evaluate the expression of beta(4) in primary colon cancers and to investigate the occurrence of a previously identified intestinal nonfunctional variant of beta(4) (beta(ctd-)(4)) for adhesion to laminin. Immunodetection of beta(4) using a panel of antibodies and RT-PCR analyses were performed on series of paired primary colon tumors and corresponding resection margins. The beta(4) subunit was found to be significantly overexpressed in cancer specimens at both the protein and transcript levels. Surprisingly, beta(4) levels of expression were closely correlated with those of the oncogene c-Myc in individual specimens. In vitro studies of c-Myc overexpression showed an upregulation of beta(4) promoter activity. Finally, the beta(ctd-)(4) form was identified in the normal proliferative colonic cells but was found to be predominantly absent in colon cancer cells, both in situ and in vitro. We concluded that the beta(ctd-)(4) form is lost from colon cancer cells, while the level of the wildtype form of beta(4), which is functional for adhesion to laminin, is increased in primary tumors in relation with the expression of c-Myc.	Univ Sherbrooke, CIHR Grp Funct Dev & Physiopathol Digest Tract, Dept Anat & Biol Cellulaire, Fac Med, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Fac Med, Dept Physiol & Biophys, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke	Beaulieu, JF (corresponding author), Univ Sherbrooke, CIHR Grp Funct Dev & Physiopathol Digest Tract, Dept Anat & Biol Cellulaire, Fac Med, Sherbrooke, PQ J1H 5N4, Canada.	Jean-Francois.Beaulieu@USherbrooke.ca	Beaulieu, Jean-Francois/D-2054-2010					ASTLER VB, 1954, ANN SURG, V139, P846, DOI 10.1097/00000658-195406000-00015; Basora N, 1999, J BIOL CHEM, V274, P29819, DOI 10.1074/jbc.274.42.29819; BEAULIEU JF, 1989, J BIOL CHEM, V264, P20000; BEAULIEU JF, 1991, BIOCHEM J, V280, P599, DOI 10.1042/bj2800599; BEAULIEU JF, 1994, GASTROENTEROLOGY, V106, P829, DOI 10.1016/0016-5085(94)90740-4; BEAULIEU JF, 1992, J CELL SCI, V102, P427; BEAULIEU JF, 1990, GASTROENTEROLOGY, V98, P1467, DOI 10.1016/0016-5085(90)91077-J; BEAULIEU JF, 1999, FRONT BIOSCI, V4, P310; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; CHANTRET I, 1988, CANCER RES, V48, P1936; CLARKE AS, 1994, CELL ADHES COMMUN, V2, P1, DOI 10.3109/15419069409014197; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dans M, 2001, J BIOL CHEM, V276, P1494, DOI 10.1074/jbc.M008663200; de Melker AA, 1999, BIOESSAYS, V21, P499, DOI 10.1002/(SICI)1521-1878(199906)21:6<499::AID-BIES6>3.0.CO;2-D; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; Escaffit F, 2005, J CELL PHYSIOL, V203, P15, DOI 10.1002/jcp.20189; FALCIONI R, 1994, INT J ONCOL, V5, P573; Gauthier R, 2001, AM J PHYSIOL-CELL PH, V280, pC1540, DOI 10.1152/ajpcell.2001.280.6.C1540; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; HESSLE H, 1984, DIFFERENTIATION, V26, P49, DOI 10.1111/j.1432-0436.1984.tb01372.x; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; LaFlamme SE, 1997, MATRIX BIOL, V16, P153, DOI 10.1016/S0945-053X(97)90003-2; Lavigne P, 1998, J MOL BIOL, V281, P165, DOI 10.1006/jmbi.1998.1914; Levens D, 2002, P NATL ACAD SCI USA, V99, P5757, DOI 10.1073/pnas.102173199; Liu SC, 2000, J CELL SCI, V113, P3563; Lohi J, 2000, APMIS, V108, P161, DOI 10.1034/j.1600-0463.2000.d01-40.x; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Nikolopoulos SN, 2004, CANCER CELL, V6, P471, DOI 10.1016/j.ccr.2004.09.029; Nishida K, 1997, BIOCHEM BIOPH RES CO, V241, P258, DOI 10.1006/bbrc.1997.7808; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Sanders RJ, 1998, CANCER INVEST, V16, P329, DOI 10.3109/07357909809084653; SCHUG J, 1997, ISMB, V5, P268; SMITH DR, 1993, BRIT J CANCER, V68, P407, DOI 10.1038/bjc.1993.350; Sordat I, 1998, J PATHOL, V185, P44, DOI 10.1002/(SICI)1096-9896(199805)185:1<44::AID-PATH46>3.0.CO;2-A; STALLMACH A, 1992, GUT, V33, P342, DOI 10.1136/gut.33.3.342; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; Takaoka AS, 1998, J BIOL CHEM, V273, P33848, DOI 10.1074/jbc.273.50.33848; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; Tani T, 1997, AM J PATHOL, V151, P1289; Tani T, 1996, AM J PATHOL, V149, P781; VACHON PH, 1995, AM J PHYSIOL-GASTR L, V268, pG857, DOI 10.1152/ajpgi.1995.268.5.G857; VACHON PH, 1992, GASTROENTEROLOGY, V103, P414, DOI 10.1016/0016-5085(92)90829-N; vanLeusden MR, 1997, BIOCHEM BIOPH RES CO, V235, P826, DOI 10.1006/bbrc.1997.6892; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0	58	44	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6820	6829		10.1038/sj.onc.1208848	http://dx.doi.org/10.1038/sj.onc.1208848			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007143				2022-12-17	WOS:000232527800009
J	Adiseshaiah, P; Peddakama, S; Zhang, Q; Kalvakolanu, DV; Reddy, SP				Adiseshaiah, P; Peddakama, S; Zhang, Q; Kalvakolanu, DV; Reddy, SP			Mitogen regulated induction of FRA-1 proto-oncogene is controlled by the transcription factors binding to both serum and TPA response elements	ONCOGENE			English	Article						AP1; proto-oncogene; SRF; Elk1; transcription; ATF/CREB	C-FOS TRANSCRIPTION; BRONCHIAL EPITHELIAL-CELLS; FAMILY-MEMBERS; CANCER CELLS; UV-LIGHT; ERK; EXPRESSION; TRANSFORMATION; ACTIVATION; GENE	FRA-1, a member of the FOS family of transcription factors, is overexpressed in a variety of human tumors, and contributes to tumor progression. In addition to mitogens, various toxicants and carcinogens persistently induce FRA-1 expression in vitro and in vivo. Although the mitogen induced expression of c-FOS is relatively well understood, it is poorly defined in the case of FRA-1. Our recent analysis of the FRA-1 promoter has shown a critical role for a TRE located at - 318 in mediating the TPA-induced expression. The - 379 to - 283 bp promoter segment containing a critical TRE ( - 318), however, is insufficient for the induction of FRA-1 promoter. Here, we show that a 40-bp (- 276/- 237) segment, comprising a TCF binding site and the CArG box ( collectively known as serum response element, SRE), and an ATF site, is also necessary for the FRA-1 induction by TPA and EGF. Interestingly, the - 283 to +32 bp FRA-1 promoter fragment containing an SRE and an ATF site alone was also insufficient to confer TPA sensitivity to a reporter gene. However, in association with the - 318 TRE, the SRE and ATF sites imparted a strong TPA-inducibility to the reporter. Similarly, EGF also required these motifs for the full induction of this gene. Using ChIP assays we show that, in contrast to c-Jun, SRF, Elk1, ATF1 and CREB proteins bind to SRE and ATF sites of the FRA-1 promoter, constitutively. RNAi-mediated knockdown of endogenous SRF, ELK1 and c-JUN protein expression significantly reduced TPA-stimulated FRA-1 promoter activity. Thus, a bipartite enhancer formed by an upstream TRE and the downstream SRE and ATF sites and the cognate factors is necessary and sufficient for the regulation of FRA-1 in response to mitogens.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Div Physiol, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Univ Maryland, Greenbaum Canc Ctr, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine	Reddy, SP (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Div Physiol, Dept Environm Hlth Sci, Rm W7006,615 N Wolfe St, Baltimore, MD 21205 USA.	sreddy@jhsph.edu	Adiseshaiah, Pavan/R-3917-2018		NCI NIH HHS [CA78282, CA105005] Funding Source: Medline; NHLBI NIH HHS [HL58122, HL66109] Funding Source: Medline; NIEHS NIH HHS [ES011863, ES30819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078282, R01CA105005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058122, R01HL066109, R01HL058122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011863] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adiseshaiah P, 2003, J BIOL CHEM, V278, P47423, DOI 10.1074/jbc.M303505200; Andersen H, 2002, ONCOGENE, V21, P4843, DOI 10.1038/sj.onc.1205590; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Gupta P, 2002, J BIOL CHEM, V277, P50550, DOI 10.1074/jbc.M209799200; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; Hu YC, 2001, CLIN CANCER RES, V7, P2213; Hurd TW, 2002, BIOCHEM J, V368, P573, DOI 10.1042/BJ20020579; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; MATSUI M, 1990, ONCOGENE, V5, P249; Papaiahgari S, 2004, J BIOL CHEM, V279, P42302, DOI 10.1074/jbc.M408275200; Parks WC, 2001, RESP RES, V2, P10, DOI 10.1186/rr33; Patterson T, 2001, ONCOGENE, V20, P634, DOI 10.1038/sj.onc.1204134; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Ramos-Nino ME, 2002, CANCER RES, V62, P6065; REDDY SP, 2002, AM J RESP CRIT CARE, V165, pA828; Reddy SPM, 2002, AM J PHYSIOL-LUNG C, V283, pL1161, DOI 10.1152/ajplung.00140.2002; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; RUNKEL L, 1991, MOL CELL BIOL, V11, P1270, DOI 10.1128/MCB.11.3.1270; Schreiber M, 1997, ONCOGENE, V15, P1171, DOI 10.1038/sj.onc.1201460; Selvaraj A, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-13; Soh JW, 1999, MOL CELL BIOL, V19, P1313; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; Tulchinsky E, 2000, HISTOL HISTOPATHOL, V15, P921, DOI 10.14670/HH-15.921; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; van Riggelen J, 2005, J BIOL CHEM, V280, P3286, DOI 10.1074/jbc.M409915200; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WISDOM R, 1993, MOL CELL BIOL, V13, P2635, DOI 10.1128/MCB.13.5.2635; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zajchowski DA, 2001, CANCER RES, V61, P5168	41	44	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4193	4205		10.1038/sj.onc.1208583	http://dx.doi.org/10.1038/sj.onc.1208583			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15806162				2022-12-17	WOS:000229815300004
J	Jones, LP; Li, ML; Halama, ED; Ma, YX; Lubet, R; Grubbs, CJ; Deng, CX; Rosen, EM; Furth, PA				Jones, LP; Li, ML; Halama, ED; Ma, YX; Lubet, R; Grubbs, CJ; Deng, CX; Rosen, EM; Furth, PA			Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer	ONCOGENE			English	Article						Brca1; tamoxifen; mammary gland; transgenic mice	ESTROGEN-RECEPTOR MODULATORS; BRCA2 MUTATION CARRIERS; TRANSGENIC MICE; TUMOR; WOMEN; GLAND; PREVENTION; INHIBITION; ALPHA; RISK	Loss of full-length Brca1 in mammary epithelial cells of the mouse mammary tumor virus (MMTV)-Cre Brca1 conditional exon 11 deletion mouse model results in the development of mammary adenocarcinomas with similar genetic changes to those found in human BRCA1-mutation-related breast cancers. We used this experimental model to evaluate the chemopreventive effect of tamoxifen on the development of mammary preneoplasia and adenocarcinoma. No protective effects of tamoxifen administration on mammary cancer development were found. Instead, tamoxifen treatment significantly increased rates of mammary epithelial cell proliferation and the prevalence of mammary hyperplasia at 6 months of age. Tamoxifen-exposed mice developed adenocarcinomas at younger ages than control mice and a higher percentage of mice developed adenocarcinomas by 12 months of age. Both whole mouse and tissue culture cell models were used to test if loss of full-length Brca1 was associated with a relative increase in the agonist activity of tamoxifen. Tamoxifen induced increased ductal growth in MMTV-Cre Brca1 conditional mice compared to wild type. Estrogen receptor alpha (ER alpha) expression was downregulated in the tamoxifen-induced hyperplasias. Reducing BRCA1 levels in MCF-7 cells using siRNA resulted in a relative increase in the agonist activity of tamoxifen. Results suggest a model of mammary cancer progression in which loss of full-length Brca1 altered the agonist/antagonist activity of tamoxifen, resulting in tamoxifen-induced mammary epithelial cell proliferation with subsequent loss of ERalpha expression and development of ER alpha-negative hyperplasias and adenocarcinomas.	Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20057 USA; NCI, Div Chemoprevent, Bethesda, MD 20892 USA; Univ Alabama, Chemoprevent Ctr, Birmingham, AL USA; NIDDKD, NIH, Bethesda, MD 20892 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Furth, PA (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Res Bldg Room E520A,3970 Reservoir Rd, Washington, DC 20057 USA.	paf3@georgetown.edu	deng, chuxia/N-6713-2016		DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005024] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009686, N01-CN-05024, 2T32CA09-686-08] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachelier Richard, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P512; Bischoff ED, 1999, J NATL CANCER I, V91, P2118, DOI 10.1093/jnci/91.24.2118; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Brown PH, 2000, BREAST CANCER RES TR, V62, P1, DOI 10.1023/A:1006484604454; Cavalli LR, 2004, CANCER GENET CYTOGEN, V149, P38, DOI 10.1016/S0165-4608(03)00282-6; Cheng GJ, 2004, P NATL ACAD SCI USA, V101, P3739, DOI 10.1073/pnas.0307864100; Chlebowski RT, 2002, ANNU REV MED, V53, P519, DOI 10.1146/annurev.med.53.082901.103925; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dutertre M, 2000, J PHARMACOL EXP THER, V295, P431; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2002, CANCER RES, V62, P141; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Foulkes WD, 2004, CLIN CANCER RES, V10, P2029, DOI 10.1158/1078-0432.CCR-03-1061; Gallo M A, 1997, Semin Oncol, V24, pS1; Graham JD, 2000, J STEROID BIOCHEM, V74, P255, DOI 10.1016/S0960-0760(00)00101-1; Grubbs CJ, 2003, CANCER LETT, V201, P17, DOI 10.1016/S0304-3835(03)00461-0; Heldring N, 2004, MOL CELL BIOL, V24, P3445, DOI 10.1128/MCB.24.8.3445-3459.2004; Jordan VC, 2004, CANCER CELL, V5, P207, DOI 10.1016/S1535-6108(04)00059-5; Kadouri L, 2004, INT J CANCER, V108, P399, DOI 10.1002/ijc.11531; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; King MC, 2001, JAMA-J AM MED ASSOC, V286, P2251, DOI 10.1001/jama.286.18.2251; KOTOULA V, 1993, HISTOL HISTOPATHOL, V8, P627; Kurokawa H, 2003, CLIN CANCER RES, V9, p511S; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Lonard DM, 2004, MOL CELL BIOL, V24, P14, DOI 10.1128/MCB.24.1.14-24.2004; McDonnell DP, 2002, AM J CARDIOL, V90, p35F, DOI 10.1016/S0002-9149(01)02221-4; Meijers-Heijboer H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; Menard S, 2000, CANCER RES, V60, P273; Metcalfe K, 2004, J CLIN ONCOL, V22, P2328, DOI 10.1200/JCO.2004.04.033; Moller P, 2002, INT J CANCER, V101, P555, DOI 10.1002/ijc.10641; Mote PA, 2004, GENE CHROMOSOME CANC, V39, P236, DOI 10.1002/gcc.10321; Narod SA, 2000, LANCET, V356, P1876, DOI 10.1016/S0140-6736(00)03258-X; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Osborne CK, 2003, BREAST, V12, P362, DOI 10.1016/S0960-9776(03)00137-1; OSBORNE M P, 1990, Steroids, V55, P114, DOI 10.1016/0039-128X(90)90006-W; PLOTKIN D, 1978, JAMA-J AM MED ASSOC, V240, P2644, DOI 10.1001/jama.240.24.2644; Rebbeck TR, 2001, CANCER RES, V61, P5420; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; REDDEL RR, 1984, EUR J CANCER CLIN ON, V20, P1419, DOI 10.1016/0277-5379(84)90062-2; Reiter R, 2004, ONCOGENE, V23, P403, DOI 10.1038/sj.onc.1207202; Rendi MH, 2004, CANCER RES, V64, P3566, DOI 10.1158/0008-5472.CAN-04-0234; Robson M, 2002, EUR J CANCER, V38, pS18; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Schrag D, 2000, JAMA-J AM MED ASSOC, V283, P617, DOI 10.1001/jama.283.5.617; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525; Tilli MT, 2003, AM J PATHOL, V163, P1713, DOI 10.1016/S0002-9440(10)63529-8; VELDHUIS JD, 1979, JAMA-J AM MED ASSOC, V241, P2506, DOI 10.1001/jama.241.23.2506; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Xiong JB, 2003, MOL CELL BIOL, V23, P8668, DOI 10.1128/MCB.23.23.8668-8690.2003; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yang XH, 2003, CANCER RES, V63, P2425; Yoshidome K, 2000, CANCER RES, V60, P6901; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	55	44	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3554	3562		10.1038/sj.onc.1208426	http://dx.doi.org/10.1038/sj.onc.1208426			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15750629				2022-12-17	WOS:000229221800003
J	Iwatsuki, K; Tanaka, K; Kaneko, T; Kazama, R; Okamoto, S; Nakayama, Y; Ito, Y; Satake, M; Takahashi, S; Miyajima, A; Watanabe, T; Hara, T				Iwatsuki, K; Tanaka, K; Kaneko, T; Kazama, R; Okamoto, S; Nakayama, Y; Ito, Y; Satake, M; Takahashi, S; Miyajima, A; Watanabe, T; Hara, T			Runx1 promotes angiogenesis by downregulation of insulin-like growth factor-binding protein-3	ONCOGENE			English	Article						angiogenesis; endothelial cell; IGFBP-3; Runx1; transcriptional repression	GONAD-MESONEPHROS REGION; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; ACUTE MYELOID-LEUKEMIA; ENDOTHELIAL-CELLS; GENE-TRANSCRIPTION; CORPUS-LUTEUM; MOUSE EMBRYO; STEM-CELLS; EXPRESSION; AML1	Mouse embryos lacking the Runx1 transcription factor exhibit an angiogenic defect accompanied by the absence of hematopoietic stem cells ( HSCs). To ask whether Runx1 plays a direct role in angiogenesis, we established a novel endothelial progenitor cell line, designated AEL-DeltaR1, from the aorta-gonad-mesonephros ( AGM) region of Runx1-null mouse. We introduced Runx1 cDNA into AEL-DeltaR1 cells under the doxycycline-inducible promoter. The ability of AEL-DeltaR1 cells to form vascular networks on matrigel was highly enhanced by the restored expression of Runx1. By molecular comparison of mRNAs in AEL-DeltaR1 cells before and after the induction of Runx1, we found that mRNA expression of insulin-like growth factor-binding protein 3 (IGFBP-3) is downregulated by Runx1. Gel retardation and reporter assays revealed that Runx1 binds to the promoter region of mouse IGFBP-3 gene and represses its transcription. When IGFBP-3 was exogenously added in the matrigel assay, the angiogenesis-enhancing activity of Runx1 was suppressed in a dose-dependent manner. These results demonstrate that Runx1 is directly involved in angiogenesis by repression of IGFBP-3 mRNA expression.	Tokyo Metropolitan Inst Med Sci, Dept Tumor Biochem, Tokyo Metropolitan Org Med Res, Bunkyo Ku, Tokyo 1138613, Japan; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore; Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	Tokyo Metropolitan Institute of Medical Science; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Tohoku University; University of Tokyo; University of Tokyo	Hara, T (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Tumor Biochem, Tokyo Metropolitan Org Med Res, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	thara@rinshoken.or.jp	Okamoto, Shiki/X-7274-2018	Okamoto, Shiki/0000-0002-2802-0527; Takahashi, Shin-Ichiro/0000-0002-2323-2010				BAE SC, 1993, ONCOGENE, V8, P809; Bertrand-Philippe M, 2004, J BIOL CHEM, V279, P24530, DOI 10.1074/jbc.M311804200; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; Dahlfors G, 2000, ENDOCRINOLOGY, V141, P2062, DOI 10.1210/en.141.6.2062; Delafontaine P, 1996, BIOCHEM BIOPH RES CO, V222, P478, DOI 10.1006/bbrc.1996.0769; ERICKSON GF, 1993, ENDOCRINOLOGY, V133, P1147, DOI 10.1210/en.133.3.1147; Erondu NE, 1996, GROWTH REGULAT, V6, P1; Erondu NE, 1997, ENDOCRINOLOGY, V138, P2856, DOI 10.1210/en.138.7.2856; Franklin SL, 2003, J CLIN ENDOCR METAB, V88, P900, DOI 10.1210/jc.2002-020472; Fraser HM, 1998, HUM REPROD, V13, P2180, DOI 10.1093/humrep/13.8.2180; Fraser HM, 2000, J CLIN ENDOCR METAB, V85, P1672, DOI 10.1210/jc.85.4.1672; Gucev ZS, 1996, CANCER RES, V56, P1545; Hara T, 1999, IMMUNITY, V11, P567, DOI 10.1016/S1074-7613(00)80132-6; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; Iwatsuki K, 2000, BIOL REPROD, V62, P1352, DOI 10.1095/biolreprod62.5.1352; Javed A, 2000, J CELL SCI, V113, P2221; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; Keller G, 1999, EXP HEMATOL, V27, P777, DOI 10.1016/S0301-472X(99)00024-7; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; LEE GH, 1995, AM J PATHOL, V147, P1811; Lee WH, 1999, ENDOCRINE, V11, P181, DOI 10.1385/ENDO:11:2:181; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Mukouyama Y, 2000, DEV BIOL, V220, P27, DOI 10.1006/dbio.2000.9617; Mukouyama YS, 1998, IMMUNITY, V8, P105, DOI 10.1016/S1074-7613(00)80463-X; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; North T, 1999, DEVELOPMENT, V126, P2563; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; OLNEY RC, 1995, J ENDOCRINOL, V146, P279, DOI 10.1677/joe.0.1460279; Ongeri EM, 2004, ENDOCRINOLOGY, V145, P1776, DOI 10.1210/en.2003-1552; Schmid MC, 2003, INT J CANCER, V103, P577, DOI 10.1002/ijc.10874; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Sun LX, 2004, ONCOGENE, V23, P4722, DOI 10.1038/sj.onc.1207589; Sun LX, 2001, CANCER RES, V61, P4994; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Tamura H, 2002, EXP HEMATOL, V30, P957, DOI 10.1016/S0301-472X(02)00822-6; Tanaka K, 2002, DEV BIOL, V246, P466, DOI 10.1006/dbio.2002.0671; Tucci M, 1998, J ENDOCRINOL, V157, P13, DOI 10.1677/joe.0.1570013; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Watsuji T, 1997, BIOCHEM BIOPH RES CO, V234, P769, DOI 10.1006/bbrc.1997.6705; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925-4773(01)00428-2	53	44	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1129	1137		10.1038/sj.onc.1208287	http://dx.doi.org/10.1038/sj.onc.1208287			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592512				2022-12-17	WOS:000226898700001
J	Fan, QW; Weiss, WA				Fan, QW; Weiss, WA			RNA interference against a glioma-derived allele of EGFR induces blockade at G(2)M	ONCOGENE			English	Article						siRNA; EGFR; Delta EGFR; PI3 kinase; LY294002; combination therapy	GROWTH-FACTOR RECEPTOR; G(1) ARREST; LUNG-CANCER; EXPRESSION; GENE; P27(KIP1); AMPLIFICATION; INHIBITION; PHASE; CELLS	Amplification and mutation of the epidermal growth factor receptor (EGFR) is common in astrocytoma. The most frequently occurring mutation (DeltaEGFR, EGFRvIII) deletes exons 2-7 from this receptor tyrosine kinase (RTK), and signals constitutively in the absence of ligand. DeltaEGFR is not found in normal tissue, and therefore represents an attractive therapeutic target. Here, we show that a small interfering RNA (siRNA) directed against the unique exon 1/exon 8 junction sequence of DeltaEGFR efficiently suppressed expression of DeltaEGFR in rodent fibroblasts and in two human glioblastoma cell lines. SiRNA-mediated depletion of DeltaEGFR led to reduction in the levels of phosphorylated Akt in glioma cells, was associated with increased apoptosis, and induced partial arrest at the G(2)M phase of the cell cycle. Inhibitors of PI3 kinase cooperated with siRNA treatment, leading to further increases in both cell cycle blockade and apoptosis. Importantly, cell cycle blockade could be reversed, and apoptosis rescued using a conditional allele of Akt, implicating Akt as a primary target of combination therapy. This study demonstrates the therapeutic potential of siRNA to impact DeltaEGFR as a glioma-specific target, and offers a mechanistic rationale for combining siRNA and small molecule inhibitor therapies against distinct components in the EGFR signaling pathway.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weiss, WA (corresponding author), Univ Calif San Francisco, Dept Neurol, 533 Parnassus Ave,Room U-441O, San Francisco, CA 94143 USA.	weiss@cgl.ucsf.edu		Weiss, William/0000-0003-2230-9132	NATIONAL CANCER INSTITUTE [P50CA097257, U01CA084290] Funding Source: NIH RePORTER; NCI NIH HHS [U01CA84290, 1P50CA097257-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baselga J, 2002, J CLIN ONCOL, V20, P4292, DOI 10.1200/JCO.2002.03.100; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; BIGNER SH, 1990, CANCER RES, V50, P8017; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chow JPH, 2003, J BIOL CHEM, V278, P40815, DOI 10.1074/jbc.M306683200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; DEL PL, 1997, SCIENCE, V278, P687; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Fan QW, 2003, CANCER RES, V63, P8930; Fan QW, 2002, CURR BIOL, V12, P1386, DOI 10.1016/S0960-9822(02)01070-9; Gottschalk AR, 2001, CANCER RES, V61, P2105; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hansen LA, 1997, AM J PATHOL, V150, P1959; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Hidalgo M, 2001, J CLIN ONCOL, V19, P3267, DOI 10.1200/JCO.2001.19.13.3267; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; HUMPHREY PA, 1988, CANCER RES, V48, P2231; Johns TG, 2002, INT J CANCER, V98, P398, DOI 10.1002/ijc.10189; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Kunath T, 2003, NAT BIOTECHNOL, V21, P559, DOI 10.1038/nbt813; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Luwor RB, 2001, CANCER RES, V61, P5355; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Peng D, 1996, CANCER RES, V56, P3666; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shir A, 2002, NAT BIOTECHNOL, V20, P895, DOI 10.1038/nbt730; Shtivelman E, 2002, CURR BIOL, V12, P919, DOI 10.1016/S0960-9822(02)00843-6; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653; Williams JI, 2001, CLIN CANCER RES, V7, P724; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wu XP, 1996, ONCOGENE, V12, P1397	48	44	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					829	837		10.1038/sj.onc.1208227	http://dx.doi.org/10.1038/sj.onc.1208227			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15580296				2022-12-17	WOS:000226577100009
J	Yoo, MH; Song, HW; Woo, CH; Kim, HG; Kim, JH				Yoo, MH; Song, HW; Woo, CH; Kim, HG; Kim, JH			Role of the BLT2, a leukotriene B-4 receptor, in Ras transformation	ONCOGENE			English	Article						BLT2; cancer; leukotriene B-4; Ras transformation	CELL LUNG-CANCER; COLLAGEN-INDUCED ARTHRITIS; TERNARY COMPLEX-FORMATION; SIGNAL-REGULATED KINASE; SERUM RESPONSE ELEMENT; CYCLOOXYGENASE-2 COX-2; TRANSCRIPTION FACTOR; MEDIATES CHEMOTAXIS; PHOSPHOLIPASE A(2); GENE-EXPRESSION	Oncogenic Ras is known to drive both the Rac and Raf-MAP-kinase pathways, which act in concert to cause cell transformation. Unlike the Raf-MAP-kinase cascade, however, the downstream elements of Rac pathway are not fully understood. Previously, we showed that cytosolic phospholipase A(2) (cPLA(2)) and subsequent metabolism of arachidonic acid act downstream of Rac to mediate the transformation signaling induced by Ha-Ras(V12). In the present study, we observed that leukotriene B-4 (LTB4) and its synthetic enzymes as well as BLT2, the low-affinity LTB4 receptor, are all elevated in Ha-Ras(V12)-transformed cells. In addition, the malignant phenotypes of Ras-transformed cells were markedly inhibited by BLT2 blockade, as was their tumorigenicity in vivo. Finally, in situ hybridization analysis revealed that expression of BLT2 is significantly upregulated in a variety of human cancers. Taken together, our results suggest that an LTB4-BLT2-linked cascade plays a crucial mediatory role in the cell transformation induced by oncogenic Ha-Ras(V12), possibly acting downstream of Rac-cPLA(2).	Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea	Korea University	Kim, JH (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, 5-1 Anam Dong, Seoul 136701, South Korea.	jhongkim@korea.ac.kr	Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208				Abou-Issa HM, 2001, ANTICANCER RES, V21, P3425; Bae SH, 2001, CLIN CANCER RES, V7, P1410; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bauer AK, 2000, CARCINOGENESIS, V21, P543, DOI 10.1093/carcin/21.4.543; Blaine SA, 2001, J BIOL CHEM, V276, P42737, DOI 10.1074/jbc.M107773200; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; Capella G, 1996, DIAGN MOL PATHOL, V5, P45, DOI 10.1097/00019606-199603000-00008; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; COROMINAS M, 1991, ONCOGENE, V6, P645; Dang CT, 2002, ONCOLOGY-NY, V16, P30; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; Fournier DB, 2000, J CELL BIOCHEM, P97; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOLDMAN DW, 1991, J IMMUNOL, V146, P2671; GRIFFITHS RJ, 1995, P NATL ACAD SCI USA, V92, P517, DOI 10.1073/pnas.92.2.517; Gunning WT, 2002, CANCER RES, V62, P4199; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; Hennig R, 2002, AM J PATHOL, V161, P421, DOI 10.1016/S0002-9440(10)64198-3; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Izumi T, 2002, J BIOCHEM, V132, P1; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kim BC, 1997, BIOCHEM J, V326, P333, DOI 10.1042/bj3260333; Kim BC, 1998, MOL CELLS, V8, P90; KOCH K, 1994, J MED CHEM, V37, P3197, DOI 10.1021/jm00046a001; Kreimer-Erlacher H, 2001, PHOTOCHEM PHOTOBIOL, V74, P323, DOI 10.1562/0031-8655(2001)074<0323:HMFAHR>2.0.CO;2; KUJUBU DA, 1991, J BIOL CHEM, V274, P24372; KUMAR CC, 1992, CANCER RES, V52, P6877; Kundu N, 2001, INT J CANCER, V93, P681, DOI 10.1002/ijc.1397; Latinkic BV, 1996, NUCLEIC ACIDS RES, V24, P1345, DOI 10.1093/nar/24.7.1345; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEEVERS SJ, 1996, SIGNAL TRANSDUCTION; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Patti R, 2002, CANCER LETT, V180, P13, DOI 10.1016/S0304-3835(02)00003-4; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Showell HJ, 1996, BRIT J PHARMACOL, V117, P1127, DOI 10.1111/j.1476-5381.1996.tb16706.x; Shureiqi I, 2001, CANCER RES, V61, P6307; Tong WG, 2002, CLIN CANCER RES, V8, P3232; Turner CR, 1996, J CLIN INVEST, V97, P381, DOI 10.1172/JCI118426; Woo CH, 2003, J IMMUNOL, V170, P6273, DOI 10.4049/jimmunol.170.12.6273; Woo CH, 2002, J BIOL CHEM, V277, P8572, DOI 10.1074/jbc.M104766200; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yang JQ, 2002, MOL CARCINOGEN, V33, P206, DOI 10.1002/mc.10037; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 2001, ARCH BIOCHEM BIOPHYS, V385, P231, DOI 10.1006/abbi.2000.2168; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200; Yoo MH, 2001, J BIOL CHEM, V276, P24645, DOI 10.1074/jbc.M101975200	55	44	49	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9259	9268		10.1038/sj.onc.1208151	http://dx.doi.org/10.1038/sj.onc.1208151			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15489890				2022-12-17	WOS:000225638000011
J	Pajonk, F; Weil, A; Sommer, A; Suwinski, R; Henke, M				Pajonk, F; Weil, A; Sommer, A; Suwinski, R; Henke, M			The erythropoietin-receptor pathway modulates survival of cancer cells	ONCOGENE			English	Article						cancer; Epo; EpoR; NF-kappa B; radiation response	NF-KAPPA-B; QUALITY-OF-LIFE; EPOETIN-ALPHA; DOUBLE-BLIND; TUMOR-CELLS; ANEMIA; RADIOSENSITIVITY; CHEMOTHERAPY; RADIOTHERAPY; SENSITIVITY	Anemia in cancer patients is associated with reduced quality of life and local failure after radiation treatment. However, the use of erythropoietin to correct cancer anemia and to improve radiation efficacy was disappointing. Erythropoietin-receptor signaling mainly acts via activation of STAT 5, but also crossactivates the antiapoptotic transcription factor NF-kappaB. This causes neuroprotection against oxidative stress and implies radioprotection. In order to investigate possible radioprotective effects of erythropoietin-receptor signaling, we used an in vitro model system employing HeLa TetOff cells, stably transfected with an expression vector for the erythropoietin-receptor gene. Using electrophoretic mobility shift assays, we could demonstrate strong activation of NF-kappaB by erythropoietin-receptor signaling in HeLa cells. Activation of NF-kappaB did not require degradation of IkappaBalpha and was not prevented by proteasome inhibition. Furthermore, stimulation with erythropoietin resulted in a 50% increased clonogenicity of erythropoietin-receptor-expressing cells but did not alter radiation sensitivity itself. As most human tumors express erythropoietin receptor, we advocate a restricted use erythropoietin to patients suffering from erythropoietin-receptor-expressing cancers.	Radiol Univ Clin, Dept Radiat Therapy, Clin & Expt Radiat Biol Res Sect, D-79106 Freiburg, Germany; Maria Sklodowska Curie Mem Inst Oncol, Ctr Oncol, Dept Radiat Oncol, Gliwice, Poland	University of Freiburg; Maria Sklodowska-Curie National Research Institute of Oncology	Pajonk, F (corresponding author), Radiol Univ Clin, Dept Radiat Therapy, Clin & Expt Radiat Biol Res Sect, Robert Koch Str 3, D-79106 Freiburg, Germany.	pajonk@uni-freiburg.de	Pajonk, Frank/E-4247-2010	Suwinski, Rafal/0000-0002-3895-7938				Acs G, 2003, AM J PATHOL, V162, P1789, DOI 10.1016/S0002-9440(10)64314-3; Acs G, 2001, CANCER RES, V61, P3561; ALBRIGHT N, 1987, RADIAT RES, V112, P331, DOI 10.2307/3577260; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Batra S, 2003, LAB INVEST, V83, P1477, DOI 10.1097/01.LAB.0000090156.94795.48; Buemi M, 2003, J NEUROPATH EXP NEUR, V62, P228, DOI 10.1093/jnen/62.3.228; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Damen JE, 1996, EXP HEMATOL, V24, P1455; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dunst J, 2003, INT J RADIAT ONCOL, V56, P778, DOI 10.1016/S0360-3016(03)00123-8; Fallowfield L, 2002, BRIT J CANCER, V87, P1341, DOI 10.1038/sj.bjc.6600657; Frommhold H, 1998, STRAHLENTHER ONKOL, V174, P31; Gabrilove JL, 2001, J CLIN ONCOL, V19, P2875, DOI 10.1200/JCO.2001.19.11.2875; Harrison LB, 2002, ONCOLOGY-BASEL, V63, P11, DOI 10.1159/000067147; Henke M, 2003, LANCET, V362, P1255, DOI 10.1016/S0140-6736(03)14567-9; HIRST DG, 1984, INT J RADIAT BIOL, V46, P345, DOI 10.1080/09553008414551521; HIRST DG, 1987, INT J RADIAT BIOL, V51, P597, DOI 10.1080/09553008414552131; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; JOINER B, 1993, BRIT J CANCER, V68, P720, DOI 10.1038/bjc.1993.417; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Leyland-Jones B, 2003, LANCET ONCOL, V4, P459, DOI 10.1016/S1470-2045(03)01163-X; Littlewood TJ, 2001, J CLIN ONCOL, V19, P2865, DOI 10.1200/JCO.2001.19.11.2865; Pajonk F, 1999, J NATL CANCER I, V91, P1956, DOI 10.1093/jnci/91.22.1956; POSKITT TR, 1987, CANCER INVEST, V5, P231, DOI 10.3109/07357908709011739; Ribatti D, 2003, HISTOPATHOLOGY, V42, P246, DOI 10.1046/j.1365-2559.2003.01581.x; SANTUCCI MA, 1994, STEM CELLS, V12, P506, DOI 10.1002/stem.5530120506; Suwinski R, 1999, RADIOTHER ONCOL, V50, P57, DOI 10.1016/S0167-8140(99)00014-6; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Westphal G, 2002, TUMORI, V88, P150, DOI 10.1177/030089160208800214	29	44	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8987	8991		10.1038/sj.onc.1208140	http://dx.doi.org/10.1038/sj.onc.1208140			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480420				2022-12-17	WOS:000225354600014
J	Song, H; Jin, XH; Lin, JY				Song, H; Jin, XH; Lin, JY			Stat3 upregulates MEK5 expression in human breast cancer cells	ONCOGENE			English	Article						MEK5; Stat3; breast carcinoma; siRNA	GENE-EXPRESSION; SIGNAL TRANSDUCER; TRANSCRIPTION FACTORS; ACTIVATION; KINASE; OVEREXPRESSION; GROWTH; ADRENOMEDULLIN; RESISTANCE; PATHWAYS	The constitutive activation of signal transducer and activator of transcription 3 (Stat3) is frequently detected in breast cancer cell lines but not in normal breast epithelial cells. Stat3 has been classified as an oncogene, because constitutively active Stat3 can mediate oncogenic transformation in cultured cells and tumor formation in nude mice. Since Stat3 appears to play an important role in breast cancer, it is of interest to investigate Stat3-regulated genes and elucidate Stat3-mediated oncogenesis. In this study, we investigated the Stat3-regulated genes in human breast epithelial cells. Upon overexpression of Stat3-C, a constitutively active Stat3 form, in nonmalignant telomerase immortalized breast (TERT) cells, the total mRNA was extracted and subjected to Affymetrix microarray analysis. Our results showed that mitogen-activated protein kinase kinase 5 (MEK5) was markedly induced (more than 22-fold increase, P < 0.001) by Stat3-C expression. RT-PCR result also demonstrated that MEK5 mRNA was significantly induced by Stat3-C in TERT cells. The upregulation of MEK5 by Stat3-C was further confirmed by Western blot in MCF10A breast epithelial cells. Further more, in MDA-MB-435s breast carcinoma cells, which express high levels of activated Stat3 and MEK5, MEK5 protein was significantly reduced by using Stat3 short interfering RNA. The reduction of MEK5 was consistent with Stat3 knockdown in this breast carcinoma cell line. We also investigated MEK5 expression in different breast carcinoma cell lines and breast cancer tissues using tissue array analysis. Compared with nonmalignant breast epithelial cells or normal tissues without constitutively active Stat3 signaling, MEK5 protein levels are remarkably higher in breast carcinoma cell lines and cancer tissues with constitutively activated Stat3. Taken together, our findings suggest that constitutively active Stat3 upregulates MEK5 in the breast epithelial cells. MEK5 may be one of the Stat3-regulated genes and plays its essential roles in oncogenesis mediated by aberrantly activated Stat3 signaling in breast carcinomatosis and malignancies.	Univ Michigan, Ctr Comprehens Canc, Cellular & Mol Biol Grad Program, Dept Obstet & Gynecol,Div Gynecol Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Lin, JY (corresponding author), Univ Michigan, Ctr Comprehens Canc, Cellular & Mol Biol Grad Program, Dept Obstet & Gynecol,Div Gynecol Oncol, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	linjia@umich.edu	Lin, Jiayuh/E-3515-2011		NCI NIH HHS [R01 CA096714] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096714] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alas S, 2001, CANCER RES, V61, P5137; Atsumi T, 2002, CANCER RES, V62, P5881; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Cameron SJ, 2004, J BIOL CHEM, V279, P1506, DOI 10.1074/jbc.M308755200; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chayama K, 2001, P NATL ACAD SCI USA, V98, P4599, DOI 10.1073/pnas.081021898; Dalton WS, 1999, SEMIN ONCOL, V26, P23; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945-053X(98)90019-1; Howe LR, 2003, J MAMMARY GLAND BIOL, V8, P31, DOI 10.1023/A:1025731204719; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kauraniemi P, 2004, ONCOGENE, V23, P1010, DOI 10.1038/sj.onc.1207200; Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood-2002-11-3396; Martinez A, 2002, J NATL CANCER I, V94, P1226; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mehta PB, 2003, ONCOGENE, V22, P1381, DOI 10.1038/sj.onc.1206154; Mulloy R, 2003, ONCOGENE, V22, P5387, DOI 10.1038/sj.onc.1206839; Nakamura K, 2003, J BIOL CHEM, V278, P36989, DOI 10.1074/jbc.C300313200; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Oehler MK, 2003, BRIT J CANCER, V89, P1927, DOI 10.1038/sj.bjc.6601397; Oehler MK, 2002, ONCOGENE, V21, P2815, DOI 10.1038/sj.onc.1205374; Okano J, 2001, J BIOL CHEM, V276, P19555, DOI 10.1074/jbc.M011164200; Pollett JB, 2002, BLOOD, V100, P3819, DOI 10.1182/blood-2002-02-0608; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; Rebbaa A, 2001, MOL MED, V7, P393, DOI 10.1007/BF03402185; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shen YH, 2004, MOL CELL BIOL, V24, P407, DOI 10.1128/MCB.24.1.407-419.2004; Song H, 2004, INT J ONCOL, V24, P1017; Song H, 2004, BIOCHEM BIOPH RES CO, V314, P143, DOI 10.1016/j.bbrc.2003.12.048; Stephanou A, 1998, BIOCHEM J, V330, P189, DOI 10.1042/bj3300189; Stephanou A, 1999, J BIOL CHEM, V274, P1723, DOI 10.1074/jbc.274.3.1723; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Tan KB, 2004, HISTOPATHOLOGY, V44, P24, DOI 10.1111/j.1365-2559.2004.01774.x; Ueno H, 1997, CANCER RES, V57, P2055; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Weldon CB, 2002, SURGERY, V132, P293, DOI 10.1067/msy.2002.125389; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Yoshizumi M, 2003, J PHARMACOL SCI, V91, P172; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	54	44	50	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8301	8309		10.1038/sj.onc.1208026	http://dx.doi.org/10.1038/sj.onc.1208026			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378007				2022-12-17	WOS:000224749500012
J	Dong, G; Lee, TL; Yeh, NT; Geoghegan, J; Van Waes, C; Chen, Z				Dong, G; Lee, TL; Yeh, NT; Geoghegan, J; Van Waes, C; Chen, Z			Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor	ONCOGENE			English	Article						HGF/c-Met; angiogenesis; squamous cell carcinoma; metastasis; Gro-1/KC; VEGF	PROINFLAMMATORY CYTOKINE EXPRESSION; PAPILLARY RENAL-CARCINOMAS; HOST ENVIRONMENT PROMOTES; FACTOR-KAPPA-B; TUMOR PROGRESSION; IN-VIVO; PROANGIOGENIC CYTOKINES; CANCER PATIENTS; CDNA ARRAYS; ONCOGENE	We previously performed gene expression pro. ling in a multistep squamous cell carcinoma (SCC) progression model, and identified growth-regulated oncogene-1 (Gro1/KC) as a factor that contributes to enhanced angiogenesis, tumorigenesis and metastasis. In the present study, we explored molecular pathways coactivated with Gro-1/KC, and identified a transcript that encodes c-Met, the receptor for hepatocyte growth factor/scatter factor (HGF). Northern, Western blot, and immunohistochemical analyses confirm that expression of c-Met mRNA and protein is increased with SCC progression. In vitro, HGF preferentially promoted scattering in the metastatic LY-1 and LY-2 lines, and enhanced angiogenesis factors Gro-1/KC and vascular endothelial growth factor (VEGF) production by all tumor cell lines. In vivo, tumor growth and lung metastasis were promoted by transfection and overexpression of HGF cDNA in metastatic LY-1 cells. Our data indicate that metastatic SCC cells that overexpress c-Met exhibit angiogenesis factor expression and enhanced scattering in response to HGF in vitro, and tumorigenesis and metastasis in response to HGF in the tumor microenvironment in vivo.	Natl Inst Deafness & Other Commun Disorders, Head & Neck Surg Branch, Tumor Biol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Chen, Z (corresponding author), Natl Inst Deafness & Other Commun Disorders, Head & Neck Surg Branch, Tumor Biol Sect, NIH, 10-5D55,MSC-1419, Bethesda, MD 20892 USA.	chenz@nided.nih.gov	Lee, Tin-Lap/A-7853-2009; Lee, Tin-Lap/W-6595-2019	Lee, Tin-Lap/0000-0002-6654-0988; Lee, Tin-Lap/0000-0002-6654-0988	NIDCD NIH HHS [Z01-DC-00016] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000016, Z01DC000016] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Aebersold DM, 2001, INT J CANCER, V96, P41, DOI 10.1002/1097-0215(20010220)96:1<41::AID-IJC5>3.0.CO;2-F; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; CHAN AML, 1988, ONCOGENE, V2, P593; Chen Z, 1998, CANCER RES, V58, P3668; Chen Z, 1999, CLIN CANCER RES, V5, P1369; Chen Z, 1997, CLIN EXP METASTAS, V15, P527, DOI 10.1023/A:1018474910432; Cortesina G, 2000, INT J CANCER, V89, P286, DOI 10.1002/1097-0215(20000520)89:3<286::AID-IJC12>3.3.CO;2-L; CROWLBANCROFT C, 2001, CLIN CANCER RES, V7, P435; Dong G, 1999, CANCER RES, V59, P3495; Dong G, 2001, CANCER RES, V61, P4797; Dong G, 2001, CANCER RES, V61, P5911; Duffey DC, 1999, CANCER RES, V59, P3468; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Fukuura T, 1998, BRIT J CANCER, V78, P454, DOI 10.1038/bjc.1998.514; Gohji K, 2000, J CLIN ONCOL, V18, P2963, DOI 10.1200/JCO.2000.18.16.2963; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hu YC, 2001, CLIN CANCER RES, V7, P3519; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; Junbo Hu, 1999, In Vivo (Attiki), V13, P177; Kitadai Y, 1999, BRIT J CANCER, V81, P647, DOI 10.1038/sj.bjc.6690742; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Loukinova E, 2000, ONCOGENE, V19, P3477, DOI 10.1038/sj.onc.1203687; Luan J, 1997, J LEUKOCYTE BIOL, V62, P588, DOI 10.1002/jlb.62.5.588; Marshall DD, 1998, LARYNGOSCOPE, V108, P1413, DOI 10.1097/00005537-199809000-00031; Naughton M, 2001, J UROLOGY, V165, P1325, DOI 10.1016/S0022-5347(01)69893-8; Porte H, 1998, CLIN CANCER RES, V4, P1375; Qian CN, 2002, CANCER RES, V62, P589; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Smith CW, 1998, CLIN EXP METASTAS, V16, P655, DOI 10.1023/A:1006559811429; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Takeo S, 2001, CANCER GENET CYTOGEN, V130, P127, DOI 10.1016/S0165-4608(01)00479-4; Takigawa N, 1997, LUNG CANCER-J IASLC, V17, P211, DOI 10.1016/S0169-5002(97)00651-X; Taniguchi T, 1997, BRIT J CANCER, V75, P673, DOI 10.1038/bjc.1997.120; Thomas GR, 1999, INT J CANCER, V82, P377, DOI 10.1002/(SICI)1097-0215(19990730)82:3<377::AID-IJC11>3.3.CO;2-0; Toi M, 1998, CLIN CANCER RES, V4, P659; Uchida D, 2001, INT J CANCER, V93, P489, DOI 10.1002/ijc.1368; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Wojta J, 1999, LAB INVEST, V79, P427; Yu YL, 2002, CANCER RES, V62, P2951; YUSPA SH, 1994, J INVEST DERMATOL, V103, pS90, DOI 10.1111/1523-1747.ep12399255; YUSPA SH, 1980, CANCER RES, V40, P4694; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	50	44	48	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6199	6208		10.1038/sj.onc.1207851	http://dx.doi.org/10.1038/sj.onc.1207851			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15221009				2022-12-17	WOS:000223399000004
J	Terrinoni, A; Ranalli, M; Cadot, B; Leta, A; Bagetta, G; Vousden, KH; Melino, G				Terrinoni, A; Ranalli, M; Cadot, B; Leta, A; Bagetta, G; Vousden, KH; Melino, G			p73-alpha is capable of inducing scotin and ER stress	ONCOGENE			English	Article						apoptosis; p73; p63; p53; scotin; endoplasmic reticulum; ER; calnexin; gadd 153	KINASE C-ABL; ENDOPLASMIC-RETICULUM; APOPTOTIC RESPONSE; P73; P53; GENE; DIFFERENTIATION; TARGET; P63; NEUROBLASTOMA	p73, like its family member p53, can induce programmed cell death following DNA damage. Here, we report that this mechanism also involves endoplasmic reticulum (ER) stress and the transactivation of scotin, a protein identified recently as a p53 target able to induce ER stress. By using Tet-On inducible cell lines (Saos 2 osteosarcoma cells that lack p53), we observed that TAp73alpha elicits significant alterations in the morphology of the ER system, namely in the. ne subcellular localization of calnexin. We found that both TAp73alpha and p53 are strong inducers of scotin. On the other hand, the transcriptionally deficient short isoforms DeltaNp73alpha did not upregulate the steady-state mRNA level of scotin, as evaluated by real-time RT-PCR. Following the induction of scotin, ER staining with calnexin showed evidence of morphological alteration, with variations in the intracellular concentration of free calcium, visualized by fluo-3 staining. The induction of ER stress by p73 was further supported by the transcriptional induction of Gadd 153, a transcription factor induced under ER stress conditions. In conclusion, the data reported indicate the ability of TAp73alpha and p53 (not DeltaNp73alpha) to elicit scotin transactivation and ER stress. This molecular mechanism might contribute to the effector events inducing apoptosis downstream of p73.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, IRCCS, IDI,Biochem Lab, I-00133 Rome, Italy; Univ Calabria, Dept Pharmacobiol, I-87036 Cosenza, Italy; Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of Calabria; Beatson Institute; University of Leicester	Melino, G (corresponding author), Via Montpellier 1, I-00133 Rome, Italy.	gerry.melino@uniroma2.it	Bagetta, Giacinto/N-9716-2018; CADOT, bruno/E-1710-2013; Bagetta, Giacinto/E-8402-2012; TERRINONI, Alessandro/J-1533-2012	Bagetta, Giacinto/0000-0001-8540-6218; CADOT, bruno/0000-0002-1888-3898; Bagetta, Giacinto/0000-0001-8540-6218; TERRINONI, Alessandro/0000-0002-7442-2252	Telethon [E.1224] Funding Source: Medline	Telethon(Fondazione Telethon)		Agami R, 1999, NATURE, V399, P809; Bourdon JC, 2002, J CELL BIOL, V158, P235, DOI 10.1083/jcb.200203006; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Tschan MP, 2000, BIOCHEM BIOPH RES CO, V277, P62, DOI 10.1006/bbrc.2000.3627; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhu JH, 1998, CANCER RES, V58, P5061; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	28	44	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3721	3725		10.1038/sj.onc.1207342	http://dx.doi.org/10.1038/sj.onc.1207342			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116103				2022-12-17	WOS:000221101700025
J	Masucci, MG				Masucci, MG			Epstein-Barr virus oncogenesis and the ubiquitin-proteasome system	ONCOGENE			English	Review						EBV; LMP/EBNA; ubiquitin-proteasome system; Gly-Ala; isopeptidases; TPPII	TRIPEPTIDYL-PEPTIDASE-II; MEMBRANE-PROTEIN 2A; BURKITTS-LYMPHOMA CELLS; N-TERMINAL RESIDUE; MEMORY B-CELLS; GLY-ALA REPEAT; NUCLEAR ANTIGEN 1; GENE-PRODUCT 9.5; C-MYC; LATENT GENES	Epstein - Barr virus (EBV), a human herpesvirus associated with lymphoid and epithelial cell tumors, encodes several proteins that exploit the ubiquitin - proteasome system to regulate latency and allow the persistence of infected cells in immunocompetent hosts. Further modi. cations of ubiquitin-dependent proteolysis by activated cellular oncogenes contribute to malignant transformation. A detailed understanding of these processes may lead to the development of new therapeutic strategies for EBV-associated cancers.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Masucci, MG (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Box 280, S-17177 Stockholm, Sweden.	maria.masucci@mtc.ki.se	Masucci, Maria G/B-8588-2009; Masucci, Maria/AAC-6666-2019	Masucci, Maria/0000-0002-5541-2809				ANDERSSON ML, 1991, INT J CANCER, V47, P544, DOI 10.1002/ijc.2910470412; Aumuller G, 1999, PROSTATE, V38, P261; Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; AVILACARINO J, 1987, INT J CANCER, V40, P691, DOI 10.1002/ijc.2910400521; Babcock GJ, 2000, P NATL ACAD SCI USA, V97, P12250, DOI 10.1073/pnas.200366597; Babcock GJ, 2000, IMMUNITY, V13, P497, DOI 10.1016/S1074-7613(00)00049-2; Babcock GJ, 1999, J EXP MED, V190, P567, DOI 10.1084/jem.190.4.567; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Balakirev MY, 2003, EMBO REP, V4, P517, DOI 10.1038/sj.embor.embor824; BALOW RM, 1983, J BIOL CHEM, V258, P1622; BALOW RM, 1987, BIOCHEM J, V241, P75, DOI 10.1042/bj2410075; BALOW RM, 1986, J BIOL CHEM, V261, P2409; Blake N, 1997, IMMUNITY, V7, P791, DOI 10.1016/S1074-7613(00)80397-0; Blake NW, 1999, J VIROL, V73, P7381, DOI 10.1128/JVI.73.9.7381-7389.1999; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Boutell C, 2003, J BIOL CHEM, V278, P36596, DOI 10.1074/jbc.M300776200; Boutell C, 2002, J VIROL, V76, P841, DOI 10.1128/JVI.76.2.841-850.2002; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Brichory F, 2001, CANCER RES, V61, P7908; Brown KD, 2001, J EXP MED, V193, P943, DOI 10.1084/jem.193.8.943; CHEN F, 1995, J VIROL, V69, P3752, DOI 10.1128/JVI.69.6.3752-3758.1995; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Coscoy L, 2001, J CLIN INVEST, V107, P1599, DOI 10.1172/JCI12432; Curran JA, 2001, CANCER RES, V61, P6730; D'Andrea V, 1997, G Chir, V18, P521; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; Dantuma NP, 2000, P NATL ACAD SCI USA, V97, P8381, DOI 10.1073/pnas.140217397; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dolcetti R, 2003, J CELL PHYSIOL, V196, P207, DOI 10.1002/jcp.10263; Dukers DF, 2000, J IMMUNOL, V165, P663, DOI 10.4049/jimmunol.165.2.663; Engels N, 2001, J EXP MED, V194, P255, DOI 10.1084/jem.194.3.255; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; FALK K, 1995, J GEN VIROL, V76, P779, DOI 10.1099/0022-1317-76-4-779; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Frisan T, 1996, INT J CANCER, V68, P251, DOI 10.1002/(SICI)1097-0215(19961009)68:2<251::AID-IJC19>3.0.CO;2-D; Frisan T, 1998, J IMMUNOL, V160, P3281; Fruh K, 2002, VIRUS RES, V88, P55, DOI 10.1016/S0168-1702(02)00120-X; Gavioli R, 2001, NAT CELL BIOL, V3, P283, DOI 10.1038/35060076; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Heessen S, 2003, FEBS LETT, V555, P397, DOI 10.1016/S0014-5793(03)01296-1; Heessen S, 2002, P NATL ACAD SCI USA, V99, P1532, DOI 10.1073/pnas.022306499; Hemelaar J, 2001, J VIROL, V75, P11106, DOI 10.1128/JVI.75.22.11106-11115.2001; Herbst H, 1996, SEMIN CANCER BIOL, V7, P183, DOI 10.1006/scbi.1996.0025; Hilbi H, 2000, INFECT IMMUN, V68, P5502, DOI 10.1128/IAI.68.10.5502-5508.2000; Holowaty MN, 2003, J BIOL CHEM, V278, P47753, DOI 10.1074/jbc.M307200200; Holowaty MN, 2003, J BIOL CHEM, V278, P29987, DOI 10.1074/jbc.M303977200; HU LF, 1993, ONCOGENE, V8, P1575; IEZZONI JC, 1995, AM J CLIN PATHOL, V103, P308, DOI 10.1093/ajcp/103.3.308; Ikeda A, 2003, J VIROL, V77, P5529, DOI 10.1128/JVI.77.9.5529-5534.2003; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Ikeda M, 2002, VIROLOGY, V300, P153, DOI 10.1006/viro.2002.1562; Kelly G, 2002, NAT MED, V8, P1098, DOI 10.1038/nm758; Kessler B, 2003, J BIOL CHEM, V278, P10013, DOI 10.1074/jbc.M211221200; KIEFF E, 1996, FIELDS VIROLOGY, V2, P2343; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; KLEIN G, 1994, ANTIBIOT CHEMOTHER, V46, P110; Knecht H, 2001, ONCOLOGY-BASEL, V60, P289, DOI 10.1159/000058523; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; Lansbury PT, 2002, CURR OPIN CELL BIOL, V14, P653, DOI 10.1016/S0955-0674(02)00377-0; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Leight ER, 2000, REV MED VIROL, V10, P83, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt;83::AID-RMV262&gt;3.0.CO;2-T; Leonchiks A, 2002, FEBS LETT, V522, P93, DOI 10.1016/S0014-5793(02)02897-1; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; LONGNECKER R, 1993, J VIROL, V67, P2006, DOI 10.1128/JVI.67.4.2006-2013.1993; Longnecker R, 2000, EXP CELL RES, V257, P332, DOI 10.1006/excr.2000.4900; Lorenzo ME, 2002, J VIROL, V76, P5522, DOI 10.1128/JVI.76.11.5522-5531.2002; Masucci Maria G., 1994, Trends in Microbiology, V2, P125, DOI 10.1016/0966-842X(94)90599-1; MILLER CL, 1994, INFECT AGENT DIS, V3, P128; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; Miyashita EM, 1997, J VIROL, V71, P4882, DOI 10.1128/JVI.71.7.4882-4891.1997; MOORTHY R, 1990, J VIROL, V64, P829, DOI 10.1128/JVI.64.2.829-837.1990; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Mukherjee S, 1998, J EXP MED, V187, P445, DOI 10.1084/jem.187.3.445; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Naze P, 2002, NEUROSCI LETT, V328, P1, DOI 10.1016/S0304-3940(02)00231-8; Niedobitek G, 2000, J PATHOL, V191, P394, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH651&gt;3.0.CO;2-0; Paludan C, 2003, CURR MOL MED, V3, P341, DOI 10.2174/1566524033479771; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; RICKINSON AB, 1992, CANCER SURV, V13, P53; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Rose C, 1996, NEUROPEPTIDES, V30, P231, DOI 10.1016/S0143-4179(96)90069-4; Rothenberger S, 2002, CELL MOL LIFE SCI, V59, P171, DOI 10.1007/s00018-002-8413-y; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; ROWE DT, 1986, EMBO J, V5, P2599, DOI 10.1002/j.1460-2075.1986.tb04540.x; ROWE M, 1995, EUR J IMMUNOL, V25, P1374, DOI 10.1002/eji.1830250536; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sasaki H, 2001, JPN J CLIN ONCOL, V31, P532, DOI 10.1093/jjco/hye113; SCHUMACHER U, 1994, DNA CELL BIOL, V13, P839, DOI 10.1089/dna.1994.13.839; Seifert U, 2003, NAT IMMUNOL, V4, P375, DOI 10.1038/ni905; Sharipo A, 2001, FEBS LETT, V499, P137, DOI 10.1016/S0014-5793(01)02542-X; Sharipo A, 1998, NAT MED, V4, P939, DOI 10.1038/nm0898-939; Sohn HW, 2003, J EXP MED, V197, P1511, DOI 10.1084/jem.20021686; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Staege MS, 2002, P NATL ACAD SCI USA, V99, P4550, DOI 10.1073/pnas.072495599; Takanashi M, 1999, ARCH VIROL, V144, P241, DOI 10.1007/s007050050501; Tezel E, 2000, CLIN CANCER RES, V6, P4764; THOMAS JA, 1991, ADV CANCER RES, V57, P329; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; Tomkinson B, 1997, FEBS LETT, V405, P277, DOI 10.1016/S0014-5793(97)00173-7; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang EW, 2000, P NATL ACAD SCI USA, V97, P9990, DOI 10.1073/pnas.180328897; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; Yamazaki T, 2002, CLIN CANCER RES, V8, P192; Yanagisawa TY, 1998, TOHOKU J EXP MED, V184, P229; Yang XH, 2000, J VIROL, V74, P883, DOI 10.1128/JVI.74.2.883-891.2000; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Zhang ZS, 2000, J BIOL CHEM, V275, P15157, DOI 10.1074/jbc.M910378199	118	44	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2107	2115		10.1038/sj.onc.1207372	http://dx.doi.org/10.1038/sj.onc.1207372			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021898				2022-12-17	WOS:000220213400015
J	Ogasawara, S; Maesawa, C; Yamamoto, M; Akiyama, Y; Wada, K; Fujisawa, K; Higuchi, T; Tomisawa, Y; Sato, N; Endo, S; Saito, K; Masuda, T				Ogasawara, S; Maesawa, C; Yamamoto, M; Akiyama, Y; Wada, K; Fujisawa, K; Higuchi, T; Tomisawa, Y; Sato, N; Endo, S; Saito, K; Masuda, T			Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers	ONCOGENE			English	Article						maspin; methylation; thyroid cancer; differentiation; cell-type-specific expression	TUMOR-SUPPRESSOR GENE; BREAST-CARCINOMA; EPITHELIAL-CELLS; DNA METHYLATION; P53 MUTATIONS; EXPRESSION; HYPOMETHYLATION; MAMMARY; REGION	Cancer-associated DNA hypomethylation is as prevalent as cancer-linked hypermethylation, but the biological significance of DNA hypomethylation in carcinogenesis is less understood. The expression of Maspin (mammary serpin) in differentiated normal cells is regulated by epigenetic modi. cations in a cell-type-specific manner. Paradoxical Maspin expression due to epigenetic modification has been addressed in several cancer cell types. To elucidate the role of the Maspin gene in thyroid cancer, we studied methylation status in the promoter region and its expression in six human undifferentiated thyroid cancer cell lines and in specimens from 92 primary thyroid tumors, consisting of six follicular adenomas, 56 well-differentiated thyroid cancers (WDTCs), 17 poorly differentiated thyroid cancers (PDTCs) and 13 undifferentiated thyroid cancers (UDTCs). Three of the six cell lines overexpressed Maspin mRNA and its protein product, but the remaining three did not. The methylation status at the promoter region was inversely correlated with Maspin expression. In Maspin-negative cell lines, Maspin expression was induced by treatment with 5-aza-2'-deoxycytidine, a DNA demethylating agent. Immunoreactivity for Maspin protein was frequently detected in UDTCs (8/13, 62%) and PDTCs (7/17, 41%). Immunoreactivity for Maspin was diffusely positive in UDTCs, and was restricted to dedifferentiated components of the tumor in PDTCs. Positive immunoreactivity was infrequent in WDTCs (1/56, 2%), and all follicular adenomas and normal thyroid glands were completely negative. Their methylation status evaluated by the methylation-specific PCR method showed a good inverse correlation with their immunoreactivity in surgically resected specimens. Our data suggest that overexpression of Maspin by DNA hypomethylation is closely associated with morphological dedifferentiation in thyroid cancers.	Iwate Med Univ, Sch Med, Dept Surg 1, Morioka, Iwate 0208505, Japan; Iwate Med Univ, Sch Med, Dept Pathol, Morioka, Iwate 0208505, Japan; Iwate Med Univ, Sch Med, Dept Crit Care Med, Morioka, Iwate 0208505, Japan	Iwate Medical University; Iwate Medical University; Iwate Medical University	Ogasawara, S (corresponding author), Iwate Med Univ, Sch Med, Dept Surg 1, Uchimaru 19-1, Morioka, Iwate 0208505, Japan.	soga@iwate-med.ac.jp						Abraham S, 2003, J UROLOGY, V169, P1157, DOI 10.1097/01.ju.0000040245.70349.37; Akiyama Y, 2003, AM J PATHOL, V163, P1911, DOI 10.1016/S0002-9440(10)63549-3; BERLINGIERI MT, 1989, EXP CELL RES, V183, P277, DOI 10.1016/0014-4827(89)90388-1; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DELSENNO L, 1987, CANCER DETECT PREV, V10, P159; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Ehrlich M, 2002, ONCOGENE, V21, P6694, DOI 10.1038/sj.onc.1205890; Elisei R, 1998, CANCER, V83, P2185, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2185::AID-CNCR18>3.3.CO;2-W; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Frisk T, 2002, GENE CHROMOSOME CANC, V35, P74, DOI 10.1002/gcc.10098; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Graff JR, 1998, CANCER RES, V58, P2063; HEDINGER C, 1998, HISTOLOGIC TYPING TH; Ishiwata I, 1999, Hum Cell, V12, P37; ITO T, 1992, CANCER RES, V52, P1369; Jiang N, 2002, ONCOGENE, V21, P4089, DOI 10.1038/sj.onc.1205507; Maass N, 2001, CLIN CANCER RES, V7, P812; MATSUO K, 1993, J CLIN ENDOCR METAB, V77, P991, DOI 10.1210/jc.77.4.991; ROSAI J, 1994, TUMORS THYROID GLAND; Schagdarsurengin U, 2002, CANCER RES, V62, P3698; Seftor REB, 1998, CANCER RES, V58, P5681; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Sood AK, 2002, CLIN CANCER RES, V8, P2924; Venkataraman GM, 1999, J CLIN ENDOCR METAB, V84, P2449, DOI 10.1210/jc.84.7.2449; Wreesmann VB, 2002, AM J PATHOL, V161, P1549, DOI 10.1016/S0002-9440(10)64433-1; Xia WY, 2000, ONCOGENE, V19, P2398, DOI 10.1038/sj.onc.1203535; YOSHIDA M, 1992, CANCER RES, V52, P464; YOSHIMOTO K, 1992, CANCER RES, V52, P5061; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	34	44	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1117	1124		10.1038/sj.onc.1207211	http://dx.doi.org/10.1038/sj.onc.1207211			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14743202				2022-12-17	WOS:000188749900010
J	Nony, P; Gaude, H; Rossel, M; Fournier, L; Rouault, JP; Billaud, M				Nony, P; Gaude, H; Rossel, M; Fournier, L; Rouault, JP; Billaud, M			Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37	ONCOGENE			English	Article						LKB1; Peutz-Jeghers; tumor suppressor; Hsp90	SERINE/THREONINE PROTEIN-KINASE; TUMOR-SUPPRESSOR; GENE LKB1; CANCER; HSP90; IDENTIFICATION; MUTATIONS; CHIP; LKB1/STK11; DESTABILIZATION	Peutz-Jeghers syndrome (PJS) is an autosomal dominant disorder characterized by the presence of multiple gastrointestinal polyps and an increased risk for various types of cancers. Inactivating germline mutations of the LKB1 gene, which encodes a serine/threonine kinase, are responsible for the majority of PJS cases. Here, we show that the heteromeric complex containing the molecular chaperones Hsp90 and Cdc37/p50 interacts with the kinase domain of LKB1. Treatment of cells with either geldanamycin or novobiocin, two pharmacological inhibitors of Hsp90 causes the destabilization of LKB1. Furthermore, geldanamycin treatment leads to the ubiquitination and the rapid degradation of LKB1 by the proteasome-dependent pathway. In addition, we found that a LKB1 point mutation identified in a sporadic testicular cancer, weakens the interaction of LKB1 with both Hsp90 and Cdc37/p50 and enhances its sensitivity to the destabilizing effect of geldanamycin. Collectively, our results demonstrate that the Hsp90/Cdc37 complex is a major regulator of the stability of the LKB1 tumor suppressor. Furthermore, these data draw attention to the possible adverse consequences of antitumor drugs that target Hsp90, such as antibiotics related to geldanamycin, which could disrupt LKB1 function and promote the development of polyps and carcinomatous lesions.	Lab Genet & Canc, FRE 2692, F-69373 Lyon 08, France; Hop Debrousse, INSERM, U418, INRA UA 953,Lab Commun Cellulaires & Differenciat, F-69322 Lyon 05, France; Ecole Prat Hautes Etud, INSERM, E0343, Lab Biol Cellulaire Quantit, F-34095 Montpellier 05, France	CHU Lyon; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Universite de Montpellier	Billaud, M (corresponding author), Lab Genet & Canc, FRE 2692, Domaine Rockefeller,8 Ave Rockefeller, F-69373 Lyon 08, France.	billaud@univ-lvon1.fr	Billaud, Marc N/M-6954-2013	Rossel, Mireille/0000-0003-2275-0817				Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Blumer JB, 2003, J BIOL CHEM, V278, P23217, DOI 10.1074/jbc.C200686200; BOUDEAU J, 2002, BIOCHEM J, V19, P849; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; JEGHERS H, 1949, NEW ENGL J MED, V241, P993, DOI 10.1056/NEJM194912222412501; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Jishage K, 2002, P NATL ACAD SCI USA, V99, P8903, DOI 10.1073/pnas.122254599; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Liu WK, 2003, J BIOMED SCI, V10, P242, DOI 10.1159/000068708; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Mehenni H, 1998, AM J HUM GENET, V63, P1641, DOI 10.1086/302159; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Miyata Y, 2001, J BIOL CHEM, V276, P21841, DOI 10.1074/jbc.M010944200; Miyoshi H, 2002, CANCER RES, V62, P2261; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Olschwang S, 2001, J MED GENET, V38, P356, DOI 10.1136/jmg.38.6.356; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; Peutz JL, 1921, NEDERL MAANDSCHR GEN, V10, P134; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sapkota GP, 2002, BIOCHEM J, V362, P481, DOI 10.1042/0264-6021:3620481; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Shen Z, 2002, CLIN CANCER RES, V8, P2085; Smith DP, 1999, HUM MOL GENET, V8, P1479, DOI 10.1093/hmg/8.8.1479; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; SPIGELMAN AD, 1989, GUT, V30, P1588, DOI 10.1136/gut.30.11.1588; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Su JY, 1996, J BIOL CHEM, V271, P14430, DOI 10.1074/jbc.271.24.14430; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; TOFT DO, 1999, CONTROL HORMONE RECE; Watts JL, 2000, DEVELOPMENT, V127, P1467; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Ylikorkala A, 1999, HUM MOL GENET, V8, P45, DOI 10.1093/hmg/8.1.45; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	55	44	45	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2003	22	57					9165	9175		10.1038/sj.onc.1207179	http://dx.doi.org/10.1038/sj.onc.1207179			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668798	Bronze			2022-12-17	WOS:000187149100007
J	Bravo, SB; Pampin, S; Cameselle-Teijeiro, J; Carneiro, C; Dominguez, F; Barreiro, F; Alvarez, CV				Bravo, SB; Pampin, S; Cameselle-Teijeiro, J; Carneiro, C; Dominguez, F; Barreiro, F; Alvarez, CV			TGF-beta-induced apoptosis in human thyrocytes is mediated by p27(kip1) reduction and is overridden in neoplastic thyrocytes by NF-kappa B activation	ONCOGENE			English	Article						TGF-beta; thyroid cancer; p27; apoptosis; NF-kappa B	THYROID-TUMORS; PROLIFERATIVE ACTIVITY; MESSENGER-RNA; GROWTH; CELLS; EXPRESSION; QUIESCENCE; RESISTANCE; RECEPTOR; MODEL	Millions of people worldwide suffer goiter, a proliferative disease of the follicular cells of the thyroid that may become neoplastic. Thyroid neoplasms have low proliferative index, low apoptotic index and a high incidence of metastasis. TGF-beta is overexpressed in thyroid follicular tumor cells. To investigate the role of TGF-beta in thyroid tumor progression, we established cultures of human thyrocytes from different proliferative pathologies ( Grave's disease, multinodular goiter, follicular adenoma, papillary carcinoma), lymph node metastasis, and a normal thyroid sample. All cultures maintained the thyrocyte phenotype. TGF-beta induced cell-cycle arrest in all cultures, in contrast with results reported for other epithelial tumors. In deprived medium, TGF-beta induced apoptosis in normal thyrocyte cultures and all neoplastic cultures except the metastatic cultures. This apoptosis was mediated by a reduction in p27(kip1) levels, inducing cell-cycle initiation. Antisense p27 expression induced apoptosis in the absence of TGF-beta. By contrast, in cells in which p27 was overexpressed, TGF-beta had a survival effect. In growth medium, a net survival effect occurs in neoplastic thyrocytes only, not normal thyrocytes, due to activation of the NF-kappaB survival program. Together, these findings suggest that (a) thyroid neoplasms are due to reduced apoptosis, not increased division, in line with the low proliferative index of these pathologies, and (b) TGF-beta induces apoptosis in normal thyrocytes via p27 reduction, but that in neoplastic thyrocytes this effect is overridden by activation of the NF-kappaB program.	Univ Santiago de Compostela, Sch Med, Dept Physiol, Santiago De Compostela 15782, Spain; Hosp Clin Univ, Dept Pathol, Santiago De Compostela 15706, Spain; Hosp Clin Univ, Dept Surg, Santiago De Compostela 15706, Spain	Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela	Alvarez, CV (corresponding author), Univ Santiago de Compostela, Sch Med, Dept Physiol, San Francisco S-N, Santiago De Compostela 15782, Spain.	fscralvi@usc.es	Lopez, Susana Belén Bravo/F-8487-2016; Alvarez, Clara V/AAN-4173-2020	Lopez, Susana Belén Bravo/0000-0001-7615-3079; Alvarez, Clara V/0000-0003-1500-4058				Achenbach TV, 2000, CLIN CANCER RES, V6, P3006; ASA SL, 2001, CANC HDB, pCH9; Asmis LM, 1996, J ENDOCRINOL, V149, P485, DOI 10.1677/joe.0.1490485; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Blaydes JP, 1996, INT J CANCER, V65, P525, DOI 10.1002/(SICI)1097-0215(19960208)65:4<525::AID-IJC22>3.3.CO;2-G; Carneiro C, 1998, ONCOGENE, V16, P1455, DOI 10.1038/sj.onc.1201662; Chan JKC, 2000, DIAGNOSTIC HISTOPATH, P959; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; Derwahl M, 2002, TRENDS ENDOCRIN MET, V13, P23, DOI 10.1016/S1043-2760(01)00519-7; Derwahl M, 2000, BEST PRACT RES CL EN, V14, P577, DOI 10.1053/beem.2000.0104; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Freitas JE, 2000, SEMIN NUCL MED, V30, P88, DOI 10.1053/nm.2000.4597; Goretzki PE, 2000, WORLD J SURG, V24, P913, DOI 10.1007/s002680010174; GRUBECKLOEBENSTEIN B, 1989, J CLIN INVEST, V83, P764, DOI 10.1172/JCI113955; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Kammori M, 2002, EXP GERONTOL, V37, P513, DOI 10.1016/S0531-5565(01)00178-4; KATOH R, 1995, HUM PATHOL, V26, P139, DOI 10.1016/0046-8177(95)90029-2; Khoo MLC, 2002, J CLIN ENDOCR METAB, V87, P1814, DOI 10.1210/jcem.87.4.8353; Kimura ET, 1999, THYROID, V9, P119, DOI 10.1089/thy.1999.9.119; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; Lazzereschi D, 1997, CANCER RES, V57, P2071; LEE TK, 1985, HUM PATHOL, V16, P1042, DOI 10.1016/S0046-8177(85)80282-3; Levy O, 1998, J BIOL CHEM, V273, P22657, DOI 10.1074/jbc.273.35.22657; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Matthews P, 2001, J PATHOL, V194, P183, DOI 10.1002/path.848; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Moore D, 1998, HISTOPATHOLOGY, V32, P35; MORTENSEN JD, 1955, J CLIN ENDOCR METAB, V15, P1270, DOI 10.1210/jcem-15-10-1270; Mothersill C, 1995, Methods Mol Biol, V43, P25; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; SOARES P, 1994, CANCER, V73, P2879, DOI 10.1002/1097-0142(19940601)73:11<2879::AID-CNCR2820731135>3.0.CO;2-E; Sreelekha TT, 2000, THYROID, V10, P117, DOI 10.1089/thy.2000.10.117; Urbano AG, 2000, ENDOCRINOLOGY, V141, P1893, DOI 10.1210/en.141.5.1893; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333; Yoshida A, 1999, SURG TODAY, V29, P204	45	44	44	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2003	22	49					7819	7830		10.1038/sj.onc.1207029	http://dx.doi.org/10.1038/sj.onc.1207029			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586408				2022-12-17	WOS:000186240200012
J	Moore, L; Venkatachalam, S; Vogel, H; Watt, JC; Wu, CL; Steinman, H; Jones, SN; Donehower, LA				Moore, L; Venkatachalam, S; Vogel, H; Watt, JC; Wu, CL; Steinman, H; Jones, SN; Donehower, LA			Cooperativity of p19(ARF), Mdm2, and p53 in murine tumorigenesis	ONCOGENE			English	Article						19(ARF); Mdm2; p53; mouse cancer model; tumor suppressor	CARCINOGEN-INDUCED TUMORIGENESIS; SOFT-TISSUE SARCOMAS; ARF TUMOR-SUPPRESSOR; MDM2-DEFICIENT MICE; EMBRYONIC LETHALITY; STABILIZES P53; INK4A LOCUS; CANCER; APOPTOSIS; OVEREXPRESSION	The p19(ARF) gene product responds to oncogenic stresses by interfering with the inhibitory effects of Mdm2 on p53, thus enhancing p53 activity and its antiproliferative functions. The absence of p19(ARF) in the mouse leads to early tumor susceptibility, presumably in part due to decreased p53 activity. To examine the tumorigenic cooperativity of p19(ARF), Mdm2, and p53 in vivo, p19(ARF)-deficient mice were crossed first to p53-deficient mice and then to Mdm2 transgenic mice. The progeny were monitored for tumors. Cooperativity between p19(ARF) and p53 deficiencies in accelerating tumor formation was observed for most genotypes except p53 -/- p19(ARF) -/- mice. p53 -/- p19(ARF) -/- mice had a tumor incidence similar to p53 -/- mice. In this context, tumor suppression by ARF appears to be primarily p53 dependent. The majority of the p19(ARF) +/- tumors deleted the wildtype p19(ARF) allele, in agreement with the previous studies, suggesting that p19(ARF) is a classic 'two hit' tumor suppressor. In a p53+/- background, however, all p19(ARF) +/ - tumors retained a wildtype ARF allele and most also retained wildtype p53. In the second cross between p19(ARF)-deficient and Mdm2 transgenic mice, cooperativity in tumor incidence between Mdm2 overexpression and ARF deficiency was observed, consistent with the role of p19(ARF) in negatively regulating Mdm2 activity. These experiments further demonstrate in vivo the inter-relationships of the p19(ARF)-Mdm2-p53 signaling axis in tumor suppression.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Tennessee, Dept Biochem & Cell & Mol Biol, Knoxville, TN 37996 USA; Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; Univ Massachusetts, Med Ctr, Dept Cell Biol, Worcester, MA 01655 USA	Baylor College of Medicine; Baylor College of Medicine; University of Tennessee System; University of Tennessee Knoxville; Stanford University; University of Massachusetts System; University of Massachusetts Worcester	Donehower, LA (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA.			Vogel, Otto Hannes/0000-0002-0960-3508				Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Foster CJ, 2002, ONCOGENE, V21, P3525, DOI 10.1038/sj.onc.1205441; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; KAMB A, 1994, SCIENCE, V264, P440; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KNUDSON AG, 1984, CANCER DETECT PREV, V7, P1; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kuo ML, 2003, CANCER RES, V63, P1046; LEACH FS, 1993, CANCER RES, V53, P2231; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; LUNA RMD, 1995, NATURE, V378, P203; McDonnell TJ, 1999, J PATHOL, V188, P322, DOI 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Reinke V, 1999, CELL GROWTH DIFFER, V10, P147; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tsai KY, 2002, P NATL ACAD SCI USA, V99, P16865, DOI 10.1073/pnas.262499599; Tsuji K, 2002, BIOCHEM BIOPH RES CO, V295, P621, DOI 10.1016/S0006-291X(02)00723-4; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Venkatachalam S, 2001, TOXICOL PATHOL, V29, P147, DOI 10.1080/019262301753178555; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weber HO, 2002, ONCOGENE, V21, P3207, DOI 10.1038/sj.onc.1205429; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	44	44	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7831	7837		10.1038/sj.onc.1206985	http://dx.doi.org/10.1038/sj.onc.1206985			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586409	Bronze			2022-12-17	WOS:000186240200013
J	Cui, XJ; Lazard, Z; Zhang, P; Hopp, TA; Lee, AV				Cui, XJ; Lazard, Z; Zhang, P; Hopp, TA; Lee, AV			Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2	ONCOGENE			English	Article						breast cancer; IGFs; IRS-2; phosphorylation; progesterone; R5020	ESTROGEN PLUS PROGESTIN; REPLACEMENT THERAPY; FACTOR-I; EXPRESSION; KINASE; IRS-1; GENE; ACTIVATION; PATHWAYS; INHIBIT	Both progesterone and the insulin-like growth factors (IGFs) are critically involved in mammary gland development and also in breast cancer progression. How ever, how the progesterone and IGF signaling pathways interact with each other to regulate breast cancer cell growth remains unresolved. In this study, we investigated progesterone regulation of IGF signaling components in breast cancer cells. We found that insulin receptor substrate-2 (IRS-2) levels were markedly induced by progesterone and the synthetic progestin R5020 in MCF-7 and other progesterone receptor (PR) positive breast cancer cell lines, whereas IRS-1 and the IGF-I receptor were not induced. The antiprogestin RU486 blocked the R5020 effect on IRS-2 expression. Ectopic expression of either PR-A or PR-B in C4-12 breast cancer cells (estrogen receptor and PR negative) showed that progestin upregulation of IRS-2 was mediated specifically by PR-B. The IRS-2 induction by R5020 occurred via an increase of IRS-2 mRNA levels. Further more, progestin treatment prior to IGF-I stimulation resulted in higher tyrosine-phosphorylated IRS-2 levels, increased binding of IRS-2 to Grb-2 and the PI3K regulatory subunit p85, and correspondingly enhanced ERK and Akt activation, as compared with IGF-I-only conditions. Taken together, our data suggest that IRS-2 may play an important role in crosstalk between progesterone and the IGFs in breast cancer cells.	Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA	Baylor College of Medicine	Lee, AV (corresponding author), Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA.	avlee@breastcenter.tmc.edu		Lee, Adrian/0000-0001-9917-514X	NATIONAL CANCER INSTITUTE [R01CA094118] Funding Source: NIH RePORTER; NCI NIH HHS [CA94118] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASERGA R, 1995, CANCER RES, V55, P249; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Chang Q, 2002, CANCER RES, V62, P6035; Dupont J, 2001, J CLIN PATHOL-MOL PA, V54, P149, DOI 10.1136/mp.54.3.149; Graham JD, 1997, ENDOCR REV, V18, P502, DOI 10.1210/er.18.4.502; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lee AV, 1995, BIOMED PHARMACOTHER, V49, P415, DOI 10.1016/0753-3322(96)82678-3; LeRoith D, 1996, BAILLIERE CLIN ENDOC, V10, P49, DOI 10.1016/S0950-351X(96)80298-9; Lin VCL, 1999, CLIN CANCER RES, V5, P395; MUSGROVE EA, 1991, MOL CELL BIOL, V11, P5032, DOI 10.1128/MCB.11.10.5032; Oesterreich S, 2001, CANCER RES, V61, P5771; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Rocha RL, 1997, CLIN CANCER RES, V3, P103; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; Vassen L, 1999, MOL ENDOCRINOL, V13, P485; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WEN DX, 1994, MOL CELL BIOL, V14, P8356, DOI 10.1128/MCB.14.12.8356; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	27	44	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6937	6941		10.1038/sj.onc.1206803	http://dx.doi.org/10.1038/sj.onc.1206803			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534541				2022-12-17	WOS:000185843400015
J	Zhang, J; Choi, Y; Mavromatis, B; Lichtenstein, A; Li, WQ				Zhang, J; Choi, Y; Mavromatis, B; Lichtenstein, A; Li, WQ			Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway	ONCOGENE			English	Article						Akt/PKB; multiple myeloma; PI3K inhibitors; PTEN; signal transduction	ACTIVATED PROTEIN-KINASE; MULTIPLE-MYELOMA; TUMOR-SUPPRESSOR; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; CELL-LINE; 3-KINASE; INSULIN; APOPTOSIS; RESPONSES	We recently reported that internal deletion of PTEN tumor suppressor gene in OPM2 and Delta47 myeloma lines led to high Akt activation. Re-expression of PTEN induced strong apoptosis and growth inhibition. To understand the biologic importance of the phosphatidylinositol 3 kinase (PI3K)/Akt activation affected by PTEN deletion, we analysed apoptosis and growth inhibition by applying PI3K inhibitors to myeloma lines and by expressing Akt constructs. The PI3K inhibitors preferentially suppressed PTEN-null myeloma growth to those expressing PTEN, indicating that PI3K activation is more critical for growth and survival of those lines with PTEN mutations than others expressing a functional PTEN gene. Since PTEN- null myeloma lines exhibited much stronger Akt activation than PTEN- expressing cells in response to insulin-like growth factor I stimulation, we determined whether Akt could be responsible for PI3K-mediated cell survival and growth of PTEN- null myeloma lines. Expression of an active Akt, but not its kinase dead mutant, reversed wortmannin- and dexamethasone-induced apoptosis and growth inhibition in PTEN- null myeloma lines, suggesting that Akt lies downstream of PI3K for PTEN- null myeloma survival and dexamethasone resistance. In summary, we have provided evidence that PTEN- null myeloma cells are stringently dependent on the PI3K/Akt activation for cell survival. These results may provide a basis to treat myeloma patients with PI3K and Akt inhibitors.	Georgetown Univ, Med Ctr, Sch Med, Lombardi Canc Ctr,Dept Oncol, Washington, DC 20057 USA; W LA VA Med Ctr, Dept Med, Los Angeles, CA USA; Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA	Georgetown University; UCLA Jonsson Comprehensive Cancer Center	Li, WQ (corresponding author), Georgetown Univ, Med Ctr, Sch Med, Lombardi Canc Ctr,Dept Oncol, Box 571469,New Res Bldg,E407,3970 Reservoir Rd NW, Washington, DC 20057 USA.							Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Choi Y, 2002, ONCOGENE, V21, P5289, DOI 10.1038/sj.onc.1205650; Desikan K R, 1999, Curr Opin Hematol, V6, P216, DOI 10.1097/00062752-199907000-00004; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Feinman R, 1997, HEMATOL ONCOL CLIN N, V11, P1, DOI 10.1016/S0889-8588(05)70412-3; Gado K, 2001, HAEMATOLOGICA, V86, P227; Ge NL, 2000, ONCOGENE, V19, P4091, DOI 10.1038/sj.onc.1203801; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hsu JH, 2002, ONCOGENE, V21, P1391, DOI 10.1038/sj/onc/1205194; Hsu JH, 2001, BLOOD, V98, P2853, DOI 10.1182/blood.V98.9.2853; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Jelinek DF, 1997, J IMMUNOL, V159, P487; Jelinek DF, 1999, HEMATOL ONCOL CLIN N, V13, P1145, DOI 10.1016/S0889-8588(05)70117-9; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kyle RA, 2001, ONCOLOGIST, V6, P119, DOI 10.1634/theoncologist.6-2-119; Li WQ, 2000, CANCER RES, V60, P3909; Li WQ, 1999, ONCOGENE, V18, P6564, DOI 10.1038/sj.onc.1203065; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; NIESVIZKY R, 1993, BLOOD REV, V7, P24, DOI 10.1016/0268-960X(93)90021-U; Nishimoto N, 1997, HEMATOL ONCOL CLIN N, V11, P159, DOI 10.1016/S0889-8588(05)70421-4; Ogawa M, 2000, CANCER RES, V60, P4262; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Shi YJ, 2002, CANCER RES, V62, P5027; Shi YY, 2002, J BIOL CHEM, V277, P15712, DOI 10.1074/jbc.M200043200; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tu YP, 2000, CANCER RES, V60, P6763; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	36	44	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6289	6295		10.1038/sj.onc.1206718	http://dx.doi.org/10.1038/sj.onc.1206718			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679867				2022-12-17	WOS:000185506200018
J	Haffty, BG; Glazer, PM				Haffty, BG; Glazer, PM			Molecular markers in clinical radiation oncology	ONCOGENE			English	Review						molecular markers; radiation sensitivity; radiation oncology	SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; BREAST-CANCER CELLS; CYCLIN D1 OVEREXPRESSION; DNA MISMATCH REPAIR; RECURRENCE FOLLOWING LUMPECTOMY; BCL-2 PROTEIN EXPRESSION; PREDICT TUMOR RESPONSE; EARLY LARYNGEAL-CANCER; WILD-TYPE P53	Radiation therapy plays a critical role in the management of a majority of patients diagnosed with cancer. Identification of factors that help predict which patients are at risk for relapse within the irradiated field remains an active area of investigation. Although conventional clinical and pathologic factors have been helpful in identifying risk and guiding clinical decision-making for both local and systemic management, there is clearly a need to identify additional prognostic markers, which can aid in refining our treatment strategies and improving outcomes. A substantial amount of research efforts have been devoted to identifying molecular markers for prognostic and therapeutic strategies. The recent emergence of a powerful armamentarium of molecular tools has resulted in rapid expansion of our fund of knowledge and understanding of the molecular biology underlying tumor behavior and response. While a majority of these efforts have been focused on risk factors for metastatic disease and survival, there is a rapidly growing body of literature focused on molecular factors associated with radiation resistance and locoregional failure. In this review, we summarize recent advances and the available literature evaluating molecular markers as they relate to radiation sensitivity of solid tumors. Literature regarding the potential application of expression of genes related to apoptosis, angiogenesis, cell cycle, DNA repair and growth factors will be reviewed. Some of the basic biology and laboratory evidence demonstrating how the marker relates to radiation response and available correlative clinical studies employing these markers as prognostic tools are presented. The majority of molecular markers that have potential clinical significance with respect to radiation sensitivity and local control will be highlighted.	Dept Therapeut Radiol, New Haven, CT 06520 USA		Haffty, BG (corresponding author), Dept Therapeut Radiol, HRT 133,333 Cedar St, New Haven, CT 06520 USA.	bruce.haffty@yale.edu	Glazer, Peter/S-7651-2019	Glazer, Peter/0000-0003-4525-5560				Aebersold DM, 2000, INT J RADIAT ONCOL, V48, P17, DOI 10.1016/S0360-3016(00)00573-3; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agarwal ML, 2001, ONCOGENE, V20, P2527, DOI 10.1038/sj.onc.1204353; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Agrup M, 2000, BREAST CANCER RES TR, V63, P23, DOI 10.1023/A:1006498721508; Akervall JA, 1997, CANCER, V79, P380; Alcalde RE, 1997, ONCOLOGY, V54, P324; ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; Alsner J, 2001, RADIOTHER ONCOL, V59, P179, DOI 10.1016/S0167-8140(01)00301-2; Artese L, 2001, ANTICANCER RES, V21, P689; Barker FG, 2001, INT J RADIAT ONCOL, V51, P410, DOI 10.1016/S0360-3016(01)01609-1; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Bartelink H, 2001, INT J RADIAT ONCOL, V49, P311, DOI 10.1016/S0360-3016(00)01499-1; Bartelink H, 2000, RADIOTHER ONCOL, V55, P217, DOI 10.1016/S0167-8140(99)00055-9; Beatrice F, 1998, ANTICANCER RES, V18, P4737; BEGG AC, 1995, INT J RADIAT ONCOL, V32, P1539, DOI 10.1016/0360-3016(95)00261-V; Begg AC, 1999, RADIOTHER ONCOL, V50, P13, DOI 10.1016/S0167-8140(98)00147-9; Bellacosa A, 1996, CLIN CANCER RES, V2, P175; Bjork-Eriksson T, 2000, INT J RADIAT ONCOL, V46, P13, DOI 10.1016/S0360-3016(99)00373-9; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Bova RJ, 1999, CLIN CANCER RES, V5, P2810; Bradford CR, 1999, HEMATOL ONCOL CLIN N, V13, P777, DOI 10.1016/S0889-8588(05)70092-7; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; Cabelguenne A, 2000, J CLIN ONCOL, V18, P1465, DOI 10.1200/JCO.2000.18.7.1465; Caminero MJ, 1996, ARCH OTOLARYNGOL, V122, P769; Carr JA, 2000, ARCH SURG-CHICAGO, V135, P1469, DOI 10.1001/archsurg.135.12.1469; Chakravarti A, 2002, CANCER RES, V62, P200; Chang EH, 1997, ARCH OTOLARYNGOL, V123, P507; Ciancio G, 1997, TRANSPLANT P, V29, P2878, DOI 10.1016/S0041-1345(97)00716-1; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Condon LT, 2002, INT J CANCER, V100, P472, DOI 10.1002/ijc.10503; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Corvo R, 2000, INT J RADIAT ONCOL, V47, P57, DOI 10.1016/S0360-3016(00)00416-8; D'Atri S, 1998, MOL PHARMACOL, V54, P334, DOI 10.1124/mol.54.2.334; Danic D, 1999, J LARYNGOL OTOL, V113, P538; Davis TW, 1998, CANCER RES, V58, P767; DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915; Dijkema IM, 2000, ORAL ONCOL, V36, P54, DOI 10.1016/S1368-8375(99)00051-2; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; Edstrom S, 2001, LARYNGOSCOPE, V111, P124, DOI 10.1097/00005537-200101000-00022; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Elkhuizen PHM, 1999, INT J RADIAT ONCOL, V45, P73, DOI 10.1016/S0360-3016(99)00158-3; Elsaleh H, 2000, RADIOTHER ONCOL, V56, P239, DOI 10.1016/S0167-8140(00)00184-5; Esteva FJ, 2002, SEMIN RADIAT ONCOL, V12, P319, DOI 10.1053/srao.2002.35251; Ferrandina G, 2002, J CLIN ONCOL, V20, P973, DOI 10.1200/JCO.20.4.973; Ferrandina G, 2002, BRIT J CANCER, V87, P1145, DOI 10.1038/sj.bjc.6600578; Fink D, 1996, CANCER RES, V56, P4881; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; Formenti SC, 2002, INT J RADIAT ONCOL, V52, P397, DOI 10.1016/S0360-3016(01)02655-4; Fritzell JA, 1997, CANCER RES, V57, P5143; Gaffney DK, 2001, AM J CLIN ONCOL-CANC, V24, P443, DOI 10.1097/00000421-200110000-00006; Gaffney DK, 2001, INT J RADIAT ONCOL, V49, P1213, DOI 10.1016/S0360-3016(00)01583-2; Gallo O, 1999, INT J CANCER, V84, P573, DOI 10.1002/(SICI)1097-0215(19991222)84:6<573::AID-IJC6>3.0.CO;2-R; Gasparini G, 1995, CLIN CANCER RES, V1, P1375; Gasparini G, 1998, INT J ONCOL, V12, P1117; Geng L, 2001, CANCER RES, V61, P2413; Gong JG, 1999, NATURE, V399, P806; Gorski DH, 1999, CANCER RES, V59, P3374; Grandis JR, 1996, CANCER-AM CANCER SOC, V78, P1284, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X; Grandis JR, 1998, INT J ONCOL, V13, P375; Grandis JR, 2000, LARYNGOSCOPE, V110, P868, DOI 10.1097/00005537-200005000-00016; Gupta AK, 2001, CANCER RES, V61, P4278; Gupta AK, 2002, CLIN CANCER RES, V8, P885; Gupta VK, 2002, CANCER J, V8, P47, DOI 10.1097/00130404-200201000-00009; Haffty BG, 1996, INT J RADIAT ONCOL, V35, P751, DOI 10.1016/0360-3016(96)00150-2; Haffty BG, 2002, SEMIN RADIAT ONCOL, V12, P329, DOI 10.1053/srao.2002.35252; Harari PM, 2002, SEMIN RADIAT ONCOL, V12, P21, DOI 10.1053/srao.2002.34865; Harari PM, 2001, SEMIN RADIAT ONCOL, V11, P281, DOI 10.1053/srao.2001.26027; Harari PM, 2001, INT J RADIAT ONCOL, V49, P427, DOI 10.1016/S0360-3016(00)01488-7; Harima Y, 2000, CANCER, V88, P132, DOI 10.1002/(SICI)1097-0142(20000101)88:1<132::AID-CNCR18>3.3.CO;2-8; Hassan AB, 2002, ANN ONCOL, V13, P349, DOI 10.1093/annonc/mdf096; Homer JJ, 2001, CLIN OTOLARYNGOL, V26, P498, DOI 10.1046/j.1365-2273.2001.00512.x; Huang S M, 2001, Cancer Chemother Biol Response Modif, V19, P339; Huang SM, 2002, CANCER RES, V62, P4300; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; Izzo JG, 1998, ONCOGENE, V17, P2313, DOI 10.1038/sj.onc.1202153; Jackel MC, 2000, LARYNGOSCOPE, V110, P1339; JARES P, 1994, CANCER RES, V54, P4813; KARRAN P, 1982, NATURE, V296, P868, DOI 10.1038/296868a0; Kasid U, 2001, EXP BIOL MED, V226, P624, DOI 10.1177/153537020222600706; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kim YB, 2002, CANCER, V95, P531, DOI 10.1002/cncr.10684; Kishi K, 2000, CANCER RES, V60, P1326; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; Koch WM, 1996, JNCI-J NATL CANCER I, V88, P1580, DOI 10.1093/jnci/88.21.1580; Koelbl O, 2001, INT J RADIAT ONCOL, V49, P147, DOI 10.1016/S0360-3016(00)01356-0; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kyomoto R, 1997, INT J CANCER, V74, P576, DOI 10.1002/(SICI)1097-0215(19971219)74:6<576::AID-IJC3>3.0.CO;2-R; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Linderholm B, 1999, BRIT J CANCER, V81, P727, DOI 10.1038/sj.bjc.6690755; Linderholm B, 2000, J CLIN ONCOL, V18, P1423, DOI 10.1200/JCO.2000.18.7.1423; Linderholm B, 2000, INT J CANCER, V89, P51, DOI 10.1002/(SICI)1097-0215(20000120)89:1<51::AID-IJC9>3.3.CO;2-#; Liu LL, 1996, CANCER RES, V56, P5375; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; Mackey TJ, 1998, UROLOGY, V52, P1085, DOI 10.1016/S0090-4295(98)00360-4; Martin JMC, 1999, CANCER RES, V59, P1134; McKenna WG, 2002, SEMIN RADIAT ONCOL, V12, P27, DOI 10.1053/srao.2002.34866; Michalides RJAM, 1997, ARCH OTOLARYNGOL, V123, P497; Milas L, 2002, INT J RADIAT ONCOL, V52, P514, DOI 10.1016/S0360-3016(01)02693-1; Milas L, 2001, SEMIN RADIAT ONCOL, V11, P290, DOI 10.1053/srao.2001.26018; Mineta H, 1998, BRIT J CANCER, V78, P1084, DOI 10.1038/bjc.1998.632; MIYAGUCHI M, 1993, EUR ARCH OTO-RHINO-L, V249, P478; Miyaguchi M, 1998, ACTA OTO-LARYNGOL, V118, P428; Moonen L, 2001, INT J RADIAT ONCOL, V49, P1305, DOI 10.1016/S0360-3016(00)01503-0; Mukherjee G, 2001, INT J GYNECOL CANCER, V11, P187, DOI 10.1046/j.1525-1438.2001.01014.x; Musgrove EA, 2001, J BIOL CHEM, V276, P47675, DOI 10.1074/jbc.M106371200; Narayana A, 2000, INT J RADIAT ONCOL, V46, P21, DOI 10.1016/S0360-3016(99)00348-X; Nicholson RI, 2002, ANN NY ACAD SCI, V963, P104, DOI 10.1111/j.1749-6632.2002.tb04101.x; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Nogueira CP, 1998, LARYNGOSCOPE, V108, P345, DOI 10.1097/00005537-199803000-00007; Obata A, 2000, INT J CANCER, V89, P187, DOI 10.1002/(SICI)1097-0215(20000320)89:2<187::AID-IJC14>3.0.CO;2-V; Overgaard J, 2000, ACTA ONCOL, V39, P327, DOI 10.1080/028418600750013096; Pai HH, 1998, INT J RADIAT ONCOL, V41, P37, DOI 10.1016/S0360-3016(98)00025-X; PENTOPOULOS AJ, 2002, P ANN ASCO M, V19; Peretz S, 2002, RADIAT RES, V158, P174, DOI 10.1667/0033-7587(2002)158[0174:IREPAM]2.0.CO;2; Piccart M, 2001, ONCOLOGY-BASEL, V61, P73, DOI 10.1159/000055405; Pierce L, 2002, SEMIN RADIAT ONCOL, V12, P352, DOI 10.1053/srao.2002.35254; PIERCE LJ, 1994, INT J RADIAT ONCOL, V28, P395, DOI 10.1016/0360-3016(94)90063-9; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; Pietras RJ, 1999, CANCER RES, V59, P1347; Pignataro L, 1998, J CLIN ONCOL, V16, P3069, DOI 10.1200/JCO.1998.16.9.3069; Pirollo KF, 1997, ONCOGENE, V14, P1735, DOI 10.1038/sj.onc.1201116; Pollack A, 1997, CLIN CANCER RES, V3, P1823; Press MF, 2002, J CLIN ONCOL, V20, P3095, DOI 10.1200/JCO.2002.09.094; Pyo H, 2001, CLIN CANCER RES, V7, P2998; Rao GS, 2000, INT J RADIAT ONCOL, V48, P1519, DOI 10.1016/S0360-3016(00)01358-4; RaybaudDiogene H, 1997, J CLIN ONCOL, V15, P1030, DOI 10.1200/JCO.1997.15.3.1030; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Reitmair AH, 1997, CANCER RES, V57, P3765; Reynolds TY, 1996, CANCER RES, V56, P5754; Ringberg A, 2001, EUR J CANCER, V37, P1514, DOI 10.1016/S0959-8049(01)00165-4; Ritter MA, 2002, INT J RADIAT ONCOL, V53, P574, DOI 10.1016/S0360-3016(02)02781-5; Rockwell S, 2001, Novartis Found Symp, V240, P133; Rockwell S, 2001, NOVART FDN SYMP, V240, P142; Saunders ME, 1999, CLIN CANCER RES, V5, P2455; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Shintani S, 2000, CANCER LETT, V154, P71, DOI 10.1016/S0304-3835(00)00376-1; Shintani S, 2001, INT J CANCER, V96, P159, DOI 10.1002/ijc.1014.abs; Silvestri R, 1996, J NATL CANCER I, V88, P1499, DOI 10.1093/jnci/88.20.1499; Silvestrini R, 1997, J NATL CANCER I, V89, P639, DOI 10.1093/jnci/89.9.639; Silvestrini R, 1997, INT J CANCER, V74, P122, DOI 10.1002/(SICI)1097-0215(19970220)74:1<122::AID-IJC20>3.0.CO;2-G; Silvestrini R, 1993, Recent Results Cancer Res, V127, P71; SILVESTRINI R, 1993, INT J CANCER, V54, P231, DOI 10.1002/ijc.2910540212; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; Silvestrini R, 2000, ANN ONCOL, V11, P259, DOI 10.1023/A:1008323722156; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Sittel C, 2000, LARYNGOSCOPE, V110, P1012, DOI 10.1097/00005537-200006000-00024; Slamon Dennis, 1999, Cancer Control, V6, P7; Smith BD, 1999, RADIAT ONCOL INVEST, V7, P125, DOI 10.1002/(SICI)1520-6823(1999)7:3<125::AID-ROI1>3.0.CO;2-W; Smith BD, 2000, J CLIN ONCOL, V18, P2046, DOI 10.1200/JCO.2000.18.10.2046; Stackhouse MA, 1998, INT J RADIAT ONCOL, V42, P817, DOI 10.1016/S0360-3016(98)00330-7; Streffer JR, 2002, J NEURO-ONCOL, V56, P43, DOI 10.1023/A:1014448721327; Taylor D, 1999, HUM PATHOL, V30, P1221, DOI 10.1016/S0046-8177(99)90041-2; Tezuka M, 2001, CLIN CANCER RES, V7, P3206; Tsai ST, 1998, ANTICANCER RES, V18, P2849; Turner BC, 1997, CANCER RES, V57, P3079; Turner BC, 2000, INT J RADIAT ONCOL, V47, P1169, DOI 10.1016/S0360-3016(00)00525-3; Turner BC, 2000, CANCER-AM CANCER SOC, V88, P1091, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1091::AID-CNCR21>3.0.CO;2-Y; Unal OF, 1999, J LARYNGOL OTOL, V113, P446, DOI 10.1017/S0022215100144184; Uno M, 2001, INT J CANCER, V94, P474, DOI 10.1002/ijc.1493; Vaisman A, 1998, CANCER RES, V58, P3579; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; WALTER MA, 1991, ANN OTO RHINOL LARYN, V100, P523, DOI 10.1177/000348949110000701; Wang SC, 2001, SEMIN ONCOL, V28, P115, DOI 10.1016/S0093-7754(01)90289-1; Wang YL, 2001, CANCER RES, V61, P8211; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wen B, 2001, BRIT J CANCER, V85, P2017, DOI 10.1054/bjoc.2001.2171; Wen QH, 1996, LARYNGOSCOPE, V106, P884, DOI 10.1097/00005537-199607000-00019; Wilson GD, 1998, ANTICANCER RES, V18, P4801; WILSON GD, 1995, BRIT J CANCER, V71, P1248, DOI 10.1038/bjc.1995.241; WOLLMAN R, 1994, INT J RADIAT ONCOL, V30, P91, DOI 10.1016/0360-3016(94)90523-1; Wood NB, 1997, LARYNGOSCOPE, V107, P827, DOI 10.1097/00005537-199706000-00019; Wouters BG, 1999, ONCOGENE, V18, P6540, DOI 10.1038/sj.onc.1203053; Wu JX, 1999, MOL CELL BIOL, V19, P8292; Xia F, 2002, SEMIN RADIAT ONCOL, V12, P296, DOI 10.1053/srao.2002.35250; Yoo SS, 2000, INT J CANCER, V90, P22, DOI 10.1002/(SICI)1097-0215(20000220)90:1<22::AID-IJC3>3.0.CO;2-T; ZATTERSTROM UK, 1991, HEAD NECK-J SCI SPEC, V13, P477, DOI 10.1002/hed.2880130603; Zellars RC, 2000, J CLIN ONCOL, V18, P1906, DOI 10.1200/JCO.2000.18.9.1906; Zeng M, 2000, CANCER RES, V60, P4889; Zhang H, 1999, CANCER RES, V59, P3021	183	44	44	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5915	5925		10.1038/sj.onc.1206704	http://dx.doi.org/10.1038/sj.onc.1206704			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947398				2022-12-17	WOS:000185086100018
J	Leaner, VD; Kinoshita, I; Birrer, MJ				Leaner, VD; Kinoshita, I; Birrer, MJ			AP-1 complexes containing cJun and JunB cause cellular transformation of Rat1a fibroblasts and share transcriptional targets	ONCOGENE			English	Article						cJun; JunB; JunD; transcriptional targets	ANCHORAGE-INDEPENDENT GROWTH; BREAST-CANCER CELLS; C-JUN; PROTEIN-KINASE; V-JUN; RAT-1A CELLS; EXPRESSION; CAVEOLIN-1; FOS; GENE	To investigate the role of individual Jun proteins in cell growth and transformation, we have used a doxycycline-inducible retroviral vector to regulate their expression in rat fibroblasts. AP-1 complexes enriched with cJun and JunB result in morphological alterations and anchorage-independent cell growth consistent with a transformation-like phenotype, whereas complexes enriched with JunD had an antiproliferative effect. These results suggest that genes regulated by both cJun and JunB are potentially involved in transformation and that they can be distinguished from those regulated by AP-1 complexes containing JunD. To identify genes regulated by cJun and JunB that may have a role in anchorage-independent growth, we investigated differential gene expression by each of the Jun family members using the Affymetrix Rat oligonucleotide microarray, RG_U34A containing approximately 8000 genes. Differentially regulated genes were identified and grouped for correlation with regulation by the different Jun proteins. A total of 33 candidate genes were found to be differentially regulated by both cJun and JunB and not by JunD. These genes have roles in cell metabolism, growth, signal transduction, migration and adhesion. We validated the differential regulation by cJun and JunB of 10 candidate genes by Northern blot analysis. Of these, eight were further characterized as potential direct targets of AP-1 regulation based on Northern blot results showing differential regulation that correlate with cJun expression. Our results show that inducible cJun and JunB expression result in anchorage-independent growth of Rat1a cells, distinct from JunD-expressing cells. This model system and a functional genomic approach enabled us to differentiate AP-1-regulated genes involved in transformation from AP-1-regulated genes known as bystander genes. This approach significantly reduces the number of bystanders and allows for the targeting of genes specifically involved in transformation.	NCI, Cell & Canc Biol Dept, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Birrer, MJ (corresponding author), NCI, Cell & Canc Biol Dept, NIH, 9610 Med Ctr Dr,Room 300, Rockville, MD 20850 USA.							ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Buse P, 1999, J BIOL CHEM, V274, P7253, DOI 10.1074/jbc.274.11.7253; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; HIRAI SI, 1990, ONCOGENE, V5, P39; Ho CC, 2002, AM J PATHOL, V161, P1647, DOI 10.1016/S0002-9440(10)64442-2; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Kato K, 2002, CANCER, V94, P929, DOI 10.1002/cncr.10329.abs; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kinoshita I, 2003, ONCOGENE, V22, P2710, DOI 10.1038/sj.onc.1206371; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; Li LK, 2001, CANCER RES, V61, P4386; LIM AL, 1994, MATRIX BIOL, V14, P21, DOI 10.1016/0945-053X(94)90026-4; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; MELLSTROM B, 1991, ONCOGENE, V6, P1959; Mikosz CA, 2001, J BIOL CHEM, V276, P16649, DOI 10.1074/jbc.M010842200; NARANJO JR, 1991, ONCOGENE, V6, P223; Nishitani Junko, 2002, Cellular and Molecular Biology Online Papers, V48, pOL331; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RYSECK RP, 1991, ONCOGENE, V6, P533; Sambrook J, 1989, MOL CLONING LAB MANU; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Semb H, 1998, AM J HUM GENET, V63, P1588, DOI 10.1086/302173; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Thepot D, 2000, DEVELOPMENT, V127, P143; Timme TL, 2000, ONCOGENE, V19, P3256, DOI 10.1038/sj.onc.1203654; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Watsuji T, 1997, BIOCHEM BIOPH RES CO, V234, P769, DOI 10.1006/bbrc.1997.6705; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; Wilson E, 2002, ATHEROSCLEROSIS, V162, P289, DOI 10.1016/S0021-9150(01)00718-3; Zarka TA, 2003, INT J GYNECOL CANCER, V13, P240, DOI 10.1136/ijgc-00009577-200303000-00024; Zhong Y, 2001, CLIN CANCER RES, V7, P1683	55	44	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5619	5629		10.1038/sj.onc.1206644	http://dx.doi.org/10.1038/sj.onc.1206644			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944910				2022-12-17	WOS:000184865900011
J	Ma, Y; Koza-Taylor, PH; DiMattia, DA; Hames, L; Fu, HN; Dragnev, KH; Turi, T; Beebe, JS; Freemantle, SJ; Dmitrovsky, E				Ma, Y; Koza-Taylor, PH; DiMattia, DA; Hames, L; Fu, HN; Dragnev, KH; Turi, T; Beebe, JS; Freemantle, SJ; Dmitrovsky, E			Microarray analysis uncovers retinoid targets in human bronchial epithelial cells	ONCOGENE			English	Article						retinoic acid; bronchial epithelial cells; microarray analysis; retinoic acid resistance	TGF-BETA SUPERFAMILY; FACTOR BINDING PROTEIN-6; LOOP-HELIX PROTEINS; ACUTE PROMYELOCYTIC LEUKEMIA; ASPARAGINE SYNTHETASE GENE; PLACEBO-CONTROLLED TRIAL; TISSUE TRANSGLUTAMINASE; LUNG-CANCER; TRANSCRIPTION FACTOR; SIGNALING PATHWAY	Retinoids, the natural and synthetic derivatives of vitamin A, have a role in cancer treatment and prevention. There is a need to reveal mechanisms that account for retinoid response or resistance. This study identified candidate all-trans-retinoic acid (RA) target genes linked to growth suppression in BEAS-2B human bronchial epithelial cells. Microarray analyses were performed using Affymetrix arrays. A total of 11 RA-induced species were validated by reverse transcription polymerase chain reaction (RT-PCR), Western or Northern analyses. Three of these species were novel candidate RA-target genes in human bronchial epithelial cells. These included: placental bone morphogenetic protein (PLAB), polyamine oxidase isoform 1 (PAOh1) and E74-like factor 3 (ELF3). Expression patterns were studied in RA-resistant BEAS-2BR1 cells. In BEAS-2B-R1 cells, RA dysregulated the expression of the putative lymphocyte G0/G1 switch gene (G0S2), heme oxygenase 1 (HMOX1), tumor necrosis factor-alpha-induced protein 2 (TNFAIP2), inhibitor of DNA binding 1(Id1), fos-like antigen 1 (FOSL1), transglutaminase 2 (TGM2), asparagine synthetase (ASNS), PLAB, PAOh1 and ELF3, while prominent induction of insulin-like growth-factor-binding protein 6 (IGFBP6) still occurred. In summary, this study identified 11 candidate RA-target genes in human bronchial epithelial cells including three novel species. Expression studies in BEAS-2B-R1 cells indicated that several were directly implicated in RA signaling, since their aberrant expression was linked to RA resistance of human bronchial epithelial cells.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Med, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Hanover, NH 03755 USA; Pfizer Global Res & Dev, Groton, CT 06340 USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Pfizer	Dmitrovsky, E (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.				NATIONAL CANCER INSTITUTE [R01CA087546] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA87546] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; ARFIN SM, 1977, P NATL ACAD SCI USA, V74, P2367, DOI 10.1073/pnas.74.6.2367; Ayoub J, 1999, J CLIN ONCOL, V17, P3546, DOI 10.1200/JCO.1999.17.11.3546; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Barbosa-Tessmann IP, 1999, BIOCHEM J, V339, P151, DOI 10.1042/0264-6021:3390151; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Boyle JO, 1999, J NATL CANCER I, V91, P373, DOI 10.1093/jnci/91.4.373; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Clarke PA, 2001, BIOCHEM PHARMACOL, V62, P1311, DOI 10.1016/S0006-2952(01)00785-7; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; DELVA L, 1993, BLOOD, V82, P2175; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Ferry RJ, 1999, HORM METAB RES, V31, P192, DOI 10.1055/s-2007-978719; Freeman WM, 2000, BIOTECHNIQUES, V29, P1042, DOI 10.2144/00295rv01; Gabbitas B, 1996, J CELL PHYSIOL, V169, P15, DOI 10.1002/(SICI)1097-4652(199610)169:1<15::AID-JCP2>3.0.CO;2-H; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; HONGO S, 1990, LEUKEMIA, V4, P708; Kaiser A, 1999, FEBS LETT, V448, P45, DOI 10.1016/S0014-5793(99)00326-9; Kim DS, 2002, IMMUNITY, V16, P9, DOI 10.1016/S1074-7613(02)00264-9; Kitamura Y, 1999, NEUROSCI LETT, V262, P129, DOI 10.1016/S0304-3940(99)00055-5; KITAREEWAN S, IN PRESS CANC CHEMOP, V1; Kizaki M, 1996, BLOOD, V87, P725, DOI 10.1182/blood.V87.2.725.bloodjournal872725; Kurie JM, 2003, J NATL CANCER I, V95, P206, DOI 10.1093/jnci/95.3.206; Langenfeld J, 1996, ONCOGENE, V13, P1983; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Lippman SM, 2001, JNCI-J NATL CANCER I, V93, P605, DOI 10.1093/jnci/93.8.605; Lonardo F, 1999, CANCER RES, V59, P2470; Lonardo F, 2002, CLIN CANCER RES, V8, P54; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Nagy L, 1996, J BIOL CHEM, V271, P4355; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Ou HS, 2000, CIRC RES, V87, P881, DOI 10.1161/01.RES.87.10.881; Parrinello S, 2001, J BIOL CHEM, V276, P39213, DOI 10.1074/jbc.M104473200; REDDEL RR, 1988, CANCER RES, V48, P1904; Rusiniak ME, 2000, CANCER RES, V60, P1824; RUSSELL L, 1991, DNA CELL BIOL, V10, P581, DOI 10.1089/dna.1991.10.581; SARMA V, 1992, J IMMUNOL, V148, P3302; Soria JC, 2001, JNCI-J NATL CANCER I, V93, P1257, DOI 10.1093/jnci/93.16.1257; SPORN MB, 1976, FED PROC, V35, P1332; Sueoka N, 2000, AM J RESP CELL MOL, V23, P297, DOI 10.1165/ajrcmb.23.3.4013; Sueoka N, 1999, CANCER RES, V59, P3838; Sueoka N, 2000, ONCOGENE, V19, P4432, DOI 10.1038/sj.onc.1203813; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tanaka K, 1998, J BIOL CHEM, V273, P25922, DOI 10.1074/jbc.273.40.25922; Toulouse A, 2000, FASEB J, V14, P1224, DOI 10.1096/fasebj.14.9.1224; Tulchinsky E, 2000, HISTOL HISTOPATHOL, V15, P921, DOI 10.14670/HH-15.921; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Yan ZH, 1996, MOL CELL ENDOCRINOL, V120, P203, DOI 10.1016/0303-7207(96)03826-9; YokoyamaKobayashi M, 1997, J BIOCHEM-TOKYO, V122, P622; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022	59	44	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4924	4932		10.1038/sj.onc.1206728	http://dx.doi.org/10.1038/sj.onc.1206728			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894236				2022-12-17	WOS:000184344600018
J	Sreenivasan, Y; Sarkar, A; Manna, SK				Sreenivasan, Y; Sarkar, A; Manna, SK			Mechanism of cytosine arabinoside-mediated apoptosis: role of Rel A (p65) dephosphorylation	ONCOGENE			English	Article						NF-kappa B; araC; apoptosis; phosphatase; p65	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; MYELOID-LEUKEMIA CELLS; TNF-INDUCED ACTIVATION; PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; GENE-EXPRESSION; CONSTITUTIVE ACTIVATION; MULTIDRUG-RESISTANCE; LIPID-PEROXIDATION	Nuclear transcription factor kappa B (NF-kappaB) has been shown both to block apoptosis and to promote cell proliferation, and hence has been considered an important target for anticancer drug development. The pyrimidine analogue cytosine arabinoside (araC) is among the most effective agents used in the treatment of acute leukemia, and we demonstrate in this study that its chemotherapeutic activity may be mediated by its inhibition of NF-kappaB. We found that in Jurkat cells, although tumor necrosis factor (TNF), araC, or ceramide induced NF-kappaB, the induction was only transient in the case of araC. In both HuT-78 and serum-activated LPS-stimulated Jurkat (SA-LPS/Jkt) cells that expressed NF-kappaB, TNF or ceramide treatments did not affect the NF-kappaB expression whereas araC downregulated it. AraC, but not TNF or ceramide was able to induce apoptosis in these cells as detected by assays for lipid peroxidation, reactive oxygen intermediates generation, caspase activation, cytotoxicity, Bcl-2 degradation, and DNA fragmentation. AraC also potentiated apoptosis mediated by cis-platin, etoposide, or taxol in these cells. AraC was able to induce protein phosphatases (PP) 2A and 2B-A, and phosphorylation of p65 subunit of NF-kappaB in the HuT-78 and SA-LPS/Jkt cells was downregulated by araC treatment. Furthermore, calyculin A, a specific phospho-serine/phospho-threonine phosphatase inhibitor, protected HuT-78 and SA-LPS/Jkt cells from araC-mediated NF-kappaB downregulation and apoptosis. These observations collectively suggest that araC induces apoptosis in NF-kappaB-expressing cells by dephosphorylating the p65 subunit of NF-kappaB.	Ctr DNA Fingerprinting & Diagnost, Immunol Lab, Hyderabad 500076, Andhra Pradesh, India	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD)	Manna, SK (corresponding author), Ctr DNA Fingerprinting & Diagnost, Immunol Lab, Hyderabad 500076, Andhra Pradesh, India.	manna@www.cdfd.org.in						Badrichani AZ, 1999, J CLIN INVEST, V103, P543, DOI 10.1172/JCI2517; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELLAMY WT, 1994, ADV CLIN CHEM, V31, P1, DOI 10.1016/S0065-2423(08)60332-7; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; BRACH MA, 1992, BLOOD, V79, P728; BRACH MA, 1992, MOL PHARMACOL, V41, P60; Braess J, 1999, BRIT J HAEMATOL, V105, P388, DOI 10.1111/j.1365-2141.1999.01338.x; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; DOU QP, 1995, CANCER RES, V55, P5222; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Egan LJ, 1999, J BIOL CHEM, V274, P26448, DOI 10.1074/jbc.274.37.26448; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; HARRISON DJ, 1995, J PATHOL, V175, P7, DOI 10.1002/path.1711750103; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Izban KF, 2000, HUM PATHOL, V31, P1482, DOI 10.1053/hupa.2000.20370; Jarvis WD, 1998, MOL PHARMACOL, V54, P844, DOI 10.1124/mol.54.5.844; KHARBANDA S, 1994, MOL PHARMACOL, V46, P67; Kochetkova M, 1997, J CLIN INVEST, V99, P3000, DOI 10.1172/JCI119495; Lee JI, 1998, J CLIN PHARMACOL, V38, P981, DOI 10.1177/009127009803801101; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, J IMMUNOL, V162, P1510; Manna SK, 1999, J IMMUNOL, V163, P6800; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; Manna SK, 2000, J IMMUNOL, V164, P5156, DOI 10.4049/jimmunol.164.10.5156; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Nutku E, 2001, J IMMUNOL, V167, P1039, DOI 10.4049/jimmunol.167.2.1039; Perez C, 1997, J CELL SCI, V110, P337; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Rajkumar SV, 2002, J CLIN ONCOL, V20, P4319, DOI 10.1200/JCO.2002.02.116; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SUGANUMA M, 1990, CANCER RES, V50, P3521; Terada R, 2002, HEPATO-GASTROENTEROL, V49, P1545; TONKS NK, 1991, METHOD ENZYMOL, V201, P442; VAN AD, 1996, SCIENCE, V274, P787; Waddick KG, 1999, BIOCHEM PHARMACOL, V57, P9, DOI 10.1016/S0006-2952(98)00224-X; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang RH, 2001, ONCOGENE, V20, P6111, DOI 10.1038/sj.onc.1204829	52	44	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4356	4369		10.1038/sj.onc.1206486	http://dx.doi.org/10.1038/sj.onc.1206486			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853972				2022-12-17	WOS:000183978900005
J	Wilhelmsson, U; Eliasson, C; Bjerkvig, R; Pekny, M				Wilhelmsson, U; Eliasson, C; Bjerkvig, R; Pekny, M			Loss of GFAP expression in high-grade astrocytomas does not contribute to tumor development or progression	ONCOGENE			English	Article						glial fibrillary acidic protein; astrocytoma; intermediate filaments; gene targeting; p53	FIBRILLARY ACIDIC PROTEIN; CENTRAL-NERVOUS-SYSTEM; HUMAN GLIOMAS; INTERMEDIATE FILAMENTS; PHOSPHORYLATION SITES; COMPLEMENTARY-DNA; BRAIN-TUMORS; IN-VITRO; CELLS; GROWTH	In astrocytic neoplasms, the number of cells expressing glial fibrillary acidic protein (GFAP) is inversely proportional to the extent of anaplasia. The loss of GFAP expression, the principal marker of astroglial cells, in these tumors has been proposed to constitute a step in their development and progression. To test this hypothesis, we crossed p53-negative (p53(-/-)) mice, which frequently develop astrocytomas after intrauterine exposure to ethylnitrosourea, with GFAP-negative (GFAP(-/-)) mice or GFAP(+/+) controls. Brain tumors of glial origin were found in 12 of 35 GFAP(+/+) p53(-/-) mice (34%) and in I I of 27 GFAP(-/-) p53(-/-) mice (41%). The two groups did not differ in the age at which tumors were detected or in tumor histology or progression. Thus, the loss of GFAP expression frequently seen in high-grade astrocytomas does not constitute a step in tumor development. Rather, it may represent the undifferentiated state of these cells.	Univ Gothenburg, Dept Biochem Med, SE-40530 Gothenburg, Sweden; Univ Bergen, Dept Anat & Cell Biol, Bergen, Norway	University of Gothenburg; University of Bergen	Pekny, M (corresponding author), Univ Gothenburg, Dept Biochem Med, Box 440, SE-40530 Gothenburg, Sweden.			Wilhelmsson, Ulrika/0000-0003-3227-2687				BIGNER SH, 1998, GENETIC BASIS HUMAN, P661; CHEN WJ, 1994, J CELL BIOL, V127, P813, DOI 10.1083/jcb.127.3.813; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECK JHN, 1978, ACTA NEUROPATHOL, V42, P183, DOI 10.1007/BF00690355; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; ENG LF, 1978, J HISTOCHEM CYTOCHEM, V26, P513, DOI 10.1177/26.7.357640; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Engebraaten O, 1999, J NEUROSURG, V90, P125, DOI 10.3171/jns.1999.90.1.0125; HARA A, 1991, SURG NEUROL, V36, P190, DOI 10.1016/0090-3019(91)90111-L; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; JACQUE CM, 1979, J NATL CANCER I, V62, P479, DOI 10.1093/jnci/62.3.479; JACQUE CM, 1978, J NEUROL SCI, V35, P147, DOI 10.1016/0022-510X(78)90107-7; KAJIWARA K, 1992, BRAIN RES, V572, P314, DOI 10.1016/0006-8993(92)90492-R; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Leonard JR, 2001, ONCOGENE, V20, P8281, DOI 10.1038/sj.onc.1205024; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Oda H, 1997, CANCER RES, V57, P646; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; Pekny M, 1998, EXP CELL RES, V239, P332, DOI 10.1006/excr.1997.3922; Pekny M, 2001, Prog Brain Res, V132, P23; RUTKA JT, 1993, CANCER RES, V53, P3624; RUTKA JT, 1994, CANCER RES, V54, P3267; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TASCOS NA, 1982, HUM PATHOL, V13, P454, DOI 10.1016/S0046-8177(82)80028-2; TODA M, 1994, J NEUROCHEM, V63, P1975; Toda M, 1999, NEUROCHEM RES, V24, P339, DOI 10.1023/A:1022538810581; TSUJIMURA K, 1994, J BIOCHEM, V116, P426, DOI 10.1093/oxfordjournals.jbchem.a124542; VANDERMEULEN JDM, 1978, NEUROPATH APPL NEURO, V4, P177; VELASCO ME, 1980, CANCER, V45, P484, DOI 10.1002/1097-0142(19800201)45:3<484::AID-CNCR2820450312>3.0.CO;2-9; Wechsler W, 1979, Natl Cancer Inst Monogr, P219; WEINSTEIN DE, 1991, J CELL BIOL, V112, P1205, DOI 10.1083/jcb.112.6.1205; WESTERMARK B, 1973, INT J CANCER, V12, P438, DOI 10.1002/ijc.2910120215; YAHANDA AM, 1995, MOL CELL BIOL, V15, P4249; YONG VW, 1992, J NEUROL SCI, V111, P92; ZHOU Y, 2002, NAT REV CANCER, V8, P616	38	44	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3407	3411		10.1038/sj.onc.1206372	http://dx.doi.org/10.1038/sj.onc.1206372			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776191				2022-12-17	WOS:000183128500006
J	Zeisig, BB; Garcia-Cuellar, MP; Winkler, TH; Slany, RK				Zeisig, BB; Garcia-Cuellar, MP; Winkler, TH; Slany, RK			The oncoprotein MLL-ENL disturbs hematopoietic lineage determination and transforms a biphenotypic lymphoid/myeloid cell	ONCOGENE			English	Article						leukemia; MLL; fusion protein; mixed-lineage leukemia	ACUTE LYMPHOBLASTIC-LEUKEMIA; INTERNAL TANDEM DUPLICATION; ACUTE MYELOID LEUKEMIAS; BONE-MARROW; HEMATOLOGICAL MALIGNANCIES; 11Q23 TRANSLOCATIONS; DROSOPHILA-TRITHORAX; MAMMALIAN TRITHORAX; FETAL LIVER; MUTANT MICE	Mixed-lineage leukemia (MLL) fusion proteins are associated with a unique class of leukemia that is characterized by the simultaneous expression of lymphoid-specific as well as myeloid-specific genes. Here we report the first experimental model of MLL. Murine bone marrow cells were retrovirally transduced to express the MLL-eleven nineteen leukemia (MLL-ENL) fusion protein. When cultivated in flt-3 ligand, stem cell factor and interleukin-7 (IL-7) in a stroma-free culture system MLL-ENL-transduced as well as control cells showed a wave of B-lymphopoiesis. Whereas the controls exhausted their proliferative capacity in a CD19+/B220+ state, a continuously proliferating CD19-/B220+ cell population emerged in the MLL-ENL-transduced cultures. Despite the lymphoid surface marker, these cells were of monocytoid morphology. The immortalized cells contained unrearranged retrovirus, expressed MLL-ENL mRNA and were able to grow in syngenic recipients. From the diseased animals an MLL-ENL positive, B220+/CD19-cell type could be reisolated and cultivated in vitro. In analogy to human MLL, MLL-ENL-transformed cells not only coexpressed lymphocyte-specific (rag1, rag2, pax5, Tdt) and monocyte-specific genes (lysozyme, c-fms), but also showed rearrangements of the genomic immunoglobulin locus. This model shows that MLL-ENL influences events of early lineage determination and it will enable the investigation of the underlying molecular processes.	Univ Erlangen Nurnberg, Dept Genet, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Slany, RK (corresponding author), Univ Erlangen Nurnberg, Dept Genet, Staudtstr 5, D-91058 Erlangen, Germany.							Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Behm FG, 1996, BLOOD, V87, P2870, DOI 10.1182/blood.V87.7.2870.bloodjournal8772870; Butler LH, 1997, BLOOD, V89, P3361, DOI 10.1182/blood.V89.9.3361; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; Dannaeus K, 1999, EXP HEMATOL, V27, P1646, DOI 10.1016/S0301-472X(99)00106-X; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; DiMartino JF, 2000, BLOOD, V96, P3887, DOI 10.1182/blood.V96.12.3887.h8003887_3887_3893; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; Huret JL, 2001, LEUKEMIA, V15, P987, DOI 10.1038/sj.leu.2402135; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; Martensson IL, 1997, J EXP MED, V185, P653, DOI 10.1084/jem.185.4.653; Montecino-Rodriguez E, 2001, NAT IMMUNOL, V2, P83, DOI 10.1038/83210; Nutt S L, 2001, Int Rev Immunol, V20, P65, DOI 10.3109/08830180109056723; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; PUI CH, 1991, BLOOD, V77, P440; Schreiner S, 2001, CANCER RES, V61, P6480; Schreiner SA, 1999, LEUKEMIA, V13, P1525, DOI 10.1038/sj.leu.2401534; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Yagi H, 1998, BLOOD, V92, P108, DOI 10.1182/blood.V92.1.108.413k11_108_117; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	38	44	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1629	1637		10.1038/sj.onc.1206104	http://dx.doi.org/10.1038/sj.onc.1206104			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642866				2022-12-17	WOS:000181580500005
J	Arguello, M; Sgarbanti, M; Hernandez, E; Mamane, Y; Sharma, S; Servant, M; Lin, RT; Hiscott, J				Arguello, M; Sgarbanti, M; Hernandez, E; Mamane, Y; Sharma, S; Servant, M; Lin, RT; Hiscott, J			Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines	ONCOGENE			English	Article						primary effusion lymphoma (PEL); IRF-4; PU.1; Oct-2; HHV-8	CLASSICAL HODGKINS-DISEASE; CAVITY-BASED LYMPHOMAS; REED-STERNBERG CELLS; CHAIN GENE ENHANCER; KAPOSIS-SARCOMA; FACTOR PU.1; NUCLEAR FACTOR; DNA-SEQUENCES; EXPRESSION; OCT-2	Primary effusion lymphoma (PEL) is a lymphoproliferative disease of B-cell origin that is associated with HHV-8 infection. PEL cells harbor a non-B, non-T phenotype and lack significant surface immunoglobulin (Ig) expression, a characteristic that has not been fully explained. In the present study, we demonstrate that PEL cells constitutively express interferon regulatory factor (IRF)-4, a transcription factor that regulates the activity of the immunoglobulin light-chain enhancer elements 13 and KEY through binding to a composite Ets-IRF site. IRF-4 activity requires its physical interaction with PU.1, an Ets family member involved in the activation of genes essential for B-cell development. However, in PEL-derived B-cell lines, PU.1 expression was completely abrogated; expression of the B cell specific transcription factor Oct-2, which is known to regulate PU.1 expression, was also abolished. Moreover, the B-cell-specific coactivator of octamer factors, BOB-1/OcaB, was expressed at very decreased levels in PEL cells. Ectopic expression of Oct-2 was able to fully restore PU.1 promoter activity in the PEL cell line BCBL-1, while PU.1 expression also reconstituted the activity of the lambdaB Ets-IRF site. In addition, protein levels of BSAP/Pax-5 and IRF-8/ICSBP were undetectable in PEL cells. The pattern of transcription factor ablation observed in PEL was found to be comparable to that observed in classical Hodgkin's disease-derived cell lines, which also lack B-cell-specific surface markers. These observations indicate that disruption of the B-cell-specific transcriptional program is likely to contribute to the incomplete B-cell phenotype characteristic of PEL cells.	Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Hiscott, J (corresponding author), Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.		SGARBANTI, MARCO/C-2962-2016; Lin, Rongtuan/A-1442-2008	SGARBANTI, MARCO/0000-0002-0433-5110; Lin, Rongtuan/0000-0002-2238-3503				Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; Carbone A, 2001, BLOOD, V97, P744, DOI 10.1182/blood.V97.3.744; Carbone A, 2000, LEUKEMIA, V14, P1301, DOI 10.1038/sj.leu.2401802; Carbone A, 2000, BRIT J HAEMATOL, V111, P247, DOI 10.1046/j.1365-2141.2000.02329.x; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chan WC, 2001, HEMATOL ONCOL, V19, P1; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen HM, 1996, J BIOL CHEM, V271, P15743, DOI 10.1074/jbc.271.26.15743; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Dolcetti R, 2001, EUR J CANCER, V37, P1276, DOI 10.1016/S0959-8049(01)00105-8; DREXLER HG, 1993, LEUKEMIA LYMPHOMA, V9, P1, DOI 10.3109/10428199309148499; Drexler HG, 1998, LEUKEMIA, V12, P1507, DOI 10.1038/sj.leu.2401160; EHLINHENRIKSSON B, 1987, INT J CANCER, V39, P211, DOI 10.1002/ijc.2910390215; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Falini B, 2000, BLOOD, V95, P2084, DOI 10.1182/blood.V95.6.2084; FELDHAUS AL, 1992, MOL CELL BIOL, V12, P1126, DOI 10.1128/MCB.12.3.1126; Gaidano G, 1997, BLOOD, V89, P3755; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; Hecht JL, 2000, J CLIN ONCOL, V18, P3707, DOI 10.1200/JCO.2000.18.21.3707; Hertel CB, 2002, ONCOGENE, V21, P4908, DOI 10.1038/sj.onc.1205629; Himmelmann A, 1997, BLOOD, V90, P3984, DOI 10.1182/blood.V90.10.3984; JUNKER S, 1990, CELL, V61, P467, DOI 10.1016/0092-8674(90)90528-M; LIEBERMAN SA, 1993, J IMMUNOL, V151, P2588; Mamane Y, 2002, J INTERF CYTOK RES, V22, P135, DOI 10.1089/107999002753452746; Mamane Y, 2002, ONCOGENE, V21, P6751, DOI 10.1038/sj.onc.1205843; Marecki S, 2002, J INTERF CYTOK RES, V22, P121, DOI 10.1089/107999002753452737; Matolcsy A, 1998, AM J PATHOL, V153, P1609, DOI 10.1016/S0002-9440(10)65749-5; Muller S, 1996, ONCOGENE, V13, P1955; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; OMORI SA, 1993, P NATL ACAD SCI USA, V90, P11723, DOI 10.1073/pnas.90.24.11723; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Pernis AB, 2002, J INTERF CYTOK RES, V22, P111, DOI 10.1089/107999002753452728; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; RADOMSKA HS, 1994, IMMUNITY, V1, P623, DOI 10.1016/1074-7613(94)90034-5; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; Re D, 2001, CANCER RES, V61, P2080; Reya T, 1998, CURR OPIN IMMUNOL, V10, P158, DOI 10.1016/S0952-7915(98)80244-6; Schubart K, 2001, NAT IMMUNOL, V2, P69, DOI 10.1038/83190; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200; Sharif MN, 2001, J IMMUNOL, V167, P4421, DOI 10.4049/jimmunol.167.8.4421; Sharma S, 2002, J IMMUNOL, V169, P3120, DOI 10.4049/jimmunol.169.6.3120; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SINGH H, 1994, IMMUNOL RES, V13, P280, DOI 10.1007/BF02935619; Stein H, 2001, BLOOD, V97, P496, DOI 10.1182/blood.V97.2.496; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Torlakovic E, 2001, AM J PATHOL, V159, P1807, DOI 10.1016/S0002-9440(10)63027-1	51	44	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					964	973		10.1038/sj.onc.1206270	http://dx.doi.org/10.1038/sj.onc.1206270			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592383				2022-12-17	WOS:000180926100002
J	Wang, XD; Rosales, JL; Magliocco, A; Gnanakumar, R; Lee, KY				Wang, XD; Rosales, JL; Magliocco, A; Gnanakumar, R; Lee, KY			Cyclin E in breast tumors is cleaved into its low molecular weight forms by calpain	ONCOGENE			English	Article						cyclin E; calpain; breast cancer	CANCER; OVEREXPRESSION; CELLS; AMPLIFICATION; EXPRESSION; SYSTEM	Abundant levels of the hyperactive low molecular weight (LMW) forms of cyclin E contribute to deregulation of Cdk2 in breast tumors, but the mechanism through which they arise is not fully understood. Here, we explored the hypothesis that post-translational processing by a protease generates the LMW forms of cyclin E in breast tumors. In ZR75 tumor cell lysates, calcium-induced cyclin E truncation into peptides corresponding in size with LMW forms of cyclin E in tumor tissues. Calpeptin inhibited calcium-stimulated cyclin E truncation, indicating that cleavage resulted from activity of the calcium-dependent protease, calpain. Consistently, calcium + calpain caused truncation of cyclin E immunoprecipitated from tumor cells and tissues. Calcium also caused truncation of the calpain regulatory subunit in tumor cell lysates, indicating that elevated calpain activity accompanies cyclin E truncation. Increased levels of the calpain small subunit were also observed in breast tumors, and significant amounts of its proteolyzed forms indicated increased calpain activity. While elastase also caused cyclin E truncation, the cleavage pattern was distinct from that generated by calpain, suggesting discrete mechanisms in regulating the formation of LMW cyclin E in breast tumors. Treatment of ZR75 cultures with calcium + A23187 recapitulated the formation of the calcium/calpain/induced LMW forms of cyclin E. Altered calcium homeostasis and/or inability of the endogenous calpain inhibitor to control the activity of high levels of the calpain small subunit may contribute to increased calpain activity in breast tumors, causing abundant levels of LMW cyclin E.	Univ Calgary, Fac Med, Dept Cell Biol & Anat, Canc Biol & Neurosci Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary	Lee, KY (corresponding author), Univ Calgary, Fac Med, Dept Cell Biol & Anat, Canc Biol & Neurosci Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Magliocco, Anthony M/E-5723-2010	Rosales, Jesusa/0000-0002-2543-3801				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Dou QP, 1996, NAT MED, V2, P254, DOI 10.1038/nm0396-254a; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Harwell RM, 2000, CANCER RES, V60, P481; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Kawasaki H, 1996, MOL MEMBR BIOL, V13, P217, DOI 10.3109/09687689609160599; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; LEE SW, 1992, P NATL ACAD SCI USA, V89, P2504, DOI 10.1073/pnas.89.6.2504; Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; SAID TK, 1995, CARCINOGENESIS, V16, P823, DOI 10.1093/carcin/16.4.823; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SEWING A, 1994, J CELL SCI, V107, P581; Shiba, 1996, Breast Cancer, V3, P13, DOI 10.1007/BF02966957; Steeg PS, 1998, BREAST CANCER RES TR, V52, P17, DOI 10.1023/A:1006102916060	21	44	53	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					769	774		10.1038/sj.onc.1206166	http://dx.doi.org/10.1038/sj.onc.1206166			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569370	Bronze			2022-12-17	WOS:000180642100015
J	Strehl, S; Borkhardt, A; Slany, R; Fuchs, UE; Konig, M; Haas, OA				Strehl, S; Borkhardt, A; Slany, R; Fuchs, UE; Konig, M; Haas, OA			The human LASP1 gene is fused to MLL in an acute myeloid leukemia with t(11;17)(q23;q21)	ONCOGENE			English	Article						MLL gene; LASP1 gene; fusion transcript; t(11 ; 17)(q23 ; q21); retroviral transduction	HEMATOLOGICAL MALIGNANCIES; FUSION PARTNER; HRX-ENL; PROTEIN; LEUKEMOGENESIS; LIM	The MLL gene at chromosome 11q23 is frequently rearranged in acute leukemia. Here we report the identification of a new MLL fusion partner in the case of an infant with AML-M4 and a t(11;17)(q23;q21) translocation. Fluorescence in situ hybridization (FISH) and RT-PCR analyses indicated a rearrangement of the MLL gene, but no fusion with previously identified MLL fusion partners at 17q, such as AF17 or MSF. Rapid amplification of cDNA ends (RACE) revealed an in-frame fusion of MLL to LASP1, a gene that is amplified and overexpressed in breast cancer. Retroviral transduction of myeloid progenitors demonstrated that MLL/LASP1 is the fourth known fusion of MLL with a cytoplasmic protein that has no in vitro transformation capability, thus establishing a potential subgroup among the MLL fusion proteins.	St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; Univ Giessen, Dept Pediat Hematol & Oncol, D-35392 Giessen, Germany; Univ Erlangen Nurnberg, Dept Genet, D-91058 Erlangen, Germany	Saint Anna Children's Hospital; Justus Liebig University Giessen; University of Erlangen Nuremberg	Haas, OA (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.	oskar.haas@ccri.univie.ac.at	Haas, Oskar/AAM-5794-2020	Strehl, Sabine/0000-0002-0179-0628				Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Borkhardt A, 2001, GENE CHROMOSOME CANC, V32, P82, DOI 10.1002/gcc.1169; Butler LH, 1997, BLOOD, V89, P3361, DOI 10.1182/blood.V89.9.3361; Chew CS, 2000, J CELL SCI, V113, P2035; Chew CS, 1998, AM J PHYSIOL-CELL PH, V275, pC56, DOI 10.1152/ajpcell.1998.275.1.C56; Daheron L, 2001, GENE CHROMOSOME CANC, V31, P382, DOI 10.1002/gcc.1157; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; Ernst P, 2002, CURR OPIN HEMATOL, V9, P282, DOI 10.1097/00062752-200207000-00004; Felix C A, 1999, Oncologist, V4, P225; Fuchs U, 2001, P NATL ACAD SCI USA, V98, P8756, DOI 10.1073/pnas.121433898; GREIL J, 1994, BRIT J HAEMATOL, V86, P275, DOI 10.1111/j.1365-2141.1994.tb04726.x; Huret JL, 2001, LEUKEMIA, V15, P987, DOI 10.1038/sj.leu.2402135; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Megonigal MD, 2000, P NATL ACAD SCI USA, V97, P2814, DOI 10.1073/pnas.050397097; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; Schreiber V, 1998, GENE, V207, P171, DOI 10.1016/S0378-1119(97)00622-7; Schreiber VR, 1998, MOL MED, V4, P675, DOI 10.1007/BF03401929; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Taki T, 1999, CANCER RES, V59, P4261; TOMASETTO C, 1995, FEBS LETT, V373, P245, DOI 10.1016/0014-5793(95)01040-L; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; von Bergh A, 2000, GENE CHROMOSOME CANC, V28, P14, DOI 10.1002/(SICI)1098-2264(200005)28:1<14::AID-GCC2>3.3.CO;2-O	27	44	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2003	22	1					157	160		10.1038/sj.onc.1206042	http://dx.doi.org/10.1038/sj.onc.1206042			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527918				2022-12-17	WOS:000180166900017
J	Kalaitzidis, D; Davis, RE; Rosenwald, A; Staudt, LM; Gilmore, TD				Kalaitzidis, D; Davis, RE; Rosenwald, A; Staudt, LM; Gilmore, TD			The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kappa B signal transduction pathway	ONCOGENE			English	Article						RC-K8; c-Rel; Rel; Rel-nrg; NF-kappa B; I kappa B	C-REL; GASTROINTESTINAL-TRACT; TRANSCRIPTION FACTORS; HODGKINS-DISEASE; ALPHA-GENE; V-REL; MUTATIONS; EXPRESSION; PHOSPHORYLATION; TRANSFORMATION	The human large B-cell lymphoma cell line RC-K8 has a rearranged REL locus that directs the production of a chimeric protein, termed REL-NRG (Non-Rel Gene). In this study, we show that RC-K8 cells have constitutively nuclear heterodimeric and homodimeric DNA-binding complexes that consist of p50, REL, and REL-NRG. In vitro, IkappaBalpha can block the DNA-binding activity of wildtype REL homodimers but not REL-NRG homodimers. In vivo, REL-NRG cannot activate transcription of a kappaB site reporter plasmid, suggesting that it is a transcription repressing or blocking REL protein. By Western blotting, no IkappaBalpha protein can be detected in extracts of RC-K8 cells. The absence of IkappaBalpha protein in RC-K8 cells appears to be due to mutations that cause premature termination of translation in three of the four copies of the IKBA gene in RC-K8 cells. Re-expression of wild-type IkappaBalpha or a super-repressor form of IkappaBalpha in RC-K8 cells is cytotoxic; in contrast, expression of a dominant-negative form of IkappaB kinase does not affect the growth of RC-K8 cells. By cDNA microarray analysis, a number of previously identified Rel/NF-kappaB target genes are overexpressed in RC-K8 cells, consistent with there being transcriptionally active REL complexes. Taken together, our results suggest that the growth of RC-K8 cells is dependent on the activity of nuclear wild-type REL dimers, while the contribution of REL-NRG to the transformed state of RC-K8 cells is less clear. Nevertheless, the RC-K8 cell line is the first tumor cell line identified with mutations in genes encoding multiple proteins in the Rel/NF-kappaB signal transduction pathway.	Boston Univ, Dept Biol, Boston, MA 02215 USA; NCI, Metab Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	Boston University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.		Staudt, Louis/AAC-5324-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007387] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline; NICHD NIH HHS [T32-HD07387] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alizadeh A, 1999, COLD SPRING HARB SYM, V64, P71, DOI 10.1101/sqb.1999.64.71; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Barkett M, 2001, BBA-GEN SUBJECTS, V1526, P25, DOI 10.1016/S0304-4165(01)00092-7; Barth TFE, 1998, BLOOD, V91, P4321, DOI 10.1182/blood.V91.11.4321.411k08_4321_4330; Barth TFE, 2001, GENE CHROMOSOME CANC, V31, P316, DOI 10.1002/gcc.1150; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Den Dunnen JT, 1999, HUM MUTAT, V14, P95, DOI 10.1002/(SICI)1098-1004(1999)14:2<95::AID-HUMU1>3.0.CO;2-G; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; GILMORE TD, 1995, DNA PROVIRUS, P109; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Grigoriadis G, 1996, EMBO J, V15, P7099, DOI 10.1002/j.1460-2075.1996.tb01101.x; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Houldsworth J, 1996, BLOOD, V87, P25; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Jungnickel B, 2000, J EXP MED, V191, P395, DOI 10.1084/jem.191.2.395; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; KUBONISHI I, 1986, CANCER, V58, P1453, DOI 10.1002/1097-0142(19861001)58:7<1453::AID-CNCR2820580713>3.0.CO;2-B; LEBEAU MM, 1992, GENOMICS, V14, P529, DOI 10.1016/S0888-7543(05)80261-7; LU D, 1991, ONCOGENE, V6, P1235; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Palanisamy N, 2002, GENE CHROMOSOME CANC, V33, P114, DOI 10.1002/gcc.10016; Quong MW, 1999, EMBO J, V18, P6307, DOI 10.1093/emboj/18.22.6307; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; Sambrook J, 1989, MOL CLONING LAB MANU; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Staudt LM, 2000, J EXP MED, V191, P207, DOI 10.1084/jem.191.2.207; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106	45	44	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8759	8768		10.1038/sj.onc.1206033	http://dx.doi.org/10.1038/sj.onc.1206033			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483529				2022-12-17	WOS:000179734400010
J	Salesse, S; Verfaillie, CM				Salesse, S; Verfaillie, CM			Mechanisms underlying abnormal trafficking and expansion of malignant progenitors in CML: BCR/ABL-induced defects in integrin function in CML	ONCOGENE			English	Article						CML; BCR/ABL; integrin; adhesion; proliferation; molecular mechanisms	CHRONIC MYELOGENOUS LEUKEMIA; DEPENDENT KINASE INHIBITOR; CHRONIC MYELOID-LEUKEMIA; BONE-MARROW STROMA; FOCAL ADHESION PROTEINS; BCR-ABL ONCOPROTEIN; HEMATOPOIETIC PROGENITORS; SIGNAL-TRANSDUCTION; TYROSINE KINASE; MEDIATED ADHESION		Univ Minnesota, Ctr Canc, Stem Cell Inst, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Dept Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Verfaillie, CM (corresponding author), Univ Minnesota, Ctr Canc, Stem Cell Inst, MMC 708,420 Delaware St SE, Minneapolis, MN 55455 USA.		Verfaillie, Catherine/H-5148-2013	Verfaillie, Catherine/0000-0001-7564-4079				Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Bhatia R, 1999, EXP HEMATOL, V27, P1384, DOI 10.1016/S0301-472X(99)00084-3; Bhatia R, 1996, BLOOD, V87, P3883, DOI 10.1182/blood.V87.9.3883.bloodjournal8793883; BHATIA R, 1995, J CLIN INVEST, V96, P931, DOI 10.1172/JCI118141; Bhatia R, 1998, BLOOD, V91, P3414, DOI 10.1182/blood.V91.9.3414.3414_3414_3422; BHATIA R, 1994, J CLIN INVEST, V94, P384, DOI 10.1172/JCI117333; Bhatia R, 1998, LEUKEMIA, V12, P1708, DOI 10.1038/sj.leu.2401193; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CASHMAN J, 1985, BLOOD, V66, P1002; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; EAVES AC, 1986, P NATL ACAD SCI USA, V83, P5306, DOI 10.1073/pnas.83.14.5306; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; GORDON MY, 1989, CURR TOP MICROBIOL, V149, P151; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; GOTOH A, 1995, EXP HEMATOL, V23, P1153; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Hurley RW, 1997, EXP HEMATOL, V25, P321; HURLEY RW, 1995, J CLIN INVEST, V96, P511, DOI 10.1172/JCI118063; Jiang YH, 2000, BLOOD, V95, P846, DOI 10.1182/blood.V95.3.846.003k31_846_854; Jiang YH, 2000, P NATL ACAD SCI USA, V97, P10538, DOI 10.1073/pnas.190104497; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; Kramer A, 1999, P NATL ACAD SCI USA, V96, P2087, DOI 10.1073/pnas.96.5.2087; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lundell BI, 1996, BLOOD, V87, P2450, DOI 10.1182/blood.V87.6.2450.bloodjournal8762450; Lundell BI, 1997, LEUKEMIA, V11, P822, DOI 10.1038/sj.leu.2400653; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NOWELL PC, 1960, SCIENCE, V132, P1497; ODA T, 1994, J BIOL CHEM, V269, P22925; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Rosenbauer F, 2002, EMBO J, V21, P211, DOI 10.1093/emboj/21.3.211; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Salgia R, 1996, EXP HEMATOL, V24, P310; SALGIA R, 1995, ONCOGENE, V11, P1149; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Sattler M, 2002, ONCOGENE, V21, P1423, DOI 10.1038/sj.onc.1205202; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shiohara M, 1997, LEUKEMIA LYMPHOMA, V26, P35, DOI 10.3109/10428199709109155; Sugiyama Y, 2001, J BIOL CHEM, V276, P12084, DOI 10.1074/jbc.M010811200; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; VERFAILLIE CM, 1992, BLOOD, V79, P2821; Wertheim JA, 2002, BLOOD, V99, P4122, DOI 10.1182/blood.V99.11.4122; Zhao RC, 2001, BLOOD, V97, P2406, DOI 10.1182/blood.V97.8.2406	56	44	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	2002	21	56					8605	8611		10.1038/sj.onc.1206088	http://dx.doi.org/10.1038/sj.onc.1206088			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476307	Green Published			2022-12-17	WOS:000179734300010
J	Budram-Mahadeo, V; Morris, PJ; Latchman, DS				Budram-Mahadeo, V; Morris, PJ; Latchman, DS			The Brn-3a transcription factor inhibits the pro-apoptotic effect of p53 and enhances cell cycle arrest by differentially regulating the activity of the p53 target genes encoding Bax and p21(CIP1/Waf1)	ONCOGENE			English	Article						Brn-3a; p53; neuronal cells; apoptosis; cell-cycle arrest	NEURONAL DEATH; SYMPATHETIC NEURONS; GROWTH-FACTOR; EXPRESSION; BCL-2; ACTIVATION; PROMOTER; SURVIVAL; OUTGROWTH; DISTINCT	We have previously shown that the anti-apoptotic transcription factor, Brn-3a and the pro-apoptotic p53 factor have antagonistic effects on the promoter of the gene encoding the anti-apoptotic Bcl-2 protein, with p53 abolishing activation by Brn-3a. Here we demonstrate that this antagonism is also observed on the gene encoding the pro-apoptotic Bax protein with Brn-3a abolishing the ability of p53 to activate the Bax promoter and induce Bax protein expression. In contrast, Brn-3a and p53 cooperative to induce maximal activation of another p53 target gene encoding the cyclin dependent kinase inhibitor, p21(CIP1/Waf1). These differential effects of Brn-3a on p53-inducible genes involved in apoptosis or growth arrest are paralleled by its effects on these processes themselves. Thus, we show that Brn-3a antagonises the anti-apoptotic effect of p53 but co-operates with p53 to induce cell cycle arrest. The potential role of Brn-3a in determining the outcome of enhanced p53 levels is discussed.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England	University of London; University College London	Budram-Mahadeo, V (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guildord St, London WC1N 1EH, England.	v.mahadeo@ich.ucl.ac.uk			Medical Research Council [G9901318] Funding Source: Medline; MRC [G9901318] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; D'Mello SR, 1998, CURR TOP DEV BIOL, V39, P187, DOI 10.1016/S0070-2153(08)60456-1; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; EL DW, 1993, CELL, V75, P817; Eng SR, 2001, J NEUROSCI, V21, P541, DOI 10.1523/JNEUROSCI.21-02-00541.2001; Ensor E, 2001, J BIOL CHEM, V276, P5204, DOI 10.1074/jbc.M007068200; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; Johnson MD, 1999, J NEUROSCI, V19, P2996; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Railson JE, 2001, J MOL CELL CARDIOL, V33, P1209, DOI 10.1006/jmcc.2001.1384; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Savitz SI, 1998, NEUROSURGERY, V42, P555, DOI 10.1097/00006123-199803000-00026; Sieber-Blum M, 1998, BIOCHEM CELL BIOL, V76, P1039, DOI 10.1139/bcb-76-6-1039; Smith MD, 1997, J BIOL CHEM, V272, P21325, DOI 10.1074/jbc.272.34.21325; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Smith MD, 2001, MOL CELL NEUROSCI, V17, P460, DOI 10.1006/mcne.2000.0927; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950	33	44	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6123	6131		10.1038/sj.onc.1205842	http://dx.doi.org/10.1038/sj.onc.1205842			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203124	Bronze			2022-12-17	WOS:000177671300015
J	Jaiswal, AS; Bloom, LB; Narayan, S				Jaiswal, AS; Bloom, LB; Narayan, S			Long-patch base excision repair of apurinic/apyrimidinic site DNA is decreased in mouse embryonic fibroblast cell lines treated with plumbagin: involvement of cyclin-dependent kinase inhibitor p21Waf-1/Cip-1	ONCOGENE			English	Article						DNA damage; cell cycle arrest; p21; long-patch BER	POLYMERASE-BETA; NUCLEAR ANTIGEN; CDK-CYCLIN; LIGASE I; P21; PCNA; REPLICATION; EXPRESSION; BINDING; DAMAGE	Molecular interactions among cell cycle and DNA repair proteins have been described, but the impact of many of these interactions on cell cycle control and DNA repair remains unclear. The cyclin-dependent kinase inhibitor, p21, is known to be involved in DNA damage-induced cell cycle arrest and blocking DNA replication and repair. Participation of p21 has been implicated in nucleotide excision repair. However, the role of p21 in the base excision repair (BER) pathway has not been thoroughly studied. In the present investigation, we treated isogenic mouse embryonic fibroblast (MEF) cell lines containing wild-type (MEF-polbeta) or DNA polymerase beta (polbeta) gene-knockout (MEFpolbetaKO) with oxidative DNA-damaging agent, plumbagin, and examined its effect on p21 levels and BER activity. Plumbagin treatment caused a S-G(2)/M phase arrest and cell death of both MEF cell tines, induced p21 levels, and decreased p21-mediated long-patch (LP) BER by blocking DNA ligase activity in the polbeta-dependent pathway and by blocking both FEN1 and DNA ligase activity in polbeta-independent pathway. These findings suggest that plumbagin induced p21 levels play a regulatory role in cell cycle arrest, apoptosis, and polbeta-dependent and -independent LP-BER pathways in MEF cells.	Univ Florida, UF Shands Canc Ctr, Coll Med, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Narayan, S (corresponding author), Univ Florida, UF Shands Canc Ctr, Coll Med, Acad Res Bldg,Room R4-216,POB 100232, Gainesville, FL 32610 USA.	snarayan@ufscc.ufl.edu	Bloom, Linda B/F-3684-2014		NATIONAL CANCER INSTITUTE [R01CA077721] Funding Source: NIH RePORTER; NCI NIH HHS [CA77721] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Ames B N, 1991, Jpn J Cancer Res, V82, P1460; Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BEDFORD P, 1988, CANCER RES, V48, P3019; Bennett SE, 2001, J BIOL CHEM, V276, P42588, DOI 10.1074/jbc.M106212200; Bhattacharyya N, 1999, DNA CELL BIOL, V18, P549, DOI 10.1089/104454999315097; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; Boulaire J, 2000, PATHOL BIOL, V48, P190; Brozmanova J, 2001, NEOPLASMA, V48, P85; Cadet J, 2000, MUTAT RES-REV MUTAT, V462, P121, DOI 10.1016/S1383-5742(00)00022-3; Canitrot Y, 2000, FASEB J, V14, P1765, DOI 10.1096/fj.99-1063com; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dimitriadis EK, 1998, J BIOL CHEM, V273, P20540, DOI 10.1074/jbc.273.32.20540; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Esposito F, 1998, CELL DEATH DIFFER, V5, P940, DOI 10.1038/sj.cdd.4400427; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Fotedar R, 1996, ONCOGENE, V12, P2155; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; HILL BT, 1994, EUR J CANCER, V30A, P832, DOI 10.1016/0959-8049(94)90301-8; Holmquist GP, 1998, MUTAT RES-FUND MOL M, V400, P59, DOI 10.1016/S0027-5107(98)00051-7; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; Jaiswal AS, 2002, MUTAT RES-FUND MOL M, V500, P17, DOI 10.1016/S0027-5107(01)00296-2; JAMIESON DJ, 1994, MICROBIOL-UK, V140, P3277, DOI 10.1099/13500872-140-12-3277; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; KATO T, 1994, MUTAGENESIS, V9, P245, DOI 10.1093/mutage/9.3.245; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Koberle B, 1997, INT J CANCER, V70, P551, DOI 10.1002/(SICI)1097-0215(19970304)70:5<551::AID-IJC10>3.0.CO;2-G; Krokan HE, 1997, BIOCHEM J, V325, P1; Levin DS, 2000, CURR BIOL, V10, P919, DOI 10.1016/S0960-9822(00)00619-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; LI Y, 1994, ONCOGENE, V9, P2261; McDonald E, 1996, CANCER RES, V56, P2250; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; Narayan S, 2001, BRIT J CANCER, V85, P898, DOI 10.1054/bjoc.2001.2002; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; PRIETOALAMO MJ, 1993, CARCINOGENESIS, V14, P237, DOI 10.1093/carcin/14.2.237; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; SARK MWJ, 1995, BRIT J CANCER, V71, P684, DOI 10.1038/bjc.1995.135; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; Shivji MKK, 1998, ONCOGENE, V17, P2827, DOI 10.1038/sj.onc.1202352; SHORTLE D, 1983, METHOD ENZYMOL, V100, P457; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Stivala LA, 2001, ONCOGENE, V20, P563, DOI 10.1038/sj.onc.1204132; Sugie S, 1998, CANCER LETT, V127, P177, DOI 10.1016/S0304-3835(98)00035-4; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tom S, 2001, J BIOL CHEM, V276, P48781, DOI 10.1074/jbc.M109626200; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177; WANG LM, 1992, CANCER RES, V52, P4824; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0	68	44	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2002	21	38					5912	5922		10.1038/sj.onc.1205789	http://dx.doi.org/10.1038/sj.onc.1205789			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185591				2022-12-17	WOS:000177520900011
J	Scarr, RB; Sharp, PA				Scarr, RB; Sharp, PA			PDCD2 is a negative regulator of HCF-1 (C1)	ONCOGENE			English	Article						host cell factor 1 (HCF-1); MYND domain; PDCD2 protein; N-CoR/mSin3A corepressor complexes; cell cycle progression	HERPES-SIMPLEX VIRUS; ACUTE MYELOID-LEUKEMIA; PROGRAMMED CELL-DEATH; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACCESSORY FACTOR HCF; DNA-BINDING DOMAIN; OCT-1 POU DOMAIN; VP16-INDUCED COMPLEX; TRANSCRIPTIONAL REGULATION; CONFORMATIONAL ALTERATION	Temperature sensitive mutations in host cell factor 1 (HCF-1) arrest cells in the middle of the G1 phase of the cycle. We have shown that the highly conserved C-terminal WYF domain of HCF-1 protein interacts with the MYND domain of the PDCD2 protein. This interaction is conserved between human HCF-1 and HCF-2 and the C. elegans HCF. Overexpression of PDCD2, which interacts with the N-CoR/mSin3A corepressor complexes, suppresses cotransfected HCF-1 complementation of a temperature lesion in the endogenous HCF-1 protein. Overexpression of domains of either PDCD2 or HCF-1, which should interfere with interactions between these two proteins, enhances the complementation.	MIT, Dept Biol, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Sharp, PA (corresponding author), MIT, Dept Biol, Ctr Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NCI NIH HHS [P01-CA042063, P30-CA14051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014051, P01CA042063] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Ajuh PM, 2000, NUCLEIC ACIDS RES, V28, P678, DOI 10.1093/nar/28.3.678; Amiel A, 1999, CANCER GENET CYTOGEN, V112, P53, DOI 10.1016/S0165-4608(98)00255-6; BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; CLEARY MA, 1995, MOL CELL BIOL, V15, P2090; D'MELLO SR, 1993, NEUROREPORT, V4, P355, DOI 10.1097/00001756-199304000-00003; FEINSTEIN PG, 1995, GENETICS, V140, P573; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Hauptschein RS, 2000, DNA RES, V7, P261, DOI 10.1093/dnares/7.4.261; Herr W, 1998, COLD SPRING HARB SYM, V63, P599, DOI 10.1101/sqb.1998.63.599; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; Hoffmeyer A, 1998, J BIOL CHEM, V273, P10112, DOI 10.1074/jbc.273.17.10112; Huggenvik JI, 1998, MOL ENDOCRINOL, V12, P1619, DOI 10.1210/me.12.10.1619; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Johnson KM, 1999, J VIROL, V73, P3930, DOI 10.1128/JVI.73.5.3930-3940.1999; KAWAKAMI T, 1995, CYTOGENET CELL GENET, V71, P41, DOI 10.1159/000134058; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; Kristie TM, 1999, P NATL ACAD SCI USA, V96, P1229, DOI 10.1073/pnas.96.4.1229; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; La Boissiere S, 1999, EMBO J, V18, P480; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LeBoeuf RD, 1998, J BIOL CHEM, V273, P361, DOI 10.1074/jbc.273.1.361; Liu Y, 1999, MOL CELL BIOL, V19, P909; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Lu R, 2000, NUCLEIC ACIDS RES, V28, P2446, DOI 10.1093/nar/28.12.2446; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Mahajan SS, 2000, MOL CELL BIOL, V20, P919, DOI 10.1128/MCB.20.3.919-928.2000; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Michelson RJ, 1999, J BIOL CHEM, V274, P30510, DOI 10.1074/jbc.274.43.30510; Misra V, 1996, MOL CELL BIOL, V16, P4404; Morohoshi F, 2000, GENE, V241, P287, DOI 10.1016/S0378-1119(99)00481-3; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; OWENS GP, 1992, CANCER METAST REV, V11, P149, DOI 10.1007/BF00048061; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Scarr RB, 2000, MOL CELL BIOL, V20, P3568, DOI 10.1128/MCB.20.10.3568-3575.2000; Schonemann MD, 1998, ADV EXP MED BIOL, V449, P39; Sowa Y, 1997, CANCER RES, V57, P3145; Stilgenbauer S, 1999, LEUKEMIA, V13, P1331, DOI 10.1038/sj.leu.2401499; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; VAUX DL, 1995, DNA CELL BIOL, V14, P189, DOI 10.1089/dna.1995.14.189; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; Vogel JL, 2000, P NATL ACAD SCI USA, V97, P9425, DOI 10.1073/pnas.160266697; Vogel JL, 2000, EMBO J, V19, P683, DOI 10.1093/emboj/19.4.683; WALKER S, 1994, CELL, V79, P841, DOI 10.1016/0092-8674(94)90073-6; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wilson AC, 2000, MOL CELL BIOL, V20, P6721, DOI 10.1128/MCB.20.18.6721-6730.2000; WILSON AC, 1995, GENOMICS, V25, P462, DOI 10.1016/0888-7543(95)80046-O; WILSON AC, 1993, COLD SPRING HARB SYM, V58, P167, DOI 10.1101/SQB.1993.058.01.021; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6	60	44	45	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5245	5254		10.1038/sj.onc.1205647	http://dx.doi.org/10.1038/sj.onc.1205647			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149646				2022-12-17	WOS:000177193900006
J	Gu, J; Zhang, LD; Huang, XF; Lin, TY; Yin, M; Xu, K; Ji, L; Roth, JA; Fang, BL				Gu, J; Zhang, LD; Huang, XF; Lin, TY; Yin, M; Xu, K; Ji, L; Roth, JA; Fang, BL			A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo	ONCOGENE			English	Article						hTERT promoter; Bax; apoptosis; tumor targeting; adenovirus	TELOMERASE ACTIVITY; CANCER CELLS; OVARIAN-CANCER; TRANSGENE EXPRESSION; HEMATOPOIETIC-CELLS; PROSTATE-CANCER; LUNG-CANCER; BONE-MARROW; PROMOTER; THERAPY	Using a binary adenoviral system, we recently showed that the human telomerase reverse transcriptase (hTERT) promoter induces tumor-specific Bax gene expression. However, the strong cytotoxicity of Bax and other pro-apoptotic genes to packaging 293 cells has so far hindered construction of the desired single adenoviral vectors expressing toxic genes. We report here the construction of a single bicistronic adenoviral vector for tumor-specific Bax expression. The vector (Ad/gBax) utilizes the Tet-Off system and expresses a GFP/Bax fusion protein for easy detection. The hTERT promoter drives the expression of tTA, a transactivator capable of binding to TRE (tetracycline-responsive element) in the absence of tetracycline, which in turn induces expression of the GFP-Bax gene. The addition of tetracycline in 293 cells blocks the binding of tTA to TRE and substantially inhibits GFP-Bax expression and toxicity, thus allowing the packaging and production of Ad/gBax. Our data show that Ad/gBax could drive the high expression of GFP-Bax in tumor cells but not in normal cells and mouse tissues. Furthermore, the expression of GFP-Bax fusion protein elicited tumor-specific apoptosis in a variety of human cancer cells in vitro and in vivo at a level comparable to that induced by the binary system. Thus, Ad/gBax may become a potent therapeutic agent for the treatment of cancers.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fang, BL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Box 109,1515 Holcombe Blvd, Houston, TX 77030 USA.		Gu, Jian/Q-4780-2018	Gu, Jian/0000-0003-3499-0973	NCI NIH HHS [CA78778-01A1, CA 16672, 2P50-CA70970-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078778, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andriani F, 2001, JNCI-J NATL CANCER I, V93, P1314, DOI 10.1093/jnci/93.17.1314; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Chen L, 1995, J CLIN INVEST, V96, P2775, DOI 10.1172/JCI118347; Feldman E, 1997, STEM CELLS, V15, P386, DOI 10.1002/stem.150386; Gu J, 2002, GENE THER, V9, P30, DOI 10.1038/sj.gt.3301619; Gu J, 2000, CANCER RES, V60, P5359; Kagawa S, 2001, CANCER RES, V61, P3330; Kagawa S, 2000, CANCER RES, V60, P1157; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Koga S, 2000, HUM GENE THER, V11, P1397, DOI 10.1089/10430340050057477; Komata T, 2001, CANCER RES, V61, P5796; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Nishimura S, 2001, CANCER RES, V61, P7009; OSAKI T, 1994, CANCER RES, V54, P5258; Parr MJ, 1997, NAT MED, V3, P1145, DOI 10.1038/nm1097-1145; Pataer A, 2000, CANCER RES, V60, P788; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Sakakura C, 1997, SURG TODAY, V27, P90, DOI 10.1007/BF01366949; Shariat SF, 2001, CANCER RES, V61, P2562; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Tai YT, 1999, CANCER RES, V59, P2121; Tai YT, 1998, J CLIN ONCOL, V16, P2583, DOI 10.1200/JCO.1998.16.8.2583; VILE RG, 1993, CANCER RES, V53, P962; Watanabe T, 1996, BLOOD, V87, P5032, DOI 10.1182/blood.V87.12.5032.bloodjournal87125032; Xiang J, 2000, J GENE MED, V2, P97, DOI 10.1002/(SICI)1521-2254(200003/04)2:2<97::AID-JGM99>3.0.CO;2-S; Yui J, 1998, BLOOD, V91, P3255, DOI 10.1182/blood.V91.9.3255.3255_3255_3262; Zhang W, 1996, CLIN CANCER RES, V2, P799	27	44	52	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4757	4764		10.1038/sj.onc.1205582	http://dx.doi.org/10.1038/sj.onc.1205582			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101414				2022-12-17	WOS:000176716300005
J	Johnson, BA; Blackwell, TK				Johnson, BA; Blackwell, TK			Multiple tristetraprolin sequence domains required to induce apoptosis and modulate responses to TNF alpha through distinct pathways	ONCOGENE			English	Article						tristetraprolin; TNF alpha; immediate-early; apoptosis; zinc finger	NECROSIS-FACTOR-ALPHA; AU-RICH ELEMENTS; ACTIVATED PROTEIN-KINASE; ZINC-FINGER PROTEINS; MESSENGER-RNA DEGRADATION; NF-KAPPA-B; C-ELEGANS; TRANSCRIPTION FACTOR; CAENORHABDITIS-ELEGANS; CELL-DEATH	Expression of the immediate early protein tristetraprolin (TTP) is induced by numerous stimuli, including tumor necrosis factor-alpha (TNFalpha). Evidence indicates that TTP limits production of TNFalpha and other cytokines by directly binding and destabilizing their mRNAs. This effect seems to require only the conserved TTP zinc finger region, and is characteristic of the related proteins TIS11b and TIS11d. TTP, TIS11b, and TIS11d each also induce apoptosis through the mitochondrial pathway analogously to certain oncogenes, suggesting that they influence growth or survival signals. Among TTP/TIS11 proteins, TTP alone also promotes apoptosis synergistically with TNFalpha. Here we show that other regions of TTP along with the zinc fingers are required for TTP to induce apoptosis. We also demonstrate that TTP acts through an additional pathway to sensitize cells to the pro-apoptotic stimulus of TNFalpha. This modulation of TNFalpha responses specifically requires the TTP N-terminal region, which is not conserved in TIS11b or TIS11d. We conclude that the physiological functions of TTP depend upon multiple regions of the TTP protein, that TTP has diverged functionally from TIS11b and TIS11d, and that modulation of TNFa responses may be a unique and important aspect of TTP function.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Blackwell, TK (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA084418] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA84418] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai CY, 1996, MOL CELL BIOL, V16, P6661; Baker SJ, 1996, ONCOGENE, V12, P1; Barabino SML, 1997, GENE DEV, V11, P1703, DOI 10.1101/gad.11.13.1703; Batchelder C, 1999, GENE DEV, V13, P202, DOI 10.1101/gad.13.2.202; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; DUBOIS RN, 1995, CELL GROWTH DIFFER, V6, P523; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; EHRENFRIED JA, 1995, ANN SURG, V222, P51, DOI 10.1097/00000658-199507000-00009; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Guedes S, 1997, DEVELOPMENT, V124, P731; HAAS CA, 1993, NEUROSCIENCE, V53, P91, DOI 10.1016/0306-4522(93)90287-P; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HEXIMER SP, 1993, DNA CELL BIOL, V12, P73, DOI 10.1089/dna.1993.12.73; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Johnson BA, 2000, ONCOGENE, V19, P1657, DOI 10.1038/sj.onc.1203474; JOHNSON BA, 2002, J BIOL CHEM; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lai WS, 2002, J BIOL CHEM, V277, P9606, DOI 10.1074/jbc.M110395200; Landesberg LJ, 2001, AM J PHYSIOL-LUNG C, V281, pL1138, DOI 10.1152/ajplung.2001.281.5.L1138; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; MESNER PW, 1995, J NEUROSCI, V15, P7357; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; MITTELSTADT PR, 1993, J IMMUNOL, V150, P4822; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; Pennington KN, 2001, MOL CELL BIOL, V21, P1930, DOI 10.1128/MCB.21.6.1930-1941.2001; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips RS, 2002, J BIOL CHEM, V277, P11606, DOI 10.1074/jbc.M111457200; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Reese KJ, 2000, MOL CELL, V6, P445, DOI 10.1016/S1097-2765(00)00043-5; Rutault K, 2001, J BIOL CHEM, V276, P6666, DOI 10.1074/jbc.M005486200; Schubert CM, 2000, MOL CELL, V5, P671, DOI 10.1016/S1097-2765(00)80246-4; Tabara H, 1999, DEVELOPMENT, V126, P1; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J BIOL CHEM, V270, P13341, DOI 10.1074/jbc.270.22.13341; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; Tenenhaus C, 2001, GENE DEV, V15, P1031, DOI 10.1101/gad.876201; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, ONCOGENE, V4, P119; Vasudevan S, 2001, MOL CELL, V7, P1191, DOI 10.1016/S1097-2765(01)00279-9; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Zhu W, 2001, AM J PHYSIOL-LUNG C, V281, pL499, DOI 10.1152/ajplung.2001.281.2.L499; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	58	44	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4237	4246		10.1038/sj.onc.1205526	http://dx.doi.org/10.1038/sj.onc.1205526			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082611				2022-12-17	WOS:000176174200006
J	Semplici, F; Meggio, F; Pinna, LA; Oliviero, S				Semplici, F; Meggio, F; Pinna, LA; Oliviero, S			CK2-dependent phosphorylation of the E2 ubiquitin conjugating enzyme UBC3B induces its interaction with beta-TrCP and enhances beta-catenin degradation	ONCOGENE			English	Article						CK2; UBC3; beta-TrCP; phosphorylation	PROTEIN-KINASE CK2; CELL-CYCLE GENE; CASEIN KINASE-2; SACCHAROMYCES-CEREVISIAE; PROTEASOME PATHWAY; BUDDING YEAST; S TRANSITION; VPU PROTEIN; SYSTEM; INHIBITOR	Protein kinase CK2 is a ubiquitous and pleiotropic Ser/Thr protein kinase involved in cell growth and transformation. Here we report the identification by yeast interaction trap of a CK2 interacting protein, UBC3B, which is highly homologous to the E2 ubiquitin conjugating enzyme UBC3/CDC34. UBC3B complements the yeast cdc34-2 cell cycle arrest mutant in S. cerevisiae and transfers ubiquitin to a target substrate in vitro. UBC3B is specifically phosphorylated by CK2 in vitro and in giro. We mapped by deletions and site directed mutagenesis the phosphorylation site to a serine residue within the C-terminal domain in position 233 of UBC3B and in the corresponding serine residue of UBC3. Following CK2-dependent phosphorylation both UBC3B and UBC3 bind to the F-box protein beta-TrCP, the substrate recognition subunit of an SCF (Skp1, Cul1, F-box) ubiquitin ligase. Furthermore, we observed that co-transfection of CK2alpha' together with UBC3B, but not with UBC3DeltaC, enhances the degradation of beta-catenin. Taken together these data suggest that CK2-dependent phosphorylation of UBC3 and UBC3B functions by regulating beta-TrCP substrate recognition.	Univ Siena, Dipartimento Biol Mol, I-53100 Siena, Italy; Univ Padua, Dipartimento Chim Biol, I-35100 Padua, Italy; Univ Padua, CNR, Ctr Studio Biomembrane, I-35100 Padua, Italy	University of Siena; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Oliviero, S (corresponding author), Univ Siena, Dipartimento Biol Mol, Via Fiorentina 1, I-53100 Siena, Italy.	oliviero@unisi.it	oliviero, salvatore/R-6657-2019	oliviero, salvatore/0000-0002-3405-765X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; AHMED K, 1994, CELL MOL BIOL RES, V40, P1; Allende CC, 1998, J CELL BIOCHEM, P129; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BALDARI C, 1987, EMBO J, V6, P229, DOI 10.1002/j.1460-2075.1987.tb04743.x; Blanquet PR, 2000, PROG NEUROBIOL, V60, P211, DOI 10.1016/S0301-0082(99)00026-X; Block K, 2001, J BIOL CHEM, V276, P41049, DOI 10.1074/jbc.M106453200; Bour S, 2001, J BIOL CHEM, V276, P15920, DOI 10.1074/jbc.M010533200; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GAPANY M, 1995, MOL MED, V1, P659, DOI 10.1007/BF03401606; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Haas AL, 1997, FASEB J, V11, P1257; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Matuschewski K, 1996, J BIOL CHEM, V271, P2789, DOI 10.1074/jbc.271.5.2789; MEGGIO F, 1981, J BIOL CHEM, V256, P1958; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; RAYAN A, 1985, CANCER RES, V45, P2277; Raymond F, 2000, J CELL SCI, V113, P1687; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; SCHUBERT U, 1994, J MOL BIOL, V236, P16, DOI 10.1006/jmbi.1994.1114; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEITZ G, 1989, BIOCHEM BIOPH RES CO, V163, P635, DOI 10.1016/0006-291X(89)92184-0; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Sun BG, 1997, BBA-GENE STRUCT EXPR, V1351, P231, DOI 10.1016/S0167-4781(96)00209-6; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; YENICE S, 1994, PROSTATE, V24, P11, DOI 10.1002/pros.2990240105	60	44	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					3978	3987		10.1038/sj.onc.1205574	http://dx.doi.org/10.1038/sj.onc.1205574			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037680				2022-12-17	WOS:000175869900004
J	Ae, K; Kobayashi, N; Sakuma, R; Ogata, T; Kuroda, H; Kawaguchi, N; Shinomiya, K; Kitamura, Y				Ae, K; Kobayashi, N; Sakuma, R; Ogata, T; Kuroda, H; Kawaguchi, N; Shinomiya, K; Kitamura, Y			Chromatin remodeling factor encoded by ini1 induces G1 arrest and apoptosis in ini1-deficient cells	ONCOGENE			English	Article						INI1/SNF5; SWI/SNF complex; tumor suppressor; G1 arrest; apoptosis	SWI-SNF COMPLEX; MALIGNANT RHABDOID TUMOR; SINGLE-CHAIN ANTIBODY; SWI/SNF COMPLEX; VIRAL INTEGRASE; TRANSCRIPTION; MUTATIONS; PROTEINS; LINES; GENE	Ini1/hsnf5 gene encodes INI1 protein, a chromatin remodeling factor associated with the SWI/SNF complex. In yeast, this complex modifies chromatin condensation to coactivate various transcriptional factors. However, in human, little is known about the SWI/SNF complex and INI1. To elucidate cellular functions of ini1, we constructed a recombinant adenovirus (AdexHA-INI1) capable of overexpressing INI1 in ini1-deficient cells. AdexHA-INI1 produced intranuclear INI1 in three ini1-deficient cell lines, changed their morphology, and decreased the proportion of viable cells. Flow cytometry and a BrdU incorporation assay showed that after the infection, growth of these cells was partially arrested at G1. In two of the three ini1-deficient cell lines, apoptosis was found to occur after the infection, as detected by the presence of cleaved poly (ADP-ribose) polymerase. To determine functional domains of INI1, we constructed plasmids expressing INI1 and its deletion mutants, which were used for a colony formation assay. Repeats I and 2 of INI1 were found to be required to suppress the growth of the three ini1-deficient cell lines. The results support the hypothesis that ini1 is a tumor suppressor gene and suggest a novel link between human SWI/SNF chromatin remodeling complex and apoptosis.	Univ Tokyo, Inst Med Sci, Div Infect Dis, Adv Clin Res Ctr, Tokyo 1038639, Japan; Natl Inst Infect Dis, Div Mol Genet, Tokyo 2080011, Japan; Tokyo Med & Dent Univ, Sect Orthoped Spinal Surg, Dept Frontier Surg Therapeut, Div Adv Therapeut Sci,Grad Sch, Tokyo 1138519, Japan; Japanese Fdn Canc Res, Dept Orthoped Oncol, Canc Inst Hosp, Toshima Ku, Tokyo 1700012, Japan	University of Tokyo; National Institute of Infectious Diseases (NIID); Tokyo Medical & Dental University (TMDU); Japanese Foundation for Cancer Research	Kitamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Div Infect Dis, Adv Clin Res Ctr, 4-6-1 Shirokanedai, Tokyo 1038639, Japan.							Biegel JA, 1999, CANCER RES, V59, P74; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Brand A, 2001, GYNECOL ONCOL, V80, P99, DOI 10.1006/gyno.2000.6032; Brodie S G, 2001, Trends Genet, V17, pS18, DOI 10.1016/S0168-9525(01)02451-9; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; GARVIN AJ, 1993, AM J PATHOL, V142, P375; GRAHAM FL, 1977, J GEN VIROL, V36, P9; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Kitamura Y, 1999, J ACQ IMMUN DEF SYND, V20, P105, DOI 10.1097/00042560-199902010-00001; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Okui N, 1998, J VIROL, V72, P6960, DOI 10.1128/JVI.72.8.6960-6964.1998; OTA S, 1993, CANCER-AM CANCER SOC, V71, P2862, DOI 10.1002/1097-0142(19930501)71:9<2862::AID-CNCR2820710930>3.0.CO;2-D; PEEBLES PT, 1978, PEDIATR RES, V12, P485, DOI 10.1203/00006450-197804001-00732; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; SCHERER WF, 1953, J EXP MED, V97, P695, DOI 10.1084/jem.97.5.695; SEKIGUCHI M, 1985, BIOMED PHARMACOTHER, V39, P372; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Whitehouse I, 2000, BIOCHEM SOC T, V28, P376, DOI 10.1042/0300-5127:0280376; Wong AKC, 2000, CANCER RES, V60, P6171; Wu DY, 2000, J VIROL, V74, P8893, DOI 10.1128/JVI.74.19.8893-8903.2000	32	44	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3112	3120		10.1038/sj.onc.1205414	http://dx.doi.org/10.1038/sj.onc.1205414			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082626				2022-12-17	WOS:000175373600002
J	Koshikawa, K; Osada, H; Kozaki, K; Konishi, H; Masuda, A; Tatematsu, Y; Mitsudomi, T; Nakao, A; Takahashi, T				Koshikawa, K; Osada, H; Kozaki, K; Konishi, H; Masuda, A; Tatematsu, Y; Mitsudomi, T; Nakao, A; Takahashi, T			Significant up-regulation of a novel gene, CLCP1, in a highly metastatic lung cancer subline as well as in lung cancers in vivo	ONCOGENE			English	Article						lung cancer; metastasis; CLCP1	ENDOTHELIAL GROWTH-FACTOR; CELL-LINE NCI-H460-LNM35; TUMOR-CELLS; SEMAPHORIN-III; FACTOR VEGF; NEUROPILIN; RECEPTOR; ANGIOGENESIS; FAMILY	Most lung cancer patients are unfortunately uncurable and die because of widespread metastases, thus indicating the importance of identification of molecules with a crucial role in this process. Our previous expression profiling analysis of a highly metastatic lung cancer cell line, NCI-H460-LNM35, and its parental low metastatic line, NCI-H460-N15, revealed significant up-regulation of both known and unknown genes in LNM35. In this study, we describe the isolation and detailed characterizations of a novel gene, named CLCP1, which corresponds to one of such expression sequence tags with up-regulated expression in LNM35. The CLCP1 gene was found to encode a protein with 775 amino acids with structural similarities to, but distinct from neuropilins, cell surface receptors for VEGF(165), and semaphorins. Notably, CLCP1 was shown to be upregulated not only in LNM35 in association with its acquisition of metastatic phenotype during in vivo selection, but also in a significant fraction of lung cancers in vivo with high frequency in metastatic lesions, warranting future studies for a better understanding of the molecular mechanisms of lung cancer metastasis.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya Univ, Sch Med, Dept Surg 2, Showa Ku, Nagoya, Aichi 4668550, Japan	Aichi Cancer Center; Aichi Cancer Center; Nagoya University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	tak@aichi-cc.jp	Kozaki, Ken-ichi/M-6281-2014; Takahashi, Takashi/I-7262-2014	Kozaki, Ken-ichi/0000-0003-3286-819X; Takahashi, Takashi/0000-0003-0615-7001; Mitsudomi, Tetsuya/0000-0001-9860-8505; Konishi, Hiroyuki/0000-0003-1131-4905				Bachelder RE, 2001, CANCER RES, V61, P5736; Bagnard D, 1998, DEVELOPMENT, V125, P5043; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; FIDLER IJ, 2001, BIOL CANC ANGIOGENES, P917; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Fujisawa H, 1998, CURR OPIN NEUROBIOL, V8, P587, DOI 10.1016/S0959-4388(98)80085-8; Hayashibara T, 2001, CLIN CANCER RES, V7, P2719; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kozaki K, 2000, CANCER RES, V60, P2535; Kozaki K, 2001, ONCOGENE, V20, P4228, DOI 10.1038/sj.onc.1204561; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Miao HQ, 2000, CANCER METAST REV, V19, P29, DOI 10.1023/A:1026579711033; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; SEKIDO Y, 2001, CANC PRINCIPLES PRAC, P917; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 2001, AM J PATHOL, V159, P651, DOI 10.1016/S0002-9440(10)61736-1; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; *STAT INF DEP MIN, 1999, VIT STAT JAP 1999, V3, P398; STETLERSTEVENSO.WG, 2001, MOL BIOL CANC INVASI, P123; Trexler M, 2000, EUR J BIOCHEM, V267, P5751, DOI 10.1046/j.1432-1327.2000.01641.x; Veikkola T, 2000, CANCER RES, V60, P203	28	44	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2822	2828		10.1038/sj.onc.1205405	http://dx.doi.org/10.1038/sj.onc.1205405			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973641				2022-12-17	WOS:000175063700006
J	Gapuzan, MER; Yufit, PV; Gilmore, TD				Gapuzan, MER; Yufit, PV; Gilmore, TD			Immortalized embryonic mouse fibroblasts lacking the RelA subunit of transcription factor NF-kappa B have a malignantly transformed phenotype	ONCOGENE			English	Article						NF-kappa B; RelA; Rel; malignant transformation; mouse knockout cells; apoptosis	TUMOR-NECROSIS-FACTOR; INCREASED APOPTOSIS; MICE; ACTIVATION; PATHWAY; BINDING; CANCER; GENES; CELLS	The RelA transcription factor is part of dimeric complexes, most commonly either p50-RelA (NF-kappaB) heterodimers or RelA homodimers, that control a variety of cellular processes. Immortalized embryonic fibroblasts established from rela knockout mice have previously been shown to be more sensitive to apoptosis induced by tumor necrosis factor (TNF) than are control fibroblasts. In this report, we show that one line of rela-/- fibroblasts has additional phenotypes that distinguish them from control mouse fibroblasts. As compared to normal 3T3 cells, RelA-deficient fibroblasts have a spindled morphology, are less adherent to culture dishes, grow to a higher saturation density, and can form colonies in soft agar. These properties are consistent with a weakly transformed phenotype for rela-/- cells. Furthermore, RelA-deficient fibroblasts can form tumors in immunodeficient mice, but these tumors regress, probably because of the sensitivity of these cells to TNF. The ability of rela-/- fibroblasts to form colonies in soft agar can be reverted by re-expression of wild-type mouse RelA, but not by expression of RelA mutants that cannot form homodimers. There is no clear correlation between the absence of RelA and the levels of expression of other Rel/NF-kappaB family members or adhesion proteins (ICAM-1 and VCAM-1) whose genes have upstream kappaB sites. Taken together, these results suggest that RelA has tumor suppressing activity under some circumstances and that RelA complexes are involved in the control of a variety of cellular properties associated with oncogenesis.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu			NCI NIH HHS [CA 47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANCROFT GJ, 1989, J IMMUNOL, V143, P127; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; DORSHKIND K, 1985, J IMMUNOL, V134, P3798; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; GILMORE TD, 2002, IN PRESS CANC LETT; HANNINK M, 1990, ONCOGENE, V5, P1843; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; LADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ricca A, 2001, BRIT J CANCER, V85, P1914, DOI 10.1054/bjoc.2001.2174; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; Trecca D, 1997, ONCOGENE, V14, P791, DOI 10.1038/sj.onc.1200895; van Hogerlinden M, 1999, CANCER RES, V59, P3299; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441	27	44	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2484	2492		10.1038/sj.onc.1205333	http://dx.doi.org/10.1038/sj.onc.1205333			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971183				2022-12-17	WOS:000174918400005
J	Tarapore, P; Tokuyama, Y; Horn, HF; Fukasawa, K				Tarapore, P; Tokuyama, Y; Horn, HF; Fukasawa, K			Difference in the centrosome duplication regulatory activity among p53 'hot spot' mutants: potential role of Ser 315 phosphorylation-dependent centrosome binding of p53	ONCOGENE			English	Article						centrosome duplication; cancer; p53; CDK2; phosphorylation	TRANSCRIPTIONAL ACTIVATION; GENOMIC INSTABILITY; EMBRYO FIBROBLASTS; CYCLIN-E; HYPERAMPLIFICATION; MUTATIONS; CANCER; MICE; CDK2; P21	The p53 tumor suppressor protein regulates centrosome duplication through multiple pathways, and p21(Waf1/Cip1) (Waf1), a major target of p53's transactivation function, has been shown to be one of the effectors. However, it had been unclear whether the p53's Waf1-independent centrosome duplication regulatory pathways require its transactivation function. In human cancers, specific residues of p53 are mutated at a high frequency. These 'hot spot' mutations abrogate p53's transactivation function. If p53 regulates centrosome duplication in a transactivation-independent manner, different 'hot spot' mutants may regulate centrosome duplication differently. To test this, we examined the effect of two 'hot spot' mutants (R175H and R249S) for their centrosome duplication regulatory activities. We found that R175H lost the ability to regulate centrosome duplication, while R249S partially retained it. Moreover, R249S associates with both unduplicated and duplicated centrosomes similar to wild-type p53, while R175H only associates with duplicated, but not unduplicated centrosomes. Since cyclin-dependent kinase 2 (CDK2) triggers initiation of centrosome duplication, and p53 is phosphorylated on Ser 315 by CDK2, we examined the p53 mutants with a replacement of Ser 315 to Ala (A) and Asp (D), both of which retain the transactivation function. We found that S315D retained a complete centrosome duplication activity, while S315A only partially retained it. Moreover, S315D associates with both unduplicated and duplicated centrosomes, while S315A associates with only duplicated, but not unduplicated centrosomes. Thus, p53 controls the centrosome duplication cycle both in transactivation-dependent and transactivation-independent manners, and the ability to bind to unduplicated centrosomes, which is controlled by phosphorylation on Ser 315, may be important for the overall p53-mediated regulation of centrosome duplication.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521, Cincinnati, OH 45267 USA.	Kenji.Fukasawa@uc.edu	Tarapore, Pheruza/A-8876-2013	Tarapore, Pheruza/0000-0003-0911-3661; Horn, Henning/0000-0002-5885-8996	NCI NIH HHS [CA90522] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090522] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; AHNEN DJ, 1992, J CELL BIOCHEM, P143; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bates S, 1999, MOL CARCINOGEN, V24, P7, DOI 10.1002/(SICI)1098-2744(199901)24:1<7::AID-MC2>3.0.CO;2-5; BORNENS M, 1992, KALNINS, V6, P2; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chiba S, 2000, EXP CELL RES, V258, P310, DOI 10.1006/excr.2000.4916; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge RM, 1998, BREAST CANCER RES TR, V52, P79, DOI 10.1023/A:1006163101948; FUCHS B, 1995, ONCOGENE, V10, P789; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KIKUCHIYANOSHITA R, 1995, ONCOGENE, V11, P1339; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lange BMH, 2000, CURR TOP DEV BIOL, V49, P235; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MAZIA D, 1987, INT REV CYTOL, V100, P49; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Mowat MRA, 1998, ADV CANCER RES, V74, P25, DOI 10.1016/S0065-230X(08)60764-2; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nylander K, 2000, J ORAL PATHOL MED, V29, P413, DOI 10.1034/j.1600-0714.2000.290901.x; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ozen H, 2000, CURR OPIN ONCOL, V12, P255, DOI 10.1097/00001622-200005000-00012; PRICE BD, 1995, ONCOGENE, V11, P73; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sluder G, 2000, CURR TOP DEV BIOL, V49, P267; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2000, CANCER INVEST, V18, P148, DOI 10.3109/07357900009038246; Urbani L, 1999, CURR BIOL, V9, pR315, DOI 10.1016/S0960-9822(99)80201-2; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; VET JAM, 1994, WORLD J UROL, V12, P84; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; WILLIAMS NN, 1990, SURG GYNECOL OBSTET, V171, P257; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579	59	44	45	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6851	6863		10.1038/sj.onc.1204848	http://dx.doi.org/10.1038/sj.onc.1204848			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687964				2022-12-17	WOS:000171641000006
J	Lee, SH; Zhang, W; Choi, JJ; Cho, Y; Lee, SH; Kim, JW; Hu, LM; Xu, J; Liu, JS; Lee, JH				Lee, SH; Zhang, W; Choi, JJ; Cho, Y; Lee, SH; Kim, JW; Hu, LM; Xu, J; Liu, JS; Lee, JH			Overexpression of the thymosin beta-10 gene in human ovarian cancer cells disrupts F-actin stress fiber and leads to apoptosis	ONCOGENE			English	Article						thymosin beta-10; ovarian cancer; cDNA array	MESSENGER-RNA; BREAST-CANCER; EXPRESSION; PROSTATE; PROTEINS; P53; CARCINOMA; TUMORS; RAS	To understand the molecular changes during ovarian cancer development, we profiled differentially expressed genes in five paired normal and cancerous ovarian tissues. Among the genes that showed differential expression, thymosin beta -10 expression was decreased in four of five cancer tissues. The decreased level of expression was confirmed by Northern. To investigate the gene's functional role in ovarian cancers, we constructed an adenovirus vector expressing thymosin beta -10 and used it to infect ovarian cancer cell lines PA-I and SKOV3. The infected cells showed disrupted F-actin stress fibers, markedly decreased cell growth, and a high rate of apoptosis. Thus, because loss of thymosin beta -10 expression may contribute to the development of a subset of ovarian cancers, restoration of thymosin beta -10 expression may be a new strategy for ovarian cancer treatment.	Sungkyunkwan Univ, Coll Med, Mol Therapy Res Ctr, Samsung Med Ctr,Kangnam Ku, Seoul 135701, South Korea; Sungkyunkwan Univ, Coll Med, Dept Obstet & Gynecol, Samsung Med Ctr,Kangnam Ku, Seoul 135701, South Korea; Univ Texas, MD Anderson Canc Ctr, Canc Genom Core Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Pennsylvania	Lee, JH (corresponding author), Sungkyunkwan Univ, Coll Med, Mol Therapy Res Ctr, Samsung Med Ctr,Kangnam Ku, 50 Ilwon Dong, Seoul 135701, South Korea.	jeholee@samsung.co.kr		Kim, Jung-whan/0000-0002-7829-1480				Bao LR, 1996, NAT MED, V2, P1322, DOI 10.1038/nm1296-1322; Caduff RF, 1999, AM J SURG PATHOL, V23, P323, DOI 10.1097/00000478-199903000-00012; Carpintero P, 1996, FEBS LETT, V394, P103, DOI 10.1016/0014-5793(96)00888-5; DeRisi J, 1996, NAT GENET, V14, P457; Eadie JS, 2000, J CELL BIOCHEM, V77, P277, DOI 10.1002/(SICI)1097-4644(20000501)77:2<277::AID-JCB10>3.0.CO;2-Q; Fuller GN, 1999, CANCER RES, V59, P4228; Gold JS, 1997, MODERN PATHOL, V10, P1106; HALL AK, 1995, CELL MOL BIOL RES, V41, P167; HALL AK, 1991, MOL CELL ENDOCRINOL, V79, P37, DOI 10.1016/0303-7207(91)90093-8; HALL AK, 1994, RENAL FAILURE, V16, P243, DOI 10.3109/08860229409044864; HALL AK, 1994, MED HYPOTHESES, V43, P125, DOI 10.1016/0306-9877(94)90135-X; HALL AK, 1990, MOL BRAIN RES, V8, P129, DOI 10.1016/0169-328X(90)90057-K; HENRIKSEN R, 1994, GYNECOL ONCOL, V53, P301, DOI 10.1006/gyno.1994.1138; Hough CD, 2000, CANCER RES, V60, P6281; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Iguchi K, 1998, EUR J BIOCHEM, V253, P766, DOI 10.1046/j.1432-1327.1998.2530766.x; MARIAN AJW, 1993, INT J CANCER, V53, P278; Marx D, 1997, ANTICANCER RES, V17, P2233; Meden H, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P167; Morita K, 2000, PATHOL INT, V50, P219, DOI 10.1046/j.1440-1827.2000.01028.x; Nachmias VT, 1993, CURR OPIN CELL BIOL, V5, P56, DOI 10.1016/S0955-0674(05)80008-0; *NIH, 1994, NIH CONSENSUS STATE, V12, P1; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Rauh-Adelmann C, 2000, MOL CARCINOGEN, V28, P236, DOI 10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; VELCLESCU VE, 1995, SCIENCE, V170, P484; VergheseNikolakaki S, 1996, BRIT J CANCER, V74, P1441, DOI 10.1038/bjc.1996.562; YAMAMOTO T, 1993, BIOCHEM BIOPH RES CO, V193, P706, DOI 10.1006/bbrc.1993.1682; YU FX, 1994, CELL MOTIL CYTOSKEL, V27, P13, DOI 10.1002/cm.970270103; YU FX, 1993, J BIOL CHEM, V268, P502; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	31	44	57	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6700	6706		10.1038/sj.onc.1204683	http://dx.doi.org/10.1038/sj.onc.1204683			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709704				2022-12-17	WOS:000171551600006
J	O'Bryan, JP; Mohney, RP; Oldham, CE				O'Bryan, JP; Mohney, RP; Oldham, CE			Mitogenesis and endocytosis: What's at the INTERSECTIoN?	ONCOGENE			English	Article						Eps15 homology; Src homology 3; GTPase; ubiquitination	CLATHRIN-MEDIATED ENDOCYTOSIS; ACTIVATED PROTEIN-KINASE; COATED VESICLE FORMATION; GROWTH-FACTOR RECEPTORS; FAT-FACETS GENE; SIGNAL-TRANSDUCTION; EPS15 HOMOLOGY; DEUBIQUITINATING ENZYME; ADAPTER PROTEIN; TYROSINE KINASE	Endocytosis is a regulated physiological process by which cell surface proteins are internalized along with extracellular factors such as nutrients, pathogens, peptides, toxins, etc. The process begins with the invagination of small regions of the plasma membrane which ultimately form intracellullar vesicles. These internalized vesicles may shuttle back to the plasma membrane to recycle the membrane components or they may be targeted for degradation. One role for endocytosis is in the attenuation of receptor signaling. For example, desensitization of activated membrane bound receptors such as G-protein coupled receptors (GPCRs) or receptor tyrosine kinases (RTKs) occurs, in part, through endocytosis of the activated receptor. However, accumulating evidence suggests that endocytosis also mediates intracellular signaling. In this review, we discuss the experimental data that implicate endocytosis as a critical component in cellular signal transduction, both in the initiation of a signal as well as in the termination of a signal. Furthermore, we focus our attention on a recently described adaptor protein, intersectin (ITSN), which provides a link to both the endocytic and the mitogenic machinery of a cell. Thus, ITSN functions at a crossroad in the biochemical regulation of cell function.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	O'Bryan, JP (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233,Bldg Rm 101-F336,MD F3-06, Res Triangle Pk, NC 27709 USA.	obryan@niehs.nih.gov		O'Bryan, John/0000-0001-5386-1080	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090091] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams A, 2000, J BIOL CHEM, V275, P27414; BERNARD OA, 1994, ONCOGENE, V9, P1039; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Carbone R, 1997, CANCER RES, V57, P5498; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Della Rocca GJ, 1999, J BIOL CHEM, V274, P4749, DOI 10.1074/jbc.274.8.4749; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; Emlet DR, 1997, J BIOL CHEM, V272, P4079, DOI 10.1074/jbc.272.7.4079; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Fernandez-Chacon R, 2000, J BIOL CHEM, V275, P12752, DOI 10.1074/jbc.275.17.12752; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; Fish KN, 2000, J CELL BIOL, V150, P145, DOI 10.1083/jcb.150.1.145; Floyd S, 1998, TRENDS CELL BIOL, V8, P299, DOI 10.1016/S0962-8924(98)01316-6; Fry DW, 1999, PHARMACOL THERAPEUT, V82, P207, DOI 10.1016/S0163-7258(98)00050-3; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Guipponi M, 1998, CYTOGENET CELL GENET, V83, P218, DOI 10.1159/000015182; Guipponi M, 1998, GENOMICS, V53, P369, DOI 10.1006/geno.1998.5521; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; Haugh JM, 1999, J BIOL CHEM, V274, P8958, DOI 10.1074/jbc.274.13.8958; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; Johannessen LE, 2000, EXP CELL RES, V260, P136, DOI 10.1006/excr.2000.5004; Kadesch T, 2000, EXP CELL RES, V260, P1, DOI 10.1006/excr.2000.4921; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Malecz N, 2000, CURR BIOL, V10, P1383, DOI 10.1016/S0960-9822(00)00778-8; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Munn AL, 2001, BBA-MOL BASIS DIS, V1535, P236, DOI 10.1016/S0925-4439(01)00028-X; Nemoto Y, 1997, J BIOL CHEM, V272, P30817, DOI 10.1074/jbc.272.49.30817; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Okamoto M, 1999, J BIOL CHEM, V274, P18446, DOI 10.1074/jbc.274.26.18446; Parks AL, 2000, DEVELOPMENT, V127, P1373; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Pucharcos C, 1999, EUR J HUM GENET, V7, P704, DOI 10.1038/sj.ejhg.5200356; Pucharcos C, 2000, FEBS LETT, V478, P43, DOI 10.1016/S0014-5793(00)01793-2; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; Robertson H, 1997, BIOCHEM BIOPH RES CO, V240, P46, DOI 10.1006/bbrc.1997.7608; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Skarpen E, 1998, EXP CELL RES, V243, P161, DOI 10.1006/excr.1998.4127; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Tong XK, 2000, J BIOL CHEM, V275, P29894, DOI 10.1074/jbc.M004096200; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vanDelft S, 1997, J BIOL CHEM, V272, P14013, DOI 10.1074/jbc.272.22.14013; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000	81	44	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2001	20	44					6300	6308		10.1038/sj.onc.1204773	http://dx.doi.org/10.1038/sj.onc.1204773			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607832				2022-12-17	WOS:000171640600005
J	Calastretti, A; Bevilacqua, A; Ceriani, C; Vigano, S; Zancai, P; Capaccioli, S; Nicolin, A				Calastretti, A; Bevilacqua, A; Ceriani, C; Vigano, S; Zancai, P; Capaccioli, S; Nicolin, A			Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase	ONCOGENE			English	Article						apoptosis; BCL-2; mTOR; microtubules; p27; rapamycin	DOWN-REGULATES BCL-2; MAMMALIAN TARGET; DEPENDENT DEGRADATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; MESSENGER-RNA; CELL-CYCLE; APOPTOSIS; RAPAMYCIN; PROTEIN	Rapamycin, a specific inhibitor of the serine/threonine mTOR kinase, markedly inhibited both cell growth and apoptosis in human B-cell lines. Besides arresting cells in G(1) by increasing p27(kip1), rapamycin tripled the cellular level of the BCL-2 protein. The activity was dose-dependent and specific for the p27(kip1) and BCL-2 proteins. Rapamycin did not affect bcl-2 mRNA although it increased cellular BCL-2 concentration by inhibiting phosphorylation, a mechanism initiating the decay process. To add new insight, we combined rapamycin treatment with treatment by taxol, which, by damaging microtubules, can phosphorylate BCL-2 and activate apoptosis. It was found that the mTOR kinase was activated in cells treated with taxol or with nocodazole although it was inhibited in cells pre-treated with rapamycin. BCL-2 phosphorylation, apoptosis and hyperdiploidy were also inhibited by rapamycin. In contrast, taxol-induced microtubule stabilization or metaphase synchronization were not inhibited by rapamycin. Taken together, these findings indicate that mTOR belongs to the enzymatic cascade that, starting from damaged microtubules, phosphorylates BCL-2. By regulating apoptosis, in addition to the control of a multitude of growth-related pathways, mTOR plays a nodal role in signaling G(1) and G(2)-M events.	Univ Milan, Dept Pharmacol, I-20129 Milan, Italy; Ctr Riferimento Oncol, Div Expt Oncol, I-33081 Aviano, Italy; Univ Florence, Inst Gen Pathol, Florence, Italy	University of Milan; IRCCS Aviano (CRO); University of Florence	Nicolin, A (corresponding author), Univ Milan, Dept Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.	angelo.nicolin@unimi.it	Bevilacqua, Annamaria/C-6357-2008	Bevilacqua, Annamaria/0000-0002-3136-3424				Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; AIELLO A, 1992, CYTOMETRY, V13, P502, DOI 10.1002/cyto.990130509; Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Bickle M, 1998, EMBO J, V17, P2235, DOI 10.1093/emboj/17.8.2235; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Capaccioli S, 1996, ONCOGENE, V13, P105; Chadebech P, 1999, BIOCHEM BIOPH RES CO, V262, P823, DOI 10.1006/bbrc.1999.1291; Choi JH, 2000, CURR BIOL, V10, P861, DOI 10.1016/S0960-9822(00)00599-6; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; CROSSIN KL, 1981, CELL, V27, P341, DOI 10.1016/0092-8674(81)90417-7; DYER MJS, 1990, BLOOD, V75, P709; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1997, CANCER RES, V57, P229; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Itano Y, 1996, J NEUROCHEM, V67, P131; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Kitamura Y, 1997, JPN J PHARMACOL, V75, P195, DOI 10.1254/jjp.75.195; KLUINNELEMANS HC, 1991, LEUKEMIA, V5, P221; Koff A, 1995, Prog Cell Cycle Res, V1, P141; Konig A, 1997, BLOOD, V90, P4307; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KORSMEYER SJ, 1990, CURR TOP MICROBIOL, V166, P203; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; McDonnell TJ, 1996, EXPERIENTIA, V52, P1008, DOI 10.1007/BF01920110; Metcalfe SM, 1997, ONCOGENE, V15, P1635, DOI 10.1038/sj.onc.1201341; Migita K, 1997, CLIN EXP IMMUNOL, V108, P199, DOI 10.1046/j.1365-2249.1997.d01-1002.x; Morelli S, 1997, P NATL ACAD SCI USA, V94, P8150, DOI 10.1073/pnas.94.15.8150; Morelli S, 1996, ANTI-CANCER DRUG DES, V11, P1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pratesi G, 2000, BIOCHEM PHARMACOL, V60, P77, DOI 10.1016/S0006-2952(00)00300-2; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Saille C, 1999, NEUROSCIENCE, V92, P1455, DOI 10.1016/S0306-4522(99)00089-5; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; Sehgal SN, 1998, CLIN BIOCHEM, V31, P335, DOI 10.1016/S0009-9120(98)00045-9; Siegel DS, 1998, P NATL ACAD SCI USA, V95, P162, DOI 10.1073/pnas.95.1.162; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; STEUBE KG, 1995, LEUKEMIA, V9, P1841; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TERADA N, 1995, J IMMUNOL, V155, P3418; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	62	44	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2001	20	43					6172	6180		10.1038/sj.onc.1204751	http://dx.doi.org/10.1038/sj.onc.1204751			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593425	Green Published			2022-12-17	WOS:000171206300008
